	Analysis of efficacy
0	Comparisons of postoperative CA19-9 levels on survival of ESPAC-4 with the CONOKO-01 and JASPAC-1 trials
1	Pattern of disease relapse
2	Grade 1–5 adverse events with gemcitabine alone and gemcitabine plus capecitabine
3	Treatment with zoledronic acid
4	Treatment with docetaxel
5	Treatments ever used at relapse, at the discretion of the treating clinician
6	Worst adverse event  (grade)  reported over entire time on trial
7	Chemotherapy delivery and trial drug discontinuation
8	Adverse events
9	Screening effectiveness for selective and universal ultrasonographic screening for infants who are small and severely small for gestational age
10	Diagnostic effectiveness of selective versus universal ultrasonographic screening for infants who are small and severely small for gestational age
11	Association between perinatal outcomes of estimated fetal weight less than the 10th percentile and abdominal circumference growth velocity
12	Age started smoking regularly versus cause-specific mortality rate ratio  (RR)  among urban and rural men in about 2010  (second study)  and about 1995  (first study)
13	Amount last smoked versus cause-specific mortality rate ratio  (RR)  among urban and rural men in about 2010  (second study)  and about 1995  (first study)
14	Deaths attributed to tobacco in China, 2010
15	Percentage contribution of disease categories to total deaths by age groups in states grouped by ETL, 2016
16	Percentage contribution of disease categories to total deaths by age groups for all of India, 2016
17	Change in summary exposure value of individual leading risk factors in states grouped by ETL from 1990 to 2016
18	Male deaths attributed to smoking and total male deaths in the study, by population group and disease category
19	Female deaths attributed to smoking and total female deaths in the study, by population group and disease category
20	Primary and secondary outcomes
21	Serious adverse events related to hypotension
22	Side-effects potentially related to blood-pressure management
23	Randomised trials of long-term blood-pressure lowering in patients with stroke or TIA  *
24	Association of birthweight, conditional relative weight gain, and conditional height with adverse outcomes
25	Total dose received by patients and dose intensity achieved
26	Response to treatment
27	Grade 3 or 4 adverse events
28	Antibiotic therapy by class and treatment group
29	Antibiotic-associated diarrhoea and morbidity in the first 3 weeks after recruitment
30	Additional colonic investigation by reason for investigation, overall and by sex
31	Results of additional colonic investigation, by reason for investigation
32	Detection rates of colorectal cancer and large polyps
33	Serious adverse events by treatment and body system affected
34	Circumstances of death and indications for coronial referral
35	Autopsy causes of death by type of pathology and organs involved
36	Major discrepancy rate between autopsy and radiology cause of death
37	Comparison of the two independent reports for MRI and CT
38	Most common sources of major discrepancy between autopsy and consensus radiology cause of death
39	Late effects of treatment
40	Primary outcomes at 6 and 12 months
41	Secondary outcomes at 6 and 12 months
42	Additional secondary outcomes at 6 and 12 months
43	Medication use at 6 and 12 months
44	Cancer incidence and cancer mortality by site
45	Effects of allocation to simvastatin plus ezetimibe on muscle and hepatobiliary system
46	Treatment received
47	Main outcome measures
48	Toxic effects, weeks 1–12
49	Factors associated with OTU outcome  (multivariate analysis)
50	Effects of maternal anthelmintic treatment in pregnancy on infant response to BCG, tetanus, and measles immunisation
51	Effect of maternal anthelmintic treatment on response to BCG, tetanus, and measles immunisation, by maternal helminth infection status
52	Effects of maternal anthelmintic treatment in pregnancy on incidence of malaria, diarrhoea, and pneumonia in infancy
53	Effect of maternal anthelmintic treatment in pregnancy on disease incidence, by maternal helminth status
54	Effects of Phytoestrogens in Basic, Animal and Human Studies ∗
55	Final Cox Proportional Hazards Model for Hard Events
56	Predicted Rates of Hard Events by Six-Month Intervals in Patients With No History of Previous CAD
57	Predicted Rates of Hard Events by Six-Month Intervals in Patients With History of Known CAD
58	Time  (Days)  From Index Test to 0.5%, 1.0%, 1.5%, and 2.0% Predicted Risk of Hard Events in Patients With No History of Previous Coronary Artery Disease
59	Time  (Days)  From Index Test to 0.5%, 1.0%, 1.5%, and 2.0% Predicted Risk of Hard Events in Patients With Known Coronary Artery Disease
60	Clinical Features of MCH
61	Echocardiographic and Pathologic Features
62	Independent Predictors of Cardiovascular Events  (Cox Model)
63	Inclusion and Exclusion Criteria for Permanent Jarvik-2000 Implantation
64	Intraoperative and Postoperative Patient Data
65	Causes of Death Before and After Transplantation
66	Adverse Events During the Initial Hospitalization and at One Year
67	Estimated Risk Ratios for Death in Patients With Successful Percutaneous Revascularization Procedures
68	Changes in Heart Rate Before and After Ablation
69	Clinical Correlates of Coronary Artery Calcification Score
70	Clinical Correlates of Aortic Calcification Score
71	Multivariable Linear Regression With Extent of Coronary Calcification as Dependent Variable
72	Multivariable Linear Regression With Extent of Aortic Calcification as Dependent Variable
73	Treatment Groups
74	Extent of Coronary Artery Disease and Subsequent Treatment According to the CRF and the Angiographic ACL
75	Worst Major Adverse Events, in Ranking Order, and Event-Free Survival for the Four Subgroups at One Year
76	Extent and Quality of Incompleteness in Both Groups Treated With Bypass Operation or Stented Angioplasty Assessed by the ACL
77	Univariate Predictors of Pump Failure and LV Aneurysm legend
78	Multiple Logistic Regression Analysis for Pump Failure legend
79	Multiple Logistic Regression Analysis for LV Aneurysm legend
80	Univariate and Multivariate Cox Proportional Hazards Analysis for Cardiac Events legend legend
81	Univariate Analysis
82	Multivariate Analysis
83	Relative Risks  (95% CI)  for Total, Fatal and Nonfatal MI Associated With Alcohol Consumption Among Men With Type 2 Diabetes  (n = 2,419)  Enrolled in the Health Professionals’ Follow-up Study  (1986–1996)
84	Multivariate * RR  (95% CI)  of Total CHD Associated with Alcohol Consumption Among Men With Type 2 Diabetes  (n = 2,419)  Enrolled in the Health Professionals’ Follow-up Study  (1986–1996)
85	Relative Risk  (95% CI)  of CHD by Types of Alcoholic Beverage Among Men With Type 2 Diabetes  (n = 2,419)
86	Amplitude of Paced P Waves
87	Duration of Paced P Waves
88	Evaluation of Surface Electrocardiographic Criteria
89	Effects of Placebo or Oral Conjugated Equine Estrogen on Glycosylated Hemoglobin and Lipid Levels in Type II Diabetic Postmenopausal Women
90	Effects of Placebo or Oral Conjugated Equine Estrogen on Endothelial Function in Type II Diabetic Postmenopausal Women
91	Sensitivity, Specificity and Predictive Accuracy for Complete Isthmus Block legend
92	Comparison of Patients With Pure AFl and Patients With Paroxysmal AF legend
93	Individual Clinical and Echocardiographic Parameters of Patients With a Thrombogenic Milieu legend
94	Activation Mapping of the Right and Left Side of the Anterior IAS in Patients With Focal Atrial Tachycardia Originating Next to the Atrioventricular Node legend legend
95	Polarity of the P-Wave During Atrial Tachycardia legend
96	Mutations in MYBPC3That Cause Hypertrophic Cardiomyopathy legend
97	Clinical Features of Index Patients and Family Members Carrying MYBPC3 Mutations legend
98	Hemodynamic Effects of Interventions legend
99	Noninvasive Risk Assessment
100	Results of Electrophysiological Study legend
101	Symptoms During First ICD Therapy in Patients According to the Presenting Arrhythmia legend
102	Clinical Variables in Groups Defined by the Presence or Absence of Hypertension or Diabetes legend
103	Diastolic Filling Parameters in Groups Defined by the Presence or Absence of Hypertension or Diabetes legend
104	Diastolic Filling Parameters in Groups Defined by the Presence or Absence of Hypertension or Diabetes ∗   legend
105	Indices of Diabetes Control and LV Diastolic Filling in the Diabetic Population legend
106	Electrophysiologic Parameters of Two Initiation Patterns of AF legend
107	Electrophysiologic Parameters: Relationship With Left Atrium Enlargement legend
108	Ventricular Tachycardia Morphology, Mapping and Ablation Sites
109	Predictive Value of Various Echocardiographic Parameters legend legend
110	Effects of Treatment on Number of Defibrillation, Postresuscitation Ventricular Arrhythmias and Duration of Survival legend
111	Adrenergic Receptors Actions on the Heart and Peripheral Arteries legend
112	Global Distribution of Atrial Ectopic Foci Appearing Successful Electrical Cardioversion of Persistent AF With and Without Antiarrhythmic Drugs legend
113	A Comparison of Women With and Without a History of Anxiety Disorders on Three Indices of CAD Severity legend
114	Risk of Inducing Electrophysiologic Abnormalities With a Baseball Propelled at 30 mph and Impacting the Chest Wall at Different Anatomic Sites During the Vulnerable Time Period for Induction of Ventricular Fibrillation  (10 to 30 ms Before the T wave Peak)  legend
115	Mean Values of Age-Standardized Factors for Men 35 to 65 Years Old With  (MCE+)  and Without  (MCE−)  Development of MCEs Within 10 Years legend
116	Relative Risk of MCEs According to Elevated Lp (a)  and Other Risk Factors legend
117	Mean Values and Prevalences of Age-Standardized Risk Factors of Men With Estimated Global Risk in the 4th and 5th MLF Quintiles and With Lp (a)  < or ≥ 0.20 g/liter legend legend
118	Parameters of the Ablation Procedure legend
119	Effects of Lower Body Negative Pressure on Hemodynamics and Doppler Indices legend
120	Effects of Saline Solution Infusion on Hemodynamics and Doppler Indices legend
121	Relationship Between Echocardiographic Indices and Pulmonary Capillary Wedge Pressures legend
122	Apolipoprotein E Genotypes and Response of Plasma Lipids to Treatment With Fluvastatin  (n = 320)  legend
123	Apolipoprotein E Genotypes and Response of Coronary Atherosclerosis and Clinical Events to Treatment With Fluvastatin  (n = 287)  legend legend
124	Lipoproteins and Glucose Before and After Five High-Fat Meals in 10 Healthy Subjects legend
125	Heart Rate, Blood Pressure, and Brachial Artery Blood Flow, Diameter, and Flow-Mediated Vasodilation Before and After Five High-Fat Meals in 10 Healthy Subjects legend
126	Preoperative Clinical and Operative Data legend legend
127	Clinical and Hemodynamic Outcomes and Valve Function legend legend
128	Doppler Echocardiographic Variables in Patients Grouped According to Pulmonary Venous and Mitral Flow Indices legend legend
129	Interobserver Variability in Patients With Optimal or Near Optimal Pulmonary Venous Flow Velocity Recordings legend legend
130	Predictors of Cardiac Events  (Cardiac Death or Hospitalization for Worsening Heart Failure)  as Assessed by Univariate Cox Model legend
131	Predictors of Clinical Events at Multivariate Cox Models legend
132	Angiographic Data in All 39 Patients and in 16 Patients Undergoing Hypothermia Who Underwent Angiography for Suspected Acute Coronary Syndrome legend
133	Data of Mild Hypothermia Treatment ∗
134	Cerebral Performance Categories at Hospital Discharge in 23 Patients Undergoing Mild Hypothermia
135	Effect of Unsuccessful Radiofrequency Lesions legend legend
136	Pacing at 120 Beats/Min legend legend
137	Summary of Postnatally and Antenatally Diagnosed DAA legend
138	Histology of the Ductal Tissue legend
139	Results of Exercise Testing legend legend
140	Lipid Profiles and Vitamin E Concentrations Before Treatment in the Placebo and Active Therapy Subgroups legend legend
141	Individual Improvement of Exercise Capacity and Quality of Life During Both Programs legend legend
142	Clinical and Exercise Test Data on the Early Exercise Test Group  (n = 216; Mean ± Standard Error of the Mean or the Number of Patients, With Percentages Within that Group in Brackets)  legend
143	Clinical and Investigational Data on the Six Groups of Patients  (n = 540; Mean ± Standard Error of the Mean or the Number of Patients, With Percentages Within that Group in Brackets)  legend
144	Follow-up Information on the Patients Discharged Alive  (n = 510; the Number of Patients, With Percentages Within that Group in Brackets)  legend
145	Hemodynamic and pH Data ∗   legend
146	Transmural MBF ∗ in Lased and Nonlased Regions 1 and 6 h post-TMR legend
147	Mean MWC in Lased and Nonlased Regions 6 h Post-TMR legend
148	Cardiac Catheterization and Electrophysiology Study Results legend
149	Radiofrequency Ablation of Supraventricular Tachycardias and Other Procedural Issues legend
150	Current Patient Status at Last Follow-up legend
151	End-Tidal Carbon Dioxide Before Arrest and During Cardiopulmonary Resuscitation
152	Hemodynamic, Left Ventricle Function, ANP and BNP Data of the Two Groups According to ECG Pattern legend
153	Two-Dimensional Echocardiographic Data According to ECG Pattern legend
154	Transmitral Doppler Variables in Patients Grouped According to ECG Pattern legend legend
155	Exercise Treadmill Data During Symptom-Limited Treadmill Exercise Testing According to ECG Pattern
156	Procedural Variables: Clopidogrel versus Ticlopidine
157	30-Day Clinical Outcomes: Clopidogrel Versus Ticlopidine legend
158	In-Hospital Hemorrhagic Complications legend
159	Comparison Between the Group That Underwent Direct  (Group 1)  and the Group That Underwent Traditional  (Group 2)  Single-Vessel Stent Implantation
160	Angiographic Patterns and Distribution of Stigmata of an Impaired Coronary Blood Flow in the Subgroups I to III
161	Effects of Metoprolol or Carvedilol on Symptoms, Exercise Capacity, Blood Pressure and Heart Rate  (Mean ± SEM)  legend
162	Effect of Metoprolol or Carvedilol Therapy on Systolic and Diastolic LV Function legend
163	Effect of Metoprolol or Carvedilol on Spectral and Time Domain HRV Intervals legend
164	Cardiac Troponin I, CK and CK-MB levels in 118 Patients Undergoing RF Ablation and in 39 Patients  (Controls)  Undergoing Electrophysiologic Studies legend
165	Procedural Factors Associated With Higher Cardiac Troponin I Levels After RF Ablation legend
166	Discharge Treatments by Location of Ventricular Arrhythmia Presentation legend
167	Mortality Rate by Location of Presentation
168	Clinical Variables for CK-MB Elevation in 1,675 Patients legend
169	Procedural Complications in CK-MB Elevation and Normal CK-MB Group legend
170	Multivariate Predictors of CK-MB Elevation legend
171	In-Hospital Course and Adverse Cardiac Events in all Patients legend
172	Ventricular Arrhythmias Detected During Follow-up legend
173	Type of Recurrence in Relation to Induced Arrhythmia at the Electrophysiologic Study legend
174	Hemodynamic Data legend
175	Hematologic Data legend
176	Renal Involvement legend
177	Comparative Clinical and Echocardiographic Data in the Present Study Compared With That in a Previously Published Series legend
178	Surgical Procedures in Addition to Arterial Switch Operation  (ASO)  legend
179	Operative and Postoperative Variables ∗   legend
180	Univariate Analysis of Risk Factors for Early Mortality legend
181	Multivariate Analysis of Risk Factors for Early Mortality legend
182	Effects of Treatments in Patients With High Remnants Levels legend
183	Effects of Treatments in Patients With Low Remnants Levels
184	The Relationship Between the Number of ST Segment Episodes and the Level of Cardiac Troponin T at Inclusion Among Patients in Whom Both ST Segment Monitoring and Biochemical Analyses Were Performed  (n = 213)  legend
185	Univariate Analysis of Selected Risk Variables for Cardiac Death/AMI at 30 Days legend legend
186	Multivariate Stepwise Cox Regression Analysis of Potential Risk Variables in Order to Detect Independent Predictors of Cardiac Death or Acute Myocardial Infarction at 30 Days legend
187	The Relationship Between the Number of ST Segment Episodes and the Level of Cardiac Troponin T at Inclusion Among Patients With Unstable Angina Pectoris in Whom Both ST Segment Monitoring and Biochemical Analyses Were Performed  (n = 140)  legend
188	Occurrence of Cardiac Death/AMI at 30 Days According to the Level of Cardiac Troponin T at Inclusion and Continuous ST Segment Monitoring in the Subset of Patients With Unstable Angina Pectoris  (n = 152)  legend
189	Precipitator of Cardiac Events in Symptomatic LQTS1and LQTS2Carriers legend
190	Prevalence of Spontaneous Ventricular Arrhythmias During Holter Monitoring and Reduced Left Ventricular Ejection Fraction in 657 Patients Following Myocardial Infarction legend
191	Reasons for Not Performing Programmed Ventricular Stimulation in 304 Patients With Abnormal Holter ECG or Reduced EF legend
192	Response to Programmed Ventricular Stimulation in 146 Patients Following Acute Myocardial Infarction legend
193	Predictors of Arrhythmic Events and Non-Sudden Cardiac Death in 657 post-MI Patients legend
194	Independent Risk Factors for Arrhythmic Events and Non-Sudden Cardiac Death in 657 Patients Following Myocardial Infarction legend
195	Distribution and Cause of Implantable Cardioverter-Defibrillator Therapies During Follow-up legend
196	Clinical Outcome of Patients Relative to Response at Programmed Electrical Stimulation  legend
197	Clinical Outcome of Patients With Coronary Artery Disease Relative to Response at Programmed Electrical Stimulation
198	Hemodynamic Variables of Study Subjects legend
199	Plasma, Lipid, Lipoprotein and Apolipoprotein Levels for Placebo and Bezafibrate Groups During the 5-Year Follow-up legend
200	Left Ventricular Inflow and Outflow Tract Doppler Velocities and Timing  legend
201	Right Ventricular and Septal Long Axis Function legend
202	Right Ventricular Inflow and Outflow Values  legend
203	Clinical Variables for Patients With and Without Echocardiographic Evidence for Carcinoid Heart Disease
204	Symptom Duration and Urinary  ∗ 5-HIAA Levels in Patients With Stable and Progressive CVHD
205	Predictors of Carcinoid Heart Disease Progression
206	Study Groups legend
207	QCA Assessment of Arterial and Balloon Diameter at the Site of Intervention legend
208	Morphometry
209	Assessment of Cell Proliferation  (% BrdU-Positive Cells)   legend
210	Aortic Homograft Valves: Hemodynamic Results in 57 ∗ Patients 1 Week and 7 Months Postoperatively  legend legend legend
211	Aortic Homograft Valves: Results by Annulus Diameter in 57 ∗ patients 7 Months Postoperatively legend legend
212	Aortic Homograft Valves: Results at Rest and at Peak Symptom-limited Supine Exercise in 31 Patients legend legend
213	Effect of Radiofrequency Current Application According to the Type of Site  legend
214	Associated Cardiac Lesions in 101 RAI Patients  legend
215	Palliative Procedures and Outcome in 65 RAI Patients legend
216	Postoperative Supraventricular Tachycardia  (SVT)  and Early Surgical Death legend
217	Electrophysiological Data in Seven RAI Patients
218	Patient Profiles  legend
219	Echocardiographic Values legend
220	Lipid and Alpha-Tocopherol Serum Levels  legend
221	Vasodilation and Blood Flow Responses
222	Selection criteria in SICCO Study  legend
223	Clinical Events legend
224	Clinical Status at Follow-Up  (mean 34 ± 5 months)  ∗   legend
225	Predictors for Occurrence of Major Adverse Cardiac Events ∗   legend
226	Hemodynamic Variables Before and After Balloon Mitral Valvotomy and at Follow-Up in Group I Patients  legend
227	Pathologic Findings After Emergent Balloon Mitral Valvotomy legend
228	Specific Congenital Heart Defects and Incidence of Sudden and Nonsudden Cardiac Death  legend
229	Probability of Sudden Death-Free Survival by Surgical Era and Duration of Follow-Up  legend
230	Probability of Sudden Death-Free Survival by Age at Operation and Duration of Postoperative Follow-Up  legend
231	Clinical Details of the Subjects  legend
232	Neuropathic Details of the Subjects ∗
233	Change in Heart Rate and Systolic Blood Pressure Before and After Adenosine Administration ∗
234	Study Groups and Estradiol Levels
235	Incidence and Crude Relative Risk of Thromboembolic Events According to Gender and Left Ventricular Ejection Fraction Quartiles in Studies of Left Ventricular Dysfunction  (SOLVD)  Trial  a
236	Risks of Anticoagulation: Rates of Major Hemorrhage
237	Comparisons of Quality of Life Scores Between Patients After Atrioventricular Junction Ablation and Atrioventricular Junction Modification
238	Comparisons of Cardiac Performance Between Patients After Atrioventricular Junction Ablation and Atrioventricular Junction Modification
239	Comparisons of Quality of Life and Cardiac Performance Between Patients With Paroxysmal Atrial Fibrillation and Chronic Atrial Fibrillation After Atrioventricular Junction Ablation
240	Comparisons of Quality of Life and Cardiac Performance Between Patients With Paroxysmal Atrial Fibrillation and Chronic Atrial Fibrillation After Atrioventricular Junction Modification
241	In-Hospital Outcome and Follow-Up Events at 1 Year by Study Period
242	Most Aggressive Therapy  a  by Study Period for Patients Who Were Alive and Angina Free at 1 Year
243	Rates and Relative Risks of Events at 1 Year: Comparison of the NHLBI PTCA II and NACI Registries
244	Bundle Branch Blocks After Percutaneous Transluminal Septal Myocardial Ablation
245	Costs, Length of Stay and Complications
246	Univariate Predictors of Time to Cardiac Event
247	Multivariate Predictors of Time to Cardiac Event
248	Lesion Morphology by Coronary Angiography
249	Quantitative Coronary Angiography
250	Electrophysiologic Data
251	Contribution of Sudden Death to Total Mortality in Relation to Gender in Different Age Groups
252	Site of Sudden Cardiac Arrest in 501 Victims
253	Complaints in 227 Witnessed Patients Before Sudden Cardiac Arrest
254	Angiographic Findings After Primary Angioplasty and Abrupt Coronary Closure
255	Intravascular Ultrasound Findings and Abrupt Closure
256	Postangioplasty Angiographic and Intravascular Ultrasound Variables as Predictors of Abrupt Coronary Occlusion
257	Hemodynamic Measurements
258	Exercise Electrocardiographic and Scintigraphic Test Results Versus Mortality
259	Mortality in ACME Follow-Up Study
260	Late Coronary and Revascularization Events in ACME Study  a
261	Hemodynamic Data
262	Cardiac Release Kinetics of Endothelin After Myocardial Ischemia  a
263	Measurements of Diffuse Capacity of Carbon Monoxide
264	Adverse Events
265	Results of Programmed Ventricular Stimulation in Relation to Type of Underlying Heart Disease
266	Comparison of Patients With and Without Suppression of VT/VF Inducibility After d,l-Sotalol
267	Intervals Measured During Ventricular Tachycardia, Responses to Pacing During Ventricular Tachycardia and Sinus Rhythm and Presence of Isolated Diastolic Potential During Sinus Rhythm
268	Comparison of Exercise Time, Peak Heart Rate, Functional Class and Subjective Symptom Score Among the Three Pacing Modes
269	Effects of Lovastatin, Vitamin E and Amlodipine on Serum Malondialdehyde, Cholesterol, Vitamin E and Plasma Superoxide Dismutase Activity in High Cholesterol–Fed Rabbits
270	Effects of Lovastatin and Amlodipine on Low Density Lipoprotein Oxidation Induced by Leukocytes and on Superoxide Dismutase Activity in Leukocytes
271	Correlation Coefficients for Continuous Predictors of Lag Phase in 45 Subjects With Coronary Artery Disease
272	Univariate Predictive Value of High Resolution Dimension in Cox Regression Model By Therapy Group Status
273	Multivariate Cox Regression Model of Arrhythmic Death/Cardiac Arrest
274	Multivariate Cox Regression Model of Nonarrhythmic Death
275	Preoperative and Postoperative Hemodynamic Data by Group
276	Surgical Procedures by Group
277	Comparison Between Survivors and Early Deaths
278	Study Drug Treatment
279	Compliance With Study Drug Treatment
280	Clinical Outcome Through 14 Days  a
281	Endothelium-Dependent Relaxation of Segments of Canine Coronary Arteries With Endothelium
282	Endothelium-Independent Relaxation of Segments of Canine Coronary Arteries
283	Endothelium-Independent Vascular Smooth Muscle Contractions of Segments of Canine Coronary Arteries
284	Hemodynamic Response to Exercise at Low and Conventional Work Loads in 11 Study Patients
285	Left Ventricular Response to Exercise at Low and Conventional Work Loads in Nine Study Patients
286	Angiographic Data
287	Clinical, Echocardiographic and Myocardial Scintigraphic Findings in 12 Patients With Familial Amyloid Polyneuropathy
288	Effect of Dalteparin on the Rate of Death or Myocardial Infarction in Relation to Troponin T Level <0.1 or ≥0.1 μg/liter at Inclusion  (n = 971)
289	Univariate and Multivariate Logistic Regression Analysis Evaluating the Effect of Randomized Treatment, Troponin T Level and Interaction Between Treatment and Troponin T Level on the Rate of Death or Myocardial Infarction During 40 Days of Follow-Up  (n = 971)
290	Burden Analysis of Rare, Protein-Altering Variants in DCM-Related Genes Between Cohorts
291	Cardiac Involvement in the Cohort
292	PREVAIL Primary Efficacy Endpoints
293	Efficacy Rates at 5 Years  (2:1 Randomization)
294	5-Year Patient-Level Meta-Analysis of PROTECT AF and PREVAIL  (2:1 Randomization)
295	Linear Regression Analysis Evaluating Predictors of Left Ventricular Mass
296	Univariate Analyses
297	Multivariable Analyses  ∗
298	Event Rates According to Device Type and Midwall Fibrosis Status  ∗
299	Outcomes
300	Definitions of Major Stroke, Minor Stroke, and Myocardial Infarction in the Included Trials
301	Absolute Risk Metrics of Outcomes of Major Interest
302	30-Day and 1-Year Clinical Outcomes
303	Echocardiographic Outcomes
304	Prevalence of Medication Use or Lifestyle Counseling in Patients With PAD Seeing Physicians in U.S. Ambulatory Care Visits, 2006 to 2013
305	Overview of Pathogenic and Likely Pathogenic Variants in SADS Cohort
306	Association of Predictors and Positive Post-Mortem Genetic Testing
307	Results of Multivariable Cox Regression Analysis
308	Correlation of 2D and Doppler Measurements With LVFilling Pressure
309	Distribution of 2D and Doppler Variables  ∗
310	Accuracy of Diagnosis of Elevated LV Filling Pressure: Total Population
311	Accuracy of Diagnosis of Elevated LV Filling Pressure: Subgroup Analysis
312	Flow Cytometric Analysis
313	Comparison of Standardized Differences in the Means of Continuous and Binary Variable Covariates Between Treatment Groups Before and After Propensity ScoreMatching
314	Novel Loci Significantly Associated With CAD
315	Significant Associations of CAD Variants With Selected CV Risk Factors  ∗
316	Association of CAD Loci With Other Diseases or Traits
317	E1A and E2A Values
318	Comparison of Acetylsalicylic Acid Pharmacokinetics
319	Comparison of Aspirin Cmax in EC-Treated Responders and Nonresponders
320	Group A: Presence of Pathogenic/Likely Pathogenic Mutations
321	Electrocardiogram Parameters
322	Imaging and Biopsies
323	Safety and Clinical Efficacy
324	Recipient cPRA Change 6 Months Post-TESI
325	6-Month Effects of hMSCs on Immunity
326	30-Day Clinical Outcomes
327	Echocardiographic and Functional Outcomes at Day 30 in Survivors With Valve In Situ
328	Clinical Course During Admission
329	Clinical and Functional Outcomes
330	Surgical Variables and Discharge Medications By Treatment Group
331	Outcomes in Patients on DAPT and Aspirin Monotherapy
332	Outcomes in Clinically Important Subgroups
333	Breakdown of the Currently Used Cardiac Magnetic Resonance Imaging Diagnostic Criteria for Left Ventricular Noncompaction in the WholePopulation and by Sex
334	Comparison of Left Ventricular Measures Between Those Meeting 1, 2, 3, or 4 Left Ventricular Noncompaction Criteria
335	RV Deformation
336	RV Geometry and Basal Deformation
337	Clinical Endpoints  ∗
338	Intraoperative Details and In-Hospital, Follow-Up Outcomes
339	Changes of Diameters of the TL, FL, and TA at Different Measuring Levels
340	Full Models: Association of Frailty and Geriatric Domains With Poor Outcomes
341	Clinical Models: Association of Frailty and Geriatric Domains With PoorOutcomes
342	Elevated hs-cTnT and Expected Annual Change in hs-cTnT
343	CHD, Stroke, or Mortality Events
344	Elevated hs-cTnT and Events  ∗
345	Maternal and Fetal Outcomes
346	Coronary Flow and Cardiac Cycle Timing
347	Separated Cumulative Wave Intensity
348	Proportion of Net Cumulative Wave Intensity  (%)  at Rest and Hyperemia
349	Cumulative Incidence
350	Multivariable Predictors of Cardiac Recovery and Prognostic Score System
351	Pharmacotherapy for PCI in Patients With and Without a History of AF
352	Relationship Between Subclinical Atherosclerosis and Clinical Events
353	Binary Disease-Guided Reclassification Approaches  ∗   to Statin Allocation
354	Clinical, Laboratory, Echocardiographic, Hemodynamic, and Pulmonary Parameters Associated With New York Heart Association Class in Patients With Heart Failure With Preserved Ejection Fraction
355	Predictors of Outcome
356	Cox Regression of Multivariate Significant Predictors of Outcome From the Parameter Clusters
357	Early and Late Outcomes
358	Association Between Telomere Measurements and CVD Risk Factors Stratified by Sex and Adjusted by Age  ∗
359	Unmatched and Propensity-Matched In-Hospital Outcomes of Patients With and Without a History of AF Undergoing PCI
360	Risk-Dependent NNS for Subclinical Atherosclerosis
361	Safety Endpoints
362	Plaque Presence and Total Plaque Burden
363	Association of LTL and %LTL<3 kb With Plaque Burden
364	Pathological Macroscopic and Microscopic Criteria Defining Main UnderlyingDiseases
365	Multivariate Analysis of Death During Exercise
366	Clinical Study: CMR-Derived Parameters
367	Sensitivity Analysis of CMR-Derived Parameters in Patients Receiving IV Metoprolol
368	Animal Study: CMR-Derived Parameters
369	Results of Endomyocardial Biopsy
370	CMR Imaging Techniques
371	Diagnostic Performance of 1.5-T CMR Imaging
372	CMR and TTE Results
373	Pressure Volume Loops
374	Pressure–Volume Loops by ECV Level
375	Clinical and Laboratory Data
376	Grayscale- and VH-IVUS Data in the Overall Cohort of 225 Lesions
377	Changes in Efficacy Endpoints and Laboratory Values
378	Subgroup-Specific Effects of Statins According to Minimal Lumen Area, Plaque Burden, and VH-TCFA
379	Changes in Efficacy Endpoints Between Patients With Stable Versus Unstable Angina
380	Univariable Analysis for the Prediction of Changes in % NC and Normalized TAV
381	Odds Ratios of Subclinical Atherosclerosis Presence  (vs. Absence)  for CV Risk Factors  (Age-Adjusted)
382	Diagnostic ORs of Carotid and Femoral Plaques for Detection of Positive  (≥1)  or High  (≥300)  CACS, Adjusted for CV Risk Factors and Age, and Changes in Areas Under the Curve for Prediction
383	Relationship of Risk Factors in 1998/1999 and CAC Agatston Scores in the CHS-CS  (n= 311 Free of CVD in 1998/1999)   ∗
384	Causes of Death by Dementia Status to 2015 in the CHS-CS  (n= 422 [79%] of532Deaths)
385	Death and Dementia Rates  ∗   to 2011 and CAC Agatston Score Among CHS-CS Participants, White Participants Only, Alive, Not Demented, and No CVD at 1998/1999 by Sex
386	Age-Adjusted Incidence of CHD  (Excluding Participants With CVD [CHD, CHF, Stroke, MI] at 1998/1999)  and Dementia by Carotid Artery Measures and ABI by Sex Among CHS-CS Participants, White Participants Only
387	Comparison of Incidence of Dementia and CHD by Age, Race, and Sex in 1998/1999 Among CHS-CS Participants With CACMeasurement Only
388	In-Hospital Procedures, Events, and Disposition of AMI Survivors, According to Presence or Absence of Cardiogenic Shock
389	Early and Late Outcomes of Hospital Survivors of AMI According to Presence or Absence of Cardiogenic Shock
390	Early and Late Outcomes of Hospital Survivors of AMI and Cardiogenic Shock According To Myocardial Infarction Type
391	Clinical Features of Affected Patients With ALPK3 Mutations
392	6-Month Secondary Endpoints by Intention-to-Treat
393	Adverse Drug Reactions Reported in CYCLE
394	Echocardiographic, Histological, and Flow Cytometric Results
395	Association of Principal Component Factors With Clinical Outcomes in Chronic HF Cohort  (HF-ACTION)
396	CMR Imaging  ∗
397	Secondary Endpoints
398	30-day Adverse Cardiac Events
399	Safety Endpoints
400	Summary of Outcomes by Study Groups
401	Univariate and Multivariate Cox Regression Analyses of Potential Risk Factors for VT Recurrence
402	Hemodynamic Assessment  (pre-TAVR)
403	Procedural Evaluation and Performance of Patients Undergoing TAVR
404	Post-Procedure TAVR Valve Performance
405	Cardiovascular and Device Complications  (Prior to Discharge)  of Patients Undergoing TAVR
406	In-Hospital Mortality and Cause of Death of Patients Undergoing TAVR
407	Periprocedural Details in the CR and IRA-Only Groups
408	Pre-Discharge and Follow-Up CMR
409	Clinical Outcomes
410	Modifiable Risk Factors by Sex and Country
411	Cardiorespiratory Fitness Gain
412	Severity Scores for Potential Outcomes in Anti-SSA/Ro-Exposed Fetuses
413	Cord Blood Biomarkers Associated With Cardiac NL
414	MRI Examination Sequences for Study Scan
415	Summary of HFpEF Diagnosis Guidelines
416	Inclusion Criteria in Selected Previous and Ongoing Clinical Trials and Registries of Patients With HFpEF
417	In-Hospital Course
418	Predictors of the Presence of Severe  (>70%)  Carotid Stenosis  ∗
419	CREST Results in Patient Subgroups  ∗
420	Factors in Choice of Carotid Revascularization Methods
421	Elements of Intensive Medical Therapy in SAMMPRIS Study
422	Annual Risk of Stroke in Patients With AsymptomaticStenosis
423	Current and Future Carotid Stenosis Trials
424	Hazard Ratios  (95% CI)  for Primary and Secondary MACE Endpoints Associated With CAC and cPB
425	Impact of Adding cPB or CAC to Conventional Risk Factors on Model Performance for Prediction of Primary and SecondaryMACE Endpoints
426	Medical Treatment Before Procedure and During Follow-Up
427	HRs of Outcome Events During Follow-Up Depending on Post-Treatment DWI Lesions
428	Patients With HCM-Related Deaths or Major Events and Interventions
429	Univariate and Multivariate Predictors of HCM-Related Mortality or Life-Threatening Event
430	ECG Data for Athletes and ARVC Patients
431	Echocardiographic and CMRI Data for Athletes and ARVC Patients
432	SAECG, Holter Monitor, and Exercise Data for Athletes and ARVC Patients
433	Modified Poisson Regression Analysis of the Associations Between HDL-C/P Ratio, HDL-P Number, HDL-C, and the Progression of Carotid Atherosclerosis
434	Procedural and Post-operative Data
435	Overall Incidence of Complications
436	Odds Ratios for Death Derived From Multivariate Analysis
437	Odds Ratios for Various Complications Derived From Multivariate Analysis
438	Risk Factors for SCD in Patients With DCM
439	Risk Factors for SCD in Patients With HCM
440	Risk Factors for SCD in Patients With LVNC
441	Clinical Outcomes in the As-Treated Population
442	Clinical Parameters of Donors and iDCM Patients  ∗
443	Clinical Data of Patients Included in the Validation Cohort
444	Cardiomyocyte Contractility and Ca2+ Transient Parameters: SlowerContraction and Relaxation Velocities
445	Angiographic Results
446	Major Adverse Clinical Events
447	Comparison of Intraoperative Results and Clinical Outcome in HCM Patients With and Without Chordal Cutting
448	Geometry of the MV Apparatus Before and After Surgical Myectomy in 39 HCM Patients With and 25 Without Chordal Cutting
449	American College of Cardiology In-TrainingExamination Blueprint
450	In-Training Examination Fellow Participants
451	In-Training Examination Statistics
452	Cohort Score Changes Across Fellowship Years
453	Distinguishing Features of LQT1 AMCs
454	Association Between Cardiac Structure and Age Using a Linear Regression Model
455	PROTECT AF and CAP: Largest Data Sets to Evaluate Totality of Data
456	Histopathologic Exclusions  (N = 33)   ∗
457	Indications for Echocardiography
458	PFE Size in Patients Presenting With and Without NE
459	Symptoms in Group 1a and 1b Patients
460	Observed  ∗   Versus Expected †  CVA Rates
461	Clinical Outcomes According to MAGGIC Risk Score Category
462	Occurrence of Pre-Specified Adverse Events by MAGGIC Risk Score Category
463	Clinical Outcomes in PARADIGM-HF Patients  ∗   According to EMPHASIS-HF Risk Score
464	Mortality, MIR, and MIRR
465	Procedural Data and 30-Day Results
466	Functional Status, Echocardiography, and CT Scan Data at 3- and 6-Month Follow-Up
467	Clinical Outcomes at 1 Year
468	Landmark Analysis of Key Clinical Outcomes Between 30 Days and 1Year
469	Echocardiographic Follow-Up at 1 Year
470	Changes in PVL for Balloon- and Self-Expandable Valves: Echocardiography at Discharge Compared With 1 Year  (Patients With Data atBoth Time Points)
471	Procedural Results and Use of Medications During the Trial  ∗
472	Outcome Rates at 12 Months According to Treatment Group
473	Age- and Sex-Adjusted Rates of Peripheral Vascular Interventions, Surgical Revascularization Procedures, and HybridProceduresper 100,000 Medicare Beneficiaries by Year
474	Age- and Sex-Adjusted Rates of Peripheral Vascular Interventions per 100,000 Medicare Beneficiaries by Clinical Setting and Year
475	Total Costs of Peripheral Vascular Intervention by Procedure, Setting, and Year  ∗
476	Differences in Flow and Pressure in the Main Vessel Between the 2 Different Computational Models
477	Types of Late Cardiac Reinterventions
478	Standard 12-Lead and 24-h Holter Electrocardiogram, Bicycle Ergometry, and Echocardiography
479	Results of Additional Diagnostic Tests Performed Only in 2012
480	Univariable and Multivariable Adjusted HRs for the Primary 5-Dose Analysis and the Secondary Analysis Comparing Low (≤25%of Target Dose)  Versus High  (≥50% of Target Dose)  Dose on the Basis of the Pre-Specified Analyses and Using the ExtendedSetofCovariates
481	Sensitivity Analyses Showing Adjusted HRs for 3-Year Mortality Compared With the >50% of Target Dose Group UsingthePre-Specified MV Analysis, and the MV Analysis With the Extended Set of Covariates and Propensity Score Analysis for the 4Beta-Blocker Dose Groups
482	HRs and 95% CIs From MV Analysis of 2-Year Mortality in the 2 Pre-Specified Analyzed Cohorts According to Predictor
483	HRs and 95% CIs From the Multivariable Analysis With the Extended Set of Covariates of 3-Year Mortality in the 4Treated Beta-Blocker Dose Groups
484	Landmark Analysis of the Risk of Clinical Endpoints for Patients With and Without DM Treated With>12 Months Versus≤12Months of Clopidogrel After Index Percutaneous Coronary Revascularization With DES  ∗
485	Landmark Analysis of the Risk of Clinical Endpoints for Patients With and Without DM Treated With>12 Months Versus≤12Months of Clopidogrel After an Index Percutaneous Coronary Revascularization With BMS  ∗
486	Landmark Analysis of the Risk of Clinical Endpoints for Patients With and Without DM Treated With>12 Months Versus≤12Months of Clopidogrel After Percutaneous Coronary Revascularization With DES  ∗
487	Landmark Analysis of the Risk of Clinical Endpoints for Patients With and Without DM Treated With>12 Months Versus≤12Months of Clopidogrel After IndexPercutaneous Coronary Revascularization With BMS  ∗
488	Clinical Data of the Families Analyzed in This Study
489	Overview of Known Human HCN4 Mutations
490	Features Associated With High Risk of Carotid Endarterectomy
491	Multidisciplinary Carotid Stent Guidelines
492	Features Suggested to Increase the Risk of a Carotid Stent Procedure
493	Multivariate and Propensity-Matched Cox Regression Results
494	Subgroup Analysis: Association of Digoxin With Mortality
495	Summary of Published hiPSC Models of Cardiovascular Disease
496	Comparison of Patients With New Versus Those Without New LE After TAVR
497	Recapitulation of the Classification Systems for Cardiomyopathies in the Last50Years
498	Genetic Testing: Position of the Scientific Societies
499	Multivariate Predictors of an Inadequate DSM
500	Adverse Events Stratified by Defibrillation Safety Margin Status
501	Success and Failure of CTO Intervention
502	Associations With CTO Failure After MultivariateAnalysis
503	Associations With Mortality After Multivariate Analysis
504	Clinical and Electrophysiological Factors in Patients With ARVC Who Were orWere Not Implanted With an ICD
505	Predictors of Ventricular Arrhythmias in the 108 Patients With ICDs
506	Predictors of Life-Threatening VT/VF in the Patients With ICDs
507	Patterns of LGE
508	Predictors of Overall Survival After Surgical AVR on Univariate and Multivariate Cox Analysis
509	Major Adverse Events at 30 Days and at 12 Months
510	MitraClip Device Complications
511	Clinical Results
512	Hospitalizations for Heart Failure
513	Safety and Effectiveness Outcomes by MR Cause  (Degenerative or Functional)
514	Coprimary Efficacy Endpoint Results  (Stroke, Systemic Embolism, or Cardiovascular/Unexplained Death)
515	Coprimary Efficacy Endpoint Observed Events by Type: PREVAIL Subjects Only  (Intention-to-Treat)  ∗
516	Late-Ischemic Coprimary Endpoint: PREVAIL Subjects Only  (Intention-to-Treat)
517	Safety Coprimary Endpoint Results and Events by Type  (Intention-to-Treat) : Device Group Only
518	Comparison of Outcomes in Device Patients in PROTECT AF, CAP, and PREVAIL
519	Multivariate Predictors of LV Recovery
520	Cross Tabulation of the Clinical and Device-Derived AF Classifications
521	Cardiac Function Assessed by LV Pressure-Volume Loops in WT and TG Mice
522	6MW Distance by Treatment Group, HF Etiology, and NYHA Functional Class
523	Mortality Rates and HRs for Randomized Treatments, by 6MW Distance Tertile
524	Absolute Risks and Negative Predictive Values for Myocardial Infarction or Death at 30, 180, and 365 Days After Discharge From the ED  ∗
525	The 12 Most Common Discharge Diagnoses for Patients Admitted to Hospital, According to the First High-Sensitivity Cardiac Troponin T Level
526	Details of 15 Patients With Chest Pain and a First High-Sensitivity Cardiac Troponin T Level of<5 ng/l Combined With No Signs of Ischemia on an Electrocardiogram, Who Had a Final Diagnosis of Myocardial Infarction
527	Selected Predictors of Meeting Indications for an ICD at Time of Generator Replacement
528	HRs for Clinical Outcomes of Early Surgery Compared With Conventional Treatment
529	Comparison of Echocardiographic Results Between the Early Surgery and Late Surgery Groups
530	HRs for Clinical Outcomes of Early Surgery Compared With Conventional Treatment in the Propensity Score-Matched Cohort
531	HRs for Clinical Outcomes of Early Surgery Compared With Conventional Treatment According to Age
532	Coronary Grafting Profiles
533	Adjusted HRs for Death Following Off-Pump CABG Compared With On-Pump CABG
534	HRs for Death Following Off-Pump CABG Compared With On-Pump CABG: Stratified Analysis Based on Operative Years in Quintiles
535	Adjusted HRs for Death Following Off-Pump CABG Compared With On-Pump CABG: Stratified by Operators and Grafting Profiles
536	Inotropic Drugs: Mechanisms and Outcomes
537	EVEREST II Randomized Trial
538	COAPT High Risk Randomized Trial
539	RESHAPE-HF Randomized Trial
540	European Society of Cardiology Classification of Changes of the Athlete's Electrocardiogram
541	Prevalence of Group 1 and Group 2 ECG Patterns inNonathletes Compared With Athletes
542	Hazard Ratios, 95% CI, and p Values for Different Variables and Thresholds of BNP
543	1-Year All-Cause Mortality According to In-Hospital BARC Bleeding Type
544	1-Year All-Cause Mortality According to In-hospital Bleeding Status for the Different Bleeding Definitions
545	Discrimination of Cox Regression Models for 1-Year Mortality in STEMI Patients
546	One-Year All-Cause Mortality According to BARC Bleeding Data Elements
547	Clinical and Angiographic Data
548	Infarct Size in Relation to Myocardium at Risk in the Total Population and Subgroups
549	Clinical Events at Day 45 ± 15
550	Cardiac MRI, Biomarker, ECG, and Angiographic End Points
551	Clinical Studies With Pharmacological Strategies Against Integrins
552	Clinical Studies With Pharmacological Strategies Against the Complement Cascade
553	Clinical Studies With Pharmacological Strategies Against Cytokines
554	Clinical Studies With Pharmacological Strategies Against Metalloproteinases
555	Sources Used to Identify Sudden Deaths in NCAAAthletes
556	Mortality Rates in NCAA Athletes Compared With the General Population
557	Mortality Rates in NCAA Athletes Compared With the General Population Stratified According to Race/Ethnicity
558	Yield of Downstream Testing After ETT
559	Predictors of Negative Downstream Tests and No Events
560	Risk Prediction Model for 90-Day Waiting List Mortality  ∗
561	Distribution of Risk Factors for Waiting List Mortality Among Risk Groups
562	Risk Prediction Models for 90-Day and 1-Year Post-Transplantation Mortality
563	Effects of History of IAT on HF/Death in Comparing CRT-D to ICD Treatment in Patients With LBBB
564	Effects of In-Trial Development of IAT Comparing CRT-D to ICD in Patients With LBBB on the Endpoint of HF/Death
565	Clinical Outcomes After Any Cardioversion, Within 30Days, in Patients Assigned to Either Warfarin orApixaban
566	Crude and Multivariable-Adjusted HRs of Acute Myocardial Infarction and Heart Failure, by Categories of BMI and Metabolic Status
567	HRs of AMI and HF, by Categories of BMI and Metabolic Status
568	HRs of AMI and HF, by Trajectories of BMI and by Metabolic Status
569	Clinical Outcomes in Diabetic Patients in the High-Risk Cohort of the PARTNER Trial
570	Echocardiographic and Laboratory Data in Diabetic Patients in the High-Risk Cohort of the PARTNER Trial
571	Symptoms, Quality of Life, and 6-Min Walk Distance in Diabetic Patients in the High-Risk Cohort of the PARTNER Trial
572	Resource Use and Cost
573	Echocardiographic Measurements at 1-Week Post-Myocardial Infarction
574	Clinical Outcomes
575	TTE and CMR Parameters in HCM Patients
576	Pearson Correlation Coefficients of Significantly Increased miRNAs and Prognostic Clinical Parameters of HCM
577	Recommended Frailty Assessment Tools
578	Systematic Review of Frailty in Cardiovascular Disease
579	Baseline Characteristics Stratified by Presence or Absence of Subsequent Adverse Events
580	Predictors of Death or Ventricular Tachycardia
581	Comparison of Findings on Cardiac PET Examination Versus Clinical Criteria and Extra-Cardiac Findings
582	Plasma Concentrations of Total Dabigatran After Oral Administration of Dabigatran 110 or DE 150, and Dose-Normalized Concentrations
583	Trough Concentrations of Dabigatran  (ng/ml/mg)  Grouped by Outcome Event Occurrence
584	Surrogate Markers of Right Ventricular Function Among CCMP, NICMP, and ICMP
585	Clinical Outcomes of All Groups
586	Multivariate Cox Regression Analyses for All-Cause and Cardiovascular Mortality at 5 Years
587	Performance of the Models for All-Cause Mortality at 5 Years
588	Performance of the Models for Cardiovascular Mortality at 5 Years
589	Direct Comparison of Performance for All-Cause and Cardiovascular Mortality at 5 Years of Models Containing Gal-3 and ST2
590	Trends in Short-Term Mechanical Circulatory Support Outcomes
591	Management by Indication for Hospital Stay From 2008 to 2011
592	Multivariable Analysis of Mortality
593	Multivariable Analysis of Total Hospital Costs
594	Genes Associated With LVNC
595	ABR and ΔABR in Patients and Controls
596	Correlation Between ABR and Read-Out Parameters of PET/CT and MRI
597	Prediction of Severe AKI by Biomarker Composites
598	Prediction of AKI >2 Days by Biomarker Composites
599	Prediction of Transient AKI by Biomarker Composites
600	Velocity Vector Display Data in Obstructive HCM, NonobHCM, andControlPatients
601	Maximum Vortex in Obstructive HCM, NonobHCM, andControls
602	Multivariable Logistic Regression of Risk of In-Hospital Major Bleed and 30-Day Mortality
603	Impact of Radial Access Site on the ORs for 30-Day Mortality Outcomes Stratified According to Mehran Bleeding Score  (TFA as Comparator)  in a Propensity Score–Matched Cohort
604	Main Vortex Features Averaged During Diastole for the 3 Study Populations
605	Determinants of Relative Vortex Filling Fraction
606	Medication at Study Entry
607	Results of Body Composition Analysis, Treadmill Exercise Test, Holter Electrocardiography and Biomarker Analyses inControlSubjects and in Patients With CRC or CHF
608	Results of Body Composition Analysis, Treadmill Exercise Test, Echocardiography, Holter Electrocardiography and Biomarker Analyses in Chemotherapy-Treated Patients and in Therapy-Naïve Patients
609	Simple Regression Analyses  (With the Respective p Value)  With Peak VO2  (ml/min)  Serving as the Dependent Variable in Control Subjects and inPatients WithCRCor CHF
610	Cardiovascular Adverse Outcomes in Relation to the Extent of LV Trabeculations
611	AF Outcomes
612	Overall Mortality or Cardiovascular Events at Follow-Up
613	Univariate and Multivariate Predictors of the Composite Endpoint of Overall Mortality or Cardiovascular Event
614	Effect of Treatment on Lipid Parameters
615	Effect of Treatment on Lipid Parameters in Patients With and Without Diabetes
616	Adverse Events Reported and Laboratory Abnormalities of Interest
617	Unadjusted Comparison of Primary and Secondary Endpoints for the 3 Groups
618	Propensity-Adjusted 2-Staged Group and 3-Group Comparisons for the Primary Composite Endpoint
619	ACTION Registry–GWTG Processes of Care Metrics: Composite Metric Performance  (2011)
620	ACTION Registry–GWTG Processes of Care Metrics: AMI Institutional Performance Measures  (2011)
621	ACTION Registry–GWTG Processes of Care Metrics: AMI Institutional Quality Metrics  (2011)
622	CathPCI Registry Processes of Care Metrics: PCIAppropriate Use Criteria Metrics  (2011)
623	Quantitative and Qualitative CMR Findings in the Study Population
624	Clinical Presentation and Management of CoronaryObstruction Following TAVI  (n= 44)
625	Computed Tomography Data, According to the Occurrence of Coronary Obstruction Following TAVI
626	CT Data From the Case-Matched Analysis, According to the Occurrence of CoronaryObstruction Following TAVI
627	Changes in Hemodynamic and Phase Contrast Parameters During Acute Embolization
628	Changes in Hemodynamic and Phase Contrast Parameters During Vasodilator Testing
629	Estimates  (95% Confidence Intervals)  of Association Between Circulating Leukocyte-Derived Microparticles and PlaqueInstability
630	InVitro Mitochondrial Chain Complex Activities According to Post-Operative Atrial Fibrillation Onset
631	Pre-Operative Variables Associated With Post-OperativeAtrial Fibrillation Onset
632	Studies Investigating Effects of Obesity on Ventricular Mass, Dimensions, and Function in Children and Adolescents
633	Studies Investigating Effects of Obesity on Vascular Structure and Function in Children and Adolescents
634	Studies Investigating the Effects of Obesity on Autonomic Function in Children and Adolescents
635	Correlations Between Hs-cTnT and Echocardiographic Data in 183 HCM Patients
636	Cardiovascular Events in 183 Patients With Normal hs-cTnT Values and With Abnormal Hs-cTnT Values  (Univariate Analysis)
637	Multivariate Analysis of All Cardiovascular Events or Cardiac Events
638	Univariate and Multivariate Predictors of Definite Thromboembolism After Cardioversion for Atrial Fibrillation
639	Thromboembolic Complications in Patients With No Anticoagulation After Cardioversion of Acute  (<48 h)  Atrial Fibrillation in Previous Studies
640	Blood Work, Nutrition, and Exercise
641	Coronary Artery Status  (n= 203)   ∗
642	Vascular Testing in KD and Control Populations
643	Control Group and KD Patients by Worst Ever Coronary Artery Status
644	Comparison of Each Parameter Between Groups A and B
645	Hemodynamic and Biochemical Profile Before and After LVAD Unloading
646	Serial Echocardiographic Assessment of the Effects of LVAD Unloading on Myocardial Structure and Systolic Function
647	Serial Echocardiographic Assessment of the Effects of LVAD Unloading on Left Ventricular Diastolic Function
648	Key Concepts
649	Classification of High-Sensitivity Cardiac Troponin Assays
650	Interobserver and Intraobserver Variability and Minimal Detectable Change for EF Measurements by All 6 Techniques
651	Interobserver and Intraobserver Variability for EDV and ESV Measurements and Minimal Detectable Change by All 6 Techniques
652	Multivariable Adjusted HRs and 95% CIs for SCD
653	Multivariable Adjusted HRs and 95% CIs for SCD Among Women Without Prior CHD
654	SCD Population-Attributable Fractions
655	Vascular and Biochemical Measures by BMI Categories
656	Associations of Vascular Measures With Adiposity Measures
657	Associations of Birth Weight, Catch-Up Growth, and Persistent Obesity With Vascular Measures  (n = 6,919)
658	Agenda for Establishing the Role of Advanced Lipoprotein Analysis in Individualizing Treatment for Preventing Cardiovascular Disease
659	Cumulative Incidence of Heart Failure or Cardiomyopathy During First 3 Years After Diagnosis by Cancer Therapy
660	Cumulative Incidence of Heart Failure or Cardiomyopathy During the First 3 Years in Breast Cancer Patients Without Adjuvant Therapy Versus Cancer-Free Controls
661	3-Year Unadjusted and Adjusted Incidence Rate Ratios for Heart Failure or Cardiomyopathy
662	Cardiac Morphology, Function, and Regional Fibrosis
663	Relationships With Post-Contrast Ventricular T1 Time
664	Secretion, Biological Effect, and Prognostic Role of Main Inflammatory Markers Related to Atrial Fibrillation
665	Inflammatory Markers Associated With Subtypes of Atrial Fibrillation
666	Hemostatic Factors Conferring the Prothrombotic State in Atrial Fibrillation
667	Comparisons Between the Pathological Processes Underlying Aortic Stenosis and Atherosclerosis
668	Changes in Laboratory Data After Slow Continuous Ultrafiltration
669	Sample Size by LBBB Type and Treatment Group Across Years in the Study From Randomization  (Year 0)  Through Year 3
670	Summary of Ablation Procedures
671	Procedural Details and Medications
672	Angiographic Measures Post-PCI
673	Core Laboratory Electrocardiographic Results
674	Clinical Events at 30-Day Follow-Up
675	Cardiac Magnetic Resonance Imaging Substudy Results at Days 3 to 5
676	Sensitivity and Specificity of QGE LMNA  in 311 Consecutive individuals Blinded to Genotype
677	Impact of Copayment Reductions on Resource Utilization
678	Impact of Copayment Reductions on Changes in Patient, Insurer, and Combined Pharmacy, Medical, and Total Spending
679	Long-Term Post-AMI Outcomes of Patients With Various Levels of Chronic Perceived Stress
680	Main Findings on LV EAM
681	Change in Risk Factor Levels and Lifestyle-Related Factors Between Youth and Adulthood According to MetS Groups in the Bogalusa Heart Study and Cardiovascular Risk in Young Finns Study
682	Cohort Stratified and Pooled RR and 95% CI of High Carotid IMT According to MetS Groups and Decreasing cMetS Score
683	Cohort Stratified and Pooled RR and 95% CI of T2DM According to MetS Groups and Decreasing cMetS Score
684	Multivariate Predictors of In-Hospital Stroke or Death
685	NCDR CAS Risk Score System
686	Completed and Planned RCTs of PCI Compared With CABG for the Treatment of Unprotected Left Main CAD
687	Recommendations Pertaining to Unprotected Left Main Intervention in the American College of Cardiology Foundation/American Heart Association/Society of Cardiovascular Angiography and Intervention 2011 Guidelines for PCI
688	Definitions of Carotid IMT Ultrasonographic Variables
689	HRs  (95% CI)  of Combined Vascular Endpoints per 1 SD Increase for Ultrasonographic Continuous  (Log-Transformed)  Variables
690	HRs  (95% CI)  of Coronary and Cerebrovascular Endpoints per 1 SD Increase for Ultrasonographic Continuous  (Log-Standardized)  Variables
691	Reclassification Statistics for Ultrasonographic Variables as Compared With Classification Based on CC-IMTmean Only in Risk Models With Combined, Coronary, or Cerebrovascular Endpoints
692	Reclassification Statistics Comparing Ultrasonographic Variables and Plaque Information  (Presence of at Least 1 Plaque)  in Risk Models With Combined Vascular Endpoints
693	Reclassification Statistics for the Added Value of Ultrasonographic Variables in Risk Models With Combined Endpoints, Carotid Segments, and Carotid Outcomes as Compared With a Reference Model Based on FRFs Only
694	Risk Reclassification Comparing the Extrapolated 10-Year Risk According to FRFs Before and After Adding ICCAD and IMTmean-max in the Prediction of Combined Vascular Events
695	Correlation Coefficients  (Pearson)  of Univariate Correlations Between Blood Pressure and Arterial Parameters
696	Risk Ratio  (Cox Regression Analysis)  for Total Mortality and Major CV Events According to Blood Pressure and Pulse Wave Velocity
697	Clinical Features of Genotype-Positive Family Members
698	Summary Statistics for HR Measurements, Speed During Exercise, Exercise Duration, and METs During Exercise at Different Treatment Phase
699	Key Input Parameters
700	Base Case Results
701	Probands With AF Enrolled in the Vanderbilt AF Registry  (Cases)  and Controls Who Were Resequenced for Variants in Ion Channel and Non–Ion Channel Genes
702	An Interaction Between Rare  (Ion Channel and Non–Ion Channel)  and Common Genetic Variants to Determine Susceptibility to the Development of Familial AF
703	Genetic Association Between Common and Rare Variants Unstratified and Stratified by Age of Onset and Age of Unaffected Members of the Families
704	Genetic Association of Rare Variants Alone  (Ignoring Common Variants)  Unstratified and Stratified by Age of Onset and Age of Unaffected Members of the Families
705	Allele Frequencies of Chromosome 4q25 Single-Nucleotide Polymorphisms
706	Genetic Association of Common Variants in the Subset of Data With All Subjects Harboring Rare Variants: Unstratified and Stratified by Age of Onset and Age of Unaffected Members of the Families
707	Classification of Patients Into AUC Categories During Study Period
708	Primary Study Outcome: Change in AUC Across Study Period
709	Secondary Study Endpoint: CCTA Use Across Physician Specialties
710	Prevalence of Coronary Artery Calcium by CRP Cutpoints Among Waist Circumference Categories
711	Odds Ratio for Coronary Artery Calcium With High CRP or Framingham Risk Score by BMI Category
712	Correlation Coefficients for CRP and Framingham Risk Score With Aortic Wall Thickness and Aortic Plaque Burden by BMI Category
713	C-Statistic of CRP for Coronary Artery Calcium, Aortic Wall Thickness, and Aortic Plaque Burden by BMI Category
714	Biomarkers Before and After Treatment
715	CMR Protocol
716	Numbers of Patients in Each Group and Reason for Entry Into Group
717	Cardiac Catheterization Data
718	CMR Data
719	Clinical Outcome Across Cohorts
720	Linear Measurements in C+M
721	Surgical Data
722	Pre-Operative MRI Parameters  (n = 118)
723	Changes in MRI Parameters  (n = 67)
724	Comparison Between Patients With Optimal Versus Suboptimal Outcome
725	Independent Predictors for Suboptimal Outcome
726	Clinical Variables of the Population in CMR-1 and CMR-2
727	Multiple Regression Model for the Prediction of Increment of LGE Extent at CMR-2
728	Effect of 3 Months of Ramipril on Measured Parameters
729	Lone AF  ⁎   Using Data From the National Patient Register and Causes of Death Register, Denmark, 1977–2008
730	Lone AF  ⁎   Diagnosed in 9,507 IndividualsAge <60 Years From a Cohort of 3,985,446 Individuals Born in Denmark in 1950 or Later and Followed-Up From 1977 to 2008
731	IRRs of Lone AF in 9,507 Individuals Age <60 Years According to Family History of Lone AF Stratified by Type and Sex of Relative With Lone AF, Denmark, 1977–2008  ⁎
732	Multivariate Analysis: Risk Factors for Life-Threatening Ventricular Tachyarrhythmias in Study Patients
733	Multivariate Analysis: Risk Factors for Appropriate ICD Shocks in Study Patients
734	Spearman Correlations of the Concentrations of HDL-C and HDL-P P)  Among MESA Participants in Study  (n = 5,598) , 2000 to 2002
735	Predicted Difference in cIMT for a 1-SD Greater HDL-C or HDL-P Concentration Among MESA Participants  (n = 5,541) , 2000 to 2002
736	Within-Group Comparisons: Transfemoral Cohort
737	Within-Group Comparisons: Transapical Cohort
738	Between-Group Comparisons From Longitudinal Growth Curve Models
739	Clinical, Laboratory, and Hemodynamic Risk Factor for RV Failure
740	Echocardiographic Risk Factor for RV Failure
741	Predictive Model for RV Failure, Including Michigan Risk Score and Selected Echocardiographic Variables
742	Comparison of the Edwards SAPIEN XT and Medtronic CoreValve Prostheses
743	Procedural Results
744	In-Hospital Outcome
745	Clinical Outcomes at 30 Days
746	Clinical and Cardiac MRI Predictors of Time to Event
747	Relationship of Scar Morphology Variables With Time to Event
748	Multifactorial Analysis of Covariance for the Decadic Logarithm of the Plasma Concentration of PENK-A
749	Parameters for the Assessment of Aortic Stenosis
750	Clinical Data of the Family Members
751	Follow-Up and Treatment of the Family Members
752	FDG-PET Imaging Results
753	Multiple Linear Regression Analyses in the Whole Study Population Using Glucose-Corrected FDG Uptake Parameters
754	Multiple Linear Regression Analyses in Subjects With and Without Diabetic Disease
755	MBF and ΔBOLD SI in Stenosed, Remote, and Normal Segments
756	Performance of BOLD and Perfusion Imaging for Detecting Anatomically Significant CAD Using QCA as the Reference Standard
757	Performance of BOLD Imaging for Detecting Functionally Significant CAD Using Stress Perfusion CMR as the Reference Standard
758	Comparisons of Patients With and Without Pause-Dependent Changes in J-Wave Amplitude
759	Adjusted Risk  (HR)  of All-Cause Mortality and CV Mortality According to Sex in the Overall Population
760	Comparative Evaluation of Plaque Histological Features With Increased Plaque Thermal Difference
761	Comparative Evaluation of Plaque Immunohistological Features With Increased Plaque Thermal Difference
762	Univariate Analysis: All-Cause Mortality
763	Univariate Analysis: Cardiac Mortality
764	Univariate Analysis: SCD
765	Univariate Analysis: Predictors for Incomplete Recovery
766	On-Treatment Medications and Risk Factor Control
767	Serial Change in Atheroma Burden and Vessel Remodeling
768	Assigned Therapy and Measures of Atheroma Burden in Each Clinical Trial
769	Biometric and Echocardiographic Parameters of Mice Fed an Alcohol Diet for 2 Months
770	Subgroup Analysis: Close Agreement Between the iFR and FFR Across Subgroups Analyzed
771	Angiographic Outcomes at 6 Months
772	Angiographic Outcomes at 6 Months According to Type of Restenotic Stent
773	Clinical Outcomes at 6 Months
774	Quantitative Coronary Angiography
775	Clinical Outcomes at 12 Months
776	Hyperemic Stimuli for State-of-the-Art FFR Measurement
777	Reasons for Nonischemic FFR Despite Apparently Tight Stenosis
778	Cardiovascular Parameters 10  (±1)  Years Post-Transplantation
779	Counting of Y Chromosome–Positive/Negative Spindle- to Ovoid-Shaped Nuclei in Areas of Increased Fibrosis
780	Allele Constitution at 2 Loci of the COL3A1 Gene in Donor and Recipient Tissues
781	Prevalence of Peri-Device Flow and Flow Severity On Follow-Up TEE
782	Primary Efficacy Event Rates According to Peri-Device Flow and Warfarin Use
783	Primary Efficacy Event Rates in Patients With and Without Peri-Device Flow
784	Subgroup Estimation of the Effects of TMZ Therapy on Patients With CHF
785	In Vivo Myocardial Energetics Including Cardiac PCr/ATP, Creatine Phosphate Concentration, Cytosolic ADP, ΔG∼ATP, and ATP Flux Through CK
786	Cox Univariate Analysis of Parameters Significantly Associated With Risk of Overall 3-Year Mortality
787	Additional Prognostic Value of Myocardial Viability and Revascularization to Predictors of Survival
788	Multivariate Logistic Regression Analysis
789	Correlation Between Symptoms, Stress Test, and CCTA Findings
790	Predictors of Obstructive Coronary Artery Disease
791	Correlation Between Abnormal Stress Tests, CCTA, and Invasive Angiography
792	Malignant Ventricular Arrhythmias and End-Stage Heart Failure  (N = 269)
793	Identification of Risk Factors for Composite Malignant Ventricular Arrhythmias in 269 Persons Carrying a LMNA Mutation
794	Surrogate Measures of Hibernating Myocardium
795	Positron Emission Tomography
796	Single-Photon Emission Computed Tomography
797	Echocardiography
798	Cardiovascular Magnetic Resonance
799	Hazard Ratio of Death Associated With the Presence of PCA, Compared With the Normal ABI and PAD Groups
800	Variables Associated With Relative Hazard Ratio of Dying
801	PDE5Is for CHF
802	PDE5Is for HAPE and HAPH
803	Blood Pressure Reductions With PDE5Is
804	Enrollment Numbers and Age and Sex Distribution for the Overall Population and for Individual Ethnic Groups
805	Distribution of RF Among Control Subjects and Patients Divided on the Basis of hsCRP <2 or ≥2 mg/l
806	Carotid 3.-T Magnetic Resonance Imaging and B-mode Ultrasound Parameters for Carriers of LCAT Gene Mutations and Controls
807	Preoperative Predictors of Mortality Associated With Type A Dissection
808	Intra-Operative Predictors of Mortality Associated With Type A Dissection
809	Independent Pre-Operative Risk Factors for Mortality in Patients With Acute Type A Aortic Dissection
810	Univariable and Adjusted Multivariable Predictors of the Presence of ≥50% Coronary Stenosis on CCTA Among Patients With a CAC Score of 0  (n = 4,738)
811	Early  ⁎   Revascularization Rates Among Patients With and Without CAC Stratified by Stenosis Severity on CCTA
812	Adverse Events Among Patients From 8 Sites With Composite Endpoint Assessment for MAE During a Median Follow-up of 2.1 Years
813	Hazard Ratios for the Composite Outcome of All-Cause Mortality, Nonfatal MI, and Late Revascularization According to Morise Risk Score, CAC Score, and CCTA
814	Overview of Patient Population and Outcomes
815	Overview of the Intracranial Recanalization Devices
816	Overview and Comparison of the Largest Studies on CAS in Acute Stroke
817	Association of Fetuin-A With Continuous Measures of Subclinical CVD: The Rancho Bernardo Study
818	Association of Fetuin-A With Categorical Definitions of Subclinical CVD: The Rancho Bernardo Study
819	Different Truncating Mutations in the MYBPC3 Gene
820	HR  (95% CI)  for the Relation of Blood Pressure in Early and Mid-Adulthood With All-Cause and CVD Mortality  (N = 18,881) —HAHS
821	HR  (95% CI)  for the Relation of Blood Pressure in Early and Mid-Adulthood With CHD and Stroke Mortality  (N = 18,881) —HAHS
822	Comparisons of HR  (95% CI)  for the Relation of Blood Pressure Patterns in Early Adulthood With CHD Mortality: Our Results in Relation to Previously Published Studies
823	Evaluation of the Performance of Predictive Models After Adding a Urinary Biomarker to the Clinical Model
824	Summary of Biomarker Combinations in the Model: Significance, AUC Improvement, NRI, and IDI
825	National Kidney Foundation Classification of CKD Based on GFR
826	Antiplatelet and Antithrombotic Agents, Recommended Doses, Routes of Elimination, Effect of Renal Failure on Dose, and Potential Strategies to Reverse Their Effect
827	Safety and Efficacy of Antiplatelet and Antithrombotic Agents Stratified by Category of CKD
828	miRs Differentially Expressed  (p < 0.05)  on Screening Microarray and Confirmation of Expression by Individual Taqman Real-Time PCR With Pre-Amplification
829	VAD Support Alters miR Expression But Does Not Induce a “Recovery” MiR Profile
830	SF-36 Score
831	MFI-20 Scores
832	Patients With Detectable MES During the Different Phases of CAS
833	Predictors of Total MES
834	Impact of Periprocedural Events on Health Status Scores at 1-Year Follow-Up
835	Quantitative Cardiac Parameters Before and After Hiatal Hernia Repair Stratified by Left Atrial Compression Severity
836	Respiratory Function Before and After Hiatal Hernia Repair
837	Relationship Between Exercise Capacity Improvement Following Hiatal Hernia Repair and Changes in Cardiorespiratory Parameters
838	Ischemic and Safety Outcomes in the 2 Arms
839	Medication Use in the Study Population at the Time of ICD Implantation, Follow-Up, and First Appropriate ICD Intervention
840	Predictors of Appropriate ICD Intervention
841	Sensitivity and Specificity of hs-cTnT for AMI at Selected Cutoffs, Stratified by Time From Symptom Onset
842	Evaluation of hs-cTnT Use in Clinical Practi Diagnostic Performance of Initial hs-cTnT Level for Predicting Any Subsequent hs-cTnT Elevation
843	Specific Activities at Time of Exertional Sudden Death in 361 Young Adults
844	Cause-Specific Findings in 902 Cases of Adjudicated Unanticipated Sudden Cardiac Death Stratified by Age <35 Years and ≥35 Years in a Cohort Undergoing Active Surveillance
845	Leading Cause-Specific Findings in Adjudicated Unanticipated Sudden Cardiac Death Stratified by Age <35 Years and ≥35 Years and Exertional Status in a Cohort Undergoing Active Surveillance
846	Predictors of LVEF and Change in LVEF at 6 Months  (n = 292)
847	Predictors of Death/Transplantation and HF Hospitalization
848	Adjusted HR of Total and Major CVD Events Associated With Reduction in Clinic and Ambulatory BP During Follow-Up
849	Patient Characteristics, Clinical Outcomes, and Adverse Events  (N = 92)
850	Pre-Operative Vital Clinical Signs and Hemodynamic Data
851	Pre-Operative Laboratory Measurement
852	Multivariate Analysis of Predictors of 90-Day In-Hospital Mortality
853	Anthropometric and Clinical Parameters of HF Patients and Control Group
854	Biochemical and Insulin Sensitivity Parameters of HF Patients and Control Group
855	Tumor Diagnosis Prediction Table
856	Tumor/Myocardium Signal IR
857	Procedural Variables and In-Hospital Outcomes  (n = 35)
858	Outcomes in Patients With and Without sCVD
859	Multivariable Adjusted Risk of Stroke or Death, Stroke, and Death in the Study Population
860	Multivariable Adjusted Risk of Perioperative Stroke During Heart Transplant Hospitalization
861	Lipid Parameters Over Time
862	Magnetic Resonance Parameters Over Time
863	Exercise Parameters Over Time
864	Predictors of the Combined Endpoint of Death or Transplantation  (n = 34)
865	Univariate and Multivariate Analysis
866	VT/PVC Anatomic Localization by Electrocardiography
867	General Features of the 61 Study Patients With HCM
868	Individual Patient Features, Dip-MBF, and Mutational Screening Results
869	Logistic Regression Analysis Assessing Predictors of Genotype-Positive Status
870	Quality of Prospective Studies
871	Quality of Retrospective Studies
872	AUCs for BNP and the RCRI in Predicting Perioperative Outcomes  (n = 632)
873	Incidence of Adverse Cardiac Events Stratified According to the Screening, General Optimal, and Diagnostic BNP Values  (n = 632)
874	Change in Risk Stratification and its Relationship to Frequency of MACEs Following the Application of an NP Threshold
875	Univariate and Adjusted MDCT Plaque Predictors of Coronary Events
876	Univariate Predictors of Mortality
877	Multivariate Predictors of Mortality
878	Morphometric Analyses of Carotid Arteries From WT or Platelet-Derived Growth Factor Beta Receptor F3/F3 Mice 21 Days After Balloon Injury
879	Change in MRI Indexes After Surgery  (x̄ ± s)
880	Change in WMIS by Echocardiography Indexes After Surgery  (x̄ ± s)
881	Change in SPECT Indices After Surgery  (x̄ ± s)
882	Results of 6-Min Walking Test  (x̄ ± s)
883	BNP Value Before and After Surgery  (x̄ ± s)
884	Relative Coding DNA Length Versus Mutation Frequency
885	Sequence Conservation and Missense Mutations in ARVC Genes
886	Sequence Conservation and Missense Mutations in PKP2
887	Sequence Conservation and Missense Mutations in DSG2
888	Predictors of HCM-Related Adverse Events in Univariate and Multivariate Analysis of MVO and Established Major Primary Prevention Risk Factors for Sudden Death
889	Summary of Serial Cardiac Biomarkers of Patients With and Without Trastuzumab-Mediated CM in Entire Population
890	Echocardiographic Parameters of Patients With and Without Trastuzumab-Mediated CM in Entire Population
891	ROC Curve Analysis for TVI and Strain Imaging
892	Cardiac MRI Parameters of Patients With and Without Trastuzumab-Mediated CM in Entire Population
893	Echocardiography Measurements
894	Food and Water Intake by Control and Cav-3 OE Mice
895	Multiple Logistic Regression Analysis to Determine Predictors of Post-CABG Stroke  (n = 33)
896	Association of Post-CABG Stroke With Types of Atherosclerotic Disease
897	Atherosclerotic Diseases in Atherosclerotic Stroke Patients
898	Genes Reported in Association With Nonsyndromic DCM  ⁎
899	Dilated Cardiomyopathy Gene Ontology
900	Considerations for Molecular Genetic Testing
901	Cox Regression Univariate Analysis for All-Cause Death
902	Cox Regression Multivariate Analysis for All-Cause Death
903	Multiple Regression Model: Relation of cfPWV to Risk Factors and Measures of Atherosclerosis/Calcification
904	Within-Pair Comparison of Myocardial Perfusion Imaging Data According to CFR Status
905	Percentage Decrease in Inflammatory Biomarkers per 1-U Increase in CFR
906	Unadjusted Within-Pair Differences in Plasma Inflammatory Biomarker Levels Based on CFR Discordance Status
907	Adjusted Within-Pair Differences in Plasma Inflammatory Biomarker Levels Based on CFR Discordance Status
908	Protocol Required Alert Programming  (Clinical Events)
909	Summary of Time to Decision by Alert Event Type
910	Definition of Compassionate Use Criteria
911	Patient Presenting Factors in the Cardiogenic Shock or ST-Segment Myocardial Infarction PCI Cohort, Overall and Stratified by Compassionate Use
912	In-Hospital Complications and Death, Overall and Stratified by Compassionate Use
913	Adjusted Odds Ratios of Risk of In-Hospital All-Cause Mortality After PCI in the Commonwealth of Massachusetts  ⁎
914	Different Prevalence Reports of Myocardial Scarring/Fibrosis of the LV in Various Nonischemic Cardiac Pathologies as Defined With Qualitative Analysis of LGE Cardiovascular Magnetic Resonance
915	Clinical Studies Using T1 Mapping
916	Adjusted Associations of 2-Year Change in Functional Performance Measures With Mortality and Mobility Loss Among Participants With PAD
917	Frequencies of CAS Severity by the Degree of CAD Severity
918	Multivariate Correlates of Doppler-Defined CAS
919	Predictors of Changes of Ejection Fraction in n-3 PUFA–Treated Patients
920	Hospitalizations During the 12-Month Follow-Up Period
921	Periprocedural  (Within 30 Days)  Outcomes in CEA and CAS Populations
922	Periprocedural Stroke or Death Risk: Subgroup Analysis
923	Hemodynamic and Biochemical Values in All Patients in Cardiogenic Shock
924	Hemodynamic and Biochemical Values in ICM and NICM Patients in Cardiogenic Shock
925	Safety and Efficacy of Use of Tandem Heart Percutaneous Ventricular Assist Devi Complication Rate in Our Center
926	Comparison of Survivors and Nonsurvivors
927	Univariate Analysis of Pre-LVAD Values Between Survivors and Nonsurvivors
928	Multivariate Analysis of Survivors and Nonsurvivors
929	CABG Evaluations, Treatments, and Procedures in Hospital or at Discharge for Index Event  (n = 1,261)
930	Detailed Information on the Randomized Treatment
931	Outcome After Coronary Artery Bypass Graft Surgery in the Study Population
932	Bleeding Complications During and After CABG
933	Bleeding Outcomes in Subgroups With Different Intervals Between Cessation of Study Treatment and CABG  (n = 1,261)
934	Stratified Analyses of Pooled Relative Risk of Atrial Fibrillation for Highest Alcohol Intake Versus Lowest Alcohol Intake
935	Echocardiographic Indexes
936	Pressure-Volume Loop-Derived Indexes
937	Absence of Tumor Formation Related to Intramyocardial CDC or Cardiosphere Injection
938	Summary of AEs Occurring Within 24 h Post-Dose
939	Profiles of Medication at Discharge
940	Clinical Outcomes During Follow-Up
941	Cox Regression Analysis: Predictors of Composite Clinical Outcomes
942	Safety Assessments in 2 Groups
943	Effect of Resistin Transgene on Lesion Formation in Collared Rabbit Carotid Arteries
944	Homology of Mammalian Resistins
945	Sex-Specific Cardiac Outcomes Among 352 HIV-Negative Infants Born to HIV-Positive Mothers, by Exposure to Antiretroviral Therapy  *
946	Cardiac and Anthropomorphic Outcomes Among 352 HIV-Negative Infants Born to HIV-Positive Mothers, by Exposure to Antiretroviral Therapy  *    †
947	IMT Values
948	Core Laboratory Mitral Insufficiency Grades  (0 to 4)  by Randomized Treatment Group and Stratum Over Time
949	Pharmacokinetic Parameters of Met-CCL2 and PA508
950	Cell Counts of Leukocyte Populations
951	In Vivo Assessment of Cardiac Function 7 Days After Myocardial Ischemia/Reperfusion
952	Heparin and Protamine Management During CPB for Both HMS I and II Protocols
953	Heparin and Protamine Management
954	Clinical Outcomes  (p Values From Models Adjusted for Age at Surgery, Surgery Aristotle Score, and Surgeon)
955	Blood Transfusions  (p Values From Models Adjusted for Age at Surgery, Surgery Aristotle Score, and Surgeon)
956	Association of Age, Sex, and Race/Ethnicity With ABI Category, and Age-, Sex-, and Race/Ethnicity-Adjusted Distributions of Risk Factors by ABI Category
957	Risk of Incident Cardiovascular Events by ABI Level
958	Catheterization Laboratory Protocol for Assessing LVAD Function
959	An Example of a Normal Study
960	Comparison of CO and LVAD Flows in Normal and IVR Patients  (LVAD Patients Are in Auto Mode)
961	Subgroup Analysis: Transplant Vasculopathy
962	Angiotensin II Receptor Expression in Subgroups According to Average Biopsy Score
963	Duplex Criteria for Classification of Carotid Stenosis
964	Bilateral Stenosis: Change in Doppler Classification of Contralateral Stenosis After Ipsilateral Stenting
965	Anthropomorphic, Metabolic, and Vascular Profiles by Metabolic Syndrome Status
966	Prevalence of Individual Components and Clusters of Components of the Metabolic Syndrome by Age Quartiles
967	Multiple Regression Models Evaluating the Independent Determinants of Carotid Intima-Medial Thickness
968	Multiple Regression Models Evaluating the Independent Determinants of Carotid Stiffness
969	Mean Adjusted Values of Carotid Intima–Media Thickness and Stiffness, Calculated by the Least Mean Squares Method, in the Absence or Presence of the Metabolic Syndrome
970	Relationship Between Echolucency of Carotid Plaques and Angiographic Complex Coronary Plaques
971	Summary of Coronary Events During the Follow-Up Period in Patients With Stable Coronary Artery Disease
972	Univariate Cox Proportional Hazards Analysis of Risk Factors for a Coronary Event in Patients With Stable Coronary Artery Disease
973	Multivariate Cox Proportional Hazards Analysis of Risk Factors for a Coronary Event in Patients With Stable Coronary Artery Disease
974	Lipid Profile of Hyperlipidemic Patients
975	Lipid Profile of Patients With Carotid Atherosclerosis
976	Basic Procedural Data of Percutaneous Device Closure of Ventricular Septal Defects Via the Transcatheter Approach  (n = 77 Procedures)
977	Adverse Events After Device Closure of Muscular Ventricular Septal Defects  (n = 75 Patients)
978	Follow-Up After Device Closure of Muscular Ventricular Septal Defects: Echocardiographic and Clinical Data
979	Total Mean Hospital- and Physician-Derived Costs of TEE-Guided and Conventional Management Strategies for 833 U.S. Patients Over an Eight-Week Pericardioversion Period
980	Mean Costs and Added Costs * for Treatment of Patients' Adverse Events During the Eight-Week Study Period in the ACUTE Clinical Trial
981	ACUTE Trial Analytic Model of Treatment Costs Using ACUTE Trial Data on 833 Patients
982	ACUTE Trial Analytic Model of Outcomes Costs Using ACUTE Trial Results on 833 Patients
983	ACUTE Trial Analytic Model Summary
984	Patient Population
985	The Extracellular Solutions Used in the Experiments
986	Risk Factors for Postoperative Stroke  (Multivariate Analysis)
987	Dystrophin Average Staining Scores in End-Stage Cardiomyopathy and After Mechanical Support Therapy
988	Retrospective Cohort: In-Hospital Outcomes/Variables
989	Retrospective Cohort: Multivariate Predictors of Long-Term Mortality
990	Case-Matched: In-Hospital Outcomes
991	Multivariate Predictors of Mortality for AF and No AF Populations
992	Risk Factor Prevalence for Patients Undergoing Off-Pump and On-Pump CABG Surgery in New York State, 1997–2000
993	Unadjusted and Adjusted Inpatient Mortality for Off-Pump and On-Pump CABG Surgery in New York State, 1997–2000
994	Intraoperative and Postoperative Complications for Patients Undergoing Off-Pump and On-Pump CABG Surgery in New York State, 1997–2000
995	Coronary Flow and the Slope of the Pressure-Flow Loops Measured in the LAD and LCX of the HCM Group  (n = 11)  and the LAD of the Control Group  (n = 9)
996	Prevalence of CGP by Gender
997	Prevalence of Variant CGP by Prevalent CHD, CeVD, and CVD  (CHD or CeVD)
998	Predictors of Subsequent Cardiovascular Events
999	Study Results
1000	Short-Form 36 Quality-of-Life Scores
1001	Frequencies of ACD, CD, and HE Per Year as a Function of the Stress Myocardial Perfusion Single-Photon Emission Computed Tomographic Result
1002	Rates of Referral to Early Catheterization and Revascularization as a Function of the Extent and Severity of Inducible Ischemia
1003	Observed and Predicted Hard Event Rates in Patients With and Without Revascularization After Stress Myocardial Perfusion Single-Photon Emission Computed Tomography
1004	Semi-Quantitative Scores
1005	SPECT Results of Those Undergoing Early Revascularization  (<60 Days)  Versus Non-Early Revascularization Patients
1006	Unadjusted, Univariable Two-Year Cox Cardiac Death or Myocardial Infarction-Free Survival by Clinical History and SPECT
1007	Risk-Adjusted * Multivariable Cox Model Estimating Cardiac Death or Myocardial Infarction
1008	Annualized Cardiac Death or Nonfatal Myocardial Infarction Rates for SPECT Results in Key Patient Subsets
1009	Post-Test Use of Coronary Angiography, PCI, and CABG by SPECT Results *
1010	TEE and Doppler Findings in the 107 Patients With Prosthetic Valve Thrombosis
1011	Early Outcome of Thrombolytic Therapy
1012	Outcome of Thrombolytic Therapy According to NYHA Class at Presentation
1013	Complications of Thrombolytic Therapy of Prosthetic Valve Thrombosis in 107 Patients
1014	Univariate Predictors of Any Complication After Thrombolysis
1015	Cine MRI and Clinical Parameters Before and 1 Month After PTSMA
1016	Crude Mortality by Gender
1017	Univariate Predictors of Mortality in Women
1018	Univariate Predictors of Mortality in Men
1019	Multivariate Predictors of Mortality in Women
1020	Multivariate Predictors of Mortality in Men
1021	Multivariate Predictors of Mortality in Women and Men
1022	Study Patients
1023	Phospholipid Composition in BTHS Patients With TAZMutation
1024	Cardiolipin in Heart
1025	Cardiolipin in Skeletal Muscle
1026	Cardiolipin in Platelets
1027	Causes of SD by Gender and Age in Athletes and Non-Athletes
1028	Logistic Regression Multivariate Independent Predictors of Spontaneous Conversion to Sinus Rhythm
1029	Myocardial Creatine by Proton Magnetic Resonance Spectroscopy
1030	Angiographic Findings of Patients Assigned to Early Revascularization and Undergoing PCI in the SHOCK Trial by One-Year Survival Status  (n = 82)
1031	Angiographic Outcome and One-Year Survival After PCI in Patients Assigned to Early Revascularization in the SHOCK Trial  (n = 82)
1032	Multivariate Cox Regression Results for One-Year Survival *
1033	SHOCK Trial Core Laboratory Angiographic Findings by Treatment Group Assignment
1034	Relationship of SHOCK Trial Core Laboratory Angiographic Findings to One-Year Survival
1035	Multivariate Model for One-Year Survival  (n = 214) : All Angiography Patients
1036	Multivariate Model for One-Year Survival  (n = 73) : Left Ventriculogram Cohort
1037	Coronary Angiography Findings in ACS Patients With Single and Multiple Coronary Plaques
1038	Ultrasonographic Measurements of the Common Carotid Arteries
1039	Significant Independent Predictors of Carotid Positive Remodeling  (IMTmean>1.1 mm and IAD >8.0 mm)  Identified by Logistic Regression Analysis
1040	Carotid Atherosclerosis and Brachial Artery Endothelial Function Studies
1041	Pearson Correlation Coefficients Between Carotid Artery Ultrasound and Brachial Artery Endothelial Function Variables
1042	Procedure Parameters
1043	Prognostic Impact of Diabetes Mellitus for Primary and Secondary Outcomes Adjusted for Risk Factors  (Overall and by Ischemic Versus Nonischemic Etiology of Cardiomyopathy)
1044	Effect of Diabetes vs. No Diabetes on Clinical End Points in Ischemic or Nonischemic Cardiomyopathy
1045	Primary and Secondary End Points by Diabetic Status and Treatment Group *
1046	Treatment Effects on Nonclinical End Points in Diabetics and Nondiabetics  (± SD)
1047	Survival Probabilities in HCM Study Population
1048	HCM-Related Clinical Markers in Study Patients With Systemic Hypertension *
1049	Multivariate Cox Regression Model for Sudden Death in Patients Age 30 or Younger at Holter
1050	The Fetal/Maternal Ratios of Sotalol
1051	Clinical Outcome: Correlation by Age
1052	PCR Results: Viral Genome Amplified
1053	Various Data in the Three Groups of Patients With Apical Hypertrophic Cardiomyopathy
1054	Severity and Location of Defects on Thallium SPECT Immediately After Exercise in the Total 598 Segments of 46 Patients
1055	Correlation Coefficients Between cCOT, QTc, RWA, and Defect Score in Total Patients  (n = 46)
1056	Clinical and Echocardiographic Data in Children With Duchenne Muscular Dystrophy
1057	cIBS, cvIBS, and Time-Delay Mean Values in Children With Duchenne Muscular Dystrophy and Controls
1058	Results of Haplotype Mapping for 11 Genes and 10 Informative Microsatellite Markers for the Patient and First-Degree Family Members
1059	Serial Changes in Number of Patients With Certain Transesophageal Echocardiographic Indexes
1060	Statistical Measures of Performance of Different Risk Stratifiers
1061	Phenotypic and Family Data for Patients With Familial Atrial Fibrillation
1062	Phenotypic Data for Affected Family Members in FAF 1 to 4
1063	Brachial Artery Parameters
1064	Numbers of Events According to FMD
1065	Independent Predictors of a Postoperative Event
1066	Echocardiographic Features of Affected Family Members From Families 1 and 2
1067	Respiratory Chain Complex Activities in Skeletal Muscle Mitochondria and Cardiac  (Left Ventricle)  Mitochondria From the Index Case  (Patient IV-03)  of Family 1
1068	Angiographic- and PCI-Related Data
1069	Predictors of the Composite Primary End Point
1070	Predicted Upper Limits of LVWT Derived From 250 Healthy Non-Athletic Controls
1071	Gender Differences in Cardiac Dimensions for 720 Elite Adolescent Athletes
1072	LVWT and LVMI Within Each Sporting Discipline for 720 Elite Adolescent Athletes
1073	Medications Within 24h
1074	Procedures
1075	Hospital events
1076	Multivariate Logistic Regression Analysis of Predictors of Hospital Death
1077	Task Force Criteria Present in Live Index Patients, Affected and Probable Affected Relatives
1078	Cardiovascular Abnormalities Detected on Evaluation of Relatives
1079	Proposed Modification of Task Force Criteria for the Diagnosis of Familial ARVC
1080	Echocardiographic Determinants of Left Atrial Maximal Volume in the Study Population  (Univariate Analysis)
1081	Echocardiographic Determinants of Left Atrial Maximal Volume in the Study Population  (Multivariate Analysis)
1082	Predictors of Death in the Study Population  (Cox Univariate Analysis)
1083	Predictors of Death in the Study Population  (Cox Bivariate Models)
1084	Carotid Artery Pressures, Structure, and Stiffness in Normotensive and Hypertensive Subjects
1085	Independent Correlates of Carotid Anatomy and Stiffness
1086	Effects of NTG Treatment on Potency  (ED50)  and Efficacy  (Maximal Relaxations)  to Endogenous and Exogenous Nitrovasodilators in Aortas from Untreated and NTG-Treated Animals
1087	Lipid Profile of Controls and Hypercholesterolemic  (WHHL)  Rabbits With and Without NTG Treatment
1088	LV EDV, ESV, SV, CO, EF, Mass and Heart Rate in Volunteers, Patients with HHD, AVD, and DCM
1089	General Data According to Hepatic Lipase Genotype
1090	Cell Composition *  of Carotid Endarterectomy Specimens and Hepatic Lipase Genotype
1091	Multiple Regression Models for Factors Potentially Linked to the Number of Macrophages per Area Unit in the Plaque
1092	Logistic Regression Analysis  (p Values)  for Prediction of Cerebrovascular Events
1093	Putative Mutations in X-Linked DCM Patients ∥
1094	Hemodynamics
1095	DNA Repair Enzymes
1096	Predictors of the Development of Ventricular Tachycardia
1097	Multivariate Cox Proportional Hazards Analyses for Cardiac Sudden Death
1098	Hemodynamic, Functional, and Echocardiographic Data for Ovine Model of Left Ventricular Aneurysm
1099	Changes in Body Weight and Left Ventricular Weight in Each Group
1100	Prevalence of Any High-Grade and Multivessel Coronary Atherosclerosis by Age and Gender
1101	Univariate Correlations With Time to ST-Segment Depression of 0.15 mV
1102	Large Artery Mechanical Properties and Myocardial Work Indexes
1103	Stepwise Multivariate Analysis
1104	Immunologic Data
1105	Multivariate Predictors of Procedural Complications After PCI
1106	Prevalence of Structural Cardiovascular Abnormalities in 355 Competitive Athletes With Ventricular Tachyarrhythmias
1107	The Relationship of Clinical Variables to PCI in Patients With and Without an Acute MI
1108	The Relationship of Angiographic and Outcome Variables to PCI in Patients With and Without an Acute MI
1109	The Relationship of PCI-Related Complications to In-Hospital Mortality
1110	Multivariate Correlates of In-Hospital Mortality
1111	Unimputed Multivariate Model
1112	Nomogram to Predict Death
1113	Correlation of Score Based on Nomogram With Predicted Probability of In-Hospital Mortality
1114	Clinical Follow-Up or Further Evaluation *   †
1115	Plasma Substrates and Insulin, MBF, MVO2, and Myocardial Substrate Uptake
1116	Comparison of Ventricular and Myocardial Function Indices
1117	Device Data  (n = 97)
1118	Relative Risk of Early Recurrence of Atrial Fibrillation for Clinical and Device Variables  (Univariate Analysis)
1119	Relative Risk of Early Recurrence of Atrial Fibrillation for Clinical and Device Variables  (Multivariate Analysis)
1120	The Evolution of the 6-min Walked Distance, Peak VO2, QoL and NYHA Class at M6, M9 and M12
1121	Echocardiographic Data and Ejection Fraction for the Sinus Rhythm Group and the Atrial Fibrillation Group at M6, M9 and M12
1122	Hospitalizations for Heart Failure
1123	The Effect of the Presence Versus Absence of Anemia on De Novo Cardiovascular Disease
1124	Patient Profiles
1125	Etiology of Pericardial Effusion  (n)
1126	PR-segment Deviation and ST-T–Wave Changes
1127	Regression Coefficients for Men and Women Separately, Describing the Increase in Log Calcium Score per Unit Increase of the Extracoronary Variables
1128	Age-Adjusted Standardized Regression Coefficients for Men and Women Separately, Describing the Increase in Log Calcium Score per Standardized Unit Increase of the Extracoronary Variables
1129	One-Year Mortality Rates of the Cohort by Hemoglobin Quartile
1130	IART Clinical Severity Score
1131	Anatomical Diagnoses and Surgical Status of Study Group
1132	Analyses of Acute Procedural Outcomes
1133	Analyses of Chronic Procedural Outcomes
1134	Clinical and Electrocardiographic Data
1135	Electrophysiologic Data
1136	Therapy and Follow-Up
1137	Change in Heart/Body Weight Ratio  (mg/g)  in Wistar Rats Treated With AB or ADR After 2, 8 and 14 Weeks  (n = 8)
1138	Left Ventricular Function, Expressed as ±dP/dtmax (kPa/s) , in Each Group at Different Times  (n = 6)
1139	Anatomic Measurements of Hearts  (mm2)  From Each Group at the End of the Experiment
1140	Collagen Volume Fraction  (%)  of the Left Ventricle in Both the Aortic Banding and Adriamycin Groups  (n = 8)
1141	Changes in the Ratio of CD4+/CD8+Before and After Treatment in Both the AB and ADR Groups  (n = 8)
1142	Clinical Features and Plasma ANP and BNP Levels in HCM Patients and Control Subjects
1143	Correlation Between ANP and BNP Levels at Rest and Echocardiographic and Hemodynamic Variables
1144	Clinical Features of HCM Patients With or Without Inducible Myocardial Ischemia
1145	Surgical Procedures
1146	Cardiac Marker Levels  (ng/ml, mean ± SD, range)  of All Patients  (n = 224) , Uncomplicated  (n = 203)  and Complicated  (n = 21)
1147	Cardiac Marker Levels  (ng/ml, mean ± SD, range)  of Uncomplicated Patients  (n = 203)  Versus Patients With Individual Complications Such as New MI  (n = 6) , Cardiogenic Shock  (n = 16)  and Death  (n = 9)
1148	Autosomal Dominant FDC Disease Genes and/or Loci
1149	Clinical and Echocardiographic Variables in Patients With Successful Cardioversion of Nonvalvular AF and One-Year Follow-Up  (n = 186)
1150	Univariate and Multivariate Predictors of One-Year Maintenance of SR
1151	Diagnostic Value of Clinical and Echocardiographic Parameters for Assessment of Long-Term Maintenance of SR
1152	Near-Infrared Spectroscopic Determination of Lipid-to-Protein Ratio and Histologic Features of Atherosclerotic Plaques
1153	Statistical Analysis of the Temporal Changes for the T1W and T2W Data
1154	Sensitivity and Specificity of the Observers in Age Classifications
1155	Sensitivity, Specificity and Negative Predictive Value of CIMT <0.55 mm and AoIMT <3 mm in the Pilot and Prospective Studies
1156	Logistic Regression Analyses for Predicting Significant Coronary Artery Disease
1157	Univariate Association of Cardiac History and Anginal Status With In-Hospital Mortality
1158	Univariate Association of Other Noncoronary Disease Processes With In-Hospital Mortality
1159	Univariate Association of Angiographic Factors With In-Hospital Mortality
1160	Univariate Association of Procedural Factors With In-Hospital Mortality
1161	Multivariate Analysis of Factors Significantly Associated With Mortality: Results in the Training Dataset  (n = 50,123)
1162	Multivariate Analysis of Factors Significantly Associated With Mortality for Patients With Acute Myocardial Infarction Within 24 h: Results in the Training Dataset  (n = 8,921)
1163	Multivariate Analysis of Factors Significantly Associated With Mortality for Patients With No Acute Myocardial Infarction Within 24 h: Results in the Training Dataset (n = 41,202)
1164	Families With Lamin A/C Gene Mutations: Clinical Data of Probands and Their Relatives
1165	Univariate and Multivariate Predictors of Mortality of 84 Patients With Congestive Heart Failure According to Cardiovascular Death
1166	Results of PCR: Viral Genome Amplified
1167	Medication at the Time of Hospital Discharge After Defibrillator Implant and at Most Recent Follow-Up
1168	Appropriate and Inappropriate ICD Interventions and Transplant-Free Survival During Follow-Up
1169	Complications Associated With the Implantation of the Device  (Peri-Implant)  or During Follow-Up
1170	Efficacy of Antitachycardia Pacing
1171	Changes in ECG Variables During Mid-Term and Long-Term Follow-up
1172	Changes in Echocardiographic Variables in 44 Patients With Apical Hypertrophic Cardiomyopathy During a Mean Follow-Up of 9.0 ± 4.6 Years
1173	Age-specific and age-standardised prevalence of spirometry-defined COPD in the general Chinese adult population aged 20 years or older in 2015
1174	Multiple-adjusted ORs for COPD associated with risk factors in the general Chinese adult population aged 20 years or older in 2015
1175	Categorical outcomes at week 12
1176	Continuous outcomes at week 12
1177	Adverse events
1178	Efficacy measures
1179	Adverse events
1180	Most common adverse events
1181	FEV1 and SGRQ responder analysis
1182	Adverse events and serious adverse events  (safety population)
1183	Adverse events by week 48 in SWORD-1 and SWORD-2
1184	Clinical management and outcome during the intervention period  (day 0 through day 7)
1185	Outcomes
1186	Adverse events related or possibly related to the procedure or device
1187	The most commonly used medications among treated adults with hypertension
1188	Summary of response and survival data
1189	Treatment-related adverse events
1190	Treatment-emergent adverse events  (safety population)
1191	Change in blood pressure at 3 months in the intention-to-treat population
1192	Virological outcomes at week 48
1193	Adverse events
1194	Changes in quantitative measures of proteinuria
1195	Virological outcomes at week 48
1196	Adverse events
1197	Association of number of fruit, vegetable, and legume servings per day with cardiovascular outcomes and mortality
1198	Association of raw vegetable intake with cardiovascular disease and mortality
1199	Association of cooked vegetable intake with cardiovascular disease and mortality
1200	Treatment-emergent adverse events of any grade reported in at least 10% of patients in either group in the safety population
1201	Tumour response
1202	Treatment-related adverse events
1203	Adverse events
1204	Serious Adverse Events Reported During the Two-Year Follow-Up Period
1205	Reported TEAEs  (as-treated population)
1206	Summary of total adverse events and treatment-related adverse events through week 96 in the safety maintenance population
1207	Data quality rating from 0 to 5 stars, maximum percent well certified per 5-year interval and percent well certified across time series by country, 1980–2016
1208	Global deaths, age-standardised death rates per 100 000, YLL numbers, and age-standardised YLL rates per 100 000, and percent change between 2006 and 2016 for both sexes combined for all GBD causes and levels 1 through 4 of the cause hierarchy
1209	Selected causes of global neonatal, childhood, and under-5 deaths in 2016 with mean percent change between 2006 and 2016 for both sexes combined
1210	Global all-age DALYs and age-standardised DALY rates in 1990, 2006, and 2016 with mean percentage changes between 1990 and 2016, 2006 and 2016, and 1990 and 2016 for all causes
1211	Global, regional, and GBD location-specific life expectancy and HALE at birth, by sex, in 1990, 2006, and 2016
1212	Global, regional, and GBD location-specific life expectancy and HALE at age 65 years, by sex, in 1990, 2006, and 2016
1213	Global prevalence, incidence, and YLDs for 2016, percentage change of YLD counts, and percentage change of age-standardised YLD rates between 2006 and 2016 for all causes and nine impairments
1214	Effect of treatment on asthma outcomes
1215	Effect of treatment on asthma-related quality of life  (AQLQ)  domains
1216	Adverse events
1217	Treatment-emergent adverse events
1218	Primary composite outcome at 2 years  (modified intention-to-treat analysis)
1219	Oncological outcomes at 3 years  (Kaplan Meier)
1220	Morbidity and side-effects at 2 years according to type of surgery  (post-hoc exploratory analysis)
1221	Primary outcomes of venous thromboembolism events during 3-month follow-up
1222	Primary outcome and efficiency in subgroups of the total study population
1223	Causes for which mortality is amenable to health care mapped to GBD 2015 causes
1224	Correlations between different constructions of the HAQ Index and existing indicators of health-care access or quality
1225	Global, regional, and national or territory-level estimates of the HAQ Index for each 5-year interval from 1990 to 2015, frontier values in 1990 and 2015 on the basis of SDI, and the difference between observed HAQ Index and frontier values in 1990 and 2015
1226	Number of cases in which the gold standard outcome was different from the autopsy finding, and reasons for the change
1227	Discrepancies in cause of death against the gold standard
1228	Discrepancies with the gold standard in cause of death or clinically significant findings of the cause of death
1229	Summary of important treatment-emergent adverse events reported in all patients
1230	Patient disposition at data cutoff  (Aug 8, 2016)
1231	Safety and tolerability of nivolumab in the dose-escalation phase
1232	Nivolumab efficacy in the dose-expansion phase
1233	PD-L1 expression on tumour cells and response
1234	Comparison of efficacy at week 24
1235	Safety overview
1236	Comparison of the primary outcome, best corrected visual acuity, between treatment groups at 12 weeks and 52 weeks
1237	Ocular adverse events in study eye by treatment group at week 52
1238	APTC-defined events by treatment group
1239	Treatment-emergent adverse events reported by ≥5% of all patients by preferred term  (safety set)
1240	Univariate and multivariate HRs for patient-level and country-level determinants of mortality, and the effect of each determinant on the variation in mortality rate between countries
1241	Global deaths, disability-adjusted life-years, and age-standardised rates attributable to ambient particulate matter pollution in 2015
1242	2015 estimates of mortality and disability-adjusted life-years attributable to ambient particulate matter pollution and population-weighted mean particulate matter pollution in the world's ten most populous countries
1243	FEV1 and SGRQ responder analysis  (intention-to-treat population)
1244	Adverse events and serious adverse events  (safety population)
1245	Primary endpoint  (intention-to-treat analysis, n=37)
1246	Summary results of the secondary outcomes for the 28 women who completed the trial  (per-protocol analysis set)
1247	Adverse events
1248	Zero-inflated negative binomial model predicting Tsimane CAC scores
1249	Adverse events and serious adverse events
1250	Mental health, alcohol misuse, and functional impairment prevalence and odds ratios at follow-up between screening and control groups
1251	Effect of screening on help-seeking and pharmaceutical use
1252	Cost analysis
1253	Incidence of major adverse events in the standard prophylactic treatment  (H+)  and no prophylactic treatment  (H–)  groups
1254	Primary and secondary outcomes at week 8
1255	Adverse events
1256	Additional efficacy parameters and pseudospecificity measures
1257	Summary of adverse events in the safety population
1258	Changes in select laboratory parameters and vital signs in the safety population
1259	Summary of adverse events
1260	Adverse events regardless of study drug relationship in the safety set  (>15% of patients in either group)
1261	Diagnostic accuracy of TRUS-biopsy and MP-MRI in the detection of clinically significant prostate cancer using alternative secondary definitions of clinically significant cancer
1262	Adverse events
1263	Serum concentrations by dose group
1264	Adjusted absolute and differences in restricted mean patient survival of HLAi compared with matched cohort listed only, and listed or transplant in months
1265	Inter- and Intraobserver Variability of Myocardial Blush Grades
1266	Solicited and unsolicited adverse reactions
1267	Univariate and Multivariate Predictors of Cumulative Mortality
1268	Glycoprotein-specific antibody responses
1269	Correlates of Normal Myocardial Blush Following Intervention
1270	Efficacy results for primary, secondary, and sensitivity analyses, according to cumulative response analysis  (weighted GEE model)
1271	Safety summary over 24-week treatment period
1272	Long-term safety according to incidence in patient-months
1273	Treatment variables by group
1274	mRS score frequencies for the 30-day and 180-day timepoints
1275	Serious adverse events by treatment group
1276	Multivariate age-adjusted progression-free survival and overall survival
1277	Confirmed response in assessable patients
1278	Notable toxic effects defined by Common Toxicity Criteria 3.0 category
1279	Summary results of all 11-day experiments
1280	Objective response by PD-L1 status on tumour-infiltrating immune cells
1281	Treatment-related adverse events
1282	Tumour response  (efficacy population)
1283	Treatment-emergent adverse events and treatment-emergent drug-related adverse events  *    (safety population)
1284	New and total input data by estimation methods
1285	Estimated numbers of deaths by cause and cause-specific mortality rate in 2015
1286	Clinical benefit in the intention-to-treat population
1287	Adverse events with a frequency of more than 5% in any treatment group irrespective of causality in the safety analysis population
1288	Adverse event summary
1289	Eradication frequencies with first-line and second-line therapies
1290	Adverse events with first-line therapy
1291	Factors affecting eradication frequencies in first-line therapy in the intention-to-treat population
1292	Glycaemic and glucose variability measures
1293	Adverse events
1294	Crude and adjusted hazard ratios for average systolic blood pressure subgroups
1295	Crude and adjusted hazard ratios for average diastolic blood pressure subgroups
1296	Adverse events of any cause reported in more than 5% of patients in either of the everolimus treatment groups
1297	Adverse events and serious adverse events
1298	Global deaths  (thousands)  and mortality rates  (per 1000 livebirths)  for stillbirths, early neonatal, late neonatal, post-neonatal, child, and under-5 age groups, both sexes combined, 1980–2015
1299	Stillbirth rates, neonatal, post-neonatal, child, and under-5 mortality rates  (per 1000 livebirths) , total under-5 deaths, and total stillbirths in 2015, annualised rates of change for under-5 mortality for 1990–2000, 2000–15, and 1990–2015, by countries and territories and subnational units in the United Kingdom, both sexes combined
1300	GATHER checklist with description of compliance and location of information in the GBD 2015 mortality and causes of death study
1301	Number of geographies and causes at each hierarchical level for GBD 2015
1302	Distribution of empirical life tables by GBD super-region and decade, 1950–2015
1303	Global life expectancy at birth and at age 50, age-standardised death rates, age-standardised YLL rate, and total deaths, by sex, 1980–2015
1304	Global deaths in 2005 and 2015 for all ages and both sexes combined and age-standardised death rates, with percentage change between 2005 and 2015 for 249 causes
1305	Selected causes of global child deaths for both sexes combined in 2005 and 2015, with percentage change between 2005 and 2015
1306	Global counterfactual deaths and population attributable fractions for diarrhoea and lower respiratory infection pathogens for 2005 and 2015, with percentage change between 2005 and 2015
1307	Global all-age DALYs and age-standardised DALY rates in 2005 and 2015 with median percentage change between 2005 and 2015 for all causes
1308	Global, regional, and national or territory life expectancy and HALE at birth, by sex, in 2005 and 2015, and HALE at age 65, by sex, in 2015
1309	Global incidence of short duration  (less than 3 months)  sequelae in 2005 and 2015 for all ages and both sexes combined, with percentage change between 2005 and 2015 for level 4 causes with incidence greater than 1 million cases per year
1310	Global prevalence of longer duration  (more than 3 months)  sequelae in 2005 and 2015 for all ages and both sexes combined, with percentage change between 2005 and 2015 for Level 4 causes with prevalence greater than 1%
1311	Global prevalence and YLDs for 2015, percentage change of counts, and percentage change of age-standardised rates between 2005 and 2015 for all causes, Level 5 sequelae, and nine impairments
1312	Paired case and control samples tested by quantitative real-time PCR, by age stratum and study site
1313	Adjusted attributable fractions for pathogens causing moderate to severe diarrhoea assessed with quantitative molecular diagnostic methods
1314	Intervention effects on clinical and parasitological outcomes
1315	Intervention efficacy measures on mosquito densities
1316	Progression of the patient's haematological parameters and hepatic and renal biochemistry after suspected poisoning on day 1
1317	Measurements of polonium-210 in post-mortem samples and model predictions of organ content and excretion
1318	Cumulative doses to organs or tissues of a reference adult man after ingestion of 4·4 GBq of polonium-210, assuming 10% absorption to blood
1319	Patency rates of arteriovenous fistulae
1320	Change in vessel diameters before and immediately after administration of anaesthesia
1321	Risk factors for transmission of MERS-CoV in all patient contacts and in patients in group A
1322	Primary effectiveness and secondary hierarchically-tested endpoints
1323	Serious adverse events associated with procedure, device, or therapy at 12 months' follow-up
1324	Treatment-emergent adverse events and serious adverse events
1325	Primary and secondary outcomes at 12 months
1326	Depression status, recovery, and response at 12 months
1327	Economic data at 18 months
1328	Primary and secondary endpoints
1329	Time-to-event outcomes
1330	Maximal-grade toxicity during induction and during high-dose treatment, ASCT, and follow-up, by treatment group
1331	Total number of post-study anticancer treatments received  (phase 2)
1332	Adverse events  (phase 2)   *
1333	Recurrence sites
1334	Adverse events in the per-protocol population
1335	Platelet responses
1336	Incidence of adverse events
1337	Primary outcomes and their components for women entered into the treatment phase of the OPPTIMUM study and their babies
1338	Secondary outcomes
1339	Safety outcomes
1340	Grade 3 or worse adverse events
1341	Clinical results
1342	Epidemiology and outcomes by region
1343	Inherent and aetiological risk factors for acute kidney injury development by gross national income per person
1344	Logistic regression for mortality
1345	Comparison of type 1 autoimmune pancreatitis and type 2 autoimmune pancreatitis  (IDCP)
1346	Objective response rate by PD-L1 immune cell score
1347	Treatment-related adverse events in the 310 patients who received atezolizumab
1348	Reported adverse events among 16 568 patients in the safety population
1349	Primary and secondary outcomes and exacerbations of chronic obstructive pulmonary disease
1350	Overall safety profile
1351	Adverse events in the safety population
1352	Hemodynamic Effects of Immunoadsorption in Patients With Dilated Cardiomyopathy and Effects of Column Eluent  (Dilution 1:5)  on Ca2+Transient and Systolic Cell Shortening of Isolated, Field-Stimulated Rat Cardiomyocytes
1353	Adverse events
1354	Duration of secondary prophylaxis in patients with rheumatic heart disease and global and regional recommendations  40,49
1355	Indication for valvular surgery or intervention
1356	Risk factors associated with tuberculosis
1357	New or repurposed drugs against active tuberculosis in phase 2 and 3 clinical trials
1358	Progression-free survival  (full analysis set)
1359	Treatment-related adverse events reported in at least 10% of patients  (safety population)
1360	Efficacy outcomes
1361	Treatment-emergent adverse events by system organ class
1362	Changes in liver histology after 48 weeks of treatment
1363	Adverse events
1364	Proportion of individuals who had one grade 3 or 4 adverse event
1365	Adverse events
1366	Influential phase 3 trials for localised prostate cancer
1367	Cost of treatments for advanced castration-resistant prostate cancer
1368	Paired angiographic analysis
1369	Intravascular ultrasound and optical coherence tomography measurements per lesion
1370	Malaria-related perinatal outcomes by treatment group in the intention-to-treat population  (all gravidities)
1371	Serious adverse events
1372	Barriers to implementation of tuberculosis preventive therapy and proposed responses
1373	Treatment of M tuberculosis infection as part of a comprehensive approach to improve worldwide tuberculosis control
1374	Analysis of anti-AAV antibodies
1375	Global all-age DALYs and age-standardised DALYs for 306 causes in 2005 and 2013 with percentage change
1376	Decomposition of variance in 2013 global DALY rates per 100 000 people for GBD level 2 causes using hierarchical regression
1377	Life expectancy at birth and HALE at birth for 1990, 2005, and 2013 for both sexes and 188 countries
1378	Primary, secondary, and safety endpoints
1379	Cumulative vaccine efficacy against Helicobacter pylori infection in the per-protocol efficacy cohort
1380	Serious adverse events and adverse reactions in the safety cohort
1381	Mean change in bone mineral density between 0–48 months and 24–48 months
1382	Chemotherapy-related toxic effects
1383	Radiotherapy-related toxic effects
1384	Tumour response rates after treatment
1385	Types of surgery and outcomes
1386	Performance of the ReEBOV rapid diagnostic test versus real-time RT-PCR  (altona)   *
1387	Positive predictive value of the ReEBOV rapid diagnostic test, by positivity score
1388	Interoperator agreement for ReEBOV rapid diagnostic test results
1389	GBD 2013 data representativeness index by cause
1390	GBD 2013 data representativeness index by impairment, calculated as fraction of countries with data for each impairment and period
1391	Global incidence of acute sequelae  (for less than 3 months)  by cause for incidence greater than 1 million cases per year
1392	Global prevalence of chronic sequelae  (for longer than 3 months)  by cause for prevalence greater than 1%
1393	Prevalence and YLDs, with percentage of total, for anaemia by cause in 1990 and 2013, and prevalence by severity in 2013
1394	Prevalence and YLDs, with percentage of total, for hearing impairment by cause in 1990 and 2013, and prevalence by severity in 2013
1395	Prevalence and YLDs, with percentage of total, for heart failure by cause in 1990 and 2013, and prevalence by severity in 2013
1396	Prevalence and YLDs, with percentage of total, for intellectual disability by cause in 1990 and 2013, and prevalence by severity in 2013
1397	Prevalence and YLDs, with percentage of total, for vision impairment by cause in 1990 and 2013, and prevalence by severity in 2013
1398	Prevalent cases and YLDs for 2013, percentage change, and percentage change of age-standardised rates between 1990 and 2013 for all causes
1399	Primary outcome results, unadjusted and adjusted for stone location  (lower vs middle vs upper ureter) , stone size  (≤5 mm vs >5 mm) , and centre  (random effect)
1400	Pain variables and time to stone passage
1401	Summary of other efficacy variables  (intention-to-treat patients)
1402	Reported TEAEs and exposure-adjusted incidence rates organised by selected system organ classifications and preferred terms experienced by at least 10% of patients in either treatment group  (safety population)
1403	Reported TEAEs and exposure-adjusted incidence rates organised by severity  (safety population)
1404	Onset of delivery for randomly assigned women
1405	Maternal outcomes
1406	Neonatal outcomes
1407	Estimates of median time to alleviation of all symptoms by treatment group in the intention-to-treat infected and intention-to-treat populations, both overall and for each trial
1408	Meta-analyses findings for key on treatment adverse events in the safety population, by treatment received
1409	Overview of primary and secondary endpoints
1410	Complications and adverse events
1411	Effect of vitamin A on endpoints
1412	Serum retinol and retinol-binding protein concentrations in infants and mothers after supplementation
1413	In Vivo Data in Control Rats and Rats With Pressure Overload Hypertrophy With or Without Pulmonary Congestion
1414	Adverse events within 3 days
1415	Ex Vivo Data in Control Rats and Rats With Pressure Overload Hypertrophy With or Without Pulmonary Congestion
1416	Left Ventricular Chamber and Myocardial Systolic and Diastolic Function in the Control and Pressure Overload Hypertrophy Groups
1417	Left Ventricular and Myocardial Function in Pressure Overload Hypertrophy With or Without Heart Failure
1418	Changes to DDG2P over time
1419	Total number of single nucleotide variants and insertion-deletions flagged by the clinical reporting workflow in all 1133 probands  (in the November, 2013 version of DDG2P)  compared with the number of variants that would have been flagged in the same probands in the absence of parental data
1420	Likely diagnoses in the first 1133 families
1421	Clinical, Histologic and Immunohistochemical Changes in Patients With DCM, Relatives With LVE and Control Subjects
1422	Echocardiographic Data in Patients With Isolated Ventricular Noncompaction
1423	Comparison of Prognostic Power of Multivariable Models
1424	Proposed Definition of Ischemic Cardiomyopathy legend
1425	Serious adverse events in any treatment group and treatment-emergent adverse events occurring in 5% or more of patients
1426	Primary and secondary efficacy endpoints for the overall intention-to-treat population, and populations with overt cardiovascular disease or at increased risk of cardiovascular disease
1427	Adverse side-effects
1428	Efficacy of pentavalent rotavirus vaccine for prevention of rotavirus gastroenteritis and gastroenteritis for complete follow-up in Asia
1429	Efficacy of the pentavalent rotavirus vaccine for prevention of severe rotavirus gastroenteritis  (Vesikari score ≥11)  in Asia by country and follow-up period
1430	Antirotavirus IgA and SNA seroresponse rates and geometric mean titres after the third dose in recipients of pentavalent rotavirus vaccine and placebo in the immunogenicity subset  *
1431	Serious adverse events 1–14 days after any dose of pentavalent rotavirus vaccine or placebo
1432	Changes in cardiovascular and metabolic measures in patients randomly allocated to exenatide once weekly or insulin glargine
1433	Changes in β-cell function, insulin sensitivity, and triglyceride concentrations in patients randomly allocated to exenatide once weekly or insulin glargine
1434	Overview of adverse events
1435	Primary and secondary efficacy measurements
1436	Adverse events
1437	Targets and target sequences in Zaire Ebola virus  (ZEBOV)  of small interfering RNAs
1438	Macaques given four  (study 1)  or seven treatments  (study 2)  with stable nucleic acid-lipid particles containing Zaire Ebola virus  (ZEBOV)  small interfering RNAs  (siRNAs)  after ZEBOV challenge
1439	Plasma viral load in rhesus monkeys infected with Zaire Ebola virus  (ZEBOV)  and given four  (study 1)  and seven  (study 2)  postexposure treatments with anti-ZEBOV small interfering RNAs  (siRNAs)
1440	Primary and secondary outcomes
1441	Side-effects
1442	Pooled estimates of adjusted hazard ratios  (95% CI)  for all-cause and cardiovascular mortality according to categories of eGFR  (listed in the left column)  and ACR
1443	Pooled estimates of adjusted hazard ratios  (95% CI)  for all-cause and cardiovascular mortality according to categories of eGFR  (listed in the left column)  and dipstick urinalysis for proteinuria
1444	Estimated numbers of deaths by cause in 2008
1445	Estimated numbers of deaths by cause in children younger than 5 years by WHO region and country
1446	Base case assumptions for the costs of tests and visits relating to type 2 diabetes, hypertension, and cholesterol
1447	Disutilities assigned to various states relating to type 2 diabetes and its complications
1448	Mean lead time in diagnosis gained by each screening strategy compared with control
1449	Sensitivity of cost per quality-adjusted life-year to different assumptions about costs of screening, treatment costs, quality weights, disutility associated with amputation, and discount rate, by screening strategy
1450	Sensitivity of cost per quality-adjusted life-year  (QALY)  to assumptions about the disutility of type 2 diabetes diagnosed because of symptoms but before the onset of complications
1451	Reduction of systolic blood pressure by category for the 8-week treatment period
1452	Neurohormonal and biomarker measurements for the 8-week treatment period
1453	Adverse events during the 8-week treatment period
1454	Outcomes in the intention-to-treat population and in patients aged 65 years or older
1455	Adverse events
1456	Summary of events
1457	Overall survival in RE04/30012 compared with data from Motzer and colleagues,  12   by Memorial Sloan-Kettering Cancer Centre risk group
1458	Worst toxic effects reported during treatment, by Common Toxicity Criteria grade
1459	Common Toxicity Criteria grade 3 and 4 toxic effects reported in both treatment groups, by symptom
1460	Pathological responses to treatment
1461	Selected adverse events and LVEF in the safety population
1462	Overview of previous analyses of mortality rates in Darfur
1463	Number of surveys by year and indicators
1464	Regression variables in surveys of mortality rates
1465	Quasi-Poisson regression analyses of mortality rates
1466	Calculated average mortality rates and number of deaths in affected population in Darfur by period  (adjusted for population distribution by state and percentage of displaced people in total affected population)
1467	Proportion of patients with viral RNA concentration less than 50 copies per mL at week 24 in the SWITCHMRK studies
1468	Types and frequencies of clinical and laboratory adverse events during the SWITCHMRK studies
1469	Patients with grade 3 or 4 abnormalities for prespecified laboratory tests during the SWITCHMRK studies
1470	Resistance mutations in HIV from 16 patients with confirmed virological failure and vRNA concentration more than 400 copies per mL by week 24, by treatment group
1471	Major data sources used in the evaluation
1472	Coverage rates for ACSD interventions in focus districts and national comparison areas before and after ACSD in Benin, Ghana, and Mali
1473	Nutritional status in focus districts and national comparison areas before and after ACSD in Benin, Ghana, and Mali
1474	Mortality in children younger than 5 years and age-specific mortality per 1000 livebirths in focus districts and national comparison areas before and after ACSD in Benin, Ghana, and Mali
1475	Primary and secondary outcomes
1476	Side-effects after treatment and participants' reports of their intolerability
1477	Primary and secondary outcomes
1478	Side-effects after treatment and participant's reports of their intolerability
1479	Treatment-emergent adverse events
1480	Primary outcome and major clinical events of interest
1481	Number of participants with adverse events that were possibly or probably related to the study or study drug
1482	Participants with adverse events after vaccine or placebo
1483	Participants with adverse reactions by dose
1484	Pre-existing antibody against 2009 pandemic influenza A H1N1 in participants, by age-group
1485	Haemagglutination inhibition antibody response 21 days after first dose of vaccine or placebo
1486	Haemagglutination inhibition antibody response 21 days after second dose of vaccine or placebo
1487	Prevalence of health disorders and mean WHODAS 2.0 scores by site
1488	Between-site variation in zero inflation and WHODAS 2.0 score counts as modelled by zero-inflated negative binomial regression, before and after adjustment for compositional factors
1489	Relative risks for associations between disability and self-reported impairments and chronic-disease diagnoses  †
1490	Population-attributable prevalence fractions for 90th centile of WHODAS 2.0 scores and health disorders
1491	Contributions of chronic diseases and disorders to disability according to Global Burden of Disease estimates of years lived with disability  ¶   and median population-attributable prevalence fractions from 10/66 population-based studies
1492	Criteria defining patients with Fabry's disease who responded to treatment and the proportion of patients who met these criteria during 5 years of treatment with agalsidase alfa
1493	Change in mean estimated glomerular filtration rate during 5 years of treatment with agalsidase alfa in all patients with Fabry's disease  (including hyperfiltrators)  without end-stage renal disease
1494	Change in mean estimated glomerular filtration rate during 5 years of treatment with agalsidase alfa in patients with Fabry's disease without end-stage renal disease
1495	Change in mean systolic and diastolic blood pressures during 5 years of treatment with agalsidase alfa in patients with Fabry's disease without end-stage renal disease
1496	Change in mean average and worst pain scores in patients with Fabry's disease during 5 years of treatment with agalsidase alfa
1497	Changes in bodyweight, waist circumference, blood pressure, and prediabetes status from randomisation  (after a diet and placebo run-in period)  to week 20
1498	Changes in bodyweight and blood pressure from screening  (including a 2-week diet and placebo run-in period)  to week 20
1499	Safety data at week 20
1500	Adverse events with an incidence of 10% or more in any treatment group, by system organ class and preferred term
1501	Antipneumococcal IgG antibody responses 1 month after primary vaccination with PHiD-CV, DTPa-HBV-IPV/Hib, and human rotavirus vaccine with or without prophylactic administration of paracetamol  (ATP immunogenicity cohort)
1502	OPA responses 1 month after primary vaccination with PHiD-CV, DTPa-HBV-IPV/Hib, and human rotavirus vaccine with or without prophylactic administration of paracetamol  (ATP immunogenicity cohort)
1503	Antibody responses after primary vaccination with PHiD-CV, DTPa-HBV-IPV/Hib, and human rotavirus vaccine with or without prophylactic administration of paracetamol  (ATP immunogenicity cohort)
1504	Antipneumococcal IgG antibody responses 1 month after booster vaccination with PHiD-CV and DTPa-HBV-IPV/Hib with or without prophylactic administration of paracetamol  (ATP immunogenicity cohort)
1505	OPA responses 1 month after booster vaccination with PHiD-CV and DTPa-HBV-IPV/Hib with or without prophylactic administration of paracetamol  (ATP immunogenicity cohort)
1506	Antibody responses after booster vaccination with PHiD-CV and DTPa-HBV-IPV/Hib with or without prophylactic antipyretic administration  (ATP immunogenicity cohort)
1507	Effect of antipyretic administration on antipneumococcal ELISA antibody responses in 376 children primed at 2, 3, and 4 months of age with 7vCRM and DTPa-HBV-IPV/Hib  (ATP cohort for immunogenicity)
1508	Episodes of cholera in study participants during 2 years of follow-up in per-protocol and modified intention-to-treat populations
1509	Comparison of episodes of cholera according to year of follow-up in all age-groups in per-protocol and modified intention-to-treat populations
1510	Most common adverse events reported up to 14 days after receipt of either vaccine or placebo dose, by age-group
1511	Short-form McGill pain questionnaire  (SF-MPQ) , short-form 36-item general health survey  (SF-36) , and Beck depression inventory  (BDI)  scores
1512	Treatment-emergent adverse events in 5% of patients or more
1513	Annual rates of decline in prebronchodilator and postbronchodilator FEV1, FVC, and SVC
1514	Exacerbations in patients with GOLD stage II, III, or IV COPD in the tiotropium and control groups
1515	Exacerbations resulting in hospital admissions in patients with GOLD stage II, III, and IV COPD in tiotropium and control groups
1516	Deaths in patients with GOLD stage II COPD, by analysis population
1517	Efficacy by histology
1518	Drug-related toxic effects  †
1519	Post-discontinuation anticancer systemic therapy
1520	Clinical response in patients with measurable lesions
1521	Frequency of grade 3 or 4 adverse events
1522	Serious adverse events and loss to follow-up for infants in each study group  (data from both sites combined)
1523	Reported number of adverse events  (%)  at days 1, 2, 3, and 7 after intermittent preventive treatment for infants  (all treatments combined from both sites)
1524	Primary and secondary outcomes of intermittent preventive treatment for infants at the moderate-transmission site
1525	Adverse events for all randomly assigned patients
1526	Effect of treatment on primary and secondary functional and clinical outcomes in salmeterol plus roflumilast  (M2-127)  and tiotropium plus roflumilast  (M2-128)  trials
1527	Adverse events occurring in at least 2% of patients in one of the treatment groups in the salmeterol plus roflumilast  (M2-127)  and tiotropium plus roflumilast  (M2-128)  trials
1528	Lung function variables, exacerbations, and other clinical outcomes
1529	Adverse events occurring in at least 2·5% of patients in one of the treatment groups
1530	Variables included in primary analysis
1531	Occurrence of pneumonia as an adverse event or serious adverse event
1532	Adjusted risk factors for pneumonia as an adverse event or serious adverse event
1533	Regression coefficients and development of updated BODE index by variable  (i)
1534	Assignment of points for the updated BODE index
1535	Prediction of 3-year mortality in patients with chronic obstructive pulmonary disease  (COPD)  by updated BODE score
1536	Regression coefficients and development of simplified ADO index by variable  (i)
1537	Assignment of points for the ADO index
1538	Prediction of 3-year mortality in patients with chronic obstructive pulmonary disease  (COPD)  by ADO score
1539	Incidence of the secondary outcome, its components, and death from any cause by randomisation group
1540	Adverse reactions by randomised group
1541	Presenting manifestations in cases with pandemic H1N1 influenza virus infections in the USA, from April 15 to May 18, 2009
1542	Deaths in pregnant women due to pandemic H1N1 influenza virus infection in the USA, from April 15 to June 16, 2009
1543	Typical MRI variables for three-dimensional  (isotropic)  T2-weighted fast-spin echo sequence
1544	Comparison of high-field  (9·4 T)  MRI, conventional  (1·5 T)  MRI, and invasive autopsy
1545	Comparison of diagnoses obtained with MRI at 9·4 T and 1·5 T, and invasive autopsy for cases 1–17
1546	Comparison of image quality scores obtained with MRI at 9·4 T and 1·5 T
1547	Tissue contrast with MRI at 1·5 T and 9·4 T with three-dimensional turbo spin echo sequences
1548	Clinical and laboratory-associated adverse events
1549	Drug-related clinical adverse events of moderate-to-severe intensity  *   recorded in 2% or more patients in either treatment group
1550	Grade 3 or 4 laboratory-associated abnormalities  †
1551	Exposure to community interventions in IMCI and comparison areas  (ten catchments each)
1552	Secondary endpoints
1553	Adverse events occurring in at least 15% of patients on either interferon gamma-1b or placebo
1554	Immediate cause of death
1555	Tumour necrosis factor α inhibitors previously used to treat rheumatoid arthritis
1556	Clinical response to treatment
1557	Efficacy of golimumab at weeks 14 and 24
1558	Adverse events before rescue therapy phase  (weeks 1–16)
1559	Adverse events before and after rescue therapy phase  (weeks 1–24)
1560	Main outcomes
1561	Clinical outcomes  (carer-reported patient symptoms)
1562	Indicators of Synbiotic safety
1563	Most frequently reported adverse events
1564	Bodyweight and laboratory variables
1565	Treatment-emergent adverse events
1566	Efficacy outcome by treatment group  (primary and secondary analyses)
1567	Number of patients with drug-related adverse events, by treatment group
1568	Number of patients with laboratory drug-related adverse events, by treatment group
1569	Summary of safety data, by treatment group
1570	Therapy details and protocol adherence according to study group
1571	Main outcomes according to study group
1572	Function and muscle strength outcomes according to study group
1573	Subsequent location of patients after hospital discharge
1574	Compliance with randomised treatment
1575	Events contributing to disease-free survival and numbers of distant relapses, second cancers, and deaths
1576	Frequency of grade 3 or 4 adverse events during chemotherapy
1577	Simultaneous adjustment analysis by multivariables  (Cox regression analysis)
1578	Frequency of adverse events
1579	Adverse events in the safety population
1580	Reasons for permanent discontinuation of study drugs
1581	Selected adverse effects
1582	Projected and estimated effects of a polypill, comparing estimates from Wald and Law  6–8   versus that obtained in the Polycap study
1583	Adverse events  (intention-to-treat group)
1584	EQ-5D health-related quality-of-life scores
1585	Change in bone mineral density of lumbar spine and femoral neck after 1 year of treatment
1586	Clinicopathological features
1587	Common adverse events
1588	Maximum grade of adverse events per patient
1589	Summary of randomised controlled trials testing the benefit of imatinib in metastatic and unresectable gastrointestinal stromal tumour
1590	Mean blood pressure responses during low-sodium and high-sodium intervention according to number of risk factors for metabolic syndrome and metabolic syndrome status
1591	Odds ratio of high sodium sensitivity during low-sodium and high-sodium intervention according to number of risk factors for metabolic syndrome and metabolic syndrome status
1592	Adverse events reported in 3% or more of patients
1593	Primary and major secondary efficacy endpoints at week 12
1594	Safety data to week 36
1595	6-month follow-up data according to treatment assignment
1596	Mean costs according to treatment assignment
1597	Multivariate analysis of time to CSME development
1598	Decreases in HbA1c at 52 weeks for each trial intervention by previous treatment
1599	Proinsulin to insulin ratios
1600	Treatment-emergent adverse events reported by more than 5% of participants, by system organ class and preferred term
1601	Adverse events  (of more than 10% frequency)
1602	Age-adjusted risk factors and coronary heart disease mortality by employment grade
1603	Best-practice interventions and primordial prevention effects on coronary heart disease mortality
1604	Best-practice interventions and primordial prevention effects on excess risk and relative risk of coronary heart disease mortality for low versus high employment grades
1605	MRI and clinical endpoints
1606	Adverse events in the placebo-controlled treatment period  *
1607	Proportion of patients achieving a weight loss of 5 kg or more, or 10 kg or more
1608	Adverse events per treatment group
1609	Treatment emerging adverse events with probable or definite relation to study drug, leading to discontinuation of treatment
1610	Treatment outcomes of patients with MDR tuberculosis
1611	Variables associated with favourable treatment outcome
1612	Occurrence and management of adverse events
1613	Smoking scenarios
1614	Scenarios of household solid-fuel use
1615	Relative risks of smoking and solid-fuel use on COPD, lung cancer, and tuberculosis
1616	Severity and lesions defining level on the Early Treatment Diabetic Retinopathy Study scale used for the DIabetic REtinopathy Candesartan Trials  (DIRECT)  Programme
1617	Estimated hazard ratios for candesartan versus placebo for time to three-step progression of retinopathy  (intention-to-treat population)
1618	Estimated hazard ratios for candesartan versus placebo for time to regression of retinopathy  (intention-to-treat population)
1619	Adverse events for the safety population
1620	Severity and lesions defining level on the Early Treatment Diabetic Retinopathy Study scale used for the DIabetic REtinopathy Candesartan Trials  (DIRECT)  Programme
1621	Incidence of diabetic retinopathy in DIabetic REtinopathy Candesartan Trials  (DIRECT) -Prevent 1 and progression of diabetic retinopathy in DIRECT-Protect 1
1622	Adverse events in DIabetic REtinopathy Candesartan Trials  (DIRECT) -Prevent 1 and DIRECT-Protect 1
1623	Age-standardised death rates for broad cause categories and broad health-care categories in Agincourt subdistrict, 1992–2005
1624	Five most common causes of death by age and time period in Agincourt subdistrict, 1992–2005
1625	Key elements of primary health care in practice—integration of HAART and chronic non-communicable disease care
1626	Proportions of patients with HIV RNA below 50 copies per mL at week 48
1627	Treatment-emergent resistance through week 48 in isolates from patients with virological failure
1628	Grade 2–4 adverse events through week 48
1629	Selected grade 3–4 laboratory abnormalities in ≥2% patients through week 48
1630	Participants who had a treatment response or change to within normal range, by genotype
1631	Changes in primary and secondary measures of nasal potential difference  (PD)
1632	Adverse events
1633	Incidence of primary and secondary renal outcomes and of its components
1634	Changes in log urine albumin to creatinine ratio
1635	Codes for the clinical activity indicators on the quality and outcomes framework included in the study
1636	Best and worst performing 5% of practices for reported overall achievement and exclusion rates from each deprivation quintile from year 1  (2004–05)  to year 3  (2006–07)
1637	Hazards Ratios for Primary End Point  (Major Cardiovascular Events)  in Predefined Strata and Subgroups legend
1638	End Point Results legend
1639	Forward Multivariate Cox Regression Analysis for Secondary End Point  (Death)  legend
1640	Summary of efficacy measures
1641	Treatment-related adverse events of interest and those that occurred in at least 10% of patients in the everolimus group and laboratory abnormalities
1642	Adverse events by treatment group
1643	Incidence of clinical worsening components
1644	Treatment effects of bosentan at month 6 on other haemodynamic measures
1645	Adverse events that occurred in 5% or more of patients in either group
1646	Adverse events that occurred with a frequency of at least 5% in patients who received at least one dose of vitespen or had at least one post-baseline assessment
1647	Summary of clinical events committee-based assessment of recurrence-free survival and overall survival
1648	Patients included and excluded from analyses, and reasons for exclusion
1649	Incidence of events  (efficacy)
1650	Safety outcomes
1651	Adverse events during treatment
1652	Selected local and systemic adverse events reported after vaccination
1653	Immune responses to LT patch and placebo
1654	Diarrhoea incidence and severity
1655	Pathogens detected in study participants
1656	Diarrhoea episode duration and mean number of loose stools per episode
1657	Risk ratio of exacerbation affected by GOLD-defined COPD severity and treatment with carbocisteine
1658	SGRQ scores in carbocisteine and placebo groups
1659	Comparison of medication-related adverse events between carbocisteine and placebo groups  (safety population)
1660	Adverse effects
1661	Adverse events  (all causality)  that occurred with a frequency of at least 5%, including at least one grade 3 or worse event, and thromboembolic events
1662	Comparison between remission group and non-remission group before and after treatment
1663	Clinical outcomes during the study  (n=6144)
1664	Incidence of new-onset diabetes
1665	Adverse events in patients who took at least one tablet of study medication
1666	Abnormal laboratory results in patients who took at least one tablet of study medication
1667	Hazard ratios  (95% CIs)  for events of cardiovascular disease and incident diabetes associated with metabolic syndrome, and individual criteria for metabolic syndrome
1668	Reasons for patient discontinuation from studies
1669	Number of patients in the modified intention-to-treat population with 75% reduction in psoriasis area and severity index  (PASI 75)  scores at different timepoints
1670	Summary of all adverse events occurring in 5% or more of the patients in each group
1671	Revised Geneva clinical prediction rule
1672	Diagnostic contribution of tests in each group in the per-protocol analysis
1673	Mean cost  (US$)  per patient for both diagnostic strategies in per-protocol and intention-to-diagnose analyses
1674	Proportion of participants reporting at least one severe rotavirus gastroenteritis  (RVGE)  episodes  (per protocol clinical definition)  and vaccine efficacy against severe RVGE during three efficacy periods  (according-to-protocol cohorts for the 2-years' efficacy subset)
1675	Efficacy of RIX4414 against severe rotavirus gastroenteritis and severe gastroenteritis during the 2-years' efficacy period  (ATP cohort for the 2-years' efficacy subset)
1676	Proportion of participants reporting severe rotavirus gastroenteritis  (RVGE)  episodes with a score of ≥11, ≥19 and ≥20 on the Vesikari scale and efficacy of vaccine during the 2-years' efficacy period  (according-to-protocol cohort for efficacy)
1677	Compliance, treatment tolerance, and treatment response to perioperative chemotherapy
1678	Adverse events during chemotherapy and postoperative complications
1679	Patients who received surgery and resection
1680	Previous studies of adjuvant chemotherapy in patients with resected liver metastases from colorectal cancer
1681	Clinical response to treatment
1682	Summary of adverse events  (safety population)
1683	Summary of adverse events
1684	Adverse events with an incidence of 5% or higher
1685	Plasma active renin measurements
1686	Fasting plasma glucose thresholds above which the prevalence of retinopathy increases
1687	Sensitivity, specificity, and positive and negative predictive value for retinopathy at different fasting plasma glucose cutoffs
1688	Distribution of selected covariates by propensity-score deciles, according to type of lung transplantation
1689	Incidence of durable platelet response
1690	Adverse events occurring in at least 10% of patients in either treatment group  *
1691	Tumour response*
1692	Overview of adverse events  *
1693	Rate of cardiovascular and fatal events
1694	Rate of left ventricular ejection fraction  (LVEF)  less than lower limits of normal, increased troponin concentration, and hypertension
1695	Predictors of cardiovascular events: univariate associations based on logistic regression analysis
1696	Electrolyte, acid-base changes, and markers of haemolysis and cardiovascular stability
1697	Mean ambulatory systolic and diastolic blood pressure at 24 h post-dose on day 10 after administration of anacetrapib or placebo in healthy middle-aged and elderly people  (N=22)
1698	Incidence of adverse events in patients with dyslipidaemia
1699	Incidence of adverse events in ambulatory blood pressure study
1700	Number of laser treatment courses per patient during follow-up and cumulative totals by allocated treatment group
1701	Main outcomes for the ophthalmology substudy
1702	Distribution of mediating variables that were assessed before  (1997)  and after  (2003)  the intervention in the 24 sentinel areas in Salvador, Brazil
1703	Prevalence ratios of diarrhoea  (after vs before intervention)  obtained by different regression models
1704	Mean haemoglobin levels by treatment period in per-protocol population
1705	Adverse events
1706	Allergen-induced FEV1 response during the late phase
1707	Allergen-induced FEV1 response during the early phase
1708	Treatment-emergent adverse events by system organ class  (>15% of participants)
1709	Zinc and copper status by treatment group, 12 months after supplementation began
1710	Mortality by treatment group
1711	Cause-specific mortality by treatment group
1712	Morbidity incidence rates by treatment group
1713	Proportion of children with multiple episodes per year by treatment group
1714	Congestive heart failure events reported in the thiazolidinedione trials
1715	Congestive heart failure and cardiovascular deaths by type of thiazolidinedione
1716	The Comorbid Conditions in Two Groups
1717	Echocardiographic Parameters Before and After Procedures
1718	Efficacy outcomes during the treatment period
1719	Bleeding events during the treatment period
1720	Adverse events
1721	Relation between self-reported passive smoking exposure  (using different measures)  and COPD in never smokers
1722	Relation between self-reported passive smoking exposure and respiratory symptoms in never smokers
1723	Summary of sampling designs by site
1724	Estimated population prevalence of COPD according to GOLD stage
1725	Estimated population prevalence of GOLD stage II or higher COPD, separated by age and smoking exposure†
1726	Correlation between VmaxFRC of infants and lung function at ages 11, 16, and 22
1727	Association between infant VmaxFRC and lung function at ages 11, 16, and 22 years
1728	Risk factors for incident diabetes patients with recent myocardial infarction
1729	Risk of diabetes or diabetes and IFG according to consumption of a Mediterranean-type diet in patients with recent myocardial infarction
1730	Safety and tolerability of study treatments
1731	Response by treatment, age, and stage
1732	Toxic effects by treatment  *
1733	Chemotherapy regimens
1734	Grade 3 or 4 adverse events reported
1735	Overall survival log-rank comparisons
1736	Is deferred combination  (strategy B)  non-inferior to first-line combination  (strategy C) ?
1737	RECIST  *   response and progression-free survival
1738	Efficacy results
1739	Adverse effects associated with sequential versus combination treatment over all lines
1740	Adverse effects associated with sequential versus combination treatment first-line treatment
1741	Adverse events
1742	Summary of adverse events through to week 48
1743	Adverse events
1744	Clinical, Angiographic and Ergometric Data in Symptomatic  (Group P)  and Asymptomatic Patients  (Group A)  With Coronary Artery Disease
1745	Investigator-reported adverse events
1746	Relative risk of tobacco-attributable mortality in snus users compared with current smokers by cause
1747	Uncertainty assumptions and distributions
1748	Years of healthy life lost compared with people who have never used tobacco
1749	Predictors of poor outcome on univariate analysis
1750	Admission blood culture results by HIV status and age  *
1751	Urinary antimicrobial activity on admission and subsequent yield of organisms and response to therapy
1752	Organisms isolated from children who were investigated for failing to respond by HIV status and age
1753	Estimated per dose protective efficacy of mOPV1 and trivalent vaccine against paralysis by type 1 poliovirus in India
1754	Efficacy responses at week 24
1755	Drug-related adverse events occurring with an incidence of at least 5% in at least one of the treatment groups
1756	Reasons for discontinuation
1757	Proportion of patients who reached a viral load <50 copies per mL at week 48 by subgroup  (ITT-TLOVR)
1758	AIDS Clinical Trials Group grade 3 or 4 adverse events recorded in ≥1% of patients in either treatment group up to week 48, regardless of causality
1759	Subgroup analysis
1760	Adverse experiences
1761	Effect of zinc supplementation on overall mortality and by sex and age groups
1762	Effect of zinc supplementation on cause-specific mortality
1763	Cumulative risk of failure at day 42
1764	Events by treatment group  (ITT)
1765	HR  (95% CI)  for other efficacy endpoints  (exemestane vs tamoxifen group)
1766	Numbers of toxic effects reported on-treatment, by Common Toxicity Criteria grade
1767	Numbers of toxic effects reported on-treatment and post-treatment, by Common Toxicity Criteria grade
1768	Primary treatment outcomes
1769	Blinded imaging diagnosis compared to final clinical diagnosis
1770	Paired proportion analysis of CT vs MRI for the diagnosis of stroke
1771	Agreement between diagnoses by the four readers
1772	Sensitivity and specificity of blinded imaging diagnosis by time from onset to scan
1773	Site of first disease-free survival event  (ITT analysis)
1774	Adverse events
1775	Cardiac safety
1776	Adherence to treatment strategies during follow-up
1777	Major endpoints by treatment strategy
1778	Summary of primary and secondary outcomes with comparative statistics
1779	Changes in weight and risk factors
1780	Distribution of dose changes in antidiabetic medications
1781	Safety data at 1 year and adverse events in randomised and exposed patients
1782	Subgroup analyses with both the rate differences and rate ratios
1783	Adverse events that occurred with a frequency of at least 5% greater on sunitinib than on placebo in per-protocol population
1784	Primary and secondary outcomes by treatment group
1785	Primary and other outcomes
1786	Adverse events after two doses
1787	Haemagglutinin inhibition antibody response
1788	Virus neutralisation antibody response
1789	Secondary endpoints
1790	Adverse events
1791	Cox model for time to re-start HAART in scheduled treatment interruption group  (n=243)  by predictor
1792	Number  (%)  of patients with adverse events during randomised treatment phase
1793	Study outcomes at week 48 based on TLOVR analysis  (<400 copies/mL) , ITT-E population  *
1794	Summary of protocol-defined confirmed virological failure and drug-associated resistance by week 48, ITT-E population
1795	Number  (%)  of drug-related adverse events  (grades 2–4)  and laboratory abnormalities  (grades 3–4)  in ≥2% of patients through 48 weeks
1796	Treatment modalities
1797	Outcomes according to treatment group
1798	Adverse events according to treatment group
1799	Treatment received
1800	New AIDS-defining events  (number of fatal events)
1801	Grade 3 and 4 adverse events and all treatment-modifying adverse events
1802	Summary of screened statemented population by consensus ASD diagnoses with ADI-R, ADOS-G, and ICD-10 symptom count scores
1803	Prevalence estimates  *
1804	Association between age and CVD risk
1805	Parasitological responses to antimalarial treatment
1806	Relation between gametocytaemia and age
1807	Gametocyte responses to antimalarial treatment
1808	Haemoglobin values after treatment
1809	Adverse effects within the first week after treatment
1810	Ten leading causes of death by income group, 2001
1811	Age distribution of deaths  (thousands)  among children younger than age 5 years including stillbirths, 2001  28
1812	Ten leading causes of burden of disease  (DALYs)  by income group, 2001
1813	Burden of disease in low-income and middle-income countries, high-income countries, and worldwide, 2001  7
1814	Neglected low-cost opportunities and high-cost interventions in south Asia and sub-Saharan Africa
1815	Effect of treatment on primary and secondary outcome measures
1816	Adverse events  (all causalities)  reported in at least 5% of patients in either treatment group
1817	Results of observational assessment
1818	Clinical examples of overdiagnosis and overtreatment
1819	12-month post-supplementation iron status indicators by treatment group  (substudy)
1820	Mortality by treatment group
1821	Cause-specific mortality by treatment group
1822	Morbidity incidence rates by treatment group
1823	Individual Patient Data  (n = 25)
1824	M-Mode Echocardiographic Variables
1825	Basline Volumes of Chronic “Volume Non-responders” Compared to Stable Patients and “Volume Responders”
1826	Main grade 3 and grade 4 toxic effects
1827	Event-free survival probability in retrospective subgroup analyses
1828	Log10 HIV-1 viral load and percentage of CD4+ T lymphocytes
1829	Results of linear regression using generalised estimating equation
1830	Number of children with specific diagnoses at scheduled follow-up and illness visits
1831	Deaths during the study
1832	Response rates at the household, questionnaire, and spirometry levels
1833	Percentage of non-response by sex, age, and smoking status  *
1834	Description of the samples in the five sites of the PLATINO study
1835	Prevalence of COPD  (post-bronchodilator FEV1/FVC, 0·70)  according to some relevant exposures
1836	Prevalence of COPD according to GOLD severity strata
1837	Mean altitude and adjusted COPD prevalence by site
1838	Sites affected in 402 patients for whom information was available  (FUA assessment)
1839	Age and sex structure of two survey samples and population of Cambodia aged 25 years and older
1840	Number of participants, prevalence of diabetes, number of newly diagnosed cases, and prevalence of impaired glucose tolerance  (IGT) , by age  (years)
1841	Relation between age and blood glucose, BMI, waist-hip ratio, and blood pressure
1842	Multiple linear regression
1843	Adverse events occurring in more than 5% of either treatment group or with a difference of at least 3% between treatment groups
1844	Clinical and laboratory results before treatment and after 10 months of treatment
1845	Number of medical officer diagnoses in the clinic
1846	Cause of death
1847	Treatment algorithm
1848	Percentage of time on antihypertensive medication by treatment group and study period
1849	Adverse events with an incidence of more than 5% in one treatment group and a difference between treatment groups of more than 1%
1850	Change in lung function parameters after treatment with roflumilast
1851	Chronic obstructive pulmonary disease exacerbations
1852	Adverse events occurring in at least 5% of patients in any treatment group
1853	Recurrences and deaths by treatment group
1854	Serious adverse events by treatment group
1855	Predefined adverse events by treatment group in ABCSG trial 8
1856	Echocardiographic Data
1857	Treadmill Test Responses With Univariate Comparison Between Those Who DIed and Those Who Survived
1858	Previously Published Prognostic Studies Relating to the Decrease of HR After Exercise
1859	Regional Distribution of Electrogram’s Amplitude, Duration and Amplitude/Duration Ratio Values in the Control Group
1860	Follow-Up Data
1861	Left Ventricular Ejection Fraction and Contractile Reserve After 3-Year Follow-Up in Survivors and Nonsurvivors
1862	Rank Sum Two-Tailed  (Mann-Whitney)  Test: Survivors Versus Nonsurvivors
1863	Analysis of Significance and Prognostic Value of End-Diastolic Volume, Stroke Volume, Left Ventricular Ejection Fraction and Heart Rate Obtained During Dobutamine Infusion  a
1864	Analysis of Significance and Prognostic Value of Cardiac Output, Stroke Work and End-Systolic Volume Obtained During Dobutamine Infusion  a
1865	Analysis of Significance and Prognostic Value of Systolic Blood Pressure, Diastolic Blood Pressure and Mean Arterial Blood Pressure Obtained During Dobutamine Infusion  a
1866	Clinical and Ambulatory Blood Pressure Values for the Three Genotypes
1867	Costs and Utilities
1868	Clinical Features, Alcohol Consumption and Antimyosin Uptake in Alcoholic Patients, With and Without Associated Cardiac Disease, Actively Consuming Alcohol
1869	Doppler Echocardiographic and Antimyosin Studies Before and After Short-Term Alcohol Intake for Three Consecutive Days in Six Healthy Volunteers
1870	Peak Emptying Velocities of Left Atrial Appendage and Degree of Spontaneous Echo Contrast Before and After Internal Atrial Defibrillation
1871	U.S. Office Visits With Cholesterol Testing, Cholesterol Counseling and Lipid-Lowering Medications: National Ambulatory Medical Care Survey, 1991 and 1992
1872	Likelihood of Cholesterol Services in Adults Without Known Hyperlipidemia: National Ambulatory Medical Care Survey, 1991 and 1992
1873	Likelihood of Cholesterol Services in Adults With Hyperlipidemia: National Ambulatory Medical Care Survey, 1991 and 1992
1874	Atrioventricular Node Properties and His–Ventricular Interval Before and After Radiofrequency Modification in Eight Patients
1875	Lipid Profile  ∗
1876	Multivariable Cox Regression Analysis of CVEPredictors
1877	Multivariable Linear Regression Analysis of Factors Associated With UrinaryLog-11-dh-TxB2   ∗
1878	Univariate and Multivariate Cox Regression Analysis of Outcome Predictors
1879	Mortality, PGF, and CAV
1880	Mortality in Transplant Recipients: Propensity-Matched Cohorts
1881	Donor Inotrope or Vasopressor Use During Donor Management
1882	Complications
1883	Acute Conversion Testing
1884	Extracardiac Abnormalities of French and Japanese AV Block
1885	Filtering of Variants Identified in French and Japanese Congenital AV Block Cases
1886	Profiles of the Rare Variations Identified in French and Japanese AV Block Families
1887	Comparison of Clinical Phenotypes of Families With Cx45-p.R75H and ODDD
1888	Complications and Interventions After FontanProcedures
1889	Main Study Outcomes at Fontan 1 and Fontan 3  ∗
1890	Association Between PedsQL Physical Summary Score and Exercise
1891	Subjects With Paired Functional Health Status Data at Fontan 1, 2, and 3
1892	Cox Model for Predictors of Death or Cardiac Transplantation  (TotalN=545;54Events)
1893	Rate of Death and Cardiac Transplantation Since Fontan 1 by Center
1894	Types and Frequency of VHD Patients in ENGAGE AF-TIMI 48
1895	Efficacy Outcomes by Presence or Absence of Valvular Heart Disease in ENGAGE AF-TIMI 48
1896	Safety and Net Clinical Outcomes by Presence or Absence of VHD in ENGAGE AF-TIMI 48
1897	Model 4: OxPL-apoB and Events
1898	Incremental AUC for Event Prediction
1899	Change in NRI and IDI With OxPL-apoB Addition
1900	Cardiovascular Event Risk
1901	Univariate and Multivariate Predictor Analysis of Adverse Aorta-Related Events in IMH
1902	Incidence and Hazard Ratio of Efficacy and Safety Endpoints in Patients With Versus Without Increased Risk of Falls
1903	Prevalence of an FH Mutation Among Participants With Severe Hypercholesterolemia  (LDL Cholesterol≥190 mg/dl)  in CAD-Free Control Subjects and Population-Based Cohort Studies
1904	Risk of CAD in Those With Elevated LDL Cholesterol  (≥190 mg/dl)  According to FH Mutation Status in CAD Case-Control Studies
1905	Prevalence of FH According to Different LDL Cholesterol Thresholds and Mutation Classification Schemes
1906	Cox Regression Analysis for MACE in AMI Patients
1907	Stratified Cox Regression Analysis for MACE According to AMI Type
1908	Cox Regression Analysis for All-Cause Mortality, HF Hospitalization, and Recurrent AMI
1909	Clinical Outcomes of Patients With High FFR According to CFR and IMR
1910	Independent Predictors of Patient-Oriented Composite Outcomes Among PatientsWith High FFR
1911	Proportions of Patients With High P2Y12-Mediated Platelet Reactivity According to Pre-Defined Threshold Values
1912	Reproducibility of Echocardiographic Parameters
1913	Overall Performance of the 2 Serum Parameters for Predicting High Myocardial CCL According to ROC Curves
1914	IDI and NRI for Outcomes by Adding the Serum CITP:MMP-1 Ratio to a Model Including Covariables
1915	Habitat and Potential Portals of Entry of the Causative Microorganisms of Infective Endocarditis  ∗
1916	Identified Portals of Entry in 238 Patients With Infective Endocarditis
1917	Cutaneous Portals of Entry of Infective Endocarditis
1918	Microorganisms in Infective Endocarditis With a Cutaneous Portals of Entry
1919	Oral and Dental Portals of Entry of InfectiveEndocarditis
1920	Microorganisms in Infective Endocarditis With an Oral or Dental Portal of Entry
1921	Gastrointestinal Portals of Entry of InfectiveEndocarditis
1922	Microorganisms in Infective Endocarditis With Gastrointestinal Portals of Entry
1923	Microorganisms in 82 Episodes of Infective Endocarditis With Nonidentified Portals of Entry
1924	ApoB, Cholesterol Levels, and Concordance/Discordance Between ApoB and Cholesterol Categories in Relation to Risk of Y25 CAC>0
1925	Efficacy and Safety of Ticagrelor in Patients With PAD
1926	Limb Vascular Efficacy With Ticagrelor
1927	Overview of Used Risk Scores: Risk Factors Used in ATRIA Risk Score
1928	Overview of Used Risk Scores: Risk Factors Used in CHA2DS2-VASc Risk Score and CHADS2 Risk Score
1929	Risk Factors for Ischemic Stroke in Patients With AF
1930	Ischemic Stroke Event Rates Stratified by the Sum of Points for ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores
1931	Characterization of Plasma and HDL in Mice Lacking apo M
1932	ECM and Adhesion Molecule Genes Overexpressed Following p1158/59 Peptide Treatment  ∗
1933	Trial Acronyms
1934	Phase 2 Trial Results
1935	Phase 3 and Long-Term Extension Trial Results
1936	Statistical Analysis of Targeted Metabolites ∗  Between Control Subjects and Stage C Heart Failure Patients in the Discovery Phase Study
1937	Univariable and Multivariable Analyses of the Associations of BNP and Metabolites With Heart Failure Diagnosis
1938	Univariable Analysis on Prognostic Value in HF Patients
1939	Results for Primary and Secondary Endpoints at 9 Months and in Landmark Analysis From 6 Weeks to 9 Months
1940	Post-Discharge Antithrombotic Medication Persistence
1941	Measures of Study Quality
1942	Summary Estimates for the Outcomes of Interest
1943	Triglycerides, LDL-C, and HDL-C  (mg/dl)  at InitialRandom Assignment and on Assigned Treatment
1944	Risk of Cardiovascular Events After Acute Coronary Syndrome by Quintile of LDL-C or HDL-C
1945	Summary of Antiplatelet Therapy Switching
1946	Management and Outcomes of Acute Aortic Dissection
1947	Trends in Type A Dissection
1948	Trends in Type B Dissection
1949	Novel Heterozygous Disease-Causing Variants in LDLR and APOB
1950	Risk of Rapid Calcific Aortic Valve Stenosis Progression According to Plasma Levels of Lp (a)  and OxPL-apoB
1951	Laboratory Findings  ∗
1952	Changes in Coronary Atheroma Volume and Calcium Indices According to PlaqueProgression/Regression
1953	Relationships of Change in CaI With Average Follow-Up Lipoprotein and CRP Levels in Patients Receiving High-Intensity Statinsor No-Statins  ∗
1954	Clinical Outcome at 30 Days
1955	Clinical Outcome at 1 Year
1956	Angiographic Findings of TCFA
1957	OCT Findings of TCFA
1958	IVUS Findings of TCFA
1959	Incidence Rates of SSS Among Women in ARIC and CHS
1960	Incidence Rates of SSS Among Men in ARIC and CHS
1961	Risk for Major Cardiovascular Events, by Achieved LDL-C Concentration
1962	Risk for Major Cardiovascular Events, by Achieved Non-HDL-C Concentration
1963	Risk for Major Cardiovascular Events, by Achieved ApoB Concentration
1964	Categorization of Deaths in PARTNER-A Patients
1965	Categorization of Deaths in PARTNER-B Patients
1966	Other Noncardiovascular Deaths
1967	Summary of the Most Important Cytokines, Proteins, and Enzymes Involved in the Atherosclerotic Process
1968	Overview of Diverse Statin Action Through SeveralDifferent Targets
1969	Summary of Key Clinical Trials Examining the Role of Statins in Primary and Secondary Prevention of Cardiovascular Events
1970	Hemodynamic Measurements of Sham, TAC+V, andTAC+G Mice at End of Study
1971	Lipid Efficacy Outcomes Averaged at Weeks 10 and 12 and at Week 12
1972	Adverse Events
1973	Associations Between Plasma Lipid and PCSK9 Levels in Controls, Patients With FH, and Patients With FHBL
1974	Results of Ajmaline Challenge Test
1975	Long-Term Follow-Up of Children With Brugada Syndrome
1976	Genetic Causes of Familial Hypercholesterolemia Phenotypes
1977	Clinical Trials With PCSK9 Inhibitors  (PCSK9 Inhibitor Treated Patients Only, n = 1,551)
1978	Changes in Parameters of CRM Devices Exposed to Direct Radiation Beams From CT
1979	Composite Genotypes Used in the Study
1980	ORs for CAD  (>50% Diameter Stenosis)  According to Quartiles of OxPL/ApoB in IL-1 (+)  and IL-1 (–)  Patients, by Age Subgroup
1981	ORs for CAD  (>50% Diameter Stenosis)  According to Quartiles of Lp (a)  in IL-1 (+)  and IL-1 (–)  Patients, by Age Subgroup
1982	Human Subject Groups Evaluated in this Study of SLC35F3 Genetic Variation and BP, byGroup Genotyped for SLC35F3  (N= 32,063)
1983	Effects of SLC35F3 Intronic Variant rs17514104 on the Quantitative BP Traits  (SBP and DBP, in mm Hg)  in 2 Independent Population Samples: Meta-Analysis
1984	SBP/DBP Determination by SLC35F3 Tagging Variant rs16842784: Replication by Meta-Analysis Across 2 Independent StudyGroups
1985	SLC35F3 Variant rs17514104: Effect on Heritable Autonomic Traits in Twins and Siblings  ∗
1986	Summary of Efficacy Outcomes at Week 12
1987	Lipoprotein (a) , UC LDL-C, and Apolipoprotein B Response by Specific Lipoprotein (a)  Cut-Points at Week 12, Change and Percentage of Change Versus Control  ∗
1988	Periprocedural Variables According to Inoperable Category and STS Score
1989	30-Day Outcomes  (Kaplan-Meier Analysis)  According to Inoperability Category and STS Score
1990	QOL at Follow-Up According to Reasons for Inoperability
1991	Multivariable Cox Regression Model for 2-Year All-Cause Mortality
1992	The Interaction of Inoperability Category and STS Score on Mortality
1993	Summary of Patients With Ischemic Events and Unadjusted and Adjusted HRs for the Primary Efficacy Endpoint According to Smoking Status
1994	Change in HR During Cold Stress in Twins and Siblings
1995	HR Traits in Twin Pairs: Heritability and Shared Genetic Determination  (Pleiotropy)
1996	Effects of CYB561 3′-UTR Variant on HR Traits
1997	Effects of CYB561 3′-UTR Variant G+1485A on Basal/Resting HR in Multiple Independent Groups: Meta-Analysis
1998	Clinical Outcomes of CLD Patients Included in the Randomization: TAVR Versus Control
1999	Clinical Outcomes of TAVR Patients
2000	Metrics to Compare Cardiovascular Disease Mortality
2001	Heart Disease Mortality by Asian-American Subgroup  (2003 to 2010)
2002	Cerebrovascular Disease Mortality by Asian-American Subgroup  (2003 to 2010)
2003	Association of NT-proBNP With Incident CVD
2004	Association of NT-proBNP With Cardiovascular Mortality, Incident Fatal and Nonfatal MI, and Incident Fatal and Nonfatal Stroke
2005	Changes to 10-Year CVD Risk Prediction Statistics After Adding NT-proBNP to Existing Risk Prediction Models
2006	Major Bleeding Events During the 2-Year Follow-Up Period
2007	Multivariate Predictors of Major Bleeding
2008	Efficacy and Bleeding Endpoints
2009	Vorapaxar Compared With Placebo for Stroke by Qualifying Disease State
2010	Types of Major Late Bleeding  (≥30 Days)  After TAVR  (n= 142)
2011	Multivariate Predictors of Major Late Bleeding
2012	Independent Predictors of 30-Day to 1-Year Mortality
2013	Univariate Covariates of DHEA and DHEA-S Levels
2014	Multivariate Correlations of DHEA and DHEA-S Levels
2015	Adjusted Hazard Ratios of DHEA and DHEA-S as Continuous Variables forCHDand CBD Events
2016	Hazard Ratios of DHEA for CHD Events: Exclusion of Subgroups
2017	Laboratory Results
2018	OCT Measurements
2019	Main Meta-Analyses Comparing Clinical Outcomes With Different Types of Drug-Eluting Stents and Bare-Metal Stents
2020	Current FDA-Approved Drug-Eluting Stents
2021	Clinical, Echocardiography, and Anthropometric Parameters
2022	Right Heart Catheterization and Laboratory Parameters
2023	Logistic Regression Analysis of Hormonal, Cardiac, and Clinical Factors Associated With Cachexia in All HF Subjects  (n = 408)
2024	Predictors of Adverse Outcome by Cox Proportional Hazards Analysis in All HF Subjects  (N= 408)
2025	Association Between a 1 SD Increase in Apo and Lp (a)  Levels After 1 Year of Treatment ∗  and CV Events
2026	Comparison of Different Monocyte Subpopulations Phenotype and Functions
2027	Summary of Clinical Trials Using Bone Marrow Mononuclear Cells in Acute Coronary Syndrome Patients With Summary of Trial Findings
2028	Outcomes in Study Patients at 12 Months Follow-Up
2029	Safety Overview: Treatment-Emergent AEs
2030	CCEs of Patients Receiving Qili Qiangxin Capsule Therapy or Placebo
2031	Summary of Adverse Events
2032	Benefit and Safety Outcomes in Multiple Antithrombotic Regimens Within 1 Year in AF Patients After MI/PCI
2033	Adjusted Hazard Ratios for Death and Weights for Ischemic and Bleeding Events in the RE-LY and ACTIVE Trials
2034	Weighted Net Clinical Benefit of Dabigatran 110 mg bid Compared With Warfarin, Dabigatran 150 mg Compared With Warfarin,and Dabigatran 150 mg bid Compared With Dabigatran 110 mg bid
2035	Effect of Dabigatran 150 mg bid Compared With Dabigatran 110 mg bid on Mortality, Different Composites of Serious Thrombotic and Bleeding Events, and Unweighted Net Clinical Benefit
2036	Reclassification by Directly Measured LDL-C in Strata of Friedewald-Estimated LDL-C and Triglyceride Levels
2037	Effect of Endurance Exercise Training on Exercise Performance
2038	Effect of Endurance Exercise Training on Brachial Artery Diameter in Response to Cuff Ischemia  (FMD)
2039	Carotid Arterial Stiffness Measurements
2040	Effect of Endurance Exercise Training on Resting Left Ventricular Volumes and Doppler Filling
2041	Effect of Endurance Exercise Training on Health-Related Quality of Life
2042	Results of Univariate and Multivariate Linear Regression Analyses for Log [ΔcTnT  (CS-Ao) ]
2043	Results of Univariate and Multivariate Logistic Regression Analyses for Parameters That Correlated with Highest Tertile Value of ΔcTnT  (CS-Ao)
2044	Periprocedural and 30-Day Outcomes Associated With TV-in-TV and TVE
2045	Kaplan-Meier Outcomes for TV-in-TV and TVE at 1 Year
2046	Regression Coefficients and Their p Values From Fully Adjusted Models for Lipid Levels at Index Visit and Changes Before and After Index Visit
2047	Regression Coefficients and Their p Values From Fully Adjusted Models for Other Cardiovascular Risk Factor Levels at Index Visit and Changes Before and After Index Visit
2048	Thromboembolic and Bleeding Risk Scores  (N = 89)
2049	LAA Ligation Results  (N = 89)
2050	Procedural Details  (N= 150)
2051	Procedure and Device-Related Serious Adverse Events  (N= 150)
2052	Clinical Outcomes
2053	Plasma Concentrations of NO2 − in Healthy Controls and Patients With Coronary Artery Disease
2054	Quantification of Regional Myocardial Function During Dobutamine Stress Echocardiography
2055	Changes in FMD During Forearm Vascular Ischemia and Reperfusion
2056	Category-Free Net Reclassification Improvement
2057	Summary of ROC Analysis for 1-Year Death/HTx/LVAD Requirement Stratified According to Anticoagulation Treatment
2058	Univariate Analysis of Factors Associated With 3-Year Death/HTx/VAD Requirement
2059	Summary of the Multivariate Analysis Including MELD Models With the Factors Associated With 3-Year Death/HTx/VAD Requirement
2060	Efficacy and Safety for New Atrial Fibrillation Patients Treated With Dabigatran
2061	Subgroup Analysis on Dabigatran Users With More Than 1-Year Follow-Up
2062	Contraindicated or Potential Hazardous Co-Medication for Dabigatran Group
2063	Adverse Events at 6 Months
2064	Cardiovascular Events According to Thirds of Gait Speed
2065	Cox Proportional Hazards Analysis for Cardiovascular Events in Patients With ST-Segment Elevation Myocardial Infarction
2066	Hazard Ratio by Gait Speed in Multiple Adjusted Models
2067	C-Statistics for Cox Proportional Hazards Models to Predict Cardiovascular Events in STEMI Patients
2068	Reclassification by Addition of Gait Speed to Framingham Risk Score, BNP, and Comorbidity Index
2069	Clinical and Operative Data
2070	Doppler Echocardiographic and CT data
2071	Laboratory Data
2072	Determinants of ApoB/ApoA-I Ratio in Univariable and Multivariable Analysis
2073	Unadjusted and Multivariable-Adjusted Associations of LVH
2074	Multivariable-Adjusted Association of Serelaxin With 180-Day Mortality in the Relaxin in Acute Heart Failure Study
2075	Association of Substantial Biomarker Changes at 48 h From Randomization With 180-Day Mortality in the Relaxin in Acute Heart Failure Study
2076	Risk of Any Ischemic Event During 34 Years of Follow-Up According to CETP Genotype in the General Population
2077	Analysis of Covariance After Adjustment for Confounding Risk factors
2078	Association of Oxidation-specific Biomarkers With Cardiovascular Disease Risk in the Bruneck Study Cohort  (1995 to 2010)   (n = 765)
2079	Risk Reclassification Based on Oxidation Markers  (OxPL/ApoB, Cu-OxLDL IgG, and MDA IgM)  in Patients Who Experienced a Cardiovascular Disease Endpoint  (n = 138)  and in Those Who Remained Free of Cardiovascular Disease during Follow-Up  (n = 627; 1995 to 2010)
2080	In-Hospital Outcomes, According to the Occurrence of New-Onset LBBB
2081	Late Clinic Outcomes, According to the Presence of New-Onset, Persistent LBBB  (With No Pacemaker Implantation)  at Hospital Discharge
2082	Evaluations, Treatments, and Procedures in Hospital or at Discharge for Index Event
2083	Cause of Death for Patients Undergoing CABG Within 7 Days From Last Intake of Study Drug
2084	Death After CABG With Infection or Bleeding as Direct Cause or Contribution Factor  (N = 1,261)
2085	Performance of Predictive Models for 90-Day Mortality
2086	Mortality Rates by MARKED-Risk Score Categories
2087	Clinical Correlates of Gal-3 in 3,353 Participants
2088	Gal-3 Associations With Echocardiographic Traits in 2,425 Participants
2089	Association of Plasma Gal-3 Levels, Incident HF, and Mortality
2090	Performance Metrics of Gal-3 in Risk Prediction Models
2091	Outcomes at 3 Months With Anticoagulant Strategies in the Overall Population of Patients Receiving Aortic Valve Bioprostheses
2092	AUC Values for Various Tests to Identify Any Form of cTOD With or Without Ischemia
2093	Incremental Contribution of Addition of BNP and cTnT to AUC for CV Risk Scores to Identify cTOD
2094	Number of “Missed Cases” of cTOD When Cutoff Is Applied of BNP >15 pg/ml or hs-cTnT >5.93 ng/l
2095	Outcomes and BB Dose at Randomization
2096	Cardiovascular Adverse Events by BB Use at Randomization
2097	Summary of Treatment-Emergent Adverse Events  (Safety Population)
2098	Risk of First CVD Event or Death for On-Treatment Lipids, Apolipoproteins, and Ratios According to Tertiles
2099	Risk of First CVD Event or Death for Standardized On-Treatment Lipids, Apolipoproteins, and Ratios
2100	Risk of First CVD Event or Death for Standardized On-Treatment Lipids, Apolipoproteins, and Ratios According to Subgroups
2101	Individual and Multivariable Covariates of logNGAL Levels
2102	Multivariable Cox Proportional Hazards Models for Risk of Death or CVD per 1 SD Increase in log10NGAL and Other Biomarkers
2103	Univariable Analysis for Predictors of 30-Day Mortality Rate
2104	Univariable Analysis for Predictors of 6-Month Mortality Rate
2105	Unadjusted and Adjusted Hazard Ratio for 30-Day Mortality Rate Across Quartiles
2106	Unadjusted and Adjusted Hazard Ratio for 6-Month Mortality Rate Across Quartiles
2107	Clinical Outcomes
2108	Echocardiographic Data According to the Occurrence of Events
2109	Univariable and Multivariable Cox Proportional Hazard Analysis
2110	Baseline Characteristics of the Patients With and Without Adverse Events
2111	Univariate Cox Regression Analysis for Predictors of Adverse Events After Catheter Ablation
2112	Multivariate Cox Regression Analysis for Predictors of Adverse Events After Catheter Ablation Using the CHADS2 Score
2113	Multivariate Cox Regression Analysis for Predictors of Adverse Events After Catheter Ablation Using the CHA2DS2-VASc Score
2114	Procedural Data and Intraprocedural Complications
2115	Procedural Outcomes
2116	Current Publications
2117	Univariate Predictors of LVDSD
2118	Multivariate Analysis to Predict the Combined Endpoint: Derivation Set
2119	Effects of a High Cholesterol Diet and IK17-Fab or IK17-scFv on Weight and Lipid Profiles
2120	Cox Regression Analysis for Endpoints Based on the Initial NT-proBNP and LVEF Measurements
2121	Time-Dependent C-Statistic and NRI for Progressively More Complex Predictive Models of Outcomes Using LVEF and a Single Measure of NT-proBNP
2122	Time-Dependent C-Statistic AUC and NRI for Progressively More Complex Predictive Models of Outcomes Using LVEF, Diastolic Measures, and Repeated Measures of NT-proBNP
2123	Dual-Chamber ICD Recipients With an Indication for Pacemaker Therapy
2124	Single- Versus Dual-Chamber ICD Implantation Complication Rates
2125	Odds of Adverse Events Associated With Dual-Chamber ICD Implantation
2126	Summary of Coprimary Endpoints
2127	Summary of Adverse Events
2128	Prevalence of Cardiovascular Diseases and Diabetes Mellitus Type 2 Across the rs5068 Genotype
2129	Metabolic Parameters in the Study Population According to the rs5068 Genotype
2130	Adverse Events at 6-Month Follow-Up
2131	Vascular Data
2132	Clinical Correlations
2133	Distribution of the Number of Components of MetS and Events
2134	Stepwise Cox Regression of MetS Components by Outcome
2135	Rates of Death or MI by MetS/DM Subset and Treatment Group
2136	Incidence Rates per 1,000 Person-Years  (Number of Cases)  and Adjusted HRs  (95% Confidence Intervals)  for Major CVD Events by Quartiles of NT-proBNP in Men Without Diagnosed CVD and Without Diagnosis of Heart Failure
2137	Incidence Rates per 1,000 Person-Years  (Number of Cases)  and Adjusted HRs  (95% Confidence Intervals)  for Major CVD Events by Quartiles of NT-proBNP in Men With Diagnosed CVD and Without Diagnosis of Heart Failure
2138	Adjusted Standardized HRs for 1-SD Increases in log NT-proBNP and log CRP and C-Statistics
2139	Reclassification Among Men Who Develop Major CVD Events and Those Who Do Not Experience CVD Events on Follow-Up in Men With and Without Pre-Existing CVD
2140	Information on Healthy Volunteers and Dyslipidemic Patients
2141	Lipid Profiles and ECG Parameters Before and 24 h After rHDL Infusion
2142	Genotype and On-Clopidogrel PR Values
2143	Incidence of Adverse Events  (Ischemic and Bleeding)  According Genotype and Clopidogrel Responsiveness Status
2144	Independent Predictors of Attaining LDL-C <50 mg/dl at Any Visit Among Rosuvastatin-Allocated Patients
2145	Numbers and Rates  (per 100 Person-Years)  of Treatment-Emergent Adverse Events by Treatment Group and Attained LDL-C
2146	ALT or CK Elevation, Proteinuria, or Hematuria at Any Follow-Up Visit by Treatment Assignment and Attained LDL-C
2147	Lipoprotein Profiles of 8K-Lp (a)  and 8K-apo (A)  Mice Following Treatment With ASO 144367
2148	Apo (a) , OxPL/apo (a) , apo (a) /m-apoB, and OxPL/m-apoB Levels in 12K-apo (a)  Mice
2149	Pre-Operative Risk Factors
2150	Adverse Events
2151	Relationship Between Platelet Reactivity and ASA Responsiveness, Measured 3 Days After CABG Surgery, and 6-Month SVG Patency
2152	Relationship Between Platelet Reactivity and ASA Responsiveness, Measured 6 Months After CABG Surgery, and 6-Month SVG Patency
2153	Multivariate Models of Factors Associated With Odds of SVG Occlusion Versus Patency
2154	Relationship Between Percentage Change in Biochemical Parameters and Change in Percent Atheroma Volume by Treatment Group
2155	Change in Percent Atheroma Burden by Tertile of Change in Biochemical Parameter
2156	Change in Total Atheroma Burden by Tertile of Change in Biochemical Parameter
2157	Multivariable Predictors of Changes in Measures of Atheroma Burden
2158	Cox Proportional Hazards Regression Analysis
2159	Adverse Events in Overall Study Population
2160	Isoprostane Excretion: Heritability and Shared Genetic and Environmental Determination With Associated Traits in Twin Pairs
2161	Associations Among CHGB Genetic Variants, Isoprostane Excretion, and Plasma CHGB
2162	Predictors of Adverse Maternal Cardiac Events in Women With Heart Disease
2163	Univariate Analyses
2164	Multivariate Analysis for Mortality
2165	ROC Analysis of Functional Outcome
2166	Association of Predominant Rhythm on Resting ECG and Exercise Testing With History of IART
2167	Association of Anatomy and Function With History of IART
2168	Multivariable Cox Regression Model for IART  (n = 464)   ⁎
2169	Measures of Risk Factor Control in Progressors and Nonprogressors
2170	Measures of Atheroma Burden and Vessel Wall Dimensions
2171	Serum Levels of ApoA-I, HDL-C, ApoB And Lipids of Vehicle and RVX-Treated Monkeys
2172	Determinants of High D-Dimer Levels  (≥0.5 μg/ml)  by Logistic Regression Analysis
2173	Risk Factors for Thromboembolic Events by Cox Proportional Hazard Analysis
2174	Risk Factors for Combined Cardiovascular Events by Cox Proportional Hazard Analysis
2175	Predictors of Change in FMD  (%) , 1 Year After Target Quit Date  (R2 adj= 0.284)
2176	Dose Equivalence of Beta-Blockers Used in Study
2177	Respiratory Function Outcomes
2178	Secondary Outcomes
2179	NT-proBNP Changes
2180	Adverse Events After Switching Beta-Blockers
2181	Effects on Lipid Parameters Among 5-Week Treatment Cohorts
2182	Effects on Lipid and Lipoprotein Concentrations Among 5-Week Treatment Cohorts
2183	Effects on Lipid Parameters After 13 Weeks of Dosing at 200 mg/Week Mipomersen
2184	Treatment-Emergent Adverse Events by Dose Group  (Mipomersen Treated ≥10%)
2185	Predictors of Major Cardiac Events in HF Patients  (Bivariate Cox Proportional Hazard Analysis)
2186	Causes and Proportions of Death in 32,569 Patients From 162 Centers
2187	Fatality Rates According to Type of Complication
2188	Aortic Valve Radial and Circumferential Elastic Moduli
2189	Mean  (SD)  LDL-C, HDL-C, Triglyceride, and Apo Levels in Subjects From Asia and Other Regions
2190	Proportion of Subjects, n  (%) , With Different LDL-C and HDL-C Categories in Asia and Other Regions
2191	Atherosclerosis and Control Animal Groups and Nature of Interventions
2192	Clinical Criteria for HeFH in Adolescent Patients
2193	Lipid Parameters at the End of Step 2  (33 Weeks)  in Ezetimibe Plus Simvastatin 40-mg Group and Simvastatin 40-mg Group
2194	Lipid Parameters at the End of Step 3  (53 Weeks)  in the Overall Population
2195	Treatment-Emergent Adverse Events Occurring in 5% or More of Subjects Through the End of Step 2  (33 Weeks Total)  in the Pooled Ezetimibe Plus Simvastatin 40-mg Group and Pooled Simvastatin 40-mg Group
2196	Height and Weight Changes in Adolescent Subjects With HeFH Who Received Coadministration of Ezetimibe With Simvastatin or Simvastatin Monotherapy
2197	In-Hospital Complications of Patients With Acute Type B Aortic Dissection
2198	Percentages of Patients After 16 Weeks of Statin Therapy at an LDL-C or Non–HDL-C Target Who Also Reached ApoB <90 mg/dl
2199	Percentages of Patients After 16 Weeks of Statin Therapy at ApoB <90 mg/dl Who Also Reached LDL-C or Non–HDL-C Targets
2200	Multivariate Predictors of Detectable TnT or Elevated NT-proBNP
2201	Multivariate Models for Predicting All-Cause and CVD Mortality
2202	Cardiac Anatomic Diagnosis of 546 Fontan Cross-Sectional Study Subjects
2203	Change in QCA Parameters, Atheroma Volume, and Remodeling Index 18 Months After Statin Therapy in the 2 Groups
2204	Correlations Between hsCRP and OxLDL Biomarkers
2205	Association Between TpP and Clinical Events Through 10 Months
2206	HRs  (95% CIs)  Associated with TpP > Median for the Composite Outcome  (Death, Myocardial Infarction, Ischemia Requiring Revascularization, or Ischemia Requiring Rehospitalization)  After Multivariable Adjustment
2207	Doppler and Other Parameters Recorded From the LACB and LCx for Patients With LRAF and for Control Subjects
2208	Reproducibility of FMD Responses
2209	FMD Response in Subjects With Diabetes or Hypercholesterolemia Compared With That in Control Subjects
2210	Cox Regression Analysis for Death After AMI  ⁎
2211	Correlation  (r2)  Between Changes in Levels of Lipoproteins and Associated Parameters and Markers of Oxidative Stress After Statin Therapy
2212	Sterol Composition of Plant Sterol Ester Supplements Compared With Sterol Composition of Commercially Available Spread
2213	Physiologic Parameters During Cerebral Ischemia
2214	Effect of Sterol-Enriched Margarine Consumption on Plasma and Aortic Valve Campesterol Concentrations
2215	Changes in BP, Cardiac Function, and ECG Properties in the rHDL or Control Groups
2216	Primary End Points: MACE During 1-Month Follow-Up
2217	Secondary End Points: Bleeding During 1-Month Follow-Up
2218	Hazard Ratio for Mortality of Patients in Relation to NT-proBNP Dichotomized at Various Cutoff Values
2219	LVEF Over Time Between Study Groups
2220	LV Diameters After rAAV1.SERCA2a Gene Transfer
2221	Peak Aggregation Values
2222	Late Aggregation Values  (6 Min)
2223	Associations Between Osteoprotegerin Concentrations and Events During Follow-Up in Acute Coronary Syndromes
2224	Isolated Cardiomyocyte Contractility in the Different Groups
2225	Intracellular Calcium Measurements in the Different Groups
2226	Food Profile of Dietary Interventions
2227	Serum Lipids and Apo-B Concentrations Before and After the 24-Week Dietary Intervention
2228	Blood Pressure, Glucose, Insulin, HOMA-IR, and CRP Concentrations Before and After the 24-Week Dietary Intervention
2229	Experimental Design and Treatment Groups
2230	Cumulative 1-Year Event Rates
2231	Association Between Stent Type  (DES vs. BMS)  and 1-Year Adverse Outcomes
2232	One-Year Event Rates  ⁎  for Complex Lesion Types in Patients by Stent Type
2233	Distribution of Blood Lipid Parameters According to the CET Rate
2234	Pearson Correlation Analysis for the Association of CET Rate and Biologic Parameters
2235	Pearson Correlation Analysis for the Association for Age at MI Onset and Biologic Parameters  (n = 347)
2236	Age and Blood Lipid Parameters Stratified by Gender  (n = 347)
2237	Outcomes
2238	Adverse Events
2239	Association of F11R With Cardiovascular Risk Factors and Medication Use
2240	Correlation Analysis Between Plasma F11R and Other Biomarkers
2241	Univariate Analyses for CAD Score
2242	Multivariate Analysis for CAD Score  ⁎
2243	Impact of Main Parameters on Plasma proBNP Concentration in a Population With Dyspnea
2244	Electrophysiological Parameters at Idioventricular Rhythm
2245	Electrophysiological Parameters at Paced Cycle Length of 1,000 ms
2246	Pulmonary Artery Diameters
2247	Biventricular Function and Pulmonary Flow Dynamics
2248	Coagulation Screening and Platelet Function Assays
2249	VT/VF Onset Pattern by Initiating Sequence and Pacing Mode
2250	Occurrence of Pacing Facilitated S-L-S VT/VF Within the Study Population
2251	Relative Occurrence of Pacing Facilitated S-L-S Among Patients With Any Spontaneous VT/VF
2252	Comparative Features of Pacing Facilitated S-L-S VT/VF
2253	Key Time Measure Interval Data
2254	Key Time Measure Interval Data by Time of Day
2255	Outcomes at 30 Days by CrCl  (Full Trial Population)
2256	Outcomes at 30 Days by Treatment Assignment
2257	Clinical Outcomes Through 30 Days
2258	Safety Outcomes Through 30 Days
2259	Net Clinical Benefit Through 30 Days
2260	Propensity to Undergo PCI by 30 Days  ⁎
2261	Efficacy, Safety, and Net Clinical Benefit Outcomes by Treatment Group Among Patients Undergoing PCI by 30 Days
2262	Outcomes by Treatment Group Among Patients Who Underwent PCI While on Treatment With Blinded Study Drug
2263	Changes in Payment and RVUs, 1999 to 2004
2264	Numbers of Echocardiography Services by Site and Type of Service, 1999 and 2004
2265	Impact of Site-of-Service Shift, 1999 to 2004
2266	Summary of Growth in Volume and Spending, 1999 to 2004
2267	Estimated Count of Beneficiaries Using Echocardiography and Number of Scans/Beneficiary Using Echocardiography, 2001 to 2004
2268	Specialty of Physicians Performing Echocardiography
2269	Specialty of Requesting Physicians on Echocardiography Claims, 2004
2270	Average  (±SD)  TC, LDL-C, HDL-C, and TG Levels by tSNP Allele Carriage
2271	Comparison of tSNP Alleles Between CAD Case and Non-CAD Control Patients in the Primary Study Population
2272	Proportion of Common  (Frequency > 0.01)  Haplotypes and Association to CAD for the LD Groups Containing More Than 1 tSNP
2273	Inpatient Medications and Procedures Stratified by BNP Quartile
2274	Adjusted and Unadjusted In-Hospital Mortality Risk by BNP Quartile
2275	Patient Outcomes Stratified by BNP Levels
2276	Comparison of MR-proADM and NTproBNP Levels in Different Patient Subgroups
2277	Multivariate Cox Proportional Hazards Regression Model of Significant Predictors of Death or Heart Failure
2278	Concentration of Natriuretic Peptides at Presentation  (Medians in pg/ml)  for Various Patient Groups
2279	Concentration of Natriuretic Peptides  (Medians in pg/ml)  at Presentation for End Point Groups
2280	Assay Details
2281	Potency for Stimulation of cGMP Production in Primary Human Vascular Cells Treated With BNP and proBNP
2282	Cross-Reactivity of BNP Forms in 3 Assays
2283	Changes in Cardiac Time Intervals With Epicardial and Right Atrial Pacing
2284	Hemodynamic Changes With Epicardial and Right Atrial Pacing
2285	Normal Values for Mitral and Pulmonary Vein Doppler Flows by Age
2286	Diastolic Function in All Patients and Left Atrial Volume Index by Diastolic Function Class
2287	Univariate and Multivariate Analyses of Factors Related to CV Death or HF Hospitalization
2288	LV Size, Mass, Systolic, and Diastolic Function by Treatment Allocation
2289	Risk of Incident Atrial Fibrillation, Univariate Model
2290	Risk of Incident Atrial Fibrillation, Multivariate Models
2291	Cutoff Values That Best Distinguished Patients With Bradyarrhythmias Complicated by Torsade de Pointes From Patients With Uncomplicated Bradyarrhythmias
2292	Changes in High-Sensitivity C-Reactive Protein  (mg/l)  in the 3 Treatment Groups Categorized by Patients With and Without the Metabolic Syndrome
2293	Changes in Clinical Parameters in the 3 Treatment Groups
2294	Clinical and Laboratory Parameters in Nonobese and Obese Women
2295	Spearman’s Correlation Coefficients Among the Various Parameters Analyzed in 40 Obese Women
2296	Hematological and Biochemical Measurements After Clinical Stabilization in 37 Patients With End-Stage Heart Failure and Anemia
2297	Beta-Blocker Use at Discharge and BDI Scores During the First Year After MI
2298	Beta-Blocker Use at Discharge and BDI Scores at 3, 6, and 12 Months After MI
2299	Actual Beta-Blocker Use at 3, 6, and 12 Months After MI and Corresponding BDI Scores
2300	Univariate Cox Proportional Hazard Analyses in Female and Male Patients Presenting With Acute Dyspnea
2301	Multivariable Cox Proportional Hazard Analyses for the Prediction of Death in Female and Male Patients
2302	Degrees of IGF-1 and IGF-1 Receptor Staining in the Myocardial Biopsy Tissues Obtained From Patients With Impaired and Normal Left Ventricular Function
2303	Hemodynamic Effects of Inhaled Treprostinil at 12 Weeks
2304	Change in 6-Min Walk Distance at 12 Weeks
2305	One-Year Mortality in Relation to Performed Revascularization in the Initial 30 Days and Levels of Biomarkers
2306	Relative Risk of Coronary Heart Disease Across Quintiles of Oxidized LDL Among 798 Men From the Health Professional Follow-Up Study and 705 Women From the Nurses’ Health Study
2307	OxLDL in Comparison With Mutually Adjusted ApoB or Total/HDL Cholesterol Ratio in Multivariate Models
2308	Diagnostic Accuracy of Multidetector Computed Tomographic Angiography to Detect >50% Coronary Obstruction
2309	Lung Injury Parameters in Sham and CLP Septic Mice
2310	Respiration Parameters and Membrane Potential of Isolated Heart Mitochondria
2311	Univariate and Multivariate Analyses of the Value of Each Variable in Predicting Cardiac Events
2312	Electrocardiographic Parameters
2313	Effect of Sodium-Channel Blocker Challenge on QT and QTc
2314	Association Between Previous and New Arrhythmic Events
2315	Association Between QTc >460 ms and New Arrhythmic Events
2316	Disposition of Patients Entered Into the 48-Week Extension Study
2317	Safety and Tolerability Summary for 48-Week Extension Study
2318	Indices of LV Systolic and Diastolic Function as Measured by 2D and 3D Echocardiography in Patients With PDA Measured Before PDA Closure, 1 Day, and 6 Months After the Procedure and in Control Subjects
2319	Key Elements of the TIMI and GUSTO Bleeding Classifications
2320	Results From the Experimental Study
2321	Echocardiographic and Hemodynamic Parameters
2322	Patients With Syncopal Episodes During Follow-Up
2323	Final Model of a Backward Multiple Stepwise Regression Analysis for Cardiovascular Risk Predictors
2324	Results of Atrial Pacing on Select Indices of Apnea Severity
2325	Age- and Gender-Specific Ranges  (5th to 95th Percentiles)  for Plasma NT-proBNP  (pg/ml)  in Normal Patients
2326	Parameters That Significantly Contributed to NT-proBNP Values in Multivariate Analysis
2327	NT-proBNP Cutpoints, Sensitivity, and Specificity for Age and Gender Strata for the Detection of an Ejection Fraction ≤ 40%
2328	One-Year Outcomes for the Lean, Overweight, and Obese Categories Stratified by Median BNP  (452 pg/ml)
2329	B-Type Natriuretic Peptide  (BNP)  as a Determinant of One-Year Mortality in Lean, Overweight, and Obese Patients With Advanced Heart Failure
2330	Multivariate Models for sTNFR1 and All-Cause Mortality, Cardiac Death, and Composite End Point  (All-Cause Mortality, Stroke, or Nonfatal MI)  During Follow-Up  (Average 27 Months)
2331	Results
2332	Unadjusted Mortality and Morbidity Rates According to Physician-Volume Quartile
2333	Comparative Analysis of Patients Stratified by Serum Thromboxane Value
2334	Frequency of ISA in BMS and SES
2335	Persistent and Late-Acquired ISA
2336	Results of Ultrasound Measurements in the Brachial Artery
2337	Univariate and Multivariate Predictors of Adverse Outcome
2338	Economic Inputs
2339	Laboratory Data of the Three Groups of Patients
2340	Percentage of Cells Exhibiting NF-kB Activation in Patients With Unstable Angina  (UA) , Stable Angina  (SA) , and Control Subjects
2341	Diagnostic Performance of Different BNP Cutoff Values in the Diagnosis of Acute Heart Failure
2342	Occurrence of the Primary End Point  ⁎
2343	Occurrence of Secondary End Points
2344	Unscheduled Cardiac Procedures
2345	Electrocardiographic Parameters
2346	Holter Recording Parameters
2347	Signal-Averaged Electrocardiographic Parameters
2348	Plasma Concentration of Insulin, Glucose, and Free Fatty Acids During PET Study
2349	Paired Data Before and After Pulmonary Vasodilator Therapy of the Responder and Nonresponder Groups
2350	Echocardiographic Data
2351	Comparison of Echocardiographic Data
2352	Comparison of Echocardiographic Data
2353	Patients With Primary End Points—Apparent Versus Silent
2354	Pairwise Linkage Disequilibrium and r2Between PCSK9Polymorphisms
2355	PCSK9Common Haplotypes and Their Number and Estimated Population Frequencies
2356	Plasma Levels of Lipids and Severity of Coronary Atherosclerosis According to 23,968A>G  (E670G)  Genotypes  (N = 372)
2357	Echocardiographic Variables and BNP according to Patient Outcome
2358	Cox Proportional Hazards Univariate Predictors of Outcome
2359	Clinical Features of Retroperitoneal Hematoma  (n = 26)
2360	Comparison of Morphometric, Laboratory, and Procedural Variables
2361	Predictors of Retroperitoneal Hematoma Formation After Percutaneous Coronary Intervention
2362	Effect of IKrBlock With or Without Pretreated IKsBlock on the QT Interval, APD90, and Transmural Dispersion of Repolarization
2363	Transmural Heterogeneity of IKsand IKrin Feline Left Ventricle
2364	BNP and CRP by Presence of CAD on Catheterization and Troponin I Status on Admission
2365	Six-Month Outcomes by Presence or Absence of CAD and Troponin I Status
2366	Six-Month Outcomes by Presence or Absence of CAD and Marker Status  (Troponin I, BNP, and CRP)
2367	Corrected QT and QRS Intervals and Heart Rate Values for Patients in Each Study Group
2368	Exercise Testing and Gated Imaging Results
2369	Laboratory Results
2370	Laboratory Results in Ischemic Patients With and Without Fixed Defects
2371	Specificity of ΔNTproBNP in Nonischemic Patients
2372	Anticoagulation Values in Different Therapeutic Groups
2373	Number of Events in Each Treatment Group at Follow-Up
2374	Ischemic and Hemorrhagic Stroke and Systemic Embolism
2375	Clinical Data
2376	Primary Antibodies
2377	Mortality in the Study Population
2378	Effect of Using Different Cutoff Values for BNP on Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value, and Accuracy in Predicting Death  (All-Cause Including the Cardiac Death)  in Referred and Not-Referred Groups
2379	Quantitative Volumetric Analysis of the Stented Segment by Intravascular Ultrasound
2380	Quantitative Coronary Angiography of the Four Prespecified Coronary Segments
2381	Clinical Follow-Up of Study Population
2382	Primary End Points According to Diabetes Type
2383	Univariate Associations With Elevated Levels of BNP
2384	Association Between Biomarkers and Clinical Outcomes
2385	Association Between Biomarkers, Coronary Flow, and Electrocardiographic Abnormalities
2386	Electrocardiographic Data
2387	Heart Rate Changes During Tedisamil Administration
2388	Effects of L-NAME, MEG Sodium Succinate, and FeTPPS on Endotoxin-Induced Myocardial Dysfunction at 16 h After Treatment
2389	New York Heart Association Functional Classes and Hemodynamic Variables
2390	Clinical End Points
2391	Correlations With Preoperative BNP Levels
2392	Results of the Multivariate Analyses: Independent Predictors of Cardiac Survival and of Cardiac Event–Free Survival
2393	Independent Predictors of Cardiac Survival in Subgroups of Patients Divided According to Peak Vo 2
2394	Independent Predictors of Cardiac Survival in Subgroups of Patients Divided According to Plasma BNP
2395	Body and Heart Weights of Deoxycorticosterone Acetate-Salt Rats Treated With the Peroxisome Proliferator-Activated Receptor-Alpha Activator, Fenofibrate
2396	Hemodynamics in Deoxycorticosterone Acetate-Salt Rats Treated With the Peroxisome Proliferator-Activated Receptor-Alpha Activator, Fenofibrate
2397	Hemodynamics, Infarct Size, and Heart Weight in BN and BNK Rats
2398	Sensitivity of MDCT in the Detection of Different Coronary Plaques in Evaluable Vessels  (58 of 68)  and Specificity to Exclude Coronary Lesions
2399	Early  (≤1 Month)  and Long-Term Evolution of Thrombosis as a Function of the Size
2400	Model Inputs
2401	Lifetime Costs and Outcomes for Each Screening Strategy for a Cohort of 1,000 Men
2402	Lifetime Costs and Outcomes for Different Screening Strategies for a Cohort of 1,000 Women
2403	Collagen  (2 μg/ml)  and Adenosine Diphosphate  (2 μmol/l)  Induced Platelet Aggregation During Ticlopidine Treatment
2404	Nonimmunological and Infectious Variables
2405	Immunological Variables
2406	LV Function and LV Mass Among AF and RSR Groups
2407	Main Characteristics of the Patients in the Two Groups and Adverse Events After Discharge
2408	Univariate Cox Analysis Showing the Association Between Various Variables and the Risk of Death or Re-Admission During the Six Months of Follow-up in the Derivation Study
2409	P Values for Univariate Predictors  (p < 0.1 on Univariate Analysis)  of the Rest and Exercise Plasma Concentrations and of the Increase in Concentrations Between Rest and Exercise for Natriuretic Peptides
2410	Multivariate Analysis: Best Independent Predictors of the Resting Plasma Concentration of Natriuretic Peptides
2411	Multivariate Analysis: Best Independent Predictors of the Exercise Increase in the Plasma Concentration of Natriuretic Peptides
2412	Diastolic Indexes for the Study Population
2413	Univariate and Multivariate Relationships of Clinical and Echocardiographic Indexes to LognB-Type Natriuretic Peptide
2414	Myocardial Contrast Echocardiographic, Myocardial Blood Flow, and Coronary Flow Data
2415	Cholesterol and Apolipoprotein Levels of Subjects in the Three Groups
2416	In Vivo Hemodynamic Parameters
2417	In Vivo Echocardiographic and Post-Mortem Parameters
2418	Collagen Content and Synthesis
2419	Atrial Myocyte Morphometry
2420	Electrocardiographic Changes Before and After Administration of Pilsicainide
2421	Pilsicainide-Induced VA in Patients With Brugada-Type ECG
2422	Follow-Up of Treated Patients With Regard to the Respective Ablation Type: Patients Are Categorized With Respect to Results of Line Validation After the Final Ablation Session
2423	Hemodynamic and Electrophysiologic Effects of Tecadenoson in Patients Who Converted After Study Drug Administration
2424	Adverse Events Reported After Treatment With Tecadenoson
2425	Intra- and Inter-Observer Variability of Reference Segment
2426	IVUS Findings
2427	Baseline Clinical Characteristics of Patients in the Entire Study Group, and Those With and Without an Adverse Event Analyzed Separately
2428	Post-Discharge Medication Use in the Study Group
2429	Type of Surgical Procedure
2430	Procedural Information About the Eight Patients Who Suffered Adverse Ischemic Events
2431	Bleeding Complications and Transfusion Requirements
2432	Body Composition Data, Peripheral and Central Hemodynamic Indexes, and Fasting Biochemical Parameters in Healthy Female Twins
2433	Univariate Correlation Coefficients Between Age-Adjusted Augmentation Index and Anthropometric and Direct Measures of Total Body and Central Abdominal Adiposity in Healthy Female Twins  (n = 684)
2434	Independent Determinants of Augmentation Index in Healthy Female Twins: Multiple Regression Analysis  (n = 681)
2435	Epidemiologic Data and Preoperative Hemodynamics
2436	Cardiovascular Mortality and Morbidity
2437	Contribution of Fibrinogen, Creatinine Clearance, and Homocysteine to the Survival Model
2438	Univariate Predictors of Systolic Versus Non-Systolic Dysfunction
2439	Logistic Regression in Attempt to Differentiate Systolic From Diastolic Heart Failure
2440	Required Programming at Randomization
2441	Medications Used in the Efficacy Cohort
2442	AT/AF Burden and Frequency in the Efficacy Cohort
2443	Protocol Similarities and Differences Among the Analyzed Clinical Trials
2444	Qualitative and Quantitative Coronary Angiographic Analysis
2445	Follow-Up Quantitative Coronary Angiographic Analysis
2446	Proportion of Patients Experiencing Cardiac Events Before and After AIDS Diagnosis
2447	Potential Predictors of Adverse Cardiac Outcomes and Mortality byUnivariate Analysis
2448	Multiple Regression Analysis of Predictors of Mortality and Cardiac Outcomes
2449	Procedural Outcomes and In-Hospital Events
2450	Neurohumoral and Hemodynamic Measurements Immediately After Myocardial Infarction
2451	Patient Ethnicity and ACE Genotype
2452	Results of a Cox Proportional Hazards Model Analysis of Factors Predictive of Death as an End Point for the MI Cohort
2453	Fibrinolytic Regimen
2454	Efficacy According to the prosthetic Value Type
2455	LV Weight, Plasma Aldosterone Levels, Media Cross-Sectional Area of Arterioles, Results of Gene Expression Experiments, and Immunostaining to Laminin in the LV Tissue of the Five Experimental Groups
2456	Event Rate in the Study Population
2457	Event Rate for Combined Factors
2458	Univariate and Multivariate Logistic Analysis of Outcome Determinants
2459	Correlations  (“R-value”)  Among OxLDL Autoantibodies and LDL-IC
2460	Outcomes by ST↓ category
2461	Outcomes by Troponin Status
2462	Univariate and Multivariable Associations—Death/MI 6 Months
2463	Treatment Effect by ST↓ Status
2464	Treatment Effect by Troponin Status
2465	Examining the Impact of Time to ECG and Time to cTnT on Their Prognostic Significance
2466	Quantitative Coronary Analysis by Core Laboratory
2467	Volumetric Intravascular Ultrasound Measurements by Core Laboratory
2468	Individual 9-Month Outcome in 16 Patients Treated With Sirolimus Eluting Stent for ISR
2469	End Points at 30, 60 min, 24 h, and 30 days
2470	Most Frequent Concomitant Medications
2471	Predictors of Improvement in 60 min SO2to >95%
2472	Predictors of Refractory Pulmonary Edema
2473	Predictors of Acute MI During the First 24 h After Admission
2474	Distribution of Conventional Risk Factors by Causes of Death and Genotype
2475	Extent of Coronary Narrowing and Atherosclerotic Lesion Areas  (Mean ± SD)  in the Most Affected Artery Among Men With SCD and Men Who Died From Other Causes
2476	Alpha2B-Adrenoceptor Genotype Frequencies Among Men Who Died of Cardiac Diseases or Other Causes and the Corresponding Odds Ratios
2477	Patients With Syncope Documented by Implantable Loop Recorder
2478	Mechanism of Syncope, as Detected by Implantable Loop Recorder, in Patients and Control Subjects With Adenosine-Sensitive Syncope  (Both Tilt-Negative and B4-Positive)
2479	Univariate Associations With Elevated Levels of BNP
2480	Risk of Cardiac Events Through Six Months Stratified by Quartile of Elevated BNP
2481	Effect of Invasive Versus Conservative Management on Outcomes at Six months Stratified by BNP Level
2482	Doppler and Echocardiographic Findings According to Final Diagnosis
2483	Value of Various BNP Cutoff Values, LVEF <0.45, and Doppler Mitral Pattern to Diagnose Acute CHF
2484	Logistic Regression Analysis Using Significant Clinical Variables, BNP, and Doppler Mitral Pattern  (n = 138 Patients With Adequate Doppler Analysis)
2485	Fatal Outcomes in 10 Patients
2486	Clinical Events in Patients Not Treated With Angiotensin-Converting Enzyme Inhibitors: A)  Mortality and Morbidity End Points and B)  Total Investigator-Assessed Hospital Admissions
2487	Changes in Quality of Life  (Assessed by the MLHFQ) , Sitting SBP, and HR in Patients Not Treated With Angiotensin-Converting Enzyme Inhibitors
2488	Permanent Study Treatment Discontinuations
2489	Multivariate Determinants of Myocardial Flow Variables
2490	Adverse Events in Randomized Atms
2491	Procedural Details
2492	Cardiac Events at 30 and 180 Days
2493	Odds Ratios for Invasive and Conservative Management According to the Presence of Enrollment MI
2494	Logistic Regression  (Univariate)  for Death/MI and Composite End Point Stratified According to CK Elevation and Troponin Status
2495	Summary of Patient Data
2496	Changes in Risk Factors
2497	The Relation Between the Level of NT-proBNP and Diagnosis
2498	Cox Regression Analysis
2499	Included SCN5AMutations
2500	ECG Before and After Class I Antiarrhythmic Drug Challenge
2501	MMP-2, MMP-3 and MMP-12 Genotypes and Alleles
2502	Matrix Metalloproteinase-9 Alleles
2503	Multivariate Analysis
2504	Quantitative Angiographic Analysis
2505	Target Vessel Revascularization Rates in the Different Trials
2506	Clinical and Angiographic Six-Month Follow-Up
2507	Procedural and Angiographic Variables
2508	Intravascular Ultrasound Findings
2509	Correlation Between Neointimal Regrowth and Calculated Dose
2510	Mortality Rates for Study Patients at the Different Periods of Follow-Up
2511	Estimated Mortality and Absolute Benefit of Streptokinase Treatment According to Extent of Infarct
2512	Expression Levels of IL6, IL6R and gp130 in CTRL Biopsies, All Chambers of Donor Hearts and RV of FH
2513	Treatment Information
2514	Concomitant Medications During Initial Study Drug Therapy  (Number and Percent of Subjects)
2515	Healthcare Utilization and Mortality
2516	Selected Cardiovascular Adverse Events During the First 24 h of Dosing  (Number and Percent of Subjects)
2517	Endothelin-1 Ligand and Receptor Protein Expression in Normal Hearts and Syngeneic and Allogeneic Grafts 5 Days After Transplantation
2518	Effect of Bosentan  (Ro 47-0203)  on Endothelin-2 Ligand and Receptor Protein Expression in Cardiac Allografts 60 Days After Transplantation
2519	Analysis of Vessel Segments
2520	Angiographic Results  (Includes Patients Who Received Study Drug)
2521	Safety and Clinical Events Through 30 Days  (All Randomized Patients)
2522	Echocardiographic, Exercise and Clinical Variables in All, Group A and Group B
2523	Global Time Intervals in All, Group A and Group B
2524	Regional Time Intervals in All, Group A, and Group B
2525	Quantitative Angiographic Results
2526	Serial Changes in Lumen Dimensions
2527	Cardiac Hemodynamics at 48 h After MI or Sham Operation legend
2528	Effects of Tezosentan on Heart Weights After MI or Sham Operation legend
2529	Forearm Blood Flow Ratio Between Infused and Noninfused Arms During Infusion of Aminoguanidine and L-NMMA
2530	Arterial and Venous Plasma Concentrations of Nitrite/Nitrate During Infusion of Aminoguanidine and L-NMMA
2531	In-Hospital Clinical Outcome legend
2532	Clinical Outcome at Six Months legend
2533	Hemodynamic Data and Neurohumoral Variables at 100 Beats/Min Pacing Rate Before and After Rapid Pacing legend
2534	Clinical and Angiographic Outcomes legend
2535	Predictors of Long-Term Outcomes legend
2536	Six-Month Follow-Up of Left Ventricular Ejection Fraction in Patients With TIMI Flow Grade <3 at 24-h Angiography legend
2537	Angiographic Follow-Up  (Six Months)  legend legend
2538	Follow-Up in Patients With Angiographic Restenosis and TIMI Flow Grade <3 legend
2539	Long-Term Clinical Follow-Up legend legend
2540	Clinical Data legend
2541	Median  (Interquartile Range)  Serum CRP Levels  (mg/l)  in 57 Subjects Before, During and 14 Days After 31 Days of Treatment With ASA or Placebo legend legend
2542	Median  (Interquartile Range)  Serum Tx Levels in 57 Subjects Before, During and 14 Days After 31 Days of Treatment With ASA or Placebo legend legend
2543	Comparison of Studies Evaluating Effects of Low-Dose ASA on Serum CRP legend
2544	Body Composition of 120 Consecutive Patients With CHF as Assessed by Dual Energy X-ray Absorptiometry legend legend
2545	Clinical Predictors of Peak Vo 2in ml/min/kg, peak Vo 2in ml/min and VE/VCo 2Slope in a Population of 120 Patients With CHF  (Univariate Analysis)  legend
2546	Predictors of Peak Vo 2 (ml/min/kg)  and Absolute Vo 2 (ml/min)  in a Population of 120 Patients With CHF  (Multivariate Analyses)  legend
2547	Comparison of Exercise Performance 8 and 12 Weeks After LVAD Implantation in the Same Patients  (n = 10)  legend
2548	Exercise Performance 12 Weeks After Left Ventricular Assist Device Implantation  (n = 15)  legend legend
2549	Sequential Analysis of Exercise Performance in Nine Patients at 12 Weeks After Implantation and Then at 12 Weeks and One Year After HTx legend legend
2550	All Variables That Were Significantly Different Between the Genotype Groups legend
2551	Relative Risk for an Acute Coronary Event: Results of Multivariate Cox Regression Models legend legend
2552	Prevalence of Treatment for Hypertension and the Level of Blood Pressure in the α2B-AR Genotypes legend
2553	Comparison of Hemodynamics and Neurohumoral Factors Before and After Treatment in 37 Patients With Congestive Heart Failure Divided Into Two Groups: Spironolactone or Placebo legend
2554	Population Description legend legend
2555	Gender and Age Comparisons legend legend
2556	Linear Multiple Regression Analysis of Pulse Pressure as Dependent Variable legend
2557	Arterial and Cardiac Variables legend
2558	Comparison of Clinical Data in Groups A and B legend legend
2559	Results of the Two-Way Repeated Measures Analysis of Variance legend
2560	Coronary Flow Velocity and Reserve in Groups A and B legend
2561	Changes in Doppler Flow Velocities and Coronary Flow Reserve in 10 Patients With “Late” Percutaneous Transluminal Coronary Angioplasty legend
2562	Comparison of Clinical, Instrumental and Therapeutic Data in Group A  (Increased Videointensity)  and in Group B  (Unchanged Videointensity)  legend
2563	Subdivision of 10 Patients in Whom Doppler Flow Velocities and Reserve Were Computed Into Group A  (Increased Videointensity)  and Group B  (Unchanged Videointensity)  legend
2564	Relationship Between Geographical Miss and Edge Restenosis in Irradiated  (192Ir)  and Placebo Groups legend
2565	Quantitative Angiographic Edge Analysis legend
2566	Univariate Analysis of Variables legend
2567	Multivariate Analysis Using All Significant Variables With BNP Analyzed Last for All 250 Cases and for Cases Where Patients Do Not Present With a History of CHF legend
2568	Exercise ECG Parameters in Substudy B legend
2569	Comparison of Medical History Data Between Group A and Group B legend
2570	Comparison of Surgical History Data Between Group A and Group B legend
2571	Comparison of Echocardiographic Variables Between Group A and Group B legend legend
2572	Comparison in the Treatment of AVR Obstruction Between Group A and Group B legend
2573	Accuracy of TTE and TEE in Diagnosing the Pathologic Mechanism of Mechanical AVR Obstruction legend
2574	Accuracy of TTE and TEE in Diagnosing the Pathologic Mechanism of Bioprosthetic AVR Obstruction legend
2575	Clinical, Hemodynamic, Therapeutic and Follow-Up Data According to Inducibility of Ventricular Arrhythmias After Coronary Artery Revascularization legend
2576	Clinical, Hemodynamic, Therapeutic and Follow-Up Data According to the Presence of Recurrent Arrhythmic Events During Follow-up legend
2577	Changes in Plasma Lipids and Lipoproteins legend
2578	Changes in the Concentration of LDL-derived TBARS, Diameter of LDL Particles and the Prevalence of LDL Subclass Patterns legend legend
2579	Changes in Plasma Lipids and Lipoproteins According to Triglyceride Increase legend
2580	Changes in the Concentration of LDL-derived TBARS, Diameter of LDL Particles and the Prevalence of LDL Subclass Patterns According to Triglyceride Increase legend legend
2581	Exercise Stress Test legend legend
2582	Prevalence and Type of Perfusion Abnormalities Before and After EECP Treatment legend
2583	Hemodynamics and Collateral Vessels legend legend
2584	Plasma Levels of ANP and BNP Before and After EECP Treatment legend legend
2585	Hemodynamic Data legend
2586	Effects of Hormone Therapy on Hormone and Lipid Values legend
2587	Effects of Hormone Therapy on Markers of Inflammation and MMP-9 Expression in Serum legend legend
2588	Location of the Relocated MLD legend
2589	QCA Data From the Four Predefined Segments legend
2590	Exercise Capacity and Oxygen Uptake
2591	Hormonal Analysis
2592	Vascular Function
2593	Clinical Findings in Eight Patients with Repetitive Atrial Tachycardia legend
2594	Relationship Between Paced Atrial Cycle Length and the Presence of Atrial Tachycardia
2595	Results of Computer-Assisted Histomorphometric Analysis of Thick Sections from Arteries of Pigs in Control and Radiation-Treated Groups in Arteries With Injury legend legend
2596	Parameters of Dissection and Thrombus After PTCA With and Without Irradiation legend legend
2597	In-Hospital Clinical Course legend
2598	Cardiac Complications During Long-Term Follow-up legend
2599	Independent Predictors of Long-Term Event-Free Survival legend
2600	Cardiac Function of the Survivors at Follow-up legend legend
2601	Effects on Plasma Homocysteine, Plasma Folate, Plasma Vitamin B12, Serum Lipids and Plasma Malondialdehyde Levels legend
2602	Hemodynamic Data, Brachial Artery End-Diastolic Diameters and Flow, Flow-Mediated Dilation and Nitroglycerin-Mediated Dilation
2603	Assessment of Change in Heart Failure Status
2604	Change in LV Function, Brachial Blood Pressure, 24-h Urine Values and Blood Volume Over 12 Weeks  (All Patients Combined)  legend
2605	Dose-Related Changes Over 12 Weeks legend
2606	Change in Predose Neurohormones Over 12 Weeks  (All Groups Combined)  legend legend
2607	Dose-Related Changes in Neurohormone Levels Over 12 Weeks legend
2608	Vitamin B12 and Folate Determination of the Study Groups legend
2609	Vitamin B12 and Folate Determination of the Posttransplant Subgroups legend
2610	Treatment Subgroups in the BERT and MVP Studies
2611	Evolution of Dissections in Both the BERT and MVP Trials
2612	Patients With Dissections Following Intracoronary Beta-Radiation legend
2613	Rate of Late Total Occlusion by Studies, Emitters, and Doses
2614	Clinical, Procedural, and Angiographic Findings in 28 Patients Who Received Brachytherapy for In-stent Restenosis and Who Presented With Late Total Occlusion
2615	Autonomic Cardiovascular Tests legend
2616	Hormonal/Metabolic Parameters During Insulin-Glucose Infusion  (Test B)  legend
2617	Adrenaline and Noradrenaline Levels  (nmol/l)  During Saline  (Test A)  and Insulin-Glucose  (Test B)  Infusions
2618	Angioscintigraphic Parameters During Saline  (Test A)  and Insulin-Glucose  (Test B)  Infusions legend
2619	Two-Way Repeated Measures ANOVA legend
2620	Statistical Evaluation of Prolactin and Cortisol Response to the Head-Up Tilt Test With Clomipramine in the Three Groups of Subjects legend legend
2621	Cardiac Dimensional Ratios and Volume Ratios in Group I Dogs legend
2622	Effect of Aortic Constriction on Steady-State Hemodynamic Parameters legend
2623	Effect of Calcium Infusion on Steady-State Hemodynamic Parameters legend
2624	Number of Patients Randomized to Each Drug Group Compared With Final Dose Achieved legend
2625	Acute Effects of Moxonidine on Plasma Norepinephrine Concentration ∗
2626	Clinical Outcomes Worsening Heart Failure and Death legend
2627	Laboratory Variables Stratified by Fasting Blood Glucose legend legend
2628	Relationship Between Blood Glucose and PDT Arranged in Quartiles legend
2629	Effect of Spermine/NO on Histomorphometric Parameters legend legend
2630	Platelet Aggregation Responses legend
2631	Comparison of Hemodynamics, Neurohumoral Factors and Immune Factors Before Treatment in 23 CHF Patients Divided Into Two Groups: Candesartan Cilexetil Treatment or Placebo legend
2632	Hemodynamic Data and Serum Lipids legend
2633	Predictors of Drug Infusion Rate legend
2634	Quantitative Coronary Angiographic Measurements legend
2635	Primary End Point legend legend
2636	Comparative Clinical and Coronary Arteriographic Findings in the Study Patients With  (Group A)  and Without  (Group B)  Exercise-Induced U-Wave Changes legend
2637	Comparison of the Ischemic Status During Balloon Inflation in the Study Patients With  (Group A)  and Without  (Group B)  Exercise-Induced U-Wave Changes legend
2638	Comparison of Responses to Gemfibrozil, Nicotinic Acid and Combination Pharmacotherapy in Patients  (n = 14)  With Isolated Hypoalphalipoproteinemia legend
2639	Influence of ACE Genotypes on Progression or Regression of Coronary Lesions and Clinical events legend
2640	Hemodynamic, Angiographic and Plasma Norepinephrine Measurements Obtained Before Randomization and After Three Months of Follow-Up legend legend
2641	Hemodynamic, Angiographic and Plasma Norepinephrine Measurements Obtained Before Initiating Therapy and After Three Months of Therapy legend legend
2642	The Change Between Pretreatment and Post-treatment Hemodynamic, Angiographic and Plasma Norepinephrine Levels in Control Dogs and Bosentan-Treated Dogs legend legend
2643	Histomorphometric Findings legend
2644	Average Values of Mean Blood Pressure and Heart Rate ± SE During 80° HUT legend
2645	Summary of Hemodynamic Parameters legend
2646	Wall Motion Score With Incremental Dose Dobutamine  (0–40 microgram/kg/min)  Echocardiography  (n = 14)  legend
2647	Regional Perfusion Data; A: Non-PTCA Group, B: PTCA Group legend
2648	Summary of High Energy Phosphate Content legend legend
2649	Summary of Data From the Beta-Adrenergic Receptor Study legend
2650	Results of the ECG Substudy: Incidence of Complete, Partial and No ST Resolution at 90 min and 180 min in Patients Allocated to Lepirudin or Heparin Treatment
2651	Clinical Events During the 30-Day Study Period and One-Year Mortality legend
2652	Safety Variables Within 30 Days After Treatment
2653	Clinical Features of the Two Groups of Patients legend
2654	Anatomic and Hemodynamic Features of the Two Groups of Patients legend
2655	Incidence of Postoperative Atrial Fibrillation
2656	Impact of Beta-blocker Therapy in Placebo and Sotalol Groups legend
2657	Pulmonary Vascular Histopathology
2658	Inclusion and Exclusion Criteria legend
2659	Summary of Results Using Snare-Assisted Technique on Moderate to Large PDAs legend
2660	Complete Occlusion by PDA Types legend
2661	Comparison of Study Group to Small PDA Group
2662	Summary of the Published Series of Surgical Treatment of Brachiocephalic and Subclavian Obstruction legend
2663	Summary of the Published Series of Percutaneous Stenting of Brachiocephalic and Subclavian Obstruction
2664	Indications for Pacemaker Implantation in Octogenarians and Nonagenarians, 1980 to 1992
2665	Causes of Death Among 432 Octogenarians and Nonagenarians Who Had a Pacemaker Implanted Between 1980 and 1992 ∗
2666	Univariate Predictors of Mortality legend
2667	Independent Predictors of Poor Survival From Total and Cardiovascular-Related Deaths After Pacemaker Implantation in Octogenarians and Nonagenarians, 1980 to 1992, Multivariate Model for Survival ∗   legend
2668	Predictors of Dual-Chamber Pacemaker Selection in the Very Elderly, 1980 to 1992 legend
2669	Hemodynamic Responses to Sodium Nitroprusside legend legend
2670	Hemodynamic Responses to Endothelin-1 legend
2671	Hemodynamic Responses to Endothelin-3 legend
2672	Influence of Abciximab on PTRA-Induced Hypoperfusion legend
2673	Results of Analysis of Variance With Repeated Measures legend
2674	Mean Group Data legend
2675	Patients With In-Hospital Death According to Treatment Group legend
2676	Hemodynamic Findings  legend
2677	Quantitative Results of Positron Emission Tomography With N-13 Ammonia legend
2678	Visual Analysis of Regional Myocardial Perfusion in Children After ASO for TGA legend
2679	Clinical and Angiographic Data  legend
2680	Changes in Exercise Time and Hemodynamic Parameters at Rest and at 0.1 mV ST Depression With and Without Sarpogrelate Treatment  legend
2681	Comparative Sensitivity, Specificity and Predictive Values of Early Myocardial Contrast Echocardiography  (MCE) , Late MCE, Dobutamine Echocardiography  (DE)  and Serial MCE in Predicting Functional Recovery in Individual Segments  legend
2682	Visualization of Wall Segments in Group C
2683	Spectral and Time Domain Analyses According to Treatment Regime  legend
2684	VES and VT During Infusion of Exogenous Big ET and ET  legend
2685	Left Ventricular Function, Hemodynamics and Neurohormonal Profiles With Rapid-Pacing Heart Failure: Effects of Endothelin Receptor Blockade During the Progression of Heart Failure  legend
2686	Isolated Myocyte Contractile Function With Rapid-Pacing Heart Failure: Effects of Endothelin Receptor Blockade  legend
2687	Systemic Hemodynamics legend legend
2688	Regional Myocardial Function, Blood Flow and Oxygen Consumption  legend legend
2689	Left Ventricular Function  legend
2690	In-Hospital Clinical Outcome legend legend
2691	Long-Term  (2-Year)  Clinical Outcome legend
2692	Effects of Placebo, Simvastatin, HRT and the Combination of Simvastatin and HRT on Serum Lipids and Lipoprotein Levels of 16 Postmenopausal, Hypercholesterolemic Women With Coronary Artery Disease  legend
2693	Echocardiographic Results in Groups A, B and C Patients  legend
2694	Cardiac Events in Groups A, B and C Patients
2695	Follow-up Echocardiographic Results of Patients Without Cardiac Events and Those With Late Cardiac Events legend
2696	Clinical Outcomes
2697	Monoclonal Antibodies Used in This Study
2698	Plaque Histology in Atherectomy Specimens  legend
2699	Frequency of Methylenetetrahydrofolate Reductase Genotype and Odds Ratios of Nonfatal Coronary Heart Disease Among 500 Case and 500 Control Subjects  legend
2700	Odds Ratios of Nonfatal Coronary Heart Disease for +/+ Methylenetetrahydrofolate Reductase Genotype versus +/− or −/− Genotype, Stratified by Age, Alcohol Consumption, Intake of Folate, Vitamins B12, B2, B6and Methionine legend
2701	Distribution of Significant Arrhythmia Complications legend
2702	Patients With New or Increased Ventricular Arrhythmias  legend
2703	Clinical and Laboratory Variables for Safety Evaluation  legend
2704	Adverse Events Attributed to Test Agent  legend
2705	Mortality by Gestational Age and Era of Birth
2706	Outcome of 49 Pregnancies Immediately Subsequent to Birth of a Child With Congenital Heart Block
2707	Effect of HOE-140 on Steady-State Hemodynamic Data Before and After Pacing-Induced Congestive Heart Failure in Eight Dogs
2708	Effect of HOE-140 on the Pes–Ves, dP/dtmax–Vedand SW–VedRelations Before and After Pacing-Induced Congestive Heart Failure in Eight Dogs
2709	Average Values of Evaluated Variables in Groups A and B
2710	Correlation of Transplant Rejection Detected by Endomyocardial Biopsy and Antimyosin Scan
2711	Interobserver Variability in Interpretation of Endomyocardial Biopsy by Three Pathologists  (X, Y and Z)
2712	Infarct Size Data for Single-Dose Studies
2713	Hemodynamic Variables During Ischemia-Reperfusion in Single-Dose Studies
2714	Hemodynamic Variables During Ischemia-Reperfusion in Long-Term Intermittent Dosing Study
2715	Infarct Size Data for Long-Term Intermittent Dosing Study
2716	Angiographic Findings
2717	In-Hospital Clinical Course
2718	Correlation of Lipoprotein (a)  With Other Risk Factors
2719	Adjusted Risk Ratios for Ischemic Heart Disease According to Tertile of Risk Factors
2720	Significant Risk Factors in Stepwise Discriminant Analysis of Risk Factors for Ischemic Heart Disease
2721	Interaction Between Lipoprotein (a)  and Other Lipid Risk Factors for Ischemic Heart Disease
2722	Signs of Ischemia, Ventricular Ectopic Beats and Abnormal Reactions  a  in Heart Rate, Systolic Blood Pressure and Heart Rate Variability During Balloon Occlusion of Coronary Artery Stenosis by Gender
2723	Crude and Adjusted Odds Ratios With 95% Confidence Intervals for Coronary Occlusion-Induced Reactions in Women Versus Men Estimated From Logistic Regression Models  a
2724	Clinical Data and Results for 22 Patients Who Underwent Patent Ductus Arteriosus Coil Occlusion
2725	Comparison Between Reopened Patent Ductus Arteriosus Group and All Other Patients
2726	Hemodynamic Variables and Cardiac Function in Patients With Right Ventricular Overload
2727	Correlation Coefficients Between Natriuretic Peptide Levels and Hemodynamic or Cardiac Functional Variables
2728	Angiographic and Intravascular Ultrasound Data From 31 Patients Submitted to Overdilation  (n = 31)
2729	Angiographic and Intravascular Ultrasound Results at End of Procedure and at 6 Months
2730	Multivariate Predictors of Angiographic Restenosis at 6 Months  (Logistic Regression)
2731	Hemodynamic Data: Study 1
2732	Angiographic Data
2733	Hemodynamic Data: Study 2
2734	Perioperative Outcome and Complications
2735	Hemostatic Variables of the Comparative Study
2736	Resetting Responses in the 14 Study Patients
2737	Comparison of Electrocardiographic Data Based on ST Segment Elevation  (ST↑)  in Lead V1
2738	Comparison of Angiographic Data Based on ST Segment Elevation  (ST↑)  in Lead V1
2739	Clinical and Coronary Angiographic Features of the Study Patients
2740	Rate-Pressure Product During Balloon Inflation
2741	Summary of Infarct Size Data in Experiment 1
2742	Summary of Infarct Size Data in Experiment 2
2743	Complications
2744	Procedural Success  a  by Lesion
2745	Angiographic Complications
2746	Effect of Atropine on Variables of Systolic Time Interval in Young and Older Volunteers  a
2747	Effect of Pirenzepine on Variables of Systolic Time Interval in Young and Older Volunteers  a
2748	Therapy Strata After Suspicion of HIT
2749	Treatment Regimens and the Duration of Therapy With Alternative Anticoagulants
2750	4Ts Scores Stratified According to Treatment Regimen
2751	Laboratory Diagnostics for HIT
2752	Complications During Alternative Anticoagulation Stratified per First-Line Anticoagulant
2753	Complications of First-Line Alternative Anticoagulation per Treatment Day  ∗
2754	Kaplan-Meier Rates of Outcomes in Randomized Subjects With Versus Without Anatomic Lesion Complexity Between 12 to 30 Months AfterPercutaneous Coronary Intervention
2755	Treatment Comparison of Continued Thienopyridine Versus Placebo in Randomized Subjects With Versus Without Anatomical Complexity
2756	Number of Patients With Discrete Events Within Each Time Period and During the Total 1-Year Study Period
2757	Relationships Between Ischemic and Bleeding Events
2758	Average Daily Rates for Adverse Events in the Acute, Subacute, Early, and Late Periods
2759	Differences in Average Daily Rates for Adverse Events in the Acute, Subacute, Early, and Late Periods
2760	Case Sequence Categories of Patients
2761	Outcomes
2762	Operator Radiation Exposure for Radial and Femoral Access
2763	Operator Radiation Exposure for Left and Right Radial Access
2764	Cardiovascular and Renal Variables
2765	Maximal Variable Changes in Response to Hemorrhage
2766	Clinical Outcomes at 1 and 2 Years With a DCS or BMS
2767	Multivariate Correlates of Primary Safety Endpoint and Major Bleeding
2768	1-Year Mortality Following a Major Bleed or Coronary Thrombotic Event
2769	Efficacy and Safety Endpoints at 48 h After Randomization in Patients Receiving and Not Receiving GPIs
2770	Medications
2771	Unadjusted and Adjusted Associations Between Number of Antithrombotic Drugs and the Risk of Bleeding Before Coronary Angiography
2772	Unadjusted and Adjusted Associations Between Treatment Assignment and the Risk of Bleeding Before CoronaryAngiography
2773	In-Hospital, 1-Month, and 1-Year Clinical Outcomes
2774	Unadjusted and Adjusted Association Between Bleeding Before Coronary Angiography and Death Within 1 Year
2775	Overview of the Volume of the RECHARGE Registry and Annually Performed Cases Per Center
2776	In-Hospital MACCE and Complications of All Procedures  (N= 1,253)
2777	Use of CrossBoss, Stingray, Wire-Based ADR, or Retrograde Techniques
2778	Disposition After Coronary Angiography in the Study Population
2779	Event and Compliance Rates in Enrolled Patients  (0–12 Months)
2780	Ischemic and Bleeding Events in Randomized Patients  (12–30 Months)
2781	Clinical Utility of MI Status Versus DAPT Score Stratification
2782	Valve Disease Progression in MAVD Patients Undergoing AVR
2783	Predictors of Composite Adverse Events in MAVD Patients
2784	Adverse Events in MAVD and Control Groups
2785	Independent Predictors of 2-Year Coronary Thrombosis and Major Bleeding
2786	Integer Risk Score for Major Bleeding
2787	Integer Risk Score for Coronary Thrombotic Events
2788	Cumulative Mortality After Bleeding
2789	Association of Bleeding and Mortality
2790	Mortality Models: Improvement in Goodness of Fit  ∗
2791	Distribution of All Bleeding Events  ∗
2792	Unadjusted 1-Year Event Rates for Specified Outcomes in the Full Cohort andbyDES Era
2793	Individual Efficacy and Safety Endpoints Versus Placebo for the Pooled Ticagrelor Doses, 90-mg Dose, and 60-mg Dose in Patients With Diabetes
2794	Procedural Information
2795	Clinical Outcomes of the Intention-to-Treat Population
2796	Adjusted RR of CHD With 95% CI for HbA1c≥6.5% Stratified by Hp Genotypes in Men 46 to 80 Years of Age at Blood Draw From theNested Case-Control Study of CHD Events in the HPFS  (1994 to 2010)  and in Women 44 to 69 Years of Age at Blood Draw From the NestedCase-Control Study of CHD Events in the NHS  (1990 to 2004)
2797	Independent Predictors of PDB Within 2 Years
2798	2-Year Outcomes According to PDB Occurrence
2799	Independent Predictors of All-Cause Mortality at 2Years
2800	1-Year Clinical Outcomes in the Intention-to-Treat Study Population
2801	1-Year Clinical Outcomes in the High-Risk ACS Intention-to-Treat StudyPopulation
2802	Procedural and 30-Day Outcomes
2803	Predictors of Long-Term All-Cause Mortality
2804	Patient and Physician Reasons Provided for LVAD or OMM
2805	Primary Endpoint and Components that Prevented Success
2806	Secondary Composite Endpoints
2807	Adverse Events
2808	Reasons for Rehospitalizations
2809	OMM Patients Receiving Delayed LVAD
2810	Clinical Variables  (N= 78)
2811	Hemodynamic Variables
2812	Invasive Hemodynamic Data  (N= 16)
2813	Univariable Associations of PH Development
2814	Summary of PM2.5 and Meteorological Variables  (Arithmetic Mean ± SD)  in Outdoor Air, Sham-Purified Indoor Air,and Purified Indoor Air During the Intervention Periods
2815	Summary of Health Endpoints  (Geometric Mean ± SD)  in Sham-Purified Indoor Air and Purified Indoor Air During the Intervention Periods
2816	Percent Change  (Geometric Mean and 95% CI)  in Health Endpoints Comparing the True-Purified Air Scenario to the Sham-Purified Air Scenario
2817	Percent Change  (Geometric Mean and 95% CIs)  in Health Endpoints Associated With an Interquartile Range Change  (64 μg/m3)  of Continuous Indoor PM2.5 Concentration
2818	Study Population
2819	Multivariate Model of Risk Factors for Combined Outcome  (RandomIntercept,With Interaction Between Age Category and Prematurity)
2820	Procedural/In-Hospital Clinical Outcomes
2821	Echocardiographic Variables Before and After TMVR
2822	Laboratory and Hemodynamic Assessments at TimeofPLE Diagnosis
2823	Medical and Surgical Treatment Strategies for PLE After Fontan Operation
2824	Suggested Evaluation of Patients With PLE
2825	Major Bleeding by Location  (First Major Hemorrhage at Each Location)
2826	Adverse Events
2827	Bivariable Logistic Regression for CRT Response
2828	Multivariable Logistic Regression Model for Echocardiographic CRT Response
2829	Multivariable Linear Regression Model for Percent Change in LVESV
2830	Procedural Details Comparing the 2 Groups
2831	The Primary Endpoint Was More Likely to Occur intheBMS Group
2832	30-Day and 1-Year Adverse Event Rates According to Occurrence of Major Bleeding Inside 30 Days
2833	Independent Clinical Predictors of Major Bleeding Events According to Treatment Strategy
2834	Independent Predictors of 1-Year Mortality Among theTotal Population
2835	Prevalence and Incidence of Bleeding, Stroke, and Pump Thrombosis After Discharge
2836	Pre-Operative Statistically Significant Univariable Correlates  (p< 0.1)  and Multivariable Risk Factors for Post-Discharge Bleeding
2837	Pre-Operative Statistically Significant Univariable Correlates  (p< 0.1)  and Multivariable Risk Factors for Post-Discharge Hemorrhagic Stroke
2838	Pre-Operative Statistically Significant Univariable Correlates  (p< 0.1)  and Multivariable Risk Factors for Post-Discharge Ischemic Stroke
2839	Pre-Operative Univariable Correlates With p< 0.1 and Multivariable Risk Factors for Post-Discharge Pump Thrombosis
2840	Inclusion and Exclusion Criteria
2841	Results of Primary and Secondary Outcome Measures: Platelet Activation Markers by Flow Cytometry in Placebo and Clopidogrel Groups at Each Time Point
2842	Results of Secondary Outcome Measures: Light Transmission Aggregometry in Placebo and Clopidogrel Groups at Each Time Point
2843	Results of 7 Mixed Model Analyses Predicting Primary and Secondary Outcome Measures
2844	Independent Predictors of 3-Year Cardiac Mortality
2845	Independent Predictors of 3-Year Cardiac Mortality in Patients With and Without Major Bleeding at Any Time
2846	Covariate-Adjusted Independent Predictors of 3-Year Cardiac Mortality ∗
2847	Serious Adverse Events
2848	Clinical Outcomes at 12 Months Stratified According to the P2Y12 Inhibitor Used in HPR
2849	Clinical, Procedural, and Pharmacological Predictors of All-Cause Death, MI, Stent Thrombosis, or Stroke at 1 Year
2850	Partial Regression Coefficients  (β)  and SEs for the Systolic Blood Pressure Predictor Variables in the Random Intercept Model Analyses: AerobicsCenterLongitudinal Study, 1970–2006
2851	Partial Regression Coefficients  (β)  and SEs for the Diastolic Blood Pressure Predictor Variables in the Random Intercept Model Analyses: AerobicsCenterLongitudinal Study, 1970–2006
2852	Partial Regression Coefficients  (β)  and SEs for the Pulse Pressure Predictor Variables in the Random Intercept Model Analyses: AerobicsCenterLongitudinal Study, 1970–2006
2853	Bicuspid Aortic Valve Type
2854	Procedural Information and Outcomes
2855	Clinical Outcomes
2856	Predictors of 1-Year Survival
2857	Predictors of Aortic RegurgitationGrade ≥2
2858	Cox Regression Analysis for the Composite of Major Hemorrhagic Events
2859	Evaluating the Predictive Ability of the HAS-BLED Score Versus CHADS2 or CHA2DS2-VASc Score for the Detection of MajorBleeding Using C-Statistics, Relative NRI, and IDI Indexes
2860	Cox Regression Analysis: Predictive Value of CHADS2 and CHA2DS2-VASc Scores for Bleeding Events by Themselves and Adjusted by HAS-BLED Score
2861	Bleeding Subtypes and Recurrent Major Bleeding Events After HeartMate II Implantation
2862	Factors Related to Major Bleeding After HMII Implantation
2863	Factors Related to Death Incorporating Timing and Incidence of Major Bleeding After HeartMate II Implantation
2864	Hospitalizations and Outcomes of Infective Endocarditis in Medicare Fee-for-Service Beneficiaries, 1999 to 2010
2865	Hospitalizations for Endocarditis and Outcomes by Age, Sex, and Race
2866	Comparison of PCI In-Hospital Outcomes in Extremely Obese Patients  (BMI≥40 kg/m2)  and Normal-Weight Patients  (BMI 20 to 25 kg/m2)
2867	Unadjusted and Multivariate-Adjusted ORs of the Association of Extreme Obesity Versus Normal Weight With Bleeding and In-Hospital Mortality Stratified by Presentation With STEMI and Non-STEMI
2868	Health Status Outcomes Measured via the EQ5D Questionnaire by Categories of Nuisance Bleeding
2869	Independent Predictors of Bivalirudin Use
2870	Hospital Patterns of Inotrope Use  (N = 225)
2871	Hospital Factors Associated With the Use of Positive Inotropic Agents
2872	Importance of Institutional Factor in Variation of Inotrope Use
2873	Association Between Hospital Use of Inotropes and In-Hospital Risk-Standardized Mortality Rate
2874	30-Day Post-Procedural Complications and Outcomes
2875	Influence of Incremental Adjustment on Cox Models of Female HR for Mortality
2876	The AMADEUS Patients Randomized to VKA Stratified by Presence or Absence of Bleeding Events During the On-Treatment and Observational Study Period
2877	AMADEUS Cohort Stratified by the HEMORR2HAGES, HAS-BLED, and ATRIA Schemes
2878	AUCs  (or C-Indexes)  for HEMORR2HAGES, ATRIA, and HAS-BLED Scores
2879	Cox Regression Analysis of the HEMORR2HAGES, HAS-BLED, and ATRIA Score for the Outcomes of All-Cause Mortality, Major Bleeding, and Any Clinical Relevant Bleeding
2880	Comparison of AUCs or C-Indexes for HEMORR2HAGES, ATRIA, and HAS-BLED Scores
2881	Reclassification Table for Any Clinical Relevant Bleeding Risk Estimated by HAS-BLED, HEMORR2HAGES, and ATRIA Schemas
2882	NRI Analysis for the Outcomes of Any Clinically Relevant Bleeding, Major Bleeding, and All-Cause Mortality
2883	Post-Operative Outcomes for the Isolated CABG Cohort
2884	Temporal Reduction in Annual Bleeding Risk
2885	Comparison of Procedural Variables Between Patients on Dabigatran and Warfarin
2886	Comparison of Complications Between Patients on Dabigatran and Warfarin
2887	Univariate and Multivariate Predictors of Complications  (Composite of Bleeding and Thromboembolic Complications)
2888	Histology Findings
2889	Quantitative PCR Results for Nuclear Receptors, Scavenger Receptors, and ABC Transporters in M (Hb)  Versus Control Macrophages  (n = 4 Experiments per Group)
2890	Hospital Discharge Mortality for Patients Undergoing Stage I Palliation, 2002–2009
2891	Strategies for Reducing the Likelihood of Effusion Development Following Stage II Palliation
2892	Original Criteria for Fontan's Operation: The “10 Anatomic and Physiologic Commandments”
2893	Risk Factors for the Development of SVT
2894	Indications for Heart Transplantation With HLHS
2895	Intraprocedure Hemodynamic Data Pre- and Post-Pulmonary Valve Implantation
2896	Intraprocedure Adverse Events
2897	Patient Information
2898	CTA Findings
2899	Regional Myocardial Perfusion and Percentage of Diameter Stenosis
2900	Multivariable Models Describing Associations Between CTA Descriptors of Atherosclerosis Burden and MBF, MFR, and CVR
2901	Data Included in the Markov Model on CHD Primary Prevention Strategies for Asymptomatic Elderly Men and Women Identified as Being at Intermediate Risk for a CHD Event
2902	Cost, Clinical Effectiveness, and Cost-Effectiveness of Strategies for Asymptomatic Men
2903	Cost, Clinical Effectiveness, and Cost-Effectiveness of Strategies for Asymptomatic Women
2904	Optimal Strategy in 1-Way Sensitivity Analysis, With a Willingness-to-Pay of $50,000/QALY in Men
2905	Optimal Strategy in 1-Way Sensitivity Analysis, With a Willingness-to-Pay of $50,000/QALY in Women
2906	Predictors of All-Cause Mortality
2907	Frequency of Patient Withdrawal and Early Drug Discontinuation
2908	Adverse Events and Monitoring
2909	Per-Segment Analysis of Individuals Who Were Alive Versus Dead During the Follow-Up Period
2910	Clinical Predictors of Nonobstructive Plaque Extent and Burden
2911	Criteria for Selecting Patients as LVAD Candidates
2912	Associated Operative Procedures
2913	Causes of Death
2914	Functional Capacity and Quality of Life
2915	Adverse Events
2916	Primary Study Outcomes and Individual Outcome Definitions
2917	Study Medications
2918	Study Quality
2919	Age, Sex, Race, and Ethnicity of Registry Participants
2920	Risk Factors for PE and Comorbid Conditions  ⁎
2921	Signs and Symptoms at Presentation
2922	Functional Status and Comorbid Conditions
2923	In-Hospital and 30-Day Outcomes
2924	Contemporary Bleeding Risk Stratification Schemas
2925	Risk Factors for Major Bleeding by Univariate and Multivariate Analyses
2926	Major Bleeding Rates by HAS-BLED Score in the Overall SPORTIF Cohort  (n = 7,329)  and Those Taking Warfarin Only  (n = 3,665)
2927	Risk Factors for Major Bleeding According to the HAS-BLED Score: Whole Cohort  (n = 7,329)
2928	Risk Factors for Major Bleeding According to the HAS-BLED Score: Warfarin Patients Only  (n = 3,665)
2929	Predictive Value of Contemporary Bleeding Risk Schemas in Patients Taking Warfarin Compared With the Whole Study Cohort and Subgroups of Warfarin-Naive Patients and Those Taking Warfarin Plus Aspirin
2930	Hazard Ratios  (95% Confidence Interval)  of Risk Categories for the 5 Bleeding Risk Stratification Schemas Among Warfarin Patients  (n = 3,665)
2931	Perioperative Data in Relation to Tertile Distribution of the Percentage of Platelet Inhibitory Response to Clopidogrel
2932	Changes in Troponin T Values and Post-Operative Outcome in Relation to Tertile Distribution of the Percentage of Platelet Inhibitory Response to Clopidogrel
2933	Predictive Power of Selected Variables for Post-Operative Transfusion Requirement According to Logistic Regression Analysis
2934	Composition of Matched Flavanol-Containing Test Materials Ingested Twice Daily
2935	Genotype Distribution of Intervention Group Patients
2936	Unadjusted Incident Hospitalization Rates
2937	Warfarin Dosage Changes Following Genotyping
2938	Independent Predictors of Non–CABG-Related Major Bleeding Within 30 Days, With Multiple Logistic Regression
2939	Incidence of Non–CABG-Related Major Bleeding Within 30 Days According to Risk Score Category  (%)
2940	Independent Predictors of 1-Year Mortality From Multivariable Cox Regression
2941	Hierarchical Incidence of Non–CABG-Related Major Bleeding Within 30 Days
2942	Breakdown of the Primary Composite End Point
2943	Univariate Analysis of Predictors of Primary Composite End Point
2944	Multivariate Analysis of Predictors of Primary Composite End Point
2945	Summary of Secondary End Points
2946	Unadjusted 30-Day and 1-Year Event Rates According to Time to PCI
2947	Multivariable Predictors of Death at 30 Days and 1 Year
2948	Multivariable Predictors of the Combined End Point of Death or Myocardial Infarction at 30 Days and 1 Year
2949	End Points at 30-Day Follow-Up
2950	Experience With Periprocedural Impella 2.5 Support in Elective High-Risk PCI
2951	Serial Changes in Weight and Hemodynamic Status, Plasma Lipids, and Glucose During the Study
2952	Hospital Results
2953	Late Results
2954	Linearized Rate of Valve-Related Events
2955	Cox Hazards Regression: Independent Predictors of Late Mortality
2956	Multivariable Predictors of GIB in the Entire ACUITY Population and in Patients Triaged to PCI, CABG, or Medical Management
2957	30-Day and 1-Year Clinical Outcomes of Patients With and Without GIB Triaged to PCI, CABG, or Medical Management
2958	Medication Use at Different Time Intervals in Patients With and Without GIB
2959	Bleeding Events in Relation to Age <80 or ≥80 Years
2960	Odds Ratios Associated With Bleeding Risk
2961	Death, MI, Refractory Ischemia, Major Bleeding, and Net Clinical Outcome at 30 Days in Those Treated With a GP IIb/IIIa Inhibitor
2962	Death, MI, or Refractory Ischemia or Major Bleeding in Patients Undergoing PCI by Loading Dose of Clopidogrel or Type of GP IIb/IIIa Inhibitor
2963	Death, MI, Refractory Ischemia, Major Bleeding, and Net Clinical Outcome at 30 Days in Those Treated With Thienopyridines
2964	Cardiac Procedures and Concomitant Medications During Hospitalization
2965	Event Rates  (%)  in Each Treatment per Age Category at 30 Days and 1 Year for All Patients
2966	Events Rates  (%)  in Each Treatment per Age Category at 30 Days and 1 Year for PCI Patients
2967	Ischemic and Bleeding Incidents at 30 Days
2968	Post-PCI Bleeding Events, Transfusion, and Thrombocytopenia
2969	Average Peak Periprocedural Necrosis Marker Release and Mean Platelet Aggregation and TIP-FCS
2970	Clinical Outcomes
2971	Mixed Treatment Comparison Probabilities of Each Treatment at Reducing All-Cause Mortality and CVD Mortality
2972	Mixed-Treatment Comparisons of Effectiveness, All-Cause Mortality
2973	Mixed-Treatment Comparisons of Effectiveness, Cardiovascular Disease Mortality
2974	Quantitative Coronary Angiography Analysis
2975	Angiographic Complications and Subsequent Non–Q-Wave MI
2976	In-Hospital and 30-Day MACE
2977	Incidence of Post-Procedural Bleeding
2978	Platelet Aggregation and Expression of Surface Proteins According to CYP2C19 Genotype
2979	Clinical Outcome According to Pre-Discharge RPA
2980	Reasons for Prematurely Discontinuing Study Drug in the Safety Population
2981	Incidence and Risk of Confirmed Venous Thromboembolism  (VTE)  and Proximal Deep Vein Thrombosis  (DVT)
2982	Incidence of Bleeding End Points
2983	Multiple Regression Analysis Evaluating the Predictors of Last Visit SBP
2984	Predictors of Longitudinal SBP Derived From a Linear Mixed-Effects Regression Model
2985	Incidence of Ischemic Stroke Event After MR Surgery Overall and by Surgical Procedure and Post-Operative Phase
2986	First Ischemic Stroke Risk After MR Surgery Expressed as Risk Ratio to Expected First Ischemic Stroke Rates in the Population
2987	Independent Predictors of First Ischemic Stroke After MR Surgery
2988	Risk of the Combined End Point First IS-TIA After MRSurgery Compared With Expected First IS-TIA Rates in the Population
2989	Incidence of Any Thromboembolic Event After MR Surgery Overall and by Surgical Procedure and PO Phase
2990	Cox Proportional Hazards Survival Model
2991	Clinical Outcomes After Thrombolysis Versus No Thrombolysis
2992	Antithrombotic Regimen Adopted in AF Patients at Discharge
2993	Differences Between the AF Patients Undergoing PCI/Stenting, Treated at Discharge With Anticoagulation Compared to Those Not Treated With Anticoagulation
2994	Events During Follow-Up
2995	Cox Regression for the Analysis of Major Adverse Cardiovascular Events
2996	Cox Regression Analysis for Major Adverse Events
2997	30-Day Ischemic and Bleeding Complications in 1-Year Survivors and Nonsurvivors
2998	Independent Predictors of 1-Year Mortality
2999	Predictive Accuracy of MI, Urgent Revascularization, or Bleeding Within 30 Days After PCI Regarding 1-Year Mortality
3000	Unadjusted Outcome of the Cohort Categorized by Treatment
3001	In-Hospital Outcomes of the Propensity-Matched Cohort Categorized by Treatment
3002	Bleeding Events: Number of Events and Kaplan-Meier Event Rates
3003	Clinical End Points: Number of Events and Kaplan-Meier Event Rates
3004	Crude Incidence Rates of Investigator-Reported Adverse Events
3005	Arrhythmia Events Detected on Continuous ECG Monitoring Begun at Randomization
3006	Procedural Results
3007	Clinical Events Through 2 Years
3008	Angiographic Follow-Up Results at 8 Months Stratified by Vessel Size
3009	Intracranial Hemorrhage Event Rates
3010	Adjusted Hazard Ratio for Intracranial Hemorrhage
3011	Percent Time Receiving Warfarin That INR Values Were ≥2, 2–3, and ≥3 by Race/Ethnicity
3012	Anticoagulation Intensity at the Time of Intracranial Hemorrhage by Race/Ethnicity
3013	Angiographic and Procedural Results
3014	Electrocardiographic and Laboratory Results
3015	One-Month Left Ventricle Function Recovery
3016	Types of Major Bleeding by Treatment Group
3017	Antithrombotic Medications in Patients With and Without Major Bleeding
3018	Clinical Outcomes in Patients With and Without Major Bleeding
3019	Univariate Predictors of Events
3020	Treadmill Performance in the Intention-to-Treat Population
3021	Change in ABI or TBI Measurements After 24 Weeks
3022	Effect of NM-702 on Questionnaire-Based Patient Assessments in the Intention-to-Treat Population
3023	Selected Adverse Events Observed at Increased Frequency With NM-702
3024	Cardiac Serious Adverse Events
3025	Summary of Hemodynamic Measurements in 7 Sheep and Miller Angiographic Index in 9 Sheep
3026	Inclusion and Exclusion Criteria
3027	Statistical Comparisons  (p Values)  Among Treatment Groups in the Medications’ Ability to Modify Lipids, High-Sensitivity C-Reactive Protein  (hsCRP)   (mg/l) , and Lipoprotein-Associated Phospholipase A2 (Lp-PLA2)   (ng/ml)
3028	CTFC, CFI, and CFR at Various Time Points
3029	Univariate and Multivariate Correlates of Post-PCI TMPG 3
3030	Bleeding Events Through 48 Hours
3031	Correlates of Major or Minor Bleeding
3032	Rates of Bleeding Events and Transfusions According to Prior Antithrombin
3033	Frequency of Specific Complications During ICD Hospitalizations for the Entire Study Population, Stratified by Type of Implant
3034	Adjusted Incremental Hospital Resource Utilization Associated With Treating Patients Experiencing the Complication of Interest
3035	Bleeding and Hematologic Complications After Stenting
3036	Quantitative Coronary Angiographic Results of Stented Segment
3037	Intravascular Ultrasound Results
3038	In-Hospital Primary Outcomes After Stenting
3039	Age, Gender, Index INR Value, and Site of Hemorrhage for Each of the 13 Individuals With Major Bleeding  ⁎
3040	Mean Number of Days Warfarin Was Withheld by Index INR and Target INR Range  ⁎
3041	Data for 35 Patients Who Underwent the Attempt of Transcatheter Closure of Perimembranous VSD
3042	Data Before and After Implantation of the Amplatzer Membranous VSD Occluder
3043	Procedural Data
3044	Post-Treatment Angiography
3045	Clinical Events—In-Hospital
3046	Clinical Events Through 30 Days
3047	Definition of IB Values in Each of Histological Categories in Plaque
3048	Changes in Laboratory Profiles
3049	Changes in Three-Dimensional Integrated Backscatter Intravascular Ultrasound Parameters
3050	SPORTIF-VI: Pharmacodynamic Profile of Oral Ximelagatran
3051	Incidence of Primary and Secondary Events According to Assigned Treatment in SPORTIF-III  ( 47 )  *
3052	Changes in Serum Lipid Levels
3053	Number and Percentage of Primary and Secondary Outcome Events
3054	Odds Ratios of Individual and Composite End-Points According to Clopidogrel Pretreatment
3055	Bleeding Complications
3056	Efficacy End Points
3057	Bleeding Events
3058	Cerebrovascular Events
3059	Clinical Features and Follow-Up Results of Patients With or Without an Initial Response to Aspirin
3060	Etiology of Acute Pericarditis According to Clinical Risk Groups
3061	Summary of Exposure to Study Drugs  (All Treated Population, N = 1,216)
3062	Summary of Efficacy Results: Adjudicated Clinical End Points at 30 Days for Pooled Enoxaparin and UFH Groups  (Intention-to-Treat Population, N = 1,224)
3063	Summary of Efficacy Results: Adjudicated Clinical End Points at 30 Days for Pooled Tirofiban and Placebo Groups  (Intention-to-Treat Population, N = 1,224)
3064	Summary of Efficacy Results: Adjudicated Clinical End Points at 30 Days  (Intention-to-Treat Population, N = 1,224)
3065	Hemorrhage Rates at 30 Days  (All Treated Population, N = 1,216)
3066	Procedural Data in Octogenarians Undergoing PCI
3067	Bleeding Complications in Octogenarians Undergoing PCI With or Without a Glycoprotein Receptor Inhibitor
3068	In-Hospital Outcomes in Octogenarians Undergoing PCI With or Without a Glycoprotein Receptor Inhibitor
3069	Comparison of Final Outcomes in the 36–64 and ≥65 Years-Old Groups With Respect to the ≤35 Years-Old Group
3070	Angiographic and Electrocardiographic Efficacy Data
3071	Clinical Efficacy and Procedures  (Through 30 Days)  and Safety  (Through Discharge * )
3072	Bleeding Complications
3073	Vascular Complications
3074	Bleeding Complications in Those Receiving Closure Devices
3075	Vascular Complications in Those ReceivingClosure Devices
3076	Angiographic Complications
3077	Clinical End Points at 48 h
3078	Pharmacologic Interventions and Invasive Diagnostic or Therapeutic Procedures in Excluded and Non-Excluded Patients
3079	Predictors of Major or Minor Bleeding in the Whole Population
3080	Predictors of Death or Myocardial Infarction at 30 Days in the Whole Population
3081	Eligible Trials
3082	Subgroup Analyses for Mortality
3083	Secondary Outcomes
3084	Individual Results of the Nine Included Randomized, Controlled Trials
3085	Sensitivity Analyses of Thrombolytic Regimen, Clinical and Radiologic Severity of Pulmonary Embolism, and Methodologic Quality *
3086	Response of Exhaled Nitric Oxide and Hemodynamic Variables to Heart Failure Therapy
3087	Chest Tube Outputs and Transfusions
3088	Clinical Outcomes
3089	Patients With Clopidogrel Exposure
3090	Patients Without Clopidogrel Exposure
3091	Results of Univariable Proportional Hazards Modeling: Hazard Ratios, 95% Confidence Intervals and p Values for Echocardiographic Variables
3092	Results of Univariable Proportional Hazards Modeling: Hazard Ratios, 95% Confidence Intervals and p Values for Clinical and Hemodynamic Variables
3093	Results of Multivariable Modeling: Hazard Ratios, 95% Confidence Intervals and p Values for Significant Multivariable Predictors of Outcome in Models That Incorporate Echocardiographic, Clinical and Hemodynamic Variables
3094	Patient Overview
3095	Complications Reported by Different Authors
3096	In-Hospital Ischemic and Hemorrhagic Stroke Among Postmenopausal Women With Acute Myocardial Infarction According to Use of Hormone Therapy on Admission
3097	Mean Variable and Total Cost, by Department *
3098	Multiple Regression Analysis of Total Cost and Length of Stay  (n = 1,949)  *
3099	Hemodynamic and Echocardiographic Parameters of Patients With PPH legend
3100	Coronary Doppler Velocities  (Diastolic and Systolic)  and Hemodynamic Data at Rest and Hyperemia in 24 Control Subjects and 43 Patients With LAD Disease legend
3101	Morphometric Analysis of Pig Coronary Arteries 72 H After Angioplasty legend
3102	Tear Location legend
3103	General Management legend
3104	Univariate Analysis legend
3105	Accuracy for the Detection of CAD According to Extent of Disease legend
3106	Segmental Findings on DMIBI and DASE According to Vascular Territory and Angiographic Data  (Peak Stress Data)  legend
3107	Derivation of Primary Cohort and Ideal Subgroup from CCP Population legend legend
3108	In-Hospital Events and Mortality Rates for Patients Without Absolute Contraindications to Thrombolytic Therapy ∗   legend
3109	Unadjusted and Adjusted Mortality Rates of Patients Ideal for Reperfusion Therapy ∗
3110	History, Risk Factors and Procedural Details of the Study Group legend
3111	A Summary of Time Frames of PTCA, Surgery, Antiplatelet Therapy and Complications in Patients Who Experienced Major Complications After Noncardiac Surgery Preceded by Intracoronary Stent Placement legend
3112	Incidence of Strands and Thrombi at Nine Days legend
3113	Incidence of Strands and Thrombi at Five Months
3114	Principal Outcome Events at One Year
3115	Early Thrombi and Morbidity legend
3116	Risk Factors of Morbidity legend legend
3117	Enzymatic and Echocardiographic Data of Patients With Elevated Troponin legend
3118	Relationship Between Abnormal Troponin I and Clinical, Radiological, ECG, and Echocardiography Data
3119	Relationship Between Abnormal CK and Clinical, Radiological, ECG, and Echocardiography Data
3120	Hemodynamic Variables and Blood Gases in Response to Inhaled NO and Aerosolized Iloprost legend
3121	Bleeding and Vascular Events of Patients Undergoing Successful Percutaneous Coronary Intervention legend
3122	Selected Mitral Leaflet Variables in Relation to Papillary Muscle Settings legend legend
3123	Chordal Force Distribution in Relation to Papillary Muscle Settings legend legend
3124	Impact of Chordal Force Distribution on Occlusional Leaflet Area and Mitral Regurgitant Fraction legend
3125	Histological Findings
3126	Angiographic Data of the Patient Groups legend
3127	Medical Therapy
3128	In-Hospital Clinical Outcome
3129	One-year Follow-up From Admission  (110 Patients)
3130	Distribution of Major and Minor Complications
3131	Mortality legend
3132	Interventional Cardiac Procedures and Related Complications ∗
3133	Independent Risk Factors for Any Complication
3134	Independent Risk Factors for Major Complications
3135	Comparison of Procedural Results
3136	Comparison of Economic Variables
3137	Thrombocytopenia in the Hospital and Within 24 H by Treatment Assignment
3138	Relation of Clinical Outcomes at 30 Days With Thrombocytopenia ∗ by Treatment Assignment
3139	In-Hospital Hematologic Variables Observed With Thrombocytopenia ∗ by Treatment Assignment
3140	Relation of Bleeding Events at 30 Days With Thrombocytopenia ∗ by Treatment Assignment
3141	Prediction and Overall Incidence of Thrombocytopenia
3142	Angiographic and Procedural Variables of 91 Chronic Total Coronary Artery Occlusions
3143	Clinical Variables of Patients Grouped According to the Occurrence of Restenosis
3144	Angiographic and Procedural Variables in Patients Grouped According to the Occurrence of Restenosis
3145	Significant Correlates of Restenosis by Logistic Regression Analysis
3146	Hemodynamic Variables Before and During Infusion of Isoproterenol and Dopamine in Chronically Instrumented Lambs With and Without Aortopulmonary Left to Right Shunt
3147	Oxygen Consumption-Related Variables Before and During Infusion of Isoproterenol and Dopamine in Chronically Instrumented Lambs With and Without Aortopulmonary Left to Right Shunt
3148	Renal Blood Flow and Vascular Resistance During Infusion of Dopamine in Chronically Instrumented Lambs With and Without Aortopulmonary Left to Right Shunt
3149	Reasons for Discontinuation Among 776 Patients With Acute Myocardial Infarction Randomized to Treatment With Dalteparin or Placebo
3150	Left Ventricular Thrombus Formation Among Patients With Acute Anterior Myocardial Infarction Randomized to Receive Dalteparin or Placebo
3151	Odds Ratios  (95% confidence intervals)  of Left Ventricular Thrombosis in Patients With Acute Anterior Myocardial Infarction by Study Treatment, Peak Aspartate Aminotransferase Values and Gender  a
3152	Type of Hemorrhage According to Assigned Treatment in Patients Given Dalteparin or Placebo for Acute Myocardial Infarction
3153	Procedural Information for 50 Patients With 50 Lesions
3154	Angioscopic Findings in 50 Patients With 50 Lesions
3155	Angioscopic Findings in 50 Lesions According to Presence or Absence of Calcifications on Angiography
3156	Hemodynamic Variables
3157	Procedure-Related Variables
3158	Outcome Statistics for Type of Dressing
3159	Thirty-Day Outcomes and Diabetic Status
3160	Thirty-Day Outcome According to Thrombolytic Strategy
3161	Other Clinical Outcomes at 30 Days
3162	Coronary Angiographic Findings
3163	Early Mortality and Diabetic Status in Randomized Trials
3164	In-Hospital Outcomes of 908 Randomized Patients Risk Stratified Into High Risk and Low Risk Groups
3165	Secondary In-Hospital Outcomes in 437 Randomized High Risk Patients
3166	Vascular and Hemorrhagic Complications in the Study Cohort
3167	Reasons for Excluding 144 High Risk Patients From Randomization
3168	Selected Outcomes in High Risk Registry Patients Stratified by Requirement for Intraaortic Balloon Counterpulsation
3169	Association Between Elevated Depressive Symptoms and Definite/Probable MI or Death
3170	Attenuation in Association Between Elevated Depressive Symptoms and Definite/Probable MI or Death, After Addition of Clinical and Behavioral Variables
3171	Depression, Anxiety, and Risk of CHD and AMI
3172	Causes of Syncope  (n = 341)
3173	Comparison of Clinical Features of Syncope legend
3174	Diagnostic Examinations That Established the Cause of Syncope  (n = 341)  legend legend
3175	Predictors of the Cause of Syncope in Patients With Suspected or Certain Heart Disease After the Initial Evaluation  (n = 191)  legend
3176	Predictors of the Cause of Syncope in Patients Without Suspected or Diagnosed Heart Disease After the Initial Evaluation  (n = 146)  legend
3177	Sensitivity, Specificity and Post-Test Probability of the Variables Predictive of Cardiac and Neurally Mediated Causes of Syncope in Patients With and Without Suspected or Certain Heart Disease After the Initial Evaluation
3178	General Features of Cardiac Patients and Controls legend
3179	Results of the Psychological Tests in Cardiac Patients and Controls According to Sex and Age
3180	Results of Cluster Analysis in Cardiac Patients and Controls  legend
3181	Multivariable Logistic Regression Analysis for Risk Factors of CAD in Diabetic Patients
3182	Risk of Death, MI, HF, Stroke, and Repeat Revascularization in Patient With T1D Who Underwent Multivessel PCI or CABG in Sweden From 1995–2013
3183	Absolute Risks of Death From Any Cause, MI, HF, Stroke, Repeat Revascularization, and Death From CHD in Patients With T1D Who Underwent PCI or CABG From 1995–2013 in Sweden
3184	Hemodynamic Response to Nitroprusside in Low-Flow Low-Gradient Severe Aortic Stenosis
3185	Hemodynamic Response to Nitroprusside in Normal-Flow Low-Gradient Severe Aortic Stenosis
3186	Comparison of Hemodynamic Change With Nitroprusside in Low-Flow and Normal-Flow Low-Gradient Severe Aortic Stenosis
3187	Comparison of Invasive Hemodynamic Variables on Nitroprusside in Low-Flow and Normal-Flow Low-Gradient Severe Aortic Stenosis
3188	Summary of Changes in Serum Concentrations of Cardiovascular Biomarkers, eGFR, and Hematocrit
3189	Serial Coronary Physiology, Endothelial Function, and Endothelial Progenitor Cell Data
3190	Echocardiographic Parameters of the Test and Validation Cohorts
3191	Echocardiographic Parameters of the Test Cohort
3192	AUC for Continuous Single Leads and the Proposed Criteria  (SD+ SV4)  Predictive Performance of LVH in the TestCohort
3193	McNemar Test Among the Electrocardiographic Criteria Against the Left Ventricular Mass Index in the Test Cohort
3194	AUC for Continuous Single Leads and the Proposed Criteria  (SD+ SV4)  Predictive Performance of LVH in the Validation Cohort
3195	McNemar Test Among the Electrocardiographic Criteria Against the Left Ventricular Mass Index in the Validation Cohort
3196	McNemar Test Among the Electrocardiographic Criteria Against the Left Ventricular Mass Index in the Combined Population
3197	Adjusted Associations Between LTPA Levels and Risk of Overall HF and its Subtypes
3198	Adjusted Associations Between BMI Categories and Risk of Overall HF and Its Subtypes
3199	1-Year Adjusted Risk of Stroke/Systemic Embolic Events  ∗
3200	Risk of Thromboembolic Events
3201	Comorbidity Pattern Stratified by T2DM
3202	Unadjusted and Adjusted HRs of Mortality by T2DM Status in Groups Stratified by History of IHD and Revascularization
3203	Statistical Analysis of Diagnostic Biomarkers: Discovery Phase
3204	Medications at Deferral
3205	Cumulative Events at Follow-Up
3206	Cox Proportional Hazards Model
3207	Unadjusted, Trial-Adjusted, and Multivariable-Adjusted HRs for the Composite Endpoint and the Individual Components From Cox Regression Models  (N= 5,034)
3208	Primary Composite Outcomes
3209	Primary Outcome Measure Components
3210	Secondary Outcomes
3211	Costs
3212	Pharmacokinetic Profiles of Prasugrel’s Active Metabolite After Administration of LD of Whole Versus CrushedPrasugrel
3213	Cumulative 6-Month Resource Use and Costs
3214	Plasma Lipid and Lipoprotein Concentrations
3215	LLT and LDL-C Goal Achievement  (Cohort)
3216	Summary of Long-Term Effectiveness and Cumulative Long-Term Effectiveness Over 3 Years Post-Ablation
3217	Summary of HADS Results Before Ablation and at 6 Months Post-Ablation for the Total Efficacy Cohort and Patients With or Without ICDShocks, ATP Therapies, and Any VT Episodes
3218	Association Between Estimated Duration of Diabetes and Incidence of Ischemic Stroke
3219	Association Between HbA1c Values and Incidence of IschemicStroke
3220	Association Between Time-Varying HbA1c Values and Incidence of Ischemic Stroke Using Different Rules for Classifying Time-Varying HbA1c Values
3221	Adjusted Hazard Ratios for Composite Cardiovascular Events Associated With Each Hypertension Classification Compared With Participants With Normal Blood Pressure
3222	HbA1c and DM Duration in Patients With T1DM andT2DM
3223	Absolute and Relative Risks of Death or MACE+Death After Primary Isolated CABG in Patients With T1DM or T2DM Compared With Patients Without DM Stratified bySex
3224	Incident Rates and HRs for Black and White Patients and ACE Inhibitor Use
3225	Sex-Specific Unadjusted and Multivariate-Adjusted HRs  (95% CIs)  for Risk for CVD Mortality, CHD Mortality, and Stroke Mortality by Hypertension Subtype
3226	Sex-Specific Unadjusted and Multivariate-Adjusted HR  (95% CIs)  for BP as aContinuous Variable for Risk for CVD Mortality, CHD Mortality, and Stroke Mortality
3227	Perioperative Data, Death, and Nonfatal Events
3228	Univariate and Multivariate Predictors of 30-Day Mortality
3229	Univariate and Multivariate Analysis of Overall Survival
3230	Joggers Categorized as Light Joggers, Moderate Joggers, or Strenuous Joggers on the Basis of Self-Reported Pace, Quantity, andFrequency of Jogging
3231	Association Between Quartile of Percent PVC Count, LVEF Reduction, IncidentCHF, and Mortality
3232	HR  (95% CI)  for Coronary Heart Disease by Healthy Lifestyle Factors
3233	HR  (95% CI)  of Diagnosis With a Clinical CVD Risk Factor  (Diabetes, Hypertension, or Hypercholesterolemia  ∗  )  by HealthyLifestyle Factors
3234	HR  (95% CI)  of Diagnosis With a Clinical CVD Risk Factor  (Diabetes, Hypertension, or Hypercholesterolemia)  or CHD by Optimal Lifestyle Factor Status
3235	Echocardiographic Parameters of the 4 Groups of Patients With Aortic Stenosis
3236	Relative Risk of All-Cause Mortality in Patients With Severe Aortic Stenosis  (LG/LF, LG/NF, and HG)  Compared With Moderate Aortic Stenosis
3237	Event Rates and Relative Risks for a Combination of All-Cause Mortality or Major Adverse Cardiovascular Events  ∗   After PrimaryIsolated Coronary Artery Bypass Grafting in 764 Patients With Type 1 Diabetes, According to Baseline HbA1c
3238	Comparison of Global Strain in Patients and HealthyVolunteers
3239	ROC Cutoff Values Predicting Impaired RVEF
3240	ROC Cutoff Values Predicting 24-Month Mortality
3241	Kaplan-Meier Cutoffs to Predict Mortality
3242	Bland-Altman Data for Repeated Measures
3243	CAC Score Ratios  ∗   by BMI Categories in 14,828 Metabolically-Healthy Participants
3244	Prevalence Ratios  ∗   for CAC by BMI Categories in 14,828 Metabolically-Healthy Participants
3245	Mediation Analysis of the Association Between BMI Categories and CAC in 14,828 Metabolically-Healthy Participants
3246	CAC Score Ratios  ∗   by BMI Categories in Clinically-Relevant Subgroups of Metabolically-Healthy Participants
3247	Efficacy Outcomes
3248	Adverse Events
3249	Echocardiography and CMR Parameters at the Time ofCMR Examination
3250	Correlation of ECV and LGE With Diastolic Function Parameters
3251	Clinical Outcome at 4 Years
3252	Adherence to DAPT
3253	Echocardiography, Electrophysiology, and Scar Size
3254	KCNQ1-G269S Affects the Activation Gate of I Ks Channels
3255	ORs  (95% CIs)  of ACEI/ARB Initiation During the First Year of the Cohort
3256	Pharmacokinetic Parameters of Clopidogrel and its Active Metabolite After a Loading Dose of 600 mg
3257	Exploratory Analysis of Genetic Polymorphisms and Differences in Clopidogrel Active Metabolite
3258	American Heart Association Recommended Criteria for Right Ventricular Hypertrophy by Study
3259	Sensitivity, Specificity, PPV, and NPV for AHA Criteria for Right Ventricular Hypertrophy in Participants With Normal Left Ventricular Morphology
3260	Practice and Patient Factors Associated With Optimal Combined Prescriptions of Secondary Prevention Medications Following Multivariable Adjustment
3261	ITDM Versus Non-ITDM Hazard Ratios for FREEDOM Trial Outcomes
3262	Kaplan-Meier Event-Free Estimated Event Rates for CABG Versus PCI
3263	5-Year Kaplan-Meier Estimated Event Rates for the Primary Endpoint  (Death/Stroke/MI)
3264	5-Year Kaplan Meier Estimated Event Rates With 95% CI and HR for the Primary Endpoint  (Death/Stroke/MI)  for ITDM Status by SYNTAX Score
3265	PCI Versus CABG Hazard Ratios for FREEDOM Primary Outcome of All-Cause Death/Stroke/MI: Time-Dependent Cox Regression Modeling Results  ∗
3266	Hazard Ratios for All-Cause Mortality After Incident HF
3267	Feasibility and Correlation of EchocardiographicParameters With Mean PCWP  (N= 40)
3268	Accuracy of Echocardiographic Parameters to Predict PCWP >15 mmHg
3269	Left Ventricular Compliance and Distensibility
3270	Relative Risk of Myocardial Infarction Associated With Modifiable Lifestyle Factors in 20,721 Men
3271	Effect of Combined Low-Risk Behaviors in Relation to Risk of Myocardial Infarction  ∗
3272	Effects of LVMI and LVH on BMI and SBP  (LinearandLogistic Regression Analyses)
3273	Effects of BMI and SBP on LV Remodeling Patterns, Adjusted forRace, Sex, andAdulthood Age  (Logistic Regression Analysis)
3274	Results on a Per-Patient and Per-Vessel Level Using Hyperemic MBF as a Perfusion Parameter to Assess Diagnostic Accuracy of [15O]H2O PET
3275	Diagnostic Accuracy of Quantitative [15O]H2O PET MPI Using Hyperemic MBF as a Perfusion Parameter
3276	Diagnostic Accuracy of Quantitative [15O]H2O PET MPI for Detecting Angiographic Obstructive CAD
3277	Univariate and Multivariable Regression Analysis Describing the Relationship Between Hyperemic MBF, CAD Risk Factors, and Functional CAD Severity
3278	The Influence of Sex and Age on the Diagnostic Performance of [15O]H2O Hyperemic MBF Imaging
3279	Effect of 10% Weight Loss on Clinical Parameters Stratified by Insulin Level
3280	Medication Discontinuation Following Weight Loss Across Treatment Classes Stratified by Insulin Status
3281	Classification of Patients According to Doppler Echocardiographic Assessment of Stenosis Severity
3282	Clinical, Doppler Echocardiographic, and MDCT Data According to Group Classification
3283	Univariable and Multivariable Analysis of Predictors of MG or Vmax
3284	Accuracy of AVC, AVCi, and AVCd to Identify Severe AS
3285	Prevalence of Patients With Evidence of SevereStenosis on the Basis of AVC or AVCd Criteria
3286	Risk of Vascular Events by HDL-C According to Lipid-Lowering Treatment
3287	Risk of Vascular Events by HDL-C According to LDL-C Level
3288	Risk of Vascular Events by HDL-C in Categories of Increasingly Potent Lipid-Lowering Therapy
3289	Cumulative Proportions of CV Events Over 4.3 Years inGroups of Patients With Normal Weight, Overweight, and Obesity
3290	Impact of Overweight and Obesity on Outcome in Univariate Analyses
3291	Impact of Overweight and Obesity on Outcome in Multivariate Analyses
3292	Multiple Logistic Regression Models for the Association Between Salivary Cortisol Response to Standard Laboratory Mental Stress Tasks  (Binary Exposure)  and Plasma Detectable hs-cTnT  (Binary Outcome)
3293	Comparison Between Study Group and Patients With VVS
3294	Interaction Between Sex and Association Between Adiposity and Cardiometabolic Risk
3295	Multiple Logistic Regression Analysis for Silent Cerebral Infarcts
3296	Ongoing Trials of Anti-Inflammatory Therapies for Atherosclerosis
3297	Professional Society Recommendations for hsCRP Testing
3298	Within-Person Variability of HbA1c Values by Mean HbA1c Categories During Follow-Up
3299	Number of Subjects, Proportion With Each Outcome, and Incidence of Outcomes per 1,000 Person-Years Adjusted for Age, Sex, and Duration of Diabetes, by HbA1c Category
3300	Clinical Events
3301	HRs for Association Between Sitting Time, Physical Activity, and Risk of CHD, Stroke, or Total CVD
3302	Univariate and Multivariate Results of Combined Clinical and Echocardiographic Cox Regression Models
3303	Relation Between GLS and Outcome
3304	Reclassification TableWith Added Value of GLS in Relation to Outcome
3305	Primary Efficacy Parameters: Change in Troponin I at 16 and 24 h
3306	Secondary Efficacy Parameters: Changes in Troponin I and CK-MB
3307	Safety Summary
3308	30-Year Cumulative Risk for HF at Index Age by Sex–Race Group in the CHA Study by BMI Strata
3309	30-Year Cumulative Risk for HF at Index Age 45 by Sex–Race Group in CHA by BP Strata
3310	Cumulative Risk for HF at Selected Index Ages Through Given Follow-Up Ages by Sex/Race Groups
3311	CMR Changes Seen After Allopurinol Treatment
3312	Effect of Allopurinol on Hemodynamics and Endothelial Function
3313	Primary and Secondary Endpoints
3314	Risk Factors for Adverse Outcome in PCI
3315	Final Cox Proportional Hazards Models for the WC and WHR Ratio Predictors
3316	Overview of Treatment Rates for CAD Quality-of-Care Indicators, by Healthcare Insurance Status  ⁎
3317	Association Between Insurance Status and Treatment Rates for CAD Quality-of-Care Indicators  ⁎
3318	Medication Use in the First Year After Initial CABG or PCI
3319	Diet Composition
3320	Circulating Humoral Factors
3321	Hemodynamic Factors
3322	Imputation and Sequence Confirmation of rs10757278 Genotypes of the Lymphoblastoid Cells Used in This Study
3323	Concomitant Medications
3324	OR Estimate of Each Outcome for Each Drug Treatment Group Compared With Placebo
3325	Univariable Hazard Ratios for Cardiac Death  (n = 6,037)
3326	Multivariable Cox Proportional Hazard Models Estimating Cardiac Death  (n = 6,036)
3327	Risk Reclassification for Risk in 6,037 Patients With and Without Cardiac Death
3328	Details of Multiple Variable Regression Analyses of Factors Associated With Troponin I/T–Defined PPMI
3329	Primers for Real-Time Quantitative PCR
3330	Individual Mutations Identified in the Non-SA Population
3331	Absolute HR and HR Changes  (Δ)  During ExStrT in Washout in the Entire Study Population, According to Genetic and Clinical Status
3332	Correlation Between Cholesterol Efflux and Inflammatory Markers Among Patients With ESRD-HD and Controls
3333	Matching Thresholds in Different Datasets
3334	Univariate and Multivariate Associations Between Total Plasma Lp-PLA2 Mass and Activity, HDL-Lp-PLA2 Mass and Activity, Ratios of Lp-PLA2 to HDL-Lp-PLA2 Mass and Activity, Natural Log of hsCRP, and Cardiac Death at Follow-Up
3335	Patient Variables
3336	Transesophageal Echocardiogram Parameters Examined
3337	Results of Coronary CTA in Relation to Summary XECG Results
3338	Major Adverse Cardiac Events According to Summary XECG and Severity of CAD by Coronary CTA Subset
3339	Univariate and Multivariate Analysis for Prediction of Major Adverse Cardiac Events
3340	C-Statistics for Prediction of 5-Year Risk of Major Adverse Cardiac Event Using XECG, Coronary CTA  (Severity of CAD) , and Combined Model
3341	Summary of Hemodynamic Data for All Participants During Imaging Studies
3342	Quantitative Perfusion Values in Patients With and Without Significant CAD
3343	Subgroup Analysis
3344	Recommendations for Normal SE With Submaximal APHR
3345	Risk of Incident AF According to the Presence or Absence of T2D
3346	HbA1c and Risk of Incident AF Among 24,890 Women With Available HbA1c Levels
3347	RR  (95% CI)  of SCH for All-Cause and CVD Mortality in Several Different Models
3348	RR  (95% CI)  of SCH for All-Cause and CVD Mortality Stratified by Age and by TSH Levels at Entry
3349	PR  (in PRU)  at the End-of-Treatment Periods
3350	Medical Therapies According to the rSS
3351	rSS Components in Patients With Incomplete Revascularization According to Tertile
3352	30-Day and 1-Year Outcomes According to the rSS
3353	Independent Predictors of 1-Year Ischemic Outcomes
3354	Effect of Exposure to Secondhand Smoke on Systemic Nitrotyrosine Levels
3355	Effect of Exposure to Secondhand Smoke on Systemic Levels of ADMA and SDMA
3356	Univariate and Multivariate Logistic Regression Analyses for Prediction of Cardiac Troponin Elevation
3357	Beta-Coefficients for Individual and Multivariable Regressions on Fetuin-A Levels
3358	Multivariable Cox Proportional Hazards Models for the Association of Quartile of Fetuin-A With CVD Mortality
3359	Multivariable Hazard Ratios for CVD Mortality by Low Fetuin-A  (Quartile 1)  Versus Higher  (Quartiles 2 to 4)  Stratified by Potential Moderators
3360	Multivariable Hazard Ratios for CVD Mortality by Low Fetuin-A  (Quartile 1)  Versus Higher  (Quartiles 2 to 4)  Adjusting for, or Excluding, Potential Covariates and Effect Modifiers
3361	18F-NaF and 18F-FDG SUV Max and TBR Max Values
3362	Correlation of 10-Year Framingham Risk Scores With the Coronary Calcium Score and PET Uptake
3363	Prolongation of QTc and Risk of Incident Stroke in the REGARDS Study
3364	ClopidogrelAM Pharmacokinetics With and Without PPIs
3365	VASP P2Y12 PRI in Clopidogrel-Treated Subjects With and Without 9 Days of PPI Coadministration
3366	Platelet Aggregation Measured by Light Transmission Aggregometry in Response to 5 and 20 μmol/l ADP in Clopidogrel-Treated Subjects With and Without 9 Days PPI Coadministration
3367	Platelet Aggregation Measured by VerifyNow P2Y12 PRU in Clopidogrel-Treated Subjects With and Without 9 Days of PPI Coadministration
3368	Change in HPR Status After the Coadministration of PPIs With Clopidogrel Compared With the Administration of Clopidogrel Alone
3369	Biochemical Markers, CT, and Technetium-99m SPECT Findings According to the Cardiac Events
3370	Univariate Analyses for Prediction of Cardiac Events
3371	Multivariable Cox Proportional Hazards Model for Prediction of Cardiac Events
3372	Results of Multivariable Modeling of Referral for Cardiac Catheterization at 90 Days
3373	Maximum and Minimum Values of Aortic Annulus Dimensions in Normal Subjects and Patients With Severe Aortic Stenosis
3374	Associations of Reported CHD SNPs With CHD Risk in NHS, HPFS, and JHS
3375	Joint Effect of the Loci Significantly Associated With CHD
3376	Potential Advantages and Disadvantages of Targeting Chemokines
3377	Study Outcomes With Adjusted HRs
3378	Study Outcomes With Adjusted HRs for the Propensity Score–Matched Cohort Analysis
3379	Adjusted HRs for the Impact of ACE Inhibitors or ARBs on Outcomes Stratified by the Severity of Regurgitation
3380	Clinical Variables
3381	Early and Late Clinical Events
3382	Study Outcomes: Efficiency, Cost, and Safety
3383	Univariate and Multivariate Models of Performance and Quality Measures by Payment Source
3384	Univariate and Multivariable Models of In-Hospital Outcomes by Payment Source
3385	Relationship Among the 5 Metabolic Criteria Used in the Definition of MetS, the Presence of MetS, BMI, and HF Incidence During the 6-Year Follow-Up Period
3386	Histological and Immunohistochemical Data 21 Days After MI
3387	Coronary Artery Stenosis Severity by Segment For Individuals Who Lived Versus Died
3388	Univariable and Adjusted Hazard Ratios for All-Cause Mortality by Per-Patient, Per-Vessel, and Per-Segment Analysis by Obstructive CAD at the 50% and 70% Stenosis Level
3389	Adjusted Hazard Ratios for All-Cause Mortality for Patients <65 Versus ≥65 Years of Age
3390	Adjusted Hazard Ratios for All-Cause Mortality for Female Versus Male Patients
3391	Multivariable Adjusted Hazard Ratios for All-Cause Mortality as Stratified by Age and Sex
3392	Comparison of Patients With and Without Hard Cardiac Events
3393	Comparison of Patients With and Without MACE
3394	Incidence of Hard Cardiac Events and MACE Across Group Categories
3395	Multivariable Cox Models of Hard Cardiac Events for Prognostic Value of MFR Compared With SSS
3396	Multivariable Cox Models of MACE for Prognostic Value of MFR Compared With SSS
3397	Total Number of Events
3398	Adjusted and Unadjusted HRs for All-Cause Mortality and CV Events
3399	Adjusted HRs for All-Cause Mortality and CV Events Stratified by Severity of AS
3400	Association of Serum Phosphate Concentration With Aortic Valve Sclerosis, Mitral Annular Calcification, and Aortic Annular Calcification
3401	OR  (95% CI)  of Aortic Valve Sclerosis, Mitral Annular Calcification, and Aortic Annular Calcification by PTH and 25-OHD Levels
3402	Contraction and Relaxation Time Intervals
3403	Tag SNPs From the IRS-1 Gene Region and Genotype Frequency
3404	Prevalence of Patients With HPR Among Carriers and Noncarriers of the C Allele of the rs956115 Marker
3405	Examples of Adiposity and Adiposopathy Disorders Related to Cardiovascular Disease
3406	Adiposopathy  (“Sick Fat”) : Summary of Causality and Examples of Anatomic, Pathophysiological, and Clinical Manifestations  ⁎
3407	Adipose Tissue as an Endocrine Organ: Adipocytes and Adipose Tissue Produce Factors Actively Involved in Metabolic Processes Important for Human Health  ⁎
3408	Adipose Tissue as an Immune Organ: Adipocytes and Adipose Tissue Produce Factors Actively Involved in Immunological Processes Important for Human Health  ⁎
3409	Examples of Diseases Other Than Adiposopathy That Cause Common Metabolic Diseases
3410	Clinical Presentations of Patients in the Test Set
3411	Number and Percentage of Patients in the Test Set in Relation to Threshold Values From the Development Set
3412	Pathophysiology of Pressure-Overload TAC Heart in Mice Given Captopril Chronotherapy at Sleep Versus Wake Time
3413	Echocardiography Measurements
3414	Univariate and Multivariate Analyses of Predictors of New-Onset T2DM in the TNT Trial
3415	Univariate and Multivariate Analyses of Predictors of New-Onset T2DM in the IDEAL Trial
3416	Univariate and Multivariate Analyses of Predictors of New-Onset T2DM in the SPARCL Trial
3417	Relationships Among Diameter Stenosis and TIMI Flow Grade, TIMI Frame Count, and CCO Gradients Vessels With Obstructive CAD
3418	CCO in Patients With Abnormal Resting Coronary Blood Flow
3419	Abnormal and Normal CCO Gradients
3420	Percentage Changes in Conventional Lipid and Inflammatory Parameters
3421	Biochemical Safety Parameters
3422	Echocardiographic Parameters in HFNEF Versus Controls
3423	Collagen Cross-Linking in Patients With HFNEF Versus Controls
3424	Correlation of Diastolic Indexes From Mitral-Flow and Tissue Doppler With CVF, Insoluble Collagen, Collagen Cross-Linking, and LOX Expression
3425	Clinical Parameters
3426	Plasma Parameters
3427	Details of Fetuses Diagnosed With AS, Severe MR, and Severe LA Dilation
3428	Echocardiographic Findings in 14 Fetuses With AS, Severe MR, and Severe LA Dilation
3429	Pollutant Levels and Environmental Conditions During Exposures
3430	Effects of CAP and Ozone Exposure on cTp-e Interval Changes During Exposures
3431	Effects of CAP and Ozone Exposure on QT Dispersion Interval Changes During Exposures
3432	MRI Data
3433	Segment Location and Orientation of CC and SI Channels
3434	Blood Pressure and Heart Rate Responses to Transdermal GTN
3435	FBF Responses
3436	Analysis of Lipid Parameters
3437	Procedural Results and Angiographic Outcomes in Diabetic and Nondiabetic Cohorts
3438	Clinical Outcomes at 1 Year According to Presence of Diabetes
3439	Clinical Outcomes at 1 Year in Noninsulin- and Insulin-Dependent Diabetic Patients
3440	Clinical Outcomes at 12 Months According to Stent Randomization
3441	Multivariable Predictors of 12-Month Ischemic Target Lesion Revascularization Among Patients Randomized to Bare-Metal Stents
3442	Clinical Outcomes at 24 Months According to Stent Randomization
3443	Strongest Risk Factors for Sudden Cardiac Death Among Men
3444	Comparison of Sudden Cardiac Death Prediction Models Without  (Model 1)  and With  (Model 2)  Cardiorespiratory Fitness
3445	Effect of Adding Cardiorespiratory Fitness to Traditional Risk Factors: Reclassification of Men Between Predicted Cardiovascular Risk Categories and Comparison of Observed and Predicted Risk of Sudden Cardiac Death
3446	Protocols for Cardiosaver and DETECT Phase I Studies
3447	Sensitivity and Specificity for BMIPP SPECT Images for the Efficacy Population  (n = 448)
3448	Evaluation of BMIPP SPECT Imaging Compared With Angiography Results: Correlation With Culprit Lesion Anatomy
3449	Hemodynamic Parameters, Cardiac Dimensions, and Function in the Study Population
3450	Univariable and Multivariable Linear Regression Analysis of Liver Triglyceride Content, Myocardial Metabolic Rate of Glucose, and PCr/ATP Ratio
3451	Sensitivity Analyses of CYP2C19 Genetic Variants
3452	Sensitivity Analyses of the Impact of PPI Coadministration
3453	Antibody Profiles of 111 Children With  (Yes)  or Without  (No)  Noncardiac NLE
3454	Exclusion Criteria
3455	Clinical Outcome at 12 Months of Follow-Up
3456	Indices of Global Left Ventricular Performance at Rest and During Hemodynamic Interventions  (P-V Loop Analysis)
3457	Indices of Left Ventricular Systolic and Diastolic Function at Rest and During Hemodynamic Interventions  (P-V Loop Analysis)
3458	Potential Mechanism of Heart Failure With Preserved Ejection Fraction
3459	Univariate and Multivariate Cox Proportional Hazards Ratio Comparison for CAC Progression in Propensity-Matched Cohort
3460	Platelet Activation Profiles According to HPPR Status
3461	1-Year Clinical Outcomes in Patients With and Without Medically Treated Diabetes
3462	1-Year Clinical Outcomes in Diabetic Patients Treated With Oral Hypoglycemic Agents or Insulin
3463	Arterial Diameter and Blood Flow Data
3464	Analysis of Lipid Parameters
3465	Magnetic Resonance Imaging Variables
3466	Major End Points at 1 Year
3467	Outcomes in Subgroups of Interest
3468	SPECT Protocol and Tc-99m Radiopharmaceutical Doses
3469	Annualized All-Cause Mortality Rates Between Subgroups
3470	Univariate and Multivariable Predictors of Mortality
3471	Comparison Between Echocardiographic and MSCT Measurements
3472	Impact of the Method of Aortic Annulus Measurement on TAVI Strategy
3473	Hypertension and Left Ventricular Hypertrophy by Race-Ethnicity and Hispanic Subgroups
3474	Odds Ratios of Left Ventricular Hypertrophy by Race-Ethnicity and Hispanic Subgroups After Sequential Adjustment for Covariates
3475	Odds Ratios of Ventricular Remodeling  (Elevated M-C Ratio ≥95th Percentile)  by Race-Ethnicity and Hispanic Subgroup After Sequential Adjustment for Covariates
3476	Angiographic Findings and Clinical Presentation
3477	Observations in the Group With Late Optical Coherence Tomography
3478	Multivariate Parameter Estimates, p Values, and Risk Equation From Final Cox Proportional Hazards Model, Including All Variables for Predicting Stroke, MI, or Vascular Death in the NOMAS Cohort
3479	Comparison of the 10-Year Estimated Vascular Risks by the Model With Traditional Framingham Variables  ⁎  and the NOMAS GVRS
3480	Procedural and Angiographic Findings, Comparison Between BMS and PES
3481	Procedural and Angiographic Findings, Comparison Between BMS and SES
3482	Angiographic Complications of the Patients Enrolled in the 2 Groups
3483	Changes in Cardiac Enzymes After PCI in the Patients Enrolled in the 2 Groups
3484	Compendium of RYR2 Mutations and Polymorphisms Reported to Date
3485	Multivariable Predictors of Events
3486	Subjects With a Normal Stress SPECT: Relative Risk of Events Based on CACS Severity
3487	Histological Definition and Grading of the Aortic Tunica Media
3488	Elastic Tissue Configuration of the Pulmonary Trunk
3489	Exposure to Respiratory Disturbance During Hazard Period and 3 Matched Referent Periods  (n = 62 Matched Sets) *
3490	Risk of Arrhythmia After Respiratory Disturbance Compared With Risk of Arrhythmia During Normal Nocturnal Breathing
3491	Risk of Death/Transplantation in Year 2 Based on cTnT Profiles During Year 1 of Clinical Follow-Up
3492	Criteria for the Definition of Heart Failure With Preserved Systolic Function
3493	Reduced Function Alleles of Statin Pharmacokinetic Genes and Frequency in the STRENGTH Study
3494	Simvastatin and Pravastatin Metabolite Concentrations in the STRENGTH Study
3495	Sensitivity Analyses Using Various End-Point Definitions
3496	Comparison of εPEAKand Tε After Occlusion and Reperfusion in 30 Both Proximal and Distal At-Risk Segments and 30 Remote Nonischemic Segments
3497	Comparison of Strain Values and SI-DI After Occlusion and Reperfusion in 30 Both Proximal and Distal At-Risk Segments and 30 Remote Nonischemic Segments
3498	The Diagnostic Discrimination Between Seemingly Healthy Subjects and Patients With the Acute Coronary Syndrome  (GUSTO IV)  at Different Cutoff Levels of the High-Sensitivity cTnI Access Assay
3499	Outcomes in Patients With the Acute Coronary Syndrome  (GUSTO IV)  at Different Cutoff Levels of the High-Sensitivity cTnI Access Assay
3500	A Comparison of the Effects of Dietary and Surgical Weight Loss
3501	MRI, Functional, and Laboratory Results
3502	Relationship Between Noninvasive Measures
3503	Relationship Between Imaging and Functional Parameters
3504	Procedural Features in the Atorvastatin Reload and Placebo Groups
3505	Individual and Combined Outcome Measures of the Primary End Point at 30 Days in the Atorvastatin Reload and Placebo Groups
3506	Load, Contractility, and Ventricular-Arterial Coupling
3507	Incidence of MACE and Cardiac Death  (10-Year Follow-Up)
3508	Predictors of Events at Univariate and Multivariate Analyses
3509	Comparison of Clinical Profile of All Subjects Who Did and Did Not Develop ACS
3510	Multivariate Cox Regression Analysis for Development of Acute Coronary Syndrome
3511	Comparison of Clinical Profile of Subjects With 2- or 1-Feature Positive Plaques in Whom ACS Did and Did Not Develop
3512	Cytokine Concentrations in the Collateral and Coronary Samples  (in pg/ml)
3513	Correlations of Collateral-Coronary Cytokine Gradients With Oxygen Gradient in Patients With Subtotal Stenosis
3514	Exercise Echocardiographic Data of the 4,004 Patients
3515	Univariate Predictors of Mortality and Major Cardiac Events
3516	Multivariate Predictors of All-Cause Mortality
3517	Multivariate Predictors of Major Cardiac Events
3518	Inclusion and Exclusion Criteria
3519	Diagnostic Accuracy of Coronary CTA for the Detection of Acute Coronary Syndrome and Myocardial Infarction During Index Hospitalization Among Patients With Acute Chest Pain Based on the Presence of Any Coronary Plaque or the Presence of Coronary Artery Stenosis  (>50% Luminal Narrowing)
3520	Detailed Information on the Results of Standard Care and Coronary CTA Results in Subjects Who Were Determined to Have ACS During Index Hospitalization But in Whom No Significant Stenosis Was Detected by Coronary CTA
3521	Adjusted RR of Restenosis Pairwise Comparison Between Stents
3522	Drug Regimens Used in Each Constituent Trial
3523	Univariate Analysis for CIN
3524	Composition of High-Density Lipoproteins After rHDL Infusion
3525	Distribution of ST Across Quintiles
3526	Clinical Outcome
3527	Univariate Logistic Regression Analysis of Clinical and Humoral Factors for Prediction of IR in Patients With HF
3528	Multiple Logistic Regression for Each Variable to Predict IR in Patients With HF
3529	Correlations Among Absolute Values and Percentage Inhibition Values With Different Methods
3530	Antiarrhythmic Medications Utilized for the Treatment of JET
3531	Medications Reported to be Successful in the Treatment of JET
3532	Outcomes of Radiofrequency Ablation and Cryoablation for Junctional Tachycardias
3533	Comorbidities or Complications During the Treatment of Patients With JET
3534	Imaging Results
3535	Univariate Predictors of Events
3536	Clinical and Therapeutic Data in 16 Patients With Electrical Storm
3537	Nucleotide Sequences of TLR2, TLR4, and Scrambled siRNA
3538	Chemokine Release After Stimulation With TLR Agonists
3539	Blood Pressure Changes After 12 Months of Treatment Presented According to CF PWV0
3540	Predictors of SBP and DBP Decline After 12 Months of Treatment
3541	Comparison of Subgroups of Participants  (Tertiles)  Divided by CF PWV0
3542	Measurements of the SAECG, HRV, and QT Dispersion in Patients With and Without SCD
3543	Univariate and Multivariate Cox Proportional Hazard Analysis for the Identification of CHF Patients at Risk of Sudden, Pump Failure, and Cardiac Death in Total Study Patients
3544	Univariate and Multivariate Cox Proportional Hazard Analysis for the Identification of CHF Patients at Risk of Sudden, Pump Failure, and Cardiac Death in Patients With Sinus Rhythm
3545	Prediction of SCD and Cardiac Death in Patients With Chronic Heart Failure by a Combination of Abnormal WR and LVEF ≤35% in Total Study Patients
3546	Correlation Between the Measured Parameters and the Results of Cardiac Metaiodobenzylguanidine Imaging in Total Study Patients
3547	Brachial Artery Diameter and Blood Flow
3548	Comparison of Medication Usage
3549	Univariate and Multivariate Cox Proportional Hazards Analyses of Risk Factors for Cardiovascular Events
3550	DSE Data
3551	Anglographic Data
3552	Results
3553	Univariate and Multivariate Predictors
3554	Normal Reference Values of Effective Orifice Areas for Prostheses Implanted in This Series
3555	Univariate and Multivariate Predictors of Late Overall Mortality
3556	Univariate and Multivariate Predictors of Late Cardiovascular Mortality
3557	PRI in the VASP Phosphorylation Assay of Clopidogrel Patients Treated With Different Classes of CCBs
3558	Gene Identification and Primer Sequences
3559	Clinical, Biochemical, and Cardiac Catheterization Data of the Study Subjects
3560	Differences in CD34+ Subpopulations
3561	Serum RANKL, OPG, and MGP Levels in the Study Subjects
3562	ROC Analysis
3563	Association of Cardiovascular Risk Factors and Severity of CAD Diagnosed by CTA
3564	Hazard Ratios of Death and 95% Confidence Interval  (in Parentheses)  According to CAD Status
3565	Hazard Ratios of Death and 95% Confidence Interval  (in Parentheses)  Across Groups of Patients With Increasing CACS Among Those With CTA-Diagnosed Nonobstructive CAD  (n = 1,060)
3566	Use of AVJ Ablation in AF Patients
3567	PI Achieved With Clopidogrel in the Presence or Absence of Categorical Variables
3568	Correlation Between Platelet Inhibition With Clopidogrel and Continuous Variables
3569	Results of Multiple Variable Analysis
3570	Metabolic Response to 16 Weeks of Caloric Restriction in Obese Patients With T2DM
3571	Intraindividual Effects of 16 Weeks of Caloric Restriction on Systolic and Diastolic Function in Obese Patients With T2DM
3572	Increase in Plasma CGRP Concentration 12 Min After Sublingual GTN Administration and Association With ALDH2 Glu504Lys Mutation
3573	Hemodynamic Response to Exercise
3574	Neurohormonal Response to Exercise in Subjects With or Without an Exaggerated BP Response to Exercise
3575	Changes in Measures of Atheroma Burden and Vessel Dimensions in Patients With and Without Diabetes
3576	Association of Plasma Levels of Adiponectin and Leptin With Coronary Artery Calcification in Tobit Multivariable Models
3577	Incremental Value of Metabolic Syndrome, CRP, Adipocytokines, or HOMA-IR in Predicting Coronary Calcium Scores Beyond Established Risk Factors
3578	Absolute Plasma t-PA Antigen and Activity Concentrations
3579	Plasma von Willebrand Factor Concentrations During SFLLRN and Bradykinin Infusions
3580	Absolute Plasma PAI-1 Antigen and Activity Concentrations
3581	Components of Primary End Point  (ITT Population)
3582	Secondary and Tertiary Clinical Events
3583	Quality of Life and Clinical Status Outcomes
3584	Components of the Primary End Point Within SUA Subgroups  (ITT Population)
3585	Secondary and Tertiary Clinical Events by SUA Subgroup  (ITT Population)
3586	Quality of Life and Clinical Status Outcome by SUA Subgroup  (ITT Population)
3587	Biological and Clinical Features of ED Patients With and Without MACE
3588	The Role of NOS
3589	The Role of EDHF and COX-Derived Products
3590	Lack of a Role of Distending Pressure in L-FMC
3591	FMD and L-FMC in Health and Disease
3592	Features Associated With TAV Versus BAV in Girls and Women With TS
3593	Genotype and BAV Prevalence
3594	Percent Platelet-Monocyte Binding
3595	Linear Regression of Plasma Cotinine  (Independent, ng/ml)  and Biological Parameters  (Dependent)
3596	Unadjusted and Adjusted Hazard Ratios for Symptomatic CHF in Relation to Novel Metabolic Risk Factors in the MESA Study  (n = 6,814)
3597	Clinical Outcomes for African-American Compared With Non–African-American Patients
3598	Independent Association of African-American Race and Quality of Care
3599	Associations of Functional Performance Measures With Mortality Among Participants With PAD After Additional Adjustment for Physical Activity Levels: Normal Paced 4-m Walking Velocity
3600	Associations of Functional Performance With Total and Cardiovascular Mortality Among Participants With PAD After Additional Adjustment for Physical Activity Levels: Fast-Paced 4-m Walking Velocity
3601	Effects of Weight Loss on LV Geometry and Systolic Function
3602	Effects of Weight Loss on Left Ventricular Diastolic Function
3603	Associations Between Calendar Year and Mortality After the Index Date in 21,484 Survivors of MI
3604	Associations between Calendar Year and Mortality in 21,484 Survivors of MI: Impact of Increasing Utilization of Coronary Interventions  ⁎   and of Recommended Cardiovascular Medications after Discharge
3605	Quantitative Angiographic Measurements
3606	Angiographic Patterns of Restenosis  ⁎
3607	Clinical Outcomes at 9 Months
3608	Predictors of Angiographic Restenosis and Clinical Outcomes on Multivariate Analysis
3609	Adverse Drug Effects
3610	Antiplatelet Treatment at the Time of ST
3611	Multivariate Analysis for Predictors of ST in a Subgroup of 14,120 Patients
3612	Clinical Presentation, Treatment, and Outcome
3613	Independent Predictors for Mortality and Recurrent Thrombosis
3614	Percentage of Plaque Showing CS  (CV <20 cm/s)  or CB  (CV <10 cm/s)  During Pacing From the Plaque Corners
3615	Total Plaque Activation Time  (Inferior Corner Pacing)
3616	Conduction Anisotropy: Anisotropy Index
3617	Conduction Heterogeneity
3618	Effects of Ramipril Treatment on Endothelial Function and Inflammatory Process in Patients With Successfully Repaired Coarctation of the Aorta
3619	4-Year Efficacy Outcomes
3620	4-Year Safety Outcomes
3621	Efficacy and Safety Outcomes Among Diabetic Patients According to Insulin-Dependent Status
3622	Acute Hemodynamic Effects of Inhaled Iloprost
3623	Iloprost Dosing
3624	Chronic Hemodynamic Effects of Inhaled Iloprost
3625	Cutoff Values for Predicting Cardiac Death Obtained by ROC Analysis
3626	Multivariate Analysis of Clinical Factors Predicting Cardiac Death in Hemodialysis Patients Using Stepwise Cox Hazard Model
3627	Adjusted Odds Ratios for the Combined Primary End Point, Myocardial Injury, or Ischemic Heart Disease Admission at 1 Year, According to Subgroups
3628	Anatomy From the Initial Echocardiogram at Presentation
3629	Z-Scores of Left Heart Structures at Presentation
3630	Significant Predictors for Time-Related Outcomes
3631	Effects of In Vivo GTN Treatment or In Vitro ALDH-2 Inhibition on Vascular Reactivity
3632	ALDH Activity in Human Bypass Graft Vessels Without Prior GTN Treatment
3633	Effect of the Treatment  (16 Weeks)  on Clinical and Laboratory Parameters
3634	Effect of the Treatment  (16 Weeks)  on Hemodynamic Data and PET Measurements
3635	Presenting Signs and Symptoms  (n = 24)
3636	Positive Post-Operative Ischemia Tests  (n = 9)
3637	Breakdown of Hyperkalemia Outcomes in CHARM-Overall
3638	Clinically Important Hyperkalemia in CHARM
3639	Clinically Important Hyperkalemia by Subgroups, CHARM-Overall
3640	Multivariable HRs for Clinically Important Hyperkalemia
3641	Age-Adjusted Hazard Ratio
3642	Univariate and Multivariate Predictors of Cardiovascular Events  (Myocardial Infarction and Cardiac Death)
3643	Stepwise Cox Proportional Model for the Prediction of Cardiovascular Events
3644	Comparison of RV EDV, ESV, SV, and EF Between 3D US and MRI
3645	Relationships Between Calcium in Different Vascular Beds and HTN
3646	Laboratory Data of the Entire Cohort and According to Quartiles of Platelet Aggregation
3647	Platelet Function Profile Analyses
3648	Univariate Analysis of Predictors of Reoperation
3649	Multivariate Analysis of Predictors of Time to Reoperation
3650	Multivariate Analysis of Predictors of Recurrence
3651	Univariate and Multivariate Prognostic Predictors
3652	The Small Artery and Arteriolar Diameter Measurements at Rest and During Cardiac Pacing
3653	Hemodynamic Status at Rest and During Cardiac Pacing
3654	Univariate and Multivariate Predictors of Cardiac Events  (Myocardial Infarction and Cardiac Death)
3655	Age-Adjusted Relative Risk
3656	Outcomes for Ticlopidine- and Clopidogrel-Associated TTP Cases
3657	BP and HR at Rest Before and After Treatment
3658	Blood Biochemistry Before and After Treatment
3659	Risk Factors for Cardiac Mortality
3660	Patient Examination Findings and Clinical Status at Hospital Discharge by Ventricular Function
3661	Post-Discharge 60- to 90-Day Clinical Outcomes by Ventricular Function
3662	Discharge Medications and Risk- and Propensity-Adjusted Outcomes After Hospital Discharge in Patients With Reduced and Preserved Systolic Function
3663	Dose-Dependent Effects of Saline on Responses to Intranasal Cocaine
3664	Dose-Dependent Effects of Dexmedetomidine on Responses to Intranasal Cocaine
3665	Dose-Dependent Effects of Dexmedetomidine in Subjects With the α2CDel322-325 Variant Allele
3666	Functional Assessment Before and After LDLLT
3667	Latest WHO Functional Class
3668	Subgroup analysis for mono-infected and co-infected patients who received 12 weeks of treatment
3669	Safety of grazoprevir plus elbasvir with or without ribavirin
3670	Risk Estimates for Cancer Incidence and Cancer Mortality Attributable to Radiation Exposure During Atrial Fibrillation Ablation
3671	Heart Failure Hospitalization and Mortality by Diabetic Drug Category
3672	Mean Daily Intake of Individual Foods According to Quartiles of Energy-Adjusted Dietary Glycemic Load
3673	Adjusted Hazard Ratios  (With 95% CI)  of Cardiovascular Disease According to Quartiles of Energy-Adjusted Dietary Glycemic Load and Glycemic Index Among 15,714 Women
3674	Adjusted  ⁎  Hazard Ratios  (With 95% Confidence Intervals)  of Cardiovascular Disease According to Quartiles of Energy-Adjusted Carbohydrates, Mono- and Disaccharides, and Polysaccharides Among 15,714 Women
3675	Adjusted  ⁎  HRs Among BMI Subgroups According to Quartiles of Dietary Glycemic Load and Glycemic Index
3676	Correlation Coefficients Between Serum Concentrations of LBP and Coronary Risk Factors in Men  (n = 247)
3677	Multivariable Logistic Regression Predicting the Likelihood of CAD According to Quartiles of LBP Levels, Markers of Systemic Inflammation, and Established Cardiovascular Risk Factors
3678	Assessment of Regional Myocardial Function in the Systemic RV Free Wall Compared With the RV and LV Free Wall in Healthy and Operated Control Subjects
3679	Assessment of Regional Myocardial Function in the IVS of the Senning-Operated TGA Patients Compared With the IVS in Healthy and Operated Control Subjects
3680	Lipoprotein and C-Reactive Protein Levels
3681	Spearman Correlation Coefficients Between HOMA-IR and the Continuously Distributed Individual Components of the Metabolic Syndrome
3682	Relationship Between the Metabolic Syndrome Based on IDF Criteria, HOMA-IR Expressed Both as a Categoric Variable and as a Continuous Variable, and Risk of Cardiovascular Disease With Successive Inclusion of Variables in the Models
3683	Relationship Between the Metabolic Syndrome Based on NCEP Criteria, HOMA-IR Expressed Both as a Categoric Variable and as a Continuous Variable, and Risk of Cardiovascular Disease With Successive Inclusion of Variables in the Models
3684	Relationship Between Risks of Cardiovascular Events According to the Individual Components in the Metabolic Syndrome Compared With Their Respective Counterparts Based on Both IDF Criteria and NCEP Criteria
3685	Relationship Between the Metabolic Syndrome Based on IDF Criteria, HOMA-IR Expressed Both as a Categoric Variable and as a Continuous Variable, and Risk of Cardiovascular Disease With Adjustment for the Framingham Risk Score
3686	Relationship Between the Metabolic Syndrome Based on NCEP Criteria, Insulin Resistance as Assessed by Homeostasis Model Assessment, Expressed Both as a Categorical Variable and as a Continuous Variable, and Risk of Cardiovascular Disease With Adjustment for Framingham Risk Score
3687	Cox Proportional Hazards Analysis of Factors Predictive of Death
3688	3-Chlorotyrosine Levels in Total Plasma Protein From MI Patients With High or Low MPO and Protein Carbonyls
3689	Simple Linear Regression Analysis for Determinants of sCD40L and 8-OHdG in Children
3690	Cox Regression Investigating Predictors of Survival After MI
3691	Frequency of Revascularization Procedures and Cardiac Events During Follow-Up Results in the CAC Cohort
3692	Frequency of Revascularization Procedures and Cardiac Events During Follow-Up in the MPS Referral Cohort
3693	Echocardiography
3694	Multivariate Analysis of Determinants of Left Ventricular Internal Dimension in Diastole
3695	MRI Measurements
3696	Early and 6-Month Clinical Outcomes
3697	Hemodynamic Measurements in Rats With ACF and Age-Matched Sham Rats
3698	Isolated Cardiomyocyte Function in Age-Matched Sham and ACF Rats
3699	Hemodynamic and Morphometric Parameters in 2-Day Untreated ACF, 2-Day ACF + Hoe 140, and 2-Day ACF + Ang II
3700	Clinical Outcome in ARTS II According to Clinical Presentation
3701	Summary Estimates of Event Rates After a Negative Test and Negative Predictive Values for MI and Cardiac Death, and Revascularization and Unstable Angina After a Negative Test
3702	Summary Estimates of Rates After a Negative Test and Negative Predictive Value for Myocardial Infarction or Cardiac Death for Women and Men in Exercise Myocardial Perfusion Imaging and Exercise Echo
3703	Studies of the Value of Exercise Echocardiography to Predict Revascularization and Unstable Angina
3704	Comparison of Indexes of Diastolic and Systolic Asynchrony as Well as Myocardial Systolic and Diastolic Velocities Among Patients With DHF, SHF, and Normal Controls
3705	Incidence and Interobserver Agreement for the Qualitative Magnetic Resonance Variables
3706	Predictors of Exercise WMSI >1
3707	In-Hospital Outcomes
3708	Multiple Cox Model for Long-Term Mortality
3709	Multivariate Proportional Hazards Regression Model Results
3710	Left Ventricular Ejection Fraction  (LVEF)  and Left Ventricular Diastolic Diameter  (LVDD)  at 6 Months by −344 Genotype and Treatment
3711	Raw and Weight Change-Adjusted Differences in Metformin Versus Placebo Recipients for Change in Vascular Response  (AUC for ACh-Mediated Perfusion) , HOMA-IR, and ST-Segment Depression
3712	Clinical Information in the Subjects, Classified According to Left Ventricular Systolic Function and Inertia Force
3713	p Values for Comparisons of Effects of Different Loading Doses on Inhibition of Platelet Aggregation
3714	Incidence of Bleeding Complications by Treatment Group, Day 1 to Hospital Discharge  ⁎
3715	Platelet Function Profiles of the Study Population
3716	Multivariate Linear Regression Analysis of ADP-Induced Platelet Aggregation
3717	Risk Factors, Cardiac Functions, and Medications During the Follow-Up Period in Patients With Acute Myocardial Infarction
3718	Effect of Patient Group on Heart Rate Dependence of Cardiac and Hemodynamic Parameters
3719	Changes After Dobutamine Infusion
3720	Severity of PAD Based on Pulse Volume Recordings
3721	Cardiac Geometry in Normal Weight, Overweight, and Obese Adolescents
3722	Cardiac Function in Normal Weight, Overweight, and Obese Adolescents
3723	Daily Caffeine Consumption
3724	Site of Ischemia in Relationship to Major Vessels
3725	Perfusion Defect Extent and Size Without and With Caffeine
3726	Incidence of Clinical Worsening  ⁎
3727	Treatment-Related Side Effects  ⁎
3728	ANOVA for Repeated Measures Results  (df = 1,17)  on the Improvement of Subjects’ Performance From Trial 1 to Trial 5
3729	Test-Retest Reliability Values and Standardized Coefficient Alpha Values for the 18 Subjects Across Five Different Measures
3730	Results in 20 BAV Patients and 20 Age- and Gender-Matched Healthy Subjects
3731	Clinical Manifestations of Metabolic Syndrome and Control Subjects
3732	Partial Correlation Coefficient Adjusted for Smoking Status Between Clinical and Biochemical Parameters With Rho Kinase Activity Among Metabolic Syndrome Subjects
3733	Adjusted Odds Ratios of Greater ROCK Activity With the Number of MetS Components
3734	Standing Blood Pressure and Heart Rate Responses to IS-5-MN
3735	FBF Responses: Ratio of Infused to Noninfused Arm
3736	FBF Responses: Ratio of Infused to Noninfused Arms
3737	Comparison of the CAC and MPS Patient Groups
3738	Comparison of Patient Populations
3739	Comparison of 64-Slice CT Myocardial Lack of Hyperenhancement With Low-Dose Dobutamine Echocardiography
3740	Detection of CAD by Cardiac PET-CT in 64 Patients Who Underwent Coronary Angiography
3741	Extent of CAD by Cardiac PET-CT in the 44 Patients With Significant Angiographic CAD
3742	Diagnostic Efficiency
3743	Effect of Hoe 140 on Hemodynamic and Echocardiographic Measurements in Control Rats  (2-Day SHM)  and Rats 2 Days After ACF
3744	Effect of RAM on Hemodynamic and Echocardiographic Measurements in Control Rats  (4-Week SHM)  and Rats After 4 Weeks of ACF
3745	Summary of the Differences Between Implant and Millar Pressure Readings  (in mm Hg)  in the Studied Animals  (Bland-Altman Method)
3746	Studies of the Value of Exercise Myocardial Perfusion Imaging to Predict MI and Cardiac Death
3747	Studies of the Value of Exercise Myocardial Perfusion Imaging to Predict Revascularization and Unstable Angina
3748	Studies of the Value of Exercise Echocardiography to Predict MI and Cardiac Death
3749	Comparison of 16- Versus 64-Slice Multi-Slice Computed Tomography  (MSCT)
3750	MBF and MGU, Tissue Fraction, and Glucose Extraction in Patients With Normal Glucose Tolerance and Those With T2DM
3751	Task Force Criteria for the Diagnosis of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy
3752	Univariate Predictors of Death and Combined End Point
3753	Short-Axis Left Ventricular Function With Circumferential S and SR and Radial S and SR in Control, Dysfunctional, and Subendocardial Infarct and Transmural Infarct Segments
3754	Long-Axis Function With Longitudinal S and SR in Control, Dysfunctional, Subendocardial Infarct, and Transmural Infarct Segments
3755	Comparison of Measurements in Normal Subjects Versus MR Patients
3756	Detection of Significant Coronary Artery Stenosis  (>50%)  With 64-Slice Computed Tomography
3757	Age- and Sex-Adjusted Means and Proportions of Risk Factors by Ethnic Group
3758	Traditional Risk Factors for PAD
3759	Odds of PAD Associated With a 1-SD Increment in Each Novel Risk Factor
3760	Cardiac Events Over the Follow-Up Period for Different Summed Stress Scores
3761	Multivariable Cox Proportional Hazard Models for Cardiac Death/Nonfatal MI and Total Cardiac Events Showing the Incremental Prognostic Value of Summed Stress Score
3762	Cardiac Events Over the Follow-Up Period for Ischemia and Summed Stress Score
3763	Image Quality Comparison and Diagnostic Certainty of Image Comparison Between 99mTc SPECT and 82Rb PET MPI
3764	Cardiac Events in Obese Patients
3765	Summary of Hemodynamic Variables of the Subjects in Each Group
3766	Incidence of Bleeding Complications by Treatment Group, Day 1 to Hospital Discharge  ⁎
3767	Secondary outcomes at days 7 and 90
3768	Number of site-years in database by source type
3769	Global deaths for 235 causes in 1990 and 2013 for all ages and both sexes combined and age-standardised death rates
3770	Selected causes of global child deaths in 1990 and 2013
3771	Counterfactual deaths and population attributable fractions for diarrhoea and lower respiratory infection pathogens for 1990 and 2013
3772	Comparison of GBD and CHERG estimated child deaths for select causes in 2010
3773	Prognostic value of anti-PLA2R antibodies
3774	Pairwise and network estimates of the effects of different drug regimens compared with placebo on primary and some secondary safety outcomes
3775	Effect of vitamin A on primary and secondary outcomes
3776	Adverse events between supplementation and 3 days after dosing
3777	Serum retinol concentrations of infants aged 2 weeks, infants aged 3 months, and mothers of infants aged 3 months
3778	Chronic obstructive pulmonary disease exacerbations, lung function variables, and other outcomes
3779	Adverse events occurring in at least 2·5% of patients in either treatment group
3780	Key safety outcomes
3781	Proportion of patients with plasma hepatitis C virus RNA concentration lower than the quantification limit  *
3782	Adverse events and abnormalities on laboratory tests during treatment
3783	Antihypertensive medications
3784	Adverse events related to arteriovenous coupler placement or device
3785	Virological response
3786	Safety and adverse events  (initial treatment period and first 14 days after completion of treatment)
3787	Maximal Absolute  (ml/100 ml tissue/min)  FBF Changes During Simultaneous L-NMMA and Sulfaphenazole
3788	Comparison of secukinumab versus placebo at week 24 for prespecified primary and secondary endpoints
3789	Efficacy of secukinumab at week 24 in anti-TNF-naive and anti-TNF-IR patients in a prespecified exploratory analysis
3790	Safety and tolerability profile of secukinumab until week 16  (placebo-controlled period)  and for the entire treatment period  *
3791	Responder rates in the ITT population for respiratory function test results
3792	Adverse events, changes from baseline in vital signs, and treatment-emergent dulaglutide antidrug antibodies from baseline to 52 weeks
3793	Adverse events in the safety population
3794	Hazard ratios for progression-free and overall survival by number of risk factors
3795	Treatment-emergent adverse events with an incidence of 10% or more in the brentuximab vedotin group, in the safety analysis set
3796	Adverse events
3797	Reasons for follow-up of less than 21 months
3798	Adverse events occurring in 1% or more of patients in either treatment group
3799	Comparison of Biochemical Data for Peripheral Blood Treated With or Without the Column
3800	Changes in histological features of the liver after 72 weeks of treatment
3801	Adverse events
3802	On-treatment and post-treatment HCV virological response
3803	Discontinuations, adverse events, and haematological abnormalities in patients who received 12 weeks or 24 weeks of combined sofosbuvir and ribavirin
3804	Primary outcomes at various timepoints
3805	Secondary process outcomes
3806	Treatment-emergent adverse events
3807	Common adverse events  (all grades)  in ≥5% of patients
3808	Summary of solicited adverse reactions and unsolicited adverse reactions occurring within 28 days of vaccination
3809	Antibody responses to the glycoprotein of the 2014 Zaire Ebola virus
3810	Adverse events after treatment with dabigatran etexilate alone and after administration of idarucizumab or placebo
3811	Postsurgery FIGO stage and histological diagnosis
3812	Surgery details
3813	Postoperative grade 3 or 4 adverse events and mortality
3814	Chemotherapy received
3815	Factors associated with change in cycle endurance time at 3 months
3816	Responder rates according to lung function, health status, and exercise criteria
3817	Adverse events
3818	Serious adverse events, defined as major morbidity
3819	Primary and key secondary endpoints
3820	Serious adverse events
3821	Details of suture techniques
3822	Secondary outcomes
3823	Incidence and HR for all-cause mortality and subdistribution HR for outcomes per 5 kg reduction in grip strength
3824	HR for all-cause mortality and subdistribution HR for cardiovascular mortality and cardiovascular disease
3825	Medication use, by class, during the study
3826	Longitudinal clinical data and drugs used
3827	Mean systolic and diastolic blood pressure levels and prevalence of hypertension by age group and sex in the 2011 Health Survey for England
3828	Blood pressure levels and hypertension from 1994 to 2011
3829	Type of drugs used among participants treated for hypertension
3830	Randomised, controlled, cardiovascular outcome trials  (>1000 subjects, >1 year of follow up)  of glucose-lowering drugs or strategies in people with type 2 diabetes
3831	Ongoing cardiovascular outcome trials of glucose-lowering drugs or strategies  (in order of starting date)
3832	Occurrence of contrast-induced acute kidney injury
3833	Occurrence of contrast-induced acute kidney injury in prespecified patient subgroups
3834	Major adverse events at 30 days and 6 months
3835	Ischaemic heart disease risk factors and event rates
3836	Adult sleep staging and arousal scoring
3837	Adult respiratory event scoring
3838	Comparison of trial outcome measures between dulaglutide and liraglutide
3839	Safety assessments and vital signs up to 26 weeks' follow-up
3840	Clinical endpoints for first and second phases
3841	Tobit regression model exponentiated estimates—dependent variable natural log 6-month NOAEL
3842	Adverse events during treatment presented
3843	Outcomes for plasma HIV-1 RNA of less than 50 copies per mL at week 48
3844	Common adverse events  (≥5% incidence in either treatment group)
3845	Summary of serious adverse events by system organ class
3846	Summary and statistical analysis of HIV Treatment Satisfaction Questionnaire scores by week
3847	List of interventions included in the analysis
3848	Additional estimated costs for high and medium scenario compared to low scenario  (US$, 2011)
3849	Estimated direct cost per intervention package
3850	Additional health workers needed based on coverage increases above 2012 estimated coverage in respective scenario
3851	Summary investment metrics, by region to 2035 and 2050, at 3% discount rate
3852	Summary investment metrics, for economic benefits and all benefits, all countries, selected periods and discount rates
3853	Treatment-emergent adverse events occurring in 10% or more of patients in either group during the double-blind period  (safety population)
3854	Adverse events occurring in at least 10% of patients or of special interest irrespective of cause
3855	Antitumour activity of pembrolizumab at 2mg/kg and 10 mg/kg
3856	Summary of adverse events in the pembrolizumab 2mg/kg and 10 mg/kg groups
3857	Kaplan-Meier estimates of relapse-free efficacy at 6 months after treatment in the intention-to-treat population
3858	Results by country for Kaplan-Meier estimates of relapse-free efficacy at 6 months after treatment
3859	Median parasite and fever and gametocyte clearance times
3860	Most frequent adverse events of any cause reported in the safety  (intention-to-treat)  population
3861	All serious adverse events of any cause reported in the safety  (intention-to-treat)  population
3862	Most common adverse events during study phase 1, by dose
3863	Most common adverse events during study phases 2 and 3
3864	Frequency of Death and Conversion to an SV Circulation
3865	Nausea, vomiting, and abnormal LFT results during study phases 2 and 3, by dose
3866	Distribution of Threshold Scores Among New Patients  (n = 89)  Who Did  (Survivors)  and Did Not  (Events)  Survive With a Biventricular Circulation
3867	Clinical scale ratings for disease progression  (study phases 2 and 3)
3868	Efficacy of the vaccine against gastroenteritis in the per-protocol population
3869	Protective efficacy of the vaccine against severe gastroenteritis caused by different RV genotypes
3870	Serious adverse events coded by the Medical Dictionary for Regulatory Activities system of organ classification and preferred terms
3871	Adverse events by body system
3872	Estimated change per month in secondary and metabolic outcome measures
3873	Outcomes
3874	Adverse events
3875	Diagnostic results by modality
3876	Overall adverse events and serious adverse events
3877	Virological responses
3878	SVR12 by subgroup
3879	Summary of on-treatment safety
3880	Summary of findings for catheter venography and ultrasound criteria, by group
3881	Catheter venography and ultrasound findings by centre
3882	Number of ultrasound criteria met by the participants, grouped by whether or not CCSVI criteria were fulfilled
3883	Structural abnormalities detected by ultrasound
3884	Agreement between ultrasound  (at least two of five criteria positive)  and presence of venous narrowing on catheter venography
3885	Effect of isoniazid on rate of tuberculosis or death
3886	Effect of isoniazid on the rate of all tuberculosis stratified by markers of Mycobacterium tuberculosis infection status at enrolment
3887	Effect of isoniazid on the risk of stopping the study drug because of adverse events
3888	Myocardial Velocities, Displacement, and Strain During Systole and Isovolumic Phases in the Anterior Mid-Segment  (n = 10)
3889	Systolic and Post-Systolic Measurements in Six Regions in the LV Anterior Wall in Patients With Recent LAD Occlusion  (n = 10)  and Healthy Volunteers  (n = 15)
3890	Mean total cost  (£)  per patient over 24 months follow-up
3891	Virological response over time  (RVR and SVR12) , and on-treatment failure and relapse, according to treatment group in the intention-to-treat population
3892	Proportion of patients meeting criteria for response-guided treatment in the simeprevir, peginterferon alfa 2a and ribavirin group and corresponding SVR12 in the intention-to-treat population
3893	Summary of adverse events during the first 12 weeks and during the entire treatment
3894	Virological response with time  (RVR and SVR12) , on-treatment failure, and relapse in the intention-to-treat population
3895	Patients meeting criteria for response-guided therapy in the simeprevir group and corresponding SVR12 in the intention-to-treat population
3896	SVR12 in patients according to subgroups
3897	Summary of adverse events during the first 12 weeks of treatment and during the entire treatment
3898	Summary of adverse events during the entire treatment by type of peginterferon alfa
3899	Proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 24 or week 48, or both
3900	Clinical adverse events and laboratory abnormalities at week 48
3901	Multivariable Model for Prediction of Cardiac Death in Patients With Known CAD
3902	Multivariable Model for Prediction of Cardiac Death in Patients With Suspected CAD
3903	Three-Year Risk-Adjusted Rates of Cardiac Death in Patients With Known CAD by MPS Results, Gender, Age, Stress Type, and LVEF
3904	Three-Year Risk-Adjusted Rates of Cardiac Death in Patients With Suspected CAD by MPS Results, Gender, Age, Stress Type, and LVEF
3905	Wilson-Jungner  23   principles of early disease detection and screening for chronic kidney disease
3906	Haematological and blood chemical values for patient 1
3907	Haematological and blood chemical values for patient 2
3908	Genetic analysis of specimens
3909	Mortality rates and variables for selected municipalities  (N=2853)
3910	Fixed-effect negative binomial models for association between under-5 mortality rates and Bolsa Familia Programme  (BFP)  and Family Health Programme  (FHP)  coverage
3911	Fixed-effect negative binomial models for adjusted associations between Bolsa Familia Programme  (BFP)  and Family Health Programme  (FHP)  coverage and under-5 mortality rates for some relevant groups of causes
3912	Fixed-effect models for associations between primary care indicators, rates of admission to hospital, and Bolsa Familia Programme  (BFP)  coverage
3913	Changes in bone-mineral density and differences between groups at 12 months
3914	Adjusted attributable fraction  (AF, expressed as weighted percent of total episodes with 95% CI)  of pathogens significantly associated with moderate-to-severe diarrhoea  (MSD) , by age stratum and site
3915	Weighted annual incidence  (per 100 child-years)  of total MSD, MSD attributable to a pathogen, and MSD attributable to a specific pathogen, with 95% confidence interval, by age stratum and site, in ordinal rank for specific pathogens
3916	Mortality in children with moderate-to-severe diarrhoea and their matched controls between enrolment and follow-up, by site
3917	Weighted unadjusted and adjusted hazard ratios for selected pathogens and risk of death between enrolment and follow-up, in cases of moderate-to-severe diarrhoea  (MSD)   *
3918	Comparison of enrolment length or height for age Z score  (HAZ) , and change in HAZ  (ΔHAZ)  between enrolment and follow-up 50–90 days later,  *   between cases with moderate-to-severe diarrhoea and their matched controls, by site
3919	Haemoglobin and serum micronutrient status by treatment group
3920	Anthropometric status at 6, 18, and 24 months of age by trial group  *
3921	Reported diarrhoea longitudinal prevalence by trial group and age group  *
3922	Reported diarrhoea incidence by trial group and period after intervention  *
3923	Reported incidence of respiratory signs and fever by trial group and period after intervention  *
3924	Total under-5 deaths, pneumonia deaths, and diarrhoea deaths, and usage rates of key commodities in the 39 collaborating countries
3925	Barriers and recommendations to reduce childhood deaths due to diarrhoea and pneumonia
3926	Annual rates of change in cause-specific mortality 2000–10.
3927	Five disorder meta-analysis results for regions with p<5×10−8
3928	Modelling analysis results for single-nucleotide polymorphisms  (SNP)  showing genome-wide significant association in previous genome-wide association studies from the Psychiatric Genome-Wide Association Study Consortium
3929	Expression quantitative trait loci enrichment analysis for single-nucleotide polymorphisms  (SNPs)  from primary meta-analysis by p-value cutoffs
3930	Summary of safety data
3931	Summary of laboratory data
3932	Global and regional burden of diarrhoea and pneumonia per year in children aged 0–4 years, by WHO region
3933	Contribution of specific pathogens to severe episodes of, and deaths from, childhood diarrhoea and pneumonia, by WHO region
3934	Risk factors with direct biological links to diarrhoea and pneumonia
3935	Interventions common to both childhood diarrhoea and pneumonia
3936	Interventions for the prevention and management of diarrhoea
3937	Interventions for the prevention and management of pneumonia
3938	Diarrhoea and pneumonia deaths averted in the 75 high-burden Countdown countries between 2011 and 2025 with the historical trends and ambitious scale-up approaches
3939	Estimated incremental costs  (US$ million)  by packages in 2025 for the 75 Countdown countries
3940	Summary of studies of diagnostic molecular markers on thyroid FNAB specimens with indeterminate cytology
3941	Comparison of different molecular diagnostic approaches to FNAB with indeterminate cytology
3942	Results of clinical trials of kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer
3943	Comparisons of Responses to Graded Dobutamine Infusion, Y Versus O
3944	Representative clinical features of the autoimmune rheumatic diseases  *
3945	Comparison of clinicopathological features of systemic vasculitides
3946	Autoantibody prevalence in autoimmune rheumatic diseases
3947	Episodes of invasive pneumococcal disease and the vaccine effectiveness for the ten-valent PHiD-CV10 in infants enrolled before 7 months of age
3948	Number of episodes of culture-confirmed invasive pneumococcal disease by serotype
3949	GMT, seroconversion rate, and GMFI of neutralising antibody against EV71
3950	Incidence of adverse reactions within 28 days after vaccinations, by treatment and age groups
3951	Notable events in the history of Bangladesh
3952	Major learning and innovations in cyclone management
3953	Major learning and examples of innovations in flood management
3954	Drug-related adverse events in ≥10% of patients during double-blind treatment period
3955	Treatment-related adverse events occurring in ≥5% of patients in either group from start of treatment to 30 days after end of treatment  (safety population)   *
3956	Treatment-emergent adverse events
3957	Patients with plasma HIV-1 RNA less than 50 copies per mL at week 48
3958	Plasma HIV-1 RNA less than 50 copies per mL at week 48 in per-protocol analysis, and Kaplan-Meier estimates
3959	Plasma HIV-1 RNA less than 50 copies per mL at week 48
3960	Genotypic analysis at PDVF
3961	Criteria for risk-stratification of GIST recurrence after surgery
3962	Adverse events
3963	HIV incidence by subgroup
3964	Helicobacter pylori eradication in first-line and second-line treatments
3965	Adverse events in first-line and second-line treatment
3966	Factors affecting eradication in first-line treatment
3967	Overall safety and selected adverse events
3968	Efficacy of ustekinumab versus placebo at week 24 in randomly assigned patients
3969	Summary of adverse events at week 16 and week 24
3970	Proportion of patients with HCV genotype 1 and undetectable hepatitis C virus RNA
3971	Treatment-emergent adverse events
3972	Grade 3 or 4 haematological and liver chemistry abnormalities
3973	Adverse events of any cause experienced by 10% or more patients in the everolimus treatment group, by grade
3974	Number with known dementia status and dementia prevalence
3975	Number with known dementia status and dementia prevalence by age, sex, and residential status
3976	Sensitivity analyses for effect of sample non-response on estimate of dementia prevalence in 2011
3977	Age-standardised death rates, YLLs, and YLDs, and life expectancy at birth and HALE at birth for 1990 and 2010 for both sexes combined for 19 members countries of the G20
3978	Deaths  (in thousands)  and age-standardised death rates per 100 000 for 231 causes in 1990 and 2010 for all ages, both sexes combined, and percentage change from 1990 to 2010 in China
3979	Deaths  (in thousands) , percentage of all-cause mortality, and median percentage change by cause from 1990 to 2010 for children younger than 5 years  (both sexes)  in China
3980	DALYs  (in thousands)  for 285 causes in 1990 and 2010 for all ages, both sexes, and per 100 000 with 95% UI and percentage change, in China
3981	Disability-adjusted life-years  (in thousands)  attributable to risk factors or risk factor clusters in China
3982	Development  (SYNTAX Trial)  and validation  (DELTA Registry)  data for SYNTAX score II
3983	Summary of enrolment for primary and secondary endpoints
3984	Effects of the intervention
3985	Effects of the programme pathways
3986	Comparison between initial diagnosis of rejection made by international classification and the diagnosis of the new approach
3987	Multivariate analysis of factors associated with graft loss in patients with antibody-mediated vascular rejection
3988	Age-standardised death rates, YLLs, and YLDs, and life expectancy at birth and HALE at birth for 1990 and 2010 for both sexes combined
3989	DALYs for 259 causes in 1990 and 2010 for all ages and both sexes combined, and per 100 000 for the UK
3990	Disability-adjusted life-years  (in thousands)  attributable–risk factors or risk factor clusters in the UK
3991	Decomposition analysis of the change of global death numbers  (thousands)  by level 1 causes from 1990 to 2010 into total population growth, population ageing, and changes in age-specific, sex-specific, and cause-specific death rates
3992	Global deaths for 235 causes in 1990 and 2010 for all ages and both sexes combined  (thousands)  and age-standardised rates  (per 100 000)  with 95% UI and percentage change
3993	Global disability-adjusted life years for 291 causes in 1990 and 2010 for all ages, both sexes combined, and per 100 000 with 95% UI and percentage change
3994	Decomposition analysis of the change of global disability-adjusted life years  (thousands)  by level 1 causes from 1990 to 2010 into total population growth, population ageing, and changes in age-specific, sex-specific, and cause-specific disability-adjusted-life-year rates
3995	Disability-adjusted life years for 291 causes by region for 1990 and 2010, and the percentage change from 1990 to 2010
3996	Estimated numbers of deaths by cause in 2010
3997	Global and regional average annual rate of change in cause-specific child mortality rates between 2000 and 2010, by age range and WHO region
3998	Study outcomes in Millennium Village intervention sites and comparison village sites
3999	Diagnostic Performance of Individual CMR Components in Detecting Future Adverse Cardiac Outcome
4000	Change in visual acuity after hESC-RPE transplantation in patient with Stargardt's macular dystrophy
4001	Overview of strategies for prevention, detection, evaluation, and management to improve outcomes of chronic kidney disease in adults
4002	Summary of selected randomised trials for chronic kidney disease
4003	Adverse events
4004	Diagnostic criteria for prediabetes
4005	Examples of externally validated diabetes risk models  6
4006	Rate of symptomatic, severe, and nocturnal hypoglycaemia during 24-week treatment with glargine or sitagliptin in the safety population
4007	Serious treatment-emergent adverse events in the safety population
4008	Effect of zinc given orally on treatment failure
4009	The effect of zinc given orally on secondary clinical outcomes
4010	Component symptoms and signs of probable serious bacterial infection at the time of treatment failure
4011	Prognostic factors for progression-free survival
4012	Common adverse events
4013	Patients with increased concentrations of liver enzymes
4014	Mothers reporting exclusive, mixed, or no breastfeeding during study intervals by group
4015	Proportional hazards modelling of possible risk factors for infant HIV infection by 48 weeks
4016	Rates of clinical serious adverse events by group and study period
4017	Patient Data Before and Six Months After Treatment With Continuous Positive Airway Pressure  (CPAP)
4018	Treatment-emergent adverse events in at least 5% of patients at week 16
4019	Global prevalence of the 50 most common sequelae
4020	Global years lived with disability  (YLDs)  for a comprehensive set of 289 causes and select sequelae in 1990 and 2010, for all ages, both sexes combined, and per 100 000
4021	Decomposition analysis of the change of global years lived with disability  (thousands)  by level 1 causes from 1990 to 2010 into total population growth, population ageing, and changes in age-specific, sex-specific, and cause-specific years lived with disability rates
4022	Hazard ratios for all-cause and cardiovascular mortality in the combined general and high-risk populations according to eGFR and albuminuria clinical categories in individuals with and without diabetes
4023	Hazard ratios for end-stage renal disease in chronic kidney disease populations according to eGFR and albuminuria clinical categories by the presence or absence of diabetes
4024	Side-effects from treatment with vaginal misoprostol or placebo
4025	Cervical outcome variables
4026	Immediate and delayed complications of vacuum aspiration for first-trimester abortion surgery
4027	Efficacy outcomes at week 12
4028	Adverse events and laboratory results
4029	Incidence of veno-occlusive disease up to 30 days after HSCT
4030	Drug-related adverse events in patients included in the safety analysis
4031	Summary of clinical adverse events during 2 years in the treated set of patients
4032	Outcome variables
4033	Adverse events
4034	Patients with HIV RNA concentration of 50 copies per mL or less at week 48
4035	Treatment-emergent adverse events leading to premature discontinuation of study drug
4036	Treatment-emergent adverse events occurring in at least 10% of patients in either group
4037	Laboratory test results at week 48
4038	Treatment-emergent adverse events
4039	Patients reporting hypoglycaemia at any time during the study
4040	Drug-related adverse events in at least 10% of patients  (safety set)
4041	Summary of efficacy measures in intention-to-treat population
4042	Common treatment-emergent all-causality adverse events
4043	Analysis of endpoints in the intention-to-treat population
4044	Response to treatment by treatment group
4045	Toxic effects by treatment group
4046	Cluster-adjusted cumulative treatment failure by day 6  (primary outcome)  in children with severe pneumonia in the intervention and control clusters
4047	Reasons for relapse between days 6 and 14 in children with severe pneumonia in the intervention and control clusters
4048	Antibiotics given to children with severe pneumonia in the control clusters and treatment outcomes
4049	Changes in lipids, lipoproteins, and hs-CRP during the study period
4050	Adverse events, safety variables, and adjudicated cardiovascular events throughout the study
4051	Translational processes underlying the effect of risk exposure on brain and behavioural development
4052	Effects of early interventions on cognitive and social–emotional development
4053	Neural consequences of institutionalisation
4054	High priority developmental risk and protective factors
4055	General base-case model inputs
4056	Base-case model inputs for quality of life weights and costs
4057	Base-case analysis results  (probabilistic analysis) —cost-effectiveness
4058	Sensitivity analyses results  (deterministic analysis; men aged 60 years)
4059	Clinical Data in 141 Patients With Stable or Unstable Angina
4060	Medical Treatment at the Time of Directional Coronary Atherectomy
4061	Histology and Immunocytochemistry in Patients With Stable or Unstable Angina
4062	Histologic Morphology and Immunocytochemistry According to Clinical Presentation; Unstable Angina Is Analyzed in Acute or Subacute Subgroups
4063	Hemodynamic Results and Myocardial Blood Flow  (MBF)  During Positron Emission Tomography
4064	Entire Study Group
4065	Overweight Group
4066	Obese Group
4067	Clinical and Echocardiographic Features of the Study Group, Categorized by Stress Echocardiography Results
4068	Clinical and Echocardiographic Features of the Study Group, Categorized by LAVI Results
4069	Logistic Regression Showing the Effect of Normal LAVI  (≤28 ml/m2)  on Normal Stress Echocardiography After Adjusting for Age, Gender, Low Resting EF  (<0.50) , LVH, and LVDD
4070	Exercise Parameters of Male Versus Female Subjects Before and After Exercise Training  (Mean ± SD)
4071	Exercise Parameters of Young Versus Older Subjects Before and After Exercise Training  (Mean ± SD)
4072	Mean Values for Exercise Parameters of All Subjects Before and After Training  (Mean ± SD)
4073	Dobutamine Stress Echocardiographic Data
4074	Predictors of All-Cause Mortality
4075	Predictors of Cardiovascular Morbidity
4076	Independent Predictors of All-Cause Mortality and Cardiovascular Morbidity Using a Three-Step Model
4077	Exacerbation rate in patients allocated N-acetylcysteine or placebo
4078	Modified intention-to-treat analysis day-28 cure rates
4079	Mean lumefantrine concentrations on days 3 and 7
4080	Changes in metabolic and cardiovascular risk factors in ITT population
4081	Changes in selected metabolic and cardiovascular risk factors in patients who completed 1 year follow-up
4082	Patients reporting adverse events  (≥5% in any treatment group)
4083	Serious adverse events by system organ class during the double-blind period of the trial
4084	Patients reporting adverse events leading to discontinuation
4085	Incidence of cardiovascular events during the 10-year follow-up in healthy men, snorers, and patients untreated and treated for OSAH
4086	Unadjusted, part adjusted, and fully adjusted odds ratio for cardiovascular death associated with clinical variables and diagnosis status, according to the logistic-regression analysis
4087	Unadjusted, part adjusted, and fully adjusted odds ratio for non-fatal cardiovascular events associated with clinical variables and diagnosis status, according to the logistic-regression analysis
4088	Treatment-Induced Laboratory Parameter Changes
4089	Treatment-Induced Receptor Expression and Collateral Flow Changes
4090	Main outcome data for patients with proteinuric chronic nephropathies included in randomised trials of intensified and conventional blood-pressure control
4091	Primary and associated efficacy assessments
4092	UPDRS secondary analyses and ancillary study efficacy assessments
4093	Incidence of dopaminergic adverse events by affected body system  *
4094	Interleukin 6 response  *   of icodextrin-containing dialysate and icodextrin in the PBMC assay from three representative donors  †
4095	Relation between complaints per million units sold and peptidoglycan concentration in icodextrin solution
4096	Cases reported to the WHO database of the SSRI and neonatal convulsions and/or neonatal withdrawal syndrome association until the second quarter of 2003
4097	Symptoms  (WHO preferred terms)  concomitantly reported with neonatal withdrawal syndrome and/or neonatal convulsions on the 51 cases of neonatal withdrawal syndrome associated with paroxetine
4098	Potency  (Ki inhibition constant in nmol/L)  of some antidepressants for monoamines transporters
4099	Potency  (Ki inhibition constant in nmol/L)  of some neurotransmitter transporters
4100	Educational inequalities by cause specific mortality in men in western Europe, by age
4101	Contribution  (%)  of specific causes of death to the difference between low and high-educational groups in total mortality in men  *
4102	Educational inequalities in cause specific mortality in women in western Europe
4103	Contribution  (%)  of specific causes of death to the difference in total mortality between low and high-educational groups in women  *
4104	Educational inequalities in total mortality by population in men and women aged ⩾45 years
4105	Contribution  (%)  of specific causes of death to the difference between low and high-educational groups in total mortality in men and women aged .45 years  *
4106	Symptoms of participants
4107	Diagnosis of tuberculosis in patients with HIV
4108	Response at the end of treatment and the end of follow-up
4109	Common adverse events
4110	Mortality rates for major complex emergencies 1991–2002
4111	Numbers of refugees and internally displaced people in countries with ≥500 000 in 1992 or 2001  61–66
4112	Refugee population by region  *   of asylum, 1992–2001  (thousands)   61
4113	Mortality and morbidity rates among participants with HIV infection during and before co-trimoxazole prophylaxis
4114	Enrolment by study site
4115	Cumulative treatment failures by specific causes at 48 h, 5 days, and 14 days
4116	Isolation and resistance frequency of nasopharyngeal organisms
4117	Treatment interruptions and dose reductions in patients who started protocol treatment
4118	Side-effects by grade of toxic effect
4119	Comparison of toxic effects between treatment groups
4120	Best overall response to treatment  (intention-to-treat analysis)
4121	Efficacy of tacrolimus and ciclosporin microemulsion in children after liver transplantation
4122	Reasons for study withdrawal
4123	Reasons for graft loss after liver transplantation
4124	Most frequent adverse events
4125	Overall incidence of infections
4126	Rates of tonsillar haemorrhage and return to theatre with tonsillar haemorrhage  (primary and secondary combined)  by surgical technique
4127	Unadjusted and adjusted odd ratios of tonsillar haemorrhage by surgical technique
4128	Rate of primary and secondary tonsillar haemorrhage by surgical technique
4129	Treatment group outcomes
4130	Outcomes in high-risk subgroups of patients
4131	Patients with events on phase A
4132	Patients with events on phase B
4133	Serum creatinine concentration μmol/L)  in patients throughout phase B
4134	Summary of study methods and data sources
4135	Estimates of children's exposure to four environmental risk factors in the European subregions
4136	Deaths and DALYs attributable to selected environmental factors among children and adolescents in the European region
4137	Distribution of deaths and DALYs from injury by external cause and age-group in the European region
4138	Deaths and DALYs attributable to selected environmental factors as a proportion of deaths and DALYs from all causes among children and adolescents in the European region by age-group
4139	Sensitivity analyses for outdoor air pollution and deaths
4140	Sensitivity analyses for indoor air pollution and deaths and DALYs from acute lower-respiratory-tract infections
4141	Sensitivity analyses for inadequate water and sanitation and diarrhoea deaths and DALYs
4142	Sensitivity analyses for lead exposure and DALYs due to mild mental retardation
4143	Antihypertensive and other medications in the study
4144	Endpoints  (first time occurrence in each category)
4145	Blood pressure and odds ratios throughout the study
4146	Adverse events
4147	Laboratory values
4148	L hongkongensis isolation from targeted food surveillance
4149	Documentation of important clinical signs for classification and treatment of malaria and pneumonia
4150	Performance indicators with system organisation implications
4151	Parenteral drug doses prescribed
4152	Number of patients with the most frequently reported treatment emergent signs and symptoms
4153	Number of randomised patients with available data whose laboratory indices were judged clinically significant at any time during study follow-up
4154	Laboratory values: all randomised patients with data available
4155	G6PD status for patients with ≥ 20 g/L fall in haemoglobin
4156	Breakdown of PCR-confirmed new infections and recrudescence by trial site  (all randomised patients with data available)
4157	Summary of treatment outcome  (all randomised patients with data available)
4158	Time course of rejection and infection episodes
4159	Diagnostic accuracy of three classifiers
4160	Outcome of efficacy analyses before and after protocol change in randomisation
4161	Number of patients with treatment failure, components of treatment failure, and number of patients with plasma HIV-1 RNA concentration <50 copies per mL
4162	Numbers of patients with treatment failure or virological failure by region
4163	Reasons for temporary or permanent discontinuation of study drugs
4164	Numbers of patients with at least one grade 3 or 4 clinical adverse event and laboratory toxicities
4165	Hazard ratios for developing diabetes within 5 years
4166	Radiographic analysis at 52 weeks
4167	Treatment-emergent adverse events
4168	Microbiology results in different diagnostic subgroups
4169	Bacteria grown from sputum, bronchoalveolar lavage, and blood cultures in different subgroups
4170	Clinical outcome in all patients with lower respiratory tract infections according to treatment algorithm
4171	Clinical outcome in subgroup with acute exacerbations of COPD
4172	Serum cytokine concentrations of patients with influenza subtype H5N1, patients with influenza A and B infection, and healthy controls
4173	Follow-up Outcomes at 36 Months, Unadjusted
4174	Serious adverse events  (SAE)  and study drug discontinuations
4175	Factors Independently Associated With Risk of Death or MI in a Multivariable Analysis
4176	Changes in secondary endpoints
4177	Adjusted Hazard Ratios  (95% Confidence Intervals)  for Follow-up Events by MEDS
4178	Subgroup analyses comparing effect of rosiglitazone and placebo on changes in limb fat mass at week 48
4179	Adverse events to week 48
4180	Risk of Ischemic Heart Disease as a Function of ABCA1K776N Genotype in the General Population
4181	Magnetic resonance gradient echo sequences
4182	Sensitivity and specificity of L/M ratio for every sequence
4183	Correlation between L/M ratio and B-HIC with determination of B-HICmax according to every magnetic resonance sequence
4184	Risk of Ischemic Heart Disease as a Function of ABCA1K776N Genotype in the Case-Control Study
4185	Facilities in participating households 1995–98
4186	Relation between height and household water source
4187	Relation between height and water storage
4188	Relation between height and sanitation facility
4189	Diarrhoeal diseases by water and sanitation
4190	Household water source, water storage practices, sanitation facilities, and prevalence of C parvum and G lamblia
4191	Adverse reactions to both injections of influenza A/Hong Kong/1073/99  (H9N2)  vaccine
4192	Seroconversions on day 21 and day 42
4193	Haemagglutinin-inhibition results for A/Hong Kong/1073/99  (H9N2)  in relation to European Committee of Proprietary Medicinal Products  (CPMP)  criteria
4194	Structures entered with MRI guidance only, or by use of fluoroscopic images
4195	Comparison of flow and pulmonary vascular resistance calculated with Fick's method and with MRI
4196	Advantages, limitations, and potential refinements of cardiac catheterisation guided by fluoroscopy or MR
4197	Sequence comparison of SARS-CoV isolates of hospital and community outbreaks restricted to nucleotide positions with sequence differences between community and hospital isolates
4198	Rates of primary and secondary events according to assigned treatment
4199	Adverse events  (%)   *   among patients in each treatment group
4200	Individuals with positive SMR concentrations by disease category
4201	Echo Doppler Indices in Patients With AL Pain and in Normal Control Patients During the Maximal Dosage of Dobutamine
4202	Biochemical Analysis in Patients With AL Pain With and Without Abnormal IFV
4203	Primers used for MCP screening
4204	Biochemical data for proband and her brother
4205	Rotavirus antigen in serum samples obtained from children and animals during the acute stage of intestinal infection
4206	Mean systolic blood pressure  (SBP)  and diastolic blood pressure  (DSP)  by birthweight and childhood social class at every age
4207	Regression coefficients  (95% CIs)  from individual models fitted at each age, adjusted for sex
4208	Effect of birthweight and childhood social class on blood pressure between age 36 and 53 years
4209	Joint effect of birthweight and childhood social class on systolic blood pressure between age 36 and 53 years
4210	Primary clinical problems necessitating hospital admission in 100 patients
4211	Classification of pivotal findings of physical examination
4212	Patients with pivotal physical findings  (n=26)
4213	HIV-1 transmission and HIV-1 free survival at birth and at ages 6–8 weeks, 14–16 weeks, 12 months, and 18 months
4214	Prognostic factors for HlV-1 infection
4215	Number of mothers and infants with adverse events
4216	Estimated mortality attributable to smoking in developing and industrialised countries in 2000
4217	Estimated global mortality attributable to smoking by age, sex, and cause of death in 2000
4218	Estimated mortality attributable to smoking in people aged 30 years and older by GBD subregion in 2000
4219	Estimated mortality  (thousands of deaths)  attributable to smoking in industrialised countries by age, sex, and cause of death in 2000
4220	Estimated mortality  (thousands of deaths)  attributable to smoking in developing countries by age, sex, and cause of death in 2000
4221	Protection induced by primary infections with Escherichia coli positive for different enterotoxins
4222	20 leading global risk factors, exposure variables, theoretical minima, and contributions to global burden of disease  (GBD)   *
4223	Individual and joint contributions of 20 selected risks to ten leading diseases and total burden of disease  (expressed in disability-adjusted life years, DALY)  in the world
4224	Individual and joint contributions of 20 selected risks to ten leading diseases and total burden of disease  (expressed in disability-adjusted life years, DALY)  in high-mortality developing regions
4225	Individual and joint contributions of 20 selected risks to ten leading diseases and total burden of disease  (expressed in disability- adjusted life years, DALY)  in lower-mortality developing regions
4226	Individual and joint contributions of 20 selected risks to ten leading diseases and total burden of disease  (expressed in disability- adjusted life years, DALY)  in developed regions
4227	Origin of patients fitting WHO case definition for SARS
4228	Diagnosis of SARS-CoV and human metapneumovirus in patients fitting the WHO SARS case definition
4229	Excretion of SARS-CoV by experimentally inoculated cynomolgus macaques
4230	Virological detection of SARS-CoV in postmortem tissues of experimentally infected cynomolgus macaques
4231	Risk factors associated with development of ARDS requiring ventilatory support and intensive care
4232	Independent risk factors predicting development of ARDS by multivariate analysis
4233	Outcomes in SARS patients at the time of writing
4234	Subsequent analysis of clinical samples of 20 patients with initial RT-PCR-positive nasopharyngeal aspirates and antibody seroconversion to SARS-associated coronavirus
4235	Virological investigations of patients with fatal SARS
4236	Summary of histological findings
4237	Serious adverse events
4238	Other drug-related adverse events
4239	Effect of intervention on reported breastfeeding practices at age 3 months
4240	Effect on intervention on reported breastfeeding practices at age 4, 5, and 6 months
4241	Effect of intervention on diarrhoea morbidity during the first 6 months of life
4242	Weights and lengths of all children and low birthweight children at age 6 months
4243	Echocardiography and haemodynamic variables
4244	Echocardiography and potential sources of cardiogenic embolism
4245	Univariate Cox regression analysis of survival in patients on dialysis  (n=312)
4246	Change of p values in a forward stepwise Cox regression analysis of all-cause and cardiovascular mortality
4247	Coronary  (Agatston score)  and aortic-ring calcifications  (semi-quantitative score) , and individual AHSG serum concentrations in subgroups of patients on long-term and short-term dialysis
4248	Distance and Velocity Moved in the Two Groups
4249	Worst symptom related to trial regimen reported by clinicians
4250	Comparison of randomised and non-randomised patients in MRC CR06 trial
4251	Association Between TF-BRS and Major Clinical Variables With Categorical Scale  (n = 228)
4252	Results From Cox Analysis and Figures of Predictive Accuracy for Dichotomized TF-BRS  (≤3.1 ms/mm Hg vs. >3.1 ms/mm Hg)  and for the TF Index
4253	Composition of Cocoa Drinks
4254	Anthropometric and Laboratory Parameters of Study Groups
4255	Left Ventricular Morphology and Systolic Function
4256	Left Ventricular Diastolic Function
4257	Results of the Linear Regression Analysis Between the PCr/ATP Ratio and Uremia, Diabetes, and LVMI
4258	Echocardiographic Parameters and Electrocardiogram Findings
4259	Comparisons of TDI, SRI, and WMS Among Trans-MI, Nontrans-MI, Subendo-MI, and Control Segments
4260	TDI and SRI Measurements in Normal Subjects
4261	Dobutamine Stress Hemodynamic and Echocardiographic Data
4262	Univariate and Multivariate Association of Clinical, Electrocardiographic, and Echocardiographic Data With Cardiac Death
4263	Univariate and Multivariate Association of Clinical, Electrocardiographic, and Echocardiographic Data With All-Cause Mortality
4264	Aspirin Use Throughout the Study
4265	Mean Differences Between Treatments in Change in HR, QT, and QTcI
4266	Mean Difference Between Treatments in the Change in QTc Measured at TmaxH Using Five QT Correction Methods
4267	Platelet Function Tests in PRP Before and After Clopidogrel  (CLOP)  and/or Acetylsalicylic Acid  (ASA)
4268	Responsiveness to Clopidogrel by Blood Preservative and Tests of Platelet Function Used
4269	Predictors of the Primary End Point  (Death or Myocardial Infarction)
4270	Cardiopulmonary Hemodynamics
4271	Incidence and Severity of Aminotransferase Abnormalities
4272	Comparison of LV Geometry and Function
4273	Independent Predictors of LV Diastolic Dysfunction
4274	Independent Predictors of LV Systolic Dysfunction Defined as an LV Ejection Fraction <50%
4275	Comparison of Measurements Among the Three Pacing Sites
4276	Effect of Metyrapone on FMD, GTNMD, and BRS
4277	Proportion of Patients With Enzymatically Confirmed AMI or Myocardial Necrosis Among Those With LBBB at Randomization
4278	Application of ST-Segment Criteria for the Diagnosis of AMI in the 300 Patients With LBBB at Randomization
4279	Enzymatically Confirmed AMI and Mortality in Patients With and Patients Without ST-Segment Changes  ⁎  During LBBB
4280	Multivariable Logistic Regression Models for Predictors of 30-Day Mortality
4281	Hemodynamics During Study
4282	Inflammatory Markers and Daily Fish Consumption
4283	Inflammatory Markers and Fish Consumption  (in g/Week)
4284	Primer Sequences, Sequence Accession Numbers, Annealing Temperatures, and Cycle Numbers
4285	No Expansion of Th2 or Th0 Cells in Patients With Different Stages of Atherosclerosis
4286	Reasons for Excluding Mice From the Study for Infarct Size
4287	Hemodynamic Data
4288	Effects of Atorvastatin, Combined Therapy, and Fenofibrate on Lipid Levels and Endothelial Function in Patients With Combined Hyperlipidemia
4289	Effects of Atorvastatin, Combined Therapy, and Fenofibrate on Adiponectin Levels and Insulin Resistance in Patients With Combined Hyperlipidemia
4290	Adverse Effects of Atorvastatin, Combined Therapy, and Fenofibrate in Patients With Combined Hyperlipidemia
4291	Effect of Folate on Hemodynamic Variables  (Mean ± SD)
4292	Effect of Folate on MBF  (Mean ± SD)
4293	Multivariate Linear Regression Analysis
4294	Relationships of Coronary Risk Factors  (Continuous Variables)  With the Percent  (%)  Changes in Diameter of Epicardial Coronary Arteries and Coronary Blood Flow Response to ACh Using Univariate Linear Regression Analysis
4295	Comparisons of Percent  (%)  Changes in Diameter of Epicardial Coronary Arteries and Coronary Blood Flow Response to ACh Using Categorical Variables to Classify Patients
4296	Multiple Linear Regression Analysis for the Association of Risk Factors With Relative Changes in Epicardial Coronary Diameters and Coronary Flow Response to ACh
4297	Mean MBF Responses and Coronary Vascular Resistance to CPT for Each Study Group
4298	Cardiovascular Events During Long-Term Follow-Up  (n = 72)
4299	Univariate and Multivariate Cox Regression Analysis in the Study Group  (n = 72)  Implying Cardiovascular Events  (A)  or Cardiac Events  (B)
4300	Multiple Linear Regression Analyses Between Progenitor Cells  (Dependent Variables)  and Risk Factors or Clinical Conditions  (Independent Variables)
4301	Procedural Outcomes in Patients Stratified by the Presence of Diabetes Mellitus
4302	Clinical Outcomes Through 12 Months Stratified by Diabetes
4303	Angiographic Measures at Nine Months Stratified by the Presence of Diabetes
4304	Angiographic Outcomes in the Diabetic Subgroup According to Diabetic Treatment
4305	MR Determined Regional E/Ea
4306	MR and Doppler Parameters of LV Filling
4307	ROC-AUCs for Plasma and Urinary N-BNP for Diagnosis of Systolic Heart Failure With Sensitivities, Specificities, and PPV and NPV
4308	Binary Logistic Regression Analysis of Various Predictors of Left Ventricular Systolic Dysfunction
4309	ROC-AUCs for Plasma and Urinary N-BNP for Diagnosis of LVSD in High-Risk Subjects  (Age >65 Years, History of Hypertension, or Ischemic Heart Disease)
4310	ROC-AUCs With 95% CI for Plasma, Urinary, and Plasma × Urinary N-BNP Product for Diagnosis of LVSD in At-Risk Groups  (as Defined)  and Also in Remainder of Population Without Risk Factors Indicated
4311	A Number of Different Strategies for Screening Are Analyzed for the Total Number of Scans and N-BNP Tests Resulting From the Screening
4312	ROC-AUCs for Detection of Other Cardiac Abnormalities in Those With Preserved Systolic Function and ina Combined Group Comprising Those With Atrial Fibrillation, Valvular Abnormalities, and LVSD  (These Diagnoses Are Not Mutually Exclusive)
4313	Regional Myocardial Deformation and Time Intervals: Comparison Between Healthy Control Subjects and Patients After Tetralogy of Fallot Repair
4314	Regional Myocardial Deformation and Time Intervals: Comparison Between Patients After TOF Repair Without and Those With LV Asynchrony
4315	Hemodynamic Parameters, MSNA, and Biochemical Measurements Before and After Placebo and Tobacco Sessions  (n = 16)
4316	Anatomic Observations
4317	Quantative Data
4318	Combined Outcomes of Death or Arrhythmia
4319	Arrhythmia and Mode of Death
4320	Applications With Transient AV Block
4321	AVNRT Versus AVRT
4322	Logistic Regression in Those Without Prevalent Anemia at Randomization and With Complete Data at One Year  (n = 4,174) , Demonstrating the Effect of Enalapril on the Development of New Anemia at One Year, With Adjustment for Confounders
4323	Logistic Regression in all SOLVD Participants With Complete Data at Randomization  (n = 6,436) , Demonstrating the Effect of Enalapril on the Development of Anemia at Any Time During the Trial, With Adjustment for Confounders
4324	Results of Adjusted Cox Regression of All-Cause Mortality by Anemia Episode During the Trial
4325	Results of Adjusted Cox Regression of All-Cause Mortality by Time-Varying Hematocrit During the Trial
4326	Medications
4327	Results of Multivariable Cox Regression Model Using Backward Stepwise Selection, for Combined End Point of Death, Ventricular Assist Device Implantation, or United Network for Organ Sharing-1 Transplantation
4328	Revascularization Therapy of LMCA
4329	Long-Term Follow-Up
4330	Univariate Predictors of MACE
4331	Multivariate Predictors of MACE
4332	Number of Patients Who Were Hyporesponsive or Hyper-Responsive to Clopidogrel Based on the Change in ADP-Induced Aggregation Who Were Determined to be Hyporesponsive and Hyper-Responsive by Other Methods of Measuring Platelet Inhibition
4333	Diagnostic Performance of Multi-Slice Computed Tomography Coronary Angiography to Detect ≥50% Stenoses
4334	Valvular and Cardiac Chamber Dimensions and Functional Parameters
4335	P Values From Adjusted Multivariate Association Models
4336	Dobutamine Stress Echocardiographic Data
4337	Follow-Up Events in Both Genders
4338	Univariate Predictors of Hard Cardiac Events
4339	Multivariate Predictors of Hard Cardiac Events
4340	Univariate Analysis of Potential Clinical Predictors of the RH-PAT Index
4341	ACE Inhibitor Utilization
4342	Relative Risk of Events by Treatment
4343	Unadjusted and Adjusted Linear Regression Analysis With Ln-CRP as the Dependent Variable
4344	In-Hospital Clinical Complications
4345	Univariate Hazard Ratios for the Combined End Point  (Cardiac Death, MI, CVA, or Revascularization)
4346	Multivariate Hazard Ratios for the Combined End Point Using Uncorrected  (Absolute)  Leptin Values or Leptin Values Corrected for BMI  (i.e., Leptin/BMI ratio)
4347	Unadjusted Correlation Between MCP-1 Levels and Continuous Variables
4348	Variables Independently Associated With Log MCP-1  (n = 2,777)
4349	Odds of Subclinical Atherosclerosis  (CAC ≥ 10)
4350	125I-fibrin (ogen)  Deposition  (Mean Values ± SEM)  on Stents After 120 Min Perfusion in the Three Different Sets of Experiments
4351	Multivariate Predictors of One-Year Mortality
4352	Adjusted All-Cause Mortality Risks With Prescribed Medications
4353	Mortality Associated With Renal Insufficiency Among Women With Heart Failure and Coronary Disease
4354	Risk of Death Associated With 10-ml/min Increment Decreases of Creatinine Clearance Among Women With Heart Failure and Coronary Disease
4355	Association Between Renal Insufficiency and Mortality, Stratified by Use of Angiotensin-Converting Enzyme Inhibitors
4356	Adjusted Hazard Ratios Associated With Risk Factors for All-Cause Mortality Among Women With Heart Failure and Coronary Disease
4357	Intracardiac and Peripheral Hemodynamic Parameters and Weight Data on Day 28 After Surgery
4358	Echocardiographic and Weight Parameters on Day 27 After Surgery
4359	Peak Effects of Pharmacologic Interventions on Hemodynamics and Gas Exchange Variables
4360	Diagnostic Accuracy of MSCT for the Detection of Bypass Graft Stenosis and Occluded Grafts in Evaluable Segments
4361	Cox Proportional Hazards Results for One-Year Mortality
4362	Comparison of Independent Variables in Patients With Ventricular Arrhythmias Who Received ICD Therapy and Those Without Ventricular Arrhythmias
4363	Hemodynamic Data
4364	Infarct Size Data
4365	Basal Hemodynamics and Enzyme Release for All Experimental Groups
4366	Distribution of Follow-up Events in the Study Population
4367	CD Rate by Presence of AF in Different Clinical Subsets of Patients
4368	Significant Unavailable Predictors of Cardiac Death in the Study Population
4369	Final Multivariable Cox Proportional Hazards Model  (Global Chi-Square of the Model = 1,146.1, p < 0.001)
4370	Univariate Correlates of Left Ventricular End-Diastolic Dimension and Left Ventricular Mass in Trained Male Endurance Athletes and Untrained Men
4371	Left Ventricular Dimension and Mass Indexed to Various Measures of Body Size
4372	Age Regressions for Ventricular-Vascular Coupling, Its Components and Its Determinants
4373	Cox Regression Analysis for Time to Presyncope Computed Slopes
4374	Correlations Between Plasma Oxidized LDL Level and Other Parameters
4375	Correlations Between Plasma oxLDL Levels and Coronary Vasomotor Responses to Bradykinin
4376	Univariate and Multivariate Linear Models of Epicardial Coronary Vasomotor Responses to Bradykinin
4377	Univariate and Multivariate Linear Models of Resistance Coronary Vasomotor Responses to Bradykinin
4378	Follow-Up
4379	Univariate Predictors of 5-Year Mortality *
4380	Significant Independent Predictors of Five Years' Mortality
4381	Significant Independent Predictors of Five Years' Mortality, in Patients With a First MI
4382	Occurrence of Atrial Fibrillation According to Antihypertensive Treatment: IR per 1,000 Person-Years of New-Onset Atrial Fibrillation, Adjusted Hazard Ratio, and 95% CI
4383	Occurrence of Atrial Fibrillation According to Antihypertension Treatment: IR per 1,000 Person-Years of Atrial Fibrillation-Related Hospitalization, Adjusted Incidence Ratio, and 95% CI
4384	IR per 1,000 Person-Years of AF-Related Hospitalizations, Adjusted Incidence Ratio, and 95% CI
4385	Multivariate Analysis, Including Risk Factors for Coronary Artery Disease and Clinical Presentation for Acetylcholine-Induced Forearm Blood Flow  (Dependent Variable)
4386	Polymerase Chain Reaction and Pyrosequencing Primers and Conditions
4387	Genotype Frequency  (%)  Among 95 African Americans and 95 European Americans
4388	Lesion Location and Procedural Information
4389	Initial Left Heart Structure Size Versus Need for Re-Intervention
4390	Clinical Management and Outcomes
4391	Summary of Clinical and Exercise Data of Our Study Cohort  (n = 22)
4392	Interim Clinical Events and Follow-Up Assessment *
4393	Unadjusted and Adjusted Regression Analysis
4394	Multivariate Logistic Regression Analysis: Variables Differing Between Patients With and Without Coronary Artery Disease
4395	Comparison of Drugs Administered During the Follow-Up Period in Patients With and Without Coronary Events
4396	Univariate Cox Hazards Analysis of Risk of Future Coronary Events According to Fasting Levels of RLP Cholesterol in Patients With Type II Diabetes Mellitus and Coronary Artery Disease
4397	Multivariate Cox Hazards Analysis of Risk of Future Coronary Events According to Fasting Levels of RLP Cholesterol in Patients With Type II Diabetes Mellitus and Coronary Artery Disease
4398	Platelet Aggregation and P-Selectin Expression Induced by ADP  (10 μmol/l)  or TRAP  (10 μmol/l)  in Patients With an Acute Coronary Syndrome Before and 24 Hours After Administration of Clopidogrel  (n = 21)
4399	ACEIs and ARB Use
4400	Baseline Alcohol Consumption and Adverse Cardiovascular Outcomes
4401	Level of Alcohol Consumption Reported Three Months Post MI and Adverse Cardiovascular Outcomes
4402	Relationship Between Calibrated Contrast Intensity and Remote-Stage Asynergy
4403	Univariate Correlation Coefficients for Various Risk Factors and Endothelium-Dependent, Flow-Mediated Dilation
4404	Electrocardiographic Findings of Patients Who Developed Atrioventricular Conduction Disturbance
4405	Comparison Between Patients With and Those Without Atrioventricular Conduction Disturbance
4406	Reported Atrioventricular Conduction Disturbance Associated With Device Closure of Atrial Septal Defects
4407	Mean  (± SD)  Scores on the SF-36 Subscales and the MLWHF Scales for Younger  (Age ≤64 Years)  and Older  (Age >64 Years)  Heart Failure Patients
4408	Correlation Coefficients of Quality of Life Measures With Depression Score, Age, and Left Ventricular EF
4409	Mean  (± SD)  Scores on the SF-36 Subscales for Depressed and Non-Depressed Heart Failure Patients
4410	Mean  (± SD)  Scores on the MLWHF Subscales for Depressed and Non-Depressed Heart Failure Patients
4411	Left Ventricular Dilation From Days 1 to 90 in Diabetics and Non-Diabetics With and Without Angina
4412	Clinical Presentation
4413	Extent of Coronary Artery Disease
4414	Frequency of Mutation and Polymorphism in Adiponectin Gene
4415	Clinical Profile of the Subjects With I164T Mutation
4416	Association of NANSAIDs With MI, Stratified by Aspirin Use
4417	Assessment of Effects of Recall and Non-Participation Bias
4418	Cross-Sectional Echocardiographic Indexes in All Patients Versus Controls
4419	Doppler Indexes in All Patients Versus Controls
4420	Echocardiographic Indexes in Patients With Vascular Complications Versus Those Without
4421	Primary Composite and Secondary Component End Points in Black and Non-Black Patients
4422	Distribution of Study Drug Dosage at Time of End Point or End of Follow-Up
4423	Clinical and Exercise Data
4424	Two-Dimensional and Conventional Doppler Echocardiographic Data
4425	Tissue Doppler-Derived Mitral Annular Velocities and Flow Propagation Velocity
4426	Values of Integrated Backscatter  (IB)  in the Septum and Posterior Wall, Corrected for Pericardial IB
4427	Heart Rate and Blood Pressure During Total Sleep Deprivation
4428	Heart Rate and Blood Pressure During Partial Sleep Deprivation
4429	APV at Rest and After Stress and CFR
4430	Ang-1, Ang-2, Ang Receptor Tie-2, and VEGF Levels in CHF
4431	Risk Stratification Based on CS and GSS
4432	Univariate and Bivariate  (Two-Variable)  Associations of CS and GSS With End Points
4433	Seven-Year Event-Free Survival Based on CS and GSS
4434	Aortic Sclerosis and Cardiovascular Outcomes
4435	Unadjusted Risk of Adverse Cardiovascular Events at 12 Months
4436	Myocardial Blood Flow and Myocardial Contrast Echocardiographic Data
4437	Diagnostic Performance of RT-MCE on a Segmental Basis
4438	Diagnostic Performance of RT-MCE and SPECT to Detect Significant Coronary Artery Disease in Individual Vascular Territories
4439	Diagnostic Performance of RT-MCE and SPECT to Detect Significant Coronary Artery Disease in Individual Patients
4440	Distribution of the Conduction Disorders According to the Cardiac Disease
4441	Multivariate Cox Regression Analysis for Identifying Patients With Rehospitalization
4442	Comparison Between Patients With and Without Intra-LV Electromechanical Asynchrony
4443	Multivariate Logistic Regression Analysis for Identifying Patients With Intra-LV Electromechanical Asynchrony
4444	Laboratory Data for Diabetic and Nondiabetic Patients
4445	Angiographic Data
4446	Follow-Up Data
4447	End Points After Three Months of Inactive or Active Pacing
4448	End Points After Three Months of Inactive or Active Pacing for Patients in the Long QRS Group  (QRS >150 ms)
4449	End Points After Three Months of Inactive or Active Pacing for Patients in the Short QRS Group  (QRS 120 to 150 ms)
4450	Stress Hemodynamics and Echocardiographic Results
4451	Angiography and Bypass Grafting
4452	Procedural Data and Quantitative Coronary Angiographic Analysis
4453	Intravascular Ultrasound Findings
4454	In-Hospital Events
4455	Distribution of the Study Population 1 by Quartiles of TID Ratio
4456	Results of Univariable Analysis for Prediction of TE
4457	Final Cox Proportional Hazards Model for the Prediction of TE *
4458	Comparison of Electrocardiographic Parameters Before and After Flecainide Administration in Subjects With Negative and Positive Test
4459	Changes in Luminal Diameter in the Different Groups of Patients
4460	Global Parameters of Sham-Operated Rats  (Sham)  and Rats With LV Dysfunction 10 Weeks After MI: Effects of Aldosterone Receptor Inhibition, ACE Inhibition, or Combined Aldosterone and ACE Inhibition
4461	Temporal Changes in Seniors  (Age ≥65 Years)  Hospitalized With Newly Diagnosed Congestive Heart Failure in Alberta, Canada During 1994–1995 to 1999–2000
4462	Severity of Illness and Comorbidity in Seniors  (Age ≥65 Years)  Hospitalized With CHF in Alberta, Canada During 1994–1995 to 1999–2000
4463	Physician and Hospital Factors for Seniors  (Age ≥65 Years)  Hospitalized With Newly Diagnosed CHF in Alberta, Canada, During April 1, 1994, to March 31, 2000
4464	Adjusted Mortality in Seniors  (Age ≥65 Years)  Hospitalized With Newly Diagnosed CHF in Alberta, Canada During 1995–1996 to 1999–2000
4465	Effects of Acute Low-Dose and High-Dose Metoprolol Administration on Hemodynamic Parameters at Rest
4466	Hemodynamic Responses During Dipyridamole Stress Study With Placebo, Low-Dose Metoprolol, and High-Dose Metoprolol
4467	Clinical Effects of Low-Dose and High-Dose Metoprolol on Dipyridamole Stress Testing End Points
4468	Dipyridamole Tc-99m Sestamibi Imaging Results
4469	Distribution of CK-MB Values and Follow-Up
4470	Patient Data
4471	Ejection Fraction, End-Diastolic Ventricular Volume, and End-Systolic Ventricular Mass: Magnetic Resonance Imaging Values
4472	Univariate and Multivariate Predictors of Cardiac Events
4473	Physiologic Parameters Post/Pre-Exercise or Sedentary Period
4474	Effect of GIK on 30-Day Mortality in All Patients and in Subgroups
4475	Effect of GIK on 30-Day Mortality in Patients With Killip Class 1, 2, 3, and 4
4476	Causes of Death in GIK Group and Control Group
4477	Clinical End Points at 30 Days in Overall Population and Killip Class 1 Patients
4478	Responses of Epicardial Lumen Area to CPT
4479	Hemodynamic Responses to CPT
4480	Mean MBF Responses and Coronary Vascular Resistance to CPT for Each Study Group
4481	Distribution of Prognostic Variables in Underweight, Normal Weight and Overweight Groups of Increasing BMI at Admission
4482	Distributions of Early Clinical Outcomes in Underweight, Normal Weight and Overweight Groups of Increasing BMI
4483	Adjusted ORs for Early Clinical Outcomes in Underweight, Normal Weight and Overweight Groups of Increasing BMI
4484	Reasons for Exclusion in the AAIR Versus DDDR Trial
4485	M-Mode Echocardiographic Measurements
4486	Two-dimensional Echocardiographic Measurements
4487	Morphological Echocardiographic Data
4488	Standard and Tissue Doppler Echocardiographic Measurements in Athletes With DD, ID, and II Genotype
4489	Clinical Features of the Two Groups of Patients
4490	Anatomic and Hemodynamic Features of the Two Groups of Patients
4491	Lactate Extraction Ratio and pH in the Great Cardiac Vein
4492	Multivariate Predictors of Cardiac Allograft Vasculopathy
4493	Multivariate Analysis of Predictors of Segmental Wall Function
4494	Concentrations of Water, DNA, Collagen, and Total GAGs
4495	Genetic Data of the Individual Families at Various Map Positions
4496	Clinical Data of Individuals With Crucial Recombinations
4497	Results of Substrate Mapping
4498	Incidence of Bleeding
4499	Blood Pressure
4500	Echocardiographic Data
4501	Vascular Function
4502	Predictors of 24-h Systolic BP by Multiple Regression Analysis
4503	Predictors of Left Ventricular Mass Analyzed by Multiple Regression Analysis
4504	Incidence of Major Adverse Events in Patients With the DD Genotype During the Early 30-Day Period After Coronary Stenting
4505	Follow-Up Quantitative Coronary Angiography of Patients With the DD Genotype
4506	Mean Responses to Atropine  (Mean ± SE)  in Young and Older Subjects
4507	Diastolic Filling Responses to Atropine by Age and Gender
4508	Mice Allocation
4509	Device and Pharmacologic Considerations for Therapy in Brugada Syndrome
4510	Assayed Vitamin and Nitrate Content of Juice Plus and Vineyard
4511	Percent Change in Diameter Before and After High-Fat Meal
4512	Lipoprotein, Homocysteine, and Combined Nitrite/Nitrite Levels in 38 Normal Subjects Before and After 28 Days of Placebo or Supplemental Phytonutrient Supplementation
4513	Summary of Principal Inclusion and Exclusion Criteria
4514	Most Common AEs During Active Treatment With Ximelagatran and Warfarin
4515	Clinical Evaluation
4516	Epworth Sleepiness Scale
4517	Hemodynamic Parameters
4518	Distribution of Coronary Artery Disease in Patients With Negative and Positive Results With Metoprolol
4519	Comparisons Between Patients With and Without Tilt-Induced VVS and Control Subjects, With and Without Age Adjustment
4520	Cox Multivariate Analysis for Tilt-Induced VVS
4521	Adenosine MPS Variables in Women and Men
4522	Unadjusted Rates of Referral to Early Coronary Catheterization and Revascularization as a Function of Inducible Ischemia in Women and Men
4523	Multivariable Predictors of Cardiac Death in the Overall Population, Women and Men
4524	Clinical and Adenosine MPS Data by Diabetic Status
4525	Follow-Up and Clinical Events
4526	Relationship of Risk Factors  (SBP, BMI, and Insulin)  to LV Mass Index Group by Race and Gender at Year 10
4527	Relationship of Risk Factors  (SBP, BMI, and Insulin)  to Relative Wall Thickness Subgroup by Race and Gender at Year 10
4528	Pearson Correlation Coefficients of LV Mass Index and Relative Wall Thickness With Slope From Individual Regressions of Longitudinal BMI and SBP
4529	Association of LA Size With Age, Gender, and Body Size by Bivariable Analysis in the Reference Subgroup  (n = 767)
4530	Relationship Between Indexes of LA Size and Age, Gender, and Body Size by Multivariable Analysis in the Reference Subgroup
4531	Relationship Between LAD or LAV Indexed to BSA, BMI, or Ht and Age, Gender, and Body Size by Multivariable Analysis in the Reference Subgroup
4532	Reference Ranges for LAD and LAV From the Reference Subgroup
4533	Association of Cardiovascular Disease and Indexes of Left Atrial Size in the Population-Based Cohort *
4534	Agreement * Between Left Atrial Enlargement as Defined by LAD/BSA or LAV/BSA in the Population-Based Cohort
4535	Prevalence of LAE as Defined by LAD/BSA and LAV/BSA According to Presence or Absence of Cardiovascular Disease in the Population-Based Cohort
4536	Morphologic Evaluation of Gene Therapy
4537	Functional Evaluation of Gene Therapy
4538	Clinical and Angiographic Data
4539	Parameters of Radial Segmental Deformation During Circumflex/Right Coronary Artery Coronary Angioplasty in Visually Normal  (Group I)  and Abnormal Segments  (Group II) —Long-Axis Parasternal View
4540	Parameters of Longitudinal Segmental Deformation During Left Anterior Descending Artery Angioplasty in Visually Normal  (Group I)  and Abnormal “At-Risk” Segments  (Group II) —Four-Chamber Apical View
4541	Parameters of Longitudinal Segmental Deformation During Right Coronary Artery Angioplasty in the Visually Normal  (Group I)  and Abnormal “At-Risk” Basal Inferior Segments  (Group II) —Two-Chamber Apical View
4542	Parameters of Radial Segmental Deformation Measured During Occlusion in the Group A  (Collateralized Segments Graded as 2 to 3 According to the Rentrop Scale) , and Group B  (Collateralized Segments Graded as 1 According to the Rentrop Scale) , and Group C  (Noncollateralized Segments)
4543	Contents of Various Blood Components
4544	Videodensity Values of Various Blood Products
4545	Effect of 52 weeks' treatment on lung function
4546	Effect of 52 weeks' treatment on exacerbation rate
4547	Effect of 52 weeks' treatment on health status and symptoms
4548	Treatment-related adverse events
4549	Contributions by individual poison control centres
4550	Age distribution among symptomatic exposures to dietary supplements by severity categories and unintentional circumstances
4551	Symptoms associated with calls related to dietary supplements or other substances in eight poison control centres in 1998
4552	Selected hazards associated with dietary supplements
4553	Products, ingredients, and adverse events reported in five data sources
4554	Number of cases assessed, number of cells recovered from maternal plasma, and number identified as male  (XY)  by fluorescence in-situ hybridisation  (FISH)
4555	Primary efficacy criterion and overview of primary efficacy variables
4556	Secondary efficacy variables related to disability and relapse
4557	Adverse events occurring in >5% of patients
4558	Countries with displaced persons' camps that met inclusion criteria
4559	Independent variables assessed
4560	Multivariate analysis of the effect of independent variables on age-specific mortality rates
4561	Efficacy and safety of treatment regimens
4562	Outcome of patients by treatment group
4563	Stool concentrations of study drugs and their relation to minimum inhibitory concentration  (MIC)  of infecting strains of V cholerae
4564	Cost in Bangladesh and USA of regimens for the treatment of cholera in a 10 kg child
4565	Probable cause of death by HIV stratum and treatment group
4566	Clinical and parasitological response and mortality rates by treatment group
4567	Clinical and parasitological response rates of subgroup of children 4 days after receiving additional 3-day course of open-label nitazoxanide
4568	Causes of deaths
4569	Overall and disease-free survival and time to colon-cancer-related death  (CCRD)
4570	Key adverse events
4571	Overall survival and disease-free survival in stage III colon cancer—results of previously reported randomised adjuvant trials
4572	Risks of cancer incidence and mortality after treatment with human pituitary growth hormone
4573	Clinical Outcomes at Six Months According DSE Results
4574	Multivariate  (Stepwise)  Logistic Regression Analysis, Including Clinical Variables and DSE
4575	Hazard ratios of progression to AIDS or death, and to death alone, from Weibull models
4576	Summary of data for controls and patients with type 2 diabetes mellitus  (means and SDs)
4577	Reasons for premature discontinuation
4578	Effect of acarbose and placebo on deterioration or improvement  *   of glucose tolerance in patients with IGT
4579	Frequency of adverse events
4580	Incidence of vertebral and hip fractures over 3 years  (% of patients)  and relative risk  (95% CI)  in pivotal trials done with alendronate, nasal calcitonin, raloxifene, risedronate, and the 1–34 fragment of recombinant human parathyroid hormone  (rh 1–34 PTH)  in the treatment of postmenopausal osteoporosis
4581	Clinical and Imaging Data of the Patient Population
4582	Myocardial Perfusion by 13N-ammonia PET and Wall Motion Analysis by 2D-Echocardiography Versus Coronary Angiography
4583	Tissue Characterization by PET versus Histopathology
4584	Initial 12 weeks of protocol treatment
4585	Grade 3 or 4 toxic effects reported by clinicians up to 12 weeks
4586	Clinicians’ assessment of response at 12 weeks
4587	Acceptability of treatment regimens to patients at 12 weeks
4588	Specification of primary outcome
4589	Accuracy of PET in prediction of need for thoracotomy
4590	Antidiabetic, lipid lowering, and aspirin treatment
4591	Endpoints
4592	Number of participants on study drug at endpoint or end of follow-up
4593	Adverse events
4594	Biochemical variables
4595	Albuminuria and serum creatinine concentrations
4596	Overview of Swedish trials included in overview
4597	Number of women randomised by trial study group and 5-year age group
4598	Trial time for invited group and follow-up time by age at randomisation and trial
4599	All trials combined, number of 1000 women-years and number of cases with breast cancer as underlying cause of death according to Statistics Sweden by age at randomisation
4600	Number of 1000 women-years and number of cases with breast cancer as underlying cause of death according to Statistics Sweden in invited and control groups by age at randomisation and trial
4601	Differences in cumulative breast cancer mortality per 100 000 women at 8, 12, and 16 years after randomisation between control and invited groups by trial and age at randomisation
4602	Total mortality in invited and control groups
4603	Number of women randomised to invited and control groups by year of birth and date of randomisation in Malmö trial
4604	Number of women randomised to invited group and control group by year of birth date of randomisation and method of randomisation in the Göteborg trial
4605	Number of women randomised to invited and control groups by year and day of birth and date of randomisation in Stockholm trial
4606	Number of women randomised to invited and control groups by date of randomisation and cluster in Östergötland part of Two-County trial  (n=92 872)
4607	Presence of polyomavirus and herpesvirus sequences in non-Hodgkin lymphoma and control samples from HIV-1- infected and HIV-1-uninfected patients
4608	Presence of SV40 and Epstein-Barr virus DNA sequences by histological type of non-Hodgkin lymphoma from HIV-1-infected and HIV-1-uninfected patients
4609	Association between education and socioeconomic factors and WISC-R test scores  *
4610	Relations of stunting, diarrhoeal disease and G lamblia infection to WISC-R test scores
4611	Changes in mean ambulatory blood pressure during sleep and wake as defined in the patient ‘s diary and changes in overall systolic and diastolic blood pressure
4612	Serial Electrocardiogram Parameters in Five Affected Family Members
4613	Diagnosis and exposure to potentially gonadotoxic treatment by sperm count of all study patients
4614	Testicular function in long-term survivors of childhood cancer and in controls
4615	Semen quality in long-term survivors of childhood cancer and in controls
4616	AERPs Before and After Infusion of Verapamil During Autonomic Blockade
4617	AERPs Before and After Infusion of Verapamil, in the Absence of Autonomic Blockade
4618	AERPs in Control Subjects Before and After Saline Infusion, During Autonomic Blockade
4619	Results of MPI by Visual Assessment
4620	Results of MPI by Quantitative Assessment
4621	Determinates of Abnormal Delayed Imaging
4622	Plasma Substrates and Insulin During the PET Study
4623	Hemodynamics During the PET Study
4624	Analysis of patient PBMC DNAs for porcine sequences and patient plasma for anti-PERV antibodies
4625	Numbers of women enrolled and pregnancies reported
4626	Pregnancy rates by treatment group and time since unprotected coitus
4627	Side-effects
4628	Drug therapy received after trial entry
4629	Treatment  (other than acetazolamide and furosemide)  for hydrocephalus before shunt placement
4630	Adverse effects of acetazolamide and furosemide, respiratory status, and time to hospital discharge
4631	Primary outcome—death, shunt insertion, or both
4632	Neurological examination and medical diagnoses in survivors at 1 year
4633	Overall status at 1 year
4634	Birth measurements and cardiovascular risk factors, adjusted for sex, according to degree of carotid stenosis
4635	Odds ratios for carotid stenosis according to birthweight, head circumference at birth, gestational age at birth, and cardiovascular risk factors
4636	Mean birth measurements and cardiovascular risk factors according to ABPI
4637	Odds ratios for low ABPI according to birthweight, head circumference at birth, gestational age at birth, and cardiovascular risk factors
4638	Analysis for cyanobacterial microcystins by three procedures in serum before and after haemoperfusion from one patient from IDR haemodialysis clinic, Brazil
4639	Rank of independent predictors of pulmonary function in individuals with airway obstruction by step-up ANCOVA
4640	Age, symptom severity, and diarrhoea duration relative to rotavirus excretion estimated by reverse transcription PCR
4641	Exacerbation scores for each group
4642	Mean  (SD)  clinical data at assessment
4643	Treatment at the end of the study
4644	Events in relation to target blood pressure groups  (n=6264, 6264, and 6262 in the target groups ≤90 mm Hg, ≤85 mm Hg, and ≤80 mm Hg, respectively)
4645	Events in relation to acetysalicylic acid  (n=9399)  or placebo  (n=9391)
4646	Bleeding events reported in acetylsalicylic-acid treated and placebo-treated patients
4647	Progression of cancer  (for all eligible patients)
4648	Prognostic factors for survival in univariate analysis
4649	Incidence of first operative procedure in children aged under 5 years per 1000 livebirths by country of birth within the UK
4650	Number of children identified through stated data source in Scotland and the Northern and Wessex regions
4651	Complexity of first operative procedure by source of data in Scotland and the Northern and Wessex regions
4652	Adherence rates by drug regimen
4653	Tuberculosis in study participants by chemoprophylaxis regimen
4654	Dose-Dependent Effects of Carvedilol on HW/BW and Myocardial Histology on Day 7
4655	Symptom scores recorded in daily record cards
4656	Effects of Carvedilol, Metoprolol, and Propranolol on HW/BW and Myocardial Histology on Day 7
4657	Number and severity of exacerbations
4658	Serum cortisol  (nmol/L)  after 6 months of treatment
4659	Rate of CDAD and weeks of observation for all patients initially colonised and non-colonised with C difficile
4660	Toxigenic status of isolates in colonized patients and weeks of observation
4661	Toxigenic restriction-endonuclease groups of C difficile isolates in symptom-free colonised patients and patients with CDAD
4662	Rate of CDAD and weeks of observation for patients initially colonised and non-colonised with C difficile who received antibiotics
4663	Clinical, microbiological, and histological outcomes
4664	Execution times of component tasks and complete laparoscopic cholecystectomy
4665	Surgeons' ratings of image quality
4666	Surgeons' subjective scores for adverse effects of imaging systems after surgery
4667	Postoperative median linear analogue pain and expectation scores
4668	Plasma t-PA and PAI-1 Antigen and t-PA Activity/Concentrations
4669	Progression, development, and regression of retinopa-
4670	Univariate analysis of determinants of glycaemic control  (HbA1c)
4671	Univariate analysis of hospital admissions for diabetic ketoacidosis
4672	Univariate analyses of hospital admissions for acute diabetes associated complications
4673	Distribution of samples by airways responsiveness status and covariates
4674	Incidence rates for respiratory symptoms by airways responsiveness status
4675	Remission rates for respiratory symptoms by airways responsiveness status
4676	Outcome of previous pregnancies
4677	Distribution of pre-eclampsia according to ISSHP classification and CLASP classification
4678	Distribution of complications associated with hypertension
4679	Summary of perinatal losses
4680	Retinal-photography grading before and after treatment
4681	Number and type of adverse events
4682	Side-effects within 5 days of vaccination
4683	Protective efficacy of RRV-TV against health-care-system intervention and clinical features of rotavirus gastroenteritis, and according to rotavirus G type
4684	Protective efficacy of RRV-TV during rotavirus epidemic season January to June, 1995, in relation to calendar time of dosing
4685	Clinical outcome and metabolic control
4686	Changes in counts of total white cells, neutrophils, lymphocytes, and monocytes during treatment
4687	Microbiology results
4688	Blood pressure and urinary sodium and potassium excretion in 47 participants throughout study
4689	Blood pressure and urinary sodium and potassium excretion in normotensive and hypertensive participants
4690	Preoperative and postoperative urodynamic findings
4691	Profile of included and excluded studies
4692	Effect of NIPPV on study outcomes
4693	Results from multivariable logistic regression model of factors associated with mortality at 3-months and at 12-months post-transplantation
4694	Expected and observed number of deaths at 3-months and at 12-months post-transplantation stratified by regression score  (1=lowest; 10=highest score)  in training and validation samples
4695	Causes of death at 3-months and at 12-months post-transplantation
4696	Distribution of personal habits by sex and study groups
4697	Screening history of individuals invited to screening
4698	Stage distribution of oral cancer cases
4699	Oral cancer incidence and mortality rates in all eligible individuals and eligible individuals with or without tobacco or alcohol drinking habits, or both
4700	Oral cancer incidence and mortality rates in all eligible individuals and eligible individuals with or without tobacco or alcohol drinking habits, or both, stratified by sex
4701	ORs and RRs  (95% Confidence Intervals)  for Other Correlates of Preserved Left Ventricular Systolic Function in Order of Entry Into the Full Logistic Model
4702	Prevalence of clinically active disease and C trachomatis infection at every assessment
4703	Changes in active disease and infection status between consecutive pairs of assessments
4704	Geometric mean or adjusted geometric mean of C trachomatis infection load for all assessments
4705	Analysis of associations between C trachomatis infection and various factors at every assessment
4706	Final model for HPV status as a time-dependent covariate in regression of cervical LSIL  (n=187)
4707	Frequency of monosomy X in peripheral white blood cells
4708	Vitamin D precursors in skin in burn patients and controls
4709	Results of low-dose spiral CT
4710	Results of PET
4711	Results of surgery
4712	Heart Rate Variability Measurements in Patients With Chronic Heart Failure in Relation to Cardiac Events
4713	Univariate and Multivariate Cox Proportional Hazard Analyses for the Identification of Patients With Chronic Heart Failure at Risk for Cardiac Events
4714	Prediction of Cardiac Events in Patients With Chronic Heart Failure by a Combination of Abnormal Washout Rate and Normalized Very-Low-Frequency Power
4715	Group comparison analysis, with different nominal p-values
4716	Correlation of Affymetrix expression data with sqRT-PCR derived values.
4717	Antibodies and inhibitors
4718	13–17 month patients' and kidney graft survival and 1-year serum creatinine in the 47 recipients with functioning grafts
4719	Description of the EPIC cohort
4720	Patients' and graft survival and incidence of weaning in intestine and pancreas recipients at end of study
4721	Final diagnoses of the causes of the pleural effusions in all 50 patients who entered the trial
4722	Comparison of final diagnosis with the two biopsy methods in the 47 patients who actually underwent pleural biopsy
4723	Clinical and Angiographic Features of the 18 Study Patients
4724	Prevalence of Angina and Ischemic Electrocardiographic Changes, Myocardial Lactate Metabolism, Systemic Hemodynamics, and the Degree of Epicardial Constriction at Acetylcholine Testings
4725	% area of immunoreactivity of vanilloid receptor 1 and other markers
4726	Clinical outcomes for all women
4727	Laterality of subsequent invasive mammary carcinoma in relation to biopsy side in 252 women with atypical lobular hyperplasia treated by biopsy only
4728	Relative risk of invasive mammary carcinoma in women with atypical lobular hyperplasia and without proliferative disease or complex fibroadenoma  *
4729	Immunohistochemical, in-situ hybridisation, and PCR results for paraffin specimens of human colonic polyps, adenocarcinomas, and non-neoplastic tissues
4730	Relative risk of death from all causes, cardiovascular disease  (CVD) , coronary heart disease  (CHD) , stroke, and external causes by alcohol intake during the week before the interview
4731	Relative risks  (95% CIs)  of death from all causes, cardiovascular disease  (CVD) , coronary heart disease  (CHD) , stroke, and external causes by typical dose per occasion in men who drink at least once a month
4732	Relative risks  (95% Cis)  of death from all causes, cardiovascular disease  (CVD) , coronary heart disease  (CHD) , stroke, and external causes, by frequency of drinking
4733	Relative risks  (95% Cis)  of death from all causes, cardiovascular diseases, and coronary heart disease, by frequency of drinking, stratified by typical dose per drinking occasion-drinkers only
4734	Relation between C-reactive protein in the first 3 months post-transplantation and ICAM-1, development of coronary artery disease  (CAD) , ischaemic events, and graft failure
4735	Adjusted hazard ratios of coronary artery disease and graft failure based on C-reactive protein concentrations during the first 3 months’ post-transplantation
4736	Primary outcomes at 12 months
4737	Primary cause of all deaths and reasons for all retransplants
4738	Rejection patterns
4739	Primary reason for withdrawal unrelated to composite primary outcome or rejection
4740	Reported side-effects of immunosuppression treatment within 12 months of trial entry
4741	White cell and differential counts of index case
4742	Biliary events during follow-up
4743	Complications of cholecystectomy
4744	Univariate risk factor analysis for patients to develop at least one recurrent biliary event during follow-up
4745	Clinical outcome after mean follow-up of 24·1 years, by symptoms at onset
4746	ISKDC grade of first kidney biopsy specimen and primary treatment
4747	Clinical outcome for 19 participants in 1981 and 2000
4748	Numbers of patients with poor outcome, by severity of renal symptoms at onset of Henoch-Schönlein purpura
4749	Clinical and laboratory data of children with vasculitis at time of sampling
4750	Proteolysis of high-molecular-weight-kininogen  (HK)  and bradykinin and HBP concentrations in patients
4751	Concentrations in skeletal muscle of ATP, ADP, AMP, phosphocreatine, and creatine
4752	Activities of mitochondrial complexes and concentrations of reduced glutathione and nitrite/nitrate in skeletal muscle
4753	Mutations, inclusions, and severity of disease in the five families studied
4754	Follow-up and completeness in the PBC1, Myeloma 4, and ovarian cancer datasets
4755	Frequency of acute rejection and histological severity  (intention-to-treat analysis)
4756	Survival at 6 months  (intention-to-treat analysis)
4757	Adverse events occurring with greater frequency in either of the treatment groups
4758	Comparison of microbiological, serological, and immunological results by presence or absence of histologically diagnosed endometritis
4759	Number of women who developed incident vulvovaginal or perianal lesions
4760	Univariate and multivariate analysis of potential risk factors for development of vulvovaginal or perianal lesions
4761	Multivariate analysis of potential risk factors for developing vulvovaginal or perianal lesions in HIV-1-positive women
4762	: Number of countries, institutions, and patients participating in the ITP Registry  *
4763	Clinical, molecular, and immunohistological data of patients from the retrospective series
4764	Features of SEN-D-infected and SEN-H-infected patients
4765	Final diagnoses of patients fulfilling criteria for irritable bowel syndrome
4766	Coeliac antibody results
4767	Estimates of time spent and financial cost of the screening campaign, 1997–99
4768	Clinical features and laboratory results
4769	Yellow fever viruses characterised by nucleotide sequencing
4770	Identification of yellow fever viral isolates by indirect immunofluorescence
4771	Serum plaque-reduction neutralising antibody responses and one-way cross-neutralisation tests of clinical samples from yellow-fever vaccinees against patients' isolates and reference isolates
4772	Complete genomic characterisation of yellow-fever viruses isolated from cases 1 and 2
4773	Quasispecies nature of yellow fever virus isolated from case 1
4774	Diagnostic value of biochemical markers for clinically significant fibrosis  *
4775	Sensitivity, specificity, and predictive value of the six-marker fibrosis index—second-year group
4776	Systemic Hemodynamics in the Subjects With Diabetes and in the Healthy Controls
4777	MBF and Coronary Vascular Resistance in the Subjects With Diabetes and in the Healthy Controls
4778	Results for recipient  (A3, A24)  and donor  (A9, 24, A19)
4779	Correlation between rejection score and presence of host-type cells in peritubular capillaries
4780	Non-transmitted HLA alleles
4781	Responses
4782	Adverse events during treatment
4783	Comparison of serial liver biopsy samples in case and control HCV-infected women
4784	Genotypes identified in affected neonates
4785	Immunoreactive trypsin and sweat chloride concentrations according to genotype
4786	Estimation of cost of neonatal screening programme in 1998
4787	Respiratory-chain enzyme activity in circulating lymphocytes of patients 1 and 3 and of 163 controls
4788	Functional and cognitive improvement in patients given ubidecarenone
4789	Testing for SLA/LP autoantibodies in 2000 serum Samples
4790	Exclusion of cytokeratin 8 and 18 as major target antigen
4791	Exclusion of glutathione-S-transferase isoenzyme as major target antigen
4792	Treatment regimen and outcome in 14 girls with vaginal yolk-sac tumours
4793	Virological and histopathological results in 45 sustained responders to interferon alfa plus ribavirin
4794	Crude rates of polyp occurrence during follow-up and adjusted odds ratios according to polyp presence at first surveillance examination
4795	Odds ratios of polyp occurrence during the follow-up according to polyp multiplicity at first surveillance examination
4796	Results of endometrial biopsy and blood hormone concentrations
4797	Number of end points in randomised controlled trials of UDCA versus placebo
4798	Results of sensitivity analyses  (Mantel-Haenszel method)
4799	Death or liver transplantation, or both, in trials of UDCA versus placebo with these endpoints separated into randomised and switch-over phases
4800	Effect of detection of occult lymph-node metastases on 10-year disease-free survival and overall survival
4801	Intestinal biopsy findings in group A
4802	Specificity of primers and probes for bacterial DNA tested
4803	PCR detection and quantitative PCR results for  M tuberculosis  DNA
4804	PCR detection and quantitative PCR results for  P acnes  and  P granulosum  DNA
4805	Overall results for the two non-invasive diagnostic techniques
4806	High-risk human papillomavirus status during study and risk for end histology of CIN 3
4807	Standardised incidence rates of breast cancer by age-groups and time after aspiration of first cyst
4808	Standardised incidence rate of breast cancer in relation to women classified by factors at first cyst aspiration
4809	Standardised incidence rates of breast cancer in women with palpable breast cysts
4810	Results derived from time-intensity curves
4811	Potential prognostic factors in 51 evaluable patients by recurrence of tumours
4812	Potential prognostic factors in 51 evaluable patients by expression of CK20
4813	Test results by study phase
4814	Results of screening tests
4815	Detection rates and predictive values for VIA and Pap smear
4816	Phase II screening-test results by reference standard outcomes
4817	Phase II sensitivity and specificity of each test
4818	Necropsy lymphoreticular tissues
4819	Clinical features and investigations in patients with positive tonsil-biopsy samples
4820	Clinical features and investigation of patients with negative tonsil-biopsy samples
4821	Frequencies of MRD positivity per treatment group at the various follow-up time points
4822	Numbers of relapses and cumulative relapse rates at 3 years for different degrees of MRD during follow-up
4823	Multivariate analysis of treatment group and MRD information at I-BFM-SG time points one and two
4824	Patients  (n=129)  categorised according to degree of MRD at time points one and two
4825	Rate of treatment effectiveness by group
4826	Prenatal detection of congenital abnormality includingand excluding ultrasound markers
4827	Prenatal detection of congenial abnormilities in the Oxford population 1996-91
4828	Detection of specified anomalies as a result of reporting of some ultrasound soft markers
4829	Reasons for termination of 171 pregnancies and severity of fetal condition
4830	Clinical, immunological, neurophysiological, and radiological features of 28 patients with gluten ataxia
4831	Feasibility and toxic effects of up-front FE120C chemotherapy  (289 courses)  in all patients before randomisation
4832	Clinical and pathological responses to up-front FE120C chemotherapy
4833	Haemopoietic recovery after PBPCreinfusion in 35 patients on high-dose chemotherapy
4834	Clinical and biological findings in patients with macrophagic myofasciitis
4835	Symptoms of patients with macrophagic myofasciitis
4836	Abnormal laboratory findings in patients with macrophagic myofasciitis
4837	Myopathological findings in patients with macrophagic myofasciitis
4838	Histopathological categories and palpability
4839	Multivariate analysis for all patients except those with premalignant lesions  (lobular carcinoma-in-situ or atypia)
4840	Median values and positivity rates at 90% sensitivity for cross-validated index by disease severity in palpable lesions
4841	Influence of high cumulative annual frequency of rejection on development of TCAD  *
4842	Positive lymphocyte-growth assay as predictor of progression of a low-grade biopsy to high-grade cellular rejection in recipients of cardiac transplantation
4843	Presence of IgG antibodies against MHC class II molecules  (IgG anti-II)  as predictor of progression of a low-grade biopsy to high-grade cellular rejection in cardiac-transplantation patients with complete donor-recipient mismatches at HLA-DR locus
4844	Multivariate equation  *   describing incremental factors in patients associated with 90-day progression from a low-grade biopsy to a high grade rejection during first year after cardiac transplantation
4845	Clinical disorders and tryptophan-hydroxylase antibodies in 80 patients with APS1
4846	Clinical and biochemical findings and liver histology
4847	Antibody, alanine, and small intestine biopsy follow-up
4848	Hazard ratios of HCC  (multivariate analysis)
4849	Frequency of HIV-1 p24 and HIAP immunoblot reactivity in patients with primary biliary cirrhosis and comparison groups
4850	Frequency of IgG autoantibodies in all patients with chronic liver diseases
4851	Autoantibody prevalence compared with serum reactivity to HIV-1 p24 and HIAP in chronic liver disease patients
4852	Classification of CT diagnoses by high-resolution CT
4853	Location of tumours in CT-detected lung cancer
4854	Multivariate analysis of survival of 240 evaluable patients
4855	Multivariate analysis of survival
4856	Leukaemia markers used to study minimal residual disease by double or triple colour flow-cytometry
4857	Detection of residual disease with immunological markers in children with ALL in clinical remission
4858	Continuous complete remission and cumulative incidence of leukaemic relapse according to detection of residual disease
4859	Results of strip test
4860	Biochemical and immunological measurements before transplant, at diagnosis of autoimmune hepatitis, and during treatment
4861	Histological score of seven index patients at time of graft dysfunction,  *   at diagnosis of autoimmune hepatitis, and at follow-up
4862	Operative findings
4863	Postoperative outcome
4864	Results of trial
4865	Frequency of HHV-8, mycobacterial, and Epstein-Barr virus  (EBV)  DNA sequences in sarcoid and non-sarcoid tissues
4866	Assignment of HHV-8 sequences into groups and mycobacterial DNA sequences into species, and identification of base substitutions in unique HHV-8 sequences
4867	Rejection episodes 6 months after transplantation  (intention-to-treat analysis)
4868	Summary statistics of cyclosporin daily dose and whole-blood trough levels
4869	Graft and patient survival 12 months after transplantation  (intention-to-treat analysis)
4870	Neurohormonal Values
4871	Nerve ingrowth into deeper levels of intervertebral disc as assessed by PGP9·5 staining in control and biopsy samples
4872	Criteria for pathological diagnosis of a gastric lesion
4873	Distribution of diagnoses by individual pathologists
4874	Diagnoses and findings of biopsies and endoscopic resections from all 19 gastric lesions
4875	Agreement between viewpoints for all 35 slides
4876	Results of endoscopic stone removal after EBD and EST
4877	Early complications  (<15 days after ERCP)  after EBD and EST and complications during follow-up  (>15 days after ERCP)
4878	Results of endoscopic stone removal after EBD and EST in relation to stone size and number
4879	Rate of fibrosis progression in patients by risk factors
4880	Validation of estimated rate of liver fibrosis progression per year
4881	Age and sex distribution and results of stool examination according to study group
4882	Colonoscopic findings and ELISA results
4883	Number of participants with histological abnormalities found in colonic biopsy samples
4884	Response to initial course of treatment in all symptomatic patients
4885	Follow-up data
4886	Clinical and laboratory data
4887	Production of EMA by in-vitro cultured intestinal explants from CD patients and controls
4888	Alcohol drinking
4889	Use of cannabis and other illicit drugs
4890	Association between cannabis, tobacco, and alcohol use
4891	Association between cannabis use, LSD, and Ecstasy
4892	HAD scores
4893	Associated medical conditions
4894	Repeat procedures required to establish biliary drainage
4895	Complications within 72 h
4896	Overall success for both treatment groups
4897	Subgroup analysis for patients with initially abnormal defaecation dynamics: relation with treatment success
4898	Relationship between post-treatment defaecation dynamics and success in all patients, independent of the treatment group
4899	Results of anorectal manometry  (median and range)
4900	Tissue concentration near ischaemic ulcers  (mcg/g wet weight)  and blood concentration  (mcg/mL)  of gentamicin and clindamycin: comparison of intravenous and intra-arterial infusion with transvenous pressure injection in Bier's arterial arrest
4901	Median TCA-enhancement factors and confidence intervals  (CI)  of the individual ratios of TVA-Bier  (C)  vs intravenous  (A) —and TVA-Bier  (C)  vs intra-arterial  (B)  application at both measurement times
4902	Axillary node metastases according to pathological variables
4903	Distribution of 85 cases with positive axillary nodes according to sentinel-node biopsy results
4904	Clinical details of patients receiving IA
4905	Volumes of plasma treated by one or two immediately pretransplant IA sessions and effects of IA on patient serum/donor cell crossmatches and on serum IgG
4906	Details of transplantation and outcome
4907	Secondary efficacy endpoints in the per-protocol set
4908	Treatment-emergent adverse events in the safety population
4909	Primary outcome and outcomes related to delivery
4910	Maternal and neonatal outcomes
4911	Primary and secondary outcomes
4912	Functional outcome by diary analysis
4913	Functional outcome by ASCRS quality of life assessment
4914	Functional outcome by SF-36 quality of life assessment
4915	Continence at a median follow-up of 77 months in 38 patients without a stoma or further surgery after sphincter repair
4916	Continence scores in 38 patients without a stoma or further surgery after sphincter repair
4917	Analysis to seek predictive variables
4918	Results of voiding/incontinence diary measures comparing pre treatment  (pre)  with subchronic test period  (test) , 6 months, and last follow-up  (last)   †
4919	Urodynamic data before implant  (pre)  and 6 months after implant
4920	Postoperative complications
4921	Results of Magnetic Resonance Imaging Parameters and uptake by Positron Emission Tomography, According to Wall Motion
4922	Magnetic Resonance Imaging Parameters in Severely Dysfunctional Segments  (n = 165)  According to the Viability Status by Positron Emission Tomography
4923	Sensitivity and Specificity of Different Thresholds of Segmental Extent of Hyperenhancement for the Detection of Non-Viable Myocardium by 18F-Fluorodeoxyglucose–Positron Emission Tomography
4924	Viability by Contrast-Enhanced Magnetic Resonance Imaging According to Viability Status by Positron Emission Tomography
4925	Outcomes of the randomised intention-to-treat set  (patients with positive PET-2 recruited before June, 2011, and all patients with negative PET-2)
4926	Therapy adherence, acute toxicities and supportive measures during chemotherapy of patients with negative PET-2, randomised intention-to-treat set
4927	Logistic regression model including 628 patients predicting incident postoperative delirium
4928	Postoperative pain levels by visual analogue scale for pain, 0–100 mm
4929	Postoperative opioids in morphine equivalents
4930	Remission, response, and mucosal healing rates at week 12 with central and local endoscopy readings
4931	Kaplan-Meier estimates of the likelihood of recurrent upper gastrointestinal bleeding and serious cardiovascular events at 18 months
4932	Disease-activity score of celecoxib and naproxen for arthritis
4933	Efficacy endpoints at week 12
4934	Adverse events  (on treatment at week 12)
4935	Definitions of PRAE assessed
4936	Anaesthetic management of participants
4937	Frequency of PRAE during perioperative, intraoperative, and postoperative periods
4938	Frequency of perioperative respiratory adverse events in infants having deep or awake airway device removal during minor elective surgery
4939	Efficacy analyses for primary and secondary outcomes using primary analysis with the stratification covariates as additive terms in the model
4940	Most common treatment-emergent adverse events occurring in at least 2% of patients receiving LMTM that were greater than in the control group
4941	Efficacy analyses for primary and secondary outcomes using prespecified analysis with the covariate for LMTM as monotherapy or add-on as an interaction term with treatment and an interaction term with visit in the model
4942	Perioperative variables
4943	Effectiveness outcomes
4944	Safety outcomes
4945	Common drug-related adverse events
4946	Global, regional, and national or territory number of maternal deaths, maternal mortality ratio  (MMR; number of deaths per 100 000 livebirths) , and annualised rates of change in percent, 1990–2015
4947	Average coverage of reproductive health services between including one visit of antenatal care  (ANC) , four ANC visits, in-facility delivery, and skilled birth attendance by MMR strata, all years from 1990 to 2015 combined
4948	Key secondary efficacy endpoints
4949	Treatment-emergent adverse events up to week 24 in the safety population
4950	Adverse events
4951	Various definitions of acute chest syndrome from highly cited studies
4952	Asthma definitions in individuals with sickle-cell disease and main findings of the article
4953	Top ten causes of death in males, females, and both for ages 10–14 years, 15–19 years, and 20–24 years, 1990, 2005, and 2013
4954	Top ten causes of years lost due to disability  (YLDs)  in males, females, and both for ages 10–14 years, 15–19 years, and 20–24 years, 1990, 2005, and 2013
4955	Top 10 causes of disability-adjusted life-years  (DALYs)  in males, females, and both for ages 10–14 years, 15–19 years, and 20–24 years, 1990, 2005, and 2013
4956	Incidence of Selected Outcomes in Cardiovascular Health Study Participants by Creatinine Level
4957	Hazard Ratios and 95% CIs for Association Between Serum Creatinine and Incident Cardiovascular Outcomes, Stratified by Gender
4958	Overall best responses
4959	Most common  (≥20%)  treatment-emergent adverse events
4960	Laboratory parameters of intention-to-treat population at final assessment
4961	Serious adverse events
4962	Descriptive statistics Bayley-III and MacAthur-Bates scores by group
4963	Between-group comparisons in Bayley-III and MacArthur-Bates scores
4964	2-year non-psychometric outcome data
4965	Interruptions to treatment because of clinical or laboratory adverse events, by participant
4966	Bacterial sexually transmitted infections
4967	Subgroup analysis and interaction between transfusion groups and mortality
4968	Underlying primary cause of death overall and by transfusion strategy
4969	Incidence of adverse events for each group and by age
4970	Active range of motion for each patient of the affected limb after brachial plexus reconstruction but before amputation
4971	Functional outcome scores for all patients before and after bionic reconstruction
4972	Differences between eligible patients who were enrolled versus those not enrolled
4973	Protocol adherence, red blood cell transfusion, and haemoglobin results
4974	Clinical outcomes  (patients with haemoglobin concentration of less than 120 g/L)
4975	Effects of methylprednisolone on outcomes
4976	Disease-free survival and overall survival events in the intention-to-treat population
4977	Adverse events occurring in at least 5% of any one group
4978	Grade 3 and 4 toxicities, and grade 2 neurotoxicities possibly related to CD19-CAR T-cell therapy
4979	Efficacy outcomes
4980	Adverse events
4981	Number and simple rates of the efficacy and safety outcomes of the study
4982	Adverse events, except bleeding, occurring in more than 5% of the patients or more than grade 2 in severity in any of the treatment groups
4983	Coverage and quality of the interventions by study group
4984	Malaria outcomes in the child cohort by treatment allocation
4985	Stratification by geographical area and cluster size
4986	Efficacy against clinical malaria  (primary case definition)  of a primary schedule with or without a booster dose and incremental efficacy of the booster dose
4987	Efficacy against severe malaria  (primary case definition)  of a primary schedule with or without a booster dose
4988	Number of cases averted per 1000 participants in children or young infants immunised with a primary vaccination schedule with or without a booster dose
4989	Primary outcome
4990	Procedure details
4991	Procedure-related complications
4992	Anaesthetic and other intraoperative procedures
4993	Outcomes
4994	Adverse events
4995	Primary and secondary outcomes
4996	Transplant outcome after HLA-matched related-donor transplants  (n=21)
4997	Transplant outcome in HLA-matched unrelated-donor transplant recipients  (n=35)
4998	Pooled safety outcomes for cohorts 1 and 2 during treatment
4999	Treatment of uncomplicated malaria
5000	Response during and after treatment
5001	Treatment-emergent adverse events in more than two patients
5002	Outcomes of the study
5003	Adverse drug reactions
5004	Objective tumour response
5005	Adverse events, according to grade
5006	Adverse events in the safety population  (all randomly assigned patients)   *
5007	Drug-related adverse events
5008	UPDRS part III scores in on and off states for each patient, by timepoint
5009	Total UPDRS score in on and off states for each patient, by timepoint
5010	Levodopa equivalent daily dose  (mg)  for each patient, by timepoint
5011	Treatment resistance, IVIG infusion reactions, duration of hospital stay, and days of fever in the study population by treatment group
5012	Coronary artery classification and Z scores for the study population by treatment group
5013	Adverse events
5014	Factors that differentiated caseload midwifery and standard care in the trial groups
5015	Primary and secondary maternal and infant outcomes
5016	Perineal status after vaginal birth
5017	Other infant outcomes
5018	Adverse outcomes in individual infants older than 24 weeks' gestational age, by trial group
5019	Hospital cost  (AUS$) , by mode of birth
5020	Prevalence of vitamin A deficiency  (1995–2005) , iodine deficiency  (2013) , inadequate zinc intake  (2005) , and iron deficiency anaemia  (2011)
5021	Global deaths in children younger than 5 years attributed to nutritional disorders
5022	Prevalence and numbers of children younger than 5 years with stunting, wasting, severe wasting, and underweight using estimates from UN and NIMS, by UN regions for 2011
5023	Review of nutrition interventions for women of reproductive age and during pregnancy
5024	Review of nutrition interventions in neonates
5025	Review of evidence for nutrition interventions for infants and children
5026	Review of evidence for disease prevention and management
5027	Effect of packages of nutrition interventions at 90% coverage
5028	Total additional annual cost of achieving 90% coverage with nutrition interventions, excluding management of moderate acute malnutrition, in 34 countries with more than 90% of the burden
5029	Thresholds for cost-effectiveness of interventions worldwide in 2010, by income group or region
5030	Primary outcome and its components
5031	Secondary outcomes
5032	Neonatal outcomes
5033	Sensitivity analyses of the primary outcome
5034	Primary outcome
5035	Secondary outcomes—hospital complexity index
5036	Secondary outcomes—medical practice
5037	Completion times  (s)  and total scores in the action research arm test
5038	Performance in the three-cone-stacking task
5039	Causes of death
5040	Estimated number of cases and age-standardised and sex-standardised prevalence of cannabis, amphetamine, cocaine, and opioid dependence in 2010, by region
5041	Estimated YLDs, YLLs, and DALYs for drug use disorders, by sex, in 2010
5042	Estimated DALYs attributable to illicit drug use as a risk factor for other health outcomes, 2010
5043	Donation intervals  (weeks)  in countries with national guidelines for blood donation
5044	Storage time for transfusion products
5045	90-day mortality by age and sex
5046	Changes in mortality by year of primary operation
5047	Univariable and multivariable Cox proportional hazards models of 90-day mortality
5048	Post-approval clinical trials of erythropoiesis-stimulating agents
5049	Detection rates of colorectal cancer and large polyps
5050	Additional colonic investigation in patients who had their randomised procedure, by reason for investigation
5051	Results of additional colonic investigation in patients who had their randomised procedure, by reason for investigation
5052	Haemoglobin concentrations and blood-transfusion details
5053	Numbers of clinically important complications and serious adverse events
5054	Summary of patients with serious adverse events
5055	Data from transfusion studies in patients with sickle-cell disease
5056	Exploratory subgroup analysis to assess the progression-free survival benefit of bendamustine plus rituximab versus CHOP plus rituximab
5057	Haematological toxic events in patients receiving at least one dose of study treatment
5058	All grades of non-haematological toxic events in patients receiving at least one dose of study treatment
5059	Primary endpoints
5060	Clinical events during the trial and status at end of the trial
5061	Grade 3 and 4 clinical and laboratory events
5062	Comparison of recommendations or guidelines for the management of cervical cancer during pregnancy in patients wishing initially to preserve pregnancy  (management for common histological subtypes: adenocarcinoma, squamous-cell, or adenosquamous carcinoma)
5063	Drugs used for the treatment of ovarian and cervical cancer during pregnancy
5064	Cumulative incidence of HIV-1 infection or death in infants uninfected at age 6 weeks
5065	Adverse events, rash, and grade 3 or higher laboratory abnormalities in infants who received at least one dose of study drug
5066	Spinal length and curvature before and after implantation of magnetically controlled growing rod in patients 1 and 2
5067	SRS-30 mean clinical outcome assessment scores
5068	Paralympic Games, 1948–2012
5069	Paralympic sports
5070	Bactericidal activity of agents and regimens determined by growth of log10CFU of Mycobacterium tuberculosis on solid media
5071	Activity of agents and regimens determined by time  (h)  to positivity in liquid culture
5072	Adverse events
5073	Risk factors included, exposure variables, theoretical-minimum-risk exposure distributions, and outcomes affected
5074	Proportion of ischaemic heart disease disability-adjusted life-years attributable to individual risk factors, worldwide, 2010
5075	Deaths attributable to risk factors and risk factor clusters, worldwide
5076	Disability-adjusted life-years  (1000s)  attributable to risk factors and risk factor clusters, worldwide
5077	Adverse events by treatment group
5078	Efficacy outcomes by treatment group
5079	Survival rate by treatment group  (per-protocol analysis set)
5080	Effect of preoperative anaemia on mortality and morbidity at 30 days
5081	ORunadjusted and ORadj-2 of mortality at 30 days for patients with anaemia or risk factors and anaemia and risk factors, compared with reference populations of patients with neither anaemia nor risk factors
5082	ORunadjusted and ORadj-2 of morbidity at 30 days for patients with anaemia or risk factors and anaemia and risk factors, compared with reference populations of patients with neither anaemia nor risk factors
5083	Effect of immunosuppressive drugs on cardiovascular risk factors
5084	Risk factors for admission to hospital with bacteraemia, 1999–2002
5085	Treatment recommendations and targets in the intensive treatment group
5086	Cardiovascular events and all-cause mortality in the two treatment groups
5087	Efficacy and safety
5088	Description of all-cause mortality up to day 360
5089	Spleen function  (primary endpoint)
5090	DTPA GFR  (primary endpoint)
5091	Splenic function at exit  (secondary endpoint)
5092	Comparisons between entry and exit values  (secondary endpoint)
5093	Adverse events
5094	Toxic effects
5095	Prevalence at enrolment, and incidence and clearance of human papillomavirus  (HPV)  infections in men
5096	Factors independently associated with infection with human papillomavirus  (HPV)
5097	Factors independently associated with clearance of human papillomavirus  (HPV)  infections
5098	Patients with first on-study skeletal-related events by type
5099	Adverse events and adverse events of interest in patients receiving at least one dose of study treatment
5100	Studies of antiresorptive drugs for the prevention of skeletal-related events in castration-resistant prostate cancer
5101	Cox regression analysis of time to sputum culture conversion
5102	Secondary outcome measures at 56 days, by allocation
5103	Adverse events
5104	Angiographic and Procedural Details in the Study Population
5105	Population At Risk and Cumulative Three-Year Mortality Rates Associated With Ascending Levels of CK-MB Elevation
5106	Effect of Oral CEE or Transdermal Estradiol on Hormones and Lipids After One Month
5107	Effect of Oral Conjugated Equine Estrogen or Transdermal Estradiol on Hemostatic Factors After One Month
5108	Reports Evaluating Hemostatic and Fibrinolytic Markers in Postmenopausal Women After Estrogen
5109	Reports Evaluating Hemostatic and Fibrinolytic Markers in Postmenopausal Women After Estrogen
5110	Echocardiographic Parameters in Healthy Volunteers and in Patients
5111	Outcomes After CABG vs. PCI
5112	Multivariate Correlates of In-Hospital Mortality  (C Index 0.807, Validated 0.801)
5113	Multivariate Correlates of Long-Term Mortality  (C Index 0.687, Validated 0.684)
5114	Distribution of Male, Female, and Indeterminate ECG Patterns Among Males and Females of Different Age Groups
5115	Distribution of Heart Rate, QTc Duration, and T-Wave Amplitude
5116	ST Segment Angle >20° in Males and Females With Male Pattern
5117	Comparison of ECG Patterns Recorded at Different Times and at Different Heart Rates  (Group I)
5118	Predictors of All-Cause Mortality and Predictors Specific to Progressive Heart Failure Death
5119	Physician Perceptions of the Barriers of Care in Managing Cardiovascular Disease Risk in Patients With Diabetes *
5120	Clinical Goals of the American Diabetes Association *
5121	Hemodynamic Data at Rest and During Hyperemia in the Three Groups of Patients
5122	Comparison Between Coronary Artery Lesions Demonstrated by the Angiography and CFVR Values Measured by Transthoracic Doppler Echocardiography
5123	Relationship Between Coronary Artery Lesions and Perfusion Defects on Thallium-201 Single Photon Emission Computed Tomography
5124	Admission Medication According to Diagnosis of Diabetes and Glycemic Status
5125	Admission Electrocardiogram and Course in Hospital According to Diagnosis of Diabetes and Glycemic Status
5126	Independent Predictors of Outcome
5127	LA Volumes and Fractions in the Two Groups
5128	Pulmonary Vein Flow Parameters for the Two Groups  (Mean ± SD)
5129	Bland-Altman Analysis for Interobserver and Intraobserver Variability
5130	Hemodynamic Responses to ATL-146e Bolus Injections in the Absence or Presence of Propranolol, Enalaprilat, Verapamil, or Caffeine
5131	Hemodynamic Responses to Adenosine and CGS-21680 in the Absence or Presence of Verapamil
5132	Effect of Increasing Verapamil Infusion Rates on the Hemodynamic Responses to Adenosine and ATL-146e
5133	Intensity of preamputation pain during treatment with bupivacaine and morphine  (blockade group)  or saline  (control group)
5134	Effect of bupivacaine and morphine or saline on rate of phantom pain, intensity of stump and phantom pain, and consumption of opioids during first year after amputation
5135	Mean  (SD)  oral and parenteral morphine requirements
5136	Differences in pain scores between treatment groups
5137	Withdrawals and deaths during main follow-up  (to 52 weeks)
5138	Rates of admissions and outpatients visits by group and by follow-up period in all children who started supplementation, including those withdrawn during study
5139	Incidence of severe anaemia  (PCV <25%)  and malaria during main follow-up period
5140	Transmission intensity estimates among five childhood populations
5141	Age-specific period prevalence rates  *   of severe malaria, cerebral malaria, severe malaria anaemia and acute respiratory-tract infections from five communities in The Gambia and Kenya
5142	Age distribution  *   of patients admitted with malaria or acute respiratory-tract infection presenting to hospital from five communities in The Gambia and Kenya
5143	Abdominal injuries in children age 0–14 years
5144	Pattern of injuries in abused children
5145	Estimated annual running costs of providing preventive interventions for child survival at 2000 coverage levels and universal coverage levels
5146	Estimated annual running costs of delivering treatment interventions for child survival at 2000 coverage levels and universal coverage levels
5147	Effects of varying selected assumptions on the estimated additional annual running costs of providing child survival interventions at universal coverage, from reported levels in 2000  (US$5134 million)
5148	Predictors of NVAF, Adjusted for Age and Gender
5149	Multivariate Models for Prediction of NVAF
5150	Imaging Tests Used to Diagnose Pulmonary Embolism
5151	Echocardiographic Parameters of Study Patients Grouped According to Left Ventricular Geometric Pattern
5152	Clinical Echocardiographic, and Hemodynamic Features of 13 Patients With False Positive Results for Dobutamine Stress Echocardiography
5153	Clinical Echocardiographic, and Hemodynamic Features of 22 Patients With False-Negative Results for Dobutamine Stress Echocardiography
5154	Treatment phases of the hybrid chemotherapy protocol
5155	Grade 3 and 4 toxic events by treatment phase
5156	Univariate and multivariate analysis of prognostic factors
5157	Outcomes of treatment protocols for acute lymphoblastic leukaemia in infants
5158	Prespecified criteria for upper gastrointestinal clinical events
5159	Upper gastrointestinal clinical events in intention-to-treat population
5160	Upper gastrointestinal clinical events related to concomitant use of low-dose aspirin or PPIs for at least 75% of the study period in intention-to-treat population
5161	Upper gastrointestinal clinical events related to combinations of concomitant PPIs and low-dose aspirin use for at least 75% of the study period in intention-to-treat population
5162	Patient discontinuations due to dyspepsia related to concomitant use of low-dose aspirin and PPIs for at least 75% of the study period in intention-to-treat population
5163	Summary of clinical trials of antihypertensive drugs that reported new cases of diabetes
5164	Results of sensitivity analyses
5165	Treatment during phases of the BFM ALL 95 intermediate-risk trial protocol
5166	Pattern of events by time after random assignment
5167	Incidence of thrombotic cardiovascular events
5168	Incidence of thrombotic cardiovascular event types in per-protocol population
5169	Included trials of HAART regimens in treatment-naive or minimally experienced HIV-1 infected patients
5170	Virological suppression in head-to head trials of initial HAART with an NNRTI versus a PI
5171	Withdrawal due to adverse events in head-to-head trials of initial HAART with an NNRTI versus a PI
5172	Virological suppression in trials of initial HAART versus two-drug treatment
5173	Comparison of outcomes between direct and indirect estimates of initial highly HAART with an NNRTI versus a PI
5174	Numbers of events and percentage rates at 5 years by thiopurine randomisation
5175	Effect of 6-thioguanine on isolated CNS relapse within subgroups
5176	Causes of deaths in remission by randomised treatment
5177	Number needed to treat for various background proportions of spontaneous stone passage
5178	Outcomes of the studies pooled and of the studies excluded for absence of a true control, stratified by treatment regimen
5179	Risk of ruptured abdominal aortic aneurysm in relation to other medications
5180	Hemodynamic Changes Between 10 Min and Exercise Termination in Younger Versus Older Subjects
5181	Main features of the HOPE, EUROPA and PEACE trials
5182	Effect of ACE inhibitors on main outcomes
5183	Primary and secondary outcome measures
5184	Incidence of new onset diabetes in various studies  40
5185	Endpoints for amlodipine and perindopril versus atenolol and thiazide  (ASCOT trial)   42
5186	Specific indications for various classes of antihypertensive drugs  32
5187	Trials included in the meta-analyses
5188	Secondary endpoints
5189	Extent of plasma viraemia by week
5190	Frequency of infection in resting CD4+ T cells on standard HAART
5191	Frequency of infection in resting CD4+T cells before and after addition of enfuvirtide and valproic acid to HAART
5192	Recruitment from the different centres
5193	Outcome after treatment
5194	Mitral Valve Features and Associated Echocardiographic Features of MVP
5195	Features of LA and LV Chambers
5196	Proportion of Increased LA and LV Measures
5197	Effect of Methionine on Myocardial Blood Flow and Conductance  (Mean ± SD)
5198	Effect of l-NMMA on Myocardial Blood Flow and Hemodynamic Variables  (Mean ± SD)
5199	History of fertility problems by treatment status
5200	Infertility investigations and diagnoses in women who had seen a doctor because they were having trouble becoming pregnant, by treatment for tall stature
5201	Symptoms and physical signs of allergic disease in Tirana, Albania, and West Sussex, UK
5202	Selected symptoms and physical signs of allergic disease by skin-prick test response in each center
5203	Prognostic factors in minimal residual disease defined groups at day 36
5204	Symptoms suggestive of allergic disorders
5205	Different outcomes in risk groups compared with the high-risk control group
5206	Sensitisation to dust mites, cat, dog, mixed grasses, milk, and egg assessed by skin-prick testing at age 1 year
5207	History of hypersensitivity reactions and contact allergies
5208	Risk factors for development of coronary-artery disease and restenosis
5209	Effects of IL-12 on biomarker responses to allergen challenge
5210	Treatment outcome
5211	Allergy-related symptoms, diagnoses, and sensitisations by age of entry to day nursery in children aged 5–14 years
5212	Number of children with information on all covariates by age  (months)  at entry to day nursery
5213	Effect of age of entry to day nursery on allergy-related variables in children aged 5–14 years with information on all covariates
5214	Grade 3 or 4 toxic effects  (WHO)  experienced during treatment
5215	Results of χ2 tests to assess whether CAP or carboplatin was more or less effective in different subgroups on endpoint of overall survival
5216	Treatment on progression by treatment allocated
5217	Distribution by age, sex, and smoking status in urban and rural groups
5218	Percentages of participants reporting wheeze in the previous year, asthma, and cough for 3 months of the year by age in urban and rural groups
5219	Percentage of participants with positive allergen skin tests by age in urban and rural groups
5220	Exposure rates and odds ratios for wheeze and skin sensitivity to D pteronyssinus adjusted for age, sex, and urban or rural residence
5221	Coefficients of variation within and between hormone assays
5222	Enrolment and follow-up
5223	Distribution of measures of previous malaria exposure before vaccine administration
5224	Number of children with side-effects observed within 1 week of vaccination
5225	Measures of vaccine efficacy
5226	Number of children with severe malaria
5227	Geometric mean parasite density in first cases of malaria
5228	Number of children with pure P vivaxmalaria
5229	Aneurysm locations
5230	Technical outcome of first procedure
5231	Time to second procedure on same aneurysm
5232	Outcome at 2 months in 1906 patients
5233	Outcome at 1 year in 1594 patients  (primary outcome)
5234	Non-procedural bleeding from target aneurysm
5235	Age and sex distribution of 368 individuals with loss of vision in the non-amblyopic eye
5236	Category of vision loss at presentation by category at 1-year follow-up
5237	Total population lifetime risk and annual rate of permanent visual impairment or blindness attributable to loss of vision in the non-amblyopic eye
5238	Projected lifetime risk and annual rate of permanent visual impairment or blindness attributable to loss of vision in the non-amblyopic eye in individuals with amblyopia
5239	Disorders causing vision loss by age group
5240	Frequency and transmission of HIV-1 in child-bearing women attending rural immunisation clinics in KwaZulu Natal
5241	Age distribution of HIV-1 infected children born to HIV-1-positive mothers
5242	Comparison of absolute and relative numbers of HIV-1 RNA copies within erythrocyte and leucocyte preparations of 17 HIV-1-infected individuals
5243	Variables involved in formation and binding of immune complexes  (total)
5244	Distribution of events
5245	Annual recurrence rates
5246	Hazard ratios for different prognostic factors for breast-cancer events
5247	Occurrence of prespecified adverse events
5248	New primary cancers with an incidence of more than 0·2% before recurrence in all patients who received trial treatment
5249	Overall adverse events
5250	Factors associated with low serum retinol concentrations in 301 women infected with HIV-1
5251	Distribution of alcohol intake over subtypes of alcoholic beverage in the Rotterdam Study
5252	Hazard ratios of dementia and subtypes of dementia according to alcohol consumption
5253	Hazard ratios of dementia and subtypes of dementia according to alcohol consumption, stratified for APOE  *   4 status
5254	Plasma BNP  (Biosite [BNP-B] and Shionogi [BNP-S] Assays)  by Age and Gender in Normal Subjects
5255	Age and Gender-Specific Ranges  (5th–95th Percentiles)  for Plasma BNP  (pg/ml)   (Biosite and Shionogi Assays)  Derived From the Regression Analysis in Normal Subjects
5256	Variables Examined for Association With Age, Gender, and Plasma BNP Concentration in Normal Subjects
5257	Parameters Independently Associated With BNP
5258	Sensitivity and Specificity of BNP for Detection of Systolic Dysfunction at the Discriminatory Value for BNP as Determined by the ROC Analysis and at the 95th Percentile Reference Limit by Age, Gender, and Assay System
5259	Genital tract infections and HIV-1 shedding  (n=311)
5260	Relation between HIV-1 shedding in the genital tract and presence of HIV-1 RNA or infectious virus in blood
5261	Association of virologic, immunologic, and clinical variables with HIV-1 shedding in genital secretions  (n=247)
5262	Association of clinical variables with HIV-1 shedding in genital secretions  (n=247)
5263	Odds ratios of coronary heart disease in men who had values of the relevant cell adhesion molecule in the top third of the distribution of controls relative to those who had values in the bottom third of this distribution
5264	Number of patients who received concomitant medications during stay in hospital
5265	Frequency of composite and single endpoints at hospital discharge and at 30 days
5266	Frequency of in-hospital cardiac events and procedures
5267	In-hospital stroke rates
5268	Rate of in-hospital thrombocytopenia and non-cerebral bleeding complications
5269	Mean  (SD)  birthweight of individual twins
5270	Comparison of variables between groups
5271	Distribution of all patients with necrotising enterocolitis
5272	Details of patients with necrotising enterocolitis
5273	Risk factors for definite necrotising enterocolitis
5274	Definite necrotising enterocolitis and recruitment by hospital
5275	Summary of predictors of counterfeit artesunate
5276	Regional prevalence of xerophthalmia and active trachoma
5277	Variables associated with active trachoma
5278	Adjusted mean values for markers of systemic inflammation according to daily alcohol intake
5279	Adjusted mean values for markers of alcohol consumption in categories of daily alcohol intake
5280	Mean blood concentrations of homocysteine,  *   folate, vitamins B6 and B12 after 3 weeks consumption of red wine, beer, spirits and water
5281	25-hydroxycholecalciferol concentrations in untreated tuberculosis patients and tuberculosis contacts
5282	VDR genotype in tuberculosis patients and tuberculosis contacts
5283	Association between tuberculosis and combinations of VDR genotypes and 25-hydroxycholecalciferol status
5284	Relative risk of HIV-1-induced death and AIDS associated with changes in TREC, HIV-1 RNA, CD4 T-cell count, and age at seroconversion
5285	User satisfaction by provider and type of operation
5286	Cost-effectiveness of cataract surgery  (costs per operation in Indian rupees)
5287	Studies that report cataract-surgery outcomes in developing countries
5288	Percentage of patients who received concomitant medications given during stay in hospital
5289	30-day mortality
5290	30-day mortality in subgroups
5291	Frequency of in-hospital cardiac events and procedures
5292	Frequency of strokes
5293	Non-cerebral bleeding complications
5294	Outcomes during double-blind treatment period
5295	Outcome during total treatment period
5296	Death, myocardial infarction, or both in predefined subgroups in double-blind treatment period
5297	Safety during double-blind treatment period
5298	Proportions LCR-positive by clinical grade of trachoma  (WHO stages)  and country
5299	Effect of treatment on conjunctival LCR positivity
5300	Odds ratios  (95% CI)  for new cases of diabetes comparing extreme quartiles of inflammatory markers
5301	Risk of developing diabetes mellitus associated with white-cell count and various metabolic factors
5302	Risk of developing diabetes mellitus for individuals in subgroup with values higher than the median for sialic acid and three acute-phase proteins
5303	CYP2C9 genotype distribution
5304	Comparison of low-dose group with random clinic controls
5305	Age-Standardized Distribution of Potential Coronary Risk Factors According to History of Diabetes and CHD in the Health Professionals Follow-Up Study in 1986 *
5306	Relative Risks and 95% CIs of Death From All Causes and CHD According to Duration of Diabetes in the Health Professionals Follow-Up Study 1986–1996 *
5307	Association between CD4, viral load, and risk factors among HIV-infected IDUs
5308	Female/male ratio for viral load reported as estimated difference from log-based viral-load threshold in men among two samples of HIV-infected IDUs
5309	Relative hazard of developing AIDS for women compared with men among HIV-infected IDUs
5310	Cerebrospinal-fluid and plasma HIV-1 RNA before and after treatment
5311	Intention-to-treat analysis
5312	Per-protocol analysis
5313	Crude and adjusted odds ratios for risk of breast cancer associated with intake of phyto-oestrogens
5314	Excretion rates of lignans, isoflavonoid phyto-oestrogens, and total nitrogen  ?
5315	Follow-up events and 1-year estimates  *   for cars
5316	INR measurements for all treatment groups at weeks 1 and 4, and month 6
5317	Study groups
5318	Visual status at 1 year follow-up in the first operated eye of 1827 patients
5319	Causes of poor functional visual outcome and blindness at 1 year follow up in the operated eye of 1827 patients
5320	Source and number of upper gastrointestinal bleedings after randomisation by intention-to-treat
5321	Comparison of laboratory data  (mean [SD])  of both treatment groups during a follow-up of 12 months
5322	Multivariate analysis of the prognostic value of selected clinical variables on the first occurrence of variceal rebleeding, death, and clinically significant or refractory encephalopathy  *
5323	General data of the two populations
5324	Mean  (SD)  percentage composition of main fatty acids of plasma lipids and their ratios in participants matched for age and sex
5325	Plasma creatinine before and after steroid withdrawal
5326	Relation of changes in plasma creatinine following steroid withdrawal to presence or absence of early rejection episodes and to DR antigen matching
5327	Changes in metabolic, cardiovascular, and haematological indices after steroid withdrawal
5328	Association between percentage energy from macronutrients and clinical outcomes  (n=135 335)
5329	Association between percentage energy from types of different fat and clinical outcomes  (n=135 335)
5330	Tumour response
5331	Adverse events
5332	Reasons for changes in recommended antibiotic therapy in the per-protocol population
5333	Proportion of patients in the full analysis set who had an ACR response, low disease activity, or remission
5334	Summary of adverse events, serious adverse events, and discontinuations in the safety analysis set
5335	Liver function tests as multiples of upper limit of normal
5336	Secondary efficacy outcomes at week 16
5337	Adverse events in initial treatment and treatment withdrawal periods
5338	Adverse events in re-treatment period
5339	Clinical responses at weeks 16 and 52
5340	Adverse events of special interest
5341	Adverse events
5342	Recurrence at 12 months after procedure
5343	Serious adverse events
5344	The mean difference in total costs and QALYs for HAL versus RBL
5345	Global and regional food availability, and consumption of fruits and vegetables and red meat in 2010 and 2050 for the reference scenario without climate change and for the mean  (SD)  of the main climate change scenarios
5346	Deaths avoided  (in thousands)  due to changes in dietary and weight-related risk factors between 2010 and 2050 for different climate and socioeconomic scenarios
5347	Antibiotic items dispensed per 1000 weighted population for the feedback intervention, September, 2014, to April, 2015
5348	Antibiotic items dispensed per 1000 weighted population for the patient-focused intervention, December, 2014, to March, 2015
5349	Antibiotic items dispensed per 1000 weighted population for all experimental groups, September, 2014, to April, 2015
5350	Effects of interventions on breastfeeding outcome measures, by setting
5351	Estimated economic losses from cognitive deficits associated with regional infant feeding practices compared with every infant breastfeeding until at least 6 months of age
5352	Electrocardiographic Data of the Study Population
5353	Electrocardiographic Variables in the Different HERG K897T Genotypes
5354	Potentially effective control interventions and challenges in the development of generalisable policies
5355	Policies that require international collaboration
5356	Overall recommendations for policy interventions
5357	Potential national indicators in the WHO global action plan, by policy area
5358	Benefits and costs accrued by a coherent package
5359	Key elements of a data-driven, locally tailored approach to tuberculosis elimination
5360	Possible data items to be collected on individual tuberculosis cases, in addition to the WHO minimum set of variables,  13   by purpose and data type
5361	Examples of potential benchmarks for success of locally targeted strategies to end tuberculosis in five emblematic settings
5362	Increase in vitamin A and folate deficiencies by region
5363	Health burden attributed to losses of indigenously grown versus imported foods and nutrients
5364	Results based on questionnaire at 16 weeks
5365	Results based on monthly questionnaires
5366	Results based on notes review
5367	Stratified disease approach to acute appendicitis
5368	Clinical trials comparing primary antibiotic treatment versus surgery for acute appendicitis
5369	Primary outcome analyses of patients with vertebral osteomyelitis according to duration of antibiotic treatment
5370	Secondary outcomes and adverse events
5371	Duration and type of antibiotics used in the study
5372	Reasons for treatment failure, by treatment group
5373	Comparison of the secondary outcomes and post-hoc analyses, by treatment group
5374	Treatment adherence and follow-up of enrolled infants
5375	Per-protocol analysis
5376	Intention-to-treat analysis
5377	Elements of smart food-policy design in three policy areas
5378	Bactericidal activity characterised by joint Bayesian NLME modelling of the daily rate of change in mean count of log10CFU of Mycobacterium tuberculosis per mL sputum  (efficacy analysis population)
5379	Bactericidal activity characterised by joint Bayesian NLME modelling of the daily rate of change in mean log10TTP  (efficacy analysis population)
5380	Key adverse events and laboratory abnormalities
5381	Accountability relations and mechanisms for enforcing accountability by governments and the private sector for actions and policies on food environments
5382	Reasons for not reintroducing CAPOX-B after first progression with ≥5% incidence
5383	Outcome according to response after six cycles of treatment given before randomisation
5384	Outcome according to stage of disease
5385	Treatment-related adverse events during observation or maintenance treatment with an incidence of ≥5%
5386	Cost-effectiveness of childhood obesity prevention interventions
5387	Endoscopic and clinical outcomes based on modified intention-to-treat analysis
5388	Adjudicated and non-adjudicated clinical outcomes
5389	Number of participants diagnosed with tuberculosis and cryptococcal meningitis at trial enrolment
5390	All-cause mortality and first hospital admission in the 12 months after initiation of antiretroviral therapy
5391	Adherence to antiretroviral therapy during the previous 28 days, as measured at 6 and 12 months
5392	Mortality according to cryptococcal serum antigen status in the clinic plus community support group
5393	Modified intention-to-treat outcomes by treatment group  (unless stated)
5394	Adverse events associated with receipt of either study drug
5395	Locus tags of chromosomal antimicrobial resistance gene orthologues in reference sequences from the S flexneri 2a lineage
5396	Availability of data from randomised trials beginning before the year 2000 and comparing radiotherapy to the chest wall and regional nodes after mastectomy and axillary surgery versus no radiotherapy but the same surgery
5397	Overview of interventions showing effect on selected outcomes
5398	Interventions modelled for effect
5399	Comparison of multi-country costing exercises of relevance to maternal, newborn, and child health
5400	Effect of provision of facility care on lives saved by 2020, hence reducing the quality gap
5401	Incremental cost of the scale-up plan by intervention package for the years 2020 and 2025
5402	Bivariate Pearson Correlations of Year 10 LV Mass  (g)  With Predictor Variables by Race/Gender Group
5403	Multiple Linear Regression Coefficients Relating Year 10 LV Mass to Predictor Variables, by Race/Gender Group
5404	Predictor Variables by Percent Change in LV Mass  (Mean Level of Predictor, Adjusted for Race and Sex)
5405	Number of biobanked isolates with drug-specific genotypic and phenotypic resistance
5406	Outcomes of 107 patients with extensively drug-resistant tuberculosis after treatment, by duration of follow-up
5407	Outcomes of the 45 patients who were discharged into the community
5408	Treatment-related outcomes by conversion status
5409	Number of patients achieving first culture conversion, net conversion, or net reversion, by follow-up time
5410	Cox cause-specific hazards model of time from treatment start to net conversion  (under competing risk of death)  and multivariate Cox proportional hazards model for risk of death from treatment start
5411	Primary and secondary endpoints
5412	Serious adverse events reported
5413	Primary and secondary analysis
5414	HPA's daily situation reports and updates of events
5415	Mean number of medical presentations per day during Euro 2012
5416	Specific causes of death, 1999–2011
5417	Incidence rate ratios of underlying cause of death, by year
5418	Safety summary
5419	Solicited injection site adverse events
5420	Release schedule for biofortified crops and status of related nutrition studies
5421	Epidemiological and clinical features of patients with avian influenza A H7N9 virus infection
5422	Laboratory measurements in four patients with avian influenza A H7N9 virus infection
5423	Virological findings in patients with avian influenza A H7N9 virus infection
5424	Substitutions of critical aminoacid residues in human and avian isolates of avian influenza A H7N9 virus, by residue
5425	Antibiotic resistance patterns for M abscessus isolates; by patient number
5426	Design and eligibility criteria of included trials
5427	Number of people with incident cancers at specific sites, by duration of treatment
5428	Effectiveness of CRP and enhanced-communication training in reducing antibiotic prescribing rates
5429	Effectiveness of CRP training and enhanced-communication training on symptom control
5430	Description of Study Population
5431	Outcomes Stratified by DM and Treatment
5432	Unadjusted and Adjusted Risk Associated With Diabetes Mellitus Overall and Stratified by Type of Treatment *
5433	Causes of Death Stratified by Treatment for DM
5434	Primary and secondary trial outcomes
5435	Sensitivity analysis of interaction between recruiting hospital and primary outcome
5436	Timing of report of CAUTI relative to catheterisation status
5437	Participant health state measured by responses to the EQ-5D questionnaire
5438	Manifestations, brief clinical case definitions, and recommended diagnostic approach for the diagnosis of Lyme borreliosis in routine clinical practice
5439	Considerations for differential diagnosis of Lyme borreliosis
5440	Recommended treatment for patients with Lyme borreliosis  *
5441	Cumulative treatment failure
5442	Cluster specific cumulative treatment failure by day 6
5443	Relapse at days 7–14
5444	Treatment received by children in the control clusters
5445	Adverse events reported by ≥10% of patients  (safety population  *  )
5446	Mean treatment coverage during mass antibiotic distributions by study visit
5447	Estimated prevalence of ocular chlamydial infection in children aged 0–9 years by state team
5448	Estimated prevalence of ocular chlamydial infection in people aged 10 years and older by state teams
5449	Reasons for exclusion from the study and per-protocol analysis at short-term follow-up
5450	Clinical outcomes in the per-protocol population
5451	Secondary outcomes
5452	Class of consensus indications for catheter ablation of atrial fibrillation
5453	Unadjusted Incidence and Relative Risk for Progression Asymptomatic Left Ventricular Dysfunction in Black and White Participants According to Randomization to Enalapril or Placebo
5454	Multivariate Analyses: Risk Associated With Randomization to Enalapril Versus Placebo for Progression of Asymptomatic Left Ventricular Dysfunction
5455	Adjusted Risk for Progression to End Points in Black Relative to White Participants in SOLVD Prevention Trial
5456	Subtypes of non-Hodgkin lymphoma according to the 2008 WHO classification  13
5457	Ann Arbor staging system
5458	Angiographic and clinical efficacy endpoints
5459	Safety endpoints and intracranial haemorrhage subtypes
5460	Pre- Versus Post-PTE Echocardiographic and Hemodynamic Parameters
5461	Cost-effectiveness results for selected interventions evaluated in Australia
5462	Adherence to treatment of patients that returned for 6-week follow-up, by treatment group
5463	Helicobacter pylori eradication by treatment group for three definitions of analysis population
5464	RyR2 Mutations Detected in Affected Families
5465	Arrhythmic Symptoms in Patients Carrying RyR2 Mutations
5466	Twelve-Lead ECG, SAECG and Two-Dimensional Echocardiographic Findings in RyR2 Mutation Carriers
5467	Median urinary iodine concentrations in participating UK centres
5468	Probability of iodine deficiency in Belfast compared with other UK centres following binary logistic regression analysis
5469	Urinary iodine concentrations analysed according to dietary habits
5470	Incidence of primary endpoint events and complicated appendicitis with peritonitis and postoperative peritonitis within 30 days after the start of treatment in both groups  (intention-to-treat population)
5471	Duration of post-therapeutic pain, hospital stay, and disability  (intention-to-treat population)
5472	Aspects of appendices during appendicectomies done in 44 of 120 patients treated initially with antibiotics  (intention-to-treat population)
5473	Association between risk factors and complicated appendicitis with peritonitis in the appendicectomy group
5474	Association between risk factors and absence of improvement of appendicitis in the antibiotic-treatment group
5475	Rates of tuberculosis and death in participants receiving 6 months' open-label isoniazid followed by 30 months' masked placebo  (control group)  or isoniazid  (continued isoniazid group)
5476	Multivariable analysis of the effect on tuberculosis incidence of antiretroviral therapy
5477	Effect of interventions estimated by use of a model based on the Lives Saved Tool
5478	Modelled interventions, data sources, and effect estimates used for analysis
5479	Interventions modelled at various stillbirth rates
5480	Estimated effects of individual interventions on stillbirths according to coverage level in 2015
5481	Estimated effects of intervention combinations on stillbirths according to coverage level in 2015
5482	Total additional costs of interventions at 99% coverage across the 68 Countdown countries at various stillbirth rates in 2015
5483	Ranking of research priorities for development of interventions to reduce stillbirths in low-income and middle-income countries
5484	Laboratory procedures
5485	HIV statuses in patients with suspected cases of tuberculosis and multidrug-resistant tuberculosis
5486	Sensitivity, specificity, and predictive values of a one-off direct MTB/RIF test
5487	Sensitivity and specificity of smear microscopy  (two to three microscopy examinations as per routine practice)  and a one-off direct MTB/RIF test, stratified by HIV status of patients
5488	MTB/RIF test sensitivity and specificity for detection of rifampicin resistance after change to software cutoff
5489	Thousands of cases and hundreds of deaths from cholera projected between March 1 and Nov 30, 2011, by province under base case and under each intervention scenario
5490	Variables used to distinguish viral from bacterial pneumonia
5491	Occurrence of pneumonia and other findings in 4277 children with laboratory-confirmed viral respiratory infection at Turku University Hospital, Finland
5492	Possibilities for antiviral treatment and prevention of severe viral pneumonia
5493	Treatment and prophylaxis of Ebola haemorrhagic fever
5494	Triggers for non-fatal myocardial infarction
5495	Prevalence of exposure within the population, pooled OR, and PAF for the studied triggers of myocardial infarction
5496	Summary of selected emerging infectious diseases in southeast Asia
5497	ADHD rating scale, abbreviated Conners' scale, and structured psychiatric interview scores at start and end of the first phase
5498	Grade 3 and 4 adverse events  *   experienced by 2% or more of patients and adverse events leading to treatment discontinuation, after randomisation to rituximab maintenance or observation
5499	Serum concentrations of immunoglobulins at randomisation, after 1 year of maintenance, and at the end of the maintenance phase
5500	Summary of coverage, main effects, and costs of selected preventive interventions
5501	Effectiveness and cost-effectiveness of interventions after 20 years and 50 years
5502	Estimated yearly cost per head  (in US$)  of a chronic disease prevention package by intervention and country
5503	Immunohistochemistry scoring for HER2 in gastric and gastro-oesophageal junction cancer, by type of diagnostic specimen
5504	Secondary efficacy endpoints
5505	Adverse events
5506	Estimated population-level effect of pricing policies on alcohol consumption and health outcomes
5507	Estimated population-level effect of pricing policies on alcohol consumption and health economic outcomes
5508	Estimated effect on alcohol-related disorders of a £0·50 minimum-price policy on disease prevalence by age  (10 years after implementation)
5509	Estimated population subgroup effect of alcohol pricing policies
5510	Hemodynamic Parameters
5511	Actuarial life table for cumulative proportion of healing for both treatment groups, by time interval
5512	M ulcerans isolated by culture of tissue specimens after 8-week treatment period
5513	Efficacy of ticagrelor versus clopidogrel
5514	Safety of ticagrelor versus clopidogrel in patients intended to undergo an invasive strategy
5515	Silent Cerebrovascular Disease
5516	Neurohumoral Profiles
5517	Findings in the Three Groups of Subjects: NT, WHT and EHT
5518	Cox Regression: Univariate Predictors of CHD Events
5519	Comparison of Individual and Combined Test Performance in the Prediction of Coronary Events
5520	Lipid Levels and Blood Cells in Patients With Coronary Artery Disease and Control Subjects
5521	Propranolol-Induced Changes in the Mean cQTe, Mean cQTp, Mean cTp-e, Maximum cQTe, Minimum cQTeand cQTe-D in the LQT1 and LQT2 Groups
5522	Epinephrine-Induced Changes With Oral Propranolol in the Mean cQTe, Mean cQTp, Mean cTp-e, Maximum cQTe, Minimum cQTeand cQTe-D in the LQT1 and LQT2 Groups
5523	HR and QT Interval Responses to Exercise, Atropine and Isoproterenol
5524	Parameters of Smoke Exposure and Endothelial Function of the Study Population
5525	Reported adverse effects
5526	Change in body-mass index after antipsychotic drug treatment
5527	Association of genotype with weight gain
5528	General features of NM2 genome compared with those of N315 and Mu50
5529	Classification of S aureus genomic islands
5530	Treatments received during study by patients assessed for primary efficacy outcome
5531	Frequency of venous thromboembolic events by day 11
5532	Safety outcomes
5533	Treatments received during study by patients assessed for primary efficacy
5534	Frequency of venous thromboembolic events by day 11
5535	Safety outcomes
5536	Surgical details
5537	Examination of resected specimen
5538	Sites of first failure, survival status, and cause of death
5539	Dysphagia and performance status scores at 1 year
5540	Chemotherapy regimens and hazard ratios for randomised trials comparing surgical resection with or without preoperative chemotherapy
5541	Radiological and biological findings in 52 patients with community-acquired Staphylococcus aureus pneumonia
5542	Median  (IQR)  concentrations of folate, vitamin B12, and total homocysteine concentrations in the two interventions
5543	Shift in circulating homocysteine dependency from folate to vitamin B12 with folic acid intervention
5544	Intervention studies testing the effect of specified doses of folic acid, up to 1 mg/day, on serum folate concentration
5545	Serum folate concentrations after increases in folic acid intake in younger women according to background serum folate and the predicted reduction in neural tube defect risk
5546	Significant and important non-significant associations of acute lymphoblastic leukaemia with variables for which there was direct evidence of an association with childhood leukaemia before analysis
5547	Significant associations of acute lymphoblastic leukaemia with variables for which we had no specific hypothesis of an association with childhood leukaemia before the analysis was done
5548	Details of use of iron and folate supplements
5549	Overview of drugs, diseases, and factors
5550	Logrank analysis for treatment and prognostic factors
5551	Regression analysis of chemoradiotherapy adjusted by prognostic factors and background chemotherapy and chemotherapy adjusted by prognostic factors and background chemoradiotherapy
5552	Age and anthropometric variables 3·5 years after discontinuation of intervention
5553	Differences between calcium-supplemented and placebo groups in standing height and L2–L4 height gains
5554	Differences between calcium-supplemented and placebo groups in lumbar spine bone mineral content
5555	Relative resistance of P falciparum DHFR genotypes to trimethoprim and pyrimethamine
5556	Effect of Lipid-Lowering Treatment on Lipid Profile
5557	Postoperative outcomes
5558	The effects of warming therapies compared with standard treatment
5559	Age-adjusted genotype-resistance index  (GRI)  and genotype-failure index  (GFI)  at three sites in Mali from 1997 to 1999
5560	Median pill-taking compliance and taking pills through first trimester of pregnancy among women who took folic acid by education and occupation
5561	Rates of miscarriages and crude and adjusted risks of miscarriage among women pregnant for the first time in Jiaxing city, according to the use of folic acid pills during pregnancy  *
5562	Regular follow-up, treatment, and symptoms during preceding 3 months
5563	Risks of food cooked or prepared outside the home by source and timing of exposure
5564	Quantitative angiographic data at angiographic follow-up, and target vessel revascularisation during the year after stent placement
5565	Odds ratios for treatment effect on angiographic restenosis and target vessel revascularisation in strata defined by C pneumoniae titres
5566	Patient treatment
5567	Diary data from last 3 days and last 7 days of each treatment period
5568	Outpatient antibiotic sales in 1997 in the European Union
5569	Odds ratios and 95= CIs of odds ratios for Cox regression with treatment groups, severity of oesophagitis at study entry, and sex as factors
5570	Rate ratios of prostate cancer according to fish consumption
5571	Resistance to other antimicrobials in sulphonamide-resistant and sulphonamide-susceptible E coli isolates
5572	Frequencies of sulI and sulII genes among E coli isolates in 1991 and 1999
5573	Main clinical features of neutropenic patients with S prolificans infection
5574	General features of Staphylococcus aureus N315 and Mu50 genomes
5575	Genes likely to have undergone horizontal transfer
5576	Antibiotic resistance genes identified in N315 and Mu50 genomes
5577	Known virulence genes and new candidates identified in N315 and Mu50 genomes
5578	Susceptibility results for linezolid-resistant VREF
5579	Total IgE antibodies, antigen-specific IgE antibodies, and skin-prick test reaction
5580	Distribution of 84 people with vCJD by standard region of residence on Jan 1, 1991
5581	Comparison of cumulative vCJD incidence between the north  *   and south  †   of Great Britain
5582	Regional variations in quantities of foods consumed per week from 1986 to 1987  *
5583	Regional variations in quantities of foods per week brought into the home from 1984 to 1986  *
5584	Hemodynamic Measurements at 56 Days After Infarction
5585	Summary of the effect of an increase of 2% energy in trans fatty-acid intake on coronary heart disease  *   reported in prospective studies
5586	Cell-wall-deficient blood-culture isolates from BMT recipients and their antibiotic-sensitivity patterns
5587	Details of diagnosis and other factors in patients with syncope and presyncope
5588	Results of autonomic tests in major groups of patients with chronic autonomic failure, vasovagal syncope, carotid sinus hypersensitivity, psychiatric comorbidity and no definitive diagnosis
5589	Cardiovascular Medication Taken at the Time of the Study
5590	Hemodynamic Parameters for the Three Groups at the Time of IVUS Study of the LAD
5591	Morphologic and Mechanical Properties of the Proximal LAD in the Three Groups
5592	Average K1 distribution volume  (mL/gm) , and Bmax/Kd of [C-11]raclopride of obese individuals and controls
5593	Regional brain metabolic measures  (mmol/100gm/min)  in obese individuals and controls
5594	Severity of index reactions  (before management)  and subsequent follow-up reactions in patients with peanut and nut allergy
5595	Treatment self-administered by patients who had a follow-up reaction
5596	Link between amount of nut eaten and severity of follow-up reaction
5597	Prevalence of other allergies in patients with peanut and tree nut allergy
5598	Comparison of severity of index and follow-up reactions in 88 patients
5599	Treatment administered in hospital for patients who had follow-up reactions
5600	Link between current asthma control and the severity of follow-up reactions
5601	t (11;18, q21;q21)  in H pylori eradication responsive and non-responsive gastric MALT lymphomas
5602	Susceptibility to ciprofloxacin for clinical isolates of N gonorrhoeae from 1991 to 1999
5603	Details of primary and health-care worker cases
5604	Absolute and relative risks of secondary meningococcal disease in health-care workers  (HCW)  and sensitivity analysis
5605	Tailored FEC doses
5606	FEC dose-modification schedule
5607	Number of patients receiving tailored FEC doses
5608	Number of patients experiencing grade 3 or 4 toxicity at any time during therapy
5609	Study population and response rates
5610	Concentrations of major mite and cat allergens in carpet and mattress dust samples at different times
5611	Odds ratios for exposure to indoor allergens at age 6 months and asthma at age 7 years
5612	Drugs taken by patients
5613	Renal disease in fluorspar mining and non-mining areas of Upper Weardale and local renal clinic
5614	Occupational silica exposure, and renal diagnosis of identified cases
5615	Occurrence of early  (during oral ganciclovir prophylaxis)  and late cytomegalovirus disease
5616	Inhaled and intravenous pharmacokinetic parameters
5617	Results of cortisol measurements as measure of effects on the hypothalamoic-pituitary-adrenal axis function
5618	Survival hazard ratios for experimental over bolus fluoropyrimidines  (control) , according to initial performance status and tumour response to treatment
5619	Plasma uracil concentrations before 18F-fluorouracil injection in each period
5620	Blood flow in spleen and tumour
5621	AUCs for time-activity curves
5622	Concentrations of selected dioxin congeners
5623	Birth and deaths before age 1 year and between 1 and 5 years
5624	Clinicopathological features of patients
5625	Univariate analysis of survival
5626	Univariate analysis of survival benefit from chemotherapy for tumour site and sex
5627	Correlation between house-dust endotoxin concentrations and proportions of T lymphocytes in peripheral blood expressing type 1 or type 2 cytokines
5628	Randomised trials of MAB vs AS in advanced prostate cancer
5629	Causes of death other than prostate cancer
5630	Number of patients who had taken oral, parenteral, nasal, or dermal corticosteroids in the past
5631	Effect of potential confounding factors on bone- mineral density at L2–L4 in univariate analysis
5632	Effect of a doubling in cumulative dose of inhaled corticosteroid on bone-mineral density at lumbar spine and proximal femur
5633	Cells received by patients
5634	Immune-cell populations 4 weeks after transplantation
5635	Risk factors for QTc lengthening
5636	Risk factors for QTc lengthening by logistic regression and backwards stepwise regression
5637	Antipsychotic dose and risk of QTc lengthening
5638	Number of trials  (patients)  by type and timing of chemotherapy in meta-analysis comparing locoregional treatment with and without chemotherapy
5639	Meta-analysis of locoregional treatment with and without chemotherapy: effect on survival
5640	Randomised trials comparing neoadjuvant combination of cisplatin  (C)  and fluorouracil  (F)  followed by radiotherapy in responders or by radical surgery plus radiotherapy in non-responders  (arm 1)  with radical surgery plus radiotherapy  (arm 2)
5641	Larynx preservation: patients' status for disease-free Survival
5642	Quantitative Coronary Angiographic and Coronary Blood Flow Velocity Data of the Patients With an Optimal and Suboptimal Result After Balloon Angioplasty
5643	Frequency of Major Adverse Cardiac Events
5644	Number of isolates collected from each hospital during 3 years
5645	Code below as a table
5646	Effect of treatment with folic acid plus vitamin B6 on occurrence of abnormal test results
5647	Effect of 2-year treatment with folic acid plus vitamin B6 on main outcome variables in 158 healthy individuals
5648	Geometric mean  (approximate SD)  homocysteine concentrations  (μmol/L)  in cases and controls, for Europeans and Asians separately
5649	Percentage difference in homocysteine concentrations between cases and controls, for Europeans and Indian Asians separately
5650	Percentage difference in homocysteine concentrations, for controls alone, in Indian Asians compared with Europeans
5651	Deaths from CHD attributable to elevated homocysteine concentrations in Europeans and Indian Asians
5652	Proportions of eligible cases and controls interviewed by age, sex, and current residence
5653	Association of hip fracture with potentially confounding variables
5654	Lifetime exposure of study participants  (cases and controls combined)  to fluoride in drinking water according to current residence
5655	Associations of hip fracture with exposure to fluoride in drinking water
5656	Casein, β-lactoglobulin, and mTG in samples of salmon/mean  (SD)
5657	Risk factors
5658	Strongest risk factors for acute coronary events in conditional multivariate logistic regression models
5659	Mean  (SE)  blood pressure and serum lipid concentrations in quarters of distribution of serum enterolactone concentrations from ANOVA
5660	Final mortality results in three heart-failure trials with negative trends
5661	Results for two cancer prevention trials of β-carotene
5662	Dose response for HFA and CFC formulations
5663	Antimicrobial activity in the urine as detected by Bacillus stearothermophilus, Streptococcus pyogenes and Escherichia coli
5664	Number of serum folate tests, rate of testing, number and per-centage of test results <2·7 μg/L, and ≥20 μg/L, and medi-an serum folate value, 1994–98
5665	Endocervical microbial flora cultures from the mock ET and ET catheter tips
5666	Embryology events, implantation and clinical pregnancy rates
5667	Mean Segmental TRin Healthy Volunteers  (CONTROL Group)
5668	Overall efficacy profile of n-3 PUFA treatment
5669	Overall efficacy profile of vitamin E treatment
5670	Overall efficacy profile of n-3 PUFA plus vitamin E treatment
5671	Abnormal laboratory and clinical findings and toxic effects  (WHO grade ≥3)
5672	Status of patients at median follow-up of 72 months
5673	Types of recurrence
5674	Birth rates, death rates, and net migration rates
5675	Primary source of food by year
5676	Hemodynamic Responses to Dobutamine
5677	Neurochemical Responses to Dobutamine
5678	Signs of atopy according to clinical examination, skin- prick test, and blood tests in children from Steiner schools and control schools
5679	Odds ratios for atopy  (95% CI)  associated with exposure to factors typical for children in Steiner schools, plus heredity and sex
5680	Clinical syndromes in 314 patients with pneumococcal infection
5681	Antimicrobial susceptibility test results of S pneumoniae isolates
5682	Distribution of serotypes by age-group
5683	Distribution of serotypes from blood and CSF
5684	Relative risk of cancer by quintile of total heterocyclic amine intake
5685	Relative risk of cancer by quintile of estimated intake of the five heterocyclic amines studied
5686	Relative risk of cancer by quintile of total meat and fish intake
5687	STD prevalence/symptoms at round 1  (before intervention)  and rounds 2, 3  (follow-up)  intention-to-treat cohort
5688	Incidence rates of HIV-1 infection and rate ratios
5689	STD prevalence at delivery in mother and infant study
5690	Distribution of population and of observed and expected numbers of cases of variant CJD living within specified distances of 52 plants rendering bovine material in 1988
5691	Cases of variant CJD and distance from plants rendering bovine material in 1988
5692	Serological and molecular typing and presence of prtF1 gene in strains recovered from patients with eradication-failure
5693	Systolic Blood Pressure, Left Ventricular Weight and Echocardiographic Variables at the Left Ventricular Hypertrophy and Congestive Heart Failure Stages
5694	Serum Hormone Measurements
5695	Skeletal Muscle Mass and Function
5696	Mortality risk according to alcohol intake
5697	Mortality risk according to alcohol intake and age-group
5698	Effects of Vitamin Supplementation on Cytokine and Adhesion Molecule Parameters in Normal Subjects and Type 2 Diabetic Patients
5699	Antibiotic regimens and intestinal colonisation with Oxalobacter formigenes in CF patients
5700	Urine analyses of CF patients
5701	Availability of data from randomised trials that began before 1990 of prolonged polychemotherapy
5702	Clinical findings related to 102 cases of sutama in February, 1997
5703	Serological cross-reactivity between sutama-patient serum and R prowazekii and R typhii antigens before and after adsorption tests
5704	Nationwide surveillance and serological findings among sutama patients between January and September, 1997
5705	Comparison of attack rates and death rates for sutama among inmates of three jails in Burundi
5706	Failure of therapy
5707	Predictors of therapy failure by multivariate analysis
5708	Therapy failures among bacteraemic children by treatment allocation, drug sensitivity of isolate, and species isolated
5709	Status of IUD 90 days after insertion
5710	Clinic visits for gynaecological care within 90 days of IUDinsertion
5711	Univariate matched analysis of food-exposure variables
5712	Univariate matched analysis of animal and other exposure variables
5713	Conditional logistic regression analysis
5714	Quinolone resistance  (MIC μg/mL)  in K pneumoniae, E coli, and P aeruginosa
5715	Mutation frequency
5716	Quinolone susceptibility  (MIC μg/mL)  of E coliJ53 pMG252 ciprofloxacin-resistant mutants
5717	Reasons for exclusion before randomisation
5718	Clinicians' final diagnoses and patterns of antibiotic use
5719	Management at initial consultation, and subsequent use of health facilities
5720	Clinical Data of the Patients
5721	Metabolite Contents
5722	Clinical and Angiographic Data on 45 Patients
5723	Means and 95% Upper Limits for Raw, Height-Adjusted, and BSA-Adjusted LV Variables
5724	Grading Scale of the Contractile Proteins *
5725	Proportion of patients free from relapses at different time points
5726	Annualised relapse rate, expanded disability status scale  (EDSS)  score at end of study, and number of patients with EDSS score progression during the study
5727	Outcomes of magnetic resonance imaging  (MRI)  at different time points
5728	Adverse events
5729	Data on kidneys and ureters for all patients
5730	Outcome for glomerular filtration rate  (GFR)  at 4 and 10 years' follow-up
5731	Outcome at 6 months
5732	Intended and actual amount of therapy
5733	Primary outcomes
5734	Secondary outcomes
5735	Site of first recurrence by treatment
5736	Effect of radiotherapy on disease-free survival and overall survival
5737	Frequency and localisation of local recurrences by treatment
5738	Cox's proportional hazards models by time periods since surgery
5739	Cox's proportional hazard model by time periods since surgery
5740	Numbers of patients on various DMARDs and glucocorticoid use, and median dose of drugs during study
5741	Number of patients who had adverse events during the trial
5742	Logistic-regression analysis for the odds to reach remission after 2 years of treatment
5743	Effects of Atorvastatin Therapy on Lipids and Glucose
5744	Clinical endpoints
5745	Time in months to confirmed progression in disability
5746	Adverse events  (% of patients)  in first 3 months of therapy
5747	Clinical features of nine patients with pulmonary hypertension
5748	Results of echocardiography in all patients
5749	Clinical disability according to EDSS score
5750	Acute relapses
5751	Withdrawals and adverse events
5752	Health-related goals, targets, and health-related SDG indicators used in the present analysis and further details regarding any indicator modifications, and inclusion in the health-related MDG index or health-related non-MDG index
5753	Health-related SDG goals and targets proposed by the Inter-Agency and Expert Group on SDG Indicators, and health-related SDG indicators used in this analysis
5754	Health-related SDG indicators  (proposed by the Inter-Agency and Expert Group on SDG Indicators)  excluded in the present analysis, and measurement needs and strategy for future reporting, by SDG target
5755	Performance of health-related SDG indicators across all countries, 2015
5756	Serious adverse events
5757	Efficacy outcomes from the pooled data
5758	NIHSS score
5759	Safety outcomes at 90 days
5760	Treatment-emergent adverse events  (MedDRA HLT or PT)  occurring in 5% or more of patients in the placebo or combined dupilumab doses groups  *
5761	Causes of death
5762	Frequency of cancers other than breast cancer
5763	Adverse events of any severity reported at any time
5764	Definitions
5765	Change in daily prednisolone dose before and after randomisation, by group
5766	Adverse events
5767	Grade 3–4 adverse events
5768	Blood concentrations of rituximab
5769	Country-specific birthweight percentiles and prevalence of birthweight 4000 g and greater, maternal obesity, and diabetes
5770	Risk factors for macrosomia
5771	Risk of caesarean section by birthweight percentile
5772	Indication for caesarean section by birthweight in primiparous and multiparous mothers who underwent caesarean section
5773	Risk for maternal and perinatal morbidity and mortality by birthweight percentile
5774	Results of secondary efficacy analysis
5775	Safety results
5776	Adverse effects
5777	Efficacy analysis for gabapentin versus placebo in the treatment of refractory chronic cough
5778	LCQ score according to presence of central sensitisation of the cough reflex
5779	Effect of HP802-247 on wound area and wound closure
5780	Adverse events reported by at least 3% of patients
5781	Exposure to violence perpetrated by occupation forces or settlers in 2005
5782	Odds ratios  (95% CIs)  of intimate partner violence by type of political violence exposure in separate adjusted  *   multinomial regression models
5783	Odds ratios  (95% CIs)  of intimate partner violence by political violence exposures modelled simultaneously in adjusted  †   multinomial regression model
5784	Non-surgical treatments received in kyphoplasty and non-surgical care groups
5785	Patients with adverse events in the kyphoplasty and non-surgical care groups
5786	Thrombotic events
5787	Thrombotic events in secondary randomised comparisons
5788	Disease-specific outcomes by randomisation group
5789	Self-reported benefit, compliance, and frequency of use of health service resources by randomisation group
5790	Association between two single nucleotide polymorphisms and bone mineral density at lumbar spine
5791	Effect of both single nucleotide polymorphisms on bone mineral density at lumbar spine, osteoporotic fracture, and osteoporosis
5792	Digoxin Dosages and Corresponding SDCs in the Study Treatment Groups
5793	Risk of Treatment Failure Based on Randomization SDC Group
5794	Cancer risk factors, exposure variables, theoretical-minimum-risk exposure distributions, disease outcomes  *
5795	Individual and joint contributions of risk factors in  table 1  to mortality from site-specific cancers
5796	Total cancer deaths  (thousands)  by age and cancer site
5797	Survival and progression-free survival
5798	Association between TPE response and pathological pattern of multiple sclerosis, expanded disability status scale score, and neurological deficit
5799	Vaccine efficacy against first episode of radiological pneumonia  (per-protocol analysis)
5800	Vaccine efficacy against first episode of clinical or severe clinical pneumonia  (per-protocol analysis)
5801	Vaccine efficacy against first episode of invasive pneumococcal disease  (per-protocol analysis)
5802	Vaccine efficacy against first admission and all-cause mortality  (per-protocol analysis)
5803	Number of consultations, with primary diagnoses, in the week after every dose of vaccine or placebo  (intention-to-treat analysis)
5804	Degree of symptomatic carotid stenosis stratified according to subgroup variables  *
5805	Relation between subgroup variables and risk of each main element of the primary outcome measure
5806	Significance of treatment-effect modifiers for relative and absolute treatment effect for subgroup variables
5807	Estimated yearly atrophy rates according to time and method of measurement of atrophy
5808	Rate ratios  (n)  of cerebral palsy by Z-score band in gestational age-groups with use of conventional and fetal growth standards
5809	Main familial tumour syndromes associated with gliomas
5810	Effects of adjuvant CT in patients with primary CNS lymphoma treated with or without whole-brain radiotherapy
5811	Temporal relation between onset of cytomegalovirus reactivation during lactation and symptomatic primary infection of preterm infants
5812	Discordant HCMV transmission to twins during lactation
5813	Antibodies to neuronal antigens in cerebellar syndromes   Sera were screened by routine immunohistochemistry on frozen sections of rat cerebellum and positive staining patterns1 were confirmed, as appropriate, by western blotting on rat cerebellar extracts or recombinant Hu or Yo polypeptides. VGCC antibodies were measured by immunoprecipitation of 125I-ω-conotoxin MVIIC-labelled VGCCs extracted from human cerebellum,  2   and antibodies to glutamic acid decarboxylase measured with a commercial kit  (RSR Ltd, Cardiff, UK) .
5814	Fetal death in same-sex twins and different-sex twins  (1993–95)
5815	Cerebral palsy in live-born twins of same-sex stillborn co-twins and different-sex stillborn co-twins
5816	Cerebral impairments in live-born twin of same-sex stillborn co-twin, and different-sex stillborn co-twin
5817	Gestational-age specific cerebral palsy prevalence rates
5818	MRI diagnoses by suspected type of CJD
5819	Estimates of the sensitivity of radiological diagnosis of vCJD by different MRI criteria for positivity
5820	Neuroradiological assessment of MRI from 36 histologically confirmed cases of vCJD
5821	Patients' severity of illness scores, haemodynamics, biological data and treatments at inclusion
5822	Comparison of iNOS activity between tissues and degrees of infection
5823	Comparison of TNFα concentrations between tissues and degrees of infection
5824	Comparison of IL-1β concentrations between tissues and degrees of infection
5825	Virological studies on 21 patients with neurological manifestations of dengue infection
5826	Clinical features
5827	Distribution of deprivation index
5828	Distribution of cases and controls by age, sex, deprivation index, and diagnosis of case
5829	Distribution of exposure by age and deprivation status among cases and controls
5830	Odds ratios for acute lymphoblastic leukaemia, all leukaemia, cancers of the central nervous system, and other malignant disease by exposure
5831	Estimated exposure before and after adjustment for historical line-load data, among those with relevant external-source questionnaires, for cases and controls
5832	Clinical manifestations and outcome of EV71 infection in patients with pulmonary oedema
5833	Factors significantly associated with CNS involvement without pulmonary oedema
5834	Factors significantly associated with pulmonary oedema
5835	Hendra IgM antibodies and results of viral culture
5836	Summary of presenting symptoms, signs, and investigations
5837	Correlation Coefficients  (Pearson’s R2Values)  Comparing Selected Vascular Blood Flow Parameters With Indices of Plasma RAS Activation
5838	Summary of therapy directed at central nervous system for patients who received prophylactic irradiation on Total protocols X, XI, and XII
5839	Relation between parasite count and a in cultured parasites
5840	Cellular distribution of complexin mRNAs in human hippocampus and cerebellum
5841	Complexin mRNAs in schizophrenia
5842	Complexin proteins in schizophrenia
5843	Mean  (range)  values for MDMA use
5844	Mean  (SE)  values of injected doses
5845	Clinical and laboratory data
5846	Increases in blood flow during an induced attack of acute cluster headache compared with the pain-free state
5847	Unadjusted proportion of participants with chronic disease, symptoms, and poor quality of life by action level
5848	Odds ratios  (95% CI)  for chronic disease, symptoms, and poor quality of life with reference to action level 1, adjusted for age, smoking, alcohol consumption, education and physical activity, and for quality of life, employment status, household
5849	Notch3 mutations in CADASIL patients
5850	Polymorphisms in Notch3 coding sequence
5851	Haplotype analysis in families with recurrent Notch3 mutations
5852	Logistic regression of association between PCR result of virus detection in CSF nd clinical features in Oxford cohort
5853	Correlation of PCR result with clinical classification of viral infection of the CNS
5854	SDNN, RMSSD, pNN50, QRS, QRSd, QTd and QTcd: Comparison Between Patients With and Without Arrhythmias
5855	MIBG Scintigraphy Results: Comparison Between Patients Operated On and the Control Group
5856	Sensitivity and specificity of the EITB with HAMA  *
5857	MIBG Scintigraphy Results: Analysis of the Operated Patients With and Without Arrhythmias
5858	Correlations Between Scintigraphic and HRV Data  (16 patients)
5859	Mean  (SE)  concentration of serum GH, plasma, GHRH, and plasma noreprephrine before and after clonidine infusion
5860	Blood clearance of mannose-terminated glucocerebrosidase  (mt-GCR)
5861	Clearance of 123I-mt-GCR from liver and spleen over a 48 h period
5862	Estimated number of patients diagnosed with an index cancer worldwide each year around 2012
5863	Definition of malignancies and number of contributing countries and registries by calendar period of diagnosis
5864	Data quality indicators: patients diagnosed during 2000–14 by continent and country
5865	Population covered by participating registries  (number of people and percentage of national population)  and number of adults diagnosed with cancer of the oesophagus, stomach, colon, rectum, liver, pancreas, or lung, or melanoma of the skin during 2000–14 by continent and country
5866	Population covered by participating registries  (number of people and percentage of national population)  and number of patients diagnosed with cancer of the breast  (women) , cervix, ovary, prostate, or brain, or myeloid or lymphoid malignancies  (adults) , and brain, acute lymphoblastic leukaemia, or lymphoma  (children)  during 2000–14 by continent and country
5867	Age-standardised 5-year net survival  (%)  with 95% CI: adults  (15–99 years)  diagnosed with one of eight common malignancies  (oesophagus, stomach, colon, rectum, liver, pancreas, lung, or melanoma of the skin)  by continent, country, and calendar period of diagnosis
5868	Age-standardised 5-year net survival  (%)  with 95% CI: adults  (15–99 years)  diagnosed with one of seven common malignancies  (breast, cervix, ovary, prostate, brain, myeloid, and lymphoid)  and children  (0–14 years)  diagnosed with one of three common malignancies  (brain, acute lymphoblastic leukaemia, and lymphoma)  by continent, country, and calendar period of diagnosis
5869	Summary results of primary and secondary endpoints
5870	Summary of SAEs
5871	Risk of adverse events of interest
5872	Rates of all adverse events, stratified by system organ classification, in the blinded randomised phase
5873	Rates of all adverse events, stratified by system organ classification, in the non-blinded non-randomised phase
5874	Competing-risk model for disease complications and early anti-TNFα comparative effectiveness analysis
5875	Competing-risk model including extracellular matrix gene signature
5876	Number of deaths and person-years in the 2001 Spanish Census Cohort of people aged 10–74 years, by indicators of household wealth and calendar year
5877	Comparison of time trends in premature mortality before and during the 2008 economic crisis, by cause of death  (ICD-10 code  *  )  and socioeconomic group according to household space in the 2001 Spanish Census Cohort of people aged 10–74 years
5878	Comparison of time trends in premature mortality before and during the 2008 economic crisis, by cause of death  (ICD-10)   *   and socioeconomic groups  †   and household car ownership, in the 2001 Spanish Census Cohort of people aged 10–74 years
5879	Comparison of time trends in all-cause premature mortality before and during the 2008 economic crisis, by two indicators of household wealth  *   and sex and age group  †  , in the 2001 Spanish Census Cohort of people aged 10–74 years
5880	Percentage of patients in the intention-to-treat population fulfilling response criteria
5881	Adverse reactions deemed by investigator to be possibly, probably, or definitely related to treatment
5882	Health-care costs and QALYs over 12 months
5883	Intraoperative data and early postoperative complications within 6 months of surgery
5884	Causes of small bowel obstruction
5885	Multivariable logistic regression analysis for the effect of treatment on the primary endpoint  (ACR20 at 48 weeks post randomisation)
5886	Univariable analysis  (χ 2 test of independence)  for the proportion of patients in the evaluable patient population achieving a response at 48 weeks post randomisation for the key secondary endpoints
5887	Intrasubject and Intersubject Variabilities and Reproducibilities
5888	Primary outcome at 6 months
5889	Mortality at 6 months
5890	Thrombotic events and adverse events
5891	Efficacy outcomes
5892	Adverse events
5893	Estimated average differences between levodopa and levodopa-sparing groups, and between dopamine agonist and MAOBI, in the different PDQ-39 subscales and in EQ-5D utility score
5894	Adverse events possibly or probably related to study drug, by dose group
5895	Adverse events overview
5896	Anti-phenylalanine ammonia lyase antibody response, by dose group
5897	Anti-polyethylene glycol antibody response, by dose group
5898	Summary of efficacy parameters
5899	Total and specific treatment-emergent adverse events reported by at least 3% of patients in either treatment group
5900	Comparison of the efficacy of EMA401 versus that of approved postherpetic neuralgia treatments
5901	Site of first disease-free survival event
5902	Adverse events  (safety populations)
5903	Types of diseases and surgical procedures in patients undergoing upper gastrointestinal surgery
5904	Types of diseases and surgical procedures in patients undergoing lower gastrointestinal surgery
5905	Primary outcome and its components in modified intention-to-treat population
5906	Secondary outcomes in the modified intention-to-treat population
5907	Emergent mutations in participants who had virological failure
5908	Safety results: deaths, serious adverse events, and adverse events
5909	Serious adverse events
5910	Primary outcome measures at 52 weeks, stratified by dementia status at randomisation
5911	Treatment-related adverse events of grade 2 or higher reported in at least 5% of patients by dose
5912	Primary outcomes of research worker rated CSDD score
5913	Comparisons of secondary participant and carer outcomes and depression severity
5914	Adverse reactions definite, probable, and possibly related to study intervention by week 39
5915	Overview of the locus, gene, and function of definite and probable genetic risk factors for ankylosing spondylitis
5916	Pooled analysis of the effect of allocation to aspirin on risk of death due to cancer during the seven trials from which individual patient data were available,  17–21,23,24   stratified by type of primary tumour and period of follow-up
5917	Pooled analysis of the effect of allocation to aspirin on the 20-year risk of death due to cancer during and after the trial treatment periods in the 10 502 patients with scheduled treatment duration of 5 years or longer in the three trials with long-term follow-up,  17–19   stratified by type of primary tumour and period of follow-up
5918	Effects on primary and major secondary endpoints
5919	Incidence of relevant serious adverse events during the study by system organ class
5920	Selected adverse events and those leading to definitive withdrawal of study drug
5921	Efficacy of pentavalent rotavirus vaccine for prevention of rotavirus gastroenteritis and gastroenteritis for complete follow-up in Africa
5922	Efficacy of the pentavalent rotavirus vaccine for prevention of severe rotavirus gastroenteritis  (Vesikari score ≥11)  in Africa by country and follow-up period
5923	Antirotavirus IgA and SNA seroresponse rates and geometric mean titres after the third dose in recipients of pentavalent rotavirus vaccine and placebo in the immunogenicity subset  *
5924	Serious adverse events 1–14 days after any dose of pentavalent rotavirus vaccine or placebo
5925	Dose conversion for inhaled insulin to rapid-acting insulin analogue
5926	Treatment-emergent adverse events  (safety population)
5927	Hypoglycaemia incidence and event rate  (safety population)
5928	Severe hypoglycaemia event rates by time of the day  (safety population)
5929	Recurrence and survival  (all patients) , after a median follow-up of 45 months
5930	Recurrence and survival for patients at true high-intermediate risk after pathology review  (n=366)
5931	Design and eligibility criteria of primary prevention trials
5932	Comparison of proportional and absolute effects of aspirin in primary and secondary prevention trials
5933	Rate ratios  (95% CI)  associated with risk factors for selected outcomes in people with no known vascular disease in primary prevention trials
5934	Inclusion and exclusion of the study participants who underwent randomisation
5935	Incidence of events for efficacy analysis
5936	Safety outcomes
5937	Admission risk markers for GBS  5
5938	Endoscopic findings in phase one, by GBS
5939	Comparison of GBS and admission and full Rockall scores for prediction of intervention or death across the four study sites
5940	Comparison of data before and after introduction of GBS low-risk criteria into clinical practice
5941	Vaccine efficacy against any and severe rotavirus gastroenteritis, admission, and medical attention  (according-to-protocol cohort)
5942	Vaccine efficacy against any and severe rotavirus gastroenteritis according to detected rotavirus G types  (according-to-protocol cohort)
5943	Vaccine efficacy against all-cause severe gastroenteritis and admission  (according-to-protocol cohort for efficacy)
5944	Incidence of venous thromboembolic events up to day 14 in the efficacy group
5945	Occurrence of venous thromboembolism  (VTE)  and deep vein thrombosis  (DVT)  according to National Institutes of Health Stroke Scale  (NIHSS)
5946	Occurrence of haemorrhage according to National Institutes of Health Stroke Scale  (NIHSS)
5947	Safety outcomes
5948	Effect of treatment on primary and secondary outcomes  15
5949	Clinical and laboratory evidence of safety of fenofibrate
5950	Efficacy of treatment
5951	Secondary outcomes
5952	Morbidity and survival
5953	Vaccine efficacy for incident HPV-16/18 infections
5954	Vaccine efficacy for persistent HPV16/18 infections
5955	Vaccine efficacy in preventing cytological abnormalities associated with HPV-16/18 infection  (intention-to-treat cohort)
5956	Timeline of virological, cytological, and histological findings among the seven women with HPV-/-associated abnormal cytology that was histologically confirmed as CIN  (intention-to-treat cohort)
5957	Adverse events after any vaccine dose in according-to-protocol cohort for safety
5958	Anti-HPV antibody response to HPV-16 and HPV-18 virus-like particles  (according-to-protocol cohort)
5959	Response classified by underlying cause
5960	Adverse events reported during first 14 days of study
5961	Numbers of fractures in the olpadronate and placebo groups
5962	Clinical features of patients with MADH4 mutations
5963	Features of previously reported juvenile polyposis patients with associated hereditary haemorrhagic telangiectasia phenotypes
5964	Cox proportional-hazards models
5965	Adverse events in 553 patients  (safety population)
5966	Secondary endpoints
5967	Endpoints of PROSPER
5968	Incidence of primary end point, according to subgroup
5969	First new cancer diagnoses by site and year
5970	Outcomes in the two study groups
5971	Per protocol analysis
5972	Most relevant side-effects  (grade 2 and 3)  during first 8 weeks, dose reductions, and dose intensity
5973	Duration and severity of illness in intention-to-treat population and influenza-infected patients
5974	Effect of oseltamivir treatment on antibiotic use
5975	Concomitant drug treatments
5976	Figures, hazard ratios and p-values for the study cumulative endpoints and individual components
5977	Summary of adverse events
5978	Event rate in patients taking β-blockers with or without diltiazem
5979	Macronutrient composition per L and fatty acid composition of standard and supplemented study formula as percentage of total fat
5980	Withdrawals in the randomised trial because of adverse events
5981	Developmental outcomes in the randomised trial at 9 months
5982	Formula tolerance and intake in randomised trial
5983	Growth of infants in the randomised trial during the intervention period and throughout follow-up
5984	Exploratory analysis on infection-related events arising up to 9 months in the course of the randomised trial
5985	Comparison of adjusted developmental and growth outcomes at 9 months and 18 months in formula roups with reference breastfeeding groups
5986	Effect of raw and cooked parent, parent+GNA, and GNA+GM potatoes on histological indices of rat gut
5987	GNA binding to the jejunum and ileum of rats given diets containing GNA-GM potatoes or parent potato diets spiked with GNA
5988	Incidence  (per 100 000, 95% CI)  of inflammatory bowel disease among individuals below 17 years of age in northern Stockholm, Sweden, 1990–98
5989	Effect of Placebo, Quinapril and Losartan on Plasma t-PA Antigen and Activity Concentrations in the Infused and Noninfused Forearms During Substance P, Sodium Nitroprusside and Bradykinin Infusion
5990	Incidence of PCP
5991	Risk of developing PCP
5992	Primary, secondary, and further endpoints
5993	Subgroup analysis, stratified by onset-to-treatment interval  (analyses of patients who actually received treatment)
5994	Cases of intracranial haemorrhage up to day 7 in patients who actually received treatment
5995	Adverse events during initial curative treatment and chemosuppression
5996	Percentage predictive efficacy of treatment
5997	Clinical profile of 12 cases of influenza A subtype H5N1 infection
5998	Risk factors associated with severe disease requiring intensive care and ventilatory support
5999	Clinical and laboratory data at randomisation
6000	Rate of and reasons for treatment failure
6001	Adverse events during infusion period
6002	Number of live births per neonatal screening period by team
6003	Neonatal screening by location and risk categories and presence of individual risk factors
6004	Percentage of babies not given neonatal screening during screening periods two, three, and four by annual birth rate, hospital, and cause
6005	Numbers of babies by severity of PCHI in periods with and without neonatal screening by risk status, source of referral, and age distribution at stages of management
6006	Comparison of periods with and without neonatal screening by increment in yield and relative risk of yield of PCHI
6007	Contraindications to warfarin therapy among patients with AF
6008	Risk factors for stroke among patients with AF
6009	Proportion of patients with AF eligible for anticoagulation and those anticoagulated by risk classification
6010	Proportions of patients with AF with irreversible contraindications, and with reversible contraindications and clinical and echocardiographic risk factors
6011	Symptoms of people examined
6012	Experimental neuropsychological measures at time 1
6013	Change scores on experimental neuropsychological measures
6014	Experimental neuropsychological measures at time 2
6015	Risk factor exposures for C psittaciamong cases and controls
6016	Number of study participants who mowed lawns by sex
6017	Serological results for cases
6018	Details of probands with their affected offspring
6019	Recurrence data by defect category
6020	Risks to siblings and offspring
6021	Risk for ovarian cancer by use of over-the-counter or prescription analgesics
6022	Risk for ovarian cancer by features of used paracetamol
6023	Odds ratio for paracetamol use and various histological types and grades of ovarian cancer
6024	Univariate logistic regression analysis
6025	Accuracy of BNP  (cut-off 17·9 pg/mL)  in detection of left-ventricular systolic dysfunction
6026	Results of multivariate logistic regression analysis
6027	Diagnostic value of natriuretic peptides in detecting heart failure when negative predictive value is 98%
6028	Prediction of presence of heart failure in logistic regression analyses of 106 referred patients for whom concentrations of all three natriuretic peptides were available
6029	Prediction of presence of heart failure in logistic regression analyses of 96 referred patients for whom cardiothoracic ratio  (CTR)  and BNP concentration were available
6030	Presence of ICA and GADA at different ages of diagnosis
6031	Association of ICA with different concentrations of GADA by age-group
6032	Sensitivity, specificity, and positive predictive value of ICA and GADA measurements for insulin requirement by 6 years
6033	Stepwise logistic regression analysis of contribution of clinical variables, ICA and GADA in prediction of insulin requirement
6034	Pacemaker complications necessitating reoperation
6035	Causes of death
6036	Multivariate Cox proportional hazard regression analysis of clinical variables evaluated as risk factors for evelopment of death, thromboembolic events, and chronic atrial fibrillation during follow-up
6037	Association between thromboembolism, brady-tachy syndrome at randomisation, and atrial fibrillation during follow-up
6038	Fractures that occurred during treatment period
6039	Selection of children with early BCG vaccination and controls
6040	Signs of atopy according to clinical examination, SPT, and serological tests in children with early BCG vaccination and controls
6041	Clinical and histological features of four women with unclassified coeliac disease
6042	Serological pattern of four women with unclassified coeliac disease
6043	Clinical characterisrics of 171 consecutive CHF patients
6044	Univariate analysis—predictors of 18-month mortality in 171 patients with CHF  (Cox proportional hazard)
6045	Multivariate analysis—predictors of 18-month mortality in 171 patients with CHF  (Cox proportional hazard)
6046	Tissue-factor antigen concentrations and activity
6047	Primary and secondary events according to assigned therapy number  (event rate per patient year)
6048	Association between genotypes of proteases on chromosome 14 and atopic diseases
6049	Clinical details of participants
6050	Core Laboratory Quantitative Coronary Angiography Data
6051	Odds Ratios for In-Stent Restenosis at Follow-Up Angiography
6052	Availability of individual and classes of medications among all primary health-care sites
6053	Distribution of the annual number of safe, less-safe, and least-safe abortions by UN DESA, Population Division region for the period 2010–14
6054	Distribution of abortion safety categories for countries grouped by legal status and income level
6055	Outcome of treatment of incomplete abortion by provider
6056	Reported secondary outcomes
6057	Ambulatory, home, and office blood pressure measurements at randomisation and after 6 months follow-up in the renal denervation and control group  (modified intention-to-treat population)
6058	Efficacy of CYD-TDV vaccination against symptomatic, virologically-confirmed dengue due to any serotype
6059	Serotype-specific vaccine efficacy against symptomatic, virologically-confirmed dengue  (VCD) , irrespective of protocol deviations
6060	Correlation coefficient  (r)  between pretransplantation parameters and DLCO before or after transplantation
6061	Effect of cardiac function and sex on lung and skin disease in patients with systemic sclerosis
6062	Echocardiogram, right heart cardiac catheter parameters before and after fluid challenge, and cardiac MRI in 12 consecutive patients with systemic sclerosis referred for HSCT
6063	Quality of life by SF-36 before and after HSCT
6064	Serotype-specific and overall efficacy of CYD tetravalent dengue vaccine against virologically confirmed dengue disease
6065	Summary of all reported SAEs and of AEs reported in the reactogenicity subset after at least one injection
6066	Summary of dengue episodes classified as severe according to independent data monitoring committee or WHO 1997 classifications  20
6067	Skin and pulmonary function results
6068	Quality of life
6069	Main histological features of chronic pancreatitis subtypes  (at diagnosis in stable disease)
6070	Absolute blood pressure at each visit and adjusted differences between the reductions on each initial treatment regimen
6071	Number of responders in each treatment regimen and their comparison with combination therapy
6072	Adverse events and laboratory abnormalities
6073	Primary and secondary outcomes
6074	Hazard ratios  (top vs bottom quintile)  for risk of subsequent stroke  (ie, after the measurement period)  in the UK-TIA trial from a model combining mean SBP and visit-to-visit variability in SBP  (SD or CV or VIM) , repeated with increasingly precise estimates of both variables
6075	Blood-pressure parameters and their predictive values  (HRs and 95% CI for risk of stroke in the top vs bottom decile of each measure)  in the four independent cohorts of patients with TIA and minor stroke
6076	Rates of virological failure, mortality, and admission by group
6077	Diagnoses at first admission after start of antiretroviral therapy
6078	Frequency of outpatient attendance overall and in which a physician was seen and a new clinical disorder diagnosed
6079	Distribution of drug substitutions to first-line regimens according to initial regimen
6080	Costs of health-service delivery and costs incurred by patients to access care  (in US$)
6081	Kaplan-Meier estimates of the time from meeting the criteria for switch based on viral load >500 copies per mL to meeting the criteria for the other monitoring strategies
6082	Predicted outcomes of monitoring strategies at 5, 10, and 20 years from start of antiretroviral treatment
6083	Life years, discounted costs over 20 years, and incremental increases for each strategy
6084	Univariate comparison of S pneumoniae infections that were susceptible or not susceptible to levofloxacin isolated from children aged under 15 years in South Africa between 2000 and 2006  (nationwide surveillance)
6085	Univariate comparison of S pneumoniae infections that were susceptible or not susceptible to levofloxacin isolated from children aged under 15 years in South Africa between 2003 and 2006  (enhanced sentinel surveillance)   *
6086	Phenotypic and genotypic characterisation of levofloxacin-non-susceptible pneumococci causing invasive disease in children under age 15 years in South Africa, 2000–06
6087	Mortality in HIV-infected adults during co-trimoxazole prophylaxis and antiretroviral therapy  (ART)  in Tororo and Busia Districts, Uganda, 2001–05
6088	Hospital admissions in HIV-infected adults during co-trimoxazole prophylaxis and antiretroviral therapy  (ART)  in Tororo and Busia Districts, Uganda, 2001–05
6089	Study design
6090	Risk of HIV transmission and death among infants at 6 weeks and 6 months by study regimen and country  (modified intention-to-treat population)
6091	Risk ratios for HIV transmission, death, and HIV transmission or death in the full intention-to-treat population
6092	Infants with grade 3 and 4 adverse events  (modified intention-to-treat population)
6093	Outcomes of treatment by treatment group  *
6094	Relative risk of failure to achieve complete abortion and failure to terminate pregnancy  †
6095	Women with pregnancy-related symptoms and side-effects related to the abortion process, listed by group at different timings
6096	Complications by country and provider
6097	Number  (%)  of women reporting adverse symptoms from follow-up interviews at the clinic, by telephone, or a home visit, by country and provider, excluding women with confirmed complications
6098	Estimates of hospitalisation rates from induced abortion complications from 13 countries, 1989–2003
6099	Estimates of number of women admitted to hospital for induced abortion complications each year in developing world regions and subregions, 2005
6100	Relative risks of clinical events for primary and secondary prevention with selected drugs
6101	Region-based costs of cardiovascular disease interventions
6102	Lifetime risk of death from cardiovascular disease according to regimen strategies  *   for World Bank regions
6103	Incremental cost-effectiveness ratios  ($/QALY)  for treatment regimens compared with no treatment
6104	Recommendations for initiating ART on the basis of immunological and clinical stage
6105	Age-specific CD4-cell threshold for defining severe immunodeficiency
6106	Plasma viraemia of non-human primates after challenge with MARV and treatment with rVSV vectors
6107	Serological response profiles of MARV infection after treatment with VSVΔG/MARVGP vectors
6108	Effectiveness of single dose live-attenuated Japanese encephalitis vaccine  (SA14-14-2)
6109	In-trial associations between accumulated mean concentrations of selected variables and coronary and stroke events  (Cox regression analyses)
6110	Pooled HR  (95% CI)  for coronary and stroke events associated with amlodipine-based therapy compared with atenolol-based therapy adjusted after serial mean matching of systolic blood pressure
6111	HRs associated with amlodipine-based therapy compared with atenolol-based therapy after adjustment for accumulated mean values of each of the selected variables
6112	End-of-life decisions for children aged younger than 1 year
6113	Responses to mucosal immunisation with BHPIV3/SARS-S and BHPIV3/Ctrl
6114	Responses to challenge with SARS coronavirus in monkeys immunised with BHPIV3/SARS-S or BHPIV3/Ctrl
6115	Primers used for PCR amplification of human P450 oxidoreductase
6116	Primers for site-directed mutagenesis of wild-type P450 oxidoreductase cDNA
6117	Kinetic constants  (SE)  for cytochrome c reductase activity of bacterially expressed human wild-type and mutant P450 oxidoreductase proteins
6118	Hazard ratios for events in immediate blood-pressure responders  ¶   compared with non-immediate responders to initial treatment, and in controlled  §   compared with non-controlled patients, respectively
6119	Comparison of EPS and traditional purge by study site for the excretion of scolices, gravid proglottids, and the number of eggs evacuated
6120	Infant relinquishment among mothers according to HIV-1 infection and prenatal care status, St Petersburg, Russia, 2002
6121	Unadjusted proportion of babies infected with HIV-1 by group
6122	Adjusted probability of HIV-1 infection between birth and 6–8 weeks
6123	Activity of compounds against SARS-associated coronavirus in Vero cell cultures
6124	Patients' evaluation of the consent process
6125	Children with low concentrations of HIV-1 RNA in plasma below 50 and 400 copies/mL
6126	Children with concentrations of HIV-1 RNA in plasma below 50 copies/mL and 400 copies/mL
6127	Distribution of MDR1, CYP2D6, CYP2C19, CYP3A4, and CYP3A5 genotypes in 113 study participants  *
6128	Suspected adverse drug reactions reported by family doctors during prescription-event monitoring studies 1997–2000
6129	Comparison of the main efficacy and tolerability measures for the oral triptans versus 100 mg sumatriptan
6130	Included trials; numbers of patients based on 2 h headache response rates
6131	Excluded trials for efficacy analysis
6132	Efficacy and tolerability in direct comparator trials
6133	Pregnant Zambian women's preferences on strategies for perinatal nevirapine prophylaxis  (n=310)
6134	Primary and secondary outcomes according to treatment group
6135	Rate of blood loss of 1000 mL or more by centre
6136	Shivering, body temperature greater than 38°C, and other side-effects according to treatment group
6137	Shivering and body temperature above 38°C according to treatment group and use of epidural analgesia during labour and delivery
6138	Design of trials included in the meta-analysis.
6139	Out-of-hospital symptomatic venous thromboembolism
6140	Out-of-hospital symptomless venographic deep vein thrombosis
6141	Out-of-hospital data: minor and major bleeding, and death
6142	Out-of-hospital symptomatic venous thromboembolism
6143	Out-of-hospital symptomless venographic thrombosis
6144	Out-of-hospital data: minor and major bleeding, and death
6145	Reasons for selection of misoprostol administration site and experiences with home administration
6146	Pain management and unscheduled consultations
6147	Satisfaction with method
6148	Base-case values for model epidemiological parameters
6149	Base-case values for model economic parameters
6150	1-year cost-effectiveness of HIV-1 VCT per 10 000 clients
6151	One-way sensitivity analysis
6152	Multiway sensitivity analysis
6153	Study Population  (n = 308)
6154	Dobutamine Stress Variables
6155	Follow-Up Events  (n [% per year])
6156	Lymphoma status, therapy, and outcome of patients
6157	CD4-cell counts and HIV-1 RNA load before and after stem-cell transplantation
6158	Estimated base-case values and ranges for model input parameters
6159	Cost effectiveness of HIVNET 012
6160	Cost-effectiveness of HIVNET 012, PETRA, and Thai regimens at 30% HIV-1 seroprevalence
6161	Results of sensitivity analysis
6162	Threshold analysis
6163	Paired body composition and metabolic data in patients receiving or naïve to protease inhibitors at both assessments
6164	Body composition and metabolic variables in 105 protease-inhibitor recipients followed up for a mean 21 months according to lipodystrophy self-report scale
6165	Prevalence of clinically significant dyslipidaemia at both assessments
6166	Lipodystrophy severity after 21 months of protease-inhibitor therapy in relation to metabolic variables after 14 months of therapy
6167	Misoprostol dose and phenotypic effects
6168	Summary of investigated polymorphisms
6169	Frequency of wild-type allele and mutant alleles M1, M2, and M3 among patients and controls
6170	Summary of patient details
6171	Crude vaccination rates and age  (median and interquartile range)  at first vaccination  (under 5 years)
6172	Odds ratios  (95% CI)  for IBD in vaccine recipients
6173	Reasons for withdrawal from study after immunisation
6174	Frequencies of acute adverse reactions by treatment group
6175	Frequencies of persistent adverse reactions by treatment group
6176	Model fit for the production of cytokines from a pedigree-based maximum-likelihood method
6177	Production of cytokines in relatives of patients who survived or did not survive meningococcal disease
6178	Gene frequencies in first-degree relatives of patients with meningococcal disease
6179	Postoperative outcomes in the African Surgical Outcomes Study
6180	Postoperative complications in the African Surgical Outcomes Study
6181	Association between the primary indication for surgery and postoperative complications and in-hospital mortality.
6182	Clinical symptoms and quality of life outcomes
6183	Objective measures of prolapse at 1-year clinical review
6184	Serious adverse effects related to prolapse surgery, readmissions, and treatment
6185	Trials included in the individual patient data meta-analysis  (IPDMA)
6186	Pregnancy history of study participants
6187	Primary, secondary, and safety outcomes
6188	Primary outcome according to patient subgroup
6189	Outcomes associated with abdominal entry
6190	Outcomes associated with repair of uterus
6191	Outcomes associated with closure of uterus
6192	Outcomes associated with closure of peritoneum
6193	Outcomes associated with uterine repair sutures
6194	Age-standardised and sex-standardised mortality ratios of all-cause, suicide-related, and cancer-related mortality in patients with chronic fatigue syndrome, compared with the general population in England and Wales in 2011
6195	Univariate and multivariate analysis outcomes for risk factors of suicide mortality by competing risk regressions in patients with chronic fatigue syndrome  (n=2174)
6196	Change in BMI between first and second pregnancies and adjusted  *   relative risks of stillbirth and infant, neonatal, and postneonatal mortality
6197	Change in BMI between first and second pregnancies and adjusted  *   relative risks of stillbirth, infant, neonatal, and postneonatal mortality after the second pregnancy according to BMI in the first pregnancy
6198	Top ten countries for absolute numbers of stillbirths and maternal and neonatal deaths in 2015
6199	Proportion of all stillbirths reported to be associated with congenital abnormalities in 18 national reports and subnational reports in South Africa showing status of screening and legality of termination of pregnancy
6200	Disorders associated with stillbirth reviewed for risk factor analysis
6201	Common mental disorders and health risks in adolescence and young adulthood before conception in women with at least one pregnancy during the study period
6202	Perinatal depressive symptoms overall and by parity
6203	Perinatal depressive symptoms according to preconception mental health problems
6204	Preconception predictors of perinatal depressive symptoms
6205	Incident suicide attempts at 3 and 12 month follow-up
6206	Incident severe suicidal ideation at 3 and 12 month follow-up
6207	Elements of the extensive health and psychosocial assessment for potential living kidney donors
6208	Summary of medium-term and long-term health outcomes after living kidney donation
6209	Proposed policies and practice guidelines to protect living kidney donors from medical and financial risks
6210	Description of changes in proximate factors modelled and associated interventions by code
6211	Main, secondary, and other maternal outcomes
6212	Other neonatal outcomes
6213	HIV prevalence among samples of men who sell sex, 2000–12
6214	Commercial sex behaviours that are significant risk factors for HIV infection among men who have sex with men, 2000–12
6215	Reported HIV prevention studies for men who sell sex
6216	Human rights violations and their effect on HIV and safety
6217	Health and human rights profiles across policy climates
6218	Research agenda for sex workers and HIV
6219	Studies on the molecular epidemiology of HIV-1 in sex workers
6220	Clinical outcomes at 12 months after stent implantation
6221	Interventions and assumed unit costs
6222	Interventional procedure and results
6223	Clinical outcomes at 1 year
6224	Outcomes of discharged patients treated for shellshock at a not yet diagnosed nervous centre near St Omer between Jan 2, and Nov 9, 1917
6225	A comparison of UK war pensions by diagnosis
6226	Equations for the estimation of the mean and SD  (in mm)  of each fetal biometry measurement according to exact gestational age  (in weeks)
6227	Results of primary  (local recurrence in the conserved breast) , secondary  (death) , and exploratory  (any other recurrence)  outcomes for all patients and the two strata as per timing of randomisation and delivery of TARGIT
6228	Causes of death other than breast cancer in all patients
6229	Calculation of pnon-inferiority for the whole cohort, the mature cohort, and the earliest cohort
6230	Women aged 15–49 years in developing countries wanting to avoid pregnancy, by need for and use of contraception, and number not in need, in 2003, 2008, and 2012
6231	Number  (millions)  of women aged 15–49 years in developing countries and those wanting to avoid pregnancy, by region and subregion and by country income in 2003, 2008, and 2012
6232	Number  (millions)  of women using modern methods and proportion of those wanting to avoid pregnancy using modern methods, by region and subregion and by country income in 2003, 2008, and 2012
6233	Percentage distribution of women in developing countries using modern contraceptives, by type of method, region and subregion, and country income, in 2003, 2008, and 2012
6234	Number  (millions)  of women with an unmet need for modern methods and proportion of those wanting to avoid pregnancy with unmet need for modern methods, by region and subregion and by country income, in 2003, 2008, and 2012
6235	Survival outcomes
6236	Sensitivity analysis excluding non-treatment-related terminations of pregnancy  *
6237	Other outcomes
6238	Complications of vesicoamniotic shunting
6239	Prevalence of Chlamydia trachomatis, human papillomavirus, and Neisseria gonorrhoeae in urine in participants aged 16–44 years, by age group and sex
6240	Risk factors for Chlamydia trachomatis in urine in participants aged 16–44 years, by sex
6241	Uptake of sexual health interventions and services, by sex
6242	Risk factors for high-risk human papillomavirus in urine among in participants aged 16–44 years, by sex
6243	A research agenda for MSM and HIV with questions to be addressed
6244	Timeline for the study
6245	Prevalence of sexually transmitted infections in control and intervention cities
6246	Hemodynamics and LV Function at the Acute Phase and After One Month
6247	Neurohumoral Factors
6248	Univariate and Multivariate Linear Model of LVEDVI One Month After Onset in 57 Patients With AMI
6249	Coverage and timing of intervention
6250	Cord infections
6251	Neonatal deaths and mortality risks
6252	Paediatric and adult psychiatric population-based and community-based studies
6253	Paediatric cognitive population-based and community-based studies
6254	Epilepsy syndromes and anticipated cognitive and psychiatric complications
6255	Temporal relations between psychiatric disorders and epilepsy
6256	Cognitive and psychotrophic effects of seizure drugs
6257	Categories of HIV prevention interventions for MSM and effects on frequency of unprotected anal intercourse and incidence of HIV infection
6258	Key drivers of HIV epidemics in MSM and related biomedical and behavioural interventions
6259	Candidate HIV prevention packages for MSM, by intervention type
6260	Dose changes based on FENO and ACQ results for the FENO intervention algorithm
6261	FENO algorithm treatment steps
6262	Dose changes based on clinical assessment for the clinical algorithm  (control)
6263	Clinical algorithm treatment steps
6264	Participant data at randomisation
6265	Efficacy results at end of study
6266	Unethical behaviours and willingness to report ethical violations among soldiers deployed to Iraq, according to US army Mental Health Assessment Team reports
6267	Association of battlefield-ethics training with ethical attitudes and behaviours of soldiers
6268	Association of mental health problems, time working outside the forward operating base, and combat exposure with unethical behaviours
6269	Interventions and strategies to address priority areas for stillbirth prevention
6270	Top ten research priorities in discovery science
6271	Top five research priorities in epidemiological information and top five in epidemiological measurement
6272	Top ten research priorities in development and delivery
6273	Estimated stillbirth rates and percentage of intrapartum stillbirth by world region in 2008
6274	Top ten countries for absolute number of stillbirths, maternal deaths, and neonatal deaths in 2008
6275	Countries grouped by stillbirth rate, with variation of maternal and neonatal outcomes and health-system indicators
6276	Variation in the distribution of antepartum stillbirth causation and associated maternal conditions
6277	Variation in the distribution of intrapartum stillbirth causation and associated maternal conditions
6278	Stillbirth epidemiological research priorities for low-income and middle-income countries
6279	Occurrence of adverse maternal outcomes by mortality or morbidity event  *
6280	Univariable analyses of candidate predictor variables with p<0·1 and obtained in more than 80% of cases
6281	Risk stratification table assessing the value of the fullPIERS model in risk prediction, by predicted probability of adverse maternal outcome within 48 h
6282	Collaborative-stepped care intervention
6283	Process indicators of fidelity and quality for intervention facilities
6284	Primary efficacy outcome: HIV-1 incidence in the primary and secondary efficacy analyses
6285	Secondary efficacy outcomes
6286	Reported serious adverse events, selected genital adverse events, and primary safety events
6287	Trials assessing the effect of vitamin A supplementation on maternal mortality, by target group
6288	Adherence to study treatment
6289	Effect of weekly vitamin A supplementation on serum retinol concentration in pregnant and non-pregnant women
6290	Effect of weekly vitamin A supplementation on pregnancy-related deaths
6291	Effect of weekly vitamin A supplementation on all-cause female mortality  (intention-to-treat analysis)
6292	Effect of weekly vitamin A supplementation on pregnancy-related hospital admissions  (intention-to-treat analysis)
6293	Effect of maternal weekly vitamin A supplementation on rate of stillbirth and perinatal, neonatal, and infant mortality  (intention-to-treat analysis)
6294	Salvage, area at risk, and final infarct size, according to vessel patency before primary percutaneous coronary intervention  (pPCI) , with or without remote conditioning, and infarct location  (per-protocol analysis)
6295	Left ventricular ejection fraction estimated by echocardiography 24 h and 30 days after primary percutaneous coronary intervention  (pPCI) , with or without remote conditioning  (intention-to-treat analysis)
6296	International centres and accrual in the three main strata, by site and country
6297	Extent of surgery
6298	All complications
6299	Clinically significant complications
6300	Sample size calculations for different scenarios
6301	Intent-to-treat analysis of early-onset sepsis in neonates and maternal post-partum sepsis by intervention group and HIV exposure status
6302	Intent-to-treat analysis of vertical transmission of selected maternal-vaginal colonising bacteria from mother to newborn babies in the chlorhexidine and control groups, by neonatal colonisation status
6303	Female partner retention rates
6304	HIV acquisition at 6 months in female partners in the control group and in the intervention group by timing of resumption of sexual intercourse  *
6305	Sexual behaviours and sexually transmitted infections in female partners during follow-up, by study group
6306	Prevalence of sexual violence  (lifetime or past 12 months)  in girls younger than 18 years, reported by girls and women aged 13–24 years
6307	Circumstances of first incidents of sexual violence in girls younger than 18 years, reported by girls and women aged 13–24 years
6308	Self-reports of lifetime experience of health-related conditions and behaviours reported by girls and women aged 13–24 years, who had or had never had experience of sexual violence before age 18 years
6309	Summary of HIV seroconversions, overall and by site  (n=6004)
6310	Cumulative probability of seroconversion at month 24 in select population subgroups, in the efficacy population
6311	Summary of safety findings, by group, in the intention-to-treat population
6312	Comparison of changes in rates of diagnosable major depression after intervention at 6 months and 12 months postnatally
6313	Effect of intervention on depression, disability, functioning, and perceived social support scores
6314	Effect of intervention on infant growth
6315	Effect of intervention on activities affecting infant health
6316	Expected transmission probabilities  (with lower and upper uncertainty bounds)  per sexual act and cumulatively over 100 acts in a serodiscordant partnership, assuming the HIV-infected person has a viral load of 10 copies per mL
6317	Expected number of HIV seroconversions out of 10 000 serodiscordant couples in a hypothetical population over 1000 acts per partnership, with lower and upper uncertainty bounds
6318	Percentage of ever-partnered women reporting selected symptoms of ill health  *   according to experience of physical or sexual violence, or both, by an intimate partner, by site
6319	Logistic regression models for the associations  *   between selected health conditions and experience of intimate-partner violence in ever-partnered women, on pooled dataset for 15 sites
6320	Mean SRQ-20 scores for emotional distress in ever-partnerned women according to experience of physical or sexual violence, or both, by an intimate partner, by site  *
6321	Prevalence of injures among physically abused women; severity and frequency of injuries in women ever-injured by an intimate partner, by site
6322	Findings from clinical examinations at 6 and 12 months after end of pregnancy
6323	Findings from interviews at 3, 6, and 12 months after end of pregnancy
6324	Odds ratios for adjusted comparisons of each group of women with severe obstetric complications with the group with uncomplicated deliveries for self–reported health at 3, 6, and 12 months
6325	Summary of HIV seroconversions, overall and by site  (n=4948)
6326	Reported adverse events and serious adverse events, by group
6327	Trial retention rates
6328	HIV incidence by study group and follow-up interval, and cumulative HIV incidence over 2 years
6329	Prevalence of self-reported symptoms of sexually transmitted infections per visit, cumulatively over 24 months follow-up
6330	Sexual risk behaviours by study group and follow-up visit
6331	Adjusted effect of the timing and type of prenatal treatment on the risk of mother-to-child transmission in European prenatal screening centres in subsample of treated mothers  (n=1438 mothers, 398 infected children)
6332	Adjusted effect of timing and type of prenatal treatment on risk of clinical manifestations diagnosed during first year of life in infected children identified by prenatal and neonatal screening in European centres
6333	Adjusted odds ratios for adverse perinatal outcomes during second pregnancy in relation to change in BMI from the first pregnancy for all women and for women with a BMI of less than 25 at the time of both pregnancies  *
6334	Adjusted odds ratios for obstetric complications in second pregnancy associated with changes in BMI since first pregnancy, by categories of BMI at first pregnancy  *
6335	Life expectancy and years spent in different states of dependency at age 65 years in 1991 and 2011, and differences between 1991 and 2011
6336	Projected numbers of people aged 65 years or older and of care home places needed by 2025 and 2035
6337	Outcome measures
6338	Participants with reductions in episodes of faecal incontinence at follow-up  (n=227)
6339	Treatment-related adverse events
6340	Monogenic forms of Parkinson's disease, by gene
6341	Pharmacological treatments for motor symptoms and complications
6342	Pharmacological treatments for non-motor symptoms
6343	Randomised controlled trials of surgical interventions for early management of traumatic brain injury
6344	Odds ratios for primary and secondary endpoints at 90 days
6345	Most relevant or frequent adverse events reported during the study
6346	Gas Exchanges During the Incremental Exercise Test legend legend legend legend
6347	Enzymes and MHC legend legend legend
6348	Efficacy endpoints
6349	Safety endpoints
6350	Clinical prediction rule variables
6351	The predictive value of the AIS grading system to discriminate between the ability to walk independently or not 1 year after injury
6352	Primary and secondary study endpoints
6353	Major adverse events and device functionality
6354	Case-fatality rates for pandemic influenza A H1N1 infection and population mortality rates by age in England from June 26, 2009, to March 22, 2010
6355	Frequency of presenting symptoms and signs among children who died from pandemic influenza A H1N1 infection
6356	Frequency of pre-existing disorders in paediatric deaths related to pandemic influenza A H1N1 infection
6357	Age-standardised mortality rate for deaths related to pandemic influenza A H1N1 for children aged between 6 months and 18 years with specific pre-existing disorders
6358	Variability of Regional Pulse Wave Velocity by Age
6359	Surgical compliance, mortality, and morbidity
6360	Clinical outcomes for congenital anomaly groups  (with a minimum of ten recorded pregnancies)  notified to the Northern Congenital Abnormality Survey, 1985–2003
6361	Estimates of survival at selected ages up to 20 years for congenital anomalies  *    (with a minimum of ten recorded livebirths)  notified to the Northern Congenital Abnormality Survey, 1985–2003
6362	Number of livebirths and compliance with screening objectives throughout Japan  (1980–98)
6363	Cases of neuroblastoma diagnosed at younger than 72 months of age and rates of incidence for the three cohorts
6364	Stages of neuroblastoma diagnosed between 6 and 72 months of age in the three cohorts
6365	Distribution of cases of neuroblastoma diagnosed at younger than 72 months of age according to age at diagnosis and stage in the three cohorts
6366	Mortality rates of neuroblastoma diagnosed at younger than 72 months of age for the three cohorts
6367	Neurosensory deficits at 5 years of age in children born very preterm  (24–32 completed weeks' gestation  §  )
6368	Neurodevelopmental outcome by week of gestational age, sex, and type of pregnancy
6369	MPC scores for very preterm children compared with those for a reference group born at term
6370	Scores for MPC and achievement scale for children born very preterm compared with those for a reference group born at term
6371	Overall disabilities and use of special health care and rehabilitation by gestational age group
6372	Use of special health care and rehabilitation of children by level of disability
6373	Prevalence of severe mental and neurological disorders in Maputo and Cuamba, Mozambique
6374	Causal models and help-seeking for cases of severe mental and neurological disorders in Maputo and Cuamba, Mozambique
6375	Radiological data
6376	Motion at the affected discs
6377	Patients with a favourable neurological outcome at 30 days after cardiac arrest
6378	Estimation of kuru incubation periods in 11 patients identified in current study
6379	Genetic analysis in kuru patients identified in current study
6380	Types of neural tube defects in babies born between Oct 1, 2002, and Sept 30, 2003, in two areas of Balrampur District, Uttar Pradesh, India
6381	Major adverse events and postnatal complications
6382	Primary and secondary outcomes and components
6383	Primary outcome logistic regression results  (n=218)
6384	Primary and secondary outcomes for the intermediate aEEG group and for the severe aEEG group
6385	Clinical features of ten individuals with Parkinson's disease in families with the mutation
6386	Surgical compliance, mortality, and morbidity during first 5 years after randomisation
6387	Probable type and severity of worst non-perioperative stroke within 5 years of randomisation
6388	Combined analysis of results from ACST and ACAS
6389	Average use of statin  (study or non-study) , and average plasma LDL cholesterol concentrations, during follow-up
6390	Amount of PrPres detected as a percentage of that present in the brain
6391	p values for comparisons of ischaemia score, apoptosis score, TNFα expression, and iNOS expression in patients with septic shock and two control groups
6392	Cardiac measurements in patients 2 and 3 before and after treatment
6393	Distribution of pregnancies other than the proband according to maternal age, gravidity, outcome, and order in families at risk of NTD
6394	Details of families with aneuploidy
6395	Down's syndrome cases observed  (O)  and expected  (E)  from the maternal age distribution in families at risk of NTD
6396	Details of NTD cases in families at risk of Down's syndrome
6397	Differences between users and non-users of N2O
6398	Age and sex of serosurvey respondents compared with 1990 census population
6399	Exposures associated with West Nile virus seropositivity
6400	Renal function, protein concentrations, and plasma and urinary TNF-α in patients treated with pentoxifylline
6401	Average  (95% CI)  joint-space narrowing after 3 years
6402	Average  (95% CI)  total WOMAC percent change after 3 years
6403	Proportion of patients reporting adverse events recorded with an at least 5% frequency
6404	Distributions of preliminary neuropathological diagnosis  (without knowledge of clinical status)  by observed dementia status for first neuropathological diagnosis  (rank 1)  and all diagnoses  (All ranks)
6405	Number of individuals  *   with general neuropathological findings by age at death and dementia status
6406	Unconditional logistic regression univariate  (adjusted for age)  and multivariate  (adjusted for all other factors in the table)  analyses
6407	Cases discussed by expert group up to May, 2000
6408	Ten most commonly occurring confirmed diagnoses
6409	Neurological and IQ measures before and after BMT
6410	Comparison of Body Weight, Blood Pressure and Heart Rate in Different Groups of Rats Before Acute Myocardial Infarction and at the End of Study Period legend
6411	Quantitative Results of Myocardial Interstitial Collagen in the Noninfarcted Regions of Left Ventricle  (Septum)  and RV After AMI legend
6412	Quantitative Results of Macrophages and Activated Myofibroblast Infiltration in the Infarct Zone as Well as Transforming Growth Factor-β1 in the Noninfarcted Regions of Left Ventricle  (Septum)  and RV in Rats After AMI legend
6413	NFI occurring for variables used
6414	Multivariable hazard ratios of clinical prediction models
6415	Occurrence and risk of NFI among three risk groups
6416	Surveillance recommendations of patients according to risk groups
6417	Mortality from all causes, 1952–97
6418	Mortality from Parkinson's disease and other degenerative neurological disease, 1952–97
6419	Number of deliveries after in-vitro fertilisation in Swedish Medical Birth Registry by type of birth and delivery
6420	Risk ratios  (95% CI)  for short duration of gestation and low birthweight among singletons born after in-vitro fertilisation
6421	Odds ratios  (95% CI)  for short duration of gestation  (<37 weeks)  of low birthweight  (<2500 g)  according to in-vitro-fertilisation method  *
6422	Observed and expected number of children with specific malformations
6423	Delivery outcome in 1994 and 1995 in Sweden
6424	Livebirths and stillbirths by decade, social class, and birth order  (non-Sellafield cohort)
6425	Livebirths and stillbirths by decade, social class, and birth order and paternal age  (Sellafield cohort)
6426	External preconceptional doses of ionising radiation  (radiation-worker cohort)
6427	Total internal preconceptional gonadal doses of ionising radiation  (radiation-worker cohort)
6428	Results of logistic-regression analysis of external preconceptional doses  (radiation-worker cohort)
6429	Effects of nucleoside exposure before and during pregnancy, and after birth
6430	Respiratory-chain enzyme investigations in isolated skeletal-muscle mitochrondria, tissue homogenates, and circulating lymphocytes from patients
6431	Respiratory-chain enzyme investigations in isolated skeletal-muscle mitochrondria, tissue homogenates, and circulating lymphocytes from controls
6432	Change in anal manometry and PNTML after first and second vaginal deliveries  (n=59)
6433	The clinical signs and symptoms seen in each subgroup
6434	Consumption of fruit and herbal tea in cases and controls
6435	Odds ratio associated with consumption of fruit and herbal tea
6436	Patient details
6437	Overall classification and details of MRI findings
6438	Neurodevelopmental findings at 14–15 years in controls and cases according to MRI
6439	Disability scores
6440	Annual incidence rates  (per million)  for neuroblastoma in four European countries
6441	Mantel-Haenszel  *   relative rates for neuroblastoma by country, stage, and age group
6442	Manner of diagnosis of neuroblastoma in three European countries
6443	Background information on cases of congenital anomaly and controls
6444	Odds ratios for non-chromosomal congenital anomalies for each study area
6445	Odds ratios for congenital anomalies among residents within 3 km of a hazardous-waste landfill site
6446	Clinical features of 12 patients
6447	Clinical neurological data and findings of necropsy
6448	Cohort of 649 patients treated for a first cancer in childhood
6449	First and second cancer types among 25 patients in case-control study
6450	Sites of cancers with onset at age ≤ 45 years among family members of probands in case-control study
6451	Odds ratio of SMN according to familial aggregation index and local radiation dose
6452	Odds ratio of SMN according to FI and local radiation dose when accounting for interaction
6453	Clinical classification of all conjugal pairs
6454	Results of cranial magnetic resonance imaging  (MRI)  in 39 offspring of 45 conjugal pairs with multiple sclerosis
6455	Tuber location In 18 patients with and without autistic psychopathology
6456	Laboratory findings in post-malaria neurological syndrome
6457	Health-care utilisation
6458	Patient-reported outcomes
6459	Disease outcomes
6460	Incidence of incisional hernia in all patients with 2-year follow-up and by subgroups
6461	Quality-of life scores
6462	Quality-of-life scores for patients with and without incisional hernia
6463	Secondary outcomes
6464	Further surgical interventions and patient-reported recurrence
6465	Serious adverse events by treatment received
6466	Serum retinol and retinol binding protein levels in infants at 2 weeks and 3 months of age and in mothers at 3 months post supplementation, by trial group
6467	Adverse events within 3 days of supplementation, by trial group
6468	Effect of vitamin A on primary and secondary outcomes, overall and stratified by sex
6469	Haemostatic efficacy and rapid INR reduction by type of procedure  (ITT-E population)
6470	Summary of adverse events  (ITT-S population)
6471	Development indicators and health outcomes for Bangladesh and neighbouring countries and regions
6472	Health-system indicators and health outputs in Bangladesh and neighbouring Asian countries and regions
6473	Coverage and concentration index of family planning, maternal, and child health services in Bangladesh  (2011) , Nepal  (2011) , India  (2006) , and Pakistan  (2007)
6474	Effects of albendazole allocation on prevalence of worm infection, weight, height, haemoglobin, and recent ill health  (generally as reported by the child's guardian)  in a subsample from each of the 72 blocks during the second half of the study, by age
6475	Associations within 116 of the 4180 control villages between faecal worm eggs  (absent/present)  and mean weight, height, and haemoglobin during the second half of the study  (analyses of individuals)
6476	Effects of albendazole allocation on pre-school child mortality: absolute numbers of deaths per anganwadi child-care centre  (AWC)  by allocated treatment, albendazole versus control  (A vs C) , and, from these, mortality rate ratio  (A/C)  and approximate absolute risk of death from age 1·0 to 6·0 years
6477	Correlations between maternal 25 (OH) D concentrations in pregnancy, exposure to ultraviolet B in the third trimester, and offspring 25 (OH) D concentrations
6478	Deaths and Hospital Admissions: Comparison Between Patients With Normal Cardiac Troponin I Levels and Those With Elevated Levels legend legend
6479	Multivariable associations between predicted maternal third-trimester 25 (OH) D concentrations and offspring BMC
6480	Multivariable associations between predicted third-trimester maternal 25 (OH) D categories and offspring BMC
6481	Multivariable associations between maternal estimated exposure to ultraviolet B in the third trimester and offspring BMC
6482	Effects of novel CYP2C variation on warfarin dose prediction with the IWPC dosing algorithm
6483	Pharmacokinetic parameters of warfarin R-enantiomer and S-enantiomer by rs12777823 genotype
6484	Incidence rate of first or the only episode of pneumonia  (intention-to-treat analysis)
6485	Person-time at risk and incidence rate of repeat episodes of pneumonia from all sources  (intention-to-treat analysis)
6486	Patients with recurrent venous thromboembolism  (primary efficacy endpoint)  during treatment and follow-up
6487	Safety outcomes during the study period for all patients randomly allocated to treatment groups
6488	Post-trial follow-up of outcomes  (other than cancer and death) , by year of follow-up
6489	In-trial and post-trial statin use  (study and non-study) , by year of follow-up
6490	In-trial and post-trial mean  (SE)  lipid levels
6491	Cumulative incidence before and after 9/11 of physical disorders, mental health symptoms, and spirometric abnormalities in the World Trade Center Screening, Monitoring, and Treatment Program study population
6492	Annual conditional incidence after 9/11 of physical disorders, mental health symptoms, and spirometric abnormalities in the World Trade Center Screening, Monitoring, and Treatment Program study population
6493	Secondary efficacy endpoints at week 72
6494	All-cause and idiopathic-pulmonary-fibrosis-related mortality in the pooled population
6495	Treatment-emergent adverse events  *
6496	Basic health professional statistics for countries in southeast Asia
6497	Production capacity of doctors, nurses, and midwives in southeast Asian countries
6498	Level of engagement in trade in health services in southeast Asian countries
6499	Number of doctors and nurses from southeast Asia working in OECD countries, by country of birth and country of training
6500	Efficacy outcomes
6501	Bleeding events during treatment
6502	Summary of safety endpoints with onset during treatment and follow-up
6503	Adverse events reported by investigators during treatment  (not including study endpoints)
6504	Single nucleotide polymorphisms identified in genome-wide association analyses for 25-hydroxyvitamin D concentrations
6505	Mean 25-hydroxyvitamin D concentrations by genotype, season, and supplementation status
6506	Genetic variants and risk of vitamin D insufficiency
6507	Primary and secondary clinical outcomes
6508	Maternal and neonatal outcomes
6509	Growth measures at birth and at postnatal follow-up  (6–12 weeks of age)
6510	Rates of pre-eclampsia in 11 predefined subgroups
6511	Children aged 2–4 years who screened positive for disability to the Ten Questions in the 2005–06 Multiple Indicator Cluster Survey, by breastfeeding status and country
6512	Children aged 2–4 years who screened positive for disability to the Ten Questions in the 2005–06 Multiple Indicator Cluster Survey, by vitamin A supplementation and country
6513	Children who screened positive for disability to the Ten Questions in the 2005–06 Multiple Indicator Cluster Survey, by participation in early-learning activities, school attendance, and country
6514	Definitions of asthma at 22 years on the basis of physician diagnosed asthma and current symptoms
6515	Prebronchodilator and postbronchodilator FEV1/FVC ratio and response to bronchodilator for asthma groups at age 22 years
6516	Proportion of participants with early-life risk factors and current smoking by asthma group at age 22 years
6517	Multinomial odds ratio for asthma groups at age 22 years by different risk factors in early life
6518	Estimates of mortality in children younger than 5 years
6519	Comparison of non-health system changes between 1999 and 2005 that might be expected to affect child survival
6520	Educational attainment of men and women aged 15–49 years
6521	Risk factors for child stunting in families in Indonesia
6522	Risk factors for child stunting in families in Bangladesh
6523	Multivariate logistic regression model for maternal education, paternal education, and other risk factors in relation to stunting in children in Indonesia
6524	Multivariate logistic regression model for maternal education and other risk factors in relation to stunting in children in Bangladesh
6525	Effect of length of primary school education on the odds of child stunting
6526	Effect of combined level of parental education on risk of child stunting
6527	Maternal and paternal education and caregiving behaviours in families in Indonesia
6528	Vitamin A supplementation schedule
6529	Tests and sample collection
6530	Plasma and breastmilk retinol concentrations
6531	Indicators of respiratory and gastric mucosal infection
6532	Indicators of damage to mucosal defences
6533	Lymphocyte counts
6534	Morbidity rates of study infants
6535	Plasma acute-phase markers
6536	Association between 8-year lung-function growth and several indicators of residential traffic exposure
6537	Sensitivity analysis of freeway-distance effects on 8-year FEV1 growth
6538	Joint effect of regional pollution and local distance to a freeway on 8-year FEV1 growth
6539	Cumulative effect of residential distance in the 1445 children with full 8-year follow-up
6540	Regression analysis of phase one cumulative grant implementation
6541	Maternal pregnancy outcomes by treatment allocation
6542	Pre-eclampsia stratified by risk at enrolment
6543	Neonatal outcomes by treatment allocation
6544	Umbilical-vein blood chemistry and whole-body BMC at age 9 years
6545	Smoking status at each survey for participants with data about change in lung function
6546	Age, lung function, and BMI at ECRHS I by smoking group
6547	Smoking intensity between surveys  (26 centres) , and unadjusted ΔFEV1, ΔFVC, and ΔBMI by smoking group
6548	Difference in change in lung function from those who had never smoked, adjusted for centre, age, age-squared, and height
6549	Change in lung function from smoking, change in weight, or change in BMI
6550	Summary of randomised trials of β carotene treatment
6551	Summary of randomised trials of vitamin E treatment
6552	VAS, MQS, and MOS SF-36 scores at 3, 6, and 12 months
6553	Within-group changes and differences between groups after 12 months' follow-up for quality of life scores  (MOS SF-36 domains)
6554	Outcomes by decision rule and secondary variables at 3 months
6555	Adverse events and complications at 3 months
6556	Effect of covariables on primary and secondary outcomes
6557	Compliance with study vitamins  (≥80% taken)  during follow-up
6558	Average plasma concentrations of vitamins and lipids during follow-up
6559	Variables and variable values used to estimate effectiveness and cost-effectiveness
6560	Adverse effects in 466 patients who underwent re-treatment with second-line drugs
6561	Follow-up and treatment outcome in patients who underwent re-treatment with second-line drugs
6562	Average cost per patient treated for patients who completed the full course of treatment,  *   standardised second-line drug treatment programme implemented in Peru 1997–2000
6563	Mean cost, affordability, effectiveness, and cost-effectiveness indicators for alternative strategies, highest cost scenarios assessed  *    (5th and 95th centiles)
6564	Cost and cost-effectiveness indicators for alternative strategies under different cost assumptions
6565	25-hydroxyvitamin D-1-α-hydroxylase  (1αOHase)  mRNA expression in tumour and paired healthy mucosa samples and in control samples, and ages of individuals biopsied
6566	Description of study population
6567	The effect of vitamin A supplementation, sex, and one versus two doses of vitamin A on measles-specific antibody concentrations
6568	Changes in coronary ultrasonographic variables by pullback method
6569	Changes in coronary ultrasonographic variables by matched sites
6570	Physiological variables in climbers with and without clinical evidence of oedema, at low and high altitude
6571	Incidence rate and rate ratio  (RR)  of type 1 diabetes by the use of vitamin D supplements and suspected rickets in infancy
6572	Results of automated perimetry
6573	Effectiveness of confrontation field tests
6574	Mean percentage change in FEV1 over each treatment period  (final FEV1 minus initial FEV1, expressed as a percentage of initial FEV1)
6575	Heart Rate and Blood Pressure Responses to Transdermal GTN legend
6576	Mean costs  (UK£)  over each 12-week treatment period, and differences between treatment groups
6577	Forearm Blood Flow Responses legend
6578	Distribution of variables by sex-specific quintiles of ascorbic acid in men and women
6579	Age-adjusted rates for all-cause, cardiovascular disease, and ischaemic heart disease mortality by sex-specific ascorbic acid quintile in men and women
6580	Cox multivariate regression for all cause, cardiovascular, and ischaemic heart disease mortality with ascorbic acid in 8860men and 10636 women
6581	Predictors of vertebral fractures after cardiac or liver transplantation
6582	Efficacy profile of aspirin and vitamin E treatment
6583	Safety profile of aspirin and vitamin E treatments—severe and unexpected non-fatal events according to treatment group
6584	Intravascular Ultrasound Results for Debulking Plus Stenting and Stenting-Only Groups legend legend
6585	Univariate Predictors of Angiographic Restenosis legend legend
6586	Systemic Hemodynamics at Rest, 1-mm ST-Depression and at Peak Exercise, Before and After Treatment With Enalapril legend legend
6587	Adjusted Odds of Developing AMI According to Levels of Circulating Monocyte-Platelet Aggregates legend
6588	Association of Serum Creatinine Level With Cardiovascular Events legend legend
6589	Association of Estimated Creatinine Clearance With Cardiovascular Events legend legend
6590	Multivariate Predictors of Troponin-I Positivity legend legend
6591	Maximum Troponin-I  (μg/l)  Concentrations According to Univariate Predictors of Troponin Release legend legend
6592	Troponin Status According to ACE genotype legend legend
6593	Cytokines legend
6594	Changes in Lipid and Cytokine Values, Intimal Thickening and Coronary Hemodynamics  (Prospective Study)  legend
6595	Incidence of Angiographic Complications legend
6596	Incidence of CK-MB Enzyme Elevation Among Patients With Angiographic Complications  (Excluding Patients With Abnormal CK-MB Enzyme Elevation Immediately Before or During Procedure)  legend
6597	Incidence of CK Enzyme Elevation Among Patients With Angiographic Complications Excluding Patients With Abnormal CK-MB Enzyme Elevation Before or During Procedure legend
6598	Clinical End Points in Patients With Versus Without Angiographic Complications During Coronary Intervention
6599	Effects of Eptifibatide Observed in This Study, Extrapolated to an Imaginary Cohort of 1,000 Patients legend
6600	Single-Photon Emission Computed Tomographic Results
6601	Referral to Coronary Angiography legend
6602	Referral to Revascularization legend
6603	Magnetic Resonance Imaging and Exercise Data Unadjusted for Age and Gender  (Mean ± Standard Error of the Estimate)  legend
6604	Magnetic Resonance Imaging and Exercise Data Adjusted for Age and Gender  (Mean ± Standard Error of Estimate)  legend
6605	Predictors of Peak Oxygen Consumption legend
6606	Final Hemodynamic Data on the Four BMI Categories After the Pulmonary Artery Catheter-Guided Unloading Protocol legend
6607	Medicine Use Among the Four Categories of BMI legend
6608	Prediction of One-Year Survival by Univariate Analysis legend
6609	Predictors of Survival by Multivariate Cox Regression Analysis legend
6610	Clinical Background and CBF Responses in the Studied Patients legend
6611	Patients’ Data legend
6612	Cardiac Magnetic Resonance legend
6613	Ascorbate Free Radical Data  (nmol/l)  legend legend
6614	Hemodynamic Data legend legend
6615	Myocardial Perfusion legend
6616	Clinical Predictors of Chronic AF legend
6617	Hazard Ratios and 95% Confidence Intervals for Subgroup Analysis legend
6618	Echocardiographic Findings legend legend
6619	Peak Pulmonary Vein Blood Flow Velocity  (cm/s)  of Patients With Pulmonary Venous Pathway Obstruction from MR Velocity Mapping and Doppler Echocardiography legend legend
6620	Comparison of MR, Doppler Echocardiography and Catheterization-Derived Peak Pulmonary Vein Blood Flow Gradients  (mm Hg)  in Patients With Pulmonary Venous Pathway Obstruction
6621	Comparison of Sensitivities, Specificities, NPVs and PPVs for Prediction of Functional Recovery on a Segmental Basis Using Early and Delayed Myocardial Contrast Echocardiography legend
6622	Chi-Square and Significance Values for Univariate Predictors of Segmental Functional Recovery legend
6623	Unipolar Electrogram Amplitude and Linear Local Shortening in Regions Defined by Nuclear Imaging legend
6624	Right Ventricular Apical Pacing Data of Patients Paced for 1 to 19 Years legend
6625	Predictors of Left Ventricular Fractional Area of Change in Patients Who Had Right Ventricular Apical Pacing  (n = 24)
6626	Follow-Up of Patients With Negative/Nondiagnostic Tests legend
6627	Results of the Follow-Up Questionnaire for 229 Patients Who Responded legend legend
6628	Angiographic Results by Agency for Health Care Policy and Research Risk Group legend legend
6629	Angiographic Results by Agency for Health Care Policy and Research Risk Group Excluding Normal Angiograms and Mild CAD Patients legend legend
6630	PCR Conditions for Amplification of NHE-1, NBC-1 and GAPDH legend
6631	Platelet Aggregation  (Ohms)  in Response to 1 μmol/liter ADP in Whole Blood From Normal Subjects, Nonischemic Patients  (NIP) , Patients With Stable Angina Pectoris  (SAP)  and Patients With Acute Coronary Syndromes  (ACS)  legend
6632	Multivariate Analysis: Significant Correlates of Impaired  (<28%)  Platelet Response to Sodium Nitroprusside  (10 μmol/liter)  in Blood Samples From Patients With Stable Angina Pectoris  (n = 82)  or Acute Coronary Syndromes  (n = 153)  legend
6633	Hemodynamic Data legend
6634	Mean 24-h Values: Effect of Spironolactone or Placebo on Various Biochemical, Hemodynamic and Autonomic Indices legend
6635	Diurnal Effects of Spironolactone and Placebo on Autonomic Indices legend
6636	Resting Hemodynamics, Stenosis Severity and Function legend
6637	Subendocardial Perfusion  (ml/min/g)  and Connective Tissue Staining  (%)  legend
6638	Clinical Features of Patients With and Without Hard Cardiac Events legend
6639	Exercise Stress Test and Echocardiographic Data of Patients With and Without Cardiac Events legend
6640	Univariate Association of Clinical, Exercise Stress Test and Echocardiographic Variables With Risk of Cardiac Death and Nonfatal Myocardial Infarction legend
6641	Independent Predictors of Cardiac Events Using Four-Step Model
6642	Comparison of Brugada Patient and Control Groups legend
6643	Univariate and Multivariate Analyses of Three Noninvasive Indices Associated With Life-Threatening Events legend
6644	Predictive Values of Three Noninvasive Indices Associated With Life-Threatening Events legend
6645	Patients Hospitalized by Treatment Group and Reason for Admission legend
6646	Total Number of Hospitalizations and Hospitalizations per Patient  (Mean ± SD)
6647	Effect on Inpatient Resource Utilization and Costs legend
6648	Utilization of Selected Cardiovascular Procedures, by Treatment Group legend
6649	Clinical Features and Medical Therapy legend legend
6650	Effects of Lidocaine and Verapamil on Local Conduction Times Measured During Entrainment legend
6651	Number of Patients in Echocardiographic Study at Each Time Point
6652	Clinical Outcome by Treatment Group Among Patients With Paired Echocardiograms legend
6653	Effects of Etiology and Functional Class on Venous Endothelial Function legend
6654	Dose-Response Effects of Nitroglycerin on Cerebral Blood Flow legend
6655	Effects of Nitroglycerin or Nicorandil on Epicardial Coronary Artery Diameter During Continuous Administration of Nitroglycerin legend legend
6656	Independent Predictors of Total Cardiac Mortality Based on Clinical Variables and Results of Dobutamine Echocardiography legend
6657	Predictors of Cardiac Death in Patients With Negative Dobutamine Echocardiograms legend
6658	The Sequence for the Primers
6659	Comparison of mRNA and Protein Expression for Patients With Persistent and Paroxysmal AF With their Matched Controls in Sinus Rhythm legend
6660	Echocardiographic Parameters of the Study Cohort legend legend
6661	Instrumentation Settings for Pulse Inversion Doppler Imaging With Intravenous Optison and Definity
6662	Global Ventricular Function of Patients and Age-Matched Control Subjects legend legend
6663	Regional Myocardial Function in the Perfusion Territory of the Left Anterior Descending Coronary Artery  (LAD-Infarct Area)  and the Area Adjacent to and Remote From the LAD Perfusion Territory, as Assessed by Wall Thickening and Strain Analysis legend legend
6664	Exercise Test Parameters legend
6665	Ischemic Burden Demonstrated by Tc-99m Sestamibi  (MIBI)  and Tc-99m Tetrofosmin  (TETRO)  in Mild to Moderate Coronary Artery Disease
6666	Segmental Analysis of Perfusion Defects in Patients With Mild-to-Moderate Coronary Artery Disease legend legend
6667	Image Quality legend legend
6668	Hemodynamic Variables, Myocardial Blood Flow and Side Effects at Rest and During Pharmacological Stress in 20 Normal Men legend
6669	Regional Myocardial Blood Flow at Rest and During Pharmacological Stress
6670	Echocardiographic Variables in the Normal Population legend
6671	LV Mechanics During and After ARF legend
6672	Group II Patients Treated With  (n = 5)  and Without  (n = 14)  Surgery legend legend
6673	Patient Data, Scintigraphic Findings and Coronary Flow Reserve at 100 Beats/Min in Patients With Permanent Ventricular Pacing legend
6674	Left Anterior Descending and Dominant Coronary Artery Doppler Flow Velocity Measurements in Patients With Permanent Ventricular Pacing, With  (Group I)  and Without  (Group II)  Dipyridamole Scintigraphic Perfusion Defects, and in Control Subjects legend
6675	Clinical and Echocardiographic Data Stratified According to the X-Chromosomal Located+1675 G/A Polymorphism of the Angiotensin II AT2-receptor Gene legend
6676	Clinical Data Stratified According to the +1675 G/A Polymorphism of the Angiotensin II AT2-Receptor Gene legend
6677	Echocardiographic Data Stratified According to the +1675 G/A Polymorphism of the Angiotensin II AT2-Receptor Gene legend
6678	Left Ventricular Hemodynamic Variables of Isolated Rat Hearts Measured During the Preischemic Perfusion Period legend legend
6679	Mean Ventricular Volume Indexes for Each of the Studies Separately  (CATS, FAMIS and CAPTIN)  legend
6680	Hemodynamics  (Mean ± SD) —Positron Emission Tomographic Study legend
6681	Hemodynamics  (Mean ± SD) —Dobutamine Echo Study legend legend
6682	Regional Myocardial Blood Flow  (ml/min/g; Mean ± SD)  by Viability Criteria legend
6683	Adhesion Molecule Expression on Aortic Valve Endothelium legend
6684	Correlation Between Soluble Adhesion Molecule Levels and the Intensity of Staining on Valvular Endothelium legend
6685	Correlation of Antimyosin Uptake Heart-to-lung Ratio With Clinical and Echocardiographic Variables legend
6686	Multiple Linear Regression Analysis of Heart-to-lung Ratio of Antimyosin Uptake legend legend
6687	Effect of the Two Enalapril Dose Regimens on Mortality in Patient Subgroups legend legend
6688	One-Year Morbidity  (Hospital Admissions)  in the Two Study Groups
6689	Prevalence of Coronary Calcification  (Score > 0)  by Diabetes Status and Gender
6690	Age-Adjusted Odds Ratio  (95% CI)  for the Association Between Each Risk Factor and Coronary Calcification by Gender and Diabetes Status legend
6691	Clinical Profiles of the Study Patients legend
6692	Univariate Predictors of Cardiac Death legend legend
6693	Multivariate Cox Proportional Survival Analysis for Independent Predictors of Cardiac Death legend
6694	Cardiac Pathology legend
6695	Neurohumoral Data legend
6696	Clinical Outcomes Stratified by Cardiac Troponin I Results legend legend
6697	Multivariate-Adjusted Risk Relation Between Elevated Cardiac Troponin I and Adverse Outcomes at 14 Days legend legend
6698	Clinical Information for the 23 Study Patients
6699	Ventricular Parameters and Distal LAD Diameter Before and After AVR legend legend
6700	Distal Left Anterior Descending Coronary Artery Flow Velocities and Flow Reserve Before and After AVR legend legend
6701	Absolute FBF Responses in the Infused and Noninfused Arms After Losartan and Placebo Treatment legend
6702	FVR Responses in the Infused Arm After Placebo and Losartan Treatment legend
6703	Clinical Data of the Patient Population legend
6704	Forearm Blood Flow Responses of Women and Men to Brachial Artery Administration of Vasodilator Agonists legend
6705	Multivariable Logistic Regression Models for Perioperative Complications by Outcome ∗   legend
6706	Multivariable Cox Regression Models for Mortality ∗   legend
6707	Multivariable Cox Regression Models for Hospitalization ∗   legend
6708	Interaction of Factor V Leiden With Other Risk Factors legend
6709	Clinical Presentation
6710	Mechanisms of Aortic Regurgitation in Patients With Minimal Versus Significant Aortic Regurgitation ∗
6711	Case Analysis of Patients Undergoing Aortic Valve Repair or Replacement: The Mechanisms and Severity of Aortic Regurgitation Correlated With the Type of Aortic Valve Surgery legend
6712	Identifying Diagnostic Features of LAI
6713	Summary of Cardiac Defects
6714	Extracardiac Conditions and Anomalies
6715	Univariate Estimates  (Cox Proportional Hazards Modeling)  of Relative Hazard for Time-Related Death legend
6716	Independent Factors Associated With Time-Related Mortality ∗   legend
6717	Left Ventricular Volumes Determined by RT3DE and 2DE in the Sheep Animal Model legend
6718	The LV EDV, ESV and EF Determined by RT3DE, 2DE and MRI in Patients legend
6719	Purkinje Potentials During Sinus Rhythm After Ablation legend
6720	Effects of Fatty Meals on Serum Lipoproteins, Insulin, Glucose, Free Fatty Acids and Homocysteine Levels legend
6721	Effect of Fatty Meal on Endothelial Function and Hemodynamic Variables legend
6722	Quantitative Data of IVUS legend legend legend legend
6723	Multiple Regression Analysis of %Intima + Media Area legend
6724	Gas Exchange and Hemodynamic Variables After Breathing the Test Gas Mixture at Rest, at the End of the 6-Minute Exercise Period and After 3 Minutes of Resting Recovery legend legend
6725	Curve-fit Parameters of the V̇O2, V̇CO2 and Heart Rate Responses and O2 Deficit and EPOC During Exercise and Recovery in Normal Subjects and Patients with PPH Breathing Air and Air Supplemented With NO 20 ppm legend legend
6726	Cox Proportional Hazards Analysis of Survival in 159 CHF Patients legend
6727	Regional Contraction  (V c )  and Lengthening Rate  (V e )  in the Control Group legend legend
6728	Myocardial Velocities at Rest and During Dobutamine Challenge legend
6729	Withdrawals After Randomization legend
6730	Determinants of Change in FMD legend legend
6731	Hemodynamic and Sympathetic Nervous Effects of L-NMMA and Phenylephrine legend legend
6732	The Descriptive Data of the AMI Patients legend
6733	Effects of Long-Term Treatment With Carvedilol, Metoprolol and Captopril on Infarct Size and Cardiac Tissue Weights in Rats With MI legend legend
6734	Effects of Long-Term Treatment With Carvedilol, Metoprolol and Captopril on Hemodynamic Parameters in Rats with MI legend legend
6735	Bleeding, Hematological and Transfusion Parameters in All Patients legend
6736	Bleeding, Hematological and Transfusion Parameters in CABG Patients legend legend legend
6737	Bleeding, Hematological and Transfusion Parameters in Non-CABG Patients legend legend legend
6738	30-Day Clinical Outcomes legend
6739	Six-Month Clinical Outcomes legend
6740	Serum Tumor Necrosis Factor-Alpha Levels in Patients With Aortic Stenosis and Mitral Regurgitation, According to New York Heart Association Functional Class legend
6741	Serum Levels of Tumor Necrosis Factor Receptors in Patients With Aortic Stenosis and Mitral Regurgitation, According to New York Heart Association Functional Class legend legend
6742	Hemodynamic Data legend legend legend
6743	Positron Emission Tomographic Measurements legend legend
6744	Correlation Between Coronary Vascular Resistance and Lipids legend
6745	Sensitivity, Specificity, Accuracy, Relative Risk, Positive Predictive Value, and Negative Predictive Value for Each Testing Method legend
6746	Electron Beam Computed Tomographic Coronary Calcium Score Threshold Value: Increasing Threshold Value Lowers Sensitivity and Raises Specificity legend
6747	Reasons for Patient Exclusion legend
6748	Morphometric Analysis legend
6749	Stanford Classification Distribution legend
6750	Individual Effects of Pulse Pressure, Mean Arterial Pressure, Systolic Blood Pressure, Diastolic Blood Pressure and Hypertension Classification on the Study End Points ∗   legend
6751	Joint Effects of Pulse Pressure and Other Blood Pressure Parameters on the Study End Points legend
6752	Use of ASA Early After MI in the Four Different Trials legend
6753	Prevalence and Extent of Coronary Artery Disease in Patients With a Positive or Negative Cardiac Troponin T Result legend legend
6754	Ability of Multivariate Models to Predict One-Year Adverse Cardiac Events legend
6755	Effect of Oral Vitamin C Therapy on Measured Vascular Parameters legend
6756	RR Interval Power Spectral Analysis Results  (Mean ± SEM)  legend legend
6757	Blood Pressure Results  (mean ± SEM)  legend
6758	Angiographic and Procedural Patient Data legend
6759	Lesion-Related Variables by CK-MB Level legend
6760	Procedure-Related Variables by CK-MB Level legend
6761	In-Hospital Clinical Events by CK-MB Levels legend
6762	Late Outcome by CK-MB Group Levels legend
6763	Logistic Regression Analyses legend
6764	Mortality Levels in Patients With Eligible Holter Recordings  (Population of the Substudy)  legend legend
6765	Heart Rate Variability Measures in Patient Categories Considered in the Study legend
6766	Heart Rate Variability in Survivors and Nonsurvivors  (All-cause Mortality During Follow-up of EMIAT)  legend
6767	Numbers of Patients Fulfilling the Prospective Criteria of Depressed Heart Rate Variability legend
6768	All-cause Mortality in Prospectively Selected Patients With Reduced and Preserved Heart Rate Variability legend legend
6769	Statistical Significances of Multivariate Cox Models legend legend
6770	Mortality in Retrospectively Selected Patients With Reduced and Preserved Heart Rate Variability  (HRV Index ≤ 19 U and > 19 U)  legend legend
6771	Univariate Correlation Between Serum Neopterin Levels and Angiographic Data
6772	Multiple Regression Analysis With Significant Univariate Predictive Variables for Number of Complex Lesions legend legend legend
6773	Hemodynamic Measurements Pre- and Post-ASD Device Closure legend legend
6774	Comparison of groups
6775	Patients affected by adverse events
6776	Doses and plasma concentrations
6777	Types of severe combined immunodeficiency
6778	Group differences in memory and correlations with age
6779	Cases of clozapine-associated myocarditis
6780	Cases of clozapine-associated cardiomyopathy
6781	Maximum flow velocity of superior ophthalmic vein on colour doppler flow imaging in patients and controls
6782	Maximum doses
6783	Incidence of adverse events
6784	RR of SUDEP associated with other disorders
6785	RR of SUDEP associated with different antiepileptic-drug therapies
6786	RRs of SUDEP associated with combinations of seizure frequency and number of antiepileptic drugs
6787	Prevalence and incidence of treated epilepsy in 1995
6788	Age-specific fertility rates
6789	Patients excluded from study
6790	Clinically diagnosed seizure types in 300 first-seizure patients
6791	Epileptiform EEG abnormalities in 300 patients with clinically diagnosed epilepsy syndromes
6792	Diagnosis of epilepsy syndromes in 300 patients based on clinical, EEG, and MRI data
6793	Epileptogenic lesions shown by MRI and computed tomography  (CT)
6794	Classification of specific epileptic syndromes
6795	11C-DPN binding in the left parieto-temporo-occipital cortex in patients and controls
6796	Side-effects reported at clinic and numbers of children who did not complete the trial for any reason
6797	Distribution of behavioural problems at outcome
6798	Multiple logistic regression model for behavioural problems at outcome
6799	Outcome by treatment group
6800	Primary and secondary glycaemic outcomes in both study groups
6801	Quality of life
6802	Adverse events
6803	Participants reporting solicited injection site reactions or systemic adverse events after any dose in the different study cohorts
6804	Immunogenicity for the different study groups 14 days after the third vaccination, with GMTs in groups with more than 50% responders, by injection route and application device
6805	Mean HAM-D and MADRS total scores
6806	Treatment-emergent adverse events
6807	Successfully Tested Anti-PDGF Agents
6808	The nine key concepts included in the podcast  12
6809	Main podcast episodes
6810	Main results
6811	Self-reported intervention use in the previous 3 months, recorded at 3, 12, and 24 months
6812	Colorectal cancer incidence and mortality in control and intervention groups
6813	Colorectal cancer incidence and mortality by randomisation and compliance with screening
6814	Cumulative incidence of and mortality from colorectal cancer and the number needed to screen to prevent one event in the follow-up period
6815	Colorectal cancer incidence and mortality by sex, age group, randomisation, and compliance with screening
6816	Differences between number of male individuals circumcised in each village pair
6817	Diagnostic accuracy of ultrasound and iuMRI by age of fetus in the 570 cases constituting the primary group
6818	The tabulated results of prognostic grade given to pregnant women before and after iuMRI assessments
6819	Primary and secondary outcomes
6820	Costs per person and QALYs gained  (2015 international dollars)
6821	Cost-effectiveness analyses from health system and societal perspectives  (2015 international dollars)
6822	Postprocedure OCT measures
6823	Procedural safety outcomes
6824	Clinical outcomes at 30 days
6825	Participant ratings of appropriateness and helpfulness of brief intervention
6826	Weight loss actions taken by 3 and 12 months
6827	Births, abortions, and pregnancies in the intervention and control groups  *
6828	Relative risk estimates for any pregnancy before the age of 20 years
6829	Competing risks model for a birth or induced abortion before the age of 20 years
6830	Clinical outcomes
6831	Continuous outcomes
6832	Effects of successively stricter precautions against bias on analyses of six WHO defined groups of BMI versus all-cause mortality
6833	Nine groups of BMI versus all-cause mortality, with use of the primary prespecified analysis
6834	Summary of primary neuropsychiatric composite safety endpoint and its components
6835	Columbia-Suicide Severity Rating Scale  (C-SSRS)
6836	Mild, moderate, or severe adverse events  *   coding to the MedDRA category psychiatric disorders reported by at least 1% of participants in any treatment group
6837	Cross-validation performance of the tuberculosis risk signature in the ACS training set by days before tuberculosis diagnosis
6838	Blind prediction performance of the tuberculosis risk signature on the ACS test set by RNA sequencing and qRT-PCR and on the GC6-74 cohorts from South Africa and The Gambia by qRT-PCR
6839	Descriptive statistics of objectively-assessed environmental attributes
6840	Pooled associations of environmental attributes with daily minutes of moderate to vigorous physical activity by model  (n=6679)
6841	Differences in estimated MVPA between participants with low and high values for significant environmental correlates
6842	Long-term clinical outcomes from randomised access and open access periods
6843	Primary and secondary outcomes
6844	Distribution of Patients According to Oral Glucose Tolerance or Presence of Manifest Diabetes Mellitus Over the Five-Year Study Period legend
6845	Univariate and Multivariate Stepwise Regression Analyses of the Relations of On-Trial Body Mass Index, Glucose and Insulin Responses to the Oral Glucose Tolerance Test, Homeostasis Model Assessment Index and Insulin-like Growth Factor-I and Insulin-like Growth Factor Binding Protein-1 Levels to the Angiographic Outcome Measurements legend
6846	Calculations of vaccine efficacy and vaccine effectiveness based on different study populations
6847	Distribution of confirmed Ebola virus disease cases in vaccinated and unvaccinated individuals in immediate and delayed clusters
6848	Obstetric data after study entry and neonatal data at delivery
6849	Short-term fetal and neonatal outcomes
6850	Primary outcome at 2 years corrected age
6851	Developmental and neurosensory outcomes in survivors to 2 years
6852	Local reactions
6853	Systemic reactions
6854	Antibody responses 4 weeks after the third vaccination
6855	Self-reported adverse events during the study and health-care register follow-up
6856	Design features of 27 trials, with numbers of women and of those with a documented history of vascular disease
6857	Analysis of primary outcome
6858	Mean scores on knowledge subscales
6859	Analysis of secondary outcomes
6860	Use and acceptability of decision aids
6861	Findings of CTCA  (n=1778)
6862	Changes in investigations and treatments at 6 weeks
6863	Percentage of Rats With Ventricular Fibrillation in the Three Groups legend
6864	Clinical outcomes
6865	Myocardial Infarct Size in the Three Groups of Rats legend
6866	Tumour stage and histological risk groups
6867	Event-free and overall survival for the intention-to-treat and per-protocol populations
6868	Sites of relapse in the intention-to-treat population
6869	Percentage changes in lipid and lipoprotein concentrations
6870	Rates of adverse events and key safety variables of interest
6871	Outcomes
6872	Treatment-related adverse events
6873	Impairments and predictors of quality of life  (QoL)  for young people with cerebral palsy who self-reported QoL
6874	Description of each KIDSCREEN domain
6875	KIDSCREEN scores on each domain for self-reporting adolescents with cerebral palsy  (cross-sectional sample, n=431)
6876	Linear regression models relating KIDSCREEN scores on each domain to type and level of impairment in adolescents with cerebral palsy  (cross-sectional sample, n=431)
6877	KIDSCREEN scores on each domain for young people with cerebral palsy who self-reported in both childhood and adolescence  (longitudinal sample, n=355)
6878	Vaccine efficacy and number of cases prevented for the combined primary endpoint, 6-month persistent infection, CIN1+, CIN2+, and ASC-US+ associated with HPV 16/18
6879	Vaccine efficacy against 6-month persistent infection with vaccine and non-vaccine oncogenic HPV types  (according-to-protocol cohort for efficacy)
6880	Safety and pregnancy outcomes up to month 48  (total vaccinated cohort)
6881	Treatments received for depression
6882	Trial outcomes
6883	Change from allocated trial treatment to non-trial treatment for each group
6884	Summary of serious and non-serious adverse events, by group
6885	Adjusted  *   annual costs and quality-adjusted life-years
6886	Vaccine efficacy against varicella in the per-protocol efficacy cohort
6887	Participants reporting solicited injection-site  (local)  symptoms up to 4 days after each dose and of fever up to 15 days after each dose in the reactogenicity subset
6888	Serious adverse events deemed by the investigator to be related to vaccination in the total vaccinated cohort
6889	Pharyngeal carriage prevalence of disease-associated sequence types of capsB in 4CMenB and control groups and serogroups A, C, W, or Y  (combined)  of Neisseria meningitidis in MenACWY-CRM and control groups  (primary endpoints; modified intention-to-treat population)
6890	Odds ratios  (GEE model)  for carriage prevalence of Neisseria meningitidis in 4CMenB and control groups at any timepoint from 3 months after second vaccination  (visits 4 to 6)  in modified intention-to-treat population
6891	Percentage of participants with new acquisition of pharyngeal carriage at 3, 5, or 11 months after second vaccination with 4CMenB versus controls  (pharyngeal carriage; individuals with all six swabs)
6892	Odds ratios  (generalised estimating equation model)  for carriage prevalence of Neisseria meningitidis in MenACWY-CRM and control groups at any timepoint after 2 months of one vaccine dose  (visits three to six; modified intention-to-treat population)
6893	Percentage of individuals with new acquisition of pharyngeal carriage at 2, 4, 6, or 12 months after first dose or 1, 3, 5, or 11 months after second vaccination with MenACWY-CRM or placebo versus controls  (pharyngeal carriage; participants with all six swabs)
6894	Number of physiotherapy appointments attended by women in the intervention group
6895	Self-reported prolapse symptoms at 6 months and 12 months
6896	Change in prolapse  (pelvic organ prolapse quantification)  stage at 6 months, and uptake of further prolapse treatment by 12 months
6897	Self-reported effect of prolapse symptoms, and prevalence of urinary and bowel symptoms at 6 months and 12 months
6898	Treatment-emergent adverse events
6899	Changes in objectively measured continuous outcomes, self-reported outcomes, and self-reported psychological health outcomes
6900	5-year clinical outcomes in the SORT OUT III trial
6901	Adjusted mean scores for body-mass index and eating disorder pathology, by treatment group
6902	Performance of smear microscopy, clinic-based nurse-administered Xpert MTB/RIF, and laboratory-based technician-administered Xpert MTB/RIF, per treatment site and overall
6903	Patients with a positive smear microscopy, Xpert MTB/RIF, or culture result, and days to result, per allocation group
6904	Proportions of patients on anti-tuberculosis treatment, and days to treatment initiation according to reason for treatment initiation, per allocation group
6905	Dropout and loss to follow-up data, per allocation group
6906	Effect estimates from multivariable models for three coprimary GDS-15 outcomes
6907	Secondary outcomes for all cohort participants  (N=891)
6908	Secondary outcomes for all cross-sectional participants  (N=751)
6909	Summary of admission outcomes at follow-up
6910	Secondary outcome measures by randomisation group
6911	Summary of admission outcomes at follow-up by randomisation group for black subgroup
6912	Projected deaths averted from cardiovascular diseases, cancers, and chronic respiratory diseases by reduction of key risk factors in people aged 30–69 years in Pakistan in 2025 and cumulatively from 2015 to 2025
6913	Evidence-based priority interventions for prevention and control of non-communicable diseases and injuries in Pakistan
6914	ITT analyses of primary and secondary outcomes at 6 month follow-up
6915	Sensitivity analyses of the primary and secondary BDI outcomes at 6 months, including imputed data for those with missing BDI outcome data
6916	ITT repeated measures analyses of outcomes at 6 and 12 month follow-up
6917	Patients with at least one serious adverse event
6918	Summary of adverse events during 24 weeks in the treated set of patients
6919	Summary of adverse events during 24 weeks in the treated set of patients not receiving concomitant sulfonylurea treatment
6920	Adverse events
6921	Outcomes by study group
6922	Outcomes in women with a cervical length of less than 38 mm
6923	Outcomes in women with a cervical length of at least 38 mm
6924	Changes in echocardiographic measures at 12 weeks and 36 weeks
6925	Adverse events and abnormal laboratory values
6926	Clinical symptoms at diagnosis, reported for 5% or more of all patients with confirmed pulmonary hypertension  (PH confirmed) , according to pulmonary hypertension groups and subgroups
6927	Incidence of clinical endpoints
6928	Subgroup analysis of the primary endpoint at 6 months
6929	Eligibility and follow-up criteria
6930	Effects of cash transfer intervention on outcome measures
6931	Included studies
6932	Overall hazard ratios for each endpoint per one SD increase in mean common carotid artery intima-media thickness in four models
6933	Pooled analysis of five trials of aspirin versus control showing the effect of allocated treatment on the risk of in-trial incident cancers stratified by metastatic status and by histological type
6934	Numbers of participants and number of first major vascular events  (MVEs)  in each study contributing to vascular disease risk categories
6935	Eligibility of CTT participants without a history of vascular disease for statin therapy under existing major guidelines, by estimated 5-year major vascular event risk
6936	Daily insulin dose in the insulin degludec and insulin glargine groups
6937	Hypoglycaemic episodes in the insulin degludec and insulin glargine groups
6938	Summary of adverse events
6939	Daily insulin dose for patients in the safety analysis set
6940	Hypoglycaemic episodes
6941	Treatment-emergent adverse events reported by 5% or more of participants
6942	Causes of death in the safety analysis set
6943	Study population
6944	Cox proportional hazards analysis and Poisson regression for colorectal cancer, non-colorectal Lynch syndrome cancers, and all Lynch syndrome cancers  (adjusted for sex)  in participants randomly assigned to aspirin or aspirin placebo
6945	Mode of delivery
6946	Maternal and neonatal outcome
6947	Biopsy-based rates of detection and relative sensitivity estimates for the HPV and cytology screening strategies according to the per-protocol or the intention-to-screen analyses
6948	Positive predictive value of the HPV test and Pap cytology test by age
6949	Per-protocol relative sensitivity and PPV of HPV versus Pap for a CIN2 or worse endpoint in different age groups with different cutoffs of HPV tests
6950	Mean change in scores with the Roland and Morris Disability Questionnaire  (primary outcome measure)  during 4-month and 12–month follow-ups
6951	Summary data for secondary outcome measures at follow-ups of 4 months and 12 months
6952	Mortality risk, by exercise volume and intensity
6953	Hazard ratios for cancer mortality and incidence, by volume of leisure-time physical activity
6954	Primary and secondary outcomes
6955	Angiographic and clinical composite outcomes at 18 months
6956	Sensitivity analyses on the composite primary outcome
6957	Independently assessed modified Rankin score at 18 months
6958	Composite primary outcome by hydrogel treatment achieved  (per-protocol analysis)
6959	Composite primary good outcomes by use of assist device
6960	Efficacy of Vero-cell-culture-derived vaccine in culture-confirmed influenza infection
6961	Immunological response  (reciprocal haemagglutination inhibition titre)  to immunisation with Vero-cell-culture-derived influenza vaccine or placebo
6962	Sensitivity and specificity of different cutoff haemagglutination inhibition titres for matching A/Brisbane/59/2007 strains  (n=63)
6963	Relative risk of treatment-emergent non-serious related adverse events with incidence greater than 1% in any treatment group
6964	Composite vascular endpoint during 6 months' follow-up
6965	Secondary events during 6 months' follow-up
6966	Secondary clinical outcomes
6967	Treatment effects
6968	HPV prevalence in women at enrolment, and at 12 months and 24 months follow-up, by male circumcision study group  (intention-to-treat analysis)
6969	HPV prevalence in women at enrolment, and at 12 months and 24 months follow-up, by male circumcision status  (as-treated analysis)
6970	HPV incidence in women by study group and follow-up interval for participants with amplifiable cellular or viral DNA at sequential study visits
6971	Genotype-specific female high-risk HPV incidence during 2 years, by study group
6972	Clearance of pre-existing genotype-specific female high-risk HPV infections, by study group
6973	Dosing scheme
6974	Echocardiogram assessment of left atrial function
6975	Adverse events
6976	CHD and CVD events by CAC status in the MESA population eligible for JUPITER
6977	Estimated 5-year NNT to prevent an event of CHD or CVD, by CAC burden in population eligible for JUPITER
6978	CAC versus hsCRP for risk prediction in patients eligible for JUPITER
6979	Compliance with study simvastatin  (>80% taken)  at scheduled follow-up visits
6980	Reasons for stopping study simvastatin tablets before scheduled end of study
6981	Mean differences in plasma concentrations of lipids during follow-up, by allocated treatment
6982	Myopathy and raised alanine aminotransferase and creatine kinase concentrations
6983	Interventional Procedures legend
6984	In-Hospital Procedural Results and Clinical Outcomes at 12 Months Follow-up legend
6985	Independent Predictors of Any Cardiac Event and TLR During One-Year Follow-up Period
6986	Participation and cumulative yield of smear-positive tuberculosis cases in the community during six rounds of intervention
6987	Prevalence of tuberculosis disease before intervention and before round six of intervention
6988	Absolute and relative changes in dyspnoea and quality of life during the 7-day study period
6989	Predictors of response to medical gas
6990	Patient-reported rating of side-effects
6991	Antiretroviral therapy  (ART)  use and risk of HIV-1 transmission
6992	HIV-1 transmission rates by CD4 cell count and plasma HIV-1 concentration in couples in whom the HIV-1 infected partner had not initiated antiretroviral therapy
6993	Colorectal cancer incidence and mortality in control and intervention groups
6994	Colorectal cancer incidence and mortality by randomisation and compliance with screening
6995	Cumulative incidence of and mortality from colorectal cancer, and the number needed to screen to prevent one event in the present follow-up period
6996	Study-drug coverage during follow-up by study group*
6997	Effect of aciclovir on measures of HIV-1 disease progression during study follow-up
6998	Comparison of biomedical clinical trials of non-antiretroviral therapy interventions to reduce HIV-1 disease progression
6999	Births, deaths, and crude mortality rates in intervention and control clusters during the trial period  (2005–07)
7000	Comparison of mortality rates in intervention and control clusters  (2005–07)
7001	Process indicators in intervention and control clusters
7002	Estimates of clinical effectiveness at 3, 6, and 12 months after randomisation
7003	Data for non-diabetic participants in 13 placebo-controlled and standard care-controlled statin trials that reported incident diabetes
7004	Outcomes of APCam01 and APCam03
7005	Secondary comparisons in APCam01 and APCam03
7006	Comparisons in APCam02
7007	Frequency and duration of hypoglycaemia and hyperglycaemia during closed-loop delivery and continuous subcutaneous insulin infusion
7008	Comparisons between closed-loop delivery and continuous subcutaneous insulin infusion after pooling APCam01 and APCam03 data  §
7009	Efficacy of emergency contraception in single studies and meta-analysis, according to time from unprotected sexual intercourse to intake of emergency contraception  (efficacy-evaluable population)
7010	Haemagglutination inhibition antibody response against 2009 influenza A H1N1 before and 21 days after one injection of vaccine or placebo
7011	Participants with at least one solicited injection-site or systemic reaction within 7 days after vaccination with 2009 influenza A H1N1 vaccine or placebo by age group
7012	Clinical and safety outcomes
7013	Risk ratios  (RRs)  for coronary heart disease and ischaemic stroke per three-fold higher usual C-reactive protein  (CRP)  concentration with progressive adjustment for usual levels of potential confounders
7014	Risk ratios  (RRs)  for coronary heart disease and ischaemic stroke per three-fold higher usual C-reactive protein  (CRP)  concentration with adjustment for usual levels of conventional risk factors plus different inflammatory markers
7015	Vaccine efficacy against HPV-16/18 incident and persistent infection in cervical samples and HPV-16/18 associated cytological and histopathological endpoints up to 6·4 years of follow-up
7016	Cumulative number of endpoint events associated with HPV 16/18
7017	Vaccine efficacy against cytological and histopathological endpoints independent of HPV DNA in lesions up to 6·4 years of follow-up
7018	Occurrence of adverse events, serious adverse events, and new onset chronic disease in the follow-up study
7019	Outcomes after 18 weeks of treatment with inhaled corticosteroid plus placebo or salmeterol in B16 Arg/Arg and B16 Gly/Gly participants
7020	Number of enrolled participants, number eligible, and percentage enrolled by sex, ethnic and racial origin, diabetes status, and treatment group
7021	Incidence  (cases per 100 person-years)  of diabetes during DPP, bridge period, and DPPOS
7022	Cardiovascular disease risk factors averaged over all follow-up since randomisation to DPP
7023	Pregnancy outcome and onset of labour in randomised patients
7024	Maternal outcome
7025	Method of delivery
7026	Neonatal outcome
7027	Intention-to-treat analyses of primary and secondary outcomes at 4-month follow-up
7028	Intention-to-treat analyses of primary and secondary outcomes at 8-month follow-up
7029	Secondary analyses of primary and secondary BDI outcomes at 4-month and 8-month follow-ups
7030	Primary outcome  (proportion of women delivering or with intrauterine death before 34 weeks)  overall and by subgroup of chorionicity
7031	Gestational age at birth and duration of labour  (secondary outcomes)
7032	Method of delivery  (hierarchical; secondary outcome)
7033	Neonatal complications  (secondary outcomes)
7034	Safety issues  (secondary outcomes)
7035	Maternal symptoms  (tertiary outcome)
7036	Maternal satisfaction  (tertiary outcome)
7037	Summary of sexual history at enrolment
7038	Efficacy against the combined incidence of vaccine-type-related infection of at least 6 months' duration, cervical intraepithelial neoplasia, and external genital lesions  §
7039	Summary of clinical adverse events  (days 1–15 after any vaccination visit)
7040	Hazard ratios for incident cardiovascular events in the JUPITER trial according to magnitude of reduction in LDL cholesterol  (LDLC)  in participants allocated to rosuvastatin
7041	Hazard ratios for incident cardiovascular events in the JUPITER trial according to magnitude of reduction in high-sensitivity C-reactive protein  (hsCRP)  in participants allocated to rosuvastatin
7042	Hazard ratios for incident cardiovascular events in the JUPITER trial in the placebo group and according to achieved concentrations of both LDL cholesterol and high-sensitivity C-reactive protein  (hsCRP)  in participants allocated to rosuvastatin
7043	Major efficacy and safety endpoints at 30 days
7044	Major efficacy and safety endpoints at 15 months
7045	Main outcomes of comparative studies for open and laparoscopic pyloromyotomies
7046	Minimisation criteria
7047	Primary outcomes
7048	Secondary outcomes
7049	Comparison of primary outcomes stratified by grade of primary surgeon
7050	Long-term survival and cognitive outcomes by treatment dose and mean antibody titre compared with placebo group
7051	Effect of AN1792 or placebo on exploratory measures in the assessable population at 6 year follow-up
7052	Summary of HIV seroconversions, overall and by subgroups of sex, region, study drug adherence, and genital ulcer disease at enrolment
7053	Relative risk of incidence of genital ulcers  *
7054	Incidence of serious adverse events by study group
7055	Comparison of outcomes at 3 months
7056	Service-delivery strategies by study arm
7057	Neonatal mortality rates  (NMR)  for home-care, community-care, and comparison arms by year and every 6 months
7058	Incidence of diabetes, CVD, and mortality in the active intervention  (1986−92)  and entire follow-up period  (1986−2006) , and CVD and mortality in the post intervention period  (1993−2006)
7059	Summary of outcomes overall plus comparative statistics  (intention-to-treat population)
7060	Summary of poison-specific outcomes plus comparative statistics  (intention-to-treat population)
7061	Endpoints
7062	Pathogens isolated from 87 patients with an infectious complication*
7063	Number of participants with diabetes by trial
7064	Adjusted mean intervention effect on physical activity variables at 6 and 12 months for combined intervention groups versus comparison group
7065	Adjusted mean intervention effect on secondary outcomes for combined intervention groups versus comparison group
7066	Person-years and numbers of deaths attributed to IHD, stroke, and other vascular causes, by age at risk
7067	Combined PSC and MRFIT hazard ratios for IHD, stroke, and other vascular mortality for 1 mmol/L lower usual total cholesterol
7068	Incidence rates for intervals of follow-up
7069	Adverse events recorded by severity and relatedness to the surgery
7070	Eligibility and follow-up criteria
7071	Outcome measures  *
7072	Estimates of effect on outcome indicators
7073	Distribution of FGM status and total FGM by country
7074	Estimated rates of perinatal death per 1000 births in infants born to women with and without FGM
7075	Distribution of pairs of placebo-controlled trials by clinical topic
7076	Univariable meta-regression analysis of treatment effects in 110 placebo-controlled trials of homoeopathy and 110 matched trials of conventional medicine
7077	Anatomical extent of FGM among respondents
7078	Types of FGM classified according to WHO criteria
7079	Association between extent of FGM and primary infertility
7080	Proportion of primary and secondary endpoints
7081	Risk of treatment failure in individuals with suspected meningitis
7082	Indicator variables retained in Cox regression models for prediction of long-term mortality
7083	Type and frequency of vascular events
7084	Indicator variables retained in Cox regression models for prediction of long-term vascular event risk
7085	Indicator variables retained in Cox regression models for prediction of fatal and non-fatal stroke
7086	Summary of interventions from 392 case notes audited, by treatment group
7087	RMDQ scores at 3 months and 12 months follow-up
7088	Participants' assessment of overall change at 12 months' follow-up, by treatment group
7089	Secondary outcome measures at 3 months' and 12 months' follow-up, by treatment group
7090	Estimated 5-year rate of a first major vascular event  (MVE) , major coronary event  (MCE) , or vascular death in univariate and multivariate risk subgroups
7091	Total  (first and subsequent)  vascular and non-vascular outcomes during 5-year mean follow-up
7092	Mean days in hospital and costs of hospitalisation per person during 5-year mean follow-up
7093	Days on statin and costs of statin per person during 5-year mean follow-up
7094	Participants’ concern about future breast cancer after being offered results
7095	Estimated effect of gabapentin vs placebo
7096	Mortality and hospital and institutional admissions
7097	Quality of life and morale  *
7098	Per-protocol population: mortality, hospital and institutional admissions
7099	Per-protocol population: quality of life and morale  *
7100	Comparison of results with meta-analysis
7101	Normalised brain volumes and percentage changes of brain volumes
7102	Correlations between percentage change of brain volume and MRI measures of disease activity
7103	Geometric mean titres  (95% Cl)  for antibodies against circumsporozoite and HbsAg
7104	Vaccine efficacy
7105	Mortality and causes of death during the double-blind trial,5-year extension, and 10-year follow-up
7106	Number of first postrandomisation cancers during 10-year follow-up  *
7107	Number of pregnancies recruited by gestational age and umbilical artery end diastolic flow velocity  (EDF)  waveform result
7108	Main fetal outcomes at 2 years of age
7109	Cause of death
7110	Disability details
7111	Outcomes of Griffiths assessments
7112	Lipoprotein profile in relation to early diet
7113	Regression analyses of lipoprotein profile on human milk intake
7114	Relative risk  (RR)  of HIV-1 and other STIs in circumcised and uncircumcised men
7115	Mean peak flow and symptom scores immediately before and during treatment with the study inhalers
7116	Mean peak flow and symptom scores immediately before and during treatment with the study inhalers in individuals taking 1000 μg/day or less of inhaled corticosteroid  (n=162)
7117	Total patients recruited and followed up by background drug
7118	Included trials
7119	Day 14 failures categorised as early
7120	Serious adverse effects events: clinical details by study
7121	Results of assessment at 90 days
7122	Results of multiple logistic regression model for intention-to-treat analysis
7123	Compliance with study drug
7124	Primary composite endpoint results for intention-to-treat and on-treatment analyses
7125	Secondary endpoints—intention-to-treat analysis
7126	Bleeding events—intention-to-treat analysis
7127	Liver enzyme concentrations
7128	Average use of statin  (study or non-study)  and average plasma LDL cholesterol concentrations during follow-up
7129	Average differences in plasma lipid concentrations during follow-up in participants with or without diabetes at study entry
7130	Effects of simvastatin allocation on first and all major vascular events in participants with or without diabetes
7131	Effects of simvastatin allocation on plasma creatinine concentrations in participants with or without diabetes
7132	Outpatient semi-rush hyposensitisation regimen
7133	Outcomes of randomised study phase
7134	Sting challenge reaction grade and previous worst reaction grade in the placebo group
7135	Adverse reactions to VIT from randomised and crossover phases
7136	Clinical and parasitological outcomes after 14 days of follow-up
7137	Odds ratios of treatment failure at 2 week intervals after each episode of malaria
7138	Numbers of deaths attributed to stroke, ischaemic heart disease  (IHD) , other vascular causes, and non-vascular causes, by age at risk
7139	Relative ability of different blood pressure indices  (measured once only)  to predict stroke and ischaemic heart disease  (IHD)  mortality rates
7140	Status 12 months after start of chemotherapy
7141	Death rates by HIV status and allocated treatment group
7142	Significant regression coefficients  (B) , standard errors  (SE)  and 95% CI from regression of MDI, PDI, cooperation and emotional tone  (n=168)
7143	Sites of disease progression
7144	Multivariate prognostic-factors model
7145	Risk categories
7146	Compliance with study simvastatin  (≥80% taken)  and/or use of non-study statin during follow-up
7147	Differences in plasma concentrations of lipids during follow-up
7148	Average use of statin  (study or non-study) , and average plasma LDL cholesterol concentrations, during follow-up
7149	Numbers of participants with elevated liver or muscle enzymes during follow-up
7150	Self-reported difficulty hearing
7151	Results of whispered voice test
7152	Hearing aid ownership in people who failed the whispered voice test
7153	Perceived benefit and level of use of hearing aids in hearing aid owners
7154	Incidence of death or myocardial infarction by allocated treatment
7155	Summary of efficacy results by allocated treatment
7156	Rate of death or myocardial infarction by allocated treatment according to early use of coronary revascularisation
7157	30-day safety endpoints by allocated treatment
7158	Criteria for the three fatigue syndromes
7159	Univariate relative risks  (95% CIs)  for the three differently defined fatigue syndromes
7160	Univariate relative risks of mood disorders
7161	Logistic regression models for the empirically defined fatigue syndrome
7162	Logistic regression models for the Oxford and CDC criteria for CFS
7163	Logistic regression models for mood disorders
7164	Participants' reports of the informed consent process
7165	Participants' and providers' responses to selected questions on the quality of informed consent  (QuIC)
7166	Correlates of improved knowledge score in cancer clinical trial participants
7167	Incidence rate ratios of squamous cell carcinoma by treatment for patients who used ciclosporin
7168	Incidence rate ratios for squamous cell carcinoma for all cohort patients by time, ciclosporin treatment, and amount of PUVA and methotrexate
7169	Adjusted incident rate ratio  *   for squamous-cell carcinoma associated with ciclosporin treatment by amount of use of PUVA at first ciclosporin use
7170	Interferon treatment
7171	Response rates
7172	Patient details
7173	Postoperative outcome
7174	Outcome measure results
7175	Adverse events
7176	Local and systemic reactions to both injections
7177	Number of seroconversions
7178	SRH results in relation to CPMP criteria  *   for the assessment of interpandemic influenza vaccine
7179	Respondent age, sex, experience with negative reactions, and h of clinical work per week by specialty
7180	Doctors’ experiences with various types of negative reactions from patients or relatives
7181	Logistic regression analysis of the likelihood of having experienced an actual negative reaction  (n=869)
7182	Action taken by doctors in response to scenarios presented with or without threats
7183	Treatment-emergent adverse events attributed to study drug
7184	Treatment-limiting adverse events attributed to study drug
7185	Estimates of minimum and maximum efficacy for malaria prophylaxis
7186	Treatment compliance according to treatment group
7187	Risk of adenoma recurrence associated with fibre or calcium treatment
7188	Age, procedure, analgesic type, and nocturnal melatonin AUC for postoperative nights one, two, and three
7189	Main findings and subgroup analyses
7190	Retention rates
7191	Presence of dyspepsia at 2 years according to treatment group
7192	Dyspepsia symptom types at 2 years according to treatment group
7193	Quality of life at 2 years according to treatment group
7194	Expected and reported deaths for the study cohort
7195	Proportional mortality ratios
7196	HLA haplotype, HLA class-I expression, and lymphocyte subpopulation from peripheral blood
7197	Relative risks of outcomes
7198	Outcomes for intracranial haemorrhage
7199	Cause of death and associated disorders
7200	Incidence of skin cancers in terms of people treated for skin cancer and tumours treated on the head, neck, arms, and hands by sunscreen treatment group
7201	Incidence of skin cancers on all sites by betacarotene treatment group
7202	Outcomes  (number of patients)  by treatment group
7203	Mean  (SD)  antibody concentration to the three viral strains
7204	Repeated measures ANOVA between groups over time by each viral strain
7205	Cumulative probabilities of hospital admission for UTI
7206	Findings on risk of UTI and circumcision
7207	Comparison of mean scores on questionnaire
7208	Comparisons at review between the two trial groups
7209	Number of events and incidence rates for three categories of the frontal T axis
7210	Hazard ratios of abnormal and borderline T axis and cardiovascular risk factors for cardiac death, sudden death, non-fatal cardiac events, fatal or non-fatal cardiac events and total mortality
7211	Hazard ratios for cardiac death of abnormal and borderline T axis and other ECG abnormalities
7212	Study Population legend
7213	Follow-up and compliance
7214	Other cancers and events
7215	Univariate analysis of prognostic factors for breast-cancer-free survival in all 2494 participants
7216	Odds ratios for AMI associated with acute respiratory- tract infection, urinary-tract infection, body-mass index, and smoking status
7217	Effect of breathing rate on respiratory indices in patients with CHF and controls
7218	Respiratory indices in CHF patients and controls
7219	Laboratory results for 2018BP
7220	Structure of CBT and control programmes
7221	Summary of psychological tests used
7222	Group differences in psychological variables measured by χ2 analysis at postcourse and follow-up
7223	Job-seeking activities
7224	Between-group differences in job-seeking activities
7225	Job-seeking outcomes for CBT and control groups
7226	Distribution of types of AMI by region
7227	Odds ratios for AMI in relation to use of combined OCs by region
7228	Odds ratios for AMI in relation to current use of combined OCs by age, oestrogen dose, and whether blood pressure was checked before current episode of OC use
7229	Odds ratios for AMI in relation to current use of combined OCs according to other risk factors
7230	Odds ratios for AMI associated with current use of combined OCs among low-risk women  *   by reported blood-pressure check before current episode of OC use and smoking status
7231	Estimated incidence rates and attributable risks per 106 woman-years associated with current OC use by age and smoking status among European women
7232	Cases of cholera requiring inpatient care in vaccine and no-vaccine groups, and protective impact of vaccination
7233	Cases of cholera requiring inpatient care among fully vaccinated participants and no-vaccine participants, and protective efficacy of vaccination
7234	Visits for treatment of diarrhoea to hospital, polyclinics, and commune health centres  (CHCs)  in vaccine and no-vaccine groups
7235	Age and sex distributions at entry to study
7236	Acceptance of first FOB screening by sex and age
7237	Outcome of screening
7238	Stage of CRC in screening and control groups
7239	CRC incidence and mortality rates and mortality ratios in screening and control groups
7240	Patients with adenomas in screening and control groups
7241	Age and sex of participants at initial screening
7242	Compliance during repeated screening
7243	Screening-group individuals who underwent further investigations after a positive FOB test and predictive value of a positive test for neoplasia
7244	Stage of CRC and presence of large adenomas in screening and control groups between August, 1985, and August, 1995
7245	Causes of death in screening and control groups between August, 1985, and August, 1995
7246	Incidence and mortality rates for CRC between August, 1985, and August, 1995
7247	5-year risk of death definitely or probably due to CHD or non-fatal MI in WOSCOPS placebo-group men
7248	Benefits of treatment in WOSCOPS, 4S, and MRC trial
7249	Number of patients who need to be treated to prevent a major coronary event in WOSCOPS
7250	Frequency of symptoms of chronic bronchitis by smoking status and sex
7251	Risk ratios for first coronary event and coronary death associated with symptoms of chronic bronchitis, adjusted for age and study year  (model 1) , for age, study year, and amount of smoking  *    (model 2) , and multifactorially adjusted  †    (model 3)
7252	Risk ratios for first coronary event and coronary death associated with symptoms of chronic bronchitis stratified by smoking status  (13-year follow-up, multifactorially adjusted)
7253	Risk ratios for first coronary event and coronary death associated with symptoms of chronic bronchitis stratified by occupation  (13-year follow-up, multifactorially adjusted  *  )
7254	HIV-related minor clinical events by treatment group
7255	Hazard ratios for major cardiovascular outcomes in current drinkers, without and with adjustment for usual levels of systolic blood pressure, high-density-lipoprotein cholesterol, or body-mass index
7256	Clinical primary and secondary outcomes at 18 months
7257	Physical activity by country income level
7258	Summary of fatal and non-fatal events by physical activity
7259	Summary of risk of mortality and major CVD events stratified by country income level and physical activity
7260	Safety events by achieved LDL-cholesterol concentration at 4 weeks after randomisation
7261	Stillbirth rate, neonatal, post–neonatal, child, and under–5 mortality rates, number of stillbirths, and total number of under–5 deaths in 2016 and annualised rate of change in under–5 mortality for 2000–16, for global, SDI groups, GBD regions and super–regions, countries, and territories, both sexes combined
7262	Life expectancy at birth and at age 65 years, age-standardised death rates, and total deaths by sex for global, SDI groups, GBD regions and super-regions, countries, and territories in 2016
7263	Univariate and multivariate analysis of neural tissue activity vs cardiovascular disease events
7264	Subgroup analyses of amygdalar activity vs cardiovascular disease
7265	Analysis of neural tissue activity vs events—additional event definitions
7266	Adjusted HRs for high vs low amygdalar activity
7267	Correlation of amygdalar activity with haemopoietic activity and arterial inflammation
7268	Platelet reactivity and antiplatelet therapy
7269	Endpoints at 12 month follow-up
7270	Electrocardiographic Findings of Affected Patients
7271	Echocardiography and Right Ventricular Cineangiography legend
7272	Histological Findings of Endomyocardial Biopsy Samples legend
7273	Direct, indirect, and total costs attributable to physical inactivity, by country and WHO region  (in 1000 Int$, 2013)
7274	Multipoint LOD Score  (LOD)  at Theta = 0 and Two-Point LOD Scores for Different Recombination Fractions for Eight Different Markers of the Chromosome 1q42–q43
7275	Direct health-care costs attributable to physical inactivity paid by the public sector, private sector, and households, by country and WHO region  (in 1000 Int$, 2013)
7276	Comparison of mean direct and indirect costs of physical inactivity and lifetime disease burden  (measured by disability-adjusted life-years, DALYs)  by country income group  (2013)
7277	Meta-regression analysis of the association between total Teenage Pregnancy Strategy funding per head and absolute and percentage change in the conception rate in women younger than 18 years between 1994–98 and 2009–13
7278	Current participation of women aged 18–24 years in England by experience of early motherhood  (1990–91, 1999–2001, and 2010–12)
7279	Estimated abortion rates per 1000 women 15–44 years old, by geographic area and time period
7280	Estimated annual numbers of abortions  (in millions)  by geographic area and time period
7281	Percent of pregnancies ending in abortion, by geographical area and time period
7282	Abortion rate per 1000 women aged 15–44, by grounds under which abortion is legally allowed, 2010–14  *
7283	Abortion rates per 1000 women aged 15–44 years in groups of women defined by marital status, 2010–14
7284	Peri-procedural and post-procedural risks for CEA and CAS treatment, by age group
7285	Descriptions of individual serious allergic reactions
7286	Efficacy endpoints
7287	Bleeding endpoints
7288	Association between alcohol consumption and outcomes
7289	Risk of composite prespecified exploratory endpoint and first occurrence of components
7290	Risk of events assessed in the post-hoc analysis, by history of heart failure
7291	Intention-to-treat analysis of cumulative risks and hazard ratios of main outcome events
7292	Per-protocol analysis of cumulative risks and hazard ratios of main outcome events
7293	Past severe nuclear accidents  (International Nuclear and Radiological Event Scale level 5 or higher)
7294	Irradiation dose and number of workers involved with the emergency and recovery operations at Fukushima Daiichi nuclear power plant  (March 11, 2011, to Aug 31, 2013)
7295	Study outcomes by selected LARC method
7296	Pregnancy outcomes  *
7297	Dose quantity
7298	Intervention summary
7299	Outcomes at 3 months
7300	Deaths and serious complications at 3 months
7301	Changes in Heart Rate and Blood Pressure After Albuterol and Glyceryl Trinitrate in Patients With Type II Diabetes Mellitus and Control Subjects legend
7302	Primary care contacts and costs after index consultation request over the 28-day follow-up period, by group
7303	Patient safety
7304	Patient experience of care, overall satisfaction, health status, and problem resolution, by group
7305	Propensity-score matched survival models by timepoints up to 8 years by outcome
7306	Crude and matched logistic models for complications
7307	Reasons for revision in unicompartmental knee replacement  (UKR)  and total knee replacement  (TKR; matched analysis, revisions recorded in NJR only)
7308	Type of revision operation  (matched analysis, revisions recorded in NJR)
7309	Study treatments in the safety population
7310	Effect of losmapimod on laboratory endpoints in the safety population
7311	Kaplan-Meier estimates for effects of losmapimod on major adverse cardiac events in the safety population
7312	Effect of losmapimod on laboratory endpoints in the efficacy population
7313	Cardiac MRI substudy results
7314	Use of antiplatelet drugs during trial
7315	Study endpoints during follow-up
7316	Mediators analysed by participating cohorts in the main analysis
7317	Number of analysed cohorts, participants, and events by region
7318	HRs and excess risk of overweight and obesity mediated through different combinations of metabolic risk factors
7319	Stratified analyses of percentage of excess risk  (95% CI)  per 5 kg/m2 higher BMI mediated through the combination of blood pressure, cholesterol, and blood glucose
7320	Age-adjusted annual incidence and mortality rates  (per 100 000 person-years) , disability-adjusted life-years  (DALYs)  lost, prevalence  (per 100 000 people) , and mortality-to-incidence ratio  (MIR)  by age groups in high-income and low-income and middle-income countries, and globally in 1990, 2005, and 2010
7321	Mean age of incident stroke in 1990, 2005, and 2010 by country income level
7322	Outcomes at 12-month follow up
7323	Treatment process
7324	Primary outcomes, adjusted scores, differences, p values, and ICC according to questionnaire
7325	Outcomes by pre-enrolment angiography
7326	Efficacy of prasugrel versus clopidogrel by angiographic status
7327	Ischaemic events
7328	Safety outcomes
7329	Study outcomes at 5 years’ follow-up in patients in the PCI-only and CABG-only registries
7330	Effects of allocation  (continue tamoxifen to 10 years vs stop at 5 years)  on mortality with and without previous recurrence in each category of ER status at entry, and on various outcomes without previous recurrence in all women of any ER status
7331	Event rate ratios  (95% CIs)  in ER-positive disease, by time period from diagnosis
7332	Suboutcomes of treatment failure for ciclosporin and infliximab
7333	Severe adverse events during the study period according to treatment received
7334	SMR by causes of death according to ICD-10 groups
7335	SMRs for external and all underlying causes of death in the study sample by socioeconomic deprivation category on the basis of the IMD 2007 for the postcode of the location of the most recent episode of self-harm
7336	Population projections  (2010–50) , by region, UN medium variant
7337	Efficacy endpoints at 3 years
7338	Safety and combined endpoints at 3 years
7339	Sex ratio at birth, conditional on sex of previous birth  (99% CIs)  by birth order from 1990–1997
7340	Sex ratio at birth, conditional on sex of previous birth  (99% CIs)  by birth order from 1998–2005
7341	Estimates of annual gaps in girls to boys at ages 0–6 years due to selective abortion of female fetuses, in millions by birth year
7342	Estimates of decennial gaps in girls to boys at ages 0–6 years due to selective abortion of female fetuses, in millions
7343	Coverage of indicators for reproductive, maternal, and child health from national surveys
7344	Prevalence of selected risk factors for chronic diseases
7345	Intervention strategies categorised by level of health system and cost-effectiveness
7346	National policies for chronic diseases and injuries in India
7347	Mental health status of Afghan 11–16-year-old students and caregivers
7348	Variables associated with child mental health outcomes
7349	Interaction of social labour market protections with the effect of unemployment on suicide rates  (in people younger than 64 years) , 1980–2003
7350	Associations of a 1% rise in alternative economic measures with percentage change in death rates in European Union countries, 1970–2007
7351	Data sources used for estimating fire-related deaths in India in 2001
7352	Estimates of fire-related deaths in India in 2001
7353	Ratios of females to males in national estimates of fire-related deaths
7354	Ratios of females to males in local studies of fire-related deaths
7355	Association of spousal violence with early and late fetal loss
7356	Preventive fractions at different levels of effectiveness of spousal abuse intervention
7357	Relation between violence, violence subtype, and recurrent fetal loss
7358	Outcomes between Sure Start Local Programme  (SSLP)  and non-SSLP areas
7359	Intracerebral haemorrhages detected by CT/MR study at 22–36 h and at any imaging scans after treatment
7360	Main and additional outcomes for patients treated between 3 h and 4·5 h compared with those treated within 3 h
7361	Global and regional estimated numbers of induced abortion and abortion rates, 2003 and 1995
7362	Estimated number of safe and unsafe induced abortions and abortion rates by region and subregion, 2003
7363	Global, regional, and subregional estimated abortion ratios and percentages of pregnancies that ended in abortion, 2003
7364	Incidence of asthma and occupation
7365	Occupations and exposures  *   at high risk of asthma
7366	New-onset asthma and inhalation events
7367	Status of patients 2 years after admission to hospital
7368	Associations between type of service
7369	Intracerebral haemorrhages detected by CT or MRI study at 22–36 h after treatment and any post-treatment imaging scans
7370	2-day, 7-day, and 90-day risk of stroke by California score
7371	2-day, 7-day, and 90-day risk of stroke by ABCD score.
7372	2-day, 7-day, and 90-day risk of stroke by ABCD2 score
7373	Predictors from multivariable models of stroke at 2 days, 7 days, and 90 days after TIA in the six groups combined
7374	Leading 15 causes of death and numbers of deaths by age group for both sexes in WHO European Region, 2002  4
7375	Standardised injury mortality rates and rate ratios comparing low-and-middle-income countries  (LMIC)  with high-income countries  (HIC)  in the WHO European Region, 2002  4,10
7376	Primary and secondary outcomes and bleedings  (full analysis set)
7377	Pregnancy intendedness instrument  4
7378	Association between mean age  (years)  and intendedness
7379	Trends in maternal age, gestational stage, and pregnancy intendedness among women using emergency contraception
7380	Relative risk for 1 mmol/L increase in FPG, by age group  (after adjustment for confounding and regression dilution bias)
7381	Age-standardised mean  (SD)  of FPG  (mmol/L)  by sex and region
7382	Number  (thousands)  and proportion of deaths attributable to higher-than-optimum FPG by World Bank region, age group  (years) , and sex for ischaemic heart disease and stroke
7383	Sensitivity of estimated attributable mortality to choice of exposure variable, data sources on relative risk, and TMRED
7384	Inclusion and exclusion criteria
7385	Outcome events up to 30 days after treatment
7386	Primary endpoint results in predefined subgroup
7387	Treatment use over time
7388	Occurrence of first outcome events, according to treatment
7389	Quantitative Coronary Angiography Variables in 20 Patients Before and After Standard Balloon Angioplasty, After IVUS-Guided Balloon Angioplasty and After Stent Implantation legend
7390	Intravascular Ultrasound Variables After Standard Balloon Angioplasty, After IVUS-Guided Balloon Angioplasty and After Stent Implantation legend
7391	Hemodynamic and Distal Blood Flow Velocity Variables Measured Before and After Standard Balloon Angioplasty, After IVUS-Guided Balloon Angioplasty and After Stent Implantation in All Patients legend
7392	Sensitivity analyses for statin use and subsequent sepsis
7393	Cerebrovascular and common clinical features in young adult patients with cryptogenic stroke with and without Fabry disease
7394	7-day risk of stroke after presenting TIA in relation to potential risk factors
7395	7-day risk of stroke stratified according to ABCD score at first assessment in the OXVASC validation cohort of patients with probable or definite TIA
7396	Multivariate Cox regression analysis of predictors of 7-day risk of stroke in patients with probable or definite TIA derived from the pooled data  (stratified by study)  from OCSP and OXVASC
7397	7-day risk of stroke stratified according to ABCD score at first assessment in all referrals with suspected TIA to OXVASC and risk of stroke before scheduled clinic appointment in all referrals with suspected TIA to the non-OXVASC hospital-referred weekly TIA clinic
7398	Incidence rates per 100 000 population of first-ever stroke, by age and sex
7399	Age-specific and sex-specific incidence rates per 100 000 of first-ever stroke, by pathological subtype
7400	Frequency, incidence, and case-fatality rate of first-ever infarction, by subtype
7401	Case-fatality rates of incident stroke, by pathological subtype
7402	Premorbid cardiovascular risk factors and use of antithrombotic medication in patients with incident stroke, cerebral infarction, and intracerebral haemorrhage
7403	Prognosis at 6 months after first-ever stroke, by sex and age-group
7404	Outcome at 6-months after first-ever stroke, by pathological and infarction subtype
7405	Causes of death after stroke
7406	Age-standardised annual incidence  (95% CI)  per 1000 strokes, by pathological subtypes, in Iquique Chile and other population-based studies
7407	Weighted mean difference in plasma homocysteine concentrations according to the MTHFR C677T genotype  (TT vs CC)  among people without cardiovascular disease
7408	Assessment of consistency between odds ratios derived by extrapolation from phenotype–disease studies and those derived from meta-analysis of genetic studies
7409	Chemotherapy and surgical requirements of the 15 patients who did not have histology at the time of pregnancy termination
7410	Comparison of surgical and chemotherapeutic interventions needed in patients who did and did not have histology at the time of pregnancy termination
7411	Primary endpoint analysis
7412	Frequency of secondary endpoint events
7413	Number  (%)  of patients with bleeding events
7414	Age and sex structure of the study populations and crude incidence per 1000 population of first-ever stroke
7415	Standardised  *   overall incidence per 1000 per year  (95% CI)  of first stroke in OCSP and OXVASC stratified by sex, age, pathological type, and degree of disability at follow-up 30 days after stroke
7416	Overall incidence of transient ischaemic attack in OXVASC and OCSP by sex and age
7417	Premorbid risk factors and medication in patients with incident stroke
7418	Premorbid risk factors and medication in patients with incident transient ischaemic attack
7419	Description of studies included in analyses of the risk of breast cancer after abortion
7420	Stimulation type, peak oestradiol concentration, and follicle sizes on day of human chorionic gonadotropin administration, and oocyte retrieval outcome from ovarian transplant
7421	Odds ratio for a favourable outcome at 3 months after stroke
7422	Frequency of parenchymal haematoma between 0 and 360 min after treatment
7423	Cause of death
7424	Number of patients having a serious adverse event within 48 h of trial entry
7425	Data used in base-case analysis
7426	Quality-adjusted life years, cost, and incremental cost-utility ratios by age
7427	One-way sensitivity analyses on selected utilities  *
7428	Miscarriage cohort, group according to the date of sample collection relative to diagnostic ultrasound
7429	Overall mortality in carriers of haemophilia
7430	Cause-specific mortality in carriers of haemophilia
7431	Relative reduction in crash risk associated with a conviction
7432	Frequency  (% of total per period)  of accidents per half-hour for each work period and relative risks for all periods combined
7433	Risks/death and stroke or death within 30 days/surgery in patients who underwent trial surgery by degree/symptomatic carotid stenosis
7434	Pregnancies included in the study
7435	Adjusted relative risks of fetal death according to fever in pregnancy week 1–16
7436	Mortality rates for accidents at work in UK fishing and seafaring, all workers, and workers in five main industrial sectors, in Great Britain
7437	Proportion of boys born to individuals exposed and unexposed to dioxins, 1980–99
7438	Risk of death and severe injury for drivers and front-seat passengers by front and rear seatbelt use
7439	Risk of death and severe injury for belted drivers and front-seat passengers by rear seatbelt use and by mode of car crash
7440	Frequency of thyroid cancer in the Gomel region of Belarus  (1998–2000)
7441	Age, use of contraception, and sexual competence at first intercourse; parenthood and abortion before age 18 years
7442	Prevalence and adjusted odds ratios for first intercourse before 16 years, non-use of contraception, and sexual noncompetence at first intercourse  (16–24 year olds)
7443	Prevalence of contextual factors surrounding first intercourse, 16–24 year olds
7444	Prevalence and adjusted ORs for motherhood and abortion before 18 years and for even having had an STI  (18–24 year olds) , among women who had first intercourse before 18 years
7445	Prevalence and adjusted odds ratios for ever having had an STI  (18–24 years olds) , among men who had first intercourse before 18 years
7446	Contraceptive use and unmet need by area, 1984 and 1990
7447	Childbearing intentions, pregnancy, and abortion, by area, 1984–89 and 1990–95
7448	Contraception, abortion, and fertility in MCH-FP and comparison areas, 1984–86 and 1996–98
7449	Logistic regression model of stroke recovery for Boston patients
7450	Illustration of the logistic regression model for the original Boston patients and its application to Australian patients for the allotted categories
7451	A three-item scale for the prediction of stroke recovery shortly after admission
7452	Observed % of patients with stroke recovery across three probability ranges of the logistic regression model and three levels of the three-item scale
7453	Risk and duration of HPV infection and risk of high-grade CIN according to HPV type
7454	Risk of moderate or severe dyskaryosis in relation to time from first HPV exposure
7455	Risk of high-grade CIN in relation to time since first exposure to HPV 16
7456	Rates of perioperative  (30-day)  stroke and death by age category in 1415 patients who actually underwent carotid endarterectomy
7457	Absolute reduction in risk of ipsilateral ischaemic stroke and number needed to treat at 2 years according to degree of stenosis and age category
7458	Kaplan-Meier risk estimates of cause of death at 2years according to age category
7459	Age-standardised death rates per 100 000 at age 15–24 years for selected causes of death
7460	Age-standardised death rates per 100 000 at age 15–74 years for selected causes of death
7461	Comparison between groups of patients with normal and abnormal computed tomography  (CT)  scans
7462	Secondary endpoints for patients with ischaemic stroke
7463	Secondary endpoints for all treated patients
7464	Adverse events occurring up to 7 days after treatment or before hospital discharge in all treated patients
7465	Assessment of agreement between observers
7466	Source of information about deaths resulting from intentional and unintentional injuries in Bangladesh
7467	Reported causes and numbers of intentional and unintentional injury-related deaths
7468	Reported causes of intentional and unintentional injury-related deaths by age-group
7469	Women's ability to estimate pregnancy duration and differences between women's and providers' estimates
7470	Microsatellite polymorphisms identified after PCR, gel electrophoresis, and GeneScan analysis
7471	Comparison of retrospective and prospective cohorts
7472	Clinically important errors in junior doctors' and nurse practitioners' assessments of patients
7473	Radiographic requests compared with judgment of research registrar and interpretation compared with radiologist's report
7474	Outcome of patients at 28 days
7475	Unplanned follow-up visits reported by patients at 28 days
7476	Clinical predictors of M tuberculosis bacteraemia in febrile hospital inpatients
7477	Therapy and diagnostic testing on or before the day of admission
7478	Antimicrobial resistance among M tuberculosis isolates from blood
7479	Validity of checklist
7480	Study outcomes by treatment group
7481	Developmental stages and abnormalities in failed pregnancies
7482	Main outcomes after surgery
7483	Results for secondary outcomes and wound pain
7484	Resting and Peak Exercise Hemodynamics legend
7485	Comparison Between Patients With Normal and Increased PVR legend
7486	Odds ratios for developing antibodies to thyroid by age, sex, and radiation exposure
7487	Mean  (SD)  serum free T4, free T3, and TSH
7488	Pregnancy outcome for the 4374 randomised women
7489	Estimated gestational age at first amniocentesis attempt based on crown-rump length  (mm)
7490	Procedure analysis
7491	Congenital anomalies  (reported at birth)
7492	Developmental and background variables and risk of death during follow-up
7493	Independence of risk factors for  (sub) intentional self-destruction
7494	Association of vaginal flora morphology and prevalence of HIV-1
7495	HIV-1 prevalence associated with vaginal flora morphology and numbers of sexual partners in previous year
7496	HIV prevalence associated with bacterial vaginosis in women with concurrent STDs
7497	Classification of causes of death
7498	Life expectancy at birth in Russia by sex and year  1
7499	Age-standardised  (to European population)  mortality rates per 106 for Russia by sex, year, and cause
7500	Mortality in 1987 and relative changes in mortality 1984–94 by cause and sex at age 40–44 years in Russia
7501	Adjusted relative risk of death according to reproductive status after diagnosis of breast cancer, age at
7502	Main clinical events in hospital during scheduled  (4-week)  treatment period by allocated treatment
7503	Functional status at discharge
7504	Main outcome events within 14 days
7505	Outcome at 6 months
7506	Effect of heparin and aspirin on recurrent stroke within 14 days among patients with and without atrial fibrillation
7507	Direct randomised comparison of effects of subcutaneous heparin 12 500 and 5000 IU twice daily
7508	Absolute benefits observed in the IST of low-dose heparin or aspirin compared with control
7509	Summary of study data
7510	Relations of skull fracture shown on radiography and presence of neurological abnormalities to CT-defined intracranial abnormality
7511	Neuroexcitatory aminoacids in plasma and CSF samples
7512	Multiple logistic regression analysis of progressing ischaemic stroke with plasma concentrations of excitatory aminoacids as covariates
7513	Multiple logistic regression analysis of progressing ischaemic stroke with CSF concentrations of excitatory aminoacids as covariates
7514	VEE virus strains characterised genetically and/or antigenically
7515	Distribution of location and direction of spinal curve
7516	Potential risk factors for progression in relation to final magnitude of the curve in 30 patients followed up after age 20 years
7517	Nucleotide and aminoacid sequence homologies of the gene segments of HK97 and CkHK97
7518	Plasma Levels of CRP and SAA and Serum Levels of IL-6 During the Study Period legend
7519	Hispanic Enrollment by Region
7520	Socioeconomic Information from GUSTO-III legend
7521	Time to Treatment
7522	Use of Cardiac Medications legend
7523	Use of Cardiac Procedures legend
7524	Major Clinical Outcomes
7525	Outcomes by Thrombolytic Treatment
7526	ART received
7527	Incidence of measles in 32 participating European countries  (2006–07)
7528	Measles cases with known vaccination status  (2006–07)
7529	Statistical association of risk variables with mortality
7530	AUC of ROC of deceleration capacity  (DC) , acceleration capacity  (AC) , LVEF, and SDNN, as well as of combinations of DC and LVEF, AC and LVEF, and SDNN and LVEF, by cohort
7531	Association of risk variables with total mortality in a multivariate analysis
7532	Sensitivity and positive predictive accuracy of high-risk groups
7533	Clinical and serological features of Rickettsia sibirica infection in affected paleontologists
7534	Coverage achieved during measles catch-up vaccination campaigns and routine vaccination
7535	Results of measles case-based surveillance, southern Africa, 2000
7536	Timing of follow-up measles vaccination campaigns, southern Africa, 2000–02
7537	Rotashield administration, and number and excess infant intussusception admissions during the Rotashield period in ten US states, 1993–99
7538	Summary data on excess hospital admissions for intussusception and population attributable risk estimates, for infants 45–210 days old
7539	Cause of death
7540	Risk factors for death
7541	Logistic regression analysis to predict death
7542	Risk factors for coronary events
7543	Clinical, Hormonal and Metabolic Details of the Subjects in the Study  (Mean ± SE)  legend legend
7544	Similarities and Differences Between “Cardiac” and “Metabolic” Syndrome X legend
7545	mRNA expression in various human tissues
7546	Quantification of verapamil metabolites in microsomal ventricular tissue
7547	Details of primers used to amplify rickettsial genes
7548	Details of PCR cycles used to amplify rickettsial genes
7549	Median  (in elapsed months of age)  for age at diagnosis, age at parental concern, and age at regression, and intervals between these, according to diagnostic category
7550	Relative incidence and numbers of events in risk periods after vaccination with one or more MMR vaccine or one or more MMR, single-antigen measles and mumps plus rubella vaccines, by event type in children with core or atypical autism
7551	Estimates of the mean difference in KI score between each S21400 group and the placebo group
7552	Linear and multiple regression analysis of severity of nephrotoxicity on potential risk factors
7553	Primary and secondary outcomes
7554	Clinical outcomes
7555	Adverse events  (number of patients)  and safety outcomes
7556	Lipid efficacy outcomes at week 12 and at the mean of weeks 10 and 12
7557	Adverse events and laboratory results
7558	Treatment adherence and follow-up
7559	Per-protocol analysis
7560	Intention-to-treat analysis
7561	Glycaemic control in each treatment group
7562	Procedures and study drugs
7563	Clinical outcomes at 90 days
7564	Efficacy at 12 weeks adjusted for placebo
7565	Adverse events
7566	Adverse events in cardiac-stem-cell-treated and control patients
7567	Pulmonary embolism severity index
7568	Effectiveness and safety outcomes
7569	Medical resources used by treatment group
7570	Overdose mortality rate in Vancouver between Jan 1, 2001, and Dec 31, 2005  (n=290) , stratified by proximity to the SIF
7571	Effectiveness and cost input variables used in the analysis
7572	Incremental health outcomes, costs, and cost-effectiveness of prereferral artesunate treatment for a cohort of 1000 children younger than 5 years living in a stable endemic area during 5 years
7573	Cox proportional hazard models for progression to all-cause mortality
7574	Study drug, cardiac drugs, and procedures
7575	Efficacy outcomes up to 7 days
7576	Safety outcomes up to 7 days
7577	Effects of trial treatment on early and later mortality and on permanent disability in Africa  (three study sites) , Asia  (one study site) , and all four study sites
7578	Effects of trial treatment  (artesunate or placebo)  on death or permanent disability, subdivided by study site and time taken to reach clinic
7579	Non-comatose patients only: effects of trial treatment  (artesunate or placebo)  on death or permanent disability, subdivided by time taken to reach clinic
7580	Standard treatments of children with pneumonia in hospitals in Papua New Guinea
7581	Risk of mortality for children with pneumonia in Papua New Guinea in the five study hospitals
7582	Costs of the improved oxygen system
7583	Birthweight and gestational age of singletons in the general population and of consecutive-singleton siblings conceived spontaneously and after assisted fertilisation
7584	Risk of adverse outcomes in singletons in the general population and in consecutive-singleton siblings conceived spontaneously and after assisted fertilisation
7585	Risk of adverse outcomes in singletons after in-vitro fertilisation and intracytoplasmic sperm injection
7586	Clinical responses at week 12 and week 28 as reported by physicians and patients
7587	Adverse events during the three phases of the trial
7588	Symptom palliation at 3 months  ‡
7589	Plasma Glucose and Insulin Levels and Serum Levels of Lipids, HDL-C, and Apolipoproteins in 54 Pairs of Cases and Controls legend
7590	Associations Among HOMA Insulin Resistance, HDL-C and CHD Before and After Adjusting for Concomitant Variation in Serum Lipids and Conventional Risk Factors: Multivariate Conditional Logistic Analysis of 54 Case-Control Pairs legend
7591	Comparison of the Association Among Hyperinsulinemia, Hypoalphalipoproteinemia and CHD With the Association Between Hyperinsulinemic Hypoalphalipoproteinemia and CHD by a Conditional Logistic Regression Analysis of 54 Case-Control Pairs
7592	Stepwise Conditional Logistic Regression Analysis of Variables Associated with CHD and Conventional Risk Factors
7593	Adverse events
7594	Off and on state UPDRS scores
7595	Study design and comparison of protocols 007, 013, and 015
7596	Number of individuals included in the efficacy analyses and reasons for exclusion from the indicated efficacy analysis populations
7597	Vaccine efficacy in preventing high-grade vulval and vaginal lesions associated with HPV16 or HPV18, and all high-grade vulval and vaginal lesions  (irrespective of cause)
7598	Treatment success in the per-protocol population
7599	Treatment success in the modified intention-to-treat population
7600	Susceptibility of Candida spp isolates from patients in the micafungin group who had recurrence of infection during follow-up in the per-protocol population
7601	Summary of adverse events and changes in laboratory values in the intention-to-treat population
7602	Severe and mild asthma exacerbations in patients using maintenance budesonide–formoterol plus alternative reliever medications
7603	Changes from run-in in symptom control and lung function in patients using maintenance budesonide-formoterol plus alternative reliever medications
7604	Adverse events reported as asthma and pharmacologically predictable adverse events
7605	Primary clinical outcomes for liveborn infants, assessed before hospital discharge
7606	Measures of infant growth for liveborns at birth and at discharge from hospital
7607	Neonatal morbidity for liveborn babies in the first hospital stay
7608	Side-effects at time of trial injection and maternal outcomes
7609	Multivariate logistic regression of factors associated with syringe sharing
7610	Parasite density over time by allotted treatment group
7611	Observed and population-based expected drug-related deaths in health board areas for 2000 and 2001
7612	Observed and expected drug-related deaths for each sex in 2001
7613	Observed and expected drug-related deaths by age group for 2001
7614	Case reports of non-cardiogenic pulmonary oedema after intravenous radiographic contrast
7615	Outcome measures
7616	Bacteria and antibiotic sensitivities from blood culture and lung aspirate isolates
7617	Summary of all previously published European data on CAG repeat numbers among infertile men and controls
7618	Detection of chromosomes 1, 21, X, and Y in a patient with Klinefelter's syndrome and in three healthy controls
7619	Details of treatment cycles
7620	Outcome of treatment
7621	Number of years between last HIV-negative and first HIV-positive test result
7622	Number of controls matched per case
7623	Risk-factors assessed at first follow-up interview after positive HIV-antibody-test result and corresponding control interview
7624	Risk factors for HIV seroconversion in bivariate analysis
7625	Risk factors for HIV seroconversion in multivariate analysis
7626	Comparison between diseases for degree of pain, treatment by specialist, desire for additional therapy, and reasons why additional therapy was not sought
7627	Extent of pain, degree of treatment, and type of care provider
7628	Assessment of vascular occlusive disease with DSA in six patients  (121 vessel segments)
7629	Assessment of vascular occlusive disease with MRA by two readers in six patients  (180 vessel segments)
7630	Number of assessable segments in 31 patients
7631	Reasons for non-assessability of vessel segments
7632	Diagnostic accuracy of MSCT coronary angiography to detect stenoses of >50% diameter
7633	Follow-up status of vaccine groups in trial resurveys
7634	Frequency of visceral leishmaniasis overall and by village
7635	Frequency of visceral leishmaniasis by vaccine group, age, and sex
7636	Rates of conversion on leishmanin skin test at follow-up visits
7637	Frequency of visceral leishmaniasis in relation to leishmanin response  (induration size)  at first follow-up visit  (42 days)
7638	Details of surgery
7639	Clinical outcomes at 1 week after operation
7640	Patients' return to usual activities at 3 months  (for those in whom it is relevant)
7641	Outcomes at 1 year after operation
7642	Clinical and subclinical measles after exposure by age at exposure and vaccination status
7643	Clinical and subclinical measles after exposure by titre of measles haemagglutinin-inhibiting antibody at exposure and vaccination status
7644	Clinical and subclinical measles after exposure by intensity of exposure and vaccination status
7645	Geometric mean antibody titres at exposure and 1 month and 6 months after exposure for children with clinical measles, subclinical measles, and no measles
7646	Grey values within total echocardiographic sector
7647	Absolute and relative average endocardial grey value
7648	Absolute and relative average myocardial grey value
7649	Outcome at 1 year
7650	Side-effects and results of leishmanin skin test following vaccination
7651	Cases of leishmaniasis in vaccine groups by time since vaccination
7652	Prophylactic efficacy of a single dose of ALM+BCG compared with BCG alone against cutaneous leishmaniasis
7653	Side-effects
7654	Findings of US government-funded studies of efficacy of needle-exchange programmes
7655	Side-effects reported as possibly or probably due to study drug administration
7656	Continuing-injectors HIV incidence studies
7657	Recent HIV seroincidence studies among injecting drug users in New York City area
7658	Proportional-hazards regression for HIV incidence in pooled sample  (n=1630, 45 seroconverters)
7659	HIV-incidence hazard ratios for non-use versus continuing use of syringe exchange
7660	Study outcomes by treatment group
7661	Health-related quality of life by treatment groups without interaction of displacement
7662	Medically related adverse events
7663	Definition of the Study Sample legend
7664	Nomenclature for suicidal and related behaviours and suicidal ideation
7665	Thematic sentences derived from meta-synthesis of studies assessing psychological effect of stillbirth on parents and on health-care professionals.
7666	Intervention process measures among women identified as at high risk for preterm birth in intervention clusters
7667	Antenatal corticosteroid use and delivery care by intervention group
7668	Perinatal and 28-day neonatal outcomes by intervention group
7669	Prevalence, incidence, and sex differences  (when reported)  for major depressive disorder from large population cohort studies of adolescents by age  (years)
7670	Examples of global public health goals and the contribution of adolescence
7671	Primary and secondary outcomes for the intention-to-treat population
7672	Other outcomes of the intention-to-treat population
7673	Disease activity in cohort with inflammatory bowel disease
7674	Risks of venous thromboembolism by activity of inflammatory bowel disease and hospitalisation
7675	Results from self-controlled case-series analysis of state of inflammatory bowel disease at time of first venous thromboembolism
7676	Descriptive data for patients with venous thromboembolism and their population control cohorts
7677	Relative risks of arterial cardiovascular disease during follow-up in patients with venous thrombosis or pulmonary embolism, and in population controls
7678	Risks of arterial cardiovascular disease in patients with unprovoked venous thrombosis or pulmonary embolism, and in population controls
7679	Relative risks of arterial cardiovascular disease in patients with provoked venous thrombosis or pulmonary embolism, and in population controls
7680	Mean EPDS  (clinical)  and SF-36 scores  (functional)  in the intervention and usual care group at 3 and 6 months
7681	Adjusted difference in mean scores for intervention minus usual care at 3 months
7682	12-month service use by sectors in the WMH surveys
7683	12-month service use by severity of mental disorders in the WMH surveys  §
7684	Mental health specialty sector use for respondents using any services in the WMH surveys‡
7685	Follow-up treatment for respondents using services in the WMH surveys  §
7686	Minimally adequate treatment use for respondents using services in the WMH surveys  ¶
7687	Methodological quality of eligible studies
7688	Subgroup analyses
7689	Age-adjusted incidence ratios of a first deep vein thrombosis after respiratory or urinary tract infections
7690	Age-adjusted incidence ratios of a first pulmonary embolism after urinary tract infection
7691	Comparison of GFR, height, and mean growth velocity the CAD and LRD groups over 5 years
7692	Multivariance analysis between HSDS at years 1–5 after transplantation, GFR at time of transplantation  (Tx) , and LRD versus CAD recipients  (p=0·04 for overall analysis)
7693	Covariance analyses
7694	Comparison of change in FEV1 between treatment groups according to type of analysis
7695	Asbestos exposure by case-control status
7696	Occupations associated with ≥10 fibre-years of asbestos exposure among the RPF cases and the controls
7697	Adjusted odds ratios for potential risk factors for retroperitoneal fibrosis
7698	ERT use in cases and control diagnostic groups
7699	Odds ratio of VTE in relation to ERT use
7700	Odds ratio of VTE by duration of current episode of use, oestrogen dose, and ERT regimen
7701	Measured variables before and after placebo and before and after L-NAME
7702	Adjusted difference in mean scores for stepped-care minus usual-care programmes  *
7703	Outcome according to HDRS score
7704	SF-36 outcomes according to treatment group and follow-up assessments
7705	Talairach coordinates and Brodmann's areas for regions of reduced grey-matter volume in people in the cross-sectional comparison who developed psychosis
7706	Deaths possibly or certainly related to pulmonary embolism
7707	Venous thromboembolic events during 3-month follow-up in untreated patients with low or intermediate clinical probability and negative findings on spiral CT and leg venous compression ultrasonography
7708	3-month thromboembolic risk of untreated patients in whom PE was excluded on the basis of various diagnostic strategies
7709	Description of studies included in the final sample
7710	Aggregate effect sizes and 95% CIs for type of intervention and symptom group
7711	Effects of interventions on post-traumatic stress disorder  (PTSD)  and other symptoms
7712	Interobserver variation between two observers for magnetic resonance angiography  *
7713	Results of magnetic resonance angiography versus digital subtraction angiography
7714	Sensitivity of magnetic resonance angiography  (MRA)  in the diagnosis of pulmonary embolism as a function of size of emboli
7715	ICD10 diagnoses for 15 people with Prader-Willi syndrome who had a detailed psychiatric assessment
7716	Respiratory and haemodynamic variables during and after treatment with O-nitrosoethanol gas  (ENO)
7717	Risk factors for relapse or reinfection in 326 patients  (univariate analysis)
7718	Adjusted hazard ratios for risk factors for relapse or reinfection in 326 patients
7719	Unadjusted and adjusted hazard ratios according to HIV-1 status for riskfactors for recurrent tuberculosis in 326 patients
7720	Haemodynamic effects of placebo and bosentan at week 12
7721	Growth velocity, predicted adult height, testis volume, and pubertal stage during follow-up
7722	Serum IGF-I and IGFBP3 concentrations during follow-up
7723	Estimated effect of CBT compared with support groups and natural course on fatigue severity  (CIS)  and functional impairment  (SIP)
7724	Estimated effect of CBT compared with support groups and natural course on secondary endpoints
7725	Clinically significant improvement in the treatment groups for fatigue severity, Karnofsky performance status, and self-rated improvement
7726	Frequency and adjusted odds ratio of congenital malformations according to different exposure
7727	Frequency and adjusted odds ratio of congenital malformations according to exposure, types of life events
7728	Frequency and adjusted odds ratio of groups of congenital malformations according to time of exposure to death of a child and whether the death was expected
7729	Current use of combined oral contraceptives
7730	Response to bronchodilator according to severity of airways obstruction and type of spacer
7731	Haemodynamic measurements
7732	Comparison of screen-negative individuals selected for follow-up interview with those not selected
7733	Frequency of serious psychiatric disorder and substance dependence
7734	Comparison of defendants with serious psychiatric disorders referred and not referred to court diversion programme
7735	Protocols for lung and nasal components of trial
7736	Estimates of prevalence of  (inherited)  thrombophilic defects in patients with confirmed deep-vein thrombosis and in general population
7737	Symptomatic venous thrombotic events during 3–6 months' follow-up
7738	Meta-analysis of 13 randomised trials comparing LMWH with unfractionated heparin in initial treatment of venous thromboembolism
7739	Diagnostic yield of D-dimer measurement and lower-limb venous compression ultrasonography in patients with suspected venous thromboembolism, DVT, or PE
7740	Accuracy of empirical clinical probability assessment
7741	3-month thromboembolic risk in patients in whom venous thromboembolism was ruled out by diagnostic stragegy
7742	Tests necessary to reach definitive diagnosis in various stragegies for venous thromboembolism
7743	Clinical and Angiographic Features and In-Hospital Clinical Course in Patients Who Developed an Early Adverse Event legend
7744	Clinical Events at One Year Follow-Up legend
7745	Logistic Regression Analysis for Early Adverse Events legend
7746	Logistic Regression Analysis for Clinical Restenosis at One Year Follow-Up legend
7747	Social class gradient in poor health  *   at ages 23 years and 33 years
7748	Odds ratios for poor health  *   at age 23 years  9   and 33 years  (in classes IV and V versus I and II  †  )
7749	Odds ratios for poor health  *   at age 33  (classes IV and V vs I and II)  adjusted for health-related behaviour, family structure and social support, working haracteristics, and material circumstances
7750	Poor health  *   at age 33  (classes IV and V vs I and II) , adjusted  †   for child, adolescent, and early-adulthood factors
7751	Risk of death after transplantation relative to continued waiting
7752	Background details of patients
7753	Mean scores on satisfaction scale at 3 and 9 months
7754	Randomised trials of amiodarone after MI and in CHF
7755	Mortality summary
7756	Subgroup analyses for total mortality
7757	Subgroup analyses for arrhythmic/sudden death
7758	Major adverse experiences associated with early permanent drug discontinuation in placebo-controlled trials
7759	Age-adjusted odds ratios of new reports of CHD according to employment grade in the Civil Service
7760	Age-adjusted odds ratios of new reports of CHD at phase 2 or 3 by sex-specific quartiles of height, unadjusted and adjusted for employment grade at phase 1
7761	Age-specific incidence rates of primary PE, 1976–92
7762	Risk of primary PE by postmenopausal hormone use among postmenopausal women and OC use by whole cohort
7763	Rate of venogram-proven DVT
7764	Adverse events and laboratory data
7765	Anthropometric and endocrine data of 16 short children at start of treatment with r-hGH compared with 7 short untreated children
7766	Changes in blood glucose and serum insulin after oral glucose tolerance test during treatment with r-hGH
7767	Primary and secondary outcomes
7768	Intervention effect modification by prespecified subgroup
7769	Methods of self-harm  (fatal and non-fatal)  other than self-poisoning in individuals aged 14 years or older
7770	Descriptive cataloguing of the epidemiological evidence used to assess whether each risk-outcome paper meets the causal criteria for inclusion in the Global Burden of Disease Study 2016 by risk level
7771	GBD 2016 risk factor hierarchy and accompanying exposure definitions, theoretical minimum risk exposure level, and data representativeness index for each risk factor, pre-2006, 2006–16, and total  (across all years)
7772	Global age-standardised SEVs for all risk factors, 1990, 2006, and 2016, with mean percent change for three time periods, between 1990 and 2006, 2006 and 2016, and 1990 and 2016, by risk level
7773	Global all-age attributable deaths and DALYs, in 2006 and 2016, and percentage change of deaths, age-standardised death rates, DALYs, and age-standardised DALY rates between 2006 and 2016, for all risk-outcome pairs, both sexes combined
7774	Incidence rate and incidence rate ratio of severe pneumonia defined according to IMCI criteria, oxygen saturation less than 90%, or death
7775	Meals cooked using intervention cookstoves at 3, 12, and 24 month follow-up visits
7776	Incidence rate and incidence rate ratio of serious adverse events excluding pneumonia
7777	Descriptive statistics by country
7778	Attributable mortality by country
7779	Tobacco control policies at national and local level in China published by government bodies, 2008–14
7780	Complications, treatment, and clinical outcome of the patient
7781	Clinical blood biochemistry tests
7782	Mutations in AH/1 and JX346 viruses, by gene
7783	Primary and secondary nausea and vomiting outcomes
7784	Comparison of Left Ventricular Morphology and Function at Rest Between Patients With a Stented Bioprosthesis and Patients With a Stenless Bioprosthesis legend
7785	Comparison of Maximal Workload and Oxygen Consumption During Maximal Exercise Between Patients With a Stented Bioprosthesis and Patients With a Stentless Bioprosthesis legend
7786	Change in Doppler Echocardiographic Data With Exercise in Patients With a Stented Bioprosthesis and Patients With a Stentless Bioprosthesis legend
7787	Description of the included cohort studies
7788	Descriptions of the different pollutants and two traffic intensity indicators at participant addresses in each cohort
7789	Results of random-effects meta-analyses for the association between natural cause mortality and exposure to air pollution and traffic intensity indicators  (using main confounder models 1, 2, and 3)
7790	Results from random-effects meta-analyses for the adjusted association between natural cause mortality and exposure to PM2·5 below various threshold values
7791	Results from random-effects meta-analyses from one-pollutant and two-pollutant models for adjusted association between natural-cause mortality and various pollutants
7792	Main European Union bodies for health
7793	Treatment outcomes in the minocycline versus control group
7794	Pain associated with treatment in the minocycline versus control group
7795	Thoracoscopic surgical findings and outcomes for patients with pneumothorax recurrence
7796	Long-term pulmonary function tests
7797	Emergence of the NA R292K mutation that confers resistance to NA inhibitors
7798	MERS-CoV genome data
7799	MERS-CoV genome variation in support of human transmission pairs
7800	Cox proportional hazards models for 5 year overall mortality in the Kaiser Permanente validation cohort
7801	Cox proportional hazards models for 5 year overall mortality in the China Clinical Trials Consortium validation cohort
7802	Algorithm genes
7803	Features of the microarray gene expression profiling for defined molecular subtypes of breast cancer
7804	Commercially available prognostic multigene signatures for breast cancer
7805	Associations between randomised chimney stove intervention and pneumonia by endpoint of ALRI
7806	Health outcomes included in this assessment, effect estimate for exposure to second-hand smoke, and rating of the strength of evidence for every outcome
7807	Proportion of children and adult non-smokers exposed regularly to second-hand smoke based on survey data and modelling for 2004, by WHO subregion  *
7808	Number of deaths from exposure to second-hand smoke in 2004, by WHO subregion  *
7809	Number of DALYs from exposure to second-hand smoke in 2004, by WHO subregion  *
7810	Number of blood-culture specimens tested
7811	Frequency of bacteria identified from blood-culture specimens during assessment by reference method and sepsis assay
7812	Frequency of organisms identified from blood-culture specimens that are not covered by sepsis assay
7813	Accuracy of sepsis assay analysed with all blood-culture specimens  (3284)
7814	Discrepancies between Prove-it sepsis assay and reference method for identification of bacteria from blood culture
7815	Hazard ratio  (HR)  of all-cause mortality in participants in relation to change in total arsenic concentration in urine
7816	Number of studies with Streptococcus pneumoniae disease burden data that populated the meningitis and non-pneumonia, non-meningitis disease models  *  , by WHO region
7817	Pneumococcal cases and deaths, with uncertainty estimates, by syndrome and WHO region
7818	Patients with adverse events more than 3% and at least twice the rate of the other group
7819	Adverse events and deaths
7820	Distribution of symptoms
7821	Changes in US admission rates by December, 2004
7822	Occurrence of coronary heart disease events in different tertiles of mean telomere length
7823	Changes in plasma lipid levels and other markers from recruitment to end of year 1 with pravastatin treatment in individuals in different tertiles of mean telomere length
7824	Percentages of ever  (former+current) , former, and current smokers in controls by region, sex, and age
7825	Risk of AMI associated with various durations of cessation in former smokers
7826	Prevalence  (%)  of exposure to SHS  (per week)  in controls by sex and smoking status
7827	Effect of tobacco use in strata defined by presence of other risk factors
7828	PAR as percentage  (95% CI)  from current smoking by region, sex, and age
7829	Laboratory and clinical features at diagnosis
7830	Bone-marrow trephine histology, erythropoietin, and iron stores.
7831	Major thrombotic, haemorrhagic, and transformation events after trial entry and in the year before diagnosis
7832	Age distribution, crude and age-standardised prevalence of HPV in women without cervical abnormalities in IARC HPV prevalence surveys by study area
7833	Type-specific HPV prevalence in 15 613 women without cervical abnormalities in IARC HPV prevalence surveys
7834	Multilevel models for aircraft noise and reading comprehension and recognition
7835	Cognitive and health outcomes and aircraft noise exposure
7836	Multilevel models for road traffic noise and cued recall
7837	Cognitive and health outcomes and exposure to road traffic noise
7838	Frequency of JAK2 Val617Phe mutation in patients with myeloproliferative disorders and controls.
7839	Pattern of mutation frequency in different haemopoietic colonies from four patients with myeloproliferative disorders who showed a mixed pattern of mutation on sequencing
7840	Antibodies used in immunocytochemistry
7841	Primers used for RT-PCR analysis
7842	Isolation of skeletal-muscle stem cells from adult human skeletal-muscle samples
7843	Escalation of proliferation of skeletal-muscle stem cells by PDGF-BB
7844	Prevalence of anti-HIV and anti-HCV antibodies in the 3049 donors of organs, tissues, or corneas
7845	Prevalence of anti-HIV and anti-HCV antibodies in TMA-reactive and TMA-negative donors of organs, tissues, or corneas
7846	Analysis of overall mortality in children
7847	Analysis of mortality in uninfected children
7848	Analysis of mortality in infected children
7849	Unadjusted and adjusted infant mortality rates for infected children from age at acquisition of infection  (n=693)
7850	Clinical features of two patients with SNCA duplications
7851	Clinical data and MAP test results of participants
7852	Variation in RT-PCR positive rates for SARS coronavirus in different specimens with day after onset of illness
7853	Variation in geometric mean titre  (GMT, copies per μL)  for SARS coronavirus with day after onset of illness
7854	Comparison of results from microscopy and nested PCR for detection of Plasmodium species
7855	Nasal responses after exposure to allergen plus clean air or allergen plus diesel exhaust particles
7856	Effects of GSTM1, GSTT1, and GSTP1 genotype on nasal IgE  (U/mL)  and histamine  (nmol/L)  when exposed to allergen plus clean air or allergen plus diesel exhaust particles  (DEP)
7857	IgE  (U/mL)  and histamine  (nmol/L)  differences by joint GSTM1 and GSTP1 genotype
7858	Effects of GSTM1, GSTT1, and GSTP1 genotype comparing differences and ratio of responses to allergen plus diesel exhaust with allergen plus clean air
7859	MICs  (mg/L)  for parental strain, transformants, and transconjugant
7860	Cost-effectiveness analysis of treatment costs for 100 patients admitted to a district hospital when antitoxin was and was not available
7861	Expression analysis of myelination and oligodendrocyte-related genes in schizophrenia and bipolar disorder
7862	Nuclear morphology and lamin localisation
7863	Schedule of routine vaccinations for participants
7864	Criteria for inclusion in subgroup analyses
7865	Vaccine allocation by study group and main reasons for exclusion from per protocol analysis
7866	Frequency of invasive disease and PnCRM7 vaccine efficacy by analysis group and vaccine type
7867	Serotype distribution of invasive disease in primary efficacy group as of May 31, 2001
7868	Regional polyposis registers and families with MYH polyposis
7869	Mutations and phenotypes in 25 index cases of MYH polyposis
7870	Survival data in the CLL subsets defined by P2X7R genotype and VH gene mutation status
7871	Frequency of the P2X7R 1513A→ polymorphism in patients with CLL and healthy controls
7872	Identification, functional assignment, and variation in mean hepatic mRNA expression of infants with biliary atresia at 4 months of age or younger  (fold change above or below expression in age-matched infants with neonatal intrahepatic cholestasis)
7873	Reprogramming of genes during clinical progression of biliary atresia
7874	Age-standardised mortality rates for Dublin County Borough before  (1984–90)  and after  (1990–96)  ban of sale of coal, by season
7875	Change in age-standardised total, cause-specific, and age-specific mortality rates for Dublin County Borough for 72 months before and after ban of sale of coal in Dublin
7876	Number of deaths during follow-up, 1986–94, NLCS subcohort  (n=4492)
7877	Description of estimated air pollution exposures  (μg/m3)  in the NLCS subcohort  (n=4466)
7878	Risk of cardiopulmonary, non-cardiopulmonary non-lung cancer, and all-cause mortality associated with long-term exposure to traffic related air pollution, NLCS subcohort 1986–94
7879	Univariate Predictors of Nonculprit 90-min Flow  (CTFC) : Categorical Variables ∗   legend
7880	Univariate Predictors of Nonculprit 90-min Flow  (CTFC) : Continuous Variables ∗
7881	Relationship Between Pulsatile Flow in Culprit Artery and Flow in Nonculprit Artery legend
7882	Lung diseases identified at necropsy, by HIV-1 status
7883	Three most common lung diseases found at necropsy, by HIV status and age
7884	Selected pathological findings by age and HIV status
7885	Sequence analysis of protein kinase A RLα transcripts from T cells of patients with SLE and of healthy controls
7886	Types of nucleotide substitutions observed in protein kinase A RIα gene transcripts of SLE T lymphocytes
7887	Frequency distribution of mutations identified in protein kinase A RIα-subunit gene transcripts from T lymphocytes of SLE patients
7888	Neutralisation of American dengue-2, Asian dengue-2, and dengue-1 viruses by dengue-1 and dengue-2 sera
7889	Numbers of people with polyps or cancer detected in distal colon
7890	Numbers of people with polyps or cancer detected in proximal colon
7891	Numbers of patients with cancer according to method of treatment, Dukes' stage, and TNM status
7892	Acceptability of flexible sigmoidoscopy screening
7893	Angiotensin-Converting Enzyme Inhibitor Genotype Distributions in Subjects ≥85 Years Old and Young Subjects Whose Families Originated From the Same Geographic Region legend
7894	Ten-Year All-Cause and Cardiovascular Disease Mortality Risks According to Angiotensin-Converting Enzyme Inhibitor Genotype in Subjects ≥85 Years Old legend
7895	Plasminogen Activator Inhibitor-1 Genotype Distributions in Subjects ≥85 Years Old and Young Subjects Whose Families Originated From the Same Geographic Region legend
7896	Ten-Year All-Cause and Cardiovascular Disease Mortality Risks According to Plasminogen Activator Inhibitor-1 Genotype in Subjects ≥85 Years Old legend
7897	Hemodynamic Parameters During Rest legend
7898	Hemodynamic Parameters During Dobutamine Stress legend
7899	Myocardial Blood Flow: Nonischemic Regions legend
7900	Myocardial Blood Flow: Ischemic Regions legend
7901	Dobutamine Coronary Reserve legend
7902	Interventions and action to prevent and respond to stillbirths along the continuum of women's and children's health care  2,24,48
7903	Summary of materials and methods by policy domains
7904	Progress and unfinished business for agenda setting and priorities for stillbirths
7905	Coverage of indicators of intervention for stillbirth prevention
7906	Tuberculosis case notification rates and World Development Indicators of poverty and deprivation
7907	Life expectancy at birth by quintile of deprivation
7908	Capacity building for universal health coverage and action on social determinants of health
7909	Use of antenatal corticosteroids in preterm births  (n=17 705 deliveries)
7910	Coverage of antenatal corticosteroids and tocolytic drugs in countries studied
7911	Use of tocolytic drugs in women with uncomplicated, spontaneous preterm deliveries at 26–34 weeks' gestation
7912	The theoretical domains of homelessness in European Typology on Homelessness and Housing Exclusion  4
7913	Prevalence of infectious diseases in homeless people
7914	Prevalence estimate for non-communicable diseases in homeless people
7915	Prevalence of neuropsychiatric disorders in homeless people
7916	Smoothed centiles for birthweight of boys and girls according to gestational age
7917	Smoothed centiles for birth length of boys and girls according to gestational age
7918	Smoothed centiles for head circumference of boys and girls according to gestational age
7919	Progress toward Millennium Development Goals  (MDGs)  4, 5, and 6 in Rwanda
7920	Descriptive statistics by variable for 2001 and 2010 surveys
7921	Associations of risk of maternal death and independent factors
7922	Clinical outcome of the non-oncological fertility preservation
7923	Livebirths after ovarian cortical tissue transplantation
7924	Pregnancy and livebirth rates after ovarian cortical tissue transplantation
7925	Clinical, Electrocardiographic and Imaging Data in Nine Patients Who Presented With Large T Wave Inversion and Marked QT Prolongation After an Episode of Nonischemic Pulmonary Edema legend
7926	Mortality in pooled Analysing Longitudinal Population-based HIV/AIDS data on Africa  (ALPHA)  network data by pregnancy and HIV status, 1990–2012
7927	Deaths in women and girls aged 15–49 years by study site, pregnancy, and HIV status
7928	Crude rate ratio of mortality rates in HIV-infected and HIV-uninfected women and population-attributable fraction for HIV, by study site
7929	Planning status of pregnancy by age at interview, outcome, relationship status, and number of children
7930	Prevalence of unplanned pregnancy with outcome in the past year and age-adjusted odds ratios
7931	Age at menarche  (women only) , first sexual intercourse, first live-in relationship, and first born child by age at interview
7932	Effect of the Newhints intervention on coverage of key behaviours and coverage gaps
7933	Effect of the Newhints intervention on neonatal mortality rates after the end of training of community-based surveillance volunteers and after introduction of new implementation strategies
7934	Trends in knowledge and practice of contraceptive methods by currently married women aged 15–49 years during 1984–2007
7935	Types of delays associated with maternal, newborn, and child deaths in Pakistan
7936	Maternal, newborn, and child deaths averted at 90% coverage with care packages
7937	Key features of specific health-related commitments in 2013 manifestos for some of the main political parties
7938	Health-relevant subjects enumerated in the 18th Constitutional Amendment's legislative lists
7939	Primary and secondary outcomes
7940	Rebound and recurrent hypoglycaemia in babies assigned to dextrose or placebo gel
7941	Distribution of preterm birth according to gestational age subgroup based on meta–analysis of 345 datapoints from 41 countries  (n= 131 296 785 live births)
7942	Variables tested for prediction of preterm birth rates in statistical models showing risk ratio estimates
7943	Estimated preterm birth rates and total number of preterm births for 2010, by Millennium Development Goal region
7944	The ten countries with the highest numbers of preterm births in 2010
7945	Preterm birth rates and totals for 1990 and 2010 for Developed and Latin America and Caribbean Millennium Development Goal regions
7946	Multivariable assessment of associations between number of embryos transferred, livebirth, multiple birth, and adverse perinatal outcomes
7947	Adjusted relative association of number of embryos transferred with any livebirth and adverse perinatal outcomes stratified by women's age
7948	Adjusted absolute association of number of embryos transferred with any livebirth and adverse perinatal outcomes stratified by women's age
7949	Correlation of hCG concentrations at 6 months with time from initial uterine evacuation to remission
7950	Regional summary of maternal deaths averted in 2008 by contraceptive use estimated by model I
7951	Maternal deaths averted in 2008 by contraceptive use in 172 countries estimated by model I
7952	Maternal deaths averted in 2008 by contraceptive use in 167 countries estimated by model II
7953	Primary and secondary outcomes in the cervical pessary and expectant management groups
7954	Cause–specific proportions of neonatal deaths by days since birth in China from 1996 to 2008
7955	Annual rate of change in neonatal mortality by socioeconomic region and cause of death in China from 1996 to 2008
7956	Neonatal mortality rates, relative risks, and preventable fractions by place of birth and socioeconomic region from 2002 to 2008
7957	Cause–specific neonatal mortality rates and relative risks by place of birth and socioeconomic region in China between 2002 and 2008
7958	Comparison of  references  (1–6)   for classification  *   of infants SGA with respect to the ability to predict adverse perinatal outcomes
7959	Major causes of death in mothers, stillborn babies, and neonates in low-income countries
7960	Output indicators and payments
7961	Services and weights used to construct the quality score for P4P formula
7962	Estimated effect of P4P schemes on maternal and child health-care services
7963	Summary of stillbirth rate data inputs meeting inclusion criteria, by  Millennium Development Goal region
7964	Risk ratio estimates for categorical variables predictive of stillbirth rates
7965	Predicted stillbirth rates and totals for 1995 and 2009, by Millennium Development Goal region
7966	Comparison of estimated stillbirth rates for 18 countries with reported rates by use of the same definition between 2007 and 2009
7967	Responses regarding perceptions of the stillborn baby and the mother, and regarding causes, from the web-based survey of health-care professionals
7968	Comparative responses from the web-based surveys of parents affected by stillbirth and of health-care professionals
7969	Responses regarding advocacy and understanding from the web-based survey of health-care professionals
7970	Percentage of deaths averted with 99% coverage of selected interventions for the ASEAN region and for subgroups, as defined by mortality reduction patterns
7971	Intervention package description
7972	Summary outcomes of quarterly surveillance  (rounds 1–8)
7973	Household practices before, during, and after delivery from surveillance rounds 2–8
7974	Early neonatal, late neonatal, postneonatal, childhood, and under-5 mortality in 2011
7975	Maternal mortality ratio per 100 000 livebirths, annualised rate of decline, and maternal deaths by country for 1990, 2000, and 2011
7976	Worldwide official development assistance to maternal, newborn, and child health, 2003–08
7977	Official development assistance to maternal, newborn, and child health by type and source of aid flow for the 68 Countdown priority countries, 2003–08
7978	Official development assistance to maternal, newborn, and child health by donor for the 68 Countdown priority countries, 2003–08
7979	Official development assistance to maternal, newborn, and child health by aid modality and project purpose for the 68 Countdown priority countries, 2003–08
7980	Official development assistance to child health per child and to maternal and neonatal health per livebirth, total to maternal, newborn, and child health in 2007 and 2008, and trends statistics, 2003–08
7981	Ventilatory support
7982	Primary and secondary outcomes
7983	Incidence of adverse events reported  (safety population)
7984	Most common serious adverse events reported by gestational age  (safety population)
7985	Analysis of association between receipt of financial assistance from Janani Suraksha Yojana and intervention coverage and health outcomes by use of three analytical approaches at the national level
7986	Analysis of association between receipt of financial assistance from Janani Suraksha Yojana and intervention coverage and health outcomes by use of two analytical approaches by high-focus, northeast, and non-high-focus states
7987	Under-5 mortality  (uncertainty interval)  per 1000, by decade
7988	Neonatal, postneonatal, and childhood mortality  (uncertainty interval)  per 1000 in 1990 and 2010
7989	Definitions of maternal death and maternal mortality
7990	Summary of site-years of observation by source, 1980–2008
7991	Maternal mortality ratio  (uncertainty interval)  per 100 000 livebirths by region  *   and country
7992	In-Hospital Events legend
7993	Serum samples obtained in 2008 with antibody titre equal to or more than the minimum detection limit and with antibody titre at least four times higher than the minimum detection limit, by age group and test method
7994	Comparison of mortality rates in intervention and control clusters
7995	Kessler-10 depression scores in mothers in intervention and control clusters
7996	Process indicators in intervention and control clusters
7997	Cause-specific mortality for early neonatal deaths during study
7998	Comparison of mean height-for-age and BMI-for-age Z scores, and cognitive, language, and behaviour scores
7999	Separate effects of randomisation to treatment and cumulative cash transfers on growth, cognition, and behaviour problems, adjusted for covariates  §
8000	Relative risk and population-attributable risk of all-cause and cardiovascular deaths due to blood pressure in China, 2005
8001	Prevalence of prehypertension and hypertension, relative risk, population-attributable risk, and absolute number of cardiovascular deaths related to blood pressure by age group in China, 2005
8002	Logistic regression analyses  §   between ever-married women aged 20–24 years, who were married as adults or children, and both fertility and fertility-control outcomes
8003	Children aged less than 5 years who were protected by an insecticide-treated bednet  (ITN)  in 2007 according to classes of Plasmodium falciparum and poverty risks across 40 malaria-endemic countries
8004	Unregistered births  (1000s)  in 2003 by region and level of development
8005	Overall life expectancy  (years)  in 15 high-income countries
8006	Estimated effects of family policy generosity on infant mortality
8007	Estimated effects of pension rights on old-age excess mortality
8008	Changes in coverage of malaria interventions and febrile illness between 2000 and 2006, shown in multiple indicator cluster surveys  (MICS)  in The Gambia
8009	Hemodynamic Assessment of Prostacyclin Therapy legend
8010	Direct household visits by community health workers  (overall coverage by intervention arm)
8011	Group interventions  (approximate monthly coverage per intervention cluster)
8012	Comparison of practice indicators by study arm
8013	Comparison of mortality rates by study arms
8014	Summary of the target status of Vision 2020 and indicators of Millennium Development Goals  (MDGs) .
8015	Indicators measured during household surveys in Cyangugu province after introduction of performance-based pay initiative
8016	Progress toward the MDG 4 target for reduction of child mortality in 68 priority countries
8017	Progress toward the MDG 5 target for maternal mortality in 68 priority Countdown countries
8018	Ten best and ten worst performing countries on progress towards MDG 4 since 1990
8019	Ranking of selected countries for maternal mortality as a proxy for progress towards MDG 5
8020	Changes for selected interventions since 2000 for Countdown countries with at least two measurements
8021	Attributable deaths and disability-adjusted life years  (DALYs)  for high blood pressure for various cardiovascular endpoints in 2001 by World Bank region
8022	Attributable deaths and disability-adjusted life years  (DALYs)  per 100 000 population per year for high blood pressure for various cardiovascular endpoints in 2001 by region
8023	Deaths and disability-adjusted life years  (DALYs)  attributable to high blood pressure in 2001
8024	Amounts paid to Oportunidades beneficiaries by age-group in 1997 Mexican pesos
8025	Dependent variables
8026	Effect of doubling cash transfers in Oportunidades on developmental outcomes in children  (24–68 months)  5·5 years after programme inception  ‡
8027	Maternal mortality estimates for 2005 by UN MDG regions
8028	Country estimates of maternal mortality ratios for 2005
8029	Random-effects model estimates of trends in the maternal mortality ratio by income region, data source type, and initial level of ratio
8030	Comparison of 1990 and 2005 regional and global estimates of maternal mortality ratios
8031	Other maternal outcomes
8032	Other infant outcomes
8033	Subgroup analyses of pre-eclampsia outcome
8034	Sample sizes for the 20% sample of the 1990 and 2000 censuses
8035	U5MR per 1000 population, by quintiles of household economic status
8036	Pregnancy outcome after mild and standard IVF treatment
8037	Total costs of IVF treatment per couple over 12 months  (€)
8038	Maternal age and gestational age for the 60 patient samples
8039	Comparison of mean fetal DNA ratios for chromosome 13 and 21 in 60 maternal plasma samples
8040	Description of SCPE data on children with cerebral palsy included in the study
8041	PCA and MPR by quarter for 987 patients who started antiretroviral treatment
8042	Multivariate model for viral load ≥1000 copies per mL in second quarter and fourth quarters
8043	Description of surveys by country
8044	Variable definitions: living standards and out-of-pocket health payments by country
8045	Out-of-pocket payments for health care as percentage of total household resources by country  *
8046	Poverty head counts: effect of accounting for out-of-pocket payments for health care
8047	Poverty gaps: effect of accounting for out-of-pocket payments for health care
8048	Pregnancies after intrauterine insemination in relation to follicular growth patterns
8049	Final model used for prediction of the log of the stillbirth rate per 1000 deliveries, by independent variable
8050	Estimated stillbirth rates per 1000 deliveries and uncertainty values, by world region for the year 2000
8051	The Expression of Tenascin-C in the Patent and Occluded Human Vein Grafts legend
8052	Effect of Intravenous Losartan  (1.0 mg/kg + 0.03 mg/kg/min) , EXP3174  (0.1 mg/kg + 0.01 mg/kg/min) , Captopril  (1.0 mg/kg + 0.5 mg/kg/h)  or Vehicle on Sinus Heart Rate, Mean Arterial Pressure and Electrocardiographic Intervals in Postinfarction Dogs legend
8053	Effect of Intravenous Losartan  (1.0 mg/kg + 0.03 mg/kg/min) , EXP3174  (0.1 mg/kg + 0.01 mg/kg/min) , Captopril  (1.0 mg/kg + 0.5 mg/kg/h)  or Vehicle on Cardiac Electrophysiologic Parameters in Postinfarction Dogs legend
8054	Plasma Renin Activities in Postinfarction Dogs Administered Intravenous Losartan  (1.0 mg/kg + 0.03 mg/kg/min) , EXP3174  (0.1 mg/kg + 0.01 mg/kg/min) , Captopril  (1.0 mg/kg + 0.5 mg/kg/h)  or Vehicle legend
8055	Effect of Intravenous Losartan  (1.0 mg/kg + 0.03 mg/kg/min) , EXP3174  (0.1 mg/kg + 0.01 mg/kg/min) , Captopril  (1.0 mg/kg + 0.5 mg/kg/h)  or Vehicle on the Incidence of Lethal Ischemic Arrhythmias Developing in Response to Secondary Acute Posterolateral Myocardial Ischemia in Postinfarction Dogs
8056	QT Intervals at Specified Heart Rates During Exercise and Recovery
8057	QT/Heart Rate Slopes  (ms/min−1)  During Exercise and Recovery legend
8058	Application of Various Diagnostic Alternatives in LQTS in Regard to Molecular Classification of Patients and Controls Subjects
8059	Blood Pressure, Heart Rate and Rate-Pressure Product Changes During Handgrip legend legend
8060	Results of Analysis of Variance With Repeated Measures legend
8061	p Values of the Multiple Comparisons in the Two Groups of Patients legend legend
8062	Interobserver Variability Assessed by the Intraclass Correlation Coefficient
8063	Renin–Angiotensin System Genotypes in 80 Endurance Athletes
8064	Left Ventricular Mass  (g/m)  in Different Genotypes
8065	Comparison of Athletes with Different AGT Genotypes legend legend
8066	Exercise Parameters Recorded on Study Patients legend
8067	Relative Performance of the Three Tests for the Diagnosis of CAD legend legend
8068	Sensitivity of Dipyridamole, Dobutamine Stress Echocardiography and Myocardial Perfusion Scintigraphy for the Detection of Single-, Double- and Triple-Vessel Disease
8069	Sensitivity of Dipyridamole, Dobutamine Stress Echo and Myocardial Perfusion Scintigraphy for the Detection of Isolated Left Anterior Descending Coronary Artery Disease With and Without Multivessel Disease legend
8070	Patients Developing Angina, Diagnostic ST-segment Depression or Both, During Dipyridamole and Dobutamine Stress Echocardiography legend legend
8071	Immunoreactive Endothelin Concentrations legend
8072	Arterial Endothelin Concentrations and Coronary Vasomotor Responses During Rapid Atrial Pacing legend
8073	Coronary risk factors in men and women in Mysore
8074	Percentages of men and women with coronary heart disease according to birth measurements
8075	Odds ratios for coronary heart disease in men and women aged 45 years and over according to weight, length, and head circumference at birth
8076	Mean weight, length, and head circumference at birth and prevalence of coronary heart disease according to mother's weight in pregnancy
8077	Frequency of coronary heart disease according to birthweight and mother's weight in pregnancy
8078	SMRs among men in Hertfordshire according to birthweight and weight at 1 year
8079	SMRs among men born in Sheffield according to birthweight and head circumference
8080	SMRs and relative risks among 13 249 men born in Hertfordshire and Sheffield according to birthweight
8081	SMRs for stroke among men born in Sheffield according to head circumference, birthweight, and placental weight
8082	SMRs among men born in Sheffield according to placental weight
8083	Mean birthweight, head circumference, and placental weight for infants born in Sheffield whose mothers had flat pelvises
8084	Results of multivariate regression analysis on tPTEF/tE
8085	Cases of congenital heart disease by group
8086	Distribution of types of arterial stroke by region
8087	Odds ratios of haemorrhagic stroke in relation to combined OC use by region
8088	Odds ratios of haemorrhagic stroke in relation to current combined OC use by age-group and oestrogen dose
8089	Odds ratios of haemorrhagic stroke in relation to current combined OC use by smoking status
8090	Odds ratios of haemorrhagic stroke in relation to current combined OC use by history of hypertension
8091	Odds ratios of intracerebral and subarachnoid haemorrhage in relation to current combined OC use
8092	Objectives for each visit in the new programme
8093	Antenatal practice, labour interventions, and pregnancy outcome
8094	Women referred to hospital antenatally or during labour
8095	Causes of maternal mortality
8096	Odds ratios for invasive breast cancer in relation to perinatal factors reported by mothers
8097	Odds ratios for invasive breast cancer in relation to birthweight reported by mothers and stratified by age at diagnosis in daughters
8098	Odds ratio for invasive breast cancer in relation to birthweight reported by nurses
8099	Angiographic Outcome After 27 Procedures
8100	Semiquantitative Analysis of Plaque Material in Vein Graft Aspirates legend legend
8101	Interpretation of Regional Endocardial Motion legend legend
8102	Statistics of Agreement of the Conventional Interpretation of Gray-scale Images by the Inexperienced Reviewers and the Objective Evaluation of Regional Endocardial Motion Based on Segmental Analysis of Systolic Color Kinesis Images legend legend
8103	Diagnoses of Ischemic Response to Dobutamine on a Patient-by-Patient Basis Made by Two Inexperienced Reviewers of Conventional Gray-scale Images, and the Objective Technique Based on Color Kinesis legend legend
8104	Estimated yearly risk of infection by region of the world  *
8105	Average contact numbers for smear-positive tuberculosis cases calculated from the ratio of the annual risk of infection and smear-positive tuberculosis prevalence by country
8106	Meta-analysis of BCG efficacy against tuberculous meningitis and miliary tuberculosis from case–control studies
8107	Effectiveness and cost of BCG for the prevention of tuberculous meningitis and miliary tuberculosis, by region and for the world
8108	Tuberculosis diagnosis by type and age in each group
8109	Efficacy of revaccination against tuberculosis by tuberculosis type and city, controlled for age.
8110	Results of post-travel tuberculin skin tests with purified protein derivative  (PPD)  of M tuberculosis and of M scrofulaceum among 656 long-term travellers to high-endemicity areas
8111	Destination-specific incidence rates of tuberculin conversion among 656 long-term travellers to high-endemicity areas
8112	Comparison of individuals with and without intestinal nematode infestation
8113	Summary of events by treatment and stage
8114	Summary of clinical effects of widow spider bites from different regions of the world  29,31–35
8115	Health-care use, expenditure, and resources in Japan compared with selected OECD member countries, 2008  *
8116	Determinants of hospital-standardised mortality ratio  (observed/estimated)  of acute inpatient care in Japanese hospitals, 1999–2008
8117	Changes in self-rated health around retirement
8118	Estimated number of AIDS-related deaths for the years 2015, 2030, 2050, and 2008–50 with different strategies
8119	Study population size, stratified by exposure to green space and by income deprivation
8120	Probable causes of death in 574 adults aged older than 14 years
8121	Probability of dying between the ages of 15 and 60, 20 and 50, and 30 and 65 years in the surveillance population before opening of the antiretroviral therapy clinic in June, 2005, adjusted for area
8122	Trends in adult mortality before and after opening of the antiretroviral clinic in Karonga district
8123	Visit and medication compliances
8124	Major endpoints at 5 years and end of study
8125	Lipid concentrations over the course of the study
8126	Incidence of cancers
8127	Country totals for numbers of centres and children, response rate, 12-month prevalence of asthma, allergic rhinoconjunctivitis, and eczema symptoms in both phases, average change per year, and SE of the change by age-group  (full information in  webtables 1 and 2 )
8128	Number of centres with changes  (increase ≥1SE, decrease ≥1SE and little change <1SE)  by region, disorder, and age-group
8129	Absolute numbers of CEP and concentrations of angiogenic factors in circulation of participants
8130	Estimated costs of 3 by 5, 2004–05  (US$ billions)
8131	Summary of clinical, virological and immunological studies of participants
8132	Excess death rates  (EDR)  per 1000 patient-years in Swiss patients of the SHCS, 1997–2001
8133	Patients who received additional maintenance anti-asthma therapy
8134	Overall change in postbronchodilator FEV1  (% predicted)  and effect of age, sex, and smoking status
8135	Overall result and influence of age, sex, and smoking status on the 1-year and 3-year changes in prebronchodilator FEV1  (% predicted)
8136	Incidence of infusion reactions during infliximab infusions by antibodies to infliximab status up to week 54
8137	Summary of safety findings for all patients  (n=573)  up to week 54
8138	Mortality hazard ratio for methotrexate use compared with no methotrexate use
8139	Mortality hazard ratios for use of disease modifying antirheumatic drugs  (DMARD)  compared with no drug use
8140	Interferon gamma gene polymorphism and susceptibility to rheumatoid arthritis
8141	Interferon gamma gene polymorphism and severity of rheumatoid arthritis
8142	3-year cumulative incidence  *   of stroke, according to the presence of retinal microvascular abnormalities
8143	Relative risk of incident stroke in relation to retinal microvascular abnormalities
8144	Relative risk of incident stroke in people with and without hypertension or diabetes, in relation to retinal microvascular abnormalities
8145	Relative risk of incident stroke in relation to retinal microvascular abnormalities  (all retinal variables entered simultaneously)   *
8146	Summary of initial findings in 20 patients who complained of visual symptoms after viewing solar eclipse
8147	Language and video questionnaire used, response rates, and sample sizes by centre
8148	Distribution of centres by tertiles, based on written and video asthma questionnaires
8149	Concentrations of study drug in plasma
8150	Safety variables and adverse events
8151	Primary and secondary outcomes in the modified intention-to-treat population
8152	Rates of adjudicated clinical events in the safety population
8153	Definition of malignant diseases
8154	Data quality indicators for patients diagnosed during 1995–2009, by continent and country  (all cancers combined)
8155	Population coverage and number of patients diagnosed during 1995–2009, by continent and country
8156	5-year age-standardised net survival for adults  (aged 15–99 years)  diagnosed with one of ten common malignant diseases and children  (aged 0–14 years)  with ALL, by continent, country, and calendar period of diagnosis
8157	Accuracy of screening methods for detection of major and critical congenital heart disease in asymptomatic newborn babies
8158	Detection rate for individual critical congenital heart disease in asymptomatic newborn babies
8159	Accuracy of screening methods for detection of critical congenital heart disease by age in asymptomatic newborn babies  (n=120 707)
8160	Estimated UK population effects for cancers with evidence of a net positive association with body-mass index  (BMI)
8161	Comparison of prevalence of congenital anomalies in the BiB and BINOCAR datasets
8162	Clinical application of engineered tissues
8163	Outcomes
8164	Haematological toxicity
8165	Non-haematological toxicity
8166	Estimated radiation doses to the brain and red bone marrow from one CT scan, by scan type, sex, and age at scan, as used in this study for scans after 2001
8167	Cases of leukaemia and brain tumours and person-years for patients in the assessed cohort
8168	Excess relative risk per mGy for cancer subtypes in relation to organ-specific radiation doses received from CT scans
8169	Effect of wireless implantable haemodynamic monitoring on safety and efficacy endpoints
8170	Definition and quality grade of structural and sustainable indicators
8171	Structural and sustainable indicators by country
8172	Results of meta-regression analyses assessing association between healthy life years at 50 years of age and the structural and sustainable indicators for all 25 EU countries
8173	Results of meta-regression analyses assessing association between healthy life years at 50 years of age and the structural and sustainable indicators for EU country groups
8174	Hazard ratios for graft survival in the first year after transplantation, and after 10 years of follow-up for kidney transplants which were functioning 1 year after transplantation
8175	Multivariable Cox regression analysis
8176	Enrolled children
8177	Primary diagnoses by site and age-group for severe illness requiring hospital admission
8178	Prevalence of individual clinical signs, and odds ratios for association with severe illness requiring hospital admission  (random effects meta-analysis)
8179	Independent clinical predictors of severe illness requiring hospital admission in the 0–6 days age-group  (excluding jaundice)
8180	Sensitivity and specificity of a range of decision rules  (algorithms)  for identification of the sick infant requiring hospital admission, for each study site and age-group, with combined estimates obtained by random-effects meta-analysis
8181	Cumulative probabilities of neutrophil and platelet recovery
8182	Multivariable analysis of acute and chronic GVHD
8183	Multivariable analysis of transplant-related mortality, relapse, and treatment failure
8184	Causes of death and type of transplant
8185	Yearly case reports of syphilis classified by stage, nationwide STD surveillance system
8186	Age of people with syphilis in 2005 by region
8187	LV volume and mass indices, global and regional LV function, and late contrast enhancement 4 days after intracoronary infusion and at 4 months' follow-up
8188	Estimated hazard ratios  (95% CI)  associated with assigned treatment, by time from first complete remission
8189	Clinical outcomes
8190	Neurohormones concentration in plasma
8191	Blood pressure, heart rate and bodyweight
8192	ANXA1 protein expression in B-cell lymphomas
8193	Details of patients with discordant findings
8194	Hazard ratios for the effects of ZAP-70 protein, CD38, and IgVH gene status on survival
8195	Primary and secondary outcomes
8196	Number of hospital admissions for worsening heart failure  *
8197	Permanent study-drug discontinuation for adverse events, by reason for previous ACE-inhibitor intolerance
8198	Reasons for permanent treatment withdrawal
8199	Frequency of primary and selected secondary outcomes
8200	Quantitative Angiography in the 476 Lesions With Angiographic Follow-up legend
8201	Multiple Logistic Regression Analysis for the Dependent Variable of Restenosis legend
8202	Primary and secondary outcomes
8203	Number of hospital admissions for worsening heart failure*
8204	Multiple Logistic Regression Analysis for the Dependent Variable of Late Vessel Occlusion legend
8205	Permanent study-drug discontinuation for adverse events
8206	Results of Prior Studies on Angiographic Outcome in Diabetic Patients legend
8207	New breast disease events and deaths by treatment received
8208	New breast events in patients in the tamoxifen comparison
8209	New breast events in patients in the radiotherapy comparison
8210	Events in patients randomised to tamoxifen stratified by whether or not they had radiotherapy
8211	Effect of tamoxifen in patients by age at randomisation: a comparison with results from the NSABP B-24 trial
8212	Exposure to study medication
8213	Number of segments affected by hibernation, or hibernation or ischaemia
8214	Analysis of change in LVEF in intention-to-treat population
8215	GATA1 exon 2 alterations in patients with Down's syndrome with transient myeloid disorder or acute megakaryoblastic leukaemia
8216	Inclusion criteria
8217	Crude rates and relative risks for prespecified
8218	Causes of death
8219	Adverse events
8220	Clinical and laboratory features of patients according to type of 11q23 abnormality
8221	Prognostic factors of event-free survival according to a stratified Cox's proportional hazards model
8222	Estimates of event-free survival at 5 years according to type of 11q23 abnormality and age
8223	Types of failures and estimated hazard ratios for disease-free survival according to transplant subgroup versus chemotherapy alone in complete responders with the t (4;11)  translocation
8224	Estimated hazard ratios for overall survival according to transplant subgroup versus chemotherapy alone in complete responders with the t (4;11)  translocation
8225	Frequency of the 1513A→C polymorphic allele for the P2X7 receptor in unrelated patients with chronic lymphocytic leukaemia  (CLL)  and in aged-matched unrelated controls
8226	Expression and function of P2X7 receptor in T lymphocytes from members of two families in  figure 2  with chronic lymphocytic leukaemia  (CLL)
8227	Clinical data and response to treatment
8228	Point mutations and clinical sample analysis
8229	Genes highly differentially expressed in acute lymphoblastic leukaemia cells, which are secondarily resistant to STI571
8230	Odds ratios for chromosomal anomaly in residents within 3 km of a hazardous waste landfill site
8231	Odds ratios for chromosomal anomaly in residents within 3 km of a hazardous waste landfill site
8232	Response of left-ventricular mass to a 10-week training period
8233	Incidence of childhood cancer in Yorkshire across 5-year periods and percentage change in incidence between 1974–97 and 1980–97
8234	Germline PTEN mutations detected in patients with Proteus syndrome and Proteus-like syndrome
8235	Features in Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, and Proteus syndrome and four patients with PTEN mutation
8236	Biomarkers of exposure
8237	Biomarkers of effect
8238	Dose-effect relations
8239	Flow-Mediated Dilation Pre- and Postprandial During Placebo, Quinapril and Losartan Treatment
8240	Lipid Values Before and After Oral Fat Load During Placebo, Quinapril and Losartan Treatment legend
8241	Nitroglycerine-Induced Dilation Pre- and Postprandial During Placebo, Quinapril and Losartan Treatment legend
8242	Blood Pressure and Forearm Hemodynamics in the Three Treatment Groups  (Means ± SEM)  Before Randomization legend
8243	Correlation of Baroreflex Sensitivity Measured by the Downward Tilting or Phenylephrine Method With Frequency Domain Analysis of Heart Rate Variability legend
8244	Mean 3-year decline in knee extensor muscle strength and walking speed
8245	Detection of Neisseria meningitidis by nasopharyngeal swabbing and immunohistochemistry
8246	Results of Mapping and Injection Procedures
8247	Frequency of adolescent onset multiple sclerosis in BC
8248	Heart Rate Variability Analysis legend
8249	Studies included in the meta-analysis
8250	Clinical variables
8251	Counts of gadolinium-enhancing lesions
8252	Predictive value of gadolinium-enhancing-lesion counts for relapse rate
8253	Predictive value of gadolinium-enhancing-lesion count for increase in EDSS
8254	Mean changes in body composition with training by ACE genotype
8255	Changes in body morphology over 10-week training period in army recruits by ACE genotype
8256	Relative Content of Myosin Heavy Chain  (%)  in Patients With Class II–III CHF and Normal Subjects
8257	Skeletal Muscle Enzyme Activity in Patients With Class II–III CHF and Normal Subjects  (mol/kg protein/h)
8258	Frequency of infections by protocol and by intention to treat
8259	Angiography and PTCA results
8260	Clinical events, 30 days' follow-up
8261	Clinical events during 6 months of follow-up
8262	Medication at discharge and at 6-month follow-up  (% of patients)
8263	Features of patients at entry to the trial by treatment group
8264	Change in median EDSS, ambulatory index, and arm index between treatment groups
8265	The Mitral Regurgitation Index: Grading of Its Six Constituent Variables legend
8266	Clinical, Doppler and Echocardiographic Variables  (Mean ± SD)  Among the Three Grades of Mitral Regurgitation
8267	The MR Index  (Mean ± SD)  of Normal and Low Ejection Fraction  (EF)  Subgroups
8268	Cox Regression Analysis for Predicting Cardiac-related Mortality
8269	Countries included in analyses with number of communities, households, and patients with cardiovascular disease
8270	Monthly household capacity-to-pay, and costs of each of the four cardiovascular disease medicines in different countries
8271	Participants with a history of cardiovascular disease who reported medicine use across tertiles of income in a range of country incomes
8272	Associations between availability and affordability and use of cardiovascular disease medicines in patients with a history of this disease in low-income and middle-income  (including India)  countries
8273	Event rates during follow-up
8274	Outcomes at 5-year follow-up
8275	Components of the genetic risk score, listed by locus
8276	Risk of coronary heart disease across genetic risk score categories, by study
8277	Risk of coronary heart disease associated with statin therapy across genetic risk score categories
8278	Relation between patient-specific D2B time, annual D2B time, and mortality
8279	Multivariate Model ∗ for Predictors of Impaired Endothelial Function in the Brachial Artery
8280	Primary and secondary outcomes after ruptured abdominal aortic aneurysm in England and the USA
8281	Comparison of outcomes in teaching and non-teaching hospitals in England and the USA
8282	Comparison of outcomes in low, middle, and high bed capacity hospitals in England and the USA
8283	Primary risk factors according to treatment and visit
8284	Comparison of treatment groups for the primary endpoint, secondary endpoints, and other major adverse events
8285	Comparison of treatment groups for the primary endpoint in pre-specified subgroups
8286	Angiographic follow-up at 6–8 months
8287	Clinical results at 1 year by treatment group
8288	Findings of Cardiac Catheterization and Bubble Contrast Echocardiography legend legend
8289	Summary of included trials
8290	Clinical outcomes during 3 years of follow-up  *
8291	Adjusted risk for outcomes associated with early-generation and newer-generation DES compared with bare-metal stents
8292	Clinical outcomes
8293	Randomised controlled trials included in the meta-analysis
8294	Odds ratios and 95% CIs for definite stent thrombosis up to 2 years between different stent types
8295	Odds ratios and 95% CIs for definite or probable stent thrombosis between different stent types
8296	Absolute FBF Responses in the Infused and Noninfused Arms After Enalapril and Placebo Administration legend legend
8297	Clinical adverse events
8298	Primary, secondary, safety, and exploratory outcomes
8299	Procedural complications and outcomes and patient preference
8300	Overall patient-related and stent-related composite and detailed clinical outcomes at 2 years
8301	Timing and event details for the six patients who had an ARC definite or probable stent thrombosis event in year 2
8302	Stent-related efficacy and safety of early and new generation drug-eluting stents from randomised trials in unrestricted populations at 2 years
8303	Association between SNPs and incident coronary heart disease, cardiovascular disease, and myocardial infarction  *
8304	Association between genetic risk score and incident coronary heart disease, cardiovascular disease, and myocardial infarction  *
8305	Association between genetic risk score and prevalent coronary heart disease, cardiovascular disease, and myocardial infarction  *
8306	Reclassification of individuals in the FINRISK 1992 and 1997 cohorts on the basis of 10-year predicted risk of coronary heart disease with and without genetic risk score
8307	Net reclassification improvement of genetic risk score for coronary heart disease in the FINRISK 1992 and 1997 cohorts  *
8308	Efficacy and safety outcomes for the clopidogrel dose comparison
8309	Efficacy and safety outcomes for the aspirin dose comparison
8310	Outcome events occurring within 120 days of randomisation  (intention-to-treat analysis)
8311	Outcome events occurring within 30 days of treatment  (per-protocol analysis)
8312	Mean TRV with 95% Confidence Intervals for Athletes Versus Nonathletes by Workload legend
8313	Haematology and biochemistry results
8314	Effect of allopurinol on total exercise time, time to ST depression, and time to symptoms
8315	Haemodynamic responses during exercise testing
8316	Angina episodes
8317	Clinical outcomes
8318	Definite stent thrombosis and symptom-driven restenosis
8319	Time from randomisation and from most recent ipsilateral event to allocated treatment
8320	Outcome measures within 120 days of randomisation  (intention-to-treat population)
8321	Number of outcome events between randomisation and 120 days in the intention-to-treat  (ITT)  analysis and between initiation of treatment and 30 days after treatment in the per-protocol analysis
8322	Outcome measures between initiation of treatment and 30 days after treatment  (per-protocol analysis)
8323	Quantitative coronary angiography and procedural results
8324	Clinical events during follow-up
8325	Overall clinical outcomes by treatment assignment
8326	Summary effects from direct comparisons and combined direct and indirect comparisons
8327	Hemodynamic Data legend
8328	Exercise Data legend
8329	Coronary Cross-Sectional Area: Absolute Values legend
8330	Rate of bleeding events in the primary percutaneous coronary intervention cohort over 60 days of maintenance therapy
8331	Major secondary efficacy outcomes for primary percutaneous coronary intervention cohort over 60 days of maintenance therapy
8332	Safety outcomes in patients receiving study drug who subsequently needed coronary artery bypass grafting
8333	Rate of bleeding events during 60 days of maintenance therapy in the secondary non-percutaneous coronary intervention cohort  (treated medically)
8334	Clinical events for prasugrel versus clopidogrel in patients with at least one stent
8335	Clinical events for prasugrel versus clopidogrel stratified by stent type
8336	Stent thrombosis rates for prasugrel compared with clopidogrel using Academic Research Consortium definitions and stratified by stent type
8337	Multivariable Logistic Regression Analysis for the Prediction of ACS UsingClinical Predictors and Coronary CTA Assessment
8338	Occurrence of Major Adverse Cardiac Events During Initial Hospital Attendance or 30-Day Follow-Up According to Individual and Combinations of the ADP Test Parameters in the ADAPT and APACE Cohorts
8339	Accuracy  (95% CI)  of ECG, hs-TnI, TIMI, and ADP for Exclusion of MACE
8340	Frequency of Major Adverse Cardiac Events During Initial Hospital Attendance or 30-Day Follow-Up Period in the ADAPT and APACE Cohorts
8341	Participants With Detectable Troponin Values  (>1.2ng/l)  on Presentation
8342	Subsegmental quantitative coronary angiographic analysis  (matched pairs)
8343	Serial intravascular ultrasound analysis
8344	Serial radiofrequency backscattering analysis  (virtual histology)
8345	Metabolite Levels in Angiographic Controls and in Angioplasty-Induced Ischemia Patients
8346	Metabolite Levels in Patients With Spontaneous Chest Pain With and Without Final Diagnosis of Myocardial Ischemia
8347	Diagnostic Accuracy of CTA for Detecting ≥50% Coronary Arterial Stenosis
8348	Distribution of Calcium Scores and Associated Disease Prevalences
8349	Odds ratios, confidence intervals, and C-indices in the prediction of postoperative renal dysfunction with propensity adjustment and the renal risk model
8350	ICERs in different subgroups
8351	Regression results for overall health
8352	Use of Reperfusion Therapy by Pre- Versus In-Hospital ECG Utilization
8353	Acute  (≤24 h)  Medications by Pre- Versus In-Hospital ECG Utilization
8354	Timing of Reperfusion Therapy by Pre- Versus In-Hospital ECG Utilization
8355	In-Hospital Clinical Outcomes by Pre- Versus In-Hospital ECG Utilization
8356	Changes in blood pressure and blood samples
8357	Angiographic results in 224 patients who underwent follow-up angiography
8358	Major adverse cardiac events within 6 months
8359	Drug discontinuation in the celecoxib group
8360	Clinical Outcomes at 1 Year in Patients Undergoing PCI
8361	Angina status during hospital stay and at follow-up intervals after 4, 6, 12 months
8362	Clinical events during hospital stay and at follow-up
8363	Quantitative coronary angiographic data
8364	Medications Taken at the Time of Myocardial Infarction, According to the Presence or Absence of OSA
8365	Medications at the Time of the Sleep Study, According to the Presence or Absence of OSA
8366	Diagnostic Performance and Predictive Value of 64-Slice CT Coronary Angiography for the Detection of ≥50% Stenosis on QCA: Analysis for High, Intermediate, and Low Pretest Likelihood for Obstructive CAD
8367	Presence and Severity of Plaque by CCTA in Different Coronary Arterial Segments
8368	Univariable and Multivariable Cox Models of CCTA Results for All-Cause Mortality  ⁎
8369	Prognostic Value of CCTA Results in Subsets of Population
8370	False Positives by Troponin I and/or ECG Criteria
8371	Comparison of ECG Criteria With ceMRI Scan
8372	Study medications
8373	Procedural details
8374	Core angiographic laboratory analysis
8375	Clinical outcomes at 30 days
8376	Medication therapy at discharge and during follow-up
8377	Event rates and hazard ratios for cardiovascular events
8378	Event rates from hospital discharge until end of follow-up
8379	Univariate and multivariate Cox proportional hazards analysis
8380	Periprocedural and postprocedural clinical outcomes of patients with stent thrombosis
8381	Precipitating Factors
8382	Causes of Death
8383	Univariate Analysis for Predictors of Death After ABS Index Presentation
8384	In-Hospital Events and Cumulative Events After 5 Years
8385	Use of Antianginal and Lipid-Lowering Medication
8386	Predictors of death, by group  (time-dependent covariate model)
8387	Predictors of death, by group  (logistic regression model)
8388	In-Hospital Outcomes
8389	Cox Proportional Hazards Survival Model Results for Long-Term Survival
8390	OXVASC population by age and sex
8391	Rates of invasive investigations and interventions for vascular disease in OXVASC population
8392	Rates of acute events in men and women in the OXVASC population
8393	Relative event rates in men versus women by age for different types of acute vascular events
8394	Performance Indexes of CTCA and SPECT/CTCA for Detection of Hemodynamically Significant Coronary Lesions in 170 Segments in 44 Patients
8395	Angiographic, Pressure-Derived, Electrocardiographic, and Clinical Variables During DES Implantation in Chronic Total Coronary Occlusions
8396	Costs per patient  (€)
8397	MDCT Measurements of Coronary Vessel Lumen and Atherosclerotic Plaque
8398	Medication Use
8399	Procedures and Clinical Outcomes
8400	Gender Differences in Invasive Procedures and Clinical Outcomes by TIMI Risk
8401	PAMI Database
8402	Comparison of Six-Month Clinical Outcomes Between Study Groups
8403	Rates of revascularisation
8404	Cause of death and primary events over all follow-up assessments
8405	Multivariate predictors of death or myocardial infarction at 5 years' follow-up
8406	Treatment effect by risk of death or myocardial infarction to 5 years' follow-up
8407	Incidence of VF Relative to the Timing and Energy of Chest-Wall Impact *
8408	Consequences of Chest-Wall Impact at a Variety of Velocities in the Experimental Commotio Cordis Model
8409	Procedures, Complications and Clinical Outcomes of Patients at Hospital Discharge in Invasive and Conservative Therapy Groups *
8410	Procedures, Complications and Clinical Outcomes of Patients at Hospital Discharge in Invasive and Conservative Therapy Groups Following Matching by Propensity Analysis
8411	Clinical and Angiographic Features of Studied Patients
8412	Tissue Velocities and Wall Thickening in the Ischemic and Nonischemic Regions Throughout the Experiment
8413	Odds ratios of invasive endometrial cancer and endometrial atypical hyperplasia in relation to use of oral oestriol  (1–2 mg)
8414	Odds ratios  (OR)  of endometrial cancer after menopausal use of oral oestriol, by histological grade and degree of invasion of the myometrium
8415	Odds ratios of invasive endometrial cancer and endometrial atypical hyperplasia in relation to use of vaginal oestrogens
8416	Myocardial Infarction Therapy Use, In-Hospital Course and Complications by Patient Age Group legend
8417	Odds of Short- and Long-Term Mortality Among Patient Age Groups legend legend
8418	Clinical and pathological features of patients with FPTMC
8419	Number of patients at risk of relapse by concentration of TNFα
8420	Most commonly studied genetic changes in sporadic colorectal cancer4
8421	Possible colorectal cancer screening programmes for at-risk populations
8422	Survival results of trials comparing 5FU/FA with control in adjuvant treatment
8423	Electron Beam Tomography for Hard and All Coronary Events at Various Calcium Score Thresholds legend
8424	Multivariate Analyses of the Association of Coronary Artery Calcium Scores and Traditional Risk Factors With All Events legend
8425	Late toxic effects of radical radiotherapy
8426	Kinetics Parameters During 125I-Ang I Infusion and Arterial-Venous Concentrations of Endogenous Ang I and II legend
8427	Comparison of Coronary Risk Factors in Three Patient Groups of Single-Vessel CAD, Multivessel CAD and Controls legend
8428	Multiple Logistic Regression Analysis for Discriminating CAD Patients From Control Subjects legend
8429	Multiple Logistic Regression Analysis for Discriminating Acute Coronary Syndrome From Chronic CAD legend
8430	Exercise ECG Data for the Two Exercise Tests legend legend
8431	Regional EF  (%)  of Ischemic and Nonischemic LV Sectors Before, During and After the Two Exercise Tests legend
8432	Global LV EF, Volume Changes and Systolic Blood Pressure Before, During and After the Two Exercise Tests legend
8433	Ages of cases and controls
8434	κ values according to histopathological features
8435	Sensitivity and Specificity of Serum Markers for Acute Myocardial Infarction ∗   legend
8436	Histological type/subtype diagnosis according to familial predisposition
8437	Grading according to familial predisposition
8438	Association of Clinical and Electrocardiographic Factors With the Occurrence of Myocardial Infarction legend legend
8439	Predictors of Myocardial Infarction legend
8440	Main problems at presentation and final diagnosis
8441	Performance of CAM 17·1 mucin assay in patients with and without jaundice
8442	Sensitivity of investigations for diagnosis of pancreatic cancer
8443	Sensitivity of investigations for diagnosing pancreatic cancer according to presence of jaundice
8444	Palliation of major symptoms  (cough, pain, anorexia, and shortness of breath scores)  3 months after randomisation
8445	Moderate or severe  (WHO grade 2 or worse)  adverse effects of treatment reported by clinicians during the first 3 months of treatment
8446	Contingency table of differences between attained and projected adult height by GH therapy status
8447	Comparison of Admitting Diagnosis and Initial Hospital Bed Assignments of 29,585 Patients With LBBB and Acute MI in the National Registry for Myocardial Infarction 2  (June 1, 1994–March 31, 1998)  legend
8448	Comparison of Treatments Received by 29,585 Patients With Acute MI and LBBB With and Without Chest Pain in the National Registry for Myocardial Infarction 2  (June 1, 1994–March 31, 1998)  legend legend
8449	Mortality Estimates and Causes of Death for Patients With LBBB Stratified by Presence of Chest Pain in the National Registry for Myocardial Infarction 2  (June 1, 1994–March 31, 1998)  legend legend
8450	In-hospital Mortality of LBBB Patients With MI Stratified by Age and the Presence of Chest Pain
8451	Sensitivity and Specificity of the Exercise Treadmill Test Using the 1 mm ST Segment Depression Criterion legend legend legend
8452	Sensitivity and Specificity of the Exercise Treadmill Test in Patients With Resting ST Segment Depression When Using 2 mm or More of Additional ST Segment Depression to Define an Abnormal Exercise Treadmill Test legend legend legend legend
8453	Area Under the Curve  (AUC)  of ROC Plots and Predictive Accuracy legend
8454	Recommendations for national and international agencies
8455	Patient Population legend
8456	Sensitivity, Specificity and Cost of Individual and Combined Screening Tests for Recoarctation, Aneurysm and Recoarctation or Aneurysm
8457	Cost of the Most Sensitive Combinations for Recoarctation or Aneurysm
8458	Presence of an integrated non-communicable disease policy, operational status, and inclusion of specific risk factors for 22 countries with high burdens of non-communicable diseases
8459	Presence of surveillance data in national health-reporting systems in 22 countries with high burdens of non-communicable diseases
8460	Countries reporting key elements of non-communicable disease prevention capacity, 2000 and 2010
8461	Number of countries with a high burden of chronic, non-communicable diseases that had implemented demand-reduction measures in December, 2008
8462	Rate of hypertension in people aged 20 years and older in world regions
8463	Age-specific rate of hypertension by world region
8464	Comparison of Patients With and Without Moderate to Severe Mitral Regurgitation legend
8465	In-Hospital Complications
8466	Insonated venous segments
8467	Subgroup analysis of ulcer healing rates
8468	Adverse events
8469	Summary of genome-wide screen results on 1599 families
8470	Locus counting analysis
8471	Clinical features of PTLD cases
8472	IgH genotype and presumed cell of origin of PTLD
8473	Predictive Properties of Creatine Kinase, MB Fraction  (CK-MB)  and P-Selectin for Acute Myocardial Infarction At Time of Presentation legend
8474	Predictive Properties of Creatine Kinase, MB Fraction  (CK-MB)  and P-Selectin for Acute Coronary Syndrome At Time of Presentation legend
8475	Suture material used and time taken to complete repair
8476	Secondary outcome measures
8477	Predictive Properties of Creatine Kinase, MB Fraction  (CK-MB)  and P-Selectin for Serious Cardiac Events At Time of Presentation legend
8478	Myocardial Blood Flows in Control and PB1.3 Groups
8479	Left Ventricular Ejection Fraction
8480	Clinical activity index
8481	Hospital and 6-Month Outcome legend
8482	Number of patients at each stage of trial
8483	Non-serious adverse events of possible, probable, or uncertain association with medication
8484	Exercise Test Variables, DTS Groups and Cardiac Catheterization Results  legend
8485	Multivariable Models Testing for Interaction Between the DTS and Gender for the Diagnosis of Significant, Severe Disease, and Survival
8486	Incremental Information Provided by Duke Treadmill Score Over Clinical Predictors for Significant Disease
8487	Frequency of Coronary Disease Subsets in Women and Men legend
8488	Final Diagnosis and Major Cardiac Events ∗ Within 72 h After Presentation to Emergency Department  legend
8489	Diagnostic Performance of Cardiac Troponin I and Creatine Kinase-MB Fraction Assays for Acute Myocardial Infarction Relative to Peak Level in First 24 h After Presentation to Emergency Department  (1,047 study patients)  legend
8490	Diagnostic Performance of First Sample of Cardiac Troponin I ≥0.4 ng/ml for Acute Myocardial Infarction and Major Cardiac Events Within 72 h in 808 Study Patients
8491	Diagnostic Performance of Peak Cardiac Troponin I ≥0.4 ng/ml and Creatine Kinase-MB Fraction Mass ≥5.0 ng/ml for Major Cardiac Events Within 72 h in Entire Cohort and in Patients Ruled Out for Myocardial Infarction
8492	Probability of Major Cardiac Events Within 72 h by Presence of Independent Predictors ∗ or Ischemia on Admission Electrocardiogram and Peak Cardiac Troponin I Level in First 24 h After Presentation to Emergency Department for All Patients
8493	Use of Aspirin and Heparin on Hospital Admission and Aspirin at Discharge Among Patients Without Contraindications
8494	Use of Aspirin and Heparin on Hospital Admission and Aspirin at Discharge Among Patients Without Contraindications by Time Period
8495	Distribution of total lipid-corrected DDT and PCB serum concentrations in cases of non-Hodgkin lymphoma and matched controls
8496	Total lipid-corrected serum concentrations of DDT and PCB and risk of non-Hodgkin lymphoma
8497	Interaction between total lipid-corrected PCB serum concentration and EBV-EA for risk of non-Hodgkin lymphoma
8498	Mean  (SEM)  urinary excretion of total nitrate and 15N nitrate after infusion of 15N-labelled arginine
8499	Main Features of Patients With Syndrome X and Control Subjects
8500	Individual Results of Atrial and Ventricular Stimulations in Patients With Syndrome X
8501	Median and 5-year overall and progression-free survival
8502	Comparison of Patients With Positive and Negative Rest Sestamibi Perfusion Imaging Studies
8503	Comparison of Patients With and Without Myocardial Infarction
8504	Comparison of Patients With and Without Myocardial Infarction or Revascularization
8505	Summary of False Positive Early Perfusion Imaging Studies Based on Results of Coronary Angiography
8506	Summary of response data
8507	Adverse events reported in 5% or more of patients in either treatment group
8508	Inclusion and exclusion criteria, predictor variables, and outcome measures of PECARN, CATCH, and CHALICE clinical decision rules  8,9,12
8509	Presence of PECARN, CATCH, and CHALICE predictor variables in the validation and comparison cohort analysis
8510	Diagnostic accuracy of PECARN, CATCH, and CHALICE clinical decision rules when analysed using rule-specific inclusion criteria, exclusion criteria, predictor variables, and outcome measures
8511	Diagnostic accuracy of PECARN, CATCH, and CHALICE clinical decision rules in the comparative analysis of all patients with mild injury presenting within 24 h
8512	Adverse events after first, single incontinence procedures in Scotland, 1997–98 to 2015–16
8513	Direct comparison of adverse events following specific mesh first, single incontinence procedures in Scotland, 2006–07 to 2015–16
8514	Adverse events following first, single prolapse procedures in Scotland, 1997–98 to 2015–16
8515	Direct comparison of adverse events after specific mesh and non-mesh first, single procedures for prolapse, by anatomical compartment of index procedure in Scotland, 2006–07 to 2015–16
8516	Life expectancy, cognitive-impairment-free life expectancy  (CIFLE) , and proportion of life free of cognitive impairment at age 65 years in 1991 and 2011
8517	Life expectancy, healthy life expectancy  (self-perceived health) , and proportion of life spent healthy at age 65 years in 1991 and 2011
8518	Life expectancy, disability-free life expectancy  (DFLE) , and proportion of life free of disability at age 65 years in 1991 and 2011
8519	In-Hospital, 1-Year and 5-Year Survival
8520	Multivariate Analysis Assessing Predictors of Death During 5-Year Follow-Up
8521	Primary outcomes
8522	Analysis of secondary outcomes and other prespecified analyses, excluding results from stool culture and PCR
8523	Analysis of stool culture and PCR results on stools collected at 2 weeks’ postnatal and 36 weeks’ postmenstrual age
8524	Secondary analysis—primary outcomes by colonisation status at 2 weeks’ postnatal age
8525	Clinical severity scores of all patients with MoCD type A treated with cPMP
8526	1-year angiographic and intravascular ultrasound outcomes
8527	Cardiac biomarkers less than 48 h after the index procedure
8528	Results of exercise testing
8529	Secondary clinical outcomes at 1-year follow-up
8530	Randomisation, participants, and results of screening all centres  (core age group, cutoff date Dec 31, 2010, data truncated at 13 years of follow-up)
8531	Prostate cancer incidence in the intervention and control groups during three time periods truncated  (all centres, core age group, France excluded except for years 1–9)
8532	Heart Rate and Mean Arterial Pressure in 53 Study Dogs
8533	Prostate cancer mortality in the intervention and control groups during three time periods truncated  (all centres, core age group, France excluded except for years 1–9)
8534	All cause and prostate cancer mortality by age at randomisation  (France excluded)
8535	Regional Function  (percent thickening fraction)  in Ischemic Zone During Interventions in Three Canine Models
8536	Absence of Necrosis
8537	Primary outcomes  *
8538	Secondary outcomes
8539	Women's assessment of participating in the trial
8540	Estimates of clinical effectiveness for the comparison of Usual Care Emergency Departments versus Active management/Whiplash Book Emergency Departments  *  —Step 1
8541	Estimates of clinical effectiveness for the comparison of a physiotherapy package versus reinforcement of advice—Step 2
8542	Health service resource use: mean  (SD)  resource use per patient and unit costs of resource items by type of care  (UK£, 2009 prices)
8543	Continuous smoking abstinence and 7 day point prevalence, nicotine e-cigarettes versus patches
8544	Continuous abstinence and 7 day point prevalence, nicotine e-cigarettes versus placebo e-cigarettes
8545	Adverse events by type  (serious or non-serious)  and relation to study treatment
8546	Characterization of Infarction, Therapy and Outcome Based on Race
8547	Independent Predictors of Therapy and Outcome
8548	Characterization of Infarction, Therapy and Outcome Based on Age
8549	ST Segment Elevation Among Racial Groups: Use of Thrombolytic Agents and Invasive Therapy
8550	Timeliness of Thrombolytic Therapy During Hospital Shifts
8551	Patient Profiles Based on Evolution of Q Waves
8552	Patient Profile and Treatment During Index Hospital Period
8553	Studies of Acute Myocardial Infarction: Management and Outcome
8554	Effect of treatment at 6 months on fatigue severity, functional impairment, and school attendance in FITNET and usual care groups
8555	Recovery at 6 months in FITNET and usual care groups
8556	Results of reassessment at 12 months  (n=127)
8557	Detection of enzyme deficiencies and corresponding lysosomal storage disorders  (n=34 736)
8558	Mutations and enzyme activities of neonates
8559	Reported incidences of lysosomal storage disorders
8560	Typical Effective Doses of Some Sources of Radiation
8561	Epidemiological Studies of Thyroid Cancer After Childhood Radiotherapy
8562	Comparison of Estimated ERR/Gy Between Selected Medical Studies and the LSS of Japanese Atomic Bomb Survivors
8563	Best confirmed response to treatment, by independent review
8564	Treatment-related adverse events grade 2 or higher, experienced by at least 5% of patients on either group
8565	Estimated group difference for primary and secondary outcomes at 3 months, 8 months, and 12 months, based on intention-to-treat analysis
8566	Study outcomes by treatment group  (per-patient analysis)
8567	Microbiological and clinical information for 15 positive blood cultures from 13 patients
8568	Comparison of resource use and costs by treatment group  (per patient analysis)
8569	Numbers and incident rate ratios for recorded referrals and identifications of women experiencing domestic violence in general practice and domestic violence referrals received by specialist agencies, 12 months after intervention
8570	Primary and secondary endpoints
8571	Serious adverse events reported
8572	Multivariable analyses to identify factors associated with pancreatic fistula occurrence
8573	Structured Questionnaire
8574	Symptom Frequency During Tachycardia Episodes
8575	Multivariate Logistic Regression Results for the Diagnosis of AVNRT  (vs. ORT)
8576	Distribution of prediction rule variables and outcomes, according to age group and study phase
8577	Multivariate Logistic Regression Results for the Diagnosis of AVNRT  (vs. ORT)  in Patients With and Without Positive ECG Findings
8578	Bivariable analysis of tree predictor variables of ciTBI for children younger than 2 years
8579	Bivariable analysis of tree predictor variables of ciTBI for children aged 2 years and older
8580	Hazard ratios for AIDS or death for deferral of combination antiretroviral therapy to a lower CD4 cell count range versus initiation at a higher CD4 cell count range
8581	Hazard ratios for death for deferral of combination antiretroviral therapy to a lower CD4 cell count range versus initiation at a higher CD4 cell count range
8582	Lead Removal Indications, Techniques, and Outcomes
8583	Studied Risk Factors for TTR in Univariate and Multivariate Analysis
8584	Outcomes
8585	Medium-chain acyl-CoA dehydrogenase deficiency cases in screened and unscreened cohorts, age at diagnosis, and numbers of cases with severe adverse events by 4 years of age
8586	Medium-chain acyl-CoA dehydrogenase  (MCAD)  deficiency diagnosed by the age of 2 years in babies born in Australia from April, 1994 to March, 2004
8587	Number of hospital admissions and length of stay for cohorts born April, 1994 to March, 2002
8588	Major Clinical Events at Six Months
8589	Report of Side Effects and Their Severity Associated With the Study Medication
8590	Clinical attributes and incident characteristics of adverse events by indigeneity
8591	Rates of adverse events by indigeneity
8592	Adjusted odds ratios of patient-related factors for association with a preventable in-hospital adverse event
8593	Age-standardised distribution of preventable in-hospital adverse events by indigeneity and areas of effort for prevention
8594	Multivariable Model of Mortality After Surgery for Constrictive Pericarditis: Results of Sequential Bootstrapping Cox Proportional Hazards Analyses
8595	Nosocomial infections and period of exposure by group
8596	Nosocomial infection IRR comparisons between treatment groups and the control group
8597	Agents of nosocomial infections by treatment group
8598	Valvular Disease Following Irradiation
8599	LV Size and Function Following Irradiation
8600	Electrocardiogram Findings Following Irradiation
8601	Health resource use over weeks 0–60
8602	Countries included in the early discharge analysis
8603	30-day and 1-year mortality by early discharge eligibility by country and trial
8604	Patients' data at admission
8605	Outcome at discharge and at 3 months
8606	Recovery and adverse events
8607	Incidence of GM Using the Different Radiation Sources
8608	Incidence of Restenosis Within Different Analyzed Segments at Follow-Up
8609	Angiographic Results at Follow-Up Comparing Various Injured Segments
8610	Neuropsychological test scores of low-grade glioma patients, NHL/CLL patients, and healthy controls
8611	Quantitative Coronary Angiography
8612	Major Clinical Events at Six Months
8613	Predictors of Angiographic Restenosis and MACE  (TVR)  at Six Months
8614	Reported psychopathology in exposed and non- exposed children
8615	Effect of streptolysin S gene mutation on group G streptococcus and group A streptococcus virulence in the murine model of necrotising fasciitis
8616	Difference in overall  (123I)  β-CIT binding ratios
8617	Differences in regional  (123I)  β-CIT binding ratios in men and women
8618	Test scores of DDT-exposed individuals and controls
8619	Significant relations of DDT-application years with test outcome  (n=54)
8620	Thallium SPECT Models for Prediction of All-cause Mortality With Akaike Information Criterion Scores and Weights legend
8621	Nuclear and Exercise Predictors of Risk of Death After Adjustment for Potential Confounders: Results of Multivariable Cox Regression Analyses ∗
8622	Results of observational studies of statin use and fractures
8623	Number of fractures necessitating hospital admission by body region and study group
8624	Hazard ratios of fracture with pravastatin use
8625	Metabolic activity before grafting  (T3)  and at the final assessment  (T5)
8626	Comparison of results of neuropsychological tests between T3 and T5
8627	Odds ratios of developing venous thromboembolism associated with use of antipsychotic and antidepressant medications
8628	Categories of antipsychotic drugs
8629	Risk of MCD by self-reported and job-related exposure to potential neurotoxins
8630	Adverse events
8631	Postsurgical recurrence
8632	Analyses on recurrence
8633	Week 54: Related † Adverse Events Experienced by at Least 3% of Patients in Any Randomized Treatment Group ‡  (Number [%] of Patients)
8634	Patient profile upon referral: the 7 patients who underwent transplant
8635	Toxic effects.
8636	Resting and activated T cells CD69 expression before and after transplantation
8637	Interleukin 4 and interferon-gamma expression beforeand after transplantation
8638	Effect of praziquantel and repeated artemether treatment on Schistosoma mansoni infection prevalence and intensity of study
8639	Number of positive, percentage, and mean differences for all parasites assessed  (except S mansoni) , at beginning and end
8640	Adverse events due to artemether treatment after 24 h and reported illness episodes
8641	Clinical Outcomes
8642	Predictors of CICU Mortality
8643	Vulnerability factors and exposure situations in and out of work
8644	Objective work problems in cases and controls
8645	Logistic-regression analysis to predict cases
8646	Logistic-regression analysis to predict cases versus controls
8647	Neutralising antibodies to dengue viruses in the student cohort
8648	Demonstration of Coronary Plaque Progression/Regression
8649	Comparison Between PAV Regression and Progression
8650	Cellular yield during the 14 cell-selection and expansion procedures
8651	Haematopoietic recovery and transfusion use
8652	Results of a masked screening test for sphingolipid-storage diseases
8653	Neutralising antibody titres to H9N2 viruses in serum samples from blood donors in Hong Kong
8654	Efficacy and Safety Outcomes
8655	Clinical, Procedural, and Bioimpedance Data of StudyPopulation
8656	ROC Curve BIVA Threshold Values Predictive of CI-AKI
8657	Multivariable Logistic Regression Models of Predictors of CI-AKI
8658	Correlation between three measures of myelopathy both preoperatively and postoperatively  (two-tailed Spearman's test, p<0·001 in each case)
8659	Results of Conditional Analysis at the Chromosome 4q25 Locus in the AFGen Consortium
8660	Marginal and SNP-Adjusted Associations Between Distinct AF Susceptibility SNPs and AF in the AFGen Consortium and BioBankJapan Sample
8661	Association Between Multimarker Risk Scores and AF in the AFGen Consortium andBioBank Japan Samples
8662	Percentages  (95% CI)  renting homes according to Registrar General's Social Class and educational qualifications
8663	Prevalence and odds ratios for neurotic disorder by sex and social class
8664	Prevalence and odds ratios for neurotic disorder by sex, housing tenure, and car access
8665	Prevalence and odds ratios for neurotic disorder by sex and educational qualifications
8666	Hantavirus serotyping by focus reduction netralisation test  (FRNT)
8667	Prevalence and Incidence of the Brugada-Type ECG from 1958 to 1999
8668	Distribution of conventional prognostic factors between menstrual phases
8669	Seven Cases of Unexpected Death, With a Brugada-Type Electrocardiogram legend
8670	Age- and Gender-Standardized Mortality of 32 Subjects With a Brugada-Type Electrocardiogram and 4,756 Control Subjects
8671	Mean preoperative z scores for each cognitive area by preoperative depression status
8672	Relation of decline in cognitive area to change in depression status at 1 month and at 1 year after surgery
8673	Cognitive testing at intake  (mean, SD)
8674	CSF findings
8675	Diagnostic serological tests for EMV
8676	Cardiovascular Prognosis legend
8677	Cox Regression Analysis for Stroke  (n = 958)  legend
8678	Relative Risks for Stroke and Silent Cerebral Infarct  (n = 585)  legend
8679	Frequency of Right Bundle Branch Block and ST Segment Elevation in the Right Precordial Leads  (V1to V3)  in a Japanese Working Population in the Tokyo Metropolitan Area legend
8680	Clinical Background of Patients With Right Bundle Branch Block and ST Segment Elevation  (Leads V1to V3)  legend legend
8681	Reclassification of 10-year predicted risk and changes in risk discrimination for cardiovascular disease after addition of adiposity measures to a model including Framingham risk score covariates
8682	Changes in Hemodynamic Variables, Angiographic Variables and Coronary Blood Flow in the Two Groups of Patients legend
8683	Biochemical Values Before and After Catheterization
8684	Two-Way Repeated-Measures ANOVA for the Biochemical Parameters
8685	The Change  (Δ)  in Biochemical Values Before and After Catheterization
8686	Design features of cohort studies of cancer incidence in people with HIV/AIDS included in the meta-analysis
8687	Design features of cohort studies of cancer incidence in people after organ transplantation included in the meta-analysis
8688	Cancer in people with HIV/AIDS: study specific standardised incidence ratios  *
8689	Cancer in transplant recipients: study-specific standardised incidence ratios  *
8690	Operations for abdominal aortic aneurysm  (AAA)  and subsequent 30-day mortality
8691	Mortality related to abdominal aortic aneurysm  (AAA)  and incidence of ruptured AAA
8692	All-cause mortality
8693	Timing of incidence of ruptured abdominal aortic aneurysm  (AAA)  and deaths for individuals invited for screening
8694	Mortality related to abdominal aortic aneurysm  (AAA) , ruptured AAA incidence, and all-cause mortality, by attendance at screening
8695	Mood and health status outcomes
8696	Patient Data  legend
8697	Episodes of acute abdominal pain in patients with hereditary angioneurotic oedema
8698	Correlation Coefficients Relating Hemodynamic Parameters to Plasma Levels of ANP and BNP  legend
8699	The effect of eradication on frequency of clinical manifestations and drug dose
8700	Details of patients in the EuroSIDA study
8701	Association between latest CD4 lymphocyte count, treatment regimen, and incidence of ADIs
8702	Contribution of individual ADIs over time
8703	Sex, age, admission delay, and hospital stay related to clinical severity and cause for pancreatitis patients
8704	Final diagnoses for controls
8705	Value of clinicobiochemical systems, plasma C-reactive-protein, and urinary TAP concentrations in prediction of severe acute compared with mild acute pancreatitis
8706	Heart Rate and Mean Blood Pressure Before and After Sublingual Administration of Nitroglycerin legend
8707	Forearm Blood Flow  (ml/min/100 ml arm)  and Platelet cGMP Level  (pmol/109Platelets)  Before and After Sublingual Administration of Nitroglycerin legend
8708	Number of readmissions
8709	Outcome readmissions
8710	Rate of readmissions
8711	Mean costs and cost differences by resource category
8712	Sensitivity analysis of mean cost differences  (95% CI)  between surveillance and early-surgery groups
8713	In-Hospital Adverse Events
8714	Clinical Trial Participation of Women Across CVD Areas
8715	Screened and Enrolled Participants by Gender
8716	Age-standardised asthma mortality for the 5–34-year age group for 46 countries
8717	Crude asthma mortality for the 5–34-year age group for nine countries, for the years 1960–2012, weighted by country population
8718	Numbers of unconfounded randomised trials of an adjuvant bisphosphonate identified, and numbers with data received, by duration and type of bisphosphonate treatment
8719	Estimation of the effect of 5 years of an aromatase inhibitor versus no endocrine treatment
8720	Primary outcomes 90 days after hospital admission
8721	Secondary outcomes, processes of care measures for fever, glucose, and swallowing screening
8722	Number of individuals screened and incidence of low-grade cervical cytological abnormalities and high-grade cervical histopathological abnormalities before and after introduction of the national human papillomavirus vaccination programme, by age group
8723	Comparison of trends in incident high-grade cervical abnormalities in the two youngest age groups, before and after introduction of the HPV vaccination programme
8724	Availability of data from randomised trials of radiotherapy after breast-conserving surgery for invasive cancer that began before the year 2000
8725	Left Atrial Remodeling CMR Parameters: Time Course by Group
8726	Time Course of LV Remodeling and Mitral Regurgitation Parameters by Study Groups
8727	DAPT Use and Adherence
8728	Clinical Outcomes Through 3 Years
8729	Multivariable Predictors of Outcomes
8730	Clinical Outcomes Through 3 Years Stratified by Core–Laboratory-Assessed Reference Vessel Diameter of Treated Lesions
8731	Instrumental Diagnostic Findings According to EM Different Etiologies
8732	In-Hospital Events and Treatment and Post-Discharge Events According to EM Different Etiologies
8733	Comparison of Resting Indices According to Different Angiographic and Hemodynamic Stenosis Severity
8734	Comparison of Clinical Outcomes According to Resting Pressure-Derived Physiological Indices
8735	Mortality and complications according to treatment group
8736	Recovery times in surviving patients according to treatment group
8737	Categorisation of risk of recurrence in endometrial cancer
8738	Overall, disease-specific, and recurrence-free survival of patients with endometrial carcinoma according to type of lymphadenectomy and risk of recurrence
8739	Multivariate analysis of prognostic factors in overall survival for patients with endometrial carcinoma of intermediate or high risk of recurrence  (n=407)
8740	Distribution of adjuvant therapy across patients with endometrial carcinoma of intermediate or high risk of recurrence
8741	Multivariate analysis of prognostic factors in overall survival for patients with intermediate-risk or high-risk endometrial carcinoma who were treated with adjuvant radiotherapy or chemotherapy  (n=328)
8742	Echocardiographic, Histological, and Flow Cytometric Results of LVConstraint Versus Losartan-Treated Sheep
8743	Factors associated with plane of surgery achieved
8744	3-year local recurrence rates for the plane of surgery achieved
8745	3-year disease-free survival rates for plane of surgery achieved
8746	Factors associated with local recurrence
8747	Cumulative Incidence of Arterial Thromboembolism, Stratified by Cancer Type
8748	Relative Hazards of Arterial Thromboembolism During Discrete Time Periods, Stratified by Cancer Type and ThromboembolismType
8749	Cumulative Incidence of Secondary Outcomes, Stratified by Cancer Type
8750	Relative Hazards of Arterial Thromboembolism During Discrete Time Periods, Stratified by Cancer Stage and Thromboembolism Type
8751	Cumulative Incidence of Arterial Thromboembolism, Stratified by Cancer Stage
8752	Metabolite Levels in the Experimental Model
8753	Intravascular Ultrasound Measurements
8754	RPA class definitions
8755	RTOG CNS toxicity criteria
8756	Reasons for not receiving stereotactic radiosurgery
8757	Treatment-related toxicities
8758	Causes of death
8759	Univariate and multivariate survival analyses
8760	Performance measurements at 6 months' follow-up
8761	Radiographic responses at 3 months' follow up
8762	Summary of radiosurgery treatment variables
8763	Literature review of adjuvant treatments with or without WBRT for brain metastases
8764	Unadjusted In-Hospital Mortality  (%)
8765	Full and Pre-Cath Simplified Risk Models
8766	NCDR CathPCI Risk Score System
8767	C-Indices for NCDR Models
8768	Pathogens cultured at the first AOM episode after completion of the vaccination scheme
8769	Geometric mean concentrations  (mg/L)  of IgG anti-pneumococcal antibodies against conjugate vaccine pneumococcal serotypes
8770	Per Cell Fluorescence 24 h After IV Injection
8771	Heart and Body Weights
8772	Incidence of invasive melanoma  (level 2 or higher)
8773	Survival by age group and tumour thickness
8774	Survival by year of diagnosis
8775	Frequency of major wound complications with criteria for 182 evaluable patients
8776	Type of wound closure, and wound complications by anatomical site and wound reconstruction in evaluable patients
8777	Mortality and causes of death for all eligible patients
8778	Results for Measures of CMR After 5 Days and 6 Months
8779	Left Ventricular Wall Thickness in the Infarcted Myocardium and in the Remote Nonischemic Myocardium at 5 Days and 6 Months
8780	Proportion of M1 and M6 isolates detected during two different periods
8781	Echocardiographic Data
8782	Results from lung-cancer trial at about annual intervals
8783	Results from head and neck cancer trial at about annual intervals
8784	CTA Imaging Parameters and Results
8785	Severity of CAD  (Models 1 and 2)  and Adverse Cardiac Events  (N = 2,076)
8786	Cox Models of CTA Measures  (CAD Model 1)  and MACE
8787	Cox Models of CTA Measures  (CAD Model 1)  and All-Cause Mortality and Nonfatal MI
8788	Cox Models of CTA Measures  (CAD Model 1)  and All-Cause Mortality
8789	Effect of preoperative radiotherapy, at biologically effective dose 30 Gy, and of postoperative radiotherapy, on risk of isolated local recurrence by Dukes' stage, age, sex and radiotherapy schedule for curatively resected patients
8790	Effect of preoperative radiotherapy, at biologically effective dose 30 Gy, on death from rectal cancer, on death from other cause, and overall mortality by age and stage in patients who have been curatively resected
8791	Procedural Results
8792	Stent Thrombosis
8793	Association between fracture risk and dispensing of statins and non-statin lipid-lowering drugs
8794	Randomised trials of radiotherapy versus the same management without radiotherapy
8795	Availability of data from unconfounded randomised trials of radiotherapy versus control that began before 1990
8796	Effects of radiotherapy allocation on 10-year probability of recurrence, by type of surgery and nodal status  *
8797	Effects of radiotherapy  (RT)  allocation on particular causes of death for women dying without any breast cancer recurrence
8798	Differences in ophthalmic findings at 24 weeks between patients in radiotherapy and sham-irradiation groups  *
8799	Clinical Outcome at 3 Years
8800	Clinical Events During 12- to 36-Month Follow-Up
8801	Angiographic Outcomes at 8 Months
8802	IVUS Findings at 8 Months
8803	Clinical Outcomes at 30 Days
8804	Clinical Outcomes at 9 and 12 Months
8805	Multivariate Predictors of TLR and TVF at 12 Months
8806	Results of tests before and after study period
8807	Crude survival and cause of death
8808	Number of patients and relative hazard of ischaemic heart disease and acute myocardial infarction by radiotherapy group, side of tumour, and menopausal status
8809	Number of patients and relative hazard of ischaemic heart disease according to radiotherapy and side of tumour censored at time of recurrent breast cancer
8810	Patient Data, by Culprit Lesion
8811	MI Status, by Culprit Lesion or Thrombus Age
8812	Morphometry Data
8813	Hemodynamic Data
8814	D2B Alliance Hospitals' Participation in Activities Sponsored by the D2B Alliance
8815	Association Between D2B Alliance Enrollment and Door-to-Balloon Time Within 90 Min
8816	Long-Term Mortality Risk After First AMI Associated With Smoking Categories Modeled as Time-Varying Covariates
8817	Number of Any CV and Deaths  *
8818	Relationships Among Culprit Plaque Morphology, Embolization, Occlusive Thrombus, Myocardial Necrosis, and Sex
8819	Clinical profiles of patients
8820	Laboratory data
8821	Results of microbiological tests
8822	Expansion of Vb2-positive T cells in NTED patients
8823	Sequence analysis of junctional regions of T-cellreceptor b chains containing Vb2 elements in peripheral T cells of patients 10 and 11
8824	30-Day and Long-Term Mortality According to Degree of ST-Segment Resolution at 90 Min and 4 Hours After Initiation of Reperfusion Therapy
8825	Predictors of Long-Term Outcome in Relation to ST-Segment Resolution 4 Hours After Start of Reperfusion Therapy
8826	30-Day and Long-Term Reinfarction According to Degree of ST-Segment Resolution at 90 Min and 4 Hours After Initiation of Reperfusion Therapy
8827	Sensitivity of main results to exclusion of patients
8828	Clinical Summary
8829	Health State-Specific Life Expectancy by Age and Sex From Framingham Data
8830	Costs, Life-Years Lost, and QALY of 30 Days and Lifetime by Treatment Group
8831	Cost Effectiveness
8832	Distribution of factors affecting prognosis by cervical diameter in patients in surgery and radiotherapy groups
8833	Pathological risk factors in surgery-group patients by cervical diameter
8834	Relapses and morbidity
8835	Univariate and multivariate analysis of overall survival
8836	Index cases for all newborn infants delivered
8837	Index cases of infants with VUR
8838	Sex distribution of index cases and infants with VUR
8839	Confirmed/assumed VUR in index cases
8840	Average age of patients and intended initial treatment according to cancer grade in patients with clinically localised prostate cancer
8841	10-year disease-specific survival in patients with clinically localised prostate cancer by intention to treat and by treatment received
8842	10-year overall survival in patients with clinically localised prostate cancer and age-matched cohorts
8843	Survival in patients with grade 3 disease 5 years after diagnosis
8844	10-year prostate cancer-specific survival  (with 95% CI)  in patients with clinically localised prostate cancer
8845	Comparison of the Invasive and Noninvasive Measures of Microvascular Perfusion
8846	Left Ventricular Volumes and Ejection Fraction at 2 Days and 6 Months and Infarct Size at 6 Months
8847	Unblinded study of APA in SBI recipients, women with autoimmune disease, and healthy blood donors
8848	Proportions of participants positive for APA and ANA  (blinded study)
8849	Late complications during first 5 years after surgery
8850	Type of surgery by allocated treatment
8851	Postoperative complications by allocated treatment
8852	Pathological assessments by allocated treatment
8853	Cumulative Clinical Outcomes Up to 5 Years and Between 1 and 5 Years
8854	Incidence of ST According to Academic Research Consortium Definition
8855	Annualized Hazard Ratio per 100 Patient-Years
8856	Clinical Outcomes in Diabetic Patients
8857	Crude and Adjusted Hazard Ratios of Clinical Outcomes According to Stent Group
8858	Cohorts of patients followed up for tonsillar SCC, other oral SCC, and anogenital SCC after initial HPV-associated and HPV-unrelated cancers, SEER 1973–94
8859	Tonsillar SCC, other oral SCC, and anogenital SCC after initial HPV-associated cervical, vulvar/vaginal, and anal SCC and HPV-unrelated cancers of colon, stomach, and breast, SEER 1973–94
8860	Clinical Outcomes After Index PCI Among On- and Off-Label Patients
8861	Clinical Outcomes Associated With the Use of DES in Patients With Off-Label Indications: Multivariate Cox Proportional Hazards Models  *
8862	Controls used in multiple regression and sensitivity analyses
8863	Population estimates of countries included in multiple regression and time-series analyses, 2009
8864	Cancer mortality rates in year of unemployment controlling for universal health coverage  (UHC)
8865	Rate ratios between projected mortality rates based on 2000–07 observation base and observed mortality rates in 2008, 2009, and 2010 for all cancers and all age groups  (0–84 years)  in different country categories
8866	Cancer mortality in year of rise in public-sector expenditure on health care controlling for universal health coverage
8867	Cumulative Clinical Events at 1- and 5-Year Clinical Follow-Up
8868	Stent Thrombosis According to the Protocol and ARC Definitions  (Up to 5 Years Follow-Up)
8869	Cumulative Clinical Events at 5-Year Clinical Follow-Up, SES Versus BMS, in Patients With and Without DM
8870	Frequency of Different Off-Label Criteria
8871	BMS Versus DES
8872	Results
8873	Outcome concordance in individual patients  (by patient number)  during AF-219 treatment in per-protocol dataset, ranked by percentage change in daytime cough frequency
8874	Treatment-emergent adverse events reported by more than one AF-219-treated patient
8875	Randomised controlled trials comparing percutaneous coronary intervention with the use of stents against coronary artery bypass grafting
8876	Factors associated with oral human papillomavirus  (HPV)  incidence
8877	Comparison of transplant outcomes
8878	Cox proportional hazards regression model for graft failure with interactions
8879	Number of Cardiac Deaths, MIs, and the Combination of Cardiac Death or MI While Patients Were Taking Dual Antiplatelet Therapy
8880	Poisson Multivariable Analysis Assessing the Incidence Rate Ratio of Cardiac Mortality and MI During the Course of Dual AP and After Clopidogrel Discontinuation
8881	Incidence of Cardiac Mortality and MI After Stopping Clopidogrel in Relation to Dual Antiplatelet Therapy Duration
8882	Unpaired angiographic analysis  *
8883	Paired greyscale measurements with intravascular ultrasonography  (per lesion)
8884	Serial radiofrequency backscattering analysis
8885	Multivariable risk factors for 3 year survival after lung transplantation
8886	Quantitative Coronary Angiography Analysis of the Lesions Treated in the Total Cohort and in the Angiographic Subgroup
8887	In-Hospital, Cumulative 30-Day, and Cumulative 9-Month Clinical Events
8888	Serial Intravascular Ultrasound Serial Analysis of Lesions Treated
8889	Factors associated with the absence of antibodies to measles virus in oral fluid from 943 Zambian children
8890	Clinical outcomes at 2 years
8891	Results from imaging methods immediately after the procedure, at 6 months, and at 2 years
8892	Details of studies and women included
8893	Relative risk of ovarian cancer in users of oral contraceptives compared with never users, by duration of oral contraceptive use
8894	Relative risk of ovarian cancer in ever-users of oral contraceptives compared with that in never users, by time since last use and duration of use of oral contraceptives  *
8895	Relative risk of ovarian cancer in ever-users of oral contraceptives compared with that in never users, by age at first use and duration of use of oral contraceptives
8896	Relative risk of ovarian cancer in ever-users of oral contraceptives compared with that in never users, by calendar year of use and time since last use of oral contraceptives
8897	Estimated proportion of ovarian cancers prevented before age 75 years by past patterns of use of oral contraceptives in different countries over five decades
8898	Lesions Treated With DES or BMS in Western Denmark From January 2002 Through June 2005
8899	Incidence Rate and RR of Definite Stent Thrombosis in Lesions Treated With DES  (n = 5,422, SES = 3,426, PES = 1,991)  or BMS  (n = 11,730)  in Western Denmark From January 2002 Through June 2005
8900	RR Estimates for Death, Myocardial Infarction, and Stent Thrombosis  (Definite, Probable, and Possible)  Among Patients Treated With BMS  (n = 8,847)  or DES  (n = 3,548)  in Western Denmark
8901	RR Estimates of Definite ST and Mortality in Lesions Treated With DES  (n = 5,422, SES = 3,426, PES = 1,991)  or BMS  (n = 11,730) , Cumulative Time Periods
8902	Univariate and multi-covariate analysis of NSAID and paracetamol use, smoking status, and oral cancer risk
8903	Risk of cardiovascular-disease-related death in long-term users of NSAIDs and paracetamol
8904	Summary of patients
8905	Cervical cancer death rate per 100 000 in England and Wales
8906	Risk-Adjusted  ⁎   Odds Ratio for In-Hospital Mortality by Various Annual Hospital and Physician Volume Thresholds for Primary PCI
8907	Average Mortality by Physician and Hospital Volume
8908	Patient characterisitics and transgender CNS engraftment
8909	Neuron chromosome analysis
8910	Donor's relationship to the recipient  *
8911	Perioperative mortality and morbidity according to graft type
8912	Operative morbidity
8913	Two most frequent complications by graft type
8914	Postoperative hospital stay according to graft
8915	Graft type and frequency of reoperation
8916	Mortality from breast, uterine, and ovarian cancer in relation to total duration of oral contraceptive use and number of cigarettes smoked per day at entry to the study
8917	Mortality from other cancers in relation to total duration of oral contraceptive use and number of cigarettes smoked per day at entry to the study
8918	Mortality from cardiovascular disease in relation to total duration of oral contraceptive and body mass index use  (months)  and number of cigarettes smoked per day at entry to the study
8919	Mortality from other causes and all causes in relation to total duration of oral contraceptive use  (months)  and number of cigarettes smoked per day at entry to the study
8920	Mortality from all causes in relation to age and number of cigarettes smoked per day
8921	Prevalence of glucose abnormalities at discharge and 3 months after discharge in patients with myocardial infarction
8922	Multiple logistic regression analysis of independent predictors of diabetes mellitus and abnormal glucose tolerance at oral glucose tolerance test 3 months after discharge
8923	Multiple logistic regression analysis of independent predictors of diabetes mellitus and abnormal glucose tolerance at oral glucose tolerance test 3 months after discharge
8924	Early efficacy of HIV-1 infection and HIV-1 infection or death
8925	Frequency of laboratory and congenital abnormalities, and neurological events observed, according to treatment arms
8926	Cardiac Magnetic Resonance Imaging Results
8927	Outcome measurements among the races
8928	2-year graft and 2-year patient survival  *   among races based on the cause of liver disease
8929	Results of univariate analysis for patient survival at 2 years
8930	Results of multivariate Cox regression model for patient survival at 2 years
8931	Results of multivariate Cox regression model for graft survival at 2 years
8932	Randomized, Placebo, or Active-Controlled Trials of at Least 2 Years' Duration With a Primary End Point of Cardiovascular Events or Atherosclerosis Imaging
8933	Probability of HIV-1 infection diagnosis in 391 children during the first 15 months of life
8934	Mean values for assessment data at time of acceptance for transplantation
8935	Univariate regression values
8936	Relative risks of renal transplant survival after transplantation
8937	Frequency of kidney damage
8938	Type of kidney damage
8939	Kidney damage according to organs retrieved and surgical teams
8940	Incidence of myocardial infarction, stroke, or cardiovascular death
8941	Bleeding complications
8942	Primary-outcome events at 3 months
8943	Failure rates at 30 days and 3 months after endarterectomy
8944	Mobilization of CD34+CD133+VEGFR2+ EPCs, CD34+CXCR4+ Cells, and lin−CD133+CD45− VSELs in Patients With Acute MI in Comparison With Healthy Control Subjects
8945	Outcome of treatment
8946	Adverse events
8947	Medical Therapy and Invasive Coronary Revascularization Within 30 Days of Index Myocardial Infarction
8948	Intercurrent Hospitalizations in the First Year After Index Myocardial Infarction
8949	Multivariable Multistate Modeling for Predictors of Heart Failure or Mortality
8950	Prevalence of current use and ever use of HRT among cases and control subgroups
8951	Odds ratios of VTE in relation to current HRT use
8952	Odds ratios of VTE in relation to current HRT use by duration of current episode of use, type of preparation, oestrogen dose, and route of administration
8953	Distribution of types of arterial stroke by region
8954	Odds ratios of ischaemic stroke in relation to combined OC use by region
8955	Odds ratios of ischaemic stroke in relation to current combined OC use by age-group and whether blood pressure  (BP)  was checked before current episode of OC use
8956	Odds ratios of ischaemic stroke in relation to current combined OC use by smoking status and history of hypertension
8957	Odds ratios of ischaemic stroke in relation to current combined OC use by progestagen type and oestrogen dose
8958	Odds ratios of ischaemic stroke in relation to current use of combined OCs containing second-generation progestagen by whether blood pressure  (BP)  was checked before current episode of use
8959	Classification of Animals Used in the Study
8960	Echocardiographic Parameters of LV Remodeling and Function
8961	Serum Caffeine Concentration
8962	Hemodynamic Response to Adenosine Stress
8963	Side Effects During Adenosine Stress
8964	Cumulative sodium and water balance over days 0–4
8965	Secondary endpoints
8966	Side-effects and complications
8967	ST changes that prompted clinical intervention if cardiotocography was suspicious or abnormal
8968	Operative interventions and neonatal outcome analysed according to intention to treat
8969	Operative interventions and neonatal outcome analysed after exclusions of inadequate recordings and fetal malformations
8970	CD14/16 and CD14/69 cells in individual participants
8971	Age and sex distribution of cases  (n=182  *  )
8972	Clinical signs at entry into the study  (definite and probable CJD cases n=104)
8973	Concentrations of neuron-specific enolase  (NSE)  and detection of p130/p131  (n=176 sporadic cases plus n=6 genetic cases)
8974	Initial classification of neuropathologically confirmed sporadic cases  (n=52)
8975	Frequency of distribution of HLA alleles
8976	Distribution of genotypes and frequency of alleles of A/G polymorphism in exon 1 of CTLA4 gene
8977	Classification of thyroid sizes by means of WHO's 1960 and 1994 criteria
8978	Angiographic Analysis
8979	Prevalence of goitre as assessed by WHO 1960 and WHO1994 classifications, and by ultrasonography
8980	In-Hospital and 6-Month Follow-Up Outcomes
8981	κ values on agreement of goitre diagnosis between examiners A, B, and C, between different classification systems in morning sessions, and between morning and afternoon sessions with the same classification system
8982	Mean width, depth, and length of two thyroid lobes from morning ultrasonography session in children without visible goitre by 1960 system
8983	Sensitivity and specificity of repeated goitre diagnosis by palpation
8984	Association of estimated urinary sodium excretion with death and major cardiovascular events  *
8985	Prevalence and awareness of chronic kidney disease by socioeconomic status in cohort participants
8986	Randomized Controlled Trials Included in the Meta-Analysis
8987	Hazard ratio for five stages of chronic kidney disease from all causes, cardiovascular disease, expanded cardiovascular disease, and non-cardiovascular disease mortality
8988	Registries Included in Meta-Analysis
8989	Attributable fraction of all-cause mortality from different stages of chronic kidney disease
8990	Results of Pooled Analysis With Point Estimates for Clinical Events in RCTs and Registries
8991	Hazard ratios  (95% CIs)   *   for stress-urinary-incontinence surgery when comparing exposed and unexposed cohorts
8992	Risk for stress-urinary-incontinence surgery after hysterectomy in relation to number of vaginal childbirths
8993	Risk for stress-urinary-incontinence surgery in relation to mode of hysterectomy
8994	Occurrence of intraventricular haemorrhage
8995	Patent ductus arteriosus
8996	Complications and renal effects
8997	Distributions of age and major cardiovascular risk factors by 24 h urinary sodium excretion in men and women
8998	Hazards ratios of coronary heart disease, cardiovascular, and all-cause mortality associated with 24 h urinary sodium excretion
8999	Hazards ratios of coronary heart disease and stroke incidence associated with 24 h urinary sodium excretion
9000	Adjusted hazards ratios of cardiovascular and all-cause mortality associated with 24 h urinary sodium excretion in men of normal weight and in overweight men
9001	Urinary total isothiocyanate concentration in relation to risk of lung cancer in men in Shanghai
9002	GSTM1 and GSTT1 genotypes in relation to lung cancer risk among a cohort of men in Shanghai
9003	Urinary total isothiocyanate concentration in relation to risk of lung cancer according to GSTM1 and GSTT1 genotypes
9004	GSTM1 and GSTT1 genotypes in relation to lung cancer risk according to urinary total isothiocyanate concentration
9005	Variables included in multiple linear-regression models
9006	Multiple regression analysis  (follow-up)
9007	Likelihood ratios
9008	Registered infant and newborn mortality rates in three townships
9009	Odds ratios of iodine treatment and other variables on neonatal and infant mortality
9010	Procedural Success and Outcomes After PCI  ⁎
9011	Multivariate Predictors of 30-Day and Long-Term Outcome  ⁎
9012	Secondary endpoints
9013	Results of scintigraphy
9014	Complications within first 30 days after treatment
9015	Histopathological and clinical data
9016	Hormone concentrations in college-aged people before and after liquorice consumption
9017	Ethnic origin of patients with tuberculosis who were tested for HIV-1 infection
9018	Patients with tuberculosis who tested positive for HIV-1
9019	Relative risk of endometrial cancer in relation to tamoxifen use
9020	Immunohistochemical Distribution of Adhesion Complex Proteins in Myocardial Specimens Obtained From Patients With and Without Infarct Rupture
9021	Effects of weight, body-mass index, and HRT on the relation between tamoxifen use and endometrial cancer
9022	Prognostic factors influencing endometrial cancer-specific survival
9023	Patients Receiving DES Compared With Historical BMS Controls  ⁎
9024	Patients Receiving DES Compared With Contemporary BMS Controls  ⁎
9025	Unadjusted Clinical Outcomes  ⁎
9026	Results of Multivariable Models: Clinical Outcomes  ⁎
9027	Results From Multiple Logistic Regression Analysis That Evaluated the Association Between Physical Activity Status and Cardiovascular Events
9028	Clinical Outcomes at 30 Days by Diabetic Status
9029	Clinical Outcomes at 30 Days in Diabetic Patients by Randomized Treatment Group
9030	Myocardial Deformation and ceMRI Parameters Before Revascularization for Segments With and Without Functional Recovery at Follow-Up
9031	Prediction of Segmental Functional Recovery After Revascularization Using Myocardial Deformation and ceMRI Parameters
9032	Mean Lipid Values at Each Time Point
9033	Changes in LDL-C Over Time After Hospitalization for ACS
9034	Cardiac Morphometry, Hemodynamics, and Levels of Glucose and Insulin at End of Study
9035	Medication Use in Control and PCI Groups for Each Study
9036	Correlation Between Lp-PLA2 and Other Risk Factors
9037	HRs  (95% CIs)  for Incident CHD by Lp-PLA2 Quartile  ⁎
9038	Predictive Accuracy of Various Multivariate Models to Predict Incident CHD as Measured by an Increase in the AUC
9039	Adjusted Utilization of Cardiac Catheterization by Regional Invasive Intensity
9040	RCTs of BMS Versus DES With MACE as an Outcome
9041	Use of the Term MACE as an Outcome in the Journal  (2006)
9042	Post-Index PCI Medications Use by Stent Type and Procedure Indication
9043	Cox PH Multivariate Analysis of Nonfatal MI or Death and Stent Thrombosis to 2 Years
9044	Correlation  (R Value)  Between Measures of Microvascular Function and Peak CK and 3-Month WMS
9045	Association of KIF6 Trp719Arg With CHD, MI, and Ischemic Stroke
9046	Association Between KIF6 719Arg and Risk of CHD*
9047	Association of 35 Polymorphisms With MI in CARE and CHD in WOSCOPS
9048	Assoociation of KIF6 Trp719Arg with MI and CHD in the Placebo Arms of the CARE and WOSCOPS Trials
9049	Association of the THBS4 Ala387Pro SNP With MI and CHD in the Placebo Arms of the CARE and WOSCOPS Trials
9050	Effect of Pravastatin on MI and CHD in KIF6 Trp719Arg Subgroups in the CARE and WOSCOPS Trials
9051	Absolute Risk and Absolute Risk Reduction of MI in the CARE Trial and of CHD in the WOSCOPS Trial: Effect of Pravastatin in KIF6 Trp719Arg Subgroups
9052	Use of Nonstudy Lipid-Lowering Therapies During Follow-Up
9053	Cumulative Probability of Outcome Measures During Extended Follow-Up  ⁎
9054	Bezafibrate- Versus Placebo-Allocated Patients’ Risk for the Combined End Point of Cardiac Death or Nonfatal Myocardial Infarction During the Extended Follow-Up Period: Overall Effect
9055	Bezafibrate- Versus Placebo-Allocated Patients’ Risk for the Combined End Point of Cardiac Death or Nonfatal Myocardial Infarction During the Extended Follow-Up Period: Effect in Risk Groups  ⁎
9056	Clinical and Angiographic Features in the 2 Groups of Patients
9057	Hemodynamic Features in the 2 Groups of Patients
9058	Values of ST-Segment Shift, Time of Onset of ST-Segment Shift ≥1 mm, Time to ST-Segment Shift Normalization, and Cardiac Pain Severity
9059	Detection of the Culprit Plaque by IVUS
9060	IVUS Analysis in Patients With LAD Reperfusion
9061	IVUS Analysis in Patients With LAD Total Occlusion
9062	Hazard Ratios for 1-Year All-Cause Mortality
9063	TnI and H-FABP Concentration Quartiles
9064	All-Cause Mortality According to H-FABP Diagnostic “Cutoff” With Hazard Ratio Adjusted Using GRACE Risk Factors Plus hs-CRP With TnI as an Additional Continuous Variable
9065	QCA Analysis of the Main and Side Branch
9066	IVUS Analysis of the Main Branch
9067	Reasons for “No Revascularization” or “No Revascularization Work-Up” in Patients With High or Medium Viability
9068	Reasons for “Revascularization” or “Revascularization Work-Up” in Patients With Low Amounts of Viability
9069	Reasons for Not Undergoing Revascularization in 30 Patients With High or Moderate Viability Who Underwent “Revascularization Work-Up”
9070	Short-Term and Long-Term Major Adverse Clinical Events in PCI Patients
9071	Major Bleeding in PCI Patients According to the Day After Randomization
9072	Clinical Outcomes at Day 9 in Patients Undergoing Early PCI  (Within 24 h of Randomization)
9073	PCI-Related Angiographic and Clinical Outcomes According to Use of Open-Label UFH Given in the Catheterization Laboratory Before PCI
9074	Graft Area  (mm2)
9075	Procedural Outcomes and Angiographic Results  (Intention to Treat)
9076	30-Day Hierarchical MACE: Intention to Treat
9077	Multivariable Predictors of MACE  (to 30 Days) : Intention-to-Treat Analysis
9078	Multivariable Predictors of MACE  (to 30 Days) : Device Analysis
9079	End Point Definitions in Each Trial Included in the Meta-Analysis
9080	Morbidity and Mortality
9081	Cumulative Incidence of MACE Observed Up to 5 Years in 120 SES Versus 118 BMS Recipients
9082	Stent Thromboses Adjudicated Per Protocol and According to the ARC Definitions in Each Study Group
9083	Deaths During Follow-Up in Each Study Group
9084	Preintervention IVUS Findings
9085	Valuation of Infarct Size in Each Risk Factor and Subgroup
9086	Multiple Logistic Regression Analysis for LVEF <50% at Chronic Phases
9087	Unadjusted Adverse Outcomes at 9 Months Comparing SES and PES Groups
9088	Unadjusted and Adjusted Hazard Ratios for Clinical Outcomes Comparing SES and PES Groups at 9 Months
9089	Cardiac Function by Echocardiography
9090	Distribution of Ruptured Plaque and Fibrous Cap Atheroma by Gender, Cause of Death, and Presence of Rupture
9091	Morphometric Dimensions of Ruptured Plaques and Fibrous Cap Atheromata
9092	Effects of Treatment on Clinical Parameters Assessed in the 2 Groups of Patients With Chronic Heart Failure
9093	Clinical and Cardiac Parameters Assessed in Normotensive Subjects and in the Whole Group of Patients With Chronic Heart Failure
9094	Effects of Treatment on Parameters Related to Myocardial Fibrosis and Collagen Type I Synthesis and Degradation Assessed in the 2 Groups of Patients With Chronic Heart Failure
9095	Classification of Thrombus Burden
9096	Independent Predictors of Clinical Outcomes
9097	Procedural Outcome
9098	Independent Predictors of Infarct-Related Artery Stent Thrombosis
9099	Lesions Treated With DES or BMS in Western Denmark, January 2002 Through June 2005
9100	Risk of Definite Stent Thrombosis in Lesions Treated With BMS  (n = 11,730)  or DES  (n = 5,422)  in Western Denmark
9101	Relative Risk Estimates for Death, Myocardial Infarction and Stent Thrombosis  (Definite, Probable, and Possible)  Among Patients Treated With BMS  (n = 8,847)  or DES  (n = 3,548)  in Western Denmark
9102	Cox Model for Predictors of Cardiac Death
9103	Cox Model for Predictors of Cardiac Death or Nonfatal Acute Myocardial Infarction
9104	Angiographic Data
9105	Scintigraphic Data According to Change in the LVEF
9106	Independent Predictors of the Change in 6-Month LVEF  (ΔEF)
9107	Results of Univariable Logistic Regression Analysis Regarding CAD Status  (Stable CAD vs. ACS)  in Whole Patient Group  (n = 212)
9108	Results of Multivariable Logistic Regression Analysis Regarding CAD Status  (Stable CAD vs. ACS)  in Whole Patient Group  (n = 212)
9109	Event Rates Per 1,000 Person-Years According to Cumulative Mean Follow-Up Anxiety Score Classification
9110	Relationship Between the Cumulative Mean Anxiety Score and the Primary Outcome  (Nonfatal Myocardial Infarction or All-Cause Mortality)
9111	Relationship Between Cumulative Mean Follow-Up Anxiety Score and Cardiac Events and Total Mortality
9112	Procedural Results
9113	Angiographic Results at 1-Year Follow-Up
9114	Clinical Outcome at Hospital Discharge and at 1 Year
9115	LVdP/dtmax (mm Hg/s)  and Cardiac Output  (ml/min)  in Isolated Rabbit Hearts
9116	Hemodynamic Assessment of Pig Hearts
9117	Regional Myocardial Blood Flow in Epicardial and Endocardial Tissue Samples
9118	Procedural Features in the Atorvastatin and Placebo Groups
9119	Individual and Combined Outcome Measures of the Primary End Point at 30 Days in the Atorvastatin and Placebo Groups
9120	Angiographic and Procedural Data
9121	Quantitative Findings at Follow-Up Angiography
9122	Hemodynamics
9123	Patient Data
9124	Trial Design of Rescue PCI Trials
9125	Sensitivity Analysis of the Effect of Rescue PCI or Repeat Fibrinolytic Therapy on Mortality
9126	Trial Design of Repeat Fibrinolytic Therapy Trials
9127	INSPIRE Inclusion and Exclusion Criteria  ( 14 )
9128	Medication Ranking for Determining the Intensity of Medical Therapy
9129	Therapeutic Considerations for Patients Randomized to Strategy 2  ( 14 )
9130	Comparison Between Patients Who Did or Did Not Have Repeat SPECT
9131	Medical Therapy Administered to Patients in Both Strategies Who Had Two SPECT Studies
9132	Coronary Revascularization Results Based on Stenosis Severity in Patients Randomized to Strategy 2 Who Had Two SPECT Studies
9133	Primary End Point: Gated SPECT Results: Strategy 1 Versus Strategy 2 Patients
9134	Quantitative Coronary Angiography and Intravascular Ultrasound Volumetric Analysis of Lesions Treated in the Two Groups
9135	In-Hospital, 30-Day, and 6-Month Clinical Events in the Two Groups
9136	Procedural Data
9137	Clinical, Biochemical, and Procedural Data of STEMI Patients Stratified by Platelet Reactivity at Entry  ⁎
9138	Overview of the Results of the Conventional Diagnostic Tests, Compared With the Results of LE-CMR
9139	Results of the Non-CMR Tests of Patients With Small Versus Large Right Ventricular Infarcts, as Defined by LE-CMR
9140	Frequency of Discharge Diagnoses for ACS Patients, Other Study Patients, and Non-Study Patients
9141	Odds Ratios  (With 95% Confidence Intervals)  for Univariate Predictors of Mortality and for Those Same Predictors Together With Log10Troponin in Bivariate Models
9142	Independent Predictors of One-Year Mortality With Multivariable Cox Regression Analysis
9143	Results of Quantitative Angiographic Analysis at Follow-Up
9144	One-Year Clinical Outcome
9145	Randomized Trials That Have Examined the Role of Rescue PCI
9146	Early and Systematic Versus Guided or Delayed PCI  (Stent Era and Balloon Era)  After Fibrinolysis for STEMI
9147	Facilitated PCI With Thrombolytic Agents
9148	Logistic Regression Analysis for the Presence of Complex Coronary Lesions in Patients With Stable Coronary Artery Disease
9149	Polytomous Logistic Regression Analysis of Factors Associated With Single and Multiple Complex Lesions in Patients With Stable Coronary Artery Disease
9150	Daily Weather Summaries by Season in Olmsted County, Minnesota, 1979 to 2002
9151	Standardized Rates and RRs  (95% CI)  of MI and SCD for Seasonal and Climatic Variables
9152	Hazard Ratios for Incident CHF According to Current Alcohol Consumption
9153	Individual Trials As Well As the Numbers of Patients Treated With Single Versus Multiple Overlapped SES or BMS  (Control)
9154	Post-Procedure and Late  (8-Month)  Quantitative Coronary Angiography by Stent Type and Stent Overlap Status
9155	Periprocedural and Late  (1-Year)  Clinical Events by Stent Type and Stent Overlap Status
9156	Predictors of In-Stent Binary Stenosis by Multiple Logistic Regression
9157	Pathological Mechanisms of Stent Thrombosis >30 Days Other Than Delayed Stent Healing
9158	Initial and Follow-Up Angiographic Results
9159	In-Hospital and One-Year Clinical Events
9160	Data Completion, by Treatment Arm
9161	Average Costs and Utilization, by Treatment Arm
9162	Accumulated Discounted Costs, Discounted Life Expectancy, and the iCER, at 3.5 Years
9163	Subgroup Analyses of Cost, Life Expectancy, and iCER, at 3.5 Years
9164	Odds Ratios as Estimates of Relative Risk for Premature Myocardial Infarction in Carriers of 807T and 1648A Alleles
9165	Echocardiographic Measurements
9166	Physical Examination and Laboratory Parameters  (n = 654)
9167	Angiographic  (QCA)  and IVUS Measures of Disease Burden  (n = 654)
9168	Univariate Predictors of IVUS Disease Burden  (n = 654)
9169	Univariate Predictors of Angiographic Percent Area Stenosis  (n = 654)
9170	Multivariate Predictors of IVUS Disease Burden  (n = 654)
9171	Multivariate Predictors of QCA Disease Burden  (n = 654)
9172	Disease Burden in Patients With Diabetes Versus Patients Without Diabetes
9173	Disease Burden in the Metabolic Syndrome
9174	Multivariate Analysis: ICD Efficacy by Elapsed Time From CR
9175	Two-Year Kaplan-Meier Cumulative Probabilities of All-Cause Mortality and Sudden Cardiac Death in Each Subgroup of CR Type by Time From CR
9176	Adjusted Mortality Risk by Elapsed Time from Revascularization in the Conventional Group
9177	Crude and Adjusted Door-to-Reperfusion Times
9178	Case Selection Protocol at ISJ
9179	Definition of In-Hospital Clinical Outcomes
9180	In-Hospital Clinical Outcomes
9181	Requirements for a PCI Program Without Onsite Cardiac Surgery
9182	Associations Between Metabolic Syndrome and Clinical Outcomes
9183	Metabolic Syndrome and Clinical Outcomes Stratified by Presence or Absence of Diabetes
9184	Cumulative Effect of Multiple Risk Factors on the Rates of Outcomes
9185	Technical Parameters and Infarct Size Measured by MRI at Day 1, Day 2, and by Observer 2
9186	Number of Events Between One and Two Years
9187	Separate Cox Regression Analyses Performed to Determine Independent Predictors of MACE and TVR at Two-Year Follow-Up
9188	Cumulative Clinical Events at One and Two Years’ Clinical Follow-Up
9189	Stent Thrombosis  (Up to Two Years’ Follow-Up)
9190	Changes in Lipid Parameters
9191	Accuracy of Multislice Computed Tomography for the Detection of Significant Coronary Plaque  ⁎  : Comparison With IVUS for the Entire Region of Interest and for its 5-mm Subsegments
9192	Quantitative Angiographic Parameters  (n = 67)
9193	Quantitative IVUS  (n = 58)  and Echogenicity  (n = 55)  Parameters
9194	Plaque Characterization With Palpography  (n = 49 Patients/52 Vessels)
9195	Strains  (Mean ± SD)  According to Traditional Risk Factors
9196	Multivariable Regression Coefficients  (95% Confidence Intervals)  for Myocardial Strain According to Categories of DBP and SBP
9197	Multivariate Regression Coefficients  (95% Confidence Intervals)  for Myocardial Strain According to Categories of Traditional CHD Risk Factors
9198	Death or MI at 30 Days and 12 Months Among the Two Risk Groups
9199	Echocardiographic Parameters in Sham-Operated and Banded WT and Nox2−/−Mice
9200	Hemodynamic Parameters in Sham-Operated and Banded WT and Nox2−/−Mice
9201	Assessment of IB-IVUS and Conventional IVUS Parameters for Classifying Vulnerable Plaques
9202	Probability of Outcomes Used in the Decision Model
9203	Costs, Effectiveness, and Incremental Cost-Effectiveness Ratio for Upstream Use Strategy Compared With Selective Use Strategy
9204	Incremental Cost-Effectiveness Ratios in Sensitivity Analyses
9205	Hemodynamics
9206	Myocardial Blood Flow, Flow Reserve, and Coronary Resistance
9207	In-Hospital Outcomes by Door-to-Balloon Time
9208	Multivariable Predictors of Late Cardiac Mortality by Cox Regression
9209	Late Cardiac Mortality by Door-to-Balloon Time in Patient Subsets
9210	Description of the Patient Samples
9211	Description of the Hospital Samples and Time to Reperfusion
9212	Factors Associated with Blood Transfusion
9213	In-Hospital Death and Myocardial Infarction by Transfusion Status
9214	Percentage of MBG 2/3, Transmural Necrosis, and Severe Microvascular Obstruction in Patients According to TIMI Flow Grade at Index Angiography
9215	Ischemic Time and Enzymatic Data According to the CE-MR Evidence of TN and/or SMO in Patients Without TIMI Flow Grade 3 of Infarct-Related Artery at Index Angiography
9216	Univariate Survival Analysis
9217	Multivariable Analysis of the Predictors of Death or MI
9218	Included Observational Studies: Quality of Reported Multivariable Modeling
9219	Treatment Effects of OPCAB on Mortality and Morbidity
9220	Post Hoc Stratified Analyses That Employed Data From Randomized Trials
9221	Effect of Study Quality and Statistical Model on Estimated Treatment Effects
9222	Events at Early and Long-Term Clinical Follow-Up
9223	Parameters of LV Function and Postmortem Morphometry
9224	Total Number of Patients With Major Clinical Events Within Interval of Time  (Randomization to 1, 3, and 5 Years)
9225	Listing of Deaths and Causes of Death
9226	Major Adverse Cardiac Events at 5 Years in Patients With Diabetes Stratified According to Treatment
9227	Major Adverse Cardiac Events at 5 Years in Patients Without Diabetes Stratified According to Treatment
9228	Quantitative Coronary Angiography Analysis by Core Laboratory  (Per Protocol Population)
9229	Side Branch Quantitative Coronary Angiography Analysis by Core Laboratory  (Per-Protocol Population, In-Segment Analysis)
9230	Major Adverse Cardiac Events  (MACE)  Hierarchical Analysis  (Intent-to-Treat Population)
9231	Comparison With Other Bifurcation Studies With Bare Metal Stents and One With Sirolimus-Eluting Stents
9232	Type and Results of PCI Procedure of Lesions Undergoing PCI According to Bifurcation or Nonbifurcation Lesions
9233	Major Adverse Cardiac Events at Nine Months According to Bifurcation or Nonbifurcation Lesions
9234	Major Adverse Cardiac Events at Nine Months in Patients With Bifurcation Lesions According to Enrollment or Not in the Angiographic Substudy
9235	Predictors of MACE and TVR at Follow-Up in Patients With Bifurcation Lesions
9236	Correlation Between Mean Platelet Volume and Other Laboratory Measurements
9237	Prognostic Significance of Mean Platelet Volume
9238	Secondary End Points
9239	Thirty-Day Major Adverse Events
9240	Postprocedural Angiographic Data
9241	Electrocardiographic Analysis
9242	Clinical Outcome at One- and Six-Month Follow-Up  (MACCE Are Given in Hierarchical Order per Patient)
9243	Final Predictive Models of Overall Mortality, CVE, Hospitalization for CHF, and Late-Onset Diabetes for Control Subjects, Patients With METS, and Diabetic Patients Adjusted for Potential Confounders  (see Methods) : Distribution, RR, 95% CI, p Value
9244	Release Formulations
9245	Clinical Events and MACE
9246	Serial QCA Analyses
9247	IVUS Analyses
9248	Patient Profile
9249	Determinants of the MR Fraction
9250	Twenty-Year Cumulative Mortality, Absolute Benefits of Reperfusion Therapy, and Life Expectancy Overall and in Specific Subgroups
9251	Life Expectancy  (Years)  Comparing a 1-Year Model  ( 8 )  With a 20-Year Model
9252	Apparent Diffusion Coefficients of Lipid-Rich and Fibrotic Tissues Obtained From Homogenous Aortic Samples Representing the Extreme Tissue Type for 100% and 0% Lipid Concentration, Respectively
9253	Correlation of MRI Diagnosis and Histopathology in Intermediate Coronary Lesions
9254	Evaluation of Cardiac Segments for the Visualization of Acute Myocardial Infarction
9255	Major Adverse Cardiac Events During Hospitalization and at Follow-Up
9256	Proportion of Patients in the PROVE-IT TIMI-22 Trial Reaching Dual Goals of Low-Density Lipoprotein Cholesterol <70 mg/dl and C-Reactive Protein <2 mg/l in the Total Cohort and According to Statin Allocation
9257	Relative Efficacy of Pravastatin 40 mg and Atorvastatin 80 mg in Achieving LDL-C Levels <70 mg/l and CRP Levels <2 mg/l in the PROVE-IT TIMI-22 Trial
9258	Stepwise Multiple Regression Analysis of Variables Associated With the Cumulative CK Release
9259	Stepwise Multiple Regression Analysis of Variables Associated With the Cumulative CK Release in Patients Without Preinfarction Angina
9260	Differences in the Patients With and Without Rapidly Progressive Transplant Vasculopathy
9261	Procedural Results in Patients With Acute Coronary Syndromes
9262	Clinical Outcomes in Patients With Acute Coronary Syndromes
9263	Angiographic Follow-Up in Patients With Acute Coronary Syndromes
9264	Odds Ratio From Multiple Logistic Regression for Triglyceride and HDL Categories
9265	Odds Ratios for Different Combinations of Plasma Triglycerides and HDL-Cholesterol
9266	Left Ventricular Volumes, Mass, and Volumes of Nonenhanced and Enhanced Tissue
9267	Test Performance of Contrast-Enhanced Magnetic Resonance Imaging in the Diagnosis of Preserved Wall Thickening in the Chronic Phase
9268	End Points in Patients With and Without Atrial Fibrillation
9269	End Points in Losartan- and Atenolol-Treated Patients With Atrial Fibrillation
9270	CeMRI Myocardial Enhancement Over Time in Comparison With SPECT Perfusion Defect and Other Parameters of Infarct Size
9271	Hemodynamics During Myocardial Ischemia-Reperfusion Injury in Dogs
9272	Results  (Normalized to the Normal Remote Bed)
9273	Selected Results From Groups 2 and 3 Dogs
9274	Hospital Stay and Frequency of Cardiac Revascularizations and Testing
9275	Reference Costs of Resources and Costs Per Patient by Reperfusion Group
9276	Sensitivity Cost Analysis Using U.K and U.S. Costs
9277	Intravascular Ultrasound Measurements at the Lesion Segment
9278	Patients With Angiographic Restenosis
9279	Type of Acute Coronary Syndrome in Patients With Recurrence According to Aspirin Intake
9280	Risk Factors for Non-Reperfusion Following Fibrinolytic Therapy for Acute Myocardial Infarction
9281	Risk Factors for Death, Reinfarction, or Urgent PCI at 24 h
9282	Indications for PCI
9283	Valve + CABG Surgery
9284	Bleeding and Other Complications
9285	Statistical Analysis
9286	Clinical Data of Patients
9287	Hierarchical Incidence of MACE During Hospitalization and 12-Month Follow-Up in Patients With Successful Recanalization of a CTO
9288	Target Vessel Failure After Recanalization of a CTO in Patients With and Without Diabetes Mellitus
9289	Overview of Studies on Stent Therapy in CTOs Compared With the Present Study
9290	Adverse Clinical Outcomes at 30 Days and 9 Months After PCI
9291	Lesion-Specific Angiographic Follow-Up at 9 Months After PCI
9292	Cox Proportional Hazards Models for Death, MI, and TVR
9293	Adjusted Cox Proportional Hazards Models for Death, MI, and TVR
9294	Procedural Resource Utilization and Cost
9295	Initial Hospital Outcomes, Resource Utilization, and Cost
9296	Follow-up Events, Resource Utilization, and Cost
9297	Multivariable Linear Regression Model of Initial Hospital Costs
9298	Identification of the Analyzed Proteins
9299	α-1-Antitrypsin Isoforms in Plasma From Patients During an Acute Coronary Syndrome
9300	Fibrinogen Gamma Chain Isoforms in Plasma From Patients During an Acute Coronary Syndrome
9301	Expression of Apolipoprotein A-I Isoforms and Gamma Immunoglobulin Heavy Chains in Plasma From Patients During an Acute Coronary Syndrome
9302	Serial Quantitative Coronary Angiographic Analyses
9303	Most Severe  (Hierarchical)  and Total Count of Cardiac Events Up to 12 Months in Each Treatment Group
9304	Incidence of Vessel Segment Restenosis in Patients With and Without Intravascular Ultrasound
9305	Clinical Outcomes at 30 Days and Time from Symptom Onset to Treatment
9306	Predictors of Adverse Events at Nine Months  (Univariate Analysis)
9307	Attributable Risk of Non-Participation, in the Entire Cohort, Stratified by Age and Gender and Quartile of Propensity Score
9308	Frequency of Atherosclerosis Risk Factors, Previous Cardiac or Cerebrovascular Events, and Aortic Atherosclerotic Plaques  ⁎
9309	Risk of CAD or CVD End Points in Relation to Clinical Risk Factors
9310	Risk of CAD or CVD End Points in Relation to Clinical Risk Factors, Adjusted for Age and Gender
9311	Multivariate Cox Proportional Hazard Models of Cardiac or Cerebrovascular End Points
9312	Risk of CAD or CVD End Points in Relation to Severity of Aortic Atherosclerosis
9313	Procedural Data and In-Hospital Outcome
9314	Relationship Between TIMI Risk Index and In-Hospital Mortality  (%)
9315	Odds Ratios for Mortality and Discriminative Capacity  (cStatistic)  for Individual Components of the Risk Index and for the Index as a Continuous Variable
9316	Variables Independently Associated With CABG in Multivariate Analysis
9317	Doppler Data and CTFC Data
9318	Correlates of CTFC
9319	Correlates of CFVR
9320	Changes in LV Geometry
9321	Hemodynamic Responses to Isoproterenol Infusion
9322	Microvessel Data
9323	Intravascular Ultrasound Volumetric Measurements in 60 Stented and Reference Segments
9324	Intravascular Ultrasound Morphologies in 60 Culprit Lesions
9325	Coronary Angiographic Results
9326	In-Hospital Treatment
9327	Thirty-Day End Points
9328	Thirty-Day End Points for Anterior Myocardial Infarction
9329	Regional Wall Motion Score at 30 Days
9330	Predictors of the Composite Secondary End Point by Multivariate Logistic Regression Analysis
9331	In-Hospital Major Adverse Cardiovascular Events Following Percutaneous Coronary Intervention
9332	Major Adverse Cardiovascular Events Based on the Mayo Clinic Risk Score and ACC/AHA Lesion Score
9333	Discriminatory Measures of Mayo Clinic and ACC/AHA Lesion Risk Scores
9334	Description of Studies Included in the Meta-Analysis
9335	Description of Populations and Procedures of Included Studies
9336	Subgroup and Sensitivity Analyses
9337	Factors Contributing to the Development of Collateral Vessels
9338	Odds Ratio for the Development of Collateral Vessels
9339	Odds Ratio for In-Hospital Death  (Below 70 Years of Age)
9340	Odds Ratio for In-Hospital Death  (Above 70 Years of Age)
9341	Measurement of Hemodynamics and Systolic and Diastolic Function
9342	Time to Treatment in the Air PAMI-No SOS Study
9343	Treatments Received in the Air PAMI-No SOS Study
9344	Angiographic Data
9345	In-Hospital Complications
9346	Multivariate Predictors of Mortality at One Year in the Air PAMI-No SOS Study
9347	Noninfarcted  (Nonhyperenhanced) , Infarcted  (Hyperenhanced) , and Total LV Masses  (Noninfarcted Plus Infarcted)  at 3 Days, 10 Days, 4 Weeks, and 8 Weeks After Infarction
9348	Crude In-Hospital Mortality Rates
9349	Hospital Annual PCI Volume and Odds of In-Hospital Mortality
9350	Independent Predictors of Dilation  (>5%)
9351	Independent Predictors of Severe  (>20%)  Dilation
9352	Univariate Analysis: Predictors of Fatal Outcome
9353	Multivariate Cox Proportional Hazard Model
9354	Comparison Between EDWT and Myocardial Perfusion as Prognostic Indexes of Recovery of Contractile Function at Two Months' Follow-Up
9355	Cause of Death by Treatment Group
9356	Chronology of Cardiac Death by Treatment Group
9357	Location of Sudden and Non-Sudden Cardiac Death by Treatment Group
9358	Hemodynamic Measurements
9359	Capillary Density One Month After Cell Transplantation
9360	Myocardial Contrast Intensity  (AU2)  One Month After Cell Transplantation
9361	Ratio of Wall Thickness  (Systole/Diastole)
9362	Quantitative Coronary Angiographic Results
9363	Procedural Success and Complications
9364	In-Hospital and 30-Day Outcome
9365	Six-Month Clinical Outcome
9366	Predictors of TLR, TVR, and MACE by Cox Regression Analysis
9367	Ischemic Outcomes at Six-Month Follow-Up
9368	Variables Included in the Propensity Analysis for Discharge Aspirin Doses ≥150 mg
9369	Important Multivariable Predictors of Six-Month Death, MI, or Stroke
9370	Results of Complete Blood Count and Coagulation Tests
9371	Results of Platelet Function Tests *
9372	Most Common Drugs Given After the Intervention
9373	Scintigraphic Results
9374	Kaplan-Meier Estimates of Adverse Events at 30 Days and at 300 Days
9375	Multivariate Predictors of 300-Day Major Adverse Cardiac Events
9376	Resting and Exercise Test Values, With Univariate Comparison Between Ages Above and Below 65 Years for Total, Surviving, and Nonsurviving Patients From Cardiac Causes of Death
9377	Clinical and Exercise Test Variables, Chosen in the Cox Proportional Hazards Model as Significantly and Independently Associated With Time Until Death Due to Cardiac and All Causes
9378	Comparison of AUC for Above and Below 65 Years Age-Specific Prognostic Scores and the Duke Treadmill Score
9379	AUC of ROC Plots for ST Depression, DTS, and VA/UWV Score
9380	Number  (%)  of Patients With Each Condition
9381	The Charlson Comorbidity Index as Compared With the CAD-Specific Index
9382	Frequency of Scores by the Charlson and CAD-Specific Indexes
9383	Cox Linear Regression Models
9384	Hemodynamic Data
9385	Echocardiography Data
9386	Univariate Predictors of All-Cause Mortality
9387	Outcomes in Relation to Treatment Modality
9388	Reasons for Failed Percutaneous Coronary Intervention Leading to Urgent Coronary Artery Bypass Graft
9389	Accuracy of the +VIC to Predict the Recovery of Segmental Contractile Function
9390	Patient Selection for Current Analysis
9391	Incidence of Ischemic Events on the Day Before Treatment Discontinuation  (Day −1) , and the First Day and the First Week After UFH or Short-Term Enoxaparin Treatment Cessation
9392	Crude Mortality, Relative Risk, Univariate Odds Ratios, and Risk Scores for Clinical Risk Factors
9393	Risk Classification
9394	Multivariate Logistic Regression Model of In-Hospital Mortality
9395	Various Combinations of Risk Factors That Would Fit Individual Risk Classes
9396	Determinants of ERO at Rest
9397	Determinants of the ERO Changes During Exercise
9398	Angiographic Data and Cath-Lab Complications of Study Patients
9399	In-Hospital Complications and Long-Term Outcomes
9400	Adjusted Odds Ratios of Clinical Variables Associated With the Risk of Final TIMI ≤2 Flow
9401	Inclusion Criteria
9402	Risk Scores and Significant Univariate Predictors of Mortality After 30 Days
9403	Risk Scores and Significant Univariate Predictors of First Year Mortality
9404	Significant Univariate Predictors of First-Year Mortality in 114 Patients With Documented CAD and in 59 Patients With High-Risk of CAD
9405	Multivariate Analysis to Predict All-Cause First-Year Mortality
9406	Multivariate Analysis to Predict All-Cause First-Year Mortality
9407	Incremental Value of HRV Measurement and cTnI in Predicting All-Cause Mortality
9408	Mayo Clinic Risk Score: Multivariate Predictors of Procedural Complication After Percutaneous Coronary Intervention
9409	Univariate Association of Angiographic Risk Factors With Major Procedural Complications in the NHLBI Dynamic Registry
9410	Multivariate Predictors of Major Procedural Complications After Percutaneous Coronary Intervention in the NHLBI Dynamic Registry
9411	STS TMR Outcomes by Procedure Type
9412	STS TMR Outcomes by Patient Subgroups
9413	Outcomes Among Patients With Three-Vessel Disease Receiving Two or Fewer Bypass Grafts With or Without TMR in STS
9414	Angiographic and Procedural Data
9415	Clinical and Electrocardiographic Outcomes
9416	Multivariate Predictors of Heart Failure Development and Heart Failure and Death in Long-Term Survivors of MI
9417	Description of the Risk Profiles Based on the Final Model
9418	PAMI Database
9419	Distribution of Patients in the Different Subgroups
9420	Bleeding Episodes After Urgent PCI Compared With Elective PCI and No PCI in ASSENT-3 Population
9421	Clinical Events During 30-Day Follow-up in Six of 111 Patients Who Underwent MRI Within Eight Weeks of Coronary Stent Placement
9422	Deaths, MIs, and New Interventions During a Median Seven Year Follow-Up
9423	Multivariate Predictors of Cardiac Death and Non-Fatal MI, and Angina Grade 2 or Worse at Five Years
9424	Clinical End Points at 30 Days, 6 Months, and 1 Year According to Clopidogrel Pretreatment
9425	Influence of Clopidogrel Pretreatment on Relative Efficacy of Tirofiban Versus Abciximab on Various End Points
9426	Independent Predictors for Death or MI After Coronary Stenting
9427	Incidence of Bleeding and Transfusion During Index Hospitalization
9428	Procedural Data and Outcomes
9429	Predictors of Adverse Clinical Events at One Year: Results From Multivariate Analysis
9430	Predictors of One-Year Mortality at Multivariate Analysis
9431	Results: Electrocardiographic ST-Segment Changes and Thrombolytic Therapy in the Overall Study Population and in Males Alone
9432	Histological Analysis of Atrial Myocardium in Human PVs
9433	Anatomical Dimensions of Pulmonary Veins
9434	Relationship Between Clinical Presentation and High-Risk Angiographic Findings
9435	Angiographic Predictors of Outcome
9436	Independent Correlates of 30-Day Composite Incidence of Death, MI, or Urgent TVR
9437	Multilevel Logistic Regression Analysis *
9438	Logistic Regression Analysis for the Prediction of the Change in Ejection Fraction
9439	Clinical Features of Patients That Did and Did Not Reach 85% of the Age-Predicted Maximum HR
9440	Exercise Stress Test and Echocardiographic Data of Patients That Did and Did Not Reach 85% of the Age-Predicted Maximum HR
9441	Association of Various Measures of Chronotropic Response to Exercise With the End Points of All-Cause Mortality, Cardiac Death, and Myocardial Infarction Before  (Relative Risk)  and After  (Adjusted Risk)  Correction for Confounding Variables
9442	Effects of Guanethidine on Plasma NE Concentration and LV NE Contents in Normal Rats
9443	Body Weight, Ventricular Weight, and Hemodynamic Data 28 Days After Myocardial Infarction
9444	Myocardial Contrast Echocardiographic Data
9445	Myocardial Contrast Echocardiographic Signal Intensity Data Within Risk Area  (n = 3)
9446	Coronary and Myocardial Blood Flow
9447	Blood Chemistry at Four Weeks After Streptozotocin or Vehicle Injection in Mice
9448	Echocardiographic, Hemodynamic Data, and Organ Weights of Mice
9449	Left Ventricular Angiotensin-Converting Enzyme Activity and Amount of Reactive Oxygen Species in Mice
9450	Selected Predictors of Early GP IIb/IIIa Inhibitor Use
9451	In-Hospital Events by Early Use of GP IIb/IIIa Inhibitor
9452	Association of Early GP IIb/IIIa Inhibitor Use and In-Hospital Mortality
9453	NRMI-NSTE MI Risk Model  (9)
9454	Incidence of Recurrent MI by In-Hospital Medication Use
9455	Mortality by In-Hospital Reinfarction and Use of PCI
9456	Echocardiographic Data at 13 Months
9457	Hemodynamic Data at 13 Months
9458	Unadjusted Rates of Discharge Medical Therapy, 30-Day Cardiac Procedures, and 30-Day and 6-Month Outcomes  (Data Shown Are Percentages)
9459	Unadjusted Rates of Medical Therapy, Procedures, and Outcomes Stratified by Age  (Data Shown Are Percentages Unless Otherwise Indicated)
9460	Adjusted Hazard Ratios of Discharge Medical Therapy and 30-Day Cardiac Procedures, and Adjusted Hazard Ratios of 30-Day and 6-Month Death or Recurrent MI for Low-Income Patients Relative to High-Income Patients
9461	Technical and Procedural Success and In-Hospital Complications of 376 Patients
9462	Multivariable Predictors of Technically Unsuccessful Procedures
9463	12-Month Clinical Outcome of 369 Patients Discharged Free of Q-Wave MI and CABG
9464	Clinical Status After 12 Months of a PCI on a CTO in Patients Discharged Free of Q-Wave MI and CABG and MACE-Free During Follow-Up
9465	Quantitative Coronary Angiographic Data
9466	Clinical Events During Follow-Up
9467	Eligibility Criteria
9468	Clinical Events
9469	Change in Heart Failure Score
9470	Adverse Events During Randomized Treatment and Within 48 Hours After the End of Treatment
9471	Adverse Events Requiring Discontinuationof Treatment
9472	Blood Pressure Changes During Study Treatment
9473	The Effect of Serial Exercise in Early  (IEP)  and Late  (SWOP)  Preconditioning Groups
9474	Myocardial Hemodynamic and Ischemic Changes During PCI
9475	Analyses of Time-to-Event Among Patients According to Aspirin Sensitivity
9476	Correlates of Long-Term Mortality for All Patients
9477	Independent Predictors of Cardiovascular Events at 5 Years Follow-Up by Stepwise Multivariate Logistic Regression Analysis
9478	Events for the Interval PET1–PET2 in All 409 Patients  (Without Exclusions)
9479	Procedural Data
9480	Angiographic Data at Follow-up
9481	All Trials
9482	Trials Without Stents
9483	Trials With Stents
9484	Trials of Single-Vessel  (Proximal LAD)  Disease Only
9485	Trials of Multivessel Disease
9486	Trials of Diabetics and Nondiabetics
9487	Unadjusted Rates of In-Hospital Outcomes of Women and Men Undergoing a PCI in Northern New England by Era of Stenting
9488	Adjusted * Rates of In-Hospital Outcomes of Women and Men Undergoing a PCI in Northern New England by Era of Stenting
9489	Mortality During Two Years in Six-Month Periods in the Invasive and Noninvasive Groups
9490	Patients With Myocardial Infarctions During Two Years in Six-Month Periods in the Invasive and Noninvasive Groups
9491	Number of Spontaneous and Procedure-Related MIs * During the First Six Months in the Invasive and Noninvasive Groups
9492	Death or Myocardial Infarction in Six-Month Periods in the Invasive and Noninvasive Groups
9493	Revascularized Patients During Two Years in Six-Month Periods in the Invasive and Noninvasive Groups
9494	Patients Re-Admitted to the Hospital During Two Years in Six-Month Periods in the Invasive and Noninvasive Groups
9495	MACCE at Midterm Follow-Up  (by Intention-to-Treat Analysis)
9496	Clinical Outcome at Midterm Follow-Up (by Intention-to-Treat Analysis)
9497	Coronary Blood Flow Velocity Variables
9498	Coronary Flow Velocity and Hemodynamic Variables in Patients With Inferior Acute Myocardial Infarction
9499	Temporal Changes in Left Ventricular Function and Volume and Clinical Outcomes
9500	30-Day Adverse Cardiac Events in 48 Patients Undergoing SVG Intervention of 60 Lesions With FilterWire Distal Protection in the Phase I Registry
9501	Procedural Results, Comparing Patients Enrolled in Phase I and Phase II
9502	Variables Correlating With MACE Within 30 Days
9503	Adverse Events at One-Year Follow-Up *
9504	Total Plasma Homocysteine Levels According to Event Type at One-Year Follow-Up *
9505	Univariate Predictors of Endpoints by Cox Regression Analysis *
9506	Infarct Size, Body Weight, and Cardiac Magnetic Resonance Imaging Parameters of Rats With Myocardial Infarction
9507	Angiographic and Coronary Collateral Data
9508	Cardiac Ischemic Events
9509	Hemodynamic Parameters, Infarct Size, and No-Reflow Zone Size in Experiment 1
9510	Hemodynamic Parameters, Infarct Size, and No-Reflow Zone Size in Experiment 2
9511	Relationship Between Pulsed Doppler Parameters Adequately Recorded in 52 Patients Distributed According to Recanalization or TIMI Flow Scores
9512	Predictive Covariates of Changes of Contractile Function Investigated by Echocardiography at Both Segmental-Wall and Chamber Levels in 58 Patients  (with Complete Data Sets)  Followed Up for 3 Months After Anterior Myocardial Infarction
9513	Treatment, Left Ventricular Volumes, and TIMI Flow for Each of the 61 Patients
9514	Myocardial Beta-AR Density and Blood Flow for Each of the 61 Patients
9515	Relationship Between TIMI Flows and Left Ventricular Volumes  (Improved vs. Dilated)  at Six Months
9516	Ventricular Fibrillation, Death, and Survival in the Experimental Groups
9517	Hemodynamic Parameters  (Protocol 1)
9518	Hemodynamic Parameters  (Protocol 2)
9519	Heart Rate, Aortic Pressure, and Left Ventricular Function
9520	Blood Flow Velocity, Time to Peak Flow, Acceleration and Left Ventricular Maximal Elastance Under a Variety of Hemodynamic Conditions
9521	MABP  (mm Hg) , HR  (beats/min) , RPP  (MABP × HR/1,000) , and Body Mass  (g)  in Mice Given Either Vehicle or 0.5 mg/kg Rosuvastatin 18 h Before Hemodynamic Assessment  (n = 4/group)
9522	Treatments Received
9523	Complications
9524	Procedures Performed
9525	Clinical Events
9526	Patients’ Complications
9527	Angiographic Findings at the Site of IVUS Plaque Rupture in 225 Lesions in 223 Patients
9528	IVUS Comparison Between Rupture Site and MLA Site
9529	Medications at Time of Coronary Angiogram
9530	Percutaneous Intervention
9531	Clinical Events
9532	Prevalence Rates of Major Cardiovascular Risk Factors in Patients With Familial P-CAD and Their Respective Age- and Gender-Matched Control Subjects, According to Parental History of CAD in Patients with Familial P-CAD *
9533	Number of Siblings With Major Cardiovascular Risk Factors in 64 Sibling Pairs *  Affected With Familial Premature Coronary Artery Disease
9534	Quantitative Angiographic Analysis in the 267 Patients With Angiographic Follow-Up
9535	Association Between Myoglobin Elevation and Angiographic Findings in TACTICS-TIMI 18
9536	Association Between Female Gender and Outcome
9537	Independent Predictors of Death or Myocardial Infarction During Follow-Up in Multivariate Analysis
9538	Age-Specific Gains in Life Expectancy Resulting From Statin Therapy in Men and Women in the Low LDL/High CRP Group
9539	Gains in Life Expectancy With Various Preventive Interventions
9540	Unadjusted OR  (± 95% Confidence Limits)  for Coronary Angiography, Specialty Follow-Up Care and Mortality in Women Relative to Men According to Age-group Categories for Patients Hospitalized With AMI in Ontario Between April 1, 1992, and December 31, 1993
9541	TIMI 2 and 3 Flow on the Initial Coronary Angiogram
9542	Clinical Outcome Variables of the Two Groups
9543	Clinical Outcome Variables According to Initial TIMI Flow
9544	Air Primary Angioplasty in Myocardial Infarction Trial: Time to Treatment
9545	Air Primary Angioplasty in Myocardial Infarction Study: Treatments Received
9546	Air Primary Angioplasty in Myocardial Infarction Study: Multivariate Predictors of Major Adverse Cardiac Events at 30 Days
9547	Kaplan-Meier Estimates  (95% Confidence Interval)  of 90-Day Events by Postprocedural Troponin I Status
9548	Kaplan-Meier Estimates  (95% Confidence Interval)  of 90-Day Events by Postprocedural Troponin I Quartiles
9549	Adverse Events in Randomized Patients
9550	In-Hospital Outcomes by Gender From the 1997–1998 Dynamic Registry
9551	Status at One Year by Gender for the 1997–1998 Dynamic Registry
9552	Comparison of 201Tl Uptake and the Morphometric Variables in Segments With and Without Recovery of Function After Revascularization
9553	Relationship Between Infarct Location and Right Ventricular Dysfunction
9554	Relationship Between Right Ventricular Dysfunction and Outcome
9555	Multivariate Regression Assessing Risk of Various Outcomes
9556	Angiographic Culprit Lesions Identified as Cause of MI
9557	Stenosis Morphology, TIMI Flow and Collaterals in Single Nontotal Occlusion
9558	Clinical, Angiographic Data and Functional Outcome of Patients Belonging to the Reperfusion Group  (Reduction of Initial MCE Perfusion Defect ≥50% at 24 h versus Nonreperfusion Group  (Reduction of MCE Perfusion Defect <50%)
9559	Coronary Flow Velocity Data and Hemodynamics Immediately After Intervention and After 24 h of Patients Belonging to the Reperfusion Group  (n = 13)   (Reduction of Initial MCE Perfusion Defect ≥50% at 24 h)  versus Nonreperfusion Group  (n = 12)   (Reduction of MCE Perfusion Defect <50%)
9560	Myocardial Infarction Patients With and Without Antecedent Hypertension  (n = 1,093)
9561	Plasma Hormones  (Mean ± SD)  After MI in Patients With and Without Antecedent Hypertension
9562	Relative Odds of Coronary Events in CHD Patients With 100 ng/ml Increase in sICAM-1 Concentration
9563	Relative Odds of Future Acute Coronary Events According to sICAM-1, LDL-C and HDL-C Concentrations
9564	Inclusion Threshold Criteria
9565	Outcomes of Procedures Included and Excluded From Registry
9566	Class I Indications for Procedure by ACC Criteria
9567	Hospital Outcomes by Clinical Presentation and Procedure Setting
9568	Success and Complication Rates by Device Use
9569	Success and Length of Hospital Stay for Selected Clinical Subgroups
9570	Cardiac Catheterization Data
9571	Overview of Patients With Events Related to the Intermediate Lesion During One Year Follow-Up
9572	Primary Outcome Events Related to the Intermediate Lesion Presented for the Dichotomized Results of CFVR and SPECT for Patients in Whom a PTCA Was Deferred and Follow-Up Was Available  (Groups A, B and C; n = 180)
9573	Results of 2 Multivariate Logistic Regression Models for Prediction of Primary Outcome Events, Using the 180 Patients  (Groups A, B and C)  in Whom a PTCA of the Intermediate Lesion was Deferred and Follow-Up Was Available
9574	Clinical Differences Between Patients Treated With PA or With Thrombolysis
9575	Robustness of the Correlation of Plaque Burden and Specific Aortic Elastance Against Potential Confounding Variables
9576	Comparison of Different Parameters of Arterial Mechanics a Measures of Aortic Plaque Burden
9577	OCT Image Features of Vessel Wall Structure by Histopathologic Finding   (11–13)
9578	IVUS and OCT Findings for Corresponding Image Pairs  (n = 17)
9579	Semi-Quantitative Scoring Used to Assess Function From Resting and Dobutamine Magnetic Resonance Imaging, and Uptake of Both Thallium and Tetrofosmin
9580	Stent Implantation Strategy
9581	Quantitative Coronary Angiographic Analysis
9582	Major Adverse Cardiac Events at 31 Days in Intention-to-Treat Patients  (n = 437)  ∗
9583	Major Adverse Cardiac Events at 300 Days in Intention-to-Treat Patients  (n = 437)  ∗
9584	CABG and PCI 36-Month Survival, Survival Free of Unstable Angina and Survival Free of Unstable Angina or Repeat Revascularizations legend
9585	Procedural Data and Results legend legend
9586	Comparison of the Prognostic Value of the Three Measurements in the “Overlap” Group  (n = 753)  legend
9587	Six-Month Mortality by Left Ventricular Ejection Fraction and End-Systolic Volume Index legend
9588	Six-Month Mortality by Ejection Fraction and Infarct Size
9589	Energy-Adjusted Correlations Among Different Types and Sources of Dietary Fiber
9590	Adjusted Relative Risk  (95% CI)  of CVD ∗ According to Quintiles of Dietary Fiber Intake, the Women’s Health Study, 1993–1999 legend
9591	Adjusted Relative Risk  (95% CI)  of MI According to Quintiles of Dietary Fiber Intake, the Women’s Health Study, 1993–1999 legend legend
9592	Adjusted Relative Risk  (95% CI)  of CVD ∗ According to Quintiles of Dietary Fiber Intake Among Subgroups of Women, the Women’s Health Study, 1993–1999 legend
9593	Brachial Artery Ultrasound Measurements
9594	Flow-Mediated Dilation in Subjects Undergoing Exercise Myocardial Perfusion Imaging
9595	Exercise Treadmill Time and Flow-Mediated Dilation
9596	Results of the Exercise Test
9597	Incidence of Events
9598	Independent Predictors of Events During Follow-Up
9599	Hemodynamic Data
9600	Clinical Outcomes in the HRQOL Substudy at 6 and 12 Months After Randomization
9601	Six-Month HRQOL According to Treatment Assignment and the Need for Ischemia-Driven TVR During the One-Year Follow-Up
9602	Study Logic  (Inclusions and Exclusions)
9603	Outcomes in WBC Count Groups
9604	Outcomes in WBC Groups
9605	Thirty-Day Mortality in Patients With AMI by WBC Count Quintile  (%)
9606	Association Between WBC Count Quintile and 30-Day Mortality by Age and Gender
9607	Association Between WBC Group and 30-Day Mortality by Age and Gender
9608	Intravascular Ultrasound Measurements
9609	TIMI Flow Patency and Function of Left Ventricle
9610	AneuRx Patients’ Comorbid Conditions legend
9611	Primary Procedure Results
9612	Endoleaks legend
9613	Follow-Up Results legend
9614	Candidate Predictive Factors
9615	Crude and Adjusted Relative Risk of Death or Myocardial Infarction by 42 Days legend legend
9616	Points Assigned to Each Risk Factor legend
9617	Risk of Death or MI by 42 and 365 days, by Risk Category legend legend
9618	In-Hospital Outcomes of Coronary Angioplasty in Patients With and Without Thrombus legend
9619	Unadjusted Case Fatality in Men and Women up to 30 Days Following a First AMI legend
9620	Adjusted Probability of Death in Men and Women up to 30 Days Following a First AMI legend
9621	Angiographic Data legend
9622	Incidence of Pericardial Effusion and Congestive Heart Failure legend
9623	Stepwise Linear Regression Analysis legend legend
9624	Univariate and Multivariate Predictors of the No-Reflow Phenomenon legend
9625	Outcomes by ST Segment Depression Categories: PARAGON-A and GUSTO-IIb Studies legend legend
9626	Outcomes Among Patients With Electrocardiographic Confounders ST segment Depression Categories: PARAGON-A Data legend legend
9627	Short-Term Outcomes of Patients Randomly Assigned to CABG or PCI legend
9628	Coronary Artery Bypass Graft Surgery and PCI 36-Month Survival, Survival Free of Unstable Angina and Survival Free of Unstable Angina or Repeat Revascularizations legend
9629	Risk of Acute Coronary Events and Coronary and CVD Death According to the Presence of Silent Myocardial Ischemia in an Exercise Electrocardiogram in Men Without Prior Coronary Heart Disease
9630	Multivariate Risk Factor Analysis for CHD Death or Nonfatal MI legend
9631	Predicted Rates of CHD Death or Nonfatal MI Within 5 Years and Corresponding NNT legend
9632	Concomitant Medications During the First 48 h After Admission and Hospital Events legend
9633	Univariate Analysis of Subgroup Mortality Depending on Type of Revascularization legend
9634	Definition of the Study Sample legend
9635	Unadjusted One-Year Mortality legend
9636	Multivariable-Adjusted Risk of Dying During Hospitalization From Initial Q-Wave or Non-Q-Wave Myocardial Infarction legend
9637	Multivariable-Adjusted Risk of Dying Within Two Years of Hospital Discharge From Initial Q-Wave or Non-Q-Wave Myocardial Infarction legend
9638	Bipolar Voltage, Unipolar Voltage, Unipolar Signal Slew Rate and Impedance Values in the Noninfarcted LV and Within the Various Extent of Infarct Transmurality legend
9639	Actual Number of Events by Smoking Status and Trial legend
9640	Relative Risk of Current Smokers Versus Current Nonsmokers legend legend
9641	Mortality and Morbidity: Current Smoking, Ex-Smoking ≤2 Years, Ex-Smoking >2 Years Versus Never Smoking legend legend
9642	Multiple Logistic Regression Models With Backward Selection for Predicting the Risk Ratio of Death at 30 Days and Four Years With Emphasis on Thrombolytic Therapy legend
9643	Multiple Logistic Regressions With Backward Selection Model for Predicting the Risk of In-hospital Stroke With Emphasis on Thrombolytic Therapy legend
9644	Six-Month Follow-Up Data in the Two Patient Groups legend
9645	Psychosocial Assessment in the Short-Stay Strategy and Two Control Groups ∗   legend
9646	Distribution of Risk Factors Among Cases and Controls ∗   legend
9647	Association Between Nicotine Patch Use and Myocardial Infarction: Nicotine Patch Use in Index Week legend
9648	Association Between Nicotine Patch Use and Myocardial Infarction: Effects of Adjustment by Potential Confounders legend
9649	Temperature Differences Between Patients With and Those Without Adverse Events in Each Subgroup legend legend
9650	Independent Predictors of Adverse Cardiac Events legend
9651	Clinical Risk Factors Studied as Possible Predictors of Mortality After an AMI legend
9652	Risk Factors Included in the Ontario Acute Myocardial Infarction Mortality Prediction Rules legend
9653	Logistic Regression Models for Predicting 30-Day and One-Year Mortality After an Acute Myocardial Infarction in Ontario, 1994/95–1996/97
9654	Predictive Performance of the Ontario Acute Myocardial Infarction Prediction Rules legend
9655	Types of Restenosis
9656	Predictors of Diffuse  (≥10 mm)  In-Stent Restenosis  (n = 456)  Controlling for Person Effects legend
9657	Procedural and Angiographic Data  (per Angiographic Core Laboratory)  legend legend
9658	In-Hospital Major Clinical Events legend
9659	Long-Term Cumulative Clinical Events legend
9660	Multivariable Modeling and Predictors of Mortality at One Year legend legend
9661	Predictors of Vascular and/or Bleeding Complications legend legend
9662	Multivariate Cox Proportional Hazard Models legend
9663	Multivariate Cox Model Analysis legend
9664	Tissue Levels of Cyclic Adenosine Monophosphate and Cyclic Guanosine Monophosphate and Activities of Cyclic Adenosine Monophosphate-Dependent Protein Kinase and of Protein Kinase C in Serially Perfused Heart No. 2: Effect of Nonischemic and Postischemic Coronary Effluent of Heart No. 1 legend
9665	Hemodynamic Parameters legend
9666	Overall Results at Five Months legend
9667	Effects of Warfarin by Stratifying Countries Into Those With or Without Good Compliance legend legend
9668	Meta-Analysis of All Trials Evaluating Moderate-Intensity Oral Anticoagulation in Addition to Aspirin in Patients With Unstable Angina legend
9669	Variables in Propensity Score ∗
9670	Effect of Stents on Outcomes ∗
9671	Results of Noninvasive and Invasive Studies and Revascularization Procedures in Post-Thrombolytic and Spontaneous NQMI Patients legend
9672	Clinical Outcomes in Post-lytic and Spontaneous NQMI Patients legend
9673	Outcomes of Post-lytic and Spontaneous NQMI Patients According to Assessment Strategy legend
9674	Revascularization Procedures in Post-Lytic NQMI Patients Randomized to Invasive  (INV)  or Conservative  (CON)  Management Strategies legend
9675	Reported Cause of Death and Procedures Performed in Post-Lytic NQMI Patients Randomized to Invasive  (INV)  and Conservative  (CON)  Management Strategies legend
9676	Angiographic Lesion Morphology of Study Group  (n = 125)  legend
9677	Correlation of Angiographic Morphology and Ultrasound Variables
9678	Correlation of Ultrasound Variables With Clinical Presentation legend
9679	In-Hospital and 30-Day Results of Patients Randomized to PTCA and CABG legend
9680	Thirty-Day Mortality in Patients Randomized to PTCR or CABG According to Angina Class legend
9681	Multiple Stepwise Logistic Regression Analysis of MACE  (Death, Myocardial Infarction, Stroke, Repeat Procedures)  legend
9682	Cost of Revascularization Procedures
9683	Comparative Incidence of Death and Nonfatal Myocardial Infarction During the Entire Follow-up in Patients with Multivessel Disease Treated With Surgery
9684	Major Adverse Cardiac and Cerebrovascular Events in Descending Order of Severity and Followed by the Total Number of Events legend
9685	Causes of Death legend
9686	Absolute Myocardial Blood Flow legend
9687	Myocardial Strains in Remote, Risk and Infarcted Regions legend
9688	Cardiac Hemodynamics and Coronary Blood Flow legend
9689	Clinical Events Stratified by Year of Treatment in Patients Treated With Primary Angioplasty Compared With Patients Treated With Thrombolysis legend
9690	Sensitivity for Detection of Acute Coronary Artery Occlusion Using ST-Segment Deviation and High-Frequency QRS Components legend
9691	Significant Changes in High-Frequency QRS Components  (>0.60 μV or >20%)  During Inflation in Patients With High-Frequency Data From All 12 Leads in the LAD, LCX, and RCA Groups legend
9692	Death Rate and Univariate Significance for the Various Risk Factors legend
9693	Final Multiple Variable Cox Regression Model Showing the Independent Protective Effect of Statins legend legend
9694	Comparison of Clinical and Radionuclide Data of Pediatric Patients After Arterial Switch Operation legend
9695	Angiographic Findings legend
9696	In-hospital Outcome legend
9697	Cumulative One-year Outcome legend
9698	Correlation Between FVII Genotypes, FVIIc and FVIIa legend
9699	30-Day Composite End Point and FVII Genotypes legend
9700	Relative Risk for the Composite End Point in Logistic Regression Analysis legend
9701	Prevalence and In-patient Mortality Rates for Risk Factors Related to Primary Angioplasty: New York State 1993 to 1996 legend
9702	Significant Multivariate Preprocedural Risk Factors for In-patient Mortality for Primary Angioplasty: New York State, 1993 to 1996 legend legend
9703	Significant Multivariate Preprocedural Risk Factors for In-patient Mortality for Primary Angioplasty  (Shock Patients Excluded) : New York State, 1993 to 1996 legend legend
9704	Significant Multivariate Preprocedural Risk Factors for Long-Term Mortality for Primary Angioplasty: New York State, 1993 to 1996 legend
9705	Kaplan-Meier Adverse Outcome Rates for Primary Angioplasty New York State, 1993 to 1996  (%)  legend
9706	In-Hospital and Kaplan-Meier Mortality Rates for Primary Angioplasty for Selected Risk Factors: New York State, 1993 to 1996 legend
9707	Comparison of Different Summary Measures of ST Segment Depression for Detection of Nitrate Treatment Effects
9708	Influence of Increasing Time Prior to Peak Exercise on Detection of Nitrate Treatment Effect
9709	Bias in Measurement of the Nitrate Effect From Regression to the Mean Due to Lead Matching
9710	Qualitative and Quantitative Angiographic Analysis legend
9711	Intravascular Ultrasound Analysis legend
9712	Clinical Events legend
9713	Distribution of PlA1/A2 Genotypes in Relation to Causes of Sudden Death legend
9714	Distribution of PlA1/A2 Genotypes in Men with Acute Fatal Thrombosis and Men With SCD Without Acute Thrombosis legend
9715	Distribution of PlA1/A2 Genotypes in Men With MI With/Without Thrombosis in Different Age Groups legend
9716	Pharmakokinetics of bFGF legend legend
9717	Resting Calf Blood Flow  (ml/min/dl)  legend legend
9718	Procedural Results legend legend
9719	Six-month Angiographic Results legend legend
9720	Wallstent Implantation and Quantitative and Qualitative Angiographic Data legend
9721	Major Cardiovascular Events During Hospital Stay and After Discharge legend
9722	Anatomic Data legend legend
9723	Hemodynamic Data legend legend
9724	Comparisons of the Hepatocyte Growth Factor Levels  (ng/ml)  legend
9725	Major Adverse Events During the First 30 Days After Stent Placement According to PlA Genotype legend legend
9726	Main Results in Different Subsets During the First 30 Days After Stenting legend legend
9727	Angiographic Recurrent Restenosis Rates After Laser Angioplasty in 89 Patients With Different Lesion Length and Residual Stenosis After Ablation, Treatment With Different Types of Catheters and Catheter/Vessel Ratios and Different Risk Factors for the Development of Restenosis
9728	Recurrent Restenosis Six Months After Excimer Laser Angioplasty in 89 Patients With Different Coronary Risk Factors
9729	Plasma Levels of Soluble Adhesion Molecule P-Selectin, Soluble Thrombomodulin, von Willebrand Factor and Fibrinogen in Patients With Chronic Atrial Fibrillation and in Control Subjects legend legend
9730	Diurnal Changes in Markers of Thrombogenesis in Chronic Atrial Fibrillation ∗   legend
9731	Comparison Between Corrected TIMI Frame Counts, TIMI Flow and Ventricular Function at Three Weeks legend legend
9732	Univariate Predictors of Late Mortality legend
9733	Multivariate Predictors of Late Mortality legend
9734	Initial Angiographic Data for Patients Randomized to Angioplasty legend legend
9735	Angiographic and Procedural Data for Patients Randomized to Angioplasty Who Underwent Intervention legend legend
9736	Angiographic Data for Patients Randomized to Angioplasty Who Did Not Undergo Intervention legend legend
9737	Coagulation Data According to Diabetic Status legend legend
9738	In-hospital Events legend
9739	Events at 30 Days and OR legend
9740	Variable Entered Into Multivariate Analysis
9741	Angiographic Analysis
9742	Follow-up Results legend
9743	Univariate Predictors of Target Lesion Revascularization After Repeat Intervention legend
9744	Multivariate Predictors of Target Lesion Revascularization After Repeat Intervention legend
9745	Six- and 12-month TLR for Different Patterns of In-Stent Restenosis legend
9746	Interventional Procedures in All Lesions legend
9747	Pre- and Postintervention IVUS Analysis legend
9748	Procedural Results and Clinical Outcome at One Year legend
9749	Angiographic Data During Primary PTCA legend
9750	Hemodynamic and Flow Velocity Data legend
9751	Regional Blood Flow Ratios legend
9752	Serum Lipoprotein (a)  Levels and Incidence of Lipoprotein (a)  Levels >25 mg/dl in Study Patients legend
9753	Comparative Data of Risk Factors and Serum Lipid Profiles in Study Patients With Coronary Spasm With and Without Prior MI legend
9754	Comparison of the Incidence of Patients With Higher  (>25 mg/dl)  Serum Level of Lipoprotein (a)  in Study Patients With and Without a History of Prior MI legend
9755	Comparison of the Incidence of a History of Previous MI in Patients With Higher  (>25 mg/dl)  and Lower Serum Level of Lipoprotein (a)  in Study Patients legend
9756	Predictors of Wall-Motion Recovery Index at One-Month  (Univariate Analysis)  legend
9757	Treatment Modality and Lesion Location legend
9758	Quantitative Angiographic Results legend legend
9759	In-Hospital Outcomes legend
9760	One-Year Follow-up Results legend
9761	In-Hospital Events legend legend
9762	Treatment Variables legend legend
9763	In-hospital Events legend legend
9764	Predictors of Mortality legend legend
9765	Uni- and Multivariate Logistic Regression Analysis for Predictors of In-Hospital Heart Failure legend
9766	Univariate Cox Regression Analysis and Cox Proportional Hazards Analysis of Predictors of Cardiac Death legend
9767	Interventional Procedures legend legend
9768	In-Hospital Procedural Results and Clinical Outcomes at 18-Month Follow-Up legend legend
9769	Independent Predictors of Any Cardiac Event, Target Lesion Revascularization and Any Revascularization Rate During 18-Month Follow-Up
9770	Early Cardiac Catheterization Outcomes and Findings in Patients With Versus Without Previous Coronary Artery Bypass Graft Surgery  (Core Laboratory Analysis)  legend legend
9771	Early Coronary Angioplasty Outcomes Stratified by Infarct-related Vessel Type  (Core Laboratory Analysis)  legend
9772	In-Hospital Major Adverse Cardiac Events legend
9773	Infarct Related Artery Patency Before Angioplasty legend
9774	In-hospital Clinical Outcome legend
9775	Outcomes legend legend
9776	Logistic Regression Models legend legend
9777	Hemodynamic Parameters legend legend
9778	Regional Myocardial Blood Flow legend legend
9779	Cardiac Catheterization Data in Patients With and Without Lateral ST Segment Depression legend legend
9780	Summary of Hemodynamic Data in Experiment 1 legend legend
9781	Summary of Infarct Size Data in Experiment 1 legend legend
9782	Effects of Diazoxide on Mitochondrial Dysfunction by Ischemia/Reperfusion legend legend
9783	Effect of Diazoxide on Mitochondrial Respiration In Vitro legend legend
9784	Angiographic Data of the Total Study Population  (n = 216)  legend
9785	Univariate Analysis of Angiographic Data legend
9786	Location of Culprit Lesion: Univariate Analysis legend legend
9787	Region at Risk in Patients With Acute Occlusion on LCA: Univariate Analysis legend
9788	Multivariate Analysis: Angiographic Predictors of Out-of-Hospital VF legend
9789	Bivariate Analyses Directly Comparing Subjects with Recognized  (n = 700)  and Unrecognized  (n = 201)  Myocardial Infarction: Significant Predictors of Unrecognized Infarction
9790	Logistic Regression Analysis Directly Comparing Subjects with Unrecognized Myocardial Infarction  (n = 201)  to Those with RMI  (n = 700) : Independent Predictors of UMI legend
9791	Chi-Square Analyses of Six-Year Mortality in Participants with UMI, RMI, and No History of MI
9792	Independent Predictors of Mortality Post-MI legend
9793	In-Hospital Clinical Outcome ∗
9794	Long-term Outcome ∗
9795	Cause of Death Among the 89,299 Eligible Participants
9796	RR of Total Mortality According to Level of Alcohol Consumption legend
9797	RR  (95% CI)  of CVD Mortality According to Level of Alcohol Consumption legend
9798	RR  (95% CI)  of Cancer Mortality According to Level of Alcohol Consumption legend
9799	RR  (95% CI)  of Other Mortality According to Level of Alcohol Consumption legend
9800	Coronary Flow Velocity Measurements by TTCDE legend
9801	Predictive Value of Various Risk Stratifiers legend
9802	Left Ventriculographic Parameters legend
9803	Parameters Predicting Development of CAVB in the Thrombolytic Era legend legend
9804	Odds Ratios and Hazard Ratios of Mortality of Patients With CAVB Complicating AMI
9805	Crude Mortality Rates of Patients With CAVB Complicating AMI
9806	Univariate Comparisons of Tobacco Habits Between 25- to 64-Year-Old Male Patients With First MI and Age-Matched Controls
9807	Conditional Logistic Regression Analysis of Independent Predictors of AMI Excluding Present Smokers: 658 Valid Observations in the Analysis of Fatal and Nonfatal Events Combined and 106 Valid Observations in the Analysis of Fatal Events
9808	Genotypic Distributions and Allelic Frequencies of PAI-1∗4GPolymorphism Among Patients and Controls
9809	Multivariate Logistic Regression Models for CAD and MI legend
9810	Use of Therapies in Patients With Acute Myocardial Infarction According to Occurrence of Heart Failure: Worcester Heart Attack Study legend
9811	Time Trends in the Multivariable Adjusted Odds of Developing Heart Failure in Patients With AMI: Worcester Heart Attack Study legend
9812	Time Trends in the Multivariate Adjusted Odds of Dying in Hospital Following Heart Failure Complicating AMI: Worcester Heart Attack Study legend
9813	Annualized Rates of Procedures by Terciles ∗
9814	Unadjusted Rates of In-hospital Outcomes by Terciles of Annual Operator Procedure Rates legend
9815	Adjusted Rates of In-hospital Outcomes by Terciles of Annual Operator Procedure Rates legend
9816	Procedural and 6-month Angiographic Findings legend
9817	Procedural, In-Hospital and Long-Term Follow-up Clinical Outcomes legend legend
9818	Number of Clinical Events 6 to 12 Months After Recruitment in the Clinical Follow-up and Angiographic Follow-up Groups legend
9819	Patient Symptoms and Medication at Both Six-month and One-year Follow-up According to Randomization legend
9820	Six-month Symptomatic Status and Medication, of Those Patients Who Experienced Events Between 6 and 12 Months After Recruitment Into the Benestent II Study legend
9821	Difference in Clinical Event Rate Six Months to One Year When Those Who Received a Stent and Balloon Angioplasty Were Compared legend
9822	Linear Regression Model to Predict In-Hospital Cost legend
9823	Clinical Outcome Data for All U.S. Patients
9824	Clinical Outcome Data for Cost Substudy Patients
9825	Mean Cost Data  (± SD)
9826	Serum Cardiac Marker Concentrations and Indexes in the Study Group legend legend
9827	Diagnostic Performance of the 60-min Myoglobin Ratio
9828	Unadjusted and Adjusted Rates of In-hospital Outcomes After PCI by Year of Procedure legend
9829	Clinical Variables
9830	Angiographic Findings
9831	IVUS Findings legend
9832	Multivariate Predictors of Cardiac Events at Follow-up Procedures legend
9833	Hemodynamics in Control and Stunned Hearts legend
9834	Myocyte Intracellular Calcium Kinetics and Contractile Responses to [Ca2+]o legend
9835	Electrocardiographic Predictors of Left Anterior Descending Coronary Artery  (LAD)  Occlusion Proximal to the First Septal Perforator  (S1)  and/or the First Diagonal Branch  (D1)  legend
9836	Electrocardiographic Predictors of LAD Occlusion Distal to S1 and/or D1 legend
9837	Electrocardiographic Predictors of LAD Occlusion Site legend
9838	Study Group legend
9839	Hemodynamic Changes During Angioplasty legend
9840	Classes of Antianginal Medications Given at Exercise Tl-201 SPECT and Subsequently Prescribed for Follow-up: Description in the Overall Population and Comparison Between the Three Groups legend
9841	Comparison Between TIMI Flow and Corrected TIMI Frame Counts legend
9842	Univariate Predictors of Late Mortality legend
9843	Multivariate Predictors of Late Mortality legend
9844	Cardiovascular End Points in Revascularized and Nonrevascularized Patients
9845	Patients With Complications and Residual Diameter Stenoses by Largest Diameter Catheter Used legend
9846	Clinical Complications After Laser Treatment and Adjunctive Balloon Angioplasty in 440 Patients legend
9847	Success by Lesion Location and Lesion Length legend
9848	Success by Vessel Diameter, Largest Catheter Size and Catheter/Vessel Ratio legend
9849	Comparison of Matched and Unmatched Patients legend
9850	Hospital-Level Comparison—Process of Care and Outcome
9851	Patient-Level Comparison—Hospital Course and Medications
9852	Patient-Level Comparison—In-Hospital Mortality legend
9853	External Validity Comparison legend
9854	Exercise Treadmill Test legend legend
9855	Angina Counts legend
9856	Adverse Experiences legend legend
9857	Crude, Age-Adjusted and Multivariable-Adjusted Risk of Dying During Hospitalization for Initial Acute Myocardial Infarction: Worcester Heart Attack Study legend
9858	Crude, Age-Adjusted and Multivariable-Adjusted Risk of Surviving Within One Year of Hospital Discharge After Initial Acute Myocardial Infarction: Worcester Heart Attack Study legend
9859	Stenosis Variables Associated With Myocardial Infarction  (Multivariate Analysis)  legend
9860	Interactions Between the Stenosis Variables and Aspirin Use  (Univariate Analysis)
9861	Spearman Correlation Coefficients Between Fibrinogen Levels and Coronary Risk Factors Among 199 Men With Myocardial Infarction  (Case Subjects)  and 199 Matched Control Subjects in the Physicians’ Health Study legend
9862	Contingency Table of Reinjection-g-SPECT Visual Wall-Motion Scores Against Cine MRI Visual Wall-Motion Scores legend
9863	Contingency Table of MIBI-g-SPECT Visual Wall-Motion Scores Against Cine MRI Visual Wall-Motion Scores legend
9864	Contingency Table of Reinjection-g-SPECT Visual Wall-Thickening Scores Against Cine MRI Visual Wall-Thickening Scores legend
9865	Contingency Table of MIBI-g-SPECT Visual Wall-Thickening Scores Against Cine MRI Visual Wall-Thickening Scores legend
9866	The Difference Between Reinjection-g-SPECT and MRI legend
9867	The Difference Between MIBI-g-SPECT and MRI
9868	Mitral Flow Patterns and Timing  (in msec)  legend
9869	Hemodynamic Measurements legend
9870	Myocardial and Chamber Measurements legend
9871	Interventional Procedures in Stented Lesions
9872	In-hospital Procedural Results and Clinical Outcome at One Year
9873	Multivariate Analysis to Predict Any Cardiac Events, Target Lesion Revascularization and any Revascularization at One Year of Follow-Up
9874	Predictors of Major Ischemic Events in Follow-up in 3,899 Patients Without In-Hospital Complications legend
9875	Cumulative Rates of Major Adverse Cardiac Events at Six Months Follow-up Among 3,899 Patients Without In-Hospital Complications legend
9876	Agreement Between Techniques  (RVG-EF and Cath-EFa)  With Clinical End Points legend
9877	Cox Regression Analysis Dependent Variable: CHF or Mortality legend
9878	Low Density Lipoprotein Quartile legend
9879	Within the Cholesterol and Recurrent Events Trial: Lipids in Scandinavian Simvastatin Survival Study
9880	Admission Biochemistry legend
9881	Multivariate Predictors of Discharge Diagnosis  legend
9882	Adverse Cardiovascular Events During the 30-Day Follow-up Period  legend
9883	Results of Follow-up Angiography  legend
9884	Results of Follow-up Angiography in Diabetic Patients According to the Therapeutic Regimen  legend
9885	Profiles of Sudden Cardiac Deaths in Minnesota High School Athletes legend
9886	Multiple Logistic Regression Analysis of the Clinical Variables With the Presence of Any Debris  (1+ to 3+)  legend
9887	Multiple Logistic Regression Analysis of In-Hospital Complications With Presence of Any Debris  (1+ to 3+)   legend
9888	Overall Incidence of Debris According to Catheter Type  legend
9889	Technical Features and Angiographic Results of the Successful Procedures  legend
9890	Long-Term Clinical Outcome
9891	TIMI Flow, Mortality and Ejection Fraction Versus Time to Reperfusion  legend
9892	Multivariate Predictors of 30-Day–Plus Late Cardiac Mortality by Cox Regression ∗   legend
9893	Clinical Event Rate According to Presence or Absence of ST-Segment Elevation of ≥0.1 mV in Lead V4R
9894	Thirty-Day Mortality According to Presence or Absence of ST-Segment Elevation of ≥0.1 mV in Lead V4R legend
9895	Multivariate Analysis for Prediction of 30-Day Cardiac Mortality on the Basis of Presence of RVI ≥0.1 mV and 9 Other Variables  (A)  and After Offering Peak CK >12 Fraction of the Upper Normal Limit as Additional Variable  (B)   legend
9896	Angiographic Right Coronary Artery Data According to Presence or Absence of ST-Segment Elevation of ≥0.1 mV in Lead V4R  legend
9897	Payer Type for Patients of Cardiologists and Primary Care Physicians  legend
9898	Length of Stay for Patients of Cardiologists and Primary Care Physicians  legend
9899	Trends in NY State’s CABG Population
9900	Angiographic Outcomes  legend
9901	Univariable Outcomes  legend
9902	Multivariable Analysis legend
9903	Predictors of 6-Month Mortality by Stepwise Logistic Regression
9904	Plasma NOxin Control and AMI Patients  legend
9905	Calculation of Cardiac NOxProduction Equivalent  legend
9906	In-Hospital Clinical Outcome  legend
9907	Six-Month Clinical Outcome legend
9908	Initial Lesion Results legend
9909	Kaplan Meier Untoward Event Rates legend
9910	Clinical Events at One Month  legend
9911	Angiographic and Clinical Data at Follow-Up  legend
9912	Hemodynamic Variables  legend
9913	Plasma Lipid Concentrations in Women and Men  legend
9914	Cardiovascular Events in Women
9915	Cardiovascular Events in Men legend
9916	Test for Differential Effect of Pravastatin on Coronary Events in Women Versus Men  legend
9917	Weights, Risk and Infarct Size Data
9918	Use of Cardiac Procedures in Study Patients According to Payor Type
9919	Use of Discretionary and Nondiscretionary Angiography in Study Patients According to Payor Type
9920	Adverse Events ∗ in Study Patients According to Payor Type
9921	Univariable and Multivariable Analysis: Predictors of Seven-Year Outcome in 282 Patients With Unstable Angina
9922	Blood Pressure, Heart Rate and Ischemic Episodes in Nondippers, Dippers and Overdippers
9923	Comparison of Variables of 19 Patients With Extreme Myocardial Salvage  (<10% vs. >90% salvage index)
9924	Assessment of Historical and Hemodynamic Variables Potentially Associated With Residual Blood Flow and Myocardial Salvage
9925	Procedural Data
9926	Clinical Outcome of Randomized Patients
9927	Angiographic Outcome of Randomized Patient Groups
9928	Clinical and Angiographic Outcomes of Nonrandomized Patient Group
9929	Odds Ratios for Intravascular Ultrasound Coronary Plaque Calcification by ACE Genotype and Other Variables: Multiple Logistic Regression Analysis  a
9930	Univariate Predictors of Extent of Atherosclerosis in 149 Patients
9931	Multivariate Analysis for Predictors of Extent of Atherosclerosis
9932	Genotypic and Allelic Frequencies in Patients With Disease and Control Subjects
9933	DD and Non-DD Genotype Frequencies in Women by Age and Myocardial Infarction Status
9934	Unadjusted Risk and Adjusted Hazard Ratios for All-Cause Mortality and Death or Hospital Admission for Heart Failure in Warfarin Users Versus Nonusers in the Studies of Left Ventricular Dysfunction Combined Trial
9935	Unadjusted Relative Risk and Adjusted Hazard Ratios for Causes of Death in Warfarin Users Versus Nonusers in the Studies of Left Ventricular Dysfunction Combined Trial
9936	Hospital Admission for Unstable Angina or Nonfatal Myocardial Infarction in Warfarin Users Versus Nonusers in the Studies of Left Ventricular Dysfunction Combined Trial
9937	Adjusted Hazard Ratios for All-Cause Mortality in Warfarin Users Versus Nonusers in Subgroups of the Studies of Left Ventricular Dysfunction Combined Population
9938	Phenylephrine and Spectral Measurements of Baroreflex Gain in All Patients and Patients With LVEF ≤40% or >40%
9939	Global Results of Comparison Between Spectral Measurements of Baroreflex Gain and Phenylephrine Measurement
9940	Patency at 90 Minutes by Coronary Artery: Heparin in Early Patency Pilot Study
9941	Plaque Dimensions
9942	Aortic Atheroma: Follow-Up Events
9943	Radionuclide Variables by Classification  (expressed as percent of left ventricle)
9944	Regional Left Ventricular Ejection Fraction Values
9945	Effects of Second-Hand Smoke and Gender on Infarct Size
9946	Univariate Cox Model Rankings of Doppler Echocardiographic and Clinical Variables Predicting Cardiac Death
9947	Multivariate Cox Model Analysis
9948	Analysis of Procedural Success Rate by Occlusion Length
9949	Analysis of Procedural Success Rate by Occlusion Age
9950	Clinical Variables in the 26 Study Patients
9951	Regional Intramyocardial Percent Circumferential Shortening in Normal Subjects and in Patients at Day 5 and Week 8 After Anterior Myocardial Infarction
9952	Patient Outcome
9953	Coronary Angioplasty Variables for 244 Lesions
9954	Quantitative Angiographic Analysis
9955	Periprocedural Complications in 215 Patients
9956	Major In-Hospital End Points  (includes cardiac catheterization laboratory events)
9957	Comparison of Outcomes in Laser- and Coronary Angioplasty-Assigned Patients Substratified by Presence of Previous Myocardial Infarction and Lesional Thrombus
9958	In-Hospital Outcomes  a
9959	Quantitative Angiographic and Hemodynamic Data in 19 Patients
9960	Quantitative Measurements of Wall Thickness, Simulated Wall Motion and Simulated Wall Thickening Using the Variable Thickness Heart Phantom
9961	Agreement Table Relating Quantitative Motion and Visual Motion Scores in the 1,580 Segments Studied
9962	Agreement Table Relating Quantitative Thickening and Visual Thickening Scores in the 1,580 Segments Studied
9963	Genotypic and Allelic Frequencies in Patients With Myocardial Infarction or Coronary Artery Disease and Control Subjects
9964	Relative Risk of Nonfatal Myocardial Infarction of  (+/+)  and Non (+/+)  Genotypes in Prespecified Subgroups
9965	Angiographic Data Before and After Stenting
9966	In-Hospital Outcome of 186 Patients
9967	Clinical Follow-Up Outcomes of 177 Patients
9968	Follow-Up Angina Pectoris and Activity Classes in Surviving Patients
9969	Signal Intensity of Normal and Reperfused Infarcted Myocardium in the Three Experimental Groups
9970	Estimated Odds Ratios for Cardiac Catheterization and Coronary Revascularization According to Ethnic Group in Patients with Acute Myocardial Infarction in the Civilian External Peer Review Program
9971	Estimated Odds Ratios for Outcome Variables According to Ethnic Group in Patients with Acute Myocardial Infarction in the Civilian External Peer Review Program
9972	Five-Year Cause of Death in the 1985–1986 NHLBI PTCA Registry  (n = 2,127)
9973	Predictors of Cardiac and All-Cause Mortality
9974	Results of Longitudinal  (>1 year)  Coronary Interventional Studies  a
9975	Lipid Variables
9976	Lipoprotein Variables
9977	Angiographic Results
9978	Clinical Events During Follow-Up
9979	University of Vermont Payer Mix, 1995
9980	Costs, Incremental Costs and Contribution Margins of Complications and Salvage Techniques
9981	Exercise Testing Results
9982	Results of Diary Analysis  a
9983	Results of Ambulatory Electrocardiographic Analysis  a
9984	Quantitative and Qualitative Angiographic Results
9985	Major Adverse Cardiovascular Events and Clinical Follow-Up
9986	Timing of Clinical Events or Withdrawal of Study Medication
9987	Quantitative Coronary Angiographic Measurements
9988	Change in Culprit Lesion
9989	Results of the Three Walks
9990	Number of Patients Showing Improvement for Each Ischemic Variable
9991	Treadmill Exercise Variables
9992	Scintigraphic and Smoking Variables
9993	Indications for Transesophageal Echocardiography  a
9994	Results of Stepwise Discriminant Analysis
9995	Univariate and Multivariable Association Between Outcomes and Procedure Type
9996	Association of Procedure Type With Major Complications for Different Risk Groups of Patients  a
9997	Guide Wires Used in the Present Study
9998	Angiographic Predictors of Success
9999	Adverse In-Hospital Events in Study Group
10000	Adverse Events at 6 Months for 43 Hospital Survivors
10001	Patients Undergoing Rescue Stent Placement Versus Emergent Coronary Artery Bypass Graft Surgery for Failed Percutaneous Transluminal Coronary Angioplasty
10002	Prehospital, In-Hospital and Discharge Medications of Patients Admitted to the Hospital With Congestive Heart Failure and Treated by a Generalist Alone or by a Generalist in Consultation With a Cardiologist or a Cardiologist Alone
10003	Outcomes of Patients Admitted to the Hospital With Congestive Heart Failure and Treated by a Generalist Alone or by a Generalist in Consultation With a Cardiologist or a Cardiologist Alone
10004	Clinical Variables According to Angiotensin-Converting Enzyme Genotype
10005	Results at 6 Months
10006	Total Medical Charges in Dutch Guilders
10007	End Point by Treatment Group  a
10008	Complications by Treatment Group
10009	Timing of Complications by Treatment Group
10010	Ambulatory Electrocardiographic Results by Treatment Group
10011	Rates of Major In-Hospital Complications
10012	Logistic Regression Analysis of Core Laboratory Factors Associated With Major Complications  (death, Q wave myocardial infarction or emergency coronary artery bypass graft surgery) : Odds Ratio  (95% confidence interval)
10013	Clinical Data in Medically Treated Patients  (group C)
10014	Clinical Data for Groups A, B and C
10015	Echocardiographic and Hemodynamic Data
10016	Clinical Presentation
10017	Thrombolytic Therapy
10018	Clinical End Points
10019	Incidence of Angiographic Findings in Patients With an Identifiable Single Culprit Lesion
10020	Correlation of Recent Rest Angina  (Braunwald class III)  With Angiographic Variables: Multivariate Analysis
10021	Correlation of Postinfarction Angina  (Braunwald class C)  With Angiographic Variables: Multivariate Analysis
10022	Correlation of Refractory Unstable Angina  (Braunwald class c)  With Angiographic Variables: Multivariate Analysis
10023	Correlation of Combination of Braunwald Classes With Angiographic Variables: Multivariate Analysis
10024	Validation of Individual Braunwald Classes as Independent Predictors of Angiographic Morphology: Multivariate Analysis
10025	Number of Deaths According to Gender and Underlying Cause of Death During the First 5 Years of Follow-Up From Time of Coronary Artery Bypass Graft Surgery
10026	Relative Risk of Early Mortality With 95% Confidence Interval in Women Versus Men
10027	Relative Risk of Mortality With 95% Confidence Interval 1 and 5 Years After Coronary Artery Bypass Graft Surgery in Male and Female Patients Surviving 30 Days After Operation
10028	Immediate Angiographic Results: Nonstented Versus Stented Lesions
10029	Immediate Angiographic Results: Nonstented Versus Stented Left Main Coronary Stenoses Classified by Ostial Location
10030	Outcome of the 2,431 GUSTO-I Angiographic Study Patients According to Gender
10031	Gender and 90-Minute Angiographic Patency  (n = 1,075)   a
10032	Indexes of Global and Regional Ventricular Function According to Gender, After Thrombolysis, in Patients With Patent Infarct-Related Arteries
10033	Multivariate Analysis: Clinical and Angiographic Independent Determinants of Global and Regional Left Ventricular Function After Acute Myocardial Infarction
10034	Hemodynamic Effects of WRC-0470 During Reflow
10035	PET Flow and Glucose Uptake, Percent MIBI Uptake, Ventricular Function and Percent Fibrosis in Anterior Wall Biopsy Specimen
10036	Comparison of MIBI and PET Findings With Functional Follow-Up Data
10037	Systolic Function Variables in the Two Patient Groups
10038	Diastolic Function Variables in the Two Patient Groups
10039	Morphometric Data in the Two Patient Groups
10040	Relation of Angiographic Markers of Disease Severity to Presence or Absence of “Definite Complex Plaque”
10041	In-Hospital Clinical Outcomes of Patients Undergoing Isolated Tricuspid Valve Surgery From 2004 to 2013  (Unweighted)
10042	Multivariate Logistic Regression for Predictors of In-Hospital Death in Patients Undergoing Isolated Tricuspid ValveSurgery From 2004 to 2013
10043	Procedural Data of the 15 Patients Enrolled in the SCOUT Trial
10044	Measures of Technical Success
10045	Summary of TEE Findings in the Intention-to-Treat Study Group
10046	Summary of TTE Findings in the As-Treated Study Group
10047	QoL Outcomes for Intention-to-Treat Patients  (N= 15)
10048	Overall and Cause-Specific 30-Day and Long-Term Mortality
10049	Findings in Patients With Echocardiographic Long-Term Follow-Up
10050	Clinical Outcomes
10051	Median Total New Lesion Volume and Number of New Lesions  (Unadjusted Analysis, Day 2 to 7)
10052	Neurocognitive Assessments
10053	Cerebral Events on MRI
10054	Cerebral Events on MRI in Patients With or Without a Clinical Stroke/TIA
10055	Ischemic and Bleeding Endpoints
10056	Previous Studies Investigating the Risk of Cerebral Events by DW-MRI
10057	ECHO Findings Among Incident HD Patients  (N = 567)  With SHD Based on ECHO Criteria Proposed by the Acute Dialysis Quality Initiative
10058	Association of Age- and Sex-Adjusted Structural Heart Disease Variables With Overall Mortality
10059	Number, Rate, and Outcomes for Patients Undergoing Inferior Vena Caval Filter Placement
10060	Temporal Change in Medicare Fee-for-Service Patients With Pulmonary Embolism With and Without Inferior Vena Caval Filter Placement in 1999 and 2010
10061	Procedure Utilization Rates and Outcomes Across Age, Sex, and Racial Subgroups
10062	Observed Rates of Mortality and Nonfatal Outcomes by Year Group
10063	Trends in Mortality and Nonfatal Outcomes
10064	Multivariable Model of Predictors of 30-Day Mortality  ∗
10065	Trends in Mortality and Nonfatal Outcomes by Calendar Period Among Patients at Hospitals Participating for at Least 5 Years in the RIETE Registry
10066	Annualized Ischemic Stroke Rates in Relation to Duration of Quarantine Period
10067	Crude Event Rates per SBP and Length of Follow-Up
10068	Crude and Adjusted Hazards Ratios for Mortality/ESRD by SBP
10069	Adjusted HR on the Basis of DBP
10070	Stratified Analysis: HR for Mortality/ESRD
10071	Incidence and Predictors of Post-Procedural Atrial Fibrillation
10072	Pannus and/or Thrombus in OTPHV Diagnosed atSurgery
10073	Anticoagulation Status at Time of ClinicalPresentation
10074	Summary of Pooled Data of Thrombolysis in 756 Patients for 801 Episodes of Left Heart OTPHV
10075	Summary of Pooled Data With Surgical Treatment for Left Heart OTPHV
10076	Suggested Therapeutic Strategies for OTPHV ∗
10077	Procedure Time, Contrast Volume, and Fluoroscopy Duration
10078	Site-Reported Safety Outcomes at 30 Days and 12 Months
10079	Index Admission Resource Use and Costs, Transfemoral Cohort  (Treated as Randomized Population)
10080	Index Admission Resource Use and Costs, Transapical Cohort  (Treated as Randomized Population)
10081	Cumulative 1-Year Resource Use and Costs, Transfemoral Cohort  (mITT Population)
10082	Cumulative 1-Year Resource Use and Costs, Transapical Cohort  (mITT Population)
10083	Life-Years and QALYs Over the 12-Month Follow-Up Period  (mITT Population)
10084	Primary Cost-Effectiveness Results  (mITT Population)
10085	Factors Associated With Lower-Extremity Amputation
10086	Rate of Lower-Extremity Amputations per U.S. Census Bureau During Study Period
10087	Unadjusted and Adjusted HRs While Listed
10088	Cumulative Hazard of Adverse Events While Listed In-Status and in Any Status After Initial Listing
10089	Post-Transplant Mortality Adjusted for Age
10090	30-Day and Late Cardioembolic Events and Death According to the Occurrence of NOAF
10091	DW-MRI Findings Following TAVI
10092	Multivariate Cox Models of All-Cause and Cardiovascular Mortality
10093	5 Risk Stratification Schemes Used to Predict Thromboembolism in Persons With Nonvalvular Atrial Fibrillation  ⁎
10094	Proportion of ATRIA Cohort Categorized by 5 Risk Stratification Schemes Used to Predict Atrial Fibrillation–Related Thromboembolism and Discriminatory Ability of Risk Schemes  (c-Statistics)
10095	Summary of Adverse Events During and After Implantation
10096	Acute Results, Subgroup Analysis
10097	Univariable and Multivariable Analysis of Predictors of Restenosis After Directional Atherectomy
10098	Long-Term Results Subcohort Analysis Per Lesion
10099	Study Sample
10100	Residual Flows at Most Recent Follow-Up
10101	Complications
10102	Results of Successful and Unsuccessful Procedures
10103	Published Results of Uncomplicated ASD Closure: Comparison of ASD Devices
10104	Successful Outcomes: Comparison
10105	Correlations of MR Flow Rate With Mitral Valve Deformations in Early- and Late-Systolic Peaks
10106	The Relationships of MR Flow Ratio With Clinical and Echocardiographic Findings
10107	The Effect of CRT on Mitral Valve Deformations and MR Flow Rate
10108	Atrial Fibrillation—Analysis of Factors in the High-Risk-Not-Receiving-Warfarin Cohort Associated With Perceived or Actual Bleeding Risk
10109	Use of Warfarin in Patients ≥80 Years of Age
10110	Variables Associated With Treatment With Warfarin
10111	NABOR Study Results Comparison Published Atrial Fibrillation Anticoagulation Studies
10112	Association of Migraine Headache With Interatrial Shunts and Impact of Transcatheter Closure
10113	Pattern of Headache Improvement in Patients After Closure of Interatrial Communication
10114	Right-to-Left Shunt as Assessed by Contrast Transesophageal Echocardiography
10115	Implanted Devices
10116	Recurrent Events
10117	Procedural Resource Utilization and Cost
10118	Initial Hospital Outcomes, Resource Utilization, and Cost
10119	Follow-up Events, Resource Utilization, and Cost
10120	Multivariable Linear Regression Model of Initial Hospital Costs
10121	Subgroup Analyses of Efficacy, Cost, and Cost-Effectiveness
10122	Risk-Adjusted Mortality by Race
10123	Mortality by Race in Selected Subgroups
10124	Risk-Adjusted Rates of Healthcare Utilization
10125	Overview of Studies Used for the Analysis of Mechanical Aortic Valves
10126	Overview of Studies Used for the Analysis of Mechanical Mitral Valves
10127	Incidence Rates of Thromboembolic and Hemorrhagic Complications in Patients With Mechanical Aortic Valve, According to Vitamin K Antagonist Intensity
10128	Incidence Rates of Thromboembolic and Hemorrhagic Complications in Patients With Mechanical Mitral Valve, According to Vitamin K Antagonist Intensity
10129	Risk Ratios of Thromboembolic and Hemorrhagic Events for Patients With a Mechanical Aortic Valve Compared With Mechanical Mitral Valve
10130	Two-Year Event Rates in Patients With SA and PFO Compared With Patients Without SA or PFO
10131	Two-Year Event Rates in Patients With SA and PFO With EV or RA Filamentous Strands Compared With Patients Without SA, PFO, EV, or RA Filamentous Strands
10132	Two-Year Event Rates in Patients With Both SA and PFO Treated With Warfarin or Aspirin
10133	Diagnostic Criteria of CES
10134	Incidence of Definite and Possible CES
10135	Clinical Features of CES
10136	Clinical Features of Cholesterol Embolization Syndrome With and Without Renal Dysfunction
10137	Univariate Analysis of Predictors for Postprocedure CES
10138	Multivariate Analysis of Predictors for Postprocedure CES
10139	Mortality Rate at 14 days, in Patients With  (+)  and Without  (−)  RHTh According to Reported Treatment
10140	Mortality Rate at 3 Months, in Patients With  (+)  and Without  (−)  RHTh According to Reported Treatment
10141	Distribution of Clinical Severity Factors According to the Presence or Absence of RHTh in Patients Treated With Heparin Alone
10142	Significant Independent Predictors of Thrombotic Events Within 30 Days After Stent Placement, Identified by Logistic Regression Analysis
10143	Significant Independent Predictors of Restenosis Identified by Logistic Regression Analysis
10144	Patient Results legend
10145	Angioplasty Devices legend
10146	In-Hospital Outcomes legend
10147	One-Year Clinical Outcomes legend legend
10148	Multivariate Predictors of Late Cardiac Events legend
10149	Multivariate Predictors of Target Lesion Revascularization legend
10150	Clinical and Hemodynamic Data  (n = 14)  legend legend
10151	Indexes of Wave Reflection legend legend
10152	Summary Results ∗   legend
10153	Subgroup Analyses legend
10154	Pre- and Post fragmentation Circulatory Parameters of the Noninterference Group  (n = 15)  legend legend
10155	Residual Shunt
10156	Follow-up Data legend
10157	Stratified Kaplan-Meier Lifetable Analyses legend
10158	New Lesions legend
10159	Univariate Analysis for New Lesions legend
10160	Postoperative Neurologic Complications legend
10161	Univariate Analysis for Strokes legend
10162	P Values of the Repeated Measures Analysis of Variance legend
10163	Immediate Hemodynamic Results in 438 Completed Procedures
10164	Independent Predictors of Immediate Procedural Outcome  legend
10165	Independent Predictors of Long-Term Event-Free Survival  legend
10166	Expansion Rate and Clinical Outcomes According to Tertiles of 18F–Sodium Fluoride Uptake
10167	Effect of Low Versus High Sodium on SBP in the Context of Control andDASHDiets
10168	Data Representativeness in GBD 2015 Fatal and Nonfatal Modeling by CVDCause
10169	Global and Regional All-Age Deaths and Age-Standardized Death Rates in 2015, by Sex, for Selected Causes of CVD Mortality  ∗
10170	Global and Regional All-Age Prevalence and Age-Standardized Prevalence Rates in 2015, by Sex, for Selected Causes of CVD Mortality  ∗
10171	IVUS Parameters
10172	Difference in Proportions of Mean VA and LA Changes  ∗
10173	Plaque Composition of Mean Plaque Cross-Sectional Area
10174	Balloon Diameters and Balloon-Artery Ratios
10175	Multivariate Analysis: Predictors of Expansive Remodeling
10176	Reproductive Factors and Incident Total HF
10177	Reproductive Factors and Incident HF With Reduced Ejection Fraction
10178	Reproductive Factors and Incident HF With Preserved Ejection Fraction
10179	Ages at Menarche and Menopause and Incident HF
10180	Reproductive Factors and Incident Total HF Among Women Without Use of Oral Contraceptive Pills or MenopausalHormoneTherapy
10181	Reproductive Factors and Incident Total HF Among Women With Natural Menopause  ∗
10182	Reproductive Factors and Incident Total HF Among Women With Surgical Menopause  ∗
10183	The 5-Year NNT to Prevent 1 Cardiovascular Event for Very High-, High-, Moderate-, and Lower-Risk Individuals on Maximal Statin Therapy
10184	NNT to Prevent 1 ASCV Eventfor LDL-C Thresholds in the  Central Illustration  and Corresponding Cost Effectiveness per QALY for PCSK9 Monoclonal Antibodies  ∗     †
10185	Case Study of a 43-Year-Old Woman With LDL-C >190 mg/dl
10186	Age-Standardized Cause-Specific Mortality  ∗
10187	Risk of THV Thrombosis in Relation to Post-TAVR Antithrombotic Therapy Until 1- to 3-Month Post-TAVR Follow-Up  (Routine Follow-Up Visit 1)
10188	Echocardiograph at 1- to 3-Month Post-TAVR Follow-Up  (Routine Follow-Up Visit 1)  and 30-Day Complication Rate
10189	12-Month Post-TAVR Follow-Up 2  (Routine Follow-UpVisit 2)
10190	Age- and Sex-Adjusted Pearson Correlation Coefficients Between Changes in Abdominal Fat Volume and Attenuation With Changes in Cardiovascular Disease Risk Factors
10191	Multivariable-Adjusted Logistic Regression Models for Changes in Abdominal Fat Volume With Incident Cardiovascular Disease Risk Factors
10192	Multivariable-Adjusted Logistic Regression Models for Changes in Abdominal Fat Attenuation With Incident Cardiovascular Disease Risk Factors
10193	Multivariable-Adjusted Linear Regression Models for Changes in Abdominal Fat Volume With Changes in Cardiovascular Disease Risk Factors
10194	Multivariable-Adjusted Linear Regression Models for Changes in Abdominal Fat Attenuation With Changes in Cardiovascular Disease Risk Factors
10195	Biochemically Confirmed Smoking Cessation Endpoints
10196	Continuous Abstinence Between Months 6 and 18  (Primary Outcome)  inSubgroups
10197	Cardiopulmonary Hemodynamics  ∗
10198	CMR Analysis of Ventricular Structure and Function  ∗
10199	RV Invasive Pressure-Volume Loop Measurements  ∗
10200	Comparison of Risk Estimator Components
10201	Common Causes of Secondary Hyperlipidemia
10202	Annual Procedure Volumes Among Those Physicians Providing Services
10203	Compensation According to Sex in Meaningful Subgroups
10204	Parsimonious Model for Compensation; Variables Selected Through StepwiseSelection
10205	All-Cause Mortality
10206	Cardiovascular and Noncardiovascular Mortality
10207	Hazard Ratios  (95% Confidence Intervals)  of Coronary Heart Disease by Intake of Fatty Acids as Percentages of Total Energy Intake
10208	Hazard Ratios  (95% Confidence Intervals)  of Coronary Heart Disease by Intake of Carbohydrates of Varying Quality as Percentages of Total Energy Intake
10209	Changes in Laboratory Data
10210	CTA Measures
10211	Sequencing Summary
10212	Accumulation of Rare Coding Variants in Individuals With HTG and Control Subjects
10213	Analysis of Coronary Artery Disease Patients With the Diagnosis Determined by Angiography
10214	Lipid Profile in the Study Group According to the Presence of CVD
10215	Cox Proportional Hazards Model Showing Relationships Between Different Cardiovascular Risk Factors and CVD in Patients With FH
10216	Results From Multiple Linear Regression Models Examining Correlations Between Fasting Values of Growth Hormone and Traditional Cardiovascular Risk Factors
10217	Reclassification of Risk Estimates  (Category-Free NRI [>0])  for Addition of Growth Hormone to 1 Model With ConventionalCardiovascular Risk Factors  (Basic)  and 1 Model With 2 Additional Risk Factors  ∗
10218	Improvement of Discrimination  (C-Statistics)  of 10-Year Risk Estimates for Addition of Growth Hormone to a Model With Conventional Cardiovascular Risk Factors
10219	Index Leg ABI Values
10220	HRs for Association of PAD Status With Mortality Outcomes
10221	Adjusted HRs for Association of ABI Severity Status With All-Cause Mortality
10222	C-Index for PAD Status Classified With Traditional and Alternative ABI Methods
10223	Effect of Atorvastatin and Pravastatin on Lipid Serum Levels, CAC, and EAT
10224	Angiographic and Intravascular Ultrasound Parameters
10225	Virtual Histology Findings by Fractional Flow Reserve
10226	Correlates of Fractional Flow Reserve &lt;0.8: Multivariable Logistic Regression
10227	Multivariable Logistic Regression Predictors of ICA Utilization
10228	Multivariable Logistic Regression Predictors of Early ICA Use Within 90 Days of CCTA
10229	Multivariable Logistic Regression Predictors of Catheterization in 12,408 Patients With CCTA Stenosis ≤50%
10230	Predictors of ACS at Multivariate Analysis
10231	Association of rs5065 MA With MI and MACE at Follow-Up
10232	Cox Proportional Hazard Analysis for the Association of rs5065 MA Carriers With MACE in SA and rSA Populations
10233	Diagnostic Performance of SPECT, CMR, and PET Perfusion Imaging on Patient and Coronary Artery Territory Basis
10234	Subgroup Analyses for the Diagnostic Performance of SPECT on a Patient-Based Level  ⁎
10235	Subgroup Analyses for the Diagnostic Performance of CMR on a Patient-Based Level  ⁎
10236	Subgroup Analyses for the Diagnostic Performance of PET on a Patient-Based Level  ⁎
10237	Risk Factors for Mortality for Entire Cohort
10238	Surgical Procedures and Mortalities
10239	Risk Factors for Mortality After Neonatal Surgery
10240	Risk Factors for Mortality After BCPS
10241	Hazard Ratios  (95% Confidence Intervals)  of Noncardiac Comorbidities for Mortality in Patients With HFpEF and Those With HFrEF
10242	Relation of P1, AP, AIx, and cPP to PWV, Femoral/Aortic Diameter, and Other Factors at Follow-Up According to Multivariable Regression Analysis
10243	Heritability and Environmental Parameter Estimates and Model Fit Statistics for Progression of Central Pulse Pressure
10244	CAD Status According to Quartile of HII
10245	Effect of Statin Therapy on HII
10246	Outcomes
10247	Predictors of Mortality at 1 Year
10248	Results From Observational Studies That Evaluated the Effect of MD on Components of MS
10249	Results From Clinical Trials That Evaluated Effect of MD on Components of MS
10250	Sensitivity Analysis of Selected Studies in Present Meta-Analysis
10251	HRs for All-Cause Mortality and CVD Events for Screen-Based Entertainment Groups  ⁎   Excluding Previous CVD Hospital Stays
10252	HRs for All-Cause Mortality and CVD Events With Other Exclusions  ⁎
10253	Genes Associated With Angiogenesis Significantly Up- or Down-Regulated in CD31+Cells Compared to CD31−Cells
10254	Biomechanical Properties of Crimped, Uncrimped, and Explanted Vascular Cell- and Stem Cell-Based TEHV
10255	Quantitative Tissue Analysis of Explanted TEHV on Basis of Vascular-Derived Cells and Stem Cells
10256	Cardiac Magnetic Resonance Scan Parameters
10257	Univariate Relationships of QoL Improvement
10258	Description of Trials Selected, Lipid Parameters
10259	Results, OR, and 95% CI for Total Stroke in Single Randomized Controlled Clinical Trials Testing Efficacy of Statins, Fibrates, and Other Interventions
10260	Univariable and Multivariable Linear Regression for Effect of TC Percent Reduction on Total Stroke Reduction
10261	Univariable and Multivariable Linear Regression Analysis for the Effect of Non–HDL-C, LDL-C, HDL-C, and Triglycerides Percent Reduction on Total Stroke Percent Reduction
10262	Categorization of Individuals  *  by 10-Year CHD Risk Calculated by Framingham Risk Score and ARIC Risk Score
10263	Event Rates per 1,000 Person-Years Adjusted for Age, Race, and Sex
10264	HRs  (95% CI)  Adjusted for Age, Race, and Sex Comparing hs-CRP Groups  (≥2.0 to <2.0 mg/l)  Within Each LDL-C Strata and Comparing LDL-C Groups  (≥130 mg/dl to <130)  Within Each hs-CRP Strata
10265	Comparison of ARIC JUPITER-Eligible Group, JUPITER Placebo Arm, and JUPITER Treated Arm: Event Rates
10266	Primary Cause of Hospitalization According to Year of Diagnosis and Sex
10267	Primary Cause of Noncardiovascular Hospitalizations Based on ICD-9 Codes
10268	Predictors of Mortality in HFpEF
10269	The JUPITER Study Eligibility Criteria
10270	Population Estimates of Men Age ≥50 and Women Age ≥60 Years in Millions  (95% CI)  Meeting the JUPITER Study Eligibility by hsCRP and LDL-C Levels
10271	Population Estimates of Adults Age ≥20 Years in Millions  (95% CI)  Meeting JUPITER Study Eligibility by hsCRP and LDL-C Levels
10272	Population Estimates of Men Age ≥50 Years and Women Age ≥60 Years in Millions  (95% CI)  at NCEP/ATP-III Goals With hsCRP ≥2 mg/l
10273	Population Estimates of Adults Age ≥20 Years in Millions  (95% CI)  at NCEP/ATP-III Goals With hsCRP ≥2 mg/l
10274	Assessability of Coronary Segments by Helical Scan and Prospective Gating
10275	Diagnostic Accuracy of Helical Scan and Prospective Gating
10276	Radiation Doses of Helical Scan and Prospective Gating
10277	Medication Use in Study Population
10278	Relationship of Use of Spironolactone to Fractures  (vs. Nonuse)
10279	Relationship of Duration of Use of Spironolactone to Total Fractures  (vs. Nonuse)
10280	Use of Established Medical Therapies and Degree of Risk Factor Control of Subjects Stratified According to Gender
10281	Serial Changes in Atheroma Burden and Remodeling of Subjects in Response to a High Use of Established Medical Therapies Stratified According to Gender
10282	MetS Component Values for Male and Female Participants
10283	Age-Specific MetS Cut-Points and Corresponding Percentiles for Males
10284	Age-Specific MetS Cut-Points and Corresponding Percentiles for Females
10285	Age-Specific BMI Cut-Points  (kg/m2)  and Corresponding Percentiles for Males and Females
10286	Prevalence of MetS in 12- to 19-Year Olds by Gender, Age, and Race in NHANES, 1999–2002
10287	Intravascular Ultrasound Measurements
10288	Angiographic Results at Follow-Up
10289	Effects of Short-Term CPAP Application
10290	Effects of 6 Weeks of Nocturnal CPAP Therapy
10291	Change in Standard Lipid Parameters
10292	Change in Other Lipid Parameters
10293	Summary of Safety—Number of Subjects  (%)
10294	Longitudinal Analysis of Changes in Blood Pressure: Average of All Follow-Up Measures Over the Course of the Study  (All Subjects, Observed Cases)
10295	Change in Standard Lipid Parameters  (All Subjects Received Background Atorvastatin 20 mg/day)
10296	Change in Other Lipid Parameters  (All Patients Received Background Atorvastatin 20 mg/day)
10297	Summary of Safety—Number of Patients  (%)   (All Patients Received Background Atorvastatin 20 mg/day)
10298	Longitudinal Analysis of Changes in Blood Pressure: Average of All Follow-Up Measures Over the Course of the Study  (All Patients, Observed Cases; All Patients Received Background Atorvastatin 20 mg/day)
10299	Distribution of 10-Year Risk for CHD Among U.S. Adults Ages 20 to 79 Years, Overall and by Gender and Race/Ethnicity: NHANES III and NHANES 1999 to 2002
10300	Distribution of 10-Year Risk for CHD Among U.S. Adults Ages 20 to 79 Years Without CHD or CHD Equivalent: NHANES III and NHANES 1999 to 2002
10301	Prevalence of Component Risk Factors Used for 10-Year CHD Risk Assessment Among Survey Participants Ages 20 to 79 Years
10302	Correlation Coefficients Between PON1 Activity and Concentration and Selected Variables
10303	Multivariate Analysis of Predictors Affecting Global Percent Diameter Stenosis Index
10304	Results of Virtual Histology and In Vitro Histology Correlation Analysis
10305	Frequency of Each Plaque Phenotype Presence in In Vitro Histopathology Sections and In Vivo Virtual Histology
10306	Multivariable Odds Ratios for Having at Least One 70% or Greater Stenosis on Coronary Angiography, Adjusted for Site of Care  ⁎
10307	Adjusted Associations Between Statin Use and Functional Decline According to Statin Use Among Patients With and Without Peripheral Arterial Disease ⁎
10308	Results for Age, Gender, and Race Adjusted Linear Regression Models of Myocardial Perfusion Measurements  (PR and Hyperemic MBF, Respectively)  With Coronary Heart Disease Risk Factors as Predictors
10309	Results for Multivariate Adjusted Linear Regression Models of Myocardial Perfusion Measurements  (PR and Hyperemic MBF, Respectively)  With Coronary Heart Disease Risk Factors as Predictors
10310	Changes in Blood Pressure and Heart Rate During Intravenous Adenosine in C57BL/6DoseResponseMice
10311	Coronary Flow Velocity Measurements and CFVR
10312	Descriptive Statistics
10313	Clinical Service Statistics
10314	Example: Pro Forma Cumulative, Survival-Adjusted Hospital Contribution Analysis
10315	Accuracy of 64-Slice CT to Detect Coronary Stenosis in Comparison to QCA
10316	Consensus Table of Stenosis Severity Determined by 64-Slice CT Versus QCA
10317	Accuracy of 64-Slice CT to Detect Coronary Lesions in Comparison to IVUS
10318	Hemodynamic and Microneurographic Variables
10319	Plasma Concentrations in the Fasted State
10320	Metabolic Responses to the Test Meal
10321	Echocardiographic Parameters
10322	Left Atrial Action Potential Parameters in the Control, APS, and APSR States
10323	Gensini Score and Plasma FCR of the Emulsion Triglycerides in ACAD Group Patients Separated According to the Presence or Absence of Severe Angiographic Progression
10324	Paclitaxel Concentration in 15-mm Segments of Coronary Arteries at Various Times After the Injection of 80 ml Iopromide-370 With 200 μmol/l Paclitaxel in the LAD and Cx of Nine Pigs
10325	Results of Quantitative Coronary Angiography
10326	Histomorphometry of Stented Porcine Coronary Arteries After 28 Days
10327	Twenty Most Common Noncardiac Chronic Disease Conditions for Patients Age ≥65 Years With CHF  (n = 122,630)
10328	Association of Noncardiac Comorbidity With Ambulatory Care Sensitive CHF Hospitalization Among Medicare Beneficiaries With CHF
10329	Association of Noncardiac Comorbidity With Any Ambulatory Care Sensitive Condition Hospitalization Among Medicare Beneficiaries With CHF
10330	Association of Noncardiac Comorbidity With Death Among Medicare Beneficiaries With CHF
10331	Plasma and Tissue Biochemical Markers
10332	Single Nucleotide Polymorphisms in the Hepatic Lipase Promoter
10333	Lipids and Lipoproteins by Hepatic Lipase Promoter Single Nucleotide Polymorphisms in Cross-Sectional Study of the General Population
10334	Distribution of Follow-Up Events According to CETPGenotypes
10335	Hazard Risk Ratios of Future Cardiovascular Death According to CETPGenotype
10336	Interaction Between Statin Therapy and CETP/C-629AGenotype on Future Cardiovascular Death
10337	Effects of Glycosylation and Oxidation on Low-Density Lipoprotein
10338	Hemodynamics
10339	Results of the Multiple Regression Analysis With Augmentation Index as the Dependent Variable
10340	Results of the Multiple Regression Analysis With Estimated Aortic Pulse Wave Velocity  (TR)  as the Dependent Variable
10341	Risk Factors by Ethnicity
10342	Racial Differences in Prevalence of CAC and Obstruction on Angiography
10343	Coronary Artery Disease Model With Risk Factors, Including 95% CI  (as Compared with Whites)
10344	Analysis of Maximum Likelihood Estimates to Test Coronary Artery Disease Likelihood
10345	Comparison of Electron Beam Tomography to Coronary Angiography in Detecting Coronary Obstruction
10346	Percent Change in Each Drug Response for Per Unit Change in Risk Factor  (With 95% Confidence Interval)
10347	Difference in Drug Response Per Quartile Increase in Framingham Risk Score  (2000)   (95% Confidence Interval)  in Men and Women
10348	Percent Variance in Drug Response Explained by Framingham Risk Score Beyond That Explained by Age and Gender
10349	Results of Radiofrequency Ablation
10350	Conventional Atherosclerosis Risk Factors in Patients With and Without De Novo Lesions of Transplant Vasculopathy legend
10351	Conventional Atherosclerosis Risk Factors in Patients With De Novo Lesion Stenosis of ≤29% and >29% legend
10352	Conventional Atherosclerosis Risk Factors in Patients With and Without Donor Disease Progression legend
10353	Associated Cardiac Lesions legend legend
10354	Preoperative Transthoracic Echocardiographic Detection of Associated Lesions by Era of Repair legend legend
10355	Detection of Missed Lesions on Repeat Review of Transthoracic Echocardiographic Recordings legend
10356	Results of Papillary Muscle Measurements legend
10357	Results of Aortic and Subaortic Measurements legend
10358	Abnormalities of the Left Ventricular Outflow Tract legend
10359	Comparison of Caucasian Patients With CAD and Controls legend
10360	Logistic Regression Analysis Investigating the Predictive Value of ApoA-IV, HDL Cholesterol and Triglyceride Concentrations for CAD legend
10361	Frequency of Risk Factors by Group legend
10362	Stepwise Logistic Regression legend
10363	Age- and Gender-Adjusted Mean Values of Lipids, Lipoproteins Lipid, Apolipoproteins, and FERHDLin Patients With  (CAD+)  and Without  (CAD−)  Significant Coronary Stenosis legend legend
10364	Age- and Gender-Adjusted Linear Trends Across Fractional Ranks of Coronary Atherosclerosis-related Variables, as Tested by a Multiple Logistic Regression Analysis legend
10365	Age- and Gender-Adjusted Associations between FERHDLand Coronary Atherosclerosis by HDL-C  (in Tertiles)  and HDL-C-by-FERHDLInteraction as Assessed by a Multiple Logistic Regression Analysis legend
10366	Age- and Gender-Adjusted Relationships Between FERHDLValues and Other Lipid Variables in Patients With and Without Coronary Artery Disease as Assessed by a Multiple Regression Analysis legend
10367	Multiple Logistic Function Analysis of Coronary Risk Factors and Accompanying Odds Ratios for Each Combination of FERHDLand HDL-C After Adjusting for Age and Gender legend
10368	Anatomic Defects of Eisenmenger’s Syndrome  (n = 73)
10369	Management and Outcome of Pregnant Women With Eisenmenger’s Syndrome  (n = 73)   legend
10370	Management and Outcome of Pregnant Women With Primary Pulmonary Hypertension  (n = 27)   legend
10371	Management and Outcome of Pregnant Women With Secondary Vascular Pulmonary Hypertension  (n = 25)   legend
10372	Logistic Regression Analysis: p Value and Odds Ratio  (95% confidence interval)  ∗ for Maternal Outcome as Dependent Variable
10373	Effects of Pravastatin on Coronary and Iliac Artery Atherosclerosis in Male Cynomolgus Monkeys
10374	Potential Preoperative Patient-Specific Predictors of 3-Year Graft Occlusion by Univariate Analysis
10375	Potential Intraoperative and Perioperative Patient-Specific Predictors of 3-Year Graft Occlusion by Univariate Analysis
10376	Potential Graft-Specific Predictors of 3-Year Graft Occlusion by Univariate Analysis
10377	Multivariate Analysis: Coefficient and Standard Errors for Logistic Regression Equation for Model in Which Patient, Graft and Time Correlation Effects Were Taken Into Account
10378	Data Before Supraannular Mitral Valve Replacement
10379	Details at Time of Supraannular Mitral Valve Replacement and Clinical Course After the Procedure
10380	Procedural Data
10381	Procedural and Clinical Outcomes
10382	Predictors of All-Cause Mortality
10383	Echocardiographic Data  (N=2,952)
10384	Procedural and In-Hospital Outcomes  (N=2,952)
10385	30-Day and 1-Year Clinical Outcomes
10386	Procedure Results and Outcomes According to Post-Implant Mitral Regurgitation
10387	Community Women Survey Results  (n=1,011)
10388	Physicians Do Not Feel Well Prepared
10389	More Physicians Who Use Email, Facebook, or Twitter Have Heard of the ASCVD Risk Assessment Calculator Than Those Who Are Less Digitally Engaged
10390	Outcomes
10391	Outcomes per Year of Inclusion Within Centers Involved in Both Registries
10392	Clinical Outcomes and Health Care Costs Before and After PAP Sensor Implantation for the 6- and 12-Month Cohorts
10393	Clinical Efficacy Endpoints and Response to CRT
10394	Device- or Procedure-Related Adverse Events  (n= 35)
10395	TAVR Outcomes
10396	Mitral Leaflet Clip Outcomes
10397	TMViV or TMViR In-Hospital Outcomes
10398	Stroke and Bleeding Risk Scores  (N= 15,092)
10399	Outcomes in the Post-FDA Approval Experience
10400	Device Embolization Details
10401	Comparison of Procedural Parameters Across Watchman Studies
10402	Comparison of Procedural Complications Across Watchman Studies
10403	Factors Correlating With the WCE in 653 Subjects With WCH
10404	CT and Procedural Data
10405	Procedural and Clinical Outcomes
10406	Predictors of All-Cause Mortality
10407	Factors Associated with Increased Transvalvular Gradient Progression
10408	All-Treated Cohort: Efficacy Endpoint and Components at 5 Years  ∗
10409	Left Ventricular Dimensions by Echocardiography  ∗
10410	Quantitative Coronary Angiography
10411	Quantitative Optical Coherence Tomography
10412	Risk of Ischemic Stroke in AF patients With a CHA2DS2-VASc Score of 0  (Male)  or 1  (Female)  Stratified by Age
10413	Sensitivity and Specificity in Predicting Ischemic Stroke on the Basis of Different Cutoff Values of Age
10414	Effectiveness Outcomes at 24 Months
10415	Safety Outcomes at 24 Months
10416	Causes of Death  ∗   Through 24 Months
10417	24-Month Functional Outcomes
10418	Variables for ACS Development
10419	Cardiac Events After CTA-2
10420	Predictors of Early and Late Stroke After TAVR  ∗
10421	Predictors of Early and Late Stroke or TIA After TAVR
10422	Rates and Unadjusted and Adjusted Odds Ratios for 24-Month Mortality for ICD/CRT-D Therapy
10423	Rates and Unadjusted and Adjusted Odds Ratios for 24-Month Mortality for ICD-Only Therapy
10424	Rates and Unadjusted and Adjusted Odds Ratios for 24-Month Mortality for CRT-P/CRT-D Therapy
10425	Procedural Outcomes
10426	Echocardiographic Findings at Discharge
10427	Observed Event Rates by Year of Ventricular Assist Device Implantation
10428	Results of Multivariable Models for Each Outcome
10429	Observed Event Rates by Year and Hospital Implant Volume
10430	Echocardiographic Assessment of TEHV Directly After Implantation, at 1, 4, 8, 16, and24 Weeks Follow-Up
10431	Pooled Adjusted Hazard Ratios  (95% CIs)  of a 1-SD Increase in Loge-Transformed aPWV for All-Cause Mortality, CVD Mortality, CHD Events, Stroke Events, and CVD Events
10432	Improvement in Discrimination and Reclassification of 5-Year Risk Prediction With the Inclusion of log aPWV as a Risk Factor
10433	Net Reclassification Statistics Showing Percent Change in 5-Year Risk Prediction  (and 5- and 10-Year Overall Reclassification)  Associated With Including loge aPWV as a Risk Factor in the Fully-Adjusted Model
10434	Failure Prevalence by Lead Family
10435	Lead Failures: Clinical Presentation, Treatment Strategy, and Manufacturer Analysis by Case
10436	Predictors of Lead Failure: Simple Cox Regression Analysis
10437	Association Between Number of Ectopic Beats  (Ectopic Burden)  and Likelihood of Low BIV Pacing  (<97%)  Versus High Percentage  (≥97%)
10438	Multivariate Cox Regression Analysis of Endpoint of Hospitalization for HF or Death, VTAs, and Death Alone
10439	Event Rate of Ischemic Stroke Per 100 Person-Years in AF Patients With an ATRIA Score of 0–5
10440	Event Rate of Ischemic Stroke Per 100 Person-Years in AF Patients With an ATRIA Score of 0–5 Substratified by CHA2DS2-VASc Scores
10441	Risk of Ischemic Stroke in Patients with an ATRIA Score of 0 to 5, Stratified on the Basis of Their CHA2DS2-VASc Scores
10442	Impact of PPM on LV Mass Regression at 1 Year in the SAVR-RCT and TAVR-RCT Arms and the TAVR-NRCA Registry
10443	Impact of PPM on 2-Year Mortality in the SAVR-RCT and TAVR-RCTArms
10444	Impact of PPM on 1-Year Mortality in the TAVR-NRCA Cohort
10445	PRA and HLA Match Levels by Race/Ethnicity
10446	Univariate Predictors of Graft Failure  (Cox Regression)   (n= 5,314)
10447	Multivariate Predictors of Graft Failure  (Cox Regression)   (n= 5,314)
10448	Multivariate Cox Regression Analysis for Inappropriate Therapy for Primary Endpoints
10449	Multivariate Cox Regression Analysis for Inappropriate Therapy for Atrial Fibrillation
10450	Multivariate Cox Regression Analysis for Inappropriate Therapy for Atrial Tachyarrhythmias
10451	Transcatheter Valve Therapy Registry Overview
10452	Major Questions and Applications Potentially Addressed by the Transcatheter Valve TherapyRegistry
10453	Echocardiographic Indices of Mitral Valve Area at 4 Years
10454	Effectiveness Endpoint and Components at 4 Years
10455	Association Between Electrical Parameters and CRTResponse: Univariate Analysis
10456	Univariable Correlates of 90-Day Mortality in the Derivation Cohort
10457	Multivariable Predictors of 90-Day Mortality in Derivation Cohort and Formula for Calculating HMRS
10458	Comparisons of AUCs Between Different Risk Models Used to Predict 90-Day Mortality
10459	Survival on the Basis of HMRS in the Total HMII Sample and in the Derivation and Validation Cohorts After LVAD Implant
10460	Ramp Test Protocol  (for HeartMate II)
10461	Summary of Speed Optimization Ramp Tests  (28 Tests)
10462	Multivariate Analysis: Impact of Active Device Treatment on the Occurrence of VTE in All Patients and by QRS Morphology  ⁎
10463	Multivariate Analysis: Impact of Time-Dependent VTEs on the Occurrence of a First Heart Failure Event or Death in the Total Study Population
10464	Multivariate Analysis: Impact of Nonresponder Status at 12 Months of Follow-Up on the Occurrence of Recurrent VTEs
10465	Distribution of Brachial Artery Outcomes and Sonographers Among the MESA Participants Included in the Final Study Model  (N = 3,040)
10466	Associations Between Brachial Artery Outcomes and the Long-Term Exposures to PM2.5
10467	Associations Between Short-Term PM2.5 Concentrations and the Brachial Artery Outcomes
10468	Race-Specific Incidence Rates of HF per 100,000 Person-Years, the ARIC Cohort Study, 1987–2008
10469	Race-Specific Estimates of the Preventable Number of HF Cases, YLL, and YLD, the ARIC Cohort Study, 1987–2008
10470	Univariate Hazard Ratios of Mortality
10471	Hazard of All-Cause Mortality and Cardiovascular Mortality at Different Levels of RAC
10472	C-Statistics, IDI, and NRI for the Assessment of CAC and RAC in Addition to FRS in Predicting All-Cause and Cardiovascular Mortality
10473	Percentage of Patients With Each Component of DTRS
10474	Univariate Associations  (p Value)  of DTRS Components With 90-Day In-Hospital Mortality
10475	Univariate and Multivariate Regression Analyses on the Effect of Each Variable on LV Reverse Remodeling at 6 Months
10476	Procedural Results, Treatment Received, Per-Protocol Cohort
10477	Safety to 30 Days, Intention-to-Treat Population
10478	Efficacy at 12 Months, Intention-to-Treat Population
10479	Nonhierarchical Major Adverse Events
10480	HRS Patient Deaths Through 12 Months
10481	Rates and Hazard Ratio for All-Cause Mortality in Hypertensive Men by Thirds of Muscular Strength
10482	Criteria for Moderate to Severe or Severe Mitral Regurgitation
10483	All Patients  (N = 107)
10484	Hemodynamic and Echo/Doppler Effects of MitraClip Therapy
10485	Detailed Outcome of the Studies
10486	Subgroup Analysis
10487	Meta-Regression Analysis
10488	Procedural Outcomes
10489	Pair-Wise Comparisons Between GTF- and NPMA-CASP or GTF- and SBP2-CASP
10490	Comparison Between CAFE Study Treatment Regimens for Brachial and Central Systolic Pressure Estimated as GTF-P, NPMA, and SBP2-CASP
10491	Comparison of Invasive Aortic Root Pressures With Oscillometric, Noninvasive Brachial Pressure Measurements and NPMA-Derived Noninvasive CASP
10492	Univariate and Multivariate Logistic Regression Analysis for Strokes
10493	Isoproterenol Response on Contractile Parameters
10494	MiRNAs That Normalize After LVAD Support
10495	Predictors of ≥1 Inappropriate Shocks
10496	Causes of Inappropriate Shocks
10497	Predictors of All-Cause Mortality
10498	Factors Associated With Off-Label CRT Implantation  (Hierarchical Logistic Regression Model)
10499	Comparison of Clinical Parameters in Subgroups Stratified by Individual Guideline Criteria
10500	Multivariable Cox Proportional Regression Analysis Showing Significant Predictors of Outcome  (Death, Heart Transplant, or Left Ventricular Assist Device Implantation)  in Cardiac Resynchronization Therapy Patients
10501	Bibliographic Search Strategy
10502	Study Design and Population: Summary
10503	Pattern of Follow-Up and Monitoring Approach in the 32 Studies Included
10504	Study Outcome Summary: Event Incidence  (Incidence Rate)  and 95% Confidence Interval
10505	Meta-Analysis of the Selected Outcomes
10506	Comparison of Our Results With Selected Published Meta-Analyses
10507	Univariate Associations With Discharge Warfarin Use Among Eligible Patients With AF
10508	Multivariable Factors Associated With Nonwarfarin Use at Discharge
10509	Key Eligibility Criteria and Key Exclusion Criteria
10510	Mitral Regurgitation Grade Criteria  ⁎
10511	In-Hospital Outcomes
10512	Summary of Physiologic Parameters
10513	Summary of Impedance Trends
10514	Relationship Between Change in LV End-Diastolic Volume and Change in Impedance
10515	Relationship Between LAP and Change in Impedance
10516	Data From 24-h 12-Lead Holter Recordings
10517	Comparison of Responders and Nonresponders
10518	Survival of Patients in the 3 Groups
10519	Hazard Ratios for Post-Transplant Mortality
10520	Risk of Cause-Specific Death Within the First 12 Months After Transplant
10521	Risk of Cause-Specific Death More Than 60 Months After Transplant
10522	HF Clinical Composite Response Details in the CRT-OFF and CRT-ON Groups
10523	LV Structural Data
10524	Conventional and Tissue Doppler Echocardiographic Data
10525	Multivariate Analysis: Adjusted Values for E′ and for E/E′ According to Ethnicity
10526	Comorbidities by ABI Group
10527	Inclusion and Exclusion Criteria
10528	Predictors of Graft Function at 6 Months  (Multiple Logistic Regression)
10529	Predictors of Graft Function at 6 Months: Separate Logistic Regression Models for SVG and GEA
10530	EAPC in Unadjusted Mortality Rates From Coronary Heart Disease Among U.S. Adults Age ≥35 Years, 1980 to 2002
10531	EAPC in Age-Specific Mortality Rates From Coronary Heart Disease Among U.S. Adults Age ≥35 Years, 1980 to 2002
10532	Procedural Data and Devices Used
10533	Preoperative and Operative Data of Patients Undergoing CABG, With and Without Metabolic Syndrome
10534	Prevalence and Distribution of the NCEP-ATPIII Criteria for Metabolic Syndrome in Patients With and Without Metabolic Syndrome
10535	Univariate Analysis of Potential Risk Factors for Operative Mortality
10536	Multivariable-Adjusted Relative Risk of Operative Mortality
10537	Perioperative Cause of Mortality for Patients Undergoing CABG According to Metabolic Syndrome Status
10538	Perioperative Complications After CABG
10539	Background and Outcome of PP
10540	Characterization of PP Site
10541	Maximum Increase in Serum Cr After Contrast Exposure: Analysis by Chemical Composition and Trial Comparison
10542	Rates of Contrast-Induced Nephropathy Defined as a Rise in Cr ≥0.5 mg/dl: Analysis by Patient Subgroup
10543	IVUS Parameters Within the Stented Segment
10544	Neointimal Proliferation per Diabetes Status, Stent Length, and Stent Diameter
10545	Clinical Events at One-Year Follow-Up
10546	Mode of Death Overall, and Within Each Treatment Group
10547	Mode of Death in Selected Heart Failure Trials
10548	Changes of HR Profile and of SDANN in Patients With De Novo Implantation of a CRT Device and in Those With a Device Replacement
10549	MEDLINE Queries Used to Retrieve Papers on FMD
10550	Relation Between Endothelial Function and Cardiovascular Risk Factors, by Tertiles of Cardiovascular Risk
10551	Operative Findings
10552	Reported Cases of Tricuspid Valve Leaflet Perforation by a PPM Lead  ( 12–18 )
10553	Comparison of Patients With and Without IVR
10554	Hemodynamics Before and After Ventricular Assist Device Support
10555	Volumetric Intravascular Ultrasound Measurements
10556	Clinical Outcomes at 30 Days and 1 Year
10557	Angiographic Results at Nine Months
10558	Electrocardiographic and Pacing Variables
10559	Pacemaker Models Tested
10560	Details of the Positive Tests
10561	Mechanical Parameters of Isolated Trabeculae at Isoproterenol Stimulation
10562	Bmaxand KdValues for [3H]DHA Binding to Beta-Adrenergic Receptors in LV and RV of Nonfailing, Medical, and LVAD-Supported Hearts
10563	Stepwise Multivariate Modeling Results of Overall Patients Enrolled in PRESTO Trial *
10564	Stepwise Multivariable Modeling Results of De Novo Lesions Treated With Intracoronary Stents
10565	Effects of Subsequent Perfusion of Blood Containing One of the Anti-GP IIb/IIIa Agents on the Height and the Volume of the Pre-Existing Platelet Thrombi *
10566	Postprocedural and Six-Month Follow-Up Quantitive Angiographic Data for the Sirolimus-Eluting Stent  (Patient Number n = 33)
10567	Cox Proportional Hazards 5-Year Survival in Key Diabetic Patient Subsets Undergoing Electron Beam Tomography Coronary Calcium Measurements Including Female, Hyperlipidemic, Hypertensive, and Elderly  (≥70 Years of Age)  Diabetic Patients
10568	Multivariable Model Predicting All-Cause Mortality in Asymptomatic Diabetic Patients Undergoing Coronary Calcium Screening
10569	Multivariable Model Predicting All-Cause Mortality in Asymptomatic Nondiabetic Subjects Undergoing Coronary Calcium Screening
10570	Presenting Symptoms and Signs of Heart Failure Patients and WRF
10571	Risk Factors for WRF *
10572	Risk Score and WRF
10573	Thoracic Aortic Diameter at the Four Aortic Sites, Stratified by Age and Gender
10574	Relationship of Age, Gender, and Body Size With Thoracic Aortic Diameter *
10575	Relation of Blood Pressure and Additional Atherosclerosis Risk Factors With Thoracic Aortic Diameter *
10576	Relation of Regional Aortic Atherosclerotic Plaques * With Thoracic Aortic Diameter, Adjusting for Age, Gender, and Body Surface Area
10577	Implantable Pacemakers Studied
10578	Implantable Pacemaker Leads Studied
10579	Implantable Cardioverter-Defibrillators Studied
10580	Leads Used in Patients With an Implantable Cardioverter-Defibrillator
10581	Median CAC Scores of Men and Women With and Without Diabetes
10582	Association Between CAD Risk Factors and the Highest Age and Gender Quartile of Coronary Artery Calcium Score  (≥ 75%)  Among Men and Women  (n = 30,904)
10583	Indications for Robotically Assisted LV Lead Transplantation
10584	Independent Predictors of Change in LV Function
10585	Fitted Absolute and Incremental Changes in EF
10586	Predictors of Restenosis in the Entire Study Group, as Assessed by Univariate and Multivariable Analyses
10587	Main and Subgroup Analysis of Angiographic Data Obtained by a Mixed Linear Model With Group, Diameter and Group × Diameter Interaction and Fixed Effects
10588	In-Hospital Complications for CTO and Non-CTO Cohorts legend legend
10589	In-Hospital Complications for CTO-Success and CTO-Failure Cohorts legend legend
10590	Multivariable Predictors of Survival After PCI of CTO legend
10591	Multivariable Predictors of Survival for Patients Undergoing CABG After Failed Attempt of CTO legend
10592	Epiaortic Ultrasound Data in Patients With Atherosclerotic Disease of the Ascending Aorta  (n = 241)
10593	Logistic Multiple Regression Analysis of Postoperative Stroke on Predictive Variables  (n = 921)  legend
10594	Relationship Between Postoperative Stroke and Extent of Atherosclerotic Disease of the Ascending Aorta  (n = 220)
10595	Logistic Multiple Regression Analysis of Postoperative Stroke on Predictive Variables  (n = 921)  legend
10596	Multiple Linear Regression Analysis: Determinants of LVM/Ht2.7 (n = 875)  legend
10597	Multiple Linear Regression Analysis: Determinants of LVM/Ht2.7excluding CAD  (n = 818)  legend
10598	Quantitative Coronary Angiography Results legend
10599	Intravascular Ultrasound Results legend
10600	Predictive Value of Clinical and Echocardiographic Variables on Event-Free Survival by Univariable Analysis legend
10601	Independent Predictors of Event-Free Survival by Cox Proportional Hazards Model
10602	Deadly Quartet Hazard Ratio  (HR)  Estimating the Risk of Mortality with 95% Confidence Intervals  (95% CI)  Estimated from Cox Proportional Hazards Models Unadjusted, Age-Adjusted and Age- and Surgical Variable-Adjusted ∗
10603	Comparison of Immediate and Follow-up Results
10604	Atrial Septal Defect Closure Devices legend
10605	Preliminary Results of ASD Closure Devices   (4,18,19,23,28–37)    legend
10606	Risk Factors of Patients Undergoing Coronary Angioplasty or Stent Placement on One Lesion for the First Time in New York State, July 1994–December 1996 legend
10607	Unadjusted and Adjusted Short-term Outcomes for Balloon Angioplasty and Stent Placement legend
10608	Descriptive Statistics of Intracoronary Doppler Measurements
10609	Analysis of Covariance of CFVR  a    legend
10610	Multiple Regression Analysis of CFVR  a   Used for Prediction
10611	Predicted Values of CFVR legend
10612	Comparison of Hemodynamic Parameters in Women With Suspected Microvascular Dysfunction  (CFVR < 2.24)  and Suspected Normal Microvascular Function  (CFVR ≥ 2.24)   (data for LAD/n = 65)  legend
10613	Risk Factors for Microvascular Dysfunction  (Data for LAD/n = 135)  legend
10614	Differences Between Native Coronary Arteries and Saphenous Vein Grafts legend
10615	Clinical Features of Participants Based on Pattern of Atrial Fibrillation legend
10616	Factors Associated With Ischemic Stroke in Intermittent Versus Sustained AF: Age-adjusted Relative Risks ∗   legend
10617	Independent Predictors of Ischemic Stroke in Patients With Intermittent and Sustained AF legend
10618	Risk Stratification for Ischemic Stroke: SPAF III Exploratory Analysis Criteria ∗   legend
10619	Univariate Correlations Between Cardiovascular Risk Factors and Vasodilator Response to Nitroglycerin in All 800 Subjects legend
10620	Multivariate Model for Vasodilator Response to Nitroglycerin in All 800 Subjects ∗   legend
10621	Pertinent Patient Data  a  and Outcome After Transcatheter Atrial Septal Defect Closure With the Amplatzer Prosthesis
10622	Quantification of Atrial Shunts by Echocardiography
10623	Analysis of the Influence of Clinical, Lesional and Procedural Factors on the Degree of Late Lumen Loss After Stenting of 1,399 Lesions in 1,084 Patients
10624	Results of Percutaneous Transluminal Coronary Angioplasty in 29 Patients
10625	Results of Transcutaneous Oximetry
10626	Results of Ankle–Brachial Index Measurement
10627	Clinical Phenotype of Living Genotype-Positive Individuals in Family D.R.
10628	Model-Derived Values for APD90for the Nygren and Courtemanche Human Atrial Action Potential Models
10629	Diagnoses and Associated Findings After Testing or Surgery or Both legend
10630	Atrial Septal Defect Size by MRI Magnetic Resonance Imaging Versus Shunt Fraction legend
10631	Agreement Analysis legend
10632	Clinical and Hemodynamic Data of Patients With DCM and ICM
10633	Changes in Coagulation Parameters Induced by Intravenous Dalteparin and UFH
10634	Indices of Coagulation After Intravenous Dalteparin and Abciximab
10635	Number of nDNAf per 1,000 Cardiomyocytes in Untreated Dogs With HF and Dogs with HF Treated With Metoprolol legend legend legend
10636	Cumulative Hazard of Mortality by Urgency Group and Donor Risk Group at One Year  ∗
10637	Net Survival Benefit Between Waiting and Transplant Groups  ∗
10638	Multivariable-Adjusted HRs  (95% CIs)  for Incident Ischemic Heart Disease by Lifestyle Factors Among 461,211 Participants
10639	Multivariable-Adjusted HRs  (95% CIs)  for Incident Ischemic Stroke by LifestyleFactors Among 461,211 Participants
10640	Multivariable-Adjusted HRs  (95% CIs)  and PAR%  (95% CIs)  for Incident Ischemic CVDs by Low-Risk Lifestyle Factors  ∗   Among 461,211 Participants
10641	IQIC Sites Contributing Data
10642	Univariate Associations With Mortality  ∗
10643	Multivariable Associations With Mortality
10644	Multivariable Predictors of 3-Year All-Cause Mortality
10645	Echocardiographic Evaluation of Valve Performance Before and After TAVR and During 3-Year Follow-Up: Paired Analysis
10646	Total Mortality From Randomization in the TOHP Cohorts Through 2013 by Sodium Intervention Group
10647	Total Mortality in the TOHP Cohorts Through 2013 by Categories of Urinary Sodium Excretion and Urinary Sodium/Potassium Excretion Ratio Among Those not in a Sodium Reduction Intervention
10648	Targeted PH Therapies
10649	Discontinuations of PH Therapies
10650	Response to Targeted PH Therapy
10651	Acute Vasodilator Response Criteria
10652	Crosstab of Acute Vasodilator Response Criteria
10653	Patient Clinical Features at Presentation
10654	Clinical Features of Patients Enrolled in Clinical Surveillance
10655	10-Year Event Rates for Patients Enrolled in Clinical Surveillance
10656	Predictors of All-Cause Mortality in Patients Enrolled in Clinical Surveillance
10657	Risk of VT/VF  ∗   by Model
10658	Comparison of Predictive Value of Different Variables for VT/VF  ∗
10659	Risk of VT and Death by Model  ∗
10660	Risk of VT by RWT  ∗
10661	RWT Change During 12 Months and Risk of SubsequentVAs
10662	Definition of Poor, Intermediate, and Ideal Cardiovascular Health in Adults
10663	Proportions  (SEs)  of Each Individual Cardiovascular Health Metric According to Sex, Age, Urbanization, and Economic Development in Chinese Adults Age≥20 Years in 2010
10664	Proportions  (SEs)  of Numbers of Ideal Cardiovascular Health Metrics, Ideal Health Behaviors, and Ideal Health Factors According to Sex, Age, Urbanization, and Economic Development in ChineseAdultsAge≥20 Years in 2010
10665	Proportions  (SEs)  of Each Individual Cardiovascular Health Metric According to Major Ethnic Groups and Geographic Regions in ChineseAdultsAge≥20Years in 2010
10666	Proportions  (SEs)  of Numbers of Ideal Cardiovascular Health Metrics, Ideal Health Behaviors, and Ideal Health Factors According to Major Ethnic Groups and Geographic Regions in Chinese Adults Age≥20 Years in 2010
10667	Distribution of Nerves Stratified According to Total Number and Distance From Lumen in Relative Proximal, Middle, and Distal Location
10668	Distribution of Nerves Stratified According to Total Number and Distance From Lumen on the Basis of Anatomic Location
10669	Comparison of Nerve Anatomy Between Hypertensive Samples Compared With Nonhypertensive Samples
10670	Hazard Ratios for Disease-Specific Mortality and Nonfatal CVD, by CRF Level, in Men  (n= 34,211)
10671	Hazard Ratios for Disease-Specific Mortality and Nonfatal CVD, by CRF Level, in Women  (n= 9,145)
10672	Discrimination Statistics of Measured and Estimated CRF for Disease-Specific Mortality and Nonfatal CVD
10673	AUCs  (95% CI)  for the Modifiable Constituent Components of the Nonexercise CRF Algorithms  (Separately and Clustered)  andfor Estimated CRF
10674	Reclassification of the Predicted Risk for All-Cause Mortality in Men and Women on the Basis of Estimated CRF VersusMeasuredCRF
10675	Treatment Strategy Stratified by Center Cohort
10676	Multivariate Backward Stepwise Cox Regression Analysis of Parameters Associated With Survival  (N= 196)
10677	Predictors of Outcome Stratified by Treatment Strategy
10678	Predictors of Outcome Stratified by Use of IV/SC Prostanoids and PAH-Targeted Mono-, Dual, and Triple Therapy
10679	Indications for CTA Studies Prior to AADA Onset
10680	Mechanisms of Retrograde Aortic Dissection Type A
10681	Thoracic Aorta Diameters Prior to Aortic Dissection Type A Onset
10682	Aortic Geometry Change Due to Dissection in Primarily Nondissected Segments
10683	Associations of Serum 25 (OH) D and PTH With Incident Hypertension Among 3,002 Participants
10684	Results of the Multivariate Risk Regression of Measures of Adiposity on Incident Hypertension
10685	Results of the Multivariate Risk Regression of Specific Measures of Intra-Abdominal Adiposity on Incident Hypertension
10686	Risk of Heart Failure in Relation to Individual Lifestyle Factors, The WHI Observational Study
10687	Risk of Heart Failure in Relation to the Healthy Lifestyle Score, The WHI Observational Study
10688	Multivariable Logistic Regression Analysis for Prediction of Response to Renal Sympathetic Denervation
10689	Influence of Selective Heart Rate Reduction With Ivabradine on Hemodynamic Parameters After 8 Months of Treatment Compared With Placebo
10690	Incidence of SCD in MSHSL Athletes Compared With Italian and NCAA Rates
10691	All Reoperations and Re-Interventions  (n= 124)
10692	The Association of Ectopic Fat Depots With Incident CVD  (n= 90) , Cancer  (n= 141) , and All-Cause Mortality  (n= 71)
10693	Association of Multiple Fat Depots With Incident CVD  (40 Events in Women, 50 Events in Men)  and Incident Cancer  (68 Events in Women, 73 Events in Men)  Stratified by Sex
10694	Echocardiographic and Catheterization Parameters of Patients With Low Gradient Severe Aortic Stenosis Despite Preserved Ejection Fraction  (“Paradoxic”)  and With Conventionally Defined Severe Aortic Stenosis
10695	Classification of Patient Data According to Mean Transaortic Gradient  (Low Gradient ≤40 mm Hg, High Gradient >40 mm Hg)  and Stroke Volume Index  (Low Flow <35 ml/m2, High Flow ≥35 ml/m2)  Measured by Echocardiography
10696	Estimated Annual Rates of Progression  (Increase if Positive and Decrease if Negative)  of Each Outcome for Each Treatment Group
10697	Hemodynamic Determinants of Pre-Hypertension, Compared With Normotensive and Hypertensive Subjects
10698	Autonomic Function in Pre-Hypertension
10699	Heritabilities and Correlations of Autonomic and Hemodynamic Traits With Systolic Blood Pressure
10700	Echocardiographic and Morphometric Variables of Rats at Sacrifice
10701	Sodium Current Properties
10702	Echocardiographic Measurements in Chronic Thromboembolic Pulmonary Hypertension Patients
10703	Associations of Lower Extremity Muscle Measures With All-Cause Mortality in Men and Women With PAD  ⁎
10704	Associations of Calf Muscle Density and Isometric Strength Measures With Cardiovascular Mortality Among Men With PAD
10705	Hazard Ratios of Incident Cardiovascular Disease Risk Factors by Changes in Fitness and Fatness
10706	Reclassification of Participants by 1-Year All-Cause Mortality Status Using Model With PASP
10707	Reclassification of Participants by 1-Year Cardiovascular Mortality Status Using Model With PASP
10708	Selected Studies Reporting on PASP in the Literature 2000 to 2010
10709	Doppler Criteria for Classification of Diastolic Function and Estimation of LV Filling Pressure
10710	Univariable Surgical Predictors of POAF
10711	Univariable Echocardiographic Predictors of POAF
10712	Multivariate Logistic Regression Model for Predicting New-Onset POAF After Cardiac Surgery
10713	Adjusted Associations of Sex With Decline in Functional Performance and Changes in Lower Extremity Muscle Among Peripheral Arterial Disease Participants  (n = 380)
10714	Hemodynamic Responses During Graded Upright Tilt
10715	Cardiovascular and Sympathetic Responses During the Cold Pressor Test
10716	Cardiovascular and Sympathetic Responses During Static Handgrip to Fatigue
10717	Operative and Post-Operative Results
10718	Independent Predictors of Long-Term Death After Aortic Root Replacement
10719	Indication, Operative Findings, and Outcomes of Patients Requiring Redo Surgery
10720	Determinants of cPP and pPP Other Than Augmentation Pressure by Regression Analysis
10721	Determinants of P1 and ΔPaugby Regression Analysis
10722	Determinants of P1 and ΔPaugby Regression Analysis in a Subset of 186 Subjects With SV Measurements
10723	Intraclass Correlations for MZ and DZ Twin Pairs
10724	Heritability Estimates and 95% CIs for Best Fitting Univariate
10725	Distribution of Label Prosthesis Size According to Type of Aortic Bioprosthesis
10726	Doppler Echocardiographic Data According to Type of Aortic Bioprosthesis
10727	Aortic Regurgitation Data at Discharge and at Follow-Up Grouped According to Type of Aortic Bioprosthesis
10728	Indexed Effective Orifice Area and Incidence of Severe Patient-Prosthesis Mismatch Grouped According to Aortic Annulus Size and Type of Bioprosthesis
10729	Bi-Atrial Repolarization Dynamics
10730	Atrial Conduction Dynamics
10731	Comparison of Global Mechanics Parameters in Dysfunction  (n = 7)  and Elastic Ring  (n = 6)  Groups
10732	Adjusted Associations of Presence of Peripheral Arterial Disease and Loss of Mobility or the Ability to Walk Continuously for 6 Min at Follow-Up  (n = 638)
10733	Univariate Association of In-Hospital Outcomes With an Early Abnormal Creatinine Increase After Percutaneous Coronary Intervention
10734	Multivariable Association Between an Early Abnormal Increase in Creatinine Level After PCI and V/CrCl Ratio
10735	C-Reactive Protein Concentrations According to Gender, Region, and Residence  (mg/l)   ⁎
10736	Spearman Partial Correlation Coefficients Between CRP, BMI, and Elements of Metabolic Syndrome  ⁎
10737	Prevalence of Metabolic Syndrome According to Quartile of CRP
10738	Odds Ratios and 95% Confidence Interval for MetS and its Individual Components According to Quartile of CRP
10739	Central and Peripheral Hemodynamic Parameters
10740	Left Ventricular Structure and Systolic Function
10741	Left Ventricular Diastolic Function and Left Atrial Morphology and Function
10742	Gender-Specific Mean and Standard Deviation of LV Mass, End-Diastolic Volume, Stroke Volume, Ejection Fraction, and Cardiac Output by Cardiac MRI in MESA Participants
10743	Multivariable Analysis of Traditional Cardiovascular  (CV)  Risk Factors in Relation to LV Mass, Volumes, and Systolic Function
10744	Results of Correlation Analysis for MSCT and CVG as Compared With MRI for Evaluation of Global Left Ventricular Function in 88 Patients
10745	Results of Correlation Analysis for MSCT and Echo as Compared With MRI for Evaluation of Global Left Ventricular Function in 30 Patients
10746	IVUS Parameters at the First Year After Transplantation
10747	IVUS Parameters in Sites With Progression of Donor Lesions and Sites With New Lesions at the First Year After Transplantation
10748	IVUS Parameters During the 3-Year Follow-Up
10749	Relationship Between Echocardiographic Parameters and Systolic Blood Pressure at Four Months of Follow-Up
10750	Risk Factors for AR
10751	Threshold Levels for the Definition of MS  ( 7 )
10752	Visit 1: Age  (± SD)  and Prevalence  (%)  of CV Risk Factors According to Gender  ⁎
10753	Number of Coronary Segments With Diagnostic Image Quality
10754	Diagnostic Accuracy of MDCT Per Segment and Per Vessel
10755	Left Ventricular Pressures, Aortic Pressures, and Cardiac Index Values in 24 HHT and 43 OCT Patients
10756	SBP in Different Subgroups of Heterotopic Transplant Patients
10757	Unadjusted and Backward Stepwise Multiple Regression Models
10758	Correlation and Mean Difference Between the Sequential  (“Test-Retest”)  StudiesWith 2DE and RT-3DE  (n = 50)  *
10759	Inter-Observer Agreement With 2DE and RT-3DE  (n = 20)  Showing Correlationsand Mean Difference Between the Studies
10760	Intra-Observer Agreement With 2DE and RT-3DE  (n = 20)  Showing R Values and Mean Difference Between the Studies
10761	Mean Difference Between Echocardiographic and MRI Measurements  (n = 50)
10762	Mean Acquisition and Calculation Times  (n = 20)
10763	Multiple Regression Analysis of the Relationship Between Left Ventricular Mass Index and Other Variables for the Entire Group
10764	Relationship of Hematocrit to LVM, End-Diastolic Dimension, and Wall Thickness
10765	Severe Lesion Detection
10766	Differences Between Diagnostic Patients and Nondiagnostic Patients
10767	Anthropometric Measures, Resting Energy Expenditure for Basal Homeostasis, and Calculated Total Daily-Energy Expenditure in Patients and Controls of the Study
10768	Nutritional Intakes, Nitrogen Excretion, Calorie and Nitrogen Balances, and Energy Availability for Physical Activity in Patients and Controls of the Study
10769	Plasma Cortisol and Insulin Levels, and Cortisol/Insulin Ratio in Patients and Controls of the Study
10770	BW, LWI, RVI, and AWI of Spontaneously Hypertensive Rats, Either Control or Treated With 1, 5, 10, and 20 mg/kg/day of R
10771	SAP, DAP, MAP, HR, CI, and TPR in Spontaneously Hypertensive Rats, Either Control or Treated With 1, 5, 10, and 20 mg/kg/day of R
10772	BF and VR under Basal Conditions and MVR  (After Dipyridamole Infusion)  in Kidney, Liver, Skin, Muscle, and Brain of SHR Rats, Either Control or Treated With 1, 5, 10, and 20 mg/kg/day of R
10773	Plasma Levels of Chol, HDL, LDL, or Trigl in Control SHR and SHR Treated With 10 or 20 mg/kg/day of R
10774	MAP, CI, TPRI, RBF, RVR, SBF and SVR, MBF and MVR, CBF and CVR, MCVR, and CFR in Control WKY, WKY Given Rosuvastatin for Six Weeks, WKY Treated With L-NAME for Six Weeks, and WKY Given L-NAME and Rosuvastatin for Six Weeks
10775	Hemodynamic InterVA and IntraVA Values Before and After Induction of LBBB
10776	Maximal Increase of LV dP/dtmaxand Stroke Work Relative to Left Bundle Branch Block Values for 12 Dogs
10777	Effect of Training on the Incremental Maximal Exercise Test of HTR
10778	Effect of Training on Enzyme Activities and MyHC Distribution in HTRs
10779	Signs Indicating an Abnormal Clinical Test
10780	Diagnostic Value of Clinical Test, Electrocardiogram, and BNP to Detect LVSD
10781	Diagnostic Value of BNP in Relation to Risk Group
10782	Price and Cost-Effectiveness of BNP Compared With Echocardiogram in Relation to Risk Group
10783	LV Function and Geometry Before and After Aortic Valve Replacement Compared With Control Subjects
10784	Type and Duration of Physical Activity *
10785	Effect of Left Ventricular Hypertrophy on Risk of Stroke Depending on Presence of Physical Activity
10786	Effect of PA on LVM by Duration of PA in the Entire Cohort
10787	Interaction of LVH and Physical Activity on the Risk of Stroke
10788	Impact of AV Delay Changes on Hemodynamics for the Population, the Responder Subgroup and Nonresponders
10789	Measurements Made During the Final 5 Min of Tilt
10790	Measurements in Presyncopal Subjects During the Final 5 Min of Tilt
10791	Effects of Beta-Blockade on Resting Hemodynamics and MSNA
10792	Hemodynamic and MSNA Responses to Handgrip Exercise Before and After Beta-Blockade
10793	Differences Among End-Diastolic Volume, End-Systolic Volume, Ejection Fraction and Left Ventricular Mass as Revealed on Cine MRI and Real-Time MRI legend
10794	Left Ventricular Volume and Mass Determined by Cine MRI and Real-Time MRI in Heart Failure Patients legend
10795	Intra- and Interobserver Variability  (Mean Difference ± SD)  legend
10796	Determinants of Pulse Pressure and the PP-to-SVi Ratio legend
10797	Causes of Death and of Fatal and Nonfatal Cardiovascular Events During Follow-up
10798	Relative Hazard Rate of PP and of the PP-to-SVi Ratio for Cardiovascular Events and All-cause Mortality After Cumulative Adjustment for: A)  Age and Gender, B)  Mean Brachial Artery Pressure, and C)  Heart Rate legend
10799	Correlation and Mean Difference Between DCD Method in Two Orthogonal Planes and Flow Meter Method for Measuring Stroke Volumes and Regurgitant Fractions in an In Vitro Model legend
10800	Correlation and Mean Difference Between DCD Method in Two Orthogonal Planes and Electromagnetic Method for Measuring Stroke Volumes and Regurgitant Fractions in a Chronic Animal Model legend
10801	Results legend
10802	Effect of Phenylephrine Infusion in HD Patients and Volunteers legend
10803	Activity of Adenylyl Cyclase legend
10804	Frequency of Events at One Year legend
10805	Relation of Echocardiographic Parameters to Event Rate, by Cox Proportional Hazards Regression legend
10806	Association of Left Ventricular Mass and Ejection Fraction With Clinical Events legend
10807	Indications for Implantation of Self-Expanding Wallstents legend
10808	Angiographic and Hemodynamic Data Immediately After Stent Implantation and at Follow-up Catheterization Restudy legend
10809	Identifying Risk Factors Associated With Significant Neointimal Proliferation by Univariate Analyses
10810	Primary and Derived Echocardiographic Left Ventricular Measurements legend
10811	Likelihood of True Changes in LV Mass for Different Thresholds of Intraindividual Variability
10812	Sample Size  (n)  per Group Needed for Statistical Power of 90% or 80% to Detect Changes in LV Mass at Alpha-Errors of 5% and 1% legend
10813	Relation Between Change of LV Mass and Dimensions and Hemodynamic Parameters legend
10814	Echocardiographic Measurements of LV Systolic Function legend
10815	Predictors of HTNCM in Hypertensive Study Patients legend
10816	Multicategory Logistic Modeling of Predictive Factors for Various Types of Hypertensive Status legend
10817	DCA Procedures legend
10818	Effect of IVUS on DCA legend
10819	Acute and In-hospital Complications legend
10820	QCA Analysis legend
10821	QCU Analysis legend
10822	Cumulative Clinical Events legend
10823	Iliac Artery Morphometry 12 Weeks After Stent Implantation and Subsequent External Beam Irradiation legend
10824	Adjusted Mean Values  (and Standard Errors)  of Echocardiographic Measurements in LVH-Siblings and a Comparison Group Matched by Age and Gender legend
10825	Prevalence  (in %)  and Adjusted Odds Ratio of LVH in LVH-Siblings and A Comparison Group Matched by Age and Gender, Applying Three Different Indexations of Left Ventricular Mass legend
10826	Prevalence  (in %)  and Adjusted Odds Ratio of Increased Relative Wall Thickness in LVH-Siblings and a Comparison Group Matched by Age and Gender, Stratifying by Hypertension and Overweight legend
10827	Echocardiographic Findings in Patients Referred for Systolic Murmurs
10828	Doppler Echocardiographic Measurements of Patients With and Without Increased Intraventricular Velocities  legend
10829	Vasocontraction legend
10830	Vasorelaxation legend
10831	Left Ventricular Mass and Risk of Sudden Death
10832	Left Ventricular Hypertrophy and Risk of Sudden Death
10833	Transthoracic Echocardiographic Doppler Parameters of Malfunctioning Valves With Pannus or Thrombus Formation  legend
10834	Qualitative and Quantitative Parameters by TEE in Obstructed Valves Secondary to Thrombus or Pannus Formation legend
10835	Sensitivity, Specificity and Predictive Accuracy of Inadequate Anticoagulation and TEE Parameters for Prediction of Prosthetic Thrombosis in 24 Obstructed Valves legend
10836	Heart Rate Variability in Group I and Group II legend
10837	Average Amount of Drinking Water Consumed per Maternal Rat
10838	Maternal Parameters and Summary legend
10839	Types of Heart Malformations legend
10840	Patients, Procedures and Outcomes  legend
10841	Comparison of Hemodynamic Variables for Survival and Nonsurvival in Patients With Two-Ventricle Repair legend
10842	Comparison of Morphometric Variables for Survival and Nonsurvival in Patients With Two-Ventricle Repair  legend
10843	Echocardiographic Results of Mass, Volume and Wall Thickness Indexed to Body Surface Area in the Patients Undergoing Late Arterial Switch Operation  (n = 37)
10844	Postoperative Outcome Measurements in the Early and Late Arterial Switch Operation Group Patients
10845	Postoperative Outcome Measurements in Relation to the Pattern of Preoperative Left Ventricular Geometry in the Late Arterial Switch Operation Group  (n = 37)
10846	Diagnoses and Previous Surgical Interventions
10847	Univariate Procedural Predictors of In-Stent Restenosis
10848	Univariate Angiographic Predictors of In-Stent Restenosis
10849	Univariate Intravascular Ultrasound Predictors of In-Stent Restenosis
10850	Multivariate Predictors of Follow-Up Angiographic Results  (restenosis, diameter stenosis, late lumen loss and minimal lumen diameter)
10851	Unadjusted Procedure Rates for Cardiovascular Disease Cohort and Refined Cohorts
10852	Unadjusted Survival Rates for Cardiovascular Disease Cohort
10853	Age and Body Weight of Senescent Rats
10854	Left Ventricular Dimensions
10855	Left Ventricular Systolic and Diastolic Functional Measures
10856	Histopathologic Findings of the Ventricular Septa
10857	Patient Data
10858	Statistical Description of Results in 20 Patients
10859	Statistical Analysis of Results  a
10860	Comparison of Five Human Anatomic Validation Studies
10861	Validation Studies Using Magnetic Resonance Imaging
10862	Results of Multivariate Analysis
10863	Risk of Different Endpoints According to AF Type at Randomization
10864	30-Day Outcomes  (n=310)
10865	Early and Late Survival and Cardiac Reinterventions
10866	Outcomes in Propensity Score-Matched Patients
10867	Serial Echocardiographic Findings
10868	Outcomes Through 30 Days
10869	VARC-2 Safety Endpoints at 30 Days Based on Use of the Repositioning Feature of the THV
10870	Device Annular Sizing and Early Outcomes
10871	Frailty Scales and Geriatric Domains
10872	Incremental Value of Frailty Scales
10873	Multivariable Model to Predict 1-Yr Mortality
10874	Clinical Outcomes to 1 Yr, Stratified by Surgical Risk  (STS PROM)
10875	HRs of Intermediate and Ideal CVH for All-Cause Mortality, CHD, and Stroke
10876	HRs of Intermediate and Ideal CVH for All-Cause Mortality and for CHD and Stroke Combined: Analysis by Metric
10877	Lymphatic Imaging and Lymphatic Interventions
10878	Intervention Outcomes
10879	Procedural and Clinical Outcomes
10880	Therapy at Time of Index Echocardiography  (N= 305)
10881	Procedural Data of the Overall Study Group and According to the Occurrence of EM After Catheter Ablation
10882	Comparison of Clinical and Procedural Data Between Patients Who Died Early  (Within 31 Days)  Post-Procedure and Those Who Had Late Mortality
10883	Univariate and Multivariable Logistic Regression Analyses Testing the Association Between Clinical and Procedural Variables and EM After Catheter Ablation
10884	Details of Patients Who Died In-Hospital After a Major Procedure-Related Complication
10885	Echocardiographic Variables
10886	Predictors of Long-Term Mortality  ∗
10887	Association Between LV Dimensions and Mortality∗
10888	Criteria for Echocardiographic Grading of TR Used in the Trial Protocols
10889	Changes in TV and Right-Sided Heart Measures After TPVR in the StudyCohort (N= 300)
10890	Comparison of Clinical Prediction Models by Endpoint
10891	AIC Comparison of Clinical Prediction Models
10892	Matrix of Tested Configurations
10893	Single-Clip Treatments
10894	Single-Clip Treatments: Specific-to-Treatment Data
10895	2-Clip Treatments
10896	Pregnancy Outcomes and Verification Rates According to HeartDefectCategories
10897	Impact of the Discordances on Planned NeonatalTreatment
10898	Impact of the Discordances on Long-Term Care Strategies
10899	Types of Anatomical Discordances  ∗
10900	Number of Initial Strokes and Initial Strokes per 1,000 Person-Years of Follow-Up After Initial AF Diagnosis
10901	Hazard of Stroke by Race/Ethnicity, Relative to White Patients, After Controlling for CHA2DS2-VASc Score  (Model 1)  and CHA2DS2-VASc Score Plus Anticoagulant Use  (Model 2)
10902	Comparison of CHA2DS2-VASc and CHA2DS2-VASc-R Scores in Predicting Stroke: Relative Hazard Associated With 1-Point Increase in Stroke Risk Score, and C-Statistic
10903	Relative Contribution of Each Risk Factor of CHA2DS2-VASc-R Score in Stroke Prediction
10904	Data Completeness
10905	Survival and Freedom From Reintervention by AVR Type
10906	3-Year Clinical Outcomes
10907	Serial Echocardiography by Treatment Group for All Patients
10908	Unadjusted In-Hospital Outcomes Stratified by LVEF
10909	Unadjusted In-Hospital Outcomes Stratified by Mean AVG
10910	Health Status Outcomes at 30 Days Stratified by LVEF
10911	Health Status Outcomes at 30 Days Stratified by Mean AVG
10912	Proximal Aortic Diameters and Phenotypes in Both Study Groups
10913	Rheological Aortic Root Parameters and Sum Scores in Both Patient Groups
10914	Indicators of Indexed Cross-Sectional Aortic Diameter≥22 mm/m2 as Determined by Multivariable Logistic Regression
10915	Adverse Events Considered “Major”
10916	Definitions of Procedural Success
10917	Univariate Comparison of Definitions of Procedural Success
10918	Multivariate Models of Procedural Success
10919	Multivariate Model of Adverse Events: All Patients
10920	Multivariate Model of Major Adverse Events: Biventricular Patients
10921	ACS NSQIP Classification of CHD Based on Residual Lesion Burden and Functional Status
10922	Propensity Matching for Controls and CHD Patients
10923	Mortality and Post-Operative Outcomes for Matched Controls and Severe CHD Patients
10924	Mortality and Post-Operative Outcomes for Matched Controls and Major CHD
10925	Mortality and Post-Operative Outcomes for Matched Controls and Minor Congenital Heart Disease Patients
10926	Nonhierarchical and Hierarchical Count of Clinical Events Over 5 Years  (n= 101)
10927	Clinical Outcomes: Propensity Score–Matched Cohort
10928	Clinical Outcomes: Entire Cohort
10929	Summary of Clinical Studies in Percutaneous Pulmonary Valve Implantation
10930	Clinical Outcomes After 2 Years in the As-Treated Population
10931	Additional Outcomes at 2 Years
10932	Angiographic and Functional Nomenclature of CAV  ∗
10933	Association Between Angiographic Vasculopathy Grade and Ejection Fraction  ∗
10934	Association of Hemodynamic Abnormalities With Angiographic Vasculopathy Grade  ∗
10935	Top 5 Most Common Cardiac Discharge Diagnoses for PediatricPatients With CHD Hospitalized in California, 1983 vs. 2011
10936	Suggested Preoperative Echocardiographic Criteria  ∗    †  With Threshold Z Scores ‡  for Performance of Balloon Valvuloplasty §
10937	Pregnancy Outcomes Among FCI Patients by Procedure Type
10938	Odds Ratios of Worsening Angina for Patients Treated With CABG Compared With Patients Treated With Medical Therapy Alone
10939	Determinants of Recurrent TR  (Moderate or Greater)
10940	Determinants of RV Function Recovery During Follow-Up
10941	Top 10 Diagnoses for Hospitalization After the Index PCI
10942	Cost-Effectiveness Analysis: PSBB Adjusted
10943	Cost-Effectiveness Analysis: Matched Analytic Population
10944	Cost-Effectiveness Analysis for Matched Analytic Population Subgroups
10945	Echocardiographic Measures of RV Size and Function
10946	Echocardiographic Measures of Valve andAortic Size and Function
10947	Summary Statistics for Pre-Fontan Echocardiographic Measures byInitialShunt Group
10948	Summary Statistics for 14-Month and Pre-Fontan Echocardiographic Measures  (MBTS Group)
10949	Summary Statistics for 14-Month and Pre-Fontan Echocardiographic Measures  (RVPAS Group)
10950	Univariate Analysis of 14-Month Echocardiographic Indices as Predictors of Transplant-Free Survival From the Time of Study to Fontan Surgery
10951	Angiographic Findings
10952	OCT Findings
10953	IVUS Findings
10954	Summary Estimates for Weighted Mean Sensitivity, Specificity, PPV, NPV, and Accuracy of CCTA for theEvaluation of the Presence of Any CAV Compared With CCAG
10955	Summary Estimates for Weighted Mean Sensitivity, Specificity, PPV, NPV, and Accuracy of CCTA for the Evaluation of Significant CAV Compared With CCAG
10956	VARC-Defined Device Success
10957	VARC-Defined Safety at 30 Days  (N= 75)
10958	Pre- and Post-Echocardiographic Data  (Mean Gradient, Effective Orifice Area, LV Ejection Fraction)
10959	Aortic Regurgitation by Echocardiography
10960	Comparison of Cardiovascular Magnetic Resonance Findings in Transplant Patients and Healthy Volunteers
10961	Associations With Intravascular Ultrasound PlaqueVolume Index
10962	Associations With Index of Microcirculatory Resistance
10963	Diagnostic Performance of Coronary Angiography and Cardiovascular Magnetic ResonanceMyocardial Perfusion Reserve
10964	Parameters Predicting Risk of First Reoperation on the RVOT or the PAs by Cox Proportional Hazards Regression Analysis
10965	Mean Number of Variants Identified
10966	Variants Included in Disease Cosegregation Studies
10967	Odds Ratios  (95% Confidence Intervals)  for AcuteKidney Injury for Coronary Artery Bypass Grafting VersusPercutaneous Coronary Intervention Overall and in Selected Subgroups
10968	Specific Causes of Death in the RELAX-AHF Study
10969	Clinical Event Distribution During 1-Year Follow-Up
10970	LCBI Levels Equal to and Above the Median Value and MACCE  ∗
10971	Electrical and Hemodynamic Data Derived From Computer Simulations of a Failing Heart During LBBB, LVP, and BiVP
10972	Patient and Hospital Predictors of Inappropriate PCI
10973	Distribution of Inappropriate PCIs by Indication and Subgroup  ∗
10974	Analysis of Risk of Bias: Internal Validity
10975	Metric Elaboration for TOF Illustrating the Steps in Achieving Operationalization on the Basis of Review of Published Data
10976	All Candidate Quality Indicators and Rating Scores for Round 1 and Round 2 Ratings by the Expert Panel Separated by Lesion, Including Categorization of Indicators by Process and Structure Within Each Lesion and the Level of Evidence of Each Indicator
10977	Definitions Used to Qualify ACHD and CHD Expertise
10978	Quality Indicators Common to Several of the CHD Lesions
10979	Associated Anomalies
10980	Analyzed Parameters
10981	Follow-Up Results and Complications  (N = 74)
10982	Factors Related to Maintenance of SR After Ablation
10983	Echocardiographic Parameters in Patients With and Without Recurrence of AF
10984	Reproducibility of Strain and Strain Rate Measurements
10985	Coronary Computed Tomography Angiography Parameters of Studied Lesions as a Function of FFR Value
10986	Univariable Logistic Regression Analysis for Coronary Computed Tomography Angiography Measures to Identify Ischemic Lesions
10987	Total Number of Participants per Site and Proportion at Each Site Reporting Gap in Care
10988	Reported Reasons Why Participants Had a Gap in Cardiology Care
10989	Most Common Reasons for Gaps in Cardiology Care by Disease Complexity
10990	Reasons for Returning to Cardiology Care
10991	Clinical Events, as Estimated According to Kaplan-Meier Method
10992	Heart Failure Hospital Stay Rate/100,000 Persons
10993	Mean Length of Stay for Heart Failure Hospital Stay
10994	In-Hospital Mortality for Heart Failure Hospital Stay/100
10995	Morbidities in the Fontan Cohort  (n = 103)
10996	Correlates of Adverse Outcome
10997	Cox Proportional Hazards Regression Model
10998	Correlates of Outcome of Death or Cardiac Transplantation
10999	Mean Age, Weight, and Saturations, n = 58
11000	Interstage and Associated Procedures, n = 58
11001	Volumetric and Flow Data  (n = 58)
11002	Model for Change in Indexed End-Diastolic Volume  (r2 = 0.79, adjusted r2 = 0.75) , n = 58
11003	Pulmonary Artery and Aortic Sizes, n = 58
11004	Clinical and Angiographic Outcomes
11005	Predictors of Clinical and Angiographic Outcome
11006	Factors Associated With Thrombosis
11007	Factors Associated With Thrombosis in Multivariable Regression Model
11008	Factors Related to Graft Choice for LAD Revascularization at Reoperation
11009	Incremental Risk Factors for Death
11010	Hospital Outcomes After LITA or SV Grafting of the LAD at Reoperative CABG
11011	Comparison of Symptomatic Patients on the Basis of Occurrence of BCE on Initial Beta-Blocker
11012	Unadjusted Rates and Adjusted Hazards of Death or Recurrent Acute Coronary Syndrome at 3 Years, According to Appropriateness Categories and Coronary Revascularization
11013	EOA and EOAi in AS and VP-PM
11014	Summary of Studies That Used Measured EOAi to Assess VP-PM: Data of Moderate and Severe VP-PM Analyzed Separately
11015	Summary of Studies That Use Measured EOAi to Assess VP-PM: Data of Moderate and Severe VP-PM Are Combined
11016	EOA Determined at 6 Months After AVR for PHV Labeled Size 23
11017	PHV Areas From Randomized In Vivo Trials
11018	Factors to Consider When Choosing a PHV
11019	Odds Ratio, Heterogeneity, and Publication Bias Across Randomized Controlled Trials and Observational Studies Included in the Meta-Analysis
11020	Standard of Symptom Scoring for Orthostatic Intolerance
11021	Comparisons of Symptom Scores, Changes of Heart Rate in POTS Children Treated by Midodrine Hydrochloride
11022	Comparisons of Symptom Scores, Changes of Heart Rate, and MR-proADM Between POTS Children With Different Response to Midodrine Hydrochloride
11023	Procedural and 30-Day Outcomes
11024	HRs for Moderate or Severe Versus Mild or Less MR
11025	Multivariate Predictors of Reduced MR at 1-Year Follow-Up
11026	Surgical Procedures Performed  (N = 89)
11027	Types of TV Prostheses Used for TV Replacement  (n = 65)
11028	Univariate Predictors of Death During Follow-up
11029	Reasons for Not Taking a Beta-Blocker or Not Taking Target Dose
11030	Results of Multivariable Stepwise Logistic Regression
11031	End-of-Study Cumulative Incidence of Endpoints According to QRS Duration and LBBB
11032	HRs for QRS Duration 100 to 119 ms and LBBB Versus QRS Duration <85 ms
11033	Unadjusted Association of Quartiles of Left Atrial Functional Index With Heart Failure Hospitalization
11034	Association of LAFI With Heart Failure Hospitalization, With Multivariate Adjustment
11035	Conduction Dynamic Status
11036	Atrial Electrogram Duration and Amplitude Dynamic Status
11037	Vascular Complications According to Valve Academic Research Consortium Definitions  ( 12,13 )
11038	MDCT Measurements in Patients Without and With Vascular Complications  (n = 82)
11039	Overview of Activities and WGs Within the ACC's AC/PC Section
11040	Inclusion and Exclusion Criteria
11041	Acute Outcomes
11042	Short-Term Follow-Up Outcomes
11043	Short-Term Follow-Up Outcomes by Integrated Imaging
11044	Intermediate Follow-Up Outcomes
11045	Intermediate Follow-up Outcomes by Integrated Imaging
11046	Reintervention
11047	Subgroup Analysis, Age 6 to 12 Years
11048	Hemodynamics  ⁎
11049	Procedural Variables
11050	CAPS Scoring System
11051	Clinical Variables  (N = 657)
11052	Primary and secondary outcomes at 3, 6, and 12 months
11053	Length of hospital stay and therapy input
11054	Univariable Analysis: CCTA Variables
11055	Cox Models of CCTA Measures
11056	Evaluating the Incremental Value of CAPS to a Model With Clinical Variables Only  (Additive EuroSCORE)
11057	Use of services in first 6 months
11058	Outcome at 6 months for carers
11059	Outcome at 6 months for patients
11060	Size of differences between family support and control groups stratified by method of response
11061	Size of differences between family support and control groups stratified by admission to specialist rehabilitation wards
11062	Mean  (range)  sex-hormone concentrations
11063	Odds of cognitive impairment  (decrease of ≥3 on the mMMSE)  by tertile of sex-hormone concentration
11064	Adverse events
11065	Event-registration, survey, and quality-score data by population
11066	Age-standardised levels and trends of coronary-event rates and risk factors in men aged 35–64 years
11067	Age-standardised levels and trends of coronary-event rates and risk factors in women aged 35–64 years
11068	Correlations between trends in risk factors, risk score, and coronary-event rates
11069	Regression of trends in coronary-event rates on trends in risk scores and individual risk factors in people aged 35–64 years
11070	Regression of coronary-event rates on trends in risk scores and individual risk factors in people aged 55–64 years
11071	Valve Dimensions for Selected 18- to 23-mm Stented Surgical Bioprostheses, per Manufacturer Product Information
11072	Valve Dimensions for Selected 24- to 29-mm Stented Surgical Bioprostheses, per Manufacturer Product Information
11073	Valve Dimensions for Selected Stentless Valves, per Manufacturer Product Information
11074	Clinical and Hemodynamic Outcomes of V-in-V Implantation
11075	Clinical rating scales
11076	Primary and secondary outcomes—median  (range)  scores of clinical rating scales for defined off phase assessment
11077	Secondary outcome—median  (range)  scores of clinical rating scales for defined on phase assessment
11078	Secondary outcome—median  (range)  scores of timed tests, expressed in  (s)
11079	Secondary outcome—patients' diaries  (h per day) , from 0600 h to 2400 h, mean  (SD)
11080	Secondary outcome—adverse effects
11081	Inheritance of ankylosing spondylitis among sons and daughters of patients
11082	Inheritance of ankylosing spondylitis among brothers and sisters of patients
11083	Data and extrapolation of inheritance of ankylosing spondylitis to children
11084	Age and educational attainment of cases and controls
11085	Association of the A49T missense substitution in  SRD5A2  gene with risk of prostate cancer
11086	In-vitro kinetic properties of mutant and wild-type SRD5A2 enzyme
11087	Subscores of modified TWSTRS scale
11088	Intraobserver and Interobserver Variability of Largest Aortic Root and Ascending Aorta Measurements in Patients With Severe Aortic Stenosis
11089	Agreement Among CMR, CCT, and TTE
11090	Association of the CTLA-4A/G polymorphism in Graves' disease patients  (TAO group and Graves' disease group)  and controls
11091	Extra life-expectancy gain attributable to doubled rate of decline in specified diseases, 1990–2020
11092	Rank order of disabling effect of health conditions by severity
11093	Disability ranks associated with different health conditions by country
11094	Disablement ranks of different health conditions by informant group
11095	A comparison of the rank order between Global Burden of Disease study  1   and this study
11096	Adjusted means and proportions of risk factors for coronary heart disease by quintile of soluble thrombomodulin in cohort random sample  (n=753)  of ARIC study
11097	Adjusted means and proportions of haemostatic factors and inflammatory markers by quintile of soluble thrombomodulin in cohort random sample  (n=753)  of ARIC study
11098	Odds ratio of carotid atherosclerosis by quintile of soluble thrombomodulin in white and black participants of ARIC study
11099	Statistical association of risk variables with mortality
11100	Association of risk variables with total mortality in a univariate analysis
11101	Relative hazards of significant and independent risk variables in a multivariate analysis
11102	Medication Use as Mean Changes in Dosages During the Course of the Study
11103	Relative hazards of individual variables in a multivariate analysis involving combination of turbulence onset and slope
11104	Outcomes in the PROTECT Study
11105	Serious Adverse Events During the Study as a Function of Treatment Allocation
11106	Predictable risk
11107	Psychiatric aftercare
11108	Probability of reaching undetectable viral load with initial treatment regimen
11109	Number of CD4 cells gained within first 6 months of treatment
11110	Surgical Outcomes
11111	Determinants of Interventions for Aortic Stenosis in Patients With Discrete Subaortic Stenosis
11112	Vaccination history of cases and controls
11113	Risk factors associated with diphtheria cases among children aged 6–8 years
11114	Mean values of diastolic blood pressure and blood cholesterol concentrations in defined subgroups
11115	Overall mortality by randomised group, and by prespecified time periods and subgroups
11116	Numbers of deaths according to reported underlying cause on the death certificate by treatment group
11117	Observed versus expected numbers of individuals with different haplotypes for the CCR5 gene in blood donors
11118	Cox proportional hazard models of the data in  figure 3
11119	β-Blocker Trials: Patients and Events
11120	All-Cause Mortality Endpoint Comparison in β-Blocker Heart Failure Trials: U.S. vs. ROW
11121	Medical history and the risk of CJD
11122	Occupational history and animal exposure and the risk of CJD
11123	Consumption of organ, meat, and milk products and the risk of CJD
11124	Consumption of meat and the risk of CJD
11125	2 and 5 year actuarial outcomes for patients with  BRCA1 -mutation-related and sporadic breast cancer
11126	Crude and adjusted hazard ratios for patients with  BRCA1 -related versus sporadic breast cancer
11127	Estimated annual costs of intervention at December, 1993, prices
11128	Estimated number of HIV-1 infections averted by intervention
11129	Summary of key results on cost and cost-effectiveness of intervention
11130	Analysis of sensitivity of cost-effectiveness estimates to assumptions
11131	Morbidity and symptom prevalence at age 33 years by social class at birth
11132	Physical measurements by social class at birth
11133	Economic circumstances by social class at birth
11134	Health-related behaviour by social class at birth
11135	Social and family functioning and structure by social class at birth
11136	Infectious agents and improved vaccines of importance in the USA and developing countries targeted for accelerated vaccine development in 1985 and their status in 1996
11137	10-year mortality risks
11138	5-year mortality risks for three groups of participants
11139	Univariate Cox Proportional HR Model of Patient Factors With Relative Risk for Reintervention and Reoperation After BD for Arch Obstruction After the NP
11140	Working hours and days off work because of ill health among local-government employees in Raisio, 1991–95
11141	Sick leave due to musculoskeletal disorders and trauma by degree of downsizing
11142	Absence rates and rate ratios of factors that predict long periods of sick leave
11143	Interactions between downsizing by occupation and other predictors of sick leave
11144	Proportion of 93 head-injured patients with each APOE genotype
11145	Comparison of head-injured patients with and without an APOE  ε4 allele
11146	Distribution of final WHO stages according to initial WHO stage for HIV-positive prevalent and incident cases
11147	Stage-defining disorders for entry into stages 3 and 4
11148	Cumulative probability of progression to AIDS by initial stage and from entering a new stage
11149	Mortality rate by initial stage for prevalent and incident groups
11150	Cumulative probability of death by initial stage and from entering a new stage
11151	Diagnostic categories by sample status
11152	Prevalence of cognitive impairment by severity, sex, and age-group
11153	Percentage  (95% CI)  of elderly Canadians in each diagnostic category living in institutions
11154	Percentage of participants with each degree of cognitive impairment who experience functional limitations
11155	Details of patients used in selection
11156	Details of operations and complications
11157	Details of postoperative symptoms and complications
11158	Follow-up details
11159	Pre-Operative and Intraoperative Data
11160	Use of general-practitioner services before and after surgery
11161	Intraoperative and Early Post-Operative Results
11162	Causes of Follow-Up Deaths
11163	IDDM patients born in Lazio of either both or one Sardinian parent
11164	Observed and expected cases of newly diagnosed
11165	Age-adjusted cumulative incidence of coronary heart disease by birthweight and BMI tertiles
11166	Parameters  (standard error)  for logistic regression of log birthweight on cumulative incidence of coronary heart disease adjusted for age, risk factors, and socioeconomic status
11167	Father's social class and adult social class
11168	Childhood family amenity score and proportion of manual workers according to father's social class and adult social class
11169	Father's social class and cardiovascular risk factors at Q1
11170	Relative odds of cardiovascular disease according to father's social class with non-manual as reference group
11171	Relative age-adjusted odds of myocardial infarction and recall of a physician-diagnosed ischaemic heart disease according to adult social class and father's social class
11172	Cardiovascular risk factors at screening according to adult social class and father's social class
11173	WHO estimated and projected HIV prevalence in adults by “macro” region, July, 1995
11174	Oestrogen exposure in cases and controls by dose and by duration of use
11175	Babies in 1990–91 geographically defined cohort study and inclusion in volume expansion trial
11176	Deaths in trial groups
11177	Sensorineural impairment at age 2 years
11178	Neuromotor impairment at age 2 years
11179	Procedural Details
11180	Congenital Heart Defects Requiring Specialist Care
11181	Congenital Heart Defects Requiring Specialist or Shared Care
11182	Congenital Heart Defects for Which Nonspecialist Care Is Sufficient
11183	Treatment doses and treatment discontinuation by allocated treatment
11184	Outcomes of efficacy
11185	Outcomes of safety and tolerability
11186	National study cohort of parents in Sweden who lost their child due to a malignant disease between 1992 and 1997
11187	Bereaved parents' perception of being asked about their child's disease and death due to cancer
11188	Effect of the death of a child on parental mortality
11189	Effect of the death of a child on parental mortality
11190	Flesch reading ease score
11191	Median  (IQR)  psychological scores at 3 and 9 months in bereaved relatives by group
11192	Deaths from any cause and aneurysm-related causes, according to time since randomisation in the intention-to-treat population
11193	Causes of death in patients, by time since randomisation in the intention-to-treat population
11194	First re-interventions in patients, according to time since randomisation in the intention-to-treat population
11195	30-Day and 2-Year Clinical Follow-Up
11196	Clinical outcomes during 4 year follow-up, overall and according to a landmark analysis at 1 year
11197	Stent thrombosis
11198	Modified Rankin scores and composite endpoint  (modified Rankin score, Barthel Index score, and NIHSS score) , by OTT interval
11199	Mortality by OTT interval
11200	Intracerebral haemorrhage by OTT interval
11201	Numbers of patients and arteries per modality and bands of percentage of stenosis
11202	Meta-analysis of sensitivity and specificity for all stenosis groups and imaging techniques
11203	Test for heterogeneity in the meta-analyses of 70–99% stenosis data
11204	Key design features of trials
11205	Death or myocardial infarction, death, and myocardial infarction by qualifying event at the end of treatment
11206	Details of arthropod species identified
11207	Prevalence of self-reported chronic pain
11208	Logistic-regression model of factors significantly associated with chronic pain
11209	Self-reported cause of pain
11210	Self-reported chronic pain severity
11211	Expressed need of patients with chronic pain
11212	Results of regression analysis
11213	Invasively Measured Hemodynamic Outcomes After Percutaneous Pulmonary Valve Implantation
11214	Magnetic Resonance Imaging Data Before, Early After, and Late After PPVI in the Pulmonary Stenosis and Pulmonary Regurgitation Groups
11215	Cardiopulmonary Exercise Testing Data Before, Early After, and Late After PPVI in the PS and PR Groups
11216	Results of paired samples of synovial membrane B19 DNA and IgG antibodies to B19
11217	The Mean VNS Threshold  (in Volts)  That Slowed the Sinus Rate or AV Conduction During the Entire Experimental Period
11218	Reported intake of antiepileptic drugs
11219	Comedication with other antiepileptic drugs and presence of other confounding factors in cases of SJS and TEN
11220	Univariate risk estimates for short and long duration of antiepileptic therapy and individual antiepileptic drugs for SJS and TEN
11221	Univariate and multivariate risk estimates for short and long duration of antiepileptic therapy combined for SJS and TEN
11222	Symptoms and symptom severity associated with single-dose treatment
11223	Diet and lifestyles of the four populations
11224	Yearly onsets, classifications, and deaths from vCJD
11225	Effects on risk of zoster of contacts with limited numbers of children living in household and via childcare work in past 10 years
11226	Effects on risk of zoster of contacts with many children and exgenous exposure to varicella-zoster virus in the past 10 years
11227	IgG against varicella-zoster virus  (VZV)  in serum of blood donors by CCR5-32 genotype
11228	Incidence of disease and mean incubation period in RIII mice injected intracerebrally with 20 μL tissue homogenates or blood fractions from patients with vCJD
11229	Manifest and early pseudoexfoliation syndrome in abdominal aneurysm and carotic-artery occlusion patients
11230	Adjusted risk ratio estimates for various exposures compared with non-exposed and hyperlipidaemia
11231	Distribution of statin users in participants by duration of use and type of statin
11232	Annual number of onsets, classifications, and deaths from vCJD in UK
11233	Proportions of secondary structures in PrPSc before and 48 h after incubation with or without iPrP13
11234	Mean  (SE)  time to onset of symptoms for mice inoculated with PrPSc alone or with iPrP13
11235	Postoperative complications
11236	Effect of VPB in Healthy Volunteers on Ventilatory and Hemodynamic Parameters
11237	Age-adjusted odds ratios of Alzheimer's disease, vascular dementia, and other dementias by indicators of atherosclerosis
11238	Age-adjusted odds ratios of Alzheimer's disease, vascular dementia, and all dementia by atherosclerosis score and apolipoprotein-genotype
11239	Modern contraceptive prevalence rate  (mCPR) , unmet need for modern methods, and demand satisfied with modern methods in 2017 for 68 Family Planning 2020 countries
11240	Changes between 2012 and 2017 in the modern contraceptive prevalence rate  (mCPR) , unmet need for modern methods, demand satisfied with modern methods, and the number of women of reproductive age who are married or in a union using modern methods of contraception
11241	Results of a counterfactual analysis of changes in modern contraceptive prevalence rate  (mCPR)  since 2012
11242	Pre-Intervention and Acute Post-Intervention Aortic Valve Function Among 509 Early  (30-Day)  Survivors of Balloon Aortic Valvuloplasty for Congenital AS, 1984 to 2008
11243	Aortic Valve Reinterventions Among 509 Early  (30-Day)  Survivors of BAVP for Congenital AS, 1984 to 2008
11244	Results of Univariate and Multivariate Cox Regression Analyses of Freedom From Any Aortic Valve Surgery and Freedom From AVR
11245	HRs for AVR Among Patients With Different Combinations of Post-Dilation Residual AS and Acute AR
11246	Crude and adjusted consultation rates  (per 10 000 person-years)  with a general practitioner or nurse, by age, sex, and year
11247	Temporal trends in GP and nurse consultations by subtype of face-to-face, telephone, and home visit contacts
11248	Duration of consultations  (min)  with all types of general practitioner or nurse
11249	Total number of days  (two × 3 h sessions)  per 10 000 person-years of face-to-face, telephone, or visit consultations with a general practitioner or nurse
11250	Estimates  (%)  and uncertainty intervals of contraceptive prevalence and unmet need for family planning for 1990 and 2010, and the median absolute percentage points change  (1990–2010)
11251	Estimates and uncertainty intervals of the number of MWRA  (millions)  aged 15–49 years, for total contraceptive use, unmet need, total demand, and unmet need for modern methods, for 2010 and 2015
11252	Final multivariate Cox models
11253	Model-based probability of spermatogenic recovery to various thresholds for hypothetical man in  figure
11254	Results of laboratory testing for influenza in people possibly exposed to HPAI A/H7 in the Netherlands, grouped by presenting symptoms
11255	Reported cases by risk group and laboratory result
11256	Results of laboratory testing by category of symptoms in contacts from cases with confirmed A/H7 infection
11257	Symptoms in A/H7 positive, and /H7 and A/H3-negative cases
11258	Outcome Variables, Stratified by Gait Speed
11259	Incremental Value of Gait Speed Above Core Risk Factors to Predict Mortality or Major Morbidity
11260	Incremental Value of Gait Speed Above the STS Risk Score to Predict Mortality or Major Morbidity
11261	Adjusted matched relative-risk estimates
11262	Adjusted  *  relative-risk estimates restricted to unexposed women and women exposed to progestagens alone
11263	Standardised incidence rates for endometrial and breast cancer per 1000 women over a 5-year period in current users and never users of HRT at recruitment
11264	Rate of known non-compliance in the two treatment groups by time since study entry
11265	Rate ratios for reinfarction, cardiac death, or any death by 24 months
11266	Rate ratio of any death or a cardiac death at 3, 6, 12, and 18 months’ follow up
11267	Secondary outcome events by 24 months  *
11268	Diagnostic findings in patients that underwent endoscopy
11269	Resource use per patient
11270	Sensitivity analysis on costs
11271	Web table: Unit costs applied in economic analysis
11272	Symptoms, quality of life, and patients' satisfaction with management at entry, after 1 month, and after 1 year
11273	Mean  (per patient)  use of resources
11274	Incidence per 1000 person-years of cardiovascular diseases, breast cancer, and endometrial cancer during follow-up
11275	Mortality rate and sudden cardiac deaths per 1000 person-years during follow-up
11276	Estimated covariate adjusted RRs and 95% CIs for cardiovascular disease, CAD,  †   stroke morbidity and mortality, and breast and endometrial cancer morbidity according to use of oestrogen  *
11277	Age distribution of women in trial
11278	Phlebitis and thrombosis
11279	Endometrial cancer in users of oestrogen combined with cyclic-progestagen therapy: influence of number of days per month progestagen is added
11280	Duration of therapy and endometrial cancer in users of oestrogen combined with cyclic progestagen
11281	Duration of therapy and endometrial cancer in current users of oestrogen combined with cyclic progestagen
11282	Secondary outcomes
11283	Site-years of data, by decade
11284	Country-specific malaria mortality estimates for children younger than 5 years
11285	Country-specific malaria mortality estimates for individuals aged 5 years or older
11286	Country-specific malaria mortality estimates for individuals of all ages
11287	Verbal autopsy sensitivity analysis for all models
11288	Deaths by 6 months and functional outcome at 6 months
11289	Fatal and non-fatal cerebral and non-cerebral events within 7 days of randomisation
11290	Hierarchical Classification of Congenital Heart Disease
11291	Deaths in the 6 Restricted Cohorts of Patients With CHD
11292	Adjusted Mortality Rate Ratios in Subtypes of Congenital Heart Disease in 2002 to 2005 Relative to 1987 to 1990
11293	Cancer-attributed deaths in the present study and estimated national totals by age and sex in India
11294	Estimated rates of cancer mortality for main cancer sites by place of residence and sex in individuals aged 30–69 years
11295	Age-standardised mortality rates for selected cancers by education level and sex of deceased individuals aged 30–69 years for all India
11296	Age-standardised mortality ratios for main cancer sites by religion for men and women aged 30–69 years
11297	Efficacy for primary, secondary, and tertiary endpoints
11298	Frequency of selected adverse events
11299	HIV-1 RNA viral load assays used in British Columbia, Canada, 1996–2009
11300	Distribution of the highest HIV-1 RNA plasma concentrations for all individuals in British Columbia, Canada who ever had an HIV-1 RNA level in a plasma test, 1996–2009
11301	Vaccine efficacy during single-blind phase  (ATP8·5–21)  in cohort 1 by outcome
11302	Frequency of episodes per child in each group during single-blind phase  (ATP8·5–21)  in cohort 1
11303	Vaccine efficacy during complete follow-up period  (ATP2·5–21)  in cohort 1 by outcome
11304	Estimates of Effective Doses for Selected Cardiac Imaging Procedures  (in mSv)
11305	Number of Enrollees Undergoing Cardiac Imaging Procedures With Radiation Exposure, 2005–2007
11306	Number of Cardiac Imaging Procedures With Radiation Exposure  (per 1,000 Enrollees per Year)
11307	Number of Cardiac Imaging Procedures  (per 1,000 Enrollees per Year)  and Proportion of Overall Radiation Dose According to Location
11308	Annual Rates of Radiation Exposure From Cardiac Imaging Procedures  (per 1,000 Enrollees)
11309	Admission values
11310	Hospital course variables
11311	Short-term and long-term outcomes
11312	Short-term outcomes according to randomisation  (A and B)
11313	Response between day 2 and day 5 according to randomisation A
11314	Long-term outcomes according to randomisation
11315	Frequency of multi-organ dysfunction, sepsis, and survival by plasminogen-activator-inhibitor-1 genotype
11316	Age–specific and species-specific parasite rates and spleen rates in children on Aneityum, Malakula, and Futuna
11317	Malaria prevalence on Aneityum
11318	Study drug administration and treatment compliance
11319	Primary and secondary efficacy results
11320	Per-protocol analysis  (as treated, on treatment)  of primary endpoints
11321	Safety endpoints by treatment
11322	Long-Term End Points
11323	Number and distribution of DAT immunoreactive neurons
11324	Results obtained by the heparin induced platelet activation test  (HIPA) , and heparin-platelet factor 4 ELISA  (ELISA) , and the new ID-HPF4  (n=135)
11325	Individuals with mutations associated with resistance to RTIs at the time of primary HIV-1 infection
11326	Occurrence of HIV-1 variants with mutations associated with resistance to protease inhibitors
11327	Individuals with mutations associated with resistance to protease inhibitors at the time of primary HIV-1 infection
11328	Incidence of PCP and deaths among patients who stop any PCP prophylaxis after treatment with HAART
11329	Normal and abnormal inhibitory responses
11330	Inhibition of thrombin-stimulated or ionomycin-stimulated 86Rb+ efflux in platelets of patients with Alzheimer's disease and in controls
11331	Outcome measures
11332	Cluster-adjusted mean scores and differences for the primary and secondary outcomes
11333	Vocational, admission, and drop-out outcomes  †
11334	Socioeconomic sources of heterogeneity
11335	Protective efficacy of intermittent preventive treatment by age group
11336	Protective efficacy of intermittent preventive treatment according to the parasite threshold used to define a clinical attack of malaria with an intention-to-treat analysis
11337	Adverse reactions after 941 random drug administrations in three doses
11338	The prevalence of molecular markers of sulphadoxine-pyrimethamine resistance in children who received intermittent preventive treatment with sulphadoxine-pyrimethamine and artesunate or placebo before and after intervention, and at two time points in the year after treatment
11339	Outcome by treatment group
11340	Controlled trials of antimicrobial treatment of cholera in children
11341	Intention-to-treat analysis
11342	Evaluability analysis
11343	Comparison of active and placebo treatment in patients with severe Raynaud's syndrome
11344	Comparison of active and placebo treatment in healthy volunteers
11345	Short-Term Mortality Models: Bivariate and Multivariable Results
11346	Long-Term Mortality Models: Bivariate and Multivariable Results
11347	Reclassification of 30-Day Mortality Risk With Incorporation of Geriatric Conditions
11348	Primary and secondary outcomes at 6 month follow-up
11349	Self-reported changes in daily cigarette consumption, quit attempts, and changes in motivation and intention to quit in continuing smokers
11350	Subgroup analyses of 6 month outcomes
11351	Reclassification of 5-Year Mortality Risk With Incorporation of Geriatric Conditions
11352	Proportions of people who took up screening
11353	Adjusted odds for screening uptake, overall and by deprivation quintile
11354	Expected yields for different active case-finding strategies
11355	Key activities and strategies to be considered for prevention of tuberculosis transmission
11356	Administrative and environmental strategies for airborne infection control
11357	Use of treatments, procedures, and tests among patients with STEMI
11358	Estimated excess incidence of ovarian cancer in England associated with 5 years and with 10 years of hormone therapy use, starting at age 50 years
11359	Mortality after four surgical procedures, the number of procedures that occur annually, and how many would be necessary to detect poor performance with different statistical powers
11360	Proportion of surgeons who do sufficient numbers of different procedures every year to identify cases of poor performance
11361	A brief history of the political and health developments in Pakistan during the past six decades
11362	Main sources and uses of data in the assessment of health-systems performance
11363	Health expenditure in Pakistan by sources
11364	A snapshot of the challenges and opportunities in the governance of Pakistan
11365	Clinical events during follow-up
11366	Key features of MVP and AMC approaches to development and deployment of new vaccines for low-income countries and their potential for replication
11367	Death, myocardial infarction  (MI) , or both after 5 years
11368	Interventions during 5 years after randomisation
11369	Effect of treatment strategies on occurrence of death, myocardial infarction, or both at 5 years in predefined strata and subgroups and in different risk-groups
11370	Occurrence of death, myocardial infarction  (MI) , or both after 2 years and 5 years in relation to risk stratification with FRISC score
11371	Outbreak-associated strains of N meningitides serogroup C isolated in Anhui province by year  (month)
11372	Mean temperatures of water in solar cooker during study period
11373	Frequency of end-of-life decisions
11374	Angiographic Changes After Arterial Duct Stenting  (Group I)  or Modified Blalock-Taussig Shunt  (Group II)
11375	Guarani Indians living in Paraguay belonging to the Tupi-Guarani linguistic family
11376	Biochemical, molecular, and clinical features in patients with raised concentrations of octanoylcarnitine in neonatal blood spots
11377	Effect of the meningococcal vaccination campaign in Ghana
11378	Results of knowledge questionnaire
11379	Effect of video on patients with severe anxiety
11380	α1-AR mRNAs and Proteins in Human Epicardial Coronary Arteries
11381	Cardiac α1-AR Subtypes in Human, Mouse, and Rat
11382	Trial population and woman-years of follow-up
11383	Proportions of women attending for screening according to SES-2
11384	Breast-cancer mortality during 14 years of follow-up
11385	Breast-cancer mortality by SES-2 in cohort 1  (45–64 years)
11386	Diameter and Cross-Sectional Area Measured by MSCT at the Ventricular End of the CRS  ⁎
11387	Diameter and Cross-Sectional Area Measured by MSCT at the Level of the Nadir of the CRS Leaflets
11388	Diameter and Cross-Sectional Area Measured by MSCT at the Level of the Central Coaptation of the CRS Leaflets  ⁎
11389	Diameter and Cross-Sectional Area Measured by MSCT at the Level of the Commissures of the CRS Leaflets
11390	Axial Shape of the CRS at the Various Levels as Assessed Visually
11391	Distribution of patients in AT and PT groups
11392	Incomplete Apposition at the Ventricular End of the CRS Was Not Associated With Significant Aortic Regurgitation  (>Grade 2 of 4)  as Assessed by Transthoracic Echocardiography Immediately Post-Procedure  ⁎
11393	Univariate and multiple logistic-regression analysis of the three significant variables influencing outcome measures
11394	Subjective global assessment of AT and PT and the relationship between subjective global assessment and outcome measures of the treatments
11395	Distribution of population and of CABG rates across small areas of Ontario, 1992–93
11396	Correlation of appropriateness with rate by county of residence for CABG in Ontario, 1992–93
11397	Median transmission coefficients  (and 95% credible intervals)  estimated for each route of infection
11398	Updated summary ORs of outcomes of interest in US black MSM relative to other MSM for 174 studies done in 1981–2011
11399	Summary ORs of outcomes related to HIV acquisition or transmission risk across racially diverse comparative studies of young MSM  (aged 13–29 years)  and MSM diagnosed HIV positive in the USA done in 1981–2011
11400	Summary ORs of HIV infection disparities in black MSM relative to other MSM for outcomes of interest across Canadian, British, and US studies, 1981–2011
11401	Study population before and after the introduction of point-of-care CD4 testing at primary health clinics in Mozambique
11402	Results from a multivariable logistic regression analysis of the effect of independent variables on loss to follow-up before CD4 staging and initiation of antiretroviral therapy at primary health clinics in Mozambique
11403	Clinical Factors Affecting Heart Failure Survival
11404	Mortality rates
11405	Clinical features of patients with liver-related causes of death
11406	Predictive factors of liver-related death
11407	Overview of anti-H-Y responses in the female patient
11408	Mortality rates by cause, HIV-1 status, and HBsAg status
11409	Comparison of liver-related mortality by HIV-1 and HBsAg status
11410	Risk factors for liver death in individuals with HIV-1, according to HBsAg status
11411	Thrombosis risk for several concentrations of IgG against C pneumoniae
11412	Outcome at 30 Days
11413	Echocardiographic Valve Function
11414	T-cell data and viral load
11415	Summary of cell-mediated immune responses before and after DNA immunisation with HIV-1 regulatory genes
11416	Descriptive statistics for the CCG sample in 2014–15 and 2015–16
11417	Predictors of CCG performance in 2014–15
11418	Predictors of change in CCG performance between 2014–15 and 2015–16
11419	Predictors of CCG performance in 2015–16
11420	Overview of types of violence against women and girls
11421	Indicators for national, regional, and global action to address violence against women and girls
11422	An institutional history of health systems in Latin America
11423	Historical milestones for four phases of health system history in selected Latin American countries
11424	Health system type and segmentation in Latin America
11425	Paths to health system integration in Latin America
11426	Incidents of self-harm by year and sex in all prisoners in England and Wales, 2004–09
11427	Risk factors associated with the first episode of self-harm among prisoners in England and Wales during 2006–09
11428	Suicide in prison among individuals who self-harmed and for the whole prison population, by sex and year  (2004–09)
11429	Risk factors associated with suicide among male prisoners who self-harmed, 2006–09
11430	Risk factors associated with suicide among female prisoners who self-harmed, 2006–09
11431	Association between methylation at sites in HIF3A on chromosome 19 in whole-blood DNA and BMI in the discovery and replication cohorts
11432	Association between BMI and methylation at sites in HIF3A in adipose tissue and skin DNA in the MuTHER cohort
11433	Association between methylation level at cg22891070 and single nucleotide polymorphisms at the HIF3A locus
11434	Mortality models and excess mortality for total mortality
11435	Mortality models and excess mortality for NCD mortality
11436	Mortality models and excess mortality for injury mortality
11437	Organisational pluralism in the health sector of Bangladesh
11438	Distribution, sex, and number of various formal and informal health-care providers per 10 000 population in Bangladesh in 2007
11439	Prevalence of intimate partner violence within the past 12 months and in lifetime at each site
11440	Patients' experiences, knowledge, and perceptions about intimate partner violen participants' answers to specific questions
11441	Estimates of incidence  (per 1000 children per year)  and the number of episodes of severe ALRI and very severe ALRI in children younger than 5 years admitted to hospital in 2010, by WHO regions
11442	Case-fatality ratio due to severe acute lower respiratory infections in children younger than 5 years who were admitted, by region
11443	Summary of global annual predicted estimates of neonates with the HbS allele
11444	Summary of regional annual predicted estimates of HbAS and HbSS neonates
11445	Factors associated with low sexual function  (lowest quintile of gender-specific distribution)  in sexually active men
11446	Factors associated with low sexual function  (lowest quintile of gender-specific distribution)  in sexually active women
11447	Percentage of sexually active participants reporting problems with individual sexual response lasting 3 months or more in the past year, by sex and age group
11448	Potential effect of the internet on physical activity interventions  (based on effect estimates from web-based physical activity interventions and other physical activity interventions)  and the potential effect of mobile phones on physical activity interventions  (based on effect estimates from telephone-based physical activity interventions and from other physical activity interventions) , by country income
11449	Potential effect of car ownership on active travel min per day, by country income
11450	Events During Long-Term Follow-Up According to the Extent of LV Reverse Remodeling After CRT
11451	10/66 incidence wave data
11452	Incidence  (per 1000 person-years)  for 10/66 dementia, by country, site, sex, and age
11453	Directly standardised incidence  (per 1000 person-years)  for 10/66 dementia, by site
11454	Associations with incident 10/66 dementia
11455	Material goods, 1970–2010
11456	Coverage and use of health care service, 1970–2010
11457	Estimated health spending in 2006
11458	Supply of services, equipment, and human resources, 1970–2010
11459	Health financing in India and selected countries during 2005
11460	Health outputs, outcomes, and financing in 14 most populous Indian states
11461	Selected indicators for Tamil Nadu and Madhya Pradesh
11462	Contribution of National Rural Health Mission  (NRHM)  to health expenditures in states  (2007–08)
11463	Medical insurance schemes introduced by central and state governments
11464	Adults  (15–99 years)  diagnosed with colorectal, lung, breast  (women) , or ovarian cancer between 1995 and 2007 and followed up to Dec 31, 2007
11465	Age-standardised relative survival  (%)  at 1 and 5 years, and 5-year survival conditional on survival to the first anniversary of diagnosis
11466	Study Population  (n = 45)
11467	Intraoperative Findings in 29 Patients With Definite Infective Endocarditis
11468	Diagnostic Performance of CT
11469	Prevalence of CAD in All Patients and Valvular Stenosis/Insufficiency in Patients Who Underwent Surgery
11470	Age-standardised mean years of education  (95% uncertainty intervals)  for men and women aged 25 years or older, by country, for 1970, 1990, and 2009
11471	Changes in educational attainment between 1970 and 2009 for men and women aged 25–34 years in the world's most populous countries
11472	Coefficients from first-differences model for the effect of income per person, education of women of reproductive age  (15–44 years) , and HIV prevalence on child mortality between 1970 and 2009
11473	Results of counterfactual analysis of the effect of education in women of reproductive age, income per person, and HIV on child mortality by use of 1970 as the year of comparison
11474	Results of counterfactual analysis of the effect of education of women of reproductive age, income per person, and HIV on child mortality rate by use of 1990 as the year of comparison
11475	Cumulative probability of survival during first 10 years of life according to age at the start versus end of the cohort and survival of mother
11476	Cumulative probability of survival in the first 10 years of life according to age at start versus end of the cohort and survival of the father
11477	Age-specific death rates in children according to survival status of the mother
11478	Age-specific death rates in children according to survival status of the father
11479	Causes of death in children according to age group and survival status of the mother during 1987–2005
11480	Age-specific death rates in children according to sex of child and survival status of the mother
11481	Age-specific death rates in children according to sex of child and survival status of the father
11482	Causal effect of rolling out Seguro Popular on the reduction in the number of households suffering catastrophic health expenditures
11483	Causal effect of Seguro Popular on the self-reported out-of-pocket health expenditures
11484	Causal effect of Seguro Popular on utilisation of medical procedures and preventive care
11485	Effect of privatisation on adult male standardised mortality rates, 1989–2002
11486	Effect of privatisation on log male unemployment rates, 1991–2002
11487	Effect of unemployment on age-standardised mortality rates in working-age men, 1991–2002
11488	Path analysis of the effect on log adult male mortality rates in the former Soviet Union, 1991–2002
11489	PVR  (n = 137) : Mean Treatment Effect in Patients With or Without Previous PEA  ⁎
11490	Change in total adult male standardised mortality rates and the amount of privatisation and unemployment in post-communist countries from 1991 to 1994
11491	6MWD  (n = 140) : Mean Treatment Effect in Patients With or Without Previous PEA  ⁎
11492	Placebo-Corrected Treatment Effect of Bosentan in Hemodynamic Secondary End Points, All-Randomized Analysis Set
11493	Multivariate regression model testing the independent effect of socioeconomic components, involuntary admissions, organisational changes, and prominence of outpatient services, on the regional variation in suicide risk
11494	Effects of Tolvaptan on Hemodynamic Parameters
11495	Empirical studies of programme sustainability for low-income and middle-income countries, and disadvantaged populations in high-income countries
11496	Empirical studies of programme sustainability in high-income countries sustained for 2 years or more after the initial funding period
11497	Reviews of multiple programmes and factors relating to sustainability
11498	Association of four SNPs with uric acid concentration and gout
11499	Exposures related to the H5N1 cases and case fatality in Indonesia
11500	Clinical presentation during first 2 days of onset of human H5N1 virus infection cases in Indonesia  (n=108)
11501	Clinical and laboratory features on hospital admission of human H5N1 virus infection cases in Indonesia
11502	Factors associated with H5N1 case fatality in Indonesia, 2005–07
11503	CPR and post-CPR variables in the extracorporeal CPR group and the conventional CPR group
11504	Outcome of the extracorporeal CPR group and conventional CPR group
11505	Multivariate Cox regression analysis for the factors associated with the survival to hospital discharge
11506	Difference between effect of atole compared with fresco supplementation during different age ranges on income measures
11507	ECG Parameters in Those Patients Who Underwent the Pharmacological Test: Values Before and After Administration of the Sodium-Blocker
11508	Variables Related to the Occurrence of Cardiac Events During Follow-Up in the Entire Population  (Cox Regression Model)
11509	Pooled analyses of data from the British Doctors Aspirin Trial and the UK-TIA Aspirin Trial on the effect of randomisation to a period of treatment with aspirin on the incidence of common cancers during a median of 23 years of follow-up
11510	Incidence of colorectal cancer in all patients in the UK-TIA Aspirin Trial and the British Doctors Aspirin Trial stratified into 10-year follow-up periods
11511	Hazard ratios  (95% CI)  for incidence of colorectal cancer in a pooled analysis  (stratified by trial)  of data from the British Doctors Aspirin Trial and the UK-TIA Aspirin Trial of long-term follow-up after the scheduled trial treatment period, stratified into 5-year periods after randomisation
11512	Relationship Between On-Treatment LDL-C Levels and Incident Cancer
11513	Preventives tried without sustained improvement and doses  (total mg per day)
11514	Transitional treatments tried for cluster headache and responses
11515	Responses to abortive drugs before implantation
11516	Follow-up for main outcomes
11517	Patients' estimates of cluster frequency, severity, and duration of attacks before and after use of stimulator
11518	Settings used for occipital nerve stimulation
11519	Complications
11520	Success of Different Techniques of LAA Closure
11521	Variables That Are Related to Successful LAA Closure
11522	Allocation factors used to apportion integrated and disease-specific funds to maternal, newborn, and child health
11523	Worldwide ODA to maternal, newborn, and child health by broad purpose, type, and source of aid flow
11524	Worldwide ODA to maternal, newborn, and child health by donor
11525	Worldwide ODA to maternal, newborn, and child health by aid modality and purpose of project
11526	Aggregate and per child ODA to maternal, newborn, and child health by WHO region
11527	Aggregate and per child ODA to maternal, newborn and child health, under-5 mortality rates  (per 1000 livebirths) , and maternal mortality rates  (per 100 000 livebirths)  in the 60 priority countries
11528	Number of court cases per country
11529	Main arguments quoted in unsuccessful cases  (n=12)
11530	Suicide rates and standardised mortality ratios by age and sex
11531	ACC/AHA Heart Failure Performance Measures ICD-9-CM Diagnosis Codes
11532	Hospitalization Rates  (per 100,000)  for Heart Failure as the First-Listed Diagnosis or as Additional  (2nd to 7th)  Diagnosis by Age and Gender, 1979 and 2004: National Hospital Discharge Survey
11533	Clinical Outcomes of Follow-Up Cohort With LVSD by Beta-Blocker Treatment Group: Unadjusted
11534	Effect of Beta-Blocker Treatment Group on All-Cause Mortality and Death/Rehospitalization at 60 to 90 Days After Discharge: Risk- and Propensity-Adjusted Analyses
11535	Echocardiographic and Catheterization Variables Before Fontan
11536	Operative and Post-Operative Courses at Fontan
11537	Independent Risk Factors at S1P for Death Through Fontan Completion  ⁎
11538	ACC/AHA Indications by Clinical Subgroup
11539	Criteria for Normal and Abnormal ECGs
11540	Univariate Predictors of ECG Abnormalities in American Professional Football Players
11541	Multivariable Predictors of ECG Abnormalities in American Professional Football Players
11542	Hemodynamic Data
11543	Clinical Outcomes at 30 Days
11544	Clinical Outcomes at 30 Days According to Consistent Therapy on UFH Versus Switch From UFH to Bivalirudin
11545	Clinical Outcomes at 30 Days According to Consistent Therapy on Enoxaparin Versus Switch From Enoxaparin to Bivalirudin
11546	Definition of the RAP Score
11547	Pre-Natal Classification of Cases and Prediction of Post-Natal Surgical Pathway Versus Actual Route and Current Status
11548	Inter- and Intra-Observer Variability of TV and PV and RV Length
11549	Classification Quality of the Predictive Scores, Showing the Proportion of Fetuses Assigned Correctly to a BV or UV Circulation
11550	Underlying Diseases and Causes of Death of Individual Patients Who Died
11551	Multivariate Cox Regression Analysis of Hazard Ratio of Key Risk Variables
11552	Per-Segment Analysis of DSCT for the Detection of Coronary Stenoses
11553	Per-Vessel Analysis of DSCT for the Detection of Coronary Stenoses
11554	Per-Patient Analysis of DSCT for the Detection of Coronary Stenoses
11555	Global Biventricular Function
11556	Segmental Myocardial Function
11557	Mode of Cardiac Death
11558	Causes of Sudden and Cardiovascular Deaths
11559	Observed and Expected Causes of Deaths Unrelated to Congenital Heart Defect
11560	Temporal Trends in Coronary Revascularization, by Type, in Olmsted County, 1990 to 2004
11561	Lifetime Number and Pattern of Revascularizations Among Olmsted County Residents  ⁎
11562	Diagnostic Performance and Predictive Value of DSCT Coronary Angiography for the Detection of Significant  (≥50%)  Stenoses
11563	Influence of Agatston Score on Diagnostic Accuracy of DSCT Coronary Angiography  (a Segment-Based Analysis)
11564	Influence of Heart Rate on the Diagnostic Accuracy of DSCT Coronary Angiography  (a Segment-Based Analysis)
11565	Diagnostic Performance and Predictive Value of DSCT Coronary Angiography for the Detection of Significant  (≥50%)  Stenoses in Patients With Atypical Angina, Typical Angina, or Unstable CAD
11566	Clinical Outcomes
11567	Subject Medical History
11568	Procedure Summary
11569	Number of Subjects by Category of Major Adverse Events, Successful Device Delivery, or Surgical Closure Events Reported Through 12-Month Follow-up
11570	Residual Defect Status: Final Echo Core Lab Review
11571	Clinical Success End Point
11572	Propensity Score Analysis: Clinical Success
11573	Procedures Prior to the Ross Operation
11574	Predictors of Neo-Aortic Root Outcomes
11575	Neo-Aortic Reintervention
11576	Documented Contraindications to Acute Medical Therapies
11577	In-Hospital Treatments Among Patients Without Contraindications
11578	In-Hospital Outcomes
11579	Odds Ratio of In-Hospital Mortality According to Acute Therapy Received Among Patients Age ≥75 Years
11580	Multivariable Analysis of Admission Features Associated With In-Hospital Mortality Among the Older Elderly  ⁎
11581	Percentage of Patients With Atrial Fibrillation Taking Anticoagulation by Time Period and Age Group
11582	Procedural Angiographic Results and In-Hospital Clinical Events
11583	Angiographic and IVUS Outcomes at Eight Months
11584	Clinical Events at Nine Months
11585	Survival time and attack rate in mice inoculated with RML scrapie strain and treated with CpG oligodeoxynucleotides, and in controls
11586	Exposure to UV light derived from questionnaire responses
11587	Relation between Ep-CAM overexpression and clinical and tumour factors
11588	Efficacy of NE-1530 in prevention of acute otitis media
11589	Nasopharyngeal carriage of pathogen bacteria
11590	Model parameters, data sources, and values used in models
11591	Cumulative new AIDS cases and HIV-positive births, and life expectancy in 2005
11592	Modelled total costs, proportion per person health- care expenditure, and cost per life-year gained required to finance antiretroviral use, by scenario
11593	Outcomes at 30 Days and 1 Year in PCI Patients With or Without Nonsignificant LMCAD
11594	Crude Outcomes of the Total Cohort, by Subsequent Treatment
11595	ITT analysis of malaria infection prevalence by main effect and for each individual intervention at 4, 9, 16, and 21 months after intervention
11596	ITT analysis of anaemia prevalence by main effect and for each individual intervention at 4, 9, 16 and 21 months after intervention
11597	Entomological outcomes by intervention  (PBO LLIN vs no PBO LLIN, and IRS vs no IRS)  in 2015 and 2016
11598	Estimates of Self and Peer Life Expectancies in Years for Patients With Congenital Heart Disease  (CHD)  and a Comparison Sample of Undergraduates
11599	Significant Univariate Correlates of Shorter Life Expectancy Among Patients With Congenital Heart Disease
11600	Multivariate Logistic Regression Predicting Shorter Perceived Life Expectancy Among Patients With Congenital Heart Disease  (CHD)
11601	Medications affecting weight gain and alternative approaches
11602	Medications for weight management with mechanism of action, availability, and dosing
11603	Surgical procedures for treatment of obesity
11604	Follow-up of clinical events for up to 5 years
11605	Predicted change in odds of coverage by intervention
11606	Predicted change in coverage of interventions in 74 Countdown countries by 2020, 2025, and 2035
11607	Number of Countdown countries achieving different under-5 and neonatal mortality rates in 2010 and projected for 2035
11608	Procedural results
11609	Clinical outcomes at 12 months
11610	Source and Characterization of Primary Antibodies
11611	Circumferential Nerve Densities at the PV-LA Junction
11612	Effect of Age and Left Ventricular Hypertrophy on Structural Features and Autonomic Nerve Density
11613	Use of antiplatelet and antithrombin medications at discharge
11614	Incidence of clinical outcomes at 3 years according to Kaplan-Meier estimates
11615	Measures of the response to HIV in injecting drug users in six selected countries: an assessment matrix, 2008–10  3,4,20
11616	Procedural results
11617	Clinical outcomes
11618	Stent thrombosis
11619	Angiographic follow-up results
11620	Absolute and Relative Reductions in Target Vessel Revascularization at 8.5 Months and 1 Year
11621	Two-way frequency table on the agreement between the sumSTR and maxSTE risk groups
11622	Mortality rates by risk groups and areas under the ROC curve to compare the power to predict mortality by sumSTR and maxSTE
11623	Causes of death at 30 days by risk groups
11624	30-day cardiac mortality rates by risk groups in selected subsets of patients known to be at generally higher mortality risk
11625	Proportion of patients with various TIMI flow grades 90 min after start of streptokinase infusion related to the three groups of ST segment recovery
11626	Atrial Fibrillation Study Cohorts and Treatment Strategies
11627	Incremental Cost-Effectiveness Ratios  (ICER)  in Base-Case Estimates, Stratified by Ischemic Stroke Risk
11628	Multivariable Sensitivity Analyses
11629	Between-group comparison for changes over time in gross motor function
11630	Between-group comparison for changes over time in working memory and attention
11631	Mean Values of Cardiovascular Risk Factors at the Time of Menopause
11632	Between-group comparison for speech and language  (non-parametric tests)
11633	Relationship Between Premenopausal Cardiovascular Risk and Age at Menopause by Linear Regression Analysis
11634	Paediatric evaluation of disability inventory  (PEDI)
11635	Effect of Premenopausal Increasing or Decreasing Cholesterol Level, Relative Weight, and Blood Pressure
11636	Initial Clinical Presentation
11637	Quantitative Angiography in 59 Patients and 79 Mesenteric Arteries
11638	Overall Survival and Clinical Events of 58 Patients With Initial Angiographic Success
11639	ORs  (95% CI)  for stroke, VTE, or AMI associated with current use of therapeutic progestagens relative to non-users of any type of SHCs
11640	Effectiveness estimates
11641	Resourse use and cost per patient treated  (UK£, 1998)
11642	Cost-effectiveness of brief GP counselling plus nicotine-patch treatment, incremental to brief GP counselling alone
11643	Sensitivity analysis of incremental cost per life year saved by nicotine-patch treatment versus brief counselling alone for the 35–44 years group
11644	Bivariate Predictors of All-Cause Mortality Against SV/PP
11645	Mortality rates in all patients
11646	Mortality in all patients stratified by minimum CD4 lymphocyte count
11647	Mortality rates by treatment regimen in patients with minimum CD4 count of 200/mL or lower
11648	Clinical model for predicting pretest probability for deep-vein thrombosis
11649	Prevalence of venous thromboembolism initially and on follow-up, according to pretest probability of deep-vein thrombosis derived by the clinical model
11650	Scoring system for mild-to-moderate or severe post-thrombotic syndrome
11651	Causes of death in people diagnosed with hepatitis B, hepatitis C, or hepatitis B and C co-infection in NSW 1990–2002 by ICD-10 code  *
11652	PR Interval for AOO Mode With Shortened PR Interval With CDOO and BDOO Mode, Pacing Order for Each Patient
11653	Causes of death related to viral hepatitis in NSW 1990–2002 by ICD-10 code
11654	QRS Duration, Systolic Blood Pressure, and Cardiac Index  (Calculated by Assumed Oxygen Consumption)  for the Three Different Pacing Modes
11655	Tissue Doppler-Derived Strain Rate Data for the Three Different Modes of Pacing
11656	Anti-HBs concentrations  (IU/L)  in children and recruits vaccinated more than 10 years previously
11657	Anti-HBs concentrations at 2 weeks after booster vaccination in children with non-protective antibody concentrations at enrolment
11658	Anti-HBs concentrations at 2 weeks after booster vaccination in recruits with non-protective antibody concentrations at enrolment
11659	Anti-HBs response after a second full course of vaccination according to anti-HBs concentrations elicited after first booster injection
11660	Clinical findings
11661	Hepatobiliary pathology
11662	Liver function tests
11663	Mean choline/creatine ratios  (SD)  from the basal ganglia and white matter
11664	Titres from seven HBeAg-positive neonates and their mothers
11665	COMPANION Follow-Up Hospital Admissions by Treatment Group and Modeled Cost of Admission
11666	Additional Base Case Model Parameters
11667	Preference Weights  (Utilities)  Derived From Minnesota Living With Heart Failure Questionnaire  (MLHFQ)
11668	Costs and Survival at Selected Time Points Over the Modeled Treatment Episode  ⁎
11669	Summary Results of Cost-Effectiveness Analysis  (Base Case)
11670	Results of One-Way Sensitivity Analysis
11671	Standardised mortality rates for liver cirrhosis at all ages per 100 000 per year
11672	Comparative mortality ratios for liver cirrhosis, 1997–2001 relative to 1987–1991, by age-group
11673	Liver cirrhosis age-standardised mortality rates per 100 000 in England and Wales and in Scotland
11674	Mortality and prevalence of malnutrition among civillian population in Bahr El Gazal, southern Sudan, 1998
11675	Global Lipid Genetic Consortium 12-SNP LDL-C gene score calculation
11676	Outcome data in Whitehall II controls according to weighted LDL-C gene score deciles
11677	Examples of international collaboration and research design
11678	Perceived barriers and solutions to improved collaboration in surgical research
11679	Predictors for Emergency Coronary Artery Bypass Grafting During the Pre-Stent Era  (1979 to 1994)
11680	Predictors for Emergency Coronary Artery Bypass Grafting During the Stent Era  (1995 to 2003)
11681	Cause of Death and Indication for Bypass Surgery in 41 Patients With In-Hospital Death After Emergency Surgery
11682	Determinants of aid, year of data, and source of data
11683	Worldwide official development assistance to maternal, newborn, and child health by source of aid flow, 2003–06
11684	Worldwide official development assistance to maternal, newborn, and child health by type of aid and purpose of projects between 2003 and 2006
11685	Worldwide official development assistance to maternal, newborn, and child health by donor between 2003 and 2006
11686	Aggregate official development assistance to maternal, newborn, and child health, to child health per child, and to maternal and newborn health per livebirth in 2005 and 2006, and percentage change for the two categories between 2003 and 2006
11687	OLS estimation of log  (official development assistance)  to child health per child between 2003 and 2006
11688	OLS estimation of log  (official development assistance)  to maternal and newborn health per livebirth between 2003 and 2006
11689	Effect of new versus standard antibiotic on febrile morbidity in four age strata and overall
11690	Interim stopping levels  (p values)  for different numbers of planned interim analyses by group sequential design  14,15
11691	Standardised and crude mortality rates  (including organ transplantation) by genotype
11692	Standardised mortality rates  (including transplantation)  as deaths by CFTR functional class
11693	Comparison of low-risk and high-risk clinical examination with low-risk and high-risk final diagnosis
11694	Comparison of low-risk and high-risk examinations with OAR
11695	Associations of FEV0·4 and MEF25 with sex, body length, maternal smoking, and cystic fibrosis using multiple linear regression
11696	Overview of serious adverse events
11697	Laboratory data for patients studied
11698	Enzyme activities in patients with WD and control groups
11699	Number of interventions during labour in women with delivery details available
11700	Neonatal outcome
11701	Details of deliveries for 100 neonates with arterial cord pH <7·15
11702	Profile of pregnant patients
11703	Fatty-acid profiles of poppyseed and rapeseed oils
11704	Right Ventricular Function Before and After Pulmonary Valve Replacement
11705	Physicochemical properties of iodised oils
11706	Thyroid hormone indices
11707	Cost implications of mandatory drugs tests: cost generating events
11708	Establishment of 500 inmates: cost per month of mandatory drugs testing
11709	Prisons' need for resources
11710	Hemodynamic Effects of SNS During Sinus Rhythm and Ventricular Pacing
11711	Effective Refractory Periods During SNS
11712	Depolarization and Repolarization Parameters During SNS
11713	5 year all-cause mortality in all patients and according to disease type
11714	Key features of includes trials
11715	Adjusted relative rates of clinical outcomes in each risk group
11716	Diagnostic Accuracy of Coronary MSCT Compared to QCA for Detection of Lesions >50% in Patients
11717	The Effect of Coronary Calcification on Diagnostic Accuracy of Coronary MSCT Compared to QCA
11718	The Effect of Obesity on Diagnostic Accuracy of Coronary MSCT Compared to QCA
11719	The Effect of Heart Rate on Diagnostic Accuracy of Coronary MSCT Compared to QCA
11720	Diabetes prevalence by age-group and sex in 1995, 2000, and 2005
11721	Changes in diabetes prevalence by age-group and sex from 1995 to 2000, 2000 to 2005, and 1995 to 2005
11722	Diabetes incidence by sex and age–group, 1997 and 2003
11723	Death rates per 1000 in prevalent diabetes cases by age-group in 1995, 2000, and 2005
11724	Children with first operative procedures by year of observation
11725	Children with first operative procedures by time of screening and screening results  *
11726	Ultrasonography before age 8 weeks
11727	Hip management up to 2 years of age
11728	Hip status by age 2 years
11729	Measurements Before Replacement of the Tricuspid Valve
11730	Primary outcomes stratified by laterality, level of clinical suspicion, and clinical diagnosis at trial entry
11731	Measurements After Replacement of the Tricuspid Valve
11732	Mean resources used per patient, and mean total costs
11733	Measurements After One Month in Animals From Group 2
11734	Reperfusion therapy by geographic region
11735	Reperfusion therapy according to type of hospital
11736	Reperfusion therapy in subsets of patients
11737	Multivariate correlates of failure to receive reperfusion therapy
11738	Odds ratios for atopic diseases
11739	Incidence ratios of atopic dermatitis
11740	Catalase activities of Hungarian acatalasaemic, hypocatalasaemic, and normocatalasaemic first-degree relatives.
11741	Frequency of diabetes mellitus in Hungarian acatalasaemic and hypocatalasaemic individuals compared with normocatalasaemic relatives and a sample of the Hungarian population
11742	Prospective studies included in meta-analysis
11743	Relative risk of in-hospital mortality after myocardial infarction in patients with hyperglycaemia on admission compared with patients without hyperglycaemia
11744	Relative risk of pump failure after myocardial infarction in patients with hyperglycaemia on admission compared with patients without hyperglycaemia
11745	Populations included in the prospective mortality analysis of the DECODE study
11746	Classification of diabetes and glucose intolerance according to ADA fasting and WHO 2 h glucose criteria
11747	Hazard ratios for death  (95% CI)  adjusted for age, sex, and study centre, according to the fasting glucose and 2 h glucose classifications in individuals not known as diabetic
11748	Sex-specific estimated absolute number of excess deaths for individuals not diagnosed as having diabetes
11749	Geometric Dimensions of the Implanted Bioprostheses  (mm)
11750	Preoperative Data
11751	Operative Data
11752	Hemodynamic Results Grouped by Valve Type and Aortic Annulus Diameter
11753	Incidence of Patient-Prosthesis Mismatch Grouped by Aortic Annulus Diameter
11754	Hemodynamic Results Grouped by Aortic Annulus Diameter and PPM
11755	T-cell stimulation index  (mean [SD])  to different antigens in people studied
11756	Pandemic excess mortality calculations, based on vital registration data from 1918–20
11757	Results from two ordinary least squares regression models on the log of the pandemic excess mortality rate 1918–20 for countries with complete vital registration data
11758	Estimated number of deaths caused by the emergence of a pandemic influenza strain in 2004
11759	What Thai teenagers remember being taught in sex education classes
11760	Attitudes of Thai parents towards teaching children about sex
11761	Effect of Increasing Voltage Applied to the Autonomic Ganglia on Sinus Rate
11762	Fewest Number of APDs Required to Induce AF Without and With Voltage Applied to the AG
11763	Recommended qualitative descriptions with EU assigned frequency bands, and participants' estimates from the pilot study
11764	Estimates of probability and Likert scores  (1–6) , in response to the terms “very common” and 15%, by age-group
11765	Mean  (SD)  [11C] (R) -PK11195 binding potential
11766	Patients’ Clinical and Surgical Data
11767	Lipids, total homocysteine, and associated factors before and after 6 weeks of treatment with gemfibrozil or micronised fenofibrate in 22 men
11768	Doppler Echocardiographic Findings
11769	Health spending, health spending by source, and growth, 2015–40
11770	Three scenarios of pooled health spending, UHC index, and covered lives in 2030
11771	Average annual increases of development assistance for health by focus area
11772	Site-years of population-based cancer registry data, vital registration, and verbal autopsy data for breast and cervical cancer, 1980 to 2010
11773	The cumulative probability of breast and cervical cancer incidence for individuals aged 15–79 years
11774	Deaths from breast and cervical cancer by region and age group, 2010
11775	The cumulative probability of breast and cervical cancer death for individuals aged 15–79 years
11776	Stent Implantation and Procedural Results of Patients With LAD Lesions
11777	Clinical Outcomes After Stent Implantation in LAD Lesions
11778	Angiographic Results at Nine-Month Follow-Up of Patients With LAD Lesions
11779	Results Among Randomized Patients With Lesions in the Proximal LAD
11780	Comparative Results of Bare Metal Stent Implantation Among the Three Coronary Arteries
11781	Comparative Results of Paclitaxel-Eluting Stent Implantation Among the Three Coronary Arteries
11782	Response rate by method of contact attempted
11783	Response rates for individuals who were sent questionnaires
11784	Previous deployments
11785	Potentially traumatic experiences on last deployment
11786	Distribution of main outcomes by original cohort
11787	Relation between health outcomes and deployment stratified by regular/reservist status
11788	Distribution of main outcomes after reassigning Era participants to Iraq war group if they had served in subsequent TELIC deployments  (regulars only)
11789	Effect of date of deployment on mental health outcomes  (regulars only)
11790	Effect of combat on health  (regulars in Iraq war group only)
11791	Psychiatric morbidity by time elapsed  (months)  since end of last TELIC deployment  (regulars deployed to Iraq war only)
11792	Psychological symptoms of asylum seekers still detained and those released at follow-up
11793	Variation in lifetime prevalence of abuse in studies of gynaecology and obstetric patients
11794	Prevalence of emotional abuse and current effects
11795	Prevalence of physical abuse and current effects
11796	Prevalence of sexual abuse and current effects
11797	Prevalence of lifetime emotional, physical, or sexual abuse
11798	Babies with probable group B streptococcal infection
11799	End Points in Patients With and Without New-onset Atrial Fibrillation
11800	Univariate Predictors of New-Onset Atrial Fibrillation
11801	Multivariate Predictors of New-Onset Atrial Fibrillation
11802	Variances  (bold, diagonal) , covariances  (below diagonal) , and correlations  (italics, above diagonal)  between general health questionnaire  (GHQ) , depersonalisation  (DP) , emotional exhaustion  (EE) , and personal accomplishment  (PA) , at time1  (1997)  and time2  (2000)
11803	Proportion of children with symptoms at enrolment and on days 1 and 2
11804	Age and proportion of adults among contact cases and primary cases by place and vaccination coverage in the pertussis study, France, 1993–94
11805	Patient Data and Results of Broad-Beam Spectral Doppler and Magnetic Resonance Imaging Measurements
11806	Prevalence of stress as measured by GHQ in doctors
11807	Low-birthweight births, stillbirths, and sex ratio  (1981–91)  and fetal abnormality rates  (1986–93)
11808	Targets and realities
11809	Cost of family planning and reproductive health services
11810	Impact of selecting cost-effective family planning services assuming current 70% contraceptive prevalence
11811	Mortality after 13 years according to quartile of physical fitness at survey 2  (PF2)
11812	Relative risks of all-cause and cardiovascular mortality among 1428 apparently healthy men of survey 2 during 13 years' follow-up
11813	Safety and Efficacy Outcomes Derived From Acutely Successful Patients at 3-, 6-, and 9-Month Follow-up *
11814	Changes in physical fitness from survey 1  (PF1)  to survey 2  (PF2)  and changes in all-cause mortality
11815	Relative risk of all-cause mortality during 13 years' follow-up associated with variables measured at survey 2, with both age-adjusted PF1 and log  (PF2/PF1)  in the model
11816	Acute Measurements of Ventricular Pacing or Defibrillation Leads WithCurrent of Injury
11817	Acute Measurements of Ventricular Pacing or Defibrillation Leads WithoutCurrent of Injury
11818	Acute Measurements of Atrial Pacing Leads With Current of Injury
11819	Acute Measurements of Atrial Leads Without Current of Injury
11820	Changes in Heart Rate Variability and Heart Rate Turbulence Before Spontaneous Onset of AF
11821	Changes in R-R Dynamics Before Spontaneous Onset of AF
11822	Laboratory findings in study group and controls
11823	Total costs in the treatment groups by 12 months of follow-up
11824	Total costs per patient by 12 months of follow-up
11825	Blood chemistry values during CPR and rewarming
11826	Univariate Predictors of Cardiac Death
11827	Changes in haemodynamic and metabolic indices
11828	Ages, BMI, and Concomitant Coronary Artery Bypass, LV to Aortic PSG, and AV Areas in Seven AV Weight Groups in Men and Women
11829	Mean responses over first 3 min for swims at 25°C, 18°C, and 10°C
11830	Ages, BMI, Concomitant Coronary Bypass, and AV Weights in Men Versus Women According to AV Structure
11831	Mean values for physiological and physical measures for three 90 min swims
11832	Gender, BMI, Concomitant Coronary Artery Bypass, AV Weights, LV to Aortic PSG, and AV Areas in Three Age Groups
11833	Gender, Ages, Concomitant Coronary Artery Bypass, AV Weights, LV to Aortic PSG, and AV Areas in Three BMI Groups
11834	Ages, BMI, AV Weights, LV to Aortic PSG, and AV Areas in Patients Without Versus Patients With Concomitant Coronary Artery Bypass Grafting
11835	Gender, Age, BMI, Concomitant Coronary Artery Bypass, AV Weights, LV to Aortic PSG, and AV Areas in Three Ejection Fraction Groups
11836	Clinical Findings on 13 Patients With Moderate or Severe AR
11837	Independent determinants of rates of major obstetric interventions in rural Guéckédou, 1988–96
11838	Classification of samples in training cohort according to proteomic pattern
11839	Class prediction of samples in test cohort according to proteomic pattern
11840	Responders  (n = 59)  Versus Nonresponders  (n = 21) , Clinical and Echocardiographic Variables Before and After Six Months CRT
11841	Effects of high and low sympathetic activity  (induced by maximum whole-body cooling and warming)
11842	Relation between tuberculin skin-test response and variables related to household contact
11843	Relation between tuberculin skin-test response  (induration ≥5 mm)  and variables related to the index patient and the household setting
11844	Multivariate analysis of the relation between the tuberculin response  (induration >5 mm)  and variables related to the household contact, index case, and the household
11845	Multivariate analysis of the relation between the tuberculin response  (induration ≥5 mm)  and variables related to the housegold contact, index case, and the household, among household contacts 2–15 years of age
11846	Respiratory score used by parents to complete the symptom diary
11847	7-day day-time and night-time symptom score and daily uses of salbutamol
11848	Comparison of binary outcomes
11849	Patients' details
11850	Self-treatment regimens in the intervention group
11851	Number of relapses in each group
11852	Economic outcomes
11853	Time-Adjusted Radiation Exposure  (mGy × cm2/s)  to an Alderson-Rando Phantom in Dependency on Tube Angulation *
11854	Mean Operator Radiation Exposure  (μSv/h)  During Fluoroscopy at a Rando Phantom as a Function of Tube Angulation *
11855	Dose-Corrected Operator Scatter Exposure  (μSv/Gy × cm2)  During Fluoroscopy as a Function of Tube Angulation *
11856	Pneumocystis carinii  dihydropteroate synthase  (  DHPS  )  genotypes detected in patients with confirmed  P carinii  pneumonia by initial treatment regimen
11857	Occupational Operator Dose Reduction by Less Irradiating Tube Angulations in Invasive Cardiology
11858	Risk of poor outcomes by initial treatment and by genotype
11859	Distribution of 74 white Australian and 92 Japanese women by age and percentage oestrogen receptor a positive cells in normal breast tissue
11860	Association of percent of oestrogen receptor α positive cells in normal breast tissue with origin of the tissue from white Australian and Japanese women, after age
11861	Reasons for withdrawals
11862	Intention-to-treat analysis of serum creatinine, increase in serum creatinine, and creatinine clearance at 24 months or at time of dropout
11863	Odds ratios  (95% CI)  of ischaemic, haemorrhagic, and all strokes in relation to type of current oral contraceptive used compared with non-users
11864	Model Input Variables
11865	Mortality and Morbidity Rates by Age With Various Operations From the STS National Database, 1995–2000
11866	Absolute Differences in Quality-Adjusted Survival  (in Months)  Across Peak Aortic Valve Gradient  (Rows) and Ages  (Columns)
11867	CAC Scores and CAC Prevalence by Ethnicity and Gender
11868	OR  ⁎  of Positive CAC by Risk Factors
11869	Summary Statistics by CAC Classification  ⁎
11870	Echocardiographic Protocol
11871	Distribution of Relative Pairs Entering the Analysis
11872	Relative risk of incident Alzheimer's disease associated with use of oestrogen during postmenopausal period
11873	Duration of oestrogen use
11874	Randomised trials of ovarian ablation or suppression versus control that began before 1990
11875	Patients' data
11876	Additional Surgical or Transcatheter Interventions in Patients Undergoing Bidirectional Superior Cavopulmonary Anastomosis
11877	Distribution of variables at routine and interim visits
11878	Risk of parasitaemia and clinical malaria at routine visits by HIV serostatus, CD4-cell count, and WHO stage
11879	Rates of all interim visits and interim vists with clinical malaria, and risk of clinical malaria at interim visits by HIV serostatus, CD4-cell count, and WHO stage
11880	Attack precipitants in 200 patients
11881	Composition of synthetic UK
11882	Estimates of the effect of the QOF on age-adjusted and sex-adjusted mortality per 100 000 population
11883	Multivariate Predictors of Restenosis for PCI of Allograft Coronary Disease
11884	The Era Effect on PCI of Allograft Coronary Disease
11885	Electrocardiogram, echocardiography, Holter test, and exercise stress-test findings in first-degree relatives of SADS victims
11886	Fatty-acid composition of capsules used
11887	Effects of dietary-oil treatment on the fatty-acid composition of LDL lipid fractions
11888	Fatty-acid composition of carotid-plaque lipid fractions in different oil treatment groups
11889	Carotid-plaque morphology in different oil treatment groups
11890	N-3 polyunsaturated fatty-acid content of carotid-plaque lipids according to AHA classification and macrophage  (anti-CD68)  staining intensity
11891	T lymphocyte and macrophage staining in carotid plaques from patients in different oil treatment groups
11892	Association of APOE ɛ 2/ɛ3/ɛ4 genotype with myocardial infarction  (MI)  risk
11893	Risk of myocardial infarction  (MI)  in cigarette smokers versus non-smokers by APOE genotype
11894	Mortality rates by quartiles of cholesterol
11895	Cox proportional hazard models for association
11896	Relative risk for mortality based on change in cholesterol between examinations three and four
11897	Presence and extent of MRI hyperenhancement for patients with healed infarction
11898	Effect of treatment with folic acid plus vitamin B6 on occurrence of abnormal test results
11899	Effect of 2-year treatment with folic acid plus vitamin B6 on main outcome variables in 158 healthy individuals
11900	Linear Regression Coefficient and Intraclass Correlation Coefficient Between Noninvasive Methods  (Averaged Value of Two Observers' Measurements)  and Gorlin Estimated MVA in Both Centers
11901	Mitral Score as Assessed by Two Independent Observers by 2D and RT3D
11902	Muscular signs and symptoms in 127 carriers of Duchenne and Becker muscular dystrophy
11903	Dilated cardiomyopathy and left-ventricle dilation in DMD/BMD carriers
11904	Affected muscle groups in 22 carriers with muscle weakness
11905	Number of patients with each important outcome by degree of stenosis and treatment allocation
11906	Causes of death
11907	Surgical operations and adverse events from trial surgery
11908	Frequency  (%)  of major outcome events among patients with 80–100% symptomatic carotid stenosis
11909	Results from Cox proportional-hazards model of major stroke or death from any cause
11910	Variables associated with risk of all-cause and CVD mortality in Cox proportional-hazards regression  (full model)
11911	Criteria for Interventional Procedural Success
11912	Indications for Early Post Operative Catheterization
11913	Major Diagnostic Groups, Surgical and Catheterizations Procedures Performed
11914	Interventional Procedures Performed
11915	Angioplasty/Stent Sites Involving Suture Lines
11916	Hazard ratios for all-cause and cardiovascular mortality according to eGFR and albuminuria clinical categories, by hypertensive status in combined general and high-risk population cohorts
11917	Hazard ratios for end-stage renal disease according to eGFR and albuminuria clinical categories, by hypertension status in chronic kidney disease cohorts
11918	Incidence of adverse events*
11919	Hemodynamic Data
11920	Relative Rates  (95% CI)  of CVD Mortality, Incident CHD, and Total Mortality in Gender-Specific Quintiles of the Heart Rate-Adjusted QT
11921	Relative Rates  (95% CI)  of CVD Mortality, Incident CHD, and Total Mortality in the Highest Gender-Specific 10% Compared with the Other 90% of the QT Distribution *
11922	Relative Rates  (95% CI)  of CVD Mortality, Incident CHD, and Total Mortality in the Highest Gender-Specific 10% Compared with the Other 90% of the QT Distribution*, According to Health Status
11923	Comparison of Prognostic Value of Manual and Machine Measured QT in the Case Cohort Sample: Relative Rates  (95% CI)  of Highest Gender-Specific 10% Compared With the Other 90% of the QTc Distribution
11924	Official development assistance to reproductive health, 2009–10
11925	Worldwide official development assistance to reproductive health by donor, 2009–10
11926	Official development assistance to reproductive health to the 74 Countdown priority countries by type of aid and purpose of projects, 2009–10
11927	Official development assistance to reproductive health to the 74 Countdown priority countries 2009–10
11928	Results of ordinary least squares regression models
11929	Ranking of top HIV investment  *   countries by criminalisation and PEPFAR focus status and epidemic scenario
11930	Sensitivity analysis showing proportion of individuals with one or more drug-resistance mutation, by region and years after rollout of antiretroviral treatment  (ART)
11931	Data sources for empirical measurements of adult mortality
11932	45q15  (uncertainty interval)  per 1000 for women and men in 1970, 1990, and 2010
11933	Distributions of yearly rates of change in adult mortality  (%) , by decade
11934	Causative Microorganisms
11935	Main Indications for Surgery *
11936	Mitral Lesions *  (Surgical Findings)  According to the Timing of Surgery
11937	Surgical Techniques * According to the Timing of Surgery
11938	Ranked order of self-reported symptoms
11939	15 most frequent self-reported symptoms by deployment status
11940	Relation between deployment and fatigue and between deployment and perceived fair or poor general health
11941	Multivariable Analyses of the Association Between Race and Prevalent Atrial Fibrillation Among Hospitalized Patients With Heart Failure
11942	Frequency of resistant H3N2 viruses by geographic origin and year of isolation
11943	Biological data for rimantadine susceptibility
11944	Rate changes for selected countries and regions
11945	HIV prevalence and details of Global Fund awards by country, for rounds 1–3  (December, 2003)
11946	Interviews by respondent category and country  *
11947	Composition of country coordinating mechanism, in May, 2003, by country
11948	Predictors of Survival at 36 Months in Chronic Heart Failure Patients Derivation Study
11949	Clinical Details of the Patients in the Validation Study
11950	Comparison of Patients Below and Above the Predetermined Cut-Off Value for Cholesterol in the Validation Study
11951	Adult crude HIV-1 prevalence rate  (%)  by round
11952	Predictors of Three-Year Survival in the Validation Study
11953	Adult crude HIV-1 prevalence rate by survey round and migration status
11954	Results of laboratory studies done before and after seroconversion
11955	Frequencies of HLA-B57, HLA-B * 5701, and combination of HLA-B * 5701 and HLA-DR7
11956	Frequency of condom use
11957	Effect of health education and method of condom provision on the probability of condom use
11958	Comparison of Responders With Non-Responders *
11959	Preoperative, Postoperative, and Normative Mean QOL Values * in Different Age Groups
11960	Multivariable Analysis of the Effect of Age on Change in MCS and PCS Scores
11961	p Values Representing Heart Rate Variability Differences
11962	HRV Preceding the Onset of AF
11963	Families With Recurrent Congenital Heart Disease
11964	Overall Concordance for Families With One, Two, or Three Recurrences
11965	Recurrence Type Seen Where the Index Case Has a Left Heart Defect *
11966	Recurrence Type Seen When the Index Case Has a Septal Defect *
11967	Recurrence Type Seen When the Index Case Has an Outflow Tract Defect *
11968	Comparison of Sclerotic Process in Aortic Stenosis With That in Atherosclerosis
11969	Risk Factors Associated with Aortic Stenosis
11970	Studies on Progression of Aortic Stenosis
11971	Etiologies of Mitral Regurgitation Among 274 Patients Who Underwent Mitral Valve Plasty
11972	Changes of Echocardiographic Data Before and After Mitral Valve Repair Among 171 Patients
11973	Univariate Correlation of Postoperative Ejection Fraction With Preoperative Clinical or Echocardiographic Variables
11974	Incidence of Postoperative LV Dysfunction According to Classes of Preoperative LVEF
11975	Incidence of Postoperative LV Dysfunction Stratified by Preoperative LVDs
11976	Incidence of Postoperative LV Dysfunction According to Preoperative LVEF and Preoperative LVDs
11977	Results
11978	Independent Variables Found to Correlate With Follow-Up Neo-Aortic Valve Annulus, Root, and Sinotubular Junction Z-Scores Above the Median for This Population
11979	Comparison of Mean Z-Score for All Patients Who Underwent Interim Staging With BSCA Compared With Those Who Had Stage 1 Reconstruction Followed by Fontan Operation
11980	Independent Variables Found to Correlate With Follow-Up Neo-Aortic
11981	Causes of Death and Adverse Events During Follow-Up
11982	Impact of Treatment on LA Size and Transport Function in Patients Grouped According to the Occurrence of Recurrent Atrial Fibrillation
11983	Impact of Treatment on Hospitalization in Patients Grouped According to the Occurrence of Recurrent Atrial Fibrillation *
11984	Age and Gender Distribution for Ischemic Stroke Cases and Control Subjects
11985	Observed Prevalence  (%)  of Atrial Fibrillation Among Rochester Residents, Stratified by Gender, Age, Presence or Absence of Ischemic Stroke, and Decade
11986	Modeled Prevalence  (%)  of Atrial Fibrillation Among Rochester Residents, Stratified by Gender, Age, Presence or Absence of Ischemic Stroke, and Decade
11987	Change in Prevalence  (Odds Ratio)  for Five-Year Changes in Calendar Time for Various Comorbid Conditions
11988	Use of Electrocardiography Within 30 Days of Stroke in Case Patients or Reference Date in Control Subjects for Three Decades
11989	Number of Arteries  (LAD, LCX, and RCA)  That Underwent 0 to 6 IVUS Exams
11990	Comparison of Unadjusted Physical and Mental Health Status Outcomes From the SF-36
11991	Multivariable Risk Models for Physical and Mental Component Summary Scores for the Overall Study Population *
11992	Filling Dynamics During Development of Pacing-Induced Heart Failure
11993	Quantitative Intravascular Ultrasound Data
11994	Quantitative Intravascular Ultrasound Data
11995	Quantitative Intravascular Ultrasound Data
11996	Multiple Regression Analysis of Intima-Media Thickness
11997	Long-Term Mortality After AVR
11998	Severity of VP-PM
11999	Predictors of All-Cause Three-Year Mortality
12000	Effects of CRT on Echocardiographic Parameters
12001	PCR Primers and Optimized PCR Conditions for Amplification of Rabbit Potassium and Calcium Channel Genes
12002	Biophysical Properties of ICa,Land Ito
12003	State of the Art on Human Skeletal Myoblasts, Embryonic, and Bone Marrow Stem Cells
12004	Markers of Cardiomyocyte Differentiation from Human Skeletal Myoblasts, Embryonic, and Bone Marrow Stem Cells
12005	Radiation Failure Patients According to IRT Study
12006	Clinical Events Six Months after Radiation Failure  (n = 282)
12007	Hospital Readmission, Health Status and Social Support in Men and Women at Six Weeks After CABG Surgery  (Unadjusted)
12008	Multivariable Analysis of Gender Differences in Hospital Readmission and Health Status at Six to Eight Weeks After CABG Surgery
12009	Clinical and Angiographic Data of Study Patients
12010	Coronary Hemodynamic Data
12011	CABG and PCI Outcomes of Patients With Prior CABG
12012	Blood Pressure Differences for the First 4 h of Measurement Between the First and Second Days of a 48-h ABPM in Patients With Mild-to-Moderate Hypertension
12013	Spectrum of Disease at First Presentation  (n = 44)
12014	Surgical Data  (n = 30)
12015	Variables Predicting Need for Eventual Orthotopic Heart Transplantation in the Surgical Group *
12016	Potential Factors in the Incidence of AVF
12017	Potential Determinants of the Incidence of Spontaneous AVF Closures in Patients With Iatrogenic Femoral AVF  (n = 88)
12018	Potential Determinants of the Incidence of Time to Closure of AVF in Patients With Iatrogenic Femoral AVF  (n = 88)
12019	Person-years, observed  (O)  and expected  (E)  cases, and SIR by cancer and exposure to IVF treatment with ovarian stimulation
12020	Observed  (O)  and expected  (E)  cases and SIR by cancer and type of infertility  (exposed and unexposed to IVF treatment with ovarian stimulation combined)
12021	Observed  (O)  and expected  (E)  cases and SIR by cancer and type of ovarian stimulation and response to stimulation
12022	Fertilistion rates and paternal pesticide exposure in a series of 836 couples who underwent IVF treatment
12023	Results of intention-to-treat analysis
12024	Multivariate Predictors of Atrial Fibrillation
12025	Results of per-protocol analysis
12026	Microbiological assessment
12027	Hospital outcomes
12028	Health spending per capita by income group, region, country, and source in 2040
12029	Health spending as a share of gross domestic product, by income group, region, country, and year
12030	Benchmarking country progress by 2040
12031	Summary of significant loci
12032	Summary of risk-profile analyses
12033	Age-specific and sex-specific prevalence of Parkinson's disease
12034	Comparison of Parkinson's disease patients with or without the G2019S mutation
12035	Monthly referral rates and total number of patients admitted to Scottish Liver Transplantation Unit
12036	Risk factors in patients with acute liver failure
12037	Proportion of Differences Between ECG-Gated SPECT and Cardiac MRI Measurements
12038	Clinical and Echocardiographic Variables at the Time of Discharge From the Hospital, After Stabilization With Medication  (n = 115)
12039	Hemodynamic Results and Doppler Gradient at the Last Follow-Up
12040	Association of US$100 per capita increase in tax revenues and in GDP with health system expenditure in low-income and middle-income countries, 1995–2011
12041	Tax regime and government spending on health in low-income and middle-income countries, 1995–2011
12042	Official development assistance to maternal, newborn, and child health, 2003–10
12043	Worldwide official development assistance to maternal, newborn, and child health by donor, 2003–10
12044	Official development assistance to maternal, newborn, and child health to the 74 Countdown priority countries by type of aid and purpose of projects between 2003 and 2010
12045	Official development assistance to maternal, newborn, and child health to the 74 Countdown priority countries, 2003–10
12046	Results of ordinary least squares regression models and likelihood ratio tests
12047	Sources of Information Available for the Study
12048	Inter-Relations Among Morphologic Variables
12049	Frequency of Occurrence of Associated Malformations
12050	Perioperative and Late Deaths Related to the MTVG Among Patients Who Had AVR Replacement
12051	Success Rates of Collagen Injection
12052	Treatment credibility after the third treatment session and assessment of blinding
12053	Primary and secondary outcomes at the end of week 8
12054	Secondary outcomes after 26 weeks and 52 weeks
12055	Individual absolute and relative risks for development of contrast nephropathy
12056	Aminoacid changes caused by variable sequences
12057	Expression of chromosome 1q by comparative expressed sequence hybridisation  (CESH)  and comparative genomic hybridisation  (CGH)
12058	Cough duration according to age and sex in total study population
12059	Health-care actions taken by men and women with cough for more than 3 weeks
12060	H pylori prevalence by family composition
12061	Effect of birth order on H pylori prevalence
12062	Effect of birth spacing on H pylori prevalence
12063	Effect of H pylori status of siblings on prevalence of Hpylori in 2–9-year-olds
12064	Individual Studies
12065	Individual Study Data
12066	Effect of Rate on the Sensitivity and Specificity of Concealed Entrainment for the Identification of an Isthmus Site
12067	Morgan-Russell-Hayward subscale and total scores at recruitment, after 6 months, and at outcome
12068	Cohort outcomes
12069	Anorexia nervosa and bulimia nervosa—predictors of the Morgan-Russell-Hayward total mean score 5 years after recruitment, derived by multiple regression  *
12070	Anorexia nervosa—further predictors of the Morgan-Russell-Hayward total mean score 5 years after recruitment, derived by multiple regression  *
12071	Bulimia nervosa—further predictors of the Morgan-Russell-Hayward total mean score 5 years after recruitment, derived by multiple regression  *
12072	Univariate Logistic Regression: Unadjusted OR of Each Clinical Variable in Relation to Resolution of LAT
12073	Univariate Logistic Regression: Unadjusted OR of Each Echocardiographic Variable in Relation to Resolution of LAT
12074	The Initial Multivariable Logistic Regression Model: OR of Each Variable, Adjusted for Effects of All Other Varibles in Relation to Resolution of LAT
12075	The Final Model
12076	Comparisons of questionnaire data between groups at randomisation
12077	Mean scores for Griffiths mental development scales at randomisation and 9-month follow-up
12078	Audiological tests done at randomisation
12079	Audiological, tympanometric, and otoscopic results at randomisation
12080	Mean standardised and equivalent age scores for verbal comprehension and expressive language at 9 and 18 months
12081	1H magnetic-resonance-spectroscopy metabolite ratios obtained in each brain region
12082	Computed tomographic findings and clinical details
12083	Response amplitudes
12084	Presenting complaints
12085	Primary and secondary outcome measures in drain and non-drain groups
12086	Outcome analysis with adjusted logistic regression models, by independent variable
12087	Safety at first follow-up visit
12088	Women's attitudes towards project services
12089	Coverage rates
12090	Supervisory visit co-assessment
12091	Mean Heart Rate and Mean Blood Pressure
12092	Relation between human papillomavirus viral load and development of CIN3+ during follow-up
12093	HPV genotype distribution in all HPV-positive women and in HPV-positive women with cervical neoplasia
12094	p53 genotypes in Italian and Swedish women
12095	Frequencies of conventional and PAPNET results by classification
12096	κ values  (SE)  for agreement between PAPNET and conventional results
12097	Agreement between PAPNET and independent review and conventional screening and independent review
12098	κ values  (SE)  for agreement between PAPNET and independent review and conventional screening and independent review
12099	Sensitivity and specificity for PAPNET-assisted screening and conventional screening
12100	Discrepancies in final classification between laboratory assessments and independent review
12101	Frequencies for conventional final and primary screening
12102	Frequencies for PAPNET final and PAPNET classification results
12103	Additional procedural details of study groups
12104	Primary and secondary endpoints
12105	The AP Parameters in the Hyperthyroid and Control PV Cardiomyocytes or Atrial Myocytes
12106	Associations Between Cardiac Rhythm After the Operation and Clinical Parameters by Multiple Logistic Regression Analyses
12107	Predictive Values Associating the Combination of ANP and Duration of AF and the Duration of AF Alone With the Outcome of the Maze Operation
12108	Prevalence of rectal bleeding in patients with colorectal cancer  (n=64)  and proportion of colorectal-cancer patients with rectal bleeding, out of all new patients with abdominal complaints  (n=455)
12109	Measures before testing and 1 month after receipt of test results for individuals homozygous for Cys282Tyr and controls
12110	Relationship Between Risk Factors and the Presence of LVSD In Patients With Stroke, TIA or PVD as Compared With Age- and Gender-Matched Control Subjects
12111	Uptake of testing in first-degree relatives of C282Y homozygotes discovered by genetic testing and after clinical presentation
12112	Epidemiology of LVSD  (Ejection Fraction ≤40%)  ∗
12113	Multiple Logistic Regression Analysis ∗ of Risk Factors for Left Ventricular Systolic Dysfunction  (Ejection Fraction ≤40%)  in Patients and Control Subjects
12114	Risk Factor Analyses of Mortality of CAVB Diagnosed In Utero, in the Newborn Period or During Childhood
12115	ACC/AHA Criteria for Permanent Pacing of 67 of 102 Patients With Diagnosis of CAVB In Utero, as Newborn or During Childhood
12116	Analysis of Heart Rate on 12-Lead ECG, Holter and Exercise Test of Class 1 and Class 2 N and C Patients and Unpaced Cases
12117	Malaria-attributed deaths in the present study and estimated national totals, by age
12118	Geographical variation in absolute numbers of malaria deaths in the different populations studied by the MDS and NVBDCP
12119	Countries according to international funding awarded per person at stable malaria risk per year up to end of 2009 and per-person gross domestic product
12120	Studies of GPs' ability to diagnose depression
12121	Age Structure of the Henry Ford Health System General Population Taken From a Random Sample  (n = 3,195)  of Enrollees in 1994, the Midpoint of REACH Time Frame legend legend
12122	Age, Gender, Race and Major Insurance Carrier for 29,686 Patients With CHF in the REACH Study legend
12123	Age Structure of the REACH-CHF Population From 1989 to 1999 legend legend
12124	Deaths, person-years of observation, and mortality rates by period of follow-up, district, and age
12125	Adjusted mortality rate ratios  *
12126	Readmission and Death Within One Year of Initial Discharge ∗   legend
12127	Proportional Hazards Model: Intervention Versus Control legend legend
12128	Mean Readmission Costs  ($ Per Patient)  legend
12129	Criteria used to calculate months suitable for P falciparum malaria transmission in Africa
12130	Estimated P falciparum malaria exposure and transmission in Africa with the HadCM3 B1, A2a, and A1FI scenarios  *
12131	Estimated P falciparum malaria population exposure in Africa with the HadCM3 B1, A2a, and A1FI climate scenarios  *
12132	Outcomes for behavioural and emotional problems reported on the YSR
12133	Outcomes for smoking, excessive drinking, and use of marijuana, MDMA, and hypnotics or sedatives
12134	Differences in outcomes by sex, for adolescents of the affected school compared with those of the control schools
12135	Differences in outcomes for non-exposed and exposed adolescents of affected school compared with adolescents of control schools
12136	Nutrition Content of Active and Placebo Bars
12137	Treadmill Data of Subjects Before and After Two Weeks of Therapy legend legend
12138	Rainfall estimates for 2002 expressed as a proportion of monthly average  (1995-2001)
12139	Correlations with spirituality and depression measures
12140	Quality of Life Data of Subjects Before and After Two Weeks of Therapy legend
12141	Regression models by FACIT-SWB total score
12142	Regression models with FACIT-SWB meaning and faith subscales
12143	Physical and psychological health measures at 4 months
12144	Multi-level model of women's views about care showing effect of study group
12145	Number of home visits by midwife and general practioner  (GP)  from various sources
12146	Incidence of malaria episodes recorded by the refugee village clinics
12147	Parasite prevalence during cross-sectional surveys held in October each year.
12148	Density of indoor resting mosquitos during the treatment period of August to November
12149	Parous rates of mosquitoes in treated and untreated groups of villages during the campaign period
12150	Comparison of costs of three rounds of cattle sponging in 1997 with one round of indoor residual spraying in 1992
12151	Association of the Cd36 T188G polymorphism with severe malaria
12152	Multivariate survival analysis of hazard ratios for mortality 2 years after hip fracture in 731 elderly patients
12153	Reasons for failure of tourists to obtain valid results with rapid test for falciparum malaria
12154	Most intense level of suicidal feelings recorded in case notes of elderly persons visiting a doctor during the year preceding suicide
12155	Most intense level of suicidal feelings perceived by close informant during the year preceding suicide
12156	Six-Month Clinical Improvement in Surviving Patients
12157	Treatment Strategies for Hypoplastic Left Heart Syndrome Considered at Diagnosis
12158	Probabilities Used in the Decision Tree
12159	Key indicators of health in the countries of the former Soviet Union
12160	Estimated life expectancies at birth in the countries of the former Soviet Union in 1990, 2000, and 2009
12161	Official and WHO estimates of life expectancies in the countries of the former Soviet Union, 2009
12162	Deaths in children with biliary atresia
12163	Results of prion-protein immunohistochemistry
12164	Summary of Estimated Annual National Costs ∗ for Persons Age 35 to 84 Years
12165	Epidemiologic Impact and Costs of Changes in Risk Factors Between 1981 and 1990 on Outcomes in 1981 to 1990 and 1991 to 2015 ∗   legend
12166	Cost-Effectiveness of Risk Factor Reductions for the Population Age 35 to 84 Years ∗
12167	Number of whole blood donations over 2 years and physical component score at 2 years by sex and intervention group
12168	Selected secondary outcomes by sex and intervention group
12169	Outcome in living donors and recipients
12170	Numbers of acute and chronic rejections
12171	Mean Age, Gender Distribution and Associated Congenital or Acquired Heart Diseases in Patients With Discrete Subaortic Stenosis Who Had an Operation During Adulthood  (Group A) , No Operation  (Group B)  and an Operation During Childhood  (Group C)  legend
12172	Changes in Left Ventricular Outflow Tract Obstruction and Aortic Regurgitation Degree in 25 Patients Who Had Two Doppler Echocardiographic Assessments Separated by an Interval of ≥2 Years legend
12173	Rates of Revascularization Procedures by Numbers of Stenosed Vessels and Ethnicity legend legend
12174	Degrees of pain and disability associated with New Zealand scores of 55 and 43
12175	Self-reported pain in either hip
12176	Previous use of health services for hip disease according to attendance or non-attendance at study clinics
12177	Population prevalence and annual incidence of severe hip disease per 1000 people
12178	Estimates of annual incident hip disease requiring primary total hip replacement surgery in the population of England aged 35 to 85
12179	Mortality at 30 days in patients with initial Q waves versus those without, stratified by acute myocardial infarction location and by time to randomisation
12180	Frequency of ST resolution at 60 min in patients with initial Q waves versus those without, stratified by location of acute myocardial infarction and by time to randomisation
12181	Multivariable predictors of 30-day mortality  (n=15 222)
12182	Histology and stage of lung cancers
12183	22 breath VOC picked out by discriminant analysis  *
12184	Reported measles cases, measles vaccination coverage, estimated measles deaths, and children reached by SIAs by WHO region
12185	Comparison of SOSAS and DHS  (2009)   18   data
12186	Reported conditions in need of surgical care
12187	Anatomical location of conditions needing surgical care
12188	Conditions of deceased household members that might have benefited from surgical care, recalled as occurring in the week before death
12189	Improvement in mortality person-years of observation from 1955–59 to 1978–82, from 1978–82 to 2000–04, and from 1955–59 to 2000–04, expressed as percentage of mortality in people aged 1–34 years in 1955–59, 1978–82, and 1955–59, respectively, by age-group and sex
12190	Contributing factors to neurologically favourable 1-month survival after out-of-hospital cardiac arrests in children
12191	Age-stratified outcomes after paediatric out-of-hospital cardiac arrests of non-cardiac and cardiac origins by type of bystander CPR
12192	Description of the types of IMCI-trained health workers, by country
12193	Integrated assessment, classification, and management of children by IMCI-trained health workers, stratified by length of preservice training
12194	Index of integrated assessment of children by IMCI-trained health workers
12195	Odds ratios for correct classification and management by IMCI-trained health workers with longer duration of training compared with those with shorter duration of training
12196	Ratio of physicians and nurses, and ranking of child deaths in the four study countries
12197	Effects of Posture on Frequency Domain Measurements of Heart Rate Variability legend legend
12198	Estimated and expected under-5 deaths and under-5 mortality, with uncertainty intervals, by Global Burden of Disease 2005 study subregions and different years  (1970–1990)
12199	Estimated and expected under-5 deaths and under-5 mortality, with uncertainty intervals, by Global Burden of Disease 2005 study subregions and different years  (1995–2015)
12200	Country-specific summary of mean estimated decline in child mortality and 2005 estimates of under–5 mortality and number of deaths, with uncertainty intervals
12201	Estimated number  (thousands)  and percentage distribution of children not reached with first dose of measles vaccine and without second opportunity for measles immunisation in 2005, by WHO region
12202	Estimated cases, deaths, and DALYS  (thousands)  occurring and averted, 1999 and 2005, by WHO region
12203	Province populations and cluster allocation
12204	Pre-invasion and post-invasion deaths by age and cause  (n=629)   *
12205	Mortality rates by time
12206	Violent deaths by cause and time
12207	Health indicators in Somaliland, Uganda, and the UK
12208	Benefits of KTSP activity, 2002–05
12209	Under-5 mortality rates in the 60 countries in 1990 and 2004, and progress needed to meet the 2015 target
12210	Median coverage rates for essential interventions in the 60 countries
12211	Correlation between dependent variable  (infant mortality rate)  and independent variables in various years
12212	Correlation between dependent variable  (life expectancy at birth for women and men)  and independent variables, in various years
12213	Frequency of end-of-life decisions
12214	Nature of end-of-life decision in terms of life-shortening intention of physician for the 143 deaths in which an end-of-life decision was made
12215	Attitudes of physicians towards end-of-life decisions in neonates and infants  (n=121)
12216	Studies included in the meta-analyses
12217	Maximum accepted blood phenylalanine concentration and frequency of capillary-blood sampling as recommended by the National Society for Phenylketonuria  (UK)  consensus document  4   and by centre
12218	Results expressed as median  (IQR)  for each centre and each 5-year age-group
12219	Rates of serious coronary heart disease by study cohort and NANSAID use
12220	Rates of serious coronary heart disease by specific NANSAID
12221	Rates of serious coronary heart disease by duration of continuous NANSAID use  *
12222	Alternative analyses  *
12223	Cord, milk and serum PCB concentrations at different ages and relative to breastfeeding, and HOME scores
12224	Association of PCR and HOME with mental and motor development
12225	Risk Factors and Outcome Variable legend
12226	Outcomes legend
12227	Operative Mortality for Specific Subgroups by Procedure Type legend
12228	Risk Factors for Isolated Valve Surgery Model ∗   legend
12229	Risk Factors for Coronary Artery Bypass Graft Surgery/Valve Surgery Model ∗   legend
12230	Design of randomised trials of unfractionated heparin compared with placebo or untreated control in acute coronary syndrome without ST elevation
12231	Design of randomised trials of LMWH compared with placebo or untreated control in acute coronary syndrome without ST elevation.
12232	Design of randomised trials of LMWH compared with unfractionated heparin in acute coronary syndrome without ST elevation
12233	Number  (%)  of persisting and vanishing warts in ALA-PDT and placebo-PDT groups
12234	Relative change in wart area and area of persisting warts compared with area at entry  (%)  at week 7, 14, and 18
12235	Pain assessed by a five-point scale of individual warts  (%)  immediately and 24 h after each of six interventions
12236	Multivariate general linear model for length gain with and without children weaned because of illness or pregnancy
12237	Adjusted difference in linear growth between short-duration category and other children according to sanitation conditions
12238	Multivariate general linear model for weight gain with and without children weaned because of illness or pregnancy
12239	Age at Operation and Previous Palliative Operations
12240	Type of Previous Palliation and Systemic Venous-to-Pulmonary Connection
12241	Operative and Late Mortality by Era of Operation
12242	Length of Follow-up and Present Age of 171 Surviving Patients
12243	Populations studied, years of coronary-event registration, mean population size, and summary scores of data quality  *
12244	Number of events, age-standardised 28-day case fatality, and mean  (SE)  annual event rates per 100 000 during registration in men
12245	Numbers of events, age-standardised 28-day case fatality, and mean  (SE)  annual event rates per 100 000 during registration in women
12246	Trends in age-standardised event rates for men aged 35-64 years expressed as average  (SE)  annual relative percentage change
12247	Trends in age-standardised event rates for women aged 35–64 years expressed as average  (SE)  annual relative percentage change
12248	Populations grouped by trends in MONICA CHD mortality rates to show contribution of change in case fatality and change in coronary-event rates
12249	Summary of Procedures legend
12250	In-Hospital and Six-Month Complications legend
12251	Univariate Analysis of the Predictors of Cardiac Death legend
12252	Odds ratios of mortality associated with related variables
12253	Comparison of Patients With and Without Inducible, Sustained IART legend
12254	Odds Ratios of Independent Variables Associated With Inducible, Sustained Intra-atrial Reentrant Tachycardia
12255	Definition of indicators by intervention area used for the coverage gap index
12256	Mean coverage gap index for four intervention areas with indicators within each area by wealth quintile and measures to describe equity, most recent survey data for 54 Countdown countries
12257	Coverage gap  (%)  by period and yearly rate of change with summary measures of equity, by country
12258	Coverage trends in three groups of countries by level of coverage gap in the 1990s with absolute and relative declines
12259	Association between type and level of inequity according to the size of coverage gap in 114 national surveys
12260	Hemodynamics legend
12261	Measures of pain and happiness by sex and activity  *
12262	Average proportion of the waking day spent in each activity
12263	Sex-specific mean pulse-wave velocity measured at groin and foot according to birth size, adjusted for gestation period
12264	Change in pulse-wave velocity measured at groin and foot for 1 SD increase in size
12265	Weekly average of daily backpack loads
12266	Tissue and Cellular Responses to Stent Implantation 7, 28, 56 or 180 Days After Stent Implantation legend
12267	Neointimal Extracellular Matrix Composition 28 or 180 days After Stent Implantation legend
12268	Clinical Electrocardiographic and Radionuclide Data Before and After PVR legend
12269	Summary of country case studies
12270	Cognitive measures and depression symptomatology for the 1905 and 1915 cohorts  (in-person participants only)
12271	Activities of daily living and physical performance scores for the 1905 and 1915 cohorts
12272	Probability of an Outcome Event at 15 Years After Valve Replacement legend
12273	Causes of Death  (% of All Deaths)
12274	Genotypic Distributions and Allelic Frequencies of AMPD1 Gene Polymorphism Among Patients by Survival Status legend legend
12275	Cox Multiple Variable Logistic Regression Model ∗ for Cardiovascular Death legend
12276	Predictors of smoking initiation
12277	Effect of movie smoking exposure on smoking initiation in all participants, and the interaction between movie smoking exposure and parental smoking in relation to smoking initiation
12278	Incidence of inflammatory bowel disease by country
12279	Description of cohort of index patients with inflammatory bowel disease in Sweden 1955–95
12280	Description of first-degree relatives of patients with inflammatory bowel disease  (IBD)  in Sweden 1955–95
12281	Observed  (O)  and expected  (E)  numbers of cancers, standardised incidence ratio  (SIR)  with 95% CI for colorectal cancer in first-degree relatives of patients with either ulcerative colitis or Crohn's disease in Sweden 1955–95
12282	Observed  (O)  and standardised incidence ratios  (SIR)  with 95% CI for colorectal cancer according to location in first- degree relatives of patients with ulcerative colitis, Crohn's disease, or both in Sweden 1955–95
12283	Offspring sex ratio in the study population compared to the exposure status of parents
12284	Father's TCDD serum concentrations in 1976 and sex ratio of offspring
12285	Odds of male births compared to the TCDD serum concentrations of his parents
12286	Age and exposure status of father in 1976 and sex ratio of offspring
12287	Sex ratio at birth by quartile of father's TCDD serum concentration at time of conception
12288	Sex ratio of births in residents of A zone from Jan 1, 1966, to Dec 31, 1996
12289	Univariate Odds Ratios of Preoperative Variables for One-Year Mortality
12290	Variables Specific to Transplantation
12291	Families with IBD and FMF
12292	One- and Five-Year Survival by Treatment Path: Intention-to-Treat Versus Treatment-Received Analysis
12293	Multivariable Odds Ratios and Prediction Equation Coefficients for One-Year Mortality legend
12294	Differences in CBMN assay
12295	Relative risk of micronucleus formation in CBMN assay, adjusted according to radiation exposure, cigarette smoking, sex, and age*
12296	Differences in CBMNA assay
12297	Relative risk of micronucleus formation in CBMNA assay, adjusted according to radiation exposure, cigarette smoking, sex, and age of exposure*
12298	Comparison of Categorical Variables in Patients With Ligated and Incompletely Ligated Left Atrial Appendages
12299	Left Atrial Size Distribution in Patients With Ligated and Incompletely Ligated LAA legend
12300	Distribution of Mitral Regurgitation in Patients With Ligated and Incompletely Ligated LAA legend
12301	Extracardiac Defects and Syndromes Associated With AVSD legend
12302	Results of Cox’s Proportional Hazards Method of Analysis for Independent Variables Affecting Survival legend
12303	Caesarean rates by wealth quintile in 42 developing countries
12304	Caesarean rates by wealth quintile among urban and rural births
12305	Aneurysm-related and all-cause mortality  (intention-to-treat analysis)
12306	Causes of death by group
12307	Postoperative complications  *   after leaving theatre by operation received  (not intention to treat)
12308	Comparison of HRQL at different timepoints from randomisation
12309	Resource use during primary hospital admission for patients who had AAA repair
12310	Estimated costs  (UK£)  over 4 years follow-up based on intention to treat
12311	Arterial Remodeling Among Groups in the Study legend
12312	Effect of 8-Cl-cAMP on Laboratory Studies in Rats After Balloon Angioplasty  (Protocol IV)  legend
12313	Pearson's r correlations of visual-spatial test scores and competency scores in three Z-plasty procedures
12314	Details of diagnostic group and previous genital surgery
12315	Results of cosmetic and anatomical genital examination, and recommendations for further treatment
12316	Features of 14 of 34 patients with colorectal cancer who had at least one blood sample positive for circulating colorectal cells
12317	Results of Coronary Artery Segment Classification and Stenosis Assessment by Contrast-enhanced Magnetic Resonance Coronary Angiography Compared With Conventional Invasive Angiography  (n = 350)  legend
12318	Relation Between Magnetic Resonance Coronary Angiography and Conventional Invasive Angiography on a Patient Basis  (n = 50)
12319	EMR-contributing countries with modelled influenza-associated excess respiratory mortality or annual estimates of respiratory mortality by age group for validation
12320	Mean annual influenza-associated EMR per 100 000 population by age group for EMR-contributing countries
12321	WHO Global Health Estimates of respiratory infection mortality rate  (per 100 000 individuals)  by age group and analytic division
12322	Estimated annual influenza-associated respiratory deaths and mortality rate per 100 000 population by age group, WHO region, and World Bank income classification
12323	Posterior mean estimates from Bayesian analysis of incidence of avian influenza A H7N9 infection before and after LPM closures
12324	Incidence of active tuberculosis in household contacts during 4-year follow-up period
12325	Overall Results of Thrombolysis in 12 Patients With Stuck Mitral Valves
12326	Outcome of Treatment According to Thrombolytic Agent  (1st Episode)  legend
12327	Thrombolysis in Stuck Bileaflet Mitral Valves: Experience in the Main Series  (≥3 Cases)  legend
12328	Comparison Between Patients in the Training Population and the Validation Population legend
12329	Univariate Analysis of Clinical, Exercise and Thallium Variables to Identify Predictors of 3VLMD in the Training Population legend
12330	Multivariate Analysis for Independent Predictors of 3VLMD in the Training Population
12331	Angiographic Results by Risk Classification From Model
12332	Risk Stratification of the Validation Population legend
12333	Country pandemic influenza plans
12334	WHO pandemic influenza phases  3
12335	Distribution of 1094 bacteriologically confirmed patients in all 5800 households, 1993–98, for all patients and for patients with RFLP only
12336	Clustering of patients in Ravensmead and Uitsig for 1993–98 in community and in households
12337	Carriage of meningococci by serogroup in 15–17 year old school students in the UK in 1999 and 2000
12338	Meningococci by serogroup and centre
12339	MUC 1  variable number tandem repeat region  (VNTR)  sizes in 10 fertile and infertile women
12340	Association Between Explanatory Variables and Age in Patients Who Survived the First Postoperative Month After AVR legend
12341	Results of Univariate and Multivariate Analyses Based on Observed Late  (Deaths Within 30 Days of Aortic Valve Replacement Excluded)  Survival Using the Cox Regression Model legend
12342	Frequency of the esp gene and purK allele 1 among epidemic isolates, non-epidemic isolates, and isolates from healthy individuals
12343	Comparison of Relative Hazards at Different Time Intervals in Survivors After AVR, Based on Analyses of Observed Survival Using a Modified Cox Regression Model
12344	Basic Data Concerning Observed and Expected Deaths Based on Data From Follow-Up Years 1 through 15 ∗   legend
12345	Fully Multivariate Model Based on Relative Death Risks  (Deaths Within 30 Days After Aortic Valve Replacement Excluded)  and Considering Other Variables legend
12346	χ2 analysis of the difference in frequencies of seroconversion according to age group
12347	Age and Mode of Presentation, Duration of Follow-up and Associated Features legend
12348	Echocardiographic and Electrocardiographic Features legend
12349	Patients Subjected to Mitral Valve Repair legend
12350	Echocardiographic Results legend
12351	Univariate Analysis of the Prediction of Immediate Results legend
12352	Multivariate Analysis of the Prediction of Immediate Results legend
12353	Predicted Probability of Good Immediate Results  (%)  According to the Value of the Three Predictors Identified in the Logistic Multivariate Analysis for a Given Patient
12354	Univariate Analysis of the Prediction of Good Late Functional Results in Patients Who Had Had Good Immediate Results From PMC
12355	Multivariate Analysis of the Prediction of Late Functional Results After Good Immediate Results legend
12356	Predicted Probability  (%)  of Good Late Functional Results Five Years After Good Immediate Results, According to the Value of the Three Predictors Identified in Cox Multivariate Analysis, for a Given Patient legend
12357	Status of tuberculosis control in countries reporting to WHO, 1995
12358	Case notifications by World Bank region, 1995
12359	Case detection rates based on World Bank Development Report by World Bank region, 1995
12360	Number of registered cases and treatment results for new smear-positive cases by World Bank region and treatment strategy, 1994
12361	Results of the univariate linear regression analysis of serum lipids and dietary factors
12362	Results of multiple linear-regression analysis of serum lipids and glycaemic index  (full model)
12363	Correlation matrix of univariate correlation coefficients for biochemical, anthropometric, and dietary data
12364	Effects of Balloon Coronary Occlusion on Left Ventricular Function and Power Spectral Components Determined With Maximum Entropy Method legend
12365	Mortality data availability by country
12366	Dimensionless values of the traditional and random-walk sway parameters for control and noise trials
12367	Multivariate Predictor of Sudden Death ∗   legend
12368	Interventional Procedures
12369	Mean  (SD)  QT indices of the analysable substudy population
12370	In-Hospital Events and Eight-Month Follow-Up Clinical Outcomes in Studied Patients legend
12371	Thirty-Day and Eight-Month Follow-Up Clinical Outcomes in Studied Patients With Elevated Tn-I Levels More Than Three Times Upper Normal
12372	Independent Predictors of Any Cardiac Event  (Death, Q-wave MI, Coronary Angioplasty or Bypass Surgery)  or TLR at Eight-Month Follow-Up
12373	Standardised mortality ratio by sex and fracture type
12374	Mortality and time to death by sex and fracture type
12375	Life expectancy in years for fracture and general population
12376	Attributable risk of mortality from fractures by age-group
12377	Results of Univariate Linear Regression Analysis of Luminal Gain and Loss in the Four Stent Designs Studied
12378	Comparison of Luminal Loss in Each of the Stents Designs Used Within Each Quartile of Luminal Gain legend
12379	Results of Multiple Regression Analysis for Minimal Luminal Diameter, Luminal Loss and Net Luminal Gain at Follow-up legend
12380	Quantitative coronary angiography
12381	Major adverse cardiac events to 9 months of follow-up
12382	Waiting times and clinical outcomes by urgency category
12383	Distribution of reported incidents by verification status, availability and source of alerts, type of health facility affected, and type of attack
12384	Distribution of reported incidents by category of person involved  (several categories possible)
12385	Types  *   of violence to which health workers were subjected  (several categories possible)
12386	Distribution of victims of reported incidents, by outcome, age, and gender
12387	Number and recurrence of verified reported attacks on hospitals and primary or mobile facilities, by governorate
12388	Distribution of all reported incidents by governorate and by level of service and impact on functionality
12389	Changes in Mitral Regurgitation Overall and by Lesion Type legend
12390	Changes Observed With Regression, Stability or Progression of Mitral Regurgitation Using a Threshold of Change >8 ml legend
12391	Results of Multivariate Analysis legend
12392	Quality measures for acute myocardial infarction and acute ischaemic stroke in China, the USA, and the UK
12393	Engagement of stakeholders in quality improvement and evidence generation
12394	Quality improvement initiatives and achievements for care of acute myocardial infarction and acute ischaemic stroke care in the USA, the UK, and India
12395	Delivery channels, examples of interventions, and common bottlenecks
12396	Strategies to improve service delivery and reduce bottlenecks
12397	Diagnostic Value of Transesophageal Echocardiography for Specific Mitral Valve Lesions legend
12398	Trends in access to health services in 2003–11 by region
12399	Incremental Diagnostic Value of Transesophageal Over Transthoracic Echocardiography in Mitral Regurgitant Lesions legend
12400	Trends in health-care activities by region: 2003, 2008, and 2011
12401	Outcome of Surgery According to Gross Anatomic Classification by Transesophageal Echocardiography legend
12402	Trends towards financial protection by region: 2003, 2008, and 2011
12403	Trends in equity  (ratio between comparison groups)  in access and financial protection across regions and income groups: 2003, 2008, and 2011
12404	Outcomes after Biphasic and Monophasic Defibrillation legend
12405	Associated Cardiovascular Anomalies  (N = 202)  legend
12406	Factors Associated with Death Before Hospital Discharge in Patients Undergoing Repair of Persistent Truncus Arteriosus  (N = 148)  legend
12407	Neonatal and predischarge mortality
12408	Cause of death
12409	Frequency of secondary outcomes
12410	Univariate Correlates of Pulmonary Capillary Wedge Pressure in the Training Population  (n = 20)  legend
12411	Diagnostic Accuracy of IVRT, FPV and Related Indexes in the Entire Study Group for Detection of Pw > 15 mm Hg legend
12412	Coefficients of the Correlation Between Doppler Parameters and Pulmonary Capillary Wedge Pressure According to Left Ventricular Systolic Function in 54 Patients legend
12413	Reproducibility of IVRT and FPV legend legend
12414	Volumetric Progression—Overview legend
12415	Volumetric Progression—Changes Over Time legend
12416	Time-series analysis of PAD rates  (persons affected by disaster per 1000 population)  by region in El Niño and post-Niño years compared with pre-Niño years, and correlation with SST anomalies, 1964–93
12417	Time series analysis of PAD rates in El Niño and post-Niño years compared with pre-Niño years and correlation with SST anomalies, by type of disaster, 1964–93
12418	Quantitative Angiography Acute and Follow-up Results  (40 Patients)  and Planar Intravascular Ultrasound  (45 Patients)  Procedural Results of Rotational Atherectomy With Adjunct Percutaneous Transluminal Coronary Angioplasty  (PTCA)  for Diffuse In-Stent Restenosis
12419	Outcome by group
12420	Aortic Valve Disease at the Time of Mitral Valve Surgery and at Follow-up legend
12421	Cumulative Proportion of Significant Aortic Valve Disease-Free Patients
12422	Positions of primers and amplification products in prototypic flavivirus genome
12423	Sequence-analysis data for New York isolate genome with Kunjin and West Nile viruses
12424	Results of the Different Time Periods in Accordance With the Cutoff Points of Troponin-I Values legend legend
12425	Results in Consideration of Duration of Extracorporeal Circulation and Age in Accordance With Serum Creatinine, Urea, ASAT and ALAT  (Indicated as a Quotient of the Upper Limit of Norm) , Duration of Intubation and Troponin-I  (cTnI)  Values legend
12426	Results
12427	Effect of clomipramine on lung and brain uptake of 11C-cyanoimipramine
12428	Processes of Care During the Index Hospital Admission for 42,731 Patients Readmitted or Not Readmitted for Congestive Heart Failure ∗
12429	Resource Utilization and Crude Clinical Outcomes During the Index Hospital Admission for 42,731 Patients Readmitted or Not Readmitted for Congestive Heart Failure ∗
12430	Calculation of Simple Risk Score for Readmission
12431	Correlation Matrix  (R)  for Physician Outcomes ∗
12432	Distribution of infectivity and PrPSc of orally-infected hamsters
12433	Phantom Exposure Measurements legend
12434	Variation in Exposure Rate With Projection legend legend
12435	PEMNET Exposure Results—General Grouping legend
12436	PEMNET Exposure Results—Interventional Subgroups legend
12437	PEMNET Exposure Results—Grouped by Patient Chest Dimension for Interventional and Diagnostic Procedures legend
12438	Results for the Principal Analyzed Parameters legend
12439	Clinical and Electrophysiology Findings legend
12440	Diagnosis and Preoperative Diagnostic Modality in 503 Patients With Major Congenital Heart Defects
12441	Indications for Cardiac Catheterization in 91 Patients legend
12442	Associated Defects in 76 Patients With a Combination of Defects legend
12443	Major and Minor Diagnostic Errors in 503 Patients
12444	Risk Factors of Patients Undergoing CABG Surgery or Angioplasty for the First Time, in New York: 1993–1995 legend
12445	Three-Year Survival by Treatment in Each Anatomic Subgroup legend
12446	Study 1: Percent Success of Waveforms  legend
12447	Study 2: Percent Success of Waveforms  legend
12448	Operative and Postoperative Data in Patients Undergoing Repair of Outflow Tract Obstruction Due to AV Valvar Anomalies  legend
12449	Heart Rate  (beats/min)  and Systolic Blood Pressure  (mm Hg)   legend
12450	Forearm Blood Flow  (FBF, ml/min/100 ml arm)  and Platelet cGMP Levels  (pmol/109PLT)   legend
12451	Predisposing Factors of Preoperative Valve Regurgitation legend legend
12452	Quantitative Angiographic Data legend
12453	Six-month Angiographic Restenosis and 1-year Follow-up Clinical Events for the Stent and Optimal PTCA Groups legend
12454	Study Population Postoperative Echo Findings
12455	Indications for Dobutamine Echocardiography  legend
12456	Independent Predictors of Mortality  legend
12457	Independent Predictors of Mortality in Revascularized Patients legend
12458	Quantitative Coronary Angiographic Data legend
12459	Clinical Events in the Hospital and During Follow-Up and Length of Hospital Stay  legend
12460	Clinical Variables Before and During Combined Therapy
12461	Clinical Outcomes of Patients at Time of Last Follow-Up  (mean 20.9 ± 3.9 months)
12462	Resource Utilization After Initial Hospital Stay  a
12463	Independent Pretreatment Correlates of In-Hospital LogeCost  a
12464	Overall Independent Correlates of In-Hospital LogeCost  a
12465	Pretreatment Correlates of 12-Month LogeCost  a
12466	Overall Correlates of 12-Month LogeCost  a
12467	Preprocedural Correlates of Three-Year LogeCost  a
12468	Overall Correlates of Three-Year LogeCost  a
12469	Independent Risk Factors for Mortality  (Cox proportionate hazards modeling)   a
12470	Outcomes by Age at First Required Intervention
12471	Most Frequent Specific Cancer Sites in the Study Cohort
12472	Risk Ratio Estimates for Cancer Associated With Calcium Channel Blocking Agent Use
12473	Adjusted Relative Risk Estimates for Total Mortality Associated With Calcium Channel Blocking Agent Use  a
12474	Adjusted Relative Risk Estimates for Cancer-Related Mortality Associated With Calcium Channel Blocking Agent Use
12475	Relation Between the Associated Anomalies and Rastelli Classification  a
12476	Geometric Relation Between the Atrioventricular Valve and the Great Arteries
12477	Diametric Ratios of the Great Arteries and the Ventricular Outlets
12478	Degree of Deficiency of the Ventricular Septum
12479	Previous Surgical Procedures in the 75 Study Patients
12480	Early Postoperative Outcome After Initial Resection of Subaortic Stenosis in the 75 Study Patients
12481	Late Surgical Outcome in Patients With a Low  (Group I)  or a High  (Group II)  Preoperative Left Ventricular Outflow Tract Gradient
12482	Surgical Procedures Performed at the Second Operation in 13 Patients
12483	Clinical Outcome in Patients With a Low  (Group I)  or a High  (Group II)  Preoperative Left Ventricular Outflow Tract Gradient
12484	Invasive Hemodynamic Variables
12485	Agreement Between Invasive and Noninvasive Determinations of Hemodynamic Variables
12486	Associated Cardiac Abnormalities in Propositi and Relatives of Subjects With Familial Versus Nonfamilial Bicuspid Aortic Valve
12487	Results of Questionnaire Used to Assess Patient Discomfort at Highest Tolerable Shock Level  (n = 19 patients)
12488	Requirement for Sedation at Different Shock Levels During Low Energy Transvenous Atrial Defibrillation
12489	Profiles of 15 Patients With Truncus Arteriosus Communis
12490	Logistic Regression Results for Early Discharge Model
12491	Percentage of Patients Discharged Within 5 Days of Coronary Artery Bypass Graft Surgery by State  a
12492	Logistic Regression Results for Death and Cardiovascular Readmission or Death Models
12493	Inclusion Criteria
12494	Patient Profile
12495	Univariate Regression Analysis of Variables That Predict Survival
12496	Frequency of Thrombolysis in Myocardial Infarction Grade 3, 2 and 1 Flow Achieved in Protocols 1 and 2
12497	Success Rate of Ultrasound-Guided Compression Repair in Patients With or Without Anticoagulant Therapy, Pretreatment With a Compression Bandage and Length of the Aneurysm Track
12498	Patients Discharged From the Hospital With One or More Coronary Artery Bypass Grafts, All-Listed Percutaneous Transluminal Coronary Angioplasty and Cardiac Catheterization Procedures by Race for Those 35 to 84 Years Old in the National Hospital Discharge Survey: United States, 1980 to 1993
12499	Hemodynamic and Echocardiographic Data at Each Pacing Rate and Pacing Site
12500	Reactive Hyperemic Response Before and 6 Months After Heart Transplantation
12501	Serum Phospholipid Fatty Acids and Lipids Before and 6 Months After Heart Transplantation
12502	Cyclosporine Doses/Trough Values and Prednisolone Doses
12503	Patient Diagnoses by Primary Bidirectional Cavopulmonary Shunt and Mean Age
12504	Additional Procedures Performed at Bidirectional Cavopulmonary Shunt
12505	Variables Analyzed for Correlation With Early and Late Outcomes
12506	Morphometric Variables in Infants With Critical and Severe Pulmonary Valve Stenosis
12507	Catheterization and Balloon Pulmonary Valvuloplasty
12508	Distribution of Perfusion Defects in Patients With Abnormal Findings on Thallium-201 Exercise Myocardial Scintigraphy and Coronary Angiography
12509	Variables Considered for Entry Into Cox Proportional Hazards Models
12510	Comparison of Follow-Up Variables in African Americans and Whites
12511	Multivariate Predictors of Survival for 530 African Americans in the CASS Registry
12512	Multivariate Predictors of Survival for Medical and Surgical Group Patients in the CASS Registry
12513	Stratified Survival Analyses in African Americans and Whites
12514	Angiographic Results of Coronary Angioplasty in Elderly Patients With Unstable Angina
12515	Short-Term Clinical Outcomes
12516	Kaplan-Meier Survival Estimates for Denver High Risk Patients Treated With Coronary Angioplasty for Unstable Angina
12517	Clinical Failure of Attempted Coronary Angioplasty in 28  (21%)  of 131 Elderly Patients With Unstable Angina
12518	NT-proBNP Cutpoints for the Diagnosis or Exclusion of Acute Decompensated HF
12519	Comparison of ROC Curves for NT-proBNP–Based Diagnosis of Acute HF Across Patient Subgroups
12520	Comparisons of Area Under the ROC Curve Along With LR+ and LR− for BNP or NT-proBNP Assays to Diagnose or Exclude Acute HF in Various Large Trials of Acute Dyspnea
12521	Median Values and Mutual Differences, Spearman’s Correlation Coefficients, Coefficients of Determination, and AUC Values of Resting Diastolic Indexes With Respectto iFR
12522	Relative Risk  (95% CI)  of Cardiovascular Events According to Frequency of Nut Consumption
12523	Relative Risk  (95% CI)  of Cardiovascular Events According to Type of Nuts
12524	Appropriateness of TTEs Ordered by Intervention and Control Group
12525	Proportion of TTEs Ordered by Appropriateness Category and Treatment Group for Physicians With≥1 TTE/Month
12526	Changes in LDL-C and Other Lipids and Lipoproteins: Crossover Phase
12527	Response to Rosuvastatin in Pediatric HoFH Patients  ∗
12528	Response to Rosuvastatin in All Pediatric and Adult HoFH Patients  ∗
12529	AE Frequency
12530	Examples of Food Items Constituting the 18 Food Groups  (From the 1984 NHS FFQ)
12531	HR  (95% CI)  for CHD According to Deciles of the PDI
12532	HR  (95% CI)  for CHD According to Deciles of the hPDI
12533	HR  (95% CI)  for CHD According to Deciles of the uPDI
12534	Study Endpoints and Outcomes at the Maximum Available Follow-Up
12535	Bivariable Proportional Hazards Regression
12536	Trend of Cardiovascular Risk Factors in the Study Cohort Across 2003 to 2011
12537	Multivariable Hierarchical Logistic Regression Model for In-Hospital Mortality Among Patients With CLI Admitted to Hospitals During 2003 to 2011
12538	Subgroup Analyses for Death, Major Amputation, Likelihood of Any Revascularization, and Likelihood of Endovascular Revascularization in the Study Cohort on the Basis of A Priori–Defined Subgroups
12539	Clinical Outcomes in Matched Transcatheter Aortic Valve Replacement Plus Left Main Coronary Artery Percutaneous Coronary Intervention and Control Patients
12540	Clinical Outcomes According to Planned and Unplanned Left Main Coronary Artery Percutaneous Coronary Intervention
12541	Univariate Predictors of 30-Day and 1-Year Mortality After Transcatheter Aortic Valve Replacement Plus Left Main Coronary Artery Percutaneous Coronary Intervention
12542	Health Care Use in Later Life by Category of Midlife Fitness  (N= 19,571)
12543	Incremental Decrease in Average Annual Health Care Costs in Later Life per MET Achieved in Midlife  (N= 19,571)
12544	Health Care Use of CCLS Participants Surviving Through Medicare Follow-Up Versus CCLS Participants Deceased During Medicare Follow-Up by Category of Midlife Fitness  (N= 19,571)
12545	Quality of Care and Clinical Outcomes by EHR Status
12546	Multivariable Analyses for Primary Outcomes, Hospitals With Versus Without EHRs
12547	Events by Tertiles
12548	Risk of Endpoints  ∗
12549	Risk of Endpoints by Tertile  ∗
12550	Primary and Secondary Endpoints–Patients With 18-Month Visit
12551	Quality-of-Life Endpoints: Patients With 18-Month Visit
12552	Association Results for Ejection Fraction Response
12553	Survival per Number of Pre-Operative Malperfused Organ Systems
12554	Pre-Operative Risk Factors for Any Post-Operative Malperfusion
12555	Risk Factors for Post-Operative Coronary Malperfusion
12556	Risk Factors for Post-Operative Cerebral Malperfusion
12557	Risk Factors for Post-Operative Visceral Malperfusion
12558	Risk Factors for Post-Operative Renal Malperfusion
12559	Risk Factors for Post-Operative Spinal Malperfusion
12560	Risk Factors for Post-Operative Peripheral Malperfusion
12561	Risk Factors for Death
12562	Percentage of Women Recommended for StatinTherapy and Guideline Performance on the Basis of VaryingRisk Cutoffs
12563	Percentage of Men Recommended for Statin Therapy and Guideline Performance on the Basis of Varying Risk Cutoffs
12564	Reclassification of Study Participants Into Groups With Low, Medium, and High 15-Year Risk of CVD by Addition of Lp (a)  toaModel Containing the Reynolds Risk Score Variables  ∗
12565	Improvement in 15-Year CVD Risk Prediction by Use of Lp (a)  on Top of a Model Containing the Reynolds Risk Score Variables  ∗
12566	Risk Evaluation for Atrial Fibrillation and Alcohol Use
12567	Comparison of the Clinical Profiles of Patients With or Without Coronary Events
12568	Coronary Events During the Follow-Up Period
12569	Univariate Cox Regression Analysis of Risk Factors for All Coronary Events
12570	C-Index Analysis Demonstrating Discrimination for Prediction of All Coronary Events
12571	Best Predictive Model Selected by Stepwise Cox Regression Analysis of Risk Factors for All Coronary Events
12572	Effects 7 Days Post-Treatment Ordered According to Increasing NEPI Values
12573	FFR Thresholds on The Basis of Outcomes Using Various Models
12574	Summary of Published Data Comparing FFR-Guided or FFR-Assisted Strategy to an Anatomy-Based Strategy
12575	SYNTAX Protocol and ARC/ARC-Like Definitions of ST and GO
12576	Association of First ARC ST or ARC-Like GO Event With 5-Year Cardiac Death
12577	Multivariable Cox Regression Analyses of Early  (<30 Days)  and Late/Very Late  (30 Days to 5 Years)  ARC Definite/Probable ST and ARC-Like Definite GO at 5 Years
12578	Risk of SBI or log-WMHV Q4 Associated With the Presence of PFO or PFO+ASA
12579	Risk of Ischemic Stroke and Combined Vascular Events by PFO/ASA Status, in the Overall Study Population and in Age, Sex and Race/Ethnicity Subgroups
12580	Difference in CT Parameters Between Patients With and Patients Without ACS for Conventional CT Reading and Semiautomated Quantitative Parameters
12581	ROC Analysis of CT-Derived Parameters to Predict Occurrence of ACS
12582	Independent Predictors of ICR in All-Comers PCI and CABG Populations
12583	Independent Predictors of ICR in TO Patients Within All-Comers PCI and CABG Populations
12584	One-Year Mortality HRs Stratified by Age Groups Adjusted for Sex, Age, Comorbidity, and Pharmacotherapy
12585	Long-Term Mortality HRs Stratified by Age Groups Adjusted for Sex, Age, Comorbidity, and Pharmacotherapy
12586	Event Rates and HRs of Recurrent Syncope Stratified by Age Groups Adjusted for Sex, Age, Comorbidity, and Pharmacotherapy
12587	Angiographic Endpoints at 12-Month Follow-Up
12588	Clinical Endpoints at 12-Month Follow-Up
12589	Operative Details of Staged Palliative Procedures
12590	Predictors of Incident Heart Failure in Multivariate Analysis  (N = 5,934)   ⁎
12591	Cost of Health According to Study Assignment  ($AU)
12592	Echocardiographic and Clinical Response to CRT
12593	Univariate and Multivariate Cox Proportional Hazards Model for Death, Heart Transplantation, and Left Ventricular Assist Device Placement
12594	Acute Results in All Cases or Those With Sustained AF During Their Procedure
12595	Intragroup Pharmacodynamic Analysis
12596	Factors Predictive of VT Recurrence After Ablation
12597	Differences in OCT Measurements Between Stenoses With FFR >0.80 or ≤0.80
12598	Differences in IVUS Measurements Between Stenoses With FFR >0.80 or ≤0.80
12599	Coding Sequence Variants Identified in K+ Channel Genes
12600	Distribution of Variants in AF Probands and Control Subjects
12601	Effects of K+ Gene Variants on In Vitro Cellular Electrophysiology and Post-Translational Modification
12602	Descriptors
12603	Primary Events by Sex
12604	All-Cause Mortality by Sex
12605	OCT Measurements
12606	Association of Family History of PAD With Prevalent PAD
12607	Association of Number of First-Degree Relatives With PAD and Prevalent PAD  ⁎
12608	Predictors for Composites of Death, MI, Repeat PCI, or CABG at 1 Year
12609	Homocysteine and CV Outcomes in the MESA Population
12610	Homocysteine and CV Mortality in the NHANES III Population
12611	Comparison of Risk Prediction Models With FRS With and Without Homocysteine in the MESA and NHANES III Cohorts
12612	6-Year Risk of Hard CHD Event in the MESA Population in Models With and Without Homocysteine
12613	Ten-Year Risk of CHD Death in the NHANES III Population in Models With and Without Homocysteine
12614	Electrocardiographic Measurements and Sites of Successful Ablation in the Retrospective Cohort
12615	Value of NGAL Complements Prognosis in Patients Without Diagnostic Creatinine Increase
12616	Outcome According to Urine NGAL Versus Plasma NGAL
12617	Possible Combinations of NGAL and sCREA Status
12618	Incidence of Neoatherosclerosis Stratified by Duration of Implant
12619	Independent Risk Factors for Neoatherosclerosis
12620	Multivariate Analysis  (Total Population) : Predictors of First and Recurrent Syncopal Events  ⁎
12621	Multivariate Analysis  (Cox Model) : Recurrent Syncope as a Predictor of ACA/SCD  ⁎
12622	FDA Label: Range of Expected Therapeutic Warfarin Doses  (mg/day)  Based on CYP2C9 and VKORC1 Genotypes
12623	IWPC Cohort: Mean Therapeutic Warfarin Dose  (mg/day)  by CYP2C9 and VKORC1 Genotype in 2,858 Patients
12624	Percentage of Participants Who Reported Use of Pharmacologic Aids for Smoking Cessation During Study Period on 6-Month Survey  (n = 95)
12625	Relationship Between Study Condition and Abstinence at 3- and 6-Month Follow-Up
12626	12-Month Results by Randomization in the Non-IHD and IHD Groups and Their Interaction by Regression Model
12627	Assessment of Independent Predictors of Response
12628	Conventional Risk Factors and Biomarkers for Prediction of Incident HF and AF
12629	Discrimination and Risk Category Reclassification Using Biomarkers
12630	Risk Classification by Models With and Without Biomarkers for HF or AF
12631	Comparison of Risk During Follow-Up of Patients in Coenzyme Q10 Tertile 1 Compared to Tertile 3 in the Placebo Group  ⁎
12632	3-Dimensional Electroanatomic Atrial Mapping Data
12633	Endocardial Conduction During NCAS-AT and Pacing Protocol
12634	Readmission Rates According to Group Assignment and Depressive Symptoms
12635	Morphometric Comparison Between Flow Divider Versus Lateral Wall in DES and BMS
12636	Clinical Outcomes After Intervention
12637	Cumulative Incidence of Amputation: Univariate Fine-Gray Analysis
12638	Cox Analysis Overall Survival
12639	Comparison of Outcomes in the PaRADISE Study Versus BASIL Study: Amputation-Free Survival and Overall Survival
12640	Reasons for Missed LVESVi Paired Difference
12641	Scan Parameters in Groups 1 and 2
12642	Comparison of Evaluability and Artifacts in Groups 1 and 2
12643	Comparison of Image Quality Score in Groups 1 and 2
12644	Comparison of the Diagnostic Accuracy of MDCT for the Detection of Significant  (>50%)  Coronary Stenosis and In-Stent Restenosis Between Groups 1 and 2
12645	Comparison of Multidetector Computed Tomography Radiation Dose Parameters in Groups 1 and 2
12646	Coronary Wall MRI Measurements
12647	Multivariable Results for Those With Available Follow-Up Medication Information  (n = 7,719)
12648	Serial Intravascular Ultrasound Data
12649	Distribution of HLHS and Associated CVM in 33 Families  (208 Individuals)
12650	Distribution of BAV and Associated CVM in 102 Families  (805 Individuals)
12651	Effects of Shock Strength
12652	Vm and Cai Changes Induced by Shock on T
12653	Patient Management
12654	Diagnostic Performance of CCA and CTCA to Detect a Functionally Significant Coronary Stenosis  (FFR <0.75, FFR <0.80)
12655	Independent Predictors of AF According to Stepwise Logistic Regression Analysis
12656	Frequency of Occurrence of Unicuspid and Bicuspid Aortic Valves Morphologies  (n = 63)
12657	Cusp Morphology and Corresponding Repair Maneuvers  ⁎
12658	Commissure Morphology and Corresponding Repair Maneuvers  ⁎
12659	Multiple Regression Analyses
12660	Intraobserver and Interobserver Variability for the Different LV Dyssynchrony Parameters
12661	Linkage in Family VAF-1 to Markers at 5p15
12662	Endothelial Cell Specificity of Angiogenesis Assay
12663	Comparison of Early EPCs and OECs
12664	Predictors of High Telomerase Activity in Coronary Plaque Neutrophils in Unstable Angina
12665	Relationships Between Load and E/E′
12666	Relationships Between Load and S′
12667	Relationships Between Load and Late-Diastolic  (A)  Filling
12668	HTN Versus Non-HTN Subjects
12669	Below Heart Level Measurements
12670	Heart Level Measurements
12671	Comparison of Echocardiographic Parameters That Measured Atrial Function for Responders and Nonresponders of CRT
12672	Association of the 3 SNPs With CHD in the First Population
12673	Association of the 3 SNPs With CHD in the Second Population
12674	IVUS Measurements
12675	IVUS Measurements Stratified by the Remodeling Index
12676	Temperature Difference Stratified by Remodeling Index and Type of Syndrome
12677	Temperature Difference Stratified by Plaque Rupture and Type of Syndrome
12678	Bicuspid Aortic Valve Progression
12679	Prevalence of CAC at Year 15 in the CARDIA Study, 2000 to 2001
12680	ORs for Having CAC at Year 15 by Cardiovascular Risk Factors in 3 Multivariate Models  ⁎  Using Levels at Year 0, Year 15, and the Average Over 15 Years † From the CARDIA Study  (n = 2,433)
12681	Sleep-Related Breathing Disorders in 88 Heart Failure Patients With or Without Central Sleep Apnea
12682	Pulmonary Function Tests and Selective Blood Tests in 88 Patients With or Without Central Sleep Apnea
12683	Univariate Analysis for Survival Time and 24 Related Variables in 88 Patients With Systolic Heart Failure
12684	Agreement Between Differential Lung Perfusion Estimated by PS Versus Magnetic Resonance Flow Measurements
12685	Effect of Covariate Adjustments on the Association Between Gender and 30-Day Mortality
12686	Survival Benefit of ICD by SBP and DBP Quartiles  ⁎
12687	Medication Usage of Patients With and Without Stent Thrombosis
12688	Univariate and Multivariate Predictors of Stent Thrombosis
12689	Mortality Risk of Calendar Year 2000 Relative to 1980, Stratified by Age for the Overall Population and Various Subgroups
12690	Multivariable Models for Prediction of Early  (Within 4 Months)  or Late Death  (After 4 Months)
12691	Catheterization Data Before and After Initial Stent Placement
12692	Echocardiographic Data Before and After Initial Stent Placement
12693	Variability of Ejection Fraction Determinations  (EF Units)
12694	Outcomes at 3 Years
12695	Age-Adjusted Odds Ratios  (With 95% Confidence Intervals)  for Elevated EDPR and TR gradients
12696	Multivariate-Adjusted  ⁎  Odds Ratios  (With 95% Confidence Intervals)  per 5-mm Hg Increase in EDPR or 10-mm Hg Increase in TR
12697	Number of Veins Affected in Each Patient With the Associated Other Veins and the Total Stenosis Index of the Veins Draining Each Lung
12698	Animals and Study Protocol
12699	Quantitative Measurements in Venous Anatomy From MSCT
12700	Effects of Elastic Bandage During Tilt Testing in the 20 Patients With Progressive Orthostatic Hypotension
12701	Specific Symptom Score—Orthostatic Intolerance  (SSS-OI)  in 21 Patients and 21 Control Subjects
12702	Multivariate Predictors of Plaque Plus Media Cross-Sectional Area Increase
12703	Laboratory Tests and Serial IVUS Data of Patients With and Without Clinical End Points and/or Revascularization Procedures During Follow-Up
12704	Multivariate Predictors of Adverse Cardiovascular Events  (Clinical End Points and/or Revascularization Procedures)  During Follow-Up
12705	Antidepressant Therapy
12706	Metabolic Markers in the Subset of 20 Patients With Available Fasting Plasma
12707	Independent Determinants of the Hemodynamic Progression of Aortic Stenosis
12708	Predictors of Outcome in Univariate and Multivariate Analysis
12709	Independent Risk Factors of ACS Event by Multivariate Logistic Regression Analysis
12710	Major Adverse Cardiac and Cardiovascular Events: In-Hospital and During Follow-Up
12711	Oral Sirolimus Group at Baseline and at 21 Days: Laboratory Results and Adverse Reactions
12712	Results of Quantitative Coronary Angiography
12713	Indications for Insertion of Covered CP Stents
12714	Results
12715	Comparison of AF-Induced Electrical Remodeling and its Effect on AFCL in Normal and Dilated Atria
12716	Current Medication of the Study Population
12717	Multivariate Linear Regression Analysis
12718	Sensitivity, Specificity, and Positive and Negative Predictive Values of SPWMD ≥130 ms for Reverse Remodeling and Clinical Improvement
12719	Patients With Complications During InSync III Implant Attempts and Follow-Up
12720	Percentage Improvement in Stroke Volume  ⁎
12721	Percent Improvement in Stroke Volume for the Subset of Patients With Maximum Stroke Volume at a V-V Delay Other Than Nominal
12722	Comparison of Stroke Volume Improvement Among InSync III Subgroups
12723	Expert Panel ECG Diagnoses
12724	P-Wave Morphology During Tachycardia
12725	Serial Three-Dimensional Intravascular Ultrasound Analysis of Neointima and Plaque Volume
12726	Percent Hypoechogenic Tissue Component in the Plaque and Neointima
12727	Graft Index for All-Cause Death Without Left Main or IMA Adjustment
12728	Graft Index With Left Main and Internal Mammary Adjustments Recalculated Using All Patients
12729	Training Set Models for All-Cause Death  (n = 2,729)
12730	Validation Set Models for All-Cause Death  (n = 449)
12731	Models for All-Cause Death With the Graft Index and Clinical Variables
12732	Models for Death or Revascularization With the Graft Index and Clinical Variables
12733	ARI Restitution Slope and Magnitude of Restitution
12734	Clinical and Angiographic Data of the Patients  (n = 89)
12735	Fractional Flow Reserve and Angiographic Percent Stenosis in Jailed SideBranches
12736	Procedural, QCA, and IVUS Data for Non-LM Lesions With IVUS of Both Branches  (n = 20)
12737	Comparison Between IC Versus CC in Patients With Non-Left Main Lesions and IVUS of Both Branches
12738	Procedural, QCA, and IVUS Data LM Lesions With IVUS of Both Branches  (n = 5)
12739	Angiographic Data
12740	Exercise Hemodynamics
12741	Quantitative Coronary Angiography
12742	Details of Segmental Coronary Anatomy in the Patient Population as Defined by QCA and Diagnostic Accuracy of Visual Analysis
12743	Reasons for False Positive and Negative Evaluations by MR and MDCT
12744	Sensitivity and Specificity of Wavelet Analysis of Radiofrequency Intravascular Ultrasound Signals for Detecting Lipid-Laden Plaque
12745	P-Wave Morphology
12746	5 μM ADP-Induced Aggregation and Clopidogrel Responsiveness
12747	20 μM ADP-Induced Aggregation and Clopidogrel Responsiveness
12748	24-h Holter Monitoring Analysis in Patients With Successful Procedure
12749	Patients Symptoms and Medications Before Radiofrequency Catheter Ablation
12750	Follow-Up Data of Patients With Unsuccessful Procedure
12751	Postoperative Doppler Echocardiographic Data
12752	Independent Determinants of Postoperative Systolic Pulmonary Arterial Pressure
12753	Measurements of LV Chamber and Mitral Apparatus
12754	Serum Lipids and High-Sensitivity C-Reactive Protein Levels After 12 Months of Treatment
12755	Changes in Vessel Wall Thickness, Vessel Wall Area, and Lumen Area After 12 Months of Treatment
12756	Changes in Vessel Wall Thickness, Vessel Wall Area, and Lumen Area After 12 Months of Treatment
12757	Changes in Vessel Wall Area After 12 Months of Treatment in Patients With and Without Prior Statin Use
12758	Correlations of Changes in Vessel Wall Area With Those in Lipid and High-Sensitivity C-Reactive Protein Levels
12759	Quantitative Coronary Analysis of Angiograms
12760	Plasma Lipids
12761	Quantitative Coronary Analysis in the 387 Patients With Both IVUS-Related and Non-IVUS Arteries
12762	Clinical and Thyroid Profile in Control Subjects and Patients With Subclinical Hypothyroidism Before Therapy  (All Patients Enrolled)
12763	Clinical and Thyroid Profile in Subclinical Hypothyroidism Patients Before and After Therapy
12764	Morphologic and Global Functional Parameters of the Left Ventricle in Control Subjects and Subclinical Hypothyroidism Patients Before Therapy  (All Patients Enrolled)
12765	Morphologic and Global Functional Parameters of the Left Ventricle in the Subclinical Hypothyroidism Patients Before and After Therapy
12766	Anatomic Results of MSCT Versus ICE
12767	Measurements of Ostia Pulmonary Veins: MSCT Versus ICE
12768	Indexes of Diameters Measured in Anterior-Posterior and Superior-Inferior Direction of Pulmonary Venous Ostia, as Measured With MSCT
12769	Status of Study Patients at Each Angiographic Period
12770	Predictors of Long-Term Graft Occlusion Using All Grafts
12771	Predictors of Long-Term Graft Occlusion Given Grafts Were Open Early
12772	Patients
12773	Acute Hemodynamics Effects of CRT
12774	Mid-Term Changes Associated With CRT
12775	Recurrent Events
12776	Recurrent Events Stratified According to Treatment
12777	Individual Recurrent Events Grouped by Treatment Allocation
12778	Right Heart Catheterization Data of Patients Stratified by Severity of Tricuspid Regurgitation After Pulmonary Thromboendarterectomy
12779	Angiographic and IVUS Measurements at Postprocedure
12780	Diagnostic Values of Optimal Threshold for SES and BMS
12781	Clinical and Angiographic Data
12782	Coronary Flow Velocity Data
12783	Results of Quantitative Coronary Angiography
12784	Two-Dimensional Quantitative Intravascular Ultrasound Results
12785	Three-Dimensional Quantitative Intravascular Ultrasound Results
12786	Standardized Interpretative Advice Accompanying N-BNP Results
12787	Change in Correct Diagnoses of Patients Presenting With Suspected HF in BNP and Control Groups
12788	Peri-Procedural Complications
12789	Adverse Events
12790	In-Hospital and One Year Clinical Events
12791	Initial and Follow-Up Angiographic Results
12792	Transthoracic Impedance and Current
12793	Shock-Induced Toxicity
12794	Comparison of Patients With CTOs With and Without TVF
12795	Collateral and Coronary Hemodynamic Assessment in Patients With CTOs
12796	Factors Used to Predict Ventricular Tachyarrhythmia Recurrence in ICD Patients
12797	The P-Wave Morphology During Tachycardia
12798	Change in Mean AERP Before and During Rapid Atrial Pacing
12799	Change in Mean Intra-Atrial Conduction Time Before and During Rapid Atrial Pacing
12800	Angiographic and Hemodynamic Data in Seven Dogs
12801	Clinical, Angiographic, and Hemodynamic Data in Angina Patients
12802	Comparison of Electrophysiological Parameters in Ntg and Tg Mice
12803	Echocardiographic and Hemodynamic Parameters Are Summarized for 4-, 8-, and 9- to 12-Month-Old Ntg and Tg Mice
12804	Outcomes by Heart Failure Etiology
12805	Outcomes by Heart Failure Etiology and Treatment Assignment
12806	Discharge Medications by Heart Failure Etiology and Treatment Assignment
12807	In-Hospital Outcomes
12808	Multivariate Logistic Regression Model
12809	Unadjusted Outcomes *
12810	Multivariate Risk Models for 30-Day Mortality, 6-Month Mortality, and 30-Day Complications *
12811	Progression of Aortic Stenosis According to Statin Treatment
12812	Final Multiple Variable Cox Regression Model Showing the Independent Protective Effect of Statins
12813	Clinical Outcomes, Electrocardiographic and Hemodynamic Data for the SCD and Control Groups
12814	Regional and Global Left Ventricular Ejection Fraction  (%)
12815	Hemodynamic Effects
12816	Coronary Vascular Effects of Sildenafil
12817	Study 2: Effects of Placebo, Sildenafil, and Isosorbide Dinitrate on Exercise Parameters
12818	Stent Engineering Data
12819	Crossing Profile
12820	Stent Consumer’s Guide
12821	Left Ventricular Volumes and Regional Myocardial Shortening During Long-Term Follow-Up in Survivors  (n = 20)
12822	Lateral-Septal Phase Relationship Types
12823	Noninvasive Measures of Asynchrony and Individual Hemodynamic Response to Cardiac Resynchronization Therapy
12824	Rest Heart Rate and Number and Type of Positive Tilt Test Responses at Diagnosis and After Each Drug Treatment
12825	Anatomic Combinations of Site of Endocardial Pacing Leads
12826	Single Site Pacing
12827	Biatrial Pacing
12828	Hematologic and Coagulation Values in Each Animal Before and 60 Min After Stent Placement and Histomorphometric Values of Sections of Stented Blood Vessels
12829	Hemodynamic Parameters
12830	Treadmill Exercise Time to Moderate Angina  (s)
12831	Patients With Aneurysm After Surgical Coarctation Repair
12832	Patients With and Without Aneurysm After Coarctation Repair
12833	Reported Prevalence of Aortic Aneurysm After Coarctation Repair
12834	Multivariate Analysis
12835	Histologic and Morphometric Analysis of the Effects of the Different dODN in the Coronary Angioplasty Model
12836	Estimated Mean Number of Microbubbles After Agitation of 10% Air-90% Saline Mixture, 10% Air-10% Blood-80% Saline Mixture and 10% Air-10% Plasma-80% Saline Mixture legend
12837	Morphologic and Morphometric IVUS parameters
12838	Logistic Regression Model for Predicting Risk of In-hospital Death After CABG
12839	Observed In-hospital CABG Mortality Rates at Low- and High-volume Hospitals Across Risk Groups *
12840	Observed Lenth of Stay and Hospital Costs of CABG at Low- and High-volume Hospitals Across Risk Groups *
12841	Estimated Outcomes of Full and Targeted Regionalization of CABG *
12842	Quantitative Coronary Angiography Measurements  (means ± SE)
12843	Intravascular Ultrasound Area Measurements in mm2 (means ± SE)
12844	Relative EEL Areas
12845	Hemodynamic Data Obtained by Electromagnectic Flow Probes and Meters legend
12846	Echocardiographic Assessment of Left Ventricular Volumes: Comparison With EBCT legend legend
12847	Intraobserver and Interobserver Variabilities legend
12848	Components of Global Variability ∗ : Impact of Adding Contrast Injection on the Relative Distribution of Sources of Variability legend
12849	Admission, HF-WG, Peak and Subsequent WTs and Corresponding ECG Variables of Patients  (n = 28)  legend legend
12850	Procedural Variables legend legend
12851	In-Hospital Results legend legend
12852	Vascular Complications legend
12853	Predictors of Complications legend legend
12854	Measures of Falls Under Ambulatory Conditions  (n = 266)
12855	Fall History and Loss of Balance as Predictors of Falls During One-Year Follow-up legend
12856	Association between Orthostatic Blood Pressure Decline and Incidence of Falls on Follow-up legend legend
12857	Association of Antihypertensive Therapy With Falls on Follow-up legend
12858	Multiple Logistic Regression Analysis With Falls on Follow-up as Dependent Variable legend
12859	Correlations Between Echocardiographic Variables and Mean Left Atrial Pressure legend
12860	Hemodynamic Changes With Adenosine legend
12861	Myocardial Blood Flow and Coronary Vascular Resistance in Systemic Right and Systemic Left Ventricles legend
12862	Macrophage Count, Apoptosis Evaluation and Cell Death legend
12863	Qualitative Angiographic and IVUS Data legend
12864	Quantitative IVUS Parameters legend legend
12865	Definitions of Clinical Criteria for the Presence of Atherosclerotic Vascular Disease and Risk Factors
12866	Pre- and Posttreatment Measures of Endothelial Function legend legend
12867	Serial Echocardiogram Readings  (n = 219)  legend
12868	Side-By-Side Reads  (n = 219)  legend
12869	Reader Agreement: Serial Versus Side-by-side Reads Percentage Exact Agreement and Kappa Coefficients ∗   legend
12870	Comparison of Anterior and Posterior Right Atrial Electrogram Fractionation legend
12871	Hemodynamic Changes After Intraoperative Manipulation of Afterload
12872	Serial Two-dimensional Ultrasound Results legend
12873	Serial Volumetric Ultrasound Results in the Peristent Margins
12874	Angiographic and Hemodynamic Data on the Total 161 Coronary Lesions  (n = 127)  and for the Randomly Chosen 127 Lesions for the Per-Patient Analysis legend legend
12875	Per-Patient Analysis  (n = 127) : Accuracy for CFVR, rCFVR and FFR Versus the Results of Sestambi Single-Photon Emission Computed Tomography, Calculated for Best and Predefined Cut-Off Values legend legend
12876	Results of Previous Validation Studies for Intracoronary-Derived CFVR, FFR and rCFVR Versus the Results of Noninvasive Stress Testing legend
12877	Effects of Lipid-Lowering Treatment on Lipid Moieties legend
12878	Assessment of Coronary Artery Acetylcholine Responses, Pre- and Postlipid Lowering legend
12879	NCP, Adenonucleotides, Glycogen and Lactate in Myocardial Biopsies legend legend
12880	Hemodynamics, Transmitral Flow and TD Velocities During Volume Loading, IVC Occlusion, Dobutamine and Esmolol Infusions legend legend
12881	Intraoperative and Postoperative Course for CABG Versus MIDCAB legend
12882	Results of Univariate Logistic Regression for Postoperative AF legend
12883	Results of Multivariate Logistic Regression of Postoperative AF legend
12884	CABG Mortality, Complications, and Length of Stay by Race
12885	Comparison of Operative Mortality for Specific Subpopulations
12886	Multivariate Logistic Regression Model by Race
12887	Preintervention, Post-DCA and Stenting and Follow-up Quantitative Angiographic Measurements  (QCA Analysis)  legend
12888	PFO Detection by Three Echocardiographic Methods legend
12889	Prediction of PFO Opening Diameter by TMD Bubble Score legend
12890	Coronary Epicardial and Microvascular Responses According to the AT1 Receptor Gene Polymorphism legend legend
12891	Patient Distribution by Pacing Mode and Therapy Delivery  (n = 32)
12892	Number of Therapy Episodes in the 32 Data Pairs During Each of the 3-Month BV  (Biventricular)  Pacing and No-Pacing Periods
12893	Diagnostic Values of Various Thresholds of VCW to Identify Severe TR legend
12894	Kaplan Meyer Analysis for Major Events legend
12895	Cox Regression Analysis for Major Events legend
12896	Stepwise Multiple Regression Analysis on Pooled Data to Identify Determinants of PV Flow Variables
12897	Pulmonary Vein, LA and LV Pressures and Pulsed Doppler PV Flow Velocities legend
12898	Multivariate Predictors of SEC in NSR legend
12899	Relationship Between Ultrasound Power and Endothelial Vascular Endothelial Growth Factor Uptake With a Plateau Beyond 0.6 to 0.8 W/cm2  legend
12900	Enhanced Endothelial VEGF Uptake With US and Contrast Agent After Intravenous Injection ∗   legend
12901	Determinants of Natriuretic Peptide Levels in Multivariate Analysis legend
12902	Apolipoprotein E Genotype Frequencies in a Sample From the General Population and in Patients With IHD
12903	Fractions of IHD in the General Population Attributed to APOE Genotypes  (Relative to the epsilon33 Genotype)  and to Conventional Cardiovascular Risk Factors legend
12904	Late Lumen Loss and Relative Late Lumen Loss in Different Segments legend
12905	Distribution of Angiographic and IVUS Dimensions After PTCA Among Different Segments legend
12906	Multivariate Predictors of Late Lumen Loss and Relative Late Lumen Loss legend
12907	Uninterpretable and Sure Confidence Scores legend
12908	Wall Motion: Improved Confidence Scores legend
12909	Evaluating Segmental Wall Motion and Ejection Fragment
12910	Ejection Fraction Confidence Score legend
12911	Effects of Four Months of Treatment With Placebo and Omega-3 Fatty Acids legend
12912	Relation Between Electrocardiographic Signs of Severe Ischemia During PTCA and Three Variables for Assessing the Recruitable Collateral Extent legend
12913	Study Design: Digital Sequence Subsets
12914	Diagnostic Feature Types Within the 100 Digital Angiograms
12915	Hemodynamic and Angiographic Parameters Before and After BA  (No Missing Values)
12916	Left Ventricular  (LVEF)  and Right Ventricular  (RVEF)  Ejection Fractions, Left Ventricular  (LVMP)  and Right Ventricular  (RVMP)  Mean Phases, Left-to-Right Mean Phase Difference  (L-RMP)  and Phase Standard Deviations  (LVPSD and RVPSD)  for Both Ventricles in 14 Cases of Right Sided WPW legend
12917	Left Ventricular and Right Ventricular Ejection Fractions, Left Ventricular and Right Ventricular Mean Phases, Left-to-Right Mean Phase Difference  (L-RMP)  and Phase Standard Deviations for Both Ventricles in 30 Cases of Left Sided WPW legend
12918	Effect of Transthoracic Impedance on Delivered Current  (A)
12919	First-Shock Defibrillation Data for Monophasic and Biphasic Waveform Groups
12920	Patients Stratification legend
12921	Quality-of-Life Questionnaire
12922	Analysis of Lumen Dynamics legend
12923	Cumulative One-Year Clinical Outcome legend legend
12924	Plasma Neurohormone Concentrations for Both Groups at Rest and Peak Treadmill Exercise Both Before and After 16 Weeks of Exercise Training or Control Period legend
12925	Values of Transmitral and Pulmonary Venous Flow Parameters and Their Correlations With LA dP/dtmax  legend
12926	Procedural Outcomes and Clinical Events legend legend
12927	Quantitative Angiographic Results legend legend
12928	Final Intracoronary Ultrasound Results legend legend
12929	Predictors of Restenosis legend legend
12930	Associations of Angiographic Findings With Exercise and Recovery Blood Pressure Ratios legend
12931	Logistic Regression Analyses in Which Exercise and Recovery Blood Pressure Ratios Are Adjusted for Potential Confounders legend legend
12932	Logistic Regression Analyses in Which Potential Confounders, Recovery Systolic Blood Pressure Declines and Exercise Systolic Blood Pressure Increases Are Considered Together legend legend
12933	Measured Electrical Parameters at Defibrillation Threshold
12934	Comparison of Clinical Parameters of the High and Low Atrial Defibrillation Threshold Groups
12935	Hemodynamic and Procedural Variables for the Initial and Redo Percutaneous Mitral Balloon Valvuloplasty  (PMV)
12936	Independent Predictors of Long-Term Event-Free Survival  (Multivariate Cox Regression Analysis)  legend
12937	Color and Pulsed Wave Doppler Quality Before and After Contrast Enhancement legend
12938	Blood Flow Velocity and CFR Determined in the Left Anterior Descending Coronary Artery legend
12939	Floating Scheme of Patients Throughout the Study
12940	Serum Phospholipid Fatty Acids and Serum Lipids Before, Two Weeks and Six Months After Omacor and Placebo Treatment legend legend
12941	Restenosis Rate Per Patient and Per Treated Lesion in the Two Treatment Groups legend
12942	Primary Clinical Outcome Events legend
12943	Relationship of Preprocedural Heparin to Antithrombin Activity
12944	Association of Antithrombin Activity With Primary Outcome Events legend
12945	Univariate Association of Clinical, Angiographic, and Procedural Variables With Primary Outcome Events
12946	Relationship of Restenosis and Antithrombin Activity
12947	The Nucleotide Sequence of All Primers Used in the Study legend
12948	The Messenger Ribonucleic Acid Levels of Calcium-Handling Proteins in Patients With and Without Persistent Atrial Fibrillation for More than 3 Months legend
12949	The p Values of Correlation Between Messenger Ribonucleic Acid Levels of Calcium-Handling Genes and Clinical Parameters legend
12950	Effect of Pravastatin on Hospital Admissions by Trial Category legend legend
12951	Difference in Mean Number of Patients Hospitalized, Number of Admissions and Total Bed-Days per 1,000 Subject-Years legend
12952	Passive Compared With Single-Stage Isoproterenol Tilt Table Testing
12953	Comparison of Hemodynamics in Patients With a Vasovagal Response During Both Tests legend
12954	Angiographic End Point Analysis According to Quintiles
12955	Primary Angiographic and Clinical End Point Analysis After Controlling for the Effect of Concomitant Therapy ∗   legend
12956	Alterations in Skeletal Muscle Biopsies From CHF Patients legend
12957	Implantation Procedures  legend
12958	Defibrillation Threshold Data legend
12959	Simple Linear Regression Correlation Matrix Between Dpl-RVol and Echocardiographic Left Atrial and Doppler Variables in the Study Population legend
12960	Multiple Linear Regression Analysis Relating Echocardiographic and Doppler Variables to Dpl-RV in the Study Population legend
12961	Serial Volumetric IVUS Results in All 31 Lesions  legend
12962	Final Angiographic Results After PTCA Alone or Debulking Plus Adjunctive PTCA  legend
12963	One-Year Event Rates According to Kaplan-Meier Analysis  legend
12964	Univariate and Multivariate Predictors of Target Vessel Revascularization legend
12965	Individual and Group Hemodynamics legend
12966	Echocardiographic and Doppler Variables Before and After Therapy
12967	Individual Changes in Mitral Regurgitation Associated with Heart Failure Therapy
12968	Patient Data  legend
12969	Hemodynamic and Electrophysiologic Data With the Three Pacing Modes Tested legend
12970	Individual Hemodynamic Data in the Different Pacing Modes  (AAI, DDD RVA, DDD RVOT, DDD Biventricular)  legend
12971	Comparison of Responder and Nonresponder Patients legend
12972	Comparison Between Patients Who Had Follow-up Angiography  (Fu+)  and Patients Who Did Not Have Follow-up Angiography  (Fu−)  in the Total Study Population
12973	Procedural Variables and Quantitative Angiographic Measurements
12974	Procedural and Short-Term Events
12975	Stent Type Distribution in Patients With Follow-up Angiography  legend
12976	Quantitative Angiographic Measurements of Lesions With Follow-up Angiography
12977	A Comparison Between Patients With and Without Restenosis in the Total Cohort With IVUS Guided Stenting
12978	Multivariate Predictors of Freedom From Restenosis in Patients With IVUS-Guided Stenting in the Total Cohort: Stepwise Multivariate Logistic Regression Analysis
12979	Exclusion of Atrioventricular Reentrant Tachycardia  (AVRT)  and Atrial Tachycardia  legend
12980	Retrograde AV Nodal Conduction Time During Ventricular Pacing Versus Tachycardia  legend
12981	Demonstration of Atrial Dissociation Between the CS Orifice and the LSRA  legend
12982	Angiographic and Intravascular Ultrasound Measurements in the Restenosis or No Restenosis Groups  legend
12983	Predictors of In-stent Restenosis by Logistic Regression Analysis  (n = 1,501)   legend
12984	Predictors of In-stent Restenosis in Lesions With Intravascular Ultrasound Guidance by Multivariate Logistic Regression Analsyis  (n = 1,054)  legend
12985	Quantitative Measures of Regurgitant Volume Overload legend
12986	Value of the Aortic Effective Regurgitant Orifice Area Calculated With the Proximal Isovelocity Surface Area Method and Quantitative Doppler and Two-Dimensional Echocardiographic Methods in the Overall Study Group and in Subgroups of Patients
12987	Study Population  legend
12988	Hemodynamic Measures On Individual Patients Before and After NO and Nifedpine  legend legend
12989	Principal Diagnostic Categories  (n = 103)
12990	Risk Factors Assessed for the Development of Systemic Venous Collaterals
12991	Types of Decompressing Venous Channels
12992	Hemodynamic Data Before and After Bidirectional Cavopulmonary Anastomosis  legend
12993	Molecular Markers of Coagulation Activation and Endothelial Cell Damage in the Groups of Hypertensive Subjects With Different ACE Genotypes legend legend
12994	Relationships Between Molecular Markers of Coagulation Activation and Endothelial Cell Damage and Blood Pressure in the Groups of Hypertensive Subjects With Different ACE Genotypes legend
12995	Levels of Markers of Endothelial Cell Damage in the Groups of Normotensive Subjects With Different ACE Genotypes  legend
12996	Time Constant of Force Decay  (Tau)   legend
12997	Process of Care Measures in Patients With Fee-for-Service Versus Managed Care Insurance  legend
12998	Hospital Outcomes in Patients With Fee-for-Service Versus Managed Care Insurance
12999	Defibrillation Thresholds  (DFTs)  and Ventricular Fibrillation  (VF)  Duration in Protocol 1
13000	Defibrillation Thresholds  (DFTs)  and Ventricular Fibrillation  (VF)  Duration for Right Versus Left Ventricle VF Inductions  (Protocol 2)
13001	Transesophageal Echocardiographic Correlates of Thromboembolic Risk
13002	Independent Transesophageal Echocardiographic Correlates of Thromboembolic Risk: Multivariate Analysis ∗
13003	Summary Data of Relative Conduction Times
13004	Comparison Between Intravenous Electron-Beam Coronary Angiography and Selective Coronary Angiography in 330 Segments Comprising the Major Coronary Arteries and Side Branches in 28 Patients legend
13005	Comparison Between Intravenous Electron-Beam Coronary Angiography and Selective Coronary Angiography in 221 Segments Comprising the Proximal and Mid Major Coronary Arteries  (eight-segment model)  in 28 Patients  legend
13006	Sensitivity and Specificity Data for the Detection of Angiographically Significant Stenoses  (≥50% diameter stenosis)  With Electron-Beam Computed Tomography legend
13007	Analysis of Coronary Segments  (12 per patient)  by Intravenous Electron-Beam Computed Tomographic Coronary Angiography legend
13008	Major Cardiac Events During 6-Month Follow-Up in 463 Patients With Successful Coronary Stenting
13009	Acute Results and 6-Month Follow-Up  (405 lesions)
13010	Univariate Predictors of Restenosis: Clinical Variables
13011	Univariate Predictors of Restenosis: Lesion-Related Variables
13012	Univariate Predictors of Restenosis: Procedural Variables
13013	Multiple Linear Regression for the Dependent Variable of Late Loss
13014	Multiple Logistic Regression Analysis for the Dependent Variable of Restenosis  a
13015	Intergroup Differences in Efficacy Criteria During Six-Month Trial
13016	Change in Degree of Stenosis During Six-Month Trial
13017	Groups 2 to 4: Mean  (±SD)  Neointimal Thickness by Mean Injury Score
13018	Echocardiographic Data
13019	Echocardiographic Doppler Assessment of Mitral Regurgitation
13020	Test Accuracy of Pulmonary Venous Flow Velocity Ratios for Different Degrees of Mitral Regurgitation
13021	Sensitivity and Specificity for the Presence of Four or More Segments With a Biphasic Response on the Preoperative Dobutamine Echocardiogram to Predict ≥5% Improvement in Left Ventricular Ejection Fraction Late After Revascularization
13022	Localization of Critical Lesions Underestimated or Undetected by Conventional Projections
13023	Flow- and Valve Area-Related Variables: Response to Dobutamine
13024	Comparison of Rest Potential, APD50and APD90in Cells From Either a Paced or Control Dog Studied in the Current-Clamp Mode by Perforated-Patch  (n = 5 paced, n = 5 control)  or in the Whole-Cell Mode Before Dialysis  (n = 10 paced, n = 12 control)
13025	Comparison of Action Potential Duration Variability Before and After Dialysis in Cells From Paced and Control Animals
13026	Regression Analyses of Association Between Hemodynamic Variables and Plasma or Pericardial Fluid Levels of Atrial and Brain Natriuretic Peptides
13027	Influence of Myocardial Ischemia on Atrial and Brain Natriuretic Peptide Levels in Plasma or Pericardial Fluid  a
13028	Definition and Classification of Interventions
13029	Frequency of Interventions at Follow-Up Compared With Original CAVEAT-I Data
13030	Comparison of Frequency of Interventions by Study Site Location
13031	Statistical Comparisons of Frequency of Interventions by Study Site Location
13032	Stepwise Logistic Regression Analysis  a
13033	Comparison of Mean Point Scores, Uncorrected Tissue Doppler Endocardial Velocities and Myocardial Velocity Gradients Derived From Nonischemic and Ischemic Segments
13034	Hemodynamic Measurements During Treadmill Exercise Before and After Administration of N-Nitro-l-Arginine
13035	Myocardial Blood Flow and Subendocardial/Subepicardial Blood Flow Ratio in Normal and Collateral-Dependent Myocardium During Exercise
13036	Mean Myocardial Blood Flow and Coronary and Collateral Vascular Resistance During Exercise
13037	Hemodynamic Variables and Mean Myocardial Blood Flow During Rest  (group 2)
13038	Clinical, Doppler and Echocardiographic Variables in Normal Subjects and Those With the Three Grades of Mitral Regurgitation
13039	Sensitivity, Specificity and Positive Predictive Value of Peak E Wave Velocity >1.2 m/s for Identifying Severe Mitral Regurgitation in Normal and Low Ejection Fraction Groups
13040	Clinical and Echocardiographic Variables
13041	Patient Data
13042	Hemodynamic Findings Before and After Stent Implantation
13043	Follow-Up Angiographic Results for 80 Renal Arteries in 67 Patients
13044	Study Group
13045	Patients Without Ischemic Response During First Balloon Inflation
13046	Patients With No or Diminished Angina During Balloon Inflation
13047	Patients With No or Diminished ST Segment Shift During Balloon Inflation
13048	Patients With No or Diminished Angina Plus ST Segment Shift During Balloon Inflation
13049	Surgical Risk Factors in Combined Cardiac Care Network of Ontario/Canadian Institute for Health Information Database
13050	Prevalence and In-Hospital Mortality Rates for Different Surgical Risk Factors After Coronary Artery Bypass Graft Surgery in Ontario, Canada, 1993  (5,517 patients)
13051	Odds Ratios and p Values of Variables in Increasingly Comprehensive Risk-Adjustment Models
13052	Lipid Levels in Response to Probucol Therapy
13053	Quantitative Angiographic Analysis of Index Lesion
13054	Univariate Analysis for Prediction of Restenosis
13055	Multivariate Analysis for Prediction of Restenosis
13056	Group 1  (anterograde approach) : Clinical and Hemodynamic Data
13057	Group 2  (retrograde approach) : Clinical and Hemodynamic Data
13058	Comparison of Anterograde and Retrograde Approaches to Aortic Valve Dilation in Neonates
13059	Comparison of On-Line and Off-Line Intravascular Ultrasound Analyses
13060	Sensitivity and Specificity of Fluorine-18 Fluorodeoxyglucose Single-Photon Emission Computed Tomography for Predicting Functional Recovery After Revascularization in Different Subsets of Segments
13061	Sensitivity and Specificity of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography for Detecting Improvement in Regional Contractile Function After Revascularization  a
13062	Aortic Valve Area Determined by Transthoracic Planimetry, Continuity Equation, Transesophageal Planimetry and Gorlin Formula in 42 Patients
13063	Angiographic and Hemodynamic Data
13064	Correlations
13065	Vascular Study Results for the Chinese and White Subjects
13066	Multivariate Analysis for the Determinants of Endothelium-Dependent Dilation in the White and Chinese Subjects
13067	Quantitative Coronary Angiographic Data
13068	Intravascular Ultrasound Dimensions in 17 Patients
13069	Coronary Flow Velocity Data
13070	Correlation Between Anatomic and Physiologic Variables
13071	Clinical and Angiographic Data for 57 Patients Before Coronary Angioplasty
13072	Hemodynamic Variables in Relation to Angiographic Recruitability of Collateral Vessels and Electrocardiographic Signs of Ischemia
13073	Hemodynamic Variables During Ansae Subclaviae Stimulation in Protocols 1 and 2
13074	Correlation Between Coronary Vascular Resistance and the Neurotransmitters  (neuropeptide Y and norepinephrine)  in Protocol 1
13075	Exclusion Criteria
13076	Quantitative and Qualitative Coronary Analysis
13077	Procedural Outcome and Events  a
13078	All Major Adverse Cardiac Events and Their Ranking From PTCA Coronary Angioplasty to 1-Month Follow-Up  (intention to treat)
13079	Relation of Observed Frequency of Syncopal Spells After Tilt Test to Time to First Syncopal Spell After Tilt  a
13080	Relation Between Time to First Recurrence of Syncope and Observed Frequency of Syncopal Spells in Selected Subgroups  a
13081	Examples of Necessary Indications for Bypass Surgery, Coronary Angioplasty and Bypass Surgery or Coronary Angioplasty
13082	Receipt of Bypass Surgery or Coronary Angioplasty by Type of Necessary Procedure
13083	Biochemical and Hematologic Values Before, During and After Treatment With Study Drug
13084	Lipid Profiles Before, During and After Treatment With Study Drug
13085	Platelet Aggregation in Response to Increasing Concentrations of Collagen
13086	Interim Operative Procedures Performed in 38 Stage I Operative Survivors Before Stage II Operation
13087	Stage II Operations Performed in 72 Patients During Study Period
13088	Concomitant Procedures Performed in 28 Patients at Time of Stage II Operation
13089	Early and Late Mortality After Stage II Operation Classified by Type of Stage II Procedure
13090	Stage II Hospital Mortality Risk Factor Analysis
13091	Univariate and Multivariate Correlates of Pulmonary Capillary Wedge Pressure
13092	Univariate and Multivariate Correlates of Color M-Mode Flow Propagation Velocity
13093	Retrospective Analysis of Retrograde P Waves in Atrioventricular Reciprocating Tachycardia
13094	Incorrect Prediction of Tachycardia Mechanism and Accessory Pathway Location in 15 Patients
13095	Patients With Coronary Artery Obstruction
13096	Technical and Procedural Performance
13097	QCA Outcomes at 9 Months  (Paired Lesion Analyses)
13098	Clinical Outcomes at 12 Months  (Frequentist Analysis)
13099	Use of Guideline-Recommended Acute Medications  ⁎  and Procedures †
13100	Treatment of Patients With LAST
13101	Effect of Therapeutic Agents on Endothelial Function in HF
13102	Polymer-Based Comparator Drug-Eluting and MULTI-LINK Vision Bare-Metal Stent
13103	Validation of CTCA Compared With ICA for In-Stent Restenosis
13104	Comparison of the ISR Classification Between ICA and CTCA
13105	Correlation of Semiquantitative CTCA Grade With %DS on ICA
13106	MGS Values of Injured  (Enhanced)  Endothelial Segments Versus Non-Injured  (Non-Enhanced)  Segments 5 Minutes After 5 mg Anti-Fibrinogen ELIP Injection
13107	Intravascular Ultrasound MGS Values for Visually Enhanced Atheroma Segments
13108	Intravascular Ultrasound MGS Values for Visually Non-Enhanced Atheroma Segments
13109	Comparison of Echogenic Immunoliposome  (ELIP)  Enhancement by Intravascular Ultrasound and Immunohistochemical Molecular Expression
13110	Summary Statistics for Long-Term Exposure for 3,380 Participants in the HNR Study
13111	Summary Statistics of 3,380 Analyzed Participants of the HNR Study
13112	Estimated Percent Change in Mean CIMT per Change in PM and Distance to High Traffic by IDR
13113	Consistency of Results Between Techniques
13114	Hemodynamic Data
13115	Effect of Dantrolene on Cell Shortening and Ca2+Transient in Normal and Failing Cardiomyocytes
13116	Hazard Ratios for First Cardiac Event Age 18 to 40 Years
13117	Hazard Ratios for First Cardiac Event Age 18 to 40 Years in 570 Patients Without Cardiac Events Before Age 18 Years
13118	Hazard Ratios for Aborted Cardiac Arrest or LQTS-Related Death Age 18 to 40 Years
13119	Hazard Ratios for Aborted Cardiac Arrest or LQTS-Related Death Age 18 to 40 Years in 570 Patients Without Cardiac Events Before Age 18 Years
13120	Association of Abnormal Scoring With Statin Usage by Psychometric Scales
13121	Association Between Abnormal Scoring With Cholesterol-Lowering Treatment by Types of Cholesterol-Lowering Drugs
13122	Risk of Abnormal Psychometric Score by Cholesterol and Changes in Cholesterol
13123	Univariate Risk of Permanent Pacing in the Prediction Group
13124	Adjusted Predictors of Permanent Pacing in the Prediction Model Group
13125	Risk Score to Predict Permanent Pacing After Valve Surgery
13126	Interval Measurements Used to Distinguish Atypical Atrioventricular Node Re-Entrant Tachycardia From Orthodromic Re-Entrant Tachycardia Using a Septal Accessory Pathway legend legend
13127	Intraobserver Variability ∗   legend
13128	Summary of All Data legend
13129	Is the Hand-Carried Device Configured to Evaluate the Clinical Question?  (n = 99)  legend
13130	Did the Hand-Carried Device Answer the Clinical Question for Which It Was Configured?  (n = 84)  legend
13131	Patients in Whom Findings Were Missed  (n = 80)  legend
13132	Selected Parameters of Unstable AF Reentrant Circuits legend
13133	Wave Characterization legend
13134	Correlation of Doppler Variables of Pulmonary Venous and Mitral Flow With Mean Pulmonary Wedge Pressure
13135	Multiple Linear Regression Analysis Relating Pulmonary Venous Flow Velocity Variables to Mean Pulmonary Wedge Pressure
13136	In-Hospital Mortality and Readmission Rates
13137	In-Hospital Outcomes During 30-Day and 6-Month Readmissions Stratified By Unplanned and Planned Readmissions
13138	Multivariable Hierarchical Logistic Regression Model for In-Hospital Mortality Among Patients Admitted With Primary CLI
13139	Multivariable Hierarchical Logistic Regression Model for 6-Month Unplanned Readmission Among Patients Admitted With Primary CLI
13140	Symptomatic Endpoints
13141	Decongestion and Renal Endpoints
13142	Clinical Events
13143	Ten Most Common Chronic Comorbid Conditions Among Medicare Beneficiaries With Atrial Fibrillation   (36)
13144	Writing Group Disclosures
13145	Reviewer Disclosures
13146	Operational Rules for the NCDR Public Reporting Program
13147	Initial CathPCI Public Reporting Metrics
13148	Initial ICD Public Reporting Metrics
13149	NCDR Public Reporting Mission Statement—March 2014
13150	Mortality at 3 Years After ICD Implantation Among Subgroups Categorized by Acute and Chronic HF Burdens
13151	Multivariate Logistic Regression Analysis of Urinary Biomarkers in the Prediction of the Composite Outcome  (In-Hospital Dialysis Initiation or Mortality)
13152	Net Reclassification Improvement as Facilitated by Biomarker-Aided Prediction Models
13153	Echocardiographic Data According to the Three LVEF Cutoffs
13154	Univariate Cox Regression Analyses for Peak Vo 2and Ve/Vco 2Slope
13155	Multivariate Cox Regression Analyses for Peak Vo 2and Ve/Vco 2Slope
13156	Descriptive Statistics by Patient Race
13157	Patient-Level Predictors of Receipt of Coronary Angiography
13158	Physician and Health Care System Level Predictors of Receipt of Coronary Angiography
13159	All-cause and Cause-Specific Mortality Through 1996 Among Unstable Angina Cohort, Veterans Affairs Puget Sound Health Care System
13160	Crude and Adjusted Hazard Ratios for All-Cause Mortality Through 1996 Among Unstable Angina Cohort, Veterans Affairs Puget Sound Health Care System  legend
13161	All-Cause Mortality and Coronary Artery Disease Rehospitalizations in Washington State Residents According to First Three Discharge Diagnoses Through 1996 Among Unstable Angina Cohort, Veterans Affairs Puget Sound Health Care System
13162	Crude and Adjusted Hazard Ratios for Mortality and Coronary Artery Disease Rehospitalizations Through 1996 According to First Three Discharge Diagnoses Codes Among Washington State Unstable Angina Cohort, Veterans Affairs Puget Sound Health Care System  legend
13163	Cardiac Catheterization Data in Patients With and Without Lateral ST Segment Depression legend legend
13164	Relative Risk of Incident CAC Associated With Increasing Risk Categories According to FRS and RRS Classification
13165	Mean Change in CAC Score  (Agatston Units)  Associated With Increasing Risk Categories According to FRS and RRS Classification
13166	Relative Risk of Incident CAC and Mean Change in CAC Score With Varying FRS and RRS Groups According to Low- and High-Risk Groups Classified by FRS and RRS, Respectively
13167	Relative Risk for Incident and Mean Change in CAC Score Among Participants With Discoordinate Risk Prediction Scores
13168	Hazard Ratio for Incident CHD Among Participants With Discoordinate Risk Prediction Scores
13169	Summary of Long-Term Clinical Trials in PAH
13170	Long-Term Effects of Currently Approved PAH Therapies on Cardiopulmonary Hemodynamic Parameters
13171	Long-Term Effects of Currently Approved PAH Therapies on 6MWD
13172	Summary of Study Populations and End Points of Long-Term Clinical Trials in PAH
13173	Long-Term Effects of Currently Approved PAH Therapies on Survival
13174	Scan Parameters of the Different Scanners
13175	Definitions of Descriptive Parameters Used in the Different Diagnostic Analyses
13176	Diagnostic Performance of 64-Slice CTCA for the Detection of ≥50% Stenosis on QCA in the Per-Patient Analysis  (95% CI)
13177	Diagnostic Performance of 64-Slice CTCA for the Detection of ≥50% Stenosis on QCA in the Per-Vessel Analysis  (95% CI)
13178	Performance of CTCA to Predict the Extent of CAD as Seen on CCA
13179	Analysis of the Influence of Coronary Diameter, Image Quality, and Coronary Calcium of the Diagnostic Performance of 64-Slice CTCA for the Detection of ≥50% Stenosis on QCA in the Per-Segment Analysis  (95% CI)
13180	Inotropic and Lusitropic Potencies and Intrinsic Activities of  (−) -Norepinephrine at Polymorphic Beta1-Adrenergic Receptors in Right Atrial Trabeculae From Patients Having Long-Term Treatment With Beta-Blockers
13181	Inotropic Potencies and Intrinsic Activities of  (−) -Norepinephrine at Polymorphic Beta1-Adrenergic Receptors in Right Atrial Trabeculae From Patients Not Having Long-Term Treatment With Beta-Blockers
13182	Correlation Between Exercise Electrocardiographic and Dobutamine Echocardiographic Results and Cardiac Events During Follow-Up in the Study Group
13183	Distribution of Cardiac Events in Patients With Either a Positive Dobutamine Echocardiogram or Exercise Electrocardiogram According to the Site of Myocardial Ischemia, Addition of Atropine During Dobutamine Echocardiography and Work Load on Exercise Electrocardiography  a
13184	Summary of the Stepwise Results Considering All Spontaneous Recurring Events and Hard Events Only
13185	Endpoints
13186	Switch to Clopidogrel and Resulting Ischemic and Bleeding Risks
13187	Quantitative Coronary Angiography  (N=32)
13188	Quantitative Optical Coherence Tomography  (N=38)
13189	OCT Findings in Regions With Versus Without Thrombus
13190	Efficacy Outcomes
13191	Safety Outcomes
13192	Randomized Trials of Potent P2Y12 Inhibitors Included in the Meta-Analysis
13193	Efficacy of the Potent P2Y12 Inhibitors in Men Versus Women
13194	Safety of the Potent P2Y12 Inhibitors in Men Versus Women
13195	Full Prediction Model for Spontaneous MI
13196	Pre-Specified Clinical Endpoints in the SAVOR-TIMI 53 Trial
13197	Estimates Based on the Comparison of 2 Percentages, Illustrated by the Primary Outcome  ∗   of the CHAMPION-PHOENIX Trial
13198	6-Month Results From the SYMPLICITY HTN-3 Trial
13199	A Useful Language for Interpreting p Values
13200	The Simplest Statistical Test  ∗
13201	4 Examples Using z
13202	The HORIZONS-AMI and EUROMAX Trials
13203	Outcomes in the Pooled Study Population at 30 Days
13204	Procedural Parameters and Discharge Medications, Intention-To-Treat Population
13205	Angiographic Results  (Core Laboratory) , Intention-to-Treat Population
13206	1-Year In-Segment Late Loss in the Per-Treatment-Evaluable and Intention-to-Treat Populations
13207	1-Year Clinical Outcomes  (Intention-to-Treat Population)
13208	Angiographic Outcomes
13209	Results of the Multivariable Analysis: Independent Predictors of Recurrent Restenosis
13210	Study Outcomes at the 5-Year Follow-Up
13211	Platelet Function Testing by Period
13212	Shift Tables for the Individual Responder Status Change Between Periods
13213	Proportion of Individual Subjects With a Change in Platelet Reactivity Between Periods by Clopidogrel Dose and Assay
13214	Treatment Effect by Type of MI as Classified by the CEC or Site Investigator
13215	Comparisons: CEC and Site Investigator
13216	Description of CEC-Adjudicated MIs
13217	Measures of Platelet Reactivity  (Primary Population)
13218	Efficacy and Safety Secondary Clinical Endpoints
13219	Efficacy and Safety Endpoints
13220	Clinical Outcomes at 12 Months in the Intention-to-Treat Population
13221	Angiographic Results in Patients Enrolled in the Angiographic Substudy
13222	Covariate Analysis
13223	Data Sources Reviewed
13224	NCRI Data Elements
13225	Newly Defined NCRI Data Elements
13226	In-Hospital Outcomes
13227	Features of ATD in 7 Patients With Subsequent Events
13228	Adjusted Risk of Major Cardiac Event Associated With DAT Discontinuation During the First Year After DES Implantation
13229	Summary of Primary and Secondary Adjudicated Efficacy Endpoints
13230	Summary of Safety Endpoints
13231	Event Rates According to On-Treatment Platelet Reactivity Status
13232	Selected Subgroup Analysis by On-Treatment Platelet Reactivity Status
13233	Phenotypic Patterns of Clopidogrel Hypersensitivity
13234	Hematologic Findings in Patients With Clopidogrel Hypersensitivity
13235	Results of Skin Testing in Patients With Clopidogrel Hypersensitivity  (n = 42)
13236	Clinical Endpoints
13237	Core Laboratory Angiographic Measurements
13238	Independent Determinants of Presence of Residual Thrombus After PCI
13239	Multivariate Logistic Regression With Death and Clinical Composite Endpoint as a Dependent Variable
13240	Comparison of Cobalt Chromium and Platinum Chromium Everolimus-Eluting Stents
13241	Procedural and Angiographic Outcomes of the Randomized Study Groups
13242	1-Year Clinical Outcomes in the ITT Population
13243	Quantitative Angiographic Measurements
13244	Angiographic Patterns of Restenosis
13245	Intravascular Ultrasound Measurements
13246	Clinical Outcomes at 12 Months
13247	Adverse Drug Effects
13248	Rate-Dependent Effects of Simvastatin  (10 nM)  on Electrophysiological Parameters
13249	Deaths From Cardiovascular Disease According to Radiotherapy and the Side of the Breast Cancer
13250	Mean Graft Flow and Pulsation Index by Intraoperative TTFM in A and AC Groups
13251	Prevalence of Graft Occlusion in A and AC Groups
13252	Multivariate Analysis of Relative Risk Factors for Venous Graft Patency at 3 Months After CABG
13253	Main Studies and Published Substudies Included in This Meta-Analysis
13254	Proportions of Platelet Function Responses Greater Than Risk Thresholds for Ischemic Events
13255	Platelet Function Responses During Maintenance Therapy According to Treatment With PPIs
13256	Recurrence of Adverse Events in Study Population
13257	Predictors of Primary Composite End Point
13258	In-Hospital and Long-Term Clinical Events According to Study Group  ⁎
13259	Hazard Ratios for Primary Safety and Efficacy Clinical Outcomes After Stenting as Compared With After CABG  ⁎
13260	Univariate and Multivariate Analysis for Predictors of CEC Delta-Change
13261	Main Clinical Features
13262	Procedural Features
13263	Cardiac Function Assessment
13264	Pulmonary Function Assessment
13265	Early Cardiac and Pulmonary Function Assessments Due to Dyspnea in Ticagrelor-Treated Patients
13266	HRs for Clinical Outcomes After Stenting as Compared With After CABG
13267	HRs for Clinical Outcomes After Stenting as Compared With After CABG Among Propensity-Matched Patients
13268	Adjusted ORs for CHD
13269	Summary of Model Evaluation
13270	Effects of Adding Single Biomarkers to the TRF Model
13271	Changes in Platelet Count and Aggregation Over Time in Placebo and Omega-3 PUFA Groups
13272	CTI Delays Collagen-Induced But Not Plaque-Induced Clotting of PRP and Blood
13273	Clinical Outcome at 4 Years
13274	Design of Trials Included in the Meta-Analysis
13275	Random-Effects ORs  (95% CIs)  for Clopidogrel Therapy Versus Placebo in Subgroup Analyses
13276	Estimated Number Needed to Treat or Harm With Clopidogrel Versus Placebo in Sex-Stratified Analysis for Each Individual End Point Analyzed
13277	30-Day Clinical Outcomes According to Clopidogrel Loading Dose
13278	Independent Predictors of 30-Day Clinical Events in the Full Cohort
13279	Independent Predictors of 30-Day Clinical Events Among Propensity-Matched Patients  *
13280	In-Hospital and Long-Term Follow-Up Events
13281	Safety Outcomes Through 30 Days Stratified by the Use of a GP IIb/IIIa Inhibitor During Index Hospitalization
13282	Clinical Outcomes at 30 Days and 1 Year in Patients Undergoing CABG According to Clopidogrel Exposure Before Surgery
13283	Clinical Outcomes by Use and Timing of Clopidogrel in Relation to CABG
13284	Clinical Outcome
13285	Platelet Function Measurements by Light Transmittance Aggregometry
13286	Platelet Function Measurements by the VerifyNow P2Y12 Assay
13287	Quantitative Coronary Angiography of 112 Stented SVG Lesions
13288	Clinical Events and Clopidogrel Use During Follow-Up
13289	Background of Patients Who Did and Did Not Receive Cilostazol
13290	Details of Lesions in Patients Who Did and Did Not Receive Cilostazol
13291	Major Adverse Cardiovascular Events in Patients Who Did and Did Not Receive Cilostazol
13292	Proportion of PD Poor Responders According to Definitions Associated With Clinical Outcomes
13293	Relative  (%)  and Absolute Numbers  (n)  of Diabetic Patients Among Poor Responders
13294	Procedural Resource Use and Cost
13295	Hospital Outcomes, Resource Use, and Costs
13296	Independent Predictors of Initial Hospital Cost and Attributable Costs
13297	Subclinical Thyroid Dysfunction and the Risk of Incident Heart Failure Events  (n = 3,044)
13298	Relationship Between Aortic Plaque Presence/Thickness and Coagulation Parameters in Stroke Patients and in Control Subjects
13299	Combined Effect of Plaque Thickness/Complexity and Prothrombin Fragment F 1.2 Levels on the Risk of Ischemic Stroke
13300	Incidence of Nonfatal Stroke and Death  (Divided by Cause)  in Stroke Patients and in Control Subjects
13301	6-Month Clinical Outcome
13302	Predictors of DES Thrombosis and the Composite of Cardiac Death and DES Thrombosis
13303	Platelet Aggregation and Activation in Tertiles of RPs and When Stratified by ASA Dose
13304	Platelet Activation Parameters in ASA-LR and ASA-NR According to Platelet Size
13305	Platelet Activation Parameters in CLO-LR and CLO-NR According to Platelet Size
13306	Angiographic Data According to Post-PCI TIMI Flow Grade
13307	Thirty-Day and 1-Year Outcome According to Post-PCI TIMI Flow Grade
13308	Odds Ratio  (95% CI)  for TIMI Flow Grade 0 to 1 Versus TIMI Flow Grade 2 and TIMI Flow Grade 2 Versus TIMI Flow Grade 3
13309	The Additive EuroSCORE System
13310	Incidence of Adverse Events in the Whole Population, in Elective Patients, and in Emergent Patients
13311	ST According to ARC Definitions
13312	Multivariable Predictors of Freedom From Adverse Clinical Events
13313	Clinical and Angiographic End Points
13314	Protocol-Defined Stent Thrombosis
13315	Clopidogrel Desensitization Schedule
13316	Days of Clopidogrel Use and Extent of Initial Clopidogrel Reaction
13317	List of Patients by Status, Days From Clopidogrel Exposure/PCI to Reaction, Days From Reaction to Desensitization, and Type of Reaction During Desensitization
13318	Reactions During Desensitization
13319	Clinical and Angiographic Details on the SES Patients Who Died
13320	Details on the Specific Time-Courses and Reasons of Death in the SES Patients
13321	Clinical Events and Medical Therapy in the 2 Groups at Longest Available Follow-Up
13322	Clinical Outcome
13323	Predictors of Stent Thrombosis
13324	Mean Platelet Aggregation and Percentage of Patients With HPR
13325	Initial Adverse Events
13326	Prognostic Significance of Selected Variables for Ischemic Events According to Multivariate Cox Regression Analysis
13327	Relation Between Platelet Reactivity, GP IIb/IIIa Use, and Ischemic Events
13328	Cumulative In-Hospital, 6-Month, and 12-Month Adverse Clinical Events Among All Patients and in Each Treatment Group
13329	Intravascular Ultrasound Measurements
13330	Serial Changes for Each Intravascular Ultrasound Measurement
13331	Efficacy End Points
13332	Bleeding Events
13333	Efficacy End Points for Patients Who Received Consistent Therapy Versus Those Who Did Not
13334	Secondary End Points Through 30 Days for Consistent Therapy Subgroup
13335	Acute Care  (<24 h)  Patterns and In-Hospital Procedures by Clopidogrel Use in Patients Undergoing CABG Surgery  ⁎
13336	In-Hospital Outcomes by Clopidogrel Use in Patients Undergoing CABG Surgery
13337	Quantitative Angiographic Analysis  ⁎
13338	Quantitative Angiographic Analysis  ⁎
13339	Quantitative Angiographic Analysis and Complications  ⁎
13340	Analysis of Infarct Size by Technetium Tc 99m Sestamibi Imaging at 14 to 28 Days  ⁎
13341	Adverse Events to 30 Days  ⁎
13342	Procedure Results
13343	Clinical Outcomes
13344	Clinical Outcomes Stratified by Stent Type and Peri-Procedure Administration of Platelet Glycoprotein IIb/IIIa Inhibitors
13345	Angiographic Follow-Up Findings
13346	Quantitative Coronary Angiography Findings
13347	Relationship Between Intimal Coverage and Thrombus
13348	28-Day Bleeding Events
13349	Rates of Clopidogrel Resistance in Aspirin-Resistant Versus Aspirin-Sensitive Patients
13350	Response to Clopidogrel Among Aspirin-Resistant Versus Aspirin-Sensitive Patients
13351	Primary Results of Stroke Prevention Using Oral Thrombin Inhibitor in Atrial Fibrillation  (SPORTIF)  III and V Studies
13352	Critical Issues in the Design Conduct and Analysis of Non-Inferiority Trials
13353	Measurements of Platelet Reactivity
13354	Early  (≤24 h of Admission)  Medications and Early Procedural Care  (≤48 h of Admission)  by Age Group  ⁎
13355	Early Clopidogrel and Glycoprotein IIb/IIIa Inhibitor Use in Patients Managed With Early Invasive Strategy  (Cath ≤48 h From Admission)  Versus Conservative Care  (Cath >48 h After Admission or No Cath)   ⁎
13356	In-Hospital Outcomes After Acute Coronary Syndrome by Age  ⁎
13357	Discharge Medications by Age Group  ⁎
13358	Clinical Results Summary
13359	Life-Years Lost Because of Cardiovascular Events
13360	Top 10 Hospitalization Diagnostic-Related Groups  (DRGs)  in CREDO
13361	Cost in U.S. Dollars
13362	Long-Term Cost Effectiveness, In-Trial Costs Only
13363	Long-Term Cost Effectiveness, Including Cost Beyond the Trial Period
13364	Comparisons of Quantitative Angiographic Analysis
13365	Comparisons of Quantitative Intravascular Ultrasound Analysis
13366	Quantitative Coronary Angiography Analysis for the Main Branch
13367	Quantitative Coronary Angiography Analysis for Side Branch
13368	Clinical Outcomes
13369	Angiographic and Hemodynamic Data of Treated and Deferred Lesions
13370	Correlation Between C-Reactive Protein Levels and Continuous Variables
13371	Proportion of Subjects with C-Reactive Protein Levels >3 mg/l
13372	Serial Quantitative Coronary Angiography Analysis
13373	In-hospital Results and Clinical Outcomes at Six-Month Follow-up
13374	Procedural Data and Follow-up
13375	Unit Costs *
13376	Event Rates Between One and 12 Months After Percutaneous Coronary Intervention
13377	Modeled Outcomes and Cost-Effectiveness: Total Sample
13378	Modeled Outcomes and Cost-Effectiveness: High- and Low-Risk Subsets
13379	Clinical Outcomes at 30 Days According to Clopidogrel Loading Dose Interval Before Percutaneous Coronary Intervention
13380	Quantitative Coronary Angiographic Results
13381	1-, 6-, and 12-Month Cumulative MACE and Stent Thrombosis
13382	Multivariate Predictors of CIN After Percutaneous Coronary Intervention  (Development Dataset)
13383	Summary of Western Blot Protein Abundance and Myocyte Morphometry
13384	Twitch Parameters From Isolated Trabeculae
13385	Effect of Pre-Treatment on CK-MB and Troponin Elevation at 8 and 24 h
13386	Effect of Pre-Treatment on Outcome Events at One and Six Months and the Composite End Point After Six Months
13387	Multiple Regression Analysis for Predictors of One-Year Mortality
13388	Multivariate Analysis for Predictors of One-Year Mortality in High-Risk Patients
13389	Recovery of Global and Regional Left Ventricular Function
13390	Multivariate Predictors of Recovery of Global Left Ventricular Function *
13391	Multivariate Predictors of Recovery of Regional Left Ventricular Function *
13392	End Points
13393	Multivariate Predictors of Mortality Including Treatment Group Assignment
13394	Multivariate Predictors of Mortality Including Measures of Compliance and Health Status
13395	Pretest and Exercise Scores
13396	All-Cause Mortality Deaths  (%)
13397	All-Cause Mortality Using Both Pretest Score and Either the New Exercise Score or the Duke Treadmill Score
13398	Incremental Value of Exercise and Duke Scores Over Pretest Score
13399	Invasive Hemodynamic Measurements Six Weeks Following MI
13400	Immunosuppressant Doses, Rejection Episodes, and Hypertension Data
13401	Temporal Changes in VA of the Proximal Left Anterior Descending Coronary Artery
13402	Heart Rate  (beats/min)  During and After Occlusion/Reperfusion on Each Experimental Day
13403	Thickening Fraction  (%)  on Each Experimental Day
13404	Size of Occluded-Reperfused Vascular Bed  (Region-at-Risk)
13405	Complete Blood Count and Platelet Function Before and After ASA in Five Rabbits
13406	Medication at Discharge  (Other Than Aspirin and Study Drug)
13407	Major Adverse Events
13408	Multivariate Association Between Cardiovascular Death and Potential Risk Factors
13409	Independent Correlates of Target Lesion Revascularization
13410	Clinical Restenosis Rates in Patients With Binary Angiographic Restenosis
13411	Adjusted Odds Ratios for Early Stent Thrombosis
13412	Effect of Dose-Adjusted Warfarin  (INR 2.0 to 3.0)  on Plasma Indices of Thrombogenesis and Platelet Activation, and Platelet Aggregation in Atrial Fibrillation
13413	Effect of Combination Antiplatelet Therapy  (Aspirin + Clopidogrel)  on Plasma Indices of Thrombogenesis and Platelet Activation, and Platelet Aggregation in Atrial Fibrillation
13414	Closure-Device Outcomes  (% Incidence)
13415	Closure-Device Outcomes: Closure Device Versus Manual
13416	Closure-Device Outcomes
13417	Multivariate Logistic Regression Analysis
13418	Closure-Device Outcomes Excluding Patients With in-Laboratory Failed Angioseal and Perclose Devices
13419	Anti-Ischemic Medications legend
13420	First 48-H Ambulatory ECG and Symptomatic Ischemia legend legend
13421	Day 21 ECG and Symptomatic Ischemia legend legend
13422	Side Effects to Study Drug legend
13423	Major Adverse Cardiac Events
13424	Quantitative Coronary Angiographic Data
13425	Effect of Metoprolol CR/XL and Placebo Treatment on Cause-Specific Mortality and on the Combined End Points in the Subgroups With Severe Heart Failure legend
13426	Cause-Specific Data for Number of Patients Hospitalized at Least Once and Total Number of Hospitalizations in the Two Randomization Groups With Severe Heart Failure legend
13427	Glycoprotein Ibα Genotype Distribution by 30-Day Composite End Point and Type of Intervention in Patients Who Underwent Coronary Interventions legend
13428	Procedural Data legend legend
13429	Acute-Phase Treatment in the Hospital legend legend
13430	Primary End Point
13431	System Organs With Serious Adverse Events legend
13432	Hemodynamic Variables and Arterial Blood pH and Gases legend
13433	Hemodynamics in Part A  (In Situ Preparation)  legend
13434	Hemodynamics in Parts B  (In Vitro Preparation)  and C  (Hybrid Preparation)  legend
13435	Clinical and Angiographic Data: Comparison of Patients With and Without In-hospital Angina legend
13436	In-hospital  (Days 1 and 10)  and Follow-up Values  (Three Months)  for Plasma TAT, PAI-1, Fibrinogen and D-dimer of Patients With Acute Myocardial Infarction legend
13437	In-hospital  (Days 1 and 10)  and Follow-up Values  (3 Months)  for Plasma TAT, PAI-1, Fibrinogen and D-dimer of Patients With Unstable Angina legend
13438	Hormone Profile After Each Treatment Period legend
13439	Effects of Estrogen Alone and Combined Therapy With Medroxyprogesterone Acetate and Progesterone at Rest and During Exercise legend legend
13440	Outcome Measures—All Subjects legend
13441	Outcome Measures—Smokers legend
13442	Morphometric Analysis legend
13443	Morphometric Data in Male Pigs legend legend
13444	Morphometric Data in Female Pigs legend legend
13445	Clinical Outcomes of Treated Patients legend
13446	Platelet GPIIb/IIIa Receptor Density per Platelet Prior to and on the Final Day of Treatment legend
13447	Percent Platelets Positive for CD63  (±SEM)  During Treatment With Orbofiban  (n = 32)  or Placebo  (n = 12)  legend
13448	Circumferential Reattachment of Endothelial Cells  (Evan’s Blue Study)
13449	Quantitative Angiographic Measures legend
13450	Morphometric Analysis of the Harvested Arteries legend
13451	Classification of All Deaths Occurring During Study Follow-up, According to Hormone Use ∗   legend
13452	Thirty-Day and Six-Month Primary End Point of Death, MI or Urgent Revascularization Hazard Ratios for Each Trial Comparing Abciximab Versus Placebo legend
13453	Bleeding Complications by Gender for Patients Receiving Abciximab legend
13454	Procedural Events legend
13455	In-Hospital Clinical Events and Outcomes legend
13456	Angiographic Results legend legend
13457	Clinical Events During First 30 Days After Intervention legend
13458	Quantitative Angiographic Data legend
13459	Comparison of Group I and Group II Patients legend legend
13460	One-month Clinical Outcomes  (n = 140 Patients)  legend
13461	Outcome at Six Months  (n = 115 Patients)  legend
13462	Factors Potentially Predictive of TLR Within Six Months legend
13463	Prevalence of FDA-Defined Mitral and Aortic Valvular Regurgitation by Treatment Group ∗
13464	Prevalence of Aortic and Mitral Valvular Regurgitation by Severity and by Treatment Group legend
13465	Paired Analysis: Summary of Change From the Initial Echocardiogram to the Follow-up Echocardiogram legend
13466	M-Mode and Doppler Echocardiographic Data legend
13467	In Vivo Hemodynamics legend
13468	In-Hospital Events legend legend
13469	In-Hospital Events legend legend
13470	Univariate Correlates of Abciximab Use legend
13471	Multivariate Model for Abciximab Use legend
13472	Multivariate Model for In-Hospital Death/QWMI/Repeat Revascularization legend
13473	Correlates of Death/MI/Repeat Revascularization From Time of Procedure legend
13474	In-Hospital Events for Patients Receiving Abciximab Prior to Initiation of Intervention Versus Those Receiving Abciximab After Initiation of Intervention legend legend
13475	Indications for Registry Enrollment  (n = 265)  legend
13476	Quantitative Angiographic Results legend
13477	Antithrombotic Medications in Registry Patients and Relationship to Primary End Point and Transfusion
13478	Clinical Follow up legend
13479	Parameters of Activation of Coagulation and Platelets in Course After PTCA—Comparison Between Patients With Effective  (n = 12)  and Ineffective  (n = 8)  Anticoagulation  (AC)   (Median [Range])
13480	Parameters of Endogenous Fibrinolysis in Course After PTCA—Comparison Between Patients With Effective  (n = 12)  and Ineffective  (n = 8)  Anticoagulation  (AC)   (Median [Range])
13481	Endothelin-1  (ET-1)  and Big endothelin-1  (BET-1)  in Course After PTCA—Comparison Between Patients With Effective  (n = 12)  and Ineffective  (n = 8)  Anticoagulation  (AC)   (Median [Range])
13482	Follow-up Resource Use and Clinical Outcomes
13483	Serum Lipids and Hemostatic Parameters legend
13484	Prothrombin Fragment 1+2  (F1+2)  and Fibrinopeptide A  (FPA)  in Blood Ex Vivo legend
13485	Kinetics of Thrombin Generation Based on Concentrations of Prothrombin Fragment 1+2  (F1+2)  and Fibrinopeptide A  (FPA)  in Blood Ex Vivo legend legend
13486	Initial Treatment Received and Complications Observed
13487	Angiographic Findings of 163 Patients who Underwent Angiography on the Index Hospitalization
13488	Results
13489	Correlations Between Hemostasis Markers
13490	Ischemic Complications According to Presence of Thrombus-Containing Lesions on Angiography
13491	Ischemic Complications in Patients With Thrombus-Containing Lesions on Angiography According to Treatment Group
13492	Hemodynamic Variables
13493	Cessation of Hormonal Therapy
13494	Platelet Counts and Glycoprotein Surface Expression
13495	Arterial Study Results in 30 Genetic Males Investigated  (15 male to female transsexuals and 15 male control subjects)
13496	Vascular Variables
13497	Lipid Profiles
13498	Measures of Cardiac Tissue Response
13499	Echocardiographic Data: Morphology
13500	Echocardiographic Data: Function
13501	In Vivo Hemodynamic and In Vitro Whole-Heart Indexes of Cardiac Function
13502	Vasoconstriction in the PTCA and Control Vessels
13503	Cardiovascular End Points in the Two Patient Groups
13504	Causes of Death in the Two Patient Groups
13505	Multivariable Correlates of Cardiovascular Events  a
13506	Quantitative Angiographic Measurements  (n =137)
13507	Factors Associated With Stent Thrombosis
13508	Procedural Data
13509	Clinical Events During First 30 Days After Intervention
13510	Quantitative Angiographic Data
13511	Fibrinocoagulation Variables During Paroxysmal and Nonparoxysmal Atrial Fibrillation Periods in 21 Patients and 9 Control Subjects
13512	Comparison of Fibrinocoagulation Variables Between PAF-I and PAF-II Groups and Control Subjects
13513	Quantitative Angiographic Measurements in the Two Study Groups
13514	Correlates of Stent Thrombosis by Logistic Regression Analysis
13515	Substrate Size and Inducibility Findings in 102 Patients With BrS With Pre-Ajmaline Inducible Arrhythmias as Stratified by Clinical Presentation
13516	Variants Associating Genome-Wide Significantly With AF  (N=13,471)
13517	Replication of Loci Previously Reported to Associate With AF  (N=13,471)
13518	SHFM-Adjusted HRs  (95% CIs)  for the Effect of the ICD on Mortality Versus Controls by Quintile of SHFM and SPRM
13519	HRs for the Effect of the ICD on Mortality by SPRM/SHFM Grouping
13520	Comorbidities by Treatment Assignment
13521	Risk of Death or Nonfatal Heart Failure Events During Long-Term Follow-Up Associated With Increasing Comorbidity Burden for Patients With CRT-D vs. ICD Only
13522	Changes in Echocardiographic Measurements After CRT by Comorbidity Groups
13523	Association Between Resting Heart Rate Among AF Patients and Outcomes
13524	Macroscopic and Cellular Parameters
13525	Outcomes Stratified by Age
13526	Adjusted 2-Yr Relative Risks of Outcomes Stratified by Age
13527	Probability of New Events: Univariate Analysis TotalPopulation
13528	Probability of New Events: Multivariate Analysis ofAllData
13529	Comparison of Larger Brugada Syndrome Registries
13530	Univariable and Multivariable Cox Regression Analysis  (Continuous Variables)
13531	Univariable and Multivariable Cox Regression Analysis  (Dichotomized Variables)
13532	5-Year Mortality in Subgroups Defined by Expiration-Triggered Sinus Arrhythmia and Other Risk Predictors
13533	Single-Center Echo Use Rates  ∗
13534	HCR Registries Published Since 2008
13535	Cohorts Comparing HCR With Conventional On- or Off-Pump CABG Published Since 2008
13536	Angiographic and Clinical Follow-up Data in Patients in HCR Registries Published Since 2008
13537	Cohort Studies Comparing Angiographic and Clinical Follow-Up in Patients Undergoing HCR Versus CABG
13538	Major Trials for Ablation of AF in Patients With HF
13539	Key Questions Specific to Catheter Ablation of AF in Patients WithHF
13540	Efficiency of the Gene Addition to the AAVS1 Locus
13541	Implanted Valves and Access Site Across Studies
13542	Extracted Predictors Across Studies
13543	Summary of SCN10A Rare Variants Associated With BrS
13544	MRI Data  (6 Months After Infarction)
13545	Clinical Events
13546	Hazard Ratios for Death of Any Cause With Dronedarone, With No Dronedarone as Reference
13547	Hazard Ratios for Death in Relation to Latest Antiarrhythmic Drug Purchase Up to 30 Days After Index Date
13548	Standardized Mortality Ratios
13549	Optimal Discrimination Values for VC and VD Variants
13550	Genes With Significant Associations Between diLQTS Patients and Drug-Exposed Control or ESP Control Subjects According to Aggregated Rare Variant Analysis
13551	Proportion of Subjects Harboring 1 or More Rare Amino Acid Changing Variants  (Minor Allele Frequency<1.5% in ESP4300EA) in 20 High-Priority Genes
13552	12-Month Efficacy Endpoints
13553	Primary and Secondary Safety Endpoints
13554	RC Subgroup Analysis  (ITT Population)
13555	Electrophysiological Variables
13556	Echocardiographic Data
13557	Ischemic and Bleeding Outcomes at 30 Days and 1 Year in Large TAVI Registries
13558	Relation Between Periprocedural Stroke and Mortality After TAVI
13559	Relation Between Periprocedural Major or Life-Threatening Bleeding and Mortality After TAVI
13560	Current Recommendations for Antithrombotic Agents and Strategies for TAVI
13561	Current ACC/AHA, ACCP, and ESC Guideline Recommendations for Antithrombotic Therapy Within 3 Months AfterBioprostheticValve Replacement
13562	Possible Future Antithrombotic Strategies for TAVI That Have Not Yet Been Evaluated
13563	Rhythm During Subsequent Shocks Categorized by Rhythm at Time of First Shock
13564	Comparison of Mortality in Patients Who Received Shocks, Categorized by Rhythm at the Time of Shock, Compared With a Matched Group of Patients Who Did Not Receive a Shock
13565	Accuracy of Electrocardiomapping in Defining AblationTargets
13566	Distribution of Events
13567	Univariate Cox Proportional Hazards Analysis
13568	Multivariate Cox Proportional Hazards Analysis
13569	Patients With TGA Versus Patients With ccTGA
13570	Patient Population  (176 Subjects Followed for at Least 90 Days)
13571	Summary Statistics and Pearson’s Correlation Coefficient of Daily Mean Air Pollutant Concentrations and Meteorological Variables in Boston During the Study Period From September 1, 2006, to June 30, 2010
13572	Percent Change in Risk of ICD Detected Arrhythmias Associated With Each Interquartile Range Increase in Mean Air Pollutioninthe 2 and 24 h Prior to Arrhythmic Event, Adjusted for Temperature and Dew Point
13573	1993 to 2012 LQTS Diagnostic Criteria
13574	Molecular Basis of Cardiac Channelopathies
13575	Mortality at 1-Year Follow-Up
13576	Risk for Death From Arrhythmia, Cardiac Causes, and All Causes in Subjects With ERP
13577	Incidence Rates and Risks for Arrhythmia Death, Cardiac Death, and All-Cause Death in Subjects With ERP During Follow-Up
13578	Univariate and Multivariate Predictors of a Poorer Physical Composite Score of Quality of Life at Follow-Up
13579	Covariates Included in the Associative Regression Model
13580	Independent Predictors of POVA From a 24-Variable Associative Logistic Regression Model That Included All Bivariate  (Unadjusted)  Predictors of POVA
13581	Independent Predictors of Long-Term Survival From an Associative Cox Proportional Hazards Model That Contained All 40 Covariates
13582	Electrocardiographic and Echocardiographic Data
13583	Comparison Within the AdCx43 Group Between Noninducible and Continued Inducible Animals After Gene Transfer
13584	Predictors of 1-Year Quality of Life
13585	Animal Numbers
13586	MRI Data
13587	Multivariate Analysis: CRT-D Versus ICD-Only Risk of AT Events From Enrollment and by Echocardiographic Response to CRT-D  ⁎
13588	Multivariate Analysis: Effect of the Development of AT and Changes in Cardiac Volume at 1 Year on the Risk for HF or Death and the Separate Occurrence of Death  ⁎
13589	List of Included Studies
13590	International Participation in NIH-Sponsored Cardiovascular Randomized Clinical Trials
13591	International Participation by Disease Category, Disease Acuity, and Invasiveness of Studied Procedure
13592	Multivariate Analysis: Relative Risk of Time-Dependent CRT-D Versus ICD-Only Therapy for First and Subsequent HFEs
13593	Multivariate Analysis: Relative Risk of Time-Dependent HFEs for the Occurrence of All-Cause Mortality in All Patients and When Tracked by Active Device
13594	Electrophysiologic Findings on 22 Patients With Mitral Valve Prostheses and Concomitant AFL
13595	Procedure-Related Complications in Patients With and Without Mechanical MVR
13596	Comparison of J-Point–Positive Individuals From Relatives and Control Groups
13597	Multivariate Analysis: Risk of Ventricular Tachyarrhythmic Events by Echocardiographic Response in CRT-Treated Patients and Those Receiving ICD Only
13598	Multivariate Analysis: Risk of Ventricular Arrhythmic Events by Percentage of Reduction in LVESV Among CRT-D Patients
13599	Breakdown of SADS Familial Evaluation
13600	Kaplan-Meier Survival at 6 and 12 Months for Patients in INTERMACS Profile 1, 2 to 3, and 4 to 7 for Each Group
13601	Adverse Events for the HM II and COMPs Reported to INTERMACS
13602	Temporal Comparison of BTT Outcomes With the HM II LVAD
13603	Comparison of Major Viral Vector Systems
13604	Major Clinical Trials in Gene Therapy for Heart Failure
13605	Major Adverse Cardiac Events at 12-Month Follow-Up  (in Descending Order of Severity)  According to Intention-to-Treat Analysis
13606	Patients With Clinical End Points as a Function of AT/AF Occurrence and Duration
13607	Clinical Variables Associated With Clinical Outcomes According to Multivariate Time-Dependent Cox Regression Models
13608	Clinical and Genetic Data for Families 1, 2, and 3
13609	Predictors of Significant Residual Cardiac Lesions in Adulthood After ASO
13610	Reinterventions in Adulthood After ASO
13611	Predictors of Cardiac Intervention in Adulthood After ASO
13612	QTc Duration in the Overall LQTS Patient Cohort Shown by NOS1APSingle SNPs
13613	Unadjusted Analysis of ORs From Variables Measured During STEMI for 6-Month LVEF <50%
13614	Multivariable Associations of Variables Measured During Acute STEMI With 6-Month LVEF <50%
13615	Univariate Analysis
13616	Multivariate Analysis
13617	Clinical End Points at 5 Years  (Hierarchical and Nonhierarchical MACCE Up to 1,800 Days, Per Patient)  Counted Since Date of Procedure
13618	ST According to the ARC Definitions
13619	Independent Predictors of MACE and ST in the ARTS II Group
13620	Procedural and 30-Day Outcomes
13621	Cox Regression With Multiple Predictor Variables Including Location of Mutations for First Cardiac Event and Aborted Cardiac Arrest/Long QT Syndrome Death
13622	Mutation Group by Location, Type, and Topology
13623	Cox Regression With Multiple Predictor Variables Including Location and Type of Mutations and Their Interaction for First Cardiac Event and for Aborted Cardiac Arrest/Long QT Syndrome Death
13624	Principal Discharge Diagnosis Codes Associated With Readmissions After PCI in the Overall Cohort as Well as in Subsets of Patients Without AMI, With AMI, and With Repeat Revascularization
13625	Multivariate Analysis of Predictors of AF Termination
13626	Multivariate Analysis of Predictors of Clinical Outcome
13627	V0.5, Slope Factor k, and τ Deactivation at +20 mV
13628	Univariable Predictors of Ventricular Arrhythmias
13629	Multivariable Predictors of Ventricular Arrhythmias
13630	Comparison of MDCT and MRI at 8-mm Slice Thickness  (n = 14)
13631	Infarct Parameters at Different Slice Thickness by MDCT  (n = 12)
13632	Clinical and Echocardiographic Parameters  (n = 75)
13633	Biventricular Pacemaker Diagnostics  (n = 75)
13634	Recommendations
13635	Indications for Rest Echocardiograms Who Required Contrast Enhancement
13636	Multivariate Cox Proportional Hazards Survival Model Identifying Predictors of Death or HF Hospitalization
13637	Why Do Some Subjects Pace ≤92%?
13638	Clinical End Points at 3 Years in Nondiabetic Patients  (Hierarchical and Nonhierarchical MACCE to 1,080 Days, per Patient)  Counted Since Date of Procedure
13639	Clinical End Points at 3 Years in Diabetic Patients  (Hierarchical and Nonhierarchical MACCE to 1,080 Days, per Patient)  Counted Since Date of Procedure
13640	Clinical End Points of Diabetic Patients and Nondiabetic Patients at 3 Years in the ARTS-II Trial (Hierarchical and Nonhierarchical MACCE to 1,080 Days, per Patient)  Counted Since Date of Procedure
13641	Incidence of J-Point Elevation Among 45 Patients With Idiopathic VF and 124 Healthy Control Subjects Matched for Age and Gender
13642	Incidence of QRS “Slurring” Among 45 Patients With Idiopathic VF and 124 Healthy Control Subjects Matched for Age and Gender
13643	Incidence of ST-Segment Elevation Among 45 Patients With Idiopathic VF and 124 Healthy Control Subjects Matched for Age and Gender
13644	Multivariable Analysis, in Order of Strength of Relationship, Showing Those Variables That Made an Independent Contribution to the Model That Best Predicted All-Cause Mortality
13645	Individual and Grouped Results From EPS, PET, and MRI
13646	Characterization of Myocardial Segments With Earliest VT Activation
13647	Comparison of Magnetic Resonance Imaging of Arrhythmogenic and Nonarrhythmogenic PAPs
13648	Patients Experiencing Inappropriate ICD Shocks
13649	Rhythm Responsible for ICD Shock Episodes
13650	Predictors of Inappropriate Shock by Cox Proportional Hazards Regression Analysis
13651	ICD Programming in Patients With and Without Inappropriate ICD Shocks
13652	Predictors of All-Cause Mortality by Cox Proportional Hazards Regression Analysis
13653	The ARI of the S1 and S2 at the 2 Right Ventricular Sites
13654	QRS Duration at Premature Beats in the RVA
13655	Clinical and EP Parameters in Patients With and Without SCN5A Mutation
13656	Clinical, Genetic, and EP Parameters in Patients With and Without Spontaneous Type 1 ECG
13657	Clinical, Genetic, and EP Parameters in Patients With and Without Documented VF Episode
13658	Differences in Metabolites Between Hearts in SR and Permanent AF
13659	Differences in Protein Profiles Between Hearts in SR and AF
13660	Metabolite Concentrations in Atria of SR Patients Undergoing CABG or Valve Surgery
13661	Potential Modifiers of the Risk of an ICD Shock for VT/VF Associated With an Acute Episode of Driving
13662	Patients With Adenosine-Insensitive Focal Atrial Tachycardias
13663	Variables of Patients Who Underwent Randomized Ablation Strategy and Specific Ablation Strategy
13664	Conduction Velocity  (m/s)  in Response to Autonomic Maneuvers
13665	Diagnostic Accuracy of 64-Slice CTA in the Detection of Significant Bypass Graft Disease
13666	Hemodynamic Parameters
13667	Summary of Patient Data
13668	Operative Data
13669	Anatomy
13670	Prior Palliative Procedures
13671	Type of Fontan Connection
13672	Variables Associated With Early Mortality
13673	Comparison of the Changes in Clinical and Echocardiographic Parameters After Cardiac Resynchronization Therapy for Heart Failure Patients With Narrow and Wide QRS Complexes
13674	Changes in Individual Response Criteria at Follow-Up for All Patients, Clinical Responders, and Nonresponders to Cardiac Resynchronization Therapy
13675	Hemodynamics in Patients With EF ≥40%
13676	Hemodynamics in Patients With EF <40%
13677	Patient Inclusion
13678	Diagnostic Performance and Predictive Value of 64-Slice CTCA for the Detection of ≥50% Stenosis on QCA
13679	Influence of Coronary Calcifications on Diagnostic Accuracy of 64-Slice CTCA on a Segment-Based Analysis
13680	Sertindole-Induced Changes in Electrophysiological Parameters and Proarrhythmia
13681	Sertindole-Induced Changes in Electrophysiological Parameters and Proarrhythmia in the Presence and Absence of Elevated Plasma-Potassium Concentrations  (n = 7)
13682	Dose-Dependent Changes in Electrophysiological Parameters and Proarrhythmic Frequency Induced by Levcromakalim  (n = 7)
13683	Cardiovascular Events
13684	Clinical Parameters in Primary and Secondary Prevention Patients
13685	Clinical Parameters in Patients With and Without ICD Therapy
13686	Relationships Between Intake of Tuna or Other Broiled or Baked Fish and Other Risk Factors Among 5,096 Older Adults
13687	Electrophysiologic Measures According to Intake of Tuna or Other Broiled or Baked Fish
13688	Force Development and EAD Formation With Pacing at 36°C
13689	Force Generation and APD90− Norepinephrine/Isoproterenol + Acetylcholine
13690	Force Generation and APD90− Hypothermia
13691	Correlates of Left Atrial Dimension and Indexed Left Atrial Volume
13692	Classification of Left Atrial Size Abnormality by the American Society of Echocardiography Guidelines for Both Sinus and AF Subgroups
13693	Effect of Statin Therapy on Cardiac Death and ICD Therapy for Ventricular Tachyarrhythmias
13694	Logistic Regression Equation for Coronary Artery Bypass Grafting In-Hospital Deaths in New York State in 2002  (N = 16,120)   ⁎
13695	Risk Scores for In-Hospital Mortality for Coronary Artery Bypass Grafting  ⁎
13696	Predicted Risk of In-Hospital Mortality Associated With Individual Risk Scores and the Distribution of Total Risk Score Among Coronary Artery Bypass Grafting Patients in New York State in 2002  (N = 16,120)
13697	Side Effects
13698	QTc Prolongation and Risk of Sudden Cardiac Death
13699	Hazard Ratio for Outcomes by Definition of Inducibility Using Multivariate Cox Models
13700	Predictive Value of QRS Duration Using 10-ms Cutoffs
13701	Density of Tachycardia Episodes as Related to QRS Duration  ⁎    †
13702	Relation of Specific Conduction Abnormalities to Density of VT  ⁎
13703	Relation of QRS Duration to Mode of Death
13704	Summary of All-Cause and Cardiovascular Mortality Reduction by ICDs From Multivariate Regression Analysis
13705	Stratified Analysis of Three Year Mortality for Overall and 1999 Cohorts by Propensity Score Quintile
13706	Summary of Multivariate Regression and Propensity Score Analyses for Three-Year All-Cause, Cardiovascular, and Noncardiovascular Mortality in Overall Cohort
13707	Adverse Events During the Study
13708	The Electrophysiologic Data of Ventricular Tachycardia or Ventricular Premature Contractions Originating Within the Pulmonary Artery
13709	Study Population
13710	Prediction of Significant  (≥70%)  LIMA or Distal LAD Stenosis by LIMA and LAD Flow-Derived Indexes Using Transthoracic Doppler Ultrasound
13711	Variables Included in Multivariate Analysis to Predict Significant  (≥70%)  De Novo Stenosis in the Distal Left Anterior Descending Coronary Artery  (Best Fit Linear Models: BMDP-9R)
13712	Angiographic Findings at the Site of Stent Fracture
13713	Cryoablation Procedure Details
13714	Cryoablation Details
13715	Results of Multivariate Analyses *
13716	Programming of Detection Algorithms in the SC Group and DC Group
13717	Inappropriate Classification of Spontaneous Atrial Tachyarrhythmias for Both Groups
13718	Correlations Between the Markers of Ventricular Dyssynchrony and Those of Hemodynamic Status
13719	Clinical Variables Significantly Associated With High-Risk Quartile of QTVI in the Multivariate Logistic Regression Model
13720	Comparison of Studied Electrocardiogram Parameters in Subjects With and Without Appropriate ICD Therapy for VT/VF
13721	High-Risk Quartile of QTVN in the Multivariate Cox Model Predicting Appropriate Therapy for VT/VF After Adjustment for Relevant Clinical Covariates *
13722	Variables for Which Conditional Logistic Regression Analysis Was Performed, Noted in Mean OR With 95% CI
13723	Basal Heart Rhythm and Mean Variables on ECG and 24-h Holter Recording Before Event
13724	Echocardiography Results
13725	Brachial Blood Pressure Differences in the Population and Clinical Cohorts Showing the Percentile Distributions of Interarm Differences  (Right Arm Minus Left Arm)
13726	The Prevalence of Subclavian Stenosis in Population Cohorts and Clinical Cohorts  ⁎
13727	Cardiovascular Diseases Associated With the Presence Versus Absence of Subclavian Stenosis: Results of Multiple Logistic Regression Analysis  (n = 4,102)   ⁎
13728	Ventricular Arrhythmia Frequency
13729	Univariate Associations With VT/VF Events
13730	Study Population
13731	Hydroquinidine in Patients With Brugada Syndrome
13732	Follow-Up
13733	Prevalence of Potential Risk Factors Among Cases and Controls
13734	Unadjusted and Adjusted Odds Ratios for Ventricular Tachycardia/Fibrillation
13735	Morphologic and Biologic Parameters
13736	Echocardiographic Parameters
13737	Summary of Included Primary and Secondary Prevention Studies of Defibrillator Versus Medical Therapy
13738	Sensitivity Analysis of Secondary Prevention Trials *
13739	Ablation Outcome and Follow-Up
13740	Factors Associated with Ventricular Ectopy
13741	Clinical and Angiographic Data
13742	Hemodynamic Parameters and Respiratory Rate in Cooling and Control Groups
13743	Clinical Events During In-Hospital Period
13744	Programming Parameters
13745	Surface P-Wave Morphology During Tachycardia
13746	Defibrillation Thresholds  (Voltage)  in Chronic and Acute Amiodarone Groups
13747	Effective Refractory Periods in Chronic and Acute Amiodarone Groups
13748	Ventricular Fibrillation Activation Pattern Descriptors in Chronic Amiodarone Group
13749	Ventricular Fibrillation Activation Pattern Descriptors in Intravenous Amiodarone Group
13750	Predictors for Sudden Death Likely or Possibly Related to AV Node Ablation and Permanent Pacing in Patients With AF
13751	Biventricular Versus Univentricular Stimulation Clinical Effects
13752	Treatment Period Clinical Effects
13753	Clinical Changes After 12 Months of Long-Term Treatment
13754	Causes of Death
13755	Image Depth and Scoring
13756	Defibrillation Thresholds: Protocol 1
13757	Defibrillation Thresholds: Protocol 2
13758	Intraoperative Right Atrial Conduction Velocities
13759	Immunodetectable Connexin Amounts legend
13760	Bayesian Statistics for Five Tests Used to Predict Risk of MAEs After Myocardial Infarction
13761	Comparison of Tests for Predicting MAEs
13762	Staged Application of Tests for Prediction of a MAE *
13763	Categories of Ventricular Tachyarrhythmias Compared in This Study
13764	Putative Transient or Correctable Causes of VT/VF  (n = 278)
13765	Comparison of Post-Event Procedures and Discharge Therapies
13766	The Brugada-type ECG and the “Typical” Brugada-Type ECG
13767	Comparison of the Prevalance of the “Typical” Brugada-Type ECG in Healthy Populations legend
13768	Classification of Atrial Tachyarrhythmias on the Basis of Atrial Electrograms legend
13769	Comparison of Inducible and Noninducible Patients legend
13770	Patients With Inducible Ventricular Fibrillation legend
13771	Assignment of “Effective” Antiarrhythmic Drug Therapy by Programmed Ventricular Stimulation, by Number of Drug Trials legend
13772	Assignment of “Effective” Antiarrhythmic Drug Therapy by Programmed Ventricular Stimulation, by Drug Class and PVS End Point legend
13773	Cardiac Electrophysiologic Variables of Wild-Type and IKACh-Deficient Mice Before and After Carbachol Administration legend
13774	Hemodynamic and Infarct Size Data in Experiment 1 legend
13775	Hemodynamic and Infarct Size Data in Experiment 2 legend
13776	Hemodynamic Parameters in Experiment 3 legend
13777	Comparison of Chamber Size Dimensions and Volume in Patients Who Have Had the Fontan Operation legend legend
13778	Presence of Clinical Outcomes in Patients Who Have Had the Fontan Operation legend
13779	Coronary Angiography: Qualitative and Quantitative Results legend
13780	Intravascular Ultrasound: Qualitative and Quantitative Results legend
13781	Follow-up Data legend
13782	SF-36 Quality of Life Scores Across AF and All Control Groups ∗   legend
13783	Quality of Life Scores Across AF and Study Specific Control Groups legend legend
13784	Relationship Between “Objective” Indexes of Disease Burden and “Subjective” Quality of Life Measures ∗   legend
13785	Evolution of Arrhythmias in Affected Dogs During D,l-sotalol Protocols  (Maximum Number of Arrhythmias/min)  legend
13786	Time Constants of Adaptation of the APD90 to a Change in Pacing Cycle Length on Endomyocardial Biopsies and Purkinje Fibers in Control Conditions legend legend
13787	Effects of D,l-sotalol, E-4031 and Chromanol 293B on Repolarization of Canine Endomyocardial Biopsies and Purkinje Fibers Paced at a Cycle Length of 1,000 ms legend legend
13788	Univariate Predictors of Recurrences of Ventricular Arrhythmias Requiring ICD Intervention During Follow-up legend legend
13789	Outcome in Patients With  (Group I)  and Without  (Group II)  Lipid Lowering Drugs legend legend
13790	Origin of Human Ventricular Myocytes Used in the Study legend
13791	Criteria for Inclusion in the Study
13792	Collaborating Institutions
13793	Classification of Patient Groups
13794	Odds Ratio  (OR)  Estimates for Clinical CHF, RV Dysfunction, and LV Dysfunction
13795	Antiarrhythmic Drugs at Implantation and at the End of the Study Period legend
13796	Distribution of Atrial Fibrillation Episodes in the 45 Patients According to the Percentage of Treated Episodes That Occurred During a Valid Monitoring Period legend
13797	Number and Duration of the Treated and Nontreated Atrial Fibrillation Episodes Occurring During Valid Monitoring Periods According to Time Since Implantation legend
13798	Reduction in the Risk of a Treated Atrial Fibrillation Episode Relative to Day 7 After Atrioverter Implantation
13799	Short-Term Success Rates of Different Arrhythmia Types for the Total Group and in the Three Age Groups legend
13800	Percent of Patients in the Age Group with Each Arrhythmia Type legend
13801	Complications of Catheter Ablative Therapy and Overall Incidence in Study Population Undergoing 744 Ablation Procedures  (N = 695 patients)  legend
13802	Mitral and Tricuspid Valve Flow Patterns
13803	Effects of Chromanol 293B, d-Sotalol and ATX-II on the QT Interval, APD90and Transmural Dispersion of Repolarization in Perfused Wedge Preparations legend
13804	The Effect of Pilsicainide on Each Parameter legend
13805	Multivariable Model for Ablation of All VTs legend
13806	Procedure-related Complications legend
13807	Multivariate Logistic Regression Model: Recurrence and Survival legend
13808	Multivariate Cox Proportional Hazards Models for Prediction of Time to Recurrence legend
13809	Multivariate Cox Proportional Hazards Models for Prediction of Time to Death legend
13810	Delays in Coronary Care Unit Access, Hospital Stays and Use Rates of Procedures by Type of Hospital in Unstable Angina Patients legend
13811	Patients With Standardized Criteria for Urgent and Elective Coronary Angiogram, and Rates of Urgent PTCA and CABG Among These Patients During the 28 Days Following Onset of Unstable Angina, by Type of Hospital
13812	Primary End Points During Follow-up Among Myocardial Infarction Patients by Type of Hospital legend
13813	Adjusted RR and 95% CI for Six-Month Mortality and Readmission After UA in Patients Admitted to Three Hospitals Without On-Site In-Hospital Catheterization Laboratory and Coronary Surgery legend
13814	Graft Occlusion Rates at One Year legend legend
13815	Graft Occlusion Rates According to Location of Distal Anastomosis and Coronary Artery Lumen Diameter legend legend
13816	Clinical Outcome at One Year legend legend
13817	Multivariate Logistic Regression Analysis of Myocardial Infarction, Recurrent Angina and Any Primary Clinical End Point legend legend
13818	Previous Studies on Circadian Variation of Ventricular Arrhythmias in Which Information From an Implantable Cardioverter Defibrillator Was Used legend
13819	Therapies at Hospital Discharge from Index Hospital Period legend
13820	Crossover Rates at One and Two Years ∗
13821	Patients With Positive Electrophysiology Study legend
13822	Comparison of Inducible and Noninducible Patients
13823	Mortality Data of Patients With Available Follow-up
13824	Interval  (Mean ± SD)  Between the Onset of Atrial Activation at Two Subsequent Bipoles of the Crista Terminalis Mapping Catheter  (Top)  and at Two Opposite Bipoles of the Pacing and the Mapping Catheter  (Bottom)  legend
13825	Longest Coupling Interval That Resulted in a Functional Conduction Block at the Crista Terminalis During Programmed Atrial Stimulation
13826	Longest Coupling Interval That Resulted in a Conduction Block at the Crista Terminalis in Patients With Atrial Flutter Versus Atrial Fibrillation legend
13827	Longest Coupling Interval That Resulted in a Conduction Block at the Crista Terminalis Before and After Administration of 2 mg/kg Disopyramide legend
13828	All-cause Mortality for Groups Receiving Different Shock Therapies After Adjustment for Categorical LVEF legend
13829	All-Cause Mortality for Groups Receiving Different Shock Therapies With Stratification by Categorical LVEF
13830	Proportional Hazards Regression
13831	Stratification for Ejection Fraction
13832	Hemodynamic and Neurochemical Profile in Patients Matched by Pulmonary Artery Pressure legend
13833	Hemodynamic and Neurochemical Profile in Patients Matched by Cardiac Output legend
13834	Impedance Rises During Ablation legend legend
13835	Lesion Generation With Temperature Control legend
13836	Local Electrical Activity legend legend
13837	Catheter Placement legend legend
13838	Rhythm Outcomes legend
13839	Diagnostic Value of the Signal-Averaged Electrocardiogram in Post-MI Patients legend
13840	Comparisons of Mean Ventricular Rates  (VR)  Measured over 24 Hours, During Daytime  (6 am to 6 pm) , and During Nighttime  (6 pm to 6 am)
13841	Comparison of Phase Angle of Cosine Fit to 24 Hour Ventricular Rate Data and Calculated Time of Peak Ventricular Rate Among Different Treatment Groups
13842	Mean Exercise Parameters of Subjects Who Exercised for at Least Five Minutes legend
13843	Echocardiography and Doppler in Restrictive and Nonrestrictive Patients legend
13844	Echocardiography and Doppler data after transannular patch repair and disatolic RV physiology legend
13845	Episodes and Duration of Arrhythmia for Three Reperfusion Regimens Versus Permanent Occlusion legend
13846	Mortality After Myocardial Infarction for Permanent Occlusion and Three Reperfusion Regimens  legend
13847	Myocardial Infarct Size for Permanent Occlusion and Three Reperfusion Regimes legend
13848	Changes in Clinical, Hemodynamic and Echocardiographic Variables Observed in 18 Patients Who Developed Chronic Atrial Fibrillation During Follow-Up and in 36 Matched Patients With Sinus Rhythm legend legend
13849	Significance of Differences in Variables During Follow-Up in Measurements Obtained in Patients with Atrial Fibrillation  (before and after the event)  and in Those Remaining in Sinus Rhythm legend
13850	Probability Estimates and Sources Used in Study Model ∗
13851	Protocol for Monitoring Amiodarone Side Effects According to Wilson and Podrid   (6)  and the CAMIAT   (7)  and EMIAT   (8)  Trials legend
13852	Unit of Costs and Charges Used in the Model legend
13853	Base-Case Analysis for a 57-Year Old Postinfarction Patient, Showing Incremental Cost-Effectiveness Ratios legend
13854	Quantitative Angiographic Analysis
13855	Planimetric Analysis of the Harvested Arteries
13856	P Wave Configuration by Tachycardia Location
13857	Activation Timing by Tachycardia Location
13858	Electrophysiologic Effects of d-Sotalol and Almokalant
13859	Incidence of Early Afterdepolarizations and Torsade de Pointes Arrhythmias After Administration of d-Sotalol and Almokalant
13860	Regression Analysis of QT Duration and Other Repolarization Variables
13861	Overall Incidence of Cerebrovascular Events Complicating Acute Myocardial Infarction
13862	Mortality Rates in 1981 to 1983 Versus 1992 to 1994 Cohorts for All Patients With Acute Myocardial Infarction and Patients With Early Cerebrovascular Events
13863	Time to Coronary Care Unit Admission, Length of Hospital Stay and Use of Coronary Angiography and Revascularization Procedures by Hospital Type
13864	Emergency Coronary Angiography and Revascularization Within 28 Days of Onset of Myocardial Infarction in Patients Meeting Standardized Criteria for These Procedures in Tertiary  (group A)  and Nontertiary Hospitals  (group B)
13865	Primary End Points During Follow-Up in Study Patients Admitted to Tertiary  (group A)  or Nontertiary Hospitals  (group B)
13866	Adjusted Relative Risks and 95% Confidence Intervals for 6-Month Mortality After First Myocardial Infarction in Patients Admitted to Three Hospitals Without On-Site In-Hospital Catheterization Laboratory and Coronary Surgery
13867	Predicted Effective Therapies  a
13868	Alternative Therapies  a
13869	Two- and Five-Year Event Probabilities by Outcome
13870	Adverse Outcomes of 1,389 Angioplasty Procedures Performed at Rush-Presbyterian-St. Luke’s Medical Center During 1993 to 1995
13871	Individual Operator Outcomes
13872	Comparison of Overall Outcomes Among Studies
13873	Comparison of Adverse Outcomes
13874	Comparison of Prognostic Variables
13875	Treatments
13876	Clinical Outcomes
13877	Independent Clinical Predictors of Atrial Fibrillation After Acute Myocardial Infarction
13878	Differences Between the First Postpacing Interval and the Flutter Cycle Length  (FPPI − FCL)  From Sites Close to  (C)  and Distant From  (D)  the Tricuspid Annulus
13879	Patient Diagnoses and Frequency of Collateral Channel Development by Diagnosis  a
13880	Results of Statistical Analysis for Factors Associated With Venous Collateral Channels After Bidirectional Cavopulmonary Anastomosis
13881	Definitions of Adverse Effects and Drug Discontinuation
13882	Adverse Effects
13883	Antiarrhythmic Response to 3 Weeks of Oral Placebo and Magnesium/Potassium Therapy
13884	Clinical and Angiographic Data for 156 Study Patients
13885	Heart rate, Blood Pressure and Signs of Ischemia During Sequential Balloon Occlusions of a Coronary Artery
13886	Signs, Symptoms and Events Associated With Incident  a  Syncopal Events: Residents of Rochester, Minnesota Aged 1 to 22 Years, by Time Period
13887	Activities and Locations Associated With Incident  a  Syncopal Events: Residents of Rochester, Minnesota Aged 1 to 22 Years, by Time Period
13888	Attending Physicians’ Diagnosis After Initial Evaluation of Incident  a  Syncopal Event: Residents of Rochester, Minnesota: Aged 1 to 22 Years, by Time Period
13889	Laboratory and Clinical Tests Performed During Initial Evaluation  a  of Incident  b  Syncopal Event: Residents of Rochester, Minnesota Aged 1 to 22 Years, by Time Period
13890	Medical Conditions Reported During Follow-Up: Residents of Rochester, Minnesota Aged 1 to 22 Years With Incident  a  Syncopal Event in 1950 to 1954 and 1987 to 1991
13891	Clinical Features of Patients With and Without Automatic Junctional Tachycardia, 1986–1994
13892	Efficacy of Therapeutic Stages for Rapid Postoperative Automatic Junctional Tachycardia
13893	Effective Refractory Period at the High Right Atrium During High Right Atrial Pacing and Dual-Site Right Atrial Pacing and at the Coronary Sinus Ostium During Single-Site Coronary Sinus Ostial Pacing in the Study Patients
13894	Mean Changes in Clinical and Electrocardiographic Variables in Both Study Groups During Percutaneous Transluminal Coronary Angioplasty
13895	Electrophysiologic Study Results
13896	Predictors of Appropriate Implantable Cardioverter-Defibrillator Therapy
13897	Patients with Appropriate Therapy According to Initial Electrophysiologic Study Results
13898	Predictors of All-Cause Mortality
13899	Effect of Intravenous Dofetilide on Heart Rate and Corrected QT Interval  a
13900	Mean Plasma Dofetilide Concentrations
13901	Shortest Coupling Intervals
13902	Resting and Peak Exercise Cardiac and Physical Function Variables in HTx, Implanted and Explanted LVAD Patients, and HealthyControls
13903	Individual Patient Data for Peak Exercise Cardiac Power Output and OxygenConsumption
13904	Univariable and Multivariable Predictors of Mortality Rates From the Derivation Cohort
13905	Comparison of Significant Predictors of Mortality From Contemporary Risk Models
13906	Cardiopulmonary Exercise Test Responses
13907	Association Between Variables Measured During CPX Testing and Mortality  (Univariate Analyses)
13908	Association Between Variables Measured During CPX Testing and Mortality  (Multivariable Analyses)   ∗
13909	Variables Corresponding to Lower- and Higher-Risk Patients at1-YearFollow-Up
13910	Mortality Discrimination Based on c-Index per RER Categories
13911	Summary of Key Issues of Leaders’ Selection, Their Training, and MotivationalSession
13912	Overall BEWAT and Components: Means and Mean Differences After PGDynamics in the High- Versus Low-Adherence Sample at 1 Year  (N= 251)
13913	Overall BEWAT and Health Parameters: Means and Mean Differences After PGDynamics in the High- Versus Low-Adherence Sample at 1 Year  (N= 251)
13914	ECG Criteria
13915	HR and 95% CI for Incident AF by LVM
13916	HR and 95% CI for Incident AF by ECG-LVH Criteria
13917	Predicted Mean Values of RV Parameters by COPD Severity
13918	Predicted Mean Values for and Differences in RV Parameters by Percentage of Emphysema on Computed Tomography
13919	Multivariate Predictors of Improvements in Exercise Capacity and Response of E/e′ Ratio to Exercise in the Study Population
13920	Incidence of Adverse In-Hospital Outcomes for Lean, Overweight, Submorbidly Obese, and Morbidly Obese Versus Overweight Patients
13921	Correlations of 6MWD to CPX Indices
13922	Prognostic Utility of 6MWD Versus CPX Indices in Predicting All-Cause Hospitalization/Mortality
13923	Prognostic Utility of 6MWD Versus CPX Indices in Predicting All-Cause Mortality
13924	C-Index of 6MWD Versus CPX Indices in Unadjusted and Adjusted Models of All-Cause Hospitalization/Mortality and All-Cause Mortality
13925	6MW Test to Predict HF Outcomes and Studies Comparing 6MW and CPX
13926	Covariate Adjusted  ⁎   p Values for Exercise Volume  (MET-h per Week)  as a Linear or Logarithmic-Transformed †  Predictor of Clinical Events in Patients Event-Free for at Least 3 Months  (n = 959)
13927	Multivariate Predictive Models for Duration of Post-Operative Inotropic Support
13928	Dietary Intake
13929	Sleep Study Data
13930	Factors Independently Related to the Apnea-Hypopnea Index
13931	Factors Independently Related to the Apnea-Hypopnea Index in the Obstructive-Dominant Group  (n = 35)
13932	Factors Independently Related to the Apnea-Hypopnea Index in the Central-Dominant Group  (n = 19)
13933	Anatomic Patterns and Final LV Lead Position in Both Groups of Patients
13934	Procedural Data in Groups 1 and 2
13935	NYHA, Echocardiographic, and Functional CPET Changes in Groups 1 and 2
13936	Follow-Up Data in Both Groups of Patients
13937	Long-Term Effects of CRT: Comparison Between Groups 1 and 2
13938	Use of HF Medications Before and After CRT Procedure in Groups 1 and 2
13939	CHF Population Deaths and Hospitalizations in 6 Months
13940	CPX Measurements and Their Comparisons of Between Negative and Positive Mortality, Morbidity, and OB Subgroups in Patients With CHF
13941	Sensitivity, Specificity, AUC With 95% CI, and Best Cutoff Values for Mortality in Patients With CHF
13942	Catheterization, CMR, and Exercise Data
13943	Angiographic and Procedural Data
13944	Clinical Data at 30 Days
13945	Change in Regional Wall Motion Score Index of the Infarct Zone at 3 Months
13946	Infarct Size at 14 Days
13947	CPET Data
13948	ROC Curve Results
13949	Univariate Cox Regression Analysis
13950	Multivariate Cox Regression Analysis
13951	Distribution of Parameters of Chronotropic Incompetence, Peak Oxygen Consumption, Presence of Sinus Rhythm, and Use of Antiarrhythmic Medication by Underlying Anatomy
13952	Univariate Predictors of Mortality
13953	Multivariate Predictors of Mortality
13954	Comparisons Between Iron-Replete and Iron-Deficient Patients
13955	Viscosity Data Compared Between Iron-Replete and Iron-Deficient Patients
13956	Univariate Correlations for Determinants of Whole Blood Viscosity and Viscosity at Hematocrit of 45%  (Hct-Adjusted Viscosity)
13957	Single Values of Intracoronary Bone Marrow Stem Cell Transplantation Group
13958	Cardiac Parameters in the Transplantation Group and in Control Group at the Three Investigation Time Points
13959	Individual Algorithm Component Performance
13960	Predictors of Mortality by Multivariable Analysis: Variables Are Shown in the Order They Entered a Stepwise Cox Regression Model
13961	Association Between Severe Ventricular Ectopy During Recovery and Mortality in Prespecified Subgroups
13962	Effects of Cardiac Resynchronization Therapy on Exercise Capacity and Echocardiographic Parameters
13963	Effects of Cardiac Resynchronization Therapy on Cardiorespiratory Polygraph and Pittsburgh Sleep Quality Index  (PSQI)
13964	Effects of Cardiac Rehabilitation and Exercise Training  (n = 235)
13965	Changes in Lipids, HSCRP, and Body Mass in Control Subjects  (n = 42)
13966	Changes in Weight, BMI, Body Fat, and HSCRP Following Cardiac Rehabilitation and Exercise Training in Patients Who Achieved Weight Loss  (A)  Versus Patients Who Gained Weight  (B)
13967	One-Year Event-Free Survival in the Current Era Based on Peak Oxygen Consumption and Heart Failure Survival Score
13968	Outcomes Based on Initial Committee Decision
13969	Univariate and Multivariate Cox Proportional Hazards Model for Cardiac Death at Entry to Study
13970	Multivariate Proportional Hazards Model for All-Cause Death
13971	Interaction Table for Functional Status by Covariate
13972	Selected Secondary End Point Outcomes
13973	Changes in Antiarrhythmic Drug Use During Follow-Up
13974	Mean Comparisons in Quality of Life
13975	Mean Duration of Automatic Mode Switching  (h)
13976	Hemodynamic Evolution During Ischemia and Reperfusion
13977	Published Series of Transmyocardial Laser Revascularization With 12-Month Follow-Up
13978	Published Randomized Clinical Trials of TMR Versus Medical Therapy With 12-Month Follow-Up
13979	Studies of PMR
13980	Electrophysiologic Variables of Patients With and Without ICD Lead Failures
13981	Correlation of Clinical Presentation With Returned Lead Analysis
13982	Anthropometric and Echocardiographic Data on Endurance Athletes and Untrained Control Subjects
13983	Correlation Coefficients Between BNP Levels, Cardiopulmonary Exercise Variables and LVEF
13984	Pulmonary Function and Hemodynamics at Rest legend
13985	Change in Cardiorespiratory Function During Follow-Up legend
13986	Cardiorespiratory Variables During Exercise legend
13987	Information of 46 Patients Undergoing Angioplasty for Obstructed Modified Shunt Stenosis legend
13988	Ejection Fraction, Acetate Flow and Metabolic Index, Ammonia Perfusion Index, Fluorine-18–flurodeoxyglucose Metabolic Index and Mismatch Index for Each Patient legend
13989	Effect of Surgery on Exercise Parameters in Patients Undergoing Mitral Valve Replacement and Patients Undergoing Mitral Valve Repair legend
13990	Neurohormone Levels Before and After Surgery legend legend
13991	Vasodilator Response to Inhaled NO legend
13992	Response of Patients to Each Administered Dose of Inhaled NO legend legend
13993	Response to Inhaled 100% Oxygen by Face Mask as Compared With 40 ppm of NO legend legend
13994	Concomitant Treatment During Study Period legend
13995	Changes in Secondary End Points During Study legend
13996	Anthropometric Values of Control Group and Patients legend
13997	Spirometric Values of Control Group and Patients legend
13998	Cardiorespiratory Exercise Measurement in Control Group and Patients legend
13999	Laboratory Findings in Strong Heart Study Participants Classified by the Presence and Degree of AR legend
14000	Left Ventricular Geometry in Relation to Presence and Degree of AR ∗   legend
14001	Left Ventricular Function in Strong Heart Study Participants Classified by the Presence and Degree of AR ∗   legend
14002	Hemodynamic Data in Patients at Rest, at Peak Exercise and during Recovery legend
14003	Hemodynamic Data at Rest, at Peak Exercise, and during Recovery in Patients with Overshoot of Cardiac Output at One Minute of Recovery above the Peak Exercise Value and in Patients without Overshoot legend
14004	MBF and Hemodynamics legend legend
14005	Echocardiographic Findings legend
14006	Literature Review of OSAS and Night Ischemia legend
14007	Clinical Data for Patients With and Without IHD legend
14008	The Effects of CPAP on OSAS Severity and Hemodynamic Variables legend
14009	Clinical Parameters of Study Population legend legend
14010	Clinical Parameters in Apoptosis-Positive or -Negative Patients legend
14011	Diagnoses of Patients in Group 1  (n = 46)  legend legend
14012	Diagnoses of Patients in Group 2  (n = 25)  legend legend
14013	Hemodynamic Data for Group 1 legend
14014	Hemodynamic Data for Group 2 legend
14015	Coefficients of Correlation and Respective p Values Between RVEF and Other Variables in the Whole Population, in Patients With Ischemic Cardiomyopathy and in Patients With Nonischemic Cardiomyopathy
14016	Differences Between Patients Divided According to the Median Value of the RVEF  (Median Value: 39%)
14017	Results of the Multivariate Stepwise Cox Analysis legend
14018	Cardiac Events and Status at Follow-Up  (mean 498.8 ± 381 days)
14019	Cardiac Event Rates According to Peak Oxygen Uptake, Age and Functional Class in Male Patients
14020	Percent of Event-Free Male Patients in Functional Class I or II According to Peak Oxygen Uptake
14021	Multivariate Analysis for End Point of Death or End Point of Death or Listing as Status 1 in 154 Patients With a Peak Oxygen Uptake ≤14 ml/min per kg
14022	Muscle Bulk and Function in Patients With Chronic Heart Failure and in Healthy Control Subjects
14023	Classification According to Heart Failure Severity
14024	Correlates for Peak Oxygen Uptake in Patients With Chronic Heart Failure and in Healthy Control Subjects
14025	Hemodynamic and Oxygen Consumption Data for Dogs Undergoing Sustained Partial Occlusions
14026	Hemodynamic and Oxygen Consumption Data for Dogs Undergoing Repeated Total Coronary Occlusions
14027	Exercise and Gas Exchange Data
14028	Hemodynamic Data
14029	Magnetic Resonance Imaging Measures of Ventricular Volume and Mass Before and After Study Period  a
14030	Exclusion Criteria  a  and Enrollment During the 2-Year Study Period
14031	Changes in Baroreflex Sensitivity and Heart Rate Variability After Rehabilitation
14032	1-Year Clinical Outcomes
14033	Resource Use Over 12 Months After Enrollment
14034	Regression Analyses for Differences in ACh-Provoked Spasm Between Patients With and Without Organic Stenosis
14035	Univariate and Multivariate Cox Proportional Hazards Analyses for CorrelatedFactors of MACE During Follow-Up
14036	Regression Analyses for ACh-Provoked Spasm at Site of Organic Stenosis
14037	Pearson’s Correlation Coefficients  (r)  for Correlations Between on Treatment orPercent Change in Total, Non–ABCA1-Specific, or ABCA1-Specific Cholesterol Efflux Capacity and on Treatment or Percent Change in Lipid Variables in the Pooled Evacetrapib Monotherapy  (n= 111)  and Pooled Statins Plus Evacetrapib  (n= 114)  Groups
14038	BMI-Adapted Tube Current and Voltage
14039	Computed Tomography Acquisition Parameters
14040	Diagnostic Accuracy
14041	Computed Tomography Scan Parameters
14042	Per Vessel Territory Diagnostic Accuracy of Coronary Computed Tomography Angiography, Transluminal Attenuation Gradient, Contrast Opacification Difference  (Maximum, Mean, and Minimum) , and Quantitative Coronary Angiography Compared With Fractional Flow Reserve  (N = 78)
14043	Scene, Transport, and Scene-to-Hospital Times Before and After PH ECG Implementation
14044	Scene, Transport, and Scene-to-Hospital Times in STEMI Versus No STEMI Diagnosis After PH ECG Implementation
14045	Clinical Results at 5 Years According to Treatment Group
14046	Clinical Results at 5 Years According to DES Type
14047	In-Hospital Mortality by Operator Volume
14048	In-Hospital Mortality by Operator and Hospital Volume
14049	Procedural Data and Medication at Discharge
14050	Outcome Evaluated by CMR
14051	Effect of β-Blockers: Survival Time Inverse Probability Weighting Propensity Score Analysis
14052	Effect of β-Blockers: Instrumental Variable Analysis
14053	Association of LOF Mutations in ANGPTL3 With PlasmaLipidConcentrations *
14054	Association of ANGPTL3 Concentration With MI Risk in PROMIS
14055	Descriptive Statistics Stratified by Type of Admission
14056	Determinants of CICU LOS and 30-Day Hospital Readmission
14057	Mean Effect of CABG Versus PCI on Disease-Specific and Generic Health Status  ∗
14058	Writing Group Disclosures
14059	Incidence Rates and Hazard Ratios for Recurrent MI, CHD Events, and All-Cause Mortality Among Medicare Beneficiaries With Statin Intolerance Versus High AdherencetoStatins
14060	Validation Cohort: Model Fitting
14061	Partitioned Risk Score
14062	Risk of AF, MI, and CHF With Alcohol Abuse
14063	Comorbidities
14064	Risk Factors Associated With Adverse Cardiac Events
14065	Risk Associated With Surgery
14066	Cardiac Magnetic Resonance Variables
14067	Outcomes in PCI and CABG Groups Stratified According to SYNTAX Score
14068	Kaplan-Meier Estimates of All-Cause Mortality Stratified According to SYNTAX Score II Treatment Recommendations in the As-Treated Population
14069	Procedure and Procedure Staging
14070	Incidence of MACCE at 30 Days, 12 Months, and Through End of Study
14071	Association of HF  (Modeled as a Time-Dependent Variable)  With Subsequent Cancer Risk
14072	Type of Cancer by HF Status During Follow-Up
14073	Statin Users Versus Never-Users
14074	Weighted Comparison: Statin Users Versus Never-Users
14075	Statin Use for CAD and All-Cause Mortality
14076	Stratified Analyses of Statin Use for CAD and All-CauseMortality
14077	Medications at Discharge and Follow-Up
14078	Prevalence of Solo and Combination Antiplatelet Prescription in AF Patients at Intermediate to High Risk of Stroke, Stratified by Prescription of Aspirin Versus OAC in the Overall CHADS2 Score≥2 and CHA2DS2-VASc Score≥2 Cohorts and Subcohorts of Patients With and Without Any Coronary Heart Disease Risk Equivalent
14079	Standardized Event Rates and Hazard Ratios for Adverse Cardiovascular Events According to Status of BP Control Based on the SPRINT and 2014 Hypertension Recommendations Among Adults With Hypertension in the NHIS Health Examinee Cohort
14080	1-Year Clinical Outcomes in the Intention-to-Treat Population  ∗
14081	Observed Outcomes
14082	Relative Change in Trends in 30-Day Readmission Rates
14083	Relative Change in Trends in 30-Day Post-Discharge Mortality
14084	Observed Post-Discharge Care
14085	Adjusted Relative Change in Trends in Post-Discharge Care
14086	Predictors of ScT: Cox Proportional Hazard Analysis
14087	Quantitative Coronary Analysis Predictors of ScT
14088	Implantation Strategy Substudy: Cox Regression Analysis
14089	5-Year Clinical Outcomes
14090	Stent Thrombosis
14091	5-Year MACE, MI, and TLR After Censoring the Patient at the Time of the Stent Thrombosis  (Before Target Lesion Revascularization)  for Events Not Associated With Definite Stent Thrombosis
14092	Hazard Ratios of Incident Cardiovascular Events and Mortality and the 1-Year Number Needed to Treat to Prevent 1 Event by the Use of Statins: Intention-to-Treat Analysis
14093	1-Year Clinical Events According to Randomized Allocation
14094	Landmark Analysis at 30 Days
14095	CMR Results
14096	Tissue Changes in the Ischemic Myocardium During Week 1 Post-I/R
14097	Myocardial Water Content and Hemorrhage Score in Pigs  ∗
14098	Mortality rates by age and cause, Katale Camp, Zaire
14099	Aβ40, Aβ42 (43) , and total Aβaccording to APOE coding and promoter polymorphisms
14100	Aβ40, Aβ42 (43) , and total Aβ according to APOE coding and promoter polymorphisms after classification by APOE 4 or age
14101	Results of APOE genotyping
14102	Results of screening for AD with ∈4 allele and ∈4/∈4 genotype as test
14103	Pathological diagnoses of ten non-AD patients
14104	Results of 173 patients referred for necropsy
14105	Univariate and Multivariate Analyses of the Predictor of Poorer Outcomes Post-TAVR
14106	Return of spontaneous circulation and survival to discharge in all patients, by hospital quartile
14107	Return of spontaneous circulation in patients stratified by presenting rhythm of pulseless electrical activity or asystole versus ventricular tachycardia or fibrillation, by hospital quartile  *
14108	Survival to discharge in patients stratified by presenting rhythm of pulseless electrical activity or asystole versus ventricular tachycardia or fibrillation, by hospital quartile  *
14109	Temporal Trends in Proportion of ST-Segment Elevation Myocardial Infarction Among Younger Patients With AcuteMyocardialInfarction
14110	Temporal Trends in Revascularization in Younger Patients With ST-Segment Elevation Myocardial Infarction
14111	Temporal Trends in In-Hospital Mortality in Younger Patients With ST-Segment Elevation Myocardial Infarction
14112	Absolute changes in coverage and inequality indices between first and second surveys
14113	Genotype in relation to biochemical phenotype after TMA challenge
14114	Long-Term Mortality by Treatment Arm
14115	Multivariate Analysis of 10-Year Mortality
14116	All-Cause Mortality by Risk Group
14117	Input data and indicators for regional calculations
14118	Definitions of variables and parameters in the age-structured TB model.
14119	Estimates for transition parameters in  Table 1 .
14120	Sensitivity analysis of the tuberculosis model. Partial rank correlation coefficients  (PRCC)  of key x-variables for each of two y- variables  (a)  the annual rate of fall in incidence  (without HIV) , and  (b)  the fraction of cases prevented under DOTS  (with HIV) .
14121	Sense of dignity item scores
14122	Scores on the index of independence in activities of daily living by dignity group
14123	Disease status of preliminary and masked sets
14124	Classification of serum samples from masked validation set by proteomic pattern
14125	Number of patients with available dates 1976–95
14126	Delays for visits and treatment by different time periods
14127	Delays from family-physician visit to treatment by age, extent of disease, and grade
14128	Age- and Sex-Adjusted Cox Proportional Hazards Models for Determinants of Incident AF
14129	Hazard ratios for delays for all patients and by age younger or older than 50 years
14130	Incidence Rates of Cardiovascular Events, Heart Failure, and All-Cause Mortality per 1,000 Person-Years
14131	Association of Incident AF  ∗   With Outcomes
14132	Composition of study group
14133	Risk of cancer in carriers of 999del5 BRCA2 mutation
14134	Observed numbers of individuals with onset of regular heroin use in 1992–2004, by year of first visit to a treatment facility
14135	Effects of Randomized Treatment Allocation on the Risk of Any Coronary Events Adjusted for Parameters of LDL-C  (as a Continuous Variable)
14136	Effects of Randomized Treatment Allocation on the Risk of Any Cardiovascular Events Adjusted for Parameters of LDL-C  (as a Continuous Variable)
14137	Procedural Complications and In-Hospital Outcomes in Retrograde Lesions, 2008 to 2012
14138	Univariate and Multivariate Logistic Regression Modeling, Procedural Failure
14139	Clinical Outcomes of Short- Versus Long-Term DAPT
14140	Effect Estimates for Cumulative 1-Year Events
14141	Randomized Controlled Trials Included in Network Meta-Analysis
14142	Estimates of Risk of ST According to Various Definitions Between Different DES and BMS
14143	Estimates of Risk of Death, Cardiac Death, Myocardial Infarction, and Target-Vessel Revascularization With Different Types of Drug-Eluting Stents and BMS
14144	Smoking Pattern in SYNTAX Patients During 5-Year Follow-Up  ∗
14145	Adjusted Cumulative Effect of Smoking Status on MI
14146	Independent Predictors of Outcomes Using Smoking as Time-Dependent Covariate
14147	Quantitative Coronary Angiography Measurements
14148	Clinical Outcomes at 9 Months
14149	Type and Dose of Statin Prescriptions Filled  ∗
14150	Percentage of Medicare Beneficiaries<75 Years Filling Prescriptions for High-Intensity Statins After a CHD Event
14151	Percentage of Patients and Risk Ratio for Filling a High-Intensity Statin  ∗
14152	LV Systolic and Diastolic Dysfunction at Year 25 Predicted from Cumulative Exposure to SBP and DBP
14153	Relationship of Cumulative Exposure to BP Over 25 Years to Systolic LV Functional Indices
14154	Relationships of Cumulative Exposure to BP Over 25 Years to Diastolic LV Functional Indices
14155	Time-Segmented HR Derived by Time-Dependent CovariateCox Regression Comparing PCI Modalities  (BMSorDES) to SA- and MA-CABG Surgery
14156	Incidence rates of hypertension at 1, 2, and 3 years
14157	Odds ratios for multivariable logistic regression
14158	Efficacy and safety measures at 10, 90, and 180 days.
14159	Functional outcome and symptomatic intracranial haemorrhage by timing of treatment
14160	Reasons for withdrawal from randomised treatment
14161	Adjudicated causes of death up to day 180
14162	Causes of death in patient cohort
14163	Mortality in 3324 first-degree relatives of 862 patients with coeliac disease
14164	Annual meningitis incidence, Sé gou Region, Mali, 1989–98
14165	Time elapsed between crossing the incidence threshold and reaching the peak for 63 meningitis epidemics in 41 subdistricts, Mali 1989–98
14166	Performance of weekly meningitis incidence thresholds for detecting and predicting meningitis epidemics, SégouRegion, Mali, 1989–98
14167	Annual occurrence of epidemic meningitis and crossing of weekly incidence thresholds in 41 subdistricts
14168	Cox's-proportional hazards model to estimate risk of any coronary heart disease event in men with different APOE genotype in ex-smokers and smokers compared with combined group of never-smokers
14169	Cohorts investigated
14170	Family-based linkage and association tests in UK and German families and German trios
14171	Mutation frequency in cases and controls
14172	Concomitant therapy
14173	Clinical outcome
14174	Bleeding and thrombocytopenia
14175	DALE at birth in WHO member states in 1999
14176	6-month hazards for mortality by subgroup
14177	6-month mortality models
14178	Invasive colon and rectal cancer incidence rates and standardised incidence ratios for women with incident breast cancer
14179	Plasma lipid and lipoprotein concentrations in patients with familial hypercholesterolaemia, before and after treatment with atorvastatin or simvastatin for 2 years
14180	Blood pressure in relation to early diet
14181	Number of complete pairs and intraclass correlations for monozygotic and dizygotic twin pairs
14182	Estimates and 95% CI of genetic and environmental variance
14183	Age and sex distribution of the controls and patients with Down's syndrome
14184	Median scores for the latencies for pain sensation
14185	Median localisation scores for each site tested on the hand, face, and mouth
14186	Differences in ability of the patients with Down's syndrome and controls to localise stimuli according to age and site
14187	Distribution of clusters according to cluster size, number of mines involved in each cluster, and number of patients linked to other cluster members by current or past employment
14188	Univariate analysis of risk factors for clustering in 371 goldminers
14189	Hospitalization Rates  (per 100,000 Persons)  for Young Patients With AMIs Stratified by Age andSex,2001 to 2010
14190	Multiple logistic regression of the association of risk factors with clustering
14191	In-Hospital Mortality  (Percentages)  Among Men and Women With AMIs 30 to 54 Years of Age in the UnitedStates, 2001 to 2010
14192	In-Hospital Mortality  (Percentages)  by Race and Sex Among Patients With AMIs 30 to 54 Years of Age in the United States, 2001 to 2010
14193	Length of Stay  (Days)  Among Men and Women With AMIs 30 to 54 Years of Age in the United States, 2001to 2010
14194	Length of Stay  (Days)  by Race and Sex Among Patients With AMIs 30to54Years of Age in the United States, 2001 to 2010
14195	Cardiac Events by Use of Beta-Blockers
14196	Prohibitive Surgical Risk Factors in This Prohibitive-Risk DMR Cohort  (N= 127)   ∗
14197	Safety Outcomes in Prohibitive-Risk DMR Cohort  (N=127)
14198	Cardiac MRI Parameters of Control Subjects Versus End-Stage Idiopathic PAH Patients
14199	The Impact of NC Prolapse, Medial Tear, and Incomplete Apposition on Early Stent Thrombosis
14200	Univariate and Multivariate Analysis of Histomorphometric Parameters as Determinants of Early Stent Thrombosis
14201	PVI Location, Access Type, Device Usage, and Procedural Success in Women and Men
14202	Pre- and Post-Procedural  (Discharge)  Medication Usage Between Sexes
14203	Propensity-Matched In-hospital Adverse Events in Female and Male PVI Patients
14204	Angiography Results
14205	Major Adverse Clinical Events
14206	Individual Data From Included Studies and Individual Study Sites
14207	The Relationship of Resting Heart Rate to HF Events
14208	Stepwise Backwards Multiple Linear Regression Analysis for the Change in Regional LV Function  (Δεcc)  With Resting Heart Rate
14209	Stepwise Backwards Multiple Linear Regression Analysis for the Change in Global LV function  (ΔEF)  With Resting Heart Rate
14210	Radial Versus Femoral Access by Radial PCI Center Volume
14211	Radial Versus Femoral Access by Radial PCI Operator Volume
14212	Outcome Stratified by STEMI and NSTEACS
14213	1-Year Outcome Rates and Unadjusted and Adjusted Hazard Ratios
14214	Lesion Outcomes Among Patients Undergoing Endovascular Interventions
14215	Cardiac Magnetic Resonance Imaging Results
14216	Angiographic Results
14217	Percentages of Patients Receiving Secondary Prevention Medication, byCountry and Overall, in Phase 1
14218	Multivariable Analysis of Variables That Independently Contribute to Adherence, Phase 1
14219	Differences in Adherence Using MAQ and Pill Count, Primary Endpoint inPhase2
14220	Changes in Mean BP and Mean LDL-C Over 9 Months for Polypill Treatment and Control Groups, Phase 2
14221	AEs Reported in Fixed-Dose Combination and UsualCare Groups During the Trial, Phase 2
14222	Left Ventricular Size and Shape in Patients With Mild and Moderate/Severe MR
14223	Differences in Regurgitant Orifice Area With Different Geometric Perturbations of the Mitral Valve Using the Computational Mitral Valve Model
14224	Adverse Cardiac Events and All-Cause Mortality at 30 Days Post-Operative TimeInterval: Surgical Versus Nonsurgical Cohort
14225	Adverse Cardiac Events and All-Cause Mortality and Risk Differences in the Post-Stent Cohort Undergoing Surgery Versus the Matched Nonsurgery Cohort During the Matched 30-Day Interval, Stratified by Time From Coronary Stent Placement
14226	ΔRD for Adverse Cardiac Events in the Stent/Surgery Group, by Surgery Characteristic, When Surgery was Performed >6 Weeks After Stent Placement
14227	Temporal Trends in Stent Use During SVG PCI Performed During 2008–2011 in the VA Health System Nationwide
14228	Procedure-Related In-Laboratory Complications Seen in the Study Cohort Stratified by Stent Type
14229	Adjusted Mortality and Myocardial Infarction Rates Seen intheStudy Cohort Stratified by Stent Type
14230	Summary of Existing Evidence Comparing DES With BMS in SVG-PCI
14231	Outcome Events Stratified by IPC Tertile
14232	Clinical Outcomes
14233	Quantitative Coronary Angiographic Analysis
14234	Independent Predictors of SB Occlusion
14235	Clinical Outcomes at 12-Month Follow-Up
14236	Segmental Weighting Factors Used in SS
14237	SS Use Among Different Populations
14238	Comparison of SS and Derived SS Systems
14239	Genes Represented by the ARS and Their Correlations With Platelet Function With Aspirin
14240	Aspirin Response Signature Proteins Identified in Platelet Protein and Their Correlations With PFS onAspirin
14241	Measures of Discrimination With and Without Inclusion of Gene Expression Profiles
14242	Echocardiographic Data for 98 Patients With COPD With and Without PH and 34 Healthy Controls
14243	Invasive Hemodynamics and Echocardiographic Functional and Geometry Measurements inThose With No PH Subdivided Into 2 Groups: Mean PAP≤20 mm Hg  (Normal)  and MeanPAP 21 to 24 mm Hg  (Borderline)
14244	Randomized Controlled Trials Included in the Network Meta-Analysis
14245	Differences in Clinical Outcomes Among Different Stent Types at 1-Year and Long-Term Follow-Up
14246	Time-Related Differences Among Different Stent Types for the Risk of Definite and Definite/Probable Stent Thrombosis
14247	Event Rates per 100 Patient Years and Probability for Each Stent to Be Best at 1 Year and at the Latest Follow-Up Available
14248	Outcomes in Randomized Controlled Trials
14249	Outcomes in Observational Studies
14250	Clinical Endpoints at 5-Year Follow-Up of the Nordic Bifurcation Study
14251	MACCE in the Hybrid, CABG, and PCI Groups
14252	The Location of the Repeat Revascularization Performed in Hybrid, CABG, and PCI Groups
14253	MACCE in Hybrid, CABG, and PCI Groups From LowtoHigh EuroSCORE Tertile
14254	MACCE in Hybrid, CABG, and PCI Groups From LowtoHigh SYNTAX Score Tertile
14255	Two-Year Clinical Outcomes
14256	Outcome Differences Between 1 and 2 Years
14257	Use of Acetylsalicylic Acid, Clopidogrel, and Dual Antiplatelet Therapy
14258	Details on Definite or Probable Stent Thrombosis
14259	Incidence rates per 1000 person-years and relative risks  (RR)  of dementia in relation to the availability of social network resources in a community cohort of non-demented elderly persons with good cognition and iiving at home
14260	Adjusted relative risks and 95% CIs from Cox-regression models for combined social network elements
14261	Clinical Follow-Up
14262	Quantitative Coronary Analysis for Main Vessel and Side Branch
14263	Multivariable Adjusted Linear Regressions Between Cardiovascular Risk Factors and Epicardial Fat Volume
14264	Cox Regression for Fatal or Nonfatal Coronary Event per Each Doubling of Epicardial Fat
14265	Current diagnostic and therapeutic applications of Seldinger technique
14266	Model Inputs
14267	Health Benefits, Costs, and Incremental Cost-Effectiveness Ratio From Statin Therapy for Patients With Different Age, Sex, and Cardiovascular Risk Profiles
14268	Male death rates attributed to smoking  (Yes)  and not attributed to smoking  (No) , by social class, education, or neighbourhood income
14269	Data sources and country codes
14270	Proportion of households with catastrophic health expenditures
14271	Determinants of catastrophic health expenditure
14272	Data for individual patients
14273	Morbidity by level of education for men aged 25–69: ordered by odds ratio for perceived general health
14274	Overview for morbidity: ordered by average ranks  *
14275	Mortality by occupational class in men in manual versus non-manual occupations: ordered by risk differences
14276	Overview for mortality: ordered by average ranks  *
14277	Clinical Outcomes in Crude Population at 1 Year
14278	Stent Thrombosis in Crude Population at 1 Year
14279	Independent Predictors of Target Lesion Failure in Propensity Score-Matched Group  ⁎
14280	Mean annual rates of suicide in different population groups in China, 1995–99
14281	Leading causes of death in different population groups in China, 1995–99
14282	Crude and age-adjusted  (new Segi world population)  yearly rates per 100 000 for adults in Dar-es-Salaam, Hai district, Morogoro rural district, and England and Wales
14283	Place of death for people dying from stroke in Dar-es-Salaam, Hai district, and Morogoro rural district
14284	Analysis of death certificates and occupational records
14285	Breakdown of jobs involving metal exposure listed in lifetime occupational records
14286	Mammography screening trials according to methodological quality
14287	Relative risk of death from breast cancer in screened versus control groups
14288	Number of women and follow-up to Dec 31, 1995
14289	Attendance at screening and breast self-examination sessions by age at entry
14290	Breast-cancer detection rates at screening  (all cohorts)
14291	Observed and expected deaths from breast cancer  (diagnosed in all years)  in the initial cohort within 16 years, andrate ratios  (intervention centres vs combined comparison centres)
14292	Observed and expected deaths from breast cancer in the initial cohort within 16 years and rate ratios  (intervention centres vs combined comparison centres)  for cases diagnosed within 7 and 10 years of date of entry
14293	Breast-cancer deaths in relation to age at entry for all cohorts
14294	Breast-cancer mortality rate ratios in relation to age at entry for individual breast self-examination centres relative to comparison centres  (all cohorts)
14295	Overview of protective safeguards for patients who considered euthanasia
14296	Description of Studies Included in Meta-Analysis
14297	Fossil-fuel energy use  (1018 J)  under business-as-usual and climate-policy scenarios
14298	Annual avoided mortality with 90% CIs  (combined adult and neonatal infants)  from climate-policy cenarios  (15% below 1990 levels by 2010 for A1 countries and 10% below BAU levels by 2010 for NA1 countries)
14299	: Sensitivity analysis of avoidable deaths from climate policy: 2000 to 2020
14300	Distribution by Dukes' stage and mortality by time and stage in institution I data set
14301	Distribution by Dukes' stage and mortality in institution II data set
14302	Performance of artificial neural networks trained and validated on data from institution I
14303	Performances of clinicians and previously trained 12-month artificial neural network on data set from institution II
14304	Mortality ratios in 1991–93
14305	Mortality ratios in 1992–93
14306	Mortality ratios in the year after the first unemployment experience
14307	Fatal and non-fatal railway injury in the Cape Town metropole by injury category from April 1, 1992, to Sept 30, 1994
14308	Temporal distribution of fatal and non-fatal railway injury in the Cape Town metropole from April 1, 1992, to Sept 30, 1994
14309	Current and daily prevalence of tobacco use in individuals aged 15–64 years in Uruguay and 18–64 years in Argentina, 2001–09
14310	Conversion from ES into NNT
14311	Adherence to Performance and Quality Measures in the Study Population by Aldosterone Antagonist Use
14312	Patient and Hospital Factors Associated With Aldosterone Antagonist Use  ⁎
14313	Inhibitory activity of hyperforin in gram-positive and gram-negative bacteria and in Candida albicans
14314	Suicide data for Scotland 1990–97  3   and England and Wales 1991–95  4
14315	Questionnaire results: west African and Afro-Caribbean cases compared  (both sexes)
14316	Relative change in age-standardised prevalence of current smoking by WHO region
14317	Probability of achieving the target of a 30% relative reduction in tobacco use by WHO region
14318	Induced and No Induced Clinical VTs During the Ablation Procedure
14319	Recurrent and No-Recurrent VTs After the Ablation Procedure
14320	Recurrent VTs After the Ablation Procedure
14321	MRI protocol for patients with suspected acoustic neuroma and noise levels during different scan sequences
14322	Observed sex ratio  *   and relative odds of a boy  (OR)   †   among all liveborn children  ‡   born 1937–1996 reported by workers in the Nuclear Industry Family Study.
14323	Prevalence of overweight and obesity
14324	Efficacy and Safety Outcomes in Patients With STEMI and NSTEACS
14325	Multivariable Predictors of Mortality in RIVAL
14326	Diagnosis of patients following imaging
14327	Angiographic Outcomes at Follow-up
14328	Clinical Outcomes
14329	Subgroup Analysis of In-Stent  (In-Balloon)  Late Loss
14330	The KDIGO classification system  8
14331	Country level classifications for 0by25 initiative
14332	Comparison of AKI studies not included in meta-analysis
14333	AKI in earthquakes and regional disasters
14334	Focus areas for the 5 Rs approach to intervention in patients with AKI  1
14335	Strategies to reduce preventable deaths from acute kidney injury  (AKI)  through the 5 Rs
14336	Potential metrics for an AKI scorecard
14337	Validated health administrative data case definitions used to determine incidence of disease and their validation measures
14338	Lifetime risk of being diagnosed with chronic obstructive pulmonary disease before reaching age 80 years by age
14339	Masking scheme
14340	Modified Medical Research Council dyspnoea score
14341	Composite primary safety endpoint, 6 months post procedure
14342	Respiratory serious adverse events, at 6 months post procedure  *
14343	COPD exacerbation or infection, up to 12 months post procedure  *
14344	Functional outcomes over time
14345	Primary, secondary, and post-hoc exploratory outcomes at 1 year
14346	All serious adverse events, adverse events occurring in 10% or more of patients in any treatment group, and adverse events of special interest
14347	EBF prevalence at ages 12 weeks and 24 weeks based on 24-h recall and 7-day recall
14348	Diarrhoeal morbidity by 2-week recall at ages 12 weeks and 24 weeks
14349	Clinical Outcomes by Treatment and Tertile of Age
14350	First hospital admissions for heart failure per 1000 patient-years by category of updated mean HbA 1c
14351	Adjusted hazard ratios for development of heart failure by category of updated mean HbA1c, calculated with Cox regression
14352	Rates of Death by Treatment Stratified by Tertiles of Age and Diabetes Status
14353	Full Cox regression model for development of heart failure for updated mean HbA1c, risk factors, and comorbidities
14354	Adverse events in the safety population  (n=2485)   *
14355	Treatment-emergent adverse events leading to discontinuation of study drug in the safety population  (n=2485)
14356	AMG 145 on Lipids: Mean Percentage Change
14357	Current and emerging antiobesity drugs
14358	Subject Incidence of AEs
14359	Established treatments for osteoporosis
14360	Clinical development of novel treatments for osteoporosis
14361	Study programmes of investigational osteoporosis drugs
14362	Assessment of duration of gestation by provider
14363	Outcomes of medical abortion by type of provider
14364	Frequency and type of major adverse cardiac event during initial hospital attendance or 30-day follow-up
14365	Occurrence of MACE during initial hospital attendance or 30-day follow-up according to results of individual and combinations of the ADP test parameters
14366	Accuracy  (95% CI)  of POC biomarkers, ECG, and ADP for prediction of MACE
14367	Primary endpoints
14368	Most common adverse events and serious adverse events
14369	Estimated treatment differences in HbA1C, fasting plasma glucose concentration, and bodyweight at trial end
14370	Hypoglycaemic episodes
14371	Estimated rate ratios and odds ratios of confirmed hypoglycaemic episodes
14372	Eradication rates in the PP and ITT populations
14373	Eradication rates and antibiotic resistance in the PP population
14374	TEAEs in the treated population
14375	Progression-free survival and best overall tumour response as assessed by independent review and investigator review
14376	Adverse events with an incidence higher than 10% in either treatment group  *
14377	Review of phase 3 trials in patients with MBC previously treated with an anthracycline and a taxane, including results of the EMBRACE study
14378	Primary endpoint and secondary endpoints in intention-to-treat population
14379	Risk Loci for Coronary Artery Disease/Myocardial Infarction Discovered by Genome-Wide Association Studies
14380	Adverse events in safety population
14381	Results for primary and secondary endpoints
14382	Treatment-emergent adverse events and pregnancy outcomes during 52 weeks of study
14383	Definitive cure at 6 months, by treatment group
14384	Differences in cure rates between treatment groups and the standard group, and between groups
14385	Serious adverse events and most common adverse events related or possibly related to treatment  (ITT population)
14386	Changes in laboratory measurements during treatment  (mean values [SD])
14387	Randomisation scheme for cohorts 1–4
14388	Dosing table for cohorts 1–5
14389	Effect of omecamtiv mecarbil on echocardiogram measures
14390	Effect of omecamtiv mecarbil on vital signs and QT interval
14391	Summary of Clostridium difficile infection in countries and hospitals
14392	Determinants of complicated Clostridium difficile infection
14393	Determinants of recurrence of Clostridium difficile infection during follow-up
14394	Description of new drugs for the treatment of gout
14395	Summary of three phase 3 randomised controlled trials of febuxostat
14396	Summary of phase 2 and phase 3 clinical trials of pegloticase
14397	Adverse events during treatment  *
14398	Events of special interest
14399	Clinical Outcomes Through 1 Year
14400	Clinical Outcomes of Both Groups on a Per-Protocol Analysis
14401	Causes of death in neonates and at ages 1–59 months in this study and estimated national totals
14402	Seroconversion 30 and 60 days after vaccination
14403	Titre at birth and 30 and 60 days after vaccination
14404	Adverse events
14405	Efficacy analyses
14406	Treatment-emergent adverse events possibly or probably related to treatment in at least 1% of patients  (intention-to-treat population)
14407	Treatment-emergent adverse events leading to discontinuation of treatment  (intention-to-treat population)
14408	Selected pharmacokinetic results
14409	Adverse events during treatment occurring in at least two patients in any treatment group
14410	Procedural Results
14411	In-Hospital Clinical Outcomes and Mortality at Follow-Up
14412	Treatment received and reasons for discontinuation in the intention-to-treat population  *
14413	Response to treatment and disease progression
14414	Adverse events reported in patients who received at least one dose of study treatment  *
14415	Deaths in patients who received at least one dose of study treatment
14416	ACCORD trial microvascular outcomes and assessment frequency
14417	Change in bodyweight at 56 weeks
14418	Secondary endpoints at 56 weeks
14419	Adverse events and safety endpoints  *
14420	Adverse events leading to discontinuation  *
14421	Univariate and Multivariate Analyses of In-Hospital Deaths According to Status of Diabetes and Prior Exposure of Statins
14422	Clinical and Angiographic Outcomes
14423	Clinical and Angiographic Outcomes of the Propensity Score–Matched Groups
14424	Clinical Outcomes
14425	Definite and Probable Stent Thrombosis in First and Second Years After Index Procedure
14426	Angiographic Findings in the Patients With Significant Coronary Artery Disease
14427	Echocardiographic Findings in Patients With and Without Significant Coronary Artery Disease
14428	Univariate and Multivariate Logistic Regression Analyses of Predictors of Significant Coronary Artery Disease
14429	Echocardiographic Findings in Patients With Significant Coronary Artery Disease Before and After Revascularization
14430	BB on Discharge
14431	Dose Distribution of Metoprolol and Carvedilol on Discharge
14432	Genotype Frequencies and HW p Values
14433	Quality Improvement Resources and Performance Monitoring
14434	Medication Management Practices
14435	Discharge and Follow-Up Procedures
14436	Summary Scores of Hospital Practices to Reduce Preventable Readmissions
14437	Procedural Data and Acute Echocardiographic Outcomes
14438	Clinical Outcomes at 30 Days and 12 Months of Follow-Up
14439	Multivariable Cox Analyses Estimating HR for High NGAL  (Upper Quartile [170.1 μg/l])
14440	Cox Models for Risk of All-Cause Mortality in Groups Based on NGAL and CRP
14441	Myocardial Perfusion Abnormalities Among Patients Undertaking Myocardial Perfusion Imaging
14442	Incidences of Adverse Events Over 5 Years
14443	Adjusted HRs of Ischemia-Guided Revascularization for Events
14444	Propensity Score Matching Analyses
14445	Pooled 12-Month Event Numbers, RR  (95% CI) , and ARR  (95% CI)  for an Invasive Versus Conservative Treatment Strategy, Stratified by DM Status
14446	Angiographic Endpoints
14447	Major Adverse Cardiac Events  (n = 529)
14448	Late Cardiac Outcomes and Study Graft Failure of Adjudicated Cases
14449	Selected Publications Reporting at Least 1 VARC Criterion in TAVR Population
14450	Proportion of Studies Reporting Outcomes Using Appropriate VARC Definitions
14451	30-Day and 1-Year VARC Outcomes After TAVR
14452	VARC: Prosthesis-Related Complications
14453	LV Volumes and Mass According to the Reperfusion Strategy
14454	Multivariate Analysis: Risk of Long-Term  (8-Year)  Mortality in the MADIT-II Population by the Type and Number of Risk Factors
14455	Hazard Ratios of ICD Versus Conventional Medical Treatment by Risk Score Subgroups During 8-Year Follow-Up
14456	Angiographic and Procedural Variables From the Original Index Procedure of Patients With Subsequent In- and Out-of-Hospital Definite/Probable ST
14457	Multivariate Predictors of In-Hospital and Out-of-Hospital Definite/Probable Stent Thrombosis
14458	1-Year Clinical Outcomes in Patients With In-Hospital Versus Out-of-Hospital Definite/Probable Stent Thrombosis
14459	Adjusted Hazard Ratios for 1-Year Mortality Following In- Versus Out-of-Hospital Stent Thrombosis Adjusted for Selected Covariates  (Model 1)  and Propensity Score  (Model 2)
14460	Components of Intraprocedural Thrombotic Events  (N = 121)
14461	Clinical Outcome According to Intraprocedural Thrombotic Event Occurrence
14462	Components of IPTE as Predictors of MACE at 1 Month and 1 Year
14463	Independent Predictors of Adverse Events at 30 Days and 1 Year
14464	Quantitative Coronary Angiography and Procedural Results
14465	1-Year Clinical Outcomes in the Intention-to-Treat Study Population
14466	Quantitative Angiographic Analysis Pre-Procedure and Post-Procedure
14467	Quantitative Angiographic Analysis at 9-Month Follow-Up
14468	Clinical Events at 1-Month and 12-Month Follow-Up
14469	Optical Coherence Tomography Findings
14470	Circadian Variation of SGNA/VNA Ratio and SDNN During a 24-h Period
14471	Unadjusted 900-Day Event Rates and Adjusted HRs Comparing DES Versus BMS Stratified According to Age Group
14472	Primary respiratory outcomes by intervention group
14473	Primary diarrhoea and impetigo outcomes in children younger than 15 years by intervention group
14474	Mean pneumonia incidence by age and intervention group
14475	Mean pneumonia incidence in children younger than 5 years by nutrition status and intervention group
14476	Hemodynamic Effects of Nebivolol on Anesthetized Mice
14477	Effects of Nebivolol on Left Ventricular Function and Dimensions
14478	Bacteriological results  *
14479	Outcome measures
14480	Status of Dual Antiplatelet Therapy and Cardiac-Related Medications and Clinical Follow-Up Completeness
14481	Clinical Outcomes According to On-Treatment Platelet Reactivity
14482	Clinical Outcomes According to CRP Level
14483	C-Statistic for Cox Regression Models for Prediction of Primary Endpoint
14484	Logistic regression analysis of clinical and laboratory adverse events attributed to antiretroviral treatment regimens
14485	Logistic regression analysis of adverse events attributed to specific antiretroviral treatment agents
14486	Number of children with rotavirus infection by age and HIV status
14487	Severity of rotavirus disease among inpatients by HIV status
14488	Comparison by HIV status of children who completed follow-up
14489	Adverse reactions occurring in more than 5% of patients in any treatment group
14490	Analysis of necropsy tissues from patients with vCJD for PrPSc
14491	Concentrations of PrPC detectable in components from sporadic and variant CJD eye
14492	COMET1 data
14493	Plasma Leptin Concentration and Adjusted HR  (95% CI)  for Incident HF in Men With and Without Pre-Existing CHD
14494	Mode of delivery
14495	HR  (95% CI)  for Incident HF Associated With BMI and WC in Men With and Without Pre-Existing CHD
14496	Neonatal outcomes
14497	Retrospective analysis of CD44v6 and galectin-3 expression on resected thyroid lesions
14498	Discrimination between benign and malignant thyroid lesions by immunodetection of CD44v6 and galectin-3 in retrospective study of thyroid histological samples
14499	Retrospective analysis of cell-blocks from fine-needle aspiration cytology
14500	Discrimination between benign and malignant thyroid lesions by immunodetection of CD44v6 and galectin-3 on cellblocks from fine-needle aspiration cytology in retrospective analysis
14501	Prospective study of CD44v6 and galectin-3 expression on fresh cytological specimens
14502	Discrimination between benign and malignant thyroid lesions by CD44v6 and galectin-3 immunodetection on fresh cytological material from preoperative fine-needle aspiration
14503	Univariate hazard ratios and 95% CIs
14504	Adjusted hazard ratios and 95% CIs  (n=91)
14505	Abstinence rates during treatment and follow-up phases
14506	Observed frequencies of abstinence from week 3 to end of week 7
14507	Echocardiographic Phenotype in Bigenic Mice After Switching On and Off Expression of cTnT-Q92
14508	Comparisons of Blood Volume Flow, Blood Velocity, and Pulse Wave Velocity Between Young Smokers and Healthy Controls
14509	Efficacy of group 1 and group 2 regimens: response rates in the evaluable population
14510	Efficacy results of the group 1 and group 2 regimens: response durations and survival
14511	Haematological and non-haematological toxicity profile of group 1 and group 2 regimens
14512	Regional Stress Echocardiography Parameters Measured in Patients With Idiopathic Dilated Cardiomyopathy
14513	Number of cases positive for parvovirus B19 by different diagnostic techniques
14514	Clinical and laboratory findings in cases positive for parvovirus B19 DNA
14515	Left Anterior Descending, Left Circumflex, and Right Coronary Artery Doppler Flow Velocity Measurements in Patients With Idiopathic Dilated Cardiomyopathy and in Controls
14516	Univariate analyses on risk of severe hypoglycaemia in patients untreated with ACE inhibitors and angiotensin-II-receptor antagonists
14517	Stepwise regression analysis of risk of severe hypoglycaemia in patients untreated with ACE inhibitors and angiotensin-II-receptor antagonists
14518	Frequency of diseases for infants from zinc supplement and placebo groups during first 6 months of life
14519	Proportion of days ill during first 6 months of life
14520	Serious adverse events
14521	Schedule for controlled non-heart-beating donor lung transplantation
14522	Haemodynamics and lung function ex vivo  *
14523	Clinical Parameters and Left Ventricular Function at 0, 6, and 12 Months of Therapy in Patients With Heart Failure Receiving Either Perindopril  (ACEI-First)  or Carvedilol  (BB-First Group)  as Initial Therapy
14524	Primary and secondary endpoints at study entry and after 6 months
14525	Doses of Pharmacologic Agents Received After 12 Months of Therapy in Patients With Heart Failure in Whom Either Perindopril  (ACEI-First)  or Carvedilol  (BB-First)  Therapy Was Initiated First
14526	Univariate analyses of factors associated with recurrent C difficile diarrhoea
14527	Hospital staffing and case load
14528	Assessment or treatment factors considered likely to increase the risk of poor outcome
14529	Proportion of doctors, nurses, and medical assistants with inadequate knowledge or reported practice for assessing and managing specific conditions
14530	Supplies found in emergency treatment area or entire hospital
14531	Ratings of avoidable morbidity and mortality in study hospitals
14532	Putative HCM-Causing Mutations and Nonpathogenic, Nonsynonymous Polymorphisms Identified in MYBPC3
14533	Blood glucose thresholds  (mmol/L)  for symptoms and counterregulatory hormones in type-2 diabetic patients and controls
14534	Subgroup comparisons of calcium antagonists vs other drugs
14535	Subgroup comparisons of calcium antagonists vs ACE inhibitors and diuretics and β-blockers
14536	Clinically important genetic polymorphisms of drug metabolism that influence drug response
14537	Distribution of polymorphic genes encoding CYP2C9, CYP2D6, and N-acyltransferase 2 in different populations
14538	Clinically important genetic polymorphisms of drug targets and drug transporters
14539	Predictors of 12-month survival  (n=123)
14540	Health-related quality of life in NTDS patients and elderly people in the general population
14541	Dialysis-related and inpatient costs  (£)  during the 12-month study period  (n=171)
14542	Mean  (SE)  outcome measures before and after treatment
14543	SPECT Perfusion Results Per Vascular Territory of the Bypass Graft
14544	Mean  (95% CI)  change in secondary outcomes after prednisolone treatment compared with placebo
14545	Agreement of SPECT Perfusion and CMR
14546	Agreement Between SPECT and CMR in Four Categories
14547	Known and possible mitochondrial toxicities of nucleoside and nucleotide-analogue HIV reverse-transcriptase inhibitors
14548	Clinical features of hypersensitivity to antiretroviral drugs
14549	Other antiretroviral drug toxicities
14550	Follow-up data and specification of death causes for all participants in 1964–72, during 30 years of follow-up
14551	Relative risks of airway hyper-responsiveness and all-cause and cause-specific mortality after adjustment for major risk factors for mortality during 30 years of follow-up
14552	COPD deaths  (primary and secondary)  according to smoking habits and histamine threshold
14553	Lipids, Lipoproteins, and Apolipoproteins of Carriers and Noncarriers of ApoA-I Mutation  (L178P)
14554	Admission risk markers and associated score component values
14555	Distribution of risk scores for score development and validation groups of patients
14556	Spearman's correlations between scores and length of stay and units of blood transfused  (validation group)
14557	Fast-track screening risk predictions and numbers of patients needing clinical treatment  (validation group)
14558	Multivariate Analysis of Risk of Coronary Artery Disease Attributable to the L178P Mutation Carrier Status
14559	Effect of vitamin E treatment on cardiovascular outcomes in the SPACE cohort
14560	Causes of death by treatment and disorder in SPACE cohort
14561	LVESVI  (ml/m2)  and Mitral Valve Repair
14562	EF  (%)  and Mitral Valve Repair
14563	Preoperative and postoperative symptoms of the five patients with pain and faecal urgency at follow up
14564	Comparison of patients with and without pain and faecal urgency 6 months after stapled haemorrhoidectomy
14565	Details of anorectal physiology tests in affected patients
14566	Serious adverse events
14567	Incidence of significantly elevated prespecified plasma analyses
14568	Most commonly arising treatment-emergent adverse events
14569	Death and comorbid events of worsening heart failure
14570	Changes in neurohormones over time  (mean [SE])
14571	Antihypertensive treatment at final visit
14572	Relative risk and occurrence of endpoints
14573	12 most frequent adverse effects
14574	Numbers of patients and events by country
14575	Adverse events reported by investigators
14576	Cox's regression analysis of risk factors
14577	Individual endpoints
14578	Diagnosis in patient population
14579	Sensitivities, specificities, positive and negative predictive values, and probabilities for comparison of differences in sensitivities
14580	Detection of pancreatic carcinoma and chronic pancreatitis by MRCP and ERCP
14581	Changes in anthropometric variables during the intervention
14582	Concentration of zinc in serum and hair at the end of the intervention period
14583	Incidence of anorexia and selected illnesses during the 6 month intervention period
14584	Clinical and laboratory data before treatment
14585	Efficacy variables
14586	Numbers of participants reporting adverse events during the first 28 days after drug intake
14587	Primary outcome and in-hospital mortality
14588	Physiological factors
14589	Median nursing workload by group and time period
14590	Numbers of toxic events reported by treatment
14591	Summary of trials in advanced colorectal cancer that compared high-dose and low-dose folinic acid
14592	Organ volume, haemoglobin, platelet count, and chitotriosidase values before and during OGT 918 treatment
14593	24-H Holter Monitoring Electrocardiographic Recordings in 148 Control Group Athletes
14594	Signs and symptoms recorded during hospital stay
14595	Hemodynamic Parameters at the Time of Study Enrollment
14596	Monthly responders
14597	Summary of all adverse events
14598	Response rates
14599	Logistic regression of predictive factors for response rate
14600	Cox's model for time to progression
14601	Patients with any adverse event and with grade 3–4 adverse events related to study treatment  (weekly regimen)
14602	Patients with any adverse event and with grade 3–4 adverse events related to study treatment  (2-weekly regimen)
14603	Predictors of Ibutilide Cardioversion Success by Univariate Analysis
14604	Mean blood pressures in 5489 control patients followed up for 2 years
14605	Number of patients to treat for 5 years to prevent one event
14606	Tissue measurements
14607	Analysis on a per-woman basis
14608	Determinants of Conversion in 104 Patients With AF/AFL Treated With Ibutilide and Propafenone
14609	Comparative serological findings by vaccine group
14610	Relation of selected variables to frequency of at least four-fold increases in antibody titres 1 month after booster doses of vaccine
14611	Distribution of deaths by age and cause, and breastfeeding prevalence among controls
14612	Infant mortality associated with not breastfeeding, by country and age-group
14613	Infant mortality associated with not breastfeeding, by country, age-group, and sex
14614	Mortality at 12–23 months of age associated with not breastfeeding, by country and age-group
14615	Use of secondary care in participants admitted at least once during study period
14616	Use of primary-care facilities during the year from entry to the study
14617	Colitis in patients
14618	Polymerase Chain Reaction Primer Sequences, Cycling Methods, and DHPLC Temperatures
14619	Polymorphisms Identified
14620	Causes of acute pulmonary oedema
14621	Mean  (SD)  physiological measurements during the first 10 h of the study  (all patients included)
14622	Reasons for withdrawal from the trial, categorised by sibutramine dose
14623	Proportion of patients reporting adverse events during the weight-loss phase and by at least 5% of patients in either treatment group during the double-blind phase
14624	Clinical and Electrophysiological Data on Group I
14625	Positive and Negative Predictive Values of the Induction of Monomorphic Ventricular Tachycardia <270 beats/min and Ventricular Fibrillation to Predict All Cardiac Deaths, Sudden Death, and Death Related to Heart Failure in Group I
14626	Clinical and Electrophysiologic Data on Group II
14627	Mean  (SD)  arthritis assessment results at week 24
14628	Gastrointestinal ulcer frequency
14629	Most frequently-reported adverse events
14630	Positive and Negative Predictive Values of Positive Programmed Ventricular Stimulation  (VT and VF)  to Predict Total Cardiac Death, Sudden Death, and Death Related to Heart Failure in Group II
14631	Univariate Logistic Regression Results of Hemodynamic Parameters for In-Hospital Mortality
14632	Multivariate Logistic Regression Results for In-Hospital Mortality  (Using Cardiac Power Index)   (n = 178)
14633	Multivariate Logistic Regression Results for In-Hospital Mortality  (Using Cardiac Power Output)   (n = 181)
14634	Selected Hemodynamic Parameters of Patients With Shock Due to Predominant Left Ventricular Failure by Culprit Artery
14635	Patients achieving ACR  *   50% and 70% response at 30 weeks
14636	Adverse events
14637	Supine blood pressure  (mm Hg)
14638	Proportions of patients reporting 12 most common adverse events
14639	Frequency of events per 1000 patient-years
14640	Neurointerventional and diagnostic procedures
14641	Odds ratios from logistic regression for the training set of 432 cases
14642	Accuracy of gram stain and AOLC test for the diagnosis of catheter-related bloodstream infection
14643	Comparative accuracy of gram stain and AOLC test with three other methods for diagnosis
14644	Clinical and Echocardiographic Data Before, During, and After Pregnancy
14645	Comparisons Between Repeat Measurements of Peak Velocities, Pressure Half-Time, and Mitral Valve Area With Velocity-Encoded Cardiovascular Magnetic Resonance
14646	Congenital dislocation of the hip  (CDH)  among livebirths
14647	Operative procedures by age at diagnosis of CHD
14648	Comparison of LVIDd in a Subset of Athletes Engaged in High Impact Sports  (Cycling, Cross-Country Skiing, Canoeing, Rowing, and Soccer)    (10)  and in Professional Cyclists  (Current Study)  According to BSA
14649	Primary and secondary outcome measures
14650	Reasons for death
14651	Unadjusted Use of Evidence-Based Therapies and Outcomes in “Ideal” Patients With Acute Myocardial Infarction, n  (%)
14652	Unadjusted Use of Evidence-Based Therapies and Outcomes by Region in “Ideal” Patients With Acute Myocardial Infarction, n  (%)
14653	Association Between Admission to a CME Requiring State and Mortality From AMI
14654	Serological confirmation of cases of leptospirosis
14655	Bacteriological confirmation of cases of leptospirosis
14656	Crude and adjusted odds ratios and 95% CIs for risk factors associated with death from leptospirosis
14657	Histopathology  (central review)
14658	Results of subgroup analyses
14659	Rate of GFR decline and incidence of ESRF in patients with basal GFR of 45 mL/min or less
14660	Events leading to withdrawal of treatment
14661	Diagnosis–specific outcomes
14662	Clinical outcomes
14663	Side-effects within 7 days of the first vaccination
14664	Immune responses after two doses of vaccine or placebo
14665	Protective efficacy of 89–12 vaccine
14666	Overall risk of cancer in ESRD patients
14667	Site-specific cancer risk in ESRD patients  *
14668	Bladder cancer risk in ESRD patients
14669	Kidney cancer risk in ESRD patients
14670	Compliance  (%)
14671	Frequency of malignant disease by size of non-calcified nodule among participants with a solitary nodule on low-dose CT
14672	Effects of Ramipril on Left Ventricular Mass and Function
14673	Distribution of tumours by size  *   and stage
14674	Recommendations for biopsy and resulting diagnoses
14675	Resistance mutations
14676	Treatment regimens in control and genotypic groups
14677	Sleepiness, awake % SaO2, and NCPAP use before and after therapeutic and subtherapeutic NCPAP
14678	SF-36 scores before and after therapeutic and subtherapeutic NCPAP
14679	Laboratory test results by treatment regimen
14680	Course of illness after admission to hospital
14681	Outcome by treatment regimen
14682	Medication at Discharge
14683	Clinical Events
14684	Quantitative Angiographic Data at Angiographic Follow-Up
14685	Hazard ratios of mortality in the Leiden area versus the non-Leiden area
14686	Severe clinical side-effects and laboratory abnormalities
14687	Summary of Studies Evaluating Anemia and Cardiovascular Disease
14688	Risk factors and coexisting disorders
14689	Diagnostic investigations
14690	Adverse events in relation to thrombolytic treatment
14691	Final model  (815 patients)
14692	Secondary measures of intervention efficacy
14693	Association of Follow-Up Variables With Risk of Pacemaker Syndrome
14694	Results of analysis based on Hasemann-Elston regression algorithm
14695	Antibiotic resistance patterns by case classification at admission
14696	Course and duration of treatment
14697	Treatment success by patient group and loss to follow-up
14698	Variables independently associated with treatment failure by multivariate logistic regression
14699	Adherence to treatment
14700	Biological tolerance to treatment and vital status of women and children post partum
14701	Probability of HIV-1 infection in children during the first 6 months of life
14702	Determinants of overall HIV-1 vertical transmission according to treatment group
14703	Treatment goals for standard and intensively treated groups
14704	Drug treatment in patients at start and end of study
14705	Changes at end of study in clinical, behavioural, and biochemical variables
14706	Mortality and macrovascular events
14707	Treated Vessel and Prevalence of Diabetes Mellitus in Patients Treated With Balloon or Stent
14708	Immediate Angiographic Results
14709	Angiographic Follow-Up
14710	Relationship Between the Risk Reduction in Restenosis and Angiographic Variables
14711	Clinical Events
14712	Patients with events during follow-up by treatment group
14713	On-treatment analysis: relative risk of captopril vs conventional therapy
14714	Sensitivity testing of routine PCRs
14715	Sensitivity testing of antibody negative seroconversion panels before and after spiking PCR-negative plasma pools
14716	Comparison of RT-3DE Using the Semi-Automatic Algorithm With Manual Tracing and With Results Obtained by CMRI
14717	Observer Variability for the Semi-Automatic Algorithm and Manual Tracing
14718	Mean  (SD)  outcome measures  (intention-to-treat population)
14719	Radiographic analysis of disease activity
14720	Adverse events  (%)
14721	Study design
14722	Incidence of diarrhoea in children under 5 years during fly seasons  (March–June)
14723	Common peroneal nerve electrophysiology
14724	Sural nerve electrophysiology
14725	Median time  (days)  to alleviation of clinically important symptoms
14726	Sleep disturbance, return to normal activities, and use of relief medications
14727	Mean differences in symptom scores between patients on zanamivir and placebo
14728	Complications and associated antibiotic use in intention-to-treat and high-risk patients
14729	Clinical and laboratory results in 30 patients treated with miltefosine
14730	Responses to miltefosine treatment in 30 patients with kala-azar
14731	Clinical, Stress, and Echocardiographic Variables in the Dobutamine Echocardiography Groups
14732	Independent Predictors of Events by Dobutamine Echocardiography in the Modeling Group
14733	Relationship of Dobutamine Score With Outcome
14734	Multivariate Cox's analysis
14735	Worst score during study for each EORTC QLQ-C30 scale
14736	Patients with National Cancer Institute common toxicity criteria grade 3 or 4
14737	Cox's multivariate analysis of survival
14738	Reasons for treatment discontinuation
14739	Worst scores during study for each EORTC QLQ-C30 scale
14740	Clinical features of treatment groups at randomisation
14741	Aetiology of dementia
14742	Follow-up and treatment status by treatment group and year of follow-up in the dementia project
14743	Events leading to withdrawal during the follow-up study among patients with chronic nephropathy and base-line urinary protein excretion rate ⩾3 g/day who were originally randomised to ramipril or placebo
14744	Clinical details of women participating in study
14745	Incidence of new symptoms occurring after administration of cervical-ripening agent
14746	Results of intraoperative recordings for both randomised comparisons and observational study
14747	Comparison of WHO and ADA diagnostic categories in 1989 cohort
14748	Age categories by sex for 1989 cohort
14749	Comparison of WHO and ADA diagnostic categories in African-American cohort
14750	Age categories by sex for African-American cohort
14751	Prevalence of cardiovascular disease by WHO and ADA diagnostic categories in 1989 cohort
14752	LV Wall Thickness, Cavity Dimensions, and Shortening Fraction Four Weeks After the Designated Treatment
14753	Person-years of follow-up on assigned and actual therapies for first 15 and all centres
14754	Use of Medications During Follow-Up by Patients Assigned to One of Three Groups
14755	Frequency of Major In-Hospital Events
14756	One-Year Outcomes of the Randomized Groups
14757	Clinical features of treatment groups at randomisation
14758	Follow-up and treatment status by treatment group and year of follow-up
14759	Mortality by treatment group
14760	Non-fatal endpoints alone and combined with fatal endpoints
14761	Other events
14762	History, findings, and treatment of patients treated with systemic methotrexate who received surgical intervention
14763	Side-effects and complications
14764	Outcome measures
14765	Main toxicity-related results
14766	Main efficacy-related results
14767	Significance of prognostic factors of response, progression-free survival, and survival
14768	Distribution of mEPHX genotypes in control and disease groups
14769	Distribution of putative mEPHX phenotypes in control and disease groups
14770	Angiographic Data and Catheterization Laboratory Complications of Study Patients
14771	In-Hospital Complications and Long-Term Outcomes
14772	Adjusted Odds Ratios of Clinical Variables Associated With the Risk of Ventricular Tachycardia or Fibrillation During Primary Percutaneous Coronary Intervention
14773	Resting haemodynamic data in heart-failure patients
14774	Mean  (SD)  changes during lower-body suction
14775	Age-Adjusted Descriptive Information for Variables Included in the 10-Year Risk Estimates for Coronary Heart Disease, National Health and Nutrition Examination Survey III, 1988 to 1994
14776	Age-Specific and Age-Adjusted Distribution Risk for Coronary Heart Disease Among United States Adults Age ≥20 Years Without Self-Reported Coronary Heart Disease or a Coronary Heart Disease Equivalent, * National Health and Nutrition Examination Survey III, 1988 to 1994
14777	Age-Specific and Age-Adjusted Distribution of Risk for Coronary Heart Disease Among U.S. Adults Age ≥20 Years After Including People With Self-Reported Coronary Heart Disease or Coronary Heart Disease Risk Equivalents * in the Highest Risk Category, National Health and Nutrition Examination Survey III, 1988 to 1994
14778	Distribution of CHD Risk Equivalents Among 3,026 * U.S. Adults Age ≥20 Years With Any Such Risk Equivalent, National Health and Nutrition Examination Survey III, 1988 to 1994
14779	Clinical and laboratory data of 16 children with diarrhoea associated with infection by EAEC
14780	Percentage distribution of projected DALYs for specific two causes
14781	Worldwide deaths attributable to tobacco use in 1990 and 2020
14782	Agreement Between Parameters of Ejection Pressure Difference Curves Obtained by Micromanometers and by Doppler-Echocardiography
14783	Results of the Clinical Study Showing Clinical, Hemodynamic, and Ejection IVPG Data From Healthy Volunteers  (n = 20)  and Patients With DCM  (n = 20)
14784	Factors Related to the Peak Intraventricular Pressure Difference in the Clinical Study
14785	Rates of progression to AIDS and death
14786	Subgroup analysis of rates of progression to AIDS and death
14787	Healthcare resource use for new or recurrent HIV-related events
14788	Summary of procedures used to estimate attributable burden from ten major risk factors
14789	Distribution % of DALYs for specific causes  (level 2 categories) , 1990
14790	Thirty leading causes of worldwide DALYs for both sexes in 1990
14791	Estimated total attributable burden for selected conditions as risk factors for death and disability from other diseases and injuries
14792	Percentage worldwide DALYs attributable to each of ten risk factors, by region, 1990
14793	Sources and methods used to estimate mortality by cause for each region in 1990
14794	Distribution of deaths for specific causes  (level-two categories)  in 1990
14795	30 leading causes of death worldwide in 1990
14796	Clinical data at randomisation and change in GFR for children followed up for 2 years
14797	Clinical data at randomisation and change in GFR for children followed up for 3 years
14798	Initial and 2-year serum biochemistry and anthropometric measurements
14799	Univariate Pearson correlations with 2-year decrease in creatinine clearance
14800	Echocardiographic Variables at Rest
14801	Cardiopulmonary Exercise Testing
14802	Predictors of %Predicted Vo 2max in Patients With DCM
14803	Exposure to potential risk factors during the 3 days before onset of illness in case-patients and matched controls  (univariate analysis)
14804	Conditional logistic regression model of selected risk factors for cholera
14805	Timing, findings, and subsequent treatment of aneurysms in patients undergoing total knee replacement surgery for haemophilic arthropathy
14806	Association of duration of injecting-drug use, and HGV-RNA and anti-E2 seroprevalence
14807	Attack rates of culture-proven  S sonnei  shigellosis in recipients of  S sonnei  conjugate vaccine and placebo vaccines
14808	Antibody responses and geometric mean titre to S sonnei LPS among recipients of S sonnei-rEPA in group D
14809	Univariate associations between birthweight and maternal 24 h mean ambulatory blood pressure
14810	Birthweight by 24 h mean ambulatory diastolic pressure at mid gestation
14811	Significant predictors of birthweight in multiple regression analysis
14812	Use of interventions and medications by geographical location
14813	Outcome of cardiogenic shock by 30 days and type of revascularisation used
14814	1-year mortality
14815	Study End Points
14816	Quality of Life  (Assessed by SF-36)
14817	VAS background and peak pain scores  (mm)  with ESCS turned off and on
14818	INSS staging of 118 neuroblastoma cases in Quebec for 5-year screened cohort
14819	SIRs for neuroblastoma at 1-year age intervals versus US SEER data
14820	SIRs of early and advanced Evans' stage neuroblastoma versus Greater Delaware Valley data
14821	Inclusion criteria
14822	Exclusion criteria
14823	Non-fatal outcome events
14824	Validated events
14825	Intention-to-treat analysis—primary and secondary outcome clusters
14826	Treatment effect by subgroup—ischaemic stroke, MI, or vascular death
14827	Treatment effects of patients with a history of MI
14828	Adverse experiences  (number and percentage of patients)
14829	Primary results of meta-analysis
14830	Left ventricular  (LV)  systolic function and mass
14831	Mean  (SD)  carotid arterial compliance data
14832	Outcome of patients by serogroup and treatment group
14833	HR, Blood Pressure, and Echocardiographic Parameters in the Carvedilol and Placebo Groups
14834	Median peak serum and stool concentrations ciprofloxacin and doxycycline treatment groups
14835	Assessment of NYHA Class Over the Treatment Period
14836	Secondary End Points and Exploratory Analyses
14837	Exclusion criteria
14838	Reasons for stopping blinded trial treatment
14839	Percentage of time before clinical progression on antiretroviral treatment
14840	Survival and disease progression
14841	Adverse events while on blinded trial treatment
14842	End-tidal pCO2 during HVPT and placebo test
14843	Number of subjects who recognised symptoms during HVPT and placebo test
14844	Description of groups at trial entry
14845	Actual management between trial entry and discharge from hospital  (or death before discharge)
14846	Principal measures of outcome
14847	Overall status at 1-year follow-up of 124 infants enrolled by Dec 1, 1994
14848	Associations Between Pattern of Hyperenhancement and Clinical Phenotype
14849	Pulmonary physiology results
14850	Risk ratio for combined endpoint adjusted for changes in time-dependent covariates
14851	Events leading to withdrawal of treatment
14852	Plasma histamine and b-endorphin during study periods
14853	Effect of the 9vHPV vaccine on the incidence of persistent infection, cervical, vulvar, and vaginal disease, cervical cytological abnormalities, and medical procedures related to HPV 6, 11, 16, or 18 and HPV 31, 33, 45, 52, or 58 in the per-protocol efficacy population
14854	Effect of the 9vHPV vaccine on the incidence of persistent infection, cervical disease, cervical cytological abnormalities, and cervical definitive therapy related to each HPV type in the per-protocol efficacy population
14855	Effect of the 9vHPV vaccine on the incidence of 6 months' persistent infection  *   related to HPV 31, 33, 45, 52, or 58 in subgroups of the per-protocol efficacy population
14856	HPV-9 cLIA and PBNA geometric mean titres in the per-protocol immunogenicity population
14857	Sources of Data for Meta-Analysis From Principal Randomized Clinical Trials of ACE Inhibitors and Beta-Blockers
14858	Effect of ACE Inhibitors on Mortality From Heart Failure in Male and Female Patients
14859	Effect of ACE Inhibitors on Mortality From Heart Failure in Male and Female Patients Reported Separately for Prevention Studies and Treatment Studies
14860	Effect of ACE Inhibitors on Mortality From Heart Failure in Diabetic and Nondiabetic Patients
14861	Effect of ACE Inhibitors on Mortality From Heart Failure in Black and White Patients
14862	Effect of Beta-Blockers on Mortality From Heart Failure in Male and Female Patients
14863	Effect of Beta-Blockers on Mortality From Heart Failure in Diabetic and Nondiabetic Patients
14864	Effect of Beta-Blockers on Mortality From Heart Failure in Black and White Patients
14865	Primary endpoint and selected secondary endpoints at 1 year
14866	Summary of facial transplant indications and patient outcomes at long-term follow-up
14867	Primary and secondary outcomes across all timepoints and by surgery type
14868	Pain ratings across timepoints and by surgery type
14869	Genes included in the prediction set by array probeID
14870	Primary endpoint
14871	Secondary endpoint—win ratio
14872	Safety assessment of ixmyelocel-T
14873	Patient Data
14874	Patient Disposition
14875	Procedure-related parameters and high-risk factors for post-ERCP pancreatitis
14876	Mean Changes in SBP and DBP for Placebo, Eplerenone, and Losartan at End Point  (Week 16)
14877	Outcomes and adverse events
14878	Mean Changes in SBP and DBP in Special Patient Populations at End Point  (Week 16)
14879	Incidence of Adverse Events
14880	Results of first round of screening
14881	Distribution of clinical stages of breast cancer
14882	Histological findings
14883	Need for biopsy on the basis of first-round screening
14884	5-year cumulative incidence of ipsilateral breast tumour recurrence, overall recurrence  (local, regional, or distant metastasis) , and overall survival, by age
14885	Clinical Features of the HCM Family
14886	Diabetes remission and relapse and glycaemic control at 5 year follow-up
14887	Secondary outcome measures
14888	Early and long-term complications
14889	Primary, secondary, and safety endpoints
14890	Clinical Features of Patients With HCM Studied in Referral Centers
14891	Clinical Features of Patients With HCM Studied in Nonreferral Centers
14892	Donor heart management
14893	Causes of transplant failure
14894	All serious infections  (opportunistic or requiring admission to hospital)  within first 6 months
14895	Frequency and Racial Differences for Cardiovascular Causes of Sudden Death in 286 Young Competitive Athletes
14896	Geographical location of hospital or trust transplant centres, tertiary hepatopancreatobiliary surgical units, and the hepatitis C virus treatment-led centres
14897	Routine tests and algorithms compared with transient elastography as surrogate markers of liver fibrosis
14898	Predicted effects of a minimum unit price on different categories of drinkers in the UK  84
14899	Number of people aged 11–25 years attending paediatric specialist liver services in England before and after transition
14900	Optimum strategy to reduce the future burden of hepatitis C virus with liver disease
14901	Echocardiographic Findings in the Carriers With Arg820Gln in the MyBP-C Gene
14902	Electrocardiographic Findings in the Carriers With Arg820Gln in the MyBP-C Gene
14903	Conservation of Arginine 820 in Cardiac MyBP-C
14904	Outcomes at 12-month follow-up
14905	Descriptive data at time of discharge and at the 12-month follow-up
14906	Phenotypic Characterization   (29)  and Molecular Epidemiology of the Study Population
14907	Phenotype and Genotype of 12 Patients with DCM Heterozygous for LMNAMutations
14908	Analysis of Clinical Variables as Predictors of LMNAMutations in Patients With DCM
14909	Summary of the Reported LMNAMutations Leading to Cardiac Disease  (DCM and/or Arrhythmia/Conduction Disease)
14910	Female Sexual Function Index assessment, by domain
14911	Lung function
14912	Sequence of bronchoscopic treatments with the corresponding placed stent, condition of the transplanted airway, and subglottic stenoses
14913	Response to tenofovir treatment at year 5
14914	Adverse events and laboratory abnormalities reported during open-label phase
14915	Adverse events
14916	Psychometric assessment scores, by individual patient
14917	Summary of adverse events in patients who reported at least one event
14918	Types and severities of adverse events, by system organ class and preferred term
14919	Expression of cell nests positive for c-Jun and proteins involved in tumorigenesis in basal-cell carcinoma
14920	Concentrations of lymphocyte and inflammatory cells infiltrating in basal-cell carcinoma
14921	Summary of prostate cancer progression
14922	Rates of prostate cancer progression  (pathological and therapeutic)
14923	Adverse events
14924	Comparison of Metabolic Profile
14925	Number of patients admitted to hospital with autoimmune disorders in Sweden between 1964 and 2008
14926	Number of patients admitted to hospital for pulmonary embolism in Sweden  (1964–2008)  and subsequent pulmonary embolism in patients with autoimmune disease
14927	SIRs for subsequent pulmonary embolism in patients with autoimmune disorders without previous hospital admission for venous thromboembolism or coexisting venous thromboembolism
14928	Relation of Myocardial Perfusion Grade to Mortality
14929	Univariate Cox Model Predictors of Cumulative Mortality
14930	Multivariate Cox Model Predictors of Cumulative Mortality
14931	Clinical summary
14932	Summary of response to AVI-4658
14933	Summary of available drugs that lower blood glucose
14934	Summary of the clinical efficacy of glucagon-like-peptide-1 agonists in randomised controlled trials
14935	Summary of clinical trials of sodium–glucose-cotransporter-2 inhibitor dapagliflozin
14936	Hemodynamic, Echocardiographic, and Functional Data
14937	Anthropometric and Biochemical Data
14938	Myocardial Work and Efficiency
14939	Lung function tests
14940	Clinical and pathological findings in CFHR5 nephropathy
14941	Catheter and Doppler Echocardiographic Data Obtained In Vitro, in Animals, and in Patients *
14942	Theoretical Values of Doppler-Derived Effective Orifice Areas for Given Catheter-Derived Effective Orifice Areas and Aortic Diameters*
14943	First operation pathology details
14944	Initial and repeat operations
14945	MRI-predicted patient management
14946	Quality of life summaries for patients who completed questionnaires within set timeframes
14947	Risk of stroke associated with risk factors in the overall population  (multivariate analyses)
14948	Risk of stroke associated with key risk factors by region, sex, age, and stroke severity
14949	Population-attributable risk for various risk factor combinations
14950	Risk of ischaemic stroke subtypes  *   associated with risk factors
14951	Risk of ischaemic stroke associated with risk factors by type of respondent for cases
14952	Risk of ischaemic stroke associated with risk factors by source of controls  (community-based or hospital-based)
14953	2,3,7,8-tetrachlorodibenzo-p-dioxin  (TCDD)  concentrations  (pg/g lipid weight [LW] or pg/g wet tissue weight [WW])  as a function of time  (months)  after the day of poisoning in samples analysed
14954	Equations for the calculation of concentrations of 2,3,7,8-tetrachlorodibenzo-p-dioxin  (TCDD)  eliminated from the body and in tissue samples as a function of time
14955	Concentrations of metabolites of 2,3,7,8-tetrachlorodibenzo-p-dioxin  (TCDD)  in samples as a function of time  (months)  after TCDD poisoning
14956	Vaccine efficacy against cervical intraepithelial neoplasia grade 2 or more  (CIN2+) , or grade 3 or more  (CIN3+) , colposcopy referrals, and cervical excision procedures associated with human papillomavirus  (HPV) -16/18, five non-vaccine oncogenic types, and irrespective of HPV DNA in lesion
14957	Safety and pregnancy outcomes in the total vaccine cohort during the entire study
14958	Efficacy of Amiodarone Versus Placebo in Converting AF to Sinus Rhythm at Various Time-Points
14959	Efficacy of Amiodarone Versus Class Ic Drugs in Converting AF to Sinus Rhythm at Various Time-Points
14960	Differences  (placebo–avotermin)  in VAS scores assigned by the IESAP  (lay)  and investigators for varying concentrations of avotermin in studies 1002 and 1005  (within-participant comparisons)
14961	Treatment differences  (placebo–avotermin)  in VAS scores assigned to wound sites by the IESAP  (lay) , IESAP  (clinical) , and investigators at month 7  (LOCF)  after wounding, with varying concentrations of avotermin, in study 0036  (within-participant comparisons)
14962	Histological analysis of the orientation of collagen fibres in the reticular dermis of scars  (study 1005)
14963	Clinical Data Grouped by Etiology and Gender
14964	Cardiac and Myocyte Morphology Data Grouped by Etiology and Gender
14965	Reasons for referral to breast MRI
14966	Sensitivity of mammography and MRI for DCIS detection
14967	Biological profiles of DCIS by method of detection
14968	Distribution of Cases and Method of Diagnosis
14969	Symptoms at Hospital Presentation
14970	Screening findings by age in the intervention group
14971	Additional Care to Conventional Therapy
14972	Stage of disease by study group and detection mode
14973	Logistic Regression Model for Variables Associated With Independent Predictors of Idiopathic Giant Cell Myocarditis
14974	Incidence of and mortality from cervical cancer by study group
14975	Overall and age-specific hazard ratio for incidence for all cervical cancers, cancers at stage II or worse, and for cervical cancer deaths
14976	CIN2+ lesions with HPV16 or HPV18 DNA
14977	Efficacy against CIN2+ and CIN1+ associated with HPV16 or HPV18 in the total vaccinated cohort for efficacy
14978	Vaccine efficacy against persistent infections with oncogenic HPV types in the total vaccinated cohort for efficacy
14979	Safety outcomes
14980	Pregnancy and pregnancy outcomes in the total vaccinated cohort during the entire study
14981	Study design and comparison of protocols 005, 007, 013, and 015
14982	Number of women included in efficacy analyses and reasons for exclusion
14983	Primary analysis of efficacy against HPV16/18-related CIN2/3 and AIS
14984	Vaccine effectiveness against all CIN2/3 and AIS regardless of causal HPV type  (ITT population)
14985	Analysis of efficacy against HPV16/18-related CIN2, CIN3, and AIS by region
14986	Details of thoracoscopy procedure
14987	Side-effects of thoracoscopy
14988	Causes of death within 30 days of thoracoscopy
14989	Multivariable Predictors of the No-Reflow Phenomenon
14990	Univariate Association of Clinical, Exercise Stress Test, and Echocardiographic Variables With Risk of Hard Cardiac Events and All-Cause Mortality
14991	Independent Predictors of All-Cause Mortality Using Four-Step Model
14992	Independent Predictors of Hard Cardiac Events Using Four-Step Model
14993	Clinical Details
14994	Response to Dobutamine Stress: Intragroup Analysis
14995	Individual Contribution of Coronary Artery Disease and Left Bundle Branch Block by Analysis of Variance
14996	Clinical and Echocardiographic Data of the Study Populations
14997	Unadjusted Best Cut-Off Values of AS Indices to Predict Clinical Outcome Efficacy End Points
14998	Multivariate Clinical Efficacy Prediction Models in Group A  (n = 307)
14999	Inter-relationship Between Serum Concentrations of Iron Metabolism Parameters, Oxidative Stress, and Endothelial Function in Patients With Hereditary Hematochromatosis
15000	Pacing Threshold at Implantation and After One and Three Months
15001	Left Ventricular mRNA Expression  (Per 18S rRNA)  and Respiratory Chain Complex Activities
15002	Effects of Vardenafil 10 mg and Placebo on Exercise Parameters in Patients With Angina and ≥1 mm ST-Segment Depression
15003	Effect of Vardenafil 10 mg on HR, Blood Pressure, and Rate-Pressure Product at Rest and During Peak Exercise  (n = 41)
15004	Adverse Events Reported During Treatment With Vardenafil or Placebo
15005	Response to treatment in prognostic subgroups
15006	Progression-free survival at 3 years after randomisation in prognostic subgroups
15007	Overall survival at 3 years after randomisation in prognostic subgroups
15008	CVD Risk Factors by Case-Control Status
15009	Multivariate analysis of the effects of various prognostic variables on progression-free survival and overall survival in 524 patients
15010	Distribution of Hp Types by Case-Control and Diabetes Status
15011	Incidence of grade 3 and 4 adverse events
15012	Conditional Logistic Regression Predicting the Probability of a CVD Event
15013	Countries with and without hospital profiles or pulse oximetry data
15014	Estimated number of operating theatres per 100 hospital beds, by region*
15015	Estimated number of operating theatres per head, ranked by estimated number per 100 000 population
15016	Estimates of the number of operating theatres from our model compared with direct reports
15017	Estimated number of operating theatres without pulse oximetry, by subregion, ranked by percentage without pulse oximetry
15018	Estimated number of operations without pulse oximetry
15019	Minimum anaesthesia monitoring standards survey, by region  *
15020	Management of anaesthesia
15021	Incidence of respiratory adverse events
15022	Anaesthetic drugs, airway management, and respiratory complications
15023	Risk factors associated with perioperative bronchospasm
15024	Risk factors associated with perioperative laryngospasm
15025	Risk factors associated with perioperative cough, desaturation, or airway obstruction
15026	Risk of perioperative respiratory adverse events according to timing of upper respiratory tract infection
15027	Risk factors for perioperative bronchospasm, laryngospasm, or all complications according to timing of symptoms and respiratory adverse events
15028	Adequate clinical and parasitological response  (ACPR)  by timepoint  (per-protocol population)
15029	Adequate clinical and parasitological response  (ACPR)  by timepoint  (intention-to-treat population)
15030	PCR-corrected adequate clinical and parasitological response at day 28 in the per-protocol population by region and centre
15031	Most frequent adverse events reported in the safety  (intention-to-treat)  population
15032	Logistic Regression Analyses for the Presence of Coronary Artery Disease
15033	Virological response
15034	Rates of sustained virological response by time to first undetectable hepatitis C virus RNA
15035	Factors affecting sustained virological response
15036	Adverse events during treatment  (≥30% incidence)
15037	Haematological parameters
15038	Discontinuations and dose reductions
15039	Adjusted hazard ratios for death in the CD4 and total lymphocyte and haemoglobin prognostic models
15040	Estimates of cumulative mortality at 1 year in highest and lowest risk groups from main analysis and analysis including patients lost to follow-up.
15041	Observed and Expected Maternal Mortality in the Study Women With a First Pregnancy After 1954, and Relative Risk According to Age- and Year-Specific Maternal Mortality Rates in the General Italian Population Between 1955 and 1984
15042	Clinical Features and Echocardiographic Findings in 40 Women With Hypertrophic Cardiomyopathy and a Pregnancy Within Five Years of Evaluation
15043	Service members who were deployed, medically evacuated, and returned to duty  (RTD)  by year, military operation, and service branch
15044	Logistic regression model of probability of return to duty after medical evacuation  (n=34 006, r 2=0·1739)
15045	Proportion of individuals with psychiatric diagnoses who were medically evacuated and did or did not return to duty  (n=2978)
15046	Best overall confirmed tumour response status  (intention-to-treat population)
15047	Olaparib-related adverse events  ‡  , according to grade, arising in two or more patients
15048	Dose interruptions and reductions due to adverse events
15049	Best overall confirmed tumour response status  (intention-to-treat population)
15050	Best overall confirmed tumour response status  (intention-to-treat population)  by BRCA mutation status and hormonal status
15051	Olaparib-related adverse events, according to grade, arising in two or more patients
15052	Dose interruptions and reductions due to adverse events
15053	Manual removal of placenta
15054	Secondary outcomes
15055	Enrolment by dose
15056	Imaging results and circulating tumour cell numbers
15057	Grade 3–4 adverse events and patients who discontinued treatment because of an adverse event, by dose
15058	Differences in Electrocardiographic and Echocardiographic Parameters Before and After One Month of Cardiac Resynchronisation Therapy
15059	Rate of laboratory and clinical dose-limiting toxic effects, or grade 3 and 4 toxic effects as defined by the AIDS Clinical Trial Group,  28   by study group
15060	Comparison of One-Month Percent Variations Occurring in the Studied Parameters Between Responders and Nonresponders
15061	Subsequent drug exposure groups by first drug exposure group
15062	Comparison of antithrombotic drug exposure groups
15063	Distribution of non-fatal and fatal bleeding events
15064	Sensitivity analyses
15065	Outcomes by treatment allocation
15066	Comparison of mosquito densities between intervention and control groups
15067	Comparison of haemoglobin concentrations between intervention and control groups
15068	Anaemia and parasitaemia in intervention and control groups
15069	Short-Term CABG and PCI Outcomes of Diabetic Patients
15070	CABG and PCI 36-Month Diabetic Patient Survival, Survival Free of Unstable Angina, and Survival Free of Unstable Angina or Repeat Revascularizations
15071	Hemodynamics of EMCV-Infected and Uninfected Mice Based on Pressure-Volume Relations on Days 1, 7, and 14
15072	Effect of Hypertonic Saline on Hemodynamics of EMCV-Infected and Uninfected Mice on Days 1, 7, and 14
15073	Grade 3–4 toxic effects per treatment group
15074	Activity of both treatment groups
15075	Management and outcome in published prospective trials of primary CNS lymphomas in immunocompetent patients given chemotherapy alone or combined treatment
15076	Risk periods for each analysis
15077	Protective efficacies of IPTi with sulfadoxine-pyrimethamine
15078	Combined estimates and sensitivity analysis
15079	Deaths, non-fatal hospital admissions, and serious dermatological adverse events up to 12 months of age, or 3 months after the last dose of study treatment received, whichever is earlier
15080	Bacterial isolates from patients with bacteraemia, stratified by sickle-cell anaemia status
15081	Odds ratios for sickle-cell anaemia in children with bacteraemia versus controls
15082	Incidence of admission to hospital with bacteraemia per 100 person-years of observation, stratified by age group
15083	Serotypes of Streptococcus pneumoniae isolates by status of sickle-cell anaemia
15084	Overall worst toxicities
15085	Deaths and hospitalisations from cardiovascular causes
15086	Patients with events  (numbers of events)  for various cardiovascular hospitalisations or deaths
15087	Patients with serious adverse events
15088	Bone fractures reported as serious and non-serious adverse events
15089	Relationship Between Clinical, Morphologic and Functional Features at Initial Evaluation and Occurrence of Stroke or Other Peripheral Vascular Events in 900 Patients With Hypertrophic Cardiomyopathy
15090	Echocardiographic Parameters in SAM Groups
15091	Nonlinear Regression Parameters for y = α  (x + γ) β
15092	Incidence of antimalarial treatments and illness episodes in children in the community-based and clinic-based trials
15093	Antimalarial treatment for febrile episodes in the community-based trial
15094	Clinical assessments in the community-based trial
15095	TWA, LVEF, SAECG, LVDd, NSVT and the Combination of TWA and the OHR or LVEF as Predictor of Event-Free Survival
15096	Univariate Predictors of Arrhythmic Events in Dilated Cardiomyopathy Patients With Determinate TWA Results
15097	Multivariate Predictors of Arrhythmic Events in Dilated Cardiomyopathy Patients With Determinate TWA Results
15098	Reasons for non-compliance with randomisation to anaesthetic technique
15099	Surgical and anaesthetic procedure
15100	Primary outcomes between randomisation and 30 days after anaesthesia  (or after randomisation for patients who were not anaesthetised)
15101	Epidemiological summary of malaria in children age less than 14 years, in Kilifi, Kenya, 1990–2007
15102	Difference in all admissions and slide-positive admissions before and after the decline in slide-positive admissions
15103	Processes-of-care and outcomes in the propensity-matched pairs
15104	Effect of IPT on health outcomes: anaemia, haemoglobin, and P falciparum parasitaemia
15105	Effect of IPT on cognition: attention in class
15106	Effect of IPT on educational achievement
15107	Study Group  (n = 111)
15108	Extent and Severity Scores by Tetrofosmin and BMIPP for Three Groups
15109	Tetrofosmin and BMIPP Findings and Rates of Disease for Three Groups
15110	Comparison of countries with and without available surgical data
15111	Single-Photon Emission Computed Tomographic Scores for Coronary Angiographic Findings
15112	Average national rate of surgery for countries in each category of health expenditure, with total volume of surgery contributed by each category
15113	Effect of maternal MMN supplementation on infant deaths
15114	Effect of maternal MMN supplementation on fetal loss and maternal death
15115	Effect of maternal MMN supplementation on early infant mortality in subgroups
15116	Effect of maternal MMN supplementation on low birthweight and mean birthweight
15117	NPC training, entrance requirements, scope of practice, and practice locale in the 25 sub-Saharan African countries with NPCs
15118	Reported training cost per year for NPCs in selected sub-Saharan African countries  *
15119	NPCs and physicians per 100 000 head of population for sub-Saharan countries with NPCs
15120	Non-nucleoside reverse transcriptase inhibitor viral drug resistance
15121	Non-nucleoside reverse transcriptase inhibitor viral drug resistance at 2 and 6 weeks after delivery, according to HIV-1 viral load at time of delivery
15122	Perinatal HIV transmission at 6 weeks of life
15123	Coronary Artery Disease  (or Summed Stress Score ≥4)  According to the Number of Sites With Calcium Deposits  (or Sclerosis)
15124	Coronary Artery Disease  (or Summed Stress Score ≥4)  According to the Multiple Calcium Deposits  (or Sclerosis)  and DM or Multiple Risk Factors of Coronary Artery Disease
15125	Predictors of Coronary Artery Disease  (or Summed Stress Score ≥4)  in Multivariate Analyses
15126	Best response to treatment at 12 months
15127	Second-line treatment in patients treated as assigned
15128	Grade 3 or 4 toxic effects
15129	Details of cardiac bypass surgery
15130	Effect of consumption of iron-fortified flour on iron status, compared with placebo
15131	Kaplan-Meier estimates of the likelihood of recurrent ulcer bleeding at 13 months
15132	Efficacy of combined treatment versus celecoxib alone for arthritis
15133	Incidence of severe and important adverse events
15134	Complications
15135	Days Length of Hospital Stay *
15136	Perception of Perioperative Pain and Activity
15137	Comparison of Variable Costs/Patient Charges *
15138	Summary of most common micro-organisms by site of infection
15139	Efficacy analyses
15140	Safety analyses
15141	Design of included trials
15142	One-Year Results in the NSRT and Surgery Groups
15143	Exercise Tolerance in the NSRT and Surgery Groups
15144	Echocardiographic Parameters in the NSRT and Surgery Groups
15145	Control pattern of targeted motor reinnervation prosthesis in this patient
15146	Functional outcome comparing conventional myoelectric prosthesis with experimental TMR-controlled prosthesis
15147	The ten maternal health problems most commonly identified by women attending MaiMwana women's groups in Mchinji District across all periods  (n=172)
15148	The ten maternal health problems antepartum, intrapartum, and postpartum most commonly identified by women attending MaiMwana women's groups in Mchinji District
15149	Weights and Resting Hemodynamics in Sham and Pacing-Induced Rabbits With Heart Failure
15150	Follow-up dietary data
15151	6-month infant haematological and iron status by treatment group
15152	Indication for caesarean delivery, according to type of institution
15153	Association between proportion of risk factors, according to institutions, and proportion of caesarean deliveries  (multivariable analysis)
15154	Association between proportion of all caesarean deliveries and maternal and perinatal outcomes at institutional level
15155	Association between proportion of elective caesarean deliveries and maternal and perinatal outcomes at institutional level
15156	Association between proportion of intrapartum caesarean deliveries and maternal and perinatal outcomes at institutional level
15157	The Effect of CO, CS and Air Inhalation on HR and Blood Pressure
15158	Cox model analysis of factors associated with early death in the Chiradzulu programme, Malawi  (n=1308)
15159	Viral load measures of 397 patients in cross-sectional virological survey
15160	Clinical response
15161	Grade 3–4 adverse events
15162	Results at different times after inclusion
15163	Effect of supplementation with iron and folic acid with or without zinc on serious adverse events, deaths, and admissions to hospital overall, by age group and by duration of supplement compared with placebo.
15164	Effects on overall adverse events, deaths, and admissions to hospital and on cause-specific adverse events in the two iron and folic acid groups compared with placebo
15165	Effects of supplementation with iron and folic acid with or without zinc on adverse events overall and by iron status and anaemia  (substudy)
15166	Mortality, morbidity, and re-interventions within 30 days after first intervention
15167	Comparison of hazard of amputation-free survival and all-cause mortality
15168	Comparison of HRQL by intention-to-treat analysis at different time points from randomisation
15169	Comparison of use of hospital resources by intention to treat during first 12 months from randomisation
15170	Clinical responses at week 10, week 24, and week 50
15171	Adverse events during the placebo-controlled phase  (weeks 0–24)
15172	Macrovascular morbidity at study entry and associated medications
15173	Numbers of first events contributing to the primary composite and main secondary endpoints
15174	Effect of pioglitazone and placebo on each component of the primary endpoint
15175	Change in proportion of patients using concomitant medications
15176	Serious adverse event summary
15177	Reports of heart failure
15178	Indications for Use
15179	Summary of Outcomes/Complications
15180	Unsuccessful IABP *
15181	Risk Factors for Major Complications of IABP *
15182	IABP Complications and In-Hospital Mortality
15183	Location of colon lesions
15184	Colon imaging test sensitivity
15185	Colon imaging test specificity
15186	Colon imaging test sensitivity by preparation quality
15187	Clinical treatment outcome at day 28  (per-protocol analysis)
15188	Clinical treatment outcome at day 28  (intention-to-treat analysis)
15189	Falls and Syncope During 12-Month Follow-Up by Treatment Group by History of Falling
15190	Mortality by age and CD4% at randomisation
15191	Hospital admissions and inpatient days
15192	Grade 3 and 4 adverse events possibly or probably related to masked trial drug
15193	Outcome measures and location of recurrences
15194	Etiologies of Cardiogenic Shock by Gender
15195	Hemodynamic Findings in Patients With Predominant LV Failure
15196	Angiographic Findings and Treatment Approaches in Patients With Predominant LV Failure
15197	Summary of confirmed awareness events
15198	Summary of possible awareness events that were not confirmed by the study endpoint committee
15199	Comparison of anaesthetic procedures
15200	Recovery times and postoperative complications
15201	Number of cases of erythropoietin-induced pure red cell aplasia in France and Germany, by year of diagnosis
15202	The Predicted Success of a Series of Up to Nine Shocks Including Three at 360 J Was Not Matched in Clinical Practice *
15203	Outcome of patients with erythropoietin-induced pure red cell aplasia, by immunosuppressive treatment
15204	Maternal haemoglobin concentrations  (g/L)  at time of delivery in women with chronic pregnancy-associated P falciparum malariaaccording to their plasma IgG concentration with specificity for type of VSA
15205	Birthweights of children born to mothers with chronic pregnancy-associated P falciparum malariaaccording to mothers' plasma IgG concentration with specificity for type of VSA
15206	Multiple linear regression analysis of pregnancy outcome in 89 women with chronic pregnancy-associated malaria
15207	Biomarker correlation with oxygen saturation and haematological variables
15208	Effect of epoetin-β treatment on study endpoints
15209	Variables of the Three Groups During the Perioperative Period
15210	Analysis of Sjvo 2Values Reported by the Oximetric Catheter
15211	Analysis of Sjvo 2Values Reported by the Oximetric Catheter
15212	Number of Patients With Cognitive Impairment at Seven Days and Six Months After the Operation
15213	Results of a Multivariable Logistic Regression
15214	Intraoperative data
15215	Postoperative follow-up data
15216	PASE Activities, Performances and Weight Scores
15217	In-Hospital Outcomes of Elderly Patients With and Without Preinfarction Angina
15218	In Hospital Outcomes of Elderly Patients  (n = 510)  According to the Quartiles of Physical Activity
15219	In-Hospital Outcomes of Elderly Patients With and Without Preinfarction Angina  (n = 323)  According to the Quartiles of Physical Activity
15220	Effect of Preinfarction Angina in Elderly Patients According to the Quartiles of Physical Activity on In-Hospital Death, Cardiogenic Shock and Combined End Points of In-Hospital Death and Cardiogenic Shock
15221	Overall morbidity and complication grades
15222	Rate of malarial fever and protective efficacy of amodiaquine during the 6-month intervention phase by treatment group
15223	Rates of anaemia, protective efficacy of amodiaquine, outpatient attendances, and hospital admissions during the 6-month intervention phase by treatment group
15224	Protective effect of amodiaquine on malaria and anaemia episodes during the first and last parts of the intervention
15225	Concentration of antibodies to vaccines
15226	Crude and Adjusted Relative Risks of Cardiovascular Events According to Quartile of Plasma Level of Lp-PLA2
15227	Crude and Adjusted Relative Risks of Cardiovascular Events Associated With a One-Quartile Increase in the Concentration of Lp-PLA2and CRP
15228	Analysis of the components of the IGF-I system in ventral horn homogenates
15229	Hemodynamic and Neurohumoral Data
15230	Clinical and laboratory data of patients
15231	Molecular weight determined by MALDI-TOFMS compared with molecular weight calculated from aminoacid sequence
15232	Univariate and Multivariate Linear Model of LV Mass Index in 51 DCM Patients With CHF
15233	Effect of  NOS2 −1173 C→T genotype on malarial outcomes in Tanzanian and Kenyan children
15234	Effect of −1173 C T genotype on development of severe malarial anaemia and parasitaemia in Kenyan children
15235	Effect of CCTTTn long versus short genotype on development of severe malarial anaemia and parasitaemia in Kenyan children
15236	Effect of −1173 C®T/CCTTT12–13 genotype on development of severe malarial anaemia and parasitaemia in Kenyan children
15237	Endpoints
15238	Decreases in haemoglobin concentration or packed-cell volume between days 0 and 7
15239	Effect of interventions on the frequency of iron deficiency, defined by serum ferritin concentration <12 μg/L  *
15240	Effect of interventions on risk of malaria attacks
15241	Comparison by hazard ratio for a malaria attack between groups who received interventions or placebo
15242	Distribution of preoperative risk factors required for eligibility for randomisation in 915 patients recruited
15243	Visual analogue scale pain scores on the first 3 postoperative days
15244	Endpoints
15245	Summary of deaths within 30 days of surgery
15246	Study Group Indexed RA Area and RV Volume Over Time
15247	Groin hernia surgery in Denmark, Jan 1, 1998, to June 30, 2000
15248	Rate of reoperation in elective primary or recurrent inguinal hernia operations in 21874 patients  (23 695 operations)
15249	Virological response at the end of treatment and follow-up
15250	Histological responses in patients with biopsy samples from before and after treatment
15251	SVR rate by pretreatment variable and treatment group and according to ribavirin dose
15252	Rates of discontinuation of treatment, dose reduction, and adverse events during treatment
15253	Time Schedule of Sampling of Cardiac Lymph, Plasma and Myocardium legend
15254	Course of Plasma and Lymph cTnI Levels During and After CPB in Pigs in Moderate Hypothermia During Surgery or in Normothermia legend legend
15255	Maternal morbidity statistics for normal populations
15256	Pregnancy outcome
15257	Pregnancy complications
15258	Details of pregnancies in female recipients of allogeneic stem cell transplants
15259	Outcome among patients with renal dysfunction at presentation and SAA production within the reference range throughout the study
15260	Outcome among patients with persistently raised SAA production  (median SAA >50 mg/L between each scan)
15261	Differentially Expressed Genes in the Heart in HCM legend
15262	Use of referral facilities and hospital admissions
15263	Primary outcomes
15264	Secondary outcomes
15265	Costs to providers and women in Cuba and Thailand
15266	Women's and providers' perception and satisfaction
15267	Frequency of main outcomes during first year of life
15268	Serological responses to some EPI vaccines
15269	Categories of reproductive morbidity and their denominators for analyses
15270	Health-seeking behaviour in relation to complaint as reported to the fieldworker
15271	Findings on clinical examination
15272	Laboratory findings
15273	Six-Month Mortality by Peak CK-MB Isoenzyme Ratio legend
15274	Sex and status of patients with homozygous sickle-cell disease at end of study  (Jan 1, 1997)
15275	Six-Month Mortality by Peak CK-MB Isoenzyme Value legend
15276	Age at entry to study, duration of follow-up, and age at death
15277	Six-Month Mortality by Postcoronary Artery Bypass Graft Surgery Occurrence of Two-Step Minnesota Code Worsening Electrocardiographic Abnormalities legend
15278	Kaplan-Meier survival estimates of patients with homozygous sickle-cell disease from birth
15279	Final Multiple Logistic Regression Model ∗ Predicting Six-Month Mortality in Patients Who Had CABG legend
15280	Final Multiple Logistic Regression Model Predicting Six-Month Mortality in Patients Who Survived >10 Days After CABG legend
15281	Toxic effects of treatment in patients who received induction chemotherapy
15282	Response and survival
15283	Summary of functional results at follow-up
15284	Effect of Beta-Blockers Before Crossover of Treatment legend
15285	Prospective Crossover Comparison legend
15286	Dobutamine Stress Echocardiography legend
15287	Outcome summary to day 60
15288	Blood and colloid transfusions to day 7
15289	Relation between parity and placental weight, birthweight, and maternal serum ferritin and haemoglobin
15290	Multiple regression analysis of factors influencing placental weight in 1205 term pregnancies
15291	Morphometric analysis of villous capillarisation in term placentas and relation to serum ferritin and haemoglobin concentrations
15292	Patients' experiences of awareness during surgery
15293	Details of awareness obtained by interview
15294	Reasons for discontinuation of assigned treatment
15295	Occurrence of first outcome events
15296	Types of haemorrhage  (number of fatalities)
15297	Subgroup analysis of occlusion
15298	Physiologic Variables in Control Mice legend
15299	Physiologic Variables in Dbh  −/− Mice legend
15300	Echocardiographic Variables in Dbh −/−Mice Before and After Repletion of Norepinephrine with l-Threo-3,4-Dihydroxyphenylserine legend legend
15301	Frequency of arrhythmias during anaesthesia in children who had at least one episode
15302	Details of operative procedures
15303	Menstrual status and symptoms at 12 months
15304	Patients' satisfaction and efficacy and acceptability of treatment
15305	Aortic Atherosclerosis in Subjects With Aortic Valve Sclerosis and Upper Quintile Transaortic Velocities legend
15306	Odds Ratios of Aortic Valve Sclerosis and Upper Quintile Transaortic Flow Velocities in Relation to Presence, Location and Severity of Aortic Atherosclerosis legend
15307	Odds Ratios of Aortic Valve Sclerosis and Upper Quintile Transaortic Velocities in Relation to Clinical Coronary Artery and Cerebrovascular Disease legend
15308	Studies of prophylactic bed rest after medical procedures
15309	Randomised controlled trials examining the use of bed rest as a treatment
15310	HIV-1 transmission and HIV-1-free survival at ages 1–3 days, 6–8 weeks, and 14–16 weeks
15311	Prognostic factors for HIV-1-infection in univariate Cox's regression models
15312	Effect of vitamin A supplementation on malaria and general morbidity
15313	Age-specific effects of vitamin A on falciparum malaria morbidity and end of study malariometric indices
15314	Results of an audit of nurse-led sedation from 1995 to 1997
15315	Comparison of factors known to be associated with birth outcome in mebendazole and control groups
15316	Comparison of birth outcomes in mebendazole and control groups
15317	Congenital defects in mebendazole and control groups
15318	Incidence of birth defects according to timing of mebendazole therapy
15319	Frequency of mebendazole use according to birthweight
15320	Cumulative amputations  (%)  at 6-month and 2-year follow-up
15321	Estimated transmission risk
15322	Efficacy and timing of transmission
15323	Risk factors for transmission and transmission rates, by treatment group
15324	Logistic-regression analysis of effect of zidovudine treatment and RNA viral load at delivery on risk of transmission
15325	Defined Ranges of IB Values for the Color-Coded Maps in Each Histologic Category legend
15326	Iron content of foods cooked in different types of pot
15327	Change in haemoglobin concentration during study by type of cooking pot
15328	Growth in study groups
15329	Change in weight and length according to change in haemoglobin concentrations
15330	Effect of intermittent treatment doses of sulphadoxine-pyrimethamine compared with placebo on proportion of women with severe anaemia
15331	Effect of intermittent treatment doses of sulphadoxine-pyrimethamine compared with placebo on proportion of women with peripheral parasitaemia
15332	Effect of intermittent treatment doses of sulphadoxine-pyrimethamine compared with placebo on postnatal outcome
15333	Morphometric analysis of villous capillarisation, macrophage density, and stromal-cell proliferation in first and third trimester placentas according to haemoglobin concentrations in maternal blood
15334	Attempted Treatment for MAT legend
15335	Published Reports of MAT in children legend
15336	Postoperative complications in whole group
15337	Proportion of patients with postoperative cognitive dysfunction at 1 week and 3 months by risk factor
15338	Analysis of major risk factors in relation to first postoperative test
15339	Relation of major risk factors to results 3-month test
15340	Treatment responses
15341	HCV-RNA data at week 48
15342	Prognostic Impact of Diabetes According to Etiology of Heart Failure: Adjusted Analyses of the SOLVD Prevention and Treatment Trials Combined legend
15343	Virological responses at end of treatment and follow-up by pre-treatment HCV-RNA concentration and genotype
15344	Adjusted Analyses of Cohort Survival legend
15345	Incidence of Death and Modes of Death According to Surgical Revascularization Status in Diabetic and Nondiabetic Patients legend
15346	Toxic effects of treatment
15347	Tumour response
15348	Flow of participating infants through trial
15349	Revised infant temperament questionnaire scores
15350	Categories of adverse events
15351	Comparison of patients who had adverse events with all other patients
15352	Comparison of patients who had initial serious adverse events with all other patients
15353	Responses to the Dietary Sodium Restriction and Exercise Interventions
15354	Postoperative morbidity
15355	Unadjusted relation between preoperative haemoglobin mortality and mortality and morbidity
15356	Adjusted odds ratio  (95% CI)  for mortality and preoperative haemoglobin and decline in haemoglobin stratified by cardiovascular disease
15357	Patients considered for trial entry
15358	Comparability of treatment arms at randomisation  *
15359	Treatment received
15360	Clinical response 6 weeks after initial treatment
15361	Local failure
15362	Causes of death
15363	Morbidity
15364	Haematological measurements at end of treatment
15365	Summary of stepwise linear-regression analysis of group assignment on postintervention cognitive test scores
15366	Postintervention questionnaire
15367	Breast-duct cannulation and ductoscopy
15368	Lymphocyte phenotype and function in Fas-deficient patients
15369	Serum immunoglobulins and autoantibodies in Fasdeficient patients
15370	Serial Observations in Myosin-Binding Protein C–Affected Adult Relatives Without Phenotypic Evidence of Hypertrophic Cardiomyopathy When Initially Evaluated legend
15371	Presence of infections in AIDS-KS biopsy specimens
15372	Clinical course and complications
15373	Causes of death
15374	Univariate analysis of risk factors affecting survival
15375	Multivariate analysis of risk factors affecting survival
15376	Treatment-emergent adverse events
15377	Study Logic  (Inclusions and Exclusions)  legend
15378	Derived Model by Cox Regression Analysis  (in Derivation Set)  legend
15379	Mortality by Risk Groups: Comparison of the Derivation and the Validation Samples legend
15380	Birth outcomes
15381	Induction outcomes
15382	Neonatal outcomes
15383	Correlation Coefficients of Neurohumoral Plasma Levels legend
15384	Effect of Atenolol and Placebo on Neurohumoral Plasma Concentrations legend
15385	Causes of Death
15386	Effect of Atenolol and Placebo by Outcome legend
15387	Between-group comparison of individual prolapse symptoms at 2 years
15388	Uptake of treatment for prolapse symptoms during year 1 and year 2 of follow-up
15389	Falls in the 6 months before and after training
15390	Secondary outcome measures before and after training
15391	Findings in women who received hysteroscopy in the hysteroscopy group
15392	Pregnancy and livebirth outcomes
15393	Seroconversion for poliovirus  (types 1, 2, and 3)  from week 0 and week 18, and median antibody titres at week 18 by study group  (per protocol)
15394	Seroconversion for poliovirus  (types 1, 2, and 3)  from week 0 and week 18, and median antibody titres at week 18 by study group  (modified intention to treat)
15395	Cumulative seroconversion and median antibody titres by study group
15396	Serious adverse events
15397	Left Ventricular Contractility and Loading Conditions in Response to Intravenous Dobutamine and Intracoronary Enalaprilat and N G-Monomethyl-L-Arginine
15398	Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes based on treatment regimen
15399	Relative efficacy and safety of edoxaban compared with warfarin stratified by dose reduction status
15400	Outcomes stratified by dose reduction criteria and treatment regimen
15401	Falls outcomes compared between the intervention and the control period
15402	Falls outcomes based on cognition levels
15403	Interventions and costs
15404	Unadjusted outcomes at 36-month follow up
15405	Adjusted outcome estimates, at 36-month follow-up
15406	Possible Triggering Conditions at the Onset of Transient Left Ventricular Apical Ballooning legend
15407	Electrocardiographic Findings of Left Ventricular Apical Ballooning
15408	Catheterization Data legend
15409	Absolute and relative health inequalities over three survey cycles of the Health Behaviour in School-aged Children study
15410	Absolute health inequalities in 492 788 adolescents, 2002–10
15411	Relative health inequalities in 492 788 adolescents, 2002–2010
15412	Pooled time-series analysis of health and health inequality in 102 countries and cycles
15413	Operative and Postoperative Data legend legend
15414	Endotoxin and Interleukin-B Ranges at 30 Minutes After Cardiopulmonary Bypass and Associated Ventilation Time legend
15415	Laboratory-confirmed cases by age group
15416	Hospital admissions by age group
15417	Description of the 90 confirmed pertussis cases in infants by maternal vaccination status
15418	Effectiveness of maternal pertussis vaccine by infant age at onset and timing of vaccination
15419	Patients' clinical outcomes
15420	Primary and secondary outcomes within 30 days of randomisation
15421	All deaths and venous thromboembolic events  (including those in first 30 days)  during the 6-month follow-up
15422	Births, deaths, and mortality rates in intervention groups during 2005–09
15423	Factorial and treatment group analyses of primary outcomes
15424	Clinical and Biochemical Variables of Patients and Controls legend
15425	Secondary outcomes in intervention and control clusters for the two interventions  (women's groups and volunteer peer counselling)
15426	Individual IGF-1 Levels in Patients With AMI and Controls legend legend
15427	Estimated proportion of participants falling at least once, and average number of falls per participant, attributable to various causes of falling
15428	Differences from pairwise comparison of proportions of participants falling, and average number of falls per participant, attributable to various causes of falling
15429	Estimated proportion of participants falling at least once, and average number of falls per participant, for each activity at time of falling
15430	Differences from pairwise comparison of proportions of participants falling while undertaking various activities
15431	Combinations of cause and activity associated with six or more falls
15432	Annual suicide rates per 10 000 patients in contact with National Health Service mental health services implementing up to six recommendations compared with those implementing seven to nine recommendations
15433	Rates of suicide per 10 000 per year in target groups before and after implementation of individual recommendations
15434	Treatment outcomes  (defined by the TLOVR algorithm)  at week 48
15435	Treatment-emergent NNRTI and N (t) RTI RAMs  (occurring in two or more patients with available resistance data in either treatment group)  at 48 weeks
15436	Treatment-emergent adverse events and laboratory abnormalities at 48 weeks
15437	Primary and secondary outcomes
15438	Neutrophil recovery, engraftment, and status at last follow-up
15439	Frequency of Missed Overall and Major Cardiovascular Findings by PE and POC Echocardiography legend
15440	Frequency of Findings Missed by Exam and Echocardiography
15441	Incidence of Selected Missed Minor Findings  (Number of Observations)  legend
15442	Incidence of Missed Major Findings  (Number of Observations)  legend
15443	Adverse events  (MedDRA terms)
15444	Levels of serum creatinine and creatinine-clearance
15445	Rates of hypoglycaemia in participants receiving at least one dose of insulin  (safety analysis population)
15446	Assessment of treatment satisfaction
15447	Interventions for maternal health in Matlab between 1976 and 2005
15448	Univariate and Multivariate Linear Model of Transcardiac Gradient of oxLDL in 22 Patients With DCM legend
15449	Unadjusted  (crude)  rate of CD4 count increases  (per year)  with viral load of less than 50 copies per mL and relation with current CD4 count  (cells per μL)
15450	Adjusted rate of CD4 count increases  (per year)  with viral load of less than 50 copies per mL, and relation between CD4 count at starting cART  (cells per μL)  and time since starting cART
15451	Echocardiographic and Other Measurements Before and After Dobutamine Infusion in the Entire Study Group  (n = 27)  legend legend
15452	Echocardiographic Variables Before and After Dobutamine Infusion in the Terminal  (Group I, n = 9)  and Survival  (Group II, n = 18)  Groups legend legend
15453	Changes and Percent Changes in Echocardiographic Variables in the Terminal  (Group I, n = 9)  and Survival  (Group II, n = 18)  Groups legend legend
15454	Change in rates of conceptions among individuals younger than 18 years and proportion of such conceptions leading to abortion, 1994–98 to 1999–2003
15455	Summary of changes in conceptions, births, and abortions, 1994–98 to 1999–2003, by quartile of LIF award
15456	Summary of trachoma programme personnel, activities, and chronology of interventions
15457	Uptake of SAFE interventions at follow-up
15458	Mortality data  *   and relative risk for Aboriginal and non-Aboriginal infants and RR  (95% CI)  for Aboriginal compared with non-Aboriginal infants born in Western Australia between 1980 and 2001 according to population variables
15459	Neonatal and postneonatal mortality rates for Aboriginal and non-Aboriginal infants and RR  (95% CI)  for Aboriginal compared with non-Aboriginal infants born in Western Australia in birth-year groups, 1980–2001
15460	Mortality rates for Aboriginal and non-Aboriginal infants and RR  (95% CI)  for Aboriginal compared with non-Aboriginal infants born in Western Australia by geographical area and birth year groups, 1980–2001
15461	Mortality rates for main causes of death in Aboriginal and non-Aboriginal infants and RR  (95% CI)  for Aboriginal compared with non-Aboriginal infants born in Western Australia, 1980–2001
15462	Number  (%) , mortality rate, and RR of out of hospital deaths from infection of Aboriginal compared with non-Aboriginal infants born in Western Australia, 1980–2001
15463	Relationship Between Coronary Artery Disease and Type 2 Diabetes After Adjustment for Other Cardiovascular Risk Factors legend legend
15464	Forward Stepwise Analysis of the Best Predictors of the Various Patterns of Coronary Artery Disease in Patients not Taking Lipid-Lowering Agents legend legend
15465	Impact of the New ADA Definition of Impaired Fasting Glucose and Diabetes on Coronary Artery Disease Scores legend legend
15466	HIV-1 prevalence and correlates of infection in women attending antenatal clinics in 2000–04 in the south and north of India
15467	Individual data of high responders
15468	Proportion of high-responders per exposure, for whole group and by number of risk factors  (oral contraceptive use, factor V Leiden mutation, or both)
15469	Description of haemostatic gene polymorphisms in this review and their associated intermediate phenotypes
15470	Meta-analyses of 191 studies of seven haemostatic gene polymorphisms in 66 155 cases of coronary disease and 91 307 controls, analysed with a co-dominant genetic model
15471	Comparison of findings of present meta-analyses of 191 studies  (including 66 155 cases of coronary disease and 91 307 controls)  with those reported in previous meta-analyses of same polymorphisms in seven haemostatic genes, using the same genetic models as in earlier analyses
15472	Socioeconomic markers of SIDS families: trends in Avon over 20 years
15473	Sleeping position before death of SIDS infants: trends in Avon over 20 years
15474	Safety events during 12-week double-blind period
15475	Comparison of activities in the maternity wards to promote and support breastfeeding in 1998  (before intervention)  and 2001  (after training) , according to mothers
15476	Comparison of the proportions given water, tea, or other milk and using pacifier or bottle among infants born in hospitals in 2001 after training, with and without home visits
15477	Perioperative data and outcomes
15478	Linear regression analysis between postoperative activated C4 and six dependent variables
15479	Effect of Order of Testing legend
15480	Effect of Disease Severity legend
15481	Comparison of APP and Treadmill for All Subjects Combined legend
15482	Risk of second thyroid cancer by radiotherapy and chemotherapy
15483	Radiation dose and risk of thyroid cancer by: age at diagnosis of first cancer, type of first cancer, sex, latency, and attained age
15484	Size of thyroid cancer and lymph-node involvement based on surgical pathology report by type of first cancer diagnosis
15485	Compliance at 24 months
15486	Main outcomes by randomised group and by supplement groups
15487	Quality of life at follow-up of 4 months and 2 years
15488	Maternal nutritional biochemistry
15489	Primary, secondary, and stratified outcomes
15490	Mortality outcomes
15491	Pathogens associated with severe disease
15492	Mycobacterial disease course
15493	Left Ventricular Volume and Function legend
15494	Association between PDD and MMR vaccination before index date, before and after third birthday, and before and after age 18 months
15495	Association between diagnosis of autism or other PDD and MMR vaccination
15496	Number of patients responding at 18-month assessment
15497	Change in disease activity, radiographic damage, physical function, and quality of life between 0 and 18 months
15498	Total hospital, community, and patient costs per patient between 0 and 18 months
15499	Risk of subdural haemorrhage related to mode of delivery
15500	Initial Heart Size and Function in Patients With Cardiomyopathy and Control Subjects legend legend
15501	Association of subdural haemorrhage with other variables
15502	Neonates with asymptomatic subdural haemorrhages
15503	Symptomatic neonates
15504	Analyzed Stored ICD Electrograms legend legend
15505	Incidence of Polymorphic Ventricular Tachycardia by Patient legend legend
15506	Fracture rates and relative risks by sex-combined percentile category of BUA and VOS in men and women aged 42–82 years
15507	Cox multivariate regression of risk factors for fracture according to BUA and VOS in 14 799 men and women  *   aged 42–82 years
15508	Relative risks of fracture stratified by risk factors with Cox multivariate regression in men and women aged 42–82 years
15509	Estimated population effect on fracture reduction of different prevention strategies in men and women
15510	Factors Predictive of Recurrent Arrhythmias Among 480 ICD Recipients legend
15511	Recurrent Arrhythmia and Survival Time by Sextile legend
15512	Adverse events
15513	Classification by LVEF Versus Sextile Numbers and Mean  (± SE)  Survival Differences  (ICD-AAD)  legend
15514	Drug trial results for HNF-1α diabetes and type 2 diabetes groups
15515	Mechanism for sulphonylurea sensitivity
15516	International Classification of Disease  (ICD)  codes used to define mortality data
15517	Proportion of total strokes classified as cerebral infarct, cerebral haemorrhage, and ill defined cerebrovascular disease from routine mortality data
15518	Ratio of cerebral infarct to cerebral haemorrhage over the twentieth century and details of studies used to estimate ratios
15519	Average annual percentage change in mortality and 95% CI before and after the intervention, with relative change in annual trend from before to after the intervention
15520	Electrocardiographic, Echocardiographic and Scintigraphic Follow-Up Data  (n = 45)  legend
15521	Prevalence of first stroke subtype and of second stroke subtype in relation to first stroke subtype  (descriptive analysis)
15522	Prevalence of prothrombotic defects in paediatric ischaemic stroke in first stroke, and in second stroke in relation to first  (descriptive analysis)
15523	Independent contributions to the risk of a second ischaemic stroke for prothrombotic risk factors, antithrombotic treatment, and stroke subtypes
15524	Stroke types and restroke rate by antithrombotic treatment  (descriptive analysis)
15525	Prior probabilities of factors affecting uptake of immunisation, based on qualitative studies and elicited beliefs
15526	Prior and posterior probabilities that factors affect uptake of immunisation  (for the four factors with highest prior probabilities)
15527	Experimental firing of RCC-95 rubber bullets by the Israeli police force
15528	Injuries to the arms and legs caused by rubber bullets
15529	Specific head and neck and facial injuries caused by rubber bullets
15530	Specific chest, abdominal, and back injuries caused by rubber bullets
15531	Risk factors for venous thromboembolism
15532	Components of the homocysteine remethylation pathway
15533	Components of the homocysteine remethylation pathway divided into quartiles
15534	Multivariate model  *   predicting venous thromboembolism
15535	Odds ratios of venous thromboembolic disease for quartiles of red blood cell methylfolate, by C677T MTHFR genotype
15536	Predictive Values for Beta-Blocker-Induced Increase in LVEF legend
15537	Summary scores of outcome measures at every assessment point
15538	Problems and physiotherapy interventions
15539	Patients admitted and discharged from heroin-assisted treatment centres in Switzerland, 1994–2000
15540	Reasons for discharge
15541	Medical data for treatment cohort at time of admission and during follow-up  (n=237)
15542	Socioeconomic status of treatment cohort at time of admission and during follow up  (n=237)
15543	Nearly daily consumption of psychoactive substances for treatment cohort at time of admission and during follow up  (n=237)
15544	Data of Patients Submitted to Mitral Balloon Valvuloplasty and Mitral Valve Commissurotomy legend legend
15545	Hemodynamic Data of Patients Before and After Percutaneous Balloon Mitral Valvuloplasty legend legend
15546	Neonatal and Fetal Mortality legend
15547	Survival and adverse outcomes
15548	Neurological outcomes and quality of life of patients who survived to hospital discharge
15549	Survival in clinically important subgroups
15550	Age and haematological data in 200 passengers examined before and after air travel
15551	All drugs taken by volunteers who attended for examination before and after air travel  *
15552	Maternal Outcome in Patients With Valvular Heart Disease and Their Controls legend
15553	Fetal Outcome in Patients With Valvular Heart Disease Versus Controls legend
15554	Body Weight, Intra-arterial Blood Pressure, and Heart Rate  (HR)  Data in Conscious Animals legend
15555	Measurement of Carotid Hemodynamic Parameters legend
15556	Effects of high altitude and nitric oxide inhalation on mean  (SD)  pulmonary-artery pressure and oxygen saturation
15557	Summary of results of each screening round for the group
15558	Histomorphometric Data of the Thoracic Aorta and of the Carotid Artery legend
15559	Spironolactone: Cardiac Structural Data legend
15560	Results of 1-year follow-up
15561	Concentrations of leukotrienes in cerebrospinal fluid, plasma, and urine
15562	Formation of leukotrienes in monocytes and platelets
15563	24-h excretion of hydrogen and methane and maximum rate of gaseous excretion
15564	Faecal weight and composition and whole-gut transit time in patients and controls receiving standard and exclusion diets
15565	Findings among patients in group A
15566	Findings among patients in group B
15567	Wexner continence grading scores before and after implantation
15568	Quality-of-life scores before and after implantation in five patients with intact prosthesis
15569	Resting anal pressure, rectal maximum tolerated volume, and rectal compliance before and after implantation
15570	Frequency of MRI lesions by vegetative state 12 months after injury
15571	Predictors of non-recovery
15572	Number of eligible hip-fracture cases by age and sex
15573	Cases and controls with previous hospital admission and previous drug exposure
15574	Estimated unadjusted and adjusted odds ratios for hip fracture by timing of exposure
15575	Diagnostic investigations for 22 children presenting with AFP
15576	Clinical features of 20 children presenting with acute flaccid paralysis who had definite JEV status
15577	Blood Pressure and Echocardiographic Parameters in the Carvedilol and Placebo Groups legend
15578	Assessment of NYHA Class Over the Treatment Period legend
15579	Prevalence of respiratory and allergic disorders and bronchial hyper-responsiveness to cold-air challenge
15580	Changes in prevalence of sensitivity to specific allergens
15581	Results of multivariate logistic regression analysis with hay fever and atopy as outcome variables  *
15582	Holter Electrocardiographic Findings legend legend
15583	Univariate Predictors of Ventricular Tachycardia legend
15584	Multiple Logistic Regression Analysis legend
15585	Univariate and Multivariate Cox Proportional Hazards Analyses legend
15586	Other bleeding symptoms and symptom scores
15587	PEF values during 72 h before and after vaccine and placebo
15588	Respiratory and systemic symptoms during 72 h before and after vaccine and placebo
15589	Use of medication during 72 h before and after vaccination
15590	Hospital admissions, medical consultations, and use of antibiotics and oral steroids for respiratory complaints during 7 days after vaccine and placebo
15591	Presence of Heart Disease and Cardiac Function legend
15592	Pacemaker Implantation  (Age at and Mode of) ; and Average Heart Rate  (BPM)   (Prior to and After)  legend
15593	Histologic Findings legend
15594	Abnormal cytogenetic results
15595	Pregnancy complications after sampling
15596	Pregnancy outcome
15597	Birthweight, gestational duration, mode of delivery, and respiratory difficulties among liveborn infants
15598	Congenital defects
15599	Age-specific prevalence of active trachoma infection in 1959, 1987, and 1996
15600	Winter climate, populations, and mortality rates in each region
15601	Regression coefficients  (R)  and their significance  (p) , for cause-specific indices of cold-related mortality on personal cold-exposure factors standardised at 7°C mean daily temperature
15602	LV Changes After NSRT in the Initial Population legend
15603	LV Changes After NSRT in the Test Population legend
15604	Relation of LVOT Gradient Reduction to Changes in Outflow Geometry and LV Ejection legend
15605	French sibling-pair a-adducin linkage results
15606	Allelic frequencies of a-adducin polymorphisms in control and hypertensive groups
15607	a-adducin genotypes in pooled control and hypertensive patients
15608	Median linear analogue pain scores before treatment and at each visit during treatment
15609	Number of pregnancies and fetal loss
15610	Odds ratios of fetal loss in women with thrombophilia
15611	Odds ratios  (95% CI)  for fetal loss and type of thrombophilia, with control group as reference, adjusted for number of pregnancies and centre
15612	Percentage of women with pregnancies resulting in fetal loss with and without terminations of pregnancy
15613	Seroprevalence of HHV-8 antibodies  *
15614	HHV-8 antibody titres before and after KS diagnosis
15615	Mortality and Other Complications During Hospital Period legend
15616	Independent Predictors of Six-Month Mortality in Inferior Myocardial Infarction ∗   legend
15617	Symptoms unrelated to an appetite disorder that distinguished hyperphagic short-stature children from others
15618	Effect of aerosolised L-NMMA and D-NMMA on airway response to bradykinin and methacholine
15619	Cardiovascular effects of aerosolised L-NMMA and D-NMMA
15620	Spectral Parameters of HRV Measured Before Discharge in the Entire Group, in Patients With Early AF Recurrence and in Patients in Sinus Rhythm 12 to 15 Days After Cardioversion legend
15621	Spectral Parameters of HRV Measured Two Weeks After Cardioversion in Patients Who Were in Sinus Rhythm at Time of First Control Visit and Did or Did Not Develop AF During the Follow-up Period legend
15622	Frequency of hip fracture according to fall-related variables selected by stepwise Cox-regression analysis
15623	Effect of four fall-related factors and femoral-neck
15624	Fall-risk status and femoral-neck BMD status
15625	Mean Values for Age and Blood Pressure and Cardiovascular Deaths in Men According to the SBP and DBP Groups legend
15626	Mean Values for Age and Blood Pressure and Cardiovascular Deaths in Women According to the SBP and DBP Groups legend
15627	Total injuries in 1994 related to exposure on different types of surface
15628	Patterns of injuries on different types of surface in 1994
15629	Comparison of fractures and injuries from falls on to bark surfaces according to equipment  (1992–94)
15630	Fracture rate and height of climbing-frames on bark surfaces  (1992–94)
15631	Primary and secondary outcomes
15632	Primary and secondary outcomes
15633	Univariate Analysis of Factors Affecting Long-Term Survival After Cardiac Transplantation
15634	Hemodynamic Parameters in Long-Term Survivors at 10-Year Follow-Up legend
15635	Multivariate Analysis of Factors Affecting Long-Term Survival After Cardiac Transplantation
15636	Primary efficacy results in the intention-to-treat population for the overall study period
15637	Safety outcomes as adjudicated bleeding events  (safety population, on-treatment period)
15638	Net clinical benefit in the intention-to-treat population for the overall period, by creatinine clearance strata
15639	Treatment-emergent adverse events in the safety population for the overall study period
15640	Ranked secondary efficacy variables
15641	Adverse events  (safety population)
15642	Seroconversion and seropositivity rates against serotypes 1, 2, and 3 in the intention-to-treat population  (primary analysis)
15643	Median log2 titres of neutralising antibodies against polio serotypes 1, 2, and 3 in the five groups  (intention-to-treat population)
15644	Stool poliovirus type 2 shedding for 28 days after mOPV2 challenge in the different study groups  (intention-to-treat population)
15645	Humoral  (types 1, 2, and 3)  and intestinal  (type 2)  immunogenicity in the different groups  (per-protocol populations)
15646	Results From Cox Multivariate Analysis of Survival legend legend
15647	Efficacy analysis for primary endpoint and components
15648	Efficacy analysis for secondary endpoints and components
15649	Adverse events in efficacy population by study group
15650	Systemic and local adverse events with onset within 28 days of a dose  (safety population)
15651	Infection distribution at study entry and with respect to clinical efficacy by age and disease severity for all recipients receiving at least one dose  (modified intention-to-treat population)
15652	Efficacy during the double-blind period
15653	Incidence Rates of Recurrent Venous Thromboembolism Among 218 Men According to Presence or Absence of the G20210A Mutation in the Prothrombin Gene legend
15654	Bleeding by WHO bleeding scale
15655	Incidence Rates of Recurrent Venous Thromboembolism Among the Subgroup of Men With an Initially Idiopathic Event, According to Presence or Absence of the G20210A Mutation in the Prothrombin Gene legend
15656	Efficacy during the open-label period
15657	Dose by cohort
15658	Adverse events in the double-blind period
15659	Serious adverse events in the double-blind period
15660	Death and dependency at 10 years
15661	Number of patients who had recurrent subarachnoid haemorrhage after 1 year
15662	Incidence of recurrent subarachnoid haemorrhage from target aneurysm and of resulting death or disability  (mRS 3–5)
15663	Causes of death in all UK patients from 2 months after enrolment
15664	Standardised mortality ratios
15665	Number of patients  (aged 15–99 years)  included in analyses in England and Wales diagnosed from 1971 to 2011 and followed up to 2012, by sex and type of malignancy
15666	40-year trends in the index of net survival for all cancers combined at 1, 5, and 10 years after diagnosis in adults  (15–99 years)  in England from 1971 to 2011 and trends in the age-adjusted net survival for 21 selected cancers in England from 1971 to 2011 by sex
15667	40-year trends in the index of net survival for all cancers combined at 1, 5, and 10 years after diagnosis in adults  (15–99 years)  in Wales from 1971 to 2011 and trends in the age-adjusted net survival for 21 selected cancers in Wales from 1971 to 2011 by sex
15668	Total Study Cohort  (n = 246)  legend
15669	Comparison of Patients With PPS  (Noncomplicated and Complicated)  legend
15670	Comparison of Patients: Noncomplicated PPS legend
15671	Adherence to treatment in each trial group
15672	Subgroup analyses of treatment effect on days to relapse
15673	Intention-to-treat repeated measures amalyses at 1 month after treatment, and follow-up at 9, 12, 18, and 24 months for secondary outcomes
15674	Mean cost per participant over the 24-month follow-up period  (£)
15675	Comparison of trial management according to the eight domains of AHA taxonomy for disease management  11
15676	Pattern of recurrent admission
15677	Clinical responses at week 12
15678	Incidence of treatment-emergent adverse events  (safety population)
15679	Study population and follow-up period for endocrine disorders, by country
15680	Observed and expected numbers of first hospital contacts for endocrine disorder of any type by sex and age in 31 723 1-year survivors of childhood cancer in the Nordic countries
15681	Observed and expected numbers of first hospital contacts for endocrine disorders of any type or one or more of 22 subcategories of endocrine disorder in 31 723 1-year survivors of childhood cancer in the Nordic countries
15682	Standardised hospitalisation rate ratios for endocrine disorders of any type and for subcategories of endocrine disorders distinguished by a lower 95% confidence limit of ≥10 by main diagnostic group of childhood cancer  (ICCC)
15683	Similarity of risk estimates obtained in the ALiCCS study and the CCSS for comparable combinations of childhood cancer and endocrine disorders
15684	Diagnosis of serogroup A meningococcal meningitis in individuals from non-vaccinated and vaccinated regions in Chad
15685	Meningococcal carriage in the Mandelia district of Chad before and after vaccination with PsA–TT
15686	Stroke and mortality by randomisation assignment  *
15687	Stroke and mortality as treated  *
15688	Adverse events by randomisation assignment
15689	Univariate Analysis Between Percent Change in Carotid Artery Diameter During CPT, Carotid IMT and Coronary Risk Factors legend
15690	Comparison of costs and QALYs gained from VAT-PP versus talc pleurodesis
15691	Deaths and serious adverse events possibly or probably related to treatment
15692	Clinical Data of Study Patients legend legend
15693	Number of Sites Where the Stimulation Protocol Was Performed in Patients in the Washout and Verapamil Groups
15694	Immunogenicity of 4CMenB components before and after the three dose primary series  (modified intention-to-treat analysis  *  )
15695	Refractory Periods  (mean ± SD of All Paced Sites)  at Each Basic Cycle Length in Washout and Verapamil Groups
15696	Atrial Effective Refractory Periods in Different Right Atrial Sites in Washout and Verapamil Groups
15697	Immunogenicity of 4CMenB components before and after the booster dose at 12 months of age  (modified intention-to-treat analysis  *  )
15698	Responses  *   to DTaP-HBV-IPV/Hib antigens, and differences between groups receiving routine vaccines with or without 4CMenB
15699	Pertussis antigens 1 month after third vaccination
15700	Participants with any local and systemic reactions within 7 days of any dose of the respective vaccines
15701	Participants with any systemic reactions within 7 days of any dose of the respective vaccines
15702	Refractory Periods at Constant Pacing of 300 and 600 ms Compared With Long–Short  (600 to 300 ms)  and Short–Long  (300 to 600 ms)  Sequences legend
15703	Effects of UCT and CCT programmes
15704	Age-adjusted DALY rates per 100 000 population by cancer site and region, 2008
15705	Patients reaching the American Diabetes Association target of HbA1c less than 7% at week 12
15706	IPTi studies that included assessment of serological responses to EPI vaccines
15707	Proportion of infants in IPTi and placebo groups who did not develop seroprotective antibody concentrations after Expanded Programme on Immunization vaccines; data from Manhica, Kisumu, and Bungoma
15708	Relationship Between the Degree of Mitral Regurgitation and LVOT Peak Gradient legend legend
15709	Clinical Findings in the HCM Children: Prevalence of Risk Factors
15710	Clinical Findings in HCM Children With or Without Myocardial Bridging  (≥50% Max. Systolic Compression)  legend
15711	Clinical Findings in HCM Children With or Without Myocardial Bridging  (≥50% Max. Systolic Compression)  legend
15712	Relation of Thallium Perfusion Abnormalities to Clinical Parameters: Logistic Regression Model for Predicting Thallium Perfusion Abnormalities legend
15713	Clinical Findings in HCM Children With or Without Compression of Septal Branches of the LAD Artery
15714	Crude and Multivariable Adjusted Odds of Developing Myocardial Infarction or Death Based on Exercise Duration legend
15715	Medical Management at Last Follow-Up legend
15716	Diagnostic Tests Analysis legend
15717	Cox Proportional Hazard Model Comparisons, Including Age and Etiology of Cardiomyopathy legend
15718	Echocardiographic Features of Patients and Carriers ∗   legend
15719	Semiquantitative Perfusion and Wall Motion Scores legend
15720	In-Hospital Device-related Complications
15721	In-Hospital Clinical Outcomes
15722	1-Year Clinical Outcomes
15723	Incidence of Selected Adverse Events According to the Study Period
15724	Risk of Embolism According to the Infecting Microorganism
15725	Echocardiographic Data: Prognostic Factors of Embolism by Univariate Analysis
15726	Effect of Vegetation Size on Embolism Stratified by Type of Microorganism and Valve Infected
15727	Occurrence of Different Pathogens and Relation With Embolic Events legend
15728	Clinical Features of Infective Endocarditis in Patients With and Without Embolism legend
15729	Echocardiographic Localization of Vegetation and Risk of Embolism
15730	Results of Univariate and Multiple Stepwise Logistic Regression Analyses legend
15731	Results of Previous Studies legend
15732	The Association of CAD With Cardiac Risk Factors and Circulating CPn DNA
15733	Hematological Variables in Men With CAD According to the Presence of Circulating CPn DNA legend
15734	Definition of Patient Groups According to von Reyn and Duke Criteria
15735	Comparison Between von Reyn and Duke Criteria
15736	Repartition of Diagnostic Criteria Between Groups
15737	Repartition of Duke Major and Minor Criteria Between the Four Groups
15738	Repartition of Diagnostic Criteria in Group 4 and Causes for Misclassification legend
15739	Criteria for Infective Endocarditis
15740	Systemic Hemodynamic Parameters in Protocols I–III legend
15741	Time Controls: Action Potential Duration and QT Intervals Measured in Arterially Perfused Left Ventricular Wedge Preparations at End of Equilibration Period  (1 h)  and at End of a 4-h Period of Perfusion  *
15742	Selected Intravenous Medication and Hemodynamic Parameters During the First 72h After ICU Admission
15743	Distribution of ICHS Components in PESA
15744	Distribution of FBS Components in the PESA Study
15745	Association Between ICHS and FBS and Subclinical Atherosclerosis Measured as Plaque Presence at Any Site and CACS of≥1
15746	Association Between ICHS and FBS and Multiterritorial Extent of Subclinical Atherosclerosis and CACS Level
15747	Clinical Differences Among the Groups
15748	Incidence of Cardiac Events During Follow-Up
15749	Primary and Secondary Endpoints
15750	Improvement in LVEF Stratified According to LGE Status: Actual Treatment Analysis
15751	Echocardiographic Variables
15752	Cardiac Phenotypes According to Patient Clusters
15753	Clinical Phenotypes According to Patient Clusters
15754	Prevalence of FH Based on Clinical Scores Versus Genetic Study
15755	Clinical Scores of Patients With or Without FH Mutation
15756	Independent Association of Spontaneous Gasping or Breathing During CPR With 1-Yr Survival With CPC≤2 for Out-of-Hospital Cardiac Arrest Patients  (n=1,827)   ∗
15757	Independent Association of Spontaneous Gasping or Breathing During CPR With 1-Yr Survival With CPC≤2 Stratified by Initial Recorded Cardiac Rhythm  ∗
15758	Angiographic Findings and Procedural Outcomes
15759	Procedural Data
15760	Procedural Outcomes
15761	Clinical Outcomes
15762	Predictors of All-Cause Mortality
15763	Primary Clinical Efficacy and Safety Endpoints for the Economic Study Population
15764	Follow-Up Hospitalizations and Costs
15765	EQ-5D–Derived Utility Scores Over Time
15766	Lifetime Cost-Effectiveness Results for Base Case and Sensitivity Analyses
15767	Lifetime Cost-Effectiveness Results for Subgroups
15768	Multivariable Analysis of Mortality Risk in Patients With ATTR
15769	LQTS Treatment Summary by Sex: Pharmacotherapy, LCSD, and ICD
15770	Treatment Outcomes and Comparison by Symptomatic Status
15771	Treatment Outcomes and Comparison by LQTS Genotype
15772	Multivariate Analysis: Independent Predictors of MI During 5-Yr Follow-Up
15773	Details of the 27 Cases of Very Late Stent Thrombosis
15774	HCM Patients With LV Apical Aneurysms and HCM-Related Death or Life-Threatening Events/Interventions
15775	Relationship of LV Apical Aneurysm Size to HCM-Related Events
15776	Relative Hazards of AF With Per SD HRV Decrease
15777	Effectiveness Outcomes of Radiofrequency HotBalloon PVAblation
15778	Quality of Life  (SF-36v2)
15779	Tabulation of Major Complications
15780	List of Serious Adverse Events in HBA Group and Crossover Group
15781	Incidence Rates of Life-Threatening Arrhythmias and of Cardiovascular Mortality
15782	Predictors of Arrhythmic Risk at Follow-Up
15783	Matched-Periods Analysis for the Efficacy of Antiarrhythmic Drugs and Transcatheter Ablation  ∗
15784	Locations of Scars
15785	Non-PV Trigger Distribution During Isoproterenol Challenge
15786	Ischemic and Bleeding Outcomes in All Randomized Patients According to PCIComplexity
15787	Predictors of MACE and CTEs in All Randomized Patients
15788	Ischemic and Bleeding Outcomes in All Randomized Patients According to PCI Complexity and DAPT Duration
15789	Effect of Long- Versus Short-Term DAPT on Risk of MACE Across Clinical Subsets Within the Complex and Noncomplex PCI Groups
15790	PITX2 mRNA Expression in Left Atrial Appendages From AFAblation Patients  ∗
15791	Effect of Flecainide on Refractoriness and Repolarization in Mouse Hearts
15792	Electrophysiological Effects of Sotalol
15793	Electrophysiological Effects of Reduced Sodium Conductance in a Human Atrial Model
15794	Electrical Activation Time and Conduction Velocity in Isolated Atria in the Presence of Flecainide  (1 μmol/l)
15795	Hemodynamic and Biochemical Profile of Study Subjects
15796	Serial Echocardiographic Assessment of the Effects of LVAD Unloading on Structure and Systolic Function in Ischemic and Nonischemic Cardiomyopathy
15797	Serial Echocardiographic Assessment of the Effects of LVAD Unloading on Left Ventricular Diastolic Function in Ischemic and Nonischemic Cardiomyopathy
15798	Adverse Events After Thoracoscopic Ablation for Atrial Fibrillation
15799	Patient Deaths
15800	Echocardiographic Findings  (Within 6 Months of Diagnosis)
15801	Public OHCAs
15802	Bystander-Applied AED Use on Public OHCAs
15803	OHCA Coverage Loss of Registered AEDs
15804	OHCA Coverage Loss of Registered AEDs According to Location Type
15805	Risk Factors in the Analysis, Exposure Metrics, TMRED, and Disease Outcome
15806	Covariate-Adjusted Distribution of the Systolic Blood Pressure, Body Mass Index, Smoking, and Physical Activity Over Time  ∗    †
15807	Selected Management: Derivation Cohort
15808	Bivariate Relationship Between Categorical Variables and In-Hospital Mortality
15809	Multivariate Model of In-Hospital Mortality
15810	Model Performance in Subgroups
15811	Comparison of Different High-Output Heart Failure Etiologies
15812	Comparison of U.S. wt-ATTR and Val122Ile Subjects
15813	ATTR-attributable Symptoms and Signs in Symptomatic U.S. Subjects
15814	Electrocardiography, Echocardiography, and Biomarkers: wt-ATTR Versus Val122Ile in U.S. Subjects
15815	Univariate and Multivariate Analysis of Predictors of Survival ∗
15816	Events in Patients With or Without Aborted Sudden Cardiac Death
15817	Unadjusted and Multivariable Treatment Models
15818	Hemodynamic Data Obtained in Cardiac Catheterization Laboratory Before and After Percutaneous Mitral Plication
15819	Clinical and Echocardiographic Data at Follow-Up
15820	Discharge Interventions Stratified by Patients With and Without OHCA  ∗
15821	Primary and Key Secondary Outcomes at 6-Month Follow-Up
15822	6-Month Outcomes: STEMI and NSTEMI Subgroups
15823	30-Day MACE
15824	Algorithmic Diagnostic Accuracy for 30-Day MACE
15825	Algorithmic Diagnostic Accuracy for 30-Day MACE Without UA
15826	Electrocardiographic Parameters
15827	Probability of VF/SCD During Follow-Up Depending on Clinical and Electrocardiographic Parameters at Presentation: Univariate and Multivariate Analysis
15828	Echocardiographic Parameters
15829	CMR Parameters
15830	Independent Determinant of Presence of Angina
15831	MPRI Contributing Factors
15832	Echocardiographic Data  (n= 564)
15833	Procedural and In-Hospital Outcomes
15834	30-Day Outcomes
15835	Procedural Results and Outcomes According to Post-Implantation Mitral Regurgitation
15836	Registries of Transcatheter Mitral Valve Repair With the MitraClip
15837	EF Recovery to >35% 90 Days After MI
15838	EF Recovery to≥50% 90 Days After MI
15839	Angiographic Findings and Invasive Management ofPatients With Perioperative Myocardial Infarction
15840	Composite Outcomes and Recurrent Ischemic Stroke  (Intention-to-Treat Analyses)
15841	Composite Outcomes and Recurrent Stroke  (As-Treated Analyses)
15842	Safety Outcomes  (As-Treated Analyses)   ∗
15843	Rates of ED Visits or Hospitalizations for HF Exacerbation
15844	Rate Ratios for ED Visits and Hospitalizations for HF Exacerbation, UsingNegative Binomial Regression Model
15845	Rates of ED Visits or Hospitalizations for COPD, Pneumonia, or Dyspnea
15846	Rates of ED Visits or Hospitalizations for HF Exacerbation: Patients Who Underwent Nonbariatric Surgery
15847	Procedural Data
15848	12-Month Rhythm Outcome According to Number of Ablations
15849	Univariable and Multivariate Regression Analysis of Proportional Collagen Content, as Evaluated by Morphometric Analysis of PSR Staining in BrS Cases Versus Control Hearts
15850	Multivariable Regression Analysis of Proportional Connexin43 Content in BrS Post-Mortem Cases Versus ControlHearts
15851	Causes of Arrhythmia-Induced Cardiomyopathy
15852	An Example of the Clinical Course of AIC When the Culprit Arrhythmia Was Not Eliminated: A 54-Year-Old Man With AF and LVEF of 30%
15853	Surgical Data
15854	Kaplan-Meier Estimates  ∗
15855	Pre-Operative Clinical Features  (N = 195)
15856	Surgical Features  (N = 195)
15857	Univariate and Multivariate Predictors of Overall Mortality
15858	Most Common TTR Mutations Identified in Patients With Symptomatic Amyloidosis
15859	Selected Trials for TTR Amyloidosis
15860	28 Clinical Reports of Combining TTM and Early Coronary Angiography in Resuscitated, But Comatose Patients With STEMI on the ECG
15861	Angiographic Findings in Patients With Cardiac Arrest and No ST-Segment Elevation on ECG
15862	Outcomes of Patients With Cardiac Arrest Referred for Coronary Angiography
15863	Types of Major Infection During Index Hospitalization and Rehospitalization  (N= 4,320)
15864	Mean Extra Costs and Length of Stay During Index Hospitalization
15865	Mean Costs and Length of Stay of Readmission
15866	Univariate Cox Regression Analysis Among Patients Experiencing Appropriate Shocks
15867	Predictors of Mortality During Follow-Up in Patients With Acute Heart Failure
15868	Predictors of Short-Term Mortality in Patients With Ventricular Arrhythmia–Induced Cardiac Arrest
15869	NSE Cutoff Values
15870	Multivariable Analysis With NSE and Clinical Variables
15871	Post-Procedural and In-Hospital Outcomes  (N= 7)
15872	30-Day Follow-Up Outcomes  (N= 7)
15873	Individual Changes in TR Severity, RV Function, Exercise Capacity, and Quality of Life
15874	Multivariate Predictors of Referral to Cardiac Rehabilitation After PCI in the Overall Population
15875	Weight Loss
15876	Weight Fluctuation
15877	Absolute MMP and TIMP Concentrations in BAV Aortas
15878	Association Between Randomization, 1 Year, Change from Randomization to 1 Year in OxPL-apoB, and Clinical Outcomes  ∗
15879	Baseline Characteristics of Patients, Procedures, In-Hospital Adverse Events, and Hospitals  ∗
15880	Association of LOS on Time-to-Event Within 30 Days  ∗
15881	Association of Selected Covariates on LOS  ∗
15882	Association of Each LOS Day on Time-to-Event Within 30-Days  ∗
15883	Description of Included Studies
15884	Event Rates Per 100 PYs at 1 Year and Full Follow-Up According to Treatment Strategy Initiated at Day 14 After Discharge With Incident AF
15885	Peri-Treatment Variables and Their Association With Overall Survival
15886	Complications Related to Percutaneous Pericardiocentesis
15887	Survey of Screening Guidelines: Results of Survey Assessing Compliance With Pre-Participation Screening Guidelines Among Participants in the 2013 Tel Aviv Marathon
15888	Use of Antiplatelet Agents During Follow-Up
15889	Cumulative Incidence of Clinical Events Up to 1 Year
15890	Cumulative Incidence of Stent Thrombosis Up to 1 Year
15891	Clinical and Angiographic Details of the 7 Patients Who Had Longitudinal Stent Deformation During the Procedure
15892	Caval-Aortic Transcatheter Aortic Valve Replacement Details
15893	In-Hospital and 30-Day Outcomes
15894	Some Circulating miRNAs Found Associated With the Enlarged Heart
15895	Effects of the Administration of Some miRNAs and Anti-miRNAs on the Cardiovascular System in Animal Models
15896	Meta-Analytic Summaries of Test Performance by Predictor Category
15897	Cardiac Structural Athletic Adaptations: 35 Years ofResearch
15898	Reasons CV Specialists See Athletic Patients
15899	Controversies in Sports and Exercise Cardiology
15900	New Paradigm: Cardiovascular Care of Athletes
15901	Potential Research Directions: Sports and Exercise Cardiology
15902	Predictor of Successful Epi-LAVA Elimination From Ablation at Facing Endo Site
15903	Patients With Complete, Partial, and No Elimination of Epi-LAVA Endocardially
15904	Major and Minor Adverse Events Observed in Device Compared With Surgical Closure Groups
15905	Peri-CABG Antiplatelet Therapies
15906	Primary and Key Secondary Efficacy Endpoints Post-CABG Among Patients Who Underwent CABG During Index Hospitalization and Within 30 Days of Randomization
15907	CABG-Related Bleeding Among Patients Who Underwent CABG During Index Hospitalization or Within 30 Days of Randomization
15908	Bleeding Endpoints Post-Discharge Among Patients Who Underwent CABG During IndexHospitalization and/or Within 30 Days of Randomization
15909	Prevalence of Complications and Mortality Among Study Sample  (N= 240,632)
15910	Risk Model for Complications After ICD Implantation
15911	Parsimonious Risk Scoring System for Complications After ICD Implantation
15912	Percentage of Patients With Abnormal Strain  ∗
15913	Profile of Patients With Cardiac Events
15914	Clinical Outcome of Initial and Follow-Up Testing
15915	Univariate Predictors of MACEs
15916	Summary of Variant Filtering
15917	The 9 Variants Shared by Individuals I-2, II-3, II-5, and II-6
15918	Clinical Parameters and SCA
15919	Imaging Parameters in Subjects With SCA
15920	Significant Predictors of Time to SCA
15921	Provocation Testing Dosing Protocols
15922	Practice Guidelines for Coronary Spasm Provocation Testing
15923	Risk Factor, Echocardiographic, and AF Severity Changes
15924	Procedure Details
15925	Multivariate Models Testing the Association Between Use of Epinephrine and Good Neurological Outcome
15926	Drug-Specific Cardiac Event Rates on β-Blocker Therapy and Covariate-Adjusted Hazard Ratios Relative to Discontinuing β-Blockers  ∗
15927	Genotype- and Drug-Specific First Cardiac Event  ∗   Rates on β-Blocker Therapy and Covariate-Adjusted Hazard Ratios RelativetoDiscontinuing β-Blockers †  in Patients With LQT1 and LQT2
15928	Drug-Specific Recurrent Cardiac Event Rates  ∗   and Covariate-Adjusted Hazard Ratios Relative to Propranolol †  Among Patients With 1 Prior Cardiac Event on β-Blockers
15929	Results From Studies Evaluating Effects of Percutaneous Valve Repair on MR, Hemodynamics, and Remodeling
15930	Results of Percutaneous Valve Repair Therapy in FMR
15931	Complications Associated With Percutaneous Valve Implantation
15932	Causes of Death
15933	Univariate Analysis of Death
15934	Multivariate Analysis of Death
15935	Distribution of AAD Values by Quintiles
15936	Relationship of Proximal Aortic Stiffness to Incident Mortality
15937	Relationship of Proximal Aortic Stiffness to Incident Hard CVD
15938	Relationship Between AAD and Incident Hard CVD According to Global Framingham Risk Category
15939	Rates  (95% CI; Number of Events)  of Stroke and TE per 100 Person-Years In Patients With AF According to Renal Status, Warfarin Treatment, and CHA2DS2-VASc Score
15940	HR  (95% CI)  of Stroke and TE in Patients With AF Not Receiving Warfarin  (n=100,750  ∗  )
15941	Lifespan Gained and NNT to Gain 1 Life-Year Compared With Duration of Follow-Up After Device Implantation
15942	Study Endpoints
15943	Univariate Analyses for Associations With Mortality Among All Patients
15944	Univariate Analyses for Associations With Mortality in Patients Without Prior MIs by History or ECG
15945	Univariate Analyses for Associations With Mortality in Patients Without Evidence of MI by Clinical History, ECG, or LGE Imaging
15946	Public Indoor Locations Defined as Typical and Alternative Exercise Facilities
15947	Data Analysis for All Public Indoor Location Cardiac Arrests That Occurred Prior to EMS Arrival  ∗
15948	Site Incidence Rates of Cardiac Arrests
15949	Activities at the Time of Cardiac Arrest
15950	Data Analysis for All VF/VT Arrests in Public Indoor Locations That Occurred Prior to EMS Arrival  ∗
15951	Unmatched Data on In-Hospital Outcomes
15952	Propensity-Matched Data on In-Hospital Outcomes
15953	Recent MI Patients Prescribed a WCD
15954	Summary Data Comparing Asymptomatic Gene Carriers With Healthy Control Patients
15955	Summary Data Comparing Asymptomatic Gene Carriers With Patients With Symptomatic  (VT)  ARVC
15956	Site of Origin of the 96 PVCs Targeted for Ablation and the Number Involving Patients With SHD [in Brackets]
15957	Echocardiographic, Neurohormonal, and Clinical Response After Ablation in Patients With and WithoutSuccessful Sustained Ablation
15958	Predictors of Echocardiographic Response, Univariate and Multivariate Models
15959	Primary and Secondary Outcomes During the Follow-Up Period  (N = 1,429)
15960	Correlated Factors for MACE in VSA Patients and Assigned Score
15961	Echocardiographic Findings
15962	Correlations Between logNT-proBNP Levels and Echocardiographic Parameters
15963	Exercise Test  (n= 198)
15964	MiRNA Concentrations  (N= 21)
15965	CMR-LGE Scar Size of ICD Cohort
15966	Reclassification Analyses
15967	Predictors of All-Cause Mortality
15968	Predictors of Cardiovascular Mortality
15969	Full Model for Predictors of Survival to HospitalDischarge
15970	Final Reduced Model for Predictors of Survival toDischarge
15971	Mean Treatment Differences for DR-IPA, C-IPA, PRU, and VASP-PRI
15972	Prevalence of Patients With High Platelet Reactivity According to Treatment and Smoking Status
15973	Comparison of PK Parameters of the Active Metabolite of Prasugrel and the Active and Inactive Metabolites of Clopidogrel Between Smokers and Nonsmokers
15974	DR-IPA by Treatment, Smoking, and CYP2C19 Genetically Determined Metabolizer Status
15975	Definitions of Noncardiac Causes of Death
15976	Rs4245791 Frequency in the ABCG8 Gene and Anthropometric Parameters and Plasma Lipids and Sterol Levels in the LURICandYFS Cohorts
15977	Rs6576629 Frequency in the ABCG8 Gene and Anthropometric Parameters and PlasmaLipids and Sterol Levels in the LURIC and YFS Cohorts
15978	Rs657152 Frequency in the ABO Gene and Anthropometric Parameters and Plasma Lipids and Sterol Levels in the LURICandYFSCohorts
15979	Relationship of Ventricular Ectopic Activity With Bileaflet MVP in OHCA Survivors With Ambulatory Holter Monitoring  (n= 19)
15980	Summary of SCDs Linked to MVP Reported in the English Language
15981	Summary of OHCA and Malignant Ventricular Arrhythmias Linked to MVP Reported in the English Language
15982	Reasons for Anticoagulation Therapy Contraindication  (N= 52)
15983	Procedural and In-Hospital Findings
15984	Follow-Up Results
15985	Individual Characteristics of Patients With Major Adverse Events at Follow-Up
15986	Echocardiographic Findings According to the Presence of New Peridevice Leaks at 6-Month Follow-Up
15987	Acute Results and Clinical Events at Latest Follow-Up of Patients Undergoing Percutaneous Closure of Left Atrial Appendage in Patients With Contraindication for AnticoagulationTherapy
15988	Effects of Exogenous NO on the Proliferation of Cardiovascular-Related Cells
15989	Results of FIRM Mapping
15990	Step-by-Step Description of the TAO TAVR Procedure
15991	Procedural and Clinical Outcomes by TAVR Approach
15992	Selected Serious Adverse Events Related to Immediate Inaccessibility to Quinidine  *
15993	Relative Risks and 95% CIs for Peripheral Artery Disease According to Level of OxPL/ApoB
15994	Relative Risks and 95% CIs for Peripheral Artery Disease According to Level of Lp (a)
15995	Relative Risks and 95% CIs for Peripheral Artery Disease According to Level of AA to MDA-LDL
15996	Relative Risks and 95% CIs for Peripheral Artery Disease According to Level of IC
15997	Door-to-Balloon Times of Patients With and Without Nonsystem Delay
15998	Risk-Adjusted In-Hospital Mortality
15999	In-Hospital Adverse Outcomes of Patients With and Without Nonsystem Delay
16000	Primary Prevention Risk Factors and ICD Interventions in 188 High-Risk Children and Adolescents
16001	Event-Free Survival: Univariate and Multivariate Analysis of Potential Clinical and Echocardiographic Predictors
16002	Cardiovascular Magnetic Resonance Results
16003	Predictors of Infarct Size in Multivariate Regression Analysis
16004	Relationship of CMR Markers and Clinical Outcome at 12 Months
16005	SQTS Diagnostic Criteria: Gollob Score
16006	SQTS Diagnostic Criteria: Modified Gollob Score
16007	Genetic Mutations in the Pediatric Cohort
16008	Comparison of Patients With Versus Without Aborted Sudden Cardiac Death
16009	VARC Outcomes in the Propensity-Matched Population
16010	Multivariate RR  ⁎   of CHD With 95% CIs for Hp Genotypes, Together and Stratified According to CVD Risk Factors, in a Nested Case-Control Study of CHD in Women Aged 44 to 69 Years at Blood Draw From the NHS, 1990 to 2004
16011	Multivariate RR  ⁎   of CHD Event with 95% CIs for Hp Genotypes, Together and Stratified by CVD Risk Factors, in a Prospective Study of Diabetic Men and Women Age 22 to 95 Years From the ICARE Study, 2005 to 2006
16012	Minimally Adjusted Association Between Indices of LV Function and R-R Variation or CAN at EDIC Year 16/17
16013	Association Between Indices of LV function and R-R Variation or CAN at EDIC Year 16 to 17 After Adjustment for Traditional Cardiac Risk Factors and Glycemia
16014	Multivariable Analysis of R-R Variation and CVD Risk Factors in Relation to LV Function
16015	Study Population
16016	Withdrawals From Therapy
16017	Primary Outcome and Its Components
16018	Primary Outcome and Its Components  (On-Treatment Analysis)
16019	Comparison of Patients With LVAD Implanted as a Bridge to Transplantation or as Destination Therapy
16020	Major Primary Causes of Readmission After LVAD Implantation
16021	Statistically Significant Univariate Variables Associated Readmissions After LVAD Implantation
16022	Sex-Specific Associations of log Zc With Measures of Diastolic Function and Ventricular-Arterial Coupling
16023	Associations of Exposure Alleles With CHD Adjusted per Unit of Change in LDL-C
16024	Multivariate Analysis: Risk Factors for Cardiac Events  (Syncope, Sudden Death, and Aborted Cardiac Arrest)  Among Patients With LQT1  ⁎
16025	Multivariate Analysis: Risk Factors for Cardiac Events  (Syncope, Sudden Death and Aborted Cardiac Arrest)  Among 369 patients with LQT1 and QTc <500 ms
16026	Multivariate Analysis: Risk Factors for Cardiac Events  (Syncope, Sudden Death and Aborted Cardiac Arrest)   ⁎
16027	Multivariate Analysis: Risk Factors for SCD/ACA Among All Patients With LQT1  ⁎
16028	Univariate Predictors of Atrial Fibrillation Recurrence
16029	Site of Origin of PVCs
16030	Change in Various Echo Parameters Before and After PVC Ablation
16031	Change in Echo Parameters After Ablation Stratified by Percentage of PVC Burden
16032	Improvements in Echo Parameters and NYHA Class Post-Ablation With Percentage of Pre-Ablation PVC Burden Stratified to <22% and >22%
16033	Serial Echo Parameters and NYHA Class Before and 6 Months After Successful PVC Ablation, and 6 Months After BiV Pacing Was Turned Off
16034	Shows the Differences Between Post-PVC Ablation Responders Versus Nonresponders
16035	Summary of Brugada Syndrome-Associated Mutations
16036	Summary of Additional Rare Genetic Variants Identified in BrS Probands
16037	Management Strategies Among 64 Patients With Major VC
16038	30-Day and 1-Year Event Rates According to the Occurrence of Major VC Versus No Major VC Up to 30 Days
16039	30-Day and 1-Year Event Rates According to the Occurrence of Minor VC Versus No VC Up to 30 Days
16040	Independent Clinical Predictors of Major VCs Within 30 Days
16041	Independent Clinical Predictors of 1-Year Death After TAVR
16042	Patient Outcomes, Intraoperatively and During Follow-Up, According to Defibrillation Testing Groups
16043	Cause of Death in the 25 Patients Who Reached the Primary Endpoint During Follow-Up
16044	Comparison of LA Substrate Between Normal BMI and Obese Patients
16045	Comparison of Echocardiographic Findings Between Normal BMI and Obese Patients in Sinus Rhythm
16046	Outcome Measurements
16047	Inducibility With EPS and VEPS at Different Gray Zone Threshold Levels
16048	Comparison of Actual and Virtual VT Cycle Lengths
16049	Predictors at Admission of a Poor Outcome  (n = 158)
16050	Example of Cutoff Values for S100B on Arrival  (Day 0 Model) , Determined for Specificity of 0.95 and Sensitivity of 0.79
16051	Predictors on Day 3 of a Poor Outcome  (n = 74)
16052	Procedural Parameters and Scar Locations
16053	Monitoring
16054	Supraventricular Tachycardia Recurrence After Hybrid Procedure and Management
16055	Quantitative Coronary Angiography of the Culprit Lesions Treated in the 3 Groups
16056	Clinical Outcomes at 6 Months
16057	OCT and Endothelial Function, Follow-Up at 6 Months
16058	Effect of Pre-Dilation and Geographical Mismatch on Angiographic Outcomes
16059	Electrocardiographic Patterns in Adolescent African and Caucasian Soccer Players
16060	Cardiac Dimensions in Adolescent African and Caucasian Soccer Players
16061	Post-Procedural Complications and Outcomes
16062	Predictors for Midterm Mortality by Cox Regression Analysis
16063	Overview of All In Vivo Studies
16064	Physical Properties, Relaxivities and Half-Life of the Various Micelles
16065	Randomized Controlled Trials of Hypothermia Therapy in Cardiac Arrest
16066	Nonrandomized Clinical Studies of Hypothermia Therapy in Cardiac Arrest
16067	Clinical Studies of Hypothermia Therapy in Patients With STEMI
16068	Common Physiological Changes Occurring During Hypothermia
16069	Patients With Events at Follow-Up
16070	Prognostic Accuracy of Predictors of Outcome
16071	Cox Multivariate Models
16072	Comparison of Brugada Syndrome Registries
16073	In-Hospital Clinical Events Stratified by BMI Category
16074	Comparison of Septal VT Localization
16075	Comparison of Magnetic Resonance Imaging Data
16076	Clinical and Echocardiographic Data at Last Follow-Up Visit
16077	Overall Mortality and Equivalents of Mortality
16078	Clinical and Echocardiographic Predictors of Overall Mortality
16079	Comparison of Functional and Anatomical Parameters Between Patients With Permanent and With Valsalva-Induced Shunt
16080	Comparison of Procedural and Follow-Up Results Between Patients With Permanent and With Valsalva-Induced Shunt
16081	Food Sources of Long-Chain n-3 PUFA
16082	RCTs of n-3 PUFA and Clinical Cardiovascular Events
16083	National and International Recommendations for Consumption of n-3 PUFA in the General Population
16084	Multivariate Analysis of the Effects of LAMC and LAVI ≥33 ml/m2 on the Risk for Stroke in the Study Population  ⁎
16085	Selected Clinical Parameters for Patients Without LAMC by the Occurrence of Stroke
16086	Hemodynamics and Surrogates of End-Organ Perfusion
16087	Biodegradable Polymer Versus Permanent Polymer Drug-Eluting Stents: Clinical Outcomes Out to 3 Years
16088	EES Versus SES: Clinical Outcomes Out to 3 Years
16089	Biomarker Values Based on 90-Day Outcomes
16090	Multivariate Prediction of All-Cause Mortality
16091	Net Reclassification Index for Adding MR-proADM to the Best Clinical Model
16092	Risk Factors for SCD in Patients With ESRD  ( 16,18,23,43 )
16093	Key Questions Specific to ICD and/or CRT Placement in Patients With HF and CKD
16094	Comparison of Electrocardiographic Parameters Between Patients With Previous Cardiac Arrest, Patients With Syncope, and Asymptomatic Patients
16095	Comparison of Electrocardiographic Parameters Between Patients With Mutation in HERG and Those Without Mutation in HERG
16096	Comparison of Electrocardiographic Parameters Before and After Initiation of Hydroquinidine in 18 Patients
16097	Patients With Available Data to Compare the Efficacy of Hydroquinidine With Other Antiarrhythmic Treatments
16098	Score Table for Performance Evaluation
16099	Features of Patients Evaluated for Monomorphic VT With Mediastinal Adenopathy Due to Granulomatous Infiltration
16100	EPS/RFA Findings of Patients Undergoing RFA, Correlated With DE-CMR and 18FDG PET-CT Findings
16101	Independent Predictors of ERP in Multivariable Regression Model
16102	Prevalence of ERP by Sex and Age in the Health 2000 Survey
16103	Sibling Recurrence Risks and ORs for ERP in Siblings of ERP+ Individuals, Unadjusted and Adjusted for Age and Sex, in the FHS
16104	Arrhythmias at Visit 1  (Week 1)  and Visit 2  (Day 30)  for All Patients
16105	AEs of Interest During cECG Recording Period by Ventricular Pause Duration
16106	Incidences of Out-of-Hospital Cardiac Arrest From Cardiac and Noncardiac Causes
16107	Multivariate-Adjusted Odds Ratios  (Confidence Intervals)  of Adiposity Measures and the Presence of AF
16108	Multivariate-Adjusted Odds Ratios  (Confidence Intervals)  of Adiposity Measures and AF Chronicity
16109	Multivariate-Adjusted Regressions  (Confidence Intervals)  Between Adiposity Measures and AF Burden
16110	Multivariate-Adjusted Hazard Ratios  (Confidence Intervals)  of Adiposity Measures and AF Recurrence
16111	Clinical Outcomes at 30 Days and 12 Months for All Patients  (2.25- to 4.0-mm Stents)
16112	Angiographic and IVUS Measures at 8 Months for Angiographic Cohort
16113	Antithrombotic Regimens Up to 360 Days of Follow-Up
16114	Cumulative Rates of Adverse Clinical Events at 30-Day, 6-Month, and 1-Year Follow-Up
16115	Correlates Up to 360 Days of Death, ST, and MB by Multivariate Regression Analysis
16116	Relationships Among ARC Definite or Probable ST and Cardiac Death, Myocardial Infarction, TVR, and MB at 1-Year Follow-Up
16117	Distribution of Risk Variables in Subjects With Versus Those Without Coronary Events During 5 Years of Follow-Up
16118	Crude and Adjusted HR  (95% CI)  of Coronary Events and All-Cause Mortality in the CAC and hsCRP Categories
16119	c-Statistics, IDI, and NRI for the Combined Assessment of Traditional Markers of Risk, hsCRP, and log (CAC+1)  in Predicting Coronary Events and All-Cause Mortality
16120	Relationship of LV Diastolic Function Parameters With BMI, Multivariate Linear Regression
16121	Diastolic Function Parameters by BMI Categories
16122	Risk of Diastolic Dysfunction Associated With Overweight and Obesity
16123	Summary of Sudden Cardiac Death or Cardiac Arrest Events in Israel in the Years 1985 to 2009
16124	Longitudinal Assessment of Treatment Outcome: Post-Hoc Comparison of Prevalence at Each Time Point
16125	Clinical and Genetic Features of the Reported Cases of SQTS
16126	QT Interval Parameters in Symptomatic and Asymptomatic SQTS Cases
16127	Analysis of the Jpoint-Tpeak Interval in SQTS Cases
16128	The Genetic Subtypes of SQTS and Frequency of Culprit Genetic Mutations
16129	SQTS Diagnostic Criteria
16130	Stratification of Patients by Device Therapy
16131	Model Variables
16132	Event Rates Estimated by the Cost-Effectiveness Model Compared With the JUPITER Trial Results
16133	Base Case Results
16134	Factors Independently Associated With LVMI at Visit 2 in Multivariable Analysis
16135	Factors Independently Associated With Left Atrial Volume at Visit 2 in Multivariable Analysis
16136	Factors Independently Associated With LV Midwall FS at Visit 2 in Multivariable Analysis
16137	Factors Independently Associated With RV Fractional Area Change at Visit 2 in Multivariable Analysis
16138	Peak Myocardial Enzyme Rise After Radiofrequency Ablation
16139	Gradient Reduction During the Therapeutic Session  (p < 0.001)
16140	Significant Relief of Obstruction  (Doppler-Echocardiography, p < 0.001)  and Improvement of Exercise Capacity During 6 Months of Follow-Up  (p < 0.05)
16141	Physical and Chemical Properties of LUSPIOs and LSPIOs
16142	Multivariate Analysis: Risk for ACA or SCD Among the 3 Genotype and QTc Categories  *
16143	Risk Factors for ACA or SCD in Patients With LQTS by QTc Interval Category  *
16144	Echocardiographic Parameters by Time Since Randomization
16145	Percentage of Subjects With Abnormal Echocardiographic Values
16146	Multivariate Model for LVFS z-Score
16147	Multivariate Model for Presence Versus Absence of at Least Mild Mitral Regurgitation
16148	Outcomes and Complications Associated With Acute Lead Dislodgements
16149	Adjusted Odds Ratios of the Effect of Acute Lead Dislodgements on the Development of More Serious Adverse Events and In-Hospital Death
16150	Anatomic Diagnosis and Surgical Status  (n = 130)
16151	Predictors of Acute Procedural Success of Initial Radiofrequency Catheter Ablation
16152	Long-Term Outcome After RFCA
16153	Predictors of IART Recurrence After Radiofrequency Catheter Ablation
16154	Comparison of Voltage Map and Fat Map Patients Without Cardiomyopathy  (With Subject as Unit of Analysis)
16155	Diagnostic Criteria After CMR Examination in This Population
16156	Functional Parameters of LV and RV
16157	Incidence of VT at 24-h ECG Holter Monitoring
16158	End Points Occurrence in Groups
16159	Hazard Univariate on Prediction of End Points
16160	Hemodynamics at Rest and Peak Exercise in Patients With HFNEF and Controls
16161	Cardiopulmonary Exercise Testing Data in Patients With HFNEF and Controls
16162	Patients Without LGE Compared With Patients With LGE
16163	Univariate Analysis: All-Cause Mortality
16164	Univariate Analysis: Cardiac Mortality
16165	Univariate Analysis: SCD
16166	Resting and Exercise Echocardiographic Data
16167	Events by Indication
16168	Estimated 3-Year Mortality Rates in the Composite Traditional ICD Indications Group Compared With Individual Nontraditional ICD Indication Groups
16169	Hazard Ratios for Risk of Incident AF in Relation to BMI
16170	Weight Change Over 60 Months and Risk of Incident AF
16171	Stress Protocols and Radiopharmaceuticals
16172	Concordance of Stress Perfusion Findings
16173	TPD  (%)  by High-Speed Versus Conventional SPECT
16174	Concordance in Coronary Artery Territories
16175	Concordance in Reversible, Partially Reversible, and Fixed Defects
16176	Multivariate Analysis, Echocardiographic Measures by Treatment Group
16177	Clinical and Laboratory Data
16178	Doppler-Echocardiographic Data
16179	Multivariate Predictors of Indexes of LV Geometry
16180	Multivariate Predictors of Indexes of LV Function
16181	Association Between NCEP-ATPIII Criteria of Metabolic Syndrome and Indexes of LV Geometry and Function
16182	Characterization of All EMS-Treated Victims and Various Subgroups of Interest
16183	Multivariate Analysis of Survival by Site: Cases With Complete Data Only
16184	Survival to Hospital Discharge by Type of Location
16185	Major Versus Minor Complications
16186	Multivariable Predictors of Complications in All ICDs  (e.g., Primary and Secondary Prevention)
16187	Multivariable Predictors of Complications in Primary Prevention ICDs
16188	Frequent Major and Minor Complications
16189	Adjusted Hazard Ratios for Mortality According to Presence of a Major Nondeath Complication Within 45 Days
16190	Nucleotide Sequences of the Primers, Anchors, and Fluorescence Resonance Energy Transfer Probes for Both Variants
16191	Haplotype Frequencies  (%)
16192	Chromosome 4q25 Variants and AF Recurrence in Univariate Analysis
16193	Independent Pre-Procedural Predictors of AF Recurrence in Multivariable Analysis
16194	Cox Model for Risk Factors Related to Severe Cardiac Events in Patients Presenting With the First Syncope Event and Repeated Syncope Events On and Off Beta-Blocker Therapy
16195	Risk Factors for the First Syncope Event After the Start of Beta-Blocker Treatment in Long QT Syndrome Patients With Previous Episodes of Syncope
16196	Pooled Effect Estimates for Outcomes Comparing SA With SM
16197	Considerations to Decide Choice of Procedure for Treatment of HOCM
16198	Thromboembolic Risk Factors According to CHADS2Score in the Off- and On-OAT Groups
16199	Incidence of Thromboembolic Events and Major Hemorrhage According to CHADS2Score in Off- and On-OAT Groups
16200	Indications for Lead Extraction  (n = 1,449)
16201	Procedural and Clinical Success
16202	Adverse Events
16203	Device-Related Endocarditis and Pocket Infection
16204	Hemodynamic Parameters of Vehicle and RAD-Treated Animals 28 Days After Myocardial Infarction
16205	Effect of Apnea on Blood Pressure
16206	Comparison of AF Inducibility and Atrial Refractoriness  (Atrial Capture)  Before and After Ganglionated Plexi Ablation
16207	Blood Gas Analysis Before and After Induced Apnea
16208	Transesophageal Echocardiographic Correlates of Thromboembolic Risk  (CHADS2Score)
16209	Clinically Actionable Events
16210	CAE Summary
16211	Clinical Worsening: Cumulative Incidence of Events Through 1 and 2 Years of Treatment
16212	Most Common Adverse Events Leading to Discontinuation of Study, Study Drug, or Death Through 2 Years
16213	Description of the Study Groups
16214	Definitions
16215	30-Day Outcome
16216	Coronary Angiography Results and Revascularization Procedures
16217	Distribution of Abnormal Epicardial Electrograms in Epicardial Low-Voltage Areas
16218	Mapping Findings in Patients With Nonischemic Cardiomyopathy and Ventricular Tachycardia
16219	Endocardial and Epicardial Electroanatomical Mapping Features
16220	Multivariate Analysis: Predictors of ACA or LQTS-Related Sudden Death During Ages 1 to 10 Years
16221	Multivariate Analysis: Predictors for Second ACA or LQTS-Related Death During Ages 1 to 10 Years by First ACA in the First Year of Life Versus First ACA Ages 1 to 10 Years
16222	Univariate and Multivariate HRs of Tested Predictors
16223	Effect of 40-mg Sildenafil Dose in H-PVR Patients
16224	In-Hospital Outcomes in the Study Population
16225	Causes of Death in 75 Patients Treated With TAVI
16226	Comparison of Risk Profiles and Hospital Outcomes in First 25 and Last 50 Patients Treated With Transcatheter Aortic Valve Implantation
16227	Multivariate Analysis of the Predictors of Late Mortality in Patients Treated With TAVI
16228	Laboratory Results
16229	IVUS Results
16230	MACE and Adverse Events
16231	Electroanatomic Mapping Data
16232	Inducibility With Programmed Stimulation
16233	Results of Quantitative Coronary Angiography
16234	MACE at 12-Month Follow-Up  (in Descending Order of Severity)
16235	Correlations Among OxLDL Biomarkers at Randomization
16236	Correlation Between OxLDL Biomarkers With Lipid Parameters and Inflammatory Markers at Randomization
16237	Immunohistochemical Methods
16238	Frequencies of Concentric Vessel Morphology in Different Plaque Types
16239	Spearman ρ Correlation Coefficients of Microvessel Density and Plaque Morphology
16240	Electron Microscopy Analysis of Endothelial Cell Morphology, Junctions, and Leukocyte Infiltration in Intraplaque Microvessels
16241	Targeted Arrhythmias With Mapping and Ablation Sites
16242	Scar Involvement Relative to Mapped Chamber and Identification of Target Sites
16243	CHD Risk Factors  *  Among 63,469 Women Without Prior CHD, Stroke, or Cancer According to Depression Symptom Category in 1992
16244	HRs  (95% CI)  for Mortality/MI Among 75,718 Women Without Prior CHD, Stroke, or Cancer Followed From 1996 to 2004
16245	Predictors of Death for the Entire Group  (C Index = 0.92; n = 98)
16246	Predictors of Neurologic Deficit for the Entire Group  (C Index = 0.89; n = 98)
16247	Predictors of Death for the Unresponsive Group  (C Index = 0.90; n = 59)
16248	Angiographic Findings and Intervention in the Entire Group  (n = 98)
16249	Angiographic Findings in Unresponsive Patients  (n = 59)
16250	Prediction of Incident CHD as a Function of CAC Percentiles and CAC Absolute Scores in Women
16251	Prediction of Incident CHD as a Function of CAC Percentiles and CAC Absolute Scores in Men
16252	Risk of CHD Events Associated With Increasing Absolute CACS Across Age-Sex-Race/Ethnicity CAC Percentiles
16253	Risk of CHD Events Associated With Age-Sex-Race/Ethnicity CAC Percentiles Across Increasing Absolute CACS
16254	Univariate Analysis of Cox Regression Performed in 184 Children With Ventricular Pre-Excitation
16255	Covariate-Adjusted Cox Proportional Analysis Showing Factors Associated With Potentially Life-Threatening Arrhythmias
16256	Study Protocol
16257	Summary of Desmosomal Gene Changes Isolated in LDAC Cohort
16258	Events Recorded in LDAC Cohort
16259	Genotype-Phenotype Correlations in Families With Novel Mutations in Desmoplakin
16260	Clinical Diagnostic Features of LDAC  ⁎
16261	Repolarization and Conduction Dynamics: Clinical Data
16262	Repolarization Dynamics: Simulation Data
16263	Risk Factors for Sudden Cardiac Death
16264	Factors Associated With Presence of LDLR Mutations in Patients With Clinical Diagnosis of FCH
16265	Patients at 3-Month Follow-Up
16266	Multivariate HRs and 95% CIs of Mortality From Ischemic Heart Disease, Cardiac Arrest, Heart Failure, Stroke, Total Cardiovascular Disease, and Total Death According to Quintiles of Fish Intake, 22,881 Men and 35,091 Women
16267	Multivariate HRs and 95% CIs of Mortality From Ischemic Heart Disease, Cardiac Arrest, Heart Failure, Stroke, Total Cardiovascular Disease, and Total Death According to Quintiles of ω-3 PUFA Intake, 22,881 Men and 35,091 Women
16268	Association of Lipoprotein (a)  With Incident Cardiovascular Disease in Women Not Taking Hormone Replacement Therapy
16269	Lipoprotein (a) , LDL-C, and Hazard Ratios of Future Cardiovascular Events Among Women Not Taking Hormone Replacement Therapy
16270	Lipoprotein (a)  and Incident Cardiovascular Disease in Women Taking Hormone Replacement Therapy
16271	Lipoprotein (a) , LDL-C, and Hazard Ratios of Future Cardiovascular Events Among Women Taking Hormone Replacement Therapy
16272	Heart Rate Variability Parameters
16273	Electrophysiological Parameters
16274	Events During Follow-Up in Patients With and Without Prior CABG
16275	Events During Follow-Up in CABG Patients in the 10- and 80-mg Group
16276	Examination Protocol, Label, Definition, and Meaning of CAF Tests
16277	Comparison of Clinical Variables Among Subjects With Different Blood Pressure, Including Normotension With and Without a Family History of Hypertension, Pre-Hypertension, and Hypertension
16278	Univariate Analysis for the Comparison of Cardiac Autonomic Function Among Subjects With Different Blood Pressure, Including Normotension With and Without a Family History of Hypertension, Pre-Hypertension, and Hypertension
16279	Summary of Clinical Adverse Experiences
16280	Pre-Specified Laboratory and Clinical Adverse Events
16281	Combined Echocardiographic Measurements Made at 6 and 9 Months After 3 Months of 2-V Versus 3 Months of 3-V Biventricular Stimulation
16282	Adverse Clinical Events in 40 Patients Who Underwent Implantation of CRT Systems
16283	EuroSCORE Logistic Regression Model
16284	Distribution of Patients by Different Chronic Health Conditions and In-Hospital Risk Assessment Stratified to Their Individual Post-Operative Course
16285	Comparison of Patients With Cardiac Amyloidosis Versus Other Patients
16286	Late Gadolinium Enhancement Versus Endomyocardial Biopsy
16287	Impact of Ablation of Targeted Regions
16288	Instrumental Findings of the Overall Sample and According to Results of Voltage Mapping
16289	Electrophysiological Findings of the Overall Sample and According to Results of Voltage Mapping
16290	Patient-Reported Medication Use at Time of Enrollment and During Follow-Up
16291	Adjusted Hazard Ratios for the Capacity of the Individual Parameters to Predict Development of the Primary Outcome  (Cardiac Death or Resuscitated Cardiac Arrest)  in the Acute and Nonacute Early Post-MI Periods
16292	AUC for the Individual Parameters in Predicting the Primary Outcome  (Cardiac Death or Resuscitated Cardiac Arrest)  in the Acute and Nonacute Early Post-MI Periods
16293	Adjusted Hazard Ratios for the Capacity of the Noninvasive Parameters Alone and Combined With Ejection Fraction to Predict the Development of the Primary Outcome  (Cardiac Death or Resuscitated Cardiac Arrest)
16294	Angiographic Features and Procedural Outcomes Stratified by Gender and Stent Type
16295	Angiographic Outcomes at Follow-Up Stratified by Gender and Stent Type
16296	Clinical Outcomes Stratified by Gender and Stent Type
16297	Statin Therapy in Relation to Perioperative Ischemia and Troponin T Release in Patients Undergoing Major Vascular Surgery
16298	Statin Therapy in Relation to Perioperative and Late Cardiac Outcome in Patients Undergoing Major Vascular Surgery
16299	Association Between Heart Rate Variability and Statin Therapy
16300	Subgroup Analysis of Cardiac Resynchronization in RBBB-HF  ⁎
16301	Multivariable Regression Analysis for Prediction of LV Dyssynchrony
16302	Univariate Prognostic Relationships
16303	Multivariable Relationships With Total Mortality
16304	Multivariable Relationships With Arrhythmic Death or Cardiac Arrest
16305	Calculation of Total Mortality Score
16306	Calculation of Arrhythmic Death/Cardiac Arrest Score
16307	Prevalence of Additional Risk Factors in Relation to Ejection Fraction
16308	The Electrophysiological Findings in Patients With and Without Conduction Block Line During Sinus Rhythm
16309	Comparison Between the Different Ablation Strategies Used
16310	Accuracy to Reach the Design Line
16311	Electrical and Ultrasound Pacing Parameters of All Cardiac Chambers Evaluated
16312	Clinical and Echocardiographic Data After Alcohol Septal Reduction Therapy and Surgical Myectomy
16313	Serum Cholesterol, Body Weight, and Atherosclerotic Morphologic Analysis
16314	Effects of Right Vagosympathetic Trunk Stimulation on Sinus Rate  (beats/min)  Before and After SLGP, ARGP, and IRGP Were Sequentially Ablated
16315	Effects of Left Vagosympathetic Trunk Stimulation on Sinus Rate  (beats/min)  Before and After SLGP, ARGP, and IRGP Were Sequentially Ablated
16316	Effects of Right Vagosympathetic Trunk Stimulation on Ventricular Rate  (beats/min)  During Induced AF Before and After SLGP, ARGP, and IRGP Were Sequentially Ablated
16317	Effects of Left Vagosympathetic Trunk Stimulation on Ventricular Rate  (beats/min)  During Induced AF Before and After SLGP, ARGP, and IRGP Were Sequentially Ablated
16318	Effects of Right or Left Vagosympathetic Trunk Stimulation on ERP  (in ms)  and WOV  (in ms)  of Atria and Pulmonary Veins Before and After ARGP or SLGP Ablation  (n = 11)
16319	Univariate and Multivariable Predictors of Death in ICD Recipients
16320	Odds Ratios and 95% Confidence Intervals for the Presence of Clinical Conditions Across Increasing Myeloperoxidase Tertiles
16321	Univariate and Multivariate Cox Proportional Hazard Analyses of Death, Cardiac Transplantation, or HF Hospitalization Across MPO Tertiles
16322	Hemodynamic and Angiographic Findings in Sham-Operated and CCM-Treated Dogs With Heart Failure Before and 3 Months After Initiating Treatment or Follow-Up
16323	Treatment Effect  ⁎
16324	Chronic Histomorphometric Findings in Left Ventricular Myocardium of Normal Dogs, Sham-Operated Untreated HF Dogs, and CCM-Treated HF Dogs
16325	mRNA and Protein Expression of Fetal Program and Sarcoplasmic Reticulum Genes/Proteins in Left Ventricular Free Wall
16326	Protein Expression of Total PLB and P-PLB at Ser-16 and Thr-17 in the Interventricular Septum and LV Free Wall
16327	Angiographic Findings
16328	Histomorphometric Findings and Expression of Sarcoplasmic Reticulum Calcium Cycling Proteins in Left Ventricular Myocardium
16329	Indications for ICA in Patients of Group 2  (n = 139)
16330	Type and Dosage of Beta-Blocker Therapy
16331	Causes of Nondiagnostic MDCT Imaging in the 15 Coronary Artery Segments of the 2 Study Groups
16332	Diagnostic Accuracy of MDCT Imaging in the 15 Coronary Artery Segments of the 2 Study Groups
16333	Validation Study: Diagnostic Accuracy of P- or F-Wave Indexes for Focal AT
16334	Polymorphisms Evaluated for Their Relationship to Cognitive Decline After CABG Surgery
16335	Genotype Frequencies in European Americans  (n = 443)  for 5 SNPs Selected for Pair-Wise Modeling
16336	Patient Outcome
16337	Hemodynamic Data
16338	In Vivo Cell Shortening and Ca2+Transient in Normal and Failing Cardiomyocytes
16339	Correlation Coefficients of LV Dyssynchrony, Assessed With TDI, Versus the Different LV Dyssynchrony Parameters, Derived From Phase Analysis of GMPS  (Idiopathic Dilated Cardiomyopathy vs. Ischemic Cardiomyopathy)
16340	Regression Model With TDI as Dependent Variable
16341	Electron Beam Tomography, Ablation, and Outcome Data
16342	The Hazard Ratios for Any Cardiac Event and Life-Threatening Events  (Aborted Cardiac Arrest or LQTS-Related Death)  in the Pregnancy, Postpartum, and Post-Postpartum Time Periods for 391 Women With Live Births Between 1980 and 2003
16343	The Hazard Ratios for Any Cardiac Event for Time-Dependent Beta-Blocker Use During the Pregnancy, Postpartum, and Post-Postpartum Time Periods for 391 Women With Live Births Between 1980 and 2003
16344	Alteration of Laboratory and Lipid Parameters by the Study Medication
16345	Platelet Surface CD 63 Expression After Stimulation with ADP and TRAP
16346	Maximum Platelet Aggregation  (MA)  After ADP and TRAP Stimulation
16347	Maximal Slope of Aggregation After ADP and TRAP Stimulation
16348	Echocardiographic and Doppler Features of Sickle Cell Patients Versus Normal Controls
16349	Associations With TR Velocity, Spearman Rank Correlation Coefficient ρ
16350	Proportional Hazards  (Cox)  Regression Analysis of Mortality
16351	Clinical Features of Hypertrophic Cardiomyopathy Patients With Surgical Myectomy or Alcohol Septal Ablation
16352	Comparison of Anatomical Differences Between Surgical Myectomy and Alcohol Septal Ablation
16353	Distribution of the ApoE Polymorphism in Acute Coronary Syndrome Patients  (n = 166)  and Chronic Stable Angina Patients  (n = 70)
16354	Estimated Adjusted Means of Interleukin-10  (IL-10)  and C-Reactive Protein  (CRP)  in Different ApoE Genotypes in the Acute Coronary Syndrome Patient Group
16355	Estimated Adjusted Means of Interleukin-10  (IL-10)  and C-Reactive Protein  (CRP)  in Different ApoE Genotypes in Chronic Stable Angina Patient Group
16356	Agents Used for Pulmonary Vasoreactivity Testing
16357	Venous Access Sites
16358	Serious Adverse Events Related to Right Heart Catheter Procedures in Patients With Pulmonary Hypertension
16359	Description of Nonfatal Serious Adverse Events Related to Right Heart Catheter Procedures in Patients With Pulmonary Hypertension Performed in the Years 2000 to 2005
16360	Position Error of NICE-Based Activation Time Imaging
16361	Clinical, Electrocardiographic, and Electrophysiological Details of the Study Group
16362	Effect of Naloxone Pretreatment on Inhibition of TNF-α Production From the THP-1 Cell Culture After LPS Stimulation
16363	Regression Model of Carotid Ligation Response in Mice Receiving Naloxone or Saline Treatment
16364	Agreement Between SPWMD and Septal-to-Lateral Delay
16365	Hemodynamic and Brachial Artery Vasoactivity Values Before and Four Hours After Fatty Meals
16366	Values of LDL Oxidation Analytes Before and Four Hours After Fatty Meals
16367	P-Wave Morphology for Right Atrial Focal Atrial Tachycardia
16368	P-Wave Morphology for Left Atrial Focal Atrial Tachycardia
16369	P-Wave Morphology
16370	Adjusted Hazard Ratios for Cardiac Events for the 4 QTc Summary Measures  ⁎
16371	Adjusted Hazard Ratios for Cardiac Events for the 4 QTc Summary Measures Dichotomized at 500 ms Among Patients In Whom ≥3 and ≥4 ECGs Were Recorded Before Age 10  ⁎
16372	Adjusted HR for Cardiac Events of the Maximum QTc Summary Measure, Dichotomized at Different QTc Intervals  ⁎
16373	Relationships Between Blood Pressure Components and Change in Atheroma Volume on Multivariable Analysis  ⁎
16374	Intravascular Ultrasonographic Measures of Atheroma Burden in Patients With Normal, Pre-Hypertensive, and Hypertensive Average Blood Pressure Levels During the Study
16375	Mean PNV at the Protected Isthmus and RA Maximal PNV
16376	Summary of Cross Correlation and Absolute Timings Between Virtual and Contact Unipolar Electrograms During Sinus Rhythm
16377	Echocardiography  (n = 54)  and Blood Chemistry  (n = 55)  Analysis Before and After the Race
16378	Impedance Cardiography  (n = 27)
16379	Changes in Frequency Components of HR and BP Variability
16380	Hemodynamic Values, Right and Left Ventricular Parameters Assessed by Cardiac Magnetic Resonance Imaging
16381	Clinical Parameters Determined in Hypertensive Patients With Chronic Heart Failure
16382	Collagen Volume Fraction in Normotensive Subjects and Hypertensive Patients With Chronic Heart Failure
16383	Grade of MMP-1 and TIMP-1 Deposits in Normotensive Subjects and Hypertensive Patients With Chronic Heart Failure
16384	Collateral Flow, Pressure, and Resistance Indexes in CTO Before and After Adenosine Infusion
16385	Coronary Flow Velocity Measurements in the Donor and Recipient Coronary in Patients With and Without Coronary Steal
16386	Correlation Between Levels of Anti-OxLDL Autoantibodies and Antipathogen Antibodies in 1995 and 2000
16387	Association Between Serum and Inflammatory Parameters, Vascular Risk Factors, and Cu-OxLDL IgG and IgM Autoantibodies
16388	Association Between Levels of Anti-OxLDL Autoantibodies and Pathogen Burden and Chronic Infection
16389	Association of Anti-OxLDL Autoantibodies  (1995)  With Incident and Progressive Carotid Atherosclerosis  (1995–2000)   (n = 656)
16390	Criteria Used to Identify 41 Critical Isthmus Sites
16391	Comparison of Sites With and Without Isolated Potentials
16392	Comparison of Sites With Perfect, Good, and Poor Pace-Maps
16393	Mapping and Ablation Results
16394	Clinical Features of the Study Population
16395	QRS Duration  (ms)  During Junctional Escape Rhythm With Nodal AV Block Post-RF Ablation  (Basal) , During Hisian and Para-Hisian Stimulation  (Pacing His) , and During Right Apical Conventional Stimulation  (Pacing Apex)
16396	Comparisons Between SCD Cases That Underwent Evaluation of LV Function and All Remaining Cases of SCD
16397	Diagnosis of Myocardial Infarction or Ischemic Symptoms Among SCD Cases That Underwent Attempted Resuscitation
16398	Comparison of Cooling at Different Sites of Measurement During Protocol  ⁎
16399	Comparison of Different Cooling Techniques in Humans and Animals
16400	Atherosclerotic Events in VALIANT  ⁎
16401	Composite Cardiovascular Mortality and Morbidity Outcomes
16402	Hospital Volume for Cardiovascular Procedures by Race and Ethnicity
16403	Adjusted Predictors of Low-Volume Hospital Use by Procedure  ⁎
16404	Unadjusted In-Hospital Mortality for Cardiovascular Procedures by Race and Ethnicity
16405	Impact of Hospital Volume on Risk-Adjusted Odds Ratios for Mortality by Race and Ethnicity
16406	Historical and Current Data of 18 CR Subjects
16407	Systolic and Diastolic Function Indexes of the Study Groups
16408	Age, LVEF, Renal Function, and B-Type Natriuretic Peptides in 1,049 Patients With Stable Ischemic Heart Disease
16409	Multiple Linear Regression Assessing Age, Renal Function, Gender, BMI, and LVEF as Independent Predictors of Plasma BNP and NTproBNP
16410	Peptide Test Performance in Detection of Selected LVEF Thresholds in Patients With Stable Ischemic Heart Disease
16411	Clinical and Hemodynamic Variables After CRT
16412	Echocardiographic and Doppler Variables After CRT
16413	Tissue Doppler and Color M-Mode Variables by LVEF Response After CRT
16414	Focal AT Versus Localized Re-Entry
16415	Hazard Ratios  (95% CI)  of Mortality from Cardiovascular Disease According to Walking Time
16416	Hazard Ratios  (95% CI)  of Mortality from Cardiovascular Disease According to Sports Time
16417	Symptom Responses to G-CSF and Changes in Selected Laboratory Values
16418	Comparison of the Clinical Parameters Between the VF/PVT Group and the RVOT-VT Group
16419	Intra- and Perioperative Patients’ Data  (n = 38; Intraoperative Deaths = 4; Hospital Deaths = 9)
16420	Causes of Death  (n = 9)  and Reintervention  (n = 7)
16421	Univariate Predictors of Overall and Coronary-Related Operative Death, and Multivariate Predictors of Operative Death and Duration of Stay in the ICU
16422	Clinical, Morphologic and Functional Parameters in the Overall Patient Population
16423	Scintigraphic Findings in the Patient Population and Control Group
16424	Univariate Analysis of LPL Polymorphisms in Association With TVR and the Distributions of Polymorphisms
16425	Multivariable Cox Regression of Clinical Variables and LPL Ser447Ter Polymorphism Associated With TVR
16426	Flutter Wave Polarity in the 12-Lead ECG
16427	Flutter Wave Amplitude in the 12-Lead ECG
16428	Biochemical Data
16429	RH and 95% CIs With a BP Increase of 10 mm Hg for CVD Mortality, Stroke Morbidity, and the Composite of CVD Mortality/Stroke Morbidity
16430	Coagulation Parameters in Healthy Volunteers  (Negative Control Group) , Patients With Septic Shock  (Positive Control Group) , and Patients Admitted After Successfully Resuscitated Out-Of-Hospital Cardiac Arrest
16431	Effect of Treatment on Clinical Events
16432	Effect of Treatment on Coronary Calcium Score
16433	Medians, Interquartile Range, and Cardiovascular Event Rates for Women Below and Above the Median for Each Variable
16434	Univariate Predictors of Outcomes
16435	Cross Correlations of ECG Variables With Each Other
16436	Hazard Ratios and 95% Confidence Intervals for Significant Univariate and Multivariate Predictors of Cardiovascular Events
16437	Serum and Lipoprotein Lipids  (mmol/l)  Off and On Statin Treatment
16438	Cholesterol and Squalene in Arterial Tissue  (T)  and Serum  (S)   ⁎
16439	Ratios to Cholesterol  (102× μg/mg of Cholesterol)  of Non-Cholesterol Sterols in Arterial Tissue  (T)  and Serum  (S)   ⁎
16440	Cholesterol  (Tissue mg/100 g, Serum mg/dl)  and Ratios to Cholesterol  (102× μg/mg of Cholesterol)  of Squalene and Noncholesterol Sterols in Arterial Tissue  (T)  and Serum  (S)  Off and On Statin Treatment
16441	Annualized Death Rates in Disopyramide- and Non-Disopyramide-Treated Patients
16442	Sensitivity, Specificity, Positive Predictive Value, and Negative Predictive Value of Various Cut-Off Values for the Indicated Parameters
16443	PVAI Results and Follow-Up
16444	Changes in Hemodynamics
16445	Quantitative Coronary Angiography
16446	Major Adverse Events *
16447	Clinical Details
16448	Autonomic Neuropathy Details
16449	Heart Rate, BP, and Norepinephrine Response to CPT
16450	LV MBF Reserve on CPT
16451	LV Diastolic Function
16452	Definitions
16453	Registration Accuracy Based Upon FeO Injection “Targets”
16454	Blood Pressures  (mm Hg)  Pre-Arrest and Without Epinephrine
16455	Blood Pressures  (mm Hg)  Achieved Pre-Arrest and With Epinephrine
16456	Number of Patients  (%)  with Detectable MES During the Different Phases of CAS
16457	MES Counts During the Different Phases of CAS
16458	Angiographic Data
16459	In-Hospital Complications and Outcomes  (%)
16460	Multivariate Predictors of In-Hospital Outcome
16461	One-Month Outcomes  (%)
16462	Multivariate Predictors of One-Month Outcomes
16463	Different Gradations of Clinical Risk and 30-Day Outcomes
16464	Clinical Data and Previous CPVA Design
16465	Clinical and Electrophysiologic Data
16466	Binary Logistic Regression Analysis Showing the Independent Predictors ofReceiving a Defibrillator Among Survivors of Sudden Cardiac Death in the UnitedStates for the Years 2000 and 2001
16467	Biomarkers in the Different Patient Groups
16468	Laboratory Findings in Acute AD Patients With Versus Without Complications
16469	Laboratory Findings in Acute AD Patients With Fatal In-Hospital Course Versus Survivors
16470	Platelet Parameters According to the Presence or Absence of Target Organ Damage
16471	Analysis of Data Based on Utilization of Aspirin
16472	Principal Correlations
16473	Changes in Echocardiographic Measurements During Follow-Up
16474	KCNQ1Mutations by Location, Amino-Acid Coding, Type of Mutation, and Reported Functional Effects
16475	Electrocardiographic Measurements Before and After Exercise Testing
16476	Conduction
16477	Coronary Sinus Concentrations of Antioxidants and Lipid Peroxidation Products
16478	Electrophysiological Parameters
16479	Classification and Regional Differences of CFAE Distributions
16480	Mapping and Follow-Up Data of Patients Undergoing VF Storm Ablation
16481	Drugs and Electrocardiographic Modifications
16482	Left Ventricular Structure and Systolic and Diastolic Function
16483	Echocardiographically Calculated Individual Left Ventricular Dimensions, Ejection Fraction, QRS Duration, and Mitral Valve Regurgitation Before AVJ Ablation
16484	Comparison of Parameters During Different Types of Pacing *
16485	Echocardiographic Evaluation of Mitral Valve Regurgitation, Using the 1  (Mild)  to 4  (Severe)  Scale, at Various Pacing Modes and Consequent QRS Durations
16486	Immediate and Intermediate Follow-Up Results
16487	Echocardiographic and MRI Intermediate and Long-Term Results
16488	Alphabetical List of Randomized Trials of Atherectomy, Atherotomy, or Laser Angioplasty Versus Percutaneous Transluminal Coronary Angioplasty
16489	Follow-Up Results
16490	Pulmonary Vein Ostia Size
16491	Changes in Quality of Life Before Versus After Pulmonary Vein Isolation
16492	Complications
16493	In and Out of Hospital to Seven-Month Follow-Up Major Adverse Cardiac Events * per Patient
16494	Results of Quantitative Coronary Angiography
16495	Predictors of Angiographic Binary Restenosis Recurrence
16496	Clinical Features of the Patients
16497	Ejection Fraction and Natriuretic Peptides in Survivors and Patient Groups According to Type of Mortality
16498	Predictors of Sudden Cardiac Deaths and Non-Sudden Cardiac Deaths in Univariate and Multivariate Analyses  (Adjusted for Age, Diabetes, and New York Heart Association Class)
16499	Sensitivity, Specificity, and Positive, Negative, and Overall Predictive Accuracies of Brain Natriuretic Peptide and Left Ventricular Systolic Function for Prediction of Sudden Cardiac Death at Different Cut Points
16500	Summary of Biopsy and Survival Results
16501	Electrocardiographic Findings
16502	Echocardiographic Findings
16503	Immunohistochemical Staining Results
16504	Summary of Logistic Regression Models
16505	Predictive Ability of Model 2
16506	Results
16507	Comparison Between Group A and Group B Patients
16508	Comparison Between Patients With LBBB and Those Without
16509	Effects on Exercise Indexes of Transient Ischemia
16510	Effects on Indexes of Spontaneous Ischemia/24 h
16511	Magnetic Guidance System Navigation Success
16512	Two-Year Outcome in Relation to cTnT and IL-6
16513	Predictors of Death
16514	Systemic Hemodynamics, Laboratory Parameters, and Forearm Blood Flow
16515	Gene Polymorphisms Examined for Association With Coronary Artery Disease
16516	Primers, Probes, and Other Conditions for Genotyping
16517	Multivariate Logistic Regression Analysis of Polymorphisms Associated With Coronary Artery Disease in the Total Study Population
16518	Multivariate Logistic Regression Analysis of Polymorphisms Associated With Coronary Artery Disease in Low- or High-Risk Men
16519	Multivariate Logistic Regression Analysis of Polymorphisms Associated With Coronary Artery Disease in Low- or High-Risk Women
16520	Genomic Frequencies of the PlA1/A2, C807T, and C-5T Kozak Polymorphisms in Controls, Patients, and Aspirin-Sensitive and Aspirin-Resistant Patients
16521	Predictors of PPM Placement After NSRT by Univariable Analysis
16522	Multivariate Analysis for Prediction of PPM Placement After NSRT
16523	Comparison of Clinical and Echocardiographic Outcome of Patients Who Required PPM and Those Who Did Not Require PPM
16524	Clinical and Echocardiographic Implication of PPM Requirement: Age and LVOT Gradient Matched
16525	Left Ventricular Dimensions and Systolic Function
16526	Left Ventricular Diastolic Function
16527	Univariate Coefficients for Correlation Between Diastolic Function, Myocardial Metabolism, and Metabolic and Cardiovascular Risk Factors in Patients With Type 2 Diabetes and Controls
16528	Number and Follow-Up of LQTS Gene Carriers by Gender and Age *
16529	Relative Hazards of First Cardiac Event by LQTS Genotype and Age
16530	Cardiac Events and Sudden Death in LQTS Family Members by Family Genotype and Gender
16531	LV Systolic Function
16532	Left Ventricular Diastolic Filling
16533	Systemic Hemodynamics
16534	Sensitivity, Specificity, and Predictive Values
16535	Screening of Troponin-Positive Patients for Coronary Artery Disease *
16536	Cytokine and C-Reactive Protein Levels of Troponin-Positive Versus Troponin-Negative Patients *
16537	Clinical, Doppler Echocardiographic and Hemodynamic Parameters, and CA125 Serum Levels in CHF Patients Classified According to NYHA Functional Class
16538	Multiple Regression Analysis and Simple Correlation Between CA125 and Serum Sodium and Doppler Echocardiographic and Hemodynamic Parameters
16539	Echocardiographic LVEF, Treadmill Test, and Holter Results
16540	Adverse Events
16541	Included Trials
16542	Sensitivity Analyses Based on Quality of Randomized, Controlled Trial
16543	Resting Lung Function in PPH Patients and Control Subjects
16544	Pearson Correlation Coefficients Relating Resting Lung Function Parameters to CPET and NYHA Class in PPH Patients
16545	Resting Lung Function in PPH Patients Grouped by Severity of Reduction in Peak o 2
16546	Univariate Predictors of Cardiac Deaths
16547	Doppler-Echocardiographic parameters [Mean  (95% CI) ] and Survival
16548	Multivariate Analysis  (Backward Stepwise)  Predictors of Cardiac Mortality
16549	Systolic Blood Pressure
16550	TUNEL Staining in Isolated Cardiac Myocytes
16551	Results of Binary Logistic Regression Analysis With Use of Arrhythmic Events  (Absence/Presence = 0/1)  as Dependent Variable in the 162 Asymptomatic WPW Patients
16552	Ablation Guidance and Recurrences During Follow-Up
16553	Hemodynamic Data During the First 72 Hours
16554	Renal and Hepatic Variables at 24 Hours
16555	Evolution of Cardiac Index, Mean Arterial Pressure, and Epinephrine Requirements Through Time According to Prognosis
16556	Cardiac Diagnoses of Patients Catheterized on ECMO
16557	Indications for Cardiac Catheterization on ECMO
16558	Subsequent Interventions Based on Catheterization Findings
16559	Biological Effects of Incremental Intravenous Boluses of Ucn in Eight Normal Sheep and Eight Sheep With HF
16560	Effects of Incremental Intravenous Boluses of Ucn on Plasma Electrolytes in Eight Normal Sheep and Eight Sheep With HF
16561	Clinical and Electrophysiologic Data
16562	Group 2 Patients Separated According to Ablation Catheter Used
16563	Number of Sectors Isolated in Relation to Distal or Ostial Pulmonary Vein Isolation
16564	Group 2 Patients Separated According to Type of Atrial Fibrillation
16565	Plasma Lipid Profiles in the Three Experimental Groups at 12 Weeks
16566	Body Weight and Systemic Hemodynamics in the Three Experimental Groups at 12 Weeks
16567	Electroanatomic Maps of Atrial Tachycardia
16568	Underlying Lesions and Procedures in the Maze Group
16569	Early  (30-Day)  Crude Counts and Event Rates
16570	Late  (31-Day to 5-Year)  Kaplan-Meier Event Rates
16571	LV Echocardiographic Profile of 1,953 Children With DCM at Diagnosis, by Era of Diagnosis
16572	Unadjusted Cox Proportional Hazards Regression Analysis of Predictors of Death Among 1,953 Children With DCM Not Undergoing Heart Transplantation
16573	Final Multivariable Cox Regression Model of Predictors of Death Among 1,953 Children With DCM Not Undergoing Heart Transplantation
16574	LV Anatomy and Global Function Derived From CMR
16575	Predictors of Epicardial Vasospasm and Coronary Microvascular Dysfunction in 1,379 Consecutive Patients With Angina With Nonobstructive CAD
16576	Cardiac Parameters Among 214 HIV-Infected Children Born to HIV-Infected Mothers, by HAART Exposure Status
16577	Medication at Admission and at Discharge
16578	Number of Deaths and Mortality Within 60, 90, and 120 Days of Follow-Up
16579	Echocardiography Parameters and Heart Mass Ratio
16580	Reciprocal Bone Marrow Transplantation
16581	AT II Effect on Echocardiographic Assessments and HeartMassRatios
16582	Incidence Rates and HRs for the Main Outcomes Associated With Utah Stage of LA LGE
16583	Utilization of Care
16584	Association Between Diabetes and 2-Year Outcomes
16585	Primary Endpoint and Additional Parameter Changes in Full Analysis Set
16586	Ivabradine Dosing: Per-Protocol Population  ∗   of Children Who Reached the Primary Endpoint
16587	Adverse Events
16588	Prevalence of Atherosclerosis and Plaque Burden Distribution by 3DVUS
16589	Univariate and Multivariate Predictors of Plaque Burden
16590	Relationship With ASCVD Risk of the Number of Affected Territories, the Total Number of Plaques, and Plaque Burden
16591	PAL-HF Patient-Provider Encounters
16592	Primary Endpoint Results  ∗
16593	Secondary Endpoint Results  ∗
16594	Outcomes at 12 Months
16595	Changes in Arginine-NO Metabolite Levels at 1 and 2 Months After Doxorubicin Initiation
16596	Incidence of Mortality and Adverse Events in Newly Diagnosed AF According to Treating Specialty
16597	Association of Cardiology Care to Mortality and Adverse Events in Newly Diagnosed AF
16598	Multivariate Models for Nonfatal Myocardial Infarction or Coronary Heart Disease Death at 5 and 15 Years According to Treatment Group  ∗
16599	Comparing the Model With Conventional Parameters
16600	Design Features, Enrollment, and IS Assessment of the Included Trials
16601	C-Statistics for the Relationships Between Infarct Size and Adverse Events During Follow-Up
16602	Significant Multivariable Predictors of Adverse Events From Time of StudyEntry
16603	Comparison of Outcomes at 1 Year Among the RSS and SRI Subgroups
16604	Consistency of H2RA Use and LV Changes  ∗
16605	Comparison of Nonobstructive HCM Patients Who Developed NYHA Functional Classes III/IV Heart Failure During Follow-Up Versus Patients Who Remained in Classes I/II
16606	Nonobstructive Patients With HCM-Related Death or Aborted Life-Threatening Events
16607	Univariate and Multivariate Analysis for Predictors of Progression of HF Symptoms to NYHA Functional Classes III/IV in 249 Nonobstructive HCMPatients
16608	In-Hospital Outcomes of Nonagenarians and Patients Age<90 Years
16609	Post-Discharge Outcomes in Nonagenarians and Patients Age<90 Years and Unadjusted Hazard Ratios
16610	30-Day and 1-Year KCCQ-12 Overall Summary Scores in Nonagenarians and Others Age<90 Years
16611	Echocardiographic Measurements at Rest in Hypertrophic Cardiomyopathy Patients Without Obstruction Versus Patients With Obstruction
16612	Paradoxical Response to Exercise Patients Versus Obstructive Hypertrophic Cardiomyopathy at Rest With Increased Gradient or No Change During Exercise Patientsat Rest and During Exercise
16613	Association Between CRP Value Above Median at 6 Months and CVD and CHD in Relation to CRP Less Than Median Value With Atorvastatin and Placebo
16614	Hazard Ratios for CVD and CHD Associated With Achieved Level of CRP or LDL-c at 6-Month Relative to Placebo
16615	Hazard Ratios and 95% Confidence Intervals for CVD and CHD Associated With Achieved Level of CRP at 6 Months Relative to Placebo Using Imputed Data
16616	Hazard Ratios and 95% Confidence Intervals for CVD and CHD According to Achieved Levels of CRP and LDL Cholesterol After6Months of Atorvastatin
16617	Multivariable-Adjusted Predictors of Mortality
16618	Results of Diagnostic Polysomnography in the StudyPopulation
16619	Univariate Predictors of SCD
16620	Independent Predictors of SCD in the Total Study Population  (Results of Multivariate Regression)
16621	Independent Predictors of SCD in Subjects With OSA  (Results of Multivariate Regression)
16622	Study Endpoints in Matched Patients: Admission Rate, Length of Stay, MACE, Additional Patient Follow-Up, and Downstream Resource Utilization With CCTA Versus Standard Evaluation  (Both, n= 894)
16623	ORs of Study Endpoints: Standard Evaluation Versus CCTA  (Both, n= 894)
16624	Description of Neuropsychological Tests  ∗
16625	Impaired Performance at 90 Days on Neuropsychological Tests
16626	Clinical and Echocardiographic Features of the 275 HCM Patients in Relation to BMI
16627	Cardiovascular Magnetic Imaging Findings in 275 HCM Patients With RespecttoBMI
16628	Predictive Value of Clinical Risk Scores in the Test Group
16629	Predictive Value of Degree of Stenosis and Plaque Composition
16630	Incremental Predictive Value of Proximal Plaque in CCTA
16631	Medication  ∗   Treatment Rates, Stratified by Socioeconomic Status †
16632	Association of Socioeconomic Status  ∗   With PAD Treatment
16633	Electrophysiologic History of Patients
16634	Univariate Analysis of Risk Factors for Post-Operative VA
16635	Multivariate Cox Regression Model of RiskFactorsforPost-Operative VA
16636	Risk of Post-Operative VA With Respect to Pre-Operative VA
16637	Prolonged Ventricular Arrhythmias
16638	Causes of Death
16639	Echocardiography Data
16640	Relationship of B-Type Natriuretic Peptide to Clinicaland Echocardiographic Variables
16641	Cardiopulmonary Exercise Data
16642	Anticancer Treatment Received by Patients Prior to and During the Study Period
16643	Differences in Change in LVEF Between the Intervention and Control Groups
16644	Clinical Endpoints
16645	Examples of Recent Discoveries of Genetic Etiology of Monogenic Cardiovascular Diseases Using Next Generation Sequencing
16646	Current References on Genome-Wide Sequencing
16647	Unadjusted Odds Ratio of Age and Sex for PAD, CAS, and AAA
16648	Adjusted Odds Ratio of Age and Sex for PAD, CAS, and AAA
16649	Coefficients and Hazard Ratios From Poisson Regression Used to Predict ADHF
16650	Quantitative Angiographic Analysis
16651	In-Hospital and 30-Day Follow-Up Outcomes  (n = 164)
16652	BSA-Indexed LV Parameters per Age Group Compared With Reference Values by 1-Sample t Test
16653	BSA-Indexed RV Parameters per Sex and Age Group Compared With Reference Values by 1-Sample t Test
16654	Comparison of Ventricular Volumes and Mass Between Survivors Exposed or Unexposed to Cardiac Irradiation
16655	Intraobserver and Interobserver Variability  (Bland-Altman)
16656	Time-Dependent Multivariate Cox Regression Analysis on Endpoints Comparing Carvedilol With Metoprolol
16657	Main Outcome Measures According to Clopidogrel Dose Comparison
16658	Main Outcome Measures According to Statin Comparison
16659	Odds Ratios for the Primary Endpoint in the Clopidogrel Dose and Statin Groups According to the Factorial Design
16660	Recommendations for Competitive Sports Participation Among Athletes With Potential Causes of SCD  ( 4,29 )
16661	European Society of Cardiology Classification of Abnormalities on the Athlete's 12-Lead Electrocardiogram  ( 37 )
16662	Clinical Risk Stratification and Medications in HCM Cohort
16663	Correlation Between Change in SAS and SDS Scores and AF and Symptom Episodes
16664	Correlation Between HR, SBP, and DBP Changes and Other Measured Clinical Outcomes
16665	Differences in Clinical Outcomes at Various Compliance Levels Pre- and Post-Yoga
16666	Pre-Operative Echocardiographic Measurements
16667	Patient Variables Associated With Severe AS Alone  (Isolated AS)  Versus AS+CAD
16668	Overall Model for Incremental Risk Factors for Death After Procedure
16669	Revised Cardiac Risk Index
16670	Correlations of Computed Tomographic Findings With Post-Operative Cardiovascular Events
16671	Multivariate Analysis of Post-Operative Cardiovascular Events
16672	Comparisons of AUCs, IDI, and NRI for CTCA Parameters
16673	One-Year Mortality in Patients Undergoing Cardiac Surgery Stratified According to Pre-Operative Plasma Levels of GDF-15 and Other Risk Stratification Methods
16674	Logistic Regression for 30-Day and 1-Year Mortality
16675	Net Reclassification Improvement of Additive EuroSCORE With GDF-15 for 30-Day Mortality
16676	Hospital Admission and Mortality Rates  (95% CI)  After Heart Failure Diagnosis per 10 Person-Years
16677	Summary of Primary and Secondary Efficacy Results
16678	Individual Electrocardiographic and Echocardiographic Measurements Before and After 12 Months of Cardiac Resynchronization
16679	Patient Population  (n = 90)
16680	Prediction of Outcome Using QRS Duration
16681	Observed Annualized Event Rate According to QRS Duration
16682	Surrogate End Points
16683	Clinical End Points
16684	ST-Segment Resolution and 6-Month Clinical Outcome
16685	Predictors of Early ST-Segment Resolution and MACCE
16686	Rate of Adverse Events, Stratified by Quartiles of Hospital Annual ICD Volume
16687	Odds Ratios of Any Complication Comparing the Lowest 3 Quartiles of Hospital Annual ICD Volume With the Highest Volume Quartile
16688	Fully Adjusted ORs of Any Complication Comparing the Lowest 3 Quartiles of Hospital Annual ICD Volume With the Highest Volume Quartile as the Reference Group
16689	Definition of Lipid Parameter Combinations in MESA 2000 to 2002
16690	Mean, Minimum, and Maximum Values for HDL-C, LDL-C, and Triglycerides for Each Lipid Parameter Combination in MESA 2000 to 2002
16691	Age-Adjusted Annual Rate of CV Events  (MI, CHF, Stroke, TIA, or Death)  Among Participants With and Without Specific Depressive Symptoms
16692	Bivariate and Multivariate Associations of Specific Depressive Symptoms  (Entered as Continuous Variables)  With CV Events
16693	Exercise Performance
16694	Cardiovascular Reserve Responses at Peak Exercise
16695	Relationships Between Reserve and Peak Exercise Capacity or Symptoms at Matched Low-Level Workload  (20 W)
16696	Breakdown of Events Contributing to Overall MACE Rate in 217 HCM Patients With and Without Fibrosis
16697	Various Approaches/Incisions of Minimally-Invasive Valve Surgery
16698	STICH SVR Hypothesis Assessment of CABG Plus SVR Versus CABG in Subgroups Defined by RAR
16699	Significant Covariates in the RAR Multivariate Model
16700	Hemodynamic Parameters Before and After LVAD Unloading
16701	Correlation Matrix Showing Inter-Relationships Between Measures of Reflection and Their Timings
16702	Univariate and Multivariate Cox Regression Models of Predictors of Cardiovascular Events
16703	Multivariate Linear Regression Analysis of the Relationship Between Measures of Wave Reflection and Measures of Left Ventricular Structure and Function
16704	Index  (First)  and Total Adverse Events During Follow-Up
16705	Decreasing LogCFR and Risk for Adverse Outcomes
16706	Multivariate Modeling of Major Events
16707	Association With and Without Cardiovascular Events
16708	Clinical Laboratory Data for Those Patients Who Completed All Clinic Visits
16709	Lipid Profile Data for All Patients Who Completed All Clinic Visits
16710	Major Adverse Cardiac Events  *
16711	Adverse Events
16712	Intravascular Ultrasound Parameters
16713	Comparison of the Changes in IVUS Parameters in Lipid Sciences Selective Delipidation Trial, ApoA-I Milano Trial, and REVERSAL Trial
16714	Multiple Regression Predicting FMD Within Caregivers
16715	Cardiovascular Magnetic Resonance Results
16716	Univariable and Multivariable Linear Regression Analysis for the Prediction of MSI
16717	Predictors of Major Adverse Cardiac Events in Univariable and Stepwise Multivariable Cox Regression Analysis
16718	Acute and Delayed Major and Minor Complications Related to Epicardial and Endocardial VT Ablation
16719	Electrogram and Electroanatomical Mapping Data
16720	Distribution of LP in Low Voltage Area
16721	Results of Mapping and Ablation
16722	Predictors of Complicated 30-Day Outcome
16723	ROC Curve Analysis of Variables
16724	Results of Multivariate Regression Model Incorporating Rhythm-Control Strategy
16725	Results of Multivariate Regression Analysis Incorporating Cardiac Rhythm Status
16726	Quality of Life Improvements Over Time in Patients Implanted With the HMII
16727	Neurological Complications and Deaths Within 30 Days After Carotid Stenting
16728	Logistic Regression Analysis for the Presence of Ischemic Heart Disease in Female Patients Complaining of Chest Pain
16729	Adjusted AUC for Different Models, With 95% Confidence Interval for Difference in Adjusted AUC Comparing Various Models With TRF-Only Model
16730	Number and Percent Reclassified in CHD Risk Categories and Observed CHD Risk  ⁎  When CIMT and Plaque Information Are Added to Traditional Risk Prediction Models  (Overall Sample)
16731	Number and Percent Reclassified in CHD Risk Categories and Observed CHD Risk  ⁎  When CIMT and Plaque Information Are Added to Traditional Risk Prediction Models  (Men)
16732	Number and Percent Reclassified in CHD Risk Categories and Observed CHD Risk  ⁎  When CIMT and Plaque Information Are Added to Traditional Risk Prediction Models  (Women)
16733	NRI Using Various Comparison Models in Overall Sample, Men, and Women
16734	Indexes of LV Function at Initial and Most Recent Evaluation in the 114 Olympic Athletes
16735	Cardiac Dimensions at Initial and Most Recent Evaluation in the 114 Olympic Athletes
16736	Echocardiography Measurements
16737	Left Ventricular Physiology 3 Weeks After Transaortic Constriction
16738	AC6 Knockdown, Phenylephrine, and Cardiac Myocyte Size
16739	Diagnosis and Outcomes in 189 Patients
16740	Multivariable Probability/Hazard Analysis for Death or Transplantation
16741	Post-Operative Risk Factors by Presence of Atrial Fibrillation
16742	Discharge Medications by Presence of Atrial Fibrillation
16743	Atrial Fibrillation as a Predictor of Mortality Among Different Subgroups
16744	Clinical Features in Family EI
16745	Genes Residing in 5.7-Mb Region of Linkage
16746	ACTN2Variants Identified in Australian HCM Population Studied
16747	Summary of the Clinical Features in Australian HCM Families With ACTN2Mutations
16748	Carotid PP: Multiple Regression Analysis in Step 1
16749	Adjusted Risk of All-Cause Mortality and CV Mortality Associated With the Increase of 1 SD of Brachial PP, Carotid PP, and C/B Ratio
16750	Study Population and Comparisons According to the Presence of PAD at Each Anatomic Level
16751	Association Between Proximal Peripheral Arterial Disease and Prognosis
16752	Association of Peripheral Arterial Disease Localization and Fatal and Nonfatal Cardiovascular Events in Patients With a Single-Level Disease  (n = 130)
16753	Independent Predictors of AF Progression Resulting From Multivariate Logistic Regression Analysis
16754	Echocardiographic Parameters
16755	Aortic Dimensions of the Bicuspid Aortic Valve Population Assessed by Cardiac Magnetic Resonance Imaging
16756	Vascular and Humoral Parameters
16757	Unadjusted Odds Ratios for Peripartum Cardiomyopathy
16758	Final Statistics of the Forward-Selection Logistic Regression Analysis
16759	Stratified Odds Ratio of Peripartum Cardiomyopathy for African Americans
16760	Relative Risk of African-American Descent for Peripartum Cardiomyopathy in This and Other Studies
16761	Correlation Between ET-1 and Inflammatory Mediators
16762	Task Force Diagnostic Criteria for ARVC
16763	PKP2Gene Variants Identified in Patients With ARVC
16764	Heterozygous Mutations Identified in Desmosomal Genes Other Than PKP2
16765	Comparison of Lead Placement Strategies
16766	Basic Patient Data and Chronotropic Autoantibody Positivity in Chronic Chagas' Disease
16767	Associations of Ankle Brachial Index Categories With Left Ventricular Mass
16768	Relative Strength of Association of Risk Factors for Left Ventricular Mass
16769	Associations of High ABI With LV Morphology and Function
16770	Examples of Emotional and Physical Stressors Triggering Heart Failure in SC Patients
16771	Patients With Recurrence of SC
16772	Multivariable Associations With Subsequent Heart Failure
16773	Maternal Adverse Cardiovascular Outcomes During Pregnancy
16774	Predictors of Adverse Cardiac Events in Pregnant Women With Dilated Cardiomyopathy
16775	Obstetric and Fetal Outcomes
16776	Primary End Point Events by Randomized Therapy
16777	Cholesterol and CRP Among Patients With No Events, a Single Event, or Multiple Events  *
16778	Health State Utilities and Costs
16779	Clinical Outcomes in 55-Year-Old Men and Women With Chest Pain
16780	Health Care Costs in 55-Year-Old Men and Women With Chest Pain
16781	Changes in Body Composition, Physical Activity, and Biological Markers During the 3-Month Exercise Program in Obese Children  (Intention-to-Treat Analysis)
16782	Changes in Blood Pressure, Cardiorespiratory Fitness, and Arterial Function Parameters During the 3-Month Exercise Program in Obese Children  (Intention-to-Treat Analysis)
16783	Effect of Statin Therapy on Lipids and CRP
16784	Outcomes by Statin Therapy Among Patients With PCI for Index Event
16785	General Features of FVB and ALDH2 Mice With or Without Acute Ethanol Challenge
16786	Relationship Among Infarct Location  (LAD vs. Non-LAD)  and Time to Treatment, Infarct Size, and LVEF
16787	Influence of Time to Reperfusion on Left Ventricular Function Assessed by CMR
16788	Left Ventricular Function After Primary Angioplasty and at Follow-Up
16789	Relation of Cardiovascular Risk Factors to iLA
16790	Partition Values for Different Indexing of Left Atrial Volume
16791	Crude Prevalence of LAE
16792	Relation of Volume and Pressure Load to Indexed Left Atrial Volume
16793	Relationship of Stent Gap by CTA to ISR by CCA
16794	Blood Markers  ⁎
16795	MRI Data
16796	HCM Subjects  (n = 100)
16797	HCM and Control Patients
16798	Multivariate Analysis of In-Hospital Mortality in the Propensity-Matched Cohort
16799	Multivariate Analysis of Post-Operative Inotropic Support in the Propensity-Matched Cohort
16800	Multivariate Analysis of Post-Operative Renal Dysfunction in the Propensity-Matched Cohort
16801	Multivariate Analysis of Post-Operative Atrial Fibrillation in the Propensity-Matched Cohort
16802	Multivariable Cox Regression Models of Relation of Traditional Risk Factors and Central and Brachial PP Quartiles to Cardiovascular Outcome
16803	Performance of Central PP ≥50 mm Hg for Prediction of Cardiovascular Outcome in Population Subsets
16804	Complications Related to No Stress Versus Stress Cardiovascular Magnetic Resonance
16805	Indications, Image Quality, and Complications Related to Patient Age
16806	Impact of CMR on Patient Management
16807	Impact of CMR on Patient Management by Indication
16808	Additional Diagnostic Procedures Avoided Due to Results of CMR
16809	Clinical Status of Patients With HCM
16810	LV Structure in the Control Group and in Patients With HCM
16811	LV Function in the Control Group and in Patients With HCM
16812	LV Function Before and After Septal Ablation
16813	Effect of PON-1 Genotypes on Clinical Outcome
16814	Angiographic/PCI Findings for Patients Randomized to PCI + OMT
16815	Primary and Secondary Outcomes by Treatment Arm and Age Group
16816	Lifestyle Outcomes: Patients at Target by Age Group  (60-Month Follow-Up)
16817	Electrophysiologic Effects of IgG  (n = 14)
16818	Univariate and Multivariate Logistic Regression Analyses for 14 Variables
16819	Doppler Echocardiographic and Systemic Arterial Indexes of Valvular Load, Arterial Load, and Global LV Hemodynamic Load According to the Level of Zva
16820	Doppler Echocardiographic Data of LV Geometry and Function According to the Level of Zva
16821	Univariate and Multivariate Analysis of Predictors of Overall Death in the Total Cohort  (544 Patients)
16822	Phenotypic and Genetic Data for Families With DCM
16823	Multiple Regression Analysis Between Direct Sympathetic Nerve Activity and QT Data After Pacing-Induced CHF
16824	Data of Surviving Versus Nonsurviving Pediatric Heart Transplant Recipients Rescued With ECMO Support for Early Post-Operative Graft Failure
16825	Perioperative Data of Pediatric Heart Transplant Recipients Rescued With ECMO Support for Early Post-Operative Graft Failure Compared With the Overall Transplant Population
16826	Outcome Data of Survivors Rescued With ECMO Support for Post-Operative Graft Failure Compared With the Overall Transplant Population
16827	Stepwise Multiple Regression Analysis of Central Pressures and Hemodynamic Variables
16828	Comparison of Central Pressures and Hemodynamic Variables Between BP-Lowering Treatment Arms Before and After Adjustment for Heart Rate
16829	Impact of Cerclage Tension on Annular and Left Ventricular Dimensions  (n = 16)
16830	Measures of Mitral Valve Regurgitation and Leaflet Function Before and After Application of Cerclage Tension  ⁎
16831	Leaflet Function and Annular Motion Before and After Application of Cerclage Tension in Pigs With Secondary Mitral Regurgitation  (n = 5)
16832	Enhanced Reciprocal Constraint of LVOT and MVA During Application of Cerclage Tension  (n = 10)
16833	Associations Between Sotalol and Ventricular Arrhythmias in ARVC
16834	Echocardiographic Data
16835	Echocardiographic Data in ARVD/C Patients With and Without RV Dyssynchrony
16836	Clinical Events During Follow-Up
16837	Univariate and Multivariate Predictors of All-Cause Mortality
16838	Univariate and Multivariate Predictors of All-Cause Mortality or Severe Symptoms
16839	MRI Parameters in HCM Patients and Control Subjects
16840	Prevalence of Adult Risk Factors of Sudden Death
16841	Univariate and Multivariate Logistic Regression Analysis Testing the Association Between Myocardial Scarring and Various Parameters
16842	Cumulative Incidence of Definite Stent Thrombosis
16843	Adjusted Hazard Ratios for Pair-Wise Comparisons Between Stents
16844	Angiographic and Procedural Data
16845	Intravascular Ultrasound Data
16846	Major Diagnostic Categories for Congenital Heart Disease Patients Undergoing Heart Transplantation
16847	Multivariable Analysis for Risk Factors Associated With Both Early Phase and Constant Phase Mortality in Patients With Congenital Heart Disease
16848	Mortality Rates for Nonresponders Versus Responders at 31 and 180 Days  ⁎
16849	Statistical Analysis: Prediction of Mortality by Percent Change in BNP at Day 5 Versus Absolute BNP Level
16850	Rates of Reported Serious Adverse Events  (in Percentages)  in Nonresponders and Responders  (Entire Study Period)
16851	Laboratory Values, Anticoagulation, Bleeding, and Thrombotic/Neurological History in HMII-Treated Patients Before and After HTx
16852	Basic Laboratory Values of HMII-Treated Patients Before and After HTx and Patients With CHF
16853	Change in Magnetic Resonance Imaging Signal Intensity, Microemboli Count, and Lipid Profiles
16854	Primer Sequences for the Renin-Angiotensin-Aldosterone System Genotype Assays
16855	Echocardiographic and Hemodynamic Data
16856	Frequency of High-Risk Alleles  (n = 103)
16857	Anatomic Sites of Origin of Focal Atrial Tachycardia for Entire Study Population
16858	Unadjusted and Adjusted Results From Time-to-Event Analyses for Pre-Specified End Points
16859	Selected Pre- and Post-PCI Indicators and Peak Biomarkers According to Q-Wave and Time From Symptom Onset to PCI
16860	Univariate and Multivariate Predictors of Death/Cardiac-Related Emergency Hospital Admission
16861	Insulin Therapy, Nutrition, and Early AMI Complications
16862	Glucose-Lowering Treatment and Metabolic and Echocardiographic Parameters
16863	Clinical Features on Admission of Patients With Stress Cardiomyopathy
16864	Details of Genotyping
16865	Demograhics, Prior Symptoms, Family History, and Fulfillment of the Task Force Criteria  ( 19 )  in the Study Population
16866	Electrical and Structural Abnormalities in the Study Population
16867	Ability of the Task Force Criteria to Discriminate Between Family Members With and Without a Desmosomal Mutation Before and After Inclusion of the Accordion Sign as a Minor Criterion Under “Structural Abnormalities”
16868	Volumetric Assessment of Vascular Geometry and Progression of Allograft Vasculopathy During 12-Month Follow-Up  (n = 38)
16869	Comparison of MRI Findings Between Control and DMD Groups
16870	Sensitivity, Specificity, PPV, NPV, and AUC Data of NCEP and NHANES Classifications for Adolescent Borderline- and High-Risk Lipoprotein Variable Cut Points to Predict High Carotid IMT in Adulthood
16871	Sensitivity, Specificity, PPV, NPV, and AUC Data for Combining NCEP High-Risk Lipoprotein Variable Cut Points to Other Risk Factors Present in Adolescence to Predict High Carotid IMT in Adulthood
16872	Relative Risks From Pooled Data for the Effect of Change in LDL-C and Change in HDL-C Status Between Adolescence and Adulthood on Carotid Artery IMT ≥90th Percentile
16873	Left Atrial Sites Where CFAEs Were Ablated in All Patients
16874	TWA During Laboratory Mental Stress
16875	Predictive Value of Anger-Induced TWA and Clinical Variables for Occurrence of VT/VF
16876	Results for Measures of Cardiac Magnetic Resonance Imaging After 5 Days
16877	Safety Data and Clinical Outcomes
16878	Cardiovascular-Related Serious Adverse Events
16879	Clinical Features of Overall Sample and According to Endomyocardial Biopsy Findings
16880	Noninvasive and Invasive Instrumental Findings of Overall Sample and According to Endomyocardial Biopsy Findings
16881	Actuarial Event Rates by Group Assignment
16882	Comparison of the Performance of Various Potential Risk Stratification Strategies Derived From the Pre-Specified 1-Year Primary End Point Event Rate  (n = 39)  of the ABCD Population  (n = 566)
16883	Comparison of Patient Groups
16884	LGE Relationship to Left Ventricular Parameters
16885	Depression-Related Differences in Age and Coronary Artery Disease Severity Score Adjusted Health Care Costs by Cost Category
16886	5-Year Cardiovascular Costs by Depression Status and Presence/Absence of Significant CAD
16887	Clinical and Hemodynamic Parameters of Patients With Serological Analyses
16888	Clinical and Hemodynamic Parameters of Patients With Gene Expression Analysis
16889	The Relationship of LV End-Diastolic Volume and Mass to CHD Events
16890	The Relationship of LV End-Diastolic Volume and Mass to Stroke Events
16891	The Relationship of LV End-Diastolic Volume and Mass to HF Events
16892	Magnetic Resonance Study Parameters
16893	Univariate Correlations Between Diastolic Function and Anthropometric and Biochemical Markers and Fat Compartments
16894	Multivariable Associations Between E/A and Myocardial Triglyceride Content
16895	Clinical Presentation and Hospital Course
16896	Primary and Secondary Outcomes, Unadjusted
16897	Logistic Regression Model of Predicting Reoperation
16898	Relationship Between Clopidogrel and Transfusion and Chest Tube Output, Unadjusted
16899	Improvement in Functional Parameters by 3 Months in Relation to Changing Preferences
16900	Trial Outcome Events
16901	MTWA Prediction for VTE Within Subgroups
16902	Comparison of VTE Between MTWA Positive, Negative, and Indeterminate Groups
16903	Blood Velocity and Vessel Diameter Values for the Native and PEM-Treated UnA After 2, 4, 7, and 10 Weeks of Implantation
16904	Linear Regression Analysis Model of Factors Affecting the IMTmean of BIFmean of the Study Population  (N = 1,011)
16905	Predictors of Triggers
16906	Cellular Origins of MPs Isolated From Human Atherosclerotic Plaque Between Asymptomatic and Symptomatic Patients
16907	Mutation Type, Position  (Exons and Class With Respect to the NLS Region) , Clinical Phenotypes, and Rate of Events per Family
16908	Data at Time of First Diagnosis: Prognostic Factors for Events in 94 Patients With LMNA Mutations at Univariable Analysis
16909	Identification of Prognostic Factors of Events in 94 Patients With LMNA Mutations: Multivariable Cox Model  ⁎
16910	Data at Time of First Diagnosis: Prognostic Factors of SCD in 94 Mutated Patients at Univariable Analysis  ⁎
16911	Main Clinical and Procedural Features
16912	Predictors of the Primary and Secondary Outcomes
16913	Hierarchical Multivariate Regression for LA Dilation
16914	Hierarchical Multivariate Regression for LV Hypertrophy
16915	In Vivo ΔT of Aortic Valves in Patients With AVS and AVI
16916	Immunohistological Analysis of Aortic Valve Leaflets Between the 2 Groups of Patients
16917	Semiquantitative VEGF Immunoreactivity Between Leaflets of Patients With AVS and Patients With AVI
16918	Effects of 2 Weeks of Ang II Administration on Cardiac Function in WT and MT-TG Mice
16919	PREPARE VT/VF Programming Parameters
16920	ICD Detection and Therapy Programming
16921	Primary and Secondary End Point Analyses by Propensity Score Quintile
16922	Syncopal Adverse Events in the PREPARE Study Patients
16923	Clinical Features in 264 Patients With HCM and CMR
16924	CMR Findings According to Gender in 264 HCM Patients
16925	Extent of Atherosclerosis in Japanese, White, and Japanese-American Men in 2002 to 2006
16926	Serum Levels of Fatty Acids in Japanese Men, White Men, and Japanese-American Men in 2002 to 2006
16927	Multivariable-Adjusted Associations of Marine n-3 Fatty Acids With Intima-Media Thickness and Prevalence of Coronary Artery Calcification in Japanese Men, White Men, and Japanese-American Men
16928	Multivariable-Adjusted Mean Differences in Intima-Media Thickness and Prevalence of Coronary Artery Calcification Between Japanese Men and White Men
16929	Association of the C Allele of rs1333049 With Carotid Atherosclerosis and CVD in the Bruneck Study
16930	Results of CTA According to Gender
16931	Predictors of Subclinical Coronary Atherosclerosis on CTA
16932	Bivariate Relations Between Childhood/Adolescence Apolipoproteins and Lipids on Adulthood Carotid IMT Measured 21 Years Later
16933	Bivariate Relations Between Childhood/Adolescent Apolipoproteins and Lipids on Adulthood Brachial FMD Measured 21 Years Later
16934	Clinical Profile of the Whole Study Population and of the Surgical Subgroup
16935	Main Features of All Studied Carotid Plaques and of Surgical Lesions Only
16936	Detection of Thrombus by CMR
16937	Thrombus Morphology
16938	Risk-Adjusted Hazard Ratios  (95% Confidence Intervals)  for Death According to CAC Scores Within Separate Models by Age Decile
16939	Risk-Adjusted Hazard Ratios  (95% Confidence Intervals)  From an Interaction of Gender by CAC Score in Age Decile Subsets
16940	Cost Analysis to Identify 1 New High-Risk Case and 1 Death Among Low-Intermediate Risk Patients
16941	Relations of Brachial and Carotid Pressures to LV and Carotid Remodeling
16942	Predictors of Cardiovascular Events
16943	Independent Predictors of Cardiovascular Events
16944	Number of Index and Cumulative Events Grouped by Presence or Absence of CMR LGE
16945	Cox Proportional Hazards Analysis for the Time to Occurrence of an Index Composite Cardiac Event
16946	Univariate and Multivariate Cox Analyses of the Incidence of Death or Readmission for HF
16947	Comparison Between Black Athletes, White Athletes, and Black Control Subjects
16948	Clinical, Angiographic, and CMR Data of Patients With or Without Early Systolic Retrograde Flow on Coronary Flow Velocity Pattern
16949	Clinical, Angiographic, and CMR Data According to the Presence and Extent of MO Measured by CMR
16950	Coronary Flow Velocity Data and Hemodynamics According to the Presence and Extent of MO Measured by CMR
16951	Uni- and Multivariate Logistic Regression Analysis for the Relation Between CMR Parameters and the Presence of Early Systolic Retrograde Flow
16952	Uni- and Multivariate Linear Regression Analysis for the Relation Between CMR Parameters and the Diastolic Deceleration Rate
16953	Sensitivity and Specificity of the Binary Endocardial Appearance
16954	Previous Pediatric ICD Retrospective Series
16955	Age at First ICD Implantation
16956	ICD-Related Complications
16957	Effect of Darapladib on Lipid Parameters
16958	Effect of Darapladib on Inflammatory Biomarkers
16959	Effect of Darapladib on Platelet-Related Biomarkers
16960	Relevant Data About Animals 1 to 6
16961	Hemodynamic Data Throughout the Experiment
16962	Incidence and HRs of Heart Failure by Presence of Diabetic Retinopathy, the Atherosclerosis Risk in Communities Study
16963	Echocardiography: Effects of Increased ACVI Expression
16964	Basal Left Ventricular Function: Effects of Increased ACVI Expression
16965	Echocardiography: Nontransgenic C57BL/6 Mice ± Doxycycline
16966	Comparison of Patients Operated in the 1990 to 1999 Era and the 2000 to 2005 Era
16967	Predictors of Overall Mortality on Univariate Analysis in the 217 Patients in the Study
16968	Percentage of Segments Showing Hypoxia or CD68 Immunoreactivity
16969	Presumptive Causes for All Post-Randomization Syncopal Episodes  (458 Episodes Among 356 Patients)
16970	Univariate Predictors of Syncope Post-Randomization
16971	Syncope After Randomization Predicts Death
16972	Clinical Data and Risk Factors  (175 Patients)
16973	Strandness Criteria
16974	Prevalence of Plaque Components Based on 260 Arteries Grouped by Duplex Categories
16975	Correlation of Quantitative Plaque Area Measurements With the Occurrence of Complicated Plaque Features Based on 260 Arteries
16976	Distribution of Athletes in Relation to Sporting Discipline
16977	Echocardiographic Features in Athletes With Left Ventricular Wall Thickness >12 mm
16978	Echocardiographic and Cardiopulmonary Exercise Parameters in Athletes With Left Ventricular Hypertrophy and a Nondilated Left Ventricular Cavity Size
16979	Univariate and Multivariate Association Between Risk Factors, FMD, and Cardiovascular Events in Our Population of 2,264 Women
16980	Cardiovascular Event Rates and Association Between FMD Tertiles and Cardiovascular Events in Our Population
16981	Major Eligibility Criteria
16982	Pivotal Group Patient Qualification by High-Risk Criteria
16983	Primary End Point—Pivotal Group
16984	Adverse Event Rates in the BEACH Pivotal Group Symptomatic and Asymptomatic Patients
16985	Late Neurologic Events
16986	Internal Carotid Artery Maximum Peak Systolic Velocity
16987	Hemodynamic Measurements at Cardiac Catheterization
16988	Catheterization Criterion
16989	Adverse Short-Term Events in Admitted and Discharged Patients
16990	Reasons and Time of Death, Age, and Gender of Each Patient Who Died Within 10 Days From the Emergency Department  (ED)  Visit
16991	Major Therapeutic Procedures and Early Readmission Within 10 Days From Syncope
16992	Risk Factors for Severe Short-Term Outcomes Within 10 Days  (Univariate and Multivariate Analysis)
16993	Risk Factors for Severe Outcomes From the 11th Day Up to 1 Year After the ED Visit  (Univariate and Multivariate Analysis)
16994	Causes of Death From 11th Day Up to 1 Year After the Emergency Department Visit
16995	Hospital Admission Adjusted With Long-Term Risk Factors  (Logistic Regression)
16996	LL, Follow-Up %DS, and 1 Year TLR Rates
16997	Z-Scores  ⁎   for Treatment Difference in LL and Follow-Up %DS) , Each for In-Stent and In-Segment, and TLR for 11 Randomized Trials of Drug-Eluting Stents
16998	c-Statistics Summarizing the Strength of Association of TLR With Each of the 4 Potential Surrogate End Points With Data for All Patients  (Both Groups Combined)  in Each Trial
16999	Comparison of Actual and LL-Predicted Numbers of Patients With TLR in 22 Treatment Groups in 9 Trials, Based on Logistic Model Corrected for Vessel Size
17000	The Percentage of Treatment Effect on TLR Explained by Each of 4 Potential Surrogate Outcomes  ⁎   in the 5 Largest Trials Comparing Drug-Eluting and Bare-Metal Stents: Percent Treatment Effect Explained
17001	Multivariate Analysis
17002	Occurrence of Post-Operative AF According to Quartiles of Atrial NADPH Oxidase Activity
17003	Summary of the Enzymatic and Genetic Screening of the Index Patients
17004	Genotype and Phenotype in the Index Patients With Low Enzymatic Activity
17005	Relationship Between Statin Use and Biochemical Parameters
17006	Association Between MCP-1 Levels at 4 Months and Events From 4 Months Through End of Study
17007	Hazard Ratios Comparing 80 mg Versus 20 mg Simvastatin Stratified by 4-Month MCP-1 Levels
17008	Relationship Between Depression Group and Inflammatory Biomarkers
17009	Relationship Between Depression Group, CRP, and CVD Incidence
17010	Events During Follow-Up
17011	Role of TWA Tests  (Abnormal vs. Normal)  on the End Points
17012	Surgical Procedures
17013	Hemodynamic Variables at Cardiac Catheterization
17014	Factors Associated With Lower Weight-for-Age Z-Scores
17015	Kaplan-Meier Mortality Estimates for All GUSTO-I Trial 30-Day Survivors in the U.S. Based on Events During Index Hospitalization
17016	30-Day and Long-Term Mortality for All GUSTO-I Trial Patients in the U.S. Stratified by Shock Status and Age
17017	Multivariable Cox Regression Model for All GUSTO-I Trial 30-Day Survivors in the U.S.
17018	Comparison of Long QT Syndrome Patients With and Without a Device
17019	Primer Sequences
17020	HR by Cox Regression Analysis for a Composite of Death From Any Cause or Hospitalizations for Worsening Heart Failure From Day 31 After CABG to the End of Follow-Up Period
17021	Clinical Outcome From Day 31 After CABG to End of Follow-Up Period in 4 Groups of Patients According to Degree of Post-CABG Dyssynchrony and Myocardial Viability
17022	Severity of Heart Failure in UNOS Status 1 and 2 Candidates for Heart Transplantation Across Eras: I = 1990 to 1994, II = 1995 to 1999, and III = 2000 to 2005: U.S. Scientific Registry for Transplant Recipients  (n = 48,982)
17023	One-Year Outcomes of the Waiting List in UNOS Status 1 and Status 2 Candidates for Heart Transplantation Across Eras: I = 1990 to 1994, II = 1995 to 1999, and III = 2000 to 2005: U.S. Scientific Registry for Transplant Recipients  (n = 48,982)
17024	Multivariable Analysis of Risk Factors for Death Within 2 Months After Listing of UNOS Status 1 Candidates for Heart Transplantation: U.S. Scientific Registry for Transplant Recipients: Years 2000 to 2005  (n = 5,451)
17025	Multivariable Analysis of Risk Factors for Death Within 2 Months After Listing of UNOS Status 2 Candidates for Heart Transplantation: U.S. Scientific Registry for Transplant Recipients: Years 2000 to 2005  (n = 6,937)
17026	Multivariate Predictors of Total Mortality
17027	OCT, CAS, and IVUS Findings for Corresponding Images
17028	OCT Findings of the Culprit Lesion in 30 Patients With AMI
17029	Range of Values of Markers for RDS
17030	TBR Variability Over 2 Weeks
17031	Intraclass Correlation Coefficient Values  (95% Confidence Intervals in Parentheses)
17032	Task Force Criteria in the Study Population
17033	Details of Electrophysiology Catheter Ablation Procedure and VT Recurrence
17034	Clinical and Hemodynamic Data of Patients With DCM and ICM
17035	Univariate and Multivariate Cox Proportional Hazards Analyses of Clinical End Points in Relation to Cardiac Magnetic Resonance Variables
17036	Agreement Between TWA and EPS Results
17037	2-Year Event Rates and Univariate Hazard Ratios
17038	Hemodynamic Function During the Procedures
17039	Procedural Data
17040	Procedural MACCE  ⁎   (Nonhierarchical)
17041	30-Day Clinical Outcome
17042	Final Multivariable Model for Cardiovascular Death or Heart Failure Hospitalization in the CHARM Cohort  (Including Laboratory and Clinical Variables)
17043	Final Multivariable Model for All-Cause Mortality in CHARM Cohort  (Including Laboratory and Clinical Variables)
17044	Final Multivariable Analysis for All-Cause Mortality From Duke Databank Cohort
17045	Results of Genotyping in Probands With “Restrictive Phenotype”
17046	Echocardiographic/Doppler Findings in 31 Family Members Who Carried a Mutation
17047	Haplotypes Around the LMNA Gene
17048	Multiplex Ligation-Dependent Probe Amplification Normalized Peak Area Ratios of the LMNA Gene
17049	Linear Regression Analysis: Depending Variable EPC Number
17050	Linear Regression Analysis: Depending Variable EPC Function  (Migratory Capacity)
17051	Linear Regression Analysis: Depending Variable CFU-GM
17052	Incremental Risk Factors for Death
17053	Noninvasive Evaluation
17054	Electrophysiological Study Findings
17055	Resource Consumption and Cost Calculations for Testing
17056	Diagnostic Outcome
17057	Cost of Testing and Sensitivity Analysis
17058	Muscular Dystrophy Diagnosis and Treatment
17059	Cardiovascular Magnetic Resonance Ventricular Function and Creatine Kinase Levels in Muscular Dystrophy With and Without Myocardial Fibrosis
17060	Segmental LV MF Distribution
17061	Mortality Rate and Hazard Ratio in WBC Count Groups
17062	Mortality Hazard Ratio Comparing WBC Count Groups From the Longitudinal Time-Dependent Model
17063	Prevalence of CAC Scores by Vascular Territory
17064	Univariable Predictors of Death From All Causes—in Reverse Order by Chi-Square Value
17065	Prevalence of CAC by Dataset
17066	Risk-Adjusted Models for All-Cause Death
17067	Assessment of the Quality of the 7 Included Studies
17068	Clinical Variables Stratified by Quartiles of SUV
17069	Multiple Stepwise Regression Analysis for Factors Associated With SUV of FDG Levels in Carotid Artery
17070	Factors Associated With Severe LV Dysfunction  ⁎
17071	Risk Factors for Mortality in the Entire Group
17072	Correlation of PW Doppler and CW Doppler Velocities and Time Intervals
17073	CW Doppler Flow and TDI Parameters in Patients With OHCM, Patients With NOHCM, and Control Subjects
17074	Doppler Parameters Before and After Gradient Abolition With Disopyramide
17075	Dyssynchrony: Lateral-Septal Delay in Onset of Contraction, Peak of Contraction Velocity, and End of Contraction  (in ms)  in Patients With OHCM, Patients With NOHCM, and Control Subjects
17076	Lateral-Septal Delay in Onset of Contraction, Peak of Contraction Velocity, and End of Contraction in OHCM Patients Before and After Successful Gradient Abolition
17077	Underlying Cause/Type of SVC Obstruction
17078	Symptoms and Indications for SVC Intervention
17079	Hemodynamic Data at Initial and Follow-Up SVC Interventions
17080	Events in IHD and Non-IHD Subgroups and Interaction Between Study Medication and Subgroups
17081	Arterial Measurements in CoA Subjects and in Control Subjects
17082	Arterial Measurements in Subtypes of Aortic Arch Geometry and in Control Subjects
17083	Electrocardiographic Features of the Study Population
17084	Unadjusted Analysis of Hazard Ratio for All-Cause Mortality
17085	Cardiovascular Magnetic Resonance Imaging Measurements of the Study Population
17086	Multivariable Associations With All-Cause Mortality
17087	In-Hospital and Follow-Up Results
17088	Comparison in MP Cellular Origins Between Asymptomatic and Symptomatic Plaques
17089	Hemodynamic and Echocardiographic Parameters
17090	Ejection Fraction and Strain Echocardiographic Data
17091	The Most Important Features of the Implanted Valves
17092	Echocardiographic Data
17093	Summary of Results for Hemoglobin and Exercise End Points
17094	Health-Related Quality of Life
17095	Adverse Events
17096	Correlations Between ROCK Activity Before and After L-NMMA and Variables
17097	Correlations Between the Ratio of SNP-Stimulated Maximal FBF to Basal FBF and Variables
17098	Correlations Between Endothelial Function and Variables
17099	Correlations Between Pulse Wave Velocity and Variables
17100	Diagnostic Procedures
17101	Interventions Performed/Planned at Enrollment
17102	Treatment in Relation to Symptoms
17103	Drug Therapy at Discharge in Patients Discharged Alive
17104	Intracardiac Repolarization Alternans Prevalence and Magnitude During Atrial Pacing
17105	Episodes of Discordant Intracardiac Alternans
17106	Study End Points
17107	Stepwise Logistic Regression Analysis for Predictors of Post-CABG AF
17108	Summary of Study End Points for ICD and Non-ICD Patients Stratified by MTWA Test Status
17109	Summary of Unadjusted and Adjusted Cox Proportional Hazards Models
17110	Logistic Regression Model for Propensity Score Based on Likely Variables Predicting ICD Placement
17111	Comparison of Cardiovascular Symptoms Between Hyperthyroid and Control Cohorts
17112	Comparison of Hemodynamic Parameters Between Hyperthyroid and Control Cohorts
17113	Comparison of Electrocardiogram and Holter Data of Hyperthyroid Patients With Matched Controls
17114	Comparison of Electrocardiogram and Holter Data Between Patients With Biochemical Subclinical Hyperthyroidism During Follow-Up With Matched Controls
17115	Comparison of Electrocardiogram and Holter Data Between Patients Rendered Euthyroid at Follow-Up With Matched Controls
17116	Detailed Description of HCM Mutation Carriers
17117	Inclusion and Exclusion Criteria  ( 6 )
17118	Therapeutic Considerations  ( 6 )
17119	Coronary Angiography, Revascularization, and Events
17120	Relative Risks for Cardiac Events Based on Gated ADSPECT Variables
17121	Multivariate Predictors of Risk
17122	Cost Analysis and Length of Hospital Stay in the INSPIRE Risk Groups
17123	Unadjusted and Adjusted Cox Regression Models for Predicting New Cardiovascular Events
17124	Clinical Data for the 13 Patients
17125	Equations Using Oxygen Consumption  (Vo 2)  to Calculate Hemodynamics and Oxygen Transport Parameters
17126	Systemic Hemodynamic Condition and Oxygen Transport Before and After Termination of Dopamine in 13 Neonates During the Early Period After the Norwood Procedure
17127	Procedural Data and Angiographic Results
17128	Electrocardiographic Analysis
17129	Classifier Gene Set in DCM
17130	rhNRG-1 Inhibits Renin Angiotensin System-Activation Due to LAD Ligation
17131	rhNRG-1 Given 2 Months After LAD Ligation Improves Hemodynamics
17132	rhNRG-1 Does Not Alter Echocardiographically Determined Cardiac Dimensions or Function in Normal Rats
17133	rhNRG-1 Protects Against Doxorubicin and Coxsackie B3-Induced Cardiac Dysfunction and Myocardial Cell Damage
17134	rhNRG-1 Does Not Alter Hemodynamics or Cardiac Contractility in Normal Dogs
17135	Task Force Criteria for the Diagnosis of ARVD/C
17136	Medication During the Study of Patients Randomized to the Acute Versus Routine Serial Cardioversion Group
17137	Medication During the Study of Patients Randomized to the Digoxin Versus Verapamil
17138	Predictors of Occurrence of Permanent AF
17139	Mean Myocardial Perfusion Measures Across Levels of Coronary Artery Calcification in Subjects With No Clinical Coronary Heart Disease, Stratified By Age and Gender From the Multi-Ethnic Study of Atherosclerosis
17140	Odds Ratios  (OR)  and 95% Confidence Intervals  (CI)  of Reduced Perfusion Reserve  (<2.5)  Across Levels of Coronary Artery Calcification in Subjects With No Clinical Coronary Heart Disease From the Multi-Ethnic Study of Atherosclerosis
17141	Mean Myocardial Perfusion Measures Across Number of Coronary Arteries Containing Calcium  (Coronary Artery Calcium Score >0 in the Respective Artery)  in Subjects With No Clinical Coronary Heart Disease From The Multi-Ethnic Study of Atherosclerosis
17142	Subgroup Analysis of Differences in the Incidence of Contrast-Induced Nephropathy Between Iodixanol and Ioxaglate
17143	Blood Flow, Blood Velocity, and Pulse Wave Velocity of Elite Rowers and Sedentary Control Subjects
17144	Univariate Analysis of Cardiovascular Risk Factors in MI
17145	Univariate Analysis of Cardiovascular Risk Factors in IS Cases and Control Subjects
17146	Univariate and Multivariate Analysis of v-aCS in MI Cases and Control Subjects
17147	Univariate Analysis of Thrombophilia Results in MI Cases and Control Subjects
17148	Univariate and Multivariate Analysis of v-aCS in IS Cases and Control Subjects
17149	Univariate Analysis of Thrombophilia Results in IS Cases and Control Subjects
17150	Correlations  (r)  Between Maximal Exercise Performance and Quality of Life  (QOL)  Measures
17151	Cardiac Morbidity and Major Cardiovascular Risk Factors in Relation to Presence of MI Scars and Clinical MI
17152	Severe Adverse Event Rates for Each Trial
17153	Electrophysiologic Measurements
17154	Clinical Outcome at Follow-Up
17155	Initial Hospital, Follow-Up, and Total Costs  (in Euros)
17156	Procedural Resource Use and Cost
17157	Initial Hospital Events, Resource Use, and Costs
17158	Follow-Up Events, Resource Use, and Costs
17159	Cost Effectiveness of Paclitaxel-Eluting Stents Under Alternative Assumptions About Adjunctive Medications
17160	Cumulative In-Hospital and 9-Month Clinical Outcomes
17161	Clinical Data of Patients With CAD and CVD
17162	Serious Adverse Events
17163	Results of Multivariable Logistic Regression for 2-Year Mortality Among the Placebo-Treated Patients
17164	Results of Multivariable Logistic Regression for 2-Year Mortality Among the Acadesine-Treated Patients
17165	Results of Multivariable Logistic Regression for 2-Year Mortality Among All Patients
17166	Major Eligibility Criteria
17167	High-Risk Inclusion Criteria
17168	Exclusion Criteria
17169	Incidence of Adverse Events at 30 Days
17170	Summary of Major Adverse Events at 30 Days After CAS  ⁎
17171	Quantitative IVUS Data
17172	Correlation Between IVUS Variables and Percentage Restenotic Area at Follow-Up
17173	Association of Carotid IMT With Myocardial Systolic Strain  (Regression Coefficients for IMT)
17174	Association of Carotid IMT With Myocardial Diastolic Strain Rate  (Regression Coefficients for IMT)
17175	Association of Age With Global and Regional Left Ventricular Function  (Regression Coefficients for Age)
17176	All-Cause Mortality of Patients With Recently and Remotely Diagnosed Cardiomyopathy: 3- and 9-Month Cut Points
17177	Clinical Presentation and Plaque Histologic Types Observed in the 65 Carotid Plaques Submitted to Histologic Examination
17178	Outcome Data
17179	Factors Independently Associated With In-Hospital Mortality in Multivariate Hierarchical Logistic Regression Model  (p < 0.01)
17180	Impedance Cardiography Variables
17181	Clinical and ICG Variables Measured at Visits Immediately Preceding and Not Immediately Preceding a Heart Failure Event
17182	Multivariate Analysis of Association of Clinical and ICG Variables With Occurrence of a Heart Failure Event Within 14 Days
17183	Frequency of Occurrence and Value of ICG Scores in Predicting Occurrence of a Heart Failure Event Within 14 Days
17184	Rest and Exercise Interobserver and Intraobserver Variabilities
17185	Hemodynamic Parameters
17186	Agreement Between LV Dyssynchrony Measurements With TDI and MRI
17187	Standard Noninvasive Evaluation in 165 Survivors
17188	Preoperative Diagnosis in 165 Survivors on Follow-Up and in 28 Patients Lost to Follow-Up
17189	Previous Surgical Procedures in 193 Survivors
17190	Exercise Data During Follow-Up in 127 of 165 Patients Without Major Late Complications
17191	Patients With Conduit Obstruction
17192	Reinterventions
17193	10-Year Survival After Fontan-Type Operation
17194	Heart Failure Medication During the Course of the Study
17195	Comparison of Functional Class According to the NYHA Classification, Echocardiographic, and Electrocardiographic Parameters Before Device Implantation, After Three Months of RVP, and After Three Months of BVP
17196	Effect of RVP Versus BVP on NT-proBNP Release, Quality of Life, and Exercise Capacity
17197	Summary Table of End Points Stratified by Defibrillator Status
17198	Summary Table of Unadjusted and Adjusted Stratified Cox Models for MTWA in Predicting Mortality
17199	Mortality Comparisons Between MTWA Positive, Negative, and Indeterminate Groups
17200	The Effects of Exogenous Norepinephrine Administration in Conscious Dogs in the Control and DCM Groups
17201	Metabolic Parameters Before Treatment
17202	Causal Mutations in the Alpha-Gal Gene Identified in the 12 Fabry Families Studied
17203	Genetic, Clinical and Echocardiographic Features of Patients With Fabry Disease and MWT ≥15 mm
17204	Echocardiographic Data of Study Population
17205	Tissue Doppler Data of Study Population
17206	Diagnostic Performance of the Interpretation Algorithm According to the Severity of Coronary Stenosis
17207	Diagnostic Performance of the Interpretation Algorithm According to the Extent and Location of Coronary Disease  (Stenosis ≥70% or Left Main ≥50%)
17208	Distribution of Atrial Fibrillation Prevalence According to Height Quartiles
17209	Multivariate Regression Analysis of Factors Associated With AF Prevalence With Height Representing Stature
17210	Multivariate Regression Analysis of Factors Associated With AF Prevalence With BSA Representing Stature
17211	Transcriptional Profiling of MMP and TIMP Genes in CRP-Stimulated HUVEC
17212	Correlation Coefficients Between MMP-1, MMP-10, and Cardiovascular Risk Factors
17213	Correlation of CRP With MMP-1 and -10 in Multiple Linear Regression Analysis With MMP-1 and -10 as Dependent Variables
17214	Predictors of ΔRIALBAmong 379 Study Participants
17215	Predictors of CIMT Among 379 study participants
17216	Hemodynamic, Inflammatory, and Vascular Parameters of HIV-Infected Patients With  (MS+ Group)  and Without  (MS− Group)  the Metabolic Syndrome, Type 2 Diabetic Patients, and Healthy Control Patients
17217	Spearman Correlation Coefficients  (r)  Between Vascular Measurements and Other Parameters for the Total Group of HIV-Infected Patients  (n = 37)
17218	Incidence of Primary and Secondary Outcomes
17219	Average Longitudinal, Transverse, Circumferential, and Radial Strain Values
17220	Longitudinal and Transverse Segmental Strain Values
17221	Comparison Between Longitudinal TDI Strain and 2D Strain: Mean Values and Standard Deviations Measured on Three Consecutive Cycles by Each Method
17222	Interobserver and Intraobserver Variabilities for the Different Components of Strain Assessed by 2D Strain
17223	Interobserver and Intraobserver Variabilities for Longitudinal Strain Assessed by 2D Strain and TDI Strain
17224	Age-Standardized Prevalence Ratios for LVSD in RD Stratified by Gender
17225	Performance of the ECG in Identifying LVSD in RD Patients
17226	Features Associated With LVSD in RD Patients on Univariate Analysis
17227	Clinical and Echocardiographic Features of the 51 Study Patients Based on Dip-MBF Values
17228	Individual Features of 11 Patients With Systolic Dysfunction at Final Evaluation
17229	Unadjusted and Adjusted Cox Proportional Hazards Model for All-Cause Mortality According to Quartiles of CRP
17230	Unadjusted and Adjusted Cox Proportional Hazards Model for Admission for HF According to Quartiles of CRP
17231	Early and Late Clinical Events
17232	Quantitative Coronary Angiography Results
17233	Distribution of Angiographic In-Stent Restenosis
17234	Multivariate Analysis of Candidate Predictors for Adverse Outcomes
17235	KCCQ Score and Event-Free Survival: Multivariable Adjustment
17236	SPECT Data
17237	Cox Proportional Hazards Regression Model  (Multivariate Analysis)
17238	Coronary Risk Factor Profile for WISE Women by Menopausal Status
17239	Prevalence of Angiographic CAD for WISE Women by Menopausal Status
17240	All WISE Women: Variation of the Effect of Menopausal Status, Systolic Blood Pressure, and Pulse Pressure on the Presence of CAD, Adjusted and Unadjusted for Age
17241	Rates of Ischemia and Indeterminate Test Results  (i.e., <85% Predicted Maximum Heart Rate)  by DASI Measurements of METs
17242	Functional and Tagged Magnetic Resonance Imaging Results
17243	HR Effect on Torsion
17244	Changes in Serum Cholesterol Levels With Treatment
17245	Effects of Atorvastatin on Left Ventricular Dimensions
17246	Changes in Markers of Inflammation and Oxidation
17247	Magnetic Resonance Parameters of the Acquisitions
17248	Global Function Parameters of the Subjects
17249	Results From the Multilevel Regression Analysis of the Relation Between Onset Time  (Outcome Variable)  and Peak Time of Shortening  (Independent Variable)
17250	Orthogonal Components of the Onset of Shortening Delay Vectors and Peak Shortening Delay Vectors for Both Patients and Normal Control Subjects
17251	Patient Therapies Before and After CRT Pacemaker Placement
17252	Type of CRT System and Adverse Events by Type of Heart Disease
17253	Effect of CRT Pacing by Type of Heart Disease
17254	Acute and Late Adverse Events
17255	Clinical and Echocardiographic Variables Before and After Six Months of CRT
17256	Follow-Up Data of Patients on Pravastatin Therapy and Diet Therapy
17257	Heart Failure Morbidity in Relation to Established and Novel Risk Factors in the Total Sample  (n = 2,321)
17258	Multivariable Cox Proportional Hazards Backward Stepwise Model, Examining the Independency of Novel and Established Risk Factors to HF Incidence in the Total Sample  (n = 2,321)
17259	Comparison of Patients Showing Non-Worsening With Those Showing Worsening Changes in LV dP/dtmax
17260	Adverse Clinical Events: In-Hospital and at 30 Days
17261	Adverse Clinical Events at 6 and 12 Months
17262	Changes in Treadmill Exercise Parameters
17263	Results of Univariate and Multivariate Analysis
17264	Percentage of Patients With AF Episodes of Given Duration for the Group of Patients With and Without Arterial Embolic Events
17265	Distribution of Patients, Antiplatelet Therapy, Anticoagulation Therapy, Arterial Embolic Events, and Annual Rate as a Function of Embolism Risk Factors
17266	Procedural Variables
17267	Multivariate Predictors of Slow-Flow
17268	Clinical Events Observed in Patients Who Underwent Dilated-Hypokinetic Evolution During Follow-Up and in Patients Who Maintained Classic HCM
17269	The Relationship Between CRP at 4 Months and Individual Risk Factors  (Both Arms Combined) , and a Comparison of CRP By Statin Therapy in Subjects With Individual Risk Factors
17270	Multivariate Model of Independent Predictors of Log  (CRP)
17271	Relationship Between Statin Regimen and CRP Levels in Patients With and Without the Metabolic Syndrome
17272	Myocardial Fibrosis by MRI
17273	Major Safety and Efficacy Outcomes  (Percent of Subjects)
17274	Echocardiographic Measurements and Changes Over Time According to Gender
17275	Incidence of the Primary End Point and Its Components According to Gender  ⁎
17276	Incidence of the Primary End Point and Its Components According to Treatment Strategy and Gender  ⁎
17277	Predictors of the Occurrence of the Primary End Point Over Time of the Female and Male Patients
17278	Univariate Associations for Recurrence at One Month
17279	Multivariate Logistic Model for Recurrence at One Month
17280	Univariable and Multivariable Analysis  ⁎
17281	Left Ventricular Ejection Fraction by Fas Tertile
17282	Left Ventricular Ejection Fraction by TNFR1 Tertile
17283	Cox Regression Analyses for Cardiovascular Events Including FMD or NMD
17284	Cox Regression Analysis for Cardiovascular Events Including FMD and IMT
17285	Blood Pressure Measurements and Correlations With Echocardiographic Parameters
17286	Coarctation Index and Echocardiographic Measurements of Group 1 and Group 2 Patients
17287	Percentage of Y Chromosome-Containing Nuclei
17288	Study Protocol
17289	Effect of Medication on Exercise Indexes in the Whole Population  (n = 21)
17290	Effect of Medication on Forearm Vascular Reflexes
17291	BRS Before and During LBNP and the Effect of Medication
17292	Events Occurring During Follow-Up
17293	Univariate and Multivariate Predictors of Primary Composite End Point by Cox Regression
17294	Univariate and Multivariate Predictors of Total and Cardiovascular Mortality by Cox Regression
17295	Univariate and Multivariate Predictors of Non-Fatal Cardiovascular Events: Acute Coronary Events, Stroke or TIA
17296	The Distribution of CHD Events by Coronary Calcium, Framingham Risk Score Categories, and Family History of CHD
17297	Cox Models Evaluating the Incremental Predictive Value of Coronary Calcium Presence on the Risk of CHD Events in Men
17298	Cox Models Evaluating the Incremental Value of Coronary Calcium Severity on the Risk of CHD Events in Men With Coronary Calcium Present
17299	Early Events in Different mTIMI and TIMI Groups
17300	Early Events in Different CE Groups
17301	Intermediate Events in Different mTIMI and TIMI Groups
17302	Intermediate Events in Different CE Groups
17303	Late Events in Different mTIMI and TIMI Groups
17304	Late Events in Different CE Groups
17305	Comparisons of Frequency in Use of Medications Before PCI, Newly Added orIncreased Immediately After PCI, and Medications During the Follow-Up Period
17306	Comparisons of Clinical Data During the Follow-Up Period Between Patients With and Without ISR
17307	Brachial Artery Diameter and Blood Flow
17308	Multivariate Logistic Regression Analysis; Association of ISR With FMD, Clinical, Lesion, and Procedural Variables
17309	Sensitivity and Specificity for Identification of ISR
17310	Carotid Intima-Media Thickness Values Among Subjects With and Without Metabolic Syndrome
17311	Prevalence of Metabolic Syndrome  ⁎  and Carotid Intima-Media Thickness
17312	Components of Metabolic Syndrome  ⁎  as Predictors of Carotid Intima-Media Thickness
17313	Circumstances Leading to Initial HCM Diagnosis According to Gender
17314	Features at Final Evaluation and Clinical Outcome
17315	Relation Between Clinical Variables at Initial Evaluation and Outcome  (Age-Adjusted Multivariate Cox Proportional Hazards Analysis)   ⁎
17316	Resting Physiology
17317	Effect of Dobutamine Stress on Cardiac Physiology
17318	Predictors of Mortality
17319	NYHA Congestive Heart Failure Functional Class by SHOCK Trial Treatment Assignment, All Available Data
17320	NYHA Congestive Heart Failure Functional Class at Two Weeks After Discharge Versus Outcome at One Year After MI  ⁎
17321	MILQ Physical Function Domain Scores of One-Year Survivors by Treatment Modality and Time  ⁎
17322	Pre-Procedural Stroke Risk Factors
17323	Left Atrial Appendage Occlusion Verified by Transesophageal Doppler Color Flow and Angiography
17324	Occurrence of MAEs During 90.7 Documented Implant Years
17325	Changes in the Metabolic Parameters
17326	Changes in the Cardiovascular Risk Parameters
17327	Spearman Analysis of the Relations Between Metabolic and Macrovascular Risk Markers
17328	Bivariate Correlations  (Pearson’s Correlation Coefficients)  Between Cardiovascular Risk Factors and Ultrasound Measures of Subclinical Atherosclerosis and Endothelial Dysfunction
17329	Relationship Between Carotid IMT and Brachial Artery FMD Across Quintiles of Carotid IMT and Brachial FMD
17330	Risk of Incident Congestive Heart Failure According to Fish Consumption
17331	Heart Rate and Blood Pressure Responses to Carotid Sinus Massage
17332	Cognitive Function in Fallers and Syncopal Patients With Carotid Sinus Syndrome
17333	Multivariate Model of Predictors of the Use of Filter Instead of Distal Occlusive Embolic Protection Devices  (c= 0.746)
17334	Hospital Medication and Hospital Events
17335	In-Hospital Outcomes
17336	Unadjusted and Adjusted Odds Ratios for Death in New York Versus Michigan
17337	Multivariate Model for In-Hospital Death
17338	Hemodynamic Measurements Between CP and RCMP
17339	Modified Guidelines for the Diagnosis of Cardiac Sarcoidosis Based on the Study Report on Diffuse Pulmonary Diseases From the Japanese Ministry of Health and Welfare, 1993  ( 9 )
17340	Twelve Patients With Cardiac Sarcoidosis  (Modified Japanese Guideline)
17341	Abnormal Findings With CMR
17342	Univariate Logistic Regression Analysis of Risk Factors for CAD in Patients With DM
17343	Multivariate Logistic Regression Analysis of Risk Factors for CAD in Patients With DM
17344	Hemodynamic Variables Before and After Thrombosis
17345	Rate of Cardiovascular Events and Cardiac Structure in Primary Aldosteronism Patients and Controls
17346	Incidence of Cardiac Death, Development of Severe Heart Failure, or Atrial Fibrillation During Follow-Up in HCM Patients With or Without LV Outflow Obstruction
17347	Modifying Effect  (Interaction)  of NYHA Functional Class, Atrial Fibrillation, LV Wall Thickness, and Age on the Prognostic Power of LV Outflow Obstruction
17348	Clinical and Family Studies to Assess Frequency of Familial Dilated Cardiomyopathy
17349	FDC Disease Genes
17350	Possible Outcomes of Clinical Screening for Familial Dilated Cardiomyopathy  ⁎
17351	Fasting Plasma Glucose, Insulin, Cholesterol, and Triglyceride Concentrations in Plasma and Major Lipoprotein Fractions and Relationships to the Common Carotid Artery IMT
17352	Fasting and Postprandial ApoB100 and ApoB48 Concentrations in Lipoprotein Subfractions
17353	Fasting and Postprandial ApoCI Concentrations in Plasma, TRL Subfractions, and TRL Particles
17354	Primer and Probe Sequences
17355	Proportional Hazards Models of Time to First Appropriate ICD Discharge  (Cox Model)  and Time to Any Appropriate ICD Discharge  (Anderson-Gill Model) , All Patients
17356	Proportional Hazards Models of Time to First Appropriate ICD Discharge  (Cox Model)  and Time to Any Appropriate ICD Discharge  (Anderson-Gill Model)  Among Patients With CAD
17357	Multivariable Proportional Hazards Model of Time to First Episode of 2 or More Appropriate ICD Discharges Within 24 Hours  (Cox Model) , All Patients  ⁎
17358	Multivariate Cox Proportional Hazard Analysis: Predictors of Cardiac Events
17359	Clinical Features of Individual Families With PRKAG2 Mutations
17360	Sensitivity, Specificity, and Predictive Value of Ventricular Arrhythmias on 24-h Ambulatory ECG as Predictors of Sudden Death in HCM
17361	Univariable Cox Proportional Hazards Analysis of Electrocardiogram Variables
17362	Regression Coefficients and Weightings for Covariates From Multivariable Modeling
17363	Subgroup Analysis Within Prognostic Score Categories
17364	Beta Coefficients From the Training and Validation Sets for the Simplified Model
17365	Cardiovascular Magnetic Resonance Findings: Left Ventricular Functional Parameters and Late Gadolinium Enhancement Distribution
17366	Complication Outcomes
17367	Associations of Various Parameters With the Risk of Complications
17368	Clinical Manifestations of ARVC in 48 Subjects at High Risk Who Received an ICD and 58 Matched Control Subjects From 11 Families With ARVC Linked to 3p25
17369	Multivariate Predictors of the Combined End Point of Congestive Heart Failure or Cardiac Death in Asymptomatic Post-MI Patients
17370	Net Change in Serum Lipids Concentration in Subjects Treated With Fibric Acid Derivatives as Compared With the Control Group
17371	Risk Reduction for Major Coronary Events and Deaths From Coronary Disease, Cardiovascular Disease
17372	Net Change in Serum Lipids Concentration in Subjects Treated With Nicotinic Acid Derivatives as Compared With the Control Group
17373	Subgroup Analysis With Net Change in mg/dl of Fibric Acid Derivatives and Nicotinic Acid Derivatives in Different Study Populations
17374	Correlation of MR Myocardial Delayed Enhancement With EP and Histologic Findings in ARVD Patients
17375	Univariate Cox Regression Analysis
17376	BNP and Hemodynamic Parameters in AS Patients With and Without Impaired Preload Reserve
17377	Preoperative BNP and Hemodynamic Parameters in AS Patients With and Without Clinical Deterioration After Aortic Valve Replacement
17378	Post-infarction Body Weights, Organ Weights, and Infarct Sizes
17379	Body and Organ Weights After Chronic Isoproterenol Challenge
17380	Summary Statistics for Multivariable Logistic Regression Model of Predictors of Depressive Symptoms at One Year
17381	Strand-specific Detection of Enteroviral Genome and Clinical Outcomes
17382	Clinical Variables Between Patients With and Without Enterovirus RNA legend
17383	Clinical and Angiographic Findings of the 29 Patients legend legend
17384	Percentage of NN and MM Segments According to the Echocardiographic Wall Motion Score  (<3)  at Different Time Points legend
17385	Clinical Background of Study Subjects legend
17386	Scintigraphic and Right Ventriculographic Data of Study Subjects legend
17387	Agency for Health Care Policy and Research Risk Prediction Model of Death or Nonfatal Myocardial Infarction in Patients With Symptoms Suggesting Unstable Angina ∗
17388	Results: Comparison of Therapy by Groups∗ legend
17389	Length of Stay
17390	Complications by Agency for Health Care Policy and Research and Rush Groups
17391	Coronary Risk Factors by Reported Weight Cycling legend
17392	Significant Independent Predictors of HDL-C  (mg/dl)   (Linear Regression Model)  legend
17393	HDL-C Levels  (mg/dl)  by Presence or Absence of Obesity/Weight Cycling ∗   legend
17394	Follow-Up Data of the Patients With VF Recurrence After ICD Implantation legend
17395	Progression to Hypertension Over Six Years of Follow-up and Relative Risks as a Function of Three Categories of BP Response to Exercise legend legend
17396	Stepwise Proportional Hazards Analysis of Risk Factors for Incidence of Hypertension Over Six Years of Follow-up in Subjects With High-Normal BP legend legend
17397	Optimal Treatments for CHF in 102 Patients With CHF During Three Months
17398	Univariate and Multivariate Predictors of Mortality of 102 Patients With CHF According to Survival legend
17399	Univariate and Multivariate Predictors of Morbidity and Mortality of 102 Patients With CHF According to Cardiac Event-Free legend
17400	Effects of l-NMMA on FBF and FVC in Range of Plasma BNP Level legend
17401	Comparison of Hemodynamic Variables and Wall Motion Analysis in 35 Patients Undergoing TAPSE and DSE legend
17402	Changes in Hemodynamic Variables From Rest to Peak Stress in 35 Patients Undergoing Two-Stage TAPSE and DSE legend
17403	Comparison of Procedure Duration  (Mean ± SD)  in 35 Patients Undergoing Two-Stage TAPSE and DSE
17404	Doppler and M-Mode Measurements in 25 Patients With Systolic Anterior Motion  (SAM)  legend
17405	Clinical and Hemodynamic Data of Patients and Healthy Subjects †   legend
17406	Titers of Human, Rabbit, and Monoclonal Mouse Anti-beta1-AR Obtained for ELISA, Western Blotting, and Immunoprecipitation legend
17407	Basal and  (−) Isoprenaline-Stimulated cAMP-levels of CHW-beta1 Cells in the Presence of Rabbit  (70 nmol/liter) , Mouse  (7 nmol/liter) , or Human Anti-beta1-ECII  (2 μmol/liter)  †
17408	Mechanical Function of Spontaneously Beating Control and Hypertrophied Working Rat Heart Reperfused After Ischemia legend legend
17409	Mechanical Function and Glucose Metabolism in Spontaneously Beating Nonischemic Control and Hypertrophied Working Rat Hearts legend legend
17410	Mechanical Function of Control and Hypertrophied Working Rat Hearts Paced During Reperfusion After Ischemia legend legend
17411	Descriptors of Test Performance for Electron Beam Computed Tomography for All Coronary Events at Various Calcium Score Thresholds legend
17412	Descriptors of Test Performance for Electron Beam Computed Tomography for the Combined End Point of Myocardial Infarction and Death at Various Coronary Calcium Score Thresholds legend
17413	Multivariate Analyses of the Association of Coronary Artery Calcium Scores and Self-Reported Traditional Coronary Disease Risk Factors With All Events legend legend
17414	Results of Echocardiographic and Antimyosin Studies and ECG Pattern  (Between Parenthesis ECG Leads)  in Athletes With MRA legend
17415	Arterial Endothelial Dysfunction in Heavy Passive Smoking legend
17416	Hemodynamic Profile of Registry Patients ∗   legend
17417	Effect of Revascularization on Mortality Odds Ratio for Death Revascularization vs. No Revascularization legend
17418	Effect of Early Revascularization on Mortality Odds Ratio for Death Revascularization Within 18 h of Shock vs. No/Late Revascularization legend
17419	Profile of Patients With Predominant LV Failure in the SHOCK Trial Registry legend
17420	Hemodynamics for Patients With Predominant LV Failure in the SHOCK Trial Registry legend legend legend legend
17421	Treatment of Patients With Predominant LV Failure in the SHOCK Trial Registry legend
17422	Etiology, Complications and Hemodynamic Measures of CS in AMI legend
17423	In-hospital Treatment of AMI Patients With CS legend
17424	SHOCK Trial Mortality of AMI Patients With CS
17425	Predictors of Shock Developing Among Patients Who Have Acute Coronary Syndromes but Do Not Have Persistent ST-Segment Elevation legend legend
17426	Scoring Algorithm Predicting the Development of Shock legend
17427	Use of Coronary Angiography, Revascularization Procedures, and Assist Devices Based on Shock Status legend
17428	Predictors of Mortality Within 30 Days After Enrollment Among Shock Patients Who Have Acute Coronary Syndromes but Do Not Have Persistent ST-Segment Elevation legend
17429	Comparison of Clinical Features of Cardiac Rupture/Tamponade Patients and Other Suspected Shock Patients Excluding Those With Mechanical Causes
17430	Hemodynamic Data for Patients With CS and VSR or Predominant LV Failure legend legend
17431	Angiographic Findings in Patients With CS and VSR or Predominant LV Failure legend
17432	Management of Patients With CS and VSR or Predominant LV Failure legend
17433	Profile of Surgically Managed Patients With CS and VSR legend legend
17434	Profile of Surgical Survivors With CS and VSR legend
17435	Treatment and Outcomes of Patients With CS Due to Severe MR Versus LV Failure legend
17436	Timing of Events in Patients With Severe MR Versus LV Failure. All Times Are in Hours Unless Otherwise Noted legend
17437	Infarct Size, Hemodynamics, Treatment and In-hospital Mortality by Valve-surgery Status of Patients With Severe Complicating Acute MI. Hemodynamics Reported Are Those Closest to Shock, Which Were Often Recorded While the Patient Was on Support legend
17438	In-hospital Mortality and Intervention Rates by Angiographic Disease Severity in Patients with LV or RV Failure
17439	Etiology of CS and In-hospital Mortality
17440	Hemodynamic Findings Measured Close to Shock Onset While Patients Often on Mechanical or Pharmacological Support
17441	Registry Angiographic Findings, Overall and by Shock Etiology legend
17442	In-hospital Event Rates by Angiographic Findings in Patients with LV or RV Failure
17443	Studies Reporting Angioplasty Outcomes in Octogenarians legend
17444	Clinical Outcomes legend
17445	Multivariable Predictors of Octogenarian Mortality legend legend
17446	Age-Specific Outcome Trends 1994–1997 legend legend
17447	Resting Diastolic Indexes in Individuals with HCM, Elite Athletes With and Without LVH and Recreational Athletes legend
17448	Control Hemodynamic Values for Study Groups legend legend
17449	Countershock Success After Five Minutes of Ventricular Fibrillation legend legend
17450	Fatal and Nonfatal Cardiovascular Events During Follow-up
17451	Echocardiographic Data at Initial Presentation ∗   legend
17452	Long-Term Follow-up Data legend
17453	High Dose Chemotherapeutic Schedules Utilized
17454	Clinical Charateristics in Troponin Positive  (cTnI+)  and Troponin Negative  (cTnI−)  Groups legend legend
17455	Somatic and Cardiac Growth at 15 Weeks legend
17456	mRNA Levels and Collagen Content at 15 Weeks legend
17457	Operation and Early Postoperative Data legend legend
17458	Follow-Up in Patients With Atrial Fibrillation Requiring Cryoablation and in the Control Group legend legend
17459	Reason for North American Symptomatic Carotid Endarterectomy Trial  (NASCET)  Exclusion in 79 Patients legend
17460	Procedural Details legend legend
17461	Adverse Events by Age Group legend
17462	Histomorphometry: Results of the Different Study Groups legend
17463	Kinetic Parameters for 6-[18F]-Fluorodopamine–Derived Radioactivity in Normal Volunteers and in Patients With Hypertrophic Cardiomyopathy legend
17464	Details of the Study Patients legend
17465	Quantitation of the Bcl-2 Family of Proteins After Western Immunoprobing legend
17466	Grading of the Bcl-2 Family of Proteins After Immunocytochemistry legend legend
17467	Quantitation of TUNEL legend
17468	Amount of T-lymphocyte Subtypes Infiltrating the Biopsies of Patients With a Normal or an Altered ANT Isoform Transcription Pattern legend
17469	Two-dimensional and M-mode Echocardiographic Measurements legend legend
17470	Doppler Left Ventricular Diastolic Filling Variables legend legend
17471	The Local Electrogram Measurements Before and After Parenteral Sotalol legend
17472	Changes of Local Electrogram Parameters in Group A and Group B Patients legend
17473	Regional Left Ventricular Morphology legend
17474	Normal and Shear Strains legend
17475	Congestive Heart Failure Incidence Rates per 1,000 Person-Years legend
17476	Congestive Heart Failure Incidence Rates per 1,000 Person-Years for Selected Risk Factors legend legend
17477	Comparison of Biomedical Variables and Incident Congestive Heart Failure legend legend
17478	Percentage of Incident Congestive Heart Failure in the Population Attributable to Selected Risk Factors legend
17479	Cardiomotor Function in Response to Tilt Table Testing and Isoproterenol ∗   legend
17480	Vasomotor Function in Response to Tilt Table Testing and Isoproterenol ∗   legend
17481	Previously Published Reports of Wrong Sinus Coronary Artery Anomalies in Persons Aged ≤35 Years in Whom ECG Data Were Available legend
17482	Etiology of CHF
17483	Comparison of the Presence of Signs of Pleural Effusion Between Plain Chest X-ray and Thoracic Ultrasonogram in Normal Controls and Patients With Decompensated CHF legend legend
17484	The Frequency of the Detection of Body Fluid Accumulation in 60 Patients With Decompensated CHF by Two Clinicians
17485	Observer Disagreement on Clinical Tests for Identifying Body Fluid Accumulation in 60 Patients With Decompensated CHF
17486	Comparative Diagnostic Value of Traditional Clinical Signs and Ultrasonographic Test for Identifying Body Fluid Accumulation in Decompensated CHF
17487	Univariate Clinical and Rest Echocardiographic Predictors of Postoperative Events in 530 Patients Undergoing Nonvascular Operation legend
17488	Univariate Stress Echocardiographic Predictors of Postoperative Events in 530 Patients Undergoing Nonvascular Operation legend
17489	Multivariate Predictors of Postoperative Hard Cardiac Events in Patients With Inducible Ischemia legend
17490	Incremental Value of Dobutamine Stress Echocardiography Versus Clinical Variable for Preoperative Cardiac Risk Stratification for Nonvascular Operation legend
17491	Final Angiographic Results legend
17492	Procedural and In-hospital Outcome legend
17493	Follow-up QCA Results legend
17494	Follow-up Results legend legend
17495	Study Designs legend
17496	Internal Consistency of the KCCQ
17497	Mean Three-Month Change in Health Status Scores Among Patients  (n = 39)  in the Reliability Cohort
17498	Mean Three-Month Change in Questionnaire Scores Among Patients Initially Admitted to the Hospital With CHF (n = 39)
17499	Correlation of KCCQ Physical Limitation Scale legend
17500	The Peak LV Systemic and Coronary Hemodynamic Responses to Intravenous Cocaine in Conscious Dogs and Baboons legend
17501	The Peak LV Systemic and Coronary Hemodynamic Responses to Intravenous Cocaine in Conscious Dogs Before and After Splenectomy legend
17502	Formulas for Calculation of Stretch, Recoil and Gain
17503	Associated Cardiac Lesions
17504	Hemodynamic and Angiographic Results Immediately Before and After Angioplasty legend
17505	Comparison of Patients With Early Failure Versus Success legend
17506	Factors Associated With Decreased Time to Reintervention ∗   legend
17507	Distribution of Diagnoses for Which Emergent Repair of the Aorta was Undertaken
17508	Subgroup Analysis of In-Hospital Mortality Based on Coronary Angiography Status legend
17509	Indications for CABG in Patients With or Without a History of MI
17510	Patient Data and Preinterventional Echocardiographic Findings
17511	Morbidity and Mortality
17512	Mean  (±SD)  Values for Left Ventricular End-Diastolic Volume, End-Systolic Volume and Ejection Fraction for the Four Imaging Strategies legend
17513	Patient Classification by Systolic Function as Normal  (A, LVEF ≥55%) , Depressed  (B, LVEF >35% to <55%)  or Severely Depressed  (C, LVEF ≤35%)  ∗   legend
17514	Interobserver and Intraobserver Reproducibilities for Left Ventricular Ejection Fraction ∗   legend
17515	Summary of Clinical Data legend
17516	Drugs Used for Control of Fetal AF legend
17517	Prior Series Reporting Postoperative Mortality and Complications in Octogenarians After CABG
17518	Outcomes of Cardiac Surgery by Age Category legend
17519	Multivariate Logistic Regression Model for the Prediction of In-Hospital Mortality After CABG in Order of Descending Chi-Square legend legend
17520	Effect of Simvastatin on Hematologic Variables in Rats After Balloon Angioplasty legend legend
17521	Revascularization and In-hospital Mortality in Relation to Timing of Shock Onset legend
17522	Changes With Biventricular Pacing legend
17523	Animal Study: Effects of Inotropic Modulation legend
17524	Animal Study: Effects of Preload Alterations legend
17525	Human Study: Effects of Preload Alterations Before and During Partial Cardiopulmonary Bypass legend
17526	Genotype and Allele Frequencies of Candidate Gene Polymorphisms in Cases and Controls legend
17527	Patient Data legend
17528	Relations Between Hemodynamic Data and PET Data legend
17529	Positron Emission Tomographic Measurements in the Three Different Regions legend
17530	Doppler Echocardiographic Right Ventricular Filling Variables in Control Subjects and Patients With Hypertrophic Cardiomyopathy in the Supine Position and at 10 min of Different Degrees of Head-Up Tilting legend legend
17531	Doppler Echocardiographic Left Ventricular Filling Variables in Control Subjects and Patients With Hypertrophic Cardiomyopathy in the Supine Position and at 10 min of Different Degrees of Head-Up Tilting legend legend
17532	Doppler Echocardiographic Pulmonary Venous Flow Variables in Control Subjects and Patients With Hypertrophic Cardiomyopathy in the Supine Position and at 10 min of Different Degrees of Head-Up Tilting legend legend
17533	Hemodynamic Data in Control Subjects and Patients With Hypertrophic Cardiomyopathy in the Supine Position and at 10 min of Different Degrees of Head-Up Tilting legend legend
17534	Patient Profile legend
17535	Dimensions of the Myocardial Tracts and TH Staining legend
17536	Association of Potential Vascular Risk Factors With Incident Atherosclerosis legend
17537	Risk of Incident Atherosclerosis by Plasma Endotoxin Levels legend
17538	Patients and Procedures
17539	Complications of Endomyocardial Biopsy legend
17540	Body Weight, Blood Glucose and Serum Fructosamine legend
17541	M-Mode Measurements legend
17542	Systolic Doppler Measurements legend
17543	Diastolic Doppler Measurements legend
17544	Mechanical Variables In Vivo and in the Isolated Whole Heart legend
17545	Pre- and Immediately Post-Cardiopulmonary Bypass Echocardiographic Measurements legend legend
17546	Pre-MVRep, Immediately Post-MVRep and Final Echocardiographic Measurements of Four Group 1 Patients in Which the Final TEE Exam Showed Resolution of Both SAM and LVOTO legend legend
17547	Precardiopulmonary Measurements of Patients in Group 1 legend legend
17548	Interobserver Variability for PreCardiopulmonary Bypass Measurements legend
17549	Some Familial Ventricular Tachyarrhythmias in the Absence of Structural Heart Disease or Associated Known Syndromes legend
17550	Distribution of Important Risk Factors Within Various Treatment Groups legend legend
17551	Hazard Ratios for Death as Compared With the NST Group legend
17552	Exercise Performance During Submaximal and Supramaximal Exercise in the Normal and HFC Groups
17553	Subjective Assessment of Exercise Difficulty
17554	Heart Rate and Blood Pressure Change After Pharmacologic, Mechanical and Orthostatic Stimulation of the Carotid Sinus legend
17555	Acute and Long-Term Outcome of First and Second Internal Cardioversion  (n = 18)  legend legend
17556	Clinical and Hemodynamic Parameters of Patient Subgroups With Valvular or Hypertensive Heart Disease legend legend
17557	Load-Sensitivity of Various Time Constants of Relaxation legend legend
17558	Comparison of Quantitative Changes in Relaxation Index With Pharmacologic Stimulation in Patients With DCM  (Dobutamine or Toborinone)  legend
17559	Number of Patients With ST-Episodes in Relation to ECG on Admission legend
17560	Number of Patients With ST-Episodes in Relation to Diagnosis Within 24 H of Admission legend
17561	Univariate Analysis of Clinical, Biochemical and Electrocardiographic Predictors of Cardiac Death or MI legend
17562	Left Atrial Volumes, Ejection Force and Kinetic Energy in HCM Patients Before and Six Months After NSRT
17563	Left Ventricular Minor Axis Function and Doppler Velocities legend
17564	Left Ventricular Long Axis Function legend
17565	Electrocardiogram Values legend
17566	Independent Predictors of Hospital Death, Odds Ratios and Coefficients for the Cleveland Clinic Model and the Northern New England Model legend
17567	Observed and Predicted Mortality Rates in Patient Subgroups legend
17568	Complications legend
17569	Associations Between Angiographic, Hemodynamic and Treatment Data and In-Hospital Mortality legend
17570	Prediction of the Risk of In-Hospital Mortality After PCI legend legend
17571	Contractile Responses to Potassium  (K+125 mmol/liter)  Phenylephrine  (PE, 1 μmol/liter)  and Angiotensin II  (1 and 100 nmol/liter) , and Dilator Responses to Acetylcholine  (10 μmol/liter)  in Human Internal Mammary Artery Segments From Patients With the DD or the II/ID Genotype legend
17572	PCR Primers Used to Detect Viral Sequences in Cardiac Samples
17573	Clinical, Pathologic and Virologic Findings in HIV-Infected Patients at Autopsy legend legend
17574	Primary Anatomic Diagnoses in Patients Who Did and Did Not Undergo Fenestration
17575	Preoperative and Postoperative Data in Patients Undergoing Extracardiac Fontan With and Without Fenestration legend
17576	Univariate and Multivariate Analysis: Determinant of TWA
17577	Reasons for Beta-blocker Prescription, Randomized Patients After Their Index Arrhythmia  (n = 220)
17578	Modes of Death, Randomized Patients legend
17579	Adjusted Relative Risk Estimates, Association of Beta-blocker Use with Mortality legend
17580	Lipid Profiles: HRT Versus Control Subjects in All Subjects and in Smokers and in Nonsmokers legend legend
17581	Comparison of Group Values for IMT and SAC legend
17582	Study Population
17583	Analysis of the Difference Between Sporadic and Familial Dilated Cardiomyopathy at Uni- and Multivariate Analysis legend
17584	Summary of Clinical, Immunologic, Morphometric and Molecular Genetic Findings in Familial Dilated Cardiomyopathy  (FDC)  legend
17585	Uni- and Multivariate Analysis of the Difference Between Familial Dilated Cardiomyopathy  (FDC)  With and Without Skeletal Muscle Involvement legend
17586	Pre- and Post-treatment Data for Patients with Drug Refractory HOCM legend
17587	Differences Between Patients With ≥4 Viable Segments  (Group A)  and <4 Viable Segments  (Group B)  on Dobutamine Stress Echocardiography legend
17588	Events in Patients With ≥4 Viable Segments  (Group A, n = 23)  and <4 Viable Segments  (Group B, n = 45)  on Dobutamine Stress Echocardiography
17589	Breakdown of Vessel Type Supplying “Protected” Regions
17590	Cause of Perioperative and Long-Term Deaths
17591	Results of Univariate Analysis of Factors Correlating With Risk of Perioperative Mortality
17592	Risk Ratios for the Three Factors Which Collectively Provide the Strongest Correlation With Risk of Mortality legend
17593	Electrocardiographic and Echocardiographic Data legend
17594	Cardiac Catheterization Data legend
17595	Cardiac Anomalies Identified by Telemedical Echocardiography
17596	Neonates With Congenital Heart Disease in Whom Transfer Was Immediately Recommended or Avoided legend
17597	Influence of Treatment With Trandolapril on the Occurrence of Secondary End Points in Patients With and Without Diabetes legend
17598	Comparison Between the Two Electrode Locations legend
17599	Adverse Clinical Outcome at 30 Days legend
17600	Effect of Carvedilol Versus Metoprolol on LV Function and Remodeling in 30 Dilated Cardiomyopathy Patients
17601	Effect of Carvedilol Versus Metoprolol at 12 Months on Categorical Measures of Clinical Status, LV Function and Ventricular Arrhythmias in 30 Dilated Cardiomyopathy Patients
17602	Effect of Carvedilol Versus Metoprolol on Symptoms, Quality of Life, Exercise Tolerance and Arrhythmias in 30 Dilated Cardiomyopathy Patients
17603	Women’s Ischemia Syndrome Evaluation Common Core Protocol legend
17604	Women’s Ischemia Syndrome Evaluation Site-Specific Methodologies legend
17605	Echocardiographic Features of Affected Family Members legend
17606	Data on 13 Patients With Idiopathic Dilated Cardiomyopathy legend
17607	Mean Myocardial Trace Elements Concentration  (ng/g)  in Patients With Idiopathic Dilated Cardiomyopathy  (Group A) , Secondary Forms of Cardiac Dysfunction  (Group B) , Control Subjects  (Group C)  and Normal Subjects  (Group D)  as Determined by Neutron Activation Analysis legend
17608	Echocardiographic and Hemodynamic Data
17609	Univariate Predictors of Long-Term Neurologic Events, All-cause Mortality, and All Events legend
17610	Event Rates in the Study Patients According to Severity of Ascending Aorta Atherosclerosis legend
17611	Independent Predictors of Long-Term Neurologic Events, All-cause Mortality, and All Events legend
17612	Incidence of Long-Term Events According to Severity of Ascending Aorta Atherosclerosis legend
17613	Outcomes of 335 Primary Angioplasty Procedures legend
17614	In-Hospital Outcomes in Patients Undergoing Immediate Coronary Angiography legend
17615	Cardiac Catheterization Laboratory Complications in 506 Immediate Coronary Angiograms legend legend
17616	Preoperative Cardiac Medications legend
17617	Perioperative Cardiac Morbidity legend
17618	Perioperative Noncardiac Morbidity legend
17619	One-Way Analysis of Variance of Potential Risk Factors for Perioperative Death After Transmyocardial Laser Revascularization legend
17620	One-Way Analysis of Variance of Potential Risk Factors for Perioperative Cardiac and Noncardiac Morbidity After Transmyocardial Laser Revascularization legend
17621	Predictors of Conversion by Drug Treatment  (Univariate Assessment)  legend
17622	Conversion Rate  (%)  of Significant Predictors Dichotomized at the Statistical Median legend
17623	Studies of Carvedilol in Heart Failure legend
17624	Nonfatal Adverse Events legend
17625	Adverse Events on Carvedilol  (NYHA Class IV Patients)  legend
17626	Genotypic Distributions and Allelic Frequencies of HindIII and PvuII Polymorphisms Among CAD Patients and Control Subjects legend legend
17627	Odds Ratios for CAD Associated With Carriage of HindIII- and PvuII-Carrying Genotypes legend
17628	Associations Between HindIII and PvuII Polymorphisms: Observed  (Expected)  Genotypic Frequencies legend
17629	Estimated Haplotypic Frequencies With Association legend legend
17630	Multivariate Conditional Logistic Regression Model for CAD legend
17631	Mean Gray Scale Values  legend
17632	Statistical Analysis for Intravascular Ultrasound  (IVUS)  Images  legend legend
17633	Statistical Analysis for Transvascular Ultrasound  (TVUS)  Images legend legend
17634	Patients Population legend
17635	Reoperations legend
17636	Summary of Cardiac Events Within First Year of Follow-Up legend
17637	Rest Wall Motion and Incidence of Positive Stress Echocardiograms, Myocardial Infarctions, and Cardiac Events legend
17638	Measurement Precision legend legend
17639	Measurement Accuracy legend legend
17640	Patient Population legend
17641	Effects of IV Flecainide on ECG and Electrophysiological Parameters legend
17642	Left Atrial Appendage Velocity and Mitral A Wave Velocities Before, During and After Brief Duration Atrial Fibrillation in Patients Reverting With an Endocardial Shock  (n = 14)  or Spontaneously  (n = 10)  legend
17643	Left Atrial Appendage Velocity and Mitral A Wave Velocities Before, During and After Brief Duration Atrial Fibrillation in Patients Taking Chronic Amiodarone Therapy  (n = 14)  or Chronic Sotalol Therapy  (n = 10)  legend
17644	Left Atrial Appendage Velocity and Mitral A Wave Velocities Before, During and After Brief Duration Atrial Fibrillation in Patients With  (n = 14)  and Without  (n = 10)  Spontaneous Echocardiographic Contrast During AF legend
17645	Hemodynamics, Echocardiographic Left Ventricular Areas and Fractional Areas Changes Before and at Peak Dobutamine Dose
17646	Study Population legend
17647	Pattern of Distribution of Hypertrophy at Apical Level legend
17648	Wall Thickness  (mm)  on First MR Images legend
17649	Wall Thickness  (mm)  on Second MR Images legend
17650	Comparison of Clinical Feature legend
17651	Hemodynamic Responses to Clonidine
17652	Neurochemical and Flow Responses to Clonidine
17653	Risk of Events by Definitions
17654	Distribution of Risk Factors in Cases and Control Subjects and Associations of Risk Factors With Events Using Primary Case Definition  legend
17655	Clinical, Hemodynamic and Ventriculographic Data  legend
17656	LV Systolic and Diastolic Function Data  legend
17657	Summary of Patients Dying  (n = 12)   legend
17658	Postulated Risk Factors for Reduced Time to Death or Resuscitated Sudden Death  legend
17659	Prevalence and Type of Perfusion Abnormalities in Patients With Normal and Abnormal BPR  legend
17660	Echocardiographic Findings in the Probands With HCM legend
17661	Mutations in the Cardiac Beta-Myosin Heavy Chain  (β-MHC)  and Alpha-Tropomyosin  (α-TM)  Genes Causing Hypertrophic Cardiomyopathy
17662	LOD Scores of the Two-Point Linkage Analysis Between Familial HCM Locus  (Dominant Inheritance Mode With a Penetrance of 95%)  and Two Polymorphic Markers MYO I and MYO II of the Cardiac β-Myosin Heavy Chain Gene With Recombination Fractions  (θ)  0 and 0.01 in 16 Families With Confirmed or Suspected Familial HCM legend
17663	Clinical Features of 3 Different Subsets of Affected Family Members  legend
17664	Procedural Variables  legend
17665	Long-Term Outcome of Patients With Stable and Unstable Angina legend
17666	Cut Points for Electron Beam Computed Tomographic Coronary Calcium Scores for Differentiating Ischemic and Nonischemic Cardiomyopathy  legend
17667	Mortality During Follow-Up in 392 Discharged Patients
17668	Total Mortality in the First Year After Discharge for the Index MI  (tTest, Chi-Square Test)   legend
17669	Total Mortality After Discharge in 392 Patients  (Kaplan–Meier Method, Proportional-Hazards Model)   legend
17670	Clinical and Echocardiographic Data for Subjects Enrolled in the Comparative Study  legend
17671	Clinical and Echocardiographic Data for Patients Enrolled in the Follow-up Study Protocol Before and After the Therapy legend
17672	Transmitral Flow Velocity and Tissue Doppler Indices in the Comparative Study  legend
17673	Age-Adjusted Cox Proportional Hazards Analyses Relating Risk of Major Events to Failure to Reach 85% of the Age-Predicted Maximum Heart Rate and Echocardiographic Myocardial Ischemia
17674	Age-Adjusted Cox Proportional Hazards Analyses Relating Risk of Major Events to Chronotropic Index and Echocardiographic Myocardial Ischemia
17675	Frequency of Aortic Root and Valve Abnormalities on Transesophageal Echocardiography legend
17676	Noncardiac Mortality
17677	Clinical and Hemodynamic Variables
17678	Ultrastructural Morphometric Analysis of Gap Junctions
17679	Side Effects Considered to Be Agent Related legend
17680	Changes in Hemodynamic Variables With Nitroprusside Therapy legend
17681	Changes in Echocardiographic Markers of Severity of Mitral Regurgitation With Nitroprusside legend
17682	Multiple Linear Regression Analysis of Clinical and Hemodynamic Variables and Follow-Up Left Ventricular Ejection Fraction  legend
17683	Pravastatin Treatment Effects in the REGRESS B-Mode Ultrasound Study Group  (n = 255) : Change in Coronary Lumen and Peripheral Intima-Media Thickness
17684	Pravastatin Treatment Effect on Carotid and Femoral Artery Intima-Media Thickness
17685	Incidence of Failed Thrombolysis and Rescue Angioplasty
17686	Technical Results of Attempted Rescue Angioplasty legend
17687	Procedure-Related Complications
17688	Left Ventricular Function at 5 to 7 Days  legend
17689	Interaction of Rescue Angioplasty Attempt and Cardiogenic Shock on 30-Day Mortality in Patients With All Closed Infarct-Related Arteries  legend
17690	Echocardiographic Data
17691	Asynchrony Index Obtained From Color Kinesis Images at Different Percentages of Left Ventricular Filling Time in Normal Subjects and in Different Subgroups of Patients With Dilated Cardiomyopathy
17692	Effects of Nitroprusside and Dobutamine Infusion on Doppler and Color Kinesis Indexes of Left Ventricular Diastolic Function in Patients With Dilated Cardiomyopathy
17693	Comparison of Preoperative and Postoperative Echocardiographic Findings in all Patients legend
17694	Comparison of Postoperative Echocardiographic Findings Between Patients With Hypertrophic Obstructive Cardiomyopathy and Control Subjects  legend
17695	Defibrillation Threshold Changes in Each Treatment Group  (mean ± SD)
17696	Time From Beginning of Pacing to Shock  (mean ± SD)  legend
17697	Cumulative Number of Shocks  (mean ± SD)   legend
17698	Mean Blood Pressure Changes in Each Treatment Group
17699	Electrophysiologic Variables Before and After Administration of Vehicle, Amiodarone or Desethylamiodarone  (mean ± SD)
17700	Plasma Concentration of Amiodarone or Desethylamiodarone in Each Treatment Group  (mean ± SD)
17701	Doppler Blood Flow Velocity Measurements and Sinus Rate Before and After Endocardial Direct Current Shocks in Sinus Rhythm and Ventricular Fibrillation and Transthoracic 360-J Shocks in Sinus Rhythm in 13 Patients
17702	Time to Treatment Intervals for Lytic-Eligible Patients
17703	Baroreflex Sensitivities in Patients With Hypertrophic Cardiomyopathy Versus Control Subjects
17704	Risk Factor Associations With Angiographic Disease Severity by Multiple Linear Regression Analysis  a
17705	Risk Factor Associations With Electron Beam Computed Tomographic Total Calcium Score Quintiles by Multiple Linear Regression Analysis  a
17706	Linear Correlations With Body Height as Dependent Variable
17707	Stepwise Multiple Regression
17708	Clinical Manifestations and Diagnostic Study Results in 13 Patients With Hypertrophic Cardiomyopathy
17709	Events During Follow-Up in Patients With an Implantable Cardioverter-Defibrillator and Hypertrophic Cardiomyopathy
17710	Clinical, Hemodynamic and Echocardiographic Data of Patients With Hypertrophic Cardiomyopathy and Control Subjects
17711	Coronary Hemodynamic Variables at Basal Conditions and After Vasodilation in Patients With Hypertrophic Cardiomyopathy and Control Subjects  a
17712	Morphometric Findings in the Right Septal Subendocardium
17713	Intraobserver and Interobserver Variabilities of Morphometric Investigations
17714	Metabolic and Hemodynamic Variables on Study Entry and at 10 Weeks
17715	Multivariate Analysis of Events as Dependent Variable
17716	Comparison of Echocardiographic Variables Between Giant Left Atrium and Control Group Before and After Maze Procedure
17717	Follow-Up and Clinical Events in 10 Study Patients
17718	Coronary Events in Eight Study Patients
17719	Annualized Rates of Procedures by Tercile
17720	Unadjusted Rates for In-Hospital Outcomes
17721	Descriptive Data and In-Hospital Course of the Initial 238 Patients
17722	Angiographic Findings and Primary Angioplasty Results
17723	In-Hospital Course
17724	Factors Associated With In-Hospital Death  (univariate analysis)
17725	Multivariate Analysis for In-Hospital Death  a
17726	Vessel Size and Time-Averaged Velocity at Reactive Hyperemia in Study Participants
17727	Comparison of Clinical and Echocardiographic Indexes Among Patients Who Did and Did Not Have Spontaneous Conversion to Sinus Rhythm
17728	Comparability of Previous Medical History of Patients Receiving Saruplase or Streptokinase at Randomization
17729	Causes of Death in Patients Receiving Saruplase or Streptokinase
17730	Cardiac Events up to 30 Days in Patients Receiving Saruplase or Streptokinase
17731	In-Hospital Bleeding Events  (excluding stroke)  in Patients Receiving Saruplase or Streptokinase
17732	Strokes and Transient Ischemic Attacks at 30 Days in Patients Receiving Saruplase or Streptokinase
17733	Implantable-Cardioverter Defibrillator Variables Temporarily Reprogrammed During Clinical Testing
17734	Antenna-Generated Fields Used to Simulate Digital Cellular Telephone Technology Modulation During In Vitro Testing of Implantable Cardioverter-Defibrillators  a
17735	In Vitro Test Results of Implantable Cardioverter-Defibrillators Subjected to Near Field Effects of Analog and Digital Telephone Technologies
17736	Analog and Digital Cellular Telephone Models Used During In Vitro Testing for Near Field Effects on Implantable Cardioverter-Defibrillators  a
17737	Tachyarrhythmias and Syncope During Follow-Up
17738	Mode of Clinical Presentation
17739	Left Ventricular Function During Inotropic Stimulation by Post-Extrasystolic Potentiation or Dobutamine Infusion
17740	Hemodynamic Changes With Adenosine
17741	Myocardial Blood Flow and Flow Reserve
17742	Comparison of Exercise Performance Between Survivors of Anomalous Left Coronary Artery From Pulmonary Artery Surgical Repair and Control Subjects
17743	In-Hospital Outcome of 66 Patients With Cardiogenic Shock
17744	Six-Month Clinical and Angiographic Follow-Up of 49 In-Hospital Survivors
17745	Univariate Comparison of Indexes of Left Ventricular Function in Patients With and Without Calcium-Lowering Medications During Atrial Fibrillation
17746	Thirty-Day Mortality by Type of Bundle Branch Block
17747	Independent Predictors of 30-Day Mortality
17748	Reversion Rates by Initial Bundle Branch Block Type
17749	Infarct-Related Artery by Type of Bundle Branch Block
17750	Phenotypes of Familial Dilated Cardiomyopathy and Their Clinical Definitions
17751	Electrocardiographic and Echocardiographic Findings in 28 of 48 Families With Confirmed Familial Dilated Cardiomyopathy
17752	Prevalence of Paroxysmal Supraventricular Tachycardia per 1,000 Persons by Age and Gender
17753	Incidence Rates of Paroxysmal Supraventricular Tachycardia per 100,000 Person-Years by Age and Gender
17754	Comparison of Incident Patients With Lone Paroxysmal Supraventricular Tachycardia and With Paroxysmal Supraventricular Tachycardia and Cardiovascular Disease
17755	Progression of Disease During Follow-Up Period of 39 ± 14 Months
17756	Logistic Regression: Relation Between Progression of Left Ventricular Enlargement to Dilated Cardiomyopathy and Main Noninvasive Variables
17757	Thrombolytic Therapy Assignment and In-Hospital Management by Recurrent Angina Category
17758	Outcomes and Clinical Events  a  by Recurrent Angina Category
17759	Hemodynamic Changes During Exercise
17760	Effects of Right Atrial Pacing and Exercise on Tau
17761	Selected Clinical and Electrophysiologic Features of Study Patients  a
17762	Multiple Linear Regression Analysis Results With Augmentation Index as the Dependent Variable  a
17763	Multiple Linear Regression Analysis Results With Subendocardial Viability Index as the Dependent Variable
17764	Relation of Thromboemboli to Anticoagulation
17765	Thromboembolic Events Probably Not Related to Atrial Flutter
17766	Hemodynamic Variables
17767	Comparison of Regional Myocardial Flow Reserve
17768	Lesions and Degree of Left Ventricular “Hypoplasia”
17769	Preoperative and Postoperative Volume Variables
17770	Relations Between Preoperative and Postoperative Left Ventricular Volumes
17771	Clinical Findings at Diagnosis in 1,001 Study Patients
17772	Diagnostic Workup
17773	Treatment of Acute Major Pulmonary Embolism
17774	Contraindications to Thrombolytic Treatment in 1,001 Registry Patients
17775	In-Hospital Clinical Course
17776	Age and Gender Data of People Who Died of Atherosclerotic Cardiovascular Disease and Ischemic Heart Disease
17777	Changes in Doppler Indexes Before and After Left Ventricular Assist Device Insertion
17778	Number of Shocks, Peak Delivered Energy, Peak Current and Transthoracic Impedence in 10 Patients  a
17779	Results of Head-Up Tilt Testing
17780	Comparison of Subjects With Positive and Negative Head-Up Tilt Test Responses
17781	Comparison of Minimal and Maximal RR Intervals During Autonomic Testing in Subjects With and Without Positive Head-Up Tilt Test Responses
17782	Coronary Artery Disease Prognostic Index  a
17783	Independent Clinical Predictors of 5-Year Mortality in Patients With Cardiomyopathy
17784	Prognostic Contribution of Ischemic Cardiomyopathy Versus Extent of Coronary Artery Disease
17785	In-Hospital Outcomes of Adult Patients  (<65 years old)  With or Without Previous Angina 48 Hours Before Acute Myocardial Infarction
17786	In-Hospital Outcomes of Elderly Patients  (≥65 years old)  With or Without Previous Angina 48 Hours Before Acute Myocardial Infarction
17787	Protective Role of Angina 48 Hours Before Acute Myocardial Infarction in Adult and Elderly Patients: Unadjusted Regression Model for In-Hospital Death and Congestive Heart Failure or Shock and Combined End Points  (in-hospital death, congestive heart failure or shock)
17788	Protective Role of Angina 48 Hours Before Acute Myocardial Infarction in Adult and Elderly Patients: Adjusted Regression Model for In-Hospital Death and Congestive Heart Failure or Shock and Combined End Points  (in-hospital death, congestive heart failure or shock)   a
17789	Multivariate Analysis Including All Variables for In-Hospital Mortality in Adult  (<65 years old)  and Elderly Patients  (≥65 years old)
17790	Anatomic Diagnoses and Surgical Procedures
17791	Early Success of Radiofrequency Ablation for Intraatrial Reentrant Tachycardia in Study Group
17792	HRV Variables in Control Group and Patients With IDC
17793	HRV Variables in Control Group and Patients With IDC Without and With CHF
17794	Correlation Between Mean RR and HRV Variables in Control Group and Patients With IDC Without and With CHF
17795	Correlation Between HRV Variables and Hemodynamic Indexes in Patients With IDC
17796	HRV Variables According to Presence or Absence of Severe Ventricular Arrhythmia  (Lown grade 4b)  or Late Ventricular Potentials in Patients With IDC
17797	Holter Monitor Analysis
17798	Underlying Rhythm With Initiation of Spontaneous Atrial Flutter  a
17799	Atrial Flutter After Modified Fontan Operation
17800	Effects of Six Months of Metoprolol Treatment
17801	Effect of Clinical Variables on Recovery of Effective Mechanical Atrial Function: Odds Ratios and 95% Confidence Intervals
17802	Mitral Inflow Variables After Cardioversion: A Comparison of Electrically Cardioverted  (Group I)  With Pharmacologically or Spontaneously Cardioverted  (Group II)  Patients
17803	Repolarization Changes With Heart Failure
17804	Patient Variables for Successful Versus Unsuccessful Results
17805	Patient Variables in Hospital Survivors Versus Hospital Deaths
17806	Patient Variables: No Emergency Versus Emergency Coronary Artery Bypass Graft Surgery
17807	Clinical and Echocardiographic Data for Patients With Hypertrophic Cardiomyopathy, Athletes, Patients With Hypertension and Aged-Matched Normal Subjects
17808	Accuracy of Diagnosis of Patients With Hypertrophic Cardiomyopathy Based on Measurement of Myocardial Velocity Gradient
17809	Contraindications for Thrombolytic Therapy
17810	Reperfusion
17811	Results of Best Subsets Method and Logistic Regression
17812	Angiographic Analysis
17813	Follow-Up Results
17814	Analysis of Predictors of Clinical Events After Repeat Intervention
17815	Classification of Estimated Functional Capacity According to Age and Gender
17816	Results of Proportional Hazards Analyses for Prediction of All-Cause Mortality: Final Models
17817	Randomized Trials of Beta-Blockade in Patients With Congestive Heart Failure: Effect of Beta-Blockade on Mortality
17818	Randomized Trials of Beta-Blockade in Patients With Ischemic Cardiomyopathy: Effect of Beta-Blockade on Mortality
17819	Randomized Trials of Beta-Blockade in Patients With Nonischemic Cardiomyopathy: Effect of Beta-Blockade on Mortality
17820	Subgroup Differences of the Effect of Beta-Blockade on Total Mortality
17821	In-Hospital Course of Patients With Acute Myocardial Infarction and Cardiogenic Shock Treated With or Without Intraaortic Balloon Counterpulsation
17822	Community Hospital Complications of Patients With Acute Myocardial Infarction and Cardiogenic Shock Treated With or Without Intraaortic Balloon Counterpulsation
17823	Survival of Patients With Acute Myocardial Infarction and Cardiogenic Shock Treated With and Without Intraaortic Balloon Counterpulsation
17824	Patient Groups and Exercise Testing
17825	Comparison of Cardiorespiratory Variables in Patients With Ebstein’s Anomaly Before and After Surgical Repair
17826	Variables Predicting Maximal Oxygen Uptake Preoperatively and Postoperatively
17827	Variables Predicting Blood Oxygen Saturation at Peak Exercise Preoperatively and Postoperatively
17828	Exercise Performance Preoperatively in Patients With and Without an Atrial Septal Defect
17829	Variables Predicting Heart Rate at Peak Exercise Preoperatively and Postoperatively
17830	Histomorphometric Endomyocardial Biopsy Results
17831	Mortality and In-Hospital Outcome
17832	In-Hospital Management
17833	Clinical Outcome by Use of Angioplasty
17834	30-Day Mortality Modeling
17835	Procedural Data for 86 Study Patients
17836	Procedural Success in the 92 Stented Lesions in Relation to Implantation Strategy
17837	Catheterization Hemodynamic Data in Seven Patients
17838	First Cardiac Catheterization Hemodynamic Variables in Seven Patients
17839	Doppler Left Ventricular Outflow Tract Gradient Evaluation
17840	Exercise Treadmill Time Before and After Permanent Dual-Chamber Pacing
17841	Second Cardiac Catheterization Hemodynamic Variables in Six Patients
17842	Results of Transvenous Low Energy Cardioversion in 141 Patients Included in Multicenter Trial
17843	Clinical Data of the Patients
17844	Intracardiac Cardioversion Data
17845	Clinical, Electrocardiographic and Echocardiographic Data in Members of Pedigrees 0 and 9 Carrying the Arginine 92 Tryptophan Mutation
17846	Clinical Features Associated With Hypertrophic Cardiomyopathy in Pedigrees 0 and 9
17847	Clinical Features of Familial Hypertrophic Cardiomyopathy in 21 Individuals With the Alpha-Tropomyosin Gene Mutation Asp175Asn
17848	Disease-Gene Haplotypes in Three Families With Familial Hypertrophic Cardiomyopathy Caused by the Alpha-Tropomyosin Gene Mutation Asp175Asn
17849	Cox Regression Models for Survival: Univariate Analysis
17850	Multivariate Analysis
17851	Survival Data
17852	Device Utilization
17853	Multivariate Predictors of Mortality During Follow-Up
17854	Heart Rate Variability in the Study Patients
17855	Prevalence of Atherosclerotic Changes in the Brachial Artery, Common Carotid Artery and Left Anterior Descending Coronary Artery in 52 Subjects According to Age and Severity
17856	Clinical and Angiographic Data for Six Sites of Stent Compression in Dialysis Conduits
17857	Intravascular Ultrasound Data for Six Sites of Stent Compression in Dialysis Conduits
17858	Clinical and Angiographic Data for Six Patients With Superficial Femoral Artery Stent Compression
17859	Intravascular Ultrasound Data for Six Patients With Superficial Femoral Artery Stent Compression
17860	Correlations of the Expression of Perforin and T-Cell Intracellular Antigen With Other Endomyocardial Biopsy Markers From Patients With Idiopathic Dilated Cardiomyopathy
17861	Failure of Pharmacologic and External Cardioversion Attempts and Success of Internal Cardioversion
17862	CHGB Promoter Variants A-296C and A-261T: Context-Dependent Allelic Effects on Luciferase Reporter Activity
17863	CHGB Common Promoter Variant Effects on Blood Pressure in a European Ancestry Population Sample With Extreme BP Values
17864	Mortality Outcome in Elderly Post-MI Patients Discharged With or Without Statins
17865	Relative Risk of All-Cause Mortality for Different Subgroups in Population C  ⁎
17866	Genes With Abbreviations, Main Functions, and p Values
17867	Effects of Placebo or Atorvastatin on Lipids and Endocrine Parameters in Hypercholesterolemic Patients
17868	Effects of Placebo or Atorvastatin on Lipids and Endocrine Parameters in Hypercholesterolemic Patients With Metabolic Syndrome/Type 2 Diabetes
17869	Summary of Outcome Measures
17870	Comparison of Enrolled and Nonenrolled Patients
17871	Serial ceCMR Parameters of Left Ventricular Function for Entire Study Cohort  (n = 100)
17872	Segment-Specific Slopes for Years Before/After the FMP for Cardiovascular Risk Factors Where Piecewise Linear Trajectory Fits Better Than Linear Trajectory  (Relative Fit >1)
17873	Multiple Regression Analysis: Adjusted Models for Prediction of SCD
17874	Multivariable Analyses Performed With and Without NT-proBNP and hsCRP Included in the CORONA Multivariable Model  ( 17 )  for a Range of Pre-Specified End Points and for 2 Post-Hoc End Points
17875	Total Number  (Episodes)  of Hospitalizations According to Tertile of NT-proBNP
17876	Effect of Apneas on BNP
17877	Physical Examination Findings by the Cardiology Consultant
17878	Clinical Diagnoses in Each of the Disease Categories in the Older Age Group
17879	Clinical Diagnoses in Each of the Disease Categories in the Neonatal Group
17880	Accuracy of Diagnosing Cardiovascular Disease by the BNP Assay on the Basis of Higher Sensitivity and Best Overall Accuracy Values
17881	Accuracy of Diagnosing Cardiovascular Disease by the BNP Assay on the Basis of the Maximal NPV
17882	Univariate Predictors of LVDSD
17883	Multivariate Analysis to Predict the Combined End Point  (Derivation Set)
17884	Randomized Trials of Dronedarone or Amiodarone Versus Placebo
17885	Organ-Specific Adverse Reactions Requiring Study Drug Termination  ⁎
17886	Cardiovascular Events in Patients With High or Low EMP Levels
17887	Univariate and Multivariate Cox Proportional Hazards Analysis for Cardiovascular Events in Follow-Up Patients
17888	C Statistics for Cox Proportional Hazards Model to Predict Cardiovascular Events in Follow-Up Patients
17889	Cumulative Study Results
17890	Heart Rate Variability Variables During Dipyridamole Echocardiographic Tests With Negative Results: Comparison of Basal Value and Peak Effect
17891	Analysis of Variance for Repeated Measurements on Normal and Ischemic Group Data  (Fisher F values)
17892	Serum Cholesterol, LDL, Glucose, and Insulin Levels After Four Months
17893	Echocardiographic Evaluation of Aortic Valve in Vivo After Four Months of Normal or HF/HC Diet
17894	Univariate and Multivariate Predictors of Mortality in Diabetic and Nondiabetic Patients
17895	Univariate and Multivariate Predictors of Hard Events in Diabetic and Nondiabetic Patients
17896	Hemodynamics, MBF, and MVo 2
17897	Independent Predictors of RV smand RV emin Overweight and Obese Patients
17898	Hazard Ratio by Cox Regression Analysis for Clinical Events and All Causes of Mortality
17899	Effects on dP/dtmaxas Estimated by Mixed Model
17900	Angiographic Results at Follow-Up
17901	Clinical Outcome at One Year
17902	Evaluation of Platelet Function Tests by Light Transmittance Aggregometry and TEG
17903	Observed Frequency  (%)  of Patients Without Ischemic Events and With Ischemic Events in Risk Factor Groups, Estimates of the Parameters of the Logistic Regression Model, Odds Ratio, and 95% Confidence Intervals for the Odds Ratio
17904	Primary End Points During Follow-Up
17905	Secondary End Points During Follow-Up
17906	Individual Value of Cardiovascular Magnetic Resonance Imaging-Derived Viability Indexes Analyzed at the First Week for Predicting Normal Segmental Wall Motion at the Sixth Month  (Wall Thickening >2 mm)
17907	Value of Response to Dobutamine at the First Week  (Wall Thickening With Dobutamine >2 mm)  for Predicting Normal Segmental Wall Motion at the Sixth Month  (Wall Thickening >2 mm)  Depending on the Transmural Extent of Necrosis
17908	Outcomes Before and After Program Initiation
17909	Multiple Logistic Model for Variables Associated With Failure to Survive to Discharge
17910	In-Hospital Outcome
17911	12-Month Outcome
17912	Patient Details
17913	Effects of BCO on Left Ventricular Function
17914	Effects of BCO on Power Spectral Components of RR Intervals Determined With Wavelet Analysis
17915	Variables in Rats With Chronic Heart Failure at 12 Weeks After Myocardial Infarction, as Compared With Sham-Operated Animals legend
17916	Acetylcholine- and Sodium Nitroprusside-Induced Relaxations in the Aortic Rings of Rats With Chronic Heart Failure at 12 Weeks After Myocardial Infarction, as Compared With Sham-Operated Animals legend
17917	Changes in Plasma Catecholamine Levels and Serum Potassium and Creatinine Levels After High-Dose Versus Low-Dose Enalapril Therapy
17918	Clinical Outcomes After High-Dose Versus Low-Dose Enalapril Therapy
17919	Echocardiographic Responses After High-Dose Versus Low-Dose Enalapril Therapy
17920	Repeated Measures ANOVA for the Dose-response Curves to ACh and NP legend legend
17921	Hemodynamic Data legend legend
17922	Comparison of Diameter Measurements Between Ultrasound and MRI
17923	Adenosine-Induced Changes in Coronary Hemodynamics in Women With Normal and Abnormal Microvascular Function legend
17924	Effect of Placebo and Losartan on Exercise Parameters
17925	Effect of Losartan on Echo-Doppler Measures of Diastolic Performance legend
17926	Systolic Function Response During Exercise in Placebo and Verapamil-Treated Patients
17927	Morphometric and Echocardiographic Measures of Control and Volume Overload Hypertrophy Animals at Three Weeks of Age legend legend
17928	Acetyl Coenzyme Carboxylase  (ACC)  and 5′-Adenosine Monophosphate–Activated Protein Kinase  (AMPK)  Activity in Fetal, Newborn and Three-Week Old Pig Hearts legend
17929	Malonyl Coenzyme A levels  (nmol/g dry weight)  in Fetal, Newborn and Three-Week Old Control and Hypertrophied Pig Hearts legend
17930	Hemodynamic Effects of Intracoronary Adenosine Infusion in Normotensive Subjects and Essential Hypertensive Patients
17931	Frequency of Structural Valve Abnormalities in Patients With Normal and Elevated Levels of APA legend
17932	Patient Data, Stress Heart Rate, Scintigraphic Findings and Coronary Flow Reserve in Patients With Left Bundle Branch Block legend
17933	Family History of Diabetes Between Patients With and Those Without LVH Criterion legend
17934	Electrocardiographic Findings of Patients Having Diabetic Mothers  (M+)  and Those Having Nondiabetic Mothers  (M−)  legend
17935	Multiple Logistic Regression Analysis in 834 Diabetic Patients legend
17936	Multiple Logistic Regression Analysis in 834 Diabetic Patients legend
17937	Echocardiographic Findings of Patients With Diabetic Mothers  (M+)  and Those With Nondiabetic Mothers  (M−)  legend
17938	Angiotensin-Converting Enzyme Inhibitor Therapy of Study Subjects Prior to Study Entry
17939	Drug Discontinuation or Hospitalization for Worsening Heart Failure
17940	Hemostatic Factors in the Entire Study Population  (n = 93)  legend
17941	Arterial Study Results in 10 Male Subjects legend
17942	Plasma Lipids, Lipoproteins, Triglycerides, Free Fatty Acids, and Oxidation Products Before and After Meals legend
17943	Mortality Rates and Modes of Death
17944	Mortality Reduction Associated With the Use of Beta-Blockers in Patients Randomized to Enalapril and Placebo legend
17945	Independent Association of Beta-Blocker Use With Modes of Death and Composite End Point of Death or Hospitalization for Heart Failure legend
17946	Hemodynamic Variables of Survivors and Nonsurvivors
17947	Cox Univariate and Multivariate Analyses of Variables Predictive of One-Year and Two-Year Mortality or Urgent Transplantation  (p < 0.01 Level of Significance at Univariate Analysis)  legend
17948	Angiographic and Coronary Collateral Data legend
17949	Data on Myocardial Ischemic Adaptation legend
17950	Age, Body Mass Index and Systolic and Diastolic Blood Pressure in Control  (n = 10)  Compared With Hypertriglyceridemic  (HTg; n = 11)  and Hypercholesterolemic  (HCh; n = 10)  Subjects legend
17951	Total Plasma Lipoprotein Compositions in Control  (n = 10)  Compared With Hypertriglyceridemic  (HTg; n = 11)  and Hypercholesterolemic  (HCh; n = 10)  Subjects
17952	Lipoprotein Compositions in Control  (n = 10)  Compared With Hypertriglyceridemic  (HTg; n = 11)  and Hypercholesterolemic  (HCh; n = 10)  Subjects
17953	Late Mortality in Relation to Peak Periprocedural CK Ratio legend
17954	Univariate Survival Analysis: Cox Model  legend
17955	Multivariate Survival Analysis: Cox Model With a Backward Selection legend
17956	Comparison of Platelet Activation in Control Groups and TIMI-12 Patients legend
17957	Changes in Platelet Activation with Time in Treatment Groups legend
17958	Genotypic Distributions and Allelic Frequencies of PIA1/A2Polymorphism Among Patients and Control Subjects legend
17959	Multivariate Logistic Regression Models for CAD and MI legend legend
17960	Stress Myocardial Perfusion Tomography Results
17961	Angiographic Covariates Associated with the Outcome of Stress Echocardiography Tests by Univariate Logistic Regression Analysis legend
17962	Multivariate Predictors of the Outcome of Stress Echocardiography Tests by Logistic Regression Analysis
17963	Biochemical and Physiologic Parameters legend
17964	Angiographic Results Before and After Angioplasty legend
17965	Morphometric Analysis legend
17966	Comparison of Hemodynamic Variables Between Dobutamine Stress Echocardiography and Transesophageal Atrial Pacing Stress Echocardiography legend
17967	Comparison of Symptoms and Dysrhythmias Between Dobutamine Stress Echocardiography and Transesophageal Atrial Pacing Stress Echocardiography legend
17968	Comparison of Stress Echocardiography Interpretations Between Dobutamine Stress Echocardiography and Transesophageal Atrial Pacing Stress Echocardiography
17969	Comparison of Stress Echocardiography, Wall Motion Score Index, and Ejection Fraction Between Dobutamine Stress Echocardiography and Transesophageal Atrial Pacing Stress Echocardiography legend
17970	Hemodynamic Data legend
17971	Neurohumoral Data legend
17972	Univariate and Multivariate Linear Model of Plasma Endothelin-1 Extraction in the Lower Limb in Patients With CHF legend
17973	Clinical Outcomes
17974	Postprocedure Peak CK and CK-MB by Diagnostic Category legend
17975	Procedural Success and Abrupt Closure and Clinical Outcome
17976	Clinical Outcomes in Patients With Successful Procedures Without Abrupt Closure legend
17977	Postprocedure CK-MB by Device Type
17978	Clinical Outcomes by CK-MB Level and Device Type legend
17979	PCR Primers and Reaction Conditions
17980	The Number of Vessels  (Percentage)  Positive for C. pneumoniaeDNA by PCR
17981	Peak Values Collected in Sedentary Heart Transplant Recipients  (S-HTRs)  and in Trained Heart Transplant Recipients  (T-HTRs)  During Bicycle Tests legend
17982	Plasma Lactate, Epinephrine and Norepinephrine Peak Values During Bicycle and Treadmill Testing legend
17983	Peak Values collected in Trained Heart Transplant Recipients  (T-HTRs)  legend
17984	Inclusion and Exclusion Criteria
17985	P Wave Duration on Standard Electrocardiogram legend
17986	Sensitivity, Specificity and Predictive Accuracy of P-SAECG for AVRT legend
17987	Results of Quantitative Computerized Digital Analysis of Micro-CT Images by Normal and the Balloon-injured Coronary Arteries
17988	Comparison of U.S. Hospitals Participating in GUSTO-IIb and Other U.S. Hospitals  legend
17989	Discharge Medication Use in the Overall Population and Selected Subgroups legend
17990	Discharge Medication Use in “Ideal” Patients by Enrollment Location legend
17991	Odds Ratios with 95% Confidence Intervals for the Likelihood of “Ideal” Patients Receiving Discharge Medication  legend
17992	Estimated Lives Saved by Guideline-Recommended Use of Medications
17993	Coronary Flow and Flow Velocity Data  legend
17994	Regression Analyses Between Coronary Flow Reserve and Hemodynamic Parameters  legend
17995	Plasma Glucose and Insulin After Oral Glucose Ingestion  legend
17996	Comparison of Autopsy Specimens to Echocardiographic Measurements of Aortic Circumference legend
17997	Number, Gender and Mean Age of the Four Groups  legend
17998	Persistent Fetal Dispersion of the AV Node  legend
17999	His Bundle Fragmentation  legend
18000	Statistical Analysis  legend
18001	Correlations Between Quantitative and Visual Assessments in Total Patients  (n = 1043) , Men  (n = 678)  and Women  (n = 365)  legend
18002	Nuclear Variables of Patients With and Without Hard Events legend
18003	Multivariable Cox Proportional Hazards Models legend
18004	Prevalence of Congenital Cardiovascular Malformations  (CCM)  in Infants  (Neonatal Cohort)  of HIV-Infected Mothers  legend
18005	Summary of All Congenital Cardiovascular Malformations  (CCM)  Among 558 Infants From the Neonatal Cohort
18006	Prevalence of Congenital Cardiovascular Malformations  (CCM)  and Lesion Status at One Year of Age Among the Neonatal Cohort
18007	Summary of All Congenital Cardiovascular Malformations  (CCM)  Among 201 Infants From the Older HIV-Infected Cohort
18008	Prevalence of Congenital Cardiovascular Malformations  (CCM)  Among the Neonatal Cohort Including Patent Foramen Ovale in Children Over One Year of Age legend
18009	Exercise Test Results of the Three Patient Groups legend
18010	Forearm Blood Flow Responses to Intraarterial Infusion of Increasing Doses of Acetylcholine and Sodium Nitroprusside  legend legend
18011	Changes in Average Peak Velocity, Endothelium- Dependent and Flow-Dependent Coronary Flow Reserve of the Left Anterior Descending Artery at Each State legend
18012	Summary of Patient Data legend
18013	Absolute Difference Between Echocardiographic and Magnetic Resonance Imaging Measurements  legend
18014	Quantitative Coronary Analysis  (n = 100)  legend
18015	Univariate Predictors of Recurrent In-stent Restenosis after Rotational Atherectomy legend
18016	Frequency of Small and Large Non–Q-Wave MIs in Each Patient Group  legend
18017	Frequency of Procedure-Related Non–Q-Wave MI According to Duration of Pretreatment With Ticlopidine: Results of Stratified Analyses  legend
18018	Visual Uptake of Antimyosin Antibodies in the Ventricular Wall legend
18019	Echocardiographic Variables in Patients With Mitral Regurgitation  legend
18020	Correlation Coefficient Between Mitral Regurgitant Volume  (by ACM)  and Related Factors legend
18021	Correlation Coefficient Between Qualitative Grading of Mitral Regurgitant Severity and Related Factors legend
18022	Interobserver and Intraobserver Variability legend
18023	Activities of NOS II, NOS III and Total NOS legend
18024	Cardiac NOS II Activity and Myocardial Relaxation  legend
18025	Effect of Sodium Nitroprusside on Myocardial Contraction and Relaxation  legend
18026	Plasma Levels of Arginine, Prolactin, Insulin and Glucose
18027	Results for Variables of Myocardial Damage
18028	Changes in Tl-201 DSI and r-EF
18029	Resting Heart Rate and Heart Rate Response to Exercise in 15 Patients With the Cox-Maze III Procedure
18030	Coronary Diameters and Hemodynamic Variables Before and After Coronary Stenting in Pigs legend
18031	Age at Operation  (Months)
18032	Causes of Death  legend
18033	Patients with Echocardiographic Right Ventricular Dysfunction But Without Right Ventricular Failure: Echocardiographic, Radiographic, Radionuclide, and New York Heart Association Classification  legend
18034	Patients With Raised Pulmonary Vascular Resistance ≥4 U.m2  legend
18035	Patients With Decreased Ability Index
18036	Quantitative Angiographic Results
18037	IVUS Findings Preintervention
18038	IVUS Results Postintervention
18039	In-Hospital Complications
18040	Late Clinical Follow-Up
18041	Ninety Minute TIMI Flow Grade According to Infarct-Related Artery  legend
18042	Multivariable Analysis: Predictors of 90 Minute Infarct-Related Artery  (IRA)  TIMI 3 Flow legend
18043	Results of Muscle Testing  legend
18044	Results of Neuroendocrine Assays  legend
18045	Echocardiographic Measurements and Calculations  legend
18046	Means and SDs of Anthropometric Measurements and Blood Pressure  (BP) , by Gender
18047	Mean Values and SDs of Unindexed and Indexed Left Ventricular Mass  (LVM)  by Gender, and Absolute and Relative Gender Differences
18048	Partial Correlation Coefficients  (r) , Controlled for Age, of Body Size, Body Composition and Blood Pressure With Unindexed and Indexed Left Ventricular Mass  (LVM)
18049	Changes in Left Ventricular Mass  (LVM)  Associated With an Increase of 1 SD in Body Fat  (adiposity)  or Systolic Blood Pressure  (BP)  Results Are Expressed as Absolute Changes With 95% Confidence Intervals and as Relative Changes
18050	Total and Early Duration of Repolarization and Heart Rate Corrected QT Intervals in Symptomatic and Asymptomatic LQT1 Patients and Controls  legend
18051	Application of Various Diagnostic Alternatives in LQTS in Regard to Molecular Classification of Patients and Their Relatives
18052	Frequency of the 22q11 Deletion in Patients With a Conotruncal Heart Defect
18053	Association Between Secondary Cardiac Diagnoses and Deletions of Chromosome 22q11 in Patients With TOF, TA, IAA or PMVSD  (n = 185) , and in Patients With TOF Only  (n = 126)   legend
18054	Predicted Probability of Having a Deletion of Chromosome 22q11 Based on the Full Logistic Regression Model
18055	Summary of Model Fitting Using Logistic Regression Analysis
18056	Odds Ratios and 95% Confidence Intervals Estimated From the Full Logistic Regression Model
18057	Distribution of Clinical Variables  legend
18058	Changes in Hemodynamics and Plasma Norepinephrine Concentration  legend
18059	Benefits of Training on the Incremental Maximal Exercise Test and on the 45-Min Endurance Test  legend
18060	Results of CT of the Thigh before and after 6 Weeks of Training in C and HTRs  legend
18061	Morphometry of Muscle Ultrastructure legend
18062	Coronary Angiographic and Dobutamine Stress Echocardiographic Results for Patients With Both Positive DSE and Coronary Angiography  legend
18063	Electrocardiographic and Radionuclide Data  legend
18064	QRS Duration and Mean EF for the Subgroup of Patients with EF < 45%  (n = 80)   legend
18065	Quantitative Coronary Angiography and Intravascular Ultrasound Results in 104 Patients With Complete Studies legend
18066	Results in 28 Lesions That Were Restenotic at Follow-Up  legend
18067	Subset Intravascular Ultrasound Analyses of Changes in the Cross-sectional Area of Lumen External Elastic Membrane and Plaque+Media  legend
18068	Summary of Studies on Risk Assessment Using Stress Single-Photon Emission Computed Tomographic Technetium-99m Sestamibi  legend
18069	Summary of Studies on Risk Assessment Using Technetium-99m Sestamibi in Coronary Artery Disease legend
18070	Results of Rest Sestamibi Single-Photon Emission Computed Tomography in Patients With Chest Pain in Emergency Department legend
18071	Results of Repeated Measures Analysis of Variance  legend
18072	In Vitro Results  legend
18073	In Vivo Results [mean  (range) ]
18074	In Vivo Statistics  legend
18075	Inclusion and Exclusion Criteria for Study
18076	Semiquantitative Analysis of Regional Myocardial Function Before and After 60 s of Ischemia
18077	Hemodynamic Data  legend
18078	Preischemic and Postischemic Functional and Hemodynamic Variables of Different Groups of Hearts
18079	Coronary Vascular Resistance Determined at End of Early and Late Phase of Reperfusion and at End of Postischemic Work Phase
18080	Dobutamine Stress Echocardiographic Results, Cardiac Events, Number of Rejection Episodes and Follow-Up Time in 22 Male Study Patients  legend
18081	Number of Rejection Episodes and Angiograms and Date of Event in Three Subgroups of Patients  legend
18082	Selected Variables by Left Ventricular Geometry in Patients With or Without Coronary Artery Disease legend
18083	Mortality Rates by Left Ventricular Geometry in Patients With or Without Coronary Artery Disease legend
18084	Adjusted Relative Risk and 95% Confidence Interval of Death Associated With Left Ventricular Geometry in Patients With or Without Coronary Artery Disease
18085	Adjusted Relative Risk  (95% confidence interval)  of Death Associated With Each 40-g/m2Increment in Left Ventricular Mass Index and Each 13% Increment in Relative Wall Thickness
18086	Types of Stenosis
18087	Determinants of Change in Flow-Mediated Dilation  a
18088	Cardiovascular Events in the Baltimore Coronary Observational Long-Term Study
18089	Summary of Results
18090	Changes in Hemodynamic and Metabolic Variables During Cardiac Pacing
18091	Clinical Features of Study Groups
18092	Distribution of Coronary Scores
18093	Serum Lipid and Lipoprotein Levels in Study Groups
18094	Adjusted Odds Ratio for Risk of Patients Having Angiographic Coronary Artery Disease  (extent score ≥1)   a
18095	Comparison of Changes in Various Hemodynamic Variables With Mental Stress and Exercise in Patients With Coronary Artery Disease and Normal Subjects and Between Mental Stress and Exercise in Each Group
18096	Comparison of Changes in Various Hemodynamic Variables With Mental Stress and Exercise in Patients With a Mental Stress–Induced Fall in Left Ventricular Ejection Fraction  (Group I)  and Patients With No Fall in Left Ventricular Ejection Fraction  (Group II)
18097	Comparison of Changes in Various Hemodynamic Variables Between Two Different Mental Stressors in Patients and in Normal Subjects
18098	Comparison of Changes in Various Hemodynamic Variables With Mental Stress and Exercise in Patients With an Exercise-Induced Fall in Left Ventricular Ejection Fraction  (Group A)  and Patients With No Fall in Left Ventricular Ejection Fraction  (Group B)
18099	Primary and Secondary Cardiac Events in 357 Patients With Acute Chest Pain and Technetium-99m Tetrofosmin Single-Photon Emission Computed Tomographic Imaging
18100	Multiple Logistic Regression Analysis of Univariate Predictors of Acute Myocardial Infarction
18101	Net Cost and Cost-Effective Analysis of Early Rest Technetium-99m Tetrofosmin Single-Photon Emission Computed Tomographic Imaging in Relation to Varying Intepretation Criteria
18102	Abnormal Rest Myocardial Perfusion Imaging in the Emergency Department for Prediction of Cardiac Death or Acute Myocardial Infarction
18103	Percent Changes in Coronary Artery Lumen Diameter in Response to Acetylcholine
18104	Ventricular Fibrillation, Mortality and Exclusion  a
18105	Myocardial Protection  a
18106	Hemodynamic Variables
18107	Area at Risk  a
18108	Age-Related Coronary Flow Reserve in 47 Patients With Kawasaki Disease and Normal Coronary Arteries  (group 1)
18109	Coronary Flow Velocity Change in Coronary Aneurysms at Rest and Coronary Flow Reserve in 25 Patients With Kawasaki Disease and Aneurysmal Lesions in 29 Coronary Vessels  (group 2)
18110	Coronary Flow Velocity Dynamics in 15 Patients With Kawasaki Disease and Stenotic Lesions in 18 Vessels  (group 3)
18111	Coronary Flow Velocity Dynamics in Eight Patients With Kawasaki Disease and Ischemic Findings on Exercise Stress Testing and Normal Coronary Arteries on Angiography  (group 4)
18112	Variables Analyzed  a
18113	Exercise Thallium-201 Results in 411 Study Patients
18114	Events During Follow-Up
18115	Associations Between Clinical, Exercise and Thallium-201 Imaging Variables With Total Mortality
18116	Associations Between Clinical, Exercise and Thallium-201 Imaging Variables With Initial Cardiac Death or Nonfatal Myocardial Infarction
18117	Associations Between Clinical, Exercise and Thallium-201 Imaging Variables With Initial Cardiac Death, Nonfatal Myocardial Infarction or Late Coronary Angioplasty/Bypass Surgery
18118	Associations Between Global Stress and Reversibility Scores and Outcome
18119	Angiographic Results
18120	Diagnostic Performance of Quantitative and Semiquantitative Positron Emission Tomographic Measurements for Detection of Coronary Artery Disease  (sensitivity/specificity for all regions using a criteria of 2 SD)
18121	Age and Gender Distribution of Subjects
18122	Aging Effects on 24-h Heart Rate Variability and Heart Rate by Decade
18123	Effects of Aging on Lower and Upper 95% Confidence Limits of 24-h Heart Rate Variability and Heart Rate  a
18124	Low Heart Rate Variability With Age: Relation to Cutpoints for Risk of Mortality
18125	Regional Values for Myocardial Blood Flow, Coronary Reserve and Resistance
18126	Hemodynamic and Electrocardiographic Changes  a
18127	Comparison of Thallium-201 and Technetium-99m Tetrofosmin Single-Photon Emission Computed Tomographic Dipyridamole Imaging Data in 364 Scan Segments
18128	Inclusion and Exclusion Criteria
18129	Distribution by Randomization Variables  a
18130	Changes in Coronary Diameter, Coronary Blood Flow and Vascular Resistance in Response to Acetylcholine and Nitroglycerin
18131	Results of Quantitative Angiographic Analysis
18132	Outcome of All Diabetic Patients
18133	Outcome of Insulin-Requiring Patients
18134	Effects of 48 Hours of Treatment With NTG or Placebo on Systemic and Forearm Hemodynamic Variables in Patients With or Without Captopril Treatment  a
18135	Pertinent Data in Patients With and Without Coronary Artery Disease
18136	Frequency of Side Effects During Dipyridamole Infusion in Patients With and Without Coronary Artery Disease
18137	Summary of Cardiopulmonary Exercise Responses in the Three Study Groups
18138	Catecholamines and Fibrinolytic and Procoagulant Factors
18139	Whole-Blood Flow Cytometry
18140	Categories of Perfusion and Uptake Patterns
18141	Comparative Sensitivity, Specificity, Predictive Values and Accuracy of Perfusion by Myocardial Contrast Echocardiography and Contractile Reserve by Dobutamine Echocardiography in Predicting Late Functional Recovery
18142	Coronary Blood Flow Response to Acetylcholine, Papaverine and Glyceryl Trinitrate
18143	Clinical Outcome of Patients Receiving Vented Electric Outpatient Device Versus In-Hospital Pneumatic Device  a
18144	Complications Among Patients Receiving Outpatient Vented Electric Devices and Inpatient Pneumatic Devices
18145	Sample numbers, lithologies and localities within the Newer Volcanic Province of southeastern Australia, of the xenoliths comprising this study
18146	Serum Apolipoprotein (a)  and Other Laboratory Findings in 567 Patients With Regressing, Stable or Progressing Coronary Artery Disease  a
18147	Relations Between Adjusted Coronary Score Changes and Clinical and Laboratory Findings: Results of Multiple Regression Analyses
18148	Predictors of Arteriographic Changes  (minimal obstruction diameter, mean segment diameter)  in the 567 Patients From the REGRESS Main Study: Results of Stepwise Forward Multiple Linear Regression Analysis  a
18149	Correlations Between In-Trial Serum Apolipoprotein (a)  Levels and Changes in Coronary Scores in Selected Strata: Results of Bivariate and Multivariate Correlation Analyses
18150	Predicted Volume and 95% Confidence Interval for Discrete Values of Left Ventricular Diameter
18151	Prevalence and Distribution of Valve Excrescences Within Groups
18152	Length and Width of Valve Excrescences
18153	Embolic Substrate in Patients With Suspected Cardioembolism
18154	Prevalence of Valve Excrescences by Etiology of Stroke or Embolism
18155	Histologic and Immunohistologic Findings in 80 Patients With Clinically Suspected Myocarditis With and Without Elevated Levels of Cardiac Troponin T
18156	Clinical Data of 49 Patients With Myocarditis With and Without Elevated Levels of Cardiac Troponin T
18157	Values of Tissue-Type Plasminogen Activator, von Willebrand Factor and Plasminogen Activator Inhibitor-1 in Patients With Stable Versus Unstable Angina
18158	Values of Tissue-Type Plasminogen Activator, von Willebrand Factor and Plasminogen Activator Inhibitor-1 in Patients Receiving Stents Versus Percutaneous Transluminal Coronary Angioplasty  a
18159	Heart Rate Variability
18160	Heart Rate Variability and QTc Dispersion for the Original Study Cohort According to Presenting Clinical Arrhythmia  a
18161	RR Interval, QT Intervals and QT Dispersion
18162	Sensitivity, Specificity and Positive and Negative Predictive Accuracy of QTc Dispersion and Heart Rate Variability in Predicting Vulnerability to Ventricular Tachyarrhythmias
18163	Preoperative Data
18164	Causes of Death During Long-Term Survival
18165	Risk Factors for Short-Term Survival
18166	Risk Factors for Long-Term Survival
18167	Hemodynamic and Electrocardiographic Variables
18168	Verapamil Group Patient Data
18169	Left Ventricular Functional Outcome
18170	Exercise Stress Test Results in Patients and Control Subjects
18171	Doppler Echocardiographic Data at Rest
18172	Dobutamine Stress Hemodynamic Data at Each Stage
18173	Two-Way Analysis of Varian Patients Versus Control Subjects and Stage
18174	Peak Stress Data in Patients and Control Subjects
18175	Echocardiographic and Cardiac Catheterization Data
18176	Coronary Flow and Flow Velocity Data
18177	Systemic Hemodynamic Variables
18178	Multivariate Analysis Including Lipid Variables
18179	Percent Intramyocardial Circumferential Shortening, Iodine-123 Metaiodobenzylguanidine Uptake, Myocardial Blood Flow and Blood Flow Reserve by Level in Control Animals  a
18180	Percent Intramyocardial Circumferential Shortening, Iodine-123 Metaiodobenzylguanidine Uptake, Myocardial Blood Flow and Blood Flow Reserve by Level in Animals After Infarction
18181	Regional Myocardial Blood Flow, Blood Flow Reserve and Iodine-123 Metaiodobenzylguanidine Uptake in Control and Animals After Infarction
18182	Results of Visual, Quantitative and Regional Washout Rate
18183	Two-Dimensional Echocardiographic Results in All 14 Runners
18184	Hemodynamic Measurements for All 14 Runners
18185	Right Ventricular Echocardiographic Measurements
18186	Comparison of Age, Weight and Oxygen Saturation Levels in Runners Who Developed Right Ventricular Dilation and Those Who Did Not
18187	Mitral Inflow, Pulmonary Venous Flow and Mitral Annulus Velocity in 59 Normal Volunteers
18188	Patient Population
18189	Frequency of Coronary Angioplasty or Bypass Surgery at 42 Days After Thallium-201 Imaging
18190	Ischemia-Related Events
18191	Patients With Antianginal Medication
18192	Ischemia-Related Events During Withdrawal Period
18193	Comparison of Transesophageal Echocardiographic and Pathologic Grading of Aortic Atheroma  a
18194	Univariate Correlates of Cardiac Outcome With Clinical, Exercise and Echocardiographic Findings
18195	Clinical and Tomographic Data of Heart Transplant Recipients and Normal Volunteers
18196	Effect of Inhaled Nitric Oxide on Steady State Hemodynamic Variables
18197	Effect of Inhaled Nitric Oxide on Load-Independent Indexes of Contraction and Diastolic Compliance
18198	Nitric Oxide Metabolites Sampled From the Left Ventricle and Right Atrium Before and at 10 Minutes of 20 ppm of Inhaled Nitric Oxide
18199	Comparison of Lipid and Lipoprotein Values  (by p value)  in Subjects With Low or High Coronary Flow Reserve
18200	Dobutamine Stress Tele-Echocardiography in Emergency Department
18201	Agreement Between Dobutamine Stress Tele-Echocardiography and Conventional Interpretation and Predictive Measures of Tele-Echocardiography With Clinical Outcome
18202	Dobutamine Stress Tele-Echocardiography Versus Other Tests for Clinical Heart Disease
18203	Effect of Bradykinin on Systemic Arterial Pressure, Heart Rate, Coronary Artery Diameter and Coronary Blood Flow
18204	Blood Pressure, Heart Rate, Average Peak Velocity and Coronary Artery Diameter in Five Patients With the Adenosine Defect and Control Subjects at Rest and During Pharmacologic Stimulation
18205	Relative Coronary Flow Reserves for Adenosine and Papaverine and Volumetric Coronary Flow Reserve for Acetylcholine in Five Patients with the Adenosine Defect and Twenty-Four Control Subjects
18206	Heart Rate and T Wave During Arousal  a
18207	T Wave Configuration Before and During Arousal
18208	Measured and Interpolated QT Intervals During Arousal
18209	Relation of QT Interval and QT Apex Interval to Cardiac Cycle Length
18210	Measured and Corrected QT Intervals During Arousal
18211	Clinical, Echocardiographic and Angiographic Features of the Study Patients
18212	Hemodynamic Changes During Stress Echocardiographic Testing
18213	Effect of Pravastatin on Platelet Aggregability, Prostaglandin Production and Platelet Activity in Hypercholesterolemic Patients
18214	Heart Failure Score Computation
18215	Components of Heart Failure Score in the Patient Groups
18216	Adjusted Risk of Treatment Failure: Mild and Moderate Patient Groups Versus Digoxin-Continued Patient Group
18217	Univariate Cox Regression Analysis of Association Between Variables Studied and Survival Time
18218	Multivariate Cox Regression Analysis of Study Variables  a
18219	Mutivariate Analysis of Clinical Variables and QT Dispersion as Predictors of Death in Patients Awaiting Heart Transplantation
18220	Overall and Cause-Specific Mortality as a Function of Interlead Variability of the QT Interval
18221	Correlations of Exercise Electrocardiographic Positivity Onset, Recovery Time and Metabolic Equivalents With Angiographic and Scintigraphic Variables
18222	Exercise Electrocardiographic, Angiographic and Scintigraphic Correlations of Slope of Maximal Exercise-Induced ST Segment Depression
18223	Correlations of Angiographic and Scintigraphic Variables
18224	Distribution of Confirmed Diagnoses for 10,783 Women and Men
18225	Killip Class Distribution in 894 Patients With Acute Myocardial Infarction  a
18226	Distribution of Hospital Procedures by Gender Among 2,541 Patients With Acute Cardiac Ischemia
18227	Hospital Mortality Rates for Women and Men by Final Diagnosis
18228	Unadjusted Odds Ratios for Hospital Mortality From Acute Cardiac Ischemia
18229	Changes in Systolic Blood Pressure  (mm Hg)  in Normal Subjects and in Patients With Stable Angina
18230	Mean Diameter Changes of Proximal and Distal Segments and Coronary Stenoses in Response to Atrial Pacing During Saline and During Intracoronary N G-Monomethyl-l-Arginine  (4 μmol/min)
18231	Preoperative Data of 31 Study Patients and Results of Heart Catheterization
18232	Exercise Treadmill Variables in the Four Patient Groups
18233	Exercise Thallium Single-Photon Emission Computed Tomography in Patients With a Ventricular Pacemaker
18234	Hemodynamic/Echocardiographic Dose-Response of Digoxin
18235	Least-Squares Mean Estimates of Fractional Shortening for Each Digoxin Dose at Average Level of Load
18236	Autonomic Dose Response to Digoxin  (mean ± SD)
18237	Site of Anomalous Pulmonary Vein Connection
18238	Forearm Blood Flow During Brachial Artery Infusion of Saline, l-Arginine Alone, Nitroprusside, Acetylcholine and Acetylcholine Plus l-Arginine in Control Subjects and Hypertriglyceridemic Patients
18239	Fast and Slow Pathway Conduction Time
18240	Classification of Embolic Events by Gender
18241	Incidence and Crude Relative Risk of Thromboembolic Events According to Gender and Ejection Fraction Quartile
18242	Univariate Analysis: Relative Risk of a Thromboembolic Event According to Gender
18243	Multivariate Analysis: Relative Risk of Thromboembolic Event According to Gender
18244	Multivariate Analysis: Relative Risk of Thromboembolic Events by Gender After Exclusion of Pulmonary Emboli
18245	Accuracy of Various Modalities in Prediction of Recovery of Function After Revascularization in Severely Dysfunctional Segments
18246	Sensitivity and Specificity of Different Techniques in Hypokinetic and Akinetic Segments
18247	Sensitivity, Specificity and Accuracy for Predicting Recovery of Contractile Function: Analysis by Vascular Territory and by Patients
18248	Independent Predictive Variables Used for Univariate and Multivariate Analysis
18249	Exercise Data During Rest and at Peak Exercise
18250	Univariate and Multivariate Analysis of Predictive Variables for log V̇o 2max/kg2/3
18251	Univariate and Multivariate Analysis of Predictive Variables for Peak Exercise Oxygen Saturation
18252	Univariate and Multivariate Analysis of Predictive Variables for Maximal Heart Rate
18253	Comparison of Nuclear Imaging and Transient Response Imaging in Detecting Perfusion Abnormalities  a
18254	QT-RR Index in the Two Study Groups
18255	Body Weight, Food Ingestion, Serum Lipoprotein Levels and Extent of Intimal Lesions in the Three Study Groups
18256	Maximal Relaxation Responses to Acetylcholine in the Presence of Various Sex Hormones
18257	Multivariate Analysis of Maximal Vasoconstriction on AT1Receptor Genotypes and Covariables
18258	Stepwise Multiple Regression of Predictors of Left Atrial Size
18259	Pulmonary Function Tests in Normal Subjects and Patients With Heart Failure
18260	Hemodynamic, Metabolic and Ventilatory Response to Exercise in Normal Subjects and Patients With Heart Failure Breathing Room Air and Helium During Rest and Exercise
18261	Regional Fluorine-18 Fluorodeoxyglucose Uptake and Nitrogen-13 Ammonia–Determined Flow, Washout and Volume of Distribution
18262	Accuracy of Nitrogen-13 Ammonia Kinetic Methods for Predicting Viability Defined by Fluorine-18 Fluorodeoxyglucose in Abnormal Regions of 16 Patients
18263	Neurohumoral Variables  a
18264	Effects of Beta-Blockers According to Absence or Presence of Neurohumoral Activation in the Neurohumoral Subgroup  a
18265	Cox Proportional Hazards Analysis of Interaction Between Beta-Blocker Use and Neurohumoral Activation
18266	Electrophysiologic Anterograde and Retrograde Properties of Atrioventricular Node in Children and Adolescents
18267	Clinical, Angiographic and Hemodynamic Correlates of Collateral Vessels During Coronary Occlusion
18268	Predicted Probability of Recruitable and Spontaneously Visible Collateral Vessels and 95% Confidence Intervals
18269	Independent Clinical and Angiographic Predictors of Recruitable Collateral Vessels After Multivariate Analysis and Scoring System for the Presence of Recruitable Collateral Vessels  a
18270	Cardiac Hemodynamic Variables and Central Venous Pressure Determined in Anesthetized Rats After 9-Month Survival Study
18271	Plasma Renin Activity, Plasma Catecholamine Levels and Cardiac Morphology in Animals Killed After 9 Months
18272	Changes in Hemodynamic Variables
18273	Perfusion and Metabolism Patterns in Myocardial Segments Improving With Dobutamine
18274	Positron Emission Tomographic and Echocardiographic Detection of Myocardial Segment Viability
18275	Treadmill Stress Test Data for 48 Study Patients
18276	Dipyridamole Test Data for 37 Study Patients
18277	Thallium-201 and Technetium-99m Sestamibi Image Quality in 85 Patients and 30 Volunteers
18278	Patient Diagnosis: Thallium-201 Versus Technetium-99m Sestamibi
18279	Mean Rate-Corrected QT Values in Blood Relatives From Pooled Genotypically Characterized Long QT Syndrome Families Linked to Chromosome 7q  (HERG)  or 11p  (KVLQT1)
18280	Mean Heart Rates in Blood Relatives From Pooled Genotypically Characterized Long QT Syndrome Families Linked to Chromosome 7q  (HERG)  or 11p  (KVLQT1)
18281	Mean Absolute QT Values in Blood Relatives From Pooled Genotypically Characterized Long QT Syndrome Families Linked to Chromosome 7q  (HERG)  or 11p  (KVLQT1)
18282	Multiple Regression Analysis of Variables Predictive of Rate-Corrected QT Interval in Pooled Genotypically Characterized Long QT Syndrome Families Linked to Chromosome 7q  (HERG)  or 11p  (KVLQT1)
18283	Multiple Regression Analysis of Variables Predictive of Absolute QT Interval in Pooled Genotypically Characterized Long QT Syndrome Families Linked to Chromosome 7q  (HERG)  or 11p  (KVLQT1)
18284	Left Ventricular Angiographic Data in Normotensive and Hypertensive Subjects With and Without Coronary Artery Disease  a
18285	Severity of Atherosclerosis, All Segments  a
18286	Transesophageal Echocardiography Versus Epiaortic Ultrasound, by Segment
18287	Epiaortic Ultrasound and Transesophageal Echocardiography Versus Palpation for Detection of Ascending Aortic Atherosclerosis
18288	Atherosclerosis of Ascending Aorta Versus Aortic Arch and Descending Aorta  a
18289	Results of Morphometric Analysis of Biopsy Samples of Vastus Lateralis Muscle
18290	Sequential Intravascular Ultrasound Analysis  (according to individual lesions)
18291	Axial Distribution of the Changes in Lumen, External Elastic Membrane and Plaque Plus Media Cross-Sectional Areas  (according to individual slices)
18292	Effect of Adenosine and Dobutamine Infusion on Coronary Hemodynamic and Metabolic Variables at Cardiac Catheterization in Patients With Syndrome X and Control Subjects
18293	Comparison of Patients With Balanced Versus Unbalanced Common Atrioventricular Canal According to Presence of Down Syndrome, Unrestrictive Ventricular Septal Defect and Hemodynamically Significant Preoperative Atrioventricular Valve Insufficiency
18294	Atrioventricular Valve Index and Ventricular Cavity Ratio [mean  (SD) ] for the Various Study Groups
18295	RR Interval Measurements
18296	Correlations Between Approximate Entropy and Linear Measures of Heart Rate Variability
18297	Sensitivity, Specificity, Positive and Negative Predictive Values and Diagnostic Accuracy for Different Thresholds of Functional Improvement Assessed by the Centerline Method  a
18298	Functional Outcome in Regions With Mild  (sestamibi uptake 51% to 70%, n = 27) , Moderate  (31% to 50%, n = 15)  or Severe  (≤30%, n = 12)  Perfusion Defects by Presence or Absence of Mismatch Pattern  a
18299	Sensitivity, Specificity, Positive and Negative Predictive Values and Diagnostic Accuracy for Different Tracer Uptake Thresholds  a
18300	GRS of All Lipid Fractions and MAC Association
18301	Triglyceride GRS Associations With Triglycerides and MAC in MESA HispanicAmericans
18302	Forward Stepwise Selection Model for Incident ASCVD
18303	Change in Discrimination With Adding Cholesterol Efflux Capacity to Risk Factors for Incident ASCVD
18304	Net Reclassification of Events and Nonevents With Adding Cholesterol Efflux Capacity to Risk Factors for IncidentASCVD
18305	Distribution of CYP2C19 Genotype and Functional Phenotypes
18306	Association of CYP2C19 Functional Variants  (EM vs. RM)  With Ischemic Outcomes in Genetics Cohort
18307	Association of CYP2C19 Functional Variants With Longitudinal and 30-Day PRU Values
18308	MESA 10-Year CHD Risk Prediction Models
18309	Evaluation of Model Performance
18310	Quantitative Measures of LV Function
18311	Clinical Events
18312	Work-Related Musculoskeletal Pain and Involvement inProcedures With Radiation Exposure
18313	Medical Conditions Potentially Associated With Radiation Exposure
18314	Independent Predictors of the Presence of Moderate/Severe Target Lesion Calcification
18315	1-Year Rates of Major Events Stratified by the Severity of Target Lesion Calcification
18316	Independent Predictors of 1-Year Clinical Outcomes
18317	Risk Factors for Coronary Calcification
18318	Studies of Medical Therapies for Targeting CAC Progression
18319	Outcomes of Studies Comparing DES and BMS in Calcified Lesions
18320	Studies of Cutting and Scoring Balloons in Calcified Coronary Lesions
18321	Studies of High-Speed RA in Calcified Coronary Lesions
18322	Studies of Laser Coronary Angioplasty in Calcified Coronary Lesions
18323	Correlation Matrix Between the Number of Lp-PLA2 Transcripts and Clinical Data
18324	CHD and CVD Event Rates per 1,000 Person-Years and 5-Year NNT for Each of the Polypill Studies
18325	HRs  (95% CIs)  for CHD and CVD Events With Increasing Burden of CAC for the Polypill Studies
18326	Systolic and Diastolic BF in the 3 Main Intestinal Arteries
18327	Bowel Wall Thickness of Terminal Ileum, Ascending Colon, Transverse Colon, Descending Colon, and Sigmoid in Noncachectic and Cachectic Patients With Chronic HF and Control Subjects
18328	Concentration of Bacteria in Patients With Chronic HF and Control Subjects
18329	Logistic Regression Model With Presence of Cachexia Serving as the DependentVariable
18330	Procedural Outcomes
18331	Transthoracic Echocardiography Data
18332	Clinical Outcomes at 30 Days
18333	Pacemaker Implantation
18334	Effects of Severe Absolute AVC and Severe AVCdensity on Survival: Univariateand Multivariate Analyses
18335	Angiographic Findings
18336	OCT Measurements of Lipid Plaque
18337	Criteria for Inclusion Into Destination Therapy Clinical Trials
18338	INTERMACS Patient Profiles  ( 20 )
18339	Risk Factors for RV Failure After LVAD Implantation
18340	Descriptive Statistics: MESA
18341	Association of LDL-C or LDL-C Genetic Risk Score With CAC ≥75th Percentile in the FHS
18342	Association of Lipid Measures or Genetic Risk Scores With CAC ≥75th Percentile in the Pooled FHS Offspring and Third-Generation Cohorts  (n = 3,110)
18343	Association Between Untreated LDL-C Level and CAC ≥75th Percentile at Each Exam Cycle in the FHS Offspring Cohort
18344	Association of HDL-C or HDL-C Genetic Risk Score With CAC ≥75th Percentile in the FHS
18345	Association of TG or TG Genetic Risk Score With CAC ≥75th Percentile in the FHS
18346	ORs and 95% CIs for CAC in Adulthood in a Multivariable Logistic Regression Model  (N = 563)  Adjusted for All of the Listed Variables
18347	Age- and Sex-Adjusted Spearman's Correlations Coefficients Between Risk Variables  (LDL-C and Systolic Blood Pressure)  and Regional Calcium Scores
18348	Candidate SNPs, Their Frequencies, and Their Associations With On-Treatment Reactivity at 12 to 24 h, 30 Days, and 6 Months After PCI  ⁎
18349	Full Multivariate Generalized Linear Models of On-Treatment Reactivity at 30 Days and 6 Months After PCI
18350	Descriptive Statistics for the Total Study Cohort and According to Annular or Valvular Calcification Status
18351	Risk Ratios  (95% Confidence Intervals)  Describing the Associations Among MAC, AAC, and AVSc and Covert Brain Infarcts
18352	Risk Ratios  (95% Confidence Intervals)  Describing the Associations Among AVSc, MAC, and AAC and High WM Grade  (>4)
18353	Risk Ratios  (95% Confidence Intervals)  Describing the Associations Among AVSc, MAC, and AAC and Either Covert Brain Infarcts or High WM Grade  (>4)
18354	Covert Brain Infarct Location According to Calcific Annular or Valve Disease Status
18355	CAC Prevalence, Amount, and Number Needed to Screen Compared With Framingham Risk Score Categories
18356	CAC Prevalence and Amount Compared With Framingham Risk Score Categories, Stratified by Sex
18357	Univariate and Multivariable Odds Ratios and 95% CIs for CAC Score ≥300 by Framingham Risk Score Strata
18358	Morphometric Parameters of Rats at Sacrifice
18359	Cardiac MRI Parameters of Chronic Thromboembolic Pulmonary Hypertension Patients and Healthy Volunteers
18360	Cardiac MRI Parameters of Chronic Thromboembolic Pulmonary Hypertension Patients at Follow-Up
18361	Echocardiographic Parameters of Rats at Sacrifice
18362	Agreement Between VECAC and AS in 492 Patients With 2 Readers per Patient
18363	Individual Reader Agreement Between VECAC and AS
18364	Individual Reader Agreement Between VECAC and AS for 99 Cases From Columbia University Medical Center
18365	Agreement Between Readers in 492 Patients
18366	Prevalence of Valvular or Vascular Calcification Stratified by Bisphosphonate Use
18367	Prevalence Ratio for Vascular and Valvular Calcification With Bisphosphonate Use Stratified by Age
18368	Repartition of Genetic Polymorphisms of Cytochrome 2C19*2According to Their Response to the First Loading Dose of Clopidogrel
18369	In-Hospital Outcomes
18370	Parameter Estimates and Performance Measures of the Framingham Refitted and the Framingham Plus CAC Models
18371	Cardiovascular Risk Reclassification Comparing the Framingham Refitted Model With the Model Additionally Including CAC
18372	Cardiovascular Risk Reclassification Comparing the Framingham Refitted Model With the Model Additionally Including CAC, by Gender
18373	Number of Coronary Hard Events in the 3 FRS and ATP III Risk Categories and Relative Risks in the HNR Study During 5 Years of Follow-Up: Intermediate Risk Thresholds 10% to 20% and 6% to 20%
18374	Reclassification of Intermediate  (Defined as 10% to 20% and 6% to 20%)  Risk Participants With or Without Hard Coronary Events During 5-Year Follow-Up Based on CAC Results
18375	Reclassification for the Total Cohort Based on Models Using FRS Variables With or Without Hard Coronary Events During 5-Year Follow-Up Based on CAC With Definition of Intermediate Risk as 10% to 20% and 6% to 20%
18376	Cumulative and Relative Risks of Hard Events Associated With Increasing CAC Scores in the HNR Study
18377	NRI Using Other Variables of Extended Risk Stratification
18378	Multivariate Binary Logistic Regression Analysis for Low Response to Clopidogrel
18379	Multivariable Linear Regression Model for RPA After Stimulation With 5 μmol/l ADP
18380	Association of Long-Term Average of Individual Atherosclerosis Risk Factors  (Examinations 1 Through 7)  With the Presence of Aortic and Mitral Valve Calcium
18381	Association of Early Atherosclerosis Risk Factors  (Examinations 1 Through 3)  With the Presence of Aortic and Mitral Valve Calcium
18382	Univariable  (Crude)  and Multivariable  (Adjusted)  Logistic Regression Analysis of Factors That May Be Associated With Presence of ≥50% Coronary Lesions in Patients With 0 Coronary Calcium Score  (n = 72)
18383	Frequency  (Percentage)  of Noninvasive Test Layering at 6 Months and Downstream Follow-Up Testing at 6 Months, 1 Year, and 4 Years of Follow-Up in CAC Subsets
18384	Frequency  (Percentage)  of Noninvasive Test Layering in CAC Subsets
18385	Early and Late Revascularization Rates  (Percentage)  by CAC Subsets
18386	Estimated Annual Cardiovascular Procedural and Overall * Costs in CAC Subsets
18387	Patient-Based Analysis
18388	Vessel-Based Analysis
18389	Adjusted HR for Increasing Severity of Limb Ischemia at Presentation  ⁎
18390	HRs for Major Amputation in Patients Presenting With PAD
18391	G-CSF Therapy
18392	Pre-Operative Echocardiographic Data of the Study Population
18393	Stent Shape After Deployment According to Aortic Valve Pathology
18394	IVUS and VH Data
18395	Independent Predictors of the Highest HITS Count Tertile by Multivariate Analysis
18396	CFVR Before and After PCI
18397	Comparison Between STR Group and Non-STR Group
18398	Prevalence of Cardiac Risk Factors in 14,812 Asymptomatic Individuals Undergoing CAC Screening
18399	Multivariable Model on the Impact of Ethnicity in Clinically Risk-Adjusted and Calcium-Adjusted Cox Proportional Hazards Models
18400	Multivariable Model RRR for All-Cause Mortality by CAC Scores According to Ethnicity
18401	Quintile Ranges for Obesity Measures
18402	C-statistic Values for Univariable and Adjusted Models of Prevalent Atherosclerosis
18403	Use of Therapies and Risk Factor Control of Subjects With a Calcium Index < or ≥ Median
18404	Serial Change in Atheroma Burden and Remodeling of Subjects With a Calcium Index < or ≥ Median
18405	Definitions of Tissue Types of Each ROI
18406	Interobserver Variability of Each Imaging Diagnosis
18407	Assessment of IB-IVUS and Conventional IVUS for Plaque Characterization
18408	Comparison Between Imaging Diagnosis and Histological Diagnosis
18409	Comparison Between IVUS Diagnosis and OCT Diagnosis
18410	Angiographic Analysis
18411	Qualitative Intravascular Ultrasound Findings
18412	Quantitative Intravascular Ultrasound Findings
18413	Quantitative Analysis of Western Blot and RT-PCR
18414	Heart Weight and Histological Data 14 Days After MI
18415	Summary of Results From Ventricular Function Study  (45-Min Occlusion Protocol)
18416	Summary of Results From Ventricular Function Study  (90-Min Occlusion Protocol)
18417	Patient Data and Operating Parameters During Patient Exposures
18418	Organ and Effective Dose Values Normalized Over Total Dose-Area Product
18419	Patient Peak Skin Dose, Effective Dose, and Gonadal Dose Following Typical Cardiac Rhythm Device Implantation Procedures
18420	Risks for Fatal Carcinogenesis and Severe Hereditary Disorders Following Resynchronization Device Implantation Procedures
18421	Variables in Control and Growth Factor-Treated Groups  (Mean ± SEM)
18422	Prevalence of Coronary Artery Calcification and Calcium Score in Cases and Controls
18423	Coronary Calcium Score and All CoronaryDisease Events   ⁎
18424	Univariate Correlations: Standard Risk Factors, C-Reactive Protein, and Coronary Calcium Score  (n = 1,293)
18425	Association of Standard Risk Factors, C-Reactive Protein, Calcium Score, and All Coronary Disease Events  (n = 1,293)
18426	Lesion Detection Stenosis ≥50%
18427	Results: Detection of Significant  (≥50%)  Stenoses With 16-Row Multislice Spiral Computed Tomography Coronary Angiography
18428	Diagnostic Performance of Multislice Spiral Computed Tomography Coronary Angiography for the Detection of Significant Obstructive Lesions
18429	Association Between VE/VCO2Slope and Independent Variables in Univariate and Multivariate Analysis
18430	Association Between Lean Peak VO2and Independent Variables in Univariate and Multivariate Analysis.
18431	Blood Hormone and Cytokine Analyses
18432	Biochemical Parameters and Vitamin D Receptor Genotype of Patients With Congestive Heart Failure and of Elderly Controls
18433	Cardiovascular Risk Variables Among White and Black Patients Studied With Coronary CT
18434	Coronary Calcium Scores and Prevalence in Black and White Subjects
18435	Logistic Regression Coefficients and Confidence Intervals for a Multivariate Model Evaluating Associations With Coronary Artery Calcium
18436	Data Abstracted From Questionnaire, Telephone Interview and Medical Record Review
18437	Spectrum of Disease in Pregnant Women With History of Aortic Coarctation
18438	Obstetrical and Neonatal Data for 118 Pregnancies
18439	Contingency Table of Relation Between Hypertension During Pregnancy and Presence of Coarctation * †
18440	Calcium Scores in Symptomatic Men and Women legend
18441	Calcium Score Nomogram for 1,764 Symptomatic Subjects
18442	Exclusion of Coronary Calcium  (Score = 0)  legend legend
18443	Sensitivity and Specificity of Coronary Calcifications at Different Score Levels legend
18444	Cardiac Risk Factors legend
18445	Prevalence of Detectable Calcium  (score > 0)  and Mean Calcium Score
18446	Relation of Lipoprotein (a)  and the Other Variables to Calcium Score legend
18447	Total Calcium Score Quartiles, NCEP Risk Groups and Radionuclide Imaging Score Quartiles as a Function of CAGE ≥20 or CAGE ≥50 Scores
18448	Multiple Linear Regression Analysis to Determine Independent Predictors of the Number of Angiographic Segments with 20% or Greater Maximum Stenosis  (CAGE ≥20 score)  or 50% or Greater Maximum Stenosis  (CAGE ≥50 score)  legend legend
18449	Coronary Heart Disease Risk Factors and Ethnicity legend
18450	Medication Use by Race
18451	Comparison of the Topological Distributions of Coronary Calcium by Race legend
18452	Independent Predictors of the Presence of Any Coronary Calcium legend
18453	Coronary Events and Ethnic Origin at 70 Months of Follow-up legend legend
18454	Race, Calcification and Coronary End Points legend
18455	Independent Predictors of Any Coronary Event by Multivariate Logistic Regression, Along With Odds Ratios and 95% Confidence Intervals legend
18456	Distribution of the Study Population According to the Type of Prosthesis Implanted and the Valve Involved
18457	Outcome of Pregnancies legend
18458	Survey of Three Previously Published Studies Using EBCT and “Any” Coronary Calcium  (i.e., a Score >0)  for the Diagnosis of Obstructive Coronary Disease  (≥50% Stenosis at Angiography)  legend
18459	Input to the Model  (Noninvasive Testing and Angiography)  legend
18460	Number of Patients out of 100 in Each Prevalence Group and for Each Testing Pathway Undergoing Angiography Directly or for a Positive or Nondiagnostic Noninvasive Test legend
18461	Total Combined Costs per Patient for Each of the Eight Diagnostic Testing Pathways as a Function of Prevalence of Coronary Artery Disease in the Population Tested legend
18462	Percentage of Patients Correctly Diagnosed  (True Positive Rate)  and Absolute Number  (in Parentheses)  With Obstructive Coronary Disease out of 100 Tested in Each Prevalence Group at Completion of Any Testing Pathway legend
18463	“Cost-Effectiveness”  (Total Direct Costs in Dollars per Patient Correctly Diagnosed With Obstructive Coronary Artery Disease)  for the Individual Diagnostic Testing Pathways legend
18464	Negative Predictive Value of Testing Pathway as a Function of Prevalence of Disease in the Population Tested legend
18465	Positive Predictive Value of Testing Pathways as a Function of Prevalence of Disease in the Population Tested legend
18466	Independent Predictors of Angiographic Three-Vessel and/or Left Main Disease legend legend
18467	Predictive Power of the Noninvasive Index legend
18468	Distribution of Continuous Variable Risk Factors legend
18469	Distribution of Coronary Calcium Scores for Each Category of Disease
18470	Association of Risk Factors for Coronary Disease and the Coronary Calcium Score With the Presence of Any Angiographic Coronary Artery Disease by Multiple Logistic Regression  legend
18471	Association of Risk Factors for Coronary Disease and the Coronary Calcium Score With the Presence of Angiographic Obstructive Coronary Artery Disease by Multiple Logistic Regression  legend
18472	Odds Ratio for Any Coronary Disease and Obstructive Coronary Disease, Highest Quartile Vs. Lowest Quartile, by Multiple Logistic Regression  legend
18473	Operator Reasons for Not Stenting 72 Lesions  a
18474	Site and Core Laboratory Angiographic Measures
18475	Major In-Hospital Adverse Effects in 312 Patients
18476	Predischarge Cardiac Catheterization: Indications and Findings
18477	Adverse Events Occurring Within 30 Days After Hospital Discharge
18478	Left Ventricular Hypertrophy and Blood Pressure legend
18479	Tissue Cyclic GMP Levels legend legend
18480	Classification of Coronary Calcifications Observed on Electron Beam Computed Tomographic Images
18481	Morphologic Classification of Segments With Calcification
18482	Prediction of All Coronary Atherosclerotic Lesions by Calcification According to Segment  a
18483	Prediction of Significant Coronary Stenosis by Calcification According to Segment  a
18484	Positive Predictive Value of Calcification Morphology for All Coronary Atherosclerotic Lesions According to Patient Age
18485	Positive Predictive Value of Calcification Morphology for Significant Coronary Stenosis According to Patient Age
18486	Prevalence of Aortic Valve Abnormalities by Echocardiography
18487	Bivariate Relations of Clinical Variables to Aortic Valve Abnormalities
18488	Clinical Factors Associated With Aortic Stenosis or Sclerosis by Stepwise Multiple Logistic Regression
18489	Interlesion Comparison in Intravascular Ultrasound Calcification  (in 521 patients with two lesions imaged)
18490	Correlates of Intravascular Ultrasound Target Lesion Calcium
18491	AoD in Relation to Aneurysm Diagnosis and Previous Surgical History
18492	Antecedent Aortic Size in Relation to Subsequent AoD: Overall GenTAC Registry
18493	Antecedent Aortic Size in Relation to Subsequent AoD: MFS Population
18494	Multivariable Logistic Regression Model for Prediction of AoD
18495	Annual Hospitalizations  (2011)
18496	Cost  ∗   and Cost Differences †  Between Smokers and Nonsmokers  (2011)
18497	Electrophysiologic Changes
18498	Cytokine Changes
18499	Average BW, HW, Ratio of BW to HW, and BloodGlucoseLevels of T2DM and Control Animals
18500	Comparison of Compliance With Coronary Artery Disease Measures Among Patients Receiving Care From Advanced Practice Providers and Physicians
18501	Comparison of Compliance With Heart Failure and Atrial Fibrillation Measures Among Patients Receiving Care From Advanced Practice Providers and Physician Providers
18502	Comparison of Compliance With Coronary Artery Disease Performance Measures Between Practices With Both Physician and Advanced Practice Providers and Physician-Only Practices
18503	Comparison of Compliance With Heart Failure and Atrial Fibrillation Performance Measures Between Practices With Both Physician and Advanced Practice Providers and Physician-Only Practices
18504	Major Bleeding Events During Hospitalization in theStudy Population  (n= 154)   ∗
18505	Reasons for Procedural Failure of Left AtrialAppendage Ligation With the Lariat Device  (N= 22)
18506	Medical Therapy at Discharge After TranscatheterLeftAtrial Appendage Ligation  (n= 154)
18507	Description of the Prospective Randomized Pooled Trials
18508	Clinical Outcomes at 30 Days and 1 Year According to Diabetic Status
18509	Platelet Reactivity Before and After RBC Transfusion in the Study Population  (n= 61)  Measured With LTA, Expressed by MPA and RPA
18510	Angiogenesis Inhibitors and Stimulators
18511	Examples of Animal and Human Studies Implicating Monocytes in Angiogenesis
18512	Family of VEGF and Their Functions
18513	Monocytes Subsets and Their Functions
18514	Left Ventricle Remodeling and Dysfunction by Echocardiography at 1 and 30 Days After Myocardial Infarction
18515	Effect of MSC Therapy on Global LV Remodeling and Function With and Without Macrophage Depletion by Conventional Echocardiography at 1 and 7 Days After Myocardial Infarction
18516	Effect of MSC Therapy With and Without Macrophage Depletion on Regional and Global LV Function by Speckle-Tracking Based Strain Imaging in Parasternal Long-Axis View
18517	Components of the Metabolic Syndrome
18518	Age-Standardized Prevalence of the Metabolic Syndrome in the United States, 1999 to 2010
18519	Grades of Stenosis Severity and In-Stent Minimum Lumen Diameter on Follow-Up Coronary Angiography in Patients With Restenosis  (N = 48)
18520	Incidence of Death or MI and Death After Clopidogrel Cessation
18521	Multivariate Analyses for Selected Subgroups for Risk of Death or MI in 0- to 90-Day Interval After Clopidogrel Cessation Compared With Subsequent 91 to 365 Days
18522	Reclassification of Study Participants Into MI Risk Groups by Addition of miR-126, miR-197, and miR-223 to a Model With the FRS for Hard Coronary Heart Disease
18523	Summary Statistics of MI Risk Reclassification by Addition of miR-126, miR-197, and miR-223 to a Model With the FRS for Hard Coronary Heart Disease
18524	Lack of Association Between SNPs in PLA2G7 and Circulating Lp-PLA2 Protein Mass or Activity But Significant Relation of Multiple SNPs in CRP With Circulating CRP Levels  ⁎
18525	Association of SNPs in PLA2G7 But Not in CRP With CAC
18526	Laboratory Measurements
18527	Angiographic Results, Revascularization Procedure, and Biological Data  (n = 45)
18528	2-Way Contingency Tables for Biomarker Detection of CMR-LGE
18529	Hazard Ratios of Heart Failure According to Different Levels of Occupational Physical Activity
18530	Hazard Ratios of Heart Failure According to Different Levels of Commuting Physical Activity
18531	Hazard Ratios of Heart Failure According to Different Levels of Leisure Time Physical Activity
18532	Kaplan-Meier Cumulative Incidence of Adverse Outcomes at 4 Years
18533	Inflammatory Markers According to Incident HF Development
18534	Inflammatory Biomarkers and Incident HF Risk
18535	Inflammatory Biomarkers and Incident HF With Death as a Competing Risk
18536	Per Cell Fluorescence 24 h After IV Injection
18537	Heart and Body Weights
18538	Outcomes
18539	Novel Cardiovascular Risk Factor Concentrations by Race
18540	Multivariable Predictors of PAD
18541	Odds Ratio of Peripheral Arterial Disease Among African Americans Compared With Caucasians Across Studies
18542	Composition of Cocoa Drinks
18543	RRs of MI Incidence Associated With Anxiety Scales in Cox Proportional Hazards Models  ⁎
18544	Prediction of MI Risk by Overall Anxiety in Multivariate Cox Regression Models Controlling for Age, Education, Marital Status, Fasting Glucose, BMI, HDL-C, SBP, and Additional Psychologic Variables  (n = 735)
18545	Incidence of Stroke or Non-CNS Systemic Embolism in Patients With Paroxysmal Versus Persistent/Permanent AF Treated With Aspirin Plus Clopidogrel or OAC
18546	Effect of Allocated Treatment on the Incidence of Total and Major Bleedings in Patients With Paroxysmal Versus Persistent/Permanent AF
18547	Guideline-Based Medication and Invasive Procedure Use
18548	Guideline-Based Discharge Therapies
18549	In-Hospital Outcomes
18550	Hemodynamic and Angiographic Measures at Pre- and Post-Treatment
18551	Histomorphometric Measures
18552	In-Hospital, 30-Day, and Follow-Up Clinical Events in the 2 Groups
18553	Quantitative Coronary Angiographic Data
18554	Prevalence of Metabolic Syndrome Components by Case-Control Status
18555	Adjusted  ⁎  Association Between Joint Categories of Metabolic Syndrome  (MetS)  and Diabetes and Early-Onset Coronary Artery Disease
18556	Adjusted  ⁎  Odds Ratios  (95% Confidence Intervals)  of Early-Onset Coronary Artery Disease Associated With Categorically Defined Components of the Metabolic Syndrome  (MetS)  and With the Syndrome Above and Beyond Its Components
18557	Adjusted  ⁎  Odds Ratios  (95% Confidence Intervals)  of Early-Onset Coronary Artery Disease Associated With Continuously Defined Components of the Metabolic Syndrome  (MetS)  and With the Syndrome Above and Beyond Its Components
18558	Quantitative Coronary Angiographic Data
18559	In-Hospital and Follow-Up Clinical Events in the Total Cohort, According to the Pattern of Restenosis
18560	Outcomes of Non-Diabetic Patients Compared With Diabetic Patients
18561	Clinical Data of the Three Different Groups of Patients: Univariate Analysis
18562	Weekly Frequency Consumption  (in Servings)  of Several Food Groups, According to the Mediterranean Diet Score
18563	Inflammation and Coagulation Markers by Tertile of the Mediterranean Diet Score
18564	Results From Multivariate Regression Analysis  (Beta-Coefficient ± SE)  Regarding the Association Between the Mediterranean Diet Score  (per 10-U Increase)  and Inflammatory and Coagulation Markers in Subgroups of Participants
18565	Antioxidant Consumption in Patients With Acute Myocardial Infarction  (Group 2, n = 74)
18566	Cytokines in the Study Population
18567	Contrast Perfusion and Pathologic Diagnosis of Cardiac Masses
18568	Subset of Masses With Quantitative Echocardiographic Perfusion
18569	Specification of the Primer Sets Used to Analyze Messenger Ribonucleic Acid Expression
18570	Effects of Placebo or Oral Candesartan on Lipids and Endothelial Function in Hypertensive Patients
18571	Local Skeletal Muscle Cytokine and iNOS Expression
18572	Assessment of the Systemic Parameters of the Recipient After Surgery
18573	Morphometric, Echocardiographic, and Hemodynamic Assessment of the Donor Heart
18574	Morphometric, Echocardiographic, and Hemodynamic Assessment of the Recipient Heart
18575	Fundus Findings of Type 2 Diabetic Patients Who Underwent CABG *
18576	Causes of Death According to the Presence or Absence of Diabetic Retinopathy During the Entire Follow-Up
18577	Multivariate Analysis Among Diabetics With Retinopathy and Diabetics Without Retinopathy Who Underwent Coronary Artery Bypass Graft Surgery
18578	Association Between Severity of Diabetic Retinopathy and Overall Mortality After CABG Among Type 2 Diabetic Patients
18579	Correlations of Leukocyte Mitochondrial Transmembrane Potential With Clinical Markers of Congestive Heart Failure
18580	Outcomes of Recipient Twin Fetuses With RVOTO
18581	Morphometric Results legend
18582	Procedural Data legend
18583	Side-Branch Occlusion: Initial Stenting versus Treatment of In-Stent Restenosis. SB Occlusion  (TIMI flow grade 0)  During Intervention for In-ST Restenosis  (n = 24)  ∗   legend
18584	Laboratory Indexes in Hypercholesterolemic Patients Treated for Eight Weeks With Diet or Diet Plus Simvastatin legend
18585	Changes in Heart Rate and Blood Pressure After Albuterol and Glyceryl Trinitrate in Patients With Type II Diabetes Mellitus and Control Subjects legend
18586	Comparison of Solubilized Adhesion Molecules and Cytokine Receptors Between Patients With Coronary Heart Disease and Control Subjects legend legend
18587	Comparison of Age and Serum Levels of Solubilized Adhesion Molecules and Cytokine Receptors by Receiver-Operating Curve Analysis With Respect to the Presence of Coronary Heart Disease legend
18588	Multiple Logistic Regression Analysis of the Association Between Age, Serum Levels of Solubilized Adhesion Molecules and Cytokine Receptors and the Presence of Coronary Heart Disease as an Independent Variable legend
18589	eNOS and MCP-1 Specific Primers
18590	Univariate Analysis of Combined Major Events legend
18591	Logistic Regression Analysis of Combined Major Events legend
18592	Major Recent Trends legend
18593	Natural Variability in Cytokine Receptors legend legend
18594	Determination of Sample Size to Show Statistically Significant Changes in Cytokines and Cytokine Receptors legend
18595	Procedural Success and Complications of Angioplasty
18596	Logistic Model for In-Hospital Death legend
18597	Effects of Denopamine on HW/BW and Myocardial Histology on Day 7  legend
18598	Effects of Denopamine on HW/BW and Myocardial Histology on Day 14  legend
18599	Effects of Denopamine and Metoprolol on HW/BW and Myocardial Histology on Day 6  legend
18600	Mortality from Day 7 to Day 14  legend
18601	Frequency of Genotypes of Endothelial Nitric Oxide Synthase Gene in Control Subjects and Patients With Myocardial Infarction legend
18602	Results of Multiple Logistic Regression Analysis: Final Significant Variables in Equation Using Forward Stepwise Selection  (Wald)
18603	Results of Cytokine Assays With Log Transformed Data
18604	Results of Serum Urea, Creatinine Albumin and Protein Estimations
18605	Coronary Sinus–Aortic Differences in Leukocyte mRNA Expression After Incubation With Plasma From Patients With an Acute Myocardial Infarction  (percent of glyceraldehyde-3-phosphate dehydrogenase)
18606	Location of Papillary Fibroelastomas in Groups 1 and 2
18607	Presenting Symptoms of Patients With Papillary Fibroelastoma
18608	Indications for Echocardiography
18609	Interstitial Heart Disease Can Occur as a FinalCommon Pathway From a Variety of MyocardialInsults  ∗
18610	Treatments Targeting Myocardial Fibrosis in Development
18611	High On-Treatment Platelet Reactivityin Very Elderly and Nonelderly Patients Treated With Prasugrel  (5 mg or 10 mg)  or Clopidogrel  (75 mg)
18612	Bleeding Events Related to Study Drug in Very Elderly and Nonelderly Patients With Stable Coronary Artery Disease Treated With 5-mg Prasugrel, 10-mg Prasugrel, and 75-mg Clopidogrel
18613	Primary and Secondary Endpoints
18614	Subjects With Drug-Related Treatment-Emergent Adverse Events in the Safety Population  ⁎
18615	Age-Adjusted CVD Incidence Rates According to Framingham Risk Score and ED Status
18616	The Relationship Between ED and CVD in Various Multivariate Models
18617	Discrimination of CVD in Various Multivariate Models
18618	Number of Subjects According to CVD Risk Category, With Reclassification of Risk Category After Inclusion of ED Status in a Multivariate Statistical Model
18619	Overall Incidence of AEs, Discontinuations Due to AEs, and AEs Occurring in ≥2% of Patients During the Double-Blind Treatment Period  (Safety Population, n = 672)
18620	Sensitivity, Specificity, Overall Accuracy, and Diagnostic Odds Ratio of Each Test at the Prespecified Cutoffs
18621	Descriptive Anthropometric and Cardiac Variables of the Whole Sample
18622	Clinical Variables According to the −C664G ANP Polymorphism Genotypes
18623	Echocardiographic Variables According to the −C664G ANP Polymorphism Genotypes
18624	One-Way ANOVA Adjusted for the Following Covariates: Age, Gender, Body Mass Index, BP, Duration of Hypertension, 24-h Urinary Na+Output, ALDO/PRA Ratio, With the ANP −C664G Polymorphism as Independent Variable
18625	Clinical Variables According to the NPRA Genotypes
18626	Echocardiographic Variables According to the NPRA Genotypes
18627	Correlational Analysis Between Forearm Blood Flow as Dependent Variable, ADMA, L-Arginine, and L-Arginine/ADMA
18628	5-Item International Index of Erectile Function  (IIEF-5)  *
18629	Age-Adjusted Mean Heart Disease Risk Factors by Erectile Dysfunction Category for Men in the Rancho Bernardo Study, 1972 to 1974
18630	Primer Pairs and Probes for T−786C and Glu298Asp Polymorphisms
18631	Maximal FBF Responses to ACH and SNP in the PH and NT Control Subjects Classified by T−786C Genotype
18632	Results of the Multivariate Analysis
18633	ACE and AGT Genotype Distribution in Cases and Controls legend
18634	AGT  (M235T)  Genotype Distribution in Hypertensives and Normotensives
18635	Estimates of Risk of CHD Associated With Clinical, Biochemical and Angiotensinogen Genotypes  (Adjusted for Multiple Risk Factors)  legend
18636	Correlation Coefficients Between Indexes of Cardiac and Vascular Structure in the Different Groups
18637	Incidence and Total Number of Atherosclerotic Plaques in the Carotid Arteries  legend
18638	Cardiac Magnetic Resonance Data in Patients and Control Subjects
18639	Myocardial T1 Values in Healthy Control Subjects and Patients With CAD at 1.5-T
18640	Myocardial T1 Values in Healthy Control Subjects and Patients With CAD at 3-T
18641	Coronary Physiology and CMR Parameters
18642	Changes After Aortic Valve Replacement  (N=116)
18643	Predictors of Change in Indexed Left Ventricular Mass and Indexed Matrix Volume After Aortic Valve Replacement
18644	The Relationship of LV T1 Indices With Plasma Log NT-proBNP
18645	Cross-Sectional Association Between CMR Markers of Fibrosis and Log NT-proBNP in the Fully Adjusted Model
18646	Clinical Outcomes at 30 Days and 1 Year
18647	HRs With 95% CIs for All-Cause Mortality, MI, and Heart Failure in Relation to hs-cTnT Levels in 19,460 Patients With No MI
18648	Comparison of Marfan Patients in GenTAC Who Completed the SF-36 Versus Those Who Did Not
18649	Bivariate Analysis of PCS Subscale Scores and Composite Scores With GenTAC Variables
18650	Association of Unable to Work Due to Disability and Other Variables
18651	Adjusted Model of PCS Composite and Subscale Scores
18652	Comparison of SF-36 PCS Scores in MFS Patients Across Different Studies
18653	Performance in the PAL Test, Estimated Difference in Cognitive Age, and Mean Values of Risk Factor Variables Across the Early Life Cumulative Cardiovascular Risk Factor Burden
18654	Associations Between Cumulative Burden of Early Life Vascular Risk Factors  (Age 6 to 24 Years)  and Midlife Visual and Episodic Memory and Visuospatial Associative Learning  (PAL Test)  in 1,733 YFS Participants
18655	Cumulative Event Rate by Treatment Strategy
18656	Multivariate Predictors of Death or Spontaneous MI at 10-Year Follow-Up
18657	Hemodynamic Classification of Pulmonary Hypertension
18658	Univariate and Multivariate Associations of Cpc-PH in PH-LHD
18659	Unadjusted and Adjusted Hazard Ratio for Mortality in Cpc-PH Compared With Ipc-PH
18660	Significant Gene Ontology Groups Identified for the 141 Genes Associated With Cpc-PH and PAH Compared With Ipc-PH Control Subjects
18661	Procedural Data  (Lesion-Based Analysis)
18662	Independent Correlates of Post-Procedural hs-TnT Concentration Obtained From the Multiple Linear Regression Model
18663	Mortality According to Different Cutoffs of Post-Procedural hs-TnT
18664	Association Between TMAO and SYNTAX Scores and hs-cTnT
18665	Measurements of T2 Relaxation Time in the Ischemic and Remote Myocardium at Different Time Points During the First Week After Ischemia/Reperfusion
18666	Measurements of Myocardial Water Content in the Ischemic and Remote Myocardium at Different Time Points During the First Week After I/R
18667	Ischemic and Bleeding Outcomes in all Randomized Patients, According to Acute Myocardial Infarction Status, From12 to 30 Months After Coronary Stent Treatment
18668	Ischemic and Bleeding Outcomes 12 to 30 Months After Coronary Stent Treatment in all Randomized Patients, Stratified by Presentation With Versus Without Acute Myocardial Infarction
18669	Comparison Between Models With and Without ECG Changes and Resting Heart Rate
18670	Model Validation
18671	Calculating 10-Year Risk of Fatal CVD and of Fatal or Nonfatal CVD
18672	Proportion and Weighted Frequency of Events Occurring in the Morning  (6 am to 12 pm)  Versus the Rest of the 24-h Period
18673	Proportion and Weighted Frequency of Events Occurring in the Early Morning  (12 am to 6 am)  Versus the Rest of the 24-h Period
18674	Proportion and Weighted Frequency of Events Occurring on Mondays Versus the Rest of the Week
18675	The 99th Percentile Values and Corresponding 95% CIs for hs-cTnT and Percentiles Corresponding to cTnT= 14 ng/l in Subcohorts 1  ∗   of the DHS, ARIC, and CHS Studies, With Further Stratification by Sex, Age, and Race
18676	The 99th Percentile Value for the hs-cTnT Assay, With 95% CIs, and Percentiles Corresponding to cTnT= 14 ng/l in Subcohorts 2  ∗   of the DHS, ARIC, and CHS Studies, With Further Stratification by Sex, Age, and Race
18677	The 99th Percentile Values for the hs-cTnT Assay  (ng/l)  Stratified by Sex, Age, and Race in DHS Study Subcohort 2: Sensitivity Analyses
18678	Cardiac Catheterization Data
18679	Cardiac Magnetic Resonance Imaging and Echocardiography Data
18680	Predictors of Passive LV Stiffness Constant By Simple and Multiple Linear Regression
18681	Cox Proportional Hazards Analyses of SCD Risk in Cardiovascular Health Study Participants  (n= 3,089)  According to Serial Change in hsTnT
18682	TAVR Implants in Each Nation
18683	Implant Centers
18684	TAVR Penetration, 2011
18685	Economic Indexes and Reimbursement Schemes
18686	Adjusted Associations of Categories of 2-Year Change in WIQ Stair Climbing Score With All-Cause and CVD Mortality Among PAD Participants  (n = 438)
18687	Adjusted Associations of Categories of 2-Year Change in WIQ Distance Score With All-Cause and CVD Mortality Among PAD Participants  (n = 431)
18688	Adjusted Associations of Categories of 2-Year Change in WIQ Speed Score With All-Cause and CVD Mortality Among PAD Participants  (n = 435)
18689	Values of NRI and IDI for Myocardial Infarction and Coronary Heart Disease for Extreme Lipoprotein (a)  Levels, for Risk LPA Genotypes, and for Combinations of Extreme Levels and Risk Genotypes
18690	Follow-Up Events and Combined Endpoints
18691	Univariate Analysis of Factors Associated With All Cardiac Events
18692	Patient Treatment Assignment
18693	Superficial Femoral Artery Lesions Treatment Assignment
18694	Adverse Events
18695	X-ray Angiography Data
18696	CMR Data
18697	Sensitivity and Specificity of 3D Whole Heart Myocardial Perfusion CMR Versus Coronary Angiography and FFR on Patient Basis
18698	Sensitivity and Specificity of 3D Whole Heart Myocardial Perfusion CMR Versus Coronary Angiography and FFR on Coronary Territory Basis
18699	Sensitivity and Specificity of 3D Whole Heart Myocardial Perfusion CMR Versus Coronary Angiography and QCA on a Patient Basis
18700	Ischemia Volumes According to 3D Whole Heart Myocardial Perfusion CMR and Duke Jeopardy Scores  (n = 53)
18701	Genotype Frequencies in the Study Population
18702	Logistic Regression Analysis of Genetic Predictors of Response to AADs
18703	Response  (%)  Distribution of AAD by Class Among Responders for SNP rs10033464
18704	Distribution of AF Recurrence by Genotype
18705	Multivariable Logistic Regression Analysis for Genetic Predictors of AF Recurrence
18706	Global RV Volumes and Hemodynamics
18707	Preload Independent Indices of Systolic and Diastolic RV Function
18708	Odds Ratios  (95% CI)  for Elevated hs-TnT by Clinical Categories of HbA1c
18709	Odds Ratios  (95% CI)  for Elevated hs-TnT by Clinical Categories of Glucose
18710	Hemodynamic Status Measurements of Myocardial I/R Mice
18711	Hemodynamic Status Measurements of Il17a–/– Mice After I/R
18712	Univariate and Multivariate Predictors of Recurrent ISR  ⁎
18713	Univariate and Multivariate Predictors of Recurrent Occlusion  ⁎
18714	Fibrosis and Fatty Tissues in Relation to Age and AF History
18715	Inflammatory Cell Count in Major Atrial Pathways and Posterior Left Atrial Wall in Patients With and Without AF History
18716	Absolute and Relative Changes in Plasma cTnT Levels in Peripheral Blood
18717	Invasive Techniques for Imaging the Vulnerable Plaque
18718	Noninvasive Technique for Imaging the Vulnerable Plaque
18719	Main Features in the 2 Arms
18720	Outcome Measures in the 2 Arms
18721	Image Quality Scoring of Dynamic 3D-CMR Perfusion
18722	Timing of β-Blocker Initiation Before Surgery and Post-Operative Outcome
18723	Association of Time, Between Timing of β-Blocker Initiation and Presence of 30-Day Cardiovascular Events in Vascular Surgery Patients
18724	Association of Time, Between Timing of β-Blocker Initiation and Long-Term Mortality of Vascular Surgery Patients
18725	Univariable and Multivariable Determinants of Favorable Response to CRT
18726	Impact of High Heart Rate on Image Quality Score of Whole-Heart Coronary MRA
18727	Diagnostic Accuracy of Whole-Heart Coronary MRA Compared With Radiographic Angiography
18728	Impact of HR on Diagnostic Performance of Whole-Heart Coronary MRA
18729	Impact of BMI on Diagnostic Performance of Whole-Heart Coronary MRA
18730	Imaging Findings
18731	Cumulative Event Rate and Hazard Ratios of the Composite Outcome and the Individual Outcomes at 5 Years
18732	ECG Parameters
18733	BSPM Parameters
18734	Vectorcardiogram Parameters
18735	Summary of Study Results
18736	Inclusion and Exclusion Criteria for Patients With ICDs
18737	Study Design for ICDs in the MRI Environment
18738	ICD Data Before and After MRI and at Follow-Up in 18 ICD Patients
18739	Image Quality of 62 Patients With Successful CMRA
18740	Diagnostic Performance of 3.0-T Contrast-Enhanced Whole-Heart CMRA
18741	Copeptin Value Used With Troponin T ≤0.01 μg/l at Presentation to Rule Out Acute Myocardial Infarction
18742	Exercise and Hemodynamic Results After Randomization
18743	Changes of LV Volume and Global and Regional Function During the Protocol
18744	Predictive Value for the 20 μV Cutpoint
18745	Predictive Value for the 60 μV Cutpoint
18746	Unadjusted and Adjusted Hazard Ratio Values for the Sensitive  (20 μV)  and Specific  (60 μV)  Cutpoints
18747	Myocardial Function and Mass in Infarct-Typical, Infarct-Atypical, and Combined CE-MRI
18748	Independent Variables Examined in the Multiple Regression Models
18749	Exercise Performance for PHN Fontan Patients, Maximal and Submaximal Effort Subgroups
18750	Coefficients of Determination for PHN Fontan Patients Without Pacemakers That Achieved a Maximal Aerobic Capacity  (n = 140)
18751	Regression Results for PHN Fontan Patients Without Pacemakers That Achieved a Maximal Aerobic Capacity
18752	Electrophysiologic Data
18753	Procedural Results
18754	ST-Segment Monitoring Data
18755	Culprit Drugs
18756	Electrocardiographic Variables in Patients With TdP and LQTS
18757	Multivariate Logistic Regression Analysis
18758	Results of Timing Parameters in 21 Patients and 11 Healthy Control Subjects
18759	Paired-Samples t Tests  (2-tailed)  Between Timing Parameters of the Patients
18760	Results of Linear Regression Analysis
18761	Performance of Biomarker Estimates of Infarct Size in Various Categories
18762	Independent Predictors of Infarct Size
18763	Repolarization Dynamics
18764	Echocardiographic Parameters of Patients Without Versus With LV Remodeling
18765	Relation Between Clinical and Echocardiographic Parameters and LV Remodeling
18766	Predictors of Long-Term Outcome in Unstable Angina
18767	Aggmaxand AgglateValues in Patients Stratified According to Responsiveness to Clopidogrel and Ticlopidine
18768	Clinical Outcome in Patients Stratified According to Responsiveness to Clopidogrel and Ticlopidine
18769	Quantitative Changes in ECG Findings During Brief Episodes of Transmural Ischemia Analyzed by the MUSE Automated System
18770	Quantitative Changes in ECG Findings During Brief Episodes of Transmural Ischemia Analyzed by the Interval Editor Automated System
18771	Data for Quantitative Coronary Angiography and Intravascular Ultrasound
18772	Simple Regression Analysis With Percentage Lipid Volume or Percentage Fibrous Volume As the Dependent Variable
18773	Multiple Regression Analysis With Percentage Lipid Volume  (r = 0.40, p = 0.01)  or Percentage Fibrous Volume  (r = 0.37, p = 0.03)  as the Dependent Variable
18774	Logistic Regression Model for Prediction of Lipid-Rich Plaque
18775	Percentage WT of Intra-Acinar Pulmonary Arteries With ED From 50 to 200 μm
18776	Regional Detection of Q-Wave and Non–Q-Wave Infarction by CMR and SPECT
18777	Statistical Association of 11 Risk Variables With Serious Arrhythmic Events in Univariate and Multivariate Analyses
18778	Predictive Values of Positive Microvolt T-Wave Alternans, Nonsustained Ventricular Tachycardia, and Ventricular Late Potentials Risk Variables With Serious Arrhythmic Events
18779	Distribution of the Patients in the Categories of CAD Atherosclerotic Burden Estimated With a Modified Duke Index Prognostic Score
18780	History and Medical Treatment in the Patients Stratified by T−786C eNOS Genotype
18781	Allele Frequencies and Pairwise Linkage Disequilibrium D′ Between C894T and T−786C Polymorphisms
18782	Estimated Haplotype Frequencies Under Linkage Disequilibrium in Non-CAD and CAD Patients
18783	Cardiovascular Death-Free Survival at Cox Regression Analysis
18784	Effects of Beta-Blockers on 24-h ECG Parameters in 24 LQT1 Patients
18785	Model Variables
18786	Incremental Cost-Effectiveness Ratios in Base-Case Estimates
18787	Summary Table of One- and Two-Way Sensitivity Analyses
18788	30-Day Outcomes
18789	Quantitative Coronary Angiography in the Main Stented Branch
18790	Comparison of Target Ablation Time in Remote and Standard CPVA
18791	Pulmonary Function and Inspiratory Muscle Function Tests Before and After Intervention for Patients Randomized to P-IMT or IMT
18792	Results Obtained in the Maximal Cardiopulmonary Exercise Test for the P-IMT and the IMT Group
18793	Procedural Variables
18794	30-Day and Long-Term Outcomes
18795	Quantitative Coronary Angiography Analysis of the Main Branch
18796	Quantitative Coronary Angiography Analysis in the Side Branches
18797	Quantitative Intravascular Ultrasound  (IVUS)  Results
18798	Multivariable Adjusted Hazard Ratios for the Incidence of Death or Myocardial Infarction During Long-Term Follow-Up
18799	Individual Event Rates  (Event/Month)  and Therapy Episodes  (Episode/Month)  of Patients Pre- and Post-CRT Implantation
18800	AUC of the Different Parameters After the Ingestion of a Phenol-Rich Olive Oil Meal  (400 ppm)  as Compared to a Low Phenol Olive Oil Meal  (80 ppm)
18801	Postprandial Changes of Nitrates/Nitrites, Lipoperoxides, and 8-epi Prostaglandin Plasma Levels After the Ingestion of a Phenol-Rich Olive Oil Meal  (400 ppm)  as Compared to a Low Phenol Olive Oil Meal  (80 ppm)
18802	Multiple Regression Analysis for Variations in Ischemic Reactive Hyperemia, Oxidative Stress Markers, and NO (x) Plasma Concentrations
18803	Results of 19 Prospective Studies of Microvolt T-Wave Alternans
18804	Summary Estimates of PPV, NPV, and Univariate RR in 19 Prospective Studies of Microvolt T-Wave Alternans for the Prediction of Cardiac Arrhythmic Events
18805	Summary Estimates of PPV, NPV, and Univariate RR in Prospective Studies of Microvolt T-Wave Alternans for the Prediction of Primary versus Secondary Arrhythmic Events
18806	Multivariate Predictive Value in Three Prospective Studies of Microvolt T-Wave Alternans
18807	MRI Planimetry of MS, Predictive Values for Given CATH-MVA
18808	Clinical, Morphologic, and Morphometric Data
18809	Distribution of the Various Plaque Types in the Three Groups of Patients
18810	Distribution of the Various Plaque Types and Quantitative Evaluation of Inflammatory Infiltrate Present in the Plaques of Patients Dying of AMI
18811	ECG and intracardiac temporal and spatial regularity
18812	Comparison of Parameters of Systolic Asynchrony Derived by TSI Between Responders and Nonresponders of Left Ventricular Reverse Remodeling
18813	Correlation Analysis Between Parameters of Systolic Asynchrony Measured by TSI and ΔLVESV or Absolute Gain in Ejection Fraction after CRT
18814	The Cutoff Values of Each Parameter of Systolic Asynchrony Measured by Tissue Synchronization Imaging for the Prediction of Reverse Remodeling With Corresponding Sensitivity and Specificity
18815	MCE versus PET: Summary of Hemodynamic and Perfusion Data at Rest  (20 Volunteers)  and During Hyperemia  (5 Volunteers)
18816	Multivariable Logistic Regression Model for Death and Nonfatal Myocardial Infarction During Six Months of Follow-Up
18817	Multimarker Assessment: Stepwise Multivariable Logistic Regression Model for Death and Nonfatal Myocardial Infarction During Six Months of Follow-Up
18818	Response Rates by Health-Related Quality-of-Life Questionnaire
18819	EuroQOL 5-Dimensional Classification Component Scores and Global Utility Score
18820	EuroQOL 5-Dimensional Classification Global Utility Score
18821	Short Form-36 Component Scores at Four-Month and One-Year Follow-Up
18822	Seattle Angina Questionnaire Components at Four-Month and One-Year Follow-Up
18823	Distribution of Angina Grade by Treatment Group and Follow-Up Among Patients Who Completed a EuroQOL Questionnaire
18824	Electrocardiographic Findings in Phenotypically Affected and Unaffected Family Members
18825	Subgroup Differences in LV Volumes and EF Between MRI and Echocardiography  (n = 87)
18826	Association of Preoperative Thalium and Coronary Revascularization With Postoperative Ischemia and Infarction
18827	Peoperative Predictors of Postoperative Troponin  (Logistic Regression Analysis)
18828	Peoperative Predictors of Postoperative Troponin as Selected by the Multivariate Logistic Regression Analysis
18829	Serious Complications Classified According to the Mode of Detection
18830	Alert Events Caused by Serious Complications  (n = 14)   (True Positives)
18831	Alert Events Caused by Non-Serious Complications  (n = 10)   (False Positives)
18832	Hemodynamic Parameters and Coronary Diameters Pre- and Post-Mibefradil in 10 Patients With the CSFP
18833	Changes in Hemodynamic Parameters During Four Weeks of Placebo and Mibefradil 100 mg Therapy in 20 Patients With the CSFP
18834	Median Values  (25%, 75% Interquartile Ranges)  of Total Anginal Episodes, Prolonged Anginal Episodes  (i.e., >20 Min)  and Sublingual Nitrate Consumption During Four Weeks of Placebo and Mibefradil 100 mg Therapy in 20 Patients With the CSFP
18835	The SF-36 Scores in 20 Patients With the Coronary Slow Flow Phenomenon, After Four Weeks of Placebo or Mibefradil Therapy
18836	Cardiac Outcomes and Test Results Based on Peak Cardiac Troponin I Value
18837	Presenting Symptoms/Signs of Patients With Dissection of the Aorta, Based on Age Category
18838	Aortic Dimensions Among Patients <40, With or Without Marfan Syndrome in the International Registry of Aortic Dissection
18839	Complications of Aortic Dissections, Based on Age
18840	Patients With Kawasaki Disease: MRA and XCA Measurements
18841	Course of Plasma Total Cholesterol Levels
18842	Reflow and Patency Status
18843	Platelet Aggregation and Bleeding Time
18844	Platelet Aggregation and Eptifibatide Levels After Cessation of Eptifibatide Infusion
18845	Body Weight, LV Weight, Hemodynamics, LV Size, and LV Function
18846	Percentage of Subjects Experiencing Clinically Important Blood Pressure Findings  (Tadalafil/Placebo)
18847	Number of Clinically Important Blood Pressure Findings  (Tadalafil/Placebo)
18848	Adverse Events
18849	Location and Functional Effects of HERGMutations in Eight Study Patients
18850	Corrected QT Interval Variability  (Lead V2)  on Pre-Treatment Electrocardiograms
18851	Association of Longest Ischemia Duration With Biochemical Markers of MI
18852	Univariate and Multivariate Cox Regression Survival Analyses
18853	Effect of Cx Stenosis and IVC Occ. in Canine Experiments
18854	Clinical and Hemodynamic Findings in the Initial Population
18855	Doppler Findings in the Initial Population
18856	Clinical, Hemodynamic, and Doppler Findings in the Prospective Population
18857	Correlation Between Doppler Variables and Catheter PCWP in the Prospective Population
18858	Basic Data on the 15 Patients With Recurrent Pericarditis
18859	Clinical Findings During Initial Attack of Pericarditis and Recurrences
18860	Haplotype Frequencies in Subjects Without Significant Coronary Stenosis
18861	Relationship Between Matrix Metalloproteinase-3 Gene Polymorphisms and Number of Coronary Arteries With >50% Stenosis
18862	Analyses of Individual Polymorphisms in Relation to MI
18863	Stepwise Logistic Regression Analyses of Matrix Metalloproteinase-3 Haplotypes in Relation to Previous Myocardial Infarction
18864	Reporter Assays
18865	Total Number  (%)  of Coronary Segments Seen by SH-RT
18866	Mean Image Quality  (1 to 4)  of Each Coronary Segment
18867	Sensitivity and Specificity  (Total Number)  of SH-RT Images in the Detection of Lesions in Individual Coronary Artery and of Patients With Coronary Artery Disease
18868	Validation of Microarray Method
18869	Patient Data Before Left Ventricular Assist Device Support
18870	Genes Common to Ischemic and Nonischemic Patients Before and After Left Ventricular Assist Device Support
18871	Results of Logistic Multivariate Analysis for T-786C
18872	Presence of ECG Confounders at Presentation
18873	Differences in Treatment Outcome at One Year: Patients Classified According to Summed ST-Segment Deviation
18874	Differences in Treatment Outcome at One Year: Patients Classified According to the Total Number of Leads With ST-Segment Deviation
18875	Troponin T Values at Presentation
18876	Coronary Angiographic Findings  (Invasive Group Only)
18877	Invasive Treatment Procedures  (Invasive Group Only)
18878	Multiple Logistic Regression Analyses on Troponin T and C-Reactive Protein as Predictors of Death, MI, and Death or MI at 30 Days
18879	Mortality at 30 Days in Relation to Quartiles of Troponin T and C-Reactive Protein
18880	Rates of Death/Myocardial Infarction at 30 Days in Relation to Quartiles of Troponin T and C-Reactive Protein
18881	Study population
18882	Biventricular CMR Indices  (Tetralogy Patients, n = 85, vs. Healthy Controls, n = 26)  and Effects of RVOT Aneurysm/Akinesia on Biventricular Function
18883	Independent Predictors for CMR-Derived Ventricular Volume, Mass, and Function in Adults With Repaired Tetralogy of Fallot  (n = 85)
18884	Incidence of Deaths From Any Cause  (A)  and Cardiovascular Causes  (B)
18885	Hazard Ratios  (95% Confidence Intervals)  for All-Cause and Cardiovascular Mortality Stratified by ST-T Segment Changes and Microalbuminuria
18886	Prevalence of Echocardiographic Left Ventricular Hypertrophy and Abnormal Left Ventricular Geometry in Relation to Increasing Magnitude of ST Segment Depression in Leads V5 or V6
18887	Logistic Regression Analyses to Assess the Predictive Value of Increasing Magnitude of ST Segment Depression in Leads V5 or V6 for the Presence of Left Ventricular Hypertrophy
18888	Hemodynamic and Electrocardiographic Data in Patients With and Patients Without New or Further ST Elevation at Peak Stress Testing
18889	Echocardiographic and Scintigraphic Findings in Patients With and Patients Without ST Elevation at Peak Exercise on Pre-Discharge Exercise Treadmill Test
18890	Accuracy  (%)  of ST Elevation and T-Wave Normalization During Ergometric Exercise in Detecting Patients With Viability, Scar Tissue, and Biphasic Response
18891	Results From the Multivariate Statistical Analysis for the Evaluation of ST-Segment Elevation onPeak-Exercise Electrocardiogram
18892	Transcatheter Non-Intervention Patient Group
18893	Current Data and Literature Review
18894	Events Within Six Months of Study Entry
18895	Clinical Data at Six-Month Final Visit
18896	Resource Use Per Patient by Treatment Assignment in Constant 1998 U.S. Dollars
18897	Quantitative Angiographic Measurements
18898	Early and Late Outcomes
18899	Findings at Echocardiography  (n = 1,867)  in Relation to Troponin T Levels legend
18900	Findings at Coronary Angiography in the Invasive Cohort  (n = 1,142)  in Relation to Troponin T Levels legend
18901	Clinical End Points at 12 Months in the Noninvasive Cohort in Relation to Troponin T Levels  (n = 1,168)  legend
18902	Multivariate Logistic Regression Analyses Regarding Death and MI at 12 Months, Respectively, in the Noninvasive Group  (n = 1,148)  legend
18903	Effect of Cell and IgG Transfer on Atherogenesis in LDL-RD Mice legend
18904	Contributing Factors for Coronary Artery Disease  (Multiple Logistic Regression Analysis in 292 Patients)  legend legend
18905	Contributing Factors for Coronary Artery Disease  (Multiple Logistic Regression Analysis in 168 Patients With CP Seropositivity and 124 Without CP Seropositivity)  legend legend
18906	Contributing Factors for Myocardial Infaction  (Multiple Logistic Regression Analysis in 168 Patients With CP Seropositivity and 124 Without CP Seropositivity)  legend legend
18907	Outcomes for Studies of Troponin T legend
18908	Outcomes for Studies of Troponin I legend
18909	Summary Results for Troponin and Mortality legend
18910	Echocardiographic Findings in Relation to Electrocardiographic Strain in Hypertensive Patients With and Without Evident CHD legend
18911	Prevalence of Echocardiographic LVH, Abnormal LV Geometry and Abnormal LV Midwall Function in Relation to Electrocardiographic Strain in Hypertensive Patients With and Without Evident CHD legend
18912	Multivariate Logistic Regression Analyses to Assess the Predictive Value of Electrocardiographic Strain for the Presence of LVH, Abnormal LV Geometry and Abnormal LV Midwall Function in Patients With and Without Evident CHD ∗   legend
18913	Gender Distribution in Severity of Coronary Artery Disease in Patients Randomized to the Invasive Strategy legend
18914	Some Background and Clinical Variables of the Different Strategy Groups legend
18915	First Revascularization Procedure and Outcome at 12 Months of Follow-Up in the Group Randomized to the Noninvasive Strategy According to Gender legend
18916	Effect of Female Gender on Death or Myocardial Infarction at 12 Months legend
18917	Outcomes at 12 Months in the Group Randomized to the Early Invasive Strategy With Respect to Gender legend
18918	Outcomes at 12 Months of Follow-Up in Women and Men Randomized to the Early Invasive Strategy in Relation to the Type of First Coronary Intervention legend
18919	Outcome of Periprosthetic Regurgitation legend
18920	Metabolic and Clinical Variables on Study Entry and After Six Months in Training and Control Groups legend
18921	Results of Follow-up Angiography legend legend
18922	Quality of Life as Assessed by the Duke Activity Status Index  (DASI)  and Medical Outcomes Study  (MOS)  Questionnaires in Training and Control Groups legend
18923	Cardiac Events According to Study Group and Cause legend
18924	Perioperative Myocardial Ischemia and Infarction Details of Patients With Ischemia legend
18925	Quantitative Immunohistochemical Data of Initial Coronary Atherectomy Specimens of All Patients Without or With  (Stable or Unstable Angina Pectoris)  Recurrent Angina During One-Year Follow-Up legend
18926	Epinephrine-Induced Changes in the Mean QTc-e, the Mean QTc-p, the Mean Tcp-e, and the Mean Tcp-e/QTc-e Ratio, Which Are Averaged Among All 87-Leads, in LQT1, LQT2, and Control Patients legend
18927	Epinephrine-Induced Changes in the max QTc-e, the min QTc-e, the QTc-eD, the max QTc-p, the min QTc-p, and the QTc-pD, Which Are Obtained From all 87-Leads, in the LQT1, LQT2, and Control Patients legend
18928	Statistical Association Between Peak Troponin T Levels and Legend Variables Listed in ACS Patients
18929	Multivariate Logistic Regression Model of Positive Peak cTnT Status  (>0.1 μg/liter)  With the Legend Variables Listed in UAP Patients
18930	End Points After Six-Month Follow-Up legend
18931	Findings at the Predischarge Symptom-Limited Exercise Test  (n = 1,173)  legend
18932	Comparison of Troponin T and the Predischarge Exercise Test Regarding Different Endpoints After Six-Month Follow-up
18933	Univariate and Multivariate Logistic Regression Analysis of Clinical, ECG, and Laboratory Parameters in Relation to Myocardial Infarction and Cardiac Death During a Six-Month Follow-up Period legend
18934	Time Intervals, Reperfusion Therapy and Concomitant Medications Within the First 48 Hours legend legend
18935	Clinical Events During the Hospital Period legend legend
18936	In-Hospital Death and Combined End Point in Patients With In-Hospital Myocardial Infarction  (n = 403) : Relation to Reperfusion Therapy legend
18937	Results of Multivariate Analysis legend
18938	Acceleration- and Deceleration-Dependent Sensitivity and Specificity of V alt  ≥1.9 μV in Late Versus Throughout Repolarization for VT legend
18939	Angiographic Characteristics, Outcome and Adverse Procedural Outcomes of the Study Population legend
18940	Adverse Cardiac Events at One Year legend
18941	Predictive Values and Univariate Cox Regression Analyses Associating Three Indices Used Alone and in Combination With Arrhythmic Events legend
18942	Result of a Multivariate Cox Regression Analysis
18943	Electrocardiographic and Left Ventricular Echocardiographic Changes After AMI During Six-Month Study Period legend legend
18944	Echocardiographic Changes After AMI in Patients With %WMA ≥31.25  (Large AMI)  and in Patients With %WMA <31.25  (Small AMI)  legend
18945	ECG Changes After AMI in Patients With %WMA ≥31.25  (Large AMI)  and in Patients With %WMA <31.25  (Small AMI)  legend
18946	Clinical Features of the Patient Population and the Ventricular Arrhythmia Subgroup
18947	Statistical Performance of the Noninvasive Tests to Predict the Results of EPS legend
18948	Event-free Survival at 400 Days for Different Combinations of TWA and SAECG Outcomes legend
18949	Phases I and II of Neointimal Generation legend
18950	Phases I–III of Endothelial Regeneration legend
18951	Diagnostic Feature Type Within the 91 Cine Runs
18952	Assignments Between Rater Groups legend
18953	Rater Compliance With the Quality Scale legend
18954	Summary of Results for the Six DC+ Raters legend
18955	Summary of Results for the 13 DC− Raters  (compare  Table 5 )
18956	Comparison of Error Rates  (Rater Numbers: 1 through 6)  legend
18957	Comparison of Error Rates  (Rater Numbers: 7 through 21)  legend
18958	Diagnostic Errors in the DC+ and in the DC− Group of Raters
18959	Cardiac Markers in Patients Suffering Cardiac Events Within a Three-Month Period legend
18960	Comparison of Sensitivity, Specificity and Predictive Values of the Troponins for Cardiac Events Within a Three-Month Period legend
18961	A Comparison of Patient Variables as They Relate to Levels of Cardiac Troponin T legend
18962	A Comparison of Patient Cardiac Risk Factors as They Relate to Levels of Cardiac Troponin T legend
18963	Variables in Patients With Chronic Renal Failure Not Undergoing Dialysis legend
18964	Analysis of Risk Factors for cTNI Rise Above Cutoff Level  (Multivariate Analysis)  legend
18965	Extraction Outcomes and Reasons for Failure
18966	Total Extraction Time: Intention to Treat Analysis
18967	Complications legend
18968	Clinical Events at 2 Years legend
18969	Predictors of Death, Reinfarction or Target Vessel Revascularization
18970	Predictors of Death or Reinfarction at 2 Years in Patients Randomized to Angioplasty legend
18971	In-Hospital Clinical Events legend
18972	Pre-Discharge Cardiac Catheterization legend
18973	Cumulative Sixth Month Adverse Clinical Events ∗   legend
18974	Clinical Outcomes
18975	Sensitivity and Specificity of Biochemical Markers legend
18976	Sensitivity and Specificity of Biochemical Markers for Predicting Ischemic Outcomes by 6 months legend
18977	Extent of Stenosis Before and After Angioplasty legend
18978	Hemodynamic Measurements legend
18979	Physiologic Parameters in Normal Subjects From the Age of 2 Months Up to 19 Years: Comparison of Median  (Range)  or Mean ± SD Values Between Age Groups  legend
18980	Multivariate Analysis of Diastolic Flow Parameters and Time Intervals in Normal Subjects from the Age of 2 Months up to 19 Years  (n = 281)   legend
18981	Multiple Linear Regression Analysis in Left Ventricular Diastolic Flow Parameters in Normal Subjects from the Age of 2 Months Up to 19 Years  (n = 281)  legend
18982	Inflammatory and Immune Markers in UA vs. CSA  legend
18983	Specific IgG titre for Cp legend
18984	Inflammatory and Immune Markers in the 4 Programs’ Subgroups  legend
18985	Lumen Area, Vessel Area and Plaque Area of Cross Sections Arranged in the Six Sections  legend
18986	Composition of Ischemic ECG Findings in Men and Women  legend
18987	Age-Specific Number of CVD Deaths and Age-Standardized CVD Mortality Rates in Subgroups According to Ischemic ECG Findings in Men and Women  legend
18988	Adjusted Risk Ratios  (+95% CI)  for CVD Mortality According to Ischemic ECG Findings in Both Men and Women legend
18989	Square Table Analysis of Retrospective Intraindividual Longitudinal Comparison of Troponin T Serum Concentrations Measured by ELISA and Histological Rejection Grades in Concomitant Myocardial Biopsies in 15 Heart Transplant Recipients During Long-Term Follow-up  legend
18990	Occurrence of Spontaneous Tachyarrhythmias and Ventricular Fibrillation Threshold During Ischemia and Reperfusion legend
18991	Left Ventricular Pressures, Mean Arterial Pressure and Heart Rate legend
18992	Clinical, Electrocardiographic and Coronary Angiographic Data for Study Patients  legend
18993	Left Ventriculographic, Stress Testing and Positron Emission Tomographic Data for Study Patients legend
18994	Serial Electrocardiographic Changes Between Prehospital and Initial Hospital Electrocardiogram in Patients With Prehospital Versus In-Hospital Thrombolysis  (randomized patients)
18995	Serial Electrocardiographic Changes in Patients With Suspected Acute Myocardial Infarction Who Were Not Receive Randomized to Prehospital Versus In-Hospital Thrombolysis
18996	Leisure Time Physical Activity Score ∗
18997	Coronary Artery Disease History and Coronary Angiographic Data  legend
18998	Characterization of Coronary Collateral Circulation and Physical Activity Score legend
18999	In-Hospital Bleeding Complications of Patients With ST Segment Elevation Myocardial Infarction According to Thrombolytic and Antithrombin Therapy ∗
19000	Clinical Outcomes at 30 Days in Patients With ST Segment Elevation Myocardial Infarction According to Thrombolytic and Antithrombin Therapy ∗
19001	Clinical Data  legend
19002	Values of Biochemical Markers at Start of and 30, 60, 90 and 120 Minutes After Streptokinase Infusion legend
19003	Utility of 60- and 90-Minute Marker Ratios for Predicting Failed Thrombolysis  legend
19004	Effect of Pharmacologic Adrenergic Stimulation on Duration of Ventricular Repolarization During Sinus Rhythm and Atrial Pacing
19005	Effect of Pharmacologic Adrenergic Stimulation on QT Dispersion
19006	Effect of Pacing on QT Dispersion in Patients With Long QT Syndrome  a
19007	Effect of Time to Treatment on Patency Rate: Logistic Regression Analysis
19008	Data on the Fibrinolytic System and Hemostasis in Three Patient Groups
19009	Neg = negative rapid assay; Pos = positive rapid assay; Rec isch = recurrent ischemia.
19010	Health Outcomes After Interventions for Acute Myocardial Infarction
19011	Costs Used in Analysis of Interventions for Acute Myocardial Infarction
19012	Projected Outcomes of Primary Angioplasty and Thrombolysis Policies for a Hypothetical Cohort of 10,000 Patients With Acute Myocardial Infarction
19013	Sensitivity and Specificity of Different Tests for Predicting Sustained Ventricular Tachycardia/Fibrillation in Study Patients  *
19014	Measures of Efficiency of Thrombolysis With Study Agents
19015	Multinative Versus Multi–Saphenous Vein Graft Stenting
19016	In-Hospital Treatment and Outcome
19017	Adjusted 42-Day and 1-Year Kaplan-Meier Event Rates
19018	Relation of Degree of ST Segment Deviation and Outcome  a
19019	Multivariate Predictors of Death or Myocardial Infarction at One Year for 1,411 Patients
19020	Adjunctive Therapy
19021	Changes in Fibrinolytic Variables
19022	Effects of Saline and Each Sodium Channel Blocker on Left Ventricular Pressure and Aortic Pressure
19023	Description of Patients
19024	Correlates for Cardiac Complications Within 6 Months After Discharge
19025	Subgroup Analyses: Correlation of Postoperative TnT and CK-MB Levels With Postdischarge Cardiac Complications
19026	In-Hospital Outcomes Stratified by Reperfusion Modality
19027	In-Hospital Charges Stratified by Reperfusion Modality
19028	In-Hospital Outcomes and Charges Stratified by Reperfusion Modality in Patients Defined as High Risk and Not High Risk
19029	Univariate and Multivariate Correlates of In-Hospital Charges  a
19030	Late Events After Hospital Discharge in 340 Surviving Patients at a Mean Follow-Up Time of 2.1 ± 0.7 Years
19031	Changes of Cardiovascular Risk Factors in Well-Controlled Hypertensive Elderly Patients After the Hanshin-Awaji Earthquake
19032	Earthquake-Induced Stress and Changes in Cardiovascular Risk Factors in Well-Controlled Hypertensive Elderly Patients
19033	Relations Between d-Dimer and Other Cardiovascular Risk Factors in Elderly Patients With Well-Controlled Hypertension After the Hanshin-Awaji Earthquake
19034	Changes in Cardiovascular Risk Factors in Hypertensive and Normotensive Elderly Groups After the Hanshin-Awaji Earthquake
19035	Hemodynamic Variables at Peak Dobutamine Stages
19036	End Point Responsible for Test Termination at Peak Dobutamine Stages
19037	Timing of Coronary Artery Bypass Graft Procedures Relative to Onset of Symptoms
19038	Clinical Outcomes in Surgically and Nonsurgically Treated Patients After Acute Myocardial Infarction
19039	Clinical Outcome Events in Patients Undergoing Coronary Artery Bypass Graft Surgery: Timing Relative to Operation
19040	Clinical Outcomes in Surgically and Nonsurgically Treated Patients After Acute MI Patients, Adjusted to Eliminate Early Deaths
19041	Multivariable Analysis Predicting 30-Day Mortality for Patients Undergoing Bypass Surgery  a
19042	Reasons for Nonuse of Radial Artery
19043	Radial Artery Graft Anastomosis
19044	Changes in Hemodynamic Variables in Patients With Ejection Fraction >40%
19045	Changes in Hemodynamic Variables in Patients With Ejection Fraction <40%
19046	Changes in Plasma Norepinephrine and Plasma Renin Activity
19047	Diagnostic Performance of QFR≤0.8 and QCA Diameter Stenosis≥50% Versus FFR≤0.8
19048	Medication Use and Changes
19049	Secondary Outcomes: Changes in Individual Risk Factors
19050	Risk Stratification According to the Corelab SYNTAX Score Defined Tertiles
19051	Change in Treatment Recommendations  ∗   According to the cSS and the sSS Models
19052	Recommendations According to the cSS- and the sSS-Based SS II Models
19053	Reclassification TableComparing 4-Year Mortality Risk Strata for OriginalcSS-and the sSS-Based SS II
19054	Individual Data From Included Studies and Individual Study Sites
19055	Per-Patient and Per-Vessel Diagnostic Performance of FFRCT, Coronary CTA, and ICA
19056	Per-Patient Diagnostic Performance of FFRCT in Patients With Intermediate Stenosis Severity  (30% to 70%)  According to Coronary CTA
19057	Hemodynamic Variables With Stress
19058	Univariate and Multivariate Models of EFS  (Death+MI)
19059	Univariate and Multivariate Models of EFS  (Death+MI)
19060	Oversight Committee and Panel Membership Criteria
19061	Appropriateness Categories and Scores
19062	Long-Term Cardiovascular Outcomes
19063	Factors Associated With Long-Term Adverse Cardiovascular Outcome in Women With a Prior Pregnancy
19064	Independent Correlates of Long-Term Adverse Cardiovascular Outcome in Women With a Prior Pregnancy
19065	Syncope Frequency Depends on the Setting in Which the Measurement Is Made
19066	Established Diagnosis at Initial Evaluation: Commonly Accepted Diagnostic Criteria
19067	Short-Term High-Risk Criteria That Require Prompt Hospitalization or Early Intensive Evaluation
19068	Diagnostic Yield of the Most Used Tests for Diagnosis of Uncertain Syncope After Initial Evaluation in 2 Different Clinical Settings
19069	Diagnostic Performance of FFRCT and CCTA on a Per-Vessel and -Patient Basis
19070	Prevalence of Cerebral Ischemic Lesions in Women and Men With or Without Myocardial Infarction Scars on Cardiac Magnetic Resonance Imaging
19071	Predictive Capabilities of Cardiac Events
19072	Incidence of Cardiac Events According to Symptoms Before Exercise Testing
19073	Association of 9p21 Gene Dosage With Modified Duke and Gensini Scores
19074	Combined Analysis of Early and Late Onset Coronary Artery Disease Patients Diagnosed by Angiogram
19075	Distribution of Disease Severity Among Patients With MI Versus Non-MI
19076	Association of 9p21 With MI Once Stratified for Number of Diseased Vessels
19077	Sensitivity, Specificity, Likelihood Ratio, PPV, and NPV
19078	AEs and Rehospitalization Summary
19079	Ejection Fraction and 6-Min Walk Test
19080	Inclusion/Exclusion Criteria for Study Entry
19081	Schedule of Follow-Up Testing
19082	Primary Outcome Measures
19083	Acute Hemodynamic Catheterization Data  (n = 29)
19084	Cardiac Magnetic Resonance Imaging Results Before and 6 Months After Melody Valve  (Medtronic, Inc.)  Implantation  (n = 25)
19085	Exercise Test Variables in Patients Achieving ≥85% of Their MAPHR Relative to Workload Attained
19086	Myocardial SPECT Imaging Results Versus Exercise Capacity in Patients Achieving ≥85% of Their MAPHR
19087	Multivariable Logistic Regression Analysis Predicting ≥10% Ischemia of the Left Ventricle
19088	SPECT Imaging Results by MAPHR Achieved in Patients Attaining ≥10 METs
19089	Effects of Clopidogrel on Platelet Aggregation, Activation, and Inflammation
19090	Effects of Aspirin on Platelet Aggregation
19091	CVD Risk Factors by 3-Year Morbidity/Mortality Status, 508 Vascular Laboratory Patients, San Diego, California, Recruited 1990 to 1994
19092	Association of 3- and 6-Year CVD Outcomes With Visit 2 ABI and Change From Visit 1 in ABI, Vascular Laboratory Patients, San Diego, California, Recruited 1990 to 1994  ⁎
19093	Medications at Randomization and at Discharge
19094	Unadjusted Kaplan-Meier Estimates of Outcomes
19095	Outcomes by Continent, Relative to North America
19096	Overall Event Rates
19097	Hemodynamic Result of Acute Fontan Fenestration Occlusion  (n = 16)
19098	Exercise Performance Before and After Fontan Fenestration Closure  (n = 20)
19099	Occurrence of RV Failure Based on Pre-Operative Clinical Events and Medical Interventions
19100	Pre-Operative Intravenous Medication Requirements and Incidence of RV Failure After LVAD Implantation
19101	Echocardiographic and Cardiopulmonary Hemodynamic Measurements Before LVAD Implantation With Associated RV Failure
19102	Pre-Operative Laboratory Values and Associated Post-Operative RV Failure
19103	Right Ventricular Failure Risk Score and Likelihood of RV Failure by Score Strata
19104	Description of the 3 Cohorts and the Overall Study Population
19105	Adjusted Hazard Ratios  (and 95% Confidence Intervals)  of SS  (BSPD ≥15)  for Total and CVD Mortality  (Mean Follow-Up 9.4 yrs)
19106	Reasons for Not Accomplishing Trans-Septal Catheterization
19107	Complications Related to Trans-Septal Catheterization
19108	Evolution of Blood Pressure and Antihypertensive Regimens During 24-Month Follow-Up
19109	In-Hospital and Long-Term Major Adverse Events Among 208 Patients
19110	ECG and Laboratory Variables
19111	Univariate Analysis of the Associations Between 25 Clinical Variables and a High-Risk Scan
19112	Variables Independently Associated With High-Risk Scan by Multivariate Analysis
19113	Yield of High-Risk Scans in Selected Patient Subgroups
19114	Results of Coronary Angiography
19115	Frequency of Procedure Type by Cohort
19116	Outcomes by Procedure Type
19117	Odds Ratio for 30-Day Mortality
19118	Outcomes
19119	Observed 30-Day Mortality by Cohort, Procedure Type, and Heart Failure Stratified by Presence of CAD
19120	Semi-Quantitative Scores
19121	SPECT Results of Those Undergoing Early Revascularization  (<60 Days)  Versus Non-Early Revascularization Patients
19122	Unadjusted, Univariable Two-Year Cox Cardiac Death or Myocardial Infarction-Free Survival by Clinical History and SPECT
19123	Risk-Adjusted * Multivariable Cox Model Estimating Cardiac Death or Myocardial Infarction
19124	Annualized Cardiac Death or Nonfatal Myocardial Infarction Rates for SPECT Results in Key Patient Subsets
19125	Post-Test Use of Coronary Angiography, PCI, and CABG by SPECT Results *
19126	Final Clinical Diagnosis in 135 Patients Without Heart Failure
19127	Hemodynamic Data
19128	Doppler Collateral Channels, Chest Pain, ST-Segment Shift and MLER Among the Five Groups
19129	Heart Rate Variability Measures of Survivors, of Subjects Who Died During the Follow-up and of Subjects in Various Mortality Subgroups legend
19130	Unadjusted and Adjusted Association of Heart Rate Variability Variables With All-Cause Mortality, Cardiac Mortality, Sudden Cardiac Mortality, Sudden Cardiac Autopsy-Verified Mortality, Sudden Cardiac Mortality for Both Genders, Nonsudden Cardiac Mortality and Nonsudden Cardiac Mortality With Cerebrovascular Mortality legend legend
19131	The Number of Subjects With Short-Term Fractal Cut-Off Point Value <1 and ≥1 in Different Mortality and Clinical Variable Categories legend
19132	Medical Treatment legend legend
19133	Changes in Internal Diameter of the Radial Artery After Acetylcholine, Nitroglycerin and Reactive Hyperemia at the Beginning of the Study and After Four Weeks legend legend
19134	Serious Adverse Events at Different Dose Levels
19135	Comparison of OUES at 100%, 90% and 75% of Exercise Duration legend
19136	Regression Equations to Predict OUES legend
19137	Comparison of Treadmill Exercise Tests Two Years Apart  (Round 1 vs. Round 2)  legend legend
19138	Final Results of Ergonovine Echocardiography and Invasive Coronary Angiography With Spasm Provocation Test legend
19139	Prevalence of Positive Test According to theClinical Diagnosis  (%)
19140	Comparison of Potential Advantages and Disadvantages of Ergonovine Echocardiography Versus Invasive Spasm Provocation Test During Angiography
19141	Annual and Four-Month Operator Volume
19142	In-Hospital and One-Month MACE legend
19143	Major Cardiac Events at One Month legend
19144	Independent Predictors at One Month legend
19145	Observed and Expected Event Rates legend
19146	Procedural Differences Between Volume Groups
19147	Hemodynamic Changes During Laparoscopy  (Study 1)  legend
19148	Metabolic Changes During Laparoscopy  (Study 1)  legend
19149	Endocrine Changes During Laparoscopy  (Study 1)  legend
19150	Patient Data  (Study 2)   legend
19151	Estimated Incidence of Cardiac Perforation From Catheter-based Procedures Requiring Echo-guided Pericardiocentesis at the Mayo Clinic, January 1979 through November 1997
19152	Patients Who Underwent Surgery after Rescue Pericardiocentesis for Perforation Secondary to a Catheter-based Procedure  legend
19153	Comparison of Diabetic and Normal Rats
19154	Energy Level Changes in Control and Preconditioned Hearts in Response to Sustained Ischemia and Reperfusion
19155	Ultrastructural Changes in Skeletal Muscle After Exercise Training
19156	Muscle Fiber Distribution
19157	Reason for Ineligibility in ACIP Trial
19158	Associated Cardiac Abnormalities at Hospital Admission in 33 Neonates
19159	Immediate Results in 33 Neonates
19160	Procedure Complications in 33 Neonates
19161	Follow-Up Data
19162	Surgical and Transvascular  (percutaneous, umbilical)  Balloon Dilation Management of Neonatal Critical Aortic Stenosis
19163	Echocardiographic Variables
19164	Association Between Pre-operative Variables and Post-operative RVSP≥35 mmHg
19165	All-Cause Death
19166	All-Cause Death in Selected Populations
19167	Post-Transplantation Outcomes
19168	Correlation Between Clinical Variables and Reverse Remodeling  ∗
19169	Clinical Predictors of Mortality
19170	Linear Regression of the Association Between Psychological Distress Profiles and Adult CMR  (n= 6,714)
19171	Linear Regression of the Association Between Psychological Distress Summary Scores and CMR  (n= 6,714)
19172	Association Between Psychological Distress Profile and Individual Biomarkers, Adjusting for Sex and Child Covariates  (n= 6,714)
19173	Association Between Pre-Frailty Status  ∗   and CVD Risk
19174	Univariable and Multivariable Cox Proportional Hazards Models for Mortality
19175	Five Pre-Specified Risk Factors and Survival by Each Risk Factor and by Cumulative Number of Risk Factors, Patients Age≤80 Years, NYHA Functional Class III to IV, and NYHA Functional Class II
19176	Clinical Trials Assessing Effects of CPAP on Cardiac Function in HF Patients With OSA
19177	Observational Studies Assessing Efficacy of CPAP on Morbidity and Mortality in HF Patients With OSA
19178	Heart Weights, HW/BW Ratios, and Histological Morphometry of the Heart
19179	Repartition of Low and Slow Response According BMI Group
19180	VASP Index According to the Initial Response  (Slow vs. Fast)
19181	Hemodynamics, Vascular Function, and Blood Parameters Before and After HD
19182	Univariate Analysis for Predictors of the Change in FMD During a Single HD Session
19183	Morphometric Analysis of the Carotid Arteries 14 Days After Balloon Injury
19184	Physiological Parameters and Echocardiographic Analysis of In Vivo Cardiac Size and Function by Echocardiography 4 and 8 Weeks After Left Coronary Artery Ligation
19185	End Points for Total Population
19186	End Points for Anemic and Nonanemic Subgroups
19187	Adverse Events Profile
19188	Relationship of Retinal Vascular Calibers and Retinopathy With LV Mass, Volume, and Remodeling
19189	Logistic Regression of LV Mass, Volume, and Remodeling by Retinal Vascular Caliber and Retinopathy
19190	Relationship of Retinal Vascular Caliber, Retinopathy, and LV Concentric Remodeling  (Highest Quintile of M/V Ratio  ⁎  ) , Stratified by Race, Diabetes, Hypertension, Coronary Calcification, and Retinopathy Status
19191	Blood Pressure and Hematologic Values During the Two Observation Periods
19192	Procedural Outcome and Follow-Up
19193	Adjusted 30-Day MACE Odds Ratio and 1-Year Mortality Hazard Ratio for Anemia
19194	Blood Chemistry and Hemodynamic Data on Lean Control Subjects and Obese Subjects in the Untrained or Trained State
19195	Plasma Concentrations of Hemoglobin A1cand Glucose, Serum Lipid Concentrations, and Change in Body Mass Index Stratified by Grade of Transplant Coronary Artery Disease as Determined by Angiography
19196	Plasma Concentrations of Hemoglobin A1cand Glucose, Serum Lipid Concentrations, and Change in Body Mass Index Stratified by Mean Intimal Thickness, as Determined by Intracoronary Utrasound
19197	Univariate and Multiple Logistic Regression Analysis of Risk Factors for Transplant Coronary Artery Disease, as Identified by Angiography
19198	Univariate and Multiple Logistic Regression Analysis of Risk Factors for Transplant Coronary Artery Disease, as Identified by Intracoronary Ultrasound
19199	Fasting Serum Squalene and Noncholesterol Sterols legend
19200	Correlations Between Factors Related to CAD legend legend legend
19201	Associations Between Risk Factors and Coronary Artery Disease legend legend
19202	Procedure and In-Hospital Outcome legend
19203	Cause of Death legend
19204	Univariate Cox Analysis of Pharmacologic Treatment for Two Year Death Rates among Diabetics
19205	Univariate and Multivariate Cox Analysis for Death legend
19206	Surgical Procedures in Hemolysis Patients  (Group 1)   legend
19207	Echocardiographic Findings legend
19208	Correlation Coefficients of Monocyte  (Subset)  Counts With Traditional and Nontraditional Cardiovascular Risk Factors
19209	Adjusted Cox Regression Analysis  (Different Models)  for Cardiovascular Events
19210	C-Statistics Corresponding to the Cox Regression Analyses Reported in  Table 3
19211	Multivariate Analysis for LVEF Improvement After 4 Months in the BMC Group
19212	Clinical and Laboratory Parameters of 49 Obese Individuals and 49 Lean Controls
19213	Clinical and Laboratory Parameters of 26 Obese Individuals Before and After Successful Weight Loss
19214	Results of Quantitative Coronary Angiography Post-Procedure and at Follow-Up
19215	Results of Coronary Ultrasound Analysis at Follow-Up
19216	Clinical Events During 12-Months Follow-Up
19217	Time Course of Changes in Hematologic Parameters
19218	Time Course of Changes in Plasma VEGF Levels
19219	Time Course of Changes in Hemodynamic Parameters
19220	Plasma PlGF Levels on Third Day After AMI and the Coronary Risk Factors
19221	Multiple Regression Analysis for Chronic Phase Left Ventricular Function
19222	Multivariable Model for Death/Myocardial Infarction
19223	Univariable Results for Neutrophil/Lymphocyte Ratio  (Q4 vs. Q1)  in Primary and Three Secondary Interest Populations
19224	Physiologic, Hemodynamic, and Echocardiographic Parameters on Day 14
19225	Multiple Regression Analysis for Predicting In-Stent Neointimal Volume
19226	Regional Contractility of the Ischemic Wall ∗   legend
19227	Regional Myocardial Perfusion in Ischemic Animals legend
19228	Histopathologic Quantification of Vascularity legend
19229	Plasma Lipid Profiles in Human Subjects
19230	Fibrinogen Binding on Single Myeloid Leukocytes  (GP Ibα −)  and on Platelet-Leukocyte Aggregates  (GP Ibα +)  legend legend
19231	Immunostaining of Myeloid Leukocytes at 24 h After Revascularization in AMI legend legend
19232	Ex vivo Platelet Stimulation Studies∗ legend legend
19233	Time Course of Chimeric 7E3 Fab Effect on Detectable Platelet and Leukocyte Receptors
19234	Leukocyte–Platelet Interactions ∗
19235	Lesion Morphology
19236	Preprocedural Heparin Administration
19237	Angiographic Outcomes
19238	Frequency of Composite End Point
19239	Elements of Composite End Points at 30 Days and 6 Months  a
19240	Periprocedural Events
19241	Clinical Outcomes at 30 Days in the As-Treated Population  (CEC Adjudicated)
19242	In-Hospital Evolution and Outcome of 16,867 Episodes of IE in Spain  (2003 to 2014)
19243	Variables Independently Associated With In-Hospital Mortality Adjusted by Risk in a Multivariable Logistic Regression Model and a Multilevel Model, With Odds Ratio and 95% Confidence Intervals for Each Variable
19244	Center Volume, Length of Hospital Stay, Readmissions, and Risk-Adjusted In-Hospital Mortality: Episodes From 2014
19245	Factors Associated With Atrial Fibrillation as the Presenting Arrhythmia in Univariable and Multivariable Analyses
19246	Porcine Atrial Ablation Parameters  (N = 64)
19247	Procedural Details
19248	Study Population
19249	LV Unloading and Remodeling
19250	Kaplan-Meier Estimates for Cumulative Number  (Rate)  of MACE
19251	Conditional Logistic Regression Analyses of All MACE and NC-MACE
19252	Quantitative and Qualitative OCT Findings  (Lesion-Level Analysis)
19253	Procedural Data
19254	Termination Rates, Focal Impulse and Rotor Modulation–Guided Ablation
19255	Surface Area
19256	Distribution of Dispersion Areas
19257	Per-Procedural Outcome  (Index and Redo Procedures)
19258	Predictors of Poorer Clinical Outcomes Post-TAVR
19259	Mortality  (Including Emigrated Patients)
19260	Incidence of CHD-Related Deaths by Time Period of Operation
19261	Causes of CHD-Related Deaths by Defect Severity and Decade of Operation
19262	Summary of Recommendations for AS: Choice of Surgical or Transcatheter Intervention
19263	ASCVD Event Hazard Associated With Additional Risk Markers
19264	NRI: Risk Markers Added to cPCE
19265	NRI: Risk Markers Added to cFRS
19266	Polymorphisms Associated With Smoking Behavior in Genome-WideAssociationStudies
19267	CHADS2 and Associated Stroke Risk in the NRAF and ASSERT Trials
19268	Prevalence and Estimated Incidence of BPVT
19269	Predictors of BPVT
19270	Interobserver Variability for MRI and Echo
19271	Comparison of MR Severity: MRI Versus Echo
19272	ACC/AHA Class Indications, MRI Regurgitant Severity, the Presence of Symptoms, and Echocardiographic LV Dimensions in 38 Patients Referred for Isolated Mitral Valve Surgery
19273	Comparison of Pre-Surgical and Post-Surgical Left andRight Ventricular Indexes, as Quantified by Magnetic Resonance Imaging
19274	Clinical Outcomes at 30 Days in the AT Population
19275	Sizing Guidance for the SAPIEN 3 THV on the Basis of 3-Dimensional CT Dimensions
19276	Success Rate After Single Ablation Procedure and OffDrugs  (Effectiveness Cohort)
19277	Multivariate Logistic Regression Analyses of Risk Factors for Primary Effectiveness Endpoint  (Effectiveness Cohort, n=122)
19278	Procedural Variables
19279	Clinical In-Hospital Outcomes
19280	Ratio of Actual THV Stent Area Measured With CT to Nominal THV Area According to THV Size and Degree of Underfilling
19281	ASD Procedures
19282	PDA Procedures
19283	Pulmonary Valvuloplasty Procedures
19284	Aortic Valvuloplasty Procedures  (Single-Balloon Technique)
19285	Coarctation Angioplasty and Stenting Procedures
19286	Pulmonary Artery Stenting Procedures
19287	Objective Predictors of Heart Failure Prognosis According to Patient Clusters
19288	Multidetector Computed Tomography Annular Area Sizing Algorithm
19289	Procedural Outcomes
19290	Multivariate Predictors of AF Recurrence in PVI  (+)  Patients  (Comparison to PVI  (+)  OSA  (-)  Group)
19291	Multivariate Predictors of AF Recurrence  (Comparisonto PVI  (-)  Group)
19292	Summary of Adverse Events On-Treatment Analysis
19293	Procedure and Fluoroscopy Times With Different Balloons and 2 Balloons, Respectively, for Patients With Follow-Up Data After 3-Month Blanking Period  (n = 553)   ⁎
19294	Acute Adverse Events
19295	Correlations and Differences Between Similar Measurements Made by Cross-Sectional CT  *   and 3D-TEE  (n = 104)
19296	Evidence-Based Device Sizing Derived From ROC Curve Prediction of PVAR
19297	Selection Criteria for St. Jude Medical 23-mm Portico Transcatheter Heart  ⁎
19298	30-Day Outcome for the 23-mm Portico Valve
19299	Hemodynamic Function After Implantation and at 30-Day Follow-Up
19300	CT-Determined Cross-Sectional Aortic Annular Dimensions Compared in Systole and Diastole in 20 Randomly Selected Cases From the Original 2D TEE-Guided Cohort
19301	Clinical Data
19302	Comparison of Outcomes Related to Prosthesis Sizing With TEE- and CT-Guided Approaches
19303	Multivariable Model Applied to the Overall Cohort  (n = 136)  for Post-TAVR Paravalvular Regurgitation > Mild
19304	Area Under the Receiver-Operator Curve for the Prediction of Moderate or Severe PAR After TAVR
19305	The Relationship Between Undersizing a THV Relative to the MDCT Annular Size and Increasing Grade of PAR
19306	Change in QoL at Follow-Up by Recurrence Status
19307	Parameter Estimates and HRs From Multivariate Cox Regression Models
19308	Hemodynamic Variables, AR Index, and Laboratory Parameters at 48 h After TAVI According to the Degree of PeriAR
19309	Clinical Outcomes According to the Occurrence of Moderate/Severe PeriAR After TAVI
19310	Pre-Procedural Parameters of Patient Group as a Whole and Divided Into Subgroups Taking Into Account Post-Procedural Regurgitation
19311	Intraprocedural Parameters of Patient Group as a Whole and Divided Into Subgroups Taking Into Account Post-Procedural Regurgitation
19312	Predictive Factors of Post-Procedural Regurgitation  (Results of Univariate Logistic Regression)
19313	Predictive Factors of Post-Procedural Regurgitation  (Results of Multivariate Logistic Regression)
19314	Predictive Morphological Factors  (Parameters From Multislice Computed Tomography)  of Significant Intraprocedural and/or Post-Procedural Regurgitation  (Results of Multivariate Logistic Regression)
19315	Outcomes During and After Hospitalization for AF Ablation
19316	Multivariable Analysis for Predictors of Inpatient Complications Plus All-Cause 30-Day Rehospitalizations
19317	Procedural Considerations and Outcome
19318	Predictors of Significant Aortic Regurgitation in 50 Patients After Implantation of the Medtronic CoreValve Bioprosthesis
19319	Univariate and Multivariate Analyses of Immediate AF Recurrences After Catheter Ablation
19320	Univariate and Multivariate Analyses of Early AF Recurrences After Catheter Ablation
19321	Cox Regression Analysis of AF Recurrences After Catheter Ablation
19322	Cox Proportional Hazards Models of SHS Exposure, Smoking, and CVD Mortality
19323	Cox Proportional Hazards Models of SHS Exposure, Smoking, and All-Cause Mortality
19324	Cardiovascular Responses to Maximal Normoxic Cycle and KE Exercise in Control Subjects and CHF Patients
19325	Arterial and Venous Epinephrine, NE, and Calculated NE Spillover From the Muscle During Maximal Cycle and KE Exercise in Control Subjects and CHF Patients
19326	Type of Fracture and Clinical Outcomes
19327	Eight Patients  (9 Lesions)  With Grade V Fracture and Clinical Outcomes
19328	Primary Efficacy End Point on 7-Day Continuous Holter ECG
19329	Annual Number of Admissions for Adults With Simple Congenital Heart Disease Diagnoses in the U.S, 1998 to 2005
19330	Annual Number of Admissions for Adults With Complex CHD Diagnoses in the U.S., 1998 to 2005
19331	Frequency of Specific Diagnoses and Procedures Associated With Hospitalizations for ACHD
19332	Procedural Parameters Results for the Robotic System
19333	Sympathovagal Discharges and PAT
19334	Exclusion and Inclusion Criteria
19335	Success Rates With and Without Antiarrhythmic Drugs in Patients With Persistent and Permanent Atrial Fibrillation Who Underwent Biatrial and Left Atrial Ablation
19336	ECG, Repolarization, and Depolarization Parameters in Control and in the Brugada-ECG Condition With or Without Phase 2 Re-Entrant Extrasystoles
19337	ECG, Optical Repolarization, and Depolarization Parameters Just Before Polymorphic VT or VF in the Brugada-ECG Condition
19338	Infarction Changes in LV After MI in HIF-1α (+)  and Control Mice
19339	ECHO Parameters of LV Function
19340	Univariate and Multivariate Analysis for the Presence of Non-Pulmonary Vein, Superior Vena Cava, and Left Atrial Posterior Free Wall Ectopic Beats
19341	Univariate Predictors of Late Atrial Fibrillation Recurrence
19342	Clinical Data
19343	Electrocardiographic Data of Mahaim Fibers
19344	Echocardiographic Parameters of AVERT Patients, by Type of Valve
19345	Echocardiographic Parameters of AVERT Patients, by Type of Valve
19346	Procedure Data  (n = 123 in 100 patients)
19347	Types of Stents Used
19348	Comparison of Patients With and Without AFL During Catheter Ablation to Isolate the Pulmonary Veins
19349	Mean Cardiopulmonary Test and Echocardiographic Values Before and Six Months After Transcatheter Closure of Atrial Septal Defect
19350	Tachyarrhythmias During Sinus Node Artery Perfusion With Catecholamines Before and After Atropine
19351	Effects of Isoproterenol and Propranolol on Acetylcholine-Mediated Atrial Fibrillation
19352	Previously Reported NKX2.5Mutations *
19353	Frequency of NKX2.5Mutations Among 608 Patients With Congenital Heart Disease
19354	NKX2.5Mutations Identified Among 608 Patients With Congenital Heart Disease
19355	Waiting Times of Patients Revascularized Within One Year After AMI for Patients Hospitalized at Invasive Versus Non-Invasive Institutions Between 1994 and 1998 *
19356	Outcomes of Patients Revascularized Within One Year After AMI at Invasive Versus Non-Invasive Institutions Between 1994 and 1998 *
19357	Comparison of the Most Significant Historic Features in Patients With Seizures and Established Diagnoses of Syncope
19358	Point Scores for the Diagnosis of Seizures, in the Absence of Knowledge of the Numbers and Historic Duration of Losses of Consciousness and Lightheaded Spells
19359	Point Scores for the Diagnosis of Seizures With Knowledge of the Numbers of Spells and the Length of the History of Losses of Consciousness and Lightheaded Spells
19360	Diagnostic Questions to Determine Whether Loss of Consciousness Is Due to Seizures or Syncope
19361	Micro-CT Parameter
19362	Study Patient Profiles
19363	Response to Combined Therapy
19364	Genotypic Distributions and Allelic Frequencies of P1A1/A2Polymorphism Among Smokers and Nonsmokers
19365	Multivariate Predictors of Carriage of the P1A2Polymorphism
19366	Distribution of the AF Cycle Lengths in Different Regions of the RA in Patients With PAF and CAF legend
19367	Percentage of Time During Which Different Types of AF Are Encountered During 10 s of the Processed Data legend
19368	Right Atrial Activation Patterns legend
19369	ATP Test: Definitions ∗
19370	Anomalies of Aortic Arch Laterality or Branching and Frequencies of Chromosome 22q11 Deletion in Our Study Cohort legend legend
19371	Correlation Between Anatomic/Clinical Variables and Chromosome 22q11 Deletion legend
19372	Five Prospectively Identified Diagnostic Pacing Maneuvers and Questions Asked legend
19373	Diagnostic Value of Pacing Maneuvers during Supraventricular Tachycardia legend
19374	Pacing Protocol
19375	Postoperative Beta-Blocker Therapy legend
19376	Results of Cardiac Catheterization legend
19377	Prevalence of Coronary Artery Disease in the GUSTO Angiographic Substudy
19378	Cardiac Catheterization Rates in Various Subgroups legend
19379	Estimation of Marginal Five-year Survival Benefit with U.S. Pattern of Cardiac Catheterization ∗   legend
19380	Quantitation of Residual Ductal Shunt
19381	Clinically Used Devices for Transcatheter Occlusion of Patent Ductus Arteriosus
19382	Clinical and Electrocardiographic Data legend
19383	Summary of Medications Tried for Control of PJRT legend
19384	Electrophysiologic Data—Anterograde legend
19385	Electrophysiologic Data—Retrograde legend
19386	Histopathology Versus Dobutamine Echocardiography, PET Imaging and Tl-SPECT
19387	Sensitivity and Specificity of Dobutamine Echocardiography, PET and Tl-SPECT for the Detection of Segments With >50% and >25% Viable Myocytes
19388	Clinical and Closure Data for All Patients
19389	Distribution of Selected Variables in 336 Case Patients With Acute Myocardial Infarction Who Never Smoked and 446 Control Patients Who Never Smoked
19390	Prevalence of 336 Case Patients With Acute Myocardial Infarction Who Never Smoked and 446 Control Patients Who Never Smoked According to the Smoking Status of Their Relatives
19391	Odds Ratios  (95% confidence intervals)  for Acute Myocardial Infarction in 336 Case Patients Who Never Smoked and 446 Control Patients Who Never Smoked According to the Smoking Status of Their Close Relatives
19392	Odds Ratios  a   (and 95% confidence intervals)  for Acute Myocardial Infarction in Relation to Smoking Status of Close Relatives by Strata of Selected Covariates
19393	Odds Ratios  a   (and 95% confidence intervals)  for Interaction Between Passive Smoking and Other Selected Risk Factors for Acute Myocardial Infarction
19394	Summary of Coil Implantation in Lambs
19395	Comparison of Heart Rate Variability Between 24 and 1 h Before Onset of Atrial Flutter in 12 Patients
19396	Atrial Extrasystoles and Onset of Paroxysmal Atrial Flutter in 12 Study Patients
19397	Prejunctional Vagal Modulation of Sympathetic Effect
19398	Protocol 1: Drug-Induced Protocol for Coronary Vasospasm  a
19399	Protocol 2: Mechanical Injury Protocol for Coronary Vasospasm  a
19400	Sensitivity to Vasospasm Stimuli
19401	Hemodynamic Variable Changes at Control, Serotonin and U46619 Combination and Recovery Steps in Drug-Induced Vasospasm Protocol in Seven Ovariectomized Rhesus Monkeys  a
19402	Summary of Coil Occlusion in Piglets
19403	Clinical Features of Seven Patients With Spontaneous but Noninducible Paroxysmal Supraventricular Tachycardia
19404	Atrioventricular Node Properties in Seven Patients Without and 34 Patients With Inducible Atrioventricular Node Reentrant Tachycardia
19405	Procedures per Patient
19406	Surgical Procedures
19407	Catheter-Based Interventions
19408	Short- and Long-Term Survival
19409	Predictors of Morbidity and Costs in UnivariableAnalyses
19410	Adjusted Costs, Costs per Day, Length of Stay, and Post-Operative Length of Stay
19411	Effects of Age at Operation on Major Morbidity
19412	Effects of Age at Operation on the Log of Adjusted Costs
19413	Additional Benefits of TEE Over TTE
19414	Clinical Presentations, Signs, and Diagnostic Imaging Results of All Patients With Type A Aortic Dissection
19415	In-Hospital Treatments and Surgical Data of All Patients With Type A Dissection
19416	In-Hospital Complications  (Including Postoperative)  and Mortality of All Patients With Type A Dissection
19417	Clinical Data on Patients With  (Group I)  and Without  (Group II)  Periannular Complications
19418	Predictive Factors of Periannular Complications in 211 Patients With Left-Sided Endocarditis: Univariate Analysis
19419	Seroprevalence of Chlamydia pneumoniaeand Helicobacter pyloriInfection in Patients and Controls
19420	Odds Ratios for Chlamydia pneumoniaein Aortic Valvular Stenosis After Adjustment for Possible Confounding Factors legend
19421	Odds Ratios for CRP in Aortic Valvular Stenosis After Adjustment for Possible Confounding Factors legend
19422	CRP in Patients and Controls According to Chlamydia pneumoniaeInfection legend
19423	Self-reported Tooth Loss During Follow-up and Relative Risk of Nonfatal Myocardial Infarction, Nonfatal Stroke, Cardiovascular Death and All Important Cardiovascular Events in the Physicians’ Health Study I legend
19424	Serial Changes in Echocardiographic Parameters in Control and Hypertensive Rats legend legend
19425	Hemodynamic and Pathological Parameters at the Ages of 7, 13 and 19 Weeks in Control and Hypertensive Rats legend legend
19426	Prevalence of Antibodies Against Chlamydial LPS and Chlamydia pneumoniaein Cases and Controls
19427	Prevalence of IgG Antibodies Against Chlamydial LPS in Relation to Classical Risk Factors and Socioeconomic Variables in the Study Population  (n = 791)
19428	Association of Chlamydial LPS and Chlamydia pneumoniaewith CAD
19429	Markers of Systemic Inflammation in Relation to Serostatus Against Chlamydial LPS in Cases and Controls
19430	Hemodynamic Variables Before and Immediately After Balloon Dilation Atrial Septostomy legend
19431	Hemodynamic Data for Balloon Dilation Atrial Septostomy Patients legend
19432	Hemodynamic Variables Before and Immediately After Repeated Balloon Dilation Atrial Septostomy legend
19433	Seropositivity to Three Candidate Infectious Agents in Patient and Control Groups  legend
19434	C-Reactive Protein Concentrations in Serologic Positive and Negative Groups  legend
19435	Summary of Duke Criteria for Infective Endocarditis
19436	Predisposing Factors and Clinical Features in Patients With and Without Infective Endocarditis
19437	Comparison of Findings Detected by Transthoracic and Transesophageal Echocardiography
19438	Comparison of Clinical Outcome Among Patients With and Without Infective Endocarditis
19439	Comparison of Protocols Between Patients With and Without MACE
19440	Predictive Accuracy for MACE
19441	Clinical Presentation and Management
19442	Target Organ Damage and Cardiovascular Event Rates
19443	Chemical Parameters, CEC, and Intravascular Imaging
19444	Patients With and Without ASP Progression
19445	Factors Associated With All-Cause Death or Retransplantation
19446	Factors Associated With Cardiac Death or Retransplantation
19447	Ultrasound Treatment Regimens
19448	Angiographic Variables and Troponin Levels in STEMI Patients
19449	Changes in LV Function and Myocardial Perfusion  ∗
19450	Summary of S-ICD Trials
19451	Hemolysis Parameters at the Time of Clinical Presentation Before Treatment and 48 H After Treatment Presented According to the Type of Flow Obstruction
19452	Treatment of Blood Flow Abnormalities and Success Rate According to the Obstruction Type
19453	Effects of Nitrite on Resting Hemodynamics  ∗
19454	Effects of Nitrite on Exercise Hemodynamics  ∗
19455	Studies on Mechanisms of Atrial Fibrosis in AF in Humans
19456	Studies on Mechanisms of Atrial Fibrosis in AF in Animal Experiments
19457	Suggested Mechanisms of Predisposition of AtrialVersus Ventricular Myocardium to Fibrosis
19458	Studies on the Prognostic Significance of Atrial Fibrosis in AF Patients
19459	TTE Data: 8-Month Cohort
19460	Periprocedural Clinical Outcomes of the Propensity Score-Matched Population
19461	Clinical Outcomes of the Propensity Score-Matched Population at 1 Year
19462	Treatments for Comorbidities in Patients With HFpEF and Those With HFrEF
19463	Antiplatelet Agents and Dyspnea
19464	Primary and Secondary Angiographic and Electrocardiographic Outcomes
19465	Contrast-Enhanced Cardiac MRI Findings During IndexHospitalization and After 6-Month Follow-Up
19466	Previous Publications of Patients Having an Anomalous Cord Extending From the Raphe of a Congenitally BAV to the Wall of the Aorta Causing Either Acute or Chronic Pure Aortic Regurgitation
19467	Clinical Data for 6 Men Having AVR for a Purely Regurgitant  (4+/4+)  Congenitally Bicuspid Aortic Valve With an Anomalous Cord Extending From the Raphe of One Cusp to the Wall of the Aorta
19468	Summary of Changes of TBR at 4 and 12 Weeks
19469	Short-Term Pregnancy Outcomes
19470	Long-Term Cardiovascular Outcomes
19471	Long-Term Risk of Other Serious Events
19472	Incident Rates of AF in Comparison to 5 Previous Large, Population-Based Studies
19473	Diagnostic Performance and Accuracy of iFR ≤0.80
19474	Diagnostic Performance and Accuracy of iFR ≤0.83
19475	Recursive Partitioning Models Results
19476	Trends in Primary and Secondary Heart Failure Hospitalizations by Age and Sex Category
19477	Primary Diagnosis Category for Hospitalizations With a Primary or Secondary Diagnosis of Heart Failure
19478	Outcomes of Heart Failure Hospitalization, by Primary Versus Secondary Diagnosis of Heart Failure
19479	Most Frequent TEAEs Occurring in >10% of Patients Who Entered PHIRST-2
19480	Clinical Outcomes
19481	Quantitative Coronary Angiography Outcomes
19482	Meta-Analysis of 6 Trials of GPI in Acute Coronary Syndromes: Outcomes by Sex
19483	IVUS Parameters Measured at Each Segment
19484	Hemodynamic Changes With Nitroprusside
19485	Relation of HPV to Various Metabolic Risks
19486	Association Between Cardiovascular Disease and HPV
19487	Pathophysiological Mechanisms of Exercise Intolerance in Heart Failure
19488	Exercise Responses in Patients With Dyspnea Due to Heart Failure Compared With Pulmonary Disease
19489	Summary of Selected Adverse Events in the HF-ACTION Study  ⁎
19490	Summary of Resistance Training Studies in HF
19491	Beneficial Effects of Exercise in Heart Failure
19492	Cox Regression Survival Analysis
19493	Summary of DES Deployed for On- and Off-Label Indications for Survivors <30- and ≥30-Day Duration
19494	Morphometric Analysis of DES  (≥30 Days)
19495	Underlying Causes of Thrombosis in First-Generation DES
19496	First-Generation DES With Localized Hypersensitivity and Malapposition Secondary to Excessive Fibrin
19497	Breakdown of Major Adverse Cardiac Events at Week 16 and at End of Study
19498	MedDRA Summary of Treatment Emergent Adverse Events Occurring in >3% in Either Treatment Group by Primary System Organ Class and Preferred Term: All Subjects Population
19499	Indications for Extraction
19500	Odds Ratio Estimates of Predictors of the Need for CTS Assistance
19501	Procedural Complications
19502	Angiographic and Procedural Findings
19503	Concomitant Medication
19504	ST-Segment Deviation Analysis in the Intention-to-Treat-Analysis
19505	Cumulative Clinical Outcomes at Different Time Points
19506	Safety Events Until Day 30
19507	Electrocardiographic and Clinical Outcome in the 2 Study Phases  ⁎
19508	Clinical Outcome and Safety-Related Parameters
19509	Transcriptional Analysis of EPC and MSC
19510	Secretome of EPC and MSC
19511	MRI Data at 1 Week and 7 Weeks After AMI
19512	Univariate Analyses Showing Relations Between the Annual Rate of Changes in baPWV During Study Period and Parameters Related to Serum CRP Concentration
19513	Multivariate Linear Regression Analyses Showing Association Between the Annual Rate of Changes in baPWV During Study Period and Persistently Elevated Serum CRP
19514	Multivariate Linear Regression Showing the Relationship Between the Annual Rate of Changes in baPWV During Study Period and the Number of Cigarettes Smoked/Day
19515	Quantitative Procedural Results
19516	Overlapping Stents: Reason for Overlapping Stent Implantation per Lesion
19517	Clinical Events at 3 Years
19518	Clinical Events at 30 Days
19519	Angiographic Results
19520	CT Perfusion Scan Parameters
19521	Per Vessel and Per Patient Diagnostic Accuracy of CT Perfusion and SPECT MPI
19522	Diagnostic Accuracy of CTP With SPECT as Reference Standard for All Subjects  (n = 34)
19523	Comparison of Vasoreactivity in Proximal and Distal Segments Among SES, ZES, and BMS
19524	Multivariate Logistic Regression to Examine the Association of Psychological Distress With Behavioral and Pathophysiological Risk Factors
19525	The Extent to Which Behavioral and Pathophysiological Risk Factors Explain the Association Between Psychological Distress and CVD Events
19526	Association Between SNPs in the FGA and FGB Genes and Plasma Fibrinogen Levels
19527	Association Between FGA, FGB, and FGG Haplotypes and Plasma Fibrinogen Levels  ⁎
19528	Association Between Mean Plasma Fibrinogen Levels and SNPs rs2070011 in FGA and rs1800790 in FGB, Stratified by Quartiles of Plasma IL-6 and CRP Levels  ⁎
19529	Association Between Mean Plasma Fibrinogen Levels and FGA, FGB, and FGG Haplotypes, Stratified by Quartiles of Plasma IL-6 Levels  ⁎
19530	Incidence of CIN Among Patients at High Risk for Development of CIN
19531	Dobutamine Stress Data
19532	Standard Medication Protocols for the Cleveland Clinic Heart Failure Intensive Care Unit
19533	Hemodynamics at Admission and Time of Pulmonary-Artery Catheter Removal  (CI and PAP)  and Discharge From Hospital  (MAP)  Between Patients Who Did and Did Not Receive SNP During Hospitalization
19534	Use of Medication on Admission, During Admission, and on Discharge
19535	Primary Outcomes
19536	Predictors of All-Cause Mortality on Multivariate Analysis
19537	Clinical Events on Follow-Up
19538	CRP Values  (mg/l; Mean ± SD)  in Relation to Primary End Point and Unadjusted Odds Ratios
19539	Independent Predictors and Adjusted Odds Ratios of CRP for the Occurrence of the Primary Outcome at 1 Year
19540	Independent Predictors and Adjusted Odds Ratios of CRP for the Occurrence of Death at 1 Year
19541	Doppler and Tissue Doppler Echocardiography After Infusion
19542	Neurohormones, Renal Function, Cardiac Troponin, and Electrophysiology With Istaroxime at 6 h
19543	Adverse Events
19544	Effects of Sirolimus on Vascular Reactivity
19545	Effects of Sirolimus on the Expression of NADPH Oxidase Subunits
19546	Effects of Sirolimus on the Expression of NOX1, NOX2, and eNOS
19547	Assessment of Remodeling-Associated Parameters
19548	MRI Measurements
19549	Risk Estimates  ⁎   for Death, MI, and Recurrent ACS 30 Days After ACS Using Selected Continuous Variables
19550	Risk of Death, MI, or Recurrent ACS With LDL-C <70 mg/dl and Selected On-Treatment TG or Non–HDL-C Cut-Points 30 Days After ACS
19551	Percentage of TG Reduction and Proportion of Atorvastatin- and Pravastatin-Treated Patients Attaining Designated Cut-Points for LDL-C, TG, and/or CRP 30 Days After ACS
19552	Risk of Death, Myocardial Infarction, or Recurrent ACS by Number of Parameters Achieved  ⁎   30 Days After ACS
19553	SBP, HR, and Strain Values by VVI and Sonomicrometry From Ischemic Segment and Nonischemic Segment During Different Hemodynamic Conditions
19554	Systolic Strain Rate Values by VVI and Sonomicrometry From Ischemic Segment and Nonischemic Segment During Different Hemodynamic Conditions
19555	Univariate and Multivariate Analysis of the Day 1 Predictors of Left Ventricular Remodeling at Follow-Up
19556	Univariate and Multivariate Analysis of the Day 1 Predictors of Left Ventricular Remodeling at Follow-Up in Patients With Grade 3 TIMI Flow
19557	Multiple Linear Regression
19558	Effect of 80 mg Atorvastatin Versus 40 mg Pravastatin on Death or Major Cardiovascular Events According to KIF6 Trp719Arg Genotype
19559	Hemodynamic Parameters
19560	Variabilities of Myocardial Strain Measurement by 2-Dimensional Strain
19561	Hemodynamic Data of the 5 Dogs at the Different Series of Measurements
19562	Effect of Treatment on Lipids, Inflammation, Disease Activity, and Hemodynamics After 6 Weeks of Treatment
19563	Release Profile of the TGF-β1–Eluting Stents Used for the Animal Experiments
19564	30-Day, 12- and 24-Month Outcome
19565	Comparison of Morphometric Measurements Among Treatment Groups 42 Days After Stent Implantation
19566	Comparison of Morphometric Measurements of the Neointima Among Treatment Groups 42 Days After Stent Implantation
19567	Comparison of Histologic Findings Among Treatment Groups 42 Days After Stent Implantation
19568	Comparison of Proliferation Index and Luminal Eosinophils/Heterophils Among Treatment Groups
19569	In-Hospital Therapies and Procedures
19570	Continuous 3-Lead Electrocardiographic Results
19571	Clinical Events Through 42 Days
19572	Patients Achieving Suboptimal Platelet Inhibition With Single-Bolus Eptifibatide
19573	Patients Achieving Suboptimal Platelet Inhibition With Double-Bolus Eptifibatide
19574	Description of the 57 Interventions Among the 23 Randomized Placebo Controlled Trials Included in the Meta-Analysis
19575	Non-Inferiority Testing of Primary and Pre-Specified Secondary End Points
19576	Clinical Outcomes at 9 and 12 Months in the Intention-to-Treat Population  ⁎
19577	9-Month Angiographic Outcomes  ⁎
19578	Frequency of Adverse Effects During the Trial Period  ⁎
19579	Risk Factor Profile of the Study Participants
19580	Relationship Between Regional Ecc and Log-CRP in Men and Women
19581	Changes of Laboratory Parameters Including Stem Cell Populations
19582	Myocardial Function Parameters Assessed by Magnetic Resonance Imaging
19583	Myocardial Perfusion Assessed by Magnetic Resonance Imaging
19584	Thresholds for Ventricular Fibrillation Induction at Different Positions Before and After Cocaine Infusion
19585	Histopathological Findings in the Pig Hearts
19586	EMPIRIC Arm Programming of VT/VF Settings
19587	Additional Shock and ATP End-Points
19588	Histomorphometric Data
19589	Clinical, Histological, and CMR Features of Patient Population
19590	Hazard Ratios for Myocardial Infarction According to Tyr402His Genotype
19591	Coronary Microvascular Response
19592	Epicardial Vasomotor Response  (Percent Changes of Mean Epicardial Luminal Diameter)
19593	Echocardiographic analyses after repeated I/R
19594	Angiographic Findings Stratified by the Clinical Syndrome
19595	Individual Data of the Study Population
19596	Clinical Outcomes
19597	Restenosis Outcomes From Quantitative Coronary Analysis at Nine-Month Follow-Up
19598	TVR Rates by Country
19599	Perioperative Complications From CRT Device Implantation  ⁎
19600	Postoperative Complications From Discharge Through Six-Month Follow-Up  ⁎
19601	Unadjusted and Adjusted Mean C-Reactive Protein Levels by Ethnic Group in Participants With and Without Hypertension
19602	Relative Odds of Hypertension by Category of C-Reactive Protein
19603	Coronary Angiography: Quantitative Analysis of Vessel Diameter
19604	Coronary Angiography: Quantitative Analysis of Vessel Diameter for Each Segment in the ASO Group
19605	Intracoronary Doppler: Coronary Flow Velocity in ASO and in Control Groups
19606	Extrapolated Data for CFR Calculated With Administration of Acetylcholine
19607	Extrapolated Data for CFR Calculated With Administration of Adenosine
19608	Risk of Death, Myocardial Infarction, or Rehospitalization With Acute Coronary Syndrome in Different Subgroups by Statin Regimen for the Entire Study, at 30 Days, and Between 6 Months and End of Study
19609	Effect of Statin Therapy on LDL-C and CRP
19610	Odds Ratios as Estimates of Relative Risk for Premature Myocardial Infarction in Carriers of the 894T Allele
19611	Effects of G894T Polymorphism on eNOS Gene on the Inflammatory Process, Endothelial Cell Injury, and Oxidative Stress in the Acute Phase of Premature Myocardial Infarction, One Year After the Event and in Matched Control Patients in the Follow-Up Study
19612	Initial Versus Repeat PCI: Technical Factors
19613	Multiple Regression Analysis for Predicting Angiographic Late Lumen Loss
19614	Cardiac Catheterization and Postmortem Examination 12 Weeks After Coronary Stenosis or Myocardial Infarction
19615	Exclusion Criteria
19616	Primary Clinical End Points
19617	Adverse Events by Treatment Groups
19618	Cox Proportional Hazards Models of High-Sensitivity C-Reactive Protein and ST-Segment Depression Criteria for Prediction of All-Cause and Cardiovascular Mortality
19619	Cox Proportional Hazards Models of Combined High-Sensitivity C-Reactive Protein and ST-Segment Depression Criteria for Prediction of All-Cause and Cardiovascular Mortality
19620	Pre-Intervention Intravascular Ultrasound Findings of Culprit Lesions
19621	Angiographic Findings
19622	Distribution of Variables According to Seropositivity to Helicobacter pylori
19623	Vascular Function by Infectious Agent
19624	Hemodynamic Data in RTCE and in Conventional DSE
19625	Adverse Effects Observed in RTCE and in Conventional DSE
19626	Diagnostic Parameters of MPI and WMA by RTCE for Detecting Angiographically Significant Coronary Artery Disease
19627	Heart Rate, Hemodynamic, and Blood Flow Data at Rest
19628	Mean Pressure Gradients  (mm Hg)  at Rest and Stress
19629	Echocardiographic Parameters
19630	Hemodynamic Parameters
19631	Hematologic Parameters and Results of Coagulation Assays
19632	Hemodynamic Data
19633	Myeloperoxidase Activity  (IU/g)  in Myocardial Samples After Coronary Injury Followed by 48 min of Occlusion and 1, 2, or 4 h of Reperfusion in Swine
19634	Clinical and Angiographic Findings
19635	Effect of Annuloplasty Device on Hemodynamics and MR in the Absence and Presence of Phenylephrine
19636	Hemodynamic Parameters in Each Condition
19637	Correlation Coefficients  (r)  Between Each Variable and LAP, −dP/dtmin, or Tau
19638	Alteration of Each Variable With Hemodynamic Changes
19639	Mean Platelet Aggregation Inhibition  (%)  ± SD at Four Different Time Points
19640	Angiographic Parameters and Relationship With IPA
19641	Bleeding Complications and Thrombocytopenia During Admission
19642	Myocardial Function and Perfusion
19643	Age- and Gender-Adjusted Regression Models for Serum sICAM-1 Levels
19644	Multivariable Correlates of sICAM-1 Levels
19645	Procedural Data
19646	Clinical Outcome at Six Months
19647	Causes and Frequencies of Coronary Venous Lead Implantation Failure
19648	Causes and Frequencies of Temporary and Permanent Loss of CRT During Follow-Up in 443 Patients Who Underwent Successful Implantation of a Defibrillator With CRT
19649	Accuracy of Myocardial Contrast Echocardiography to Detect Residual Infarct-Related Artery Stenosis  (>50%)
19650	Accuracy of Myocardial Contrast Echocardiography to Detect Multivessel Disease
19651	Effect of Atrial Fibrillation on Levels of Plasma CRP, IL-6, TF and Plasma Viscosity: Linear Regression Analyses
19652	Cardiac Nerve Density With 20-Hz Versus 5-Hz Stimulation to the Left Stellate Ganglion
19653	Summary of Protocol 2
19654	Continuous ST-Segment Recovery Parameters
19655	Static ST-Segment Recovery Parameters
19656	Sixty-Minute Angiographic Results for Patients Enrolled in the Continuous ST-Segment Monitoring Substudy
19657	Thirty-Day Clinical Outcomes
19658	Correlations Between ST-Segment Recovery Parameters and Clinical Outcomes
19659	Relative Change in Systolic and Diastolic Indices of Cardiac Function in Neonatal Pigs
19660	Results of Determination of Various Laboratory Indexes Upon Emergency Department Admission (McNemar Test)
19661	Clinical, Electrocardiographic, and Echocardiographic Findings in Patients With Viral or Idiopathic Acute Pericarditis With and Without Detectable cTnI
19662	Complications and Clinical Events During a Mean Follow-Up of 24 Months  (Range 8 to 30 Months)
19663	cTnI Elevation in Viral or Idiopathic Acute Pericarditis: Comparison Between This Report and Previous Studies
19664	Bivariate and Multiple Analyses of Preoperative Levels and Risk Factors
19665	Effect of ET-1 on Hemodynamics
19666	Effect of BQ-123 on Hemodynamics
19667	BP Responses to Acute Dobutamine Infusion in CHF Patients, in Matched Controls, and in Young Controls
19668	Effects of 48 Hours of Dobutamine Infusion  (10 μg/kg/min)  on Hemodynamic Parameters and on Sympathetic Nerve Traffic in Nine Patients With Severe Congestive Heart Failure
19669	Hemodynamic Parameters During Each Hemodynamic Condition
19670	Correlation Between Strain Rate and Tissue Velocity During Isovolumic Contraction  (Peak +dP/dt)  or Isovolumic Relaxation  (Peak −dP/dt)  With Invasive Measurements
19671	Hemodynamics
19672	Regional Myocardial Blood Flow
19673	Procedure and Device Data
19674	Results of Univariate Linear Regression Analysis Between Different Covariates and Peak in ACh- and SNP-Stimulated Forearm Blood Flow
19675	Independent Predictors of Peak Increase in ACh-Stimulated Forearm Blood Flow After Multivariate Analysis
19676	Distribution of Chlamydia pneumoniaeImmunoglobin Antibody Titers in Relation to the Presence and Severity of Aortic Atherosclerotic Plaques
19677	Association of Chlamydia pneumoniaeIgG Antibody Titers With the Presence and Severity of Aortic Atherosclerotic Plaques
19678	Distribution of Chlamydia pneumoniaeIgG Antibody Titers in Relation to Frequency of Clinical Coronary Artery Disease and Cerebrovascular Disease
19679	Blood Cell Counts, Fibrinogen, and hs-CRP in Relation to Chlamydia pneumoniaeAntibody Titer
19680	Diagnostic Accuracy of Clinical Parameters Before and After Epinephrine
19681	Comparison of Different Heparin Doses in Clinical Trials in the 1990s
19682	Comparison of Bleeding Risk in ESPRIT and IMPACT-II Patients Using TIMI Major/Minor Bleeding Criteria
19683	Lipid Parameters and IMT in Patients With Familial Hypercholesterolemia Receiving 80 mg Atorvastatin  (n = 57)  or 40 mg Simvastatin  (n = 53)  Daily for 2 Years
19684	Lipid and Lipoprotein Values *
19685	Achievement of NCEP ATP II/III Target LDL-C at End Point
19686	Safety
19687	Clinical Outcome in the Hospital and During Follow-Up
19688	Levels of CK, CK-MB, and Troponin I Before and 6, 24, 48 h After the Procedure; Levels of CRP Before and 72 h After the Procedure
19689	Angiographic Outcome at 6 Months
19690	Clinical Outcomes and WBC Count
19691	WBC Count, CRP, and 6-Month Mortality
19692	Frequency of Induction of Coronary Spasm, Augmentation of ST-Segment Elevation, and Induction of Ventricular Fibrillation
19693	Frequency of Induction of Coronary Spasm, Augmentation of ST-Segment Elevation, and Induction of Ventricular Fibrillation in Six Patients With Brugada Syndrome in Whom Both Acetylcholine and Ergonovine Maleate Were Injected
19694	Prevalence of Seropositivity by Gender
19695	Prevalence of Cytomegalovirus Seropositivity by Age *  and Gender †  Group
19696	Seropositivity and Risk of Cardiovascular Disease
19697	Co-Infection and Risk of Cardiovascular Disease
19698	Prevalence of Seropositivity and Risk of Cardiovascular Disease With Variable Threshold Values
19699	Hemodynamic Responses at Rest
19700	HALT-MI: Angiographic and Angioplasty Results
19701	HALT-MI: Clinical and Adverse Events at 30 Days
19702	Hemodynamic Effects of Long-Term Epoprostenol Therapy
19703	Univariate Analysis Relating Survival Time to Selected Variables Measured After Three Months of Epoprostenol Therapy
19704	Predictors of Postprocedural Atrial Fibrillation
19705	Cost-Effectiveness Among CABG Only Patients Assuming 26% Effectiveness and $973 Cost of Intravenous Amiodarone Therapy  (1 g per day/2 days)
19706	Cost-Effectiveness Among Valve Replacement Only Patients Assuming 26% Effectiveness and $973 Cost of Intravenous Amiodarone Therapy  (1 g per day/2 days)
19707	Cost-Effectiveness Among Combined CABG and Valve Replacement Patients Assuming 26% Effectiveness and $973 Cost of Intravenous Amiodarone Therapy  (1 g per day/2 days)
19708	Marginal Cost-Utility Analysis for CABG Patients Assuming 26% Effectiveness of Therapy, 3% Discount Rate and $973 Cost of Therapy
19709	Coronary Vasomotor Response  (Mean Luminal Diameter in mm)
19710	Plasma Levels of sCD14  (μg/ml) , Genotype and Allele Distribution for CD14 Polymorphism in Patients and Controls
19711	Soluble CD14 Plasma Levels  (μg/ml)  and CD14 C (-260) →T Polymorphism
19712	Age- and Gender-Adjusted Plasma Levels of sCD14  (μg/ml)  According to Serostatus of C. pneumoniaeand Serostatus of H. pylori
19713	Crude and Adjusted OR for Coronary Artery Disease Associated With sCD14 Plasma Levels and CD14C (-260) →T Polymorphism
19714	Mean Concentrations *   † of Various Markers of Inflammation and Hemostasis in Patients and Controls in the Top Quintile of sCD14 Receptor Distribution Compared With the Combined Lower Four Quintiles
19715	Mean Concentrations *   † of Various Markers of Inflammation and Hemostasis in Patients and Controls According to CD14 Genotypes
19716	Hemodynamic Changes Induced by Dipyridamole and Dobutamine
19717	Effects of Dipyridamole Dobutamine on MBF and MCE Parameters
19718	Transthoracic Doppler Harmonic Echocardiography Results in Both Groups
19719	Sensitivity and Specificity of Echocardiographic Measurements with Respect to Group Distinction
19720	Clinical Course of the Two Patient Groups
19721	Comparison of Outcomes Between Device and Surgical Closure Groups
19722	Comparison of Complications Between Device and Surgical Closure Groups
19723	Antisense Histopathologic Findings
19724	Histomorphometric Results in Porcine Coronary Arteries 28 Days After Local Delivery of Antisense and Stent Implantation
19725	Hemodynamic Data
19726	Correlation Coefficients for CRP and Angiographic Measures of CAD
19727	Hazard Ratio of Elevated CRP for Death or Nonfatal Myocardial Infarction Among Subjects With Angiographic Adjusted for Various Angiographic Markers * on Disease Severity
19728	Hemodynamic Parameters and pO2During the AO Infusion
19729	Ergometric Parameters
19730	Clinical Events at Six-Month Clinical Follow-Up
19731	Quantitative Coronary Angiographic Analysis
19732	Hemodynamics and Coronary Flow Velocity Measurements
19733	Hemodynamics
19734	Coronary Flow Velocity Data
19735	Results of Survival Analysis  (Cox Proportional Hazards Model)  for the Combined End Point: Cardiac Mortality + Urgent Heart Transplantation + Readmission for Congestive Heart Failure
19736	Comparison of Surgical Outcomes and Survival Between Mice With MI and Sham-Operated Mice
19737	Study Schedule, Mortality Distribution and Three-Day Blood Pressure Measurements of the Various Treatment Groups
19738	Changes in Clinical Parameters After Two Weeks of Sauna Treatment legend legend
19739	Presence or Absence of Correlation Between Plaque Area and IEL Area in Right and Left Femoral Arteries legend legend
19740	Number of Plaques in Which Lipid-Rich Core Occupies ≥40% of Total Plaque Area in Right and Left Femoral Arteries legend
19741	Number of Plaques With Superficial Inflammation in Right and Left Femoral Arteries legend
19742	Histomorphometric Measurements of the Four Studied Groups One Month After Implantation in Porcine Coronary Arteries legend
19743	Two-Way ANOVA and Interaction Term of the Histomorphometric Variables Studied legend
19744	Plasma Concentrations of Arginine, Methylarginines, 8-epi-PGF2α, Lipid Profiles and Blood Pressure Before  (Visit 1)  and at the End  (Visit 2)  of Treatment With Oral Arginine/Placebo legend
19745	Exercise Tolerance and Ischemia Before  (Visit 1)  and at the End  (Visit 2)  of Treatment With Oral Arginine/Placebo
19746	CFV Ratio in the LAD During Dobutamine Infusion legend
19747	Correlation Coefficient Between CFV Ratio and Wall Motion Score Variables legend
19748	Intention-to-Treat Analysis of Mortality Reduction With Abciximab in Studies Randomizing Patients to Standard Therapy or Standard Therapy Plus Abciximab With a 12-h Infusion After PCI legend legend
19749	Mortality Over Time Among All Patients in PCI Studies Randomizing Patients to Standard Therapy or Standard Therapy Plus Abciximab With a 12-h Infusion After PCI  (Excludes Patients Not Randomized to a Common Intervention [EPISTENT PTCA/Abciximab Group])  legend
19750	Relative Changes in Platelet-Monocyte Interaction, Mac-1 Expression on Monocytes With Adherent Platelets and P-Selectin Surface Expression on Platelets legend legend
19751	Intravascular Nitroprusside Administration legend legend
19752	Change in Cineangiographic Flow with Intravascular Nitroprusside Administration legend legend legend
19753	Hemodynamic Effects of Intravascular Nitroprusside Administration
19754	Comparison of Changes in Lipid Profiles After the Two Week Treatment Period  (>Δ% ± SEM, n = 35)  With Cerivastatin or Placebo legend
19755	Comparison of Electrophysiologic and Hemodynamic Data Before and After Verapamil legend legend
19756	Verapamil-Induced Changes in AF Cycle Length, APD90and Dispersion Coefficient legend legend
19757	Plasma Hormone Concentrations  (mean ± SEM)  legend
19758	(re) Infarction by Antithrombotic Treatment
19759	Mortality
19760	Follow-up Quantitative Angiographic Analysis legend
19761	Major Adverse Clinical Events at One-Month and Six-Month Clinical Follow-up legend
19762	Logistic Regression Analysis for Stent Restenosis legend
19763	Logistic Regression Analysis for Clinical Outcome  (MI, Death, TVR)  legend
19764	MAP and HR During rhVEGF Infusion legend
19765	Regional Coronary Blood Flow  (ml/g/min)  in LAD and LCX Territory legend
19766	Comparison of BITA versus SITA for Hospital Mortality and Morbidity legend
19767	Multivariate Analysis for Determination of Propensity Score for the Performance of BITA versus SITA Revascularization legend legend
19768	Odds Ratio for Hospital Mortality and Deep Sternal Wound Infections in Bilateral versus Single Internal Thoracic Artery With Various Adjustments legend
19769	Hospital Mortality in BITA versus SITA Revascularization According to Mortality Risk Quartile legend
19770	Unadjusted 30-Day Death or Myocardial Infarction by Transfer Status and Randomized Treatment legend
19771	Incidence and Timing of 30-Day Death or Myocardial Infarction in Transfer Patients legend
19772	Safety by Transfer Status legend
19773	Angiographic Findings in Patients With and Without Coronary Steal legend
19774	Hemodynamic Findings in Patients With and Without Coronary Steal legend
19775	Clinical and Electrocardiographic Findings During Coronary Vasodilation in Patients With and Without Coronary Steal legend
19776	Correlates of Coronary Steal legend
19777	Hemodynamic and Dimension Data legend
19778	Mean Changes in Transmitral Flow Velocities legend
19779	Troponin I  (μg/l)  and C-reactive protein  (CRP)   (mg/l)  Concentrations According to Prior Aspirin Use: Data for Troponin I Are Number  (%)  of Patients With Serum Concentration >0.1 μg/l, and for CRP Are Medians  (Interquartile Range)
19780	C-Reactive Protein Concentrations  (mg/l)  as a Univariate Predictor of Death or Nonfatal Myocardial Infarction at 30 Days and 12 Months According to Prior Aspirin Treatment: Data Are Median Values  (Interquartile Range)
19781	Odds Ratios for Association of Maximum C-Reactive Protein  (CRP)  Concentrations With 30-Day and 12-Month Event-Free Survival According to Prior Aspirin Treatment legend
19782	Incidence of Adverse Events Recorded During the Early 30 Days
19783	Results at Follow-up Angiography legend
19784	Results at Follow-up Angiography in Patients <60 Years legend
19785	Patient Population legend legend
19786	Major Adverse Cardiovascular Events and Revascularization legend
19787	Changes in Closed or Partially Closed  (≥50%)  Venous Segments After 12 Months legend
19788	Degree of Postthrombotic Syndrome as Defined by Venographic Criteria ∗ After 12 Months legend
19789	Follow-up Results After 12 Months Comparing Patients With and Without Postthrombotic Syndrome legend
19790	Efficacy and Safety Results After 7 Days According to Venographic Findings legend
19791	Clinical, Angiographic and Ergometric Features of Symptomatic  (Group P)  and Asymptomatic  (Group A)  Patients During Myocardial Ischemia legend legend
19792	Systemic Hemodynamics legend
19793	Coronary Diameter and Blood Flow legend
19794	The Effect of Tranilast on the Vessel Response to Balloon Injury legend
19795	The Effect of Tranilast on the Vessel Response to Stent Injury legend
19796	Effects of L-Arginine on Brachial Artery Endothelial Function legend
19797	Effects of L-Arginine on Cell Adhesion Molecule Expression on Leukocytes legend
19798	Results of RFA of Inappropriate Sinus Tachycardia legend
19799	Clinical Features of Patients With Coronary Artery Disease legend legend
19800	Atherosclerotic Events and Macrophage Colony–Stimulating Factor Concentrations in Study Patients legend
19801	Coronary Angiographic Findings and Macrophage Colony–Stimulating Factor Concentrations in Patients With Acute Coronary Events legend
19802	Cox Proportional Hazards Regression Analysis for the Predictors of Acute Coronary Events legend
19803	Clinical Features of Patients With a Macrophage Colony–Stimulating Factor  (MCSF)  Concentration ≥950 pg/ml or <950 pg/ml legend legend
19804	Study Population legend
19805	Effects of Placebo and Dipyridamole  (15 mg in 30 min)  on Hemodynamic, Echocardiographic and Electrocardiographic Parameters legend
19806	Results of Exercise Stress Echocardiography After Placebo and Dipyridamole in the Total Population
19807	Technical Results of Angioplasty legend
19808	Initial and Convalescent LV Function by Treatment Group and by Patency Grade
19809	Adverse Outcomes
19810	Association of Traditional Risk Factors With Presence of CAD
19811	Association of CAD Risk Factors With CRP ∗
19812	Quantitative Angiographic Data of the Proximal LAD, Pre- and Postintervention, and at the Time of Study legend
19813	Multivariable Analysis of Change in Luminal Diameter in Response to Maximal Acetylcholine Infusion
19814	Coagulation Measurements Over Time Among Patients Randomized to Immediate Discontinuation of Heparin legend
19815	Coagulation Measurements Over Time Among Patients Randomized to Intravenous Heparin Weaning
19816	Coagulation Measurements Over Time Among Patients Randomized to Subcutaneous Heparin Weaning
19817	Data at Different Levels of Afterload for 10 Piglets
19818	Piglet Data After Vagotomy legend
19819	Adult Pig Data After Vagotomy
19820	Hemodynamic Findings legend
19821	Clinical, Angiographic Findings and CFR Values by Both IDFW and Enhanced TTE legend
19822	Univariate Predictors of Cardiac Mortality in Medically Treated Patients legend legend
19823	Incomplete Drug Infusion
19824	Incidence of Major Morbidity and Mortality
19825	Conduits Used for Coronary Revascularization legend
19826	Causes of Operative Death
19827	Operative Morbidity legend
19828	Conduits Used for Coronary Revascularization and Occurrence of Chest Wound Infections legend
19829	Clinical, Anatomic and Hemodynamic Features in the Two Groups of Patients legend
19830	Values of ST-Segment Shift, Cardiac Pain and Average Peak Velocity in the Contralateral Coronary Artery in the Two Groups of Patients legend
19831	Number of HLA Mismatches in A, B and DR Loci legend
19832	Comparison Between Taiwan and Western Series ∗   legend
19833	Ischemic Events and Angiographic Parameters legend legend
19834	In-Hospital Complications legend legend
19835	Functional Outcomes  (Whole Patients)  legend legend
19836	Functional Outcomes  (Cases of Onset–Reperfusion Time ≤6 h)  legend
19837	Clinical and Echocardiographic Data in DSE Subsets legend
19838	Medical Therapy vs. Revascularization in Patients With Inducible Ischemia legend
19839	Data in Medically Treated Patients With Hard, Soft and No Events legend
19840	Computer Directed and Clinically Directed Stepwise Multiple Logistic Regression and Cox Proportion Hazard Analysis of Determinants of Hard Events in Medically Treated Patients legend
19841	Hemodynamics in Each Group legend
19842	Summary of Infarct Size Data
19843	Hemodynamic Changes With Intervention
19844	Changes in Aortic Diameter and Wall Thickness in Pacing-Induced Heart Failure  (PHF)
19845	Pressure–Dimension and Stress–Strain Relations: Effects of Pacing-Induced Heart Failure  (PHF)  and Pharmacologic Agents
19846	Events at 30 Days  legend
19847	Composite Event Rates at 30 Days and During the Total Follow-up Period After Exclusion of Diabetic Subjects
19848	Events During the Total Follow-up Period
19849	Predictors of Medium-Term Outcome in Uni- and Multivariate Analysis
19850	Combined Trial Results for the 30-Day Death/Myocardial Infarction/Urgent Intervention Outcome by Case Report Form  (CRF) -Defined Lesion Morphology legend
19851	Plasma l-Arginine and Dimethylarginine Concentrations  legend legend
19852	Intensity of Single-Photon Emission Computed Tomographic Perfusion Defects, Wall Motion Abnormalities and Contrast Effects on Patients in Each Randomized Dosage Group legend
19853	Comparison of Sensitivity and Specificity of Myocardial Contrast Effect for Prediction of Moderate and Severe Single-Photon Emission Computed Tomographic Perfusion Defects at Each Dose and With Each Imaging Technique  legend
19854	Patient-Weighted Data Comparing the Sensitivity and Specificity of Myocardial Contrast Effect for Prediction of Moderate and Severe Single-Photon Emission Computed Tomography Perfusion Defects at Each Dose and With Each Imaging Technique  legend
19855	Correlation of Single-Photon Emission Computed Tomography  (SPECT)  With Harmonic Myocardial Contrast Echocardiography in the Triggered Mode, According to the Correlation of SPECT with Wall Motion Analysis  (After Exclusion of Nondiagnostic Studies)  legend
19856	Subanalysis of Sensitivity, Specificity and Feasibility of Harmonic Myocardial Contrast Echocardiography for Detection of Patients With Moderate and Severe Single-Photon Emission Computed Tomographic Defects  legend
19857	Hemodynamic Data
19858	Definitions of Events and Derived Time Indexes
19859	Time Indexes, Aortic Pressure and LAD Flow
19860	Hemostasis Parameters
19861	Perinatal and Postnatal Data  legend
19862	Effect of Incremental Dobutamine on Various Indices in Control and With Stenosis legend
19863	Arterial Pressure Response to Magnesium or Saline  (control group)  Infusion legend
19864	Hemodynamic, Myocardial Blood Flow and Myocardial Contrast Echocardiographic Data From Stenosed Bed in Ten Group I Dogs legend
19865	Hemodynamic, Myocardial Blood Flow and Myocardial Contrast Echocardiographic Data From Stenosed Bed in Eight Group II Dogs  legend
19866	Hemodynamic Effects of AFO150 in Group I and II Dogs ∗   legend
19867	Systemic Hemodynamic Variables  legend
19868	Six-Month End Points: RESTORE Angiographic Substudy  legend
19869	Flow Data: RESTORE Angiographic Substudy  legend
19870	Six-Month Follow-Up: RESTORE Angiographic Substudy
19871	Hemodynamic Data During Positron Emission Tomography  legend
19872	Vascular Access Site Complications by Treatment Received in 3,871 Study Patients
19873	Hemodynamic and Blood Gas Responses to Exercise, Dobutamine and Nitric Oxide in 11 Patients With Primary Pulmonary Hypertension  a
19874	Hemodynamic and Blood Gas Responses to Prostacyclin in Six Patients
19875	Effects of Intracoronary OPC-18790 on Heart Rate and Vascular Load
19876	Effects of Intracoronary OPC-18790 on Systolic Function, Ventriculoarterial Coupling and Myocardial Efficiency
19877	Effects of Intracoronary OPC-18790 on Diastolic Function
19878	In-Hospital Clinical Course and Adverse Events  a
19879	Hemodynamic Results
19880	One-Year Follow-Up Data
19881	Study Sample
19882	Factors Associated With Use of Heparin for Acute Myocardial Infarction, Based on Multiple Logistic Regression With Backward Stepwise Selection  a
19883	Odds of 30-Day Mortality of Patients Treated With Heparin Compared With Patients Not Treated With Heparin  a
19884	Effects of Procedure and Drugs on Coronary Diameters
19885	Wall Thickness and Systolic Thickening
19886	Left Ventricular Functional Response to Inotropic Modulation
19887	Log (ED50) , Hemodynamic and Blood Glucose Values Before and After Glibenclamide and l-NAME in 10 Dogs
19888	Clinical Data of the 30 Patients With Isolated Left Anterior Descending Coronary Artery Lesions
19889	Angiographic, Intracoronary Doppler Flow Velocity and Dipyridamole Stress Echocardiographic Data for 30 Study Patients
19890	Results of Discriminant Analysis
19891	Coronary Artery Morphometric Measurements in 21 Stented Vessels
19892	Hemodynamic Responses Before and After Addition of Atropine During Dobutamine Stress in 73 Patients
19893	Responses of Hemodynamic Variables, Regional Myocardial Function, Perfusion and Metabolism to Incremental Doses of Dobutamine at Each Stage With or Without Esmolol and Atropine
19894	Effect of Abciximab Administration on Target Vessel Stenosis, Thrombus Grade and TIMI Flow Grade
19895	Hemodynamic Data During Positron Emission Tomographic Scanning [mean  (SD) ]
19896	Results of Discriminant Analysis for Rest–Redistribution Thallium-201 Single-Photon Emission Computed Tomography
19897	Thirty-Day Outcome Among Patients With Unstable Angina in the EPIC Trial
19898	Bleeding Complications and Hematologic Values for Patients With and Without Unstable Angina in the EPIC Trial
19899	Outcome Among Patients With Unstable Angina From Study Entry Through 6 Months
19900	Outcome Among Patients With Unstable Angina From 30 Days Through 6 Months
19901	Prevalence of Morphologic Features of Plaque in the Different Groups
19902	Myocardial Contractile Effects of Intracoronary l-Arginine
19903	Clinical Profile of Patients Undergoing Coronary Angioplasty  (PTCA group)
19904	Clinical Profile of Patients Undergoing Coronary Arteriography  (control group)
19905	Summary of Heart Rate and Systolic Blood Pressure Response in 14 Patients With Paradoxical Sinus Deceleration
19906	Summary of Symptoms, Wall Motion Abnormalities and Electrocardiographic and Angiographic Findings in 14 Patients With Paradoxical Sinus Deceleration
19907	Clinical Variables and Medication in Patients Undergoing Dobutamine Stress Echocardiography, According to Heart Rate Response
19908	Symptoms and Heart Rate, Electrocardiographic and Echocardiographic Variables During Dobutamine Stress Echocardiography in Patients With and Without a Decrease in Heart Rate
19909	Hemodynamic Data  (mean ± SEM)
19910	Regional Function in Left Anterior Descending Coronary Artery Territory  (mean ± SEM)
19911	Regional Function in Left Circumflex Coronary Artery Territory  (mean ± SEM)
19912	Hemodynamic Variables and Regional Function Before Each Intervention
19913	Hemodynamic Data and Regional Function at an Ischemic Segment End-Diastolic Length of 10 Millimeters  (Mean ± SEM)
19914	Results of Multivariate Regression Analysis of Hemodynamic Determinants of Systolic Bulging
19915	Effects of Dobutamine and MCI-154 on Hemodynamic Variables
19916	Effects of Dobutamine and MCI-154 on Mechanoenergetic Variables
19917	Variables of Vo 2Relation During Control Conditions
19918	Effects of MCI-154 on Vo 2–PVA Relations
19919	Effects of Dobutamine and MCI-154 on Emax and PVA-Independent Vo 2
19920	Multivariate Stepwise Regression Analysis of Time to Detection of Angiographic Allograft Coronary Artery Disease in a Consecutive Series of 233 Heart Transplant Recipients
19921	Comparison of Risk Factors in Older and Younger Donor Groups
19922	Procedural Details of Patients Undergoing Percutaneous Transluminal Coronary Angioplasty or Directional Coronary Atherectomy
19923	Multivariable Logistic Regression Modeling for Predictors of Non-Q Wave Myocardial Infarction
19924	Thirty-Day Outcomes by Treatment Group and Interventional Device Used
19925	Bleeding Complications by Treatment Group and Interventional Device Used
19926	Six-Month Outcomes by Treatment Group and Interventional Device
19927	C-Type Natriuretic Peptide-Mediated Coronary Relaxation
19928	Cardiac Hemodynamic Responses to C-Type Natriuretic Peptide
19929	Cardiac Hemodynamic Responses to HS-142-1
19930	Cardiac Hemodynamic Responses to l-NMMA Infusion
19931	Reasons for Discontinuation of DE Treatment at 2 Years
19932	Main Predictors of DE Nonpersistence
19933	Hospital Presentation
19934	Potential Predisposing Factors
19935	Involvement With Noncoronary FMD
19936	In-Hospital and Follow-Up MACE
19937	Medications at Discharge and Last Follow-Up
19938	Univariate and Multivariate Predictors of Recurrent SCAD
19939	Serious Adverse Events and Most Common Side Effects According to Treatment Group
19940	Comparison of EPC Number, EPC Function, and HPC Number Between CAV-Negative and CAV-Positive Patients
19941	Comparison of CEC and Circulating Endothelial Microparticles Between CAV-Negative and CAV-Positive Patients
19942	Logistic Regression Model for Prediction of CAV
19943	Secondary Efficacy End Points
19944	Summary of AEs
19945	Relatives of 38 HLHS Probands Affected With CVM
19946	Valve Phenotype in 38 HLHS Probands
19947	Hypoplastic Left Heart Syndrome and CVM λR
19948	Morphometric Data and Quantification of the Inflammatory Infiltrates of Patients With ARVD and Myocarditis in Normokinetic and Ipo-Dyskinetic Right Ventricular Biopsy Sites
19949	Electrocardiographic-Arrhythmic and Morphofunctional Parameters of Patients With ARVD Compared With Patients With Myocarditis
19950	Arrhythmic Profile, Histology, Treatment, and Follow-Up of 30 Patients With Clinical Profile of ARVD
19951	Clinical Features of Patients With Akinesia at Rest Who Did  (Group A)  and Did Not  (Group B)  Develop Dyskinesia With Exercise Echocardiography
19952	Exercise Echocardiographic Features of Patients With Akinesia at Rest Who Did  (Group A)  and Did Not  (Group B)  Develop Dyskinesia With Exercise Echocardiography
19953	Predictors of Cardiac Death and Non-Fatal Acute Myocardial Infarction.
19954	Predictors of All-Cause Mortality
19955	Clinical and Echocardiographic Features of Patients With Akinesia at Rest Who Developed Dyskinesia Following Exercise  (Group A)  and Patients Who Developed Dyskinesia in Normal or Hypokinetic Myocardium and Did Not Have Akinesia at Rest  (Group C)
19956	Quantification and Location of Apoptotic Smooth Muscle Cells and Macrophages
19957	Quantitative Coronary Angiographic Results
19958	Quantitative Intravascular Ultrasound Results legend
19959	Global Assessment Data
19960	Change in NYHA Data legend
19961	Adverse Events by Treatment Group legend
19962	Angiographic and Procedural Data of Patients With Diabetes Mellitus Versus Patients Without Diabetes Mellitus With Restenosis After Successful Coronary Atherectomy legend
19963	Total and Segmental Areas of Coronary Restenotic Tissue From Patients With Diabetes Mellitus Versus Patients Without Diabetes Mellitus legend
19964	Total and Segmental Areas of Coronary Restenotic Tissue From Patients With Diabetes Mellitus Treated With Insulin or Hypoglycemic Medication Versus Patients With Diabetes Mellitus Treated With Diet legend legend
19965	Parental History of Premature CHD Death by Study, Age and Gender legend
19966	Symptomatic CHD by Study, Age and Gender in the Offspring legend
19967	Association Between Parental History of Premature CHD Death and CHD in the Offspring in the Three Studies legend
19968	Prevalences of CHD Risk Factors by Study in Men aged 45 to 64 Years legend
19969	Association Between Parental History of Premature CHD Death and CHD Risk Factors in the Offspring in the Three Studies legend
19970	Noninvasive Signs of Reperfusion
19971	TIMI Grade 3 Flow in Infarct-Related Arteries in All Patients and in Subgroups With Noninvasive Signs of Reperfusion Treated with Placebo versus Dalteparin
19972	Postthrombolytic Ischemic STVM Episodes 0–24 Hours and 6–24 Hours in All Patients and in Subgroups with Noninvasive Signs of Reperfusion legend
19973	Clinical Events Until Follow Up Day 21
19974	Mean and Maximum Lumen and Stent Measurements by QCA, IVUS and Histology
19975	Previously Reported In Vitro IVUS Validation Studies
19976	Left Ventricular Resting Echocardiography
19977	Left Ventricular Exercise Echocardiography
19978	Predictors of Ejection Fraction Increase at 60% Exercise Load
19979	Clinical Outcomes of BrS Patients According to ICD Indication
19980	Parameters Associated With ICD Therapy
19981	Resting Arterial Properties and Central Hemodynamics
19982	Submaximal  (20-W)  Exercise Arterial and Ventricular Function
19983	Peak Exercise Arterial and Ventricular Function
19984	Effect of Nitrite on Arterial Properties at Rest and Exercise
19985	Clinical Events During 10 Years
19986	Resting and Post-Exercise Echocardiographic Data in the StudyPopulation
19987	Multivariable Cox Proportional Hazard Analysis in the Study Population for Longer-Term Mortality
19988	Reclassification of Patients Who Survived and Who Died During Follow-Up
19989	Ischemic CAD Testing and Revascularization
19990	Multivariable Analysis for Noninvasive Testing
19991	Multivariable Analysis for Invasive Testing
19992	Multivariable Analysis for Revascularization
19993	Test Results and Event Rates
19994	Association Between NIT Type and Positive Test Results
19995	Association Between NIT Result and the Primary Composite Outcome
19996	Association of Pulse Pressure With Adverse Cardiovascular Events on Unadjusted and Multivariate-Adjusted Analyses
19997	Multivariable Cox Proportional Hazards Regressions: Association Between the Gender-Related Score and RecurrentACS
19998	Stepwise Proportional Hazard Regressions: Potential Pathways of the Association Between the Gender-Related Score and Recurrent ACS
19999	Resource Use Over 90 Days, by Cohort and Evaluation Strategy: Number of Times Used  (Number of Patients With Any Use)
20000	Mean Medical Costs Over 90 Days, by Cohort and Evaluation Strategy  (U.S. Dollars)
20001	Unadjusted and Adjusted Regression Coefficients for Female Sex Predicting thePercentage of YPLL  ∗
20002	Unadjusted and Adjusted Regression Coefficients for Black Race Predicting thePercentage of YPLL  ∗
20003	Overview of Reports Included in the TTE and TEE Analyses
20004	Overview of Reports Included in the SE, SPECT, and CTA Analyses
20005	Proportion of Appropriate Tests and Their Association With Publication Year in the Total Sample and Among Classifiable Imaging Studies and Examination of the Association Between the Proportion of Classifiable Tests and Publication Years
20006	Meta-Regression of the Associations of the Proportion of Appropriate Tests
20007	Meta-Regression of Proportion of “Rarely Appropriate” Tests of Total Sample and Classified Studies as Dependent Variables
20008	Meta-Regression of Proportion of “May Be Appropriate” Tests of Total Sample and Classified Studies as Dependent Variables
20009	Hemodynamics in Revascularized and Nonrevascularized Animals With Hibernating Myocardium
20010	Proteomic Profiling in Swine With Hibernating Myocardium With and WithoutRevascularization  ∗
20011	Maximum LRC and Mean LRC Changed With the Time of HFC Diet Feeding
20012	Adjusted Risks of Definite Stent Thrombosis
20013	Diagnostic Modalities for Myocardial Bridging
20014	Schwarz Classification for Myocardial Bridges and Treatment
20015	Studies of Percutaneous Coronary Intervention for Myocardial Bridging
20016	Studies of Surgical Interventions for Myocardial Bridging
20017	CT Scan Parameters  (n= 75)
20018	Per-Vessel Territory Diagnostic Accuracy of QCA, Coronary CTA, Combined CTA+ CTP, Combined CTA+ TAG320, and MDCT-IP Assessments, Compared With FFR
20019	Per-Vessel Diagnostic Accuracy of CTA+ TAG320, CTA+ CTP, and MDCT-IP Methods in 97 Vessels
20020	3-Year Outcomes for Propensity-Matched Patients With Single-Vessel Proximal Left Anterior Descending Disease Receiving CABG Surgery and Stenting With DES in NewYork State: January 1, 2008 to December 31, 2010 and Followed Through to December31, 2011
20021	MSIMI and ESIMI
20022	Procedural and In-Hospital Outcomes of Patients Receiving 6Months and 12 Months of DAPT
20023	Medication Use During Trial in Patients Receiving 6Months and 12 Months of DAPT
20024	Clinical Outcomes in Patients Receiving 6 Months and 12 Months of DAPT  ∗
20025	Predictors of the Primary Endpoint at Multivariable Analysis
20026	GRADE Method Evidence Summarizing the Outcomes Measured
20027	Sex Differences in Clinical Presentation for Patients Clinically Referred to Rb-82 Myocardial Perfusion PET
20028	Unadjusted and Adjusted Hazard for CAD Death in Women and Men Undergoing Stress Myocardial Perfusion Rb-82 PET Imaging
20029	Model Subset Including Rest LVEF Measurement and Stress Myocardial Perfusion Rb-82 PET in 2,101 Women and Men
20030	Net Re-Classification Improvement for Estimation of CAD Death Using Clinical Risk Variables Combined With Stress Myocardial Perfusion Rb-82 PET Imaging in Women and Men
20031	Performance of CTA, CTP, and Combined CTA/CTP for the Detection of Coronary ISR
20032	Performance of CTA and Combined CTA/CTP for the Detection of Any Coronary Artery Stenosis
20033	Multivariable Analysis of the Relationship Between PTSD and Incidence of Coronary Heart Disease
20034	Multivariable Analysis of the Relationship Between PTSD and STSS in the Overall Sample
20035	Multivariable Analysis of the Relationship Between PTSD and Coronary Flow Reserve in the Overall Sample
20036	Relationship Between PTSD and CHD Outcome Measures in PTSD-Discordant Twin Pairs
20037	Differences in Indications and Appropriateness Among Modalities
20038	Most Common Indications by Modality and Appropriateness Rating
20039	Likelihood of an Abnormal Result by Appropriateness Among the Most Common Indication Groups for Testing
20040	p Values for the Statistical Assessment of Interaction Between Treatment and Presence or Absence of Ischemia for Each Pre-Determined Clinical Endpoint
20041	Features Associated With Revascularization
20042	Cox Proportional Hazards Model for Aggregate Clinical Risk Score
20043	Cox Proportional Hazards Model: Aggregate Clinical Risk Score With Imaging Data
20044	Studies Regarding Coronary Intervention-Associated Oxidative Stress
20045	Temporal Prevalence of Abnormal SPECT According to Clinical Parameters
20046	Temporal Prevalence of Abnormal SPECT According to Clinical Parameters in Propensity-Matched Patients
20047	Temporal Risk-Adjusted OR for Having an Abnormal SPECT Study
20048	Multivariable-Adjusted Regression Analysis for Cross-Sectional Associations of Cardiovascular Risk Factors With Presence of Definite ER at Each Examination
20049	Left Ventricular Responses and Electrocardiographic Ischemic Change to MS and ES  (n = 290)
20050	Exercise Capacity Among Patients With/Without MSIMI or ESIMI  ⁎    (n = 290)
20051	Reactivity of Blood Pressure, HR, RPP, and Physical Symptoms During Stress Testing  (n = 290)
20052	Comparison of Diagnostic Protocols in Predicting Functionally Significant CAD  (FFR ≤0.80)
20053	Analysis of CTP in Predicting Reversible Perfusion Defects as Assessed by CMR-Perf
20054	NPY Promoter Variant ∇−880 Δrs3037354: Effects on Heritable Autonomic Traits in Twins and Sibs
20055	Meta-Analysis of a Human NPY Promoter Variant on NPY Secretion
20056	Age–Adjusted Mean SBP and DBP Among U.S. Adults  (≥20 Years) : NHANES 1999 to 2010
20057	Age–Adjusted Prevalence of Hypertension and Pre-Hypertension among U.S. Adults  (≥20 Years) : NHANES 1999 to 2010
20058	Age-Adjusted Awareness, Management, and Control of Hypertension Among U.S. Adult Hypertensive Participants: NHANES 1999 to 2010
20059	Medication at Discharge
20060	Clinical Results at 30 Days and 1 Year of Follow-Up
20061	TV Versus Remote Clinical Events During Months 7 to 60
20062	Differences Between Different Classes of Medical Therapies  (n = 76)
20063	Univariate Survival Analyses of Changes in Follow-Up Variables
20064	Dependence of Myocardial Stiffness on Pressure  (n = 6)
20065	Linear Regression Between Systolic Stiffness and Systolic Pressure
20066	DCMR Findings in Participants With and Without Pulmonary Edema
20067	DCMR Findings in Participants With and Without Isolated Pulmonary Edema and No Inducible Ischemia
20068	NF Donor and Severe Chronic HF Patient Group Details
20069	Univariate and Multivariate Logistic Regression Analysis for Prediction of Reverse Remodeling After Catheter Ablation
20070	Effects of Aging on the Heart
20071	International Classification of Diseases-9th Revision-Clinical Modification Indications for Initial Stress Testing After Revascularization
20072	Stress Testing Incidence at 24 Months After Index Coronary Revascularization
20073	Cumulative Incidence of Stress Testing at 24 Months After Revascularization in Select Patient Subgroups
20074	Unadjusted Factors Associated With SCD
20075	Significant Multivariable Predictors of SCD in Patients With CAD and LVEF >35%
20076	Unadjusted HRs/3-U Change in the Summed Stress Score for Different Outcomes
20077	SPECT SCD Nomogram
20078	SCD Rates Across SPECT Nomogram Scores
20079	3-Year Risks for SCD as Predicted by Models That Do and Do Not Include Resting Myocardial Perfusion Data
20080	Magnetic Resonance Results
20081	Clinical Outcomes in Patients Receiving SES Compared With PES
20082	Study Inclusion and Exclusion Criteria
20083	Invasive Procedures in the 2 Randomization Groups
20084	Clinical Outcomes at 30 Days and 12 Months
20085	30-Day Bleeding Events  (GUSTO Classification)
20086	Predictors of Overall Mortality on Univariate Analysis in the 81 Patients With Low-Flow/Low-Gradient Aortic Stenosis Without Contractile Reserve
20087	Acute Changes in LV Dynamics by Coronary Reperfusion in Primary PCI in 15 Patients
20088	CHGA Haplotypes Across the Locus in Subjects With Extreme BP Values in the Population  ⁎
20089	CHGA 3′-UTR Common Variant C+87T: Effect of the T Allele on BP Status and BP Values  ⁎
20090	Heritability of “Intermediate” Traits in Twin Pairs  ⁎
20091	Adjusted Cox Proportional HR for Nonpropensity- and Propensity-Matched Patients
20092	Adjusted Cox Proportional HR for Nonpropensity- and Propensity-Matched Patients According to Pre-Selected Subgroups
20093	MACE in Different Types of Lesions
20094	Stent Thrombosis
20095	Pre- and Post-Operative Data of NYHA Functional Class and of Doppler-Echocardiographic Variables in the 24 Patients Included in the MVA Group
20096	Comparison of Resting and DSE Among the Control Group  (n = 20)  and the MVA Group  (n = 24)
20097	Doppler-Echocardiographic Data at Rest and During ESE in a Subset of 9 Patients With MVA
20098	Comparisons With the Results of Previous Studies in Patients With Stenosis of Their Native Mitral Valve or With Mitral Prosthetic Valve
20099	Prioritization of Tables from ACCF/ASNC Appropriateness Criteria for SPECT MPI
20100	Agreement Between 2 Cardiovascular Nurse Abstractors on Overall Patient Classification  (n = 582)
20101	Classification of Stress SPECT and Stress Echo Patients, According to Table of Indications in Appropriateness Criteria
20102	Inappropriate Studies for Stress SPECT and Stress Echo by Appropriateness Table and Specific Indication
20103	Detailed List of MAE in CABG and PCI Group During the First Year After the Procedure
20104	Morphometry, Animal Weights, and Blood Analyses
20105	Hemodynamic Findings During BEE in 104 Individuals
20106	Interpretation by Experienced Observers With or Without Intermediate Stages in Detection of CAD
20107	Interpretation by Less Experienced Observer With or Without Intermediate Stages in Detection of CAD
20108	Comparison of Selected Echocardiographic Variables Between Patients With and Without Ischemia
20109	Comparison of Changes in LVESV From Rest and Smallest LVESV During Exercise to Maximal Exercise Between Patients With and Without Ischemia
20110	Comparison of Different Measures of Functional Capacity in Men
20111	Comparison of Different Measures of Functional Capacity in Women
20112	Per Patient, Per Coronary Territory Analysis
20113	Quality Assessment
20114	Cardiovascular Magnetic Resonance Imaging Data of the Whole Study Group and of Patients With and Without MACE
20115	Cardiovascular Magnetic Resonance Imaging Data of Patients With and Without Major Events in the Whole Study Group
20116	Independent Predictors of MACE and Major Events in the Whole Study Group and in Nonrevascularized Patients
20117	Study Population
20118	Summary of Blinded and Stenosis-Specific MPR Data
20119	Multiple Regression Analysis of Variables Associated With CD40L Levels; Entire Model  (Regression Summary for Dependent Variable: R2= 0.60, F = 5.58; p < 0.00005)  and Final Model With Stepwise Method
20120	Correlations Between Global Strain Doppler and Cardiac Markers
20121	Multivariate Regression Analysis of All Parameters Versus Magnetic Resonance Imaging
20122	Unadjusted and Multivariable Adjusted Hazard Ratios for the Primary and Secondary End Points
20123	Patient Outcome at 30 Days After Surgery
20124	Clinical Data of Patients in the Invasive Hemodynamic Study
20125	Clinical, Stress, and Echocardiographic Data of Patients in the Noninvasive Study
20126	Stress and Echocardiographic Data in the Invasive Hemodynamic Study
20127	Correlation Between Exercise Capacity and Echocardiographic Variables in the Noninvasive Study
20128	Exercise Capacity According to Resting E/E’ and Subsequent Change in E/E’ With Exercise
20129	Regression Analysis of Clinical and Echocardiographic Variables to Predict Reduced Exercise Capacity  (<8 METs)  in Patients Without Evidence of Ischemia
20130	Hemodynamic Changes and Perfusion Results During Rest and Peak Mental Stress in Individual Subjects
20131	Echocardiographic Data
20132	Hemodynamic Parameters by Cardiac Catheterization
20133	Results of the Exercise Stress Testing
20134	Single-Photon Emission Tomography Myocardial Perfusion Imaging and Left Ventricular Function for the 21 Postmenopausal Women
20135	Independent Predictors of Normal Versus Reduced Functional Capacity  (DASI ≥20 vs. <20)
20136	Response to Treadmill Exercise and Dipyridamole Stress  (n = 26)
20137	Semi-Quantitative and Quantitative Analysis of N-13 PET Myocardial Perfusion Images
20138	Image Quality of N-13 Ammonia PET Myocardial Perfusion Images  (Exercise vs. Dipyridamole)
20139	Quantitative Coronary Angiography  ⁎
20140	Major Adverse Cardiac Events During Seven Months of Follow-Up
20141	Detection of Coronary Artery Disease in Patients Without Resting Perfusion Defects
20142	Intracellular Recordings
20143	Clinical Features of the Study Patients
20144	Clinical and Stress Test Data of Patients With and Without Events
20145	Material Parameters for Arteries, Plaques, Calcifications, and Lipids Used in Finite Element Models
20146	Unadjusted Outcomes by Operator Volume According to the 75 Procedures/Year Definition
20147	Unadjusted Outcomes by Quintile of Operator Volume
20148	Relationship Between Lung Uptake and Summed Stress Score  ⁎  Category
20149	Stepwise Regression Analysis for the Occurrence of a Primary Event for All Patients
20150	Stepwise Regression Analysis for the Occurrence of a Primary Event for Patients Who Performed Treadmill Exercise Stress Only
20151	Past Medical History by Ethnic Subsets of the Stress Testing Registry
20152	Stress Test Results by Ethnic Subsets of the Stress Testing Registry
20153	Overall Rates of Major Adverse Cardiovascular Events
20154	Comparative Analysis of Ethnicity by SPECT Imaging Results for 90-Day and 2-Year Hospitalization Rates for Nonfatal Cardiovascular Events and Revascularization Procedures
20155	Dipyridamole and Exercise Treadmill Stress Clinical and ECG Data
20156	Dipyridamole and Exercise Treadmill Stress Image Data
20157	Bland-Altman and Repeatability Analysis of Summed Scores and Quantitative Defect Size
20158	Concordance of Normal and Abnormal Studies for Exercise Versus Dipyridamole Stress Studies
20159	Body and Heart Weight
20160	Histological Measurements
20161	Differentially Expressed Genes
20162	Predictors for the Healing of Nonculprit Ruptured Plaques
20163	Angiographic Data
20164	In-Hospital Complications
20165	MACE at Six Months  (In-Hospital Complications Included)
20166	Clinical Data of the Study Patients
20167	Hemodynamic Data at Different Stages of the Dobutamine Stress Test
20168	Overall Accuracy of Myocardial Contrast Echocardiography and Wall Motion Analysis for the Diagnosis of Coronary Artery Disease  (≥50% Stenosis)
20169	Regional Accuracy of Myocardial Contrast Echocardiography and Wall Motion Analysis for the Diagnosis of Coronary Artery Disease in the Three Major Arterial Regions
20170	Comprehensive CMR Analysis and Analysis of Individual CMR Components for the Detection of the Presence of Significant CAD *
20171	Combinations of Separate Analyses of CMR Components in the Detection of the Presence of CAD Requiring Revascularization  (as Confirmed by X-Ray Angiography)  *
20172	Relationship Between Percent Heart Rate Reserve Achieved and Ability to Reach 85% Maximal Age-Predicted Heart Rate
20173	Predictors of Postoperative Cardiac Events  (MI, Death)  in 397 Patients Without Inducible Ischemia During DSE Testing
20174	List of Patients and Specific Assays for Each Group of Samples
20175	Comparison Between Myocardial Contrast Echocardiography and Single-Photon Emission Computed Tomography Perfusion Scores
20176	Agreement With Single-Photon Emission Computed Tomography for a Moderate to Severe Perfusion Defect
20177	Concordance Between Myocardial Contrast Echocardiography and Single-Photon Emission Computed Tomography  (SPECT)  According to SPECT Results
20178	Independent Predictors of Subsequent Myocardial Infarction Using a Four-Step Model
20179	Comparison of Carriers Versus Non-Carriers of the Class S Allele in the Heme Oxygenase-1 Gene Promoter in 210 Patients After Femoropopliteal Balloon Angioplasty
20180	Logistic Regression Model Assessing the Independent Association of the Heme Oxygenase-1 Genotype “Carrier of the Class S Allele” and Restenosis at Six Months in 210 Patients After Femoropopliteal Balloon Angioplasty
20181	Offline Quantitative Coronary Analysis by Core Laboratory
20182	Sensitivity and Specificity of Q-Wave of ECG for Diagnosis of Myocardial Scars Identified by a Positron Emission Tomography in Different Infarct Location in the QMI Group  (n = 43)
20183	Comparison of a Signal Region With and Multiple Regional Infarctions  (Scar)  Identified by a Positron Emission Tomography
20184	Prediction of Ischemic Viable Myocardium by Echocardiography and Electrocardiography
20185	Univariate Analysis of Clinical and Doppler Echocardiographic Variables * Obtained at Rest and During Maximal Dobutamine Infusion
20186	Multivariate Analysis of Clinical and Doppler Echocardiographic Variables * Obtained at Rest and During Maximal Dobutamine Infusion
20187	Multivariate Analysis of Clinical and Doppler Echocardiographic Variables * Obtained at Rest and During Maximal Dobutamine Infusion in Patients With a Mitral Valve Area >1.0 cm2
20188	Hemodynamic and Tissue Doppler Data at Rest and During Dobutamine Stress in the Subgroup of 12 Patients Who Underwent Cardiac Catheterization
20189	Comparison of Ventricular Function Data of Systemic RV in TGA Patients  (n = 80)  With Systemic LV and Subpulmonary RV in Controls  (n = 55)
20190	Comparison of RV Function in TGA Patients With Normal and Abnormal RV Wall Motion
20191	Global Left Ventricular Function Results
20192	Poor Outcome as a Function of One Negative Emotion at a Time, Adjusting for Age, Left Ventricular Ejection Fraction, and Use of Antidepressants
20193	Independent Predictors of Major Cardiac Events and Health Care Consumption
20194	Periprocedural Events
20195	Quantitative Coronary Angiography of Patients With Angiographic Follow-Up
20196	Variables Associated With Late Occlusion at Follow-Up Angiography
20197	Occurrence of Clinical Events During Follow-Up
20198	Logistic Regression Model Predicting Early Catheterization
20199	Observed Referral Rates to Catheterization as a Function of EF and %Myocardium Ischemic
20200	Logistic Regression Model Predicting Early Revascularization
20201	Risk of Death in Prespecified Subgroups on Univariate Analysis
20202	Results of Cox Multivariate Proportional Model *
20203	Single Photon Emission Computed Tomography Myocardial Perfusion Imaging, Lipid Profile Values, and Coronary Risk Factors During Pravastatin Therapy
20204	Longitudinal Systolic Left Ventricular Function Estimated by Regional Velocities and Deformation Parameters in the Apical Four-Chamber View
20205	Longitudinal Systolic Left Ventricular Function During Isovolumic Contraction and Ejection in Mid-Wall Segments
20206	Septal and Lateral Timing of Left Ventricular Motion and Deformation During Left Bundle Branch Block and Cardiac Resynchronization Therapy in Mid-Wall Segments
20207	Effects of CRT on Echocardiographic Parameters
20208	Multivariate Analysis of Clinical, Stress, Perfusion, and Perfusion/Function Variables for Predicting Severe 3VD CAD
20209	Odds of Abnormal Scintigraphic Vascular Territories by Perfusion/Function Versus Perfusion Alone Matching Angiographic Disease
20210	Outcome Events  (n = 307)
20211	Independent Predictors of Composite End Point*
20212	Information Regarding Oligonucleotide Primers Used in Study
20213	Accuracy of Clinical, Electrocardiographic, and Exercise Echocardiographic Findings for the Detection of Significant Infarct-Related Artery Stenosis
20214	Effects of Heart Rate, Infarct Size, and Location on the Accuracy of Exercise Parameters for Detecting Infarct-Related Artery Stenosis
20215	Effects of Heart Rate and Ischemia in the Infarct Zone on the Accuracy of Exercise Parameters for Detecting Multivessel Disease
20216	Comparison Between Patients With and Without Functional Recovery
20217	Rest and Stress Findings in the Study Population
20218	Univariate Predictors of Total and Cardiac Mortality
20219	Doppler and Other Parameters Recorded at Maximum Hyperemia From the LACB and LCx
20220	Percentage Differences  (Δ)  in Time-Averaged Peak Coronary Flow Velocity Between Pacing and Rest Heart Rate, for the Left Atrial Circumflex Branch and Left Circumflex Coronary Artery
20221	Brachial Artery Parameters
20222	Premenopausal WISE Women Historical Reproductive Variables
20223	Significant Predictors of Coronary Artery Disease *
20224	Significant Predictors of Hypoestrogenemia of Hypothalamic Origin
20225	ECG, PAT Alone, and PAT-Enhanced Sensitivities and Specificities
20226	Mitral Valve Area Before and During Dobutamine Infusion in Group II Patients
20227	Comparison of Dobutamine Effect on Mitral Valve Area in Groups I and II
20228	Clinical Features of Patients With and Without Hard Cardiac Events *   †
20229	Exercise Test and Echocardiographic Data for Patients With and Without Hard Cardiac Events *
20230	Univariate Association of Clinical, Exercise Test, and Echocardiographic Variables With Risk of Cardiac Death and Nonfatal Myocardial Infarction
20231	Cumulative Event Rate During Five-Year Follow-Up According to the Presence and Extent of Exercise Echocardiographic Abnormalities
20232	Independent Predictors of Cardiac Events Using Five-Step Model
20233	Maximal and Submaximal Exercise Performance in Control and Training Groups
20234	Leg and Respiratory Muscle Strength, Endurance, and Anthropomorphic Measurements of Control and Training Groups
20235	Quality-of-Life Scales in the Control and Training Groups
20236	Patients With Redistribution Compared With Those With Reverse Redistribution
20237	Individual Values of Platelet 8-epi PGF2α Content for Each Subject
20238	Change in Serum Lipid Levels
20239	Change in Parameters from Coronary Angiogram and IVUS
20240	Echocardiographic Results
20241	Preoperative Data: Patients With or Without Evidence of Mismatch
20242	Predictors of PPM at Univariate Analysis
20243	Changes in LVMI  (g/m2)
20244	Coronary Angiography Results of Patients Who Underwent Angiography Before Discharge
20245	Clinical Outcomes of the Comparison Groups at 12 Months After Randomization
20246	Late Clinical Effects and Smoking Habits 43  (Range: 32 to 60)  Months After TMR
20247	Events by Risk Group in the Study Population During Follow-Up
20248	Events by Risk Group in the Control Population During Follow-Up
20249	Survival Rates by Risk Group in Study and Control Populations
20250	Univariate and Multivariate Predictors * of Outcome
20251	Normalized Left Circumflex Region Myocardial Perfusion* by PET
20252	Regional Wall Motion Score Index  (WMSI)  for Hibernating Left Circumflex Distribution by Dobutamine Stress Echocardiography
20253	Laboratory Data in Patients With Cyanotic and Acyanotic Congenital Heart Disease
20254	MRI Flow Reserve Indices and Coronary Flow Reserve by PET in Normals and Patients
20255	Forms of Induced AVNRT
20256	Univariable Predictors of Cardiac Events
20257	Multivariable Predictors of Cardiac Events  (Cox Regression Analysis)  in Patients Undergoing Exercise Stress Echocardiography
20258	Peak Tissue Doppler Velocity at Rest and During Dobutamine Stimulation Related to Results of 18F-Fluorodeoxyglucose Positron Emission Tomography for 192 Dyssynergic Segments at Rest
20259	Peak Systolic SR Data at Rest and During Dobutamine Stimulation Related to Results of 18F-Fluorodeoxyglucose Positron Emission Tomography for 192 Dyssynergic Segments at Rest
20260	Diagnostic Accuracy of Two-Dimensional Dobutamine Stress Echocardiography, TDI and SRI for Detection of Viability Determined by 18F-Flurodeoxyglucose Positron Emission Tomography
20261	Acoustic Intensity Ratios in the Hypoperfused Zone Compared to the Normal Bed
20262	Arteriolar Dimension and Hemodynamic Data From Intravital Microscopy Experiments
20263	Clinical Variables of Patients According to Blood Pressure Response to Exercise legend
20264	Exercise and Echocardiographic Variables of Patients According to Blood Pressure Response to Exercise legend
20265	Hemodynamic Monitoring Four Weeks After MI
20266	Heart and Lung Weight Four Weeks After MI
20267	One-Year Event Rate legend
20268	Angina Pectoris Between Six Months and One Year
20269	Temporal Changes in the DFT legend
20270	Pre-Procedural, Post-Procedural and Six-Month Follow-Up Quantitative Coronary Angiographic Analysis of Treated Lesions legend legend
20271	Multivariate Analysis: Clinical and Quantitative Coronary Angiographic Predictors of Coronary Restenosis legend
20272	Angiographic Results legend legend
20273	Intravascular Ultrasound Data legend legend
20274	Time Trajectory of High and Low Frequency HRV Components Before Ischemia and Heart Rate-matched Nonischemic Control Periods  (Mean ± SD)  legend
20275	HRT-Use Patterns by Onset of HRT legend
20276	Index Myocardial Infarction legend
20277	Unadjusted Cardiac Event Rates During Follow-Up by HRT Use legend
20278	Adjusted Risk of Cardiac Events Among Prior/Current and New Users of HRT Compared With Never Users  (Hazard Ratio and 95% CI)  legend
20279	Comparison of IVUS Findings Between the Yellow and the White Plaques legend legend
20280	Data From the Dobutamine Stress Echocardiographic Studies by Group legend legend
20281	Cox Proportional Hazard Analysis of the Effect of Surgical Treatment on Survival Duration in the Two Groups
20282	Coronary Risk Factor Variables legend
20283	Multiple Regression Analysis to Predict the Progression-Regression Score legend
20284	Incidence of Clinical End Points in Different Treatment Groups legend
20285	Two-Year Event-Free Survival Rate in Different Treatment Groups legend
20286	Incidence of TVR and MACE in Different Treatment Groups According to Diabetes Status legend
20287	Freedom From Repeat Revascularization at Six Months
20288	Six-Month Clinical Outcomes With and Without Stent-Like Results legend
20289	Predictors of Repeat Revascularization at Six Months
20290	Six-Month Clinical Outcomes and Costs for Stenting Strategies
20291	Two-Dimensional and Doppler Echocardiographic Parameters legend legend
20292	Correlations Between Pulmonary Doppler Variables and Pulmonary Vascular Resistance legend
20293	Results of Stepwise Regression Analysis of Doppler Indexes on Pulmonary Flow Versus Pulmonary Vascular Resistance legend legend
20294	Coronary Diameter Change During Mental Stress and Intracoronary Nitroglycerin in Patients With and Without Angiographic CAD legend
20295	Multivariate Analyses Predicting Mental Stress-Induced Coronary Diameter Response From Diastolic Blood Pressure Increases and Control Variables
20296	Lung and Liver Wet/Dry Weight Ratios and Hemodynamic Parameters at 16 Weeks Post-MI With and Without Losartan Treatment legend legend
20297	Myocardial Reduced  (GSH)  and Oxidized  (GSSG)  Glutathione Levels in Sham Control and Post-MI Rats at 16 Weeks With and Without Losartan Treatment legend legend
20298	Univariable Predictors of Cardiac Events  (Cox Regression Analysis)  in Patients Undergoing Exercise Stress Echocardiography legend
20299	Multivariable Predictors of Cardiac Events in Patients Undergoing Exercise Echocardiography legend
20300	Multivariable Predictors of Cardiac Death in Patients Undergoing Exercise Echocardiography legend
20301	Agreement Between MCE, SPECT and Wall Motion Abnormalities: Analysis by Patients legend
20302	Agreement between MCE, SPECT and Wall Motion Abnormalities: Analysis by Coronary Territory legend
20303	Comparison of MCE, SPECT, Wall Motion and the Combination of MCE and Wall Motion With Results of Coronary Angiography: Analysis by Patients  (n = 44)  legend
20304	Definitions of Parameters of QT Interval Dynamicity and Variability legend
20305	Mean 24-h Values  (±SD)  for QT Interval, QT Interval Variability and RR Interval in Patients With and Without MAE legend
20306	Levels of TxB2, iPF2α-III and iPF2α-VI in the Coronary Sinus and in the Left Main Coronary Artery Before PTCA legend
20307	Levels of iPF2α-III and iPF2α-VI in Patients Undergoing Diagnostic Coronary Angiography  (n = 4)  legend
20308	Independent Predictors of Cardiac Death legend
20309	Changes in Echocardiographic Parameters in the Control Rats and Rats of Group CAND (−)  and CAND (+)  legend legend
20310	Results of Hemodynamics and Pathology at 19 Weeks legend legend
20311	Effects of Candesartan and Enalapril on Geometry, Hemodynamics and Pathology at 19 Weeks legend legend
20312	Metabolic and Neuroendocrine Measurements legend
20313	Cardiac and Renal Measurements legend
20314	Clinical Data on 10 Patients With Transplant Coronary Artery Disease Who Died Suddenly With No Prior Diagnosis legend
20315	Clinical Data on 14 Patients With Angiographic Diagnosis of Transplant Coronary Artery Disease legend
20316	Rejection Frequency Following Transplantation in Patients With and Without Transplant Coronary Artery Disease legend
20317	First Cardiac Event per Patient After Randomization legend legend
20318	Accuracy, Sensitivity and Specificity of Pacing Stress Echocardiography legend legend
20319	Coronary Angiography legend legend
20320	Pacing Stress Echocardiographic Results According to Lesion Severity
20321	Adjusted Effect of Social Support and Anger Expression on Progression of Coronary Atherosclerosis legend legend
20322	Combined Adjusted Effect of Social Support and Anger Expression on Progression of Coronary Atherosclerosis legend
20323	Myocardial Perfusion at Rest legend
20324	Myocardial Perfusion at Peak Exercise legend
20325	Predictors of Future Cardiac Events According to Univariate Cox Analysis
20326	Number of Events  (%)  legend
20327	Univariable and Adjusted Relative Risks of Total Mortality, Cardiac Death, Repeat Coronary Bypass Surgery or Coronary Angioplasty legend
20328	Effects of Three-Day Nitroglycerin Treatment of Rabbits  (Continuous or 12 h Patch On/Patch Off)  on the Potency and Efficacy of Nitroglycerin or Acetylcholine to Produce Relaxations in Aortic Rings legend
20329	Effects of Continuous or Intermittent Nitrate Therapy on 50% Effective Concentration and Maximal Constrictions to Phenylephrine, Serotonin, Angiotensin II and Potassium Chloride legend legend
20330	Medications Administered in the Drug Therapy Group After Enrollment legend
20331	Quality of Life and Symptoms Scores in the Drug Therapy Group legend
20332	Quality of Life and Symptoms Scores in the Catheter Ablation Group legend
20333	Coronary Anatomy legend
20334	Mean Workload, Cardiac Output, Maximal Rate-Pressure Product, Mean Heart Rate and Percent of Age-predicted Heart Rate
20335	Univariate and Multivariate Cox Proportional Hazard Analysis for the Identification of Patients at Risk for PAF legend
20336	Prediction of the Development of Paroxysmal Atrial Fibrillation by an Abnormal P-SAECG Elevated ANP Level and a Combination of the Two legend
20337	Oxidation Parameters and Results of Ultrasound Measurements in the Brachial Artery legend legend legend
20338	Lipid Levels During Placebo and Pravastatin Treatment legend
20339	Scintigraphic Values During Dipyridamole Stress and at Rest During the Placebo and Pravastatin Phases legend
20340	Accuracy of Different Modalities in Prediction of Recovery of Function in Severely Dysfunctional Segments legend legend
20341	Prediction of Recovery of Function in Akinetic/Dyskinetic Segments and in Severely Hypokinetic Segments legend legend
20342	Sensitivity and Specificity for Improvement in Left Ventricular Ejection Fraction of ≥5% Using Increasing Cutoffs of Number of Viable, Dysfunctional Segments by EDWT, Tl-201 Scintigraphy and DSE legend
20343	Distribution of Cardiac Events in Relation to Stress Results legend
20344	Univariate Predictors of Cardiac Events legend
20345	Stepwise Predictor of Cardiac Events legend
20346	Symptoms and Clinical Findings in 25 Patients Three Months After PMR legend legend
20347	Cause of Death legend legend
20348	Cause of Death
20349	Cause of Noncardiac Deaths legend
20350	Final Classification: Events Committee Versus Principal Investigator
20351	Variables Evaluated for Association With Exercise Performance legend
20352	Ventricular Morphology in Study Patients legend
20353	Exercise Performance in the Study Population legend
20354	Association Between Candidate Predictors and V̇O2max  (Percentage Predicted)
20355	Comparison of Exercise Performance Between Early and Late Volume Unloading Groups legend
20356	Summary of Coronary Angiography, Cardiac Catheterization and Revascularization in 12 Patients With Transient Atrioventricular Block legend
20357	Clinical and Dobutamine Stress Echocardiographic Parameters in Patients With and Without AVB legend
20358	Sensitivity, Specificity, Positive and Negative Predictive Values and Accuracy With 95% Confidence Intervals of Low-Level Exercise and Low-Dose Dobutamine Echocardiography to Predict Reversible Dysfunction legend
20359	Clinical and Coronary Angiographic Data in 14 Patients legend
20360	Myocardial Blood Flow  (ml/min/100 g)  and Coronary Flow Reserve by Positron Emission Tomography legend
20361	Clinical and Angiographic Base-line Data
20362	Quantitative Coronary Angiography Results Analyzed by Intention to Treat and by Treatment legend
20363	Events and Clinical data legend
20364	Pooled End Points of the Four Stenting for Chronic Occlusion Trials SPACTO, SICCO   (9)  , Mori et al.   (10)  and GISSOC   (11)  , analysis by intention to treat legend legend
20365	Corresponding Quantitative Angiographic Data of SPACTO, SICCO   (9)  , Mori et al.   (10)  and GISSOC   (11)  , analysis by intention to treat legend
20366	Event Rate Occurrence in Relation to Dobutamine Echocardiographic Results legend
20367	Comparison of Patients With and Without Cardiac Events  (Univariate Analysis)  legend
20368	Characterization of Hypertrophy and In Vivo Left Ventricular Function legend legend
20369	Left Ventricular Gene Expression in Male and Female Normal Rats legend
20370	Comparison of Intravascular Ultrasound Measurements and Indexes Between the Two Groups With Positive and Negative Myocardial Perfusion SPECT Results legend
20371	Functionally Significant Coronary Artery Stenosis Determined by Intravascular Ultrasound Imaging legend legend
20372	Exercise Parameters and Hemodynamics During Treadmill and Supine Bicycle Exercise legend
20373	Concordance Between Results of Supine Bicycle and Post–Treadmill Exercise Echocardiography legend
20374	Aortic Atheroma Classification and Location of Aortic Plaques on Thoracic Aorta legend
20375	Treatment According to the Aortic Atheroma
20376	Follow-up According to the Aortic Atheroma legend
20377	Comparison of Events According to Aortic Atheroma and Antithrombotic Treatment
20378	Clinical Correlates legend legend
20379	Echocardiographic Correlates legend
20380	Improvement of Exercise Capacity According to the Extent of Viable Myocardium by PET
20381	Improvement of Exercise Capacity According to the Extent of Viable Myocardium by DbE
20382	Changes in Quality of Life Responses After Revascularization
20383	Correlation Between Change in Constituent QOL Indices and Extent of Viable Myocardium by PET and DbE
20384	Hemodynamic Findings legend
20385	Results of Mental Stress Testing: Changes in Skin Conductance and Catecholamine Levels and Double Product legend
20386	Results of Mental Stress Testing: Radionuclide Ventriculography legend
20387	Results of Mental Stress Testing: Radionuclide Ventriculography Diastolic Variables  legend
20388	Percentage of Viable Myocardium in Relation to 99mTc-Tetrofosmin Activity  (Number of Segments)  legend
20389	Angiographic Analysis
20390	LV Remodeling: 6 Weeks After Aortic Banding legend
20391	LV Remodeling: 20 Weeks After Aortic Banding legend
20392	Morphometric Data at 20 Weeks
20393	Utilization ∗ of Stress Tests in Olmsted County, Minnesota, 1987 to 1988 legend
20394	Incidence of Stress Tests in Olmsted County, Minnesota, 1987 to 1988 legend
20395	Indications and Stress Test Results in Persons With an Incident Stress Test, Olmsted County, Minnesota, 1987 to 1988, by Gender legend
20396	Coronary Disease  (International Classification of Diseases, 9th revision codes 410 to 414)  Mortality Rates for Olmsted County Residents for Years 1987 to 1993 legend
20397	Clinical and Echocardiographic Findings in the Three Groups of Patients Studied legend
20398	Cardiac Events During Follow-up in the Three Groups of Patients legend
20399	Univariate and Multivariate Predictors of Hard Events, Spontaneous Events and Total Events  legend
20400	Univariate Predictors of Prognosis in Medically Treated Patients  (events considered: cardiac death, nonfatal myocardial infarction)  legend
20401	Effects of Exercise on Plasma Nitric Oxide  (nitrate plus nitrite)  Concentration and Lactate Extraction Ratio in Control Subjects and Patients legend
20402	Clinical Data of Patients With a First Transmural Acute Myocardial Infarction With or Without Rupture  legend
20403	Frequency of Admission Delay  (≥24 h) , In-Hospital Unusual Physical Effort and Angina in Patients With Rupture  (years 1978 to 1989 and 1990 to 1995)  and Control Patients  legend
20404	Segment Distribution According to Visual Score of Stress Images During Single-Photon Emission Computed Tomography With and Without Antianginal Therapy  legend
20405	Results of Visual Analysis Indexes legend
20406	Quantitative Analysis: Mean Defect Size  (percent coronary artery territory at stress and rest imaging)  legend
20407	Hemodynamic Responses to Dipyridamole and Exercise Stress Testing  legend
20408	Comparison of Regional MDR in Each Region of Interest
20409	Comparison of Clinical Variables in Patients With Versus Those Without a Cardiac Event
20410	Comparison of Stress Testing Variables in Patients With Versus Those Without a Cardiac Event
20411	Comparison of Thallium Variables in Patients With Versus Those Without a Cardiac Event
20412	Data at First Operation
20413	Follow-Up Results Between Operations
20414	Follow-Up Data
20415	Relation Between the Slopes of the End-Systolic Tactile Stiffness–Volume Relation and the End-Systolic Pressure–Volume Relation
20416	Comparison Between Stiffness of Infarcted and Intact Myocardium
20417	Clinical, Left Ventriculographic, Coronary Angiographic and Prerevascularization and Postrevascularization Magnetic Resonance Imaging Findings
20418	Comparison of Magnetic Resonance Imaging Findings Based on Dobutamine-Induced Systolic Wall Thickening and End-Diastolic Wall Thickness With Postrevascularization Recovery of Systolic Wall Thickening
20419	Infarct Region–Based Predictive Accuracy of Magnetic Resonance Imaging–Assessed Dobutamine-Induced Systolic Wall Thickening and Preserved End-Diastolic Wall Thickness for Recovery of Regional Left Ventricular Function After Successful Revascularization
20420	Myocardial Infarct Size in Untreated and Treated Rats
20421	Body and Heart Weights
20422	Hemodynamic Variables Before Thoracotomy
20423	Peak Cardiac Performance
20424	Stiffness Values
20425	Operating Volume and Volume/Left Ventricular Weight Ratio
20426	Results of Quantitative Coronary Angiography
20427	Clinical Events at 1 Year
20428	Preoperative Clinical Data
20429	Left Ventricular Size and Function Before and After Mitral Valve Replacement
20430	Univariate Analysis of Stress Variables
20431	Change in Area Supplied by Collateral Flow
20432	Anginal Score, ST Segment Shift and Wall Motion Score
20433	Hemodynamic Changes During Repeated Coronary Occlusion
20434	Angiographic and Hemodynamic Data for Target Lesions
20435	Intracoronary Flow Velocity Measurements in Target Lesions
20436	Determinants of Coronary Flow Velocity Reserve: Stepwise Regression Analysis
20437	Comparison of Clinical, Rest Echocardiographic and Follow-Up Changes
20438	Subgroup Analysis of Accuracy for Reversible Segmental Dysfunction
20439	Stepwise Analysis of the Incremental Value of Clinical, Rest and Dobutamine Echocardiographic Variables in the 688 Dysfunctional Segments in Detecting Reversible Dysfunction
20440	Sensitivity and Specificity of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography for Detection of Improved Regional Contractile Function After Revascularization
20441	Sensitivity and Specificity of Thallium-201 Reinjection Imaging for Detection of Improved Regional Contractile Function After Revascularization
20442	Sensitivity and Specificity of Thallium-201 Rest–Redistribution Imaging for Detection of Improved Regional Contractile Function After Revascularization
20443	Sensitivity and Specificity for Technetium-99m Sestamibi Scintigraphy With and Without Addition of Nitrates for Detection of Functional Recovery After Revascularization
20444	Sensitivity and Specificity for Low Dose Dobutamine Echocardiography for Detection of Improved Regional Contractile Function After Revascularization
20445	Sensitivity and Specificity for the Different Imaging Techniques  (based on weighted mean values from available studies)
20446	Measurements of Peak Myocardial Videointensity, Wall Thickening and Coronary Blood Flow in the Stenosis Zone and Adjacent Perfusion Bed in the 10 Study Dogs
20447	Individual Peak Myocardial Videointensity Data  (in gray scale units)  in Middle and Lateral Segments of Original Stenosis Zone and Adjacent Perfusion Bed in the Presence of One- and Two-Vessel Stenosis During Both Rest and Dobutamine Stress Echocardiography
20448	Transluminal Extraction Catheter Atherectomy– Stent Equipment
20449	Procedural Outcomes
20450	In-Hospital Outcomes in 49 Study Patients
20451	Late Outcome in 46 Study Patients
20452	Heart Rate and Blood Pressure Changes During Dobutamine Stress Echocardiography Before and After Revascularization  a
20453	Clinical Features of Patients Undergoing Follow-Up Examination or Primary Revascularization Versus Patients Lost to Follow-Up
20454	Association of Clinical, Stress Testing and Echocardiographic Features With Total Cardiac Events by Multivariate Proportional Hazards Survival Analysis
20455	Association of Clinical, Stress Testing and Echocardiographic Features With Spontaneous Cardiac Events by Multivariate Proportional Hazards Survival Analysis
20456	Frequency of Ischemia-Related Adverse Clinical Events
20457	Factors Associated With Ischemia-Related Adverse Outcomes: Multivariate Analysis  a
20458	Sensitivity, Specificity and Predictive Values for Tc-99m Tetrofosmin and Tl-201 Imaging in Predicting Functional Recovery After Revascularization
20459	Dobutamine Stress Protocol and Hemodynamic Responses in 3,011 Patients Studied Between 1991 and 1995
20460	Major Arrhythmias in 3,011 Dobutamine Echocardiograms Between 1991 and 1995
20461	Myocardial Perfusion Patterns by Vascular Territories
20462	Multivariate Prediction of Cardiac Geometry
20463	Multivariate Prediction of Carotid Geometry
20464	Relations Between Cardiac and Carotid Geometry Independent of Stroke Volume
20465	Events After Dobutamine Stress Echocardiography
20466	Long-Term Follow-Up Results in Patients With Normal Exercise Thallium Test Results or Angiographically Normal or Minimally Diseased Coronary Arteries
20467	Clinical Findings in Patients With Painful or Silent Reversible Sestamibi Perfusion Defects During Exercise
20468	Comparison of Exercise and Scintigraphic Data in Patients With Painful or Silent Reversible Sestamibi Perfusion Defects
20469	Multivariate Predictors of Painful Reversible Perfusion Defect
20470	Thallium-201 Myocardial Perfusion Scintigraphic Studies Comparing the Amount of Ischemic Myocardium in Patients With or Without Chest Pain During Exercise Testing
20471	Diagnostic Test Results
20472	Clinical Variables Associated With Cardiac End Points  a
20473	Results of the Exercise Test and Extent of Ischemia  (polar map)  in the 20 Patients With and Without Simultaneous Dipyridamole Administration
20474	Results of 99mTc-MIBI SPECT
20475	Rest and Dobutamine Stress Findings in 778 Study Patients
20476	Event Rate Occurrence in Relation to Dobutamine–Atropine Stress Echocardiographic Results
20477	Stepwise Predictors of Cardiac Death
20478	Effect of Exercise-Induced Ischemia on Postexercise Diastolic Filling, Blood Pressure and Heart Rate in the Three Study Groups
20479	Effect of Exercise on Postexercise Diastolic Filling, Blood Pressure and Heart Rate in the Three Control Groups
20480	Effect of Exercise-Induced Ischemia on Postexercise Systolic Function in Study Groups
20481	Effect of Exercise on Postexercise Systolic Function in Control Groups  a
20482	Postexercise Ischemia-Induced Regional Wall Motion Abnormalities
20483	Clinical Events
20484	Results of Logistic Regression Analysis: Independent Predictors of Sustained Monomorphic Ventricular Tachycardia Occurrence
20485	Univariate Analysis of In-Hospital Death
20486	Results of Logistic Regression Analysis: Independent Predictors of In-Hospital Death
20487	Comparison of Patients with Sustained Monomorphic Ventricular Tachycardia and Those with Ventricular Fibrillation
20488	His-Ventricle Interval and His Potential Amplitude in Patients with 2:1 Atrioventricular Block During Atrioventricular Node Reentrant Tachycardia
20489	Arterial Pressures and Muscle Sympathetic Nerve Activity During Intrinsic Rhythm and During Single- and Dual-Chamber Pacing
20490	Incidence of Balloon Deflation
20491	Number of Patients in Total Study Group and Subgroups
20492	Electrocardiographer and Artificial Neural Network Classifications of 1,664 Electrocardiograms
20493	Quantitative Coronary Angiography Analysis  (Per-Patient Analysis, Index Lesion)
20494	Cumulative Incidence of Clinical Events Up to 1 Year  (Intention-to-Treat Per Patient)
20495	Clinical Outcomes at 6 and 12 Months According to Statin Medication
20496	Cumulative Secondary Endpoints at 12 Months According to Statin Medication
20497	Paired QCA Analysis
20498	IVUS Results
20499	Optical Coherence Tomography Results
20500	Associations of Serum 25-OHD Concentration With Study Outcomes
20501	Associations of Serum PTH Concentration With Study Outcomes
20502	Combined Associations of 25-OHD and PTH Concentrations With Study Outcomes
20503	Studies Included in the Meta-Analysis
20504	1-Year Outcomes in Left Main Patients Revascularized by PCI or CABG
20505	Outcome Data: Subsequent Aortic Valve Replacement, All-Cause Mortality, Cardiac Mortality, and Sudden Cardiac Deaths According to the Pattern of LGE
20506	Cox Proportional Hazards Model: Univariate Analysis for All-Cause Mortality
20507	Cox Regression Multivariate Analysis for All-Cause Mortality
20508	Correlations Among Psychosocial Measures in the Nova Scotia Health Survey 1995
20509	HRs for Incident IHD by Psychosocial Measures
20510	Cook-Medley Subscales and Incident IHD
20511	Adverse Events at 1 Year
20512	Multivariable Predictors of 30-Day and 1-Year Mortality and MACE
20513	1-Month Outcomes in GR  (VASP Index <50%)  and in Patients With HTPR  (VASP Index ≥50%)
20514	Univariate Analysis Comparing Patients With and Without Events
20515	Influence of rs1333040 Genotype on the Primary Endpoint and on the Individual Components of Primary Endpoint
20516	Independent Predictors of the Primary Endpoint: Estimated Hazard Ratios, 95% Confidence Intervals, and p Values
20517	Administration of Intravenous tPA to Acute Ischemic Stroke Patients
20518	Administration of Intra-Arterial Thrombolysis to Acute Ischemic Stroke Patients
20519	Outcomes of Recent CBT Trials for Acute Stroke
20520	Clinical Outcome
20521	Clinical Events During Follow-Up
20522	Outcome Differences Between 1 Year and 2 Years
20523	Aspirin and Thienopyridine Usage
20524	Adverse Events at 1- and 2-Year Follow-up According to Stent Randomization
20525	Adverse Events Between 1 Year and 2 Years  (Landmark Analysis)
20526	1-Year Clinical Outcomes According to SYNTAX Score Tertiles
20527	Independent Predictors of 1-Year Clinical Outcomes
20528	Receiver-Operator Characteristic Curve Analysis Demonstrating the Association Between SYNTAX Score and Individual Adverse Ischemic Outcomes
20529	Bleeding Complications in the 2 Groups
20530	Ischemic Complications in the 2 Groups
20531	Outcomes in the Switch Group According to the ACT at the Beginning of Cardiac Catheterization Before Bivalirudin Administration
20532	Procedural Results Stratified by Complexity
20533	Clinical Events at 30 and 360 Days Stratified by Complexity
20534	ARC-Defined ST Stratified by Complexity
20535	Angiographic Results at 13 Months Stratified by Complexity
20536	HRs for Clinical Outcomes After DES Implantation Compared With CABG, According to SYNTAX Score Category  ⁎
20537	Cox Proportional-Hazards Analyses of Time to Clinical Events Among Overall Patient Group  ⁎
20538	Pre-Randomization LDL-C and LDL-C Response to Simvastatin in the Heart Protection Study by KIF6 Trp719Arg  (rs20455)  Genotype
20539	Distribution  (Prevalence, %)  of Ideal Cardiovascular Health Metrics in Various Subgroups of the ARIC Study Participants Free of Cardiovascular Disease, 1987 to 1989
20540	Incidence Rate and Hazard Ratios of Cardiovascular Disease According to the Number of Ideal Cardiovascular Health Metrics, ARIC Study, 1987 to 2007
20541	Univariate and Multivariate Predictors of ISR
20542	Incidence Rates of CV Events in Fabry Registry Patients
20543	Univariate and Multivariate Analyses of Parameters Related to the Occurrence of CV Events
20544	QCA in Entire Cohort of Patients
20545	Quantitative Coronary Analysis for POC Area
20546	Clinical Outcome
20547	Patients With ST
20548	Wild-Type Mi Echocardiographic, Hemodynamic, and Morphometric Analyses
20549	eNOS-Deficient Mi Echocardiographic, Hemodynamic, and Morphometric Analyses
20550	Subsequent Modifications to Initial STEMI Protocol
20551	Definitions of Times and Intervals
20552	Treatment Times
20553	Median Treatment Times by Individual Community Hospital
20554	Treatment Times by Workday Hours Versus Off-Hours
20555	In Vivo Cardiac Functional Parameters After Adrenal Gene Delivery
20556	Univariate and Multivariate Cox Regression Analysis for All-Cause Death and Coronary Events
20557	Hazard Ratios for Clinical Outcomes After DES as Compared With After CABG in the Overall Population and in Selected Major Clinical Subgroups of Patients  ⁎
20558	Hazard Ratios for Clinical Outcomes After DES as Compared With After CABG According to Extent of Diseased Vessels  ⁎
20559	Hazard Ratios for Clinical Outcomes After DES as Compared With After CABG, According to Clinical Scoring  (EuroSCORE)  and Anatomic Scoring  (SYNTAX Score)  Systems  ⁎
20560	HRs  (95% CI)  for Adverse Clinical Outcomes by Different S and SRs With and Without Adjustment for LVEF and Clinical Variables
20561	HRs  (95% CI)  for All Cause Mortality With and Without Adjustment Stratified by Longitudinal S and SRs Group
20562	HRs  (95% CI)  for All-Cause Mortality With and Without Adjustment Stratified by Circumferential S and SRs Group
20563	Kinesin-Like Protein-6 Trp719Arg Polymorphism  (rs20455)  Allele Frequencies, Genotype Counts, and Odds Ratios Adjusted for Age and Sex in 19 Case-Control Studies of CAD, Stratified by Race/Ethnic Group
20564	Kinesin-Like Protein-6 Trp719Arg Polymorphism  (rs20455)  Allele Frequencies, Genotype Counts, and Odds Ratios Adjusted for Age and Sex in 19 Case-Control Studies of CAD, Stratified by Race/Ethnic Group and Restricted to Early-Onset Disease  (Age at Onset of CAD Younger Than 50 Years of Age for Men and Younger Than 60 Years of Age for Women)  and Similarly Aged Controls
20565	Angiographic Findings of Patients Previously Using and Not Using Aspirin
20566	Management of the ACS According to Prior Aspirin Use
20567	Clinical Outcomes at Day 30 According to Prior Aspirin Use
20568	Clinical Outcomes at Last Follow Up Visit  (Mean 328 Days)  According to Prior Aspirin Use
20569	Clinical Events at Follow-Up
20570	Quantitative Angiographic Analysis
20571	Treatment Strategy of Statin Therapy
20572	Assessment of Study Quality Components
20573	Summary Data on Lipid Reduction
20574	Univariable Meta-Regression Evaluating for Effect Modification of Statin Therapy on Post-Procedure Myocardial Infarction
20575	Peak Ecc Values and Ecc/s Values
20576	Spatial Resolution of Pace Mapping for 12-Lead ECG and Far-Field ICD Signals
20577	Comparison of Far- and Near-Field ICD EGMs for Determination of Spatial Resolution of Pace Mapping
20578	Comparison of ICD EGMs by Manufacturer
20579	Discriminatory Value of ICD Signals
20580	Clinical Outcomes
20581	Stent Thromboses
20582	Univariable and Multivariable Associations With All-Cause Mortality
20583	Clinical Outcomes at 360 Days After Index PCI Based on Tertiles of SXscore
20584	Procedural Results
20585	End Points at 2 Years
20586	Overview of Selected Studies Investigating the Association of Anxiety With Incident CHD
20587	Overview of Bivariate and Multivariable Associations of Anxiety With Incident CHD
20588	LDL-C as a Function of PCSK9R46L Genotype
20589	Risk of IHD, MI, and Mortality in PCSK946L Allele Carriers Versus Noncarriers in the CCHS, CGPS, and CIHDS
20590	Angiographic Outcomes at 6 to 8 Months
20591	Clinical Results at 1 Year
20592	Management and Long-Term Outcomes on the Basis of Troponin Results
20593	Number of Major Adverse Events Across the 4 Subgroups on the Basis of H-FABP Concentrations and Stratified by Troponin Results
20594	HRs for Death or MI After Median Follow-Up Period of 18 Months
20595	HRs for Death or MI Stratified by H-FABP Results Among Troponin-Negative Patients
20596	Clinical Events at 1 and 2 Years
20597	Angiographic Data at 6 to 8 Months and Composite Angiographic Data at 2 Years
20598	Outcomes by Study and Treatment
20599	Univariable Associations With CV Death or MI
20600	Multivariable Predictors of CV Death or MI  (Cox Regression)
20601	Treatment Effect by Integer Risk Category of CV Death or MI
20602	Frequency of No-Reflow and 5-Year Mortality in Patients With No-Reflow and Reflow in Each Infarct Size Tertile
20603	Correlates of 5-Year Mortality and Hazard Ratios Calculated by Cox Proportional Hazards Model
20604	Echocardiographic Values of Saline, CD34, and MSC Groups
20605	Univariate and Multivariate Cox Proportional Hazards Analysis
20606	Definition of MI
20607	All-Cause 5-Year Cumulative Mortality Rates for Matched Pairs of CR Users and Nonusers by Clinical Groups
20608	One- and 5-Year Benefit of CR Use by Analytic Technique
20609	Unadjusted and Adjusted Risk for Significantly Obstructive CAD Prevalence and MACE at 3 Years With Decreasing Quartiles of GABR and Arginine Levels
20610	Unadjusted and Adjusted Risk for Significantly Obstructive CAD Prevalence and MACE at 3 Years With Increasing Quartiles of Citrulline and Ornithine Levels
20611	Inclusion Criteria, Exclusion Criteria, and End Point Definitions of the Trials
20612	Adverse Events at 10 Years
20613	Quantitative Angiographic Measurements
20614	Angiographic Patterns of Restenosis
20615	Clinical Outcomes at 9 Months
20616	RR  (95% CI)  for Cardiovascular Disease According to Categories of Anthropometric Indexes Among 16,332 Men
20617	Multivariable Model Adjusting for the Variables in Model 1  ⁎   Plus History of Diabetes, Hypertension, or Elevated Cholesterol
20618	RR  (95% CI)  for Cardiovascular Disease According to Categories of Anthropometric Indexes Among 32,700 Women
20619	Multivariable Model Adjusting for the Variables in Model 1  ⁎   Plus History of Diabetes, Hypertension, or Elevated Cholesterol
20620	RR  (95% CI)  for Cardiovascular Disease According to WHtR and Age Among Men
20621	RR  (95% CI)  for Cardiovascular Disease According to WHtR and Age Among Women
20622	HR for Cardiovascular Events and OR for Angiographic Progression  (and 95% CI)  Among Post-CABG Participants According to BMI and Statin Treatment
20623	Comparison of Cardiovascular Events Between the Positive Group and the Negative Group
20624	Multivariate Cox Regression Analyses
20625	Relationship Between Angiographic/Electrocardiographic Parameters, and First-Pass Perfusion and Late Gadolinium-Enhanced Imaging
20626	Cases of Acute Myocardial Infarction  (Ami)  Reported Each Season to the National Registry of Myocardial Infarction BY all Core Hospitals During the Study
20627	Adjunctive Medical Therapy
20628	Diabetes and 90-Minute Angiographic Patency  *
20629	Quantitative Coronary Angiography 90-Minutes after Thrombolytic Therapy
20630	Global and Regional Left Ventricular Function in Diabetic and Nondiabetic Patients with a Patent  (Timi Flow Grade 2 or 3)  Infarct-Related Artery  *
20631	Multivariable Analysis: Clinical and Angiographic Independent Determinants of Left Ventricular Global and Regional Function in Acute Myocardial Infarction
20632	Angiographic Outcome and Frequency of Adverse Events During 30 Days After Attempted Angioplasty of an Occluded Vein Graft
20633	Clinical Features
20634	Pathologic Features
20635	Median Lipoprotein (a)  Concentrations for Different Subgroups  (univariate analysis)
20636	Risk for Acute Myocardial Infarction by Quintiles of Lipoprotein (a)  Concentrations
20637	Costs of Primary Angioplasty Under Varying Assumptions About Resources  a
20638	Probabilities and Costs in Model for Cost of Primary Angioplasty
20639	Cost of Primary Angioplasty Under Varying Assumptions About Labor, Construction and Equipment Costs
20640	Global Left Ventricular Function and Regional Wall Motion 3 Weeks After Myocardial Infarction in Patients Treated With Intraaortic Counterpulsation and in Control Subjects
20641	Clinical Outcomes in Patients Treated With Intraaortic Balloon Counterpulsation and in Control Subjects
20642	Hemorrhagic and Vascular Complications in Patients Treated With Intraaortic Balloon Counterpulsation and in Control Subjects
20643	Procedural Results of Patients Undergoing Rotational Atherectomy Compared With Patients Undergoing Coronary Angioplasty
20644	Echocardiographic Data
20645	Percent Responses of All Respondents to Selected Likert Attitude Scales  (1995)   ⊃
20646	Comparison of Doppler Echocardiography and Corresponding Magnetic Resonance Velocity Mapping Results in 12 Healthy Children and 19 Patients With Repair of Tetralogy of Fallot  *
20647	Results of Pulmonary Artery and Transtricuspid
20648	Results of Multisection Gradient-Echo Magnetic Resonance Imaging Calculations of Ventricular Volumes and Mass
20649	Indexes of Right Ventricular Diastolic Function As Assessed From Time-Filling Velocity and Time-Volume Curves
20650	Exercise Function in Patients With Repair of Tetralogy
20651	Subjects With Specific Types of Congenital Cardiac Malformations Who Were Diagnosed Prenatally, Atlanta, Georgia1990-1994
20652	Subjects With Congenital Cardiac Malformations Who Were Diagnosed Prenatally and Classified by the Presence of Associated Anomalies and Syndromes, Atlanta, Georgia, 1990–1994
20653	Pregnancy Outcomes of Subjects With Congenital Cardiac Malformation Prenatally Diagnosed With Fetal Echocardiography, Atlanta, Georgia, 1990–1994
20654	Historical Data on Signs, Symptoms and Therapy for Heart Failure in Male and Female Patients
20655	Relative Risk of Men Versus Women in Subsets Defined by Interaction of Gender and Ischemic-Nonischemic Etiology
20656	Comparison of Acute Results of Balloon Angioplasty of Native Versus Recurrent Aortic Obstruction
20657	Independent Risk Factors for a Suboptimal Outcome  *
20658	Regional Hyperemic Mean Transit Time Values in the Three Myocardial Perfusion Areas
20659	Angiographic and Electrocardiographic Findings in 18 Men
20660	Outcomes of Initial, Second, and Third Steps legend
20661	Detection of Coronary Stenoses With Hard and Soft Plaques According to Positive Electron Beam Computed Tomography Score
20662	Detection of Significant Coronary Stenoses by Electron Beam Computed Tomography Versus Coronary Angiography for 267 Analyzed Segments
20663	Results of Electron Beam Computed Tomography Versus Coronary Angiography and Intracoronary Ultrasound for 267 Analyzed Segments
20664	Statistical Values for Comparison of Electron Beam Computed Tomography, Coronary Angiography and Intracoronary Ultrasound
20665	Coronary Angiography Versus Intracoronary Ultrasound for Detection of Atherosclerotic Plaques in 267 Analyzed Segments
20666	Distribution of Angiographic Disease Severity in 213 Consecutive Patients
20667	“Optimal” Electron Beam Computed Tomographic Coronary Calcium Score Maximizing Sensitivity and Specificity for Associated Range of Severity for Maximal Angiographic Lumen Stenosis
20668	Cutpoints for Electron Beam Computed Tomographic Coronary Calcium Scores for Sensitivity of 90% and Associated Specificity and for Electron Beam Computed Tomographic Quantified Coronary Calcium Scores for Specificity of 90% and Associated Sensitivity as a Function of Decade of Associated Maximal Angiographic Lumen Stenoses
20669	Definition of Morbidity Events in SERAPHIN and GRIPHON
20670	Sensitivity Analyses of the Association Between Morbidity and Mortality in SERAPHIN and GRIPHON
20671	Overall Dietary Profile of PESA Study Participants According to Breakfast Pattern
20672	Distribution of CVD Risk Factors of PESA Study Participants According to Breakfast Pattern
20673	Association Between Breakfast Pattern and Coronary Artery Calcification
20674	Association Between Breakfast Patterns and Presence of Atherosclerotic Plaques in Several Territories According to Breakfast Habits Categories Among PESA Study Participants
20675	All-Cause and Cause-Specific Mortality According to Alcohol Consumption Status
20676	All-Cause and Cause-Specific Mortality According to Binge Drinking Status
20677	Rates of Incident HF in Patients With New-Onset RA
20678	Events and Relative Risks From Start of Follow-Up
20679	Incident HF Among Patients With RA of Any Duration
20680	Univariable Predictors of MACE
20681	Rates of MACE, Death or MI, and Urgent and Nonurgent Revascularization at 2 Years for Each FFR Quartile
20682	Multivariable Predictors of MACE
20683	Energy-Adjusted  ∗   Daily Intake of Selected Foods
20684	Determinants of Dietary Patterns
20685	CVD Risk Factors
20686	Cardiovascular Imaging
20687	Prevalent Subclinical Atherosclerosis  ∗
20688	Improvement in Goodness-of-Fit to Model for Stroke or CAD by Addition of CSBP and/or MHSBP  ∗
20689	Clinical and Echocardiographic Data  (n= 255)
20690	Echocardiographic Measurements Performed With the Various Methods in the Local and the Reference Centers
20691	Agreement and Bland-Altman Bias Matrix Between EFs Assessed Using Various Methods
20692	Interrater and Intrarater Reliability of EF and LS Measurements in MAA and PAD
20693	Time Needed for and Variability in Automated EF Measurements in Different Studies
20694	Inclusion and Exclusion Criteria
20695	HRs, PAFs, and Estimated Decreased Life Expectancy by Running and Other Mortality Predictors
20696	HRs of All-Cause and Cardiovascular Mortality by Quintile of Weekly Running Time
20697	Comparison of Various Variables Among Patients Having Isolated MV Repair or Replacement for Mitral Valve Prolapse
20698	Comparison of Various Variables Among 8 Patients Having Isolated MV Repair for MV Prolapse Whose Valves Are IllustratedBothGrossly and Histologically
20699	CBP Levels and Cardiovascular Mortalities With Different Cuff SBP and DBP Cutoffs Based on Conventional Criteria intheDerivation Cohort
20700	Determining Central SBP Cutoff Values Based on the Sensitivity and Specificity Associated With Cuff SBP Cutoff Values for Predicting Cardiovascular Mortality
20701	Proposal for Outcome-Driven Diagnostic Thresholds forCBP Measurement
20702	Hazard Ratios for Total, Cardiovascular, and StrokeMortality in Relation to CBP at Entry in the Validation Cohort  (n= 2,501)
20703	Intraoperative Measurements and Stent-Graft Choice
20704	Outcomes of Open Surgery and Medically Treated Patients
20705	Quantification of 14-Day Endothelial Cell Proliferation  (%)
20706	Quantification of 14-Day Endothelial Coverage by Scanning Electron Microscopy  (%)
20707	Comparison of Lifetime Risks  ⁎   for Cardiovascular Disease Death by Traditional Risk Factor Burden Measured at Ages 45, 55, and 65 Years  (Men)  in the CCLS and the Cardiovascular LRPP
20708	Lifetime Risk for Cardiovascular Disease Death Stratified by Fitness Level Measured at Ages 45, 55, and 65 Years in the Cooper Center Longitudinal Study
20709	Pre-BAVP and Acute Post-BAVP Aortic Valve Function  (n = 528)
20710	Most Recent Follow-Up After Post-BAVP for Congenital AS  (n = 528)
20711	Comparison of Exercise-Restricted Versus Unrestricted Patients After BAVP for Congenital AS  (n = 403)   *
20712	Deaths After BAVP for Congenital AS  (n = 528)
20713	SUD After BAVP for Congenital AS
20714	Multivariate  (Adjusted)  Analysis of Factors Related to Inappropriate Use of SPECT
20715	Most Frequent Inappropriate Indications
20716	Vessels and Lesions Characterized by FFR and IVUS
20717	Analysis of Lesion Dimensions With CTCA and IVUS
20718	Genotype and Minor Allele Frequencies of ZNF202 SNPs in the General Population
20719	Risk of Severe Atherosclerosis  (ABI >0.7 vs. ≤0.7)  in the General Population  (Cross-Sectional Study) , Risk of IHD in the General Population  (Prospective Study) , and Risk of IHD in Case-Control Studies 1 and 2 as a Function of ZNF202 g.−660A>G Genotypes, Using an Assumption-Free Model of Inheritance
20720	ZNF202 g.–660A>G and Risk Factors for Ischemic Heart Disease Among Individuals From the General Population
20721	Mean Group Data for Resting Calf Experiment During Respiratory Exercise at 2% of PImax and 60% of PImax in CHF Patients Before and After IMT and Normal Control Subjects
20722	Mean Group Data for the Forearm Exercise Experiment During Respiratory Exercise at 2% of PImax and 60% of PImax in CHF Patients Before and After IMT and Normal Control Subjects
20723	Quantitative Data of the In Vitro Effect of Everolimus on the mTOR Pathway and Protein Synthesis in Cultured Mouse Macrophages and SMC
20724	Detection of Pathology With the Four Echocardiographic Techniques
20725	Image Quality, Sensitivity, and Specificity of the Whole-Heart Coronary Magnetic Resonance Angiography in the Individual Segments
20726	Diagnostic Accuracy of Whole-Heart Coronary Magnetic Resonance Angiography to Detect Stenoses of ≥50% in 113 Patients Who Completed Acquisition of Coronary Magnetic Resonance Data
20727	Organs and Structures With Noncardiac Findings
20728	Diagnostic and Therapeutic Consequences in the Patients With Significant Noncardiac Findings During the 6 Months After the MDCT Scan
20729	Multislice Computed Tomography Scan Parameters
20730	Effective Dose from Multislice Computed Tomography Coronary Angiography
20731	Effective Dose from Conventional Coronary Angiography
20732	Age- and Gender-Specific Prevalence of Individual Components and the Number of Components of MetS Based on the Criteria of NCEP and IDF in Chinese Elderly People
20733	Odds Ratios and 95% Confidence Interval  (CI)  of Cardiovascular Diseases for MetS by the NCEP and IDF Criteria and Their Individual Components
20734	Comparison of the Serial IVUS Data According to Follow-Up Remodeling Index
20735	Regional Wall Motion Abnormalities  (RWMA)  Detected by Each of the Four Imaging Modalities
20736	Interobserver Agreement  (Kappa Value)  on Detection of Regional Wall Motion Abnormalities for Each Imaging Technique
20737	Intermethod Agreement  (Kappa Value)  for Off-Site Reader 1 on Detection of Regional Wall Motion Abnormalities
20738	Agreement  (Kappa Value)  Between Each Imaging Method on Detection of Regional Wall Motion Abnormalities and Presence of Regional Wall Motion Abnormality Defined by a Panel Decision
20739	Diagnostic Accuracy of Each Imaging Method  (Mean From All Three Readers)  to Detect the Presence of Regional Wall Motion Abnormalities Defined by a Panel Decision
20740	Quantitative IVUS Measurements at Ruptured Plaque Segments Between Culprit/Target Lesions and Non-Culprit/Non-Target Lesions
20741	Quantitative IVUS Measurements at Ruptured Plaque Segments Between ACS and SAP
20742	Feasibility of Intracardiac Echocardiographic Guided Device Closure of Atrial Septal Defects
20743	Acquisition Parameters of Gadolinium-Enhanced Three-Dimensional MRA in 67 MRAs legend
20744	Summary of Pulmonary and Systemic Venous Anomalies in 61 Patients legend
20745	Results of Univariate and Multivariate Analyses for Distinguishing Between the LMCA and LAD Groups
20746	Results of Univariate and Multivariate Analyses for Prediction of Clinical Outcome
20747	Respiratory Change in Patients With CP and Normal Sinus Rhythm legend legend
20748	Respiratory Change in Patients With CP and AF legend legend
20749	Respiratory Change in Patients With AF Without CP legend legend
20750	Comparison of the Respiratory Variation in Patients With CP and SR and With AF legend legend
20751	Plasma Triglycerides and Remnant Lipids After High-Fat Meals
20752	Systemic Arterial Compliance  (SAC)  After Low-Fat Meal  (Control)  and High-Fat Meal  (Test)  legend
20753	Duration of the Procurement Process by Donor Group, in Minutes legend
20754	Correlation ∗ Between Hospitals’ Unadjusted and Risk-Adjusted Bypass Mortality Rates
20755	Comparison of Outlier Hospitals by Observed to Expected Ratios legend
20756	Comparison of Outlier Hospitals by Observed to Expected Ratios After Recalibration legend
20757	High and Low Performers Using Random Effects Model legend
20758	Interreader Comparison of Diagnosis Prevalence  (%)
20759	Multivariate Analyses for Echocardiographic Processes
20760	Echocardiographic Measurements, Stratified by Interpreting Physician
20761	Quantitative Coronary Angiographic Results by Edge-Detection Method legend legend
20762	Quantitative Coronary Angiographic Results by Videodensitometry legend legend
20763	Quantitative Coronary Angiographic Variables— Univariate Analysis of Predictors for Long-Term Outcome legend
20764	Multivariate Models Using Quantitative Coronary Angiographic Variables legend
20765	Reference Chart Generated Using Model II legend
20766	Velocity of Labeled Erythrocytes and Vessel Diameter in Arterioles and Venules Before and After Administration of QW7437  (0.05 ml/kg)  legend legend
20767	Velocity and Transient Stoppage Frequency of Labeled Microbubbles in Venules legend
20768	Regurgitation Indexes in Three Groups of Patients legend
20769	Hemodynamic Values Measured in the Patient Group Without Collateral Vessels  (Group 1) , Recruitable Collateral Vessels  (Group 2)  and Spontaneously Visible Collateral Vessels  (Group 3)  in Patients With and Without Ischemia During Balloon Angioplasty legend
20770	Angiographic, Clinical and Procedural Variables for 120 Study Patients
20771	Logistic Regression Model
20772	Hemodynamic and Oxygenation Variables
20773	Slopes of Regression Lines Comparing Mean and Peak Frequency Shifts Recorded by Clinical Doppler Catheter at Different Rotational Positions With Reynolds Number for Scaled In Vitro Model
20774	Biophysical Variables of First Ineffective and Effective Ablation Sites in Patients Who Required Two or More Radiofrequency Pulses
20775	Risk of Ischemic Stroke by PFO/ASA Status
20776	Association Between PFO and Ischemic Stroke by Gender, Age, and Race-Ethnicity
20777	Trade-Off Between Diagnostic Accuracy and Need for Adenosine
20778	Combined Pressure-Flow Data in All Patients With Relative iFR Error by Tertile
20779	Comparison Between Best-Fit Parameters and Clinical Observations in Patients  ⁎
20780	Systolic Blood Pressure and LVW/BW Ratio
20781	Hemodynamics at the Age of 17 Weeks
20782	Summary of Hemodynamic Parameters in Protocol 1
20783	Summary of Infarct Size Data in Protocol 1
20784	Summary of Hemodynamic Parameters in Protocol 2
20785	Summary of Infarct Size Data in Protocol 2
20786	Associations Between Gestational Age at Birth and Incident HF: Unadjusted and Adjusted IRRs  (95% CIs)  for Incident HF in Relation to Gestational Age at Birth
20787	Associations Between Birth Weight for Gestational and Incident HF: Crude and Adjusted IRRs  (95% CIs)  for Incident HF in Relation to Birth Weight for Gestational Age
20788	Clinical and Procedural Outcomes
20789	Multivariate Analysis of Clinical and Procedural Predictors of Adverse Events for CFA Interventions
20790	Multivariate Analysis of Outcomes for 4 Different Patient Subgroups
20791	Per-Segment, Per-Vessel, and Per-Patient Analysis
20792	Pooled Summary Results
20793	Quality Assessment  (QUADAS)
20794	Incremental Risk Factors for Time-Related Transition to End States After Initial Operation
20795	Reoperations After Complete Intracardiac Repair
20796	Hemodynamics of the Studied Subjects
20797	Quantitative Intracoronary Ultrasound Analysis of the 37 Studied Coronary Arteries
20798	Summary of Diagnostic Accuracy of CMRA Against Conventional X-Ray Angiography in Evaluable Segments, Vessels, and Patients
20799	Subgroup Analyses of Evaluable Segment-Level Data: Random Effects Estimates and 95% CI
20800	Percentage of Total Cross Section Represented by Plaque Area  (Difference Between Lumen Area and Area Delimited by Internal Elastic Lamina)  at Either 7 or 21 Days After Treatment with rhVEGF  (2 μg/kg by a Single Intramuscular Injection)  or Albumin legend
20801	Percentage of Total Lumen Circumference Represented by Plaque at Either 7 or 21 Days After Treatment With rhVEGF  (2 μg/kg by a Single Intramuscular Injection)  or Albumin legend
20802	Maximal Plaque Thickness  (mm)  Was Determined for Cross Sections Obtained at Either 7 or 21 Days After Treatment With rhVEGF  (2 μg/kg by a Single Intramuscular Injection)  or Albumin legend
20803	Endothelial-Positive Area: Number of CD31-Positive Cells Normalized to Total Plaque Area  (cells/mm2)  at Either 7 or 21 Days After Treatment With rhVEGF  (2 μg/kg by a Single Intramuscular Injection)  or Albumin legend
20804	Macrophage Infiltration: Number of RAM-11–Positive Cells Per Cross Section Obtained at Either 7 or 21 Days After Treatment With rhVEGF  (2 μg/kg by a Single Intramuscular Injection)  or Albumin legend
20805	Patient Details: Previous Surgical Palliation, Presence of a Residual Ventricular Septal Defect, Use of a Transannular Patch, Presence or Absence of Restrictive Physiology, Inotropic Support and Details of Extended Studies legend
20806	Ventilatory Parameters During Intermittent Positive Pressure Ventilation and Negative Pressure Ventilation legend
20807	Standard Studies in All Patients. Hemodynamic Data During Intermittent Positive Pressure Ventilation and After a 15-min Period of Negative Pressure Ventilation legend
20808	Comparison of Metabolic Acid-Base Status, and of Changes in Pulmonary Blood Flow During Standard Studies in Nonrestrictive  (n = 15)  and Restrictive  (n = 8)  Patients
20809	Pulmonary Blood Flow, Oxygen Consumption and Mixed Venous Saturation in Sub-group 1  (Nine Patients)  in Whom the Study Period Was Extended to Include Measurements Made After Re-instituting Intermittent Positive Pressure Ventilation legend
20810	Hemodynamic Data for Sub-group 2: Eight Patients Who Received an Extended Period of Negative Pressure Ventilation legend
20811	Subgroup 2: Restrictive  (n = 4)  vs Nonrestrictive  (n = 4)  Patients Who Received an Extended Period of Negative Pressure Ventilation legend
20812	Summary of Published Adverse Cardiovascular Events in People Using Nicotine Replacement Therapy
20813	Pharmacokinetic and Pharmacodynamic Considerations Concerning Cardiovascular Safety of Nicotine
20814	Risk Factors Associated With Atrial Fibrillation   (7)     ∗
20815	Changes in Total Score and Score of Each Neuropsychological Dimension of the MoCA Over Time
20816	Changes in DSST, TMT A and -B, and Verbal Fluency Tests Over Time
20817	Publications Reporting the Use of Neurocognitive Tests in TAVR Recipients
20818	Predictors of Death in 46 Patients With SMV legend
20819	Stenosis Severity-Based Coefficients Versus Loss Coefficients Determined From Laboratory Model Studies
20820	Patient Data and Pressure Gradients
20821	βAR Signaling in WT, CSQ, and CSQ/PI3KγinactMice
20822	Echocardiographic Measurements in WT, CSQ, and CSQ/PI3KγinactMice
20823	Risk Ratios for Taking Nonstatin Lipid-Lowering Medications Among MedicareBeneficiaries With CHD
20824	Risk Ratios for Taking Nonstatin Lipid-Lowering Medications Among Medicare Beneficiaries With CHD
20825	Lack of Association Between SNPs in PLA2G7 and Circulating Lp-PLA2 Protein Mass or Activity But Significant Relation of Multiple SNPs in CRP With Circulating CRP Levels  ⁎
20826	Association of SNPs in PLA2G7 But Not in CRP With CAC
20827	Location of Angioplasty of Patients Who Underwent 3-Month Angiography and Restenosis Rate in Relation to the Treated Artery and Site of the Treated Segment
20828	Criteria for Evaluation of Clinical Care
20829	Basic Research Measures
20830	Criteria for Evaluation of Clinical Research Quality
20831	Effects of Statins on Lipid Profiles
20832	Aortic Pressure, Blood pH and Blood Gas Data of Dogs in Protocols 1 and 2
20833	Clinical Composite Score
20834	Hemodynamic Effects of Pacing at Various Sites in Hearts With Normal Impulse Conduction
20835	Hemodynamic Effects of Pacing at the RV and LV Septum and at the LV Apex in Hearts With Normal Impulse Conduction
20836	Acute Canine Model: Hemodynamic Indices legend
20837	Acute Canine Model: Mitral Valve and Geometric Indices legend
20838	Chronic Sheep Model: Hemodynamic, Left Ventricular and Mitral Valve Indices legend
20839	Age at Operation in 40 Patients Who Had a Fontan Operation for Pulmonary Atresia With Intact Ventricular Septum, 1979 to October 1, 1995
20840	Previous Procedures in 40 Patients Who Had a Fontan Operation for Pulmonary Atresia With Intact Ventricular Septum
20841	Management of Tricuspid Valve in 40 Patients Who Had a Fontan Operation for Pulmonary Atresia With Intact Ventricular Septum
20842	Connections Used to Direct Systemic Venous Blood in 40 Patients Who Had a Fontan Operation for Pulmonary Atresia With Intact Ventricular Septum
20843	Surgical Results in 40 Patients Who Had a Fontan Operation for Pulmonary Atresia With Intact Ventricular Septum
20844	Stent Type and Number
20845	Quantitative Angiographic Measurements
20846	Quantitative Angiographic Measurements, Procedural and Follow-Up Data in the 121 Patients With Successful Stenting
20847	Predictors of Restenosis
20848	Side-Branch Analysis
20849	Individual Defibrillation Thresholds
20850	Quality of Life Adjustments
20851	Model Predicted Number of Events/10,000 Patients
20852	General Principles to Consider in the Design of Clinical Trials   (16)
20853	Judging the Evidence for Clinical Practice Recommendations   (24)
20854	Class I, Level of Evidence A, Recommendations from Selected ACC/AHA Guidelines
20855	Class III, Level of Evidence A, Recommendations from Selected ACC/AHA Guidelines
20856	Clinical and Echocardiographic Features of Patients With Tricuspid Regurgitation
20857	Mortality Versus Echocardiographic Findings by Univariable Proportional Hazards Analysis
20858	Clinical and Echocardiographic Parameters Associated With Long-Term Survival *
20859	Description of Included Studies
20860	Final Population Pharmacokinetic Model  ⁎
20861	Age-Specific Dose Regime for Sotalol in Children With Supraventricular Tachycardia
20862	Electrophysiologic Parameters in Relation to the Site (s)  of Pacing  (A = All Dogs; B = Septal Subgroup)  legend
20863	Functional Conduction Blocks in Relation to the Site (s)  of Pacing  (n = 13)  legend
20864	Intra-Observer Analysis Between the Repeated  (t1)  and First  (t0)  Calibrations of 48 Catheters in the Original and the Compressed/Decompressed  (CR 6, 10 and 16)  Image Series legend
20865	Intra-Observer Analysis Between the Repeated  (t1)  and First  (t0)  Measurements of 48 Coronary Obstructions in the Original and the Compressed/Decompressed  (CR 6, 10 and 16)  Image Series legend
20866	Fixed Inter-Compression Analysis Between the First Calibrations  (t0)  of 48 Catheters in the Compressed/Decompressed  (CR 6, 10 and 16)  and Original Image Series legend
20867	Fixed Inter-Compression Analysis Between the First Measurements  (t0)  of 48 Coronary Lesions in the Compressed/Decompressed  (CR 6, 10 and 16)  and Original Image Series legend
20868	Variable Inter-Compression Analysis Between the Repeated Calibrations  (t1)  of 48 Catheters in the Original and the Compressed/Decompressed  (CR 6, 10 and 16)  Image Series and the First Calibrations  (t0)  in the Original Image Series legend
20869	Variable Inter-Compression Analysis Between the Repeated Measurements  (t1)  of 48 Coronary Obstructions in the Original and the Compressed/Decompressed  (CR 6, 10 and 16)  Image Series and the First Measurements  (t0)  in the Original Image Series legend
20870	Variable Inter-Compression Analysis Between the Repeated Measurements  (t1)  of 48 Coronary Obstructions in the Original and the Compressed/Decompressed  (CR 6, 10 and 16)  Image Series and the First Measurements  (t0)  in the Original Image Series legend
20871	Minimal Radiofrequency Power Required to Induce Transient Right Bundle Branch Block per Ablation Electrode–Target Distance, With and Without Intracavitary Flow
20872	Clinical and Hemodynamic Data of Patients and Healthy Subjects †   legend
20873	Titers of Human, Rabbit, and Monoclonal Mouse Anti-beta1-AR Obtained for ELISA, Western Blotting, and Immunoprecipitation legend
20874	Basal and  (−) Isoprenaline-Stimulated cAMP-levels of CHW-beta1 Cells in the Presence of Rabbit  (70 nmol/liter) , Mouse  (7 nmol/liter) , or Human Anti-beta1-ECII  (2 μmol/liter)  †
20875	Reasons for Medication Nonadherence
20876	Fixed-Dose Combinations in CV Prevention Studies
20877	Time Course of Residual Atrial Shunt Disappearance After Amplatzer Septal Occluder Implantation in All 151 Patients in the Study
20878	Clinical Data
20879	Morphologic Data for AF and No-AF Groups
20880	Morphologic Data for Men and Women
20881	Morphologic Data for Patients with Paroxysmal and Persistent AF
20882	Interobserver Agreement on Plaque Characterization and Quantitative OCT Measurements Before Development of Image Interpretation Criteria: Analysis I
20883	Interobserver Variability of Plaque Characterization and Quantitative OCT Measurements After Development of ImageInterpretation Criteria: Analysis II
20884	Provision of Cardiovascular Disease Prevention Counseling Services to US Adults, 1995; National Ambulatory Medical Care Survey legend
20885	Provision of Cardiovascular Disease Prevention Screening and Medication Services to US Adults, 1995; National Ambulatory Medical Care Survey  legend
20886	Provision of Cardiovascular Disease Prevention Services to US Adults With Specific Risk Factors, 1995; National Ambulatory Medical Care Survey
20887	Rating Cases as Appropriate for Revascularization According to ACC/AHA Appropriate Use Criteria Patients  ⁎
20888	Most Common Clinical Scenarios for CABG Surgery Patients With No ACS/No Prior CABG Surgery Classified as Inappropriate, Uncertain, and Appropriate
20889	Most Common Clinical Scenarios for PCI Patients With No ACS/No Prior CABG Surgery Classified as Inappropriate, Uncertain, and Appropriate
20890	Exploration of No ACS/No Prior CABG Surgery Eligible Cases With No Rating
20891	Comparison of TAXUS Versus Control for Patients With Angiographic Follow-Up
20892	Simulated Impact of Different In-Stent Late Loss Variances on TLR in the TAXUS Stent Population
20893	Simulated Impact of Different In-Stent Late Loss Skewedness on TLR in the TAXUS Stent Population
20894	Hemodynamic Effects of Nebivolol on Anesthetized Mice
20895	Effects of Nebivolol on Left Ventricular Function and Dimensions
20896	Hemodynamic Responses to ATL-146e Bolus Injections in the Absence or Presence of Propranolol, Enalaprilat, Verapamil, or Caffeine
20897	Hemodynamic Responses to Adenosine and CGS-21680 in the Absence or Presence of Verapamil
20898	Effect of Increasing Verapamil Infusion Rates on the Hemodynamic Responses to Adenosine and ATL-146e
20899	Results on a Per-Patient and Per-Vessel Level Using Hyperemic MBF as a Perfusion Parameter to Assess Diagnostic Accuracy of [15O]H2O PET
20900	Diagnostic Accuracy of Quantitative [15O]H2O PET MPI Using Hyperemic MBF as a Perfusion Parameter
20901	Diagnostic Accuracy of Quantitative [15O]H2O PET MPI for Detecting Angiographic Obstructive CAD
20902	Univariate and Multivariable Regression Analysis Describing the Relationship Between Hyperemic MBF, CAD Risk Factors, and Functional CAD Severity
20903	The Influence of Sex and Age on the Diagnostic Performance of [15O]H2O Hyperemic MBF Imaging
20904	Alcohol-Related Variables Assessed in 9 Administrations of the NHIS
20905	Adjusted Summary HRs  (and 95% CIs)  for Cardiovascular Mortality Among NHIS Participants in 1988, 1990, 1991, and 1997 to 2000
20906	Adjusted Summary HRs  (and 95% CIs)  for Cardiovascular, Coronary Heart Disease, and Stroke Mortality Among NHIS Participants in 1987, 1988, 1990 to 1992, and 1997 to 2000
20907	Correlation Between FVII Genotypes, FVIIc and FVIIa legend
20908	30-Day Composite End Point and FVII Genotypes legend
20909	Relative Risk for the Composite End Point in Logistic Regression Analysis legend
20910	Key Issues Regarding Composite Endpoints
20911	Key Issues Regarding Randomization Methods
20912	New Methods for Quantitative Assessment of MR: Clinical Use, Advantages, and Disadvantages
20913	Real-Time 3DE Studies of the Accuracy and Reproducibility of the VCA Technique for MR Quantification and the Relevant 2D Methods Compared
20914	Real-Time 3DE Studies of the Accuracy and Reproducibility of the Mitral and LVOT SV Quantification and the Relevant 2D Methods Compared
20915	CMR Studies Using Direct and Indirect Methods of Quantifying MR
20916	Cardiac CT Study for MR Quantification by LV and RV Planimetry
20917	3DE Studies for 3D PISA and Anatomic Regurgitant Orifice Area  (Last Row Only)  Techniques
20918	CMR and CCT Studies Using Direct Planimetry To Measure Anatomic Regurgitant Orifice Area
20919	Stakeholders and Their Interest in Public Reporting
20920	Advantages of Clinical  (Registry)  Data Over Claims Data in Public Reporting
20921	American College of Cardiology Foundation’s Principlesof Public Reporting
20922	American College of Cardiology Measures to Be Publicly Reported
20923	LV EDV, ESV, SV, CO, EF, Mass and Heart Rate in Volunteers, Patients with HHD, AVD, and DCM
20924	Crude and Adjusted Relative Risks of Cardiovascular Events According to Quartile of Plasma Level of Lp-PLA2
20925	Crude and Adjusted Relative Risks of Cardiovascular Events Associated With a One-Quartile Increase in the Concentration of Lp-PLA2and CRP
20926	Number of Initial Strokes and Initial Strokes per 1,000 Person-Years of Follow-Up After Initial AF Diagnosis
20927	Hazard of Stroke by Race/Ethnicity, Relative to White Patients, After Controlling for CHA2DS2-VASc Score  (Model 1)  and CHA2DS2-VASc Score Plus Anticoagulant Use  (Model 2)
20928	Comparison of CHA2DS2-VASc and CHA2DS2-VASc-R Scores in Predicting Stroke: Relative Hazard Associated With 1-Point Increase in Stroke Risk Score, and C-Statistic
20929	Relative Contribution of Each Risk Factor of CHA2DS2-VASc-R Score in Stroke Prediction
20930	Univariate and Multivariate Associations Between Total Plasma Lp-PLA2 Mass and Activity, HDL-Lp-PLA2 Mass and Activity, Ratios of Lp-PLA2 to HDL-Lp-PLA2 Mass and Activity, Natural Log of hsCRP, and Cardiac Death at Follow-Up
20931	Electrocardiographic Measurements and Sites of Successful Ablation in the Retrospective Cohort
20932	Clinical Variables Stratified by Quartiles of SUV
20933	Multiple Stepwise Regression Analysis for Factors Associated With SUV of FDG Levels in Carotid Artery
20934	Proportion of Patients in the PROVE-IT TIMI-22 Trial Reaching Dual Goals of Low-Density Lipoprotein Cholesterol <70 mg/dl and C-Reactive Protein <2 mg/l in the Total Cohort and According to Statin Allocation
20935	Relative Efficacy of Pravastatin 40 mg and Atorvastatin 80 mg in Achieving LDL-C Levels <70 mg/l and CRP Levels <2 mg/l in the PROVE-IT TIMI-22 Trial
20936	Change in Heart/Body Weight Ratio  (mg/g)  in Wistar Rats Treated With AB or ADR After 2, 8 and 14 Weeks  (n = 8)
20937	Left Ventricular Function, Expressed as ±dP/dtmax (kPa/s) , in Each Group at Different Times  (n = 6)
20938	Anatomic Measurements of Hearts  (mm2)  From Each Group at the End of the Experiment
20939	Collagen Volume Fraction  (%)  of the Left Ventricle in Both the Aortic Banding and Adriamycin Groups  (n = 8)
20940	Changes in the Ratio of CD4+/CD8+Before and After Treatment in Both the AB and ADR Groups  (n = 8)
20941	Effects of Tolvaptan on Hemodynamic Parameters
20942	Pathology details
20943	Surgery details
20944	Adjuvant radiotherapy received  (within 3 months after surgery)
20945	Adjuvant radiotherapy received  (within 3 months after surgery) , nodes removed, nodal status, and external-beam radiotherapy  (EBRT)  received in node-positive patients by risk group defined according to ASTEC radiotherapy eligibility
20946	Cause of death
20947	Site of recurrence
20948	Unadjusted and adjusted analysis using the Cox model for overall survival and recurrence-free survival  (deaths from all causes) , and for disease-specific survival and recurrence-free disease-specific survival  (disease and treatment specific deaths only)
20949	Unadjusted and adjusted analysis classifying centres by median number of nodes harvested, with the Cox model for overall survival and recurrence-free survival
20950	Events after allocated treatment
20951	Overview of stage I seminoma treated with adjuvant carboplatin
20952	Deaths, myocardial infarctions, and new interventions during median 2·7 years' follow-up
20953	Secondary events during follow-up  *
20954	Antianginal medication
20955	Angina grade and exercise time at 6 months
20956	Frequency of increases in serum creatinine
20957	Deaths  (and causes of death)  and admissions for heart failure or for any reason
20958	Primary reason for discontinuation of study medication before completion of study
20959	Characterlstlcs of cases and controls
20960	Adjusted relative risk estimates for all cancer associated with use of calcium-channel blockers and ACE Inhibitors
20961	Adjusted relative risk estimates for all cancers associated with use of calcium-channel blockers by age, dose, and duration of use
20962	Adjusted relative risk estimates for specific calcium-channel blockers
20963	Adjusted relative risk estimates for calcium-channel blockers for specific cancer sites
20964	Geometric mean CRP and SAA concentrations by risk-factor status
20965	Relative risk of coronary events for each 1 SD increase in CRP or SAA concentration, and for CRP concentration by angina type
20966	Relative risk of coronary events by CRP concentration
20967	Responses to questions on assisted suicide in 322 psychiatrists in UK and Ireland
20968	Translocations and physical estimates of dose in controls and residents of contaminated homes
20969	Linear fit to the data in  table 1
20970	Median life expectancy by radiation dose or distance from hypocentre of bomb
20971	Mutations within the TULP1 gene in 171 patients with autosomal recessive retinitis pigmentosa
20972	Relative risk of mortality from coronary heart disease and occurrence of myocardial infarction during 10 years of follow-up by tertile of flavonoid intake  (Zutphen Elderly Study)
20973	Packed-cell volume in elite athletes and in controls
20974	Alcohol consumption and health status at age 33 years
20975	Frequencies of MBL genotypes in patients and controls
20976	Hair mercury concentrations and dental fillings for different occupations within the crematoria
20977	Confirmed culture-positive melioidosis in England and Wales, 1988–September 1998
20978	Changes in plasma lipoprotein apolipoprotein and chitotriosidase activity in Gaucher's disease patients treated  (n=36)  and not treated  (n=9)  with alglucerase
20979	Prefrontal regions showing hypofunction during left-hand movement in two patients with hysteria and two feigners
20980	Summary data of AECP patients with cancer
20981	Rate of detection of colorectal cancer according to age and sex
20982	Presenting symptoms of patients from the patient consultation questionnaire and diagnostic value for colorectal cancer
20983	Malignancy score distribution  (%)  from general practitioner's letter and from patient consultation questionnaire  (PCQ)
20984	Referral patterns of the weighted numerical score, malignancy risk score, and NHS guidelines
20985	Cancer risk and the weighted numerical score
20986	Cancer cases seen at Tenwek Hospital between 1989 and 1998 by sex
20987	Prevalence of valvular heart diseases in population-based studies
20988	Valvular heart diseases diagnosed in Olmsted County
20989	Cardiac chamber remodelling associated with valvular heart diseases in the population
20990	Quit attempts among smokers before, during, and after the Tips campaign
20991	Communication about the dangers of smoking and recommendation of cessation services by non-smokers before, during, and after the Tips campaign
20992	Effects of herb extracts and alpha-tocopherol respectively, on formation of lipid peroxidation products  (LPP)  in cultured lung cells exposed to iron or ozone
20993	Faecal exctretion of 2,3,7,8-TCDD before and during the olestra regimens
20994	Adverse drug reactions reported by nurses
20995	Accounts that included a dispute with doctors
20996	Accounts without a dispute with doctors
20997	Population-based family designs
20998	Overview of data sources
20999	Data included in the maternal mortality model
21000	Categorisation of countries based on evidence for progress in reducing the maternal mortality ratio between 1990 and 2015
21001	Projections of MMR and maternal deaths for 2030
21002	Expected health spending in 2030 and 2040
21003	Expected health spending by source in 2040
21004	Potential total and government health spending for low-income and middle-income countries in 2040
21005	Health spending by source, 2014
21006	Health spending relative to expected health spending, 2014
21007	Factors associated with BMI and changes in BMI
21008	Habitual activity scores  (MET-times per week)  by overall activity status and by study year
21009	Factors associated with sum of skinfold thickness and changes in sum of skinfold thickness
21010	Details of patients
21011	Effects of sildenafil on retinal function
21012	Performance of filariasis antigen card test
21013	Cases of childhood empyeme at Birmingham Children's Hospital, 1992–96
21014	Mean  (SD)  MMSE and age according to APOE genotype
21015	Genotype frequencies of the DLST gene in AD patients and age-matched controls
21016	Plasma concentrations of homocysteine and vitamins mean  (SD)  and presence of vascular risk factors  (%)  in the study populations
21017	Patients enrolled and proportions with complete data
21018	Biochemical findings
21019	Risk of ovarian cancer mortality according to reported use of paracetamol. Cancer Prevention Study II, 1982–1994
21020	Pathogens isolated from writing tools
21021	Cases in community outbreak November, 1995–January, 1996
21022	Number of individuals recommended per 2000 of population  *
21023	Attitudes to xenotransplantation
21024	Results in wound-protector and control groups
21025	Effects of treatments
21026	Surgical procedures by the pelvic floor service
21027	Diagnostic sensitivities  (SE) , specificities  (SP) , false-negative  (FN)  and false-positive  (FP)  cases in each conventional BIT subtest and in combinations of two and three subtests  (n=52)
21028	Coronary events by tertile of calcium score
21029	Stepwise Poisson regression of incidence of severe respiratory infections in infancy 1947–48 on overcrowding, social class, maternal capacity, and age of other children in the household
21030	Genotype and allele frequencies of −1438G/A 5-HT2A promoter polymorphism in OCD and two populations of eating-disorder patients
21031	Distribution of 21438G/A genotypes and allele frequencies
21032	Scores of language function  (SLTA)  and in cerebrospinal fluid  (CSF)  in four patients with fluent aphasia and anomia
21033	Uroflowmetric and anorectal manometric values in four patients
21034	Percentage of codon 129 PRP genotypes in sporadic CJD by 10-year age groups in the European study 1993–1998  (numbers of cases in parentheses) , and codon 129 distribution in the normal population and in previous studies of sporadic CJD
21035	Clinical, parasitological, and laboratory findings of patients
21036	Rate of P vivax and P falciparum infection by age and sex in Boktar district
21037	Susceptibility to HSV-1 infection in patients with and without AD
21038	Features of autosomal dominant episodic ataxias
21039	Patient details
21040	Details of patients with neuroleptic sensitivity
21041	Relative odds for appendicectomy associated with mothers' and cohort members' smoking
21042	Mean number  (SE)  of nuclei of non-melanised neurons, melanised neurons, and blood vessel endothelial cells
21043	Incidence of first non-melanoma skin cancer by immunosuppressive regimen
21044	Mean  (SD)  plasma lipids, apolipoproteins, and glucocerebrosidase enzymatic activities in each group
21045	Decile values for statistic blood pressure by age group and sex
21046	Risk classification by systolic blood pressure
21047	Hazard ratios for mortality in men per 10 mm Hg increase in systolic and diastolic blood pressure
21048	Autosomal dominant acute porphyrias
21049	Symptoms and signs of acute porphyria
21050	In-vitro mefloquine susceptibility of P falciparum isolates
21051	Distribution by age and sex, of malaria cases in Maela
21052	Clinical and parasitological outcomes
21053	Pairwise comparison of treatment efficacy
21054	Parasitological results
21055	Yearly population and mortality data for children enrolled in the sponsorship programme
21056	Results by treatment group
21057	Results of prespecified subgroup analyses
21058	Prevalence of subtle chromosomal abnormalities in children with mental retardation and in normal controls
21059	Extent and origin of chromosomal rearrangements
21060	Percentage frequency of cytogenetic abnormalities and fragile X syndrome in individuals with unexplained moderate to severe mental retardation  6,28–36
21061	Patients' age and circumstances of injury
21062	Injuries sustained and outcome of surgery
21063	The discrimination by auxotype/serovar classes compared with  opa -type for classes with five or more cases
21064	The link between epidemiological and microbiological cluster size for the 120 Sheffield cases
21065	Values used in calculations of PIDrisk
21066	Results of analysis of faecal DNA for BAT26 alterations
21067	Results of genital examinations
21068	Sexual function of 28 participants, according to GRISS
21069	Protective measures reported by infected and non-infected staff
21070	Effect of Interferons on virus-induced cytopathogenic effects of SARS-CoV and vesicular stomatitis virus
21071	Origins and epidemiological data of the key virus isolates used in the study
21072	Primer sequences used for nested PCR and sequencing
21073	WHO study survey sites by country
21074	Household and individual sample obtained and response rates, by site
21075	Lifetime and current prevalence of physical and sexual violence against women by an intimate partner among ever-partnered women, by site
21076	Controlling behaviours by an intimate partner, by site
21077	Sexual partners, practices, behaviours, and attitudes reported by men in Natsal-3, by age group
21078	Sexual partners, practices, behaviours, and attitudes reported by women in Natsal-3, by age group
21079	Change in numbers of sexual partners and prevalence of sexual practices, behaviours, and attitudes in Natsal-3 and Natsal-1 relative to Natsal-2, by sex
21080	Univariate relative risk of cardiac mortality
21081	Multivariate Cox proportional-regression models
21082	First six clinical cases of computer-assisted cardiac surgery
21083	Adverse events during the 24-h treatment period
21084	Changes in haemological and biochemical variables
21085	Results of electrophysiological studies before and after n-3 PUFA infusion and changes in fatty acid concentrations
21086	Seroconversion to HIV-2 infection according to age and sex, 1987–92
21087	Mortality according to HIV-2 infection and age, 1987–95
21088	Reported causes of death
21089	Effect of NEPs on HIV seroprevalence
21090	Complications after caesarean section in HIV-1-positive mothers and in HIV-1-negative mothers
21091	Molecular analysis of glioblastoma multiforme, its recurrent and metastatic lesions, and normal tissues of donor and recipient
21092	Plasma glucose and insulin, and fasting plasma free-fatty-acid concentrations before and after glucose challenge
21093	P carinii ITS sequence types and clinical variables in first episode PCP
21094	Statistical associations  (p<1·0×10−7)  between Affymetrix SNPs and circulating concentrations of LDL cholesterol in a genome-wide meta-analysis of five study populations consisting of up to 11 685 participants
21095	Statistical associations  (p<1·0×10−7)  between Illumina SNPs and circulating concentrations of LDL cholesterol in a genome-wide meta-analysis of three UK study populations consisting of up to 4337 participants
21096	Imputed SNPs showing genome-wide statistical association  (p<1·0×10−7)  with circulating concentrations of LDL cholesterol; meta-analysis of four study populations consisting of up to 9988 participants
21097	Revised injury severity classification  (RISC)  score
21098	Logistic regression models 1  (TRISS+whole-body CT)  and 2  (RISC score+whole-body CT)
21099	Logistic regression model 3  (TRISS+whole-body CT+level of hospital+year)  based on data from 2259 patients
21100	Logistic regression model 4  (RISC+whole-body CT+level of hospital+year)  based on data from 4113 patients
21101	Care quality across the 42 time categories in the week
21102	Adjusted odds ratios of receiving each care-quality indicator
21103	Reading habits and attendance at cultural events
21104	Type of literature read by doctors who reported reading books during the previous 24 h
21105	Proportions of participants who wanted change in how they spent their time
21106	Effects of oestrogen replacement therapy and smoking history among female patients and controls
21107	Distribution of cases and controls according to menopause category
21108	Relative risk  (RR)  of breast cancer by time since last use, duration of use, and type and dose of preparation mainly used
21109	Estimated cumulative incidence of breast cancer in 1000 women in North America or Europe associated with postmenopausal use of HRT for various durations, beginning at various ages
21110	Some examples of biological, virulence, and vaccine potential of pathogenic bacteria
21111	Results in hypercholesterolaemic patients treated for 8 weeks with diet or diet plus simvastatin
21112	Acceptable pelvic measurements for vaginal delivery
21113	Statistical analysis of differences between study group and control group
21114	Outcome for women in planned vaginal-delivery category in study and control groups
21115	Mean  (SD)  birthweight and 1 min and 3 min Apgar scores of infants
21116	Univariate predictors of death
21117	Univariate predictors of death or non-fatal myocardial infarction
21118	Thallium-perfusion defects and risk of death: results of multivariate Cox proportional hazards regression analyses
21119	Thallium-perfusion defects and risk of death or non-fatal MI: results of multivariate Cox proportional hazards regression analyses
21120	Associations of thallium ischaemia with death and major events in stratified Cox proportional hazards analyses: impact of time elapsed since bypass surgery
21121	Hepatic antimony concentrations in infants
21122	Frequency of mtDNA haplogroup U among patients who had had occipital stroke, patients with migraine, and population controls
21123	Water hardness and prevalence of eczema among primary-school children
21124	Chlorine content of water supply and prevalence of eczema among primary-school children
21125	Water hardness and prevalence of eczema among secondary-school children
21126	Factors significantly associated with increased or reduced risk of unsafe sex in men
21127	Factors significantly associated with increased or reduced risk of unsafe sex in women
21128	Concentrations of organochlorine compounds in blood samples
21129	Risk of breast cancer in relation to lipid-adjusted serum concentrations of organochlorines in quartiles
21130	Results of exploratory factor analysis  (factor loadings×100)  of symptoms reported in past month in Gulf War cohort  (n=3214)
21131	Confirmatory factor analysis of factor structure of Gulf War  (n=3225) , Bosnia  (n=1770) , and Era  (n=2384)  cohorts
21132	Factor structure of Gulf War cohort to be tested in confirmatory factor analysis
21133	Structure of “Haley model” based on our symptoms
21134	SSLRs for GHQ-12
21135	Hazard ratios, risk points, and predictive score for independent predictors of outcome in medical and surgical models
21136	5-year actuarial risk of ipsilateral carotid territory major ischaemic stroke in 394 patients with 70–99% stenosis in medical-treatment group
21137	30-day risk of any major stroke or death after carotid endarterectomy in 596 patients with 70–99% stenosis in surgery group
21138	Effect of endarterectomy on 5-year risk of ipsilateral carotid territory major ischaemic stroke and operative major stroke or operative death in patients with 70–99% stenosis
21139	Non-validated Cox's proportional hazards model for ipsilateral carotid territory major ischaemic stroke on treatment derived from 1208 patients with 0–99% stenosis in medical-treatment group
21140	Non-validated logistic regression model for any major stroke or death from other causes within 30 days of carotid endarterectomy derived from 1799 patients with 0–99% stenosis in surgery group
21141	Accuracy of three risk factors  (age >60 years, %TBSA >40%, inhalation)  for predicting mortality in adults with severe burns
21142	Responses of elderly people  (n=443)  versus younger people  (n=189)  to standing aside in the queue for cardiac services for a younger or self-employed person
21143	Independent predictors of elderly people's beliefs that they should stand aside for younger or self-employed persons in the queue for cardiac services
21144	Early results of primary surgical treatment for biliary atresia in individual centres over a 2-year period  (March1993–February 1995)
21145	Early results of primary surgical treatment for biliary atresia grouped by centre caseload
21146	Mammographic outcomes for women attending first round screening in 1994  (n=103 770)
21147	Age-specific sensitivity  (2-year interval)  and specificity by HRT use
21148	Multiple logistic-regression analyses—sensitivity, specificity, positive predictive value, and small-cancer detection rate
21149	Summary of studies on HRT use and sensitivity of screening mammography
21150	Methods of randomization
21151	Covariate adjustment in analysis of patients' response by treatment
21152	Subgroup analyses
21153	Mean results for dark adaptation and ERGs
21154	Significance of variables analysed for risk effects on socket survival
21155	Significance of variables assessed for risk effects on femoral-prosthesis survival
21156	CDT results at each test interval after cochlear implantation
21157	Correlation analysis of CDT with variables at the 5 year interval
21158	Nipple fluid bFGF  (ng/L)
21159	Number of patients and procedures by country
21160	Survival after liver transplantation in Europe according to different risk factors in univariate analysis
21161	Risk factors for death after liver transplantation in multivariate analysis
21162	Interactive factors in multivariate analysis for adults and children
21163	Estimated mortality after correction for risk factors  (normalised intrinsic mortality risk)
21164	Comparison of causes of death between total population and optimum group
21165	Estimated mortality rate in relation to each single factor, in adults
21166	Methodological standards satisfied by studies
21167	Relative risks
21168	WEB: Metholological standards
21169	WEB: Metholological standards
21170	Descriptive data for cases and controls
21171	Use of treated and untreated nets in cases and controls
21172	Correlation weighted by population size between income inequality  (gini coefficient)  with mortality and life expectancy OECD among 16 countries  (1989–92) , adjusted for gross domestic product per capita
21173	Correlations between mortality, life expectancy, low birthweight, self-rated health, and distrust, organisation membership, volunteering, control, trade union membership, and the % of women elected to national government among OECD countries  (1989–92) , adjusted for gross domestic product per capita and weighted by population size
21174	Association between type of abuse and major depression
21175	Association between stage of abuse and major depression
21176	Association between severity of abuse and major depression
21177	Distribution of numbers of heterosexual partners over lifetime and in the past 5 years by gender and age-group: Natsal 2000
21178	Distribution of behaviours with regard to new partners and concurrency in past year, partners from outside the UK in past 5 years, and frequency of heterosexual sex in past 4 weeks, by gender and age-group: Natsal 2000
21179	Prevalence of sexual behaviours and injecting drug use: Natsal 2000 and Natsal 1990 by gender and by residence in Greater London and rest of Britain for selected variables
21180	Change in prevalence of behaviours in Natsal 2000 compared with Natsal 1990 by gender  (all variables)  and for London and the rest of Britain  (for sexual partners and drug use)
21181	Distribution of the 344 patients in five WCEI classes  *
21182	Frequency of ten elements of NDE
21183	Factors affecting frequency and depth of near-death experience  (NDE)
21184	Significant differences in life-change inventory-scores  16   of patients with and without NDE at 2-year follow-up
21185	Total sum of individual life-change inventory scores  16   of patients at 2-year and 8-year follow-up
21186	PCR primers used for amplification of EGF promoter
21187	EGF genotype and allele frequencies in patients with malignant melanoma and in healthy controls
21188	Association between EGF genotype and allele frequencies with Breslow thickness in malignant melanoma patients
21189	Contribution of combined or individual loci of 57·1 ancestral haplotype to susceptibility to abacavir hypersensitivity
21190	Distribution of combined and individual alleles of 57·1 ancestral haplotype
21191	Parental periconceptional smoking and the offspring sex ratio  (male:female)
21192	Univariate and bivariate analysis of effects of aspects of sexual exposure on risk of HIV infection in sexually-experienced male and female respondents aged 17–24 years
21193	Multivariate analysis of effects of aspects of sexual exposure on risk of HIV infection in sexually·experienced male and female respondents aged 17–24 years
21194	Univariate analysis of predictive factors
21195	Multivariate analysis of predictive factors
21196	Direction of association between birthweight and subsequent systolic blood pressure  (SBP)  in the 55 studies that contributed to previous quantitative estimates  (web references 1–37)  and in the 48 studies that did not  (web references 38–75)
21197	Adjustment for potential confounding factors in the 55 studies that reported regression coefficients for the association between birthweight and subsequent blood pressure
21198	Prohibitin 3 untranslated region C/T polymorphism: genotype distribution in patients with breast cancer and in controls
21199	Risk of breast cancer associated with Prohibitin 3’ untranslated region C/T polymorphism
21200	Description of journals reviewed in 1997
21201	Examples of non-supporting claims
21202	Numbers of participants in each group in every centre
21203	Discriminatory ability  (areas under ROC curves, with 95% Cls)  of individual tests by region
21204	Discriminatory ability of individual tests and combined algorithm
21205	Number  (%)  within each group accorded GMS/AGECAT  (stage 2)  diagnoses by region  *
21206	Calibration model  (logistic regression)  derived from the development dataset including the four assessments independently predictive of dementia status  (n=1413)
21207	Independent predictor variables in GMS/AGECAT dementia diagnosis and CSI ‘D’ probable dementia screening
21208	Breast-cancer cases and deaths from breast cancer by period and age at diagnosis in two Swedish counties
21209	Unadjusted breast-cancer incidence and mortality from incident tumours, with unadjusted and adjusted relative risks of breast-cancer death
21210	Adjusted relative risks of all-cause and all-cancer mortality in 1978–97 compared with 1958–77, for women diagnosed with breast cancer at 40–69 years
21211	Adjusted relative risks of breast cancer, all-cause and all-cancer mortality in 1978–97 compared with 1958–77, in women diagnosed with breast cancer at 40–49 years
21212	Adjusted and unadjusted Cox regression results for all-cause mortality by depression status
21213	Crude death rate by course of depression
21214	Adjusted and unadjusted Cox regression results for all-cause mortality by course of depression
21215	Mean  (SD)  left-ventricular dimensions and mass 8 weeks after myocardial infarction and 12 weeks after myocardial infarction  (4 weeks after cell transplantation)
21216	Estimated organ-specific radiation doses  (mGy)   11–13   by type of diagnostic X-ray
21217	Estimated cumulative risk of cancer to age 75 years and number of cancer cases per year from diagnostic X-rays in the UK
21218	Estimated number of radiation-induced cases of cancer per year in the UK by type of X-ray
21219	Estimated number of radiation-induced cases of cancer per year* in the UK by age at exposure
21220	Effect of varying assumptions on UK radiation-induced cumulative risk estimates
21221	Frequency of diagnostic X-rays per 1000 population, percentage of cumulative cancer risk to age 75 years attributable to diagnostic X-rays, and number of radiation-induced cases of cancer per year for 15 countries
21222	Estimated population, total deaths, deaths due to injuries and suicides, and percentage of deaths due to suicides, 1992–2001
21223	Numbers and rates of suicides by age and sex  *
21224	Descriptive statistics for the analysed population
21225	The 15 most common exposure combinations  (of 149)
21226	Final estimated overall logistic regression model predicting long-term sickness absence and hospital admission in 1997–99 by exposure to workforce changes 1991–96  (n=24 036)
21227	Logistic regression model predicting long-term sickness absence for men and women working during 1997–99 by exposure to workforce changes 1991–96
21228	Mean viewing hours and correlation between ages
21229	Regression of health outcomes at age 26 years on television viewing during childhood, adolescence, and early adulthood
21230	MCC vaccine effectiveness in immunised cohorts to end of March, 2004
21231	Follow-up for outcome after melarsoprol by treatment schedule
21232	Prevalence of schizophrenia in people aged 15 years or older in mainland China:1995-99
21233	Estimated rates, relative risk, and attributable risk proportion of suicide in people with schizophrenia aged⩾15 years in mainland China:1995-99
21234	Proportion of children with positive ELISPOT and TST results by diagnostic category
21235	Concordance of TST and ELISPOT results for all categories of children with both test results available
21236	Effect of age, HIV infection, and malnutrition on test sensitivity in children with confirmed or highly probable tuberculosis  (n=133)
21237	Summary information on selected papers
21238	Cox model for 5-year risk of ipsilateral ischaemic stroke on medical treatment in patients with recently symptomatic carotid stenosis derived from ECST
21239	Variation in health system coverage and capacity and functioning across settings with different NMRs  (based on 192 countries)
21240	Obstacles to and strategies for scaling up of neonatal care for family-community, outreach, and clinical services
21241	Predicted effect and incremental cost per year of various scenarios for increasing coverage of neonatal health care in Ethiopia, Madagascar, and Gujarat State, India
21242	Aneurysm-related and all-cause mortality  (intention-to-treat analysis)
21243	Causes of death by group
21244	Postoperative complications  *   for all patients receiving EVAR  (not intention to treat)
21245	Comparison of HRQL at different timepoints from randomisation by intention-to-treat groups
21246	Estimated costs  (UK£)  over 4 years of follow-up based on intention to treat
21247	Human resources for health by destination country
21248	Schematic illustration of some factors involved in producing migration outcomes in health labour market
21249	Person-years available for analyses and proportions with complete smoking data and complete smoking and socioeconomic data
21250	Person-time and deaths among 45–74-year-old individuals, by strata of census-cohort, sex, ethnicity, and smoking
21251	Standardised rates  (SR)  of all-cause mortality per 100 000 and SRR and SRD age-standardised and age-smoking-standardised
21252	Poisson regression rate ratios for Māori compared with non-Māori non-Pacific
21253	Clinical manifestations and outcomes
21254	Serum CRP and SAA in FMF patients, carriers, and controls
21255	Preoperative  (KPS 0) , discharge  (KPS 1) , and at 6 months follow-up  (KPS 2)  scores
21256	Patients' views of the advantages and disadvantages of a patient-held record  (PHR)
21257	Financial burden of AIDS response in low-income and middle-income countries, grouped by epidemic category
21258	Resource needs of low-income and middle-income countries in four scenarios, grouped by epidemic category, 2014–30
21259	Performance of national treatment programmes of selected countries, 2013  116
21260	Domestic spending by top ten countries with highest numbers of people living with HIV
21261	Welfare gains and benefit–cost ratios from modelled scenarios relative to Current Effort scenario, by epidemic category
21262	HIV spending in selected sub-Saharan African countries  200
21263	Prevention interventions for high-risk populations in high-incidence areas of Kenya
21264	Clinical features and gastric emptying results
21265	Oral surveys of institutionalised elderly
21266	MRI findings in all relatives
21267	Sleep variables in DQB1 * 0602 positive and negative volunteers
21268	Patients' recall of the risk of stroke without the operation and as a result of CEA
21269	Studies examining the relation between H pylori infection and NSAID use in patients with uncomplicated peptic-ulcer disease  (listed in order of year of publication)
21270	Contribution of each study to the Cochrane Q, the statistical test of heterogeneity in a fixed-effects model
21271	Analysis of studies with controls matched for age and sex by H pylori status
21272	Sensitivity analysis of controlled studies with matching for age, sex, or both, by H pylori status
21273	Analysis of effects of H pylori infection and NSAID use on the site of peptic ulcer
21274	Studies examining the relation between H pylori infection and NSAID use in patients with peptic-ulcer bleeding
21275	Predictors for carotid plaque and carotid intima-media thickening
21276	SNPs, primers, and molecular beacons
21277	Effect of predictors on recurrence  (Cox's proportional hazard model)
21278	Twin-pair correlation coefficients  (r)  of the activation markers
21279	Estimates of heritability  (h2)  and unique environment  (e2)  from best fitting models
21280	Characterisation of patients according to detection of a RET germline mutation and disease phenotype
21281	RET c135G/A genotypes and association with phenotype of Hirschsprung's disease and with RET germline mutations
21282	Primers and probes for allele-specific oligonucleotide hybridisation and ligation-detection reaction
21283	MBL genotype in patients with invasive pneumococcal disease and in controls
21284	Comparison of clinical data in patients with invasive pneumococcal disease with and without homozygous MBL variant genotypes
21285	Single nucleotide polymorphism  (SNP)  haplotype frequency estimates in German and Norwegian patients with Crohn's disease and controls
21286	Analysis of the genotype-phenotype relation of three NOD2 polymorphisms
21287	Single nucleotide polymorphism  (SNP)  haplotype frequency estimates in patients with Crohn's disease with and without ileal disease
21288	Single nucleotide polymorphism  (SNP)  haplotype frequency estimates in patients with Crohn's disease with and without right-colonic disease
21289	Prevalence of obesity and severe obesity at 39–42 months by risk factor
21290	Poisson regression analyses for predictors of tuberculosis
21291	Numbers of study participants and odds ratios for developing future cardiovascular events, according to quartiles of MIC-1
21292	Gene frequencies for MIC-1 polymorphism, overall and according to case or control status
21293	Bivariate and multivariate analysis of time to reinfection as a function of reinfection event and total number of reinfections
21294	Effect of age and work experience on susceptibility to reinfection with schistosomiasis in univariate and multivariate analyses
21295	Egg counts at time of enrolment for individuals in the groups with different total number of reinfections
21296	Household income and per-capita health expenditure  ($US)  in south Asian countries
21297	Prevalence of cardiovascular disease risk states in south Asian countries
21298	Relatives identified for cases and controls, and rates of suicide and psychiatric admission
21299	Family history distribution and risk of suicide
21300	Familial information in people with and without history of admission to hospital for psychiatric disorder and risk of suicide
21301	Number of individuals recruited, by area
21302	Median scores  (IQR)  on all measures for YAT and ad hoc areas
21303	Odds ratios  (95% CI)  of participation in society based on all variables from conceptual model
21304	Odds ratios  (95% CI)  of participation in society based on significant variable from conceptual model
21305	Estimated costs for YAT and ad hoc services
21306	Comparison of MRI and EUA findings
21307	Significant factors associated with recurrent primary sclerosing cholangitis according to univariate analysis
21308	Psychiatric morbidity, disability, and costs  (unadjusted)
21309	Mixed model for analyses of repeated CISR scores from 2 to 12 months
21310	Mixed model for analyses of repeated BDQ scores from 2 to 12 months
21311	Differences in incremental cost, effect, and cost-effectiveness
21312	MHC typing in patients with variant Creutzfeldt-Jakob disease and controls
21313	MHC typing in relation to age of onset and duration of disease in variant Creutzfeldt-Jakob disease
21314	Meta-analyses included in our study
21315	Type of immunodeficiency, according to donor origin and HLA matching
21316	Factors affecting outcome in SCID patients after HLA-identical or after related HLA-mismatched stem-cell transplantation
21317	Immunological reconstitution, according to SCID phenotype
21318	3-year survival in non-SCID patients, according to primary disease and donor–recipient compatibility
21319	Protective effectiveness of meningococcal C conjugate vaccine  (MCCV) , dependent on presence of risk factors
21320	Presence of HLA B27 in controls and haemophilia patients with and without chronic synovitis
21321	Mean  (SD)  plasma concentrations by visit and treatment
21322	Hazard ratio of atorvastatin treatment on primary, secondary, and tertiary endpoints
21323	Hazard ratio of atorvastatin treatment on primary endpoint by subgroup
21324	Clinical information for discordant cases
21325	Case-control study: association of + 874A →T with tuberculosis
21326	TDT: association of + 874A→T with tuberculosis
21327	Distribution of codon 129 genotype
21328	Numbers of women flagged on the NHS Central Registers numbers  (%)  who ever used HRT, and numbers of incident invasive and fatal breast cancers
21329	Cumulative and excess incidence of invasive breast cancer in 1000 women who had never used and ever used HRT, based on incidence rates typical of developed countries
21330	Variation in the hazard ratio of progression to AIDS over calendar time
21331	Variation in the hazard ratio of death over calendar time
21332	Incidence of invasive group B streptococcal disease in infants in the UK and Republic of Ireland
21333	Incidence of invasive group B streptococcal disease in infants in England by birthweight
21334	Determinants of carotid intima-media thickness of children with familial hypercholesterolaemia and unaffected siblings  (n=281)
21335	Crude odds ratios for HIV seropositive status by experience of intimate partner violence
21336	Crude odds ratios for HIV seropositive status by self- reported participation in HIV risk behaviours
21337	Odds ratios and 95% CI for self-reported participation in risk behaviours by reported experience of gender-based violence
21338	Association between risk behaviour, intimate partner violence, SRPS score, and HIV serostatus
21339	Cross-tabulation for colonisation with S pneumoniae and S aureus
21340	Odds ratios of colonisation with S aureus for co-colonisation with S pneumoniae and other independent risk factors  (n=3085)
21341	Relative risk of nosocomial S aureus bacteraemia by nasal carrier status
21342	Comparison of patients with nosocomial S aureus bacteraemia by nasal carrier status
21343	Cardiovascular risk factors, income, education, and other psychosocial variables in controls  (both working and non-working)  by general stress score
21344	Psychosocial risk factors in cases and controls
21345	Psychosocial risk factors in cases and controls by sex
21346	General stress by age, smoking, income, and education in cases and controls
21347	Odds ratios for combined effect of general stress and depression or locus of control on risk of acute myocardial infarction
21348	Prevalence of incapacity
21349	Individual capacity ratings  (interviewed sample)
21350	Associations of incapacity
21351	Outcomes 6 months after injury by treatment allocation
21352	Surgery details
21353	Outcomes at 6 months
21354	Summary of all outcomes for ESD services versus conventional care
21355	Crude and age-standardised prevalence of the individual components of the metabolic syndrome  *   and overweight  †
21356	Crude and age-standardised prevalence of one or more components of the metabolic syndrome  *
21357	Rate of clinical malaria from 1 month after dose three until end of follow-up
21358	Interview measures
21359	Number  (%)  of incidents of physical abuse, neglect, and total incidents  (physical abuse or neglect)  per family by group, over the 3-year follow-up, based on CPA records
21360	Number of incidents of physical abuse, neglect, and total incidents  (physical abuse or neglect)  per family by group, over the 3-year follow-up period, based on hospital records
21361	Secondary outcome measures for families
21362	Secondary outcome measures for index children from the revised behaviour problem checklist
21363	Association of prognostic factors with starting HAART
21364	Comparison of HAART versus no treatment or dual therapy for progression to AIDS or death
21365	Numbers of cases of bilateral PCHI ⩾40 dB hearing level at age 7–9 years in children born during periods with and without universal newborn screening, by risk status, source of referral, and age at referral
21366	Numbers of true and false positive newborn screening tests for PCHI ⩾40 dB hearing level
21367	Descriptive statistics of study subjects and correlations with telomere terminal restriction fragment  (TRF)  length before and after adjusting for chronological age
21368	Standardised incidence ratios for cancers of the breast, prostate, and all other sites in the first-degree relatives of bilateral breast cancer cases
21369	Comparative effect of 1 standard deviation increase in a specific measure of obesity in the overall population and separately in men and women
21370	Increases in odds ratio for myocardial infarction for 1 SD increase in body-mass index, waist circumference, or waist-to-hip ratio in different ethnic groups adjusted for age and sex
21371	Odds ratios and population-attributable risk of myocardial infarction for raised waist-to-hip ratio or body-mass index
21372	Randomised trials of breast screening in women younger than 50 years
21373	Mortality from all causes and from breast cancer in the intervention and control groups
21374	Mortality in attenders and non-attenders at first screen in intervention group
21375	Breast cancer mortality in intervention and control groups by time period
21376	Total number of school children enrolled, illnesses, and DALYs lost to illness, by year
21377	DALYs lost to dengue illness
21378	The burden of dengue in Thailand compared with other infectious diseases in the region in 2002
21379	Cost and duration of dengue and non-dengue illnesses
21380	Analyses of the cost of dengue illness
21381	Age at onset, course, and treatment for lifetime major depressive disorder
21382	Quality of life  *   of people with and without 12-month major depressive disorder  (MDD)   (n = 134)
21383	Severity of role impairment associated with 12-month major depressive disorder  (n=134)  assessed by the Sheehan disability scale
21384	Pattern and correlates of symptom severity of 12-month major depressive disorder
21385	Numbers of women with ER-poor disease, by age, in trials of polychemotherapy, tamoxifen, or both, that began before 2000
21386	Summary of the sites and samples
21387	Prevalence  (95% CI)  of 10/66 dementia by age group, sex, and country
21388	Prevalence  (95% CI)  of DSM-IV dementia by age group, sex, and country
21389	Prevalence  (95% CI)  of 10/66 dementia and DSM-IV dementia, by region and clinical severity, to compare prevalence from 10/66 studies with EURODEM DSM-IV prevalence and prevalence estimates from the ADI and  Lancet  consensus study
21390	Prevalence ratios  (95% CI)  from a Poisson regression for the independent effects of age, sex, education, and assets on dementia prevalence
21391	Distribution of WHODAS disability scores by dementia status and site, and the effects of dementia  (main effect of 10/66 dementia, modified by DSM-IV dementia)  on WHODAS score
21392	Independent correlates of community screening instrument for dementia informant report of intellectual and functional decline  (RELSCORE)
21393	Preinfluenza periods and influenza seasons
21394	Classification of WHO budget lines according to disease classification, 2006–07
21395	Sensitivity analyses
21396	Sensitivity analyses
21397	Responses for positive and negative experienced discrimination
21398	Responses for anticipated discrimination by category
21399	Regression models for total experienced discrimination
21400	Kaplan-Meier event rates for efficacy and safety endpoints in the TRITON-TIMI 38 trial
21401	Adjusted hazard ratios  (95% CI)  for the association between different types of proton-pump inhibitors and the risk of MI or the composite of CV death, MI, or stroke through long-term follow-up
21402	Effects of influenza A H1N1 by age-group and region, April–July 2009
21403	Incidence and relative incidence of HIV infection, by exposure to forms of violence and inequity
21404	Relative HIV incidence with exposure to both partner violence and relationship inequity
21405	Effects of behavioural variables on relative incidence of HIV
21406	Population attributable fractions
21407	Follow-up in ablation and control groups
21408	Endpoints in ablation and control groups
21409	Summary of previous prospective studies on catheter ablation of ventricular tachycardia in patients with structural heart disease
21410	Abnormalities in free light-chain ratios by presence of intact heavy-chain immunoglobulin
21411	Age-specific and sex-specific prevalence of light-chain MGUS and any MGUS
21412	Risk of progression to multiple myeloma and related disorders
21413	Association between light-chain MGUS and renal disease
21414	Primary and major secondary endpoints in the ivabradine group, according to groups defined by heart rate achieved at 28 days  (bpm)
21415	Estimated total number of DALYs per 1000 population for those aged between 10 and 24 years, and 25 years and older
21416	Main causes of DALYs for 10–24-year-olds and for 5-year age groups  14
21417	Association of published GWAS loci for myocardial infarction with angiographic CAD  (study A: angiographic CAD versus control)  and myocardial infarction in patients with angiographic CAD  (study B: myocardial infarction versus no myocardial infarction)
21418	Study A: Association of ADAMTS7 rs1994016 with angiographic CAD  (angiographic CAD versus control)
21419	Study B. Association of ABO SNPs with myocardial infarction in patients with angiographic CAD  (myocardial infarction versus no myocardial infarction)
21420	Association of  (A)  the ABO rs514659C allele and  (B)  ABO blood groups with CAD phenotypes in PennCath
21421	Estimates of dementia prevalence worldwide according to the Delphi consensus study in 2005
21422	Alzheimer's disease risk genes
21423	Treatments for Alzheimer's disease
21424	Meta-analyses or systematic reviews of risk factors for dementia and Alzheimer's disease
21425	Mean number of disability-adjusted life years lost per million population with and without vector control
21426	Sensitivity, specificity, and positive and negative predictive values for identification of individuals with impaired fasting glucose at different HbA1c thresholds
21427	Full output from interval-censored parametric survival analysis showing the effect of community-level mean lifetime partners and prevalence of partnership concurrency in men on a woman's hazard of acquiring HIV infection  (N=7284)
21428	Sensitivity analysis of the effect of size and shape of the kernel  (used to derive the male community-level sexual behaviour variables)  and an alternative community-level concurrency measure on a woman's hazard of HIV acquisition  (N=7284)
21429	Input parameter definitions, prior distributions, and posterior distributions
21430	HIV sentinel surveillance of women in antenatal-clinic sites in the six Avahan states
21431	Mean, median, and highest HIV prevalences per 1000 in sentinel surveillance antenatal-clinic sites in 2003
21432	Estimated fixed-effect coefficients from the mixed-effects logistic model  (sample size, n=626 232)
21433	Reduction in HIV prevalence in the six Avahan states and infections averted from 2003 to 2008
21434	Common operations or tasks that involve exposure to free crystalline silica
21435	Radiographical classification of silicosis
21436	Recommended measures for detection and treatment of LTBI and tuberculosis in patients with silicosis
21437	Suggested preventive measures
21438	Proportion of adults reporting walking to work, cycling to work, or using any type of active transportation  (walking or cycling)  by country
21439	Relevant risks and developmental period for illustrative preventive interventions by age group
21440	Prevention programmes with evidence of efficacy
21441	Cost–benefit of selected programmes
21442	Pathologies noted in eyes with pathological myopia
21443	Association summary statistics for the eight replicating signals
21444	Age-standardised prevalence of diabetes and hypertension in Iran
21445	Diabetes and hypertension diagnosis and treatment coverage in Iran
21446	Coefficients of regression to estimate the effect of diabetes and hypertension treatment on fasting plasma glucose and systolic blood pressure of treated individuals
21447	Coefficients of regression to estimate the effect of Behvarz-worker density  (per 1000 population aged 25 years or older)  on fasting plasma glucose and systolic blood pressure in Iran
21448	Prevalence of self-harm by wave and category and summarised over adolescence and young adult phases, by sex
21449	Longitudinal association between background factors and time-varying exposures measured in the previous wave with incident adolescent self-harm in 1672 cohort participants who responded to the self-harm component in at least two consecutive waves in the adolescent phase  (wave two in addition to waves three to six)
21450	Adolescent measures associated with incident young adult self-harm in cohort participants with no reports of self-harm in adolescence and at least one observation in both adolescent and young adult phases  (N=1507)  and restricted to participants with complete data for all seven waves of data  (N=880)
21451	Systematic reviews of correlates and determinants of physical activity in children and adolescents
21452	Systematic reviews of correlates and determinants of physical activity in adults
21453	Systematic reviews of environmental correlates of physical activity in adults
21454	Relationship between platelet reactivity and subsequent definite or probable stent thrombosis through 1 year follow-up
21455	Clinical, angiographic and laboratory test correlates of stent thrombosis occurring within 1 year  (unadjusted analyses)
21456	Propensity-adjusted multivariable risk of high platelet reactivity for subsequent 1-year adverse events
21457	Predictive accuracy of P2Y12 PRU higher than 208 for 1 year events in 8449 patients
21458	Relationship between adverse events and death though 1 year follow-up
21459	Independent predictors of all-cause mortality, including adverse events occurring during follow-up as time-adjusted covariates
21460	Surgery details
21461	Prespecified outcomes at 6 months
21462	Key enabling advances, 1993–2013
21463	Examples of interventions delivered across key delivery platforms
21464	Policy instruments to reduce risk of disease and injury, by risk factor cluster
21465	Health indicators in 4C countries and in other selected regions and countries, 2011
21466	Years of life expectancy lost relative to the 4C countries in 2008, by region
21467	Effect of enhanced investment scenario across low-income countries as a group
21468	Incremental costs of enhanced investment scenario across low-income countries as a group
21469	Effect of enhanced investment scenario across lower-middle-income countries as a group
21470	Incremental costs of enhanced investment scenario across lower-middle-income countries as a group
21471	Key population-based interventions for non-communicable disease risk factors
21472	Tobacco and alcohol taxes as percentage of GDP in selected countries
21473	Five potential pathways to universal health coverage
21474	Four essential functions of international collective action
21475	Priorities for research and product development identified by World Development Report 1993
21476	Examples of products that could help achievement of convergence
21477	Years of life lost per person in major mortality shocks of the 20th century
21478	Lifestyle interventions for patients with chronic kidney disease to prevent progression and cardiovascular disease
21479	Pharmacological interventions in patients with chronic kidney disease to prevent progression and cardiovascular disease
21480	Age-standardised regional and national estimates of the prevalence of overweight and obesity combined and obesity alone for girls, boys, men, and women for 2013, for 188 countries and 21 GBD regions
21481	Casemix and treatment for patients with AMI in Sweden and the UK
21482	30-day mortality in patients with acute myocardial infarction in Sweden and the UK, by clinically relevant subgroups
21483	Hospitals sampled in nine European countries with patient discharge data, numbers of surgical patients discharged, and numbers of patient deaths  (RN4CAST data)
21484	Nurse staffing and education in nine European countries
21485	Partly and fully adjusted odds ratios showing the effects of nurse staffing and nurse education on 30 day inpatient mortality
21486	Global mortality rate  (deaths per 1000 livebirths)  for early neonatal, late neonatal, postneonatal, child, and under-5 age groups for 1970, 1980, 1990, 2000, and 2013
21487	Global number of deaths  (thousands)  for early neonatal, late neonatal, postneonatal, child, and under-5 age groups for 1970, 1980, 1990, 2000, and 2013
21488	Early neonatal, late neonatal, postneonatal, childhood, and under–5 mortality rate and under–5 deaths in 2013, and annualised rates of change in mortality rates for 1990–2000, 2000–2013, and 1990–2013 for 188 countries and 21 Global Burden of Disease regions
21489	Regression models for the log of the under–5 mortality rate for different model specifications for 188 countries 1970–2013
21490	Shapley decomposition analysis of the change in the number of under-5 deaths  (thousands)  related to changes in income per person, maternal education, HIV child death rate, births, secular trends, and unexplained factors, 2013 versus 1990, worldwide and in the 21 GBD regions
21491	Population at risk  (millions)  by malaria endemicity class in 2000 and 2010 in malaria-endemic countries in Africa
21492	Outcomes by treatment group
21493	Procedural and discharge data
21494	Clinical outcomes
21495	Procedure-related complications
21496	Detection of AKI in adult patients admitted to hospital in China by region
21497	Recognition of AKI by physicians in charge during hospital stay
21498	Multivariate logistic regression analysis for factors associated with all-cause in-hospital mortality in AKI
21499	The Edmonton obesity staging system and stratified management scheme  34,47
21500	Pooled average weight loss recorded from interventional trials of dietary programmes lasting 12 months or longer  38–51
21501	Comparison of the energy deficit required for weight loss with the energy deficit to maintain weight after weight loss, by initial body-mass index
21502	Efficiency of airport-based interventions to screen international travellers departing Guinea, Liberia, and Sierra Leone by frontier
21503	Modelled estimates of Ebola virus exportation from Guinea, Liberia, and Sierra Leone via commercial air travel
21504	Top 20 final destination countries of individuals initiating air travel from within Guinea, Liberia, and Sierra Leone and corresponding indicators of health system capacity
21505	Clinical outcomes
21506	Subsequent myocardial infarction or cardiac death in patients with troponin concentrations below the 99th centile in the derivation cohort
21507	Phenotype distribution of primary cohort
21508	Associations between genotype and age at diagnosis achieving genome-wide significance
21509	Associations between genotype and disease location, behaviour, extent, surgery, and colectomy achieving genome-wide significance
21510	Predictions of public health impact and cost-effectiveness of RTS,S for the 6–9 month three-dose and four-dose immunisation schedules at 15 years of follow-up in regions with a parasite prevalence in 2–10 year olds of 10–65%
21511	Procedural and angiographic results  (core laboratory assessments) , pooled across the four trials
21512	Meta-analysis summary for all ischaemic endpoints
21513	Deaths, YLLs, YLDs, and DALYs attributable to viral hepatitis, by year
21514	Deaths, YLLs, YLDs, and DALYs attributable to viral hepatitis in 2013, by region
21515	Meta-analyses of the associations between sitting time and all-cause mortality  (N=1 005 791; 84 609 deaths)  stratified by quartiles of physical activity  *
21516	Meta-analyses of the associations between TV-viewing time, and all-cause mortality  (N=465 450; 43 740 deaths)  stratified by quartiles of physical activity  *
21517	Death and recurrent myocardial infarction  (including repeated events)
21518	Total death and cardiac death
21519	Death and readmission to hospital for ischaemic heart disease  (including repeated events)
21520	Multivariable analysis for out-of-hospital Thrombosis in Myocardial Infarction major or minor bleeding, study stratified with backward selection at an α level of 0·1
21521	Discriminative ability of the PRECISE-DAPT score in the derivation cohort and discriminative–reclassification ability in comparison with the PARIS score in the validation cohorts for out-of-hospital bleeding occurring while on-treatment with dual antiplatelet therapy  (DAPT)
21522	Mortality, disability in ADL, and cognitive and physical function for cohorts born in 1909–18  (aged 80–89 years in 1998)  and born in 1919–28  (aged 80–89 years in 2008)
21523	Mortality, disability in ADL, and cognitive and physical functions for cohorts born in 1899–1908  (aged 90–99 years in 1998)  and born in 1909–18  (aged 90–99 years in 2008)
21524	Mortality, disability in ADL, and cognitive and physical function between cohorts born in 1893–98  (aged 100–105 years in 1998)  and born in 1903–08  (aged 100–105 years in 2008)
21525	Annual rates of changes in mortality, ADL disability, and physical and cognitive function between same-age cohorts across the two survey timepoints
21526	Age-standardised prevalence of daily smoking in 2015 and annualised rate of change in age-standardised prevalence from 1990–2015, 1990–2005, and 2005–2015 for men and women
21527	Size of the smoking population, prevalence, and 1990–2015 percent change in prevalence, by sex, for the ten countries with the largest smoking populations and worldwide
21528	Total health spending and spending by source, 2015
21529	Health spending on HIV/AIDS, 2015
21530	Effect of mecamylamine  (MEC)  in Tourette's syndrome in seven patients with follow-up information
21531	Observed number of deaths and standardised mortality ratios  (SMR)
21532	Risk of death for individuals with a serum thyrotropin concentration <0·5mU/L compared with those with a concentration of ≥ 0 5mU/L
21533	Laboratory measurements before, 48 h after, and 6 weeks after treatment
21534	Relative risks of oral, lung, and pancreatic cancer in relation to tobacco smoking status at entry
21535	Relative risks of oral, lung, and pancreatic cancer in relation to snus use in 125 576 never-smokers
21536	Rate of smoking in the past week and intracluster correlation coefficients at every follow-up point according to experimental group
21537	Odds ratios of smoking in the past week at every follow-up point according to experimental group
21538	Concordance and discordance between self-reported smoking behaviour and salivary cotinine findings at 1-year and 2-year follow-up
21539	Patterns of tobacco use, by sex, in the UK, USA, and 14 GATS countries
21540	Current smoking prevalence  (%) , by sex and age, in the UK, USA, and 14 GATS countries
21541	Prevalence of ever smoking and mean age of initiation of daily smoking among ever daily smokers, by sex and age in the UK, USA, and 14 GATS countries, and similar estimates for ever regular smokers in the UK and USA
21542	Percentage of ever daily smokers  (and ever regular smokers)   *   who are former smokers, by sex and age, in the UK, USA, and 14 GATS countries
21543	Indication for oral anticoagulation
21544	Bleeding events
21545	Bleeding events stratified by risk factors
21546	Multivariate risk ratios
21547	Other diseases and risk factors at start of oral anticoagulation in 78 of 141 patients with bleeding complications
21548	Disability classes based on person-trade-off method
21549	Prevalence per 1000 for seven classes of disability for age, sex, and region
21550	DFLE at birth by sex and region in seven classes of disability
21551	Life expectancy at birth with and without disability and proportion of life affected by disability
21552	Life expectancy at age 60 years with and without disability and proportion of life affected by disability
21553	Results of first 3 weeks' treatment for stabilization patients in computer-dose and traditional-dose group
21554	Results from study centres for computer-dose and traditional-dose groups
21555	Results from all ranges, all sites
21556	Proportion of INRs lower and higher than target ranges
21557	Mean proportion of time in target range
21558	Cycling test
21559	Peak systolic velocity measurements with Doppler examination
21560	Results of preoperative imaging
21561	Exposures to occupational driving and possible confounding
21562	Differences in lumbar degenerative findings in upper and lower lumbar regions between drivers and their co-twins
21563	Recent history of back problems in drivers and their twin siblings
21564	Reasons for diagnostic angiography
21565	Medical and behavioural risk factors and associated disorders that might predict rupture of an unruptured intracranial aneurysm
21566	5-year cumulative rupture rates according to size and location of unruptured aneurysm
21567	Outcome 30 days and 1 year after surgery
21568	Sequences of synthetic peptides derived from HR1 and HR2 regions of SARS-CoV spike protein
21569	Comparison of pairwise aminoacid identity and similarity of spike glycoproteins of SARS-CoV and other coronaviruses
21570	Molecular masses of the isolated peptides NP-1 and CP-1 and the NP-1/CP-1 complex measured by sedimentation equilibrium
21571	Genotype and predicted phenotypes, by treatment
21572	Outcomes in relation to the CYP2C19 genotype
21573	Outcomes in relation to the ABCB1 genotype
21574	Angiographic and intravascular ultrasound analyses before and after the procedure, and at 3 year follow-up
21575	Exercise test  (intention-to-treat population, excluding tests subsequent to any revascularisation)
21576	Secondary clinical outcomes at 3 year follow-up
21577	Unadjusted odds ratios between cases and controls by drug regimen at index date
21578	Use of calcium antagonists and history of cardiovascular disease
21579	Adjusted odds ratios by logistic regression
21580	Relative risks of first myocardial infarction associated with sICAM-1 concentrations of more than 260 ng/mL after control for other lipid and non-lipid risk factors
21581	Availability of data from randomised trials that began before 1990 of adjuvant tamoxifen versus no adjuvant tamoxifen
21582	Effects of treatment allocation on selected outcomes
21583	Analysis of selected Polish cigarette brands, 1994
21584	Glycoprotein IIb-IIIa blockers
21585	15 most frequent self-reported symptoms by deployment
21586	15 most frequently self-reported medical disorders, plus chronic fatigue syndrome and multiple chemical sensitivity, by deployment
21587	SF36 and other health outcomes in three groups
21588	Odds ratios for health outcomes in three groups
21589	15 most frequently self-reported exposures  *   by deployment
21590	Association of 15 most frequent exposures and exposures of interest with principal health outcomes
21591	Frequency of reported vaccines by theatre of war and vaccine records
21592	Associations between reported vaccinations and CDC syndrome, stratified by theatre of war and whether respondent had vaccination record
21593	Associations between multiple vaccination and CDC syndrome
21594	Associations between multiple vaccination and CDC syndrome, controlled for experience of side-effects and biological warfare vaccine, Gulf only
21595	Self reported symptoms, association by deployment
21596	Self reported medical conditions: association by deployment
21597	Self reported exposures, by deployment
21598	Association  (OR,  (95% CI) )  between exposures and and principal health outcomes.
21599	Event rates for three periods of time by troponin-I status
21600	Distribution of cases and controls according to predictors included in the study
21601	Predictors for suicide in the general population adjusted for age and sex
21602	Attributable risk
21603	Summary of recurrence
21604	Recurrences and deaths in patients by DPI status and Dukes' stage
21605	Age-specific and sex-specific mortality rates
21606	Classification of low, standard, and high doses of β-blocker therapy
21607	Admission for heart failure in relation to β-blocker dose in 8232 patients with no history of heart failure
21608	Mortality in relation to β-blocker dose in 13 623 survivors of myocardial infarction
21609	Sensitivity analyses of survival in relation to dispensing of β-blocker therapy
21610	Number of adenocarcinomas/adenosquamous carcinomas in the analysis, by year of diagnosis
21611	Estimated trends in adenocarcinoma of the cervix in five cancer registries in four age-at-diagnosis groups
21612	Number of months gained with chemotherapy  (chemotherapy minus control)  within first 10 years' follow-up for each Q-TWiST clinical health state subdivided by age, nodal status, and ER status  (patients' age <50 years)
21613	Number of months gained with chemotherapy  (chemotherapy minus control)  within first 10 years' follow-up for each
21614	Number of months gained with chemotherapy  (chemotherapy minus control)  within median follow-up of each trial for each Q-TWiST clinical health state
21615	Any indication of a mental health problem or social maladjustment by year of birth
21616	Logistic-regression models for mental health disorders and social maladjustment
21617	Crude rates of specific indicators of mental health disorders and social maladjustment
21618	Logistic regression of risk factors in the adoptee study group
21619	Detection of Y-chromosome-positive cells in cheek scrapings from female transplant-recipients
21620	Summary of eligible DNA microarray studies
21621	Potential predictors of significant association between molecular subtypes and clinical outcomes or correlates
21622	Univariate and multivariate analyses for distant-metastasis-free survival in the testing set of 171 patients
21623	76 genes from the prognostic signature
21624	Pathway analysis of the 76 genes from the prognostic signature
21625	Comparison of the 76-gene signature and the current conventional consensus on treatment of breast cancer
21626	Parental postnatal depressive symptoms and emotional and behavioural problems in children aged 42 months
21627	Paternal depression and subsequent emotional and behavioural problems in children  (controlling for later paternal depression at 21 months)
21628	Differential effects of parental depression on boys and girls
21629	Actual management after randomisation
21630	Death and severe disability
21631	Length of stay
21632	Follow-up assessment at 6 months
21633	Cost-effectiveness of allocation to extracorporeal membrane oxygenation versus conventional management
21634	Cost-utility analysis results for CESAR trial  (bootstrap estimates)
21635	Mortality by cause and incidence of second cancers, for ER-positive disease only
21636	Patient populations in randomised trials of MRI for selection of local therapy
21637	Outcomes of randomised trials of MRI for selection of local therapy
21638	MRI for contralateral cancer detection
21639	Proportion of the male sample  (n=12 359)  with a lifetime record of any offence and a lifetime record of a violent offence by age group at the time of data linkage
21640	Effect of combat role and traumatic experiences during deployment on risk of violent offending in 8280 male military personnel on return from deployment
21641	Post-deployment mental health and behaviour problems and violent offending
21642	Examples of inadequate reporting in studies other than randomised controlled trials and systematic reviews
21643	Main features of the four randomised controlled trials
21644	Cases of invasive cervical carcinoma, number of person-years, and median duration of follow-up
21645	Study-adjusted pooled relative detection rate of invasive cervical carcinoma
21646	Study-adjusted pooled relative detection rate of invasive cervical carcinoma, by morphology, stage, and age at enrolment
21647	Biopsy procedures undertaken in the four randomised trials, individual and pooled effects
21648	The global tobacco industry  (2013 data)
21649	Studies included in analysis
21650	Age distribution of women in each study group
21651	Distribution of grade of cervical intraepithelial neoplasia at initial diagnosis in each study group
21652	Number of woman-years of follow-up and invasive cancers, cumulative rate of invasive cervical cancer at end of follow-up, and rate of invasive cancer during follow-up by treatment method and centre
21653	Pretreatment data of the three patients treated with LDDM
21654	Urodynamic results
21655	Correlations and partial correlations between birthweight and leg length, trunk length  (or sitting height) , and overall height in four longitudinal studies
21656	Observed and expected numbers of invasive breast cancer and corresponding standardised primary incidence rates, after a primary diagnosis of carcinoma in situ
21657	Distributions of genotypes and alleles at VNTR polymorphism in serotonin transporter gene in puerperal psychosis probands and comparison controls
21658	Mean  (SD)  total problem score and scores on internalising and externalising broad-band categories in extremely low-birthweight  (ELBW)  group and reference group  (norm or control)  in four cohorts by sex
21659	Frequency of selected cancers in longshoremen by exposure level and year of hire
21660	Mean breastfeeding-associated differences between first and second babies
21661	Mean milk output at 1 week by quartiles for first and second babies
21662	Entry criteria and distribution by treatment group
21663	Thromboembolic, cerebrovascular, and cardiac events according to treatment
21664	Side-effects reported at any time and of any severity, according to allocated treatment
21665	Gynaecological procedures and gynaecological and vasomotor symptoms in premenopausal and postmenopausal women  (defined at randomisation)  according to allocated treatment
21666	Detailed breakdown of deaths
21667	Relative risk of acquiring a cytological abnormality after exposure to HPV-18 and HPV-16, after controlling for exposure to other HPV types, according to severity of cytological abnormality
21668	Odds ratios for the associations of polymorphisms in NAT and GST genes and bladder-cancer risk
21669	Examples of some polymorphisms or haplotypes that have shown consistent association with complex disease
21670	Criteria for selection of candidate genes
21671	Approximate sample sizes necessary to detect significant association  (power=90%, two-sided α=0·001)  by effect size and allele frequency for predisposing allele
21672	Effect of differing statistical significance levels on sample size
21673	Number of women who completed visits in extended follow-up phase, according to timing of visit relative to their enrolment in initial efficacy study
21674	Numbers of women, according to type of analysis
21675	Vaccine efficacy for incident HPV-16/18 infections, in cervical samples
21676	Vaccine efficacy for persistent HPV-16/18 infections, in cervical samples
21677	Overview of combined initial and extended follow-up vaccine efficacy against cytological and histological endpoints
21678	Vaccine efficacy against incident infection with HPV 45, HPV 31, HPV 52, HPV 33, and HPV 58 in cervical samples from intention-to-treat analyses
21679	Reported adverse events
21680	Associations with use of combined oral contraceptives in control women by subgroup
21681	Effect of stratification by potential confounding factors on the relative risk of invasive cervical cancer per year of use of combined oral contraceptives in current users  (restricted to 4716 cases and 9157 controls with data for all variables)
21682	Expected genetic and environmental correlations in disease liability
21683	Recurrence risks for schizophrenia and bipolar disorders
21684	Estimates of genetic and environmental effects for liability to schizophrenia, bipolar disorder, and their comorbidity
21685	Genome-wide association studies of bipolar disorder in European-origin samples
21686	Genome-wide significant association in European-origin samples for bipolar disorder
21687	Significance of variables for prediction of hepatocellular carcinoma from Cox regression analysis
21688	Relative risks of progression to hepatocellular carcinoma
21689	Relative risks of progression to hepatocellular carcinoma among patients for HCV
21690	Efficacy of tamoxifen within subgroups defined by covariates in multivariate analysis
21691	Meta-analysis of trials comparing tamoxifen alone versus no active treatment in HCC
21692	CSF hypocretin-1 levels and clinical features of narcoleptic and control subjects
21693	AIDS-defining opportunistic illnesses and causes of death according to HCV serostatus
21694	Age distribution of cytotoxic activity by follow-up status
21695	Relative risk of cancer incidence for cytotoxic activity levels
21696	Summary of skin tests, serological assays, and HPV-DNA analysis in three groups of women with CIN
21697	Data from ten patients with positive recall reactions to HPV-16 E7  (cytology/histology in regressors before regression occurred)  and from seven cancer patients with negative skin test
21698	Initial, postprocedure, and follow-up angiographic results
21699	Major adverse cardiac events, acute and late
21700	Causes of death
21701	Reasons for treatment discontinuation among patients who received embolisation  *
21702	Cox's proportional hazards analyses for probability of death
21703	Primers used in TP53 sequence analysis
21704	IP53 mutations in disseminated cancer cells
21705	Incidence per 100 PYFU of AIDS, all deaths, and HIV 1 related deaths according to treatment era and latest CD4 count
21706	Relative hazard  (RH)  of AIDS or death according to treatment era
21707	Progression to AIDS or death and death from 6 months after starting HAART
21708	Percentage of patients positive for binding to peptides by ELISA
21709	Intrafamilial correlation coefficients for TRF length
21710	Expression of cell surface markers on undifferentiated hES cells and their haemopoietic progeny
21711	Primary outcomes  *
21712	Secondary outcomes  *
21713	Serological response and survival after lethal H5N1 virus challenge in mice immunised with HAd-H5HA vaccine
21714	Treatment response at 6 months after initiating therapy by calendar year of starting HAART, ART-CC, 2004
21715	Odds ratios  (95% CI)  for reaching HIV-1 RNA concentrations ≤ 500 copies per mL at 6 months after starting HAART, by calendar year of starting HAART, ART-CC, 2004
21716	Crude and adjusted hazard ratios for AIDS and death by year of starting HAART, ART-CC, 2004
21717	Crude and adjusted hazard ratios for tuberculosis and AIDS defining conditions other than tuberculosis, ART-CC, 2004
21718	Formulae for calculation of the rate of AIDS, AIDS/death, and death for any CD4–cell count according to WHO clinical stage
21719	Rate and 6-month risk of death according to CD4-cell count and WHO clinical stage
21720	Rate and 6-month risk of AIDS and AIDS or death according to current CD4-cell count and WHO stage
21721	Health indicators for overall  (20 years or older)  population by period of follow-up
21722	Crude and standardised rates of mortality by period of initiation and period of follow-up
21723	Health indicators stratified by sex and injecting drug use
21724	Lung cancer mortality by study group
21725	Observed death rates and standardised mortality ratios based on 77 936 person-years of follow-up from 38 997 patients
21726	Regions of the genome showing the strongest association signals with the continuous trait
21727	Relative risk of hip fracture for one SD reduction in ultrasonographic and densitometric values
21728	Multivariate models of association between ultrasonographic and densitometric values and risk of hip fracture
21729	Number and incidence of hip fracture according to calcaneal broadband ultrasound attenuation  (BUA)  and femoral-neck BMD
21730	History and allergy tests in five children with atopic dermatitis due to cow dander
21731	Single, low-dose PS after scrapie infection
21732	Complications and persistent or recurrent dysphagia, after brachytherapy and stent placement
21733	Medical costs of brachytherapy and stent placement
21734	Time of onset of clinical features of meningococcal disease before hospital admission
21735	Age-specific frequency of clinical features of meningococcal disease before hospital admission
21736	Overall frequency and time of onset of clinical features of meningococcal disease in children before hospital admission
21737	Cumulative proportion of children developing clinical features during the course of meningococcal disease
21738	Frequency of type of cancer by Indigenous status, and distribution of cancers treated in public hospitals in Queensland
21739	Frequency of use of cancer treatments in Indigenous and non-Indigenous patients
21740	Hazard ratios of selected variables for overall survival
21741	Problems and referrals
21742	Timely completion of referrals according to outreach availability  *
21743	Adjusted main effects, other than outreach, in the final survival analysis and logistic regression models  *
21744	Hazard ratio  (95% CI)  of altered fractionated radiotherapy versus conventional radiotherapy on overall population and by type of radiotherapy for locoregional, local, regional, and metastatic control  (n=7073)
21745	Events at long-term follow-up
21746	Type and timing of first active treatment for the patients who relapsed in the wait-and-see group
21747	Comparison between the SWOG S8794 and EORTC 22911 trials
21748	Withdrawal from the ORBIT study after randomisation
21749	Change in IBDQ-B score
21750	Change in score of the gastrointestinal secondary endpoints
21751	Changes in quality-of-life secondary endpoints
21752	Frequently used chemotherapeutic regimens in non-small-cell lung cancer
21753	Approved targeted drugs for non-small-cell lung cancer
21754	New diagnoses and deaths from cancer in 2008: number and proportion by sex of patients and economic development  2,82
21755	Grade 3 and higher toxic effects
21756	Recurrences
21757	Severity of main symptoms of interest
21758	Response to treatment
21759	Cause of death and number of deaths by prognostic category, tumour type, and response to treatment
21760	Chemotherapy delivery
21761	Worst toxicity experienced
21762	Child contact, nappy changing, and risk of giardiasis
21763	Frequency of intercourse and relative risk of HIV transmission
21764	Probabilities of HIV-1 transmission per coital act  *
21765	Rate of absence or presence of nasal bone in trisomy 21 and chromosomally normal fetuses at 11–14 weeks
21766	Estimated sensitivity and false-positive rate for risk cutoffs in screening for trisomy 21 by maternal age, nuchal translucency thickness, and presence or absence of the nasal bone by comparison with the results obtained in a multicentre study of screening by maternal age and fetal nuchal translucency thickness
21767	Cumulative incidence of reported STIs  *
21768	Prevalence of undiagnosed C trachomatis infection among male participants
21769	Prevalence of undiagnosed C trachomatis infection among female participants
21770	Coverage and follow-up
21771	HIV-1 prevalence and incidence, and incidence rate ratios
21772	HSV-2 and syphilis incidence and incidence rate ratios, and gonorrhoea and chlamydia prevalence and prevalence ratios
21773	Behavioural change outcomes at rounds 1, 2, and 3
21774	Prevalence and prevalence ratios for behavioural indices
21775	Coverage by country of contributing registries and constitution of datasets for various analyses
21776	Neoadjuvant pharmacotherapy to reduce the effects of chemotherapy on the ovaries
21777	Summary of the deployment by main administrative divisions  (townships)  from May, 2014, to April, 2017
21778	Changes in malaria yearly cumulative incidence by main administrative divisions  (townships)  from May, 2014, to April, 2017
21779	Effect of the interventions on incidence of clinical episodes of falciparum and vivax malaria
21780	Detection of molecular markers of antimalarial resistance in rapid diagnostic tests or dried-blood spots
21781	Degree of desensitisation for maximum  (max)  and 6 h bronchodilator responses after treatment with formoterol for β2 adrenoceptor homozygous polymorphisms at codon 16 and codon 27
21782	Geometric mean  (GM)  sensitivity with 95% CI to inhaled spasmogens before  (day 0) , and after  (day 7) , regular inhalation of salbutamol
21783	Epidemiology of death
21784	Use of medical interventions
21785	Proportions of cases  (asthma deaths)  and controls prescribed fenoterol in studies in New Zealand, Saskatchewan, and Japan
21786	Haplotype distribution
21787	Difference in FEV1 by maternal cigarette smoking compared with FEV1 of offspring whose mothers never smoked
21788	Reported adverse events  (in order of frequency)
21789	Summary of changes in PEF for days 1–14
21790	ECRHS study population
21791	Odds ratios for asthma in occupations with excess asthma risk >30%
21792	Asthma risk in cleaners
21793	Risk of asthma and occupational exposure to specific agents assessed by job-exposure matrix or self-reported by questionnaire
21794	Attributable risk of asthma and occupational exposures
21795	Patient details with mean  (95% CI)  change in measures after treatment with budesonide in those stratified according to sputum eosinophil  (eos)  count
21796	Prevalence of CCR5Δ32 and asthma in Scottish children  (n[%])
21797	Responses of hospital physicians and GPs to the euthanasia attitude questionnaire
21798	Stepwise introduction of interventions and coverage  *
21799	Home-based case management of suspected neonatal sepsis and outcome  (1995–98)
21800	Effect of interventions on mortality rates
21801	Change in case fatality by birthweight and maturity
21802	Change in cause-specific neonatal mortality rates in the intervention area from 1995–96 to 1997–98
21803	Exacerbations in the two randomised groups
21804	Peak flow, symptoms, rescue inhaler use, and time off work recorded by patients in daily diary cards
21805	Estimated adjusted odds ratios for new asthma attacks obtained from dynamic logistic-regression model—risk changes after severe life events with and without chronic stress
21806	Observed and estimated frequency of ELDs in medical practice in Flanders in 1998
21807	Estimated rate of ELDs in medical practice in Netherlands, Australia, and Flanders
21808	Relationship of sensitisation-specific IgG antibody, and exposure
21809	Univariate logistic regression analysis of risk factors for asthma
21810	Multivariate logistic regression analysis of risk factors for asthma
21811	Frequency and risk  (adjusted  *   odds ratio, 95% CI)  of asthma, hay fever, and atopic sensitisation in relation to exposure to stables and farm milk in the 1st year of life
21812	Frequency and risk  (adjusted  *   odds ratio, 95% CI)  of asthma, hay fever, and atopic sensitisation in relation to farming activity of pregnant mothers in farmers' children exposed to stables and farm milk in the 1st year of life
21813	Frequency and risk  (adjusted  *   odds ratio 95% CI)  of asthma, hay fever and atopic sensitisation in relation to amount and duration of exposure to stables
21814	Evaluable patients reporting efficacy by treatment group
21815	Effect of treatment  (adjusted means of severity scores)  on migraine-associated symptoms at 2 h after dosing and patient overall impression
21816	Patients reporting common adverse events  (frequency >10% over all treatment groups or significant)  by treatment
21817	Plasma concentration and resulting pain intensity at 2h
21818	Definitions of index complications associated with stroke during the first 3 months
21819	A comparison of the processes of acute assessment and investigation between patients randomised to the stroke unit and general medical wards with specialist support
21820	Types of treatment received in the first 7 days by patients randomised to the stroke unit or general wards with specialist support
21821	Processes of multidisciplinary coordination and communication in the first 4 weeks between the stroke unit or general wards with specialist support
21822	Proportion of patients suffering stroke-related complications in the first 3 months after stroke between the stroke unit or general wards with specialist support
21823	Multivariate analysis of preventive measures, and their effect on Rankin score 4–6  (poor outcome)
21824	IL12B promoter genotype and asthma severity
21825	Effect of IL12B promoter heterozygosity on asthma severity
21826	IL12B genotype and asthma severity by atopic status
21827	Patients and findings
21828	Plasma S-adenowlymethionine concentrations after treatment for pneumocystis or bacterial pneumonia
21829	Median NO2 exposures before and after infection by exposure tertile
21830	Change in white matter lesion volume in each group
21831	End-of-life practices in the Netherlands in 1990, 1995, and 2001
21832	Interview study findings on euthanasia, physician-assisted suicide, and ending of life without a patient's explicit request in 1990, 1995, and 2001
21833	Interview study findings on physicians' attitudes towards end-of-life decision making in 1990, 1995, and 2001
21834	Causes of death
21835	Multivariate and univariate analyses of overall  (A)  and cause-specific survival  (B)
21836	Interleukin 9 mRNA and protein production on day 1 and day X
21837	Change in outcome variables at 16 weeks within each genotype and between genotypes
21838	Genotype frequencies and prevalence of minor alleles for ADRB2 single nucleotide polymorphisms in relation to incidence of asthma, wheeze, or both
21839	Genotype frequencies and prevalence of minor alleles for ADRB2 single nucleotide polymorphisms in relation to prognosis of childhood asthma, wheeze, or both
21840	Combined Arg16Gly and Gln27Glu genotypes in relation to prognosis of childhood asthma, wheeze, or both
21841	Genotype frequencies and prevalence of minor alleles for ADRB2 single nucleotide polymorphisms in relation to frequency of asthma, wheeze, or both in childhood and adulthood
21842	Regression analyses  *   for age-adjusted mortality rates  †   of asbestos-related diseases versus historical asbestos consumption  ‡   weighted by the size of sex-specific national populations
21843	Cytological and HPV DNA test results at subsequent round
21844	Number of CIN3+ and CIN2+ detected
21845	Number of CIN3+ and CIN2+ detected, stratified for cytological and HPV DNA test results
21846	Referral rates and biopsy, CIN3+, and CIN2+ rates for women referred to colposcopy
21847	Association between paracetamol use for fever in the first year of life and symptoms of asthma, rhinoconjunctivitis, and eczema at 6–7 years of age
21848	Association between paracetamol use for fever in the first year of life and symptoms of asthma, rhinoconjunctivitis, and eczema at 6–7 years of age worldwide
21849	Association between paracetamol use and severe asthma symptoms in children aged 6–7 years
21850	Association between paracetamol use in the past 12 months and symptoms of asthma, rhinoconjunctivitis, and eczema in children aged 6–7 years  *
21851	Association between paracetamol use in the past 12 months and symptoms of asthma, rhinoconjunctivitis, and eczema in children aged 6–7 years worldwide  *
21852	Summary of hypothesis testing with closed testing procedure
21853	Summary of efficacy for primary and secondary endpoints
21854	Summary of efficacy for selected exploratory endpoints
21855	Adverse events reported by 2% or more of participants in any study group
21856	Alcohol, illicit drug use and measures of anxiety and stress in house officers
21857	Jhum-jhum symptom profile
21858	Clinical and laboratory features of patients with sexual dysfunction
21859	ELISA analysis of mean  (ng/mL; SE)  TGFβ1 and TGFβ2 concentrations in IVIG preparations
21860	Course of the mean  (ng/mL; SE)  TGFb plasma concentrations in IVIG-treated patients as measured by ELISA
21861	Frequency of axillary lymph-node metastasis according to tumour size in BRCA1-associated breast cancer cases and controls
21862	Chills, bacteraemia, endotoxaemia, and cytokines in febrile patients
21863	Mitochondrial DNA genotype, ponderal index at birth in ALSPAC children, and IGT/type 2 diabetes in Hertfordshire men, in changers and non-changers
21864	Site, cumulative incidence, rate, and rate ratios of first events
21865	Relation between selected chcracteristics of patients and tumours and rates and relative risks of ipsilateral-breast tumours
21866	Adverse events by treatment group
21867	Relation of micrometastases to prognostic factors
21868	Estimates of relapse-free and overall survival
21869	Relapse-free survival  (distant relapse or breast-cancer death)  and overall survival  (all-cause mortality)
21870	Relapse-free survival  (distant relapse or breast-cancer death)
21871	Age-specific incidence of culture-confirmed typhoid detected by active surveillance over a 1-year period in urban Dehli
21872	Severity of culture-confirmed typhoid cases detected in active surveillance during a 1-year period in urban Delhi
21873	Correlations between absolute errors of NPH insulin suspension, blood-glucose tests, and HbA1c
21874	Primary treatment methods by tumour size
21875	Deaths from 1–9 mm and 10–14 mm tumours by mammographic findings, lymph-node status, and histological grade
21876	Relative hazards of death from breast cancer by mammographic findings and tumour size
21877	Summary registration information for 44 EURODIAB centres
21878	Summary of Poisson-regression analyses showing the incidence trend in each country during 1989–94
21879	Summary of Poisson-regression analyses of incidence trends for data from 40 centres grouped into 29 countries
21880	Actuarial disease-free survival related to the most important prognostic factors in stage I ovarian carcinoma by univariate analysis
21881	Significant variables for actuarial disease-free survival in final multivariate model
21882	TNF-α genotype and allele distribution between groups
21883	Interaction between TNF-α and apolipoprotein E ∈ 4 in Alzheimer's disease
21884	Interaction between TNF-α and apolipoprotein E ∈4 in vascular dementia
21885	Frequency of T16189C variant in patients and controls
21886	Comparison of clinical and biological variables before and after 12 weeks of treatment
21887	Response to chemotherapy and TP53 status
21888	Relative risk of type 2 diabetes by volume of coffee consumption
21889	Viruses, source, passage history, and genetic homology with H5N1/97 viruses
21890	cDNA array profile of cytokine gene expression of primary human macrophages 3 h after infection with H5N1/97 or other human and avian influenza viruses
21891	Transmission of ICAM-1 R241 in 3695 families affected by type 1 diabetes
21892	Relative hazards  (RH)  for risk of new breast-cancer event in HRT group versus non-HRT group
21893	Clinicopathological features of patients
21894	HLA class II genotypes in Golden Years and BOX cohorts, subdivided according to age at onset
21895	Relation between completeness of excision for primary basal-cell carcinomas and clinical variables
21896	Comparison of defect after multiple MMS stages or incomplete SE
21897	Mean TNFα and interleukin-1β response  (ng/L)  with five TLR ligands in wild-type cells
21898	Data on microsatellite and single-nucleotide-polymorphism markers
21899	Allele frequencies of 11 consecutive markers in EBV-positive and EBV-negative subgroups
21900	Sex-adjusted odds ratios for risk locus in EBV-positive patients
21901	Frequencies of TNFα and TNFβ single-nucleotide polymorphisms
21902	Adverse effects from acute radiation
21903	Events in long-term outcome
21904	Treatment effects by postoperative prognostic factors
21905	First active salvage treatment for patients who relapsed in wait-and-see group  (n=207)
21906	Global Fund programme evaluation scores
21907	Components and timings of the complex intervention
21908	Differences in outcomes between intervention and control group, adjusted for potential confounding and clustering
21909	Intervention costs and incremental cost-effectiveness over 2 years
21910	Summary information for 20 EURODIAB centres with registration data
21911	Summary of Poisson regression analyses of incidence trends
21912	20 non-governmental organisations registered in the USA with highest cumulative overseas health expenditure from 2002 to 2006
21913	Independent risk factors for lymphoproliferative disorder
21914	Standardised incidence ratios of lymphoproliferative disorder according to thiopurine therapy and anti-TNFα therapy at clinical onset  *
21915	Summary of events
21916	Hazard ratios for overall survival
21917	Time to first deterioration in quality of life score or death for subscales of EORTC QLQ-C30 questionnaire
21918	Effect of low-dose  (75–300 mg)  aspirin versus control on subsequent long-term incidence and mortality due to colorectal cancer
21919	Effect of aspirin  (75–1200 mg)  versus control on long-term risk of colorectal cancer
21920	Causes of protocol deviation
21921	First events and deaths
21922	Multivariate analysis of overall survival and recurrence-free survival
21923	Sources of data inputs for USA and UK
21924	Projected health and quality-adjusted life-year outcomes, 2010–30, under three hypothetical scenarios of population-wide change in body-mass index distribution
21925	Summary of estimates of the prevalence of physical inactivity, RRs, and PAFs for coronary heart disease, type 2 diabetes, breast cancer, colon cancer, and all-cause mortality associated with physical inactivity
21926	Estimated PAFs, calculated with adjusted relative risks,  *   for coronary heart disease, type 2 diabetes, breast cancer, colon cancer, and all-cause mortality associated with physical inactivity, by WHO region and country
21927	Estimated gains in life expectancy if physical inactivity were eliminated, by WHO region and country
21928	Adverse events of any cause in more than 10% of patients in the everolimus group
21929	Summary of the effects of filgotinib and placebo on clinical remission, clinical response, endoscopic response, and quality of life in the overall population and by previous anti-TNF exposure at week 10
21930	Safety endpoints and treatment-emergent adverse events of special interest, by treatment assignment over weeks 0–10  (study part 1)  and weeks 10–20  (study part 2)
21931	Prevention of myocardial infarction and other events by aspirin and anticoagulants in coronary artery disease patients
21932	Clinical profile
21933	Cumulative CHD events during 5 years of follow-up
21934	Mean  (SD)  PDS hostility and submissiveness scores by age in 774 men and 740 women  *
21935	Mean  (SE)  submissiveness and hostility scores by CHD category in men and women
21936	Relative risks of CHD for 1 SD increase in submissiveness and hostility scores in men and women
21937	Cytomegalovirus and Chlamydia pneumoniae seropositivity in patients with and without restenosis after PTCA
21938	Interpretation of and response to case history by sex and ethnic subgroup
21939	Predictors of immediate care-seeking action by univariate and multivariate associations
21940	Main effects, warfarin: numbers of events  (rates/1000 person-years) , proportional and absolute reductions
21941	Main effects, aspirin: numbers of events  (rates/1000 person-years) , proportional and absolute reductions
21942	Separate group effects: numbers of events  (rates/1000 person years)
21943	Numbers of men having major, intermediate, or minor bleeding episodes  (fatal events in parentheses)
21944	Comparison of equipment use and procedural costs
21945	Outcome of procedures
21946	Rates of clinical and haemodynamic success
21947	Results of acetylcholine challenge and diameter stenosis after isosorbide dinitrate in patients who underwent coronary sinus catheterisation
21948	Effects of 17β-oestradiol at rest and during exercise
21949	Cross-reactivity of bradykinin precursors and metabolites with antiserum
21950	Accuracy of captopril renography in prediction of presence of significant renovascular disease
21951	Stent and technical data
21952	Stroke and bleeding complications
21953	Heparin and anticoagulation
21954	Frequency of primary clinical endpoints during follow-up
21955	Functional class at 6 months' follow-up or at time of repeat intervention for 823 patients in intention-to-treat analysis
21956	Immediate and long-term angiographic results among patients assigned angiographic follow-up
21957	Costs and efficiency after 12 months
21958	Deaths, myocardial infarctions, and reinterventions by treatment group and extent of disease
21959	Changes in angina grade between 1-year and 5-year follow-up visits
21960	Mean health-service costs per patient after 5 years' follow-up
21961	Main clinical features and follow-up data of patients
21962	First manifestations of coronary heart disease for cases, and causes of death for people who died free of coronary heart disease
21963	Lifetime risk of first coronary heart disease event at different ages reached free of coronary heart disease
21964	Lifetime risk of a first coronary heart disease event, excluding angina pectoris
21965	Success and complications of the primary procedure
21966	Outcomes at 6 months  (intention to treat)
21967	Clinical results at 6 months  (intention to treat)
21968	Limiting factors in exercise testing
21969	Number of myocardial sites with reversible or irreversible ischaemia
21970	Changes in median lifetime in subgroups
21971	Results of coronary angiography in invasive and non-invasive groups
21972	Coronary procedures in invasive and non-invasive groups
21973	Death, myocardial infarction, or both after 6 months
21974	Effect of invasive and non-invasive treatment strategies on death, myocardial infarction, or both at 6 months in predefined strata and subgroups
21975	Symptoms, re-admission, and medication during 6 months' follow-up in invasive versus non-invasive groups
21976	Medication in invasive and non-invasive groups after 3 months' follow-up
21977	Effect of invasive and non-invasive treatment strategies on symptoms of angina pectoris in different predefined strata and subgroups at 6 months
21978	Adverse events in invasive and non-invasive treatment strategies for open-label treatment with dalteparin
21979	Adverse events in invasive and non-invasive treatment strategies for double-blind treatment with dalteparin
21980	Major events at 1-year follow-up
21981	Events according to presence or absence of diabetes
21982	Economic and resource use in US patients
21983	Distribution of ACE I/D genotypes among confirmed myocardial infarction cases and controls
21984	Risk ratios confirmed for myocardial infarction with ACE I/D genotypes
21985	Distribution of ACE I/D genotypes among confirmed myocardial infarction cases and controls, classified by prespecified risk criteria
21986	Risk ratios confirmed for myocardial infarction with ACE I/D genotypes, according to prespecified risk criteria
21987	Chronology of evidence-based coronary care
21988	Populations, time-periods, numbers of events studied, and data quality scores
21989	Acute-coronary-care and coronary-event data for two time periods in men
21990	Acute-coronary-care and coronary-event data for two time periods in women
21991	Correlation of changes in treatments with treatment scores, coronary endpoints, and quality-control items for men  (top triangle)  and women  (bottom triangle)
21992	Regression of percentage change in coronary endpoints against change in treatments and treatment scores  (univariate analysis)
21993	Endpoint results
21994	Angiographic and procedural findings
21995	Event rates at 6 months in the routine stent and optimum PTCA with provisional stent groups
21996	Differences in blood lipid concentrations between pravastatin and placebo treatment groups at the end of the LIPID trial
21997	Effects of pravastatin on prespecified cardiovascular endpoints
21998	Treatment indices
21999	Stroke and bleeding complications
22000	Quantitative coronary angiography  (per protocol population)
22001	Outcome events within 30 days after first treatment
22002	Technical outcome of first attempt at endovascular treatment
22003	Comparison of vascular risk factors and perioperative complication rates in surgical patients in CAVATAS, ECST, and NASCET
22004	Major outcome events
22005	Primary outcome  (cardiovascular death, myocardial infarction, urgent revascularisation)  events prevented at various times within 30 days of PCI  (intention-to-treat analysis)
22006	Main outcomes adjusted for covariates that influence likelihood of undergoing PCI  (propensity score)
22007	Bleeding after PCI
22008	Cardiac events during 12 months of follow-up
22009	Prediction of cardiac events in Cox proportional-hazard model
22010	Percentage of depressed or not depressed patients with cardiac events
22011	Cardiac procedures since randomisation
22012	Deaths, myocardial infarctions, and refractory angina by treatment strategy
22013	RITA 3 data analysed according to ESC/ACC definition of myocardial infarction
22014	Cardiovascular events during main LIPID study, during extended follow-up, and over total period by original treatment group
22015	Treatment effects within subgroups for the prespecified outcome, coronary heart disease  (CHD)  death or non-fatal myocardial infarction, over total study period by original treatment group within prespecified subgroups
22016	Comparison of treatment effects in selected subgroups in main LIPID study and in total study period
22017	Absolute benefits of pravastatin during main LIPID study and total study period
22018	Serious adverse events, including cancer, during total follow-up period and relative risk of adverse events with long-term pravastatin treatment  (number of patients having at least one adverse event)
22019	Differences in primary outcome between groups
22020	Concomitant medications and hospital procedures
22021	Occurrence of primary endpoint at 30 days
22022	Occurrence of selected secondary endpoints and events at 30 days
22023	Death by cause during a median 2·0 years’ follow up
22024	Anginal symptoms and number of antianginal drugs taken at 1 year
22025	Number of patients with events by 1 year
22026	Randomised clinical trials investigating DES
22027	Clinical events and restenosis rates in randomised clinical trials investigating DES
22028	Edge restenosis and potential complications of DES
22029	Outcome by intention-to-treat and per-protocol analysis
22030	Detection of apoptosis induced on an immortalised macroglial cell line by urine samples from MS patients, non-MS patients, and healthy controls
22031	Histories and results for patients
22032	Borna disease virus  (BDV)  in cerebrospinal fluid
22033	Prevalence of type 1 diabetes in individuals with multiple sclerosis  (MS)  and in their parents and siblings
22034	Odds ratio for risk of type 1 diabetes in patients with multiple sclerosis  (MS)  and their healthy siblings, calculated according to individual and familial MS status in first-degree and second-degree relatives with logistic regression
22035	Prevalence of type 1 diabetes according to personal and family multiple sclerosis  (MS)  status
22036	Prevalence of type 1 diabetes mellitus according to personal and family multiple sclerosis  (MS)  status in families with only one diabetic offspring
22037	Multivariate model of risk factors for suicide comparing suicides and deaths due to other types of injury in China
22038	Patients' serum antibody titres to α-L-iduronidase
22039	Immunohistochemistry primary antibodies
22040	Summary of immunohistochemical and organ bath results, for both circular and longitudinal muscle, in controls and diverticular disease
22041	Age-adjusted risks for full-siblings and half-siblings of 1567 index cases
22042	Age-adjusted risks for maternal and paternal half-siblings
22043	Global healthy life expectancy by age, in 1990, and 2010
22044	Life expectancy and healthy life expectancy at birth in 1990, and 2010, by country  (95% uncertainty intervals)
22045	Country rankings for healthy life expectancy at birth in 1990
22046	Country rankings for healthy life expectancy at birth in 2010
22047	Odds ratios  (OR)  for any mental health disorder by age, sex, socioeconomic status, and number of physical disorders
22048	Clinical outcomes at 12 months
22049	Predictors of 12 month mortality in univariable and stepwise multivariable Cox regression analysis
22050	Incidence of fractures and other disorders associated with acute extremity compartment syndrome
22051	Effect of vaccine on cases of Ebola virus disease in different study populations
22052	Distribution of confirmed cases of Ebola virus disease among enumerated contacts and contacts of contacts in all clusters
22053	Frequency of solicited adverse events by time since vaccination in children and adults.
22054	Hazard ratios and 95% CIs for the associations between residential proximity to major roadways in 1996 and the risks of incident dementia, Parkinson's disease, and multiple sclerosis in Ontario, during the follow-up period 2001–12
22055	Hazard ratios and 95% CI for associations between residential proximity to major roadways in 1996 and the risk of incident dementia in Ontario during the follow-up period 2001–12
22056	Hazard ratios and 95% CI for associations between residential proximity to major roadways in 1996 and risk of incident Parkinson's disease and multiple sclerosis in Ontario, during the follow-up period 2001–12
22057	Site of first disease-free survival event
22058	Donor/recipient mismatched combinations with significant influence  (adverse or beneficial)  on graft survival
22059	Magnitude of effect of taboo combinations
22060	Clinical features of treatment groups at randomisation
22061	Outcome measures
22062	Distribution of aneurysms detected by MRA and DSA according to vascular location
22063	Size of incidental IAs measured from DSA in the FIA and PCKD groups
22064	Number of affected members per family in FIA and PCKD families
22065	Relationships between affected family members after screening  *
22066	Pretransplantation clinical and immunological variables
22067	Distribution of cancers
22068	Number of individuals with PKD1, PKD2, and controls from each centre
22069	Prevalence of complications in PKD1 and PKD2
22070	Mixed model regression analysis for creatinine clearance rate
22071	Comparison of lipid profiles of individuals from Algeria, France, and Ireland
22072	Age-adjusted risk ratios  (one SD change)  in different model specifications
22073	Age-adjusted risk ratios  (one SD change)  in models with LDL-cholesterol  (LDL-C)  with and without apolipoprotein B  (ApoB)
22074	Composition per 100 g of RUTF
22075	Outcome data
22076	Sphere key indicators  14   for therapeutic feeding programmes and study results
22077	Immunohistochemical analysis of renal angiomyolipoma
22078	Clinical and mutation details of patients with vascular phenotype
22079	Comparison of PKD1 pedigrees with and without vascular disease
22080	HLA types of HLA-homozygous donors selected from a series of 10 000 consecutive cadaveric organ donors
22081	Blood samples available from study participants with myocardial infarction and controls by ethnic origin
22082	Concentrations of lipids and their ratios in cases and controls
22083	Mean concentrations of lipids, lipoproteins, apolipoproteins and their ratios in the control population of men and women by ethnic origin
22084	Change in risk for myocardial infarction with a 1 SD change in each of the lipid measures in each ethnic group
22085	Prediction of risk by age with a 1 SD change in each lipid measure
22086	Population-attributable risks for ratios of total cholesterol to HDL cholesterol and apolipoprotein B100/apolipoprotein A1
22087	APOA5 −1131T>C genotypes and lipoprotein particle size and concentration in controls in the EPIC-Norfolk Study  10
22088	Unadjusted transplant outcomes
22089	Cox proportional hazards regression model for graft failure in first-time recipients of kidneys from cardiac-death donors, adjusted for age of donors and recipients, and cold ischaemic time
22090	Cox proportional hazards regression model for individual factors affecting graft failure in first-time recipients of kidneys from cardiac-death donors, adjusted for age of donors and recipients, and cold ischaemic time
22091	Multiple linear regression model of graft function in first-time recipients of kidneys, adjusted for age of donors and recipients, cold ischaemic time, and cause of death in donors
22092	Association of myocardial infarction  (MI)  with single nucleotide polymorphisms  (SNPs)  previously found to relate to plasma LDL cholesterol
22093	Association of myocardial infarction  (MI)  with single nucleotide polymorphisms  (SNPs)  previously found to relate to plasma HDL cholesterol
22094	Instrumental variable analysis estimate of the association of genetically raised HDL cholesterol and risk of myocardial infarction using LIPG Asn396Ser as an instrument
22095	Estimate of the association of genetically raised LDL cholesterol or HDL cholesterol and risk of myocardial infarction using multiple genetic variants as instruments
22096	Patients readmitted after 12 major operations in five surgical specialties
22097	Sensitivity analysis
22098	Cause-specific mortality
22099	Non-fatal cardiac events
22100	Adverse events requiring discontinuation of study medication
22101	Changes In severity of symptoms of heart failure
22102	Causes of death and hospital admission during an average of 19 months of follow-up
22103	Causes of death
22104	Univariate analysis of 1-year mortality in selected subgroups of patients in whom excess mortality was associated with ibopamine treatment
22105	Frequency of GSTM1 and GSTT1 genotypes in MDS patients and controls
22106	Extent of myocardial infarction measured by enzymatic infarct size and left-ventricular ejection fraction
22107	Frequencies of GvHD and other procedure-related complications
22108	Causes of death
22109	Prevalence of definite left-ventricular dysfunction  (left-ventricular ejection fraction ≤30%)
22110	Risk factors for left-ventricular dysfunction in symptomatic and asymptomatic participants
22111	Blood pressure and urinary sodium-excretion rates during low-sodium and high-sodium diets by sodium-sensitivity status
22112	Total cardiovascular events
22113	Relative risks of total cardiovascular events by Cox's proportional-hazards regression
22114	Distribution of genotypes for mutation 35delG in GJB2 gene in autosomal recessive and sporadic deafness
22115	Distribution of mutations in GJB2 gene in unrelated patients with congenital deafness
22116	Composition of treatment regimens
22117	Deaths in complete remission by risk group
22118	Outcome after relapse
22119	Clinical variables, left-ventricular dimensions, and functional class
22120	Number of children with cancer in developed and less developed countries
22121	Distribution of new children with neoplastic diseases diagnosed and treated at La Mascota hospital in 1990–97
22122	Distribution and sources of funding by institutions and solidarity groups from Italy and Switzerland for La Mascota programme
22123	Clinical symptoms of congenital syphilis
22124	Odds ratios for selected treatments by age
22125	Independent predictors of death during the first year after acute myocardial infarction
22126	Risk of death within first year of acute myocardial infarction
22127	Correlates of forearm bone-density in stepwise multiple regression
22128	Relative risk  (95% CI)  of fracture and height loss in stepwise Cox regression
22129	CX26 mutations in 43 deaf families
22130	Variations in the severity of hearing loss between both ears in prelingually deaf children
22131	Distribution of audiogram shapes in children with prelingual deafness with biallelic CX26 mutations or no mutation
22132	rCBF analyses for control group
22133	Comparison of statistical parametric maps of control groups and dyslexic groups
22134	Cancer diagnoses and deaths
22135	Details of radioiodine treatment and cancer diagnoses and deaths in patients with thyroid and small-bowel cancers
22136	Clinical features of eight infants of diabetic mothers with left-isomerism sequence
22137	Volumetric brain analyses in patients and controls
22138	Proportion of raw brain volume to whole brain volume in patients and controls
22139	Childhood leukaemias and the time-weighted average of residential 24-h electric and magnetic field measurements in the bedroom and living room  (overall measurement values combining both rooms) . Restricted to case-control pairs where each child lived in the same house as that monitored 2 years before the reference date
22140	Flight activity of 3790 male pilots and cockpit crew members
22141	Observed and expected cancers and standardised incidence ratios in Danish pilots and cockpit crew for all cancers and selected sites
22142	Observed and expected cases of leukaemia, melanoma, and skin cancer and standardised incidence ratio by aircraft type and accumulated flying hours
22143	Abnormalities of chromosomes 5 and 7 in cases of myelodysplasia and acute myeloid leukaemia
22144	Paired urine and semen samples from 44 men in Androvakely
22145	Observed and expected site-specific number of cancer cases among 2814 individuals with Down's syndrome
22146	Person-years at risk and observed and expected numbers of solid tumours in 5-year age-groups
22147	Observed and expected number of all malignant diseases combined and analysed separately for solid tumours and leukaemias
22148	Observed and expected number of leukaemia cases according to age
22149	Recurrence-free intervals and hazard ratios according to treatment
22150	Daytime and night-time blood pressure and left ventricular mass index in patients and controls
22151	Multivariate analysis with all reported variables including centres  (n=427)
22152	Multivariate analysis after stepwise selection of variables  (n=456)
22153	Relative risk for each centre in relation to the average centre and adjusted for other prognostic factors
22154	LFS estimated by the product limit method8 at 3 years
22155	TRM estimated by the product limit method8 at 3 years
22156	Detection of BCR/ABL fusion gene in haemopoietic cells and cultured endothelial cells
22157	Matched case-control analysis of household radon levels at diagnosis
22158	Phenotype of admission HIV-1 viral isolates  (labelled 1–17) , classified as either syncytia inducing  (SI)  or non-syncytia inducing  (NSI) , and admission CD4 cell count
22159	HIV inhibitory effects in vitro of sera from typhusinfected patients and mice
22160	Case numbers  (incidence rate per 1000 000 child years)  by period and diagnostic grouping
22161	Clinical indices of heart failure and device function
22162	Serial echocardiographic measurements
22163	Relation between pump speed and pulse pressure in systemic circulation
22164	Clinical and echocardiographic features in relation to maximum wall thickness
22165	5-year survival estimates in relation to wall thickness and number of risk factors
22166	Clinical features in velopharyngeal incompetence patients with and without 22q11 deletion
22167	Leukaemia deaths in wartime and postwar cohorts of Orkney and Shetland children
22168	Primary, secondary, and other endpoints
22169	T-cell repertoire and proliferative responses to candidin after transplantation
22170	Details of PPRA and GPRA patients
22171	QTc time as determined by the longest QT time divided by the square root of the RR interval
22172	Susceptibility of Salmonella typhi strains to antimicrobial agents
22173	Median  (range)  urinary 3-methylglutaconate and 3-methylglutarate concentrations
22174	Estimates of incidence of cholera among travellers and expatriates in three studies
22175	Guidelines for clinical evaluation of dehydration and recommendations for rehydration and maintenance fluid therapy
22176	Pregnancy prevalence rates associated with HIV-1 infection and other sexually transmitted diseases  (STDs)
22177	Clinical and echocardiographic data
22178	Growth data at birth
22179	Frequency of chronic illness at 18 months of age
22180	Frequency of common disorders
22181	Major malformations identified by 18 months of age
22182	Physiological responses to a laboratory based submaximal treadmill test
22183	Crude risk ratios and adjusted odds ratios for study outcomes in HIV-1-infected and non-infected women
22184	Risk of death in relation to physical activity at Q92 among men without cardiovascular diseases or self-reported “poor health” at Q92
22185	Type of physical activity and adjusted relative risk for all-cause mortality among men without cardiovascular disease or self-reported “poor health” at Q92
22186	Physical activity changes between Q1 and Q92
22187	Risk of mortality in relation to changes in physical activity between Q1 and Q92
22188	Changes in physical activity, mortality rates, and risk of mortality for men with coronary heart disease, stroke, or heart trouble, excluding men with “poor health”
22189	Indicators of deficiency and WHO severity grades1 in different groups
22190	Number of pregnancies with nuchal-translucency thickness above 95th centile and an estimated risk for trisomy 21 of 1 in 300 or greater
22191	Accuracy of estimated risk of trisomy 21 by a combination of maternal age and fetal nuchal-translucency thickness
22192	Quality of reporting of 127 RCTs assessed by a scale  16,17   and individual quality components under masked and unmasked conditions  3
22193	Influence of different method of quality assessment on treatment-effect estimates
22194	Relation between different methods of incorporating quality scale into meta-analyses and resulting estimates of intervention effects
22195	Comparison of measured volumes with 3D volume estimates of test objects
22196	Estimates  (SE)  of regression coefficients by linear regression analysis
22197	Distribution of embryos and fetuses according to Carnegie staging system
22198	Pregnancies after discontinuation of contraception in 430 participating couples
22199	Pregnancies during entire follow-up period of six menstrual cycles
22200	Mantel-Haenszel estimates for comparison of pregnancyassociated breast cancer in rererence groups BRCA1 and BRCA2
22201	Proportion of 356 patients with CHD risk >2% per year  (≥20% over 10 years)  or >3% per year  (>15% over 5 years)  by Framingham equation and proportions recommended statin treatment by NCEP guidelines and Sheffield table
22202	Numbers of women enrolled and pregnancies by centre and treatment group
22203	Details of pregnancies
22204	Pregnancy rates and prevented fractions by treatment group
22205	Prematurity and maternal breast cancer risk among uniparous Swedish women
22206	Principal diagnoses in 28 pregnancies with umbilical- artery AEDF
22207	Outcome data for 19 pregnancies showing a return of end-diastolic flow and nine pregnancies with persistent AEDF
22208	Risk factors for perinatal death
22209	Relation between the risk of perinatal death and infertility in the index pregnancy
22210	Epithelial ovarian cancer risk in mothers with twin births among parous women in Sweden, 1961–1995
22211	Selected model variables for prevention in childhood
22212	Selected model variables for prevention in pregnancy
22213	Selected model variables for improvement in case management
22214	Mid-trimester maternal serum immunoglobulin concentrations among women delivering prematurely
22215	Method of antenatal screening for Down's syndrome offered by Health Authorities and Boards in the UK in 1991, 1994, and 1998
22216	Fetal diagnosis of common lesions  (1993–95)
22217	Population, livebirths, serious congenital heart disease, and terminations of pregnancy for England and Wales, Scotland, and Northern Ireland  (1994)
22218	Effect of prenatal diagnosis  (1993–95)
22219	Significance of continuous variables in estimating cumulative measure of atherosclerosis in univariate analysis
22220	Significance of dichotomous variables in estimating cumulative measure of atherosclerosis in univariate analysis
22221	Models of multiple linear-regression analysis assessing role of group, age of child, birthweight, maternal age, and coronary heart disease history on atherosclerosis of child
22222	Deaths from intentional and unintentional injuries in women
22223	Male to female ratio in offspring of Swedish women with hyperemesis gravidarum during pregnancy, 1987–1995
22224	Distribution of patients, numbers of cycles, and outcome of the three treatment programmes
22225	Calculated costs per pregnancy resulting in at least one livebirth after a maximum of six treatment cycles for groups of 100 fictional couples in each age and treatment category
22226	Summary of comparative studies on congenital malformations associated with the treatment of asthma during the first trimester of pregnancy
22227	Birthweight/placental weight ratios of pregnancies delivering at or beyond 25 weeks gestation at Monash Medical Centre
22228	Summary of case histories
22229	Serum and urine hCG assay results
22230	Distribution of respondents by starting time of exposure to unprotected intercourse
22231	Time to pregnancy in Great Britain, 1961–93
22232	Trends in fertility in Great Britain, 1961–63
22233	Associated chromosomal anomalies with HLHS and outcome
22234	Extracardiac structural anomalies associated with HLHS  (including hydrops fetalis)
22235	Study participants and pregnancies  *
22236	Fetal death among reported singleton pregnancies by parental monitoring before conception
22237	Fetal death among singleton pregnancies reported by women according to employment and monitoring around the time of conception
22238	Reported congenital malformations among pregnancies which were conceived after first employment in the nuclear industry
22239	Details of stillbirths and neonatal deaths  (excluding lethal anomalies)
22240	Perinatal or neonatal mortality at <28 days of age and serious neonatal morbidity
22241	Details of neonatal morbidity
22242	Maternal mortality and morbidity
22243	Hazard ratio  *    (95% CI)  for mortality according to a 1 SD  †   increase in birth outcome measure or for premature delivery
22244	Comparison of cases and controls
22245	Effect of tubal ligation on ovarian cancer risk in BRCA1 carriers.
22246	Maternal serum DDE concentration in relation to odds of preterm or small-for-gestational-age birth
22247	Differences between non-responders and responders among Aboriginal people and European people
22248	Frequency of single or combined cardiovascular events
22249	Determinants of atherosclerosis  *
22250	Determinants of low income
22251	Determinants of CVD
22252	Details of studies included in these analyses
22253	Risk ratios for breast cancer, by number of first-degree relatives with a history of breast cancer
22254	Age-specific risk ratios for breast cancer in women with one first-degree relative with a history of the disease, according to the relative's age at diagnosis of breast cancer
22255	Age-specific risk ratios for breast cancer in women with two first-degree relatives with a history of the disease, according to the relatives' ages at diagnosis of breast cancer
22256	Probability  (%)  that women in more-developed countries who are free from breast cancer at certain ages would develop breast cancer over the next 10 years, according to the number of affected relatives
22257	Probability  (%)  that women in more-developed countries who are free from breast cancer at certain ages would develop breast cancer by age 50 and by age 80, according to the number of affected relatives
22258	Distribution of women with and without breast cancer in studies from more-developed countries, according to their age and family history of breast cancer
22259	Example of how to compare the respective variances of the unstratified and fully stratified data  (from table 2  *   )
22260	Clinical details and FISH results
22261	Correlation of FISH results with pathological diagnoses
22262	Children who required treatment at a childhood disability centre
22263	Distribution of diagnoses among children born after in-vitro fertilisation  (IVF)  and controls
22264	Logistic regression analysis showing independent effects of in-vitro fertilisation  (IVF) , maternal age, male sex, and low birthweight  (upper panel)  or low gestational age  (lower panel)  on the risk of needing contact with a childhood disability centre, risk of cerebral palsy, and risk of suspected developmental delay
22265	Percent distribution for all causes of death
22266	Number of reported barriers to health care and number of women reporting ≥1 barrier by level among Afghan refugee women who died of maternal and non-maternal causes
22267	Compliance with allocated treatment
22268	Side-effects and problems at injection site, for women who received trial treatment
22269	Eclampsia and maternal death
22270	Secondary outcome for all women
22271	Hospital stay and use of intensive care facilities, for all women
22272	Baby deaths before discharge from hospital for those randomised before delivery
22273	Gestation at birth and age at death for liveborn babies, without lethal congenital malformation
22274	Outcomes relevant only to women randomised before delivery
22275	Neonatal morbidity for liveborn babies of women randomised before delivery
22276	Relation between lifetime duration of breastfeeding and various other aspects of childbearing in parous cases and controls  *
22277	Relative risk of breast cancer in parous women, in relation to lifetime duration of breastfeeding
22278	HB-EGF expression in placental tissues
22279	Nutrient indices at entry to study and after 2 years
22280	Numbers and rate ratios for separate and combined cardiac endpoints
22281	Cardiac complications and non-cardiac morbidity and mortality
22282	Pregnancies by centre and treatment group
22283	Pregnancy rates and prevented fractions
22284	Efficacy analysis stratified by intercourse-treatment interval, intercourse after treatment, and ethnic group
22285	Side-effects within 7 days and delay of menses
22286	Mortality rate ratios associated with short versus long telomeres in whole-blood DNA
22287	Results of antenatal screening for Down's syndrome with quadruple test  (including maternal age)  and with maternal age alone
22288	Detection rates  (DR)  and odds of being affected given a positive result  (OAPR)  for a fixed 5% false-positive rate by method of screening
22289	Mean width of the intervillous space and of fetoplacental villous arteries in subchorionic and basal half of human placenta
22290	Risk of antepartum stillbirth after 24 weeks’ gestation in relation to previous caesarean section in 120 633 second births
22291	Number of events and life table analysis of unexplained stillbirths at or after 34 weeks’ gestation in second pregnancies in relation to previous caesarean delivery  (n=119 350)
22292	Risk of adverse pregnancy outcome in second pregnancies in relation to previous caesarean delivery adjusted for outcome of first pregnancy  (n=103790)
22293	Country, study region, and number of cases and controls
22294	Prevalence of multivariately significant potential risk factors for SIDS in cases and controls
22295	Multivariately significant potential risk factors for SIDS not recorded by all centres
22296	Change in sleeping position on last occasion of cases and controls with ORs
22297	PAFs for avoidable risk factors for SIDS derived from adjusted ORs, in order of magnitude, with intercentre IQRs
22298	Effect of HIV on amount of antibody according to gravidity and malaria status
22299	Univariate and multivariate analysis of factors influencing concentrations of antibody to CS2 VSA, AMA-1, and MSP
22300	Primary analyses of outcome measures
22301	Effect of second opinion policy on caesarean section rates
22302	Effect of second opinion policy on maternal and perinatal outcomes
22303	Second opinion process
22304	Effect of the second opinion policy on women's preferences and satisfaction with care process
22305	Completion rates for different types of referral in children
22306	Caretakers' reasons for not completing referral
22307	HIV prevalence in women attending antenatal clinics in the WHO Africa region
22308	HIV prevalence trends in pregnant women attending antenatal clinics by country and subregion in the same clinics
22309	Unprotected first heterosexual intercourse  *   by sex and school
22310	Comparison of teacher-led  (control)  and peer-led SRE in relation to knowledge, attitudes, and sexual experiences
22311	First ten women's group meetings
22312	Mortality rate comparisons between intervention and control clusters
22313	Process indicator outcomes
22314	Cumulative prevalence rates and 95% CIs of detrimental actions undertaken by parents to stop the crying of their child
22315	Prevalence of at least one of three parental actions induced by infant crying that are detrimental to infant health  (smothering, slapping, and shaking)
22316	Means  (SDs)  of variables
22317	Multiple regression equations with human resources for health as an independent variable
22318	Multiple regression equations with doctors and nurses as separate independent variables
22319	Maternal gestational histories
22320	Findings and treatments of neonates born after gestational IVIG therapy
22321	Outcomes of previous affected pregnancies selected randomly versus index pregnancies during which mothers received IVIG therapy  (all participants)
22322	Plausible ODA needs for achievement of MDGs
22323	Evidence of efficacy for interventions at different time periods  *
22324	Evidence-based packages of interventions at different periods
22325	Cause-specific effect of intervention packages delivered at different periods  *
22326	Estimated number of neonatal deaths in 75 countries by region that could be averted by universal  (99% coverage)  delivery of all  *   evidence-based interventions
22327	Estimated number of neonatal deaths that could be averted by delivering packages of interventions  *   during the indicated periods at 90% coverage in 75 countries
22328	Effect of interventions packaged by service delivery mode  *   and delivered in programmatically relevant models of implementation in 75 countries
22329	MDGs for maternal and child health
22330	HIV incidence among pregnant or lactating women and women who were neither pregnant nor lactating
22331	Male reported sexual behaviours and HIV acquisition in married women linked to their male partners
22332	HIV acquisition among women in discordant relationships with an HIV-infected male partner
22333	Risk of maternal premature cardiovascular disease after maternal placental syndrome in index pregnancy
22334	Risk of maternal premature cardiovascular disease, according to type of maternal placental syndrome and concomitant presence of poor fetal growth or intrauterine fetal death
22335	Retrospective cohort studies of risk of cardiovascular disease after maternal placental syndromes  (MPS)
22336	Description of project activities
22337	Key results on the cost and cost-effectiveness of the intervention
22338	Socioeconomic determinants of use of basic professional obstetric care with a midwife at home or in a health facility  (1987–2001)
22339	Trends in use of basic obstetric care with a midwife by wealth quintile  (1987–2001)
22340	Perinatal outcomes
22341	Adverse events in women
22342	Pregnancy data per woman
22343	Pregnancy data per embryo transfer  *
22344	Summary of Indigenous and benchmark population measures and methods of identification
22345	Summary of data sources for measures
22346	Population information by country
22347	Indicator measures by country
22348	Clinical events during 1 year follow-up
22349	Primary and secondary outcomes
22350	Process outcomes after trial entry
22351	Health and development outcomes at 2 years in a sample of surviving infants without the primary outcome selected for follow-up
22352	Study indicators and source
22353	Hierarchical mixed modelling results
22354	PASI scores
22355	TDT for S gene polymorphisms in psoriasis family trios
22356	Mean  (range)  resource use by the control and intervention groups
22357	Correlation between NDE scale scores and DES scores
22358	Adverse events reported by two or more patients
22359	Reasons for patients' withdrawal from treatment
22360	Functioning, disability and use of health services by psychiatric status
22361	Categories of trauma
22362	Associations between indices of psychiatric status and trauma exposure
22363	DSM-IV disorders in people with and without exposure to armed-conflict-associated violence  (ACAV)
22364	1-year comorbid categories of DSM-IV disorder in people with and without experience of armed-conflict-associated violence  (ACAV)
22365	12-month prevalence and severity of DSM-IV disorders  *
22366	Associations of exposure to war-related traumatic events with 12-month DSM-IV disorders
22367	Distribution of 12-month DSM-IV disorder severity as a function of exposure to war-related traumatic events
22368	12-month treatment by severity of DSM-IV disorders
22369	Estimated crude rate and number of victims by type of violation for greater Port-au-Prince area
22370	Perpetrators of human rights violations
22371	Post-stratification analysis
22372	Forms of partner violence during pregnancy
22373	Association of postnatal depression with level of exposure to partner violence during pregnancy
22374	Association of postnatal depression with psychological partner violence or physical or sexual partner violence during pregnancy
22375	Hazard ratios for the association between psychotropic medication and violent crime in a Swedish population cohort of 82 647 patients with prescriptions
22376	Hazard ratios for different crime outcomes in 82 647 patients prescribed mood stabilisers, antipsychotics, and clozapine, compared with periods when these same patients are not on medication  (within-individual analyses)
22377	Hazard ratios for violent crime in patients with different psychiatric disorders who have been prescribed antipsychotics and mood stabilisers  (within-individual analyses)
22378	Hazard ratios for the association between violent crime and different exposures to psychotropic medications
22379	Interventions
22380	Maternal outcomes
22381	Major maternal complications  (as diagnosed by clinician at the time)
22382	Fetal and neonatal interventions and outcomes
22383	Neonatal complications and fetal and neonatal loss
22384	Overall satisfaction with maternity care
22385	Satisfaction with choice, information, decision-making, and individualised care
22386	Estimated risk of late postnatal transmission from eight included studies by breastfeeding practice
22387	Induction of labour and mode of delivery in lawyers, doctors, and controls
22388	Mutual information scores for use of “you just” and “look” by doctor
22389	Comments on diagnosis and prognosis: doctors' and patients' use of worr*, concern*, anxi*
22390	Prevalence of reproductive-tract infections in women with symptoms
22391	Risk factors with significant  (p<0·10)  association with endogenous infections and STIs
22392	Accuracy of algorithms compared with microbiological findings
22393	Costs of drugs and diagnostic aids for treating women with vaginal discharge  (n=320)
22394	Results of preoperative evaluation
22395	Complications during and soon after fundoplication as seen in 57 laparoscopic and 46 open Nissen fundoplications
22396	Number of patients with primary endpoints requiring medical treatment or intervention  (oesophageal dilatation, reoperation)  after laparoscopic and open Nissen fundoplication
22397	Endocrinological test results
22398	Headache as a symptom of myocardial ischaemia cases reported in English publications
22399	Frequency of clinical features in 48 patients with A3243G
22400	Mitochondrial transfer DNA sequence haplogroups in patients with A3243G and A12308G
22401	CSF laboratory findings in 905 children undergoing lumbar puncture and the proportions with proven acute bacterial meningitis
22402	Comparison of laboratory diagnosis of acute bacterial meningitis with signs and tests that might be available at a district hospital in sub-Saharan Africa
22403	Case-mix and crude outcome of study cohort related to birthweight quintile
22404	Crude and adjusted hazard ratios  (95% CI)  for death from any cause, death due to IHD, and admission for or death from IHD in relation to birthweight quintile, preterm delivery, and pre-eclampsia
22405	Crude and adjusted hazard ratios  (95% CI)  for death from any cause, death due to IHD, and admission for or death from IHD in relation to combinations of adverse obstetric outcomes
22406	Crude and adjusted hazard ratios  (95% CI)  for death from any cause, death due to IHD, and admission for or death from IHD related to absolute values of birthweight
22407	Multivariate analysis of risk factors for overall survival after histocompatible bone marrow transplantation
22408	Results of porphyria screen
22409	Comparison of titres of IgM and IgG antibodies against staphylococcal slime polysaccharide antigens  (SSPA)   (ELISA units [EU])  in sera from patients with an ongoing staphylococcal late-onset infection of synthetic vascular graft  (LO-SVGI)  and in controls
22410	Data related to surgical intervention and morbidity
22411	Tumour recurrence and mortality in patients with non-metastatic colon cancer
22412	Results of Cox's regression analysis in patients with non-metastatic colon cancer
22413	Presenting features and final diagnostic categories
22414	Frequency of haemoglobin S in diagnostic groups
22415	Laboratory results for each diagnostic group
22416	Number of patients in each diagnostic group with specific discriminators
22417	Univariate analysis comparing admission variables between patients with tuberculous and bacterial meningitis
22418	Second cerebrospinal fluid analysis taken after 48–72 h of parenteral ceftriaxone
22419	Change in cerebrospinal fluid variables after 48–72 h of parenteral ceftriaxone
22420	Multivariate logistic regression analysis of admission data
22421	Weighted diagnostic index scores for dichotomized clinical variables used for admission diagnostic rule
22422	Sensitivity and specificity of diagnostic aids
22423	Results of household investigations
22424	Biochemical measures of galactosaemia
22425	Thrombophilic defects identified by laboratory testing
22426	Main outcomes for women with minimal screening abnormalities
22427	Persistence of HPV in women in surveillance group  (n=411)
22428	Initial and follow-up cytology and HPV results in women in surveillance group who attended follow-up and had adequate cytology and HPV tests  (n=296)   *
22429	Perioperative outcomes
22430	Complications of surgery
22431	Survival and recurrence  (stage I–III diseases)
22432	Maternal health indices in Adjumani district
22433	Population and sample size in the four study sites
22434	Frequency distribution of maternal causes of death among women in the four study sites
22435	Likelihood ratios for white-blood-cell count in diagnosing appendicitis
22436	Likelihood ratios for prostate-specific antigen in diagnosing prostate cancer
22437	Likelihood ratios and bedside estimates
22438	Examples of likelihood ratio applications
22439	Operative details and postoperative recovery
22440	Operative procedure undertaken
22441	Intraoperative complications
22442	30-day postoperative complications
22443	Diagnostic criteria for Marfan's syndrome  2,3
22444	Outcome data in relation to death of either infant from SIDS
22445	Risk of adverse outcome in the second recorded pregnancy in relation to infant outcome of preceding birth
22446	Risk of the second infant dying from SIDS in relation to obstetric outcome of preceding birth
22447	Targeted laboratory tests, brief educational messages, and cues for activating addition of messages as reminders to results report
22448	Requests for total and individual targeted tests before and during the intervention period
22449	Effect of interventions on requests for total and individual targeted tests
22450	Risk factor profile in the NHEFS population
22451	Laboratory-based and non laboratory-based models for predicting cardiovascular disease outcomes
22452	Predictive discrimination of models at different 5-year cardiovascular risk thresholds
22453	Interventions meeting selection criteria for analysis of prevention of preterm birth
22454	Treatment-emergent AEs in the safety analysis population
22455	Comparison of symptoms at illness onset of laboratory-confirmed cases of human infection with avian influenza A H7N9 and H5N1 viruses in mainland China, based on available data
22456	Average numbers of close contacts traced for laboratory-confirmed cases of human infection with avian influenza A H7N9 and H5N1 in mainland China, based on available data
22457	Outcomes
22458	CACE analyses
22459	Subgroup analyses for primary outcome  (30 day survival)
22460	Crude and adjusted ORs for gonorrhoea diagnosis
22461	Crude and adjusted ORs for gonorrhoea diagnosis excluding partly vaccinated participants
22462	Comparison of assessment of Canadian Cardiovascular Society angina class with  (masked)  and without  (investigators')  concealment of treatment allocation
22463	Changes in Seattle angina questionnaire  (SAQ)  scores
22464	Adverse events during follow-up  (including periprocedural events)
22465	Odds ratios  (95% CI)  of the relations of ELISPOT and TST with intensity of M tuberculosis exposure in school and with risk factors for exposure outside school
22466	Effect of previous BCG vaccination on ELISPOT and TST results
22467	Analysis of concordant and discordant test results
22468	Patterns of failure
22469	Results of the three tests in patients with a diagnosis of active tuberculosis
22470	Positive results obtained with tuberculin skin test, QuantiFERON-TB Gold, and T-SPOT.TB in participants recently in close contact with a patient with active tuberculosis
22471	Screening activity, identification of active and latent tuberculosis, and BCG coverage
22472	Primer sequences
22473	Purity of cell fractions by FACS analysis
22474	Risk group, CD4 and other cell counts, and blood virus load
22475	Absolute cell counts and frequency of infection of 106 cells from different subsets of peripheral blood mononuclear cells  (PBMCs)  with HIV
22476	Detection of HIV proviral sequences in cells separated by CD8-MACS beads
22477	Risk of HIV-1 infection according to duration of prostitution by calendar year
22478	Univariate Cox proportional hazards modelling of risk factors for HIV-1 seroconversion
22479	Multivariate Cox proportional hazards modelling of risk factors for HIV-1 seroconversion
22480	Observed MBP genotypes and allele frequencies in patients with acute or chronic hepatitis and HBsAg-negative controls
22481	Serum MBP concentrations in Caucasian patients with chronic HBV infection
22482	MBL genotypes in HIV-infected men, healthy controls, and HIV-negative, high-risk controls
22483	Distribution of  MBL  genotypes in HIV-infected men
22484	Multivariate analysis of serum MBL concentration and CD4 T-cell count as predictors of death in patients with AIDS
22485	Median survival  (Kaplan-Meier)  from first presentation of various infections in men who developed AIDS by  MBL  genotypes
22486	Regions of brain examined for HSV1 DNA
22487	APOE genotypes of AD patients and aged non-AD patients positive or negative for HSV1 in brain  (frontal lobe and temporal lobe)
22488	APOE genotypes of AD patients and aged non-AD patients positive or negative for HSV1 in all brain regions
22489	Odds ratios for presence of  APOE -e4 allele
22490	APOE genotypes of cold-sore sufferers and non- sufferers
22491	Mutation frequencies in patients with sporadic porphyria cutanea tarda and in controls
22492	Genotypes of patients with sporadic porphyria cutanea tarda and of controls
22493	Distribution and allele frequency of Pt u/∼ polymorphism among cases and controls
22494	Relative risks of thrombosis associated with carriage of P/∼ allele
22495	Relative risks of myocardial Infarction  (MI) , stroke, or venous thromboembolism  (VTE)  associated with carriage of Pμ2 allele for all study participants and in prespeclfled subgroup analyses
22496	Distribution and allele frequency of pμ1/A2 polymorphlsm among study participants, stratified by randomised aspirin assignment
22497	Clinical features and FGFR3 mutation status of patients in cohort
22498	Definition of children's HIV status
22499	Enrolment, follow-up, and infection status of children by mother's HIV serologic status
22500	Occurrence of late postnatal transmission by maternal and child factors
22501	Details of michrochimerism and rejection
22502	Air pollution  (24 h averages) , meteorology  (24 h averages) , and plasma viscosity on days of MONICA survey  (October, 1984, to June, 1985)
22503	Associations between raised plasma viscosity and 1985 air pollution episode
22504	Multivariate logistic regression analyses for plasma viscosity above 95th percentile
22505	Associations between plasma viscosity above 95th percentile and measures of air pollution treated as continuous variables
22506	Borna disease virus in human brains
22507	5-HT2A receptor densities and T102C polymorphism
22508	Amplification of fetal Y-chromosomal sequences from maternal plasma, serum, and blood
22509	Proportion of women with polycystic ovaries by birthweight and completed weeks of gestation
22510	Proportion of women with polycystic ovaries and plasma LH concentrations  (IU/L)  by length of gestation and adult body-mass index  (BMI)
22511	Proportion of women with polycystic ovaries by birthweight and mother's weight in early pregnancy
22512	Proportion of women with polycystic ovaries, mother's weight, body-mass index, and mean concentrations of plasma LH and testosterone according to birthweight among women whose mothers' weight in pregnancy was above 58 kg  (median)
22513	Frequency of events at 1 month by PlA  genotype
22514	Univariate and multivariate analysis of stent thrombosis
22515	Classic risk-factor scores for stent thrombosis by PlA  genotype
22516	Relative risk for recurrence of pneumonia by age, estimated by Cox proportional hazard regression
22517	Results of quantitative tests for male DNA
22518	Women with at least one HLA-compatible child for class II Loci DRB1, DQA1, and DQB1
22519	Standardised incidence ratios  (SIRs)  for all cancers
22520	Standardised cancer incidence ratios  (SIRs)  for patients admitted to hospital for VTE  *
22521	PCR-positive C pneumoniae in heart transplant donors
22522	Results of assays and predictive accuracy for aspartate-aminotransferase and alanine-aminotransferase concentrations
22523	Multiple regression models for prediction hepatitis activity index
22524	Rates  (%)  of interventions and major clinical events, by country
22525	Rates  (%)  of intervention or outcome
22526	Adjusted rates of major outcomes among patients initially admitted to hospitals with or without cardiac catheterisation facilities
22527	Adjusted rates of procedures and outcomes up to 6 months
22528	PCR analysis of pig mtDNA sequences in sera from 10 diabetic patients given pig islet cells
22529	PCR analysis of PERV proviral sequences in lymphocytes from 10 diabetic patients given pig islet-cell xenografts between June, 1990 and April, 1993
22530	RGH sequences in plasma from patients and controls
22531	Background of women and results of plasma PCR
22532	Distribution of HCMV gB genotypes in different organs from immunocompetent people
22533	Distribution of alleles and genotypes of GST polymorphisms
22534	Distribution of GSTP1-1 polymorphisms in participants exposed to pesticides
22535	Results of bronchoalveolar lavage and clinical outcomes
22536	Diagnosis of parvovirus B19 infection in four children with FH
22537	Results of PCR in microdissected epidermis and dermis of pregnant women with or without PEP
22538	Frequency of  CYP2D6  PM genotype and exposure to solvents among cases and controls
22539	WWW services linked to RIDOM in a context-sensitive manner
22540	Prevalence of major risk factors for coronary artery disease among patients and controls
22541	Genotype distribution of the C807T/G873A polymorphisms among patients and controls according to age
22542	Relative risk of myocardial infarction associated with carriage of 807T/873A
22543	Relative risk of myocardial infarction for homozygous 807T/873A collagen receptor polymorphism and/or smoking status
22544	HIV-1 viral load by CD4 strata
22545	Geographical distribution of 29 cases of EFE
22546	Signs and symptoms detected in 29 cases of EFE
22547	Distribution of potential risk factors for EFE in 27 case households and 112 control households
22548	Dicarboxylic acid concentrations in urine samples from two cases of EFE and three controls
22549	Adverse events in mothers and babies
22550	HIV-1 transmission and treatment efficacy at birth and ages 4weeks and 3 months
22551	24 h mean and median winter air pollution  (μg/m3)
22552	Estimated odds ratios  (95% CI)  for prevalence of respiratory symptoms and decrease in peak expiratory flow  (PEF)  with increase in air pollutants in children with BHR and relatively high serum total IgE  (n=121)
22553	Estimated odds ratios  (95% CI)  for prevalence of respiratory symptoms and decrease in peak expiratory flow  (PEF)  with increase in air pollutants in children without BHR and with relatively low serum total IgE  (n=167)
22554	Estimated odds ratios  (95% CI)  for prevalence of respiratory symptoms and decrease in peak expiratory flow  (PEF)  with increase in air pollutants in children with BHR and relatively low serum total IgE  (n=67)
22555	Estimated odds ratios for prevalence of respiratory symptoms and decrease in peak expiratory flow  (PEF)  with increase in air pollutants in children without BHR but with relatively high serum total IgE  (n=104)
22556	HIV-1 infection status of children according to allocated and actual mode of delivery
22557	HIV-1 infection status of children by allocated and actual mode of delivery: analysis in strata of prophylactic zidovudine therapy and maternal CD4-cell count
22558	Comparison of  MBL  variant gene frequencies
22559	OPV3 coverage by routine immunisation
22560	Number of patients in each of the groups based on the family history, the number referred as idiopathic pancreatitis, and the number with a mutation in the cationic trypsinogen gene
22561	Reported dengue cases in Guayana and bordering countries 1990-98
22562	Combined results of culture and PCR investigations of 12 middle-ear fluid samples
22563	Relation between PAI-1 concentrations, clinical presentation, and disease outcome
22564	Relation between PAI-1 concentrations,  PAI-1  genotype, and clinical presentation
22565	PAI-1  promoter region genotype frequencies
22566	Outcome of meningococcal sepsis in children classified by PAI-1 genotype
22567	Fatal cases
22568	Non-fatal AFP cases
22569	Sites of isolation of enteroviruses and adenoviruses from fatal cases
22570	DHPS genotypes according to previous or current exposure to sulpha drugs in 152 episodes of PCP
22571	Cox regression analysis of predictors for 3-month survival after diagnosis of PCP
22572	Patient-specific TEL and AML1 sequences and PCR conditions for Guthrie studies
22573	Summary of TEL-AML1 Guthrie card blood spot screening for clonotypic TEL-AML sequences
22574	Electrocardiographic findings and serum TCA
22575	Alignment of 39-UTR sequences
22576	Detection of mycobacterial DNA in lung tissue from Ethiopian necropsy samples
22577	Mycobacterial DNA in lung tissue from Mexican and Norwegian necropsy samples
22578	Odds ratios for the impact of health-care-worker vaccination on mortality in patients
22579	Results of tissue culture and PCR for influenza infection on nose and throat swabs
22580	Detection of paternal mtDNA after in-vitro fertilisation  (IVF)  and intracytoplasmic sperm injection  (ICSI)  treatments
22581	Dominant wind direction, rates of dust deposition, %PM10 and phosalone concentrations for sampling sites in eastern Turkmenistan
22582	Indications for colonoscopy
22583	Correlation of appearance with histology
22584	Correlation of size with appearance and histology
22585	Logistic-regression analysis to define the risk of CMV disease associated with a 0·25 log10 initial CMV load
22586	Univariate and multivariate logistic-regression analyses relating factors of initial CMVload, peak CMV load  (both per 0·25log10 genomes /mL increase)  and rate of change in CMVload  (per 0·25log10 genomes/mL per day increase)  to the development of CMV disease
22587	Capsular serogroups implicated in the 34 invasive pneumococcal episodes by vaccine and placebo in 25 individuals
22588	Effects of vaccination on pneumococcal events and death: numbers of events observed together wih estimated hazard ratios  (HR)  and incidence rate ratios  (IRR)  for vaccine versus placebo
22589	Effect of vaccination on first events within 6 months of vaccination and after 6 months
22590	Interaction between effect of vaccination on first events and CD4 cell count at enrolment
22591	HPV 16 status in relation to cytological diagnosis
22592	HPV 16 status in first and last smear among cases and controls with two or more smears
22593	Odds ratios  (95% CI)  for cervical carcinoma in situ in relation to HPV 16 Ct values at different years before diagnosis
22594	Odds ratios  (95% CI)  of developing cervical carcinoma in situ in relation to mean estimates of HPV 16 viral load per-actin-positive woman
22595	Odds ratios of developing cervical carcinoma in situ in relation to HPV 16 viral load in first smear among β-actin-positive women
22596	Frequency of serological markers of hepatitis B virus infection in patients with a known number of autohaemotherapy treatments
22597	Health outcome definition and sources of data
22598	Health outcomes with relative risks, outcome frequency, and attributable cases  (per 10 μg/m3 and 1 million population)
22599	Population exposure distribution of PM10
22600	Number of attributable cases to air pollution, and cases attributed to traffic pollution
22601	Sensitivity of the estimation of air pollution attributable number of cases of death  (mortality >30 years of age)  compared with the quantified uncertainty  (95% CI of epidemiological risk estimates) , based on Swiss data only
22602	Maternal risk factors for vertical HCV transmission
22603	Results of various approaches for assessing HBsAg and HBV DNA in 17 liver samples from patients with HBV infection and two donors
22604	Age, physical examination, and history relevant to reproductive system in young men prenatally exposed to PCBs/PCDFs and unexposed controls
22605	Semen indices in PCB/PCDF-exposed young men and unexposed controls
22606	Patient details: colonoscopy examination results
22607	Sedation dose and quality of bowel preparation
22608	Frequency and type of loop seen during colonoscopy
22609	Number and duration of loops and number of straightening attempts per procedure
22610	Frequency and efficacy of abdominal hand pressure  (HP)  during colonoscopy
22611	Primer and probe sequences for RT-PCR amplification of cytokeratin 19 and glyceraldehyde-3-phosphate dehydrogenase  (GAPDH)  mRNA
22612	Standardised incidence ratios  (SIR)  and 95% CIs for cancer after diagnosis of dermatomyositis or polymyositis
22613	Standardised incidence ratios  (SIR)  and 95% CIs for cancers of different histological type in dermatomyositis and polymyositis
22614	Standardised incidence ratios  (SIR)  and 95% CIs of cancer by year after diagnosis of myositis
22615	Sequence of PCR primers and sequence specific probes for different targets
22616	Proportion of vaccinated and unvaccinated individuals in Stockholm County by age and sex
22617	Hospital admissions between Dec 1, 1998, and May 31, 1999
22618	Incidence of admission for endpoint diagnoses
22619	Deaths from all causes according to age group in mean years per 1000, and vaccination status between Dec 1, 1998, and May 31, 1999
22620	Assessing the use of methylation markers for early detection of breast cancer
22621	Clinical details of 21 patients homozygous for CCR5Δ32
22622	Results of adenovirus cultures and detection of viral DNA in serum by PCR in four categories of recipients of stem-cell grafts
22623	Age distribution of samples and positives during three successive winters
22624	Matched unadjusted and adjusted odds ratios for venous thromboembolism
22625	Percentage changes of mRNA levels for Down's syndrome and control samples
22626	Effect of sports on incidence of asthma diagnoses
22627	4-year pollution concentrations in high and low pollution communities  *
22628	Effect of number of team sports played on the risk of new asthma diagnosis in high and low PM  (and other pollutant)  communities
22629	Effect of number of team sports played on the risk of new asthma diagnosis in high and low ozone communities
22630	Odds ratios for case status for polymorphisms at positions 192 and 55 of PON1
22631	Presence of SV40 T antigen sequences in lymphomas, other human tumours, and control tissues
22632	Increase in emergency department visits associated with an increase in allergen concentrations equal to their mean
22633	Distribution of thymidylate synthase genotypes in patients with acute lymphoblastic leukaemia with and without an event
22634	Distribution of cases of squamous-cell carcinoma and adenocarcinoma or adenosquamous carcinoma of cervix, and controls
22635	Risk of squamous-cell carcinoma of the cervix among HPV-positive women according to reproductive factors
22636	Risk of HPV positivity according to reproductive factors among control women
22637	Classification of erythrocytoses
22638	Results of simple two-step swallowing test in elderly patients with or without aspiration pneumonia
22639	Epidemiological findings in six confirmed yellow-fever cases resident in Santa Cruz de la Sierra
22640	Grading of dural ectasia and aortic dilatation in patients and controls
22641	Analysis of patients with suspected pneumonic plague
22642	IgG anti-F1 ELISA test for plague contact population
22643	Simian-foamy virus zoonosis among zoo workers
22644	Rates of new actinic keratoses and basal-cell carcinomas by Poisson modelling
22645	Numbers of new basal-cell carcinomas
22646	Numbers of new squamous-cell carcinomas
22647	Numbers of new melanomas
22648	Regression model summary for the period 1960–98
22649	Incidence of IE, Microbiology, and Valve Replacement From 2000 to 2011
22650	Summary of the virological investigations and sequence data
22651	Observed and expected number of deaths and excess mortality in Bristol relative to other 11 centres in England
22652	Observed and expected mortality relative to other 11 centres in England: 11 open and two closed procedure groups on children younger than 1 year during epoch 3  (April, 1991, to March, 1995)
22653	Odds ratios and sensitivity analysis for open operations on children younger than 1 year
22654	Status at admission and comorbidity for open class of procedures, Hospital Episode Statistics—April, 1991, to March, 1995
22655	Parameter estimates from the conditional logistic regression with two continuous variables and the interaction term
22656	Observed  (obs)  and expected  (exp)  numbers and standardised incidence ratios  (SIRs)  for all cancers in 42 277 siblings of children with cancer, stratified by age at diagnosis
22657	Observed  (obs)  number of sibling pairs with cancer and standardised incidence ratios  (SIR)  in siblings of children with cancer, followed-up in childhood and adolescence, stratified by type of cancer of index patient
22658	Clinical details of sibling pairs with tumour combinations  (other than retinoblastomas)  that suggest hereditary or familial cancer syndromes  (see  table 3 )  and of twins who both had cancer
22659	Observed  (obs)  number of sibling pairs with cancer and standardised incidence ratios  (SIR)  in siblings of children with cancer, followed-up in adulthood, stratified by type of cancer of index patient
22660	Results of laboratory testing
22661	Prevalence of seronegativity to rubella virus by ethnic group, as measured at antenatal screening at the Royal London Hospital  (Jan 1, 2000–Dec 31, 2000)
22662	Proportion of treatments, procedures, and complications associated with mortality in hospital and at discharge in patients younger than age 80 years  (n=21 912) , and their dispersion between different hospitals
22663	Propensity scores for revascularisation within 14 days of acute myocardial infarction  (AMI)
22664	1-year mortality by propensity score divided into quartiles
22665	Sensitivity analysis and 1-year mortality in all patients and in patients who survived until day 14, day 30, day 60, and day 90 after acute myocardial infarction  (AMI)
22666	Effect of revascularisation within 14 days compared with early revascularisation in patients with acute myocardial infarction  (AMI)
22667	Age-adjusted relative increase in risk of fracture  (with 95% CI)  in women for every 1 SD decrease in bone mineral density  (absorptiometry)  below the mean value for age  20
22668	10-year probability of fracture  (%)  in men and women from Sweden, according to age and risk relative to the average population  33
22669	Estimated low and high cumulative mortality rates among infants or children with HIV infection, by mother-to-child transmission cohort and time since birth
22670	Estimated under-5 mortality, HIV mortality, and all-cause mortality, 1999
22671	Preintervention frequency of leishmania infection in children and dogs
22672	Post intervention incidence of leishmania infection in children
22673	Post intervention incidence of leishmania infection in domestic dogs
22674	Comparison between plague RDT, bacteriology, and F1 ELISA for specimens tested at Central Laboratory
22675	Comparison between plague RDTs done at remote sites and at Central Laboratory on the same specimens
22676	Comparison between plague RDT done at remote sites and at Central Laboratory and combination of bacteriology and F1 ELISA
22677	Diagnosis of pneumonic plague in sputum with plague RDT, F1 ELISA, and bacteriology
22678	Prevalence of self-reported clinical symptoms in cases confirmed by Department of Health
22679	Summary of included studies
22680	Number of children, events, and years of follow-up by endpoint and laboratory marker
22681	Estimated risk  (%)  of AIDS and death within 12 months at selected values of age and CD4% or viral load
22682	Results of Cox proportional hazards models
22683	Occurrence of breast cancer in women grouped by result of CE MRI and mammography  (XRM)  examinations
22684	Details of the 35 breast cancers that arose during the study
22685	CE MRI screening for breast cancer in women at raised genetic risk—summary of results from our study and two other prospective studies  4,5
22686	Prevalence of T brucei sensu lato and T b rhodesiense in livestock in Soroti district in 2004, diagnosed by PCR
22687	Projected global deaths and burden of disease  (DALYs)  due to chronic diseases by age, 2005 and 2015
22688	Estimated risk of AIDS and death within 12 months at selected values of age and total lymphocyte count
22689	Modifiable factors underlying the deaths of mothers, babies, and children in South Africa, according to the three national mortality audits  2–4
22690	Risk factors, key investigations, diagnosis, and treatments by socioeconomic strata
22691	Origin of patients, mode of transport to hospital, and method of payment by diagnosis
22692	Origin of patients, mode of transport to hospital, and method of payment by socioeconomic status
22693	Mortality rates by socioeconomic strata
22694	Comparison of acute coronary syndromes in developed and developing countries
22695	Age-specific incidence rates of type 1 diabetes in Finland per 100 000 per year during 1980−2005
22696	Generalised additive models fitted to the data for type 1 diabetes incidence rates for ages 0−14 years in Finland
22697	Main effects of CYP2C19*2 gene variant on cardiovascular outcomes
22698	Number of studies with Haemophilus influenzae type b disease burden data that populated the meningitis and non-pneumonia, non-meningitis models  *  , by WHO region
22699	Haemophilus influenzae type b cases and deaths, with uncertainty estimates, by syndrome and WHO region
22700	Age-related bone loss in the intracortical and trabecular compartments
22701	Concomitant Drug Therapy at Last Follow-Up
22702	Deaths and Transplants
22703	Quality of Life Scores
22704	Primary and secondary endpoints, by patient
22705	Clinical events according to enrolment criteria and Villefranche diagnostic criteria
22706	Slope of change with time in supine brachial blood pressure, heart rate, and common carotid artery variables of randomised patients
22707	Summary of interventions and effect sizes for 15 studies of parenting education programmes, support programmes, or both, comparing interventions with standard of care
22708	Summary of interventions and effect sizes for 15 studies with preschool programmes, preschool-improvement programmes, or both
22709	Analysis of benefits and costs of increasing preschool enrolments
22710	Global life expectancy in years  (95% uncertainty interval)  by sex, year, and age, 1970–2010
22711	Life expectancy in years  (95% uncertainty intervals)  at birth, by sex and decade for 187 countries and 21 Global Burden of Disease regions
22712	Global deaths  (95% uncertainty intervals)  by sex and age group in 1970, 1990, and 2010
22713	Important pathogen threats for introduction into new regions and range extensions within endemic regions, and probable sources and pathways for introduction
22714	Patient outcomes, by hypertrophic cardiomyopathy phenotype category
22715	Univariate predictors of death or heart transplantation, by age at diagnosis of hypertrophic cardiomyopathy and causal or phenotypic subgroup
22716	Multivariable regression models for time to death or heart transplantation by age at diagnosis of hypertrophic cardiomyopathy and causal or phenotypic subgroup
22717	Transmission tree sizes resulting from our interpretation of Middle East respiratory syndrome coronavirus data
22718	Crude and cause-specific infant mortality rate for preterm and term infants
22719	Summary of adolescent prognostic factors, by sex
22720	Prevalence and continuity of common mental disorders at 15–29 years of age
22721	Adolescent predictors of persistence into young adulthood  (waves 7–9)  for 733 adolescents with at least one adolescent occurrence of common mental disorder  (CIS-R ≥12) ,  *   by adolescent risk factor
22722	Prevalence and risk of microcephaly associated with Zika virus infection for different periods of risk during pregnancy
22723	Sensitivity analysis of the estimated risk of microcephaly associated with Zika virus infection to assumptions about final attack rates and birth rates
22724	Distribution of suspected cases by category, according to sex, gestational age, and residence, and concordance with original classification
22725	Head circumference and birthweight according to sex and diagnostic categories
22726	Input datasets used in the pandemic potential framework
22727	Prevalence of skin ulcers and active yaws after mass drug administration
22728	Proportion of non-travelling versus travelling participants with yaws in the post-MDA period according to genotypes
22729	Prevalence of latent yaws in subgroups determined by age
22730	Antibodies to KSHV orf 65 protein and latent immunofluorescence antigen in different HIV risk groups and controls
22731	Comparison of antibody reactivity to orf 65 protein and to latent antigen (s)
22732	Comparison of PCRdetection of KSHV and antibody reactivity to orf 65 and latent antigen (s)
22733	Prevalence rates in US-born and Haitian-born pregnant women and their offspring
22734	Observed cases, expected cases, and relative risks of malignant diseases among people with AIDS
22735	Estimated annualised incidence of microbial keratitis and estimated relative risk of microbial keratitis
22736	Microbial isolates of ulcerative keratitis in cosmetic contact-lens wearers  (n=30)
22737	Morbidity and ultimate visual outcome in 92 cases of contact-lens-associated microbial keratitis
22738	Serum concentrations of p,p′- DDT, p,p′ -DDE, and predominant PCBs in cases of exocrine pancreatic cancer with and without a mutation in the K-ras gene
22739	Results of multivariate conditional logistic regression analysis
22740	Serum concentrations of compounds among the 26 hospital controls, and significance of differences between them and all 51 cases of pancreatic cancer, 34 cases with a K-ras mutation, and 17 cases without a K-ras mutation
22741	Median survival and time to AIDS
22742	Exposure category and age at seroconversion for individuals included in analyses of mortality
22743	Effect of age at seroconversion by exposure category and time since seroconversion
22744	Mortality and development of non-Kaposi's sarcoma AIDS by time since seroconversion
22745	Summary of results from review of studies on osteoarthritis of the knee
22746	Summary of patients' responses to the question: how helpful do you find these treatments for reducing pain and disability?
22747	Summary of patients' responses to the question: which treatments should be made a priority for researchers?
22748	HHV-8 prevalence among males and females by age
22749	Distribution of pairs according to the familial relationship and the HHV-8 serological status
22750	Distribution of sib-sib pairs according to the HHV-8 status of the mother and age difference between siblings
22751	Prognostic value of variables at the time of diagnosis, tested by the Kaplan Meier method
22752	Details of primers used in the QF-PCR multiplex
22753	Comparison of quantitative PCR results with the gold standard of karyotype analysis for chromosomes 13, 18, and 21
22754	Number of patients offered follow-up appointments  (intention-to-treat analysis)
22755	Tests, investigations, and contacts with health-care services over 6 months
22756	Patients' outcomes
22757	Incidence of vasculitis and connective tissue disease per 100 000 children per year, and by ethnic origin
22758	Annual incidence, per 100 000 children younger than age 5 years, of Kawasaki disease in children younger than age 5 years by ethnic origin
22759	Patients with venous thromboembolism
22760	Total volume of blood loss  (intraoperative and postoperative)  and total volume of blood transfused  (intention-to-treat population)
22761	Patients with severe bleeding per treatment group and type of surgery  (intention-to-treat population)
22762	Mean  (SD)  concentrations of MMP-1 and MMP-13 produced by dissociated rheumatoid synovial cells from wrist joint, encapsulating, and invasive tenosynovial samples
22763	Multivariate logistic regression analysis of sex, early-onset of treatment, and presence of MBL mutations for development of coronary artery lesions in children with Kawasaki disease
22764	Analysis of mesenchymal stem cells in bone marrow and bone
22765	Main reasons for referral for karyotyping and detection rates of abnormal results
22766	Types of abnormal karyotypes detected in samples referred after screening programmes for Down's syndrome
22767	Risk categories of undetected chromosome abnormalities after screening for Down's syndrome
22768	Proportion of abnormal karyotypes in referrals after screening for Down's syndrome detected by rapid aneuploidy diagnosis  (RAD)
22769	Comparison of rapid aneuploidy testing and karyotyping combinations for trisomies 13, 18, and 21
22770	Changes over time in mental health, job stress, and job satisfaction
22771	Univariate and multivariate analyses of change over time in psychiatric morbidity and emotional exhaustion
22772	Scenarios and key assumptions
22773	Unadjusted Outcomes at Six-Month Follow-Up
22774	Multivariate Model: Patients With Preserved Versus Depressed Ejection Fraction
22775	Subsidary Multivariate Analyses
22776	Description of comparison groups, by bearing surface
22777	Predicted revision rates for 55-year-old men by prosthesis and head size  (95% CIs)
22778	Predicted revision rates for 55-year-old women by prosthesis and head size  (95% CIs)
22779	Comparison of most commonly used brands
22780	Reasons for revision  (incidence per 1000 patient-years, 95% CIs)  by articulation and fixation
22781	Interventions directed at clinical decision making
22782	Interventions directed at health systems
22783	45-day mortality by age and sex
22784	Changes in mortality by year of primary operation
22785	Cox proportional hazards models of 45-day mortality by variables
22786	Patient survival at 5, 10, 15, and 20 years after total hip replacement
22787	Patient survival at 5, 10, 15, and 20 years after total knee replacement
22788	Details of patients by intention-to-treat analysis at screening
22789	Details of patients after transplantation
22790	Current TCDD concentrations  (ppt)  by zone and gender
22791	Pregnancy terminations in women who were users of “other” or third-generation oral contraceptives
22792	Size of final infarcts and of sub-compartments defined by initial level of residual perfusion  (in mL)
22793	Mean stroke-scale scores and lesion volumes  (on day one, five, 30 or 90)  for the recanalisation and non-recanalisation group
22794	Clinical and laboratory data  (mean [SD])  in severely ill patients with relative eosinophilia who showed an abnormal versus normal low-dose SST
22795	Changes in Total Defect Score, H/M Ratio, and WR for 123I-MIBG Imaging in Patients With Dilated Cardiomyopathy
22796	Changes in LVEDV, LVEF, and NYHA Functional Class in Patients With Dilated Cardiomyopathy
22797	Electroradiological features of the patients
22798	Clinical profile of 135 patients with partial or generalised tonic-clonic seizures
22799	Data for censored patients
22800	Odds ratio for terminal remission
22801	Results of OLIG2 in-situ hybridisation in brain tumours
22802	Additional treatments during follow-up  (6–52 weeks)
22803	Improvement in primary and secondary outcome measures
22804	Adverse reactions during 6-week intervention period
22805	Relative risk  (95% CI)  of sex, age, epilepsy type, and neurological disorder  *   for death
22806	Activity of glutamine synthetase
22807	Long-Term Treatment in the Four Patient Groups
22808	Actuarial cumulative percentages achieving each outcome at selected intervals from randomisation with differences  (95% CI)
22809	Patients reporting adverse events at any follow-up
22810	Echocardiographic Measurements in Groups IA and IB
22811	Echocardiographic Measurements in Groups IIA and IIB
22812	Results of Stress Test at 3 Months After Discharge
22813	Predictors of survival
22814	Medications given during cardiac arrest resuscitation
22815	Duration of critical steps in resuscitation sequence
22816	Outcomes
22817	Effect estimates for prespecified covariates in logistic regression model
22818	Dose taken by adults at withdrawal or last follow-up
22819	Treatment failure  (all events)
22820	Seizure outcomes by drug
22821	Frequency of clinically important adverse events
22822	Incremental cost-effectiveness ratios—cost per QALY
22823	Incremental cost-effectiveness ratios—cost per seizure avoided
22824	Probabilities that the new antiepileptic drugs are cost effective relative to carbamazepine across a range of ceiling ratios  (λ)
22825	Dose taken by adults at withdrawal or last follow-up
22826	Treatment failure
22827	Seizure outcomes by drug
22828	Frequency of clinically important adverse events
22829	Incremental cost-effectiveness ratios—cost per QALY
22830	Incremental cost-effectiveness ratios—cost per seizure avoided
22831	Probabilities that the new antiepileptic drugs are cost-effective relative to valproate across a range of ceiling ratios  (λ)
22832	Distribution of 8172 deaths and 23 million person-years at risk
22833	Adjusted mortality rate ratios  (MRR)  according to number of years since discharge with first febrile seizure
22834	Cause-specific mortality rate ratios  (MRR)  within 2 years of a first febrile seizure
22835	PCR-corrected day-28 cure rate by analysis population
22836	PCR-corrected day-28 cure rate by bodyweight group in the modified ITT population
22837	PCR-corrected day-14 and day-42 cure rates by analysis population
22838	Time since first admission with brain injury and relative risk  (RR)  of epilepsy
22839	Age at first admission with brain injury and relative risk of epilepsy
22840	Duration of first hospital stay with brain injury and relative risk of epilepsy
22841	Family history and relative risk of epilepsy after traumatic brain injury
22842	Data sources for cause-of-death estimation for 2004 Global Burden of Disease study  17
22843	Estimated total number of deaths and all-cause mortality rates  (per 100 000)  in people aged 10–24 years in 2004, classified by economic and geographic groupings
22844	2004 all-cause mortality rates  (per 100 000)  stratified by country classification, age-group, and sex
22845	Ten most common causes of death by sex and age-group
22846	Surgical procedures and pathological findings in study population
22847	Univariable and multivariable survival analysis of time to first seizure  (≥OC3)
22848	Effect of pathological findings on time to first seizure after temporal lobe resections, allowing for age at surgery
22849	Estimated percentage of patients remaining free of seizures with loss of awareness  (with 95% CIs)  at intervals after temporal surgery in patients who did, and did not have, SPS in first 2 years after surgery
22850	People remaining seizure free after continuous periods of postsurgical seizure freedom, estimated by survival analysis, at each subsequent follow-up
22851	People gaining 1 year of seizure freedom after continuous periods of ongoing seizures, estimated by survival analysis, at each subsequent follow-up
22852	Patterns of seizure remission and relapse after surgery
22853	Hemodynamic Changes During PASE  (n = 46)
22854	Risk factors for SUDEP from the ILAE Task Force on Epidemiology pooled analysis from four major case-control studies
22855	SUDEP incidence rates after epilepsy surgery
22856	Prevalence of pre-existing, new, and lifetime psychiatric morbidity in individuals with epilepsy
22857	Prevalence and odds of premature mortality in epilepsy, by International Classification of Diseases chapter
22858	Risks of premature death in individuals with epilepsy compared to population controls and unaffected siblings
22859	Mortality risks after diagnosis with epilepsy, stratified by diagnostic threshold, sex, severity, patient type, epilepsy subtype, age group, birth order, and time after first diagnosis
22860	Associations of external causes of death in epilepsy with psychiatric comorbidity
22861	Potential biomarkers  (grouped by pathway)  and targeted combination therapies to overcome resistance to targeted monotherapy
22862	Novel and rare SCN4A variants in SIDS cases of European ancestry and ethnically matched controls
22863	Biophysical parameters of NaV1.4 variants
22864	Clinical data
22865	Operations
22866	Postoperative infections and complications
22867	Distribution of blood transfusions
22868	Association between GBV-C RNA and aetiologies of fulminant hepatic failure
22869	Clinical and biochemical data
22870	Prevalence of metabolic disorders
22871	Detection of HHV-8 KS330233 DNA and RNA sequence from peripheral blood mononuclear cells  (PBMC)  of blood donor
22872	Primary composite efficacy outcomes and components  (intention-to-treat analysis)
22873	Secondary efficacy endpoints  (analysis of patients who received any amount of study drug)
22874	Adverse events  (intention-to-treat analysis)
22875	Ages of children younger than 5 testing positive for HIV-1
22876	Means of ascertainment, sex, and age of acutely infected outbreak-related cases
22877	Geographical distribution of women screened during pregnancy according to residence and serologic status
22878	Number of individuals in National Haemophilia Register exposed to blood products carrying high risk of HCV infection during 1969–85, by severity of haemophilia, HIV-1 status, and vital status
22879	Mortality from primary liver cancer and liver disease in UK haemophilia population exposed to high HCV-risk blood products, by calendar year, based on death-certificate information
22880	Mortality during 1985–92 from primary liver cancer and liver disease in UK male haemophilia population exposed to high HCV-risk blood products, by HIV-1 status and severity of haemophilia, based on death-certificate information
22881	Factors influencing mortality from chronic/unspecified liver disease or liver cancer
22882	25-year cumulative risk of death from chronic or unspecified liver disease or liver cancer
22883	Annual death rates per 1000 in UK haemophilic men and boys exposed to high HCV-risk blood products
22884	Respiratory-chain-enzyme activities in mitochondria from surgical biopsy samples from the quadriceps muscle
22885	Haemosiderosis of liver and spleen specimens, liver iron content, and serum iron metabolism
22886	Comparison of neonatal and full-term cord blood
22887	Third-stage management
22888	Primary and secondary maternal outcomes
22889	Neonatal outcomes
22890	PPH by randomly allocated active or expectant management: stratified analysis
22891	Prevalence of TTV infection in patients with chronic liver diseases and healthy controls
22892	Liver histology in 14 patients with TTV infection
22893	Detection of TTV in plasma-derived blood products
22894	TTV infection in haemophilic patients
22895	Detection of TTV in patients with idiopathic fulminant hepatic failure
22896	Effects of risk factors on leukaemia-free survival, overall survival, transplant-related mortality, and relapse incidence
22897	5-year probability of leukaemia-free survival  (LFS) , survival, transplant-related mortality  (TRM) , and relapse incidence  (RI)
22898	Haemochromatosis allele frequencies by TFR genotype in myeloma patients and controls
22899	Composite and individual efficacy outcomes at 7 days  (primary outcomes)  and 72 h  (end of masked treatment)
22900	Details of patients with refractory angina up to day 7
22901	Cardiac interventions by day 7
22902	Safety outcomes within 7 days
22903	Combined results of OASIS-1 and OASIS-2 studies at 7 days and 35 days
22904	Risk of CJD by surgical procedures
22905	Risk of CJD by residence and occupation
22906	Risk of CJD by blood transfusion
22907	Distribution of morbidity causes leading to at least one severe event
22908	Seroconversion and transmission rates in pregnant women and birth prevalence of toxoplasma infection in infants
22909	Serological findings in eluate from PKU cards from children born to 30 women who seroconverted during pregnancy  (1995–96)
22910	Effects of aspirin on non-fatal vascular events and deaths in hip-fracture patients up to day 35
22911	Effects of aspirin on bleeding episodes and related complications in hip-fracture patients up to day 35
22912	Effects of aspirin on measures of blood loss in hip-fracture patients up to day 35
22913	Effects of aspirin on non-fatal vascular events and deaths in elective-arthroplasty patients up to day 35
22914	Effects of aspirin on bleeding episodes and related complications in elective-arthroplasty patients up to day 35
22915	Results of testing for HCV infection
22916	Comparison of TGA patients and controls
22917	Adjusted excess risk of various factors for ARI and ALRI estimated with a linear model
22918	Adjusted odds ratios of various factors for ARI and ALRI estimated with a logistic model
22919	Frequency of haemochromatosis genotypes
22920	Transferrin saturation in patients with late-onset type 1 diabetes mellitus
22921	Stroke and intracerebral bleeding
22922	Non-cerebral bleeding
22923	Comparison of incidence of febrile seizure by age in the French cohort and a reference study of a general population
22924	Independent predictors of operative mortality
22925	Trends in volunteer whole-blood donation from Shenzhen City
22926	HIV test reults from whole-blood donors in Xinjiang in 2000
22927	Risk factors associated with HIV infection in whole-blood donors in Xinjiang
22928	Transfusion requirements, duration of operation, and hospital admission in the three study groups
22929	Number of recipients transfused, by year and blood component given
22930	Dead recipients  (n=31)  of labile components from vCJD donors
22931	Living recipients  (n=17)  of labile blood components donated by vCJD cases
22932	Species and geometric mean number of flies caught from the eyes of volunteer children by treatment group and triplet
22933	Age-standardised prevalence of active trachoma for people of all ages
22934	Prevalence of active trachoma in children aged 0–9 years
22935	Cohen's kappa for agreement on diagnosis of active trachoma between photograph and field grades
22936	Infectivity of wires exposed to ten-fold serial dilutions of 263K strain hamster scrapie brain homogenates
22937	Effect of various treatments on contaminated wires
22938	Distribution of infectivity in whole blood, challenge, and resin flow-through
22939	Adjusted rate ratios of cancer among recipients of precancerous blood, relative to recipients of non-cancerous blood
22940	Adjusted rate ratios of cancer among recipients of precancerous blood from donors with cancers at different anatomical sites, relative to recipients of non-cancerous blood
22941	Adjusted rate ratios of site-specific cancers among recipients of precancerous blood, relative to recipients of non-cancerous blood
22942	Lung function test results
22943	Death by cause
22944	Vascular occlusive events, need for transfusion and surgery, and level of dependency
22945	Adverse events reported in at least 10% of patients given mipomersen, and significant laboratory abnormalities
22946	Analysis of trends from 1999–2002 and 2003–06 for government health expenditure as source  (GHE-S) ; share of general government expenditure spent on health  (GHE-S/GGE) ; share of gross domestic product  (GDP)  spent by government  (GGE/GDP) ; and GDP
22947	Time-series cross-sectional regression results for government health expenditure as source  (GHE-S)  as a share of gross domestic product  (GDP)  for countries in Global Burden of Disease developing regions based on the Arellano-Bover/Blundell-Bond model
22948	Time-series cross-sectional regression results for government health expenditure as source  (GHE-S)  as a share of gross domestic product  (GDP)  for subgroups of countries based on the Arellano-Bover/Blundell-Bond model
22949	Treatment-emergent adverse events in every treatment group during the 12-week treatment period  (safety population)
22950	Risk factors for HIV transmission, stratified by treatment status of HIV-positive partner
22951	Comparison of design features of the CHAMPION studies
22952	Clinical efficacy outcomes at 48 h and at 30 days
22953	Site-reported angiographic complications
22954	Non-CABG-related bleeding events at 48 h
22955	Numbers and rates of treatment-emergent and serious adverse events in CHAMPION pooled safety population
22956	Results for the primary endpoint at 1 year
22957	Location of worst bleeding per patient
22958	Secondary and safety endpoints at 1 year
22959	Weight increase in the first 2 min after birth and mother's position during delivery
22960	Weight increase, by centre
22961	Summary of primary endpoints
22962	Summary of secondary endpoints
22963	Distribution of parasitaemic samples in exposed and non-exposed patients receiving treated or untreated whole blood
22964	Pre-transfusion and post-transfusion haematology and serum chemistry parameters  (per-protocol population)
22965	Treatment-related adverse events
22966	Secondary outcomes in the intention-to-treat population
22967	Safety outcomes occurring during hospital admission in the intention-to-treat and as-treated populations
22968	Kaplan-Meier 5 year estimates by intention-to-treat
22969	Outcomes between index procedure and 30 days of follow-up by treatment group
22970	1-year clinical outcome by treatment group
22971	Clinical bleeding by day 7 or hospital discharge and by day 21
22972	Adverse events
22973	Frequency of reduced leaflet motion in different transcatheter and surgical valve types
22974	Antiplatelet and anticoagulation therapy at the time of the CT scan
22975	Clinical outcomes
22976	1950 confirmed cases of infection-related microcephaly by diagnostic method and occurrence after the first epidemic wave of Zika virus infection in regions of Brazil; January, 2015–November, 2016
22977	Individuals recruited into Karonga Prevention Trial by previous BCG scar status and trial vaccine
22978	Comparison of vaccine groups by age, sex, initial household contact with leprosy, and by proportions later examined at least once
22979	Incidence rate ratios of leprosy among recipients of trial vaccines, by different case definitions and criteria
22980	Incidence rate ratios of tuberculosis among recipients of trial vaccines, by different case definitions and criteria
22981	Detection of HGV and HCV RNA in factor VIII and factor IX concentrates
22982	Detection of HGV in immunoglobulin and in immunoglobulin recipients
22983	Frequency of HGV and HCV infection in haemophiliacs
22984	Treatment outcomes for AFB-positive patients treated with 12-month regimen  (phase two)
22985	Treatment outcomes for AFB-positive patients treated with 8-month regimen  (phase three)
22986	Deaths associated with MgSO4 exposure
22987	Comparison of tuberculosis-control measures before and after implementation of infection-control policies, June, 1994, to August, 1995
22988	Main clinical and microbiological features
22989	Individual first outcome events at end of period 2
22990	Treatment-related adverse events  (in >1·5% of participants)  and rates of withdrawal from study medication
22991	Treatment outcome
22992	Treatment outcome by supervision method
22993	Univariate analysis of rifampin monoresistant relapse among HIV-seropositive participants assessed for relapse
22994	Univariate analysis of risk factors for relapse among HIV-seropositive participants assessed for relapse, by treatment group
22995	Multivariate Cox's proportional-hazards regression analysis of variables evaluated as factors in sputum conversion
22996	Culture status at month 6 by treatment group and HIV status
22997	Serious adverse events and causes of death
22998	Concentrations and limits of detection  (LOD)  of therapeutic drugs in drinking water, river water, and sediments
22999	Randomised trials comparing efficacy and safety of bolus compared with infusion thrombolytic treatment in acute myocardial infarction
23000	Incidence of intracranial haemorrhage and non-haemorrhagic stroke in randomised trials of bolus compared with infusion thrombolytic treatment
23001	Incidence of death and reinfarction in randomised trials of bolus compared with infusion thrombolytic treatment
23002	Treatment outcomes among enrolled patients
23003	Treatment outcomes among patients who received health-worker DOTS strategy
23004	Treatment outcomes among enrolled patients by sex
23005	Adjusted odds ratios for factors that might affect treatment outcome
23006	Number and type of drugs tested with number of samples failing to comply with British Pharmacopoeia limits
23007	Descriptive statistics of individual drug preparations tested
23008	Stroke and intracranial haemorrhage
23009	Bleeding complications and thrombocytopenia
23010	Summary of treatments used
23011	Antimicrobial resistance among isolates from 463 patients with culture positive Mycobacterium tuberculosis
23012	WHO treatment outcomes
23013	Smear, culture, and cavity conversion rates
23014	Choice of screening and prevention in 4475 women at risk of breast cancer
23015	Results of nucleic-acid-sequence-based amplification of RNA detected by electrochemiluminescence
23016	Comparison of RT-PCR,  (data from ref 2) , and NASBA results for samples of saliva and CSF from patients with rabies
23017	Plasma concentrations of aminopeptidase P and carboxypeptidase N
23018	Factors contributing to anti-HBs  (log)  immune response
23019	Factors contributing to anti-HAV  (log)  immune response
23020	Number of people carrying at least one HLA-DRB1* allele
23021	Intraclass correlations  (r)  of anti-HBs and anti-HAVs after third vaccination for monozygotic and dizygotic twins
23022	Effect of shared HLA-DRB1* alleles
23023	Study events by NSAID  *
23024	Blood cell counts, coagulation, and complement variables before and after human-islet perfusion with fresh ABO-compatible blood
23025	Breast-cancer prevention trials
23026	Major events in the tamoxifen prevention trials and other related studies  (tamoxifen vs control)
23027	Major events by age at randomisation  (tamoxifen vs placebo)
23028	Deaths from major causes in chemoprevention trials  (tamoxifen vs control)
23029	Clinical features and treatment outcomes among SARS children
23030	Primary analysis: CHF outcomes
23031	Subgroup analyses of congestive heart failure outcomes
23032	Cox's regression analysis of survival
23033	Robust linear regression analyses of CD4-cell-count slopes based on 9173 observations from 1848 patients on-treatment with stable viral load
23034	Blood component cell numbers and volumes before and after leucoreduction
23035	Concentration of TSE infectivity in whole and leucoreduced blood
23036	Information on H3N2 in fluenza A virus-infected patients from whom samples were taken
23037	Aminoacid mutations in viruses isolated from patients treated with oseltamivir
23038	Effect of aminoacid mutations on neuraminidase sensitivity to GS4071
23039	Changes in viral titre before and after treatment with oseltamivir
23040	Dates, target population, and measles vaccination coverage of SIA, 2000 to June, 2003
23041	Estimated annual measles deaths averted by SIA completed between 2000 and June, 2003
23042	Results of case-based measles surveillance with laboratory confirmation in areas after SIA, 2002–03
23043	Measles outbreaks detected at least 60 days after SIA in children aged 9 months to 14 years, 2001 to June, 2003
23044	Risk of acute myocardial infarction with use of selected NSAIDs compared with remote use of a NSAID or with current use of celecoxib
23045	Aspirin use, over-the-counter NSAID use, smoking history, and family history of acute myocardial infarction in 817 randomly selected controls with remote NSAID exposure or current exposure to celecoxib, ibuprofen, naproxen, or rofecoxib
23046	Risk of cholera and protective efficacy of killed oral cholera vaccines, by level of cholera vaccine coverage of the bari during the first year of follow-up
23047	Risk of dysentery in recipients of cholera vaccine or placebo, by level of cholera vaccine coverage of the bari during the first year of follow-up
23048	Predictors of cholera risk in recipients of vaccine or placebo, in three multivariable models
23049	Univariate odds ratios of relations between risk factors and M tuberculosis infection as determined by ELISpot and TST
23050	Multivariate adjusted odds ratios of relations between risk factors and M tuberculosis infection, as determined by ELISpot and TST
23051	Hazard ratios of progression to death in HAART programmes in low-income and high-income countries
23052	Outcomes for all new smear-positive patients registered in every district
23053	Comparison of success rates between community DOTS and family-member DOTS strategies
23054	Diagnostic performance of classifiers
23055	Seroconversion  (by PRNT50 antibody assay)  and geometric mean titre on day 56 in per-protocol population  (n=735)
23056	Antiplatelet Trialists' Collaboration  (APTC)  endpoints and overall mortality
23057	Surveys included in the secondary analysis
23058	Basket of 15 medicines found in at least 80% of surveys
23059	Average of country-level mean percentage availability of any generic product, by WHO Region
23060	Median price ratios  *   of public sector procurement prices for lowest-priced generics, overall and by WHO Region
23061	Median price ratios  *   of originator brands and lowest-priced generics in the private sector, and of lowest-priced generics in the public sector, by WHO Region
23062	Mean number of day's wages of the lowest-paid unskilled government worker needed to purchase a course of treatment, by WHO Region
23063	Cumulative percentage mark-ups between manufacturer's selling price or Cost, Insurance, and Freight price, and final patient price in the public and private sectors
23064	Event rates for cardiovascular outcomes of intensive glucose-lowering versus standard treatment  §
23065	Clinically significant bleeding  (TIMI major, TIMI minor, or requiring medical attention) , categorised by total daily dose for the entire population, stratum 1, and stratum 2
23066	Adverse events in at least 3% of patients in either treatment group by system organ class and preferred term, excluding bleeding events
23067	Death, myocardial infarction, stroke, or severe recurrent ischaemia requiring revascularisation, categorised by total daily dose for the entire population, stratum 1, and stratum 2
23068	Death, myocardial infarction, or stroke, categorised by total daily dose for the entire population, stratum 1, and stratum 2
23069	All-cause mortality by background variables at start of follow-up
23070	Adverse events  *   in group 1  (pandemic vaccine only)  and group 2  (pandemic and seasonal vaccine)
23071	Geometric mean of haemagglutinin inhibition titres before and after immunisation in group 1  (pandemic vaccine only)  and group 2  (pandemic and seasonal vaccine)
23072	Predictors of triple class virological failure
23073	Treatment outcome at week 48
23074	Most prevalent treatment-emergent NNRTI and N (t) RTI RAMs  (in two or more patients with available resistance data)  at the time of week 48 analysis
23075	Overview of treatment-emergent adverse events and laboratory abnormalities at the time of week 48 analysis
23076	Summary estimates for efficacy  (standardised mean difference and response rate)  and dropout rates in meta-analyses of direct comparisons between pairs of antimanic drugs or placebo
23077	Prescribed Medications in the Patients With Coronary Artery Disease
23078	Hemodynamic and Brachial Parameters Before and After Drug Treatment in Healthy Subjects
23079	Brachial Responses and Hemodynamics After Treatment in Patients With Coronary Artery Disease
23080	Population and process data by study group
23081	Prevalence of culture-positive Mycobacterium tuberculosis in adults  (per 100 000 adult population) , by trial group, household intervention, and ECF intervention
23082	Incidence of TST conversion in schoolchildren  (per 100 person-years) , by trial group, household intervention, and ECF intervention
23083	Details of breast cancer prevention trials
23084	Breast cancer incidence in the chemoprevention trials
23085	Major non-breast cancer events in the prevention trials
23086	Outcomes at 2 years
23087	Serious adverse events within 2 years of recruitment
23088	End-of-season surveillance of Guillain-Barré syndrome after use of influenza A  (H1N1)  2009 monovalent vaccine, according to surveillance system
23089	Analyses of the association between influenza A  (H1N1)  2009 monovalent inactivated vaccines and Guillain-Barré syndrome
23090	Attributable risk for Guillain-Barré syndrome associated with influenza A  (H1N1)  2009 monovalent inactivated vaccines, by age group
23091	Association between influenza A  (H1N1)  2009 monovalent inactivated vaccines and Guillain-Barré syndrome, by period
23092	Validation evidence of putative treatment development targets in bipolar disorder
23093	Randomised trials of adjunctive psychosocial intervention in bipolar disorder
23094	Top ten causes of disability-adjusted life-years in the Arab world by sex and overall in 1990, 2005, and 2010
23095	Decomposition analysis of the change of DALY numbers  (thousands)  by level 1 causes from 1990 to 2010 into total population growth, population ageing, and changes in age-specific, sex-specific, and cause-specific DALY rates for the Arab world
23096	Top ten causes of disability-adjusted life-years in low-income Arab countries by sex and overall in 1990, 2005, and 2010
23097	Top ten causes of disability-adjusted life-years in middle-income Arab countries by sex and overall in 1990, 2005, and 2010
23098	Top ten causes of disability-adjusted life-years in high-income Arab countries by sex and overall in 1990, 2005 and 2010
23099	Efficacy outcomes
23100	Treatment-emergent adverse events group in all participants who received ≥1 dose of study drug  (occurring in ≥5% in either treatment)
23101	Blood components associated with viraemic donations
23102	Association between transfused blood components and transmission of hepatitis E virus in 43 of 60 exposed patients in whom follow-up was possible
23103	Outcome in 18 recipients infected by transfusion of a blood component from a viraemic donor, ranked by immunosuppression
23104	Shedding of poliovirus in stool samples detected by PCR
23105	Serum neutralising antibody titres before and after vaccination with inactivated poliovirus vaccine  (IPV)  or bivalent oral poliovirus vaccine  (bOPV)
23106	Patients who met the primary endpoint
23107	Kaplan-Meier estimates of proportions of patients meeting primary endpoint at week 96
23108	Virological failure and emerging resistance mutations per trial arm
23109	Occurrence of cholera with severe dehydration and cumulative overall protection by the killed oral cholera vaccine during 2 years of follow-up
23110	Occurrence of cholera with severe dehydration and cumulative total protection by the killed oral cholera vaccine during 2 years of follow-up
23111	Properties of P2Y12 inhibitors
23112	Properties of non-vitamin K-dependent oral anticoagulants
23113	Onset and duration of action for short-acting and long-acting nitrates in patients with coronary artery disease
23114	Important side-effects and contraindications with use of β blockers and calcium-channel blockers
23115	Considerations for prescription of emerging anti-angina drugs to patients
23116	Anti-ischaemic effect of physiological anti-angina therapies
23117	Anti-ischaemic effect of emerging metabolic anti-angina therapies
23118	Treatments investigated to reduce angina or ischaemia, but not recommended for use in patients
23119	Extent of coronary artery disease and the degree of incomplete revascularisation
23120	Efficacy and safety endpoints
23121	Incidence and adjusted relative risks  (RR)  of coronary events by supplementation group
23122	Incidence and adjusted relative risk of coronary events by supplementation with either a-tocopherol or b-carotene
23123	Incidence and adjusted relative risk of total myocardial infarction and fatal myocardial infarction by supplementation group
23124	Clinical features of study children
23125	Results of logistic regression
23126	Measles antibodies in group 1
23127	Measles antibodies in groups 2 and 3
23128	Geometric mean titres  (95% CI)  in mIU according to breastfeeding at 18 months for seroconverted infants
23129	Univariate correlates of HIV-1 infected cells in cervical and vaginal secretions
23130	Fetal deaths among women who received multivitamins or vitamin A compared with those who did not receive the respective regimen
23131	Birth outcomes in women who received multivitamins or vitamin A compared with those who did not receive the respective regimen
23132	T-cell measurements in women who received multivitamins or vitamin A compared with those who did not receive these regimens
23133	LSM  (SE)  of cardiovascular risk factors in intention-to-treat population from start of the lead-in period to week 104
23134	Adverse events remotely, possibly, or probably related to treatment
23135	Reasons for premature withdrawals
23136	Pain perception in acupuncture and placebo: VAS scores
23137	Pain scores on a 100 mm visual analogue scale
23138	Relation between doctor-patient communication and patients' opinions, feelings, and choices of treatment
23139	Triglycerides, total homocysteine, and related factors before and after therapy with fenofibrate and bezafibrate in hypertriglyceridaemic men
23140	Estimated proportions of children who were HIV-1 infected by 3 months of age
23141	Unadjusted associations between socioeconomic indicators and risk of HIV-1 infection by 3 months of age in 547 children
23142	Associations between feeding practices and risk of HIV-1 infection by 3 months of age
23143	Antioxidant status in healthy controls and mild asthmatic patients
23144	Occurrence of pre-eclampsia in intention-to-treat and completed-study cohorts
23145	Logistic-regression analysis
23146	Differences in proportions of incontinent patients between the treatment and the control group
23147	Average loss of urine per 24 h
23148	Scores on the visual analogue scale preoperatively, and at 1, 6, and 12 months
23149	Reasons for stopping treatment
23150	Clinical outcomes for ramipril and placebo groups
23151	Change in blood pressure with ramipril and placebo
23152	Numbers and types of clinical trials attached to drug-licensing applications for postmenopausal hormone therapies
23153	Description of trials reporting cardiovascular events
23154	Number of women with cardiovascular adverse effects, odds ratios, and probability of finding observed odds ratios
23155	Hysteroscopical and histological findings at entry for women who completed the trial and those who withdrew
23156	Hysteroscopical and histological findings at the end of the trial
23157	Uterine changes at 6 and 12 months as assessed by transvaginal sonography
23158	Vaginal bleeding patterns at different intervals over the trial period
23159	Laboratory blood test results on admission
23160	MTHFR mating types of 167 couples ascertained for a child with NTD, genotypes of 3 of their surviving affected offspring, and 181 unaffected offspring
23161	Serum potassium before and during nadroparine
23162	Treatment outcomes
23163	Comparison of IL10.R alleles in RA patients from different locations
23164	Effects of lipid-lowering drugs on plasma aminoacids concentrations
23165	Clinical strategies to manage breastfeeding while on codeine
23166	Patient responses
23167	RF titres in different cohort subsets
23168	Current B-CLL stage  (Binet) , year of diagnosis, and treatment history
23169	ATM expression and ATM mutations in B-CLL
23170	Analysis of loss of heterozygosity  (LOH)  at 11q22-23
23171	Haematological and immune reconstruction after AHSCT
23172	Clinical rheumatological tests before and after AHSCT
23173	30-day endpoints by intervention and genotype
23174	Odds ratio for risk of coronary-artery disease among heterozygous and homozygous  (A2/A2)  carriers
23175	Relative risks for coronary artery disease and complications among heterozygous and homozygous carriers
23176	Clinical features of patients with probable or possible MSA and PSP and atypical parkinsonism
23177	Assessment of plaque-surface morphology of contralateral carotid artery stratified according to assessment of plaque-surface morphology of symptomatic carotid artery
23178	The risks of non-stroke vascular death and non- plaque-surface morphology of the symptomatic and contralateral carotid arteries
23179	Mortality due to the three subcategories of non-stroke vascular death stratified according to the assessment of the plaque surface morphology of the symptomatic carotid artery
23180	Outcome and HIV infection
23181	Comparison of clinical presentation between PCP and bacterial pneumonia
23182	Comparison of treatment response
23183	Effect of HIV infection on oxygen requirements and outcome
23184	Mortality rates and associated statistics for operations by procedure type and age-group
23185	Mortality rates and associated statistics for marker operations
23186	Mortality rates and associated statistics for operations by procedure type and operating centre
23187	Mortality rates for marker lesions by department
23188	Mortality rates and associated statistics for marker operations by surgeon
23189	Events after 14 days
23190	Frequency of symptomatic and asymptomatic cerebral haemorrhage after 14 days
23191	Causes of death  (14 days)
23192	Outcome at 14 days
23193	Outcome at 3 months
23194	Number of isolates of each pathogen identified by each diagnostic technique
23195	Distribution of pathogens observed in HIV-1-positive and HIV-1-negative patients, and in patients with different radiological categories of pneumonia
23196	Number of pneumonia patients who died or survived after 3 weeks of follow-up
23197	Adjusted odds ratios for death within 3 weeks of admission with acute pneumonia
23198	Number of pneumonia patients who died or survived after 3 weeks of follow-up
23199	Descriptive statistics of BMD measurements relative to cosmonauts who completed 1-month or 2-month missions in the Russian MIR station
23200	Friedman and Wilcoxon tests for the 6-month flight and recovery cohort
23201	Distribution of genotypes of unrelated individuals  (parents)  in the two panels
23202	Migraine symptoms in everyday life before closure of cardiac right-to-left shunts
23203	Fortification spectra after closure procedure
23204	Effect of closure of cardiac right-to-left shunts on migraine in everyday life
23205	Assessment of quality of life  (SF-36)
23206	Causes of death  (numbers of patients)
23207	All-cause mortality by subgroup of patients
23208	Adverse events occurring in 10% or more of the study population
23209	Atrial fibrillation study endpoints
23210	Stepwise logistic regression model for prediction of postoperaive atrial fibrillation
23211	β-blocker utilisation variables
23212	Potential side-effects
23213	Non-atrial fibrillation clinical outcomes
23214	Regional activation during migraine headache and rest
23215	Population prevalence and odds ratios  (1998/1990)  of respiratory symptoms, diagnoses, and health-care use
23216	Population prevalence and odds ratios of different patterns of wheeze in 1990 and 1998
23217	Population prevalence estimates and odds ratios  (1990/1998)  of environmental and social risk factors for wheeze
23218	Ethnic group distribution
23219	Prevalence of ejection fraction <40% and 40–50% by age and sex
23220	New York Heart Association functional class  (and definition)  of subjects with ejection fraction <40%
23221	Rates of definite, probable, and total heart failure on defined criteria
23222	Definite heart failure by age and sex
23223	Oligonucleotide primers used for detection of B19 NS1 and VP1 genes
23224	Clinical information and B19 markers in 12 patients with B19 meningoencephalitis
23225	Frequency of autism spectrum disorders  (ASD)  in boys
23226	Prevalence of parasite eggs in stool samples in case-control groups, and odds ratios for wheeze
23227	Distribution of dust allergens and odds ratios for wheeze
23228	Relation between IgE concentrations and allergen skin sensitisation to D pteronyssinus in the random subsample
23229	Relation between parasite eggs per gram and allergen skin sensitisation to D pteronyssinus in the random subsample
23230	Odds ratios for wheeze in relation to D Pteronyssinus allergen skin sensitisation, stratified by quartiles of total parasite infection intensity
23231	Early clinical outcomes within 30 days of surgery
23232	Midterm clinical outcome
23233	Primary outcome measures at 1 year
23234	Secondary outcomes measures at 1 year
23235	Prevalence of atopy in 1987 and 1998
23236	Relation between exposure to a cat and cat allergen at age 2–3 months and total serum IgE concentration at 2 years, stratified by maternal history of asthma
23237	Type and number of antiarrhythmic drugs being taken at cardioversion
23238	Primary outcome—moderate to severe neonatal morbidity and mortality
23239	Neonatal secondary outcome measures
23240	Maternal secondary outcome measures
23241	Antenatal risk factors in infants with evidence of acute brain injury only, or non-acute antenatal injury, or other diagnoses
23242	Detection of SMN1 mutation in fetal cells isolated from maternal blood
23243	Symptoms of 50 patients with SARS at presentation
23244	Initial laboratory findings of 50 patients with SARS
23245	Risk factors associated with severe disease requiring intensive care and ventilatory support
23246	Skin prick test reactivity
23247	Immunoreactivity to recombinant human ECM1 protein in patients with lichen sclerosus and comparison groups
23248	Coronary deaths of patients with diabetes treated with losartan or atenolol
23249	Neurological manifestations of HIV
23250	Antibodies against coronavirus in patients and controls
23251	Nucleotide sequence variation of the S gene of SARS CoV viruses
23252	Maternal serology
23253	Histological descriptions of tissues examined for maternal microchimerism
23254	Permutation analysis results for decline in distance from centre and increase in grey-matter density
23255	Environmental conditions: thermal and chemical
23256	Environmental conditions: organisms
23257	Organisms detected on surface samples  (coupons)  before and after UVGI exposure
23258	Participants’ assessment of environmental conditions
23259	Matched unadjusted analysis of reported symptoms
23260	Within-person subject estimates of effect of UVGI on symptoms, adjusted for environmental covariates measured at work sites  *
23261	Effects of antibodies to interleukin 10, interleukin 12, and interferon γ on cytokine mRNA expression and immunoreactivity in atopic mucosa from children stimulated with allergen and lipopolysaccharide
23262	Concomitant DMARD therapy and corticosteroid administration according to study drug assignment
23263	Differences after 6 months of treatment
23264	Activation and inactivation parameters from wild-type and mutant SCN5A cDNA in transiently tranfected tsA201 cells
23265	Compliance by allocated treatment in hospital
23266	Effects of metoprolol on main clinical events during scheduled treatment period in hospital
23267	Effects of metoprolol on other clinical events during scheduled treatment period in hospital
23268	Effects of metoprolol on main clinical events, by day of first such event
23269	Absolute effects of metoprolol on death alone, cardiogenic shock alone, and combined efficacy and safety endpoint in certain categories of patients
23270	Effects of metoprolol on combined efficacy  (death, reinfarction, ventricular fibrillation, or other arrest)  and safety  (cardiogenic shock)  endpoint by shock index and day of event
23271	Primary and secondary outcomes
23272	Stroke severity
23273	Clinical outcomes and use of oral anticoagulation therapy at study entry
23274	Reasons why patients identified with atrial fibrillation did not take part in the study
23275	Nature of primary events
23276	Risk of primary event and major haemorrhage by treatment allocation for different patient subgroups
23277	Risk of secondary and composite outcomes by treatment allocation for different patient subgroups
23278	Subgroup analysis for fracture
23279	Summary of metaregression analysis
23280	Sensitivity analysis by methodological criteria
23281	Distribution of patients between participating hospitals
23282	Treatments and prescribed drugs
23283	Primary endpoints and other outcomes obtained by angiography of left ventricles
23284	Study treatment exposure and discontinuation
23285	Outcome events  *
23286	Risk  (CHADS2 score)  and efficacy and safety outcome events
23287	Rate of potential confounding variables
23288	Development of diabetes in children who completed the study
23289	Number and duration of adverse events in the treatment groups
23290	Multivariable-adjusted Cox proportional hazards regression coefficients for 10-year risk of atrial fibrillation
23291	Risk scores for factors associated with 10-year risk of atrial fibrillation
23292	Predicted 10-year risk of atrial fibrillation assigned to the risk score
23293	Clinical outcomes
23294	Adverse events
23295	Association results for two variants in IL6R and chromosome 11q13.5 in the discovery, follow-up, and overall analyses
23296	CHADS2, CHA2DS2VASc, and HAS-BLED score calculators
23297	Endpoints by CHADS2 score
23298	Endpoints by CHA2DS2VASc score
23299	Endpoints by HAS-BLED score
23300	Results for composite clinical score
23301	Results of telemonitoring and clinical reactions
23302	Causes of deaths  *   in patients with heart failure and sinus rhythm or atrial fibrillation
23303	Hospital admissions for patients with heart failure and sinus rhythm or atrial fibrillation
23304	Primary and secondary outcomes
23305	Examples of devices for transcatheter closure of atrial septal defect
23306	Randomised controlled trials included in the network meta-analysis
23307	Estimated differences of the effect of interventions on percent diameter stenosis
23308	Odds ratios of the effect of interventions for binary restenosis
23309	Odds ratios of the effect of interventions for target–lesion revascularisation
23310	Association between time-varying digoxin pharmacotherapy and all-cause mortality, cardiovascular death, sudden cardiac death, and admission to hospital endpoints using time-dependent Cox proportional hazards regression models
23311	Time-dependent HF–digoxin interactions
23312	Time-dependent sex–digoxin interactions
23313	Atrial fibrillation incidence rates and age-adjusted period prevalence, by sex and decade
23314	Trends in age-adjusted and sex-adjusted hazards ratios for risk factors of incident atrial fibrillation, by decade of onset of atrial fibrillation
23315	Population-attributable risks of incident atrial fibrillation risk factors, by decade of onset of atrial fibrillation
23316	Epidemiology of frontotemporal dementia  8–10
23317	Genetic and pathological correlation in FTLD
23318	Subtypes of vascular dementia
23319	Significant benefits of drugs reported from randomised controlled trials of cholinesterase inhibitors in vascular dementia
23320	Primary and secondary outcomes
23321	Adverse events
23322	Presenting rhythm, as assessed retrospectively by electrocardiograph review
23323	Some of the more common side-effects associated with pharmacological treatment
23324	C-indices for the ABC-bleeding score  (including alternative biomarkers)  compared with the HAS-BLED and ORBIT scores in the full cohorts and in subgroups
23325	Pooled analysis of the early risk of recurrent vascular events, given per time period after randomisation, in trials of aspirin versus control in secondary prevention after transient ischaemic attack and ischaemic stroke
23326	Pooled analysis of the effect of any aspirin versus control in secondary prevention after TIA and ischaemic stroke on the early risk of any recurrent ischaemic stroke and on disabling or fatal ischaemic stroke stratified by the nature of the presenting event  (TIA and minor stroke vs major stroke)  and by time from presenting event to randomisation  (≤14 days vs >14 days)
23327	Crude data for patient outcomes
23328	Crude mortality data based on the reason for initial emergency department visit
23329	Variance between regions and effect of adjustment on outcomes
23330	Outcome descriptive statistics
23331	Summary of key efficacy results
23332	Summary of adverse events in the safety population
23333	Joints injected
23334	Differences between deprivation groups at each assessment wave
23335	Adjacent contrasts testing differences between assessment waves within deprivation groups
23336	Main results
23337	Sensitivity analyses
23338	Key secondary anticoagulation treatment outcomes in the intervention and control groups
23339	Secondary clinical outcomes in the intervention and control groups
23340	Adverse events
23341	Participants with new vertebral fractures
23342	Participants with clinical fractures
23343	Participants with upper-gastrointestinal adverse experiences
23344	Description of cases with acquired drug-resistance
23345	Clinical risk factors in cases with acquired drug-resistance  (ADR)  and control patients
23346	Participants in the analyses
23347	Relative risk of UGIB with regular and occasional use of aspirin products in week before index day
23348	Regular use of aspirin products in week before index day according to bleeding site
23349	Endpoints by groups
23350	Non-arrhythmic cardiac deaths and non-cardiac deaths
23351	Severe adverse effects
23352	Causes of early discontinuation of study medication
23353	Concomitant medication at time of enrolment
23354	Early permanent discontinuation of study medication
23355	Primary and secondary outcome events
23356	Rates of initial haemostasis and recurrent bleeding
23357	Admission rates in the West Midlands Region for infectious intestinal disease 1990–95  (per 10000 population)
23358	Risk of breast cancer in premenopausal women who had ever or never smoked
23359	Risk of breast cancer in postmenopausal women who had ever or never smoked
23360	Relation between body-mass index  (BMI)  and risk of breast cancer in postmenopausal women who ever or never smoked
23361	Numbers of Borrelia sp and malaria infections
23362	MRI and clinical outcomes of participants
23363	Primary and secondary endpoints for groups assigned MIT therapy versus no MIT therapy and prayer versus no prayer  *
23364	Primary and secondary endpoints for: no prayer versus two-tiered prayer  (subset of patients randomised after two-tier prayer was introduced)
23365	Unadjusted Kaplan-Meier rates for primary and secondary endpoints in factorial treatment groups
23366	Days of monitoring, incidence, and clinical presentation of TBRF, according to age and sex
23367	Prevalence of Borrelia infections in small mammals, by year
23368	Effect of early vs delayed interferon beta-1b on occurrence of clinically definite MS, MS according to the McDonald criteria, and confirmed EDSS progression
23369	Change in functional system scores in patients with confirmed EDSS progression  (up to day 1080)
23370	MRI and clinical outcome measures  (intention-to-treat cohort)
23371	Chemotherapy regimens
23372	Univariate and multivariate analyses of prognostic factors associated with 10-year overall and recurrence-free survival
23373	Reasons for early termination of treatment
23374	Delay of onset of clinically definite multiple sclerosis by subgroups  (post-hoc analyses)
23375	Frequency of common adverse events  *
23376	Treatment details
23377	Primary outcomes of fatigue and physical function
23378	Safety outcomes
23379	Participant-rated clinical global impression of change in overall health
23380	Secondary outcomes
23381	Adverse events
23382	MRI and clinical outcomes
23383	Safety outcomes at weeks 24 and 48
23384	Effect of covariates on parasite clearance half-life of Plasmodium falciparum examined by univariate analysis
23385	Admission variables associated with parasite clearance half-life of Plasmodium falciparum in multivariate regression analysis
23386	Clinical and MRI outcomes
23387	Adverse events
23388	Treatment efficacy at week 36 for the modified intention-to-treat population in the open-label period and at week 88 for the modified intention-to-treat subpopulations in the double-blind period
23389	Safety summary
23390	Clinical and MRI endpoints by treatment group
23391	Adverse events
23392	Adjusted PANSS and IDEAS total scores over 12 months
23393	Changes in PANSS subscale and IDEAS domain scores over 12 months
23394	Stigma and discrimination outcomes for people with schizophrenia
23395	Comparison of early palliative care intervention and standard care
23396	Palliative care intensity for intervention and control groups
23397	Sensitivity analyses using three methods for handling missing data
23398	Primary and secondary outcome variables at months 3, 6, 9, 12, 15, and 18
23399	Estimates of treatment effect  (common to all follow-up times)
23400	Number of participants achieving improvement/deterioration on adjusted PANSS total scores at 9 and 18 months
23401	Hospital admissions during the treatment phase
23402	Description of the studies  (N=22)  included in the systematic review of community empowerment approaches to address HIV among sex workers
23403	Clinical outcomes at 1 year and 5 years for the intention-to-treat population
23404	Localisation of the peak voxels of the connectivity assessment
23405	Cox regression analysis of time to sputum culture conversion
23406	Secondary outcome measures at 56 days, by allocation
23407	Adverse events
23408	Treatment-emergent adverse events and serious adverse events
23409	Melatonin in feverfew and other medicinal plants
23410	Patient's mutations and family history
23411	Estimated cumulative risk of cancers in BRCA1 and BRCA2 mutation carriers
23412	All deaths and cardiac transplantation during the double-blind eriod of MDC study, and at 18 and 36 months after randomisation during open follow-up
23413	Blood-test results, 1992–94
23414	Frequency and grade of acute rejection  (AR)  after liver transplant  (clinically significant episodes requiring treatment and untreated AR reported on protocol biopsy)  in patients receiving Neoral  (n=94/99)  and Sandimmun  (n=64/67)  based triple therapy during first 2 postoperative weeks; and 1 month and 1 yr graft and patient survival  (%)   (Kaplan Meier)
23415	Serum and urine electrolytes during terlipressin treatment
23416	Results of postal survey
23417	Liver function tests before hospital admission
23418	Der p 1 allergen on human skin
23419	Studies of oral ACE inhibitors in aortic stenosis
23420	BP measurements in diagnosis of orthostatic hypotension
23421	Distribution of the intron 8 polythymidine polymorphism of CFTR in the neonates
23422	Mean  (SD)  bone density and biochemical data of cystic fibrosis adults receiving intravenous pamidronate
23423	Blood glucose  (mmol/L)  after oral glucose-tolerance tests
23424	Death rates  (per 1000 person years) , number of deaths, and mortality ratios for various causes of death among men aged 44–55 years, according to diabetic  (NIDDM)  and non-diabetic  (non-DM)  status in the Whitehall, Paris Prospective, and Helsinki Policemen studies
23425	Thrombotest and trail lengths
23426	Lymphocyte subsets and proliferative responses to T-cell mitogens of a DGA patient treated by transplantation of blood mononuclear cells
23427	Endocrine evaluation at presentation and during follow-up period
23428	Biochemical, histological, and virological features of the four couples
23429	Associations of blood donors with GBV-C exposure
23430	SimpliRED D-dimer results overall and in each probability category
23431	Mortality rate by cause of death and treatment after acute ischaemic stroke
23432	Changes in markers of oxidative stress after streptokinase
23433	Changes in lipid concentrations and event rates after substitution of fluvastatin for simvastatin
23434	Laboratory and clinical results of erythropoietin supplementation given enterally to premature infants
23435	P3G concentrations in daily samples of early morning urine during treatment and concentrations of plasma progesterone and 17-OHP on last day of treatment
23436	Percentage incidence of oestrogen and progesterone receptors in breast tumours
23437	Standardised mortality ratios  (SMR)  of suicides in male prisoners by age band  (in years) , 1978–2003
23438	Neuroimaging in Lewy body dementias
23439	Evidence for treatment of dementia with Lewy bodies and Parkinson's disease dementia  129,130
23440	Comparison of nursing contacts for women and men in intervention group
23441	Causes of death, non-fatal MI, and readmissions for revascularisation
23442	ANCOVA of psychological factors at 1 year in intervention and control groups
23443	Clinical trials of homoeopathy
23444	Trials in meta-analysis
23445	Pooled odds ratios and 95% CI  (random-effects model)
23446	Results of four placebo-controlled randomised multicentre trials of Galphimia glauca for pollinosis
23447	Results of randomised trials of various homoeopathic remedies for postoperative ileus after abdominal surgery
23448	Screening process and rate of pulmonary tuberculosis in Zomba Central Prison
23449	Sputum smear results for prisoners with cough of longer than 1 week's duration
23450	Number of HIV-seropositive prisoners with cough of 1 or more weeks' duration
23451	Total sales of HRT preparations in Denmark, 1990–93
23452	Risk of subarachnold haemorrhage according to use of HRT and identified risk factors in women aged 45–64 years
23453	Risk of intracerebral haemorrhage according to use of HRT and identified risk factors in women aged 45–64 years
23454	Risk of thromboembolic infarction according to use of HRT and identified risk factors in women aged 45–64 years
23455	Risk of transient ischaemic attack according to use of HRT and identified risk factors in women aged 45–64 years
23456	Studies of effect of HRT use on risk of stroke
23457	Standardised mortality ratio
23458	Comparison of acid-fast-bacilli smear-positive, smear-negative, and smear-indeterminate patients
23459	Psychiatric admission rates through the criminal justice system of housed and homeless people in central London
23460	Heart rate, time-domain and frequency-domain factors of heart rate variability and mean blood pressure  (BP)  in postmenopausal women without or with HRT
23461	Arrival times and times to each stage in the assessment of stroke patients in a large UK teaching hospital
23462	Height-velocity percentiles and height percentiles in children with third-degree burns
23463	Ordered logistic regressions for predicting outcome group 21·3 years after first hospitalization
23464	Pairing of the tabias by their under-5 mortality rates
23465	Under-5 mortality rate per 1000 child-years according to intervention and control tabias from Jan 1, to Dec 31, 1997
23466	Under-5 mortality per 1000 child-years in intervention and control tabias by age and sex
23467	Cause of death according to verbal autopsy in under-5s
23468	Number of deaths according to place and treatment groups
23469	Regression models for death at home
23470	Use of nursing-home beds
23471	Use of hospitals
23472	Cholecystecomy rate  (per 100 000 population)  by age and sex category in prelaparoscopic  (1984–90)  and laparoscopic period  (1993–99)
23473	Trend in postoperative mortality after cholecystecomy in prelaparoscopic  (1981–90)  and laparoscopic  (1991–98)  periods
23474	Comparison of laparoscopic and open cholecystectomies  (1996–98)
23475	Effect of surgeon's cumulative laparoscopic experience and cholecystectomy caseload on the proportion of operations done laparoscopically, postoperative stay, and 90 day postoperative mortality  (January, 1990, to March, 1999)
23476	Potential sources of misestimation of HIV/AIDS data in CRS
23477	Overseas development budgets for sexually- transmitted disease control, including HIV/AIDS, in least developed and other low-income countries  (1990–98)
23478	Overseas development budgets for sexually-transmitted disease control, including HIV-AIDS, in sub-Saharan Africa  (1990–98)
23479	All donors and lenders  (1990–98)  and all allocations to recipient countries
23480	Nutritional regimens
23481	Number of patients with postoperative complications
23482	Complications in detail
23483	Adverse effects of artificial nutrition
23484	Cases of HIV-1 infection, Orel oblast, Russia, 1996–2000
23485	Effect of potential confounders on risk of venous leg ulcers or pressure ulcers associated with HRT use
23486	Type of accommodation at prevalence screen by sex
23487	Prevalence of dementia in respondents from institutions by age and sex
23488	HIV-1 incidence per treatment group per centre, and overall
23489	Incidence of sexually transmitted infections  (time to first event)
23490	HIV-1 incidence per treatment group and frequency of gel use
23491	Incidence of lesions with an epithelial breach per treatment group and frequency of gel use
23492	Comparison of results on questionnaire between group of participants who received a single consent meeting and group Who received three information sessions and a consent meeting
23493	A general grouping of the deaths
23494	Classification of deaths in 27 families with completed enquiries ccording to explained or SIDS
23495	Probability that index death and first CONI death were both udden unexpected deaths in infancy versus one or both were unnatural
23496	Probability that index death and first CONI death were both IDS versus one or both were probably covert homicide
23497	Prevalence of self-reported experience of racial discrimination  (ever)  by ethnic group
23498	Māori and European health inequalities, adjusted for various factors
23499	Analysis of the odds of having a unique strain
23500	Consensus disposition classification and tolerance for rate of consequential medical events
23501	Critical interventions and expert panel consensus of likelihood consequential medical event if procedure or treatment modality withdrawn
23502	Difference-in-difference estimates with nationally representative data  (CSPLC)  from 1998 and 2004
23503	All-cause, infectious, and non-infectious disease hospital admissions by 5-year periods in New Zealand  (1989–2008)
23504	Health expenditure in six countries of the Organisation for Economic Co-operation and Development
23505	Cluster-adjusted toolkit mean scores and differences in the postintervention assessment
23506	Cluster-adjusted view of informal carers-evaluation of services symptom scales in the postintervention assessment
23507	Cluster-adjusted estimates of medications administered in the last 2 days of life of the patient in the postintervention assessment
23508	Estimated differences in toolkit scales between hospital and hospice bridged by the LCP-I implementation in hospital wards
23509	Management in the comprehensive geriatric assessment and care and the orthopaedic care groups
23510	Clinical assessments
23511	Health-care use
23512	Cost per patient
23513	Firearm legislation during 2009
23514	Risk of firearm death associated with protective firearm laws in four US states in 2010
23515	Change in national firearm mortality per 100 000 people with federal implementation of the three most effective firearm laws
23516	Firearm legislation in 2009 and the risk of fatal firearm homicides and suicides
23517	Procedural results and 30-day clinical events
23518	Clinical events during 12-month follow-up
23519	Description of the PREDICT-1° cohort in women and men
23520	Adjusted hazard ratios for total CVD in the PREDICT-1° equations
23521	Beta coefficients in the PREDICT-1° equations
23522	Standard performance metrics for PREDICT-1° equations  (estimating 5-year risk of total cardiovascular disease)  and the 2013 American College of Cardiology/American Heart Association Pooled Cohort Equations  (estimating 5-year risk of hard atherosclerotic cardiovascular disease)  applied to the whole PREDICT-1° cohort
23523	Adjusted hazard ratios for hard atherosclerotic cardiovascular disease of new PREDICT-1° equation variables added to the Pooled Cohorts Equations
23524	Relation of ultrasound classification of risk of neurological deficits to quality of movements and outcome at 2 years
23525	Correlation of rCBF in different brain regions  (normalised to cerebellum)  to single positive and negative symptoms in neuroleptic-naïve patients before and after neuroleptic treatment
23526	Principal component-factor analysis of five symptoms and three regions of interest  (n=8)
23527	Principal component-factor analysis of six symptoms and four regions of interest  (n=10)
23528	Comparison of regional blood flow in drug-naïve schizophrenic patients and matched healthy volunteers
23529	Cosmetic results of abdominal scars
23530	Mamillary body values for all groups
23531	Mean  (SD)  regional brain volumes in cm3
23532	Volumes of structures of interest in high-risk group according to presence or absence of affected first-degree relatives
23533	Mean  (SD)  number of fingers per hand that showed Raynaud's phenomenon during laboratory cooling
23534	Relative risks of having received at least one conviction for those men with schizophrenia in the 1975 and 1985 groups, compared with controls matched for age, sex, and residence
23535	Frequency of diagnosess of mental disorder and learning disability, and comorbidity of substance-abuse disorders
23536	Number of criteria for Diogenes syndrome met, and variation by presence of active mental disorder and contributory physical disorder
23537	Multivariate associations with LCRS interior scale scores and with having mental disorder
23538	Previous Cardiovascular Therapies by Drug Class  a
23539	Results of Variables Used to Assess Efficacy of Treatment
23540	Clinical Status Assessment at End of Study
23541	Activity at Onset of Symptoms by Age Group
23542	Comparison of Patients by Activity at Onset of Symptoms of Myocardial Infarction
23543	Association Between Activity at Onset of Symptoms and Outcome
23544	Intravascular Ultrasound Findings of Coronary Aneurysms
23545	Factors Associated With the Propensity of Beta-Blocker Prescription
23546	Survival Benefit Associated With Beta-Blocker Use After PCI
23547	Association Between Metabolic Syndrome and Systolic and Diastolic Echocardiographic Abnormalities in Adult Survivors of Childhood Cancer  ∗
23548	Population With Central Measurements  (n = 181) : Main Cardiovascular Parameters: Adjusted % Means ± Standard Error of Means Are Presented at M0, M6, M12
23549	Clinical outcomes in the per-protocol population
23550	Adverse events reported at least once by patients on self-questionnaires completed each day after 1000 mg of methylprednisolone and until day 28
23551	Remission from depression during augmentation with aripiprazole or placebo
23552	Adverse events and tolerability measures during the augmentation phase
23553	Adverse events
23554	Common treatment-emergent adverse events  (20% or more of patients)  in the safety population
23555	Breast cancer first events
23556	Breast cancer-free interval and disease-free survival events by age group
23557	Non-breast cancer events
23558	Adverse events by treatment group
23559	Studies of TAVR
23560	Patient treatment stratified by line of therapy and the results of routine molecular analyses
23561	Outcomes stratified by line of therapy and molecular alteration
23562	Unadjusted clinical outcomes in the as-treated populations
23563	Primary endpoint composite by propensity score quintile
23564	Grade 3–4 severe treatment adverse events according to assigned treatment group
23565	Clinical outcomes of patients 30 days after device implantation
23566	Type of intervention in isolated mitral regurgitation
23567	Antibiotic susceptibility testing in mice  (15 per group) . The number  (percentage)  of mice surviving at day 24 is given for each treatment
23568	Doxycycline susceptibility testing in mouse fibroblast cell culture: mean percentage of L929 cells which contain rickettsia after 30 h  (95% CI)
23569	Input variables and sources
23570	Cost-effectiveness  ($)  of screening and treatment at age 50 years
23571	Patients infected with ceftazidime-resistant and blactam-resistant Pseudomonas aeruginosa,1987–95
23572	Distribution of variables
23573	Distribution of confirmed sites of relapse  (%)  within randomised groups
23574	Control of loco-regional  (L/R)  relapse within randomised groups and according to whether or not breast remains conserved
23575	Percentage with loco-regional  (L/R)  relapse according to variables and total follow-up for randomised groups
23576	Sites of recurrence of breast cancer in patients who received systemic therapy according to ER status of primarytumour
23577	5-year relapse rates in treated breast in trials of local excision with or without radiotherapy
23578	Modified Jerger's classification
23579	Patients' haracteristics
23580	Reported side-effects
23581	Outcome at follow-up visit at 2 weeks
23582	Prognostic factors for OME at follow-up visit
23583	Univariate analysis of risk factors for thrombosis events
23584	Multivariate analysis of risk factors for stroke and arterial thrombosis
23585	Age and sex distribution of children by treatment group
23586	Mean proportions of children with resolution and healing  (%)  at 8, 12, and 16 weeks by treatment group
23587	Effects on average hearing threshold at different time periods due to improvements in CSOM
23588	US licence applications for sale of medical products to Cuba
23589	Findings of repeat scintigraphy
23590	Patients with abnormal findings of the urinary tract
23591	Resistance to clprofloxacln in 40 clinical Isolates of Escherlchla call
23592	1-month evaluation study of patients put forward for study by 40 general practitioners
23593	Mean change in clinical variables after 1 and 2 weeks in sinusitis patients treated with antibiotics or placebo
23594	Geometric mean red-cell and plasma folate concentrations in pregnant and non-pregnant women, according to genotype
23595	Reports of S aureus from blood or cerebrospinal fluid in UK, 1989–95
23596	Resistance rates for S aureus from blood or cerebrospinal fluid, England and Wales, 1989–95
23597	Resistance rates to methicillin by former English National Health Service region, 1993–95
23598	Resistance rates to other antibiotics in MSSA and MRSA isolates, UK, 1989–95
23599	MICs of subclones of Mu3 obtained by selection with various concentrations of vancomycin
23600	Pretreatment and post-treatment red-cell folate  (RCF)  and estimated NTD risk per 1000 births
23601	Incremental changes in red-cell folate  (RCF)
23602	Selected indicators of mortality and life expectancy 1990 in Albania and selected European countries
23603	Average consumption of selected foods  (g per person per day)  in Albania and selected countries
23604	Epidemic  Salmonella typhi  from Tajikistan isolated in 1997
23605	Mean daily intakes of trans fatty acids in men and women in 14 European countries
23606	Salmonella bacteraemia in England and Wales, 1994–96
23607	PCR amplification of wild housefly abdominal extracts
23608	ELISA results
23609	Sex of 137 live births in Taiwan 1978–1985, by date of birth
23610	Rates of twinning by use of folic acid before conception
23611	Resistance to ciprofloxacin in S typhi in the UK, 1991–99
23612	Absorption of iron from a 3 mg reference dose of iron as iron  (II)  sulphate with 30 mg ascorbic acid and a 1 mg dose of reduced iron in bread
23613	Geometric means  (within treatment 95% CI)  for placebo inhaler, 2 mg nominal dose of fluticasone propionate delivered via a pressurised metered dose inhaler and spacer  (pMDI+spacer) , and via a dry powder Accuhaler  (Diskus)  device
23614	Sensitivity of bacterial isolates and place of acquisition
23615	Laboratory tests on second admission
23616	Virulence factor  (VF)  and antibiotic resistance profiles
23617	Quantification of exosomes
23618	Functional activity of bulk lymphocytes stimulated with DC +/- exosomes or tumour cells
23619	Primary outcome
23620	Risk factors for treatment failure or relapse
23621	Rate of treatment failure or relapse by presence of specified risk factor
23622	Number of adverse events by treatment group
23623	Treatment outcomes
23624	Comparison of treatment success with failure by site
23625	Ploidy status of patients, by molecular marker
23626	Prognostic and predictive value of molecular markers
23627	Observed and predicted concentrations of arsenic in cooked rice
23628	Number of cycles of allocated treatment received
23629	Side-effects in first 3 months of randomisation
23630	Tumour response rates at 12 weeks
23631	Rates of multiple birth and crude and adjusted rate ratios for multiple birth, according to folic acid pill-taking status
23632	Distribution of children by age, sex, and socioeconomic status
23633	Care-seeking behaviour by number and duration of symptoms
23634	Differences by sex in morbidity and care-seeking behaviour
23635	Socioeconomic differences in morbidity and care-seeking behaviour
23636	Primary and secondary events after randomisation
23637	Pregnancy outcomes
23638	Clinical details and indications for delivery of 11 women with elective preterm delivery
23639	Difference in percentage of spontaneous preterm deliveries and miscarriages between treatment groups by factors that might affect outcome
23640	Association between total dietary fibre and distal colorectal adenoma
23641	Association between fibre food groups and distal colorectal adenomas
23642	Description of the EPIC cohort
23643	Numbers of cancers and hazard ratios by quintile of sex-specific total fibre intake
23644	Intakes of fibre and colorectal cancer by quintile of sex-specific source of fibre intake
23645	Covariate definitions
23646	Results of neuro development tests for cognition and achievement by prenatal exposure
23647	Neurodevelopmental tests for motor, perceptual motor and memory by prenatal exposure
23648	Neurodevelopmental tests for attention and behaviour by prenatal exposure
23649	Social and environmental covariate effects
23650	Sample description of gonococcal isolates seen in participating GRASP clinics,  *  2000–02
23651	Trends in ciprofloxacin resistance in N gonorrhoeae in participating GRASP clinics,  *   2000–02
23652	Quintiles of fat and hazard ratios by quintile
23653	Proportion of resident population tested for Chlamydia trachomatis by Amplicor
23654	Relation between culture positivity, LightCycler  (LC)  positivity, and estimated number of copies of omp1 per swab in individuals from Rombo with signs of active trachoma and an Amplicor positive swab
23655	Amplicor positivity by clinical sign of trachoma in the swabbed eye
23656	Estimated copies of omp1 per swab by clinical sign of trachoma in the swabbed eye
23657	Chronological description of cases
23658	Risk factors for abandonment of treatment
23659	Environmental samples of various origins tested for the presence of E sakazakii
23660	Antimicrobial susceptibility, plasmid profile, and antimicrobial resistance phenotype of the clinical isolates of S choleraesuis  (SCB43 and SCB67)  and the control strain  (NCTC8393)
23661	Prognostic value of the variables included in univariate analysis for first episode of severe bacterial infection
23662	Chest radiograph findings on admission
23663	Age-adjusted hazard ratios by group and outcome
23664	Age-adjusted hazard ratios by group and outcome when wheezing children omitted
23665	Haematological reconstitution and transplant outcomes
23666	Primer sequences
23667	Taqman validation with laboratory isolates
23668	IC50 values for antimalarials in relation to pfmdr1 copy number
23669	Temporal trends of the efficacy of mefloquine monotherapy and parasite genotype in primary infections
23670	NSABP B-14: outcome according to treatment group, age, menopausal status, and tumour oestrogen-receptor concentration
23671	NSABP B-20: outcome according to treatment group, age, menopausal status, and tumour oestrogen-receptor concentration
23672	NSABP B-14 and B-20: quantitative concentrations of tumour oestrogen receptors by age or menopausal status and treatment group
23673	Doses of drugs
23674	Culture results at 2 months
23675	Status at the end of treatment
23676	Status 12 months after the scheduled end of treatment
23677	Difference between regimens in proportions with an unfavourable status 12 months after the end of treatment
23678	Adverse events resulting in a change of treatment or interruption of 7 days or more
23679	Relative risk of myocardial infarction comparing rofecoxib with control, from stratified meta-analyses
23680	Responses at the end of the study for overall improvement and decrease in number of inflamed lesions
23681	Treatment differences and odds ratios for specified comparisons for overall improvement according to the patient at week 18
23682	Effect of skin colonisation with tetracycline-resistant propionibacteria on treatment outcome
23683	Relative cost-effectiveness of treatment regimens based on patients' self-assessment of improvement
23684	Correlation between antibiotic use and resistance, by organism and year of isolation
23685	Comparison of transmission rates in primates and cattle infected orally with similar BSE brain inocula
23686	MRS score, primary outcome, and death
23687	Accommodation and feeding at 6 months' follow-up
23688	Number and proportion of patients with each Modified Rankin scale  (MRS)  score and with our primary outcomes by treatment allocation
23689	Incidence of invasive pneumococcal disease in metropolitan Atlanta by year, age-group, macrolide resistance, and mechanism of resistance
23690	MIC to erythromycin of mefE-containing S pneumoniae, metropolitan Atlanta, 1995–2002
23691	Incidence of invasive pneumococcal disease in metropolitan Atlanta by year, serotype, macrolide resistance, and mechanism of resistance
23692	Incidence of macrolide resistance in pneumococcal serotype 14 isolates by year and age-group
23693	Indicators of tuberculosis transmission between March, 1995, and February, 2000
23694	Treatment outcome of new and retreatment tuberculosis cases according to M tuberculosis drug-susceptibility pattern, March, 1995, to February, 2000
23695	Number of carers who correctly answered questions on age-specific feeding practices
23696	Feeding practices  (24-h recall)
23697	Child growth at 18 months by intervention group
23698	Microfilaraemia and antigenaemia values of W bancrofti from start of treatment
23699	Ultrasound detection of filarial-dance signs of adult worms at 14-month follow-up
23700	Main outcomes in children treated with chloramphenicol and placebo eye drops
23701	Disease status at two-step approach and response during the study
23702	The first 40 days of life in Sylhet district, Bangladesh
23703	Room where newborn stays during first month of life
23704	Sleeping surface of neonate during first week of life
23705	Checkup by a trained or untrained health-care provider for sick neonate during first 30 days of life
23706	Antibiotic combinations most commonly received
23707	Changes in lung function, dyspnoea, hospital length of stay, treatment failure rates, and sputum bacterial density according to treatment assignment
23708	Perioperative management
23709	Principal results
23710	Multiple logistic regression results for surgical wound infection
23711	IBCSG trials and treatment groups
23712	Disease-free survival and overall survival comparing ⩾85% dose level versus <85% dose level according to oestrogen-receptor  (ER)  cohort and body-mass index  (BMI)  group
23713	Follow-up rates of 1017 individuals included in first census
23714	Predictors of incident infection at 6 months post-treatment in participants not infected at 2 months post-treatment
23715	Infection in individuals with trachoma over time
23716	Results of genetic testing in a hypothetical patient in 2010  (from Collins,  18  ) , and updated estimates of relative risks
23717	Potential confounders by quartiles of C-reactive protein  112
23718	C-reactive protein, and potential confounders by 1059G/C genotype of the CRP gene  112
23719	Large population-based research biobanks  (planned and current)
23720	The expected rate of accrual of incident cases of selected complex diseases in UK Biobank  141
23721	Favourable responses to treatment and all-cause mortality
23722	All-cause adverse events and reasons for discontinuation from study drug in patients who received at least one dose of study drug
23723	Randomised trials for primary treatment of candidaemia in non-neutropenic patients and effect of efficacy endpoint definitions, by antifungal agents studied
23724	Odds ratios for lung cancer by cruciferous vegetable consumption  *   and GST status
23725	Odds ratios for lung cancer by cruciferous vegetable consumption and GSTM1 and GSTT1 status for ever and never smokers
23726	Pooled risks of stroke  (95% CI)  in meta-analysis according to study variables
23727	Age-specific incidence estimates of presentation to hospital with bacteraemia
23728	Sensitivity and specificity of clinical signs, malaria parasitaemia, and white blood cell count for diagnosis of bacteraemia
23729	IMCI clinical syndromes  *   of children with and without bacteraemia
23730	Pregnancy after IVF
23731	B-vitamin intake and nutrient status, and outcome of fertility treatment
23732	Genotype distribution, according to fertility status
23733	B-vitamin-related genotype, history of infertility, and outcome of fertility treatment
23734	Model of risk factors for the odds of active trachoma in children within intervention and control balozi at 6 months and 1 year
23735	Wheeze, asthma, and medication use at age 5 years in the treatment group compared with the placebo group
23736	Lung function in placebo and treatment groups at age 5 years
23737	Results from diary cards in the first 3 months of the study
23738	Change in height Z score after randomisation
23739	Subgroup analysis
23740	Distribution of culture results and drug-resistance categories by group for all patients  (n=1539)  for whom sputum culture was done
23741	Countries or geographical settings studied in the third round of the Global Project
23742	Prevalence of drug resistance in new cases in 76 countries or settings, 1999–2002
23743	Trends in resistance in new cases in 26 countries or settings
23744	Prevalence of drug resistance in previously treated cases in 66 countries or settings, 1999–2002
23745	Trends in resistance in previously treated cases in 24 countries or settings
23746	Difference in mean proportion of macrolide-resistant streptococci between groups
23747	Carriage of the macrolide-resistance genes, mef and erm (B) , in streptococci isolated from volunteers treated with clarithromycin or azithromycin
23748	Maternal antenatal CD4-cell counts and HIV point prevalence rates at 26 weeks by method of feeding at 26 weeks
23749	Mother-to-child transmission risk during exclusive breastfeeding  (n=1034)
23750	Factors associated with HIV-free survival in exclusively breastfed infants in the first 6 months of life  (n=1034)
23751	Long-term therapies  (given for 3 months or more)
23752	Cost of adding screening for cystic fibrosis to an established newborn screening service in Scotland
23753	Mean and median estimated yearly treatment costs per patient  (US$)  in 2002, by genotype and age-group
23754	Linear regression analysis results for mixed genotype and homozygous ΔF508 patients
23755	Effects of screening using a 31 CFTR mutation assay and age at diagnosis on estimated cost savings to the estimated cost of a newborn screening programme for cystic fibrosis
23756	Details of trials included in overview
23757	Hazard ratios  (95% CI)  for outcomes by age, nodal status, tumour size, and BMI in univariate and multivariate Cox models for women with hormone-receptor-positive cancer
23758	Percentage change in hazard ratios  (95% CI)  for outcomes in women with hormone-receptor-positive cancer
23759	Percentage change in hazard ratios  (95% CI)  for outcomes in women with hormone-receptor-positive cancer by age
23760	Percentage change in hazard ratios  (95% CI)  for outcomes in women with hormone-receptor-negative cancer
23761	Pooled relative risk for stroke, stratified by intervention duration, percentage change in homocysteine concentration, grain fortification, and history of stroke
23762	Relative risk of stroke and change in homocysteine concentration
23763	Participants with solicited local  (injection site)  and general symptoms within 7 days after one or both vaccinations by vaccine group
23764	Haemagglutination-inhibition antibody response to the homologous recombinant A/Vietnam/1194/2004 NIBRG-14 vaccine strain after the first and second vaccine dose
23765	Neutralising antibody response to the homologous recombinant A/Vietnam/1194/2004 NIBRG-14 vaccine strain after the first and second vaccine dose by vaccine group
23766	Stent thromboses according to ARC criteria for definite stent thrombosis and according to per-protocol definitions used in individual trials
23767	Estimated numbers-needed-to-treat and numbers-needed-to-harm for different outcomes
23768	Sensitivity analyses
23769	Results of in-situ hybridisation and immunohistochemistry in selected organs and cell types
23770	Results of in-situ hybridisation, RT-PCR, and NASBA for H5 detection assay in selected brain regions of patient 2
23771	Results of RT-PCR, strand-specific RT-PCR, real-time RT-PCR, and NASBA for H5 detection in specific tissue samples
23772	Mean GHA scores for 3-year-old and 8/9-year-old children by challenge type
23773	General GHA estimates in linear mixed models during challenge period for 3-year-old children
23774	General GHA estimates in linear mixed models during challenge period for 8/9-year-old children
23775	Hospital anxiety and depression  (HAD)  scale subscores for all eligible studies
23776	Case reports of fibrinogen-transmitted hepatitis
23777	Postoperative complications, surgery data, and hospital stay for the 1354 patients who had bowel resections
23778	Anastomotic leakage rates, according to various factors and results of multivariate analysis for the 1354 patients who had bowel resection
23779	Cumulative treatment failure and specific causes by day 3 and 6, and relapse by day 14
23780	Risk factors for venous thromboembolism
23781	Contraindications to anticoagulation
23782	Type of prophylaxis used in at-risk patients
23783	Patients at risk for VTE and prophylaxis use by country
23784	Child anthropometry by allocation group, with four analytic models for differences between group means
23785	Mean measurements at birth and at follow-up, with mean and proportional increments
23786	Underweight, stunting, and wasting according to WHO standards, and estimates of mean upper arm total and fat areas
23787	Mean child anthropometric outcomes at final survey
23788	Programme participation and use of services
23789	Trials included
23790	Outcomes of included trials
23791	Survival analyses of relapse and mortality according to fractionation schedule
23792	Incidence of ischaemic heart disease, symptomatic rib fracture, and symptomatic lung fibrosis according to fractionation schedule
23793	GVHD grade and organ involvement
23794	GVHD response and outcome
23795	Coronary heart disease and high-risk patients and their partners achieving the primary endpoints at the initial assessment
23796	Coronary heart disease and high-risk patients and their partners achieving the primary endpoints at 1 year
23797	Risk-factor distributions in coronary heart disease and high-risk patients
23798	Mortality rates for children aged 2–59 months in the IMCI intervention area before and after the modification of guidelines
23799	Comparative changes in cardiovascular parameters with exenatide once a week versus exenatide twice a day treatment over 30 weeks in the intention-to-treat population
23800	Overall incidence of treatment-emergent adverse events occurring in 10% or more of patients who received one or more doses of study drug
23801	Percentage of patients with at least one episode of hypoglycaemia, by treatment and concomitant sulphonylurea use
23802	Overall level of functional impairment at age 7 years from the mark III Multi-Attribute Health Scale in children whose mothers had SPL
23803	Deaths in ORACLE II and during OCS II in children whose mothers had SPL
23804	“Inside the table” analysis of overall level of functional impairment at age 7 years from the mark III Multi-Attribute Health Scale in children whose mothers had SPL
23805	Behaviour at age 7 years from the Strengths and Difficulties Questionnaire in children whose mothers had SPL
23806	Educational attainment in reading, writing and mathematics, for England only, for children whose mothers had SPL
23807	Medical conditions reported by parents of children at age 7 years in those whose mothers had SPL
23808	Functional impairment outcomes of the children with cerebral palsy whose mothers had SPL
23809	Overall level of functional impairment at age 7 years from the mark III Multi-Attribute Health Scale in children whose mothers had PROM
23810	“Inside the table” analysis of overall level of functional impairment at age 7 years from the mark III Multi-Attribute Health Scale in children whose mothers had PROM
23811	Deaths in ORACLE I and during OCS I in children whose mothers had PROM
23812	Behaviour at age 7 years from the Strengths and Difficulties Questionnaire in children whose mothers had PROM
23813	Educational attainment in reading, writing, and mathematics at key stage one, for England only, for children whose mothers had PROM
23814	Medical conditions reported by parents of children at age 7 years whose mothers had PROM
23815	Cumulative incidence of main endpoints and corresponding relative risks  *
23816	Quality of life scores  (EORTC QLQ-C30)  in endocrine group and endocrine plus radiotherapy group
23817	Non double-blind studies favour second-generation antipsychotic drugs
23818	Second-generation versus first-generation antipsychotic drugs—efficacy in various domains
23819	Quality of life
23820	Extrapyramidal side-effects
23821	Weight gain
23822	Sedation
23823	Effects of haloperidol dose on the effect sizes of overall symptoms and extrapyramidal side-effects
23824	Dosing classification based on lower and upper dosing range quartiles
23825	Studies included in the multiple-treatments meta-analysis
23826	Response and dropout rates for efficacy and acceptability in meta-analyses of direct comparisons between each pair of antidepressants
23827	Efficacy and acceptability using fluoxetine as reference compound
23828	Clinical, surgical, and histopathological details
23829	Disease-related events and data for time to event
23830	Estimated prevalence of infection in children aged 1–10 years
23831	Estimated prevalence of infection in adults and children aged 11 years and older
23832	Univariate and multivariate logistic regression analysis for culture conversion at week 8 in the modified intention-to-treat population
23833	Serious adverse events
23834	Summary of primary and secondary outcomes
23835	Adverse events reported from randomisation to 12 months
23836	Parameter estimates related to post-partum haemorrhage and intra-partum death in Malawi
23837	Parameter estimates related to puerperal sepsis and other post-partum maternal deaths in Malawi
23838	Survival outcomes by treatment adjusted for significant factors in the Cox multivariate model  *
23839	Mortality and morbidity during the first and subsequent years of treatment
23840	Summary of biochemical and radiological findings during treatment
23841	Stratification of patients by aldosterone/renin ratio
23842	Risk factors, exposure variables, theoretical minima, disease and injury outcome, and data sources for the risk factors assessed
23843	Mortality  (thousands of deaths)  by sex due to risk factors in 14 GBD subregions
23844	Burden of disease  (thousands of DALYs)  by sex due to risk factors in 14 GBD subregions
23845	Health outcomes at age 26 years according to childhood socioeconomic position and adult socioeconomic position
23846	Quantification of clonotypic T cells in peripheral blood
23847	Clinical features of patients presenting with acute lower-gastrointestinal haemorrhage
23848	Causes of acute lower-gastrointestinal haemorrhage and degree of diagnostic certainty
23849	Predictive performance of the three different models in the internal and external validation groups
23850	Numbers of children in each age-group, by diagnosis
23851	Yearly age-group specific incidence and cumulative incidence of SVI/BL
23852	Incidence by sex, ethnic group, country of residence, and birthweight
23853	Disorders causing SVI/BL grouped by anatomical site or sites affected
23854	Prenatal causal factors causing SVI/BL
23855	Perinatal and neonatal causal factors causing SVI/BL
23856	Childhood and unknown causal factors causing SVI/BL
23857	Potentially preventable or treatable  (avoidable)  SVI/BL
23858	Mortality risks predicted by assays
23859	Dose and time dependence of HIV inhibition by GBV-C
23860	Distribution of study population
23861	Median age  (years)  of presentation of cases
23862	Risk of acute myocardial infarction associated with risk factors in the overall population
23863	PARs associated with nine risk factors in men and women by geographic region
23864	Importance of risk factors in young and old individuals
23865	Myocardial infarction and medication at discharge and at 1 year
23866	Frequency of death and cardiac events
23867	Primary outcome variables  (intention to treat, all visits)
23868	Secondary outcome variables  (intention to treat, all visits)
23869	Prespecified adverse events on treatment or within 14 days of discontinuation
23870	Aflatoxin B1 in groundnuts at main survey points
23871	Concentration of aflatoxin–albumin adducts at follow-up surveys
23872	Compliance and reasons for discontinuation of trial treatment
23873	Effects of clopidogrel on primary and other clinical outcomes during scheduled treatment period in hospital
23874	Effects of clopidogrel on cerebral and major non-cerebral bleeding during scheduled treatment period in hospital
23875	Time intervals between onset of symptoms, randomisation, and the catheterisation procedure
23876	Medications given before, during, and after catheterisation
23877	TIMI flow grades of participants
23878	Single clinical endpoints within 90 days of randomisation
23879	Strokes and non-cerebral bleeding complications within 90 days
23880	Causes of death
23881	Presence of C trachomatis DNA assessed by PCR compared with detection by the clinical sign TF and POC assay positivity
23882	Performance of the clinical sign TF and the POC assay compared with PCR
23883	Age and sex distribution across groups
23884	Proportion of participants with solicited injection-site and systemic reactions within 7 days after one or both vaccinations
23885	Haemagglutinin inhibition antibody response on horse erythrocytes after one and two vaccinations
23886	Neutralising antibody response after one and two vaccinations
23887	Incidence rate by group and incidence rate ratio of death and of severe morbidity
23888	Summary of efficacy results at week 48 by use of enfuvirtide
23889	Number  (rate per 100 patient-exposure years)  of patients who had adverse events in combined analysis at 48 weeks
23890	Number  (rate per 100 patient-exposure years)  of grade 3–4 laboratory abnormalities
23891	Prehospital response, triage categories, and mortality
23892	Injuries sustained by seriously injured trauma patients admitted to the Royal London Hospital
23893	Radiological investigations during first 24 h at the Royal London Hospital
23894	Operations on day of major incident at the Royal London Hospital
23895	Adjusted standardised hazard ratios for mortality
23896	Adjusted standardised hazard ratios for combined, fatal, and non-fatal cardiovascular endpoints
23897	Adjusted hazard ratios  (95% CI)  associated with extreme, decreased, and reverse dipping versus normal dipping
23898	Adjusted standardised hazard ratios  (95% CI)  for systolic blood pressure excluding one cohort at a time
23899	Number of patients seeking medical attention after a first event, stratified by place of initial referral, or by type of presenting event
23900	Risk of stroke during the 90 days after first seeking medical attention, stratified according to the place of initial referral, or by type of presenting event
23901	Delay to seeking medical attention and subsequent delay in being seen in the clinic for all patients who were referred to the study clinic
23902	Measures of process of care, assessed at 1-month follow-up, in all patients with TIA or stroke who were referred to the study clinic
23903	Times, drugs at discharge, and 30-day events
23904	ECG parameters on arrival at PCI centre, and after angiography or PCI
23905	Angiographic outcomes
23906	Clinical outcome and safety parameters
23907	Grade of age-related macular degeneration according to the Age Related Eye Disease Study  (AREDS)  for both UK and US cohorts
23908	Genes tested in primary screen
23909	Allelic and genotypic tests of rs2511989 from primary screen of UK sample  (n=953) , US sample  (n=500) , and the two cohorts combined
23910	Primary and secondary outcomes
23911	Adverse events at 1 year
23912	Occurrence of the primary and major secondary endpoint events at 1 year by assigned pharmacological and stent groups
23913	Adverse events between 30 days and 1 year
23914	Major adverse cardiovascular events within 1 year according to the occurrence of major bleeding not related to coronary artery bypass graft surgery
23915	Efficacy of recombinant hepatitis E vaccine
23916	Safety outcomes
23917	Primary endpoint and its components according to centre's mean time in therapeutic range
23918	Bleeding events according to centre's mean time in therapeutic range
23919	Composite cardiovascular events and total mortality according to centres' mean time in therapeutic range
23920	Relative risk  (95% CI)  of death with tranexamic acid, overall and by time to treatment
23921	Clinical outcomes at 3 years
23922	Absolute number of events, incidence rates, and hazard ratios  (HRs)  for cardiovascular endpoints, death, and diabetes in the JUPITER trial in participants with or without major diabetes risk factors, according to random allocation to rosuvastatin or placebo
23923	Adverse events and measured laboratory values for fasting glucose and HbA1c during follow-up in participants with and without major diabetes risk factors
23924	Serious adverse events
23925	Causes of poor outcome in patients with modified Rankin scale score of 3–6 at 3 months
23926	Summary results of meta-analyses of the effect of aspirin on risk of non-vascular death during 51 trials of aspirin versus control in prevention of vascular events stratified by dose of aspirin  (<300 mg vs ≥300 mg)  and the indication  (primary vs secondary prevention)
23927	Pooled analysis of the effect of aspirin on cancer deaths in 51 trials  (77 549 participants)  of aspirin versus control in prevention of vascular events, stratified by years to death
23928	Pooled analysis of the effect of allocation to aspirin versus control on the risk of all incident cancer during trial follow-up in the six trials of low-dose aspirin in primary prevention of vascular disease,  16–21   by years to notification
23929	Visual outcomes in major treatment trials of age-related macular degeneration
23930	Keratoplasty techniques, indications, and technique selection
23931	Comparison of the advantages and disadvantages of the different keratoplasty techniques
23932	Complications of keratoplasty techniques
23933	Short-term and long-term outcomes
23934	Annual growth rate  (%)  of volume consumption per person in low-income and middle-income countries, and high-income countries between 1997 and 2009
23935	Top five companies responsible for sales of packaged foods in different countries
23936	Effects of vitamin A allocation on plasma retinol, haemoglobin, weight, height, Bitot's spots, and recent ill health  (generally as reported by the child's guardian)  in a subsample from each of the 72 blocks during the second half of the study, by age
23937	Effects of albendazole allocation on pre-school child mortality: absolute numbers of deaths per anganwadi child-care centre  (AWC)  by allocated treatment, albendazole versus control  (A vs C) , and, from these, mortality rate ratio  (A/C)  and approximate absolute risk of death from age 1·0 to 6·0 years
23938	Developmental factors associated with nephron number, kidney size, and function
23939	Clinical surrogates for nephron number
23940	Procedural details by DAPT status
23941	Cumulative incidence of adverse events  *
23942	Number of events for each clinical outcome by worst DAPT cessation status achieved before the MACE event
23943	Adverse events
23944	Secondary outcomes
23945	Ongoing pregnancy by natural conception in prespecified subgroups
23946	Age-adjusted percentage of adult population with selected chronic disease risk factors and conditions in the USA, 1999–2012  30
23947	Four domains of chronic disease prevention activities for preventing heart attacks and strokes from the Million Hearts Initiative  *
23948	Primary outcome
23949	Secondary outcomes
23950	Self-reported symptoms
23951	Risk factor scenarios used in the analysis
23952	Data sources for risk factor exposures and their associations with non-communicable diseases
23953	The impact of achieving risk factor targets on premature mortality from non-communicable diseases
23954	Hierarchical outcomes
23955	Clinical outcomes at 28 days
23956	Summary of observational and intervention studies on dietary patterns for diabetes prevention and management
23957	A comparison of nutrition therapy main recommendations for patients with type 2 diabetes from various organisations
23958	Adverse events regarded as related to treatment  (occurring in ≥2 patients)
23959	Maternal mortality ratio, numbers of maternal deaths, and annualised rates of change for 21 Global Burden of Disease regions and 188 countries
23960	Global and regional maternal deaths in 2013, by cause and timing
23961	The Chronic Liver Failure Consortium organ failure score
23962	Sensitivity analysis showing the effect size for mortality after removing individual trials included in the meta-analysis
23963	Clinical outcomes stratified by different durations of dual antiplatelet therapy established by network meta-analysis
23964	INR and dosing data among patients taking warfarin, across genotype bins
23965	Bleeding outcomes among patients taking warfarin in the first 90 days of treatment, across genotype bins
23966	Bleeding outcomes among patients taking warfarin beyond 90 days of treatment, across genotype bins
23967	The four large trials comparing non-vitamin K antagonist oral anticoagulants with warfarin for stroke prevention in atrial fibrillation
23968	Appropriate indications for use of non-vitamin K antagonist oral anticoagulants  (NOACs)  in different clinical scenarios of atrial fibrillation  20,21
23969	Laboratory test for monitoring of non-vitamin K antagonist oral anticoagulants in laboratory and emergency settings  29
23970	Antidotes to non-vitamin K antagonist  (VKA)  oral anticoagulants
23971	Current trials with non-vitamin K antagonist oral anticoagulants after percutaneous coronary intervention in patients with atrial fibrillation
23972	Primary and secondary efficacy endpoints for SET and RESET
23973	Details regarding medical treatment at inclusion, discharge, and coronary angiography
23974	Clinical outcomes and complications
23975	Procedural and discharge data
23976	Clinical outcomes
23977	Left ventricular ejection fraction at 18 months
23978	Procedure-related complications
23979	PAR for all risk factors by region  (all stroke, ischaemic stroke, and intracerebral haemorrhage)
23980	Risk factors for all stroke  (ischaemic and intracerebral haemorrhage)  in men and women
23981	Risk factors for all stroke  (ischaemic and intracerebral haemorrhage)  by age group
23982	Global Burden of Disease 2015 risk factor hierarchy, exposure definitions, theoretical minimum risk exposure level, and data representativeness index for 1985–2015, pre-2005, and 2005–15
23983	Epidemiological evidence supporting causality for risk-outcome pairs included in the Global Burden of Disease study 2015
23984	Global age-standardised summary exposure values for all risk factors for 1990, 2005, and 2015
23985	Global all-age deaths and DALYs attributable to each risk factor at each level of the risk factor hierarchy and outcome for both sexes combined in 2005 and 2015
23986	Proportion of participants experiencing at least one grade 3–5 adverse event by 52 weeks that was possibly, probably, or definitely related to study treatment using a modified intention-to-treat analysis for a model based on the raw dataset and imputed dataset
23987	Bleeding endpoints
23988	Exploratory ischaemic endpoints
23989	Effect of tranexamic acid on maternal death
23990	Effect of tranexamic acid on composite primary endpoint  (death or hysterectomy)  by subgroup
23991	Effect of tranexamic acid on need for surgical intervention
23992	Effect of tranexamic acid on thromboembolic events, complications, use of uterotonics, and quality of life
23993	Age-specific reasons for major bleeds not identified by administrative coding alone
23994	Univariate and multivariate analyses for risk factors for major bleeding events and for major upper gastrointestinal bleeding
23995	Goldmann perimetry and Humphrey computerised testing
23996	Treatment-emergent ocular adverse events in the intervention group in 1 year  (mITT)
23997	Efficacy outcomes
23998	Safety outcomes by treatment group
23999	All-cause adverse events across all uncomplicated malaria episodes treated with study drugs  (safety population)
24000	Standardised mortality ratios  (SMRs)  for homicide, suicide, and accident, by diagnostic category
24001	Prevalence of passive smoking by centre
24002	Odds ratios for respiratory symptoms, current asthma, and allergic rhinitis in passive smokers compared with participants without regular involuntary exposure to tobacco smoke
24003	Odds ratios  (95% CI)  for respiratory symptoms, current asthma, and allergic rhinitis in passive smokers categorised by daily exposure duration compared with participants without regular involuntary exposure to tobacco smoke  (<1 h daily)
24004	Estimated effect of passive smoking on total serum IgE, bronchial responsiveness  (ECRHS slope) , and lung function
24005	Estimated effect  (95% CI)  on total serum IgE, bronchial responsiveness  (ECRHS slope)  and lung function in passive smokers categorised by daily exposure duration compared with participants without regular involuntary exposure to tobacco smoke  (<1 h/daily)
24006	Severity and duration of upper-respiratory-tract  (URT)  and lower-respiratory-tract  (LRT)  symptoms associated with rhinovirus infection
24007	Results of patch testing
24008	Weight, height, lung function results, skin test results, and maternal smoking in children who had wheezed, and those who had never wheezed during the first 3 years of life
24009	Pulmonary function in children who had never wheezed in relation to risk group, as defined by parental atopic status
24010	Pulmonary function in children who had never wheezed: adjusted sRaw  (geometric means and 95% CI)  for fixed factors in the model of covariance
24011	Pulmonary function in children who had never wheezed. Specific airway resistance, geometric means, and 95% CI
24012	Effects of transfusions of cryopreserved autologous platelets and fresh allogeneic platelets
24013	Platelet aggregation response
24014	Alloimmunisation and platelet refractoriness
24015	Number of patients who received more than 90% of planned total dose or dose intensity  (based on MRC data only)
24016	Non-protocol treatments, including more than six cycles of study treatment, given before progression
24017	Moderate or severe toxic effects seen during treatment  (grade 3/4 except where stated)
24018	Treatments given on first progression
24019	Frequency of atopy  (skin test weal 2 mm)  at ages 13 and 21 years, and asthma at ages 9–26, by breastfeeding history
24020	Effect of duration of breastfeeding on development of atopy and asthma
24021	Effect of family history of allergy  (either parent reporting asthma or hayfever)  on effect of breastfeeding on development of atopy and asthma in the New Zealand birth cohort
24022	Univariate and multivariate analyses of risk factors for current asthma at age 9 years, positive skin test responses to mite or to any allergen at age 13 years, and for current asthma age 9–26 years by repeated measures analysis
24023	Classification of outcomes
24024	Relative risks for various mortality outcomes 1991–98 for children living with single parents compared with children with two parents
24025	Multivariate models for severe psychiatric diseases and injuries 1991–99 for children in single-parent families compared with those in two-parent families
24026	Topiramate dose-escalation schedule
24027	Mean difference between topiramate and placebo averaged over trial period
24028	Protocol treatments received during trial
24029	Moderate or severe toxic effects experienced during treatment
24030	Death from all medical causes, by smoking and age, among men in urban and in rural India
24031	Death from specific medical causes, by smoking, among men aged 25–69 years in urban India  (Chennai)
24032	Death from selected medical causes, by smoking, among men aged 25–69 years in rural India  (South Arcot district)
24033	Death from pulmonary tuberculosis, by smoking and age, among men in urban and in rural India
24034	Prevalence of smoking, by age, and prevalences among smokers and non-smokers of self-reported pulmonary tuberculosis  (past or current)  in population survey of urban and rural men aged ⩾ 35 years
24035	Prevalence of self-reported pulmonary tuberculosis at ages 35–69 years, by amount of cigarettes or bidis smoked, in a population survey of men in urban India  (Chennai)
24036	National numbers  (year 2000)  of male deaths attributed to smoking in all India, urban and rural
24037	Stimulation index for participants practising unprotected sex
24038	Comparison of stimulation index scores between women and men practising protected and unprotected sex
24039	Comparison of geometric means of infection with CCR5 and CXCR4 strains of HIV-1 between women or men practising protected sex longer than 12 months compared with those practising protected sex for 6–12 months
24040	Phenotype of CD4+CD25+ and CD4+CD25– T cells from non-atopic and atopic donors
24041	Relative risk for incident gout according to daily alcohol intake
24042	Relative risk for incident gout according to individual alcoholic beverage intake
24043	Alcohol intake and multivariate relative risk of incident gout according to various definitions of gout *
24044	Renal variables at birth and at most recent follow-up in patients with neonatal membranous glomerulonephritis
24045	Alcohol consumption at follow-up
24046	Determinants of SPT wheal size in HDM-SPT-positive individuals: Spearman correlation
24047	Determinants of SPT wheal size in HDM-SPT-positive individuals: multiple stepwise linear regression
24048	Asthma-associated outcomes: univariate analysis
24049	Determinants of symptomatology in HDM-sensitive atopics: univariate analyses
24050	BHR in non-atopics: univariate analyses
24051	Logistic regression modelling of relation between asthma-associated outcomes and immune response variables in children
24052	Predictors of airway hyper-responsiveness at age 7 years, stratified for wheezing at school age  (5–7 years)
24053	Predictors of lung function at ages 7, 10, and 13 years from repeated measure analysis with mixed linear models  *
24054	Summary of randomised controlled trials examining effect of folic-acid-containing supplements on cognitive function
24055	Folate status and total homocysteine concentrations throughout the study
24056	Change in cognitive performance within groups during 3 years and difference in cognitive change attributed to folic acid supplementation
24057	Outcome of questionnaire survey in cases and controls
24058	Distribution of cases and controls by outcome of proxy questionnaire interview
24059	Indicators of alcohol consumption and problems in cases and controls
24060	Association of mortality from all causes with frequency of non-beverage alcohol drinking and mean volume ethanol consumed from beverages
24061	Association of beverage ethanol volume drunk per week stratified by non-beverage alcohol drinking status  †
24062	Association of mortality from all causes with alcohol drinking pattern and problem drinking adjusted for smoking and education
24063	Total alcohol abstinence by Child-Pugh classification
24064	Effects of drug, time, and interaction on addiction and laboratory variables, estimated by ANCOVA mixed models
24065	Clinical features of the two cases
24066	Detailed exposure of case two to the index case before the onset of illness
24067	Type of exposure and sera collection of 91 close contacts
24068	Prevalence of serodiscordance among cohabiting and non-cohabiting couples in Lusaka and Kigali by sex of at-risk partner and age
24069	Estimated mean probability of incident HIV infection resulting from marriage or cohabitation and from non-cohabiting sexual partners, based only on population-based data on self-reported sexual partnerships, assuming 20% annual transmission within serodiscordant couples  (model 1)
24070	Estimated mean probability of incident HIV infection resulting from marriage or cohabitation and from non-cohabiting sexual partners, accounting for reported condom use at most recent sexual intercourse with each partner, if condom use reduces transmission risk by 50%  (model 2)
24071	Sensitivity analysis of the mean probability of incident HIV infection within marriage or cohabitation in urban Zambia and Rwanda, with changing assumptions about transmission of HIV per unit time and protection from condom use
24072	Sensitivity analysis of mean probability of incident HIV infection within marriage or cohabitation in urban Zambia and Rwanda, with varying estimates of potential error in the data sources used to estimate serodiscordance and numbers of sexual partners
24073	Univariate and multivariable analysis  (Cox regression)  of the effect of rhinitis on the cumulative incidence of asthma
24074	Asthma onset according to sensitisation in patients with allergic rhinitis
24075	Univariate and multivariable analysis  (Cox regression)  of the effect of allergic and non-allergic rhinitis defined by specific IgE on the cumulative incidence of asthma
24076	1-month prevalence of mental disorders in a sample of 63 004 individuals aged 18 years or older from Shandong, Zhejiang, Qinghai, and Gansu provinces in China
24077	Comparison of the prevalence of main groups of mental disorders and the most common specific disorders in a sample of 63 004 men and women aged 18 years or older from Shandong, Zhejiang, Qinghai, and Gansu provinces in China
24078	Comparison of the prevalence of main groups of mental disorders and the most common specific disorders in a sample of 63 004 individuals aged 18 years or older in rural versus urban areas in Shandong, Zhejiang, Qinghai, and Gansu provinces in China
24079	Comparison of the prevalence of main groups of mental disorders and the most common specific disorders by age group in a sample of 63 004 individuals from Shandong, Zhejiang, Qinghai, and Gansu provinces in China
24080	Male relative risk of death at ages 15–74 years, by proxy-reported alcohol intake  (other drinkers vs reference drinkers, excluding never-drinkers)  and certified cause  (other causes vs control diseases)
24081	Female relative risk of death at ages 15–74 years, by proxy-reported alcohol intake  (other drinkers vs reference drinkers, excluding never-drinkers)  and certified cause  (other causes vs control diseases)
24082	Male dose-related excess mortality in ever-drinkers as a proportion of all mortality in male ever-drinkers and never-drinkers, by age and underlying cause of death
24083	Female dose-related excess mortality in ever-drinkers as a proportion of all mortality in female ever-drinkers and never-drinkers, by age and underlying cause of death
24084	Deployment experiences of study participants, by deployment location
24085	Association between probable mental disorders and deployment status, stratified by engagement type  (regular or reservist status)
24086	Association between probable mental disorders and location of deployment for regular personnel
24087	Association between probable mental disorders and role on deployment for regular personnel
24088	Association between probable mental disorders and number of deployments to Iraq or Afghanistan, for currently serving regular Army personnel  (N=4098)
24089	Association between time since return from deployment and probable mental disorders for regulars
24090	Cytomegalovirus viraemia and treatment in subgroups of transplant patients with defined donor and recipient serostatus
24091	Homicide mortality per 100 000 inhabitants by macro-regions of Brazil, 1991–2007
24092	Period-prevalence  (12 months)  of psychological and physical abuse against women by region
24093	Traffic-related mortality per 100 000 inhabitants by type of victim and by age group, 2007
24094	Important benchmarks in tackling domestic violence in Brazil, by year
24095	Measures related to traffic-related injuries and deaths in Brazil, by year
24096	Grade 3 or higher toxic effects in all patients randomly assigned to treatment groups, by chemotherapy regimen over entire treatment period
24097	Second-line therapy received by KRAS wild-type patients, by chemotherapy received
24098	Proportion of YLDs, YLLs, and DALYs explained by the ten leading causes of total burden in 2010
24099	Maximum local and systemic reactogenicity
24100	Antibody titres
24101	Primary and secondary outcomes
24102	Costs per person and cost-effectiveness analyses  (2015 international dollars)
24103	Cost-effectiveness analyses from health system and societal perspectives  (2015 international dollars)
24104	Cause-specific deaths within 10 years after index injury admission, by sex and type of index injury
24105	Relative risk of cause-specific death within 10 years after adversity-related index injury vs accident-related index injury
24106	Relative risk of cause-specific death within 10 years after each type of adversity-related index injury vs accident-related index injury
24107	Plasma concentrations of functional C1-INH  (intention-to-treat population)
24108	Adverse events  (safety population)
24109	Laboratory data of patients 1–3
24110	CLCN5 mutations in cases of hypercalciuric nephrolithiasis with tubular proteinuria
24111	Use of calcium-channel blockers and their relation to cancer
24112	Relation of use of calcium-channel blockers with specific types of cancer
24113	Woman-years of exposure to steroid contraceptives and mean ages of women between 1991 and 1995
24114	Woman-years of exposure to OCs, numbers of cases, and rate of VTE in each age-group
24115	Cases of VTE by exposure, crude incidence rates, and rate ratios from cohort study
24116	Rate ratios for VTE by type of OC use adjusted for 5-year age bands
24117	Odds ratios of VTE by use of different types of OC
24118	Clinical findings in five cases of non-fatal citalopram overdose
24119	Laboratory indices before, during, and after treatment with moxonidine
24120	% Rate and intensity of microfilaraemia before  (1994)  and after  (1995)  one single-dose mass treatment
24121	Results for primary outcome measures in group A  (predominant isosorbide dinitrate)  and group B  (predominant furosemide)
24122	Results for secondary outcome measures in group A  (predominant isosorbide dinitrate)  and group B  (predominant furosemide)
24123	Laboratory data
24124	Body composition data
24125	Western Aphasia Battery  (WAB)  summary scores before and after resection for patients whose language was classified as normal  (aphasia quotient ƒ93·8)  before resection
24126	Western Aphasia Battery  (WAB)  summary scores before and after resection for patients with dominant hemispheric tumour who were dysphasic  (aphasia quotient <93·7)  before resection
24127	Western Aphasia Battery  (WAB)  subtest scores before and after resection for patients with dominant hemispheric tumour who were dysphasic  (aphasia quotient <93·7)  before resection
24128	Mean scores before and after surgery for asphasia quotient, language quotient, and Boston Naming Test  (BNT)  for patients with left-sided intracranial tumours grouped according to neuropathology
24129	Boston Naming Test  (BNT)  scores before and after resection for patients with dominant hemispheric tumour who were anomic  (score ≤48)  or not  (score ≥49)  before resection
24130	Incident and fatal cancer by treatment group
24131	Risks of different types of incident cancer
24132	Primary HIV-1 infection treated with hydroxyurea, didanosine, and indinavir
24133	Prevalence of continuing use of antihypertensive drugs among 450 000 elderly people in British Columbia
24134	Annual incidence of new use of antihypertensive drugs among elderly people in British Columbia
24135	Proportion of elderly people in British Columbia in 1996 who were newly treated with an antihypertensive drug, grouped by drug class and relative contraindication for thiazide and b-blocker
24136	Comparison of brain-dead donors
24137	Comparison of the kidney recipients
24138	Long-term follow-up in recipients
24139	Prescribing data
24140	Odds ratio for road-traffic accident in current users of anxiolytic and hypnotic benzodiazepines
24141	Odds ratio for road-traffic accident by dose of antidepressant drug or benzodiazepine
24142	Primary and secondary endpoints and exploratory analyses
24143	Phase 3 efficacy trials with meloxicam
24144	Phase 3 efficacy trials with celecoxib
24145	Phase 3 endoscopic safety studies with celecoxib
24146	Phase 3 efficacy studies with rofecoxib
24147	Incidence rate of new AIDS events and death in people treated with triple therapy when CD4 count was less than 20/μL, according to latest CD4 count after starting treatment
24148	Clinical information
24149	Number of episodes treated by seizure type
24150	Odds ratios of hip fracture associated with use of oral contraceptives
24151	Odds ratios of hip fracture associated with age at oral
24152	Mean  (SD)  plasma concentrations of endotoxin and inflammatory markers in healthy volunteers and patients with chronic heart failure
24153	Mean  (SD)  plasma concentrations of endotoxin and inflammatory markers in oedematous patients before and after diuretic treatment
24154	The drugs used for the rotation
24155	Mean supine blood pressure at study entry and at the end of the three wash-out periods
24156	Comparison of response rates to each patient's first and best drug
24157	Trials of immediate versus deferred zidovudine
24158	Trials of zidovudine plus didanosine or zalcitabine versus zidovudine alone
24159	Risk of venous thromboembolism among new users of second and third generation oral contraceptives
24160	Ecstasy-related deaths among individuals aged 15–24 years in England and Scotland
24161	Heroin-related deaths among individuals aged 15–24 years in Scotland
24162	Effect of pharmacological interventions on blood loss and number of transfused units
24163	Normalised APC sensitivity ratios during crossover study
24164	Performance of measures of arrhythmic risk at 18 months of follow-up
24165	Allergy histories
24166	HIV kinetics during sequential structured treatment interruptions
24167	Admission clinical and laboratory features by treatment group
24168	Clinical outcome
24169	Mortality in phenobarbital and placebo groups, according to number of doses of diazepam
24170	Side-effects during prophylactic treatment
24171	Standardised heart-failure scoring system
24172	Total cardiovascular events for patients in the BNP and clinical groups during median 9·5 months follow-up
24173	Key design features of trials
24174	Summary of major clinical events
24175	Outcomes according to ejection-fraction stratum
24176	Effects of ACE inhibitors on outcomes in selected subgroups from all five trials
24177	Observed opportunities for hand hygiene in consecutive observational studies, University of Geneva Hospitals, Switzerland, 1994–97
24178	Compliance with hand hygiene in successive observational surveys, and odds ratios for compliance, unadjusted and adjusted for known risk factors, University of Geneva Hospitals, Switzerland, 1994–97
24179	Details of hospital cleaning chemicals used in the study
24180	Trials included in the first round of analyses
24181	Blood-pressure differences, proportion remaining on randomised treatments, and proportion achieving blood-pressure goals
24182	Underlying diagnosis in 1014 patients with hypopituitarism
24183	Regional and national observed and expected cause-mortality rates in 1014 patients with hypopituitarism
24184	Univariate analysis of regional and national standardised mortality ratio  (SMR)  versus sex, year of diagnosis, age of diagnosis, tumour type, treatment with surgery and radiotherapy, and sex-steroid replacement therapy
24185	Effect of hormonal-axis deficiency on mortality in patients with hypopituitarism
24186	Association between degree of hormone deficiency and mortality in patients with hypopituitarism
24187	Univariate analysis of regional and national standardised mortality ratios in 573 patients with non- functioning pituitary tumours
24188	Multiple regression analysis using Cox's proportional hazards model to determine the influence of individual variables on survival in hypopituitarism
24189	Total percentage change in laboratory markers
24190	Factors associated with progression to any lipodystrophy
24191	Factors associated with progression to specific types of lipodystrophy  (multivariate models)
24192	Observed and expected number of deaths during follow-up
24193	Frequency of cancer
24194	Frequency of cancers in the STOP-Hypertension-2 cohort
24195	Frequency of cancers for every treatment group
24196	Frequency of cancers for all treatment groups in the STOP-Hypertension-2 cohort
24197	Patients who received randomly assigned drug class with or without additional antihypertensive drugs among those who attended annual visit
24198	Major adverse cardiac events
24199	Description of 10 popular magazines studied24
24200	Headlines of 15 selected advertisements
24201	Pooled estimates of advantage of new versus old antihypertensive drugs with respect to cause-specific mortality
24202	Variance explained by initial blood pressure and blood pressure difference
24203	Observed odds ratios and odds ratios predicted by differences in systolic blood pressure in metaregression
24204	PCR detection of Wolbachia in plasma after diethylcarbamazine chemotherapy
24205	Number of participants on study drug at endpoint or end of follow-up
24206	Endpoints
24207	Adverse events
24208	Biochemical variables
24209	Prevalence ratio  (PR)  of hypospadias
24210	Distribution of major clinical outcomes
24211	Severe adverse effects in chemosensitive patients
24212	Causes of death in chemosensitive patients at last follow-up
24213	Overall survival and freedom from treatment failure  (FFTF)  at 3 years
24214	Bacterial susceptibility during the study period
24215	Findings on presentation of bacterial meningitis
24216	Progress in hospital and at discharge
24217	Neurological sequelae, overall and by causative agents
24218	Outcome of survivors from hospital, overall and by causative agents
24219	Hearing outcomes, overall and by causative agents
24220	Clinical findings in patients who fully recovered, who died, and who had sequelae
24221	Time course of 24 h urinary protein excretion rate  (g/24h)  in individual patients from 24 weeks before study entry  (week 0)  up to study end  (week 20)
24222	Age, ethnic groups, and parity in the HIV-1-positive cohorts
24223	Reperfusion therapy for index myocardial infarction
24224	Medications given concurrently with study drug
24225	Subgroup analyses
24226	Multivariable logistic regression model
24227	Causes of heart disease
24228	Diagnostic investigations
24229	Treatment
24230	Outcomes
24231	Organisms isolated from blood cultures
24232	Median lactulose/mannitol ratios on the day before start of treatment  (L/M start)  and at maximum neutropenia  (L/M max) , according to treatment group
24233	Adjusted survival curves showing time to death from all causes in patients with cardiovascular disease
24234	Interventions evaluated
24235	Annual costs, effects, and cost-effectiveness of interventions
24236	Annual incremental costs, effects, and cost-effectiveness of interventions
24237	Body composition abnormalities in cases and non-assigned patients
24238	Biochemical charectoristics of cases and controls in training data set
24239	Antiretroviral and metabolic drug use in training dataset
24240	HIV lipodystrophy case definition and scoring system
24241	Model sensitivity and specificity according to lipodystrophy score
24242	Cox proportional hazard analysis for the effect of covariates on survival in patients with chronic heart failure  (SOLVD)
24243	Effect of weight loss on survival in patients with chronic heart failure  (SOLVD)
24244	Cumulative frequency of weight loss of 6% or more in the SOLVD treatment study and in V-HeFT II
24245	Peak nausea and antiemetic use
24246	Cumulative all-cause and cause-specific mortality for the enalapril and placebo groups in the prevention trial
24247	Cumulative all-cause and cause-specific mortality for the enalapril and placebo groups in the treatment trial
24248	Causes of death among fluvastatin-treated and placebo-treated patients
24249	Frequency of most relevant adverse events and abnormal laboratory values
24250	Primary endpoints and components of the composite endpoint
24251	Safety variables
24252	Secondary outcomes hierarchically ordered
24253	Permanent study-drug discontinuations for adverse events
24254	Primary and secondary outcomes
24255	Numbers of hospital admissions for worsening heart failure  *
24256	Permanent study-drug discontinuation for adverse events
24257	Immunological category, progression to a new opportunistic infection or cancer, and mortality by calendar year
24258	Details of patients with confirmed diagnosis of recent Chandipura virus infection
24259	Antibody status and relation to time of sample collection
24260	Effects of diclofenac or manipulation on secondary outcomes
24261	Cumulative risk of extensive virological failure of for individual drug classes according to years from start of that class
24262	Adherence to study medication
24263	Effects of study treatment on primary and secondary outcomes at 30 days
24264	Outcomes for patients with a non-fatal myocardial infarction and non-fatal stroke  *
24265	Independent predictors of death and stroke and their associated population attributable risks
24266	Rates of myocardial infarction by exposure to various NRTIs
24267	Exposure to NRTIs and risk of first myocardial infarction, cardiovascular death, or invasive cardiovascular procedure, and of risk of possible or definite stroke  *
24268	Summary of study events
24269	Most frequently occurring adverse events
24270	Medication at a median of 438  (402–486)  days follow-up
24271	Adverse clinical events at 1-year follow-up
24272	TIMI risk score variables of the combined endpoint of cardiac death or non-fatal reinfarction
24273	Effects of treatment-group assignment on outcomes of retention and heroin use
24274	Effects of treatment-group assignment on AIDS risk behaviours
24275	Secondary outcomes
24276	Causes of death
24277	Predefined subgroup analysis—composite endpoint of all-cause death or admission to hospital for cardiovascular reasons
24278	Permanent treatment discontinuations and adverse drug reactions
24279	Incidence of serious adverse events during the study by system organ class
24280	Primary and secondary endpoints
24281	Secondary outcomes
24282	Causes of death
24283	Predefined subgroup analysis—composite endpoint of all-cause death or admission to hospital for cardiovascular reasons
24284	Permanent discontinuations and adverse drug reactions
24285	Maternal treatments and outcomes
24286	Primary and other neonatal outcomes
24287	Primary neonatal outcome in infants born before 32 weeks' gestation and within 7 days of repeated study drug administration
24288	Effect of relaxin on primary treatment targets
24289	Improvement in signs of heart failure
24290	Adverse events
24291	Change in use of heroin and crack cocaine by treatment type and drug use group  ‡
24292	Parameters from the mixed linear model analysis  §
24293	Change categories  †   at review by treatment type and drug use group
24294	Changes in use of drugs other than heroin and crack cocaine from admission to review
24295	Hazard ratios for the primary and major secondary endpoints and components
24296	Hazard ratios for other outcomes
24297	Selected adverse events and adverse events with discontinuation
24298	Systolic and diastolic blood pressure in intervention and control groups
24299	Prescription of antihypertensive drugs
24300	Most frequent symptoms or side-effects at 12 months
24301	Quality of life as measured by EQ-5D
24302	Primary endpoint and components
24303	Summary of adverse events
24304	Drug treatment in all GREACE patients according to liver function tests during the 3 years of study
24305	Therapeutic protocol
24306	Trial outcome as at June, 2009
24307	Endpoint of progression-free survival grouped by competing risks
24308	Reported outcomes of trials in relapsed childhood acute lymphoblastic leukaemia
24309	Response to different treatment phases and best response, according to central assessment
24310	Cox regression analysis of progression-free survival in subgroups of patients with poor prognosis
24311	Multivariate analysis of variables favourably affecting progression-free survival
24312	Serious adverse events and grade 3 or 4 adverse events reported in at least 2% of patients during induction therapy
24313	Non-haematological adverse events of any grade reported in at least 10% of patients during induction therapy
24314	Number of communities and participants by country income
24315	Drug use in participants with coronary heart disease or stroke, by country economic status and overall
24316	Participants with coronary heart disease or stroke, by urban or rural locations stratified by country economic status
24317	Drug use in participants with coronary heart disease or stroke, by region
24318	Country  (between country)  and individual  (within country)  variances and their contributions as a percentage to the total variance based on multilevel modelling
24319	Triggering factors in occupational rhinitis
24320	Benefits and harms of treatments for allergic rhinitis
24321	Mean number of patients per practice for each primary outcome measure
24322	Prevalence of prescription and monitoring problems at 6 months' follow-up by allocation group
24323	Prevalence of prescription and monitoring problems at 12 months' follow-up by allocation group
24324	Costs, outcomes, and incremental economic analyses associated with PINCER intervention and simple feedback
24325	Transplacental transfer of chemotherapeutic agents in pregnant baboons, from simultaneously collected maternal and fetal plasma samples  70,71
24326	Protocol-specified additional efficacy outcomes
24327	Lipid and lipoprotein concentrations
24328	Mortality risk by fitness
24329	Mortality risk for the combined fitness and statin categories
24330	Distinguishing hypertrophic cardiomyopathy from athlete's heart when left-ventricular hypertrophy is within the grey zone of overlap  (thickness, 13–15 mm in males and 11–12 mm in females)
24331	Availability of data for analyses
24332	Infection-based hypotheses for childhood acute lymphoblastic leukaemia
24333	Key genetic alterations in B lymphoblastic leukaemia, by gene
24334	Definitions, stages, and burden of chronic kidney disease and acute kidney injury
24335	Classification of causes of chronic kidney disease based on presence or absence of systemic disease and location within the kidney of pathological-anatomical findings
24336	Monogenic and complex kidney diseases
24337	Most important causes of 166 cases of paediatric acute kidney injury in South India
24338	Home systolic blood pressure averaged across both visits for each cycle
24339	Home systolic blood pressure at final visit of each cycle
24340	Home systolic blood pressure dose response  (higher vs lower dose)
24341	Adverse events and withdrawals
24342	Clinical outcomes
24343	Safety outcomes
24344	Patient incidence of adverse events and serious adverse events in all patients who received at least one dose of study drug
24345	Summary of primary and secondary mitral regurgitation
24346	Primary and secondary outcomes in the intention-to-treat population
24347	Primary and secondary outcomes in the per-protocol population
24348	Primary and secondary cocaine use-related outcomes
24349	Longitudinal changes in secondary outcomes—cocaine craving, substance use, health problems, and criminality  (intention-to-treat sample, n=73)
24350	Adverse events reported by at least two patients
24351	Randomised controlled trials included in the systematic review and network meta-analysis
24352	Number of patients with suicidal behaviour or ideation according to study treatment
24353	Serious adverse events
24354	Prescription of antihypertensive medication
24355	Participants who reported a hypertension medication-specific symptom or adverse effect at 12 month follow-up visit  (ten most reported symptoms plus hypertension-specific symptoms not reported in the top ten)
24356	Effects of clinical variables on time to resolution and duration of oxygen therapy
24357	Effects of dexamethasone in selected patient subgroups for time to resolution and duration of oxygen therapy
24358	Smoking and risk of AMI
24359	Fasting blood glucose  (FBG)  and serum insulin
24360	Relative risk in groups by tertile of fasting blood glucose  (FBG)  and insulin
24361	Effect of multiple risk factors, modelled with logistic regression: prediction of cases versus controls
24362	Different types of VRE recovered from patients or environment
24363	Colonisation with VRE in mechanically ventilated patients and in MICU environment
24364	Proportion of severe visual impairment and blindness due to ROP in children aged 0–15 years in schools for the blind
24365	Outcome variables
24366	Linkage of insulin gene region of chromosome 11p15.5 to PCOS
24367	Association of insulin VNTR class  III  allele with PCOS
24368	Intrafamilial association analysis of  INS  VNTR allele with PCOS
24369	Logistic regression models
24370	Deaths in Trent and Victoria by diagnostic category and by expected mortality
24371	Clinical histories of patients with MDR-TB treated with interferon-γ
24372	Age-specific rate of diabetes by infant-feeding group
24373	Odds ratios for diabetes from logistic regression model
24374	Paediatricians' statements about their practices for end-of-life decisions  (interview study)
24375	Diagnosis in neonates and infants in whom death was preceded by a medical end-of-life decision  (interview study)   *
24376	Paediatricians' statements about decision-making  (interview study)
24377	Main clinical outcomes of treatment after 28 and 56 weeks of combined  (n=76)  and sulphasalazine  (n=79)  treatment
24378	Radiographic outcome of treatment
24379	Reasons for withdrawal of patients from study
24380	Clinical, parasitological, and laboratory findings on admission
24381	Total number of chemotherapy cycles received
24382	Reasons for termination of protocol chemotherapy schedule
24383	Total doses of drugs received and protocol-intended doses
24384	Grade 3 and 4 toxic effects during chemotherapy
24385	Planned and actual surgery received
24386	Outcomes for patients assigned magnesium or placebo
24387	Functional outcome for resuscitated patients
24388	Proportion of patients successfully resuscitated in predefined subgroups
24389	Inclusion and exclusion criteria
24390	Clinical outcome  (n=26)
24391	Glycaemic control, insulin secretion, insulin sensitivity, lipids, and lipoprotein  (a)  values before and after treatment
24392	Geometric means of plasma glucose and insulin concentrations
24393	Geometric mean 120 min plasma glucose concentrations by exposure, birthweight, and body-mass index
24394	Haemodynamic measurements
24395	Cardiac structure and function and growth-hormone axis data
24396	Plasma IGF-I concentrations by case or control status
24397	Relative risk of breast cancer by plasma IGF-I quintiles or tertiles
24398	Results of Bayley test on 201 ICSI and 131 IVF children between the ages of 22 and 26 months
24399	Site of first disease recurrence
24400	Most frequently occurring adverse events in 248 patients treated with interferon α-2a
24401	Infections or immunisations preceding GBS that have been confirmed by case-control studies or demonstrated in large numbers or series
24402	Fatty acid composition  (g/100 g fat)  of LCPUFA and no-LCPUFA formulae
24403	Median  (quartiles)  problem-solving scores on entire problem and each individual step
24404	Criteria for scoring intention on steps of three-step problem
24405	Sensitivity and specificity of IL-1ra, IL-6, cICAM-1, and CRP
24406	Concentrations of IL-1ra, IL-6, and cICAM-1 in those 38 study periods within the unclassified group with objective clinical evidence and subjective suspicion of sepsis
24407	Concentrations of IL-1ra, IL-6, and cICAM-1 in those 38 study periods within the unclassified group with either objective clinical evidence or subjective suspicion of sepsis
24408	Treatment response by the end of treatment and end of follow-up  (sustained response)  according to treatment received
24409	Sustained virological response to different regimens according to the number of response factors
24410	Responses according to skin detachment, SAPS, and mortality
24411	Plasma and blister-fluid TNF-a and interleukin 6 concentrations
24412	Clinical-response data
24413	Proportions of patients reporting moderate or severe symptoms
24414	APACHE II scores for patients
24415	Staff disciplines and seniority by case-management group
24416	Days in hospital over 2 years
24417	Secondary and tertiary outcomes at 2 years
24418	Premorbid estimated IQs of elderly individuals competent to complete advance directives compared with those who are incompetent
24419	Haematological data before, during, and after surgery
24420	Mean  (SD)  blood loss, blood-component transfusion, and re-exploration rates
24421	Mean  (SD)  haemodynamic data 5 min before and after study-drug administration
24422	Days in hospital and number of admission over 2 years by intelligence status
24423	Handwashing compliance by health-care workers
24424	Frequency and duration of contact between health-care workers and patients
24425	Biochemical features of autoimmune thyroid disease after Campath-1H treatment
24426	General data of patients in supine and semirecumbent position
24427	Microorganisms recovered on the day of clinical suspicion of pneumonia
24428	Univariate variable statistics for extrinsic risk factors of nosocomial pneumonia
24429	Univariate variable statistics for extrinsic risk factors of nosocomial pneumonia
24430	Association of MHC class II allele frequencies and self-limiting and persistent HCV infection  (European cohort)
24431	Association of MHC class II allele frequencies and self-limiting and persistent HCV infection  (Lookback cohort)
24432	Association of MHC class II allele frequencies and histological injury due to HCV infection
24433	Association of MHC class II allele frequencies and response to interferon in patients with persistent HCV infection
24434	Features of children in the KIGS database
24435	Incidence of diabetes or IGT for all patients and for selected disorders
24436	Incidence of type 1 diabetes by age group
24437	Consensus decisions of intensivists
24438	Relation of place enrolled, consensuses decision, and mean APACHE score
24439	Rate of patients per 1000 adult population of IMH area by quartile of deprivation and appropriate place of care
24440	Average number of critical-care beds needed by hospital  (number required to meet need 95% of times)
24441	Decreased concentrations of serum IGF-1 and serum IGFBP-3 and the risk of osteoporotic fracture in postmenopausal women
24442	Risk of colonisation with resistant gram-negative bacilli and antibiotic regimen
24443	Episodes of bacteraemia by causative organism
24444	Antibiotic use
24445	Causes of death
24446	Proportion of discharges at night from ICUs participating in UK APACHE II study compared with CMPD
24447	Case mix for night  (2200–0659)  versus day discharges
24448	Outcome for night versus day discharges
24449	Reason for discharge for night  (2200–0659 h)  versus day discharges
24450	Outcome for night versus day discharges—impact of premature discharge
24451	Discharge destination and length of stay for night  (2200–0659 h)  versus day discharges
24452	Outcome for night discharges direct to the ward versus day discharges
24453	Outcome for night discharges direct to the ward versus day discharges—impact of premature discharge
24454	Mean  (SD)  adolescent to adult personality functioning assessment scores
24455	Associations between poor functioning in love/sex relationships and friendships
24456	Comparison of guidelines used during control and intervention periods
24457	Incidence of nosocomial infections, before and after intervention
24458	Sample size and response rates
24459	Proportions of physicians who had ever decided  (alone or with others)  to set limits to intensive interventions
24460	Proportions of physicians who had made specific decisions
24461	Results of multivariate logistic regression for selected reported practices  *
24462	Adjusted proportions of physicians who had made specific decisions
24463	Association between individual measures of ICU workload and mortality
24464	Multivariate analysis of ICU workload in relation to adjusted mortality
24465	Mean  (SD)  test scores for the 68 individuals who completed all WAIS subtests at ages 50 years and 80 years and underwent MRI
24466	Correlations between MRI hyperintensity scores and 80-year WAIS results
24467	Product-moment correlations between MRI hyperintensity scores and decline in WAIS scores between age 50 and age 80
24468	Product-moment correlations between two WAIS subtests and decline in cognitive performance during each of the decades from age 50 to age 80
24469	Admission details, length of stay, and standardised mortality ratios for each study group
24470	Proportion of individuals expressing individual alleles in the first intron of the interferon-gamma gene
24471	Proportion of individuals who expressed the 126 bp allele, 122 bp allele, both, or neither in the first intron of the interferongamma gene
24472	Estimates of effects from fitted logistic regression model of clinical variables, HLA-DRB1, and interferon gamma on odds of severe disease
24473	Mean  (SD)  anthropometric variables of individual bone-marrow transplantation  (BMT)  patients and groups of former leukaemia patients and healthy controls
24474	Biochemical variables of individual bone-marrow transplantation  (BMT)  patients and groups of former leukaemia patients and healthy controls
24475	Manifestations of the metabolic syndrome
24476	Odds ratios  (95% CI)  for insulin-resistance-associated cardiovascular risk factors and being on antihypertensive, antidiabetic, or lipid-covering medication
24477	Protocol for management of patients at risk of or with pulmonary hypertension
24478	Risk of prostate cancer for all patients and stratified according to PSA concentrations for specified increments of IGF-1 and IGFBP-3
24479	Chronic illnesses in ICU patients with and without
24480	Acute organ system failures in 807 ICU patients at time of decisions to withhold or withdraw life-support treatments
24481	Reasons given for withholding or withdrawal of life-support treatments
24482	Involvement and information of patients and families in the decision-making process
24483	Life-support therapies withheld or withdrawn in 807 ICU patients
24484	Clinical features of seven identified cases
24485	Occurrence and severity of hypoglycaemic episodes
24486	Results of pulmonary-function tests
24487	Clinical profiles, plasma lipids, and parameters of glucose metabolism in five patients with CD36 deficiency
24488	Maternal outcomes of women with pPROM randomly assigned erythromycin
24489	Neonatal outcomes of babies born to women with pPROM randomly assigned erythromycin
24490	Maternal outcomes of women with pPROM randomly assigned co-amoxiclav
24491	Neonatal outcomes of babies born to women with pPROM randomly assigned co-amoxiclav
24492	Maternal outcomes of women with pPROM randomly assigned co-amoxiclav and erythromycin, or any antibiotic
24493	Neonatal outcomes of women with pPROM randomly assigned co-amoxiclav and erythromycin, or any antibiotic
24494	Maternal outcomes of women with preterm labour randomly assigned erythromycin
24495	Maternal outcomes of women with preterm labour randomly assigned co-amoxiclav
24496	Maternal outcomes of women with preterm labour randomly assigned both co-amoxiclav and erythromycin or any antibiotic
24497	Neonatal outcomes of babies born to women with preterm labour randomly assigned erythromycin
24498	Neonatal outcomes of babies born to women with preterm labour randomly assigned co-amoxiclav
24499	Neonatal outcomes of women with preterm labour randomly assigned both co-amoxiclav and erythromycin or any antibiotic
24500	Overall status by age 4 years
24501	Outcome at age 4 year by prestratified analysis
24502	Factors affecting relative risk of death, local recurrence, and metastasis by the Cox proportional hazards model
24503	Site of involvement in central nervous system during first attack
24504	Clinical endpoints
24505	MRI endpoints
24506	Tuberculosis exposure category, BCGvaccination status, ESAT-6 ELISPOT, tuberculin skin test  (TST)  and PPD ELISPOT results for all contacts
24507	Odds ratios of the relations between intensity of exposure to M tuberculosis and BCG vaccination status with each of the tests
24508	Visual acuity and ocular score of inflammation at panuveitis relapse  (day 0) , and 1, 4, and 14 days after infliximab administration
24509	Composition of preoperative oral supplement per 100 mL
24510	Infectious morbidity
24511	Multivariate analysis on survival  (Cox's regression model)
24512	Comparison of labour and delivery factors in relation to vaginal instrumental delivery and caesarean section
24513	Comparison of maternal outcome in relation to vaginal instrumental delivery and caesarean section
24514	Comparison of neonatal outcome in relation to vaginal instrumental delivery and caesarean section
24515	Comparison of maternal and neonatal factors
24516	Test probabilities to predict non-response to treatment with interferon alfa/ribavirin
24517	Univariate coefficients for correlation between body fat distribution and metabolic cardiovascular risk factors in 39 obese children
24518	Adverse effects occurring in at least 10% of patients treated with pegvisomant  (n=160)
24519	Clinicians establishing an explicit cardiopulmonary resuscitation directive
24520	Predictors of explicit cardiopulmonary resuscitation directives
24521	Average workload by unit type
24522	Relation between within-unit measures of workload and primary outcomes
24523	Admission clinical features and outcome of initial and validation samples
24524	Multiple regression analysis of clinical variables independently associated with early lactate concentration in 103 patients of initial sample
24525	Univariate logistic analysis of admission clinical predictors of a fatal outcome in 93 patients from initial sample
24526	Multivariate logistic analysis of independent clinical predictors of a fatal outcome in 93 patients from initial sample
24527	Assessment of arterial blood lactate measurement and King's College Hospital  (KCH)  criteria as prognostic indicators in 99 patients from validation sample
24528	Mean  (SE)  fasting and 8-h mean concentrations of insulin, C-peptide, glucagon, and free fatty acids during 8-h profiles
24529	Insulin, C-peptide, and glucose concentrations during hyperinsulinaemic euglycaemic clamps
24530	Mean  (95% CI)  incremental C-peptide concentrations during hyperglycaemic clamp expressed as first-phase and second-phase responses and peak values after arginine stimulation in GLP-1 group only
24531	Mean  (SE)  bodyweight, fat mass, lean body mass, and fat distribution
24532	Appetite in GLP-1 group only
24533	Association between a polymorphism in IGF-I and birthweight
24534	Number of participants who showed a postnatal gain in weight during life, stratified by genotype
24535	Details of patients and response to terlipressin
24536	Haemodynamic variables and norepinephrine dose
24537	Treatment and leucocyte and eosinophil counts in patients 1–4
24538	Mean 2-h glucose concentrations at follow-up according to tertiles of IGF-I and stratified by median concentrations of IGFBP-1, The Ely Study, 1990–96
24539	Plasma concentrations of antioxidants and total cholesterol
24540	Self-reported intake of fruit and vegetables, blood pressure, and bodyweight
24541	Percentage change in frequency of problems between the first and second interview
24542	Interventions recommended by clinicians
24543	Summary of antibiotic usage and pulmonary exacerbation rates
24544	Values of first available laboratory markers after seroconversion
24545	Univariate and multivariable analyses of all laboratory markers as time-updated covariates
24546	Neurophysiological examination before and after haemodialysis
24547	Factors associated with incidence of myocardial infarction in HOPS patients infected with HIV-1
24548	Supply of transferrin-bound iron to S epidermidis mediated by catecholamine inotropes
24549	Maximum glucose-stimulated plasma insulin and C-peptide responses during hyperglycaemic clamp and insulin sensitivity index  (M/I)  during euglycaemic clamp
24550	Composition of diets  (g per 100 mL)
24551	Early diet and fasting proinsulin, insulin, and glucose concentrations in adolescents born preterm
24552	Regression analyses of proinsulin concentrations on early growth in adolescents born preterm
24553	Comparison of adolescents born preterm and at term
24554	Primary and secondary endpoints
24555	Patients’ hormone concentrations before and during treatment with imatinib
24556	PELOD scoring system  12
24557	Relation between the number of organ dysfunctions, PELOD score, and mortality
24558	Goodness-of-fit test for the PELOD score*
24559	Relative contributions of each organ dysfunction to the PELOD score
24560	Calibration and discrimination of the dPELOD score
24561	Mean  (SE)  biochemical variables of participants
24562	Insulin concentrations, glucose infusion rates, and insulin sensitivity during the hyperglycaemic clamp
24563	Mortality
24564	Patients with resistant bacteria at inclusion
24565	Acquisition of resistant bacteria
24566	Resistant bacteria in the ICU environment
24567	Prescribed antibiotics per 1000 patients
24568	Comparability of patients who were censored at follow-up, changed preparation, or dropped out of treatment
24569	Reasons for changing preparation or dropping out of treatment
24570	Development in numbers of antibody-positive patients  (neutralisation capacity ≥20% in medium-sensitivity assay)  during treatment
24571	Pretreatment clinical features and development of neutralising antibodies
24572	Frequency of relapses in neutralising-antibody-positive and negative periods by assay sensitivity and cutoff point for positivity
24573	Development of mean EDSS in neutralising-antibody positive and negative patients
24574	Associations between detection of interleukins 6 and 10 in cord blood and indications of acute perinatal fetal distress
24575	Associations between cytokine detection and asthma and atopy responses
24576	Associations between detection of interleukin 4, interferonγ, and TNFα in cord blood and asthma and atopy outcomes at age 6 years adjusted for respective cytokine propensity score
24577	Dose of study medication
24578	Responses to category rating scales
24579	Assessment of treatment benefit at visit 8
24580	Frequency of serious adverse events
24581	Frequency of minor adverse events
24582	HSV in the throat and lower respiratory tract  (LRT)  in relation to SOFA and SOFA max scores
24583	Outcome in patients with HSV in the respiratory tract
24584	Indices of glucose metabolism
24585	Comparison of splice variant expression in normal islets and insulinomas
24586	IGF2 LOI, 11p15 LOH, and IGF2 ROI in tumours from Japanese and white children
24587	Frequency of PLNR and ILNR lesions associated with Wilms' tumours from Asian and white children
24588	Haernatological and immunological data
24589	Observed primary outcomes for all randomised neonates
24590	Factors associated with primary outcomes
24591	Primary outcomes among neonates not receiving additional analgesia
24592	Factors associated with primary outcomes among neonates who did not receive additional analgesia
24593	Effects of open-label morphine analgesia  (within each randomised group)
24594	Summary of the main outcome variables
24595	Summary of available information from questionnaires completed by parents, and from attendance for physical examination at scheduled visits
24596	Measurements of physical size at every age assessed, by time
24597	Developmental measures administered up to 8 years of age
24598	Crude, adjusted, and multivariate odds ratios for abnormal outcomes for the intensive ultrasound group relative to those in the regular ultrasound group, by developmental measure
24599	Lymphocyte proliferation responses
24600	Activities of mitochondrial enzymes and GAPDH in skeletal muscle of critically ill patients
24601	Reported frequency of fast food restaurant visits  (times per week)  by race, sex, and time in the CARDIA study
24602	Mean adjusted 15-year changes in bodyweight by three times per week year 0 differences in fast food frequency between participants, and by three times per week 15-year change in fast food frequency within participants
24603	Mean adjusted 15-year changes in HOMA insulin resistance by three times per week year 0 differences in fast food frequency between participants, and by three times per week 15-year change in fast food frequency within participants
24604	Hazard ratios for MRSA acquisition estimated from the Cox proportional-hazards model
24605	Colonisation with or acquisition of MRSA in every study phase
24606	PFGE typing of MRSA during every study phase  (excluding repeat isolates on same patient)
24607	Take rates, local signs and symptoms related to vaccination  (cohorts one to four)
24608	Local and systemic reactions within 60 days of vaccination
24609	Cell-mediated immune responses after undiluted vaccine
24610	Concordance between three results of cell-mediated immune response test in recipients of undiluted vaccination
24611	Study protocol
24612	Transaminase abnormalities in ten patients
24613	Primary cause of death in betamethasone-exposed and placebo-exposed groups who died between age 28 days and the 30-year follow-up
24614	Outcome at 30 years in betamethasone-exposed and placebo-exposed groups
24615	Calling incidence and rate of documentation of MET criteria in control and MET hospitals during study period
24616	Primary and secondary outcomes during study period
24617	Outcomes
24618	Treatment comparison by endpoint
24619	Effect of treatment on DMFI, DMFS, and survival by group after adjustment for stage of melanoma or for stage and number of lymph nodes
24620	Reported side-effects
24621	Cognitive and educational test scores at age 17–18 years
24622	Results of two regression analyses, showing effects on cognitive and educational test performance at age 17–18 years of psychosocial stimulation in early childhood and stunting in early childhood
24623	Associations between plasma CRP concentrations and components of the metabolic syndrome
24624	Allelic frequencies for CRP SNPs
24625	Common haplotypes for the CRP region
24626	Comparison of associations between CRP and other variables estimated by linear regression and with instrumental variables  (with CRP haplotypes as instruments)
24627	6-month survival of patients with severe sepsis subdivided into the major European mtDNA haplogroups
24628	Pathological findings
24629	Overall response rates and final outcomes
24630	The distribution or frequency of neonatal variables in children assessed compared with survivors not assessed
24631	Comparison of the distribution or frequency of neonatal factors among 185 infants included in unpaired analyses
24632	Frequency of death and disability in the study population
24633	Details of the functional outcome grades for children allocated CNEP  (n=69)  or standard treatment  (n=64)
24634	Comparison of the measures used to assess behavioural, cognitive and neuropsychological function, and health related quality of life in the two assigned study groups
24635	Number, age-specific and age-adjusted incidence per 100 000 children per year according to features of first ever episodes of convulsive status epilepticus in north London
24636	Numbers of children with first ever episodes of convulsive status epilepticus, according to cause
24637	Components of the metabolic syndrome and anthropometric measures by country and sex in 9-year-old and 15-year-old children
24638	Correlation between physical activity  (mean cpm)  and cardiovascular disease risk factors after adjustment for age and sex
24639	Time per day spent at physical activity intensities above 2000 cpm in the five quintiles of physical activity, and the mean intensity
24640	Bodyweight, physical activity, and dietary intake during the intervention period of the study
24641	Bodyweight, physical activity, and dietary intakes of participants of the post-intervention follow-up period who were without diabetes at the end of the intervention
24642	Children with suboptimal outcomes and their corresponding maternal seafood consumption  (unadjusted)
24643	Maternal seafood consumption and suboptimum childhood outcomes:logistic regression models adjusted for 28 factors
24644	Main and secondary endpoints
24645	Univariate analysis of risk factors for postextubation laryngeal oedema
24646	Multivariate analysis of risk factors for postextubation laryngeal oedema  (Cox regression)
24647	Adverse events
24648	Multivariable linear regression models relating KIDSCREEN domains to impairment and pain in children with cerebral palsy
24649	Percentage of variation explained by univariable and multivariable linear regression models relating KIDSCREEN domains to impairment and pain in children with cerebral palsy
24650	All-cause mortality rates
24651	Adjusted treatment effects on mortality rates at day 28
24652	Length of stay in intensive care, days not in intensive care, and pressor-free days until day 28 and day 90
24653	Serious adverse events
24654	Distribution of severe and preventable iatrogenic events by category
24655	Recurrence-free survival, distant metastasis-free survival, and overall survival in the intention-to-treat population
24656	Recurrence-free survival, distant metastasis-free survival, and overall survival in patient subgroups
24657	Subgroup analysis in patients with stage III-N1  (microscopic)  disease with only one positive lymph node or with an ulcerated primary melanoma, as indicated on case report forms
24658	Adverse events occurring in 4% or more of patients  (grade 3 and 4)
24659	Interferon-γ-secreting T-cell response rates and geometric means in case and non-case vaccine recipients at week 8  *
24660	HIV-specific CD4+ and CD8+ T-cell response frequencies in male vaccine recipients  *
24661	Interferon γ ELISPOT summaries at week 8 for the vaccine group
24662	Results of prespecified interim analysis for the subgroup with Ad5 antibody titre 200 or less  (infection and viral-load endpoints)
24663	Morbidity outcomes
24664	Mortality in the two treatment groups
24665	Comparison between Apgar score and resuscitation status
24666	Mean verbal, performance, and full-scale IQ scores for resuscitated infants, with or without symptoms of encephalopathy
24667	Proportion of low verbal, performance, and full-scale IQ scores for resuscitated infants, with or without symptoms of encephalopathy
24668	Probability of low IQ score for resuscitated infants, with or without symptoms of encephalopathy
24669	Difference in mean Weschler intelligence scale for children  (WISC-III)  scores for resuscitated infants, with or without symptoms of encephalopathy, compared with the reference group
24670	Fixed effects for multilevel models of change for fasting glucose, 2-h postload glucose, HOMA insulin sensitivity, and HOMA β-cell function before diagnosis of diabetes or the end of follow-up  *
24671	Primary and secondary endpoints and intubation condition for study patients
24672	Adrenal function assessment in study patients  †
24673	Physiological variables of patients at entry into the study
24674	Outcome variables, length of stay, and causes of death
24675	Univariate and multivariate analysis of predictors of respiratory failure after extubation
24676	Number of chest radiographs, length of stay, duration of mechanical ventilation, and mortality in intensive care units
24677	Numbers of women by country and method of delivery
24678	Risk of maternal mortality and morbidity by method of delivery
24679	Perinatal outcomes for singleton and first child of multiple births by method of delivery
24680	Perinatal outcomes for singleton and first child of multiple births by fetal presentation at delivery and method of delivery
24681	Outcome data
24682	Main outcome variables
24683	Studies that have used procalcitonin to reduce patient exposure to antibiotics
24684	Selected rare non-synonymous variants in genes associated with inherited disease
24685	Pharmacogenomic variants with summary of effects and level of evidence
24686	Pharmacogenomic rare and novel non-synonymous damaging variants  *
24687	Breakdown of admissions to 29 paediatric intensive care units by admission source and type of retrieval team
24688	Casemix for admissions from within the same hospital and from other hospitals to paediatric intensive care
24689	Resource use and outcomes for admissions from within the same hospital and from other hospitals to paediatric intensive care
24690	Casemix for children transported for admission to paediatric intensive care unit  (PICU)  by specialist and non-specialist retrieval teams
24691	Resource use and outcomes for children transported for admission to paediatric intensive care unit  (PICU)  by specialist and non-specialist retrieval teams
24692	Multivariable analysis of the effect on risk of mortality in paediatric intensive care unit  (PICU)  of additional distance travelled by patients not admitted to the nearest PICU
24693	Global burden of large, rare CNVs
24694	Overlap between CNVs identified in ADHD  (IQ>70)  and loci implicated in autism and schizophrenia
24695	Primary and secondary outcomes
24696	Case series of patients who died during treatment
24697	Treatment status
24698	Overall and progression-free survival  (intention-to-treat population)
24699	Primary causes of deaths within the first 120 days after randomisation
24700	Response rates after induction therapy  (intention-to-treat population)
24701	Adverse events  (safety population)
24702	Distribution of patients with low risk and high risk within the quarters according to prediction of complete remission  (CR)
24703	Clinical outcomes at 30 days
24704	Outcomes for all enrolled patients
24705	Number of patients by worst grade of adverse effects
24706	Number of events and patients by type of adverse event
24707	Differences between the society-managed health insurance plans
24708	Age, gender, race, income, and comorbidity distributions for 2008 Medicare decedents
24709	Comparison of patient-level mean number of hospital admissions, days in hospital, and days in intensive care for 2008 Medicare decedents, adjusted for age sex, race, income, and comorbidity, who have been admitted to hospital and did or did not undergo a surgical procedure during their last year of life
24710	Comparison of mean adjusted death rate, mean number of acute-care hospital beds, mean number of surgeons, and mean total Medicare-enrollee reimbursements by regions of high, middle, and low adjusted surgical intensity at the end of life
24711	Operative data and secondary outcome measures
24712	Adverse events
24713	Primary outcome
24714	Secondary outcomes—pulmonary outcomes
24715	Secondary outcomes—drug treatments and serious adverse events
24716	CPAP, surfactant treatment, and outcome data from published trials
24717	Efficacy endpoints at week 52
24718	Adverse events
24719	Modified WHO bleeding scale
24720	Primary and secondary endpoints by treatment and transfusion group
24721	Subtypes of Hodgkin's lymphoma, association with Epstein-Barr virus, epidemiology, and clinical features  8
24722	Risk stratification of early-stage Hodgkin's lymphoma, by research group
24723	Reductions in 5 year freedom from progression and overall survival relative to score on international prognostic index
24724	Evolution of management of haemorrhagic shock
24725	Topical haemostatic agents
24726	Distribution of maternal BMI category by country and region
24727	Association of maternal BMI category with neonatal mortality at the most recent birth, stratified by timing of neonatal death  (n=81 120)
24728	Summary of conventional bariatric procedures
24729	Guidelines and position statements for eligibility for bariatric surgery in adults with type 2 diabetes
24730	Studies comparing bariatric surgery with conventional medical treatment for type 2 diabetes
24731	Studies that have directly compared two bariatric surgical procedures for remission of type 2 diabetes
24732	Vascular actions of insulin
24733	Randomised controlled trials testing blood pressure goals in patients with diabetes and hypertension
24734	Incidence of death by study group and hazard ratios for mortality in the ADDITION-Cambridge trial
24735	De novo variants
24736	Mutations
24737	Missense, nonsense, frameshift, and splice site de-novo variants in genes associated with intellectual disability in each patient–parent trio
24738	Probable disease-causing de-novo variants in each patient–parent trio
24739	Predictors of achieving normal glucose regulation during DPPOS
24740	Primary and secondary outcomes
24741	Recommendations for diagnostic procedures
24742	Treatment and prognosis of haematological cancers
24743	Association of IL6R genotypes with levels of inflammation markers and conventional vascular risk factors
24744	Summary effects of tocilizumab  (8 mg/kg)  and the IL6R rs7529229 variant on inflammatory, lipid, hepatic, and haematological biomarkers
24745	Description of cohort
24746	Relation between country and in-hospital mortality
24747	Intraoperative data
24748	Postoperative data
24749	Mid-term follow-up
24750	Relapse, disability, and MRI outcomes
24751	Adverse event summary  (safety population)
24752	Univariable and multivariable Cox regression model for first noscomial infection during follow-up  (primary endpoint)
24753	Distribution of nosocomial infections during intervention and follow-up
24754	Secondary outcomes during follow-up and throughout duration of study
24755	Primary endpoint Bayesian analysis of ASAS20 responders at week 6
24756	Most frequent adverse events seen in more than 5% of patients on secukinumab
24757	Proposed actions to achieve universal health coverage in Bangladesh
24758	Primary and secondary efficacy endpoints
24759	Key clinical trials of red blood cell transfusions
24760	Key clinical trials of platelet transfusions
24761	Medical society clinical practice guidelines for red blood cell transfusion
24762	Medical society clinical practice guidelines for trigger for prophylactic platelet transfusions
24763	Medical society clinical practice guidelines for plasma transfusion
24764	Difference in endpoints between treatment and control units
24765	Microorganisms isolated from bacteraemia and CLABSI episodes, per-protocol population
24766	Association between confounders and maternal iodine status
24767	Proportion of children classified as having suboptimum outcomes by maternal iodine status  (unadjusted)
24768	Risk of suboptimum outcomes in children according to urinary iodine-to-creatinine ratio  (<150 μg/g vs ≥150 μg/g) , unadjusted and adjusted for potential confounders
24769	Risk of suboptimum outcomes in children according to urinary iodine-to-creatinine ratio when the less than 150 μg/g group was divided into less than 50 μg/g and 50–150 μg/g
24770	Adverse events by worst grade experienced in the canakinumab trial
24771	The number of events and participants by adverse event type in the canakinumab trial
24772	Adverse events by worst adverse effect grade experienced in the anakinra trial
24773	The number of events and participants by adverse events type in the anakinra trial
24774	Risks of adverse outcomes for patients with laboratory-confirmed infection with avian influenza A H7N9 virus who were admitted to hospital
24775	Systemic dysfunctions that impede global governance for health
24776	Clinical interpretation of serological markers of hepatitis B virus infection
24777	Phases of chronic HBV infection
24778	Most frequent ICD-10 categories of underlying cause of death for the study cohort of people with intellectual disabilities and for all deaths in England and Wales in 2011
24779	Factors identified as having contributed to the deaths that were significantly different for the intellectual disabilities subset and comparator cases
24780	Composition of study fluids
24781	Primary and secondary outcomes
24782	Adverse events
24783	Clinical responses at 12 weeks for UNCOVER-2
24784	Clinical responses at 12 weeks for UNCOVER-3
24785	Adverse events for UNCOVER-2 and UNCOVER-3 pooled
24786	Subgroup analysis by ribavirin status for 12 and 18 weeks' treatment duration combined
24787	Treatment-emergent adverse events
24788	Overview of peptic ulcer disease management
24789	Novel techniques or translational innovations for the treatment of perforated peptic ulcer
24790	Outcomes of primary and secondary endpoints
24791	List of cardiac-related serious adverse events  (as-treated population)
24792	Basic information about the three health insurance schemes in China
24793	Summary of consolidating health insurance schemes in South Korea, Japan, Taiwan, and Thailand
24794	Primary outcome results
24795	Infant and maternal outcomes
24796	Prespecified subgroup analyses for neonatal sepsis
24797	Detection of Zika RNA  (by RT-PCR) , Zika and dengue IgM  (by IFA) , Zika IgG  (MIA) , and neutralising antibodies
24798	Dengue IgG  (by microsphere-based immunoassay)  and neutralising responses  (neut)
24799	Zika virus and dengue virus serological patterns associated with Guillain-Barré syndrome
24800	Evolution of motor nerve conduction parameters  (mean values)  after onset of Guillain-Barré syndrome
24801	Positive  (>50%)  reactivity to glycolipids in sera of patients with Guillain-Barré syndrome  (n=42)  and controls  (n=20)  in French Polynesia 2013–14
24802	Endpoint frequency according to central venous catheter allocation  (intention-to-treat analyses)  and central venous catheter received  (safety analyses)
24803	Risk differences and relative effect measures by central venous catheter allocated  (intention-to-treat analyses)
24804	Effect of treatment on primary outcome
24805	Effect of treatment on the occurrence of secondary outcomes and severe adverse events
24806	Mixed-model analysis with bacterial content as outcome, from all infants whose stools were sequenced in the St Louis cohort and in all cohorts combined
24807	Treatment effect on primary and secondary endpoints
24808	Adverse events
24809	Adverse events
24810	Univariate analyses of EFS and OS
24811	Multivariate analyses of EFS and OS stratified by treatment group
24812	Change in absolute DALY numbers and age-standardised rates  (per 100 000)  for mental, neurological, and substance use disorders in China and India between 1990 and 2013, showing disaggregated change in DALY numbers due to population growth, age structure, and change in rates due to other factors
24813	Projected DALYs with uncertainty intervals, China and India, 2013 and 2025
24814	Study outcomes
24815	Safety and laboratory data
24816	Overview of treatment-emergent adverse events  (MedDRA preferred terms)  and injection-site reactions  (MeDRA high-level terms)  in the safety population
24817	Specialist intensity and weekend mortality, by trust size quintile
24818	Relative odds of in-hospital death by day of admission, adjusted for casemix
24819	Main  (primary and key secondary) , secondary, and tertiary outcomes in the intention-to-treat analyses
24820	Grade 1 and 2 reported adverse events
24821	Primary and key secondary endpoints
24822	Changes in health-related quality of life, and productivity at week 48  (secondary endpoints)
24823	Adverse events, injection-site reactions, and hypersensitivity during the on-treatment period in the safety population
24824	Improvements in health-related quality of life and productivity with benralizumab treatment at week 56  (full analysis set)
24825	Adverse events, injection-site reactions, and hypersensitivity during the on-treatment period  (all patients [n=1306])
24826	Primary and secondary outcomes
24827	Outcomes of antenatal expressing
24828	Infant and maternal outcomes
24829	Serious adverse events
24830	Efficacy outcomes
24831	Adverse events reported in patients in any treatment group during the 52-week treatment period  (safety analysis set)   *
24832	Primary and secondary efficacy endpoints at 12 weeks in reSURFACE1 part 1  (full analysis set)
24833	Primary and secondary efficacy endpoints at 12 weeks in reSURFACE2 part 1  (full analysis set)
24834	Secondary efficacy endpoints at 28 weeks in reSURFACE1 part 2  (full analysis set)
24835	Secondary efficacy endpoints at 28 weeks in reSURFACE2 part 2  (full analysis set)
24836	Summary of adverse events in reSURFACE 1
24837	Summary of adverse events in reSURFACE 2
24838	Mode and attendance of, and satisfaction with, GES
24839	Primary outcomes
24840	Sensitivity analyses
24841	Safety outcomes
24842	Secondary outcomes
24843	Incidence rates  (per 100 person-years)  and HRs for all incident cancers, lung cancers, and non-lung cancers
24844	Changes to platelet, leucocyte, neutrophil, and erythrocyte counts after 12 months of treatment
24845	Incidence rates  (per 100 person-years)  of serious adverse events and selected on-treatment safety laboratory data
24846	Glycaemic control of pregnancy trial participants based on available HbA1c data
24847	Glycaemic and adverse outcomes of pregnancy trial participants
24848	Obstetric and neonatal health outcomes of pregnancy trial participants
24849	Adverse events in pregnancy trial participants
24850	Linkage disequilibrium between CASR A986S polymorphism and adjacent loci
24851	Biochemical analytes by A986S genotype
24852	A986S genotype and total or ionised calcium concentrations
24853	Regression model for total serum concentrations of calcium
24854	Scintigraphic findings and surgical results
24855	Distribution of skin-test reactivity to mite with odds ratios and 95% CIs according to age, sex, tissue helminth infections, total IgE antibodies, and skin-test histamine wheal size in 520 schoolchildren surveyed in the Lambaréné area
24856	Odds ratios and 95% CIs for skin-test reactivity against mite for log-transformed concentrations of four immunological factors in a multivariate model
24857	Frequency of solicited symptoms during 4 days after each dose of vaccine  (not including dose 4)
24858	Lymphocyte proliferative responses 2 weeks after third vaccination
24859	Results of Cox's proportional hazards regression analysis for risk of developing parasitaemia after three doses of vaccine
24860	Comparison of screening for the SRA gene by PCR analysis with characterisation by isolation from a human being, the HSR in-vitro test, and RFLP analysis of 70 T brucei sl isolates from Tororo District, Uganda
24861	Biochemical features of the two patients
24862	Adjusted odds ratio for type of grass-pea foods consumed during neurolathyrism epidemic in Delanta Dawint district
24863	Experimental design and results
24864	Parasitological and clinical outcomes in children younger than 5 years at days 14 and 28 after treatment
24865	Difference in clinical and parasitological outcomes between each group and the next best group
24866	Parasitological failure rates in year 1, corrected for reinfection assessed by msp2 PCR genotyping
24867	Development of fluorescence in the extracellular presence of 10 μmol/L DB99 in various cell lines
24868	Drug sensitivity of P falciparum isolates in Cambodia, French Guiana, and Senegal
24869	Effect of MDA on filariasis infection variables
24870	Effect of MDA on antifilarial antibody prevalence rates in primary schoolchildren
24871	Effect of MDA on mosquito infection rates
24872	Cumulative and additive effects of co-trimoxazole prophylaxis, antiretroviral therapy, and bednets on the incidence of malaria in HIV-infected adults, Uganda, 2001–2005
24873	Effect of albendazole treatment every two months on atopy and clinical allergy
24874	Parasitological response to treatment by day 28
24875	Haematological and biochemical values in parasitaemic study women at enrolment and at days 14 and 28 after treatment
24876	Reporting of adverse effects
24877	Perinatal and postpartum outcomes
24878	Number of individuals reporting possibly or probably related solicited adverse events
24879	Clinical applications of factors affecting bone repair
24880	HR for development of adverse effects for subgroups of patients with at least two measurements of lithium concentration, by main effects, two-factor interactions, and risks
24881	HR for renal failure, hypothyroidism, hyperthyroidism, and high serum calcium  (total or adjusted)  concentrations in patients taking lithium, by age, male sex, serum median lithium concentration, length of time between first and last lithium measurements, and diabetes
24882	Association of lymphatic filariasis status and other covariates with HIV incidence
24883	Influence of different factors on HIV incidence stratified by age
24884	Effect of HIV risk factors on the association between lymphatic filariasis and HIV incidence
24885	Primary and secondary endpoints
24886	Adverse events in the safety set
24887	Comparison of livebirth rates by age of woman?
24888	Livebirth rates per embryo transfer in women who used their own eggs and women who received donated eggs
24889	Livebirth rates by duration of infertility
24890	Livebirth rates by cause of infertility
24891	Effect of previous pregnancies  (including livebirths)  on livebirth rates
24892	Livebirth rates by number of previous unsuccessful IVF attempts
24893	Multiple logistic regression for predicting probability of a livebirth
24894	Logistic regression of factors associated with serious reactions to ivermectin
24895	Transmission of forest-strain and savanna-strain O volvulus by sibling species of S damnosum s l
24896	Maximum and average pain relief and number of responders by diagnostic group
24897	Crude and adjusted odds ratio of ocular hypertension or open-angle glaucoma by past exposure to oral glucocorticoids
24898	Outcome in women receiving ACE inhibitors in early pregnancy
24899	Incidence of cytomegalovirus disease
24900	Cytomegalovirus disease in risk groups
24901	Adverse events
24902	Adjusted distribution of causes of blindness by definition
24903	Apparent adjusted distribution of causes of blindness without visual-field and detailed dilated-fundus assessments
24904	Effect of age, socioeconomic status, sex, and religion on rate of blindness in univariate analysis
24905	Effect of age, socioeconomic status, sex, and religion on risk of blindness in multivariate analysis
24906	Percentage of total blindness by age-group
24907	Patients with viral RNA loads below limit of detection
24908	Clinical and laboratory severe adverse events
24909	Mortality rates by treatment group and CD4-cell count at enrolment
24910	Hospital admission rates by treatment group and CD4-cell count at enrolment
24911	Frequency of hospital admission for specific diagnoses, by treatment group
24912	Clinical and hormonal features of patients with idiopathic spermatogenic disorders
24913	Adult death rates adjusted for exponential population growth in Mumbai, India
24914	Univariate comparisons of reproductive histories of cases and controls
24915	Number of full-term pregnancies versus nulliparity
24916	Timing of pregnancies in relation to breast cancer diagnosis
24917	Effect of trial infusion on markers of renal function
24918	Immunohistological and PCR-based comparison of onchocercomata
24919	Outcome
24920	Cox-regression analysis
24921	IBCSG trials I, II, V, and VI: study designs and drug reatments
24922	Disease-free survival and overall survival comparisons according to age at randomisation in IBCSG trials I, II, V and VI
24923	Cox's proportional hazards regression models stratified by trial for patients with known oestrogen-receptor status  (n=3098)
24924	9 month landmark analysis of disease-free survival and overall survival according to age at randomisation for subpopulations defined by amenorrhoea status and oestrogen-receptor status
24925	BRCA1 and BRCA2 test use in relation to sex, age, parenthood, and genetic risk
24926	Choices of unaffected carriers
24927	Tuberculosis recurrence rates
24928	Factors associated with treatment of first breast cancer
24929	Association between tamoxifen, oophorectomy, chemotherapy, and radiotherapy and risk of contralateral breast cancer
24930	Odds ratio  (95% CI)  for contralateral breast cancer, associated with treatment, by time since primary breast cancer
24931	Multivariate analysis of risk factors for ARF
24932	Patient management and outcomes
24933	Univariate correlation and values of variables from history for clinically important brain injury
24934	Univariate correlation values of variables from mechanism of injury for clinically important brain injury
24935	Univariate correlation and values of variables from examination for clinically important brain injury
24936	Model developed by stepwise logistic regression analysis to predict clinically important brain injury
24937	Summary of 58 potential cases of congestive heart failure
24938	Congenital anomalies in study and control groups
24939	Mean  (SD)  scores on the Griffiths scales
24940	Neurodevelopmental outcomes of case children according to paternal sperm analysis
24941	Congenital anomalies in study group according to whether the father had oligozoospermia
24942	Outcome data
24943	Variation in chimerism of CD3+ T cell and peripheral mononuclear neutrophils  (PMN)  in two patients after infusion of allodepleted cells
24944	Residual proliferation of allodepletion tested against recipient peripheral blood-mononuclear cells  (PBMCs) , third-party PBMCs, and bacterial and viral antigens for the same patients as  figure 2
24945	Immune reconstitution after haemopoietic stem-cell transplantation  (HSCT)
24946	Results of round 2 nodulectomies in August to September, 1997
24947	Results of round 3 modulectomies in May to June, 1998
24948	Results from round 4 nodulectomies in November, 1998
24949	Standardised incidence ratios  (SIRs)  of ovarian cancer in 30 552 women diagnosed with breast cancer
24950	Estimates of absolute risk of developing ovarian cancer within 30 years of breast-cancer diagnosis
24951	Clincal features of 45X/46XY patients with deletion of AZFc
24952	Buprenorphine dose regimens for control and treatment groups
24953	Composite scores in the seven subscales of the ASI for patients given buprenorphine
24954	Frequency of chlamydia by age
24955	Hormone concentrations of patients with chronic pain
24956	Pituitary-gonadal axis hormones in patients with chronic pain
24957	Summary of data on mortality and blindness obtained by the OCP from 1971 through 2001
24958	Analysis of deviance for Poisson regression between the expected number of deaths in the complete OCP dataset  (1971–2001)  and covariates
24959	Relative risks from fit of log-linear Poisson model to host mortality data  (with allowance for overdispersion)  overall, in pre-ivermectin data, and restricted to those with non-zero microfilarial load
24960	Factors associated with progression to a new AIDS-defining event
24961	Factors associated with mortality
24962	Clinical details of patients with mtDNA deletion disorders
24963	Clinical symptoms and signs of patients
24964	[18F]β−CFT uptake values
24965	Oxygen consumption and biochemical activities of respiratory-chain enzymes in isolated muscle mitochondria
24966	Cumulative yield of M tuberculosis from repeated induced sputum or gastric lavage specimens
24967	Risk factors associated with disease-free survival, survival, treatment-related mortality, relapse, acute GVHD, chronic GVHD, and neutrophil engraftment after unrelated donor bone marrow transplantation, by Cox proportional hazards regression  *
24968	Intervention coverage by treatment group
24969	Umbilical cord infection by treatment group
24970	Umbilical cord infection by treatment group stratified by timing of intervention and skin cleansing trial intervention
24971	Neonatal mortality by treatment group
24972	Neonatal mortality by treatment group stratified by timing of intervention and skin cleansing trial intervention
24973	Days of exposure to individual antiretroviral agents  (>90 days of treatment)  in individuals on HAART at diagnosis of Kaposi's sarcoma
24974	Univariate Cox regression analysis and log rank tests
24975	Validation of coefficients in Cox analysis of KS data  (HAART era)
24976	Probability of survival  (95% CI)  by prognostic score and from diagnosis of Kaposi's sarcoma
24977	Biochemical variables
24978	Adverse events occurring in more than one case
24979	Summary of studies showing distribution of smear-negative pulmonary and extrapulmonary tuberculosis in HIV-positive patients
24980	National tuberculosis control programme recommendations of selected countries for diagnosis of smear-negative pulmonary tuberculosis
24981	CMFL and nodule and microfilaria prevalence rates for O volvulus, before treatment and 1 month after ivermectin treatment, in 20 onchocerciasis-endemic communities in Ghana
24982	Geometric mean densities  (microfilaria per skin snip)  of O volvulus before treatment and at different times after treatment in ten onchocerciasis-endemic communities in Ghana
24983	Distribution of microfilaria counts at day −7, day 90, and day 180 in the study communities
24984	Protocol adherence and sedative use
24985	Main outcomes
24986	Results of the spontaneous awakening trials and spontaneous breathing trials
24987	Safety summary by treatment group
24988	Randomised clinical trials of early rheumatoid arthritis
24989	Notified proportion of drug resistance in new tuberculosis cases tested for resistance to at least isoniazid and rifampicin in 83 countries or territories, by WHO region
24990	Notified proportion of drug resistance in previously treated tuberculosis cases tested for resistance to at least isoniazid and rifampicin in 83 countries or territories, by WHO region
24991	Estimates of multidrug-resistant  (MDR)  tuberculosis in 2006 by epidemiological region
24992	Primary and secondary outcomes and adjusted treatment effect at 6 and 12 months by randomised treatment assignment  (intention-to-treat comparisons)
24993	Follow-up successful outcomes in surgical and non-surgical groups
24994	Effect of median motor latency on CTSAQ scores by treatment group assignment
24995	Successful functional outcomes  *   by MRI finding and treatment received
24996	ICD-9 and ICD-10 codes used to identify disease outcomes
24997	Incidence of disease events that might be temporally associated with vaccine, by country and age group
24998	Mortality by country, age, and sex  (2006)   30
24999	Rates of spontaneous abortion by country, surveillance year, and age group
25000	Selected rates of preterm labour or delivery  (<37 weeks gestation) , by country and year
25001	Predicted numbers of coincident, temporally associated events after a single dose of a hypothetical vaccine, based upon background incidence rates
25002	Effect of co-trimoxazole prophylaxis on death, new WHO stage 4 events, new or recurrent WHO stage 3 or 4 events, and malaria
25003	Effect of co-trimoxazole prophylaxis on death by time on ART and current CD4 cell count  †
25004	Effect of co-trimoxazole prophylaxis on CD4 cell count, body-mass index, and markers of haematological toxic effects
25005	Drugs used in treatment regimens for patients  (n=174)  with extensively drug-resistant tuberculosis
25006	Cox proportional hazards regression model of factors associated with risk of death in all patients given treatment for extensively drug-resistant tuberculosis, and in HIV-infected patients only
25007	Adverse drug reactions  (n=161)  in 67 of 115 patients from the Western Cape, Northern Cape, and Gauteng provinces started on treatment for extensively drug-resistant tuberculosis
25008	Logistic regression model of the probability of participants becoming responders  ‡
25009	Logistic regression model of the probability of participants achieving abstinence or near abstinence from street heroin, according to urinalysis, during weeks 14–26  (intention-to-treat sample)
25010	Serious adverse events
25011	Randomised controlled trials of substitution treatment with a supervised injectable opioid versus an oral opioid for treatment of opioid dependence
25012	Direct medical costs
25013	Descriptives of disease-free-survival events and causes of death in the intention-to-treat population
25014	Adverse events
25015	Clinical outcomes
25016	Clinical adverse events
25017	Cox regression analyses of mortality among men
25018	Cox regression analyses of mortality among women
25019	Cox regression analyses of mortality among participants with some form of substance abuse
25020	Incidence of omphalitis
25021	All-cause neonatal mortality
25022	Incidence of vertebral collapses
25023	Adverse events
25024	Serum 25-hydroxyvitamin D and intact parathyroid hormone concentrations
25025	Conventional drugs used in the treatment of systemic lupus erythematosus
25026	Unadjusted outcomes for each treatment group
25027	Treatment effects at 14 weeks, 6 months, and 12 months
25028	Treatment effect modification on primary outcome at 14 weeks
25029	Trial process measures
25030	Secondary outcomes during study follow-up
25031	Concomitant drugs used in weeks 1–4 and weeks 5–12
25032	Concomitant health services used in weeks 1–4 and weeks 5–12
25033	Participant flow through the vaccination schedule
25034	Completers of hepatitis B vaccination schedule and outcome analysis
25035	Own and cross-price elasticities of demand for ten beverage categories
25036	Health harm reductions in year 10 with a £0·45 minimum unit price, by socioeconomic group
25037	Number and percentage of patients with adverse events of interest during period 2 by treatment group
25038	Clinical responses at week 16
25039	AEs during the overall study period  *   in the safety population
25040	Changes in whole-brain volume between 0, 12, and 25 months and secondary clinical outcomes at 24 months
25041	Rate of new and enlarging T2 lesions between over 0 to 25 months and relapse rate over 0 to 24 months
25042	Adverse events
25043	Cox proportional hazards models of time to clinic presentation
25044	Clinical outcomes measured at 1 month after release from incarceration.
25045	Cost-associated outcomes measured at 1 month after release from incarceration
25046	Distribution of 5580 deaths and 24·9 million person-years at risk in the overall cohort
25047	MRR according to age at first diagnosis of ADHD, compared with those without ADHD at same age
25048	Mortality rate ratios in individuals with ADHD in combination with oppositional defiant disorder, conduct disorder, or substance use disorder compared with individuals with none of the four disorders, in the overall cohort
25049	Sensitivity analysis showing MRR according to age at first diagnosis of ADHD, compared with people without ADHD
25050	Outcomes
25051	Adverse events
25052	All breast cancer, invasive, and DCIS recurrences according to treatment allocation
25053	Frequency of cancers other than breast according to treatment allocation
25054	Adverse events reported at any time according to treatment allocation
25055	Ovarian and primary peritoneal cancers grouped by primary site and screening status
25056	Summary of analyses of relative reduction of ovarian and primary peritoneal cancer deaths
25057	Diagnostic accuracy of urine LAM test  *
25058	Effects of urine LAM-guided initiation of tuberculosis treatment on 8-week all-cause mortality
25059	Anti-tuberculosis treatment
25060	Effects of urine LAM testing on secondary outcomes
25061	Death or unknown survival status at week 24
25062	Grade 3 or higher laboratory events by week 24
25063	Mean per-annum S-DDD and DDD use worldwide, regionally, and at the country level in the years 2001–03 and 2011–13, ordered by 2011–13 S-DDD use, and absolute changes in use
25064	Impediments in relation to availability of opioid analgesics
25065	Primary and secondary outcomes
25066	Patient-reported and clinical primary endpoints
25067	Patient-reported and clinical secondary endpoints
25068	Adverse events
25069	Overview of incidence of treatment-emergent adverse events by treatment at adverse event onset by system organ class
25070	Numbers of laboratory confirmed MenB cases for five comparable annual time periods in England in cohorts eligible and non-eligible for 4CMenB vaccination and estimates of vaccine impact from different comparison models
25071	Previous biological treatments
25072	Major secondary endpoints and other clinical efficacy, physical function, and quality-of-life outcomes
25073	Adverse events through week 24 and week 52
25074	Analysis of mRS
25075	Analysis of secondary outcomes at months 3 and 6
25076	Relapse and mortality by treatment group
25077	Local relapse, second cancers, and deaths by treatment group
25078	Patient assessments of moderate or marked late adverse events
25079	Clinician assessment of moderate or marked late adverse events
25080	Adverse events
25081	On-treatment serious adverse events of special interest
25082	Parents' report of vaccine-associated reactions during first 48 h after vaccination
25083	Hib polysaccharide antibody concentrations
25084	Geometric mean antibody concentrations  (with 95% CI)  at age 7 months
25085	Number of cramps and cramp-days during qualification, treatment, and washout periods
25086	Side-effect
25087	The Expanded Programme of Immunisation schedule recommended by the Gambian government
25088	PRP antibody concentrations in infants before and 1 month after receiving their third dose of PRP-T vaccine or placebo
25089	Cases of confirmed invasive Hib disease by vaccination status and diagnosis
25090	Episodes of pneumonia in all children enrolled and in fully vaccinated children by pneumonia definition and vaccine group
25091	Hib disease in infants after receipt of one dose of PRP-T: comparison of convalescent PRP antibody concentrations in matched pairs discordant for tetanus toxoid priming
25092	Efficacy of vaccination with Hib conjugate vaccine in the UK
25093	Seroconversion rates 1 month after last injection
25094	Events that occurred from 72 h to day 31
25095	Events occurring in patients who completed the minimum 72 h active treatment
25096	Outcome of patients given tetanus-toxin contaminated pertussis-immune serum
25097	Relative risk of pertussis at randomisation and the third dose, in the 3 months, 5 months, 12 months schedule for the three-component and five-component vaccines compared with whole-cell vaccine
25098	Relative risk of pertussis from randomisation at the first dose, and between the second and third dose in the 3 months, 5 months, 12 months schedule for the three-component and five-component acellular vaccines, and for the whole-cell vaccine compared to the two-component vaccine
25099	Relative risk of parentally reported whooping cough from first trial dose  (RR)  to October, 1996
25100	Breast and testicular cancer cases by zygosity, sex of co-twin, and age
25101	Odds ratios for breast and testicular cancers in relation to zygosity, by age, based on zygosity identified from questionnaire, and estimated zygosity for all twins
25102	Relative risks of breast and testicular cancers in same-sex twins of probands with these cancers, by zygosity, 1971–92  *
25103	Relative risks of breast cancer in female twins of probands with this cancer by age of twin, and risk in non-twin sisters of women with breast cancer at young ages  *
25104	Relative risks of breast cancer in female twins of probands with this cancer by time since diagnosis in proband
25105	Maternal mortality ratios  (MMR)  in MCH-FP and comparison area
25106	Maternal mortality due to direct obstetric causes by area and period
25107	Serum-antibody concentrations against capsular polysaccharide of Haemophilus influenzae type b  (PRP)  in Chilean infants given different primary immunisation regimens of PRP-T and PRP-CRM197 conjugate vaccines
25108	Persistence of serum PRP antibody at 12 months of age and evidence of immunological memory assessed by inoculation with purified PRP polysacharide as an antigenic challenge that simulates natural infection with virulent Haemophilus influenzae type b
25109	Frequency of responders and non-responders/poor responders to PPS antigen and conjugated tetanus haemophilus type b antigen
25110	Serum IgA, IgG1, and IgG2 concentrations in PPS antigen responders and non-responders  (all ages)
25111	Additional table: PPS and Hib antibody concentrations prevaccination and post-vaccination and total serum IgG, IgG1, IgG2, and IgA in paediatric cardiac transplant recipients
25112	Vitamin A status of infants by visit in Ghana, India, and Peru
25113	Point prevalence of acute lower-respiratory infections and diarrhoea during previous 24 h up to age 9 months
25114	Rates per child-year of clinic visits and hospital admissions in infants aged up to 9 months
25115	Percentage of infants with bulging fontanelle within 48 h of administration of study dose
25116	Summary of statistical methods
25117	Reasons for dropping out of study and stopping treatment
25118	Time to confirmed progression: estimated probability to remain progression free by the life-table method
25119	Results of secondary and tertiary efficacy variables
25120	Adverse events significantly associated with interferon β-1b treatment
25121	Signs in children with atopy
25122	Patient's plasma biochemistry on admission to hospital
25123	Primary clinical endpoints by diagnosis
25124	Severity of coronary disease by number of protected regions
25125	Serious adverse events
25126	Comparison of proportion  (%)  of investigator and independent scores in each CCSA class at 12 months
25127	Incidence of Hib meningitis in Gambian children less than 1 year of age
25128	Adult HUS/TTP cases
25129	Reasons for patients not receiving TPE
25130	Effects of monoclonal antibody to IL-5 after allergen challenge
25131	Antioxidant status in lungs of healthy controls and asthmatics during antigen challenge
25132	Distribution of -thalassaemia in nine hospitals in Sri Lanka
25133	α-globin genotype and α-thalassaemia frequencies in β-thalassaemia major and β-thalassaemia carriers attending thalassaemia clinics in Sri Lanka
25134	Preliminary population screen  *
25135	Consequences of the common thalassaemia mutations in Sri Lanka
25136	Spearman's rank correlation coefficients between naïve T cells and numbers of TREC
25137	Number  (%)  of patients with 100% improvement in individual disease-activity measures at 12 weeks
25138	Number of adverse events of all intensities
25139	Cardiac diagnoses and surgical procedures
25140	Mean postoperative changes in echocardiographic variables
25141	Electrocardiographic, radiographic, and Holter data
25142	Reinterventions in 1985–95
25143	Multivariate analysis of predictors of ventricular tachycardia, sudden death, and atrial flutter/fibrillation after repair of tetralogy of Fallot
25144	Advantage of butyrate over placebo in the treatment of ARP
25145	Sonographic findings in mountain bikers and healthy controls
25146	Trends in age-adjusted death certification rates per 100 000 men from testicular cancers
25147	UGT1   *   1 promoter genotype, bilirubin, and gallstones in patients with HbE βthalassaemia
25148	Cancer familial index by site
25149	Immunisation status in adopted and Dutch children
25150	Poliomyelitis antibodies in adopted and UK children
25151	Standardised mortality odds ratios  (SMORs)  of selected medical disorders in people with Down's syndrome
25152	Standardised mortality odds ratios  (SMORs)  and observed number of deaths from selected medical disorders among people with Down's syndrome
25153	Standardised mortality odds ratios  (SMORs)  and observed number of deaths for selected cancer types
25154	Efficacy outcomes in the total population after 6 months
25155	Primary efficacy outcomes at 6 months in diagnostic subgroups
25156	Adverse events
25157	Peak walking time and claudication onset time at 90 and 180 days
25158	Quality-of-life findings
25159	Paired comparisons of heart and liver iron content and indices of left-ventricular function
25160	Comparison of the desferrioxamine control group with a larger population of patients with thalassaemia major treated with subcutaneous desferrioxamine
25161	Periods of diagnosis and follow-up included in most recent estimates of survival obtained by cohort and period analysis
25162	Most recent cohort and period estimates of relative survival rates, by sex
25163	Most recent cohort estimates of relative survival rates, by cancer site
25164	Most recent period estimates of relative survival rates, by cancer site
25165	Concentrations of mercury in blood, urine, and stool of infants who received vaccines containing thiomersal and those who did not
25166	DTaP-Hib doses received by children with Hib and controls matched for date of birth
25167	Oral glucose tolerance test
25168	Study design, age of administration of vaccines, and mortality in trials of HTMV
25169	Mortality rates and female-male mortality ratios between 4 and 10 months of age in the HTMV trial
25170	Mortality rates in HTMV recipients and controls according to whether they received additional DTP-IPV or IPV vaccinations at age 9–10 months
25171	Female-male mortality ratios in recipients of EZ-HT measles vaccine used in routine immunisation according to number of additional DTP-IPV vaccinations received after measles vaccine, Senegal, 1989–94
25172	DTP3 verification factors for seven countries from DQA's
25173	Primer and probe sequences for real-time PCR
25174	Genes differentially regulated after preconditioning
25175	Genes differentially regulated after injurious ischaemia
25176	Genes differentially regulated after preconditioning followed by injurious ischaemia
25177	Validation of gene regulation by real-time PCR
25178	Genes regulated suggestive of neuroprotective aspects of hibernation and hypoxia-tolerant states
25179	Detection of unmethylated XIST DNA fragments in plasma and tumour tissue
25180	Prevalence of congenital cryptorchidism according to clinical subtypes
25181	Prevalence of cryptorchidism at expected date of delivery stratified by birthweight
25182	Prevalence and risk of cryptorchidism at expected date of delivery in Finnish and Danish boys, with respect to birthweight, gestational age, and weight for gestational age
25183	Prevalence of congenital cryptorchidism in total Finnish hospital cohort at expected date of delivery and at 3 months of age stratified according to birthweight, gestational age, and weight for gestational age
25184	Incidence of clinical events
25185	Incidence of combined endpoints
25186	Association between vaccination and death from infectious or respiratory disease  (Cox model with time dependent covariates)
25187	Cox time dependent survival model for infants aged 9–60 months
25188	Association between mortality and age at BCG vaccination
25189	Technical outcome of first procedure   *
25190	Clinical outcome at 2 months and 1 year
25191	Causes of death
25192	Angiographic occlusion of target aneurysm on first follow-up angiography done after treatment
25193	Confirmed rebleeding from target aneurysm
25194	Seizure occurrence by treatment allocation  *
25195	Incidences of vaccine-preventable Hib pneumonia
25196	Incidences of vaccine-preventable Hib meningitis
25197	Vaccine-preventable Hib mortality
25198	Comparison of four studies that investigated the effect of Hib conjugate vaccine on pneumonia outcomes
25199	Proportion of preterm births and babies of low birthweight by type of delivery and year
25200	Neonatal mortality rates by birthweight and gestational age
25201	Classification of patients
25202	Frequencies of Vα 24-invariant NKT cells according to disease activity, category, and corticosteroid use
25203	Donor-lymphocyte infusions in individual patients: dose and response
25204	Interleukin 10 to interferon ratio deduced from epitope-specific cytokine production of PBMC of patients with oligoarticular and polyarticular juvenile idiopathic arthritis, respectively, in active disease and disease remission
25205	MHC binding assays
25206	Vaccine efficacy against Hib disease after one, two, and three doses of vaccine
25207	Coverage of each child-survival intervention, by country
25208	Number and distribution of interventions received by children, by country
25209	Summary of equity results, by country
25210	Protective efficacy of pneumococcal protein D conjugate vaccine for time to first occurrence of acute otitis media during per-protocol and intention-to-treat follow-up
25211	Protective efficacy of pneumococcal protein D conjugate vaccine for any episode of acute otitis media during per-protocol follow-up
25212	Carriage of S pneumoniae and H influenzae in nasopharyngeal swabs taken at 15–18 months of age
25213	Serum concentrations of antibodies against individual pneumococcal vaccine serotypes and protein D one month after the third protein D conjugate vaccine dose and before and 1 month after booster vaccination*
25214	Drug efficacy at 12 weeks
25215	Global response
25216	Adverse events and laboratory abnormalities
25217	Primary measures of efficacy of chaperonin 10 by dose
25218	Secondary efficacy outcomes by dose of chaperonin 10
25219	Actual cytokine concentrations  (pg/mL)  during treatment with chaperonin 10  (all dose groups combined)
25220	Most frequently reported adverse events  *
25221	Regression results with WHO/UNICEF-estimated or country-reported DTP3 coverage as dependent variables from PCSE models
25222	Primary and secondary outcomes
25223	Adverse events reported throughout hospital admission
25224	Effectiveness of one or more doses of pneumococcal conjugate vaccine against invasive disease in children 3–59 months of age by pneumococcal serotype and the presence of chronic illnesses or immunocompromising disorders
25225	Effectiveness of one or more doses of pneumococcal conjugate vaccine against invasive disease in children aged 3–59 months by pneumococcal serotype
25226	Effectiveness of pneumococcal conjugate vaccine against invasive pneumococcal disease caused by vaccine serotypes in children aged 3–59 months by number and timing of doses, compared with no vaccine
25227	Direct comparison of different vaccine schedules for risk of invasive disease caused by serotypes included in the seven-valent pneumococcal conjugate vaccine
25228	Model assumptions for countries eligible for support from the Global Alliance for Vaccines and Immunization, by under-5 mortality rate per 1000 births
25229	Projected outcomes of pneumococcal conjugate vaccination in 72 low-income countries, by under-5 mortality rate per 1000 births
25230	DHS country-years and vaccination coverage
25231	Means of variables
25232	Multiple regression equations
25233	Analysis of efficacy of sapropterin at week 6
25234	Adverse effects
25235	Geometric mean titres for Anti-CS and Anti-HBsAg
25236	Vaccine efficacy from 14 days after third dose  (month 3)  of Engerix-B or RTS,S/AS02D until visit at month 6
25237	Asthma exacerbations by Gly16Arg genotype for each study
25238	Clinical outcomes in white participants by haplotype pair in study 1
25239	Change in the duration of morning stiffness of the joints after 12 weeks of treatment with modified-release prednisone and immediate-release prednisone
25240	Overview of adverse events
25241	Most common adverse events  (occurring in four or more patients)
25242	Clinical responses at week 12 and week 28 as reported by physicians and patients
25243	Adverse events during the three phases of the trial
25244	Discontinuation of study medications and selected reasons for permanent discontinuations  *
25245	Components of the primary outcome
25246	Other secondary events and hospitalisations
25247	Combined analyses of the results of TRANSCEND and PRoFESS trials comparing telmisartan with placebo
25248	Regression results with the dependent variable as officially reported coverage minus survey-based coverage
25249	Additional children immunised and immunisation services support  (ISS)  payments in countries receiving Global Alliance on Vaccines and Immunisations  (GAVI)  ISS up to 2006
25250	Sleep efficacy measures
25251	Adverse events
25252	Quality of data for DTP1, by child's age at interview, for surveys with data for children aged up to 5 years
25253	Target ages and median  (IQR)  for estimated coverage at different ages across 45 countries
25254	Variation between countries in estimated coverage for BCG, DTP1, DTP3 and MCV1, and in opportunities taken
25255	Delay in vaccination  (weeks) , showing variation between and within countries, across children in a country sample
25256	Patients with endoscopic lesions at 12 weeks
25257	Adverse events
25258	Cross-tabulation of radiation doses to uterus and ovaries for survivors of childhood cancer
25259	Association between organ-specific radiotherapy doses and risk of stillbirth or neonatal death in offspring of survivors of childhood cancer
25260	Association between radiotherapy doses to uterus and ovaries and risk of stillbirth or neonatal death in offspring of survivors of childhood cancer
25261	Association between chemotherapy with alkylating drugs and risk of stillbirth or neonatal death in offspring of female and male survivors of childhood cancer
25262	Treatments given
25263	Burden of infectious diseases for India in 2004 according to estimates from the Global Burden of Disease Study  16
25264	Effect estimates for interventions before pregnancy, during pregnancy, and at birth to reduce maternal and neonatal deaths and stillbirths
25265	Potential stillbirths, neonatal deaths, and maternal deaths averted in 2015 according to level of coverage
25266	Cost per death averted in 2015 with implementation of intervention packages at 99% coverage
25267	Priorities for reduction of stillbirths and maternal and neonatal deaths according to stillbirth rates in 2015
25268	Rankings of research priorities for implementation of interventions to reduce stillbirths in low-income and middle-income countries by 2015
25269	Comparison of multicountry costing exercises for maternal, neonatal, and child health, with a target year of 2015
25270	Enrolment by study site for random assignment on day 5
25271	Outcomes by study group
25272	Organisms identified at the time of enrolment by treatment
25273	New drugs for hypertension
25274	Estimates of CSF penetration of antibiotics used for the treatment of bacterial meningitis  8,9
25275	Recommended antibiotics in patients with community-acquired meningitis by result of cerebrospinal fluid Gram stain
25276	Antibiotics for bacterial meningitis after microorganism identification and in-vitro susceptibility testing  *
25277	Cardiovascular events  (fatal and non-fatal)  and causes of death
25278	Hazard ratios by plasma ADMA concentration
25279	Cox's proportional-hazard models for all-cause mortality and fatal and non-fatal cardiovascular events
25280	Estimates of risk reduction for stroke and myocardial infarction for a given difference in systolic blood pressure
25281	Previous Cardiovascular Therapies by Drug Class  a
25282	Laboratory Results in Three Treatment Groups
25283	Clinical, Angiographic, and Intravascular Ultrasound Findings in Patients With CANs
25284	IVUS Data of Coronary Aneurysm According to Clinical Outcome
25285	Association Between Metabolic Syndrome and Systolic and Diastolic Echocardiographic Abnormalities in Adult Survivors of Childhood Cancer  ∗
25286	Population With Central Measurements  (n = 181) : Main Cardiovascular Parameters: Adjusted Absolute Means ± Standard Error of Means Are Presented at M0, M6, M12
25287	Factors Modulating Brachial and Carotid Adjusted-SBP Changes  (%)  Under Drug Treatment: Stepwise Linear Regressions for Brachial  (Upper Panel)  and Central  (Lower Panel)  Measurements
25288	Major Limitations to Angiotensin-Converting Enzyme Inhibitor Use
25289	Discharge Medications in Relation to ACEI Use or CRLimit
25290	Medication Use in Heart Failure Cohort Based on Provider Type *
25291	Medication Use * Based on Underlying Comorbidity †
25292	Unadjusted Deaths and CV Hospitalizations *
25293	Cox Proportional Hazards Analyses for Predicting Death or Cardiovascular Hospitalization *
25294	Mortality Before Surgery
25295	Cardiac Imaging Parameters for Four Patients Who Died During the Late Postoperative Period
25296	Effects of Oral Versus Transdermal Estrogen Administration on C-Reactive Protein and Inflammatory Cytokines
25297	Adverse Events for All Randomized Patients
25298	ICD Therapy Analysis
25299	Echocardiographic Data Before and After Cardiac Resynchronization Therapy
25300	Procedural Technique and Angiographic Outcomes of the Study Population
25301	3-Year Target Lesion Failure and Scaffold Thrombosis Rates According to Technique
25302	1-Year Target Lesion Failure and Scaffold Thrombosis Rates According to Technique
25303	1- to 3-Year Target Lesion Failure and Scaffold Thrombosis Rates According to Technique
25304	3-Year Outcomes in BVS-Treated Patients According to Use of Optimal Technique, Adjusted for Clinical and AngiographicVariables
25305	Subjects Whose Majority of Migraines Are With Aura
25306	Outcomes Through 30 Days  (N= 100)
25307	Key Complications
25308	Computed Tomographic Findings
25309	Risk of Cardiovascular Events for Mid/High SYNTAX Score  (≥23)  Compared With Low SYNTAX Score  (≤22)
25310	Revascularization Versus Medical Therapy By Revascularization Stratum and SYNTAX Score
25311	Univariate Correlation of Augmentation Index  (Correlation Coefficient, p Value)   legend
25312	Partial Regression Coefficients  (All Subjects, n = 262)  for Forward Stepwise Linear Regression for Dependent Variables Augmentation Pressure and Augmentation Index ∗   legend
25313	Echocardiographic and CMRI Measurements of Athletes and Nonathletes With and Without ATWI
25314	Imaging Outcomes
25315	Adjudicated Clinical Outcomes From Randomization to 4-Month Follow-Up
25316	Indications for Concomitant Mitral Valve Surgery  (N=174)
25317	Comparison of Patients Who Underwent Surgery With Single CPB Versus ≥2Periodsof CPB
25318	Imaging Modality Used for Initial Diagnosis
25319	Predictors of TEC
25320	Definition of ECG Abnormalities in Athletes According to the 2010 ESC Recommendations   (3)  , Seattle Criteria   (2)  , and Refined Criteria   (7)
25321	Cost and Frequency of Additional Investigations Following Abnormality in History and Physical Examination, or ECG
25322	Location of Aneurysm and Dissection
25323	History and Clinical Presentation of Patients with FMD
25324	Therapeutic Procedures and Complications
25325	CMR and Cardiac MRS Findings
25326	Liver Assessments
25327	Recommendations for the Diagnostic Evaluation, Follow-Up, and Timing of Surgical AVR in Patients With Asymptomatic, Severe, High-Flow, High-Gradient AS
25328	Observational Studies of Patients With Asymptomatic Severe AS
25329	Predictors of Adverse Events at Follow-Up in Patients With Asymptomatic Severe AS
25330	Abnormal Stress Test Among Large Observational Series of Asymptomatic AS
25331	Studies Evaluating Exercise Stress Tests in Patients With Asymptomatic Severe AS
25332	Studies Evaluating Stress Echocardiography in Patients With Asymptomatic Severe AS
25333	Studies Evaluating BNP in AS
25334	Theoretical Pros and Cons of Early AVR in Patients With Asymptomatic Severe AS
25335	INTERMACS Profiles and Interventions
25336	Laboratory and Hemodynamic Data
25337	Adverse Events
25338	Gastrointestinal and Cardiovascular Clinical Endpoints
25339	Kaplan-Meier Estimates of Event Rates at 180 Days Post-Randomization
25340	Determinants of Long-Term Mortality
25341	Determinants of MR Recurrence for the Entire Cohort
25342	Transition-Specific Determinants of MR Recurrence
25343	Analysis of Curve Parameters
25344	Clinical Outcomes at 1 and 2 Years After Self-Expanding TAVR
25345	All-Cause Mortality or Major Stroke for Select Subgroups
25346	Distribution of Number of Visits and Follow-Up Time by Age Group
25347	Population-Averaged Coefficients and Standard Errors for Age and CRF for Lipids and Lipoproteins From Generalized Estimating Equation Models
25348	Population-Averaged Coefficients and Standard Errors for All Predictors for Lipids and Lipoproteins From Generalized Estimating Equation Models
25349	Univariate and Multivariate Analysis Predictors of 12-Month LVEF
25350	RF Target Levels and Collection Details
25351	Achievement of RF Goals Over Time
25352	Trial Medication Status
25353	Hazard Ratios for Death and CVD Events According to Number of RFs in Controlat Year 1 and Time-Varying  ∗
25354	Hazard Ratios for Death and CVD Events According to Number of RFs In Control/Within Target Range  ∗
25355	Summary of Initial Programming
25356	All Type I to III Complications
25357	Animal Study Design
25358	Pre-Operative Risk Factors
25359	Laboratory Values
25360	Adverse Events Through 6 Months
25361	Biomarker Profile of HFpEF Patients With and Without Diabetes
25362	Ventricular and Vascular Remodeling and Function in HFpEF Patients With and Without Diabetes
25363	Indications and Highest Level of Evidence for ECMO in Cardiopulmonary Disease
25364	Hypothyroid Myopathy and Response to Hormone Replacement Therapy
25365	Development of Statin-Induced Myopathy and Response to Treatment
25366	Results of Investigations in Ambulatory Patients
25367	Comorbidities and Frailty  (N = 489)
25368	Disability Assessments  (N= 489)
25369	Clinical Outcomes at 30 Days and 12 Months  ∗
25370	Serial Echocardiography Findings in Patients Undergoing CoreValve Transcatheter Heart Valve Implantation
25371	International Registry of Acute Aortic Dissection Pre-operative Prediction Model Variables
25372	Operative Parameters
25373	30-Day/In-Hospital Adverse Events
25374	Biomarker Correlation
25375	Cardiovascular Outcomes and HRs
25376	Prognostic Discrimination
25377	Reclassification for CV Death or HF at 1 Year
25378	Biomarkers and Adjusted Risk of Cardiovascular Outcomes
25379	Left Ventricular Echocardiographic Profile at Diagnosis in Children With Idiopathic DCM and Abnormal Left Ventricular Function and Dilation at Diagnosis  (N= 741) , by Echocardiographic Status or Clinical Outcome Within 2 Years After Diagnosis
25380	Left Ventricular Echocardiographic Profile From Time of Cardiomyopathy Diagnosis to 2 Years in Children With Idiopathic Dilated Cardiomyopathy and Abnormal Left Ventricular Function and Dilation at Diagnosis  (N= 741) , by Echocardiographic Status or Clinical Outcome Within 2 Years After Diagnosis
25381	Hazard Ratios From Univariate Cox Regression Analysisof Possible Predictors of Echocardiographic Normalization in Children With Idiopathic Dilated Cardiomyopathyand Abnormal Left Ventricular Functionand Dilation at Diagnosis  (N= 741)
25382	Study Endpoints for Safety and Performance of the NeoChord DS1000 Device ∗  for Treatment of Mitral Regurgitation Due to Isolated Posterior Leaflet Prolapse
25383	MAEs in the Entire Patient Cohort as Well as in the Latter 15 Patients Who Underwent Implantation Through a Posterolateral Approach
25384	Post-Procedure MR≤2+ and 30-Day MR≤2+ Results for the Entire Cohort of Patients, Patients Who Underwent Implantation of Multiple Neo-Chordae, and Patients Who Underwent the Procedure Using a Posterolateral Approach on the Cardiac Apex
25385	Independent Predictors of IPST
25386	Relationship Between IPST and Subsequent 48-Hour and 30-Day Adverse Ischemic Events
25387	Relationship Between IPST and Subsequent 48-H and 30-Day Adverse Ischemic Events in Patients With Post–PCI TIMI Flow Grade 3
25388	Association Between IPST and Subsequent 48-Hour Bleeding Events
25389	Adverse Events in CDC-Treated and Control Patients
25390	Pooled Data of MRI-Measured Parameters in CDC-Treated and Control Patients
25391	Efficacy Endpoints Through 7 Days and 30 Days
25392	Bleeding Endpoints Through 7 Days and 30 Days
25393	Predictors of MACE in Univariate and Multivariate Cox RegressionAnalysis
25394	C-Statistics: Additive Prognostic Value of CMRMarkersofMyocardial Damage
25395	Univariate Predictors of Resuscitation Outcome
25396	PK Profile of Clopidogrel Active Metabolite in Diabetic and Nondiabetic Patients
25397	Serial Echocardiographic Assessment of the Effects of LVAD Unloading on Myocardial Structure and Systolic Function
25398	Imaging Follow-Up
25399	PmMR Findings Compared to Autopsy Findings in 76 Forensic Cardiac Cases
25400	Review of the Literature on Abdominal Alterations Underlying Cardiorenal Dysfunction in Congestive Heart Failure
25401	Electrocardiographic Findings
25402	Cardiac Hemodynamic Parameters
25403	Summary of the Primary Hypothesis: the Diagnostic Performance of the Current Guideline  (no rule out at 0 h)  Versus a Negative Troponin in Conjunction With a Negative Copeptin for Early Rule Out
25404	Cox Proportional Hazards Regression Analysis Evaluating the Risk of All-Cause Mortality Associated With the Change in cTnI Levels in a Model Adjusted for Established CV Risk Indicators  (n = 806)
25405	Clinical Outcomes in Women and Men
25406	Mechanism of Aortic Regurgitation
25407	Aortic Valve Calcification
25408	Procedural Results
25409	Clinical and Safety Outcomes According to VARC  ⁎
25410	Comparison of Secondary Prevention Risk Factor Targets by Trial
25411	Proportion Prescribed Each Medication in the 3 Trials at 1 Year
25412	Proportion of Patients Meeting Targets in the 3 Trials Over 1 Year
25413	Microbiological Data of the 152 Patients With Infection
25414	Echocardiographic Data Related to the Duke and Sohail Criteria
25415	Localization and Dimension of Intracardiac Masses in Patients With Positive ICE and Negative TEE
25416	5-Year Cumulative Rates of Outcomes and Hazard Ratios
25417	Guideline Recommendations for Surgery for Degenerative Mitral Regurgitation
25418	Mortality of Asymptomatic Patients With Degenerative MR Without Surgery
25419	Guideline Recommendations for Surgery for Functional MR
25420	Guideline Recommendations for Surgery in Patients With Aortic Regurgitation
25421	Clinical and Electrocardiographic Data of Affected  (ER+)  and Unaffected  (ER−)  Patients in 4 Families
25422	VM in Affected and Unaffected Patients at Rest
25423	Bleeding Definition
25424	In-Hospital and Follow-Up Clinical Outcomes
25425	Cause of Death: Number of Patients  (% of Total Mortality)
25426	Logistic Regression Model for Determination of Propensity Score: Adjusted OR for Risk Factors Predicting Uninterrupted Statin Use During Anthracycline Chemotherapy in Patients With Breast Cancer  (n = 628, C-Statistic = 0.87)
25427	Unadjusted HRs for Incident Heart Failure Events in Matched Patients  (n = 201)
25428	Multivariate HRs for Incident HF by Uninterrupted Statin Treatment, Adjusting for Potential Covariates
25429	Adverse Events
25430	Clinical and Doppler-Echocardiographic Data
25431	Univariable and Multivariable Analyses of Combined  (AVR or Death)  Event-Free Survival
25432	Univariable and Multivariable Analyses of Overall Mortality
25433	Univariable and Multivariable Analyses of Cardiovascular Mortality
25434	Univariate Analysis for Overall Survival
25435	Multivariable Proportional-Hazard Models
25436	Comprehensive Clinical Models
25437	Comparison of Multivariate Cox Regression Models
25438	Patient Comparison by Era
25439	Outcome Comparison by Era
25440	Risk Factors for Death or Fontan Takedown Within 30 Days of Fontan
25441	Risk Factors for Prolonged Hospital Stay  (>14 Days)
25442	Risk Factors for Prolonged Pleural Effusion  (>14 Days)
25443	Multivariate Analysis of Cardiac Catheterization Subgroup  (N = 668)
25444	Sensitivity and Specificity of PAP as a Predictor of Unfavorable Outcome
25445	Variables Associated With Total Support Time
25446	Summary of Contemporary Reports of Early Postoperative Outcomes
25447	Association of LPA Score With Carotid IMT  ⁎
25448	Association of LPA Score With Angiographic CAD Severity  ⁎
25449	Association Between LPA Score and the Age at Diagnosis of CAD  ⁎
25450	Univariate OR for Stroke/TIA
25451	Clinical Outcomes per Study Group
25452	PAPP-A Concentration and Cardiovascular Outcomes
25453	The ADAPT ADP
25454	Frequency and Type of Major Adverse Cardiac Event During Initial Hospital Attendance or 30-Day Follow-Up
25455	Test Parameter Performan Occurrence of Major Adverse Cardiac Events During Initial Hospital Attendance or 30-Day Follow-Up According to the Results of Individual and Combination of the Accelerated Diagnostic Protocol Test Parameters
25456	Diagnostic Accuracy: Accuracy of cTnI, ECG, TIMI, and ADP for Prediction of MACE
25457	Comparison of SCDs With AIDS Deaths and Other Natural Deaths
25458	Prevalent Comorbidities in SCDs and in AIDS and Other Natural Deaths
25459	Inclusion and Exclusion Criteria
25460	High-Priority Knowledge Gaps in Heart Transplantation and Potential Research Approaches
25461	Selected Grant Mechanisms
25462	Clinical and Hemodynamic Indices Stratified by Median ADMA  (1.29 μmol/l)  and Median GABR  (0.9)  in Patients With ADHF
25463	Etiology of Myocarditis
25464	Treatment Trials of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy, Randomized Controlled Studies
25465	Treatment Trials of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy, Nonrandomized Controlled/Uncontrolled and Randomized Uncontrolled Studies
25466	Multivariate Regression Analysis of Influence of Ees, Eaand Age on the Cardiac Volume Sensitivity of Systolic Blood Pressure and Cardiac Stroke Work legend
25467	Potential Measurements for HF Monitoring
25468	Future Challenges and Opportunities in Home Hemodynamic Monitoring
25469	Univariate Linear Regression Model Predicting Increase in GFR 1 Month After LVAD Implantation for Patients With Admission GFRs <60 ml/min/1.73 m2
25470	Logistic Regression of 2 Common β1-AR Polymorphisms, Arg389Gly and Ser49Gly, and Response to Rate-Control Therapy
25471	Drug Prescription Distribution Among Responders by Haplotype Arg389Arg-Ser49Ser  (n = 85)  and Arg389Gly-Ser49Ser  (n = 97)
25472	Randomized Trials Evaluating Calcium Antagonists for Hypertension and/or Coronary Artery Disease
25473	Functional Parameters of Wild-Type and Cxcr4 +/− Hearts
25474	Covariates Used in Propensity Score Model
25475	Cardiovascular Hospital Stay Profiles in the Propensity Score-Matched Patient Cohorts for Individual Antiarrhythmic Drugs in the AFFIRM Trial
25476	Relationship Between Time Dependent Changes in Clinical Status and Risk of CVH
25477	Medication Use in Patients With and Without In-Hospital Major Bleeding
25478	Cumulative Rates of Major Adverse Clinical Events in Patients With Versus Without In-Hospital Major Bleeding
25479	Independent Predictors of 3-Year Mortality After Primary PCI in All Patients and In-Hospital Survivors
25480	Regression Analysis of First-Time Heart Failure Hospitalization Risk on Education and Income, Stratified by Race/Ethnicity
25481	Resting and Exercise Measurements
25482	Revascularization Procedural Complications in Patients Randomized to Prompt Revascularization
25483	Health Status Outcomes During BARI 2D Follow-Up Based on Multivariable Regression Models  ⁎
25484	Status After Fontan Surgery
25485	Subject Profiles by Current Fenestration Status
25486	Principles of Effective Leadership
25487	Principles for Effective Teamwork to Avoid Medical Errors
25488	Properties of Beta-Blockers Approved for the Treatment of HF
25489	Randomized Controlled Trials of Cardioselective Beta-Blockers in Patients With COPD
25490	Exclusion Criteria, Prevalence of COPD, and Respiratory Symptoms in Major Beta-Blocker Trials
25491	Association Between Beta-Agonists and HF
25492	Clinical Data for 5 Pedigrees Carrying SCN5A Mutations
25493	Novel SCN5A Single Nucleotide Polymorphisms Identified in Familial Cardiomyopathy Registry Screening  ⁎
25494	Incidence and Unadjusted HRs of Adverse Clinical Outcome by the Presence/Absence of RMD
25495	Cox Proportional Hazards Models for Incident Cardiovascular Events as a Function of RMD
25496	Parameters That Significantly Contribute to ProBNP1–108   ⁎   in Multivariable Analysis
25497	Age- and Sex-Specific Median Values and Ranges for Plasma ProBNP1–108 in Normal Subjects
25498	ProBNP1–108 to NT-proBNP1–76 Ratio by Stage of Heart Failure
25499	Detection of Moderate or Severe Diastolic Dysfunction by ProBNP1–108, NT-proBNP1–76, and BNP1–32
25500	Clinical and Echocardiographic Data for Children With Prior Anthracycline Exposure
25501	Echocardiography Assessments After 4 Weeks of Doxy Treatment
25502	Bleeding Events Requiring Transfusion
25503	Transfusion Requirements During Heart Transplantation
25504	von Willebrand Factor Levels  (n = 31)
25505	Odds Ratio  (95% CI)  of CAD by Tertiles of OxPL/apoB and Lp (a)
25506	Odds Ratio  (95% CI)  for CAD Events According to Tertiles of Selected Biomarkers
25507	Relationship of OxPL/apoB and Lp (a)  Levels to the Metabolic Syndrome and Framingham Risk Score Estimates
25508	Elective Procedures Combined With Transapical Implantation
25509	Predictive Factors of 30-Day Mortality
25510	Predictive Factors of Cumulative Late Mortality
25511	Multiple Logistic Regression Comparing Atrial Fibrillation to Sinus Rhythm
25512	Multivariate Multinomial Logistic Regression Comparing Paroxysmal and Persistent AF to Sinus Rhythm
25513	Correlation Coefficients  (Rho)  Between Percent Change in FMD and Changes in Cardiometabolic Biomarkers
25514	Cut-Point Analyses for DBT, Time to Presentation, and TIMI Risk Score
25515	1-Year Mortality Rate by DBT, Time to Presentation, and TIMI Risk Score
25516	Inclusion Criteria for High-Risk  (Physiologic)  Factors: CASES-PMS and SAPPHIRE Randomized Stent and CEA Arms
25517	Inclusion Criteria for High-Risk  (Anatomic)  Factors: CASES-PMS and SAPPHIRE Randomized Stent and CEA Arms
25518	MAE to 360 Days by Physician Training Level
25519	MAE to 360 Days by Operator Volume
25520	MAE to 360 Days by Academic Versus NonAcademic Centers
25521	MAE to 360 Days by Geographic Location
25522	Hemodynamic Data Obtained From Either Sham or PCO Groups 48 h After PCO
25523	Hemodynamic and Morphometric Data Obtained From Either Sham or 3-Week PCO Groups
25524	Duration of Follow-Up
25525	Initiation of Therapy in Subtypes of LQTS  *
25526	Number of Subjects With Follow-Up
25527	Deceased LQTS Patients During Follow-Up
25528	2 Definitions of Metabolic Syndrome Used in This Study
25529	Prevalence of Metabolic Syndrome Components in Controls and Cases, Overall and by Sex
25530	Levels of Copeptin, TnT, Myoglobin, CK-MB, and NT-proBNP According to Time of Chest Pain Onset and Final Diagnosis
25531	Median Concentration of Copeptin According to Categorical Risk Factors and Correlation With Continuous Variables According to Diagnosis
25532	AUC, Sensitivity, Specificity, PPVs, and NPVs for NCCP Versus AMI for TnT, Copeptin, Myoglobin, CK-MB, and Combination According to Time of Chest Pain Onset
25533	Sensitivity, Specificity, PPVs, and NPVs for NCCP Versus AMI and ACS for a More Sensitive TnI and Copeptin in Patients Presenting Within 3 h After Chest Pain Onset
25534	Clinical Worsening Events
25535	Adverse Events Occurring in ≥10% of Patients Receiving Inhaled TRE
25536	DW-MRI Lesion Localization and Size After TAVI
25537	Individual Neurological Risk and Outcome in Consecutive TAVI Patients
25538	Hazard Ratios for Cardiovascular Mortality by Tertiles of Nitrotyrosine
25539	Hazard Ratios for Cardiovascular Mortality by Tertiles of Myeloperoxidase
25540	Risk Reclassification Table for Myeloperoxidase
25541	Procedural Data
25542	Clinical End Points and Long-Term Follow-Up
25543	Procedural Complications  (n = 105)
25544	Association of NT-proBNP and Incident Heart Failure and Cardiovascular Mortality
25545	AUC of Consecutively More Complex Models Predicting HF and CV Death
25546	HRs for Future Coronary Heart Disease According to LDL-C, Non–HDL-C, and Triglyceride Levels and the TC to HDL-C Ratio
25547	Hazard Ratios for Future CHD According to 1-SD Increase in LDL-C, Non–HDL-C, and TG Levels and the TC to HDL-C Ratio
25548	Hazard Ratios for Future CHD According to Non–HDL-C and TG Levels and the TC to HDL-C Ratio in Participants Classified on the Basis of LDL-C Levels
25549	Multivariate Odds Ratio Estimates of Clinical Predictors of Women Versus Men Age ≥35 Years With SCA, Portland, Oregon, Metropolitan Area, February 2002 to January 2007  (n = 485)
25550	Operative and Post-Operative Data
25551	Renal Function After Operation
25552	Characterization of Liposomes by Dynamic Light Scatter Analysis
25553	Effects of Liposomal Adenosine on Hemodynamic Parameters
25554	Effects of Adenosine Receptor Antagonist on Hemodynamic Parameters
25555	Hemodynamic Status and LV Function
25556	Markers of Apoptosis and Oxidative Stress
25557	Summary of Grafts
25558	Location of Angiographic Graft Finding Versus Type of Graft Intervention  ⁎
25559	Planned Versus Unplanned Hybrid Groups
25560	Biophysical Properties of WT and M1875T Channels
25561	Risk Estimates for a Major Coronary Event Per 1-SD Increase of HDL-C, HDL Particle Size, and ApoA-I in the IDEAL and EPIC-Norfolk Studies
25562	Risk Estimates for a Major Coronary Event by Categories of HDL-C  (IDEAL and EPIC-Norfolk)  or HDL Particle Size  (EPIC-Norfolk) , Unadjusted or Adjusted for ApoA-I and B
25563	Risk Estimates for a Major Coronary Event by Categories of ApoA-I in IDEAL and EPIC-Norfolk, Unadjusted or Adjusted for HDL Cholesterol Content and Apolipoprotein B
25564	Patient Disposition
25565	Results of Quantitative Angiographic Analysis at Follow-Up
25566	Cumulative MACE
25567	Stent Thrombosis According to ARC Criteria
25568	Total Exercise Time Results  (Seconds)  in Female Patients
25569	Cause of Death
25570	Identification of Independent Predictors of Death at 1 Year in Dyspneic Patients
25571	Distribution of CAD Risk Factors by MPO Quartile
25572	Odds Ratios for Future CAD Events by MPO Quartile and for MPO as Continuous Variable
25573	Odds Ratios for Fatal and Nonfatal Future CAD Events and Gender-Specific Odds Ratios by MPO Quartile  (Unadjusted)
25574	Odds Ratio and 95% Confidence Intervals for MPO in Subgroups Otherwise Associated With Low Risk
25575	Hemodynamic Data at Peak Stress for Perfusion Imaging at 1.5- and 3-T
25576	Diagnostic Performance of 1.5- and 3-T Perfusion Imaging for the Detection of Significant Coronary Artery Stenosis
25577	Diagnostic Performance of 1.5- and 3-T Perfusion Imaging for the Detection of the Extent and Distribution of Significant Coronary Artery Disease
25578	Sensitivity, Specificity, Positive Predictive Value, and Negative Predictive Value of the Parameters That Were Significantly Associated With the Occurrence of Complete Heart Block After TASH
25579	Diagnostic Accuracy of 64-Slice MSCT to Detect Significant In-Stent Restenosis
25580	Relationship Between Stent Size and Accuracy
25581	Results From the 2 Scanners From the 2 Centers Separately
25582	Estimated 5- and 10-Year Survival for BARI Randomized Patients by Assigned Treatment and by Treated Diabetes Status
25583	Estimated Cumulative Rates of Subsequent Revascularization Procedures  ⁎  at 10 Years by Assigned Treatment and by Treated Diabetes Status
25584	ACE-I Medication in LVAD Patients
25585	General Medication in Both LVAD Groups
25586	Angiotensin I and II Measurements and Collagen Characterization
25587	Stiffness Measurements
25588	Comparisons of Selected Independent Variables by Year
25589	Comparison of Hospitalizations by Age: 12 to 20 Years and 21 to 44 Years  (Aggregate 2000 to 2003)
25590	Multivariate Logistic Regression Analysis for Predictors of Admission Via the ED
25591	Spearman Correlation Coefficients Between Measured Variables  ⁎
25592	Odds Ratios for Future Coronary Artery Disease by Quartile of Lipid/Lipoprotein Variable in Univariable and Multivariable Models  ⁎
25593	Odds Ratios for Future Coronary Artery Disease by Quartile of LDL-C and LDL-P, Both Entered Into One Model  ⁎
25594	Odds Ratios for Future Coronary Artery Disease by Quartile of LDL Size, With and Without Adjustment for LDL Particle Number  ⁎
25595	Odds Ratios for Future Coronary Artery Disease After Taking Into Account the Framingham Risk Score  ⁎
25596	Summary of LQTS-Associated Mutation/Polymorphism–Positive Cases
25597	Study Population
25598	Quantitative Vessel Analysis at IVUS Stratified Into Coronary Segments
25599	Plaque Composition Along the Left Coronary Artery Stratified Into Coronary Segments
25600	Coronary Angiographic Data
25601	Hemodynamic and Collateral Circulation Data
25602	Myocardial Necrosis Markers
25603	Electrogram Results in Porcine Coronary Occlusion Model
25604	Correlation of Electrogram Data With Necropsy Findings
25605	Summary of Neuromuscular Incapacitating Device Discharges
25606	Dimensional Data
25607	Functional Data and Contractility Index
25608	Association of OxPL/apoB and Lp (a)  Level with Presence, Severity, and Progression of Carotid and Femoral Artery Atherosclerosis, and with Cardiovascular Disease
25609	Grading of Carotid Artery Stenosis by Duplex Ultrasound in Correlation With the Angiographic Degree of Stenosis
25610	Clinical Outcomes
25611	Cumulative Survival Free of MACE at Nine Months
25612	Patients With a Definite or Probable Post-Procedural Stent Thrombosis
25613	Quantitative Coronary Angiography
25614	Quantitative Coronary Angiography With Respect to the Use of Kissing Balloon Post-Dilation
25615	Univariate Predictors of Increased Coronary Calcification: Ordered Logistic Regression Analysis
25616	Bivariate Correlation Between Plasma Osteoprotegerin Levels and Cardiovascular Risk Factors
25617	Univariate Predictors of Cardiovascular Event-Free Survival, Cox Proportional Hazards Model
25618	Binary Logistic Regression Model to Predict Hemodynamic Depression
25619	Clinical and Angiographic Outcomes of Patients Stratified by CKpeak
25620	Multivariate Predictors of 1-yr Mortality
25621	Effects of N-Acetylcysteine on Cardiac Structure and Function in cTnT-Q92 Mice
25622	Consensus Table of 64-Slice CT and IVUS to Detect and Classify Coronary Plaques
25623	Results of Two-Dimensional Echocardiography, Categorized With Respect to Renal Function, GFR  (Dichotomized With GFR Cut Point of 60 ml/min/1.73 m2) , and the Presence or Absence of CHF
25624	Ablative Approach and Results of Cryothermal Balloon Ablation of Pulmonary Veins
25625	Distribution of Pulmonary Vein Ostial Diameters and Doppler Flow Velocities
25626	Concomitant Medication Used During Double-Blind Treatment Phase
25627	Body Systems With Treatment-Emergent Adverse Events Affecting Two or More Patients  (≥5%)
25628	Changes in Vital Signs at Peak at the End of Treadmill Exercise  (Week 8, 80 mg Three Times Daily)   ⁎
25629	Mini-Mental State Examination  (MMSE)  Scores
25630	Heart Rates for Six-Minute Walk Test at Initial and Follow-Up Visits
25631	Associations Between Age and Arterial Parameters for Males and Females
25632	Comparison of the Effect of Aging by 10 Years on Arterial Parameters in Younger  (20 to 30 Years)  and Older  (70 to 80 Years)  Subjects
25633	Stepwise Regression Analyses
25634	ACC/AHA Recommendation for Anticoagulation During Pregnancy in Patients With Mechanical Prosthetic Valves
25635	Recommendations of the Seventh ACCP Consensus Conference on Antithrombotic Therapy for Prophylaxis in Patients With Mechanical Heart Valves
25636	Recommended Approach for Anticoagulation Prophylaxis in Women With PHV During Pregnancy
25637	Respective Diagnostic Values for TTE and TEE Compared With Surgical Findings  (n = Specified in Echocardiographic Report)
25638	Perioperative Mortality, Frequency of Valve Repair, and Long-Term Survival in the Group as a Whole and According to Etiology of MR
25639	Multivariate Predictors of Perioperative Mortality
25640	Multivariate Predictors of Long-Term Mortality
25641	Salient Patient Details
25642	Oligonucleotides Used as Primers for PCR Reaction
25643	Relative Risk of Recurrence of Atrial Fibrillation
25644	Relative Risk of Stroke
25645	Analysis by Coronary Segments
25646	Analysis by Patients
25647	Incidence and Type of Early  (≤30 Days)  Morbidity in Patients With Pulmonary Hypertension  (n = 145)  After Noncardiac Surgery
25648	Variables Considered Independent Predictors in a Multivariate Logistic Regression Model of Short-Term Morbidity After Noncardiac Surgery
25649	Variables Considered Independent Predictors in a Multivariate Linear Regression Model of Length of Hospital Stay After Noncardiac Surgery  ⁎
25650	Clinical Outcomes at 1 Month and 9 Months
25651	Serial Quantitative Analysis of the Stented Segment by QCA and IVUS  (n = 15)
25652	Evolution of Endothelial Progenitor Cell Capture Stent: Improvement From HEALING-FIM  (H1)  to HEALING II  (H2)
25653	NYHA Functional Class Before and After Randomization
25654	Medication Use According to the Patient’s Management Plan  (PMP)
25655	Primary Outcome Measure and its Components at 240-Day Follow-Up
25656	Primary Outcome Measure and its Components at 450-Day Follow-Up
25657	Results of Multivariate Cox Regression Analysis
25658	Summary of Forward Selection
25659	Patient Contacts Not Resulting in Hospitalization
25660	Adverse Event Rates in the Derivation and Validation Sets
25661	Clinical and Angiographic Predictors of One-Year Mortality in the CADILLAC Trial
25662	Prognostic Capability of Various Risk Scoring Systems Applied to the Stent-PAMI Validation Set
25663	Initial TIMI Flow Grade According to Admission Glucose
25664	Multivariate Analysis of Initial TIMI Flow Grade 0 to 2
25665	Tachycardia Origin and Results of Radiofrequency Catheter Ablation for Idiopathic Ventricular Arrhythmias
25666	Relations of QRS Duration and Echocardiographic Variables
25667	Echocardiographic Measurements According to Type of Bundle Branch Block
25668	Angiographic and Procedural Data Stratified by Diabetic Status
25669	Conservation of Cardiac Troponin I Amino Acid Residues Affected by Missense Mutations
25670	Phenotypic Features at First Clinical Evaluation of HCM Families With TNNI3Mutations
25671	Type and Distribution of Stents
25672	Clinical Status
25673	Nucleotide Sequence of Primers Used in This Study
25674	Relative Binding of Wild-Type and Mutant Tcap to MLP, Titin, and CS-1, as Assessed by the Y2H Assays
25675	Relative Binding of Wild-Type and Mutant Tcap to MLP, Titin, and CS-1, as Measured by the GST Pull-Down Competition Assays
25676	Conservation of Cardiac Troponin T  (cTnT)  Amino Acid Residues Affected by Mutations
25677	Conservation of Cardiac Troponin C  (cTnC)  Amino Acids Affected by Mutation
25678	Clinical Features of Patients With Chronic Orthostatic Intolerance  (Frequency of Findings)
25679	Systemic and Hemodynamic Values During the Phases of the Tilt Test Entered in the Stepwise Discriminant Analysis
25680	Clinical and Operative Details
25681	Hemodynamic, Blood Gas Parameters, Oxygen Consumption, and Co-oximetry
25682	Calculated Flows, Flow Ratios, and Resistances
25683	Cerebral Blood Flow Markers
25684	Patient Description
25685	Effects of Brachytherapy on Invasively Determined Parameters of Vessel Function
25686	Effects of Brachytherapy on Flow Parameters
25687	Impact of ST-Segment Parameters on Death and Reinfarction: All Patients
25688	Impact of ST-Segment Parameters on Death and Reinfarction: Patients With TIMI Flow Grade 3 After Procedure
25689	Model Fit Statistics for the Multivariate Analyses of Outcomes, Examining the Relative Prognostic Value of Different ST-Segment Parameters *
25690	Antiarrhythmic Drug Use  ( 7–9 )
25691	Drug Therapy
25692	Arrhythmic Events
25693	Torsade de Pointes Ventricular Tachycardia
25694	Torsade de Pointes VT
25695	Potential Variables Associated With Mortality in Bootstrap Models, Presented in Descending Order of Strength; 1,000 Bootstrap Models Performed in Each Iteration
25696	Macrophage Density in Lipid-Rich Plaques
25697	Initial and Intercurrent Revascularization by Randomization Assignment
25698	Angiographic Evaluation at 5 Years by Randomization Assignment
25699	Logistic Regression Analysis of Entry Clinical and Angiographic Features Associated With Angina at 5 Years  (n = 401 Patients Who Underwent Their Randomly Assigned Treatment)
25700	Procedural Results
25701	Multivariate Predictors of Mortality
25702	Serial QCA Analyses  (Intention to Treat)
25703	IVUS Analyses  (Intention to Treat)
25704	Most Severe  (Hierarchical)  MACE, Revascularization Procedures  (Event Per Patient) , and Total Count of Cardiac Events Up to 12 Months
25705	Procedural and Angiographic Outcomes Stratified by Postprocedure Myocardial Blush Grade
25706	Clinical and Angiographic Outcomes Stratified by Myocardial Perfusion Status Postintervention
25707	Exercise Echocardiographic Parameters
25708	Outcome for Patients With Dyspnea Compared With Those Having Chest Pain
25709	Predictors of Cardiac Death or MI for Patients With Dyspnea
25710	Patient Data
25711	Catheterization Laboratory and In-Hospital Outcomes
25712	Multivariate Predictors of 30-Day Mortality Stratified by Pre-Admission Beta-Blocker Use
25713	Cytokine Substudy
25714	Clinical Outcomes Stratified by the Severity of Mitral Regurgitation
25715	Quantitative Angiographic Results
25716	In-Hospital Outcomes of Patients/Lesions
25717	Presenting Neurologic Deficits of Patients With a Cerebrovascular Accident After Percutaneous Coronary Intervention
25718	AFFIRM Definition of Adequate Ventricular Rate Control
25719	Cumulative Achievement of Adequate Ventricular Rate Control
25720	Reasons for Discontinuation of Rate-Controlling Drugs
25721	Long-Term Mortality Risk in Diabetic Patients Compared With Non-Diabetic Patients: Results of Univariate and Multivariate Models
25722	Imaging Investigation Results
25723	Univariate and Multivariate Predictors of Any Event by Cox Regression
25724	Univariate Predictors of an Event Based on the Presence of Coronary Disease and Two-Year Risk of a Cardiac Event
25725	Univariate Predictors of an Event Based on the Presence of Coronary Artery Disease, Dialysis, or Multiple Risk Factors
25726	Representative Genes Differentially Regulated Between Mice With Femoral Artery Ligation and Sham Control Operation
25727	Changes of Three Selected Genes Validated by Real-Time RT-PCR  (MCP1, MT1 at Day 1, and MMP12 at Day 7)
25728	Anthropometric and Biochemical Variables According to the Three Genotypes
25729	Echocardiographic Variables According to the Three Genotypes
25730	Simple Regressions Between Cardiac Variables Versus CYP11B2
25731	Multiple Regression Analysis
25732	Intergroup Comparisons of Treatment Effect
25733	Clinical Events at 14-Day Follow-Up
25734	Factors Independently Associated With Embolic Events
25735	Factors Independently Associated With Embolic Events Evaluated Only in Patients Without LAA Ligation Performed at Surgery  (n = 147)
25736	Multivariate Model for Prediction of First Age-Related Events
25737	Risk-Scoring Algorithm for the Prediction of First Age-Related Cardiovascular Events
25738	Kaplan-Meier Event Rates for the Study Population and Prospective Validation Cohort
25739	Findings in Patients With Hyperintense Areas on MRI
25740	Core Laboratory Angiographic Analysis
25741	Early and Late Clinical Outcomes
25742	Economic Analysis
25743	Electrocardiographic Data Summary
25744	Electrophysiologic Data Summary
25745	Crude Mortality and Cause of Death
25746	LVEF and Mortality: Multivariable Analysis
25747	Cost Calculations for Testing
25748	Cost of Testing Before and During the Study
25749	Adjusted Relative Risks and 95% Confidence Intervals for Coronary Heart Disease  (Nonfatal MI and Fatal CHD)  According to Quintile of Vitamin C Intake *
25750	Adjusted Relative Risks and 95% Confidence Intervals for Coronary Heart Disease  (Nonfatal MI and Fatal CHD)  * According to Use of Vitamin C Supplements †
25751	Antiarrhythmic Drug Use
25752	Randomization Scheme: Numbers Eligible for Treatment Arms
25753	Randomization Scheme: Totals Used for Comparison
25754	First Antiarrhythmic Drug Substudy End Points: Amiodarone Versus Class I Drugs *
25755	First Antiarrhythmic Drug Substudy End Points: Amiodarone Versus Sotalol *
25756	First Antiarrhythmic Drug Substudy End Points: Sotalol Versus Class I Drugs *
25757	Adverse Effects Causing Discontinuation of First Antiarrhythmic Drug Within the First Year
25758	Principal Indications for Intra-Aortic Balloon Pump Use in 5,495 Patients With AMI
25759	Effect of IABP Placement on Hemodynamic Measures
25760	Failure and Complications of the IABP  (n = 5,495)
25761	Percutaneous and Surgical Procedures in Patients With Acute Myocardial Infarction Receiving an Intra-Aortic Balloon Pump *
25762	Independent Correlates of In-Hospital Mortality by Logistic Regression Analysis
25763	Total Mortality According to Quintiles of Hematocrit
25764	Total Mortality According to Quintiles of Hematocrit Among Men and Women
25765	Mortality by Different Causes According to Quintiles of Hematocrit
25766	Reasons for Discontinuation of Study Medication
25767	Critical Cardiovascular Events in Intention-to-Treat Population
25768	Univariate Predictors of One-Year Mortality Plus Urgent Transplantation
25769	Multivariate Analysis of the Variables Associated With One-Year Mortality Plus Urgent Transplantation
25770	Comparison of Mortality for Clinical Profiles to Mortality in Trials of Hospitalized Patients With Advanced Heart Failure
25771	Relationship Between Exercise Stress Testing Responses, Holter Monitoring Results, and Severity of Anginal Symptoms
25772	Triggering Factors
25773	Angiographic Results
25774	Indices of Doppler Guidewire
25775	Pathologic Findings
25776	Ratios  (95% CIs)  of Shed Blood F1+2, TAT and β-TG Levels Between Comparator  (r-hirudin and Enoxaparin)  Treatment Groups and 60 mg Ximelagatran Group
25777	Model Parameters Generated by Fitting an Inhibitory Concentration-Response Model by Nonlinear Regression
25778	Ratios  (95% CIs)  of Venous F1+2, TAT and β-TG Plasma Levels Between Treatment Groups and the Control Group  (Treatment/Control)
25779	Clinical Features, Risk Profile, and Mortality Rates Among the Five LV Thickness Classes
25780	Comparison of Outcomes Among HCM Patients With Extreme Hypertrophy  (Maximum LV Thickness ≥ 30 mm)  in Three Different Patient Populations
25781	Data Reviewed
25782	Relationship Between Weaning or Survival and CPR Duration
25783	Analysis of the Factors in Weaning and Survival by the Spearman Method
25784	Predictive Levels for Different Probabilities of Weaning and Survival
25785	Adjusted Risk of Bradyarrhythmia Requiring a Permanent Pacemaker
25786	Measurements of Anticoagulation Before, During, and After PCI *
25787	Levels of Anti-Xa Activity in Patients Undergoing PCI, According to Age, Renal Failure, and Weight
25788	Clinical Events and Bleeding Complications at 30 Days Follow-Up
25789	Survival According to Creatinine Clearance  (“High” = Ranks 3 and 4; “Low” = Ranks 1 and 2)  in Selected Subgroups
25790	Variables Associated With Mortality in Multivariable Models
25791	Periprocedural Neurologic Complications According to Procedural Outcome
25792	Left Ventricular Function and Hemodynamics in MR: Effect of AT1RB
25793	Comparison Between All Patients and Patients With Myocardial Energetics Measurements
25794	Incidence and Odds Ratios of In-Hospital Events According to BMI: Percutaneous Transluminal Coronary Angioplasty Group
25795	Incidence and Odds Ratios of In-Hospital Events According to BMI: Coronary Artery Bypass Graft Surgery Group
25796	Incidence and Relative Risks of Long-Term Mortality According to BMI: Percutaneous Transluminal Coronary Angioplasty Group  (n = 2,090)  *
25797	Incidence and Relative Risks of Long-Term Mortality According to BMI: Coronary Artery Bypass Graft Surgery Group (n = 1,503)  *
25798	Definitions of Extent of Revascularization
25799	Algorithm for “Functional” Revascularization  (Strategy 2)   (Refer to  Fig. 1 )
25800	Evaluation of Definition 1: Traditional Complete Revascularization
25801	Evaluation of Definition 2: Functional Complete Revascularization
25802	Evaluation of Definition 4: Number of Distal Sites to Different Vessels
25803	Follow-Up Intravascular Ultrasound Results According to Treatment Groups
25804	Major Adverse Cardiac Events to 210 Days: Hierarchical Ranking of Worst Event per Patient  (Intention-to-Treat)  According to Treatment Group
25805	Observed Survival With 95% Confidence Intervals for Patients Undergoing PTCA vs. Observed Survival for CABG Patients in the Different Anatomic Subsets *
25806	Results in Both Treatment Groups
25807	Results
25808	Clinical Details of 28 Homozygotes With Naxos Disease
25809	Response to CPT and Exercise legend
25810	Blood Gas Analysis and Hemodynamic Data at Each of Examined Treatment Steps legend legend
25811	Underlying Disease in Nonprimary Pulmonary Hypertension legend
25812	Effect of Iloprost Inhalation on Hemodynamics and ANP and cGMP Levels in PPH and NPPH
25813	Procedures Performed on 1,142 Saphenous Vein Grafts legend
25814	In-hospital Complications in 1,062 Patients legend
25815	Incidence of MACE in 1,056 Patients legend
25816	Multivariate Predictors for Late MACE legend
25817	Blood Pressure and Heart Rate Responses to Study Drug in the Three Groups legend
25818	Aldehydes and Isoprostanes: Individual Levels and Totals of the Compounds Measured legend
25819	Effect of Digoxin and Age Group on Clinical Outcomes legend
25820	Mean Digoxin Dose Prescribed and Mean Serum Digoxin Levels by Age Group at One Month After Randomization ∗
25821	Suspected Symptoms and Signs of Digoxin Toxicity by Age Group
25822	Clinical Outcomes by Age Group and Ejection Fraction legend
25823	Cox Proportional Hazard Model Analysis to Determine the Effect of Age and Treatment on All-Cause Mortality  (n = 7,746)  ∗   legend
25824	Survey on the Diagnosis of Heart Disease in Groups of Patients With SR and AF legend
25825	Ischemic and Remote Region Circumferential Segment Shortening  (%S)  legend
25826	Pulmonary Hemodynamic Variables legend
25827	Mortality Rate in Patients for the Two Years After the One-, Three-, and Five-Year Tests Based on Whether the Test Was Taken legend
25828	Combined Mortality or Myocardial Infarction Rates for the Two Years After the Scheduled EXTs for the Test Takers and Non Test Takers legend
25829	Relationship Between Parameters Measured on Each EXT and the Univariate and Multivariate Risk Ratios for Survival for the Two Years After the Test legend legend
25830	Relationship Between Parameters Measured on Each EXT and the Univariate and Multivariate Risk Ratios for Survival Free of Myocardial Infarction for the Two Years After the Test legend legend
25831	The Number of Patients Revascularized Within 90 Days of the One-Year EXT Segregated by Angina Reported Before the Test, Angina on the Test and ST Depression legend
25832	Sensitivity, Specificity, Positive Prognostic Value and Negative Prognostic Value of the Ability to Exercise to Bruce Stage 3 and a Duke Score ≤−6
25833	Acute and Six-Month Rhythm Outcome After Linear Lesions legend
25834	Biographical and Hemodynamic Data of Cardiac Patients legend legend
25835	Metabolic and Anthropomorphic Changes Following Treatment legend
25836	Crude Five-year Mortality legend
25837	Selected Clinical and Electrophysiologic Features of Study Patients ∗   legend
25838	Right Atrial Repolarization and Refractoriness at Identical BCL in Control Patients, Patients With Aflut and Afib legend legend
25839	Influence of Atenolol on Cell Shape Alterations Caused by Norepinephrine legend
25840	Influence of β-Adrenoceptor Inhibition on the Hypertrophic Responsiveness to Norepinephrine in Cardiomyocytes From Aortic Banded Rats legend legend legend
25841	Univariate Comparisons of Specialist and Generalist Patient Cohorts legend legend
25842	Incidence of Atrial Flutter in the General Population
25843	Odds Ratio, Association Between Atrial Flutter and Clinical Variables
25844	Echocardiographic Findings in 132 Affected Family Members legend
25845	Correlation Between Arrhythmias and Extent of the Disease legend
25846	Late Potentials Values Correlated With the Extent of the Disease and the Presence of Arrhythmias legend
25847	Hemodynamic Variables at all Stages of the PLV Procedure legend
25848	Predictive Accuracy of Troponin I Value ≥ 1.0 ng/ml for Predicting Outcomes in All Patients and After Excluding Patients With Ischemic Electrocardiograms legend legend
25849	Predictive Accuracy of an Ischemic Electrocardiogram for Predicting Outcomes legend legend
25850	Multivariate Predictors of Myocardial Infarction, Death or Significant Disease legend
25851	Multivariate Predictors of Significant Complications legend
25852	Multivariate Predictors of Significant Disease Alone legend
25853	Hemodynamic, Renal and Humoral Responses to Acute Subcutaneous BNP legend
25854	Anatomic Variants of Coronary Artery Branching in TOF legend legend
25855	Diagnostic Accuracy of Coronary Echocardiography in Detecting a Major Coronary Artery Crossing the RVOT legend
25856	Surgical Approach in Patients With Tetralogy of Fallot and Coronary Anomalies From 1990 through 1995 legend
25857	Hemodynamics and Coronary Anatomy of Patients With CS Caused by Predominant LV Failure legend
25858	In-hospital Treatment of Patients With CS Due to Predominant LV Failure
25859	Summary of 36 Patients With Prosthetic Valve Thrombosis legend
25860	Comparison of Thrombolytic Success for the Initial and Subsequent Doses of Thrombolytics According to Valve Type and Location
25861	Risk of Embolization After Thrombolytic Treatment of Left-Sided Prosthetic Heart Valves  (Single Center Series With ≥8 Patients)  legend
25862	Literature Review of Dystrophin Defect Associated DCMs
25863	Diagnostic Criteria for X-linked DCM Derived From Reports
25864	Clinical Data and Genetic Defects of Dystrophin-Related CMD Patients legend
25865	Cut-off Points, Predictive Accuracy, Sensitivity and Specificity Values for All Continuous Parameters legend
25866	Results of Uni- and Multivariate Analysis for Predicting MACE legend
25867	Results of Uni- and Multivariate Analysis for Predicting MACE legend
25868	Odds Ratio and 95% Confidence Intervals of Parameters Included Multivariate Nominal Regression Analysis for Predicting MACE legend
25869	Coronary Collateral Conductance and the IZ/NZ Perfusion Ratio  (Central Venous Study)
25870	Coronary Collateral Conductance and the IZ/NZ Perfusion Ratio  (Peripheral IV Study)
25871	Final Coronary Collateral Conductance and the IZ/NZ Perfusion Ratio  (Pericardial Study)
25872	Coronary Collateral Conductance and the IZ/NZ Perfusion Ratio  (IC Study)
25873	Mean Change Values  (mg/dl, ±SD)  for All Subjects Randomized to the Placebo or Garlic Group legend legend
25874	Mean Change  (mg/dl)  by LDL Pattern After Placebo or Garlic Treatment legend legend
25875	Results of Multivariate Analyses in the SOLVD Prevention Trial legend
25876	Results of Multivariate Analyses in the SOLVD Treatment Trial legend
25877	Risk Associated With Various Degrees of Renal Insufficiency legend
25878	Relative Risk and 95% CI for Cardiovascular Mortality in the Nine Groups legend
25879	Estimated Subsequent Revascularization Procedures Rates at 7 Years legend
25880	Coronary Structural and Functional Variables and Collateral Data at Rest
25881	Effect of Adenosine on Coronary Hemodynamics legend
25882	Coronary Collateral Hemodynamics Relative to the Collateral Receiving and Supplying Vascular Bed legend
25883	Echocardiographic Findings by TEE and Presence of Atrial Fibrillation for Each Age Group legend
25884	Consecutive Patients Randomized in BARI at Four Investigative Centers legend
25885	Long-Term  (Four Year)  Clinical Events After One-Year Angiography legend
25886	Treatment Details legend
25887	Number and Percent of Patients With Assessment of Myocardium at Risk and Final Infarct Size legend
25888	Multivariable Regression Modeling ∗
25889	Final Infarct Size, Myocardium at Risk and Myocardial Salvage Index
25890	Secondary End Point Clinical Outcome Events
25891	In-hospital Cardiovascular Events legend
25892	Valvular Regurgitation ∗  (n = 226)
25893	Valvular Regurgitation by Dose and Duration of Medication legend
25894	Comparison of Groups With and Without Valvular Heart Disease
25895	Prevalence of Valvular Heart Disease in the Framingham Heart Study Compared With Our Phen-fen Subjects
25896	Biochemistry  (Mean ± SD)
25897	Histomorphometric Analysis of the Abdominal Aorta and of the Left Interventricular Coronary Artery in the Three Groups
25898	Hemodynamics and Wall Mechanics in the Iliac and Renal Arteries of Pigs legend
25899	Biochemical Analyses and Collection Sample Collection Schedule
25900	Reporting of Presence of Angina by Hot Pain Threshold legend
25901	Biochemical Measures During Exercise and Mental Stress Testing by Hot Pain Threshold  (<41°C vs. ≥41°C)
25902	Cardiovascular Responses to Mental Stress Testing by Hot Pain Threshold  (<41°C vs. ≥41°C)  legend
25903	Cardiovascular Responses to Bicycle Exercise by Hot Pain Threshold  (<41°C, ≥41°C)  legend
25904	Impact of Congestive Heart Failure on Mortality: Results of Multivariable Cox Proportional Hazards Regression Models legend
25905	Impact of Normal Versus Reduced Left Ventricular Ejection Fraction on the Mortality of Congestive Heart Failure Cases: Results of Cox Proportional Hazards Regression Models
25906	Characterization of Women Undergoing Dobutamine Stress Echocardiography  (n = 92)  legend
25907	Wall Motion Score and Coronary Anatomy in Women With Abnormal Dobutamine Stress Echocardiography legend
25908	Findings in Women With Significant Angiographic Coronary Disease and Normal or Indeterminate Dobutamine Stress Echocardiography legend
25909	Comparisons Among Women With Normal, Abnormal and Indeterminate Dobutamine Stress Echocardioraphy legend
25910	Initial Procedural Outcome  (Among 608 CABG and PTCA Patients With IR Intended and 579 PTCA Patients With CR Intended if Randomized to PTCA Who Received Their Assigned Treatment)  legend
25911	Freedom From Untoward Events at Five Years  (CABG vs. PTCA Patients With IR Intended if Assigned to PTCA)
25912	Power Calculations  (All CABG vs. PTCA Patients With IR Intended if Assigned to PTCA)  legend
25913	Freedom From Untoward Events at Five Years  (PTCA Patients With CR vs. IR Intended)
25914	Power Calculations  (All PTCA Patients With CR vs. IR Intended)  legend
25915	Ambulatory Electrocardiogram  (AECG)  and Exercise Treadmill Test  (ETT)  Findings by Presence of Mental Stress Ischemia legend
25916	Patient Outcomes for the Initial 6 Months After Placement on the UNOS Status 2 Waiting List
25917	Patient Outcomes for the 6-Month Survivors Over the Entire Follow-up Period
25918	Hemodynamic Findings legend
25919	Unidirectional Transfer Constant Values  (ml/g−1/min−1)  and Myocardial Perfusion Reserve Index Grouped According to Percent Diameter Stenosis legend
25920	Causes of Death of the 29 Patients Who Died Within the Hospital Stay Associated With the Current Acute Myocardial Infarction ∗
25921	Clinical and Investigational Data of the Patient Population  (n = 497)  legend legend
25922	Clinical Information on the 11 Deaths of Patients Discharged Home Directly From the Coronary/Intermediate Care Unit legend
25923	Procedural Variables and Angiographic Outcomes
25924	Clinical Endpoints
25925	Randomized Trials Comparing the Effects of Ionic Versus Nonionic Contrast Media in Patients Undergoing Coronary Angioplasty
25926	Comparison of Clinical Features at Presentation Between Patients in Group 1 and in Group 2
25927	Comparison of ECG, Hemodynamic, Echocardiographic and 24-h Holter ECG Data at Presentation Between Patients in Group 1 and in Group 2
25928	Primary Defects in Eisenmenger Patients Having Noncardiac Surgery
25929	Noncardiac Surgeries Performed in 24 Eisenmenger Patients
25930	Operative Records of Noncardiac Surgeries Done at Mayo Clinic
25931	Summary of Clinical, Implantation, Follow-Up and Postmortem Device Data on the 25 Study Patients legend
25932	Evidence of Terminal Tachyarrhythmic Events in the 25 Patients Who Had Out-of-Hospital Sudden Death legend
25933	Summary of Device Responses and Outcome for Stored Tachyarrhythmic Events Obtained From Postmortem Device Analysis ∗   legend
25934	Comparison of Mitral Doppler Measurements in Chronic Obstructive Pulmonary Disease and Constrictive Pericarditis legend
25935	Comparison of Superior Vena Cava Peak Forward and Reverse Flow Velocity in Chronic Obstructive Pulmonary Disease and Constrictive Pericarditis  legend
25936	Comparison of Superior Vena Cava Forward and Reverse Flow Velocity Integrals in Chronic Obstructive Pulmonary Disease and Constrictive Pericarditis  legend
25937	Cardiac Events According to the Result of Stress Echocardiography  legend
25938	Univariate Predictors of Hard Cardiac Events  (Death, Myocardial Infarction)   legend
25939	Univariate Predictors of Spontaneous Cardiac Events  (Death, Myocardial Infarction)   legend
25940	Inhibition of Platelet Aggregation, Part A legend
25941	Inhibition of Platelet Aggregation, Part B legend
25942	Inhibition of Platelet Aggregation, Part C legend
25943	Safety End Points legend
25944	Efficacy Outcomes  legend
25945	Safety and Efficacy End Points: All Lamifiban Versus All Placebo  legend
25946	Continuous Electrocardiographic Monitoring End Points
25947	Continuous Electrocardiographic Monitoring, All Lamifiban Versus Placebo
25948	Histopathologic Data  legend
25949	Clinical, Hemodynamic, Angiographic and Conventional Coronary Collateral Data legend
25950	Intracoronary Distal Flow Velocity and Pressure Data During PTCA and the Respective Collateral Flow Indices  legend
25951	Diagnostic Accuracy of Different Tests to Assess the Human Coronary Collateral Circulation  legend
25952	Major Clinical Outcomes  legend
25953	30-day Mortality
25954	Occurrence of Systemic Hypertension  (Systolic Pressure >140 or Diastolic >90 mm Hg) , Coronary Vasculopathy, and a Rejection Grade of II, III or IV in the 50 Transplanted Patients Over Their 5 to 6 Year Posttransplant Course  legend
25955	Clinical and Electrocardiographic Findings legend
25956	Radionuclide Studies legend
25957	Clinical Outcome Events legend
25958	In-Hospital Therapy by Angiotensin-Converting Enzyme Inhibitor Treatment at Discharge legend
25959	Predictors of Discharge Angiotensin-Converting Enzyme Inhibitor Use in Group 1: Treatment “Definitely” Indicated legend
25960	Predictors of Discharge Angiotensin-Converting Enzyme Inhibitor Use in Group 2: Treatment “Probably” Indicated legend
25961	Predictors of Discharge Angiotensin-Converting Enzyme Inhibitor Use in Group 3: Treatment “Possibly” Indicated legend
25962	Two-Dimensional Echocardiographic Findings
25963	Correlations among Three-Dimensional Area of Prolapse, 3D Volume of Prolapse Compared to ROA by Convergence Method, and 3D Echo Planimetry  legend
25964	Heart Rate and Pulmonary Artery Hemodynamic Variables in Patients With Chronic Pulmonary Thromboembolism and Primary Pulmonary Hypertension
25965	Cases of Acute Myocardial Infarction Reported to the Second National Registry of Myocardial Infarction by Region
25966	Cases of Acute Myocardial Infarction Reported to the Second National Registry of Myocardial Infarction by Gender and Age Group
25967	Origin of Primer Pairs Used for PCR Analysis of Viable Cardiovascular C. pneumoniaeIsolates
25968	Hemodynamic Variables After Dobutamine Administration
25969	Prebypass and Postbypass Hemodynamic Measurements Before and After Epinephrine Infusion and Administration of Bicarbonate and Calcium
25970	Total Serum Cholesterol Levels  (mg/dl)
25971	Semiquantitative Analysis of Immunohistochemical Staining
25972	Doppler Tissue Imaging Annular Velocities in the Three Study Groups
25973	Reproducibility of Doppler Tissue Imaging Measurements
25974	Respiratory Changes in Hemodynamic and Pulmonary Venous Flow Velocity Variables in the 10 Study Dogs
25975	Changes in Doppler Pulmonary Venous Flow Velocity Variables With Changes in Heart Rate in the 10 Study Dogs
25976	Doppler Pulmonary Venous Flow Velocity Variables and Intervals in the 10 Study Dogs at Different Left Atrial Pressures
25977	Echocardiographic and Electrocardiographic Results During Dobutamine Administration in 25 Patients With Right Coronary Artery Stenosis
25978	Use of Medications and Procedures
25979	Bleeding Outcomes
25980	Clinical Outcomes
25981	Thirty-Day Mortality After Revascularization
25982	Procedures Performed With Intraaortic Balloon Counterpulsation
25983	Hemodynamic Measurements in Control and Cardiomyopathic Dogs
25984	Impact of Volume Alteration on Ventricular Refractoriness
25985	Impact of Volume Alteration on Epicardial Monophasic Action Potential Duration at 90% Repolarization
25986	Treatments Received During First 6 Months in 328 Randomized Patients
25987	Adverse Events  (first event/patient)
25988	Exercise Performance, Symptoms and Quality of Life at 6 Months
25989	Percent Diameter Stenosis of Index Lesions  (coronary angioplasty-treated patients only)   a
25990	Clinical Profile, Diagnostic Investigations and Sites of Measurement of Pericardial Thickness in 11 Patients With Constrictive Pericarditis
25991	Sensitivity, Specificity and Predictive Accuracy of Using Pericardial Thickness ≥3 mm Measured With Transesophageal Echocardiography in Predicting Pericardial Thickening Found Intraoperatively
25992	Intraoperative Hemodynamic and Transesophageal Echocardiographic Data
25993	Predictors of Surface Morphology and Intimal Hyperplasia
25994	Surface Morphology and Risk Factors
25995	Pigmented Hyperplasia: Surface Contour and Risk Factors
25996	Results of Exercise Treadmill Testing
25997	Results of Transesophageal Dobutamine Stress Echocardiography
25998	Hemodynamic and Left Ventricular Volume Data
25999	Chemosensitivity and Cardiopulmonary Exercise Test Results of Patients After Placebo and Dihydrocodeine Administration
26000	Pulse, Systolic Blood Pressure, End-Tidal Carbon Dioxide Concentration and Arterial Oxygen Saturation at Rest, at 3 Minutes of Exercise, at 6 Minutes of Exercise and at Peak Exercise With Placebo and Dihydrocodeine
26001	Modified Borg Scores for Dyspnea and for Fatigue During Exercise Testing With Placebo and Dihydrocodeine
26002	Angiographic Data
26003	Morphometric Results in Animals During Phase II
26004	Medications at the Time of Hospital Discharge Based on the Clinical Setting of Index NSVT Among All Untreated Patients
26005	Event Rates Among All Untreated Patients Based on the Clinical Setting of Index NSVT legend
26006	Brachial Artery End-Diastolic Diameters and Flow, Flow-Mediated Dilation, and Nitroglycerin-Mediated Dilation
26007	Effects of Rofecoxib on Serum Lipids and Inflammatory Marker Levels
26008	Clinical Details and Absolute Ratio of IGF-I to GH of Control Subjects  (Study 1)  and Patients With CHF in Studies 1 to 3 legend
26009	Variables of the GH/IGF-I Axis in Healthy Control Subjects and Patients With CHF legend legend
26010	The Relationship of the Biochemical Marker of GH Resistance  (IGF-I/GH log ratio)  to Clinical and Biochemical Variables in Healthy Control Subjects and Patients With CHF ∗   legend legend
26011	Effects of Raloxifene and Placebo in Postmenopausal Women With Coronary Artery Disease
26012	Concomitant Medication Usage by the 33 Postmenopausal Women With Coronary Artery Disease
26013	Implantation Data
26014	The Effect of Septal Pacing on P-Wave Duration
26015	Univariate and Multivariate Linear Model of Left Ventricular End-Diastolic Volume Index in 113 Patients With CHF legend
26016	Univariate and Multivariate Linear Model of Transcardiac Gradient of Plasma Aldosterone in 113 Patients With CHF legend
26017	Hemodynamic and Neurohumoral Data legend
26018	Inclusion and Exclusion Criteria of the Study
26019	Angiographic Data: Comparison of Randomization Groups
26020	End Points: Comparison of Randomization Groups
26021	End Points: Comparison of TIMI Flow Rates After Thrombolysis in the Two Groups
26022	End Points: Six Months Follow-Up Intention-to-Treat Analysis  (Including Secondary Excluded Patients) : Comparison of Randomization Groups
26023	Multivariable Analysis for the Presence and Multiterritorial Extent of Atherosclerosis in the CVRF-Free PESA Study Population and in the CVRF-Optimal Subgroup
26024	Multivariable Analysis for the Presence and Multiterritorial Extent of Atherosclerosis in the CVRF-Free PESA Population and in the CVRF-Optimal Subgroup With LDL-C Levels<130mg/dl
26025	Summary Results of Sensitivity Analyses
26026	Number of Events, Event Rates per 100 Person-Years, and Hazard Ratios With 95% CIs
26027	Sensitivity Analysis by Mean INR of Warfarin-Treated Patients, Hazard Ratio, and 95% CI Comparing a NOAC With Warfarin  ∗
26028	Two-Dimensional, Doppler, and Speckle-Tracking Echocardiographic Parameters of the 2,996 HyperGEN Participants by ESI
26029	Association of Urinary Sodium With Systolic Strain, Early Diastolic Tissue Velocity, and Estimated LV Filling Pressure on Crude and Multivariable-Adjusted Analyses
26030	Association of Urinary Sodium With Systolic Strain and Early Diastolic Tissue Velocity in Participants With ESI >3.7 g/day on Mediation Analysis
26031	Events and Event Rates in Patients With Renal Indication for Dose Reduction
26032	Events and Event Rates in Patients Without Renal Indication for Dose Reduction
26033	Renal Function
26034	Acute Kidney Injury
26035	Associations of AKI During Index Hospitalization  ∗
26036	Association of APOL1 Risk Alleles With SBP
26037	Association of APOL1 Risk Alleles With DBP
26038	Association of APOL1 Risk Alleles with eGFR  ∗
26039	Overall Treatment-Emergent Adverse Event Incidence and Selected Adverse Events of Interest in Patients With at Least 2 Consecutive Low-Density Lipoprotein Cholesterol Values<25 or<15 mg/dl  (Pooled Safety Population)
26040	Propensity Analysis of the Risk of Certain Adverse Events of Interest in Alirocumab-Treated Patients With 2 or More Consecutive Low-Density Lipoprotein Cholesterol Values<25 mg/dl  (Safety Population; Pool of Phase 3 Studies)
26041	Fat-Soluble Vitamin Levels as Measured in ODYSSEY LONG TERM  (Safety Population)
26042	Correlation Between Low-Density Lipoprotein Cholesterol Determined by BetaQuantification and Calculated by Friedewald Equation
26043	Independent Predictors of PENK Levels
26044	Significant Predictors
26045	Logistic Regression Analysis: In-Hospital Mortality
26046	In-Hospitality: NRI
26047	Newborn Screening for Fabry Disease
26048	Multivariable Associations of Improvement in Exercise Capacity  (Increase in Peak VO2)
26049	Subject Disposition
26050	Blood Measures for Lipids, Diabetes Control, and Markers of Inflammation
26051	MACE
26052	Clinical Criteria for Enrollment
26053	Overall Organ and Tissue Involvement in Mutated Family Members
26054	Univariate Predictors of Death or Delisting DuetoWorsening
26055	Multivariable Predictors of Death or Delisting Due to Worsening in ACHD
26056	Prognostic Factors for Cardiac Amyloidosis
26057	Correlations Between CI and Selected Renal Metrics in MultipleSubgroups
26058	Correlations Between CI and Selected Renal Metrics  ∗
26059	Relationship Between Static Measurements and Changes in CI and WRF
26060	Percentage of U.S. Adults Meeting Each Sequential SPRINT Eligibility Criterion, Overall and in Subgroups
26061	Percentage of U.S. Adults, Overall and With Treated Hypertension, Meeting the SPRINT Eligibility Criteria in Select Populations
26062	Antihypertensive Medication Use Among U.S. Adults≥50 Years of Age and With Treated Hypertension, Overall and Among Those Eligible for SPRINT
26063	Percentage and Number of U.S. Adults With Systolic Blood Pressure≥120 mmHg Without SPRINT Exclusion Criteria
26064	Comparison of Thromboelastography  (ROTEM)  and the GTT, With Respect to Assessment of Thrombosis
26065	Studies From 1999 to 2015 That Utilized Multivariate Analysis in Patient Cohorts >1,000 to Assess the Predictive Value of Plasma Fibrinolysis Markers for Adverse CV Events
26066	Clinical Studies Evaluating the GTT in the Prediction of Cardiovascular Risk
26067	Studies Utilizing TEG in the Evaluation of Platelet Reactivity and its Correlation to the Risk of Ischemic Events in Nonsurgical Cardiovascular Patients
26068	Equations for Estimating GFR and CrCl
26069	Improvement in Model Calibration and Reclassification of Abeta40 Over Best Predictive Model for Endpoints
26070	Complications Associated With CRT-D and ICD Implantation Across CKD Stages
26071	Unadjusted 3-Year Event Rates and Unadjusted and Adjusted Analyses Comparing Outcomes Among CRT-D and ICD Recipients
26072	Within-Day and Between-Week Variation in Cardiac Troponin T Levels
26073	The Individual Diurnal Variation of Cardiac Troponin T Is Significant, as Described by Using a Cosine Curve
26074	Associations of Arterial Stiffness Indices of the Carotid, Femoral, and Brachial Arteries With Incident CV Events and All-Cause Mortality
26075	Associations of the cfPWV, Aix, and SAC With Incident Cardiovascular Events and All-Cause Mortality
26076	Association Between Cardiac Troponin T and Primary Outcomes Using Cox Proportional Hazards Regression Analysis
26077	Prevalence of ECG Criteria Indicative of Acute Myocardial Ischemia in Patients With and Without Elevated cTnT  ∗
26078	New York Heart Association Function Classification
26079	Echocardiography Criteria  ∗
26080	Factors Identified as Precipitating Hospital Admissionin the OPTIMIZE-HF Registry
26081	Echocardiographic Findings at the Time of Presentation in the RO-AHFS Registry
26082	Multivariate Analysis of Risk Factors Associated With the Presence of Atherosclerotic Renal Artery Stenosis
26083	Multivariate Analysis Showing Patient and Procedural Factors Associated With Lower Pre-Discharge GFR, Renal Replacement Therapy, and Longer Operative Length of Stay
26084	Patient and Procedural Factors Associated With Incremental Risk for Death After Open-Heart Surgery
26085	Univariate General Linear Model Showing Independent Predictors of PENK Levels
26086	Cox Regression Analysis for MACE at 2 Years Post-AMI
26087	Cox Regression Analysis for Death and/or MI at 2 Years Post-AMI
26088	Cox Regression Analysis for Death and/or Heart Failure at 2 Years Post-AMI
26089	Cox Regression Analysis for Re-MI at 2 Years Post-AMI
26090	Cox Regression Analysis for Endpoints at 6 Months  (MACE, Death and/or MI, Death and/or HF)
26091	Quality and Process Care Measures for Hospitalized Heart Failure Patients, by Principal Diagnosis
26092	Relationship of Quality and Process Care Measures With 1-Year Mortality Following HF Hospitalization, by Principal Diagnosis
26093	Quality and Process Care Measures for Hospitalized HF Patients for 2 Alternative Definitions of Acute HF, Physician Documentation of HF as Reason for Hospitalization, andARICAdjudicated Acute HF
26094	Univariate Analysis: WRF and Cardiovascular Death and HF Hospitalizations
26095	Multivariable Analysis: WRF and Cardiovascular Death and HF Hospitalizations
26096	WRF and Primary and Secondary Outcomes
26097	Summary of Studies With Data on Prognostic Value of Significant TR After Left-Sided Procedure
26098	Echocardiographic Parameters Used for Grading TR Severity
26099	Echocardiographic Data
26100	Causes of Death
26101	Univariable and Multivariable Cox Regression Analysis for All-Cause Mortality
26102	Clinical 30-Day Follow-Up After Contrast Medium Administration
26103	Multivariable Analysis for CI-AKI Predictors of CI-AKI
26104	Occurrence of CI-AKI in Statin-Naive and Non-Naive Patients
26105	Hemoglobin Levels and Anemia Prevalence in CI-AKI and Non-CI-AKI Patients
26106	Cumulative Incidence of Primary and Additional Endpoints by Treatment Group ∗
26107	Crude and Adjusted Odds Ratio for Primary Endpoint Occurrence in Pre-Specified Risk Subgroups
26108	Adverse Clinical Events at 30 Days by TreatmentGroup
26109	General Linear Model Showing Independent Predictors of ProSP Levels
26110	Cox Regression Analysis for MACE at 2 Years Post-AMI
26111	Cox Regression Analysis for Death and/or Reinfarction at 2 Years Post-AMI
26112	Cox Regression Analysis for Death and/or HF at 2 Years Post-AMI
26113	Cox Regression Analysis for Endpoints at 6 Months  (MACE, Death and/or Reinfarction, Death and/or HF)
26114	Reclassification Analysis Using Continuous Reclassification
26115	Primary Outcome and Major Safety Issues
26116	LDL-Independent Effects of PCSK9
26117	Therapeutic Approaches Targeting PCSK9
26118	Reasons for Hospitalizations
26119	Cox Regression Models  (Unadjusted)
26120	Independent Correlates of CI-AKI After PCI
26121	In-Hospital Complications
26122	In-Hospital Complications and Degree of Hemoglobin Decrease
26123	T1 Indices in Each Age Category
26124	Regression Models for Association of T1 Indices With Age Across Sex  (Regression Coefficients B/p Value)
26125	Candidate Predictor Variables Considered in the Models
26126	Final Model of Predictors of Urine Output
26127	Final Model of Predictors of Urine Output WithTreatment Added
26128	Cox Regression Analysis for the Association Between 30-Day Cumulative Mortality and Clinical Findings
26129	Cox Regression Analysis for the Association Between 1-Year Cumulative Mortality and Clinical Findings
26130	Coronary Artery Calcification  (CAC)  Scores ∗  in the CRIC Genetic Subsample
26131	Top Associations With CAC Traits in CRIC, With Directionally Consistent Associations in PennCAC or AFCS
26132	Association of Top CAC SNPs ∗  With MI in PROMIS
26133	American Diabetic Association 2003 to 2004 Guidelines to Assess Pregnancy at Risk for Gestational Diabetes  ( 16,72 )
26134	Approaches to the Diagnosis of GDM: 1-Step  ( 12 )  and 2-Step Algorithms  ( 14 )
26135	Canadian Diabetes Association Recommended Criteria for Diagnosis of Type 2 Diabetes and Pre-Diabetes  ( 23 )
26136	Studies Examining Vascular Responsiveness in Gestational Dysglycemia
26137	Multivariable-Adjusted Linear Regression Models of Relation of Natriuretic Peptides to Adiposity Phenotypes
26138	In-Hospital Treatment-Related Parameters
26139	Hazard Ratios for All-Cause Death, Combined Endpoints of Death and MI, and Combined Endpoints of Death, MI, and Revascularization According to Biomarker Levels
26140	C-Statistic for Cox Regression Models Predicting Major Adverse Cardiovascular Events
26141	NRI and IDI for Death and MI Using Biomarker Score
26142	Multivariable Cox Models for CV and Renal Outcomes
26143	Distribution of Reduced Model Covariates by CIN in Training Data Set
26144	Model Comparison by Risk Category
26145	Rate of Stroke/TE per 100 Person-Years in All Patients and in Patients With CHADS2 Score = 0 With and Without Renal Impairment
26146	Renal Impairment and Risk of Stroke/TE: Results From Cox Regression Analyses
26147	NRI and IDI by Adding Renal Impairment to the CHADS2 and CHA2DS2VASc Scores
26148	Procedural Data
26149	Ventricular Remodeling and Regional Function by Cardiac MRI, Stratified by BMI and NFG or IFG
26150	Table of Regression Coefficients From a Multivariate Linear Regression Model for LV Mass-to-Volume Ratio
26151	Predictors of Circulating hs-TnI and hs-TnT
26152	Final Multivariate Cox Regression Models for Cardiovascular Death or Congestive Heart Failure
26153	Final Multivariate Cox Regression Models for Myocardial Infarction
26154	Final Multivariable Cox Regressions Models for Cardiovascular Death or Congestive Heart Failure Dichotomized at Sex-Specific 99th Percentile of Healthy Subjects
26155	Risk Associated With Concordant or Discordant Levels of hs-TnI and hs-TnT
26156	C-Index and IDI: Effect of Adding hs-TnI and hs-TnT to Multivariate Models for Cardiovascular Death or Heart Failure
26157	Skeletal Muscle Analysis
26158	Adverse Events and Drug Discontinuation During Titration
26159	Concomitant Medications
26160	Summary of Adverse Events During Randomized Treatment
26161	Summary of Safety Data
26162	Causes of Death During Follow-Up Period
26163	Univariate and Multivariate Predictors of Cumulative Late Mortality
26164	Univariate and Multivariate Predictors of Cumulative Cardiac Mortality
26165	Univariate and Multivariate Predictors of Late  (>30 Days)  Mortality
26166	Cox Regression Model for Mortality Using BF and LMI as Categoric and Continuous Variables
26167	Impact of COPD on Mortality in the Coronary Cohort
26168	Echocardiography Data
26169	Hemodynamics and Aortic Mechanical Properties
26170	Association of FGF-23 With Incident HF, CVD, and All-Cause Death: The Cardiovascular Health Study
26171	Association of FGF-23 With Incident HF, CVD, and All-Cause Death Stratified by CKD: The Cardiovascular Health Study
26172	Distribution of Patients by Renal Function According to the 3 Formulas
26173	Qualitative and Quantitative Correlations Between Methods
26174	HR, AUC, Hosmer-Lemeshow Goodness-of-Fit Test, and BIC for Different Methods Using Cox Models
26175	HR of Sustained Anemia in 1,743 Outpatients With Heart Failure
26176	HRs for Death, MI, Revascularization, and Bleeding According to CKD Subgroup at 30 Months
26177	Death, MI, Revascularization, and Bleeding Rates at 30 Months
26178	HRs for Major CV Events Across Quartiles of Serum Testosterone, SHBG, Free Testosterone, and Estradiol
26179	HRs of Testosterone  (Q4 vs. Pooled Q1 to Q3)  for Major CV Events, First Years of Follow-Up Excluded and Adjustment for Covariates
26180	Multivariate Association Between Level of Renal Function and the Risk for Presentation of CHD as Acute Myocardial Infarction Versus Stable Exertional Angina
26181	Operative and Post-Operative Data
26182	Early and Late Results
26183	Post-Operative Serum Creatinine
26184	Association Among Circulating NT-proBNP, Testosterone, and SHBG
26185	Multivariable Models Assessing the Association Among Sex/Hormone Status, Androgens, and NT-proBNP Concentrations
26186	Subgroup Analysis by Menstrual Phase
26187	Hazard Ratio of Impaired Fasting Glucose Compared With Normoglycemia for the Primary Outcome of Cardiovascular Disease Events and Individual Cardiovascular Disease Outcomes in the MESA Study
26188	Uni- and Multivariable Cox Proportional Hazards Models for Time to All-Cause Mortality
26189	Laboratory Parameters According to Renal Function and Platelet Responsiveness to Clopidogrel
26190	Outcomes According to Platelet Responsiveness to Clopidogrel
26191	Outcomes According to Renal Function and Platelet Responsiveness to Clopidogrel
26192	Outcomes at Follow-Up According to PRI Quartiles in CKD Patients
26193	Univariate Analysis for Prediction of Cardiac Death and MACE in the Whole Population
26194	Multivariate Analysis for the Prediction of Cardiac Death and MACE Following PCI
26195	Hazard Ratios for Mortality for the Individual Biomarkers in Univariate Cox Regression
26196	Hazard Ratios for Mortality in the Multimarker and Adjusted Multimarker Model
26197	Multimarker Risk Score for Mortality
26198	Discrimination of Cox Regression Models in Predicting Mortality in STEMI Patients
26199	RR of All-Cause and Cause-Specific Mortality by 10th to 90th Percentiles of Cys-C Levels and Other Confounding Risk Factors
26200	Cardiorespiratory, Echocardiography, and Muscular Results Before and After 6 Months of Testosterone Supplementation Therapy
26201	Metabolic and Hormonal Results Before and After 6 Months of Testosterone Supplementation Therapy
26202	Events Prevented and Caused by Aspirin Therapy for Every 1,000 Patients Treated According to eGFR Category
26203	Difference in Change in Renal Function During Follow-Up Between Group Randomized to Aspirin and Group Randomized to Placebo, According to eGFR Categories
26204	Clinical Profile of the 2 Groups
26205	Operative and Post-Operative Data
26206	Post-Operative Data
26207	BNP, EF, ANP, and the RAAS After Operation
26208	Unadjusted Rates of CI-AKI According to Pre-Procedural Glucose Level
26209	Occurrence of Monitored Adverse Events, Measured Laboratory Values, and Other Reported Events of Interest During Follow-Up
26210	Participants Categorized by ABI  ⁎
26211	Associations of CKD  ⁎  With High and Low ABI
26212	Association of CKD With High and Low ABI, Stratified by Diabetes Status
26213	Cardiovascular, Renal Hemodynamics, and cGMP-Activating Properties With High-Dose  (33 pmol·kg−1·min−1)  mANP and Native ANP
26214	Cardiovascular, Renal Hemodynamics, and cGMP-Activating Properties With Low-Dose  (2 pmol·kg−1·min−1)  mANP and Native ANP
26215	Cardiorespiratory and Muscular Results Before and After 3 Months of Testosterone Supplementation Therapy
26216	Metabolic and Hormonal Results Before and After 3 Months of Testosterone Supplementation Therapy
26217	Prognostic Value of Biochemical Markers Measured at Different Time Points
26218	C-Statistics: Incremental Prognostic Value of Biochemical Markers Regarding the Composite of Death or Myocardial Infarction During 5-Year Follow-Up
26219	Main Efficacy Analysis: Primary, Secondary, and Additional CIMT Outcomes
26220	Major Cardiovascular Events
26221	Multiple Linear Regression Analysis Assessing the Independent Influence of Different Variables on Natriuretic Peptides
26222	ROC-Derived Optimized Cutoff Values for the Detection of LVEF <40%
26223	Cox Regression Models for the Prediction of Death
26224	Cardiovascular Hemodynamics
26225	Correlations Between GFR and FEs
26226	Relation of Age- and Sex-Adjusted Levels of Resistin and Adiponectin to Each Other and to HOMA-IR, CRP, and BNP
26227	Nested Cox Proportional Hazard Models Testing the Incidence of Heart Failure Across Adipokine Strata
26228	Primary Indication for Heart Catheterization
26229	Multivariate Stepwise Cox Regression Model
26230	Hemodynamic Variables on Admission and Time of PAC in All Patients and Stratified According to Those Who Developed WRF  (n = 58)  and Those Who Did Not  (n = 87)
26231	Cox Proportional Hazards Model Analysis of Factors Predictive of Mortality for the Cohort
26232	Single-Predictor and Multivariable Stepwise Cox Regression Analysis for 24-Month Mortality for Various Clinical Variables
26233	Stepwise Cox Regression Analysis for Predicting Survival Depending on NYHA Functional Class
26234	Renal Hemodynamic and Excretory Response to Infusion of C-Terminus
26235	Neurohumoral Response to Infusion of CD-NP in Normal Dogs
26236	Predictors of New Onset of CHD Events in 2,306 Chinese Men With Type 2 Diabetes With Multivariate Analysis
26237	Selected Safety Outcomes in Patients With CKD and Patients With Normal eGFR by Treatment
26238	Relationship Between Renal Parameters and 6-Month Outcomes
26239	In-Hospital Clinical Outcomes by CKD Agreement Groups
26240	Multivariate Nominal Logistic Regression for Independent Prediction of Anemia
26241	Multivariate Risk Ratios for Independent Prediction of All-Cause Mortality
26242	Odds Ratios and 95% Confidence Intervals by Glucose Subgroup for 4-Year Incidence of CHD According to 1997 and 2003 IFG Definitions
26243	Odds Ratios and 95% Confidence Intervals by Glucose Subgroup for 4-Year Incidence of Cardiovascular Disease According to 1997 and 2003 IFG Definitions
26244	Odds Ratios and 95% Confidence Intervals for 4-Year Incidence of Diabetes Examining the 1997 and 2003 IFG Definitions in Age- and Multivariable-Adjusted Models
26245	Treatment Benefit of Perindopril at Different Levels of Renal Function  (n = 12,056)
26246	Absolute Risk Reduction by Perindopril for the Primary End Point  (n = 12,056)
26247	Data From the EUROPA and PEACE Trials
26248	Change in Echocardiographic Measures Stratified by eGFR Group
26249	Hazard Ratios  (95% CI)  for All-Cause Mortality and/or Hospital Stay for HF Stratified by eGFR Group
26250	Univariate Associations Between Serum Sex Hormone Levels and ABI
26251	Serum Free Testosterone Positively and Independently Associates With ABI, and Estradiol Negatively and Independently Associates With ABI
26252	Low Serum Free Testosterone as Well as High Free Estradiol Independently Associate With Lower Extremity PAD
26253	Univariate Predictors of Primary End Point of Cardiac Mortality and Need for Urgent Heart Transplantation
26254	Predictors of Primary End Point and Cardiac Mortality in Multivariate Cox Regression Analysis
26255	Antibody Response to Treatment and Rate of Plaque Inflammatory Cells
26256	Framingham Probabilities and Event Rates for Men and Women in the CKD and Framingham Derivation Cohorts
26257	Cox Regression Coefficients for the Cohort of Individuals With CKD and for the Original Framingham Cohorts for 10-Year Cardiac Outcomes
26258	Gender-Specific C-Statistics Demonstrating Discrimination for Framingham Functions in Individuals With and Without CKD and in the Original FHS Derivation Cohort
26259	Differential Diagnosis of AIT
26260	Therapy Received for Hyperthyroidism  (n = 84)
26261	Time to Normalization of Thyroid Hormone Values
26262	Duration of Follow-Up and Incidence of the Primary Composite End Point in All Patients and in Patients Stratified According to Left Ventricular Function at the Time of AIT Diagnosis
26263	Surgical Procedures
26264	Number of Patients Receiving Selected Concomitant Postoperative Cardiovascular Medications
26265	Degree of Postoperative Inotropic and Vasoactive Pharmacotherapy
26266	Adverse Events
26267	Quantitation of Infarct Size in Hp 1 and Hp 2 Mice
26268	Myocardial Lipid Peroxidation Products of Arachidonic Acid in Hp 1 and Hp 2 Mice With and Without IR
26269	Spearman Correlation Coefficients Between Hormones and Natriuretic Peptides
26270	Multivariable Associations Between Menopausal Variables, Hormones, and Natriuretic Peptides
26271	Influence of Hormones on the Association Between Body Composition and Natriuretic Peptides  ⁎
26272	Comparisons of Patients With Acute Heart Failure Based on the 60-Day Survival
26273	Multivariate Analysis Using Individual and Combined Measures of Cardiac and Renal Insufficiency for the Prediction of Death by 60 Days Following Presentation With Acute Heart Failure  (HF)
26274	Clinical Laboratory Data of Patients With Acute KD, Comparing IVIG Treatment Responders and Nonresponders
26275	Serum Concentrations of MRP-8/MRP-14 and C-Reactive Protein in Patients With Acute KD, Comparing IVIG Treatment Responders and Nonresponders
26276	Relative Risks of Coronary Heart Disease and Mortality From Cardiovascular Disease in Persons With Chronic Kidney Disease  (CKD)  and Without CKD, With or Without History of Myocardial Infarction  (MI) : the ARIC Study, 1987–2001
26277	Prevalence of Coronary Heart Disease Risk Factors According to Glucose Category
26278	Prevalence of Coronary Heart Disease According to Glucose Category
26279	Relationship Between HOMA-IR and Cardiac Risk Factors
26280	Relationship Between Markers of Oxidative Stress and Inflammation Groups and Carotid IMT
26281	Univariate and Multivariate Linear Model of Transcardiac Increase in Log BNP
26282	Univariate and Multivariate Linear Model of Plasma Log BNP
26283	Group Comparison Between Patients With Chronic Heart Failure Above and Below the Median Insulin Sensitivity Value  (1.82 min−1  · μU · ml−1  · 104)
26284	Univariate Cox Proportional Hazards Analyses in Patients With Chronic Heart Failure
26285	Stepwise Cox Proportional Hazard Analysis in Patients With Chronic Heart Failure
26286	Multivariable Model of Mortality by Six Months
26287	Univariate Correlations  (r)  of Log BNP and Log NT-proBNP With Hemodynamic and Other Parameters in the Overall Cohort  (n = 40)
26288	Univariate Correlations  (r)  for Log BNP and Log NT-proBNP in Patients With eGFR >60 ml/min  (n = 15)  and <60 ml/min  (n = 25)
26289	Hazards Ratio of Future Cardiovascular Events  (n = 112)  According to Prognostic Variables in 639 Patients
26290	Univariate and Age-Adjusted Correlates of Carotid Artery Intima-Media Thickness in 236 Men
26291	Quartiles of Renal Function and Mortality Risk in Elderly Patients With Heart Failure
26292	Multivariate Analysis of Predictors for Developing Cardiac Events
26293	Comparison of Body Weight and Food Intake
26294	Comparison of Blood Chemistry
26295	Oral Glucose Tolerance Test
26296	Comparison of Hemodynamic and Echocardiographic Parameters
26297	Glucose Tolerance Status of the Two Experimental Groups  (p < 0.05)
26298	Univariate and Multivariate Predictors of All-Cause Mortality
26299	Selection Criteria for Renal Artery Angiography
26300	Results of Renal Angiography Categorized by Severity of Renal Artery Stenosis
26301	Prevalence and Severity of Renal Artery Stenosis According to Individual Selection Criteria
26302	Prevalence and Severity of Renal Artery Stenosis According to Cardiac Catheterization Findings
26303	Multivariate Associations With Severe Renal Artery Stenosis
26304	Two-Dimensional and Doppler Echocardiographic Parameters
26305	Effect of Picotamide Administrations on Hemodynamic, Serum, and Urinary Variables
26306	Univariate and Bivariate  (Adjusting for CRP or CAD Score)  Hazard Ratios for Death and/or MI for RI or RF, and Univariate Risk Among Patients With and Without ACE inhibitors at Discharge
26307	Hazard Ratio of Death or Myocardial Infarction in Multivariate Analysis
26308	Multivariable Analysis of CAC and Disease Status
26309	Genotype Frequencies of GCLC−129C/T Polymorphism in Control Subjects and Patients With MI
26310	All-Cause Mortality, ASCVD, De Novo ASCVD, and Recurrent ASCVD Events and Rates, Stratified by Level of Kidney Function
26311	The Association of Level of Kidney Function on ASCVD, De Novo ASCVD, and Recurrent ASCVD
26312	General Echocardiographic Measurements in 55 Female Patients With Anderson–Fabry Disease
26313	Systolic Function in Patients With Increased LVM  (n = 35)  Versus Normal LVM  (n = 20)
26314	Diastolic Function in Patients With Increased LVM  (n = 35)  Versus Normal LVM  (n = 20)
26315	Renal and Humoral Actions of Intra-Renal DNP
26316	Low- and High-Dose NEP Inhibition on DNP
26317	Simple and Partial Correlation Coefficients  (r)  Between Coronary Heart Disease Risk Factors, BMI, and SSPG
26318	Multiple Regression Analysis of the Relationship Between the CHD Risk Factors With BMI and SSPG Jointly, Without an Interaction Term  (Model A)  and With the Interaction Term  (Model B)
26319	Concentrations of Plasma Pteridine Derivatives and Erythrocyte Dihydropteridine Reductase Activity in the Coronary Sinus
26320	Multiple Stepwise Regression Analysis of Variables Significantly Associated With Percent Changes of Acetylcholine-Induced Left Anterior Descending Artery Diameters
26321	Comparison of the Lipid and Lipoprotein Concentrations in the Three Study Groups *  (Mean ± SEM)
26322	Comparison of the Plasma Triglyceride and Remnant Lipoprotein Responses in the Three Study Groups  (Mean ± SEM)  to the Oral Fat Load *
26323	Results of Unadjusted and Adjusted Cox Regression of All-Cause Mortality by Predicted GFR and Hematocrit legend
26324	Standardized ∗ RR for All-Cause Mortality Predicted by Level of GFR and Hematocrit  (Including the Interaction Term)  legend
26325	Prevalence of CAD in the Study Population legend
26326	Multiple Logistic Regression of Determinants of CAD legend legend
26327	Insulin Profiles and Hemostatic Factors in Hypertensive Subjects legend
26328	Multiple Logistic Regression Analysis With All Silent Cerebral Infarcts or Silent Multiple Cerebral Infarcts as the Dependent Variable in Hypertensive Subjects legend
26329	Multiple Logistic Regression Analysis of Silent Subcortical Cerebral Infarcts or Silent Basal Ganglia Infarcts as the Dependent Variable in Hypertensive Subjects legend
26330	Free Radical Scavengers in Plasma, Coronary and Myocardial Tissue, and Susceptibility of LDL for Oxidation in Normal, HC Pigs and HC Pigs that Received Daily Supplementation of a Combination of the Antioxidant Vitamins E and C  (HC + AO)  legend
26331	Cardiovascular Results in AAS Users and Bodybuilding Controls legend
26332	Glucose, Insulin and Lipid Values Before and After Oral Glucose Loading, Alone or With Vitamins legend
26333	Hemodynamics, Basal Brachial Artery Diameters, Brachial Artery Flow and Reactive Hyperemia Before and After Oral Glucose Loading, Alone or With Vitamins
26334	Systemic Markers of Oxidative Stress Before and After Oral Glucose Loading, Alone or With Vitamins legend
26335	Results of 75-G Oral Glucose Tolerance Test, Glycosylated Hemoglobin Levels and Lipid Levels legend
26336	Results of IVUS Measurements
26337	Results of Serial Intravascular Ultrasound Analysis legend
26338	Linear Regression Analysis of Predictors of the Neointimal Index at Follow-up legend
26339	Multiple Regression Analysis of Predictors of the Neointimal Index at Follow-up legend
26340	Oral Glucose Tolerance Test legend legend
26341	Plasma Vitamin C Concentration legend legend
26342	LVEF and Biochemical and Hematological Parameters by NYHA Class in 142 Patients With CHF
26343	Number  (%)  of the 26 Patients Taking Each Type of Medication Before and During the Intervention Period and the Reason Why the Medication Was Not Used legend
26344	Mean Dose of Each Medication Initially and at the End of the Intervention Period in the 26 Patients
26345	The Hematological and Clinical Data of the 26 CHF Patients at Onset and at the End of the Intervention Period legend
26346	Hemodynamic Data and Blood Sampling Data During Oral Glucose Tolerance Test legend
26347	Brachial Arterial Data During Oral Glucose Tolerance Test legend
26348	Glucose Tolerance Status of Cases and Controls
26349	Values That Best Discriminated Myocardial Infarction Cases from Controls
26350	Multivariate Odds Ratios for the Independent Determinants of Myocardial Infarction
26351	Atherosclerotic Indexes in Patients With and Without Restenosis After Percutaneous Transluminal Coronary Angioplasty legend
26352	Oral Glucose Tolerance Test Results in Patients With and Without Restenosis After Percutaneous Transluminal Coronary Angioplasty  legend
26353	Diagnosis of Early Allograft Vasculopathy
26354	Clinical, Angiographic and Scintigraphic Features of 22 Episodes of Vascular Occlusions Detected in 18 Patients and the Response to Augmentation of Immunosuppressive Treatment legend
26355	Clinical Response According to Diagnostic Criteria and the Time of Treatment After Transplantation
26356	Cardiac Medications in Patients in Each Functional Class
26357	Antioxidant Levels and New York Heart Association Functional Class
26358	Comparison of ETaand ETbReceptor–Mediated Renal Functions in Dogs With Heart Failure  a
26359	Clinical Details and Humoral Determinations in 38 Patients With Chronic Heart Failure and 20 Healthy Control Subjects
26360	Insulin and Glucose Metabolism Data Assessed in 38 Patients With Chronic Heart Failure and 20 Healthy Control Subjects
26361	Clinical Details and Measures of Carbohydrate Metabolism in Men With Chronic Heart Failure Due to Coronary Artery Disease or Dilated Cardiomyopathy and in Men With Coronary Artery Disease Without Chronic Heart Failure
26362	Lung and Liver Wet/Dry Weight Ratios in Sham and Infarcted Rats at 1, 4 and 16 Weeks After Operation and Effect of Afterload Reduction Therapy at 16 Weeks
26363	Left Ventricular Pressure in Sham and Infarcted Rats at 1, 4 and 16 Weeks After Operation and Effect of Afterload Reduction Therapy at 16 Weeks
26364	Antioxidant Enzyme Activity and Lipid Peroxidation in Sham and Infarcted Rats at 1, 4 and 16 Weeks After Operation and Effect of Afterload Reduction Therapy at 16 Weeks
26365	Linear Regression Analysis of Morphometric Results for Phase 2 High Molecular Weight Poly-l-Lactic Acid Stents  a
26366	All-Cause, Cardiovascular, and Noncardiovascular Mortality in HFpEF Patients With and Without Abdominal Obesity
26367	Admission and Discharge Medications in HF Patients by EF Groups
26368	Mortality, Readmission, and Composite Outcomes at 5 Years Post-Admission in HF Patients by EF Groups
26369	Hazard Ratios for Different Endpoints per 1 SD Increase of ST2 Level or NT-proBNP Level  (on the Log2 Scale)  at Any Point in Time Using Repeated ST2 and Repeated NT-proBNP Measurements in a Joint Model
26370	Regression Modeling for All-Cause Mortality andtheComposite Endpoint of Mortality and/or HF-Related Hospitalization
26371	Univariable Association for MACE and Death: Clinical Variables
26372	Univariable Association for MACE and Death: CMR Variables
26373	Univariable Association of LGE Parameters for MACE Based on Acuteness of Presentation
26374	Changes in HF Drug Therapy
26375	Unadjusted Mortality and Mortality Adjusted for Absolute Changes in HF Medication Dose Over 6 Months
26376	Major Lipid Classes
26377	Log-Transformed Door-to-Furosemide Time
26378	Logistic Regression Analysis  ∗
26379	Clinical Course of Congestion According to Duration of Heart Failure Diagnosis
26380	Event Rates According to Duration of Heart Failure
26381	Relative Risk of Study Endpoints According to Duration of HF Diagnosis  (Referent Group= Recently Diagnosed, 0 to 1 Month)
26382	Outcomes Related to Glucose Control at 6 and 12 Months
26383	Drug Use Within 120 Days
26384	Downstream Testing, Revascularization, and Costs Within 120 Days
26385	No Enrichment of Variations in TLR3- or IFN-α/β-Related Genes in Patients With AM
26386	Enrichment of Homozygous Rare Variations in Cardiomyopathy-Associated Genes in Patients With AM
26387	Incidence of Aortic Stenosis Accounting for Competing Risks, Stratified by Age, Sex, and Risk Factors  (per 100,000 Person-Years)
26388	Estimates of the Adjusted Hazard Ratios for Severe Aortic Stenosis in Prediction Models for All Individuals, Men, and Women
26389	Population-Attributable Risk of Aortic Stenosis by Cardiovascular Risk Factors
26390	Primary Endpoint Events at 6 Months  (Intention-to-Treat Analysis)
26391	Secondary Endpoints at 6 Months
26392	Changes in Likert Numerical Dyspnea Score  ∗
26393	Renal Function
26394	Clinical Outcomes
26395	Patients With Adverse Events  ∗
26396	Frequency of Valvular Heart Disease Subtypes in Patients Randomized in RE-LY, ROCKET AF, ARISTOTLE, and ENGAGE AF-TIMI 48 Trials
26397	Entry Criteria as Met by Trials Comparing Calcium Channel Blockers With Conventional Therapy
26398	Stroke: Calcium Channel Blocker-Based Therapy Versus Conventional Therapy of Hypertension
26399	Myocardial Infarction, Heart Failure and Major Cardiovascular Events: Calcium Channel Blocker-Based Therapy Versus Conventional Therapy of Hypertension
26400	Diabetic Hypertensive Therapy Based on Calcium Channel Blockers and Angiotensin-Converting Enzyme Inhibitors
26401	Echocardiographic Change of LV and LA Dimension
26402	Independent Predictors for LVEF at 6 Months and Change in LVEF
26403	Pooled Relative Risk of Efficacy and Safety Outcomes With Intensive Versus Standard BP Lowering in Elderly Patients
26404	Unadjusted and Adjusted Association Between Appropriateness of NOAC Dosing and Clinical Outcomes
26405	Descriptive Analysis of Causes of Death as Total Numbers and as Percentage of Total Deaths
26406	Descriptive Analysis of Causes of Death and Adjusted Event Rates per 100 Patients per Year  (All Study Patients, Regardless of TreatmentGroup)
26407	Absolute Difference in Events per 10,000 Patients Treated per Year for the Different Cause-Specific Deaths  ∗
26408	Echocardiographic Analysis
26409	CMR Results and Patient Clinical Outcomes
26410	CMR Results and Univariate Predictors of Events
26411	Net Reclassification Analysis
26412	CMR Results and Univariate Predictors of Events in High-Risk Patients
26413	Outcomes: Incidence Rates and Hazard Ratios
26414	Patient Selection Criteria
26415	Safety Data 30 Days and 6 Months After the Procedure
26416	LV Indices 6 Months After the Procedure and p Values for Paired Data
26417	Changes in MV Geometry and MR Grading After Annuloplasty
26418	Change in Primary and Secondary Outcome Variables in VINDICATE at 12Months Post-Randomization: Intention-to-Treat Population
26419	Clinical Endpoints, Serious Adverse Events, and Hospitalizations
26420	Mitral Valve Configuration and Echocardiographic Parameters
26421	Echocardiographic Parameters Before and 1, 2, and 5 Years After Surgery
26422	Comparison of Echocardiographic Parameters, QOL, and Functional Status After 5 Years of Follow-Up
26423	Previous Diagnoses and Treatments
26424	Secondary Endpoints
26425	Adverse Events
26426	Change in Mean Systolic and Diastolic Ambulatory Blood Pressure Levels
26427	Changes in Ambulatory Daytime Mean SBP and DBP
26428	Changes in Ambulatory Nighttime Mean SBP and DBP
26429	Adverse Events Reported During Treatment
26430	Metabolite Levels and Hemodynamic Indexes of RV-PV Function
26431	IDO-TM and Hemodynamic Measurements in Adjusted Models
26432	Validation Cohort: Metabolite Levels and RV-PV Function
26433	Variables Predicting the Presence of RV-PV Dysfunction
26434	Clinical Inputs Derived From Meta-Analyses and Pivotal Trials
26435	Stroke Outcomes and Health State Utilities
26436	Cost Inputs
26437	QALY and Cost Results at 5, 10, 15, and 20 Years
26438	Overall Survival Estimate Post–Fontan Operation
26439	Overall Survival Post–Fontan Operation
26440	Late Survival  ∗   Post–Fontan Operation
26441	Late Survival Post–Fontan Operation
26442	Risk of Death or Cardiac Transplant
26443	Risk of Death or Reoperation
26444	Risk of Developing PLE Post–Fontan Operation
26445	Procedural Data
26446	Primary Adverse Events
26447	MOGE (S)  Classification  ∗
26448	Examples of MOGE (S)  Annotations in Patients With DCM
26449	Association of Variables With Combined Endpoint  ∗
26450	Multivariate Logistic Regression Models
26451	HIPARCO-Score to Estimate Favorable BP Response
26452	Efficacy Endpoints for the PEGASUS-TIMI 54 Trial
26453	A Summary of Key 1- and 5-Year Findings From the SYNTAX Trial
26454	Efficacy Results From the EMPHASIS-HF Trial, With and Without Covariate Adjustment
26455	Primary Endpoint Event Rates by Risk Group and Treatment in the EMPHASIS-HF Trial
26456	CONSORT Checklist of Items to Include When Reporting a Randomized Trial
26457	Anatomical Locations of GI Bleeding Events
26458	Overall Rates of GI Bleeding by Treatment Arm
26459	Study Drug, Antiplatelet Therapy Use Relative to GI Bleed Events
26460	Predictors of GI Bleeding  (Major or NMCR)
26461	Geographic Variation in GI Bleeding Rates and Treatment Effect
26462	Updated Classification of PH  ∗
26463	Checklist for the Echocardiographic Evaluation of PH
26464	High Risk Factors
26465	Summary of Pharmacological Treatment of Hypertension in the Management of Ischemic Heart Disease
26466	Summary of BP Goals
26467	Writing Group Disclosures
26468	Reviewer Disclosures
26469	Safety at 6- and 12-Month Follow-Up
26470	CHA2DS2-VASc Risk Factor Components of AF Patients
26471	Risk of Ischemic Stroke in AF Male Patients  (CHA2DS2-VASc Score of 1)
26472	Risk of Ischemic Stroke in AF Female Patients  (CHA2DS2-VASc Score of 2: Female Plus 1 Additional Stroke Risk Factor)
26473	Changes in LVEF During Follow-Up
26474	Mortality and Appropriate Shock
26475	Incidence Rate of Appropriate Shock by Last LVEF Measurement Before Appropriate Shock
26476	Aortic Dilation Rate During Follow-Up and Association With Type B Aortic Dissection
26477	Multivariable Cox Regression Analysis for Risk of Composite Primary Endpoint and Cardiovascular Death
26478	Measurements of Performance of the Models for the Composite Endpoint of Cardiovascular Death and HF Hospitalization and for Cardiovascular Mortality at 4 Years
26479	Multivariable Predictors of Exercise Capacity
26480	Reproducibility of Myocardial Deformation Parameters
26481	Periprocedural Details, Discharge Medication, and Ischemia Testing
26482	Clinical Outcomes at 12 Months
26483	Cox Regression Models Showing the Hazard Ratio of ESVEA in Relation to Stroke and Death or Stroke, Where Subjects are Censored at the Time of Atrial Fibrillation
26484	Cox Regression Models Showing the Hazard Ratio of ESVEA in Relation to Stroke and Death or Stroke, Where Atrial Fibrillation is Modeled as a Time-Varying Exposure
26485	Number of Strokes per 1,000 Person-Years in Relation to ESVEA and AgeGroups
26486	Structure, Function, and Ischemia Evaluation
26487	Invasive Hemodynamics
26488	Multivariable Analysis for Independent Predictors of Survival in HFpEF Patients  (Cox Proportional Hazard Model)
26489	Multivariable Analysis for Independent Predictors of Survival in HFpEF Patients With CAD  (Cox Proportional Hazard Model)
26490	Comparison of Procedural Variables Between Patients on Rivaroxaban and Warfarin
26491	Comparison of Complications between Rivaroxaban and Warfarin
26492	Event Rates and HRs and 95% CIs for Bleeding Events
26493	Major Bleeding or Nonmajor Clinically Relevant Bleeding by Site
26494	HAS-BLED Score in ROCKET AF Trial and Original HAS-BLED Cohort
26495	ATRIA Score in ROCKET AF Trial and Original ATRIA Cohort
26496	Multivariable Model Predicting Major Bleeding intheROCKET AF Cohort
26497	Univariable and Multivariable Cox Regression Models for 30-Day and 1-Year Post-Discharge Mortality Among Patients With Acute HF
26498	Prevalence of PDD
26499	Natural History of PDD and Subsequent Progression to Symptomatic HF
26500	CHADS2 Scores
26501	Results of Large RCTs of New Anticoagulants Versus Warfarin
26502	Efficacy and Safety Results at 2.3-Year Follow-Up of the PROTECT-AF Trial
26503	5- and 10-Year Unadjusted Event Rates for Those With and Without AP
26504	AP as a Predictor of Outcome on Adjusted Analysis
26505	Observed Rates and Number of Events for Efficacy and Safety Endpoints in Patients With Amiodarone and No Amiodarone at Randomization andbyStudyDrug Assignment
26506	Observed Rates and Number of Events in Patients Included in the Propensity-Matched Analysis  ∗
26507	Analysis of Ambulatory Blood Pressure and Heart Rate Variability
26508	Univariate Analysis: Variables Related to Collateral Flow
26509	Univariate Analysis: Coronary Angiographic Data and Collateral Channel Assessment
26510	Management and Clinical Outcomes
26511	Change in MRI Parameters Over the 9-Month Study Period
26512	Changes in Measured Parameters Analyzed as Subgroups Above and Below Median LVM
26513	Changes in Measured Parameters Analyzed as Subgroups Above and Below Median LVMI
26514	Change in Blood Parameters Over the 9-Month Study Period
26515	Changes in Parameters of Endothelial Function, Blood Pressure, and Body Mass Index
26516	Summary of Applications and Limitations of Doppler Parameters in Patients With ValvularHeart Disease
26517	Symptoms and Signs Stratified by Age
26518	Investigative Findings Stratified by Age
26519	Clinical Presentation, Precipitating Factors, and Treatment Related to Unplanned Hospitalization for Heart Failure Occurring After Randomization
26520	Kaplan-Meier Mortality Rates for Each Age Category
26521	Summary Statistics for Echocardiographic Measurements by NYHA Functional Class
26522	Associations Between Echocardiographic Parameters and Risk of All-Cause Mortality, Cardiac Transplantation, or VentricularAssist Device Implantation
26523	Associations Between Echocardiographic Parameters and Risk of Cardiac Hospitalization
26524	Mechanisms and Markers of DM-Related Endothelial Dysfunction
26525	Agents Interfering With Endothelial Dysfunction in Diabetes Mellitus
26526	Important Biomarkers in Diabetes Mellitus
26527	AR and Excess Risk of Cardiac Mortality in Hodgkin’sDisease Survivors
26528	Effects of Radiation Therapy on the Heart
26529	Risk Factors for Radiation-Induced Cardiotoxicity
26530	Safety Evaluation
26531	Clinical Outcomes
26532	Quantitative Myocardial Perfusion and CAC
26533	Cause of Death and Cardiac Events by Groups of CAC and CFR
26534	Multivariable Survival Analysis
26535	Incidence of ECV, PCV, and AF Ablation
26536	Multivariable Model of Factors Associated With the Utilization of ECV, PCV, or AF Ablation
26537	Multivariable Model of Factors Associated With ECV or PCV
26538	Association Between ECV/PCV/AF Ablation and Outcomes
26539	Outcomes After ECV, PCV, or Catheter Ablation According to Randomized Treatment
26540	Outcomes after ECV, PCV, or Catheter Ablation Among Those Taking Study Drug on the Day of Procedure
26541	Unadjusted and Adjusted HRs for 180-Day All-Cause Mortality
26542	Efficacy Endpoints
26543	Safety Endpoints
26544	Diagnostic Performance of Key Indexes of Steady and Pulsatile Arterial Function and of Echocardiographic Measurements
26545	Univariable Logistic Regression Models Differentiating Between HFPEF and No HFPEF Patients
26546	Multivariable Logistic Regression Model Differentiating Between HFPEF and No HFPEF Patients
26547	Combined Approach to Diagnose or Exclude HFPEF
26548	Comparisons of Responses to LBPP Between Obstructive-Dominant and Central-Dominant Groups
26549	Multivariate Analysis of the Factors Associated With 30-Day Mortality in a Fully Adjusted Model
26550	30-Day Mortality Hazard Ratio in Various Clinically Relevant Subgroups
26551	Sensitivity Analyses
26552	Rate Control Targets and Drug Therapy at End of Dose-Adjustment Phase
26553	Cumulative Incidence of Composite Primary Outcome and Its Components
26554	Heart Rate During Follow-Up and Left Ventricular Ejection Fraction at End of Study
26555	Symptoms of AF at End of Study
26556	Patient-Specific Factors Stratified by Participation
26557	Trial-Specific Factors Stratified by Participation
26558	Transitions to Open-Label Vitamin K Antagonist or Aspirin Within 30 Days After Study Drug Early Study Drug Discontinuation and Study Completion  ⁎
26559	Stroke or Non–Central Nervous System Embolism Rates and Stroke, Non–Central Nervous System Embolism, Myocardial Infarction, or Vascular Death During Post–Study-Drug Discontinuation Risk Period  ⁎
26560	Discontinuation Events: Major Bleeding Occurring During Post–Study-Drug Discontinuation Risk Period  ⁎
26561	Risk for CHD Among ART-Treated HIV-Infected Patients
26562	Main Classes of Antiretrovirals and Their Impact on Lipid and Glucose Metabolism and CHD
26563	Spectrum of Cardiovascular Risk Factors in Several Studies Including HIV-Infected Patients With ACS
26564	Angiographic and Revascularization Features of CHD in HIV-Infected Patients
26565	Clinical Studies Published on CABG Surgery in HIV-Infected Patients
26566	Interactions Between Lipid-Lowering Drugs and ART
26567	Medication Profile at Randomization and at Discharge
26568	Reasons for Early Discontinuation of Study Treatment
26569	Clinical Outcome Rates Among Participants Groups Based on Site Enrollment Status
26570	Summary of Median SSS and SRS Among Readers by Number of Vessels With Coronary Stenosis
26571	Summary of SDS in Patients With Angiography-Positive Results
26572	Summary of SDS in Patients With Angiography-Negative Results
26573	Prognostic Value of Individual Elements of the 1-Week Follow-Up Examination
26574	Precipitating Factors and Multivariate Risk-Adjusted In-Hospital Clinical Outcomes
26575	General Considerations Regarding Gaps in Transitions of Care in Heart Failure
26576	Components of Early Post-Discharge Follow-Up
26577	Factors Associated With All-Cause Mortality
26578	Causes of Death
26579	Factors Associated With New-Onset Cardiomyopathy
26580	Results of ROC Analysis With Selected Cutoff Points of Variables Predicting LVRR
26581	Comparison of Individuals With and Without LVRR at 3 and 6 Months of FU
26582	AUC Calculated for Combinations of Independent Predictors of LVRR Using Logistic Regression
26583	Clinical Presentation
26584	Use of Stress Testing and Calcium Scores and Coronary CT Angiography
26585	Diagnostic Procedure Findings and Recommendations
26586	Procedure-Related Complications in Patients Without STEMI
26587	STEMI Quality Metrics and PCI Complications
26588	Univariate Correlations Between Left Ventricular Global Longitudinal Strain and Clinical and Echocardiographic Indices
26589	Univariate and Multivariate Cox Proportional Hazards Analysis
26590	Rates of HPR in LBW and HBW Patients Treated With Prasugrel 5 or 10 mg or Clopidogrel 75 mg
26591	Bleeding Events Related to Study Drug in LBW and HBW Patients Treated With Prasugrel 5 or 10 mg or Clopidogrel 75 mg
26592	Hemodynamic and Pulse Wave Analysis Parameters in Patients With Office SBP Reduction Above or Below the Median of 18 mm Hg at 1 Month After Renal Denervation
26593	Cardiovascular Events in Patients With HFNEF With Low or High RHI
26594	Cox Proportional Hazards Analysis for Future Cardiovascular Events in Patients With HFNEF
26595	C-Statistics for Cox Proportional Hazards Analysis to Predict Future Cardiovascular Events in Patients With HFNEF
26596	Reclassification of Risk of PF5 for Cardiovascular Events After Addition of RHI
26597	Pathobiological Classification of Types of Potential Mechanisms Causing Elevations of Cardiac Troponin
26598	Acronyms
26599	Bleeding Academic Research Consortium Definition for Bleeding
26600	Net Changes in Spending During Follow-up After Elimination of Copayments for Drugs Post-MI  ( 98 )   ⁎
26601	Composition of Derivation and Validation Cohorts
26602	HRs and CIs for Complete Model Covariates
26603	HRs and CIs for Abbreviated Model Covariates
26604	Univariate and Multivariate Analysis in Normotensive and Pre-Hypertensive Subjects Not on Antihypertension Medications
26605	Univariate Analysis of Biomarkers and Stage of Hypertension
26606	Univariate and Multivariate Analysis in Normotensive and Pre-Hypertensive Subjects
26607	Cardiac Events in the 2 Groups
26608	Top Drug-Induced Arrhythmia Associated SNPs  (p < 0.01)  in the Group of 27 Amiodarone Users, the Group of 15 Sotalol Users, and the Whole Group of 58 Case Subjects Compared With 87 Control Subjects
26609	Top Drug-Induced Arrhythmia Associated SNPs  (p < 0.01)  Corrected for QTc Interval in the Group of 19 Amiodarone Users, the Group of 13 Sotalol Users, and the Whole Group of 44 Case Subjects Compared With 74 Control Subjects
26610	Top SNPs From the DARE Cohort  (p < 0.05)  Associated With the Continuous QTc Interval in 74 Control Subjects Ordered According to Their Significance Together With the Results of the BRIGHT Cohort  (n = 1,480)  and of the Meta-Analysis of the 2 Cohorts
26611	Summary of the Main Clinical Trials Involving Novel Anticoagulants for Stroke Prevention in Nonvalvular AF
26612	Weighted Average Effects of New OAC Versus Warfarin
26613	Indirect Comparison Using Warfarin as Single Common Comparator, on the Basis of the RE-LY, ROCKET-AF, and ARISTOTLE Trials
26614	Guidelines and Scientific Statements
26615	State-of-the-Art Reviews
26616	Key Clinical Trials in Heart Failure From Academic Year 2010–2011
26617	Evidence Grading
26618	Published Recommendations for Testing for CAD in Asymptomatic Kidney Transplantation Candidates
26619	Summary of Survey and Registry Data Demonstrating Variation in Cardiac Evaluation Practices Across U.S. Transplantation Centers
26620	Recent Descriptions of the Outcome Implications of Angiographic CAD in Patients With ESRD, Including Transplantation Candidates
26621	Accuracy of Noninvasive Testing for Detection of Coronary Artery Stenosis in End-Stage Renal Disease Patients
26622	Summary of Recent Studies of Associations of Cardiac Biomarkers With Clinical Outcomes in Kidney Transplantation Candidates and Recipients
26623	Revascularization to Improve Survival Compared With Medical Therapy
26624	Recommendations from the 2007 AHA/ACC/SCAI/ACS/ADA Science Advisory on the “Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery Stents”  ( 159 )
26625	Summary of Published Randomized Clinical Trials of Statin Therapy in Dialysis Patients
26626	Summary of Published Randomized Clinical Trials of Statin Therapy in Kidney Transplantation Recipients
26627	Proposed Randomized Controlled Trials in Kidney and Liver Transplantation Candidates
26628	Writing Group Disclosures
26629	Reviewer Disclosures
26630	Abbreviations
26631	Sources of Pharmacogenetic Variation
26632	Main Genetic Associations With the Response to Statins
26633	Main Genetic Associations With the Response to Clopidogrel
26634	CYP2C19 Diplotype Classification  ⁎
26635	Main Genetic Associations With the Response to Warfarin
26636	Main Genetic Associations With the Response to Beta-Adrenergic Receptor Antagonists
26637	Respiratory Measurements
26638	Effects of the Clinical Algorithm Compared With Control on Primary and Secondary Outcomes Among High-Risk Individuals
26639	Agreement Between Nonphysician and Physician Healthcare Workers Using the Algorithm
26640	Effects of Health Promotion Compared With Control on Primary and Secondary Outcomes in Adults Age 30 Years or Older
26641	Characterization of the HAART
26642	Outcomes of the Lipid Profile Before, During, and After the Nutritional Intervention
26643	Changes in Functional Parameters and Laboratory Parameters With UDCA Treatment
26644	Sex-Adjusted Blood Pressure, Vascular, and Cardiac Geometry Parameters
26645	Sex-Adjusted Doppler Echocardiography Parameters
26646	Sex-Adjusted Hemodynamic, Cardiac, and Vascular Function Parameters
26647	Sex-Adjusted Matrix Correlation Between Maximum Workload During Exercise or 6-Min Walking Test and Hemodynamic Parameters
26648	Risk of Primary Study Outcome and Other Outcome Events According to SBP at Entry  (First Visit)
26649	Clinical and Echocardiographic Parameters at 6-Month Follow-Up in Responders and Nonresponders to CRT-D
26650	Cox Proportional Hazard Ratio Model to Predict Appropriate ICD Therapies
26651	Cox Proportional Hazard Ratio Model to Predict Appropriate ICD Shocks
26652	Procedure-Related Complications
26653	Survival Rate After Alcohol Septal Ablation
26654	Multivariable Predictors of Death
26655	Multivariable Predictors of Death or Repeat Septal Reduction Therapy
26656	Clinical Events
26657	Continuous and Prevalence of Categorical Patient Variables Significantly Different From the EVEREST II Study
26658	Cox Regression Analyses for Death, Cardiac Rehospitalization, or Reintervention
26659	Procedural Data
26660	Short-Term Clinical Outcomes
26661	Mid- and Long-Term Clinical Outcomes
26662	Predictors of All-Cause Mortality at 30 Months
26663	Echocardiographic and Humoral Assessment After Volume Expansion and Placebo or BNP Treatment
26664	Relationship Between the K-Sparing Effect and the Crude Event Rates
26665	Cardiorespiratory and Metabolic Responses to Maximal Normoxic Cycle and KE in Patients With CHF and in Controls
26666	Arterial and Venous Epinephrine, Ne, and Calculated Ne Spillover From the Muscle During Maximal Cycle and KE in Controls and Patients With CHF
26667	Relative Change in Measures of Aortic Geometry With Age: Comparison of Young  (Age <30 yrs)  and Older Subjects  (Age >70 yrs)
26668	Relationships Between Measures of Aortic Geometry and LV Mass and Geometry Adjusted for Age, Sex, Height, Weight, and Central SBP
26669	Iron Status
26670	Implant Details
26671	Responders and Hemodynamic Response Depending on LV Lead Position
26672	Sensitivity and Specificity for 10% Rise in LV-dP/dtmax for LV Pacing and Standard Echocardiographic Measures of Dyssynchrony Predicting 15% Reduction in ESV
26673	Sensitivity, Specificity, and AUC for 15% Reduction in ESV
26674	Differences in Hemodynamic and Chronic Response Between DCM and ICM
26675	Detection of Coronary Artery Disease by Cine, Visual, and Quantitative SENC
26676	Echocardiographic Parameters According to Randomization Strategy
26677	Echocardiographic Parameters According to Resting Heart Rate During All Follow-up Visits After the Dose-Adjustment Phase
26678	Echocardiographic Parameters in Patients With Heart Rate >110 Beats/Min During at Least 1 Follow-up Visit
26679	Clinical Factors Associated With Changes in Echocardiographic Parameters
26680	Effect of Allopurinol and Placebo on Endothelial Function, Serum Urate, and Serum Biomarkers
26681	Incidence of PPCM in the United States
26682	Outcomes of Patients With PPCM in the United States  ⁎
26683	Supine Resting Echocardiographic and Doppler Measures
26684	Cardiopulmonary Exercise Performance
26685	Predictors of Peak Oxygen Consumption
26686	Studies of Determinants of Exercise Intolerance in HFPEF
26687	Cox Analysis for the Composite of Cardiovascular Events  (Stroke, Acute Coronary Syndrome, Acute Heart Failure)
26688	Cox Regression Analysis for All-Cause Mortality
26689	Multivariate Cox Analysis for Cardiovascular Death
26690	Cox Analysis for the Composite of Major Hemorrhagic Events
26691	Additive Value of vWF Levels to CHADS2 and CHA2DS2-VASc Scores for the Composite of Thrombosis and Mortality
26692	Additive Role of vWF Levels to HAS-BLED Score for Hemorrhagic Events
26693	Event Rates *
26694	Estimated Risks * for Patients Taking PSDs Relative to That for Patients Taking Only Non-PSDs
26695	Study Design
26696	Clinical Outcomes
26697	Stent Thrombosis
26698	Post-Operative Outcomes
26699	Univariate and Multivariate Analysis for Predictors of the Late Post-Operative SVEF
26700	Univariate Cox Regression Model to Predict Post-Operative Mortality or Need for Cardiac Transplantation  (n = 58)
26701	Individual Components of Secondary Efficacy Endpoint of Persistent WRF
26702	Univariable and Multivariable Predictors of Persistent WRF
26703	Effect of Therapy on Mortality, Diastolic Function, and Exercise Capacity
26704	Change in Clinical Risk Factors, Medical Treatment, and Incurred Costs
26705	Change in Clinical Risk Factors, Medical Treatment, and Incurred Costs According to CAC Score
26706	Comparison of No-Scan Subjects and Scan Subjects With a CAC Score of 0
26707	Events in the Patients With LVRR at Mid-Term Follow-Up Compared With the Other Patients on Long-Term Follow-Up  ⁎
26708	Incremental Prognostic Role of LVRR, NYHA Functional Classes III to IV, and Moderate to Severe MR at Mid-Term Follow-Up  (Model 2)
26709	Pharmacodynamic Studies That Evaluated the Administration of Clopidogrel to Subjects Receiving Atorvastatin
26710	Pharmacodynamic Studies That Evaluated the Administration of Clopidogrel to Subjects Receiving Proton Pump Inhibitors
26711	Clinical Studies That Reported the Coadministration of Clopidogrel and Atorvastatin
26712	Clinical Studies That Evaluated the Coadministration of Clopidogrel and Omeprazole
26713	Measures of Risk Factor Control in Patients With and Without PAD
26714	Measures of Atheroma Burden and Vessel Wall Dimensions in Patients With and Without PAD
26715	Peripheral and Central Hemodynamic Parameters
26716	Simple Correlations Between Arterial Stiffness and Diastolic Function in Both Sexes
26717	Independent Correlation Between Arterial Stiffness and Diastolic Function in Men and Women
26718	Causes of Death
26719	Relationship of Adiponectin to CAD and ACS
26720	Effect of Adiponectin on Atherosclerosis and the Vulnerable Plaque
26721	Interventions That Increase Adiponectin Levels
26722	Risk of Death or Heart Failure by Sex
26723	Logistic Regression Analysis of Clinical Factors for the Presence of HFNEF Among Patients With Normal LVEF
26724	Logistic Regression Analysis of the Factors for the Presence of HFNEF Among Patients With LVDD and Normal LVEF
26725	Echocardiographic Parameters in Heterozygous Plako+/– and WT Mice Before and After Training Without and With Pre-Load–Reducing Therapy
26726	Electrophysiological Parameters of WT, Trained Treated, and Trained Untreated Heterozygous Plako+/– Mice
26727	Risk Associated With CCB Treatment
26728	Risk Associated With CCB Treatment
26729	In-Hospital Medications, Medications at Discharge, and In-Hospital Procedures by Years of Education
26730	Clinical Outcomes by Years of Education
26731	Relationship Between Years of Education and 1-Year Mortality Rates by Enrolling Country
26732	Independent Correlates of 0- to 7-Day and 8- to 365-Day Mortality Derived Using Cox Proportional Hazard Model
26733	Secondary Outcome Measures
26734	Response to Elevated NT-proBNP Levels During Follow-Up
26735	Use of Evidence-Based HF Medication at the Index Admission, Discharge, and During Follow-Up
26736	Number of Increases of HF Medication During Follow-Up
26737	Changes in NT-proBNP, Urea, and Creatinine Levels During Follow-Up
26738	Time-Dependent HR if the Outpatient NT-proBNP Level Is Above the Individually Set Target Value
26739	Regression Outcomes Predicting Changes in CTX-I to 10 nmol/l Response to Exercise With BDI and NE as Potential Moderators
26740	Correlation Coefficients Among Variables
26741	Mechanism of Action of Diuretic Classes
26742	Summary of Reviewed Studies in Heart Failure Patients
26743	Potential Benefits and Adverse Effects of CDT
26744	Important Considerations Regarding CDT
26745	Dosing and Duration of Action of TD
26746	Effects of Ranolazine  (5 μmol/l) , Dronedarone  (10 μM) , and Their Combination on Atrial Excitability and Induction of ACh-Mediated Persistent AF in the Isolated Canine Coronary-Perfused Right Atria
26747	Effects of Ranolazine  (5 μmol/l) , Dronedarone  (10 μmol/l) , and Their Combination to Terminate Persistent ACh-Mediated AF and Prevent Its Reinduction in the Isolated Canine Coronary-Perfused Right Atria
26748	Blood Pressure Results, Mean Change  (Δ)  Presented for Office and Ambulatory Readings
26749	Effects of Ranolazine on Heart Rate and Systolic Blood Pressure at Each Stage of Exercise
26750	Effects of Ranolazine on Rate Pressure Product and Change From Pre-Exercise in ST-Segment Depression at Each Stage of Exercise
26751	Effects of Ranolazine on Change From Pre-Exercise in ST-Segment Depression at Each Stage of Exercise Controlled for Rate-Pressure Product
26752	Composite Cardiovascular Score
26753	Fatal and Nonfatal Events Through 12 Weeks
26754	Serious Adverse Events by Treatment Group at 12 Weeks
26755	Nonfatal Cardiovascular Events During Long-Term Follow-up
26756	Risk of Death and Cardiac Events Among Patients With Chronic Organic MR in Sinus Rhythm Under Medical Management
26757	Drug/Device Effects of Mortality Compared With Placebo in Patients With Heart Failure and LVD
26758	Absolute Effect of Drug/Device on Change in EF Compared With Placebo
26759	Absolute Effect of Drug/Device on Change in EDV Compared With Placebo
26760	Absolute Effect of Drug/Device on Change in ESV Compared With Placebo
26761	Trends in Medication Use Before and After a First Hospitalization for Heart Failure in the VA Health Care System
26762	Trends in Procedure Use and Outcome for Patients With a First Hospitalization for Heart Failure in the VA Health Care System
26763	sAM Levels Taken on Admission and Discharge and NT-ProBNP Levels Across Different Patient Groups
26764	Multivariate Cox Regression Analyses Comparing Admission sAM, GRACE Score, and NT-proBNP for Prediction of Death at 1 Month, 6 Months, and Extended Follow-Up
26765	Improvement in Identification of Event-Free Patients and Those Who Died by Day 30 Using Admission sAM Levels in Addition to GRACE Score Tertiles Using Reclassification Analysis
26766	CEAP Classification
26767	Univariate and Multivariate Predictors for Severe CVI in Fontan Patients
26768	Comparison of Hypertension Treatment Steps in Patients With Diabetes
26769	24-h Systolic Blood Pressure Averages in Patients With Diabetes
26770	Cardiovascular, Stroke, and Renal Outcomes in All Patients With Diabetes
26771	Cardiovascular, Stroke, and Renal Outcomes in Patients With High-Risk Diabetes
26772	Cardiovascular, Stroke, and Renal Outcomes in Patients Without Diabetes
26773	Adverse Events During Treatment in Patients With or Without Diabetes
26774	Metabolic and Renal Measurements During Treatment in Patients With Diabetes
26775	Membrane Capacitances
26776	Twitch Parameters of Trabeculae From Patients in Sinus Rhythm
26777	Cardiovascular Events and Changes in Measures of Coronary Atheroma Burden in Each Study, Stratified According to Treatment Group
26778	Multivariate Model With Risk Factors Associated With Major Adverse Cardiovascular Events, Controlling for Study
26779	ARR Deciles and Mean Peripheral and Central  (Aortic)  BP Measurements After Adjustment for Important Confounders
26780	Multivariate Stepwise Regression Analysis to Identify Predictors of BP
26781	Acute Heart Failure Diagnostic Performance of MR-proANP Cut at 120 pmol/l and BNP Cut at 100 pg/ml
26782	Additive Value of MR-proANP in “Gray Zone” Areas for Logistic Regression Models to Predict Acute Heart Failure
26783	Multivariable Diagnosis Models With BNP and MR-proANP
26784	Summary of Predictive Performance for BNP, NT-proBNP, and MR-proADM for Predicting All-Cause or Cardiovascular Death, Rehospitalization, Revisit, or Any of the Previous Events at 90, 30, and 7 Days After Initial Presentation to ED
26785	Single Predictor and Multivariable Cox Proportional Hazard Models for Survival Among Patients With Acute Heart Failure  (n = 568)
26786	Clinical Features of the Study Patients and Genotype-Positive Family Members
26787	Risk Factor Goals in the COURAGE Trial
26788	Pharmacologic Therapy in the COURAGE Trial
26789	Serial Changes in Blood Pressure
26790	Outcome for Adjudicated Major Cardiovascular Events
26791	Results of Serial Volumetric IVUS
26792	Results of a Multiple Linear Regression Test
26793	Multivariate Discharge Predictors of Death in the ESCAPE Trial
26794	Simplified Discharge Score Model of Mortality From the ESCAPE Study
26795	Estimated Probability of Dying in 6 Months on Basis of Discharge Score Model
26796	The ESCAPE, EFFECT, and ADHERE Studies Model Comparison
26797	Event Rates, HRs, and p Values for End Points
26798	Serial Electrophysiological and Proarrhythmic Properties of Dofetilide Before and After Ranolazine-Lidocaine
26799	Interventions and Days in Hospital Due to HF
26800	Medical Therapy: Discharge and Follow-Up
26801	Cardiac Events in the 3 Study Groups
26802	Heart Failure Score
26803	Medications and Serial Measures
26804	Clinical Outcomes
26805	Medication at Admission and During Follow-Up  ⁎
26806	Laboratory Values According to Specific ACHD Diagnosis
26807	Comparison Between Anemic and Nonanemic Patients
26808	Development of AF/AFL During Follow-Up per 1,000 Participants by Treatment Group
26809	Development of AF/AFL During Follow-Up per 1,000 Participants, Overall and by Major Subgroups  (Doxazosin Participants Excluded)
26810	Estimated ORs and Corresponding SEs and 95% CIs for Incidence of AF/AFL Among Nondoxazosin ALLHAT Participants
26811	Relative Risk of Overall Death and Death From Cardiac Causes Associated With LVESD in Patients With Organic Mitral Regurgitation Due to Flail Leaflets: Results of Cox Univariate and Multivariable Analyses
26812	Clinical Data
26813	Magnetic Resonance Imaging Data
26814	Univariate Analysis for Prediction of Events
26815	Relation Between Diuretic Usage, Statin Usage, and Infarct Size  (Spatial Extent of Scar Tissue)  on LGE MRI
26816	Multivariable Cox Proportional Hazard Model for Prediction of Events
26817	Univariable and Multivariable Logistic Regression Analysis for Prediction of Response to CRT  *
26818	Lipid Values
26819	Brachial Artery Reactivity Data
26820	Heritability  (h2)  and Effects of NPY1R3′-UTR Variant A+1050G on Physiological Traits in Twin Siblings Pairs
26821	Changes in Blood Pressure, Laboratory, and CMR Variables
26822	Arterial Stiffness Values  (Absolute and Corrected for Changes in MAP Over Time by Linear Regression)
26823	Multivariate Regression Models for the Prediction of Change in Left Ventricular Mass
26824	Adverse Events  (n = 281)
26825	Comparison of the REACT and MERLIN Trials
26826	Hemodynamic Status and Doppler Echocardiography
26827	2-Dimensional Strain and Rotation
26828	Vp
26829	Derived Measurements
26830	Univariate Predictors of Hypertension Improvement After Stenting of RAS at 12 Months
26831	Mean Values of IVUS, Angiographic, and Hemodynamic Parameters in Patients With an HSG ≥21 mm Hg Versus <21 mm Hg
26832	Primary and Main Secondary Outcomes  (Time to First Event)  for High and Low EF
26833	Primary and Main Secondary Outcomes  (Time to First Event)  for LVEF ≥40%
26834	Management of AF Patients With Versus Without HF and LSVD-HF Versus PSF-HF
26835	Univariable and Multivariable Effect of HF on Mortality and Adverse Events in AF Patients
26836	Multivariable Determinants of All-Cause Mortality in Patients With AF and HF
26837	Efficacy Outcomes
26838	Performance on ETT at 8 Months  (s, mean ± SEM)
26839	Safety and Tolerability Outcomes
26840	Incidence of Ischemia on cECG and Association With Clinical End Points
26841	Incidence of Ischemia on cECG in Various Populations and Association With Clinical Outcomes
26842	Adjusted Risk of Cardiovascular Complications Associated With Clinical, Biochemical, and Electrocardiographic Features
26843	Inclusion and Exclusion Criteria for Study Randomization
26844	Biventricular Pacemaker Diagnostics  (n = 40)
26845	Hemodynamic and Echocardiographic Changes in Patients With CRT-ON and CRT-OFF  (n = 40)
26846	Selected Hemodynamic Changes in Patients Who Improved With CRT-OFF
26847	The SHFM Performance for Combined End Point and Mortality Predictions
26848	Observed Versus SHFM-Expected Mean Survival
26849	Recalibrated 1-Year Risk Predictions for the Combined End Point
26850	Discharge Therapy and Procedures for Eligible Patients With Heart Failure and Left Ventricular Systolic Dysfunction
26851	Hazard Ratios for Initiation of Beta-Blocker Therapy Versus No Beta-Blocker Therapy
26852	Sensitivity Analyses of Subgroups in Patients With Heart Failure and Left Ventricular Systolic Dysfunction
26853	Clinical Correlates of BRS Measurements in Treated and Untreated Patients
26854	Results From Multiple Regression Analysis Assessing the Association Between Clinical and Functional Covariates and BRS
26855	Results of Cox Proportional Hazards Multivariate Regression Analysis  (n = 247)
26856	Relative Risk of MI According to Use, Treatment Duration, and Daily Dose of NSAIDs  ⁎
26857	Relative Risk of MI According to Plasma Half-Life and Release Formulation of NSAIDs and Stratified by Daily Dose  ⁎
26858	Relative Risk of MI According to Daily Dose of Individual NSAIDs  ⁎
26859	Relative Risk of Myocardial Infarction According to Concomitant Use of Aspirin and NSAIDs  ⁎
26860	Summary Statistics of the Included Trials
26861	Univariate Correlations Between ST2, NT-proBNP, BNP, and Selected Covariates
26862	Selected Univariable and Multivariable Predictors of 1-Year Mortality in Acute Heart Failure
26863	CFR, Hemodynamic Parameters, and MCD in Individual Patients
26864	Cumulative Incidence of Cardiac and Arrhythmic-Related ED Visits or Hospitalizations
26865	Relationship Between Defibrillator Therapy and Cardiac-Related ED Visits or Hospitalizations
26866	Cardiac-Related ED Visits or Hospitalizations and ICU Stays
26867	Frequency of In-Hospital Procedures by Treatment
26868	Predictors of All-Cause Mortality by Multivariable Cox Regression Analysis
26869	Univariate and Multivariate HF Prediction Model Based on Plasma sACE2 Activity
26870	Clinical Analysis
26871	Clinical-Genetic Analysis
26872	Haplotype Frequencies and Copy Numbers for ADRB1 and ADRB2
26873	Clinical Factors in Heart Failure Survival Studies Studying Adrenergic Receptor Genetics
26874	Results of Genetic Studies in β-blocker–Treated Heart Failure Patients With Survival End Points
26875	Variables Predictive of In-Hospital Mortality
26876	Changes in Laboratory Tests After 4 and 24 Weeks of Antiretroviral Therapy
26877	Questionnaires
26878	Univariate and Multivariate Predictors of Any Reoperation
26879	Self-Reported Exercise Tolerance
26880	Univariate and Multivariate Predictors or Excellent/Indeterminate or Poor Outcomes
26881	Symptoms Reported by 285 Survey Responders
26882	Medications Indicated by Survey Responders
26883	Reasons for Subsequent Hospitalization After First Operation at Mayo Clinic as Reported by Survey Responders
26884	Pregnancies Reported by 82 of 285 Respondents
26885	Candidate Predictors Considered in the Model
26886	Univariable Predictors
26887	In-Hospital Mortality Model
26888	Risk-Prediction Nomogram
26889	Comparison With Other Prediction Models
26890	Concomitant Medications Before Randomization and at 1 Year
26891	Reasons Leading to Discontinuation by Treatment and Race
26892	Exercise and Gas Exchange Data
26893	MRI Measures of Ventricular Function
26894	PCr and ATP Concentrations and Their Ratios Measured by 31P-MRS
26895	Myocardial Work and Efficiency at 8 Months
26896	Propensity Score Risk Factor Matched PAD and CAD Population
26897	Cause of Death During the Perioperative and Long-Term Period
26898	Hemodynamic Parameters of Subjects During Coronary Dobutamine Stress Test
26899	Hemodynamic Parameters of Subjects During Coronary Flow Reserve Study
26900	Multivariate Analysis of Variables Associated With Mortality in Primary Pulmonary Hypertension legend
26901	Hemodynamic Variables on Admission and Time of Pulmonary Artery Catheter Removal in All Patients and Stratified According to IAP ≥8 mm Hg and IAP <8 mm Hg
26902	Relation of Changes in IAP or Serum Creatinine With Hemodynamic Variables Stratified According to All Patients and in Patients With IAP ≥8 mm Hg
26903	Multivariate Proportional Hazards Regression Model: Risk of All-Cause Mortality in the Conventional Therapy Group for Selected Risk Factors  ⁎    †
26904	Risk Score and Outcome in the Main Study Population: All-Cause Mortality by Treatment Group
26905	Risk Score and Outcome in the Main Study Population: Multivariate Analysis for the End Point of All-Cause Mortality  ⁎
26906	Echocardiographic Parameters at PRE, POST, 6 MO, and OFF
26907	Hematologic and Biochemical Parameters
26908	Single-Predictor and Multivariable Cox Proportional Hazard Models for Various Clinical Variables  (Derivation Study, n = 525)
26909	Calculation of the AUCs for MR-proANP and NT-proBNP at Different Time Points During Follow-Up in the Derivation Study
26910	Cox Proportional Hazard Models for MR-proANP and NT-proBNP to Predict Survival in Different Subgroups of Patients With Chronic Heart Failure  (Derivation and Validation Samples Combined)
26911	Causes of Death Among T. gondiiSeronegative and Seropositive Recipients  (n = 288)
26912	Multivariate Predictors of All-Cause Mortality Beyond 1 Year After Heart Transplantation  (n = 255)
26913	Multivariate Predictors of CAV Mortality Beyond 1 Year After Heart Transplantation  (n = 255)
26914	Etiology of Congestive Heart Failure in the 2 Groups
26915	Parameters Evaluated Throughout the Study
26916	Patient Medication
26917	ADHF Protocol Patient Disposition
26918	Urinary Sodium Concentrations  (mEq/l)  in the Diuretic-Resistant Protocol
26919	ADHF Protocol Serious Adverse Events
26920	Comparisons of AMI-Related Variables and Lesion and Procedural Variables During PCI
26921	Medications Before and After CRT
26922	Simple and Multiple Cox Regression Analysis for All-Cause Mortality
26923	Pharmacokinetic Parameters on Days 1, 6, and 10
26924	Adverse Events Reported by at Least 2 Patients  (20%)  in Any BG9928 Group
26925	CMR and Echocardiographic Results  (Mean ± SEM)  at 26 Weeks
26926	Echocardiographic and CMR Results  (Mean ± SE)  at 52 Weeks
26927	QOL and ETT Results  (Mean ± SE)
26928	Association Between BNPs as Continuous Variables and Cardiovascular Outcomes Adjusted for Randomization Status
26929	Multivariable  ⁎  Analysis of the Association Between BNPs as Continuous Variables and Cardiovascular Outcomes
26930	Multivariable  ⁎  Analysis of the Association Between Quartiles of BNPs and Cardiovascular Outcomes
26931	Overall Prognostic Merit of BNP and NT-ProBNP
26932	Incremental Prognostic Value of BNP and NT-ProBNP to the Best Available Multivariable  ⁎  Model for Cardiovascular End Points
26933	Patient Disposition
26934	Changes in Blood Pressure, Heart Rate, Electrolytes, and Renal Function
26935	Patient Global Assessment Changes by the MLHQ and VAS Scoring
26936	Patients’ Assessment of Overall Treatment Effect
26937	Changes in Measured Neurohormones
26938	Most Frequent Side Effects and Safety Assessments
26939	Concomitant Medications
26940	Primary and Secondary Efficacy and Bleeding End Points
26941	Rates of Cardiovascular Death, Myocardial Infarction, or Stroke at Different Time Intervals From the Ischemic Event to Randomization
26942	Indexes of Platelet Activation in Patients With AF Compared With “Healthy” and “Disease Control Subjects”
26943	Assessment of Platelet Activation Among AF Patients
26944	Effect of Aspirin or Warfarin Therapy on Platelet Activation in Atrial Fibrillation
26945	Glucose-Lowering Therapies in Patients With Type 2 Diabetes and Previous Myocardial Infarction
26946	Concomitant Cardiovascular Medication in Patients With Type 2 Diabetes and Previous Myocardial Infarction
26947	Effects of Add-On Pioglitazone Therapy Versus Placebo on Cardiac-Related Events in Patients With Type 2 Diabetes and Previous MI
26948	Heart Failure in Patients With Type 2 Diabetes With and Without Previous MI
26949	Time-to-Event Analysis of Major Adjudicated Clinical End Points
26950	Proportion of Patients With Other Adjudicated Clinical End Points
26951	Summary of Previous Antidiabetes and CV Medications  (All Randomized Patients)
26952	Multivariate Hazards Ratios for Mortality Rate
26953	Description of Pooled Trials
26954	Multivariable Predictors of Death: Hazard Ratios With 95% Confidence Intervals
26955	Multivariable Predictors of Death or Hospitalization: Hazard Ratios With 95% Confidence Intervals
26956	Basal Renal Function, Contrast Volume, and Serum pH in Control Group and Treatment Group
26957	Incidence of CIN and Clinical Outcomes
26958	Patient Disposition by Time on Open-Label Treatment
26959	Summary of All Adverse Events ≥4% Incidence Reported During the ROLE Program
26960	Cumulative Mortality to Date
26961	Patient Survival in ROLE and Other Published Patient Cohorts
26962	Adverse Events
26963	Changes in Hemodynamic Markers
26964	Annualized Changes in Hemodynamic Markers
26965	Changes in Serum Markers
26966	Spearman Correlations of Sol-CXCL16 Levels With Cardiovascular Risk Factors
26967	Multivariable Association of Plasma Sol-CXCL16 and CRP Quartiles* With CAD
26968	Clinical and Echocardiographic Summary of the 3 Groups: Control, SHF, and DHF
26969	Hemodynamic and Echocardiographic Measurements in DHF Patients Stratified According to Presence or Absence of Systolic and Diastolic Dyssynchrony
26970	Hemodynamic and Echocardiographic Measurements in SHF Patients Stratified According to Presence or Absence of Systolic and Diastolic Dyssynchrony
26971	Changes With Medical Therapy for DHF
26972	Cause-Specific Mortality by Gender and Treatment Groups
26973	Event Rates and Hazard Ratios for Study End Points
26974	Types of Stroke in Treatment Groups
26975	Factors Predictive of Cerebrovascular Events
26976	Cerebrovascular Events According to On-Treatment Low-Density Lipoprotein Cholesterol  (LDL-C)
26977	Mean Initial and Final Values of Ejection Fraction, Body Weight, Blood Pressure, R-R Interval, and R-R Interval Variability Parameters
26978	Clinical Parameters of CHF With or Without Famotidine
26979	Adjusted Multivariate Analysis for Death Within 60 Days and for the Composite of Death/Recurrent Heart Failure Within 60 Days
26980	SAEs  ⁎
26981	Patient Variables  (Mean ± SD)  Before  (Pre)  and After  (Post)  Enhanced External Counterpulsation  (EECP)
26982	Number of Patients  (%)  With Different NYHA Functional Class Changes Between Trimetazidine and Conventional Therapy
26983	Comparisons Between Changes Between Trimetazidine and Conventional Therapy
26984	Incidence of Adverse Cardiovascular Events and Hospitalization During Follow-Up of Study Patients
26985	Univariable Surgical Predictors of POAF
26986	Postoperative Complications
26987	Univariable Echocardiographic Predictors of POAF
26988	Multivariable Cox Model Predicting POAF
26989	Concomitant Medications
26990	Weekly Angina Frequency and Nitroglycerin Consumption
26991	Primary Efficacy End Point Stratified by Subgroup  (LAN Use, Gender, and Age)
26992	Summary of Randomized Clinical Trials With Ranolazine
26993	Systemic Hemodynamics in the Supine and Upright Position and Mean Tilt Duration
26994	Supine and Upright Catecholamines With Placebo and With NET Inhibition
26995	Summary of All Double-Blind Studies  (75 to 125 mg)
26996	Distribution of TdP Cases by Treatment Indication and Dose
26997	Univariate TdP Risk Factor Analysis
26998	Multivariate TdP Risk Factor Analysis: Logistic Regression Model
26999	Medication Use
27000	Results of Univariate Cox Proportional Hazards Survival Analysis
27001	Results of Multivariate Cox Proportional Hazards Survival Analysis
27002	Clinical Outcomes, 90 Days
27003	Mortality and Adverse Events, 180 Days
27004	Metabolic Parameters of Symptomatic Patients After Rosiglitazone and Placebo Treatments
27005	Changes in Clinical Variables During the Follow-Up Period
27006	Cox Proportional Hazards Models Adopting Major Arrhythmic Events as the Dependent Variable
27007	Unadjusted and Adjusted Outcomes Based on Beta-Blocker Use During Hospitalization
27008	Outcomes of Patients With Respect to Beta-Blocker Therapy
27009	Summary of Number of Cases and Controls for Each End Point Examined in the High- and Low-Risk Cohorts
27010	Unadjusted Risk Ratios and 95% Confidence Intervals in the High- and Low-Risk COPD Cohorts
27011	Exercise Parameters
27012	Patient Population Outcomes
27013	One-Year Transplant-Free Survival by Weber Class
27014	Treatment Effects in Patients With Low EF Depending on Heart Rhythm
27015	Cumulative Distribution and Reason for Days of Life Lost Over 4 Years
27016	Echocardiographic Features of Cushing Patients and Controls
27017	Systolic Performance and Diastolic Filling Parameters
27018	RT-PCR Analysis of the Abundance of Ca2+-Handling Protein mRNAs  (Normalized by the Amount of GAPDH mRNA)  in Endomyocardial Biopsy Specimens
27019	Univariate and Multivariate Predictors of Cardiac Events in IDCM Patients
27020	Number of Patients  (%)  Receiving Cardiac Medication
27021	Univariate and Multivariate Associations of Clinical Variables and Overall Mortality
27022	Univariate and Multivariate Association Between Cardiac Medication and Mortality
27023	Patient Population
27024	Echocardiographic Measurements
27025	Correlations Between AS Plasma-Induced Maximum in Vasoconstriction  (% KClEmax)  and CCS Functional Class, Angiographic Diameter Stenosis, and IVUS Plaque Volume and Plaque Burden of the 19 Patients
27026	Exercise Parameters of Patients on Combination Therapy
27027	Exercise Parameters of Patients on Monotherapy
27028	Medication Use of CHF Patients
27029	Prevalence of TD in CHF Patients and Control Subjects
27030	Univariate Analysis of the Relationship Between Study Variables and TD as the Dependent Variable  ⁎
27031	Multiple Logistic Regression Analysis
27032	LDL and Markers for Heart Failure, Inflammation, Endothelial Activation, Endothelial Function, and Vagal Tone
27033	Kaplan-Meier Event Rates and Hazard Ratios for Risk Predictors
27034	Interactions between Microvolt T-Wave Alternans and Other Risk Predictors
27035	Clinical Presentation
27036	Use of Non-Intravenous Medications Before Hospitalization
27037	Use of Non-Intravenous and Intravenous Medications During Hospitalization
27038	Use of Non-Intravenous Medications at Discharge
27039	Clinical Outcomes During Hospitalization
27040	Multivariate  ⁎  Odds Ratios and 95% Confidence Intervals for Identified Mortality Risk Factors
27041	Mortality According to Renal Function
27042	Mean Maximum Hemodynamic Changes With Regadenoson
27043	Imaging Visual and Quantitative Summed Scores by Pharmacologic Stress Agent
27044	Adverse Events Associated With Regadenoson Administration
27045	Clinical Signs and Symptoms of Volume Overload
27046	Early Ultrafiltration Therapy: Clinical and Laboratory Outcomes
27047	Number and Percentage of Patients Receiving Drug
27048	Medical Management During First 24 h After Enrollment
27049	Hemodynamics and Laboratory Assessment
27050	Changes in Global Heart Failure Symptoms
27051	Changes in Global Dyspnea Symptoms
27052	Changes in Lipid Parameters
27053	Changes in Ultrasound and Hemodynamic Parameters
27054	Multivariate Proportional-Hazards Model for Time to ICD Therapy, Including Interim Cardiac-Related Hospitalizations as Risk Factors
27055	Comparison of Selected Preoperative and Operative Data in Unmatched  (All Patients)  and Matched African-American  (AA)  and Caucasian CABG Patients
27056	Comparison of Operative Outcome Data in Unmatched  (All Patients)  and Matched African-American  (AA)  and Caucasian CABG Patients
27057	Multivariate Predictors of 0- to 12-Year Mortality Derived by Cox Regression Analysis Applied in All Patients
27058	Medicaid Status as a Predictor of 0- to 12-Year Survival After Isolated CABG in 6,377 at Saint Vincent Mercy Medical Center  (Toledo, Ohio, 1991 to 2003)
27059	The Patient Population
27060	Factors Associated with Aspirin Prescription at Hospital Discharge
27061	Risk Ratios for One-Year Mortality Associated With Aspirin Treatment in Subgroups
27062	Outcomes and Use of ASA Before Admission
27063	Independent Effect of Aspirin Use Before Admission on Mortality  ⁎
27064	Effect of ASA Use Before Admission on Readmission  ⁎
27065	Prevention of Type 2 Diabetes by ACE Inhibitors or ARBs
27066	Concomitant Medications at Bosentan Initiation
27067	Cardiopulmonary Hemodynamic Parameters at Bosentan Initiation and After at Least Eight Weeks of Treatment With Bosentan
27068	Patient Survival and Treatment Status at Data Cutoff Date
27069	Multivariate Analysis Relating Time to PAH Worsening to Risk Factors
27070	Cox Modeling Based on Risk Factors Selected in the Univariate Selection Process on Time to PAH Worsening
27071	Summary of End Points at 30 Days After Randomization
27072	Urinary Ca2+and Mg2+Excretion at Week 4 Treatment
27073	Clinical and Laboratory Parameters Before  (at Entry)  and After Six Days of Treatment
27074	Laboratory Parameters of Renal Function at Discharge
27075	Results of the Study  (30 Days) : Side Effects, Readmissions, and Mortality
27076	Changes in BNP Levels During the Study Period  (30 Days)
27077	Bioimpedance Analysis Parameters in Decompensated Heart Failure Patients Before and After Intravenous Treatment With HSS Plus Furosemide
27078	Bioimpedance Analysis Parameters in Decompensated Heart Failure Patients Before and After Intravenous Treatment With Furosemide Without HSS
27079	Design of Included Studies
27080	Description of the Left Ventricular Ejection Fraction  (LVEF%)  at Different Time Periods: At the Time of Transplant Evaluation, While on the Waiting List to be Transplanted, and During the Follow-Up After Kidney Transplantation
27081	Comparison of Hemodynamic and Biochemical Parameters in the Pre- and Post-Transplant Periods in All Patients and Different Groups Based on the Left Ventricular Ejection Fraction in the Post-Transplant Period
27082	Logistic Regression Models for Pre- and Post-Transplant Predictors for Normalization of Left Ventricular Ejection Fraction  (LVEF ≥50%)  in the Post-Transplant Period  (Reference Group: Group With LVEF ≥50% in the Post-Transplant Period)
27083	Echocardiographic Predictors of Outcomes on Univariate Analysis
27084	Clinical Summary
27085	DRGs, Associated Costs, and Distribution of DRGs for Initial and Subsequent Hospitalizations
27086	Life-Years Lost Attributable to Cardiovascular Events
27087	Costs
27088	Cost Effectiveness
27089	Changes in Total Defect Score, Heart/Mediastinum Count Ratio, and Washout Rate of Patients in Candesartan and Placebo Groups
27090	Changes in Left Ventricular End-Diastolic Volume, Left Ventricular Ejection Fraction, Functional Class, and Plasma Brain Natriuretic Peptide Level of Patients in the Candesartan and Placebo Groups
27091	Comparison of Asymptomatic and Symptomatic Patients With MR
27092	Correlation Among Natriuretic Peptide Levels, Age, Body Surface Area, and Echocardiographic Measures of the Severity of MR and LV Function
27093	Results From Multiple Linear Mixed Effects Model Estimated on 999 Patients *
27094	PREVENT: Comparative Mean Absolute TBARS Serum Levels With Specific Vascular Events and Procedures
27095	Multivariate Models for All-Cause Mortality, Cardiac Death, and Composite End Point  (All-Cause Mortality, Stroke, or Nonfatal MI)  During Follow-Up  (Average 27 Months)
27096	Unadjusted Risk Ratios for All-Cause Mortality and Cardiovascular Events After Various Time Points in Relation to High  (>4.1 ng/ml [4th Quartile])  and Low  (≤4.1 ng/ml [Quartiles 1 to 3])  Osteoprotegerin Levels During Follow-Up
27097	Group Hemodynamic Profile According to Adrenoceptor Genotype in Patients With Congestive Heart Failure
27098	Norepinephrine Spillover According to Adrenoceptor Genotype in Patients With Congestive Heart Failure
27099	Use of Different Antihypertensive Medication During the Study  (% Patients)
27100	Clinical Outcomes in Patients with ISH
27101	Electrolyte and Renal Data
27102	Study Flow Chart
27103	Circulating Cytokine and CRP Values
27104	Frequency of AEs
27105	Heart Period Sequences and Heart Rate Variability During the Three Recording Periods *
27106	Contributions of Each of the Specific Activities During the Scripted Activity Day Depicted in Figure 3 to the Total SDANN *
27107	Contributions of Mean Heart Period and Coefficient of Variation to the Reduced SDANN in Patients With Heart Disease
27108	Effects of Treatment on Parameters Assessed in Chronic Heart Failure Patients Who Finished the Study
27109	Predictors of Cardiovascular Morbidity in a Multivariate Cox Model in 1,742 Hypertensive Patients
27110	Prevalence and Prognostic Significance of the Single Components of the Metabolic Syndrome in 1,742 Hypertensive Patients
27111	Independent Predictors of Cardiovascular Morbidity and All-Cause Mortality in 1,637 Nondiabetic Hypertensive Patients in a Multivariate Cox Model
27112	Heart Failure Signs and Symptoms
27113	Beta-Blocker Use at 60 Days Postdischarge
27114	Percent of Target Dose Achieved for Carvedilol, Bisoprolol, Metoprolol Tartrate IR or Metoprolol Succinate XL at Day 60
27115	Withdrawal Due to Serious Adverse Events
27116	Clinical Events at 60 Days
27117	Mean Exercise Treadmill Test Parameters in Seconds *  (n = 175)
27118	Most Frequently Occurring Adverse Events, Incidence ≥3% for Any Treatment *  (n = 191)
27119	Prospective Studies Showing Superior Stroke Protection by Diuretics Compared With Placebo or Other Antihypertensive Treatment
27120	Prospective Studies Comparing Calcium Antagonists and Diuretics
27121	Frequency of Adverse Events Commonly Attributed to Adrenergic Blockade *
27122	Frequency of Adverse Effects Noted With Sildenafil and Placebo During the Trial Period *
27123	Comparison of Efficacy of Sildenafil With Placebo  (n = 22)  *
27124	Change in RR Interval, Mean Arterial Pressure  (MAP) , RR Interval Variability, and Baroreflex Sensitivity  (Alpha-Index)  Following Control Infusion of Saline or Active Treatment With Potassium Canrenoate  (K-Can)   (n = 13)
27125	Univariate Analysis of Factors Associated With Poor Clinical Status  (NYHA Class ≥III)
27126	Multivariate Analysis of Variables Associated With a NYHA Class ≥3
27127	Hemodynamic Data During PET Studies  (Mean [SD])
27128	Echocardiographic Parameters  (Mean [SD])
27129	Outcome of Patients Enrolled in GUSTO V Based on Diabetic Status
27130	Complications of MI and its Treatment in Diabetics Randomized to Standard Versus Combination Therapy
27131	Predictors of 30-Day Mortality in Diabetics in a Multivariable Model
27132	Outcome and Medication Use in Diabetics in GUSTO I, GUSTO III, and GUSTO V
27133	Prevalence of Lipid-Lowering Medication in the Study Cohort
27134	HR of Death or Urgent Transplant for Statin Treatment Versus No Statin Treatment: Univariate and Multivariate Analyses
27135	Treatment at Hospital Discharge in Patients With and Without Diabetes Mellitus
27136	Mitral Inflow Pattern at Doppler Echocardiography in the Three Groups of Patients
27137	Proteinemia, Albuminemia, COP, and PAWP in the Three Groups of Patients and in the Normal Control Group
27138	Number and Distribution of Coronary Plaques
27139	Arrhythmia Risk Variables
27140	Arrhythmia Risk Variables as Predictors of SCD and Arrhythmia Events
27141	The Number of Patients With True-Positive, False-Negative, True-Negative, and False-Positive Test Results
27142	Measures of Peak Exercise During Active and Inactive Pacing in Each Individual Patient
27143	Measures of Submaximal Exercise During Inactive and Active Pacing in Each Patient
27144	Hemodynamics and Left Ventricular Function at Supine Rest in HTRs  (n = 8)
27145	Phase Analysis in Patients With IDC With QRS Duration <120 ms or >120 ms
27146	Correlations Between QRS Duration and Ventricular Dyssynchrony  (Intraventricular in LV and RV and Interventricular)  Expressed in Degrees  (°)  and Milliseconds  (ms)
27147	Correlations Between Hemodynamic Status and Ventricular Dyssynchrony  (Left and Right Intraventricular and Interventricular)  Expressed in Milliseconds
27148	Hazard Ratio  (and 95% Confidence Intervals)  in Univariate and Multivariate Analysis of Predictors of Major Cardiac Events  (Cardiac Death or Worsening of Heart Failure Leading to Heart Transplantation)
27149	Absolute Changes in Serum Creatinine Concentrations After Coronary Procedures and the Incidence of Acute Reductions in Renal Function in the Acetylcysteine and Control Groups
27150	Goals and Tools of Care Process of Patients Exposed to Heart Failure Management Program
27151	Outcomes in Patients Grouped According to Management Strategies
27152	Economic Profile of Patients Grouped According to Management Strategies
27153	Nonfatal Cardiovascular Events Required Hospitalization Recorded During Follow-Up  (Mean 67 Months [Range 57 to 78 Months])
27154	Incidence Rates of Cardiovascular Events Among 400 Postmenopausal Women
27155	Number of Patients With Events in Both Dose Groups Combined and in the Low- and High-Dose Groups, Respectively
27156	Relative Risk Reduction and 95% CI for the Comparison of the Two Dose Groups Combined  (Cox Adjusted Estimates, see Statistical Methods)  and for the Comparison of the Low-Dose Metoprolol CR/XL Group With All Placebo and High-Dose Metoprolol CR/XL Group Versus All Placebo, Respectively
27157	Reason for Lower Than Expected Dose of Study Medicine at the Three-Month Visit in the Two Randomization Groups
27158	Reasons for Not Administering Second Bolus of Reteplase
27159	In-Hospital Events
27160	Cumulative Shock Success
27161	Progressive Tendency for Skin Tenderness Within Each Protocol, for Patients Having No Cross-Over or Nonprotocol Shocks
27162	Dependence of Success on Duration of Current AF Episode
27163	Reason for Discontinuation of Patients Randomized
27164	Hemodynamics and Medical Regimens Before and After Therapy
27165	Analysis of the Combined Study End Point of Cardiac Death or Hospital Admission Due to Worsening Heart Failure Within 12 Months
27166	Cox Regression Analysis
27167	Effects of Treatment Modifications in Patients with CHF
27168	Dietary and Supplement Intake and Plasma Levels of Antioxidant Vitamins
27169	Adjusted * Mean IMT According to Gender-Specific Quartiles of Dietary Antioxidant Vitamin Intake
27170	Adjusted * Mean IMT According to Gender-Specific Quartiles of Plasma Antioxidant Levels
27171	Changes in Left Ventricular Ejection Fraction by Etiology, Carvedilol Use and ASA Use
27172	Multivariate Analysis of Factors Influencing the Change in LVEF
27173	Pearson Correlations of Cardiovascular Disease Risk Factors and Other Markers With Serum Uric Acid Level
27174	Pearson Correlations of Cardiovascular Disease Risk Factors and Other Markers With Flow-Mediated Vasodilation
27175	Results of the Multivariate Analysis
27176	Angiographic Results of Primary Stenting  (n = 50)
27177	Primary and Secondary End Points legend
27178	Indications for Unscheduled Angiograms During Index Hospitalization legend
27179	Medications at Discharge and at Six Months in Surviving Patients legend
27180	EC50 and Maximum Responses to Bradykinin in Arteries from CHF and CHD legend legend
27181	Effects of Beta-Blocker Therapy on Hemodynamic Variables, Left Ventricular Functions and Neurohumoral Factors in Patients With Dilated Cardiomyopathy legend legend
27182	Univariate Predictors of End Points legend
27183	Exercise Variables by Study Group  legend
27184	Types of Surgery
27185	Metabolic Exercise Data legend
27186	Serial Echocardiographic Results legend
27187	Serial Hemodynamic Measurements legend
27188	Standard Pulmonary Function Tests in Controls  (n = 18)  and in Chronic Congestive Heart Failure Patients Undergoing Ultrafiltration  (n = 28)  legend
27189	Lung Diffusing Capacity for Carbon Monoxide  (DLco) , Alveolar-Capillary Membrane Diffusing Capacity for Carbon Monoxide  (Dm) , Capillary Volume  (Vc) , Alveolar Volume  (Va)  and Lung Tissue  (Lt)  in Controls  (n = 18)  and in Chronic Congestive Heart Failure Patients Undergoing Ultrafiltration  (n = 28)  legend
27190	Pulmonary Hemodynamics in 28 Chronic Congestive Heart Failure Patients Before Ultrafiltration and Four Days Thereafter legend
27191	Selected Concomitant Medications
27192	Comparison of Hemodynamic Responses Between Exercise and Dobutamine Stress legend legend
27193	Hemodynamic Responses During Dobutamine Stress Echocardiography legend legend
27194	Association Between Dobutamine Response for Regional Wall Motion and Wall Hypertrophy
27195	Flow-Mediated Vasodilation  (Percent Change in Brachial Artery Diameter)  After Release of 1, 3 and 5 Min of Transient Arterial Occlusion Before and After Study Drug Administration in Patients With Heart Failure According to Treatment Assignment
27196	Mean Brachial Artery Blood Flow Velocity  (cm/s)  After Release of 1, 3 and 5 Min of Transient Arterial Occlusion Before and After Study Drug Administration in Patients With Heart Failure According to Treatment Assignment
27197	Heart Rate and MAP Before and After Study Drug Administration in Patients With Heart Failure According to Treatment Assignment legend
27198	Hemodynamic Data and Left Ventricular Function During Supine Rest in Heart Transplant Recipients  (n = 8)  legend
27199	Fluid Volume, Plasma Electrolytes and Fluid-Regulatory Hormone Values in Heart Transplant Recipients  (n = 8)  Before and After High Dose Captopril
27200	Kaplan-Meier Analysis for Major Events legend
27201	Cox Regression Analysis for Major Events legend
27202	Delays in Minutes Between Pain and Intervention legend legend
27203	Angiographic Results  (Qualitative Assessment)  legend legend
27204	Clinical Outcome During the Hospital Period legend legend
27205	Causes of Death During the Hospital Period legend legend
27206	Predictive Factors of One-Year Mortality in 759 Patients Who Underwent Early Percutaneous Transluminal Coronary Angioplasty: Univariate Analysis legend legend
27207	Clinical Outcome From Discharge to One Year legend legend
27208	One-Year Clinical Outcome: Comparison Between Patients With Failed and Successful Angioplasty legend legend
27209	Estimated Interventional Costs in U.S. Dollars During the First Year After Acute Myocardial Infarction Treated With Rescue or Primary Percutaneous Transluminal Coronary Angioplasty legend
27210	Reasons for Premature Discontinuation of Blind Study Medication
27211	Number of Patients With a Relapse to Atrial Fibrillation in Subgroups
27212	Number  (%)  of Patients by the Most Common Adverse Events  (Occurring for >2 Patients)  legend
27213	Concomitant Cardiovascular Drugs of the Study Patients
27214	Adverse Events
27215	Causes of Death According to the Level of Alcohol Consumption
27216	Ischemic Left Ventricular Dysfunction  (n = 5,331) : Relationship Between Light-to-Moderate Alcohol Consumption and Outcome legend
27217	Nonischemic Left Ventricular Dysfunction  (n = 1,278) : Relationship Between Light-to-Moderate Alcohol Consumption and Outcome ∗   legend
27218	Relationship Between Light-to-Moderate Alcohol Consumption and Cause-Specific Mortality ∗
27219	Results of the Two-Way Repeated-Measures ANOVA legend
27220	Sensitivity and Specificity of Various Tests and Their Cutoff Values to Differentiate Full Adherence From Full Nonadherence With ACEI Therapy
27221	Pulmonary Capillary Wedge Pressure, mm Hg, Days 0 and 42  (Mean ± SE)
27222	Pulmonary Vascular Resistance, dynes/s/cm−5, Days 0 and 42  (Mean ± SE)
27223	Change in Hemodynamic and Echocardiographic Variables in Response to Dobutamine legend
27224	Variables Associated With the Use of Acute Reperfusion, Coronary Angiography, Angioplasty and CABG legend
27225	In-Hospital Invasive Coronary Procedures, Medications, Complications and Mortality of Patients Treated or Not Treated by Acute Reperfusion legend
27226	Multivariate Stepwise Logistic Regression Analyses to Predict 30-Day, 30-Day to Three-Year and Three-Year Cumulative Mortality
27227	Crude and Adjusted Mortality Rates of Patients Treated or Not Treated by Acute Reperfusion by Reason for Exclusion
27228	Cerebral Proton Magnetic Resonance Spectroscopic Data legend
27229	Factors Associated With a Decreased Level of Creatine in 50 Patients With CHF  (Univariate Analysis)  legend
27230	Changes of Cerebral Metabolites Levels in 10 Patients With Cardiac Transplantation
27231	Time-Domain and Frequency-Domain Measurements of HRV on 24-h Ambulatory ECG in Patients With IDC legend
27232	Cox Proportional Hazards Analysis for All Cause Mortality legend
27233	Cox Proportional Hazards Analysis for Cardiovascular Mortality legend
27234	Resting Hemodynamics and Patient Weights Before and After Therapy
27235	Drug Therapy at Discharge From Hospital Following Enrollment  (n = 417)  legend
27236	Procedural Factors
27237	Comprehensive Results legend
27238	Specific Renal Outcomes by Intent-to-Treat, Experimental Arm Versus IV Hydration Alone  (Control)  Arm legend
27239	Multivariable Analysis of Death: Hazard Function Regression Method legend
27240	Multivariable Analysis of Death: Proportional Hazards Segmented Time Method  (Cut Point at Nine Months)  legend
27241	Prevalence of Variables in 1-, 2- and 3-System Disease  (CASS Surgical Registry)
27242	Mean Values of Variables in 1, 2 and 3 System Disease
27243	Objective Clinical Findings of No-Echocardiography and Echocardiography Groups
27244	Medical and Surgical Therapy of No-Echocardiography and Echocardiography Groups
27245	Multivariate Analysis of Factors Predictive of Not Receiving a Doppler Echocardiographycardiographic Examination
27246	Causes of 30-Day Mortality
27247	Medication at Follow-up legend
27248	Effect of Captopril on Left Ventricular Function According to TIMI Flow Grades legend
27249	Effect of Captopril on Regional Wall Motion According to TIMI Flow Grade
27250	Effect of Captopril on Regional Wall Motion According to Corrected TIMI Frame Count
27251	Types and Doses of Beta-Receptor Antagonists  legend
27252	Univariate Regression Analysis legend
27253	Multivariate Regression Analysis legend
27254	Reasons for Premature Discontinuation During the Study  (n = 25 of 244 patients)
27255	Risk of Treatment Failure Relative to Triple Therapy legend
27256	Comparison of Patients with and without Arrhythmic Events During Follow-Up
27257	Programmed Stimulation in Patients with Dilated Cardiomyopathy without a History of Sustained Ventricular Arrhythmias  legend
27258	Events for Participants in Atrial Fibrillation Compared to Sinus Rhythm  legend
27259	Multivariate Analysis: Variables Significantly Associated With All-Cause Mortality ∗
27260	Multivariate Analysis: Variables Significantly Associated With Pump Failure Death ∗
27261	Platelet Surface Antigen Expression in Patients With Acute Myocardial Infarction During First 24 Hours After Thrombolytic Therapy
27262	Univariate Analysis: Predictors of Fatal Outcome legend
27263	Multivariate Cox Proportional Hazards Models legend
27264	Clinical Results: Noninvasive Data
27265	Medical Regimen
27266	Hemodynamic Response to Therapy
27267	Functional Status Response to Therapy in 179 Patients
27268	Failure of Therapy Profile at 6 Weeks for Men and Women by Strategy and Non–Q Wave Myocardial Infarction Status: TIMI IIIB
27269	TIMI IIIB Patients Who Had Invasive Strategy: Comparison of Angiographic Findings by Gender
27270	Adverse Events and Laboratory Abnormalities
27271	Infection Details
27272	Procedure Details by Presence or Absence of Hospitalization for Device Infection
27273	Sensitivity and Heterogeneity Analysis of Pooled RRs of Mortality or VTA  ∗
27274	Stratified Analysis and Heterogeneity Analysis of RRs of Mortality or VTA  ∗
27275	Echocardiographic Data
27276	Periprocedural Adverse Events
27277	Predictive Variables for Embolic Events Determined Using the Fine and Gray Model  (Development Sample)
27278	Echocardiographic Measurements in 2 Groups
27279	Hemodynamic Measurements by Right Heart Catheterization
27280	Assessment of Functional Capacity
27281	The ECG Parameters of the Patients With and Without VF Storms Among the Patients With J Waves
27282	Definition of Prosthetic Valve Endocarditis Accordingto the Proposed Modified PET/CT DukeCriteria
27283	Results of PET/CT According to the Final Diagnosis
27284	Results of PET/CT According to the Results of the Initial Echocardiography Study  (TTE and TEE)
27285	Diagnostic Value of the Modified Duke Criteria at Admission With  (Duke-PET/CT)  and Without the Implementation of the PET/CT Results
27286	S-ICD Related Adverse Events
27287	6-Min Walk Distance Values
27288	Hemodynamic Values
27289	Potential Effect Modifier of Δ6MWD With Change in Tau2 and Statistical Significance for Each Outcome
27290	Major Adverse Events and Limb Salvage at Follow-Up in Patients With Critical Limb Ischemia and Intermittent Claudication
27291	Patient Population
27292	Post-Operative 30-Day Mortality
27293	Literature Review of Surgical and Percutaneous Lead Extraction Mortality
27294	Pre-Operative Diagnoses
27295	Arrhythmia Incidence and Timing
27296	Perioperative Clinical Variables
27297	Immunosuppressive Regimens, Typical Doses
27298	Echocardiographic Indexes  (AF/AFL Patients)
27299	Biopsy Results  (ISHLT Grades Heart/Lung)   ⁎
27300	ARVD Diagnosis Criteria
27301	Predictors of Proper ICD Therapy
27302	Main Indications for ICD Implantation in the Study Patients
27303	Medications of the Study Population
27304	In-Hospital, 1 Year, and Very Late Clinical Events
27305	Episodes of Stent Thrombosis: First Year and Very Late
27306	Predictors of Very Long-Term Clinical Outcome
27307	Hazard Ratio and 95% CI for Risk Factors Associated With Definite ST During the Entire Follow-Up Period From Multivariable Cox Regression
27308	Using RT-PCR Primer Design for Mice
27309	Major Cardiac Events According to Diabetic Status and Extent of Coronary Artery Disease  (1-Year Follow-Up)
27310	Risk Factors for Stent Thrombosis
27311	Clinical Presentation of Patients With CDI  (n = 189)
27312	Mayo Clinic Guidelines for the Diagnosis and Management of Cardiac Device Infections
27313	Results of Doppler Examination on Carvedilol Group
27314	Results of Doppler Examination on Control Group
27315	Body and LV Weight
27316	Indexes of Cell Shortening
27317	Indexes of [Ca2+]iTransient
27318	Definition of Hematoma in Studies Included in the Meta-Analysis
27319	Clinical Features of Randomized Patients With Left-Sided Infective Endocarditis
27320	Results of Investigations of Randomized Patients With Left-Sided Endocarditis
27321	Outcome of Patients With Left-Sided Infective Endocarditis
27322	Abnormal Endocarditis Findings on Cerebral Computed Tomography
27323	Evolution of Vegetation Size and Valvular Regurgitation in Patients With Endocarditis After Four Weeks of Treatment
27324	Cumulative Incidence of Disease Progression
27325	Most Frequent Adverse Events in the BPS and Placebo Groups
27326	Peri-Interventional Complications
27327	Patients With Recurrent TIA During Follow-Up
27328	Patients With Recurrent TIA Related to Postinterventional Residual Shunt
27329	Number of Dogs Assigned to and Excluded From Each Group for Measurement of Infarct Size
27330	Coronary Hemodynamics, Collateral Blood Flow and Area at Risk Among Experimental Groups
27331	Percentage of Survival and Incidence of Ventricular Fibrillation in Each Group
27332	Myeloperoxidase Activity of the Reperfused Myocardium
27333	Clinical, Laboratory and Therapeutic Variables in 80 Patients With Congestive Heart Failure
27334	Linear Range of the Assays and 95th Percentile Levels for Each Cytokine, Soluble Receptor or Receptor Antagonist for Control Subjects
27335	Frequency, Type, and Timing of Infection
27336	Organisms
27337	Management Practices and Unadjusted Risk Ratios  (Major Infection)
27338	Process of Care Variables Associated With Infection
27339	18F-FDG PET/CT Results
27340	Patient Comorbidities
27341	Presenting Symptoms
27342	Primary, Secondary and Other Outcomes in Women and Men
27343	Reasons for Discontinuation of Study Drug in the HOPE Study Women
27344	Effect of Ramipril on Primary, Secondary and Other Study Outcomes in Women and Men
27345	Angiographic and Interventional Data of the TOPSTAR Trial
27346	Production of Anandamide and 2-Arachidonyl Glycerol in Platelets and Monocytes of Control, Sham or Coronary-Ligated  (Mycardial Infarction)
27347	Medical Conditions and Contributing Factors to Congestive Heart Failure in the 16 Patients Treated for the Anemia and in the 16 Controls legend
27348	Number and Percentage of Cases Taking Each Medication and the Doses used in mg/day in the Treatment and Control Groups During the Study legend legend
27349	The Effect of Correction of Anemia by Intravenous Iron and Erythropoietin Therapy on Various Parameters in 16 Patients in the Treatment  (A)  and 16 in the Control  (B)  Group legend legend
27350	Event Rates According to Median Levels of Prognostic Markers legend legend
27351	Myocardial Inotropic Reserve in Patients With and Without Pre-Infarction Angina legend
27352	Hemodynamic Changes During the Study Drug Infusion legend
27353	Changes in the Neurohumoral Factors During the Study Drug Infusion legend
27354	Predictors of Survival: Multivariate Analysis legend
27355	Frequency of Death and Heart Transplantation in Relation to Mitral Inflow Patterns and Maximal Oxygen Uptake legend legend
27356	Selection of Patients legend
27357	Percent of Patients with Positive Tests for Ischemia before Randomization legend
27358	Clinical Results of TMR vs. Medical Treatment legend
27359	Incidence and Risk Reduction in Cardiac Events According to Treatment Group legend
27360	Causes of Death in Study Patients According to Treatment Group
27361	Frequency  (%)  of Concurrent Cardiovascular Drug Treatment in the Two Treatment Groups in the First Year legend
27362	Antihypertensive Drugs Used in Patients With Essential Hypertension legend
27363	Clinical Variables, Left-Ventricular Dimensions and Functional Class From the 17 Patients Who Completed the 6 Month Trial legend
27364	Patient Flow From Time of Randomization to Follow-Up in the Amlodipine and Placebo Groups legend
27365	Angiographic Variables of the Per-Protocol Analysis Group legend
27366	Coronary Quantitative Angiographic Analysis in the Per-Protocol Analysis Group legend legend
27367	Clinical End Points in All Randomized Patients  (Intention-to-Treat)  and All Patients Who Underwent the Scheduled Percutaneous Transluminal Coronary Angioplasty legend
27368	Body and Left Ventricle Weight in Adult and Sedentary or Trained Senescent Rats
27369	Hemodynamic Parameters of Ischemia  (20 min)  and Reperfusion  (40 min)  in Hearts from Adult and Sedentary or Trained Senescent Rats  (Control Group)  legend
27370	Hemodynamic Parameters of Transient Ischemia Preconditioning Stimulus  (2 min)  on Ischemia  (20 min)  and Reperfusion  (40 min)  in Hearts from Adult and Sedentary or Trained Senescent Rats  (Preconditioning Group)  legend
27371	Hemodynamic Parameters of Transient Ischemia Preconditioning Stimulus  (2 min)  on Ischemia  (20 min)  and Reperfusion  (40 min)  After Pretreatment With Reserpine in Adult and Sedentary or Trained Senescent Hearts  (Reserpinized Preconditioning Group)  legend
27372	Changes in Sitting Blood Pressure and Heart Rate During Treatment  a
27373	Changes in Radial Artery Variables During Treatment
27374	Changes in Common Carotid Artery Variables During Treatment
27375	Long-Term Intraobserver Repeatability of Radial and Carotid Artery Variables Measurements in 13 Subjects and Patients With Hypertension
27376	Comparisons of Changes During Lower Body Negative Pressure in Patients With Restrictive and Nonrestrictive Left Ventricular Filling Patterns
27377	Adjusted Hazard Ratios of Mortality, Morbidity and Cause of Death in Antiplatelet Agent Users Versus Nonusers in the Studies of Left Ventricular Dysfunction Combined Trial
27378	Adjusted Hazard Ratios of Mortality and Morbidity in Antiplatelet Agent Users Versus Nonusers in the Studies of Left Ventricular Dysfunction Prevention and Treatment Trials
27379	Interaction Between Antiplatelet Agent Use and Selected Patient Variables in Relation to End Points  (reported as p values)  in the Studies of Left Ventricular Dysfunction Combined Trial
27380	Adjusted Hazard Ratios of Mortality and Morbidity in Antiplatelet Agent Users Versus Nonusers in the Studies of Left Ventricular Dysfunction Combined Trial Patients Grouped by Drug Randomization
27381	Adjusted Hazard Ratios of Mortality and Morbidity in Patients Randomized to Enalapril Versus Placebo Therapy Grouped by Antiplatelet Agent Use
27382	Hemodynamic Data
27383	Neurohumoral and Cytokine Data
27384	Univariate and Multivariate Linear Model of Plasma Interleukin-6 in Femoral Vein of Patients With Congestive Heart Failure
27385	Univariate and Multivariate Linear Model of Interleukin-6 Spillover in Peripheral Circulation of Patients With Congestive Heart Failure
27386	Univariate and Multivariate Predictors of Mortality in 100 Patients With Chronic Heart Failure
27387	Relation of Circadian Rhythm Variables Between Average Ventricular Response Interval and Lorenz Plot Measures
27388	Regression Analysis of Circadian Rhythm Variables of Average Ventricular Response Interval With Those for Lorenz Plot Measures
27389	Relations Between Clinical Features of Atrial Fibrillation and Circadian Rhythm Variables of Average Ventricular Response Interval and Lorenz Plot Measures
27390	Intraindividual Reproducibility of Circadian Rhythm Variables of Average Ventricular Response Interval and Lorenz Plot Measures
27391	Prevalence of Left Ventricular Hypertrophy at Electrocardiography
27392	Independent Predictors of Total Cardiovascular Morbid Events  (Cox model)   a
27393	Independent Predictors of Fatal Cardiovascular Events  (Cox model)   a
27394	Relative Risks and 95% Confidence Intervals for Each Drug Comparison  a
27395	Relative Risks and 95% Confidence Intervals for Calcium Antagonist Use Versus Use of Neither Calcium Antagonists nor Beta-Adrenergic Blocking Agents  a
27396	Relation Between Age Category and Use of Reperfusion-Oriented Strategy  (intravenous thrombolysis or primary percutaneous transluminal coronary angioplasty)
27397	Relation Between Usage of Beta-Adrenergic Blocking Agents or Angiotensin-Converting Enzyme Inhibitors and Killip Class or Left Ventricular Ejection Fraction
27398	Univariate Analysis of Factors Related to Five-Day Mortality
27399	Multivariate Logistic Regression Analyses of Factors Related to Five-Day Mortality
27400	Acute Hemodynamic Data at Variable Atrioventricular Delays
27401	Doppler Assessment of Cardiac and Valvular Function
27402	Incidence and Relative Risk of Ischemic Cardiovascular Disease and Myocardial Infarction in PlA1/PlA2Heterozygotes or PlA2/PlA2Homozygotes Versus PlA1/PlA1Noncarriers by Cox Regression Analysis
27403	Incidence and Relative Risk of Ischemic Cardiovascular Disease and Myocardial Infarction in PlA1/PlA2Heterozygotes or PlA2/PlA2Homozygotes Versus PlA1/PlA1Noncarriers by Cox Regression, Stratified by Age
27404	Age at First Event in PlA1/PlA2Heterozygotes, PlA2/PlA2Homozygotes, and PlA1/PlA1Noncarriers
27405	Correlations Between β-Trace Protein, Cystatin C, and Clinical Variables
27406	Performance of Measures of Renal Function and NT-proBNP for Prediction of 1-Year Mortality and/or HF Hospitalization in Patients With ADHF
27407	Cox Regression Risk Analysis for Prediction of Mortality and/or HF Hospitalization
27408	Pre-Natal Clinical Features of Patients Diagnosed With Maternal Autoantibody-Induced Cardiomyopathy
27409	Pre- and Post-Natal Medical Treatment of Fetuses and Infants With Maternal Autoantibody–Induced Cardiomyopathy
27410	Number of patients with congenital adrenal hyperplasia, by sex and year of birth
27411	Frequency of underlying mutations in the congenital adrenal hyperplasia population in Sweden
27412	Management recommendations for hyperthyroidism in patients with Graves' disease or a history of Graves' disease who become pregnant
27413	Nucleobase and nucleoside analogues used in cancer chemotherapy
27414	Differentially expressed genes between each endotype
27415	Operative details
27416	First recurrence sites
27417	Interactions of fluid management with risk factors for in-hospital early deaths
27418	Adjusted rates of occlusive vascular death among people with and without diabetes at recruitment, by age and sex
27419	Biomarkers based on treatment assignment
27420	Prevalence of RLS in patients with cryptogenic events compared with patients with events of known cause
27421	Studies included in the meta-analysis
27422	Carotid artery restenosis or occlusion after stenting compared with endarterectomy
27423	Association of at least moderate  (≥50%)  carotid artery restenosis with subsequent outcome events
27424	Association of severe  (≥70%)  carotid artery restenosis with subsequent outcome events
27425	Univariate Cox regression models for the association of neuropsychiatric and developmental disorders among individuals with a 22q11.2 deletion or duplication
27426	Investigational product exposure in the safety analysis population
27427	Adverse events during neoadjuvant treatment in the safety analysis population
27428	Adverse events during adjuvant treatment in the safety analysis population
27429	Adverse events of interest during neoadjuvant treatment in the safety analysis population
27430	Adverse events of interest during adjuvant treatment in the safety analysis population
27431	2-year depression course indicators across six age categories and linear associations with continuous age
27432	Pooled estimates for linear associations between continuous age  (per 10-year increase)  and the 2-year course of depression
27433	Clinical PROMISE score and biological PROMISE score  (clinical plus TIMP1)
27434	Treatment responses in the intention-to-treat population as assessed by computational algorithm based on IMWG-URC
27435	Adverse events in the safety population
27436	Adverse events of interest in the safety population
27437	Response by local assessment
27438	Adverse events from any cause
27439	Incidence of treatment-emergent adverse events judged to be related to tucatinib
27440	Steady state pharmacokinetic parameters of tucatinib
27441	Best response in patients with measurable disease treated with tucatinib plus capecitabine or trastuzumab at the maximum tolerated dose
27442	Adverse events
27443	Adverse events
27444	Potential immune-mediated diseases, as defined by MedDRA
27445	Patient disposition
27446	Cumulative response assessment  *
27447	Relation between best response to quizartinib and overall survival in all FLT3-ITD-positive patients in cohort 1 and between response to quizartinib, HSCT, and overall survival in all FLT3-ITD-positive patients in cohort 2
27448	Treatment-emergent adverse events in all patients  *   that occurred in 10% or more of patients  (grade 1–2)  or 2% or more of patients  (grade ≥3)
27449	Antibodies to infliximab
27450	Overall summary of adverse events during CT-P13 treatment  (safety population)
27451	Summary of best response by modified RECIST criteria in the randomised population
27452	Treatment-emergent adverse events of all grades occurring in more than 15% of patients in the safety population
27453	Genes containing SNPs notionally statistically significant  (p<1 × 10−6)  identified in the discovery cohort
27454	Pathogen isolates from the paired cough swab, sputum induction, and bronchoalveolar samples
27455	Excess cause-specific mortality at ages 35–74 years associated with previously diagnosed or undiagnosed diabetes at recruitment
27456	HbA1c level and glycaemic variability score for model 1 and model 2, by sex
27457	All-cause mortality by HbA1c level and glycaemic variability score for model 1 and model 2
27458	Associations between circadian relative amplitude quintile and mental health and wellbeing outcomes
27459	Loci identified in the age at onset analyses and followed up in the replication stage
27460	Loci identified in the case-control analysis and followed up in the replication stage
27461	Prevalence of major congenital malformations in offspring exposed prenatally to one of eight different antiepileptic monotherapies
27462	Association between prevalence of major congenital malformations and exposure to one of the four monotherapies in which a dose response was detectable
27463	Results of multivariable analysis of major congenital malformations in the study cohort  *
27464	Major congenital malformations associated with eight different antiepileptic monotherapies and their time of detection
27465	Proposed screening strategy for site-specific gastrointestinal cancer in patients with cystic fibrosis
27466	Adverse events in the safety population
27467	Associations between job strain variables at age 45 years and new onset CMD caseness at age 50 years by use of logistic regression
27468	Progression events and survival status
27469	Grade 3 and 4 adverse events deemed treatment related
27470	Variables affecting the probability of maintaining MMR 6 months after TKI discontinuation in the learning sample  (n=448)
27471	Probability of maintaining MMR 6 months after TKI discontinuation, by duration of deep molecular response  (years)  before imatinib discontinuation
27472	Adverse events
27473	Costs for the 6-month treatment period  (2014–15 prices)
27474	Treatment complications in both study groups
27475	Main and secondary study outcome measures
27476	Prevalence of hypertension and dyslipidaemia in US adults aged 20 years and older, by glycaemic status, 1988–2014
27477	Mean blood pressure and lipid concentrations by glycaemic group, hypertension, and dyslipidaemia status, in US adults aged 20 years and older, 1988–2014
27478	Estimates of 10-year risk of cardiovascular events, prevalence of myocardial infarction, and prevalence of strokes in US adults aged 20 years and older, by glycaemic status, 1988–2014
27479	Diabetic renal disease markers in US adults aged 20 years and older, by glycaemic status, 1988–2014
27480	Adverse events
27481	Total chemotherapy dose received by patients and dose intensity achieved
27482	End of treatment response by CT
27483	Adverse events by treatment
27484	Relative effects of transformed predictors
27485	Treatment-emergent adverse events occurring in the safety population of part 1 and part 2
27486	Treatment-emergent serious adverse events in the safety population in part 1 and part 2
27487	Patient outcomes at data cutoff
27488	Treatment-related adverse events in at least 10% of patients and all grade 3 or 4 events  *
27489	Best overall confirmed response by treatment group
27490	Adverse events irrespective of causality by treatment group
27491	Hazard ratios for risk of developing dementia, stratified by time since TBI and number of TBIs
27492	All adverse events  (safety population)
27493	Serious adverse events
27494	Most frequently reported treatment-emergent adverse events in the safety population
27495	Primary-composite, secondary, and other long-term outcome measures
27496	Serious adverse events, movement disorders, metabolic measures, and general side-effects  *
27497	Administered doses of chemotherapeutic drugs
27498	Surgical and pathological outcomes in patients who had potentially curative surgery
27499	Adverse events associated with preoperative and postoperative treatment
27500	Surgical complications in patients who had potentially curative surgery
27501	5-year overall survival in the validation cohort by prognostic single patient classifier groups
27502	5-year overall survival in the validation cohort by predictive single patient classifier groups
27503	Availability of data for measuring the effects of gastroprotectants
27504	Recovery of bowel function and anastomotic leakage and treatment
27505	Morbidity and mortality
27506	Clavien-Dindo complications of grade IIIa or higher
27507	Adverse events deemed at least possibly related to napabucasin or placebo by investigator
27508	Estimated age of attainment for each of the motor milestones among children in the study sample compared with the WHO reference population
27509	Relative rate of motor milestone attainment in each of the intervention groups
27510	Standardised differences in scores on the communication, gross motor, personal social, and combined scales of the Extended Ages and Stages Questionnaire
27511	Estimated age of attainment for each of the motor milestones among children in the study population compared with the WHO reference population
27512	Relative rate of motor milestone attainment after 1 year of intervention
27513	Standardised differences in scores on the communication, gross motor, personal social, and combined scales of the Extended Ages and Stages Questionnaire after 2 years of intervention
27514	Effect of the interventions on communication and executive functions after 2 years
27515	Study drug-related side-effects
27516	Quality of life and ophthalmic parameters during the treatment phase and follow-up observation
27517	Proportion of patients achieving glycaemic targets and weight loss responses at week 40
27518	Adverse events overview
27519	Intention-to-treat analysis of primary and coprimary outcomes
27520	Post-hoc per-protocol analysis of primary and coprimary outcomes
27521	Concentrations of aminoacids, haemoglobin, C-reactive protein, and haemolytic markers and measures of endothelial and non-endothelial dependent vascular function before and after RUSF treatment
27522	Comparison of effects of RUSF-v and RUSF-b, showing mean within individual differences by treatment order
27523	Causes and grade of adverse events by treatment periods
27524	Comparison of selected results  *   over time, by amyloid β deposition status and progression to prodromal Alzheimer's disease
27525	Multivariate Cox model
27526	Progression-free survival  (PFS)  according to the predictor score in each validation cohort and in FLIPI risk categories
27527	Studies of conversion  (functional neurological)  disorder included in meta-analysis
27528	Summary meta-analysis data for studies of maltreatment in conversion  (functional neurological)  disorder and associated PAFs
27529	Proportion of cases with no exposure to specific stressors when compared with controls
27530	Primary causes of death in SMaRT Oncology-2 and SMaRT Oncology-3 trial participants
27531	Distribution of events
27532	Summary of adverse events by schedule
27533	Summary of adverse events by aromatase inhibitor
27534	Maximum grade of adverse event during treatment
27535	Electroconvulsive therapy  (ECT)  and all-cause dementia in relation to age at study entry
27536	Electroconvulsive therapy  (ECT)  use and incident dementia during follow-up in patients aged 70 years and older
27537	Risk of association between electroconvulsive therapy  (ECT)  and all-cause dementia in relation to age at study entry
27538	Summary of common  (any grade in ≥10% and grade 3–4 in ≥2%)  adverse events reported, regardless of causality
27539	Adverse events
27540	Malignant lesions detected with use of fluorescence imaging
27541	Adverse events of grade 3 or worse
27542	Number of adverse events
27543	Unadjusted prevalence of overweight and obesity, hypertension, diabetes, and lifestyle risk factor categories among study participants
27544	Associations of risk factors with overweight and obesity: age-adjusted and distal-factor-adjusted risk ratios
27545	Associations of risk factors with hypertension: age-adjusted and distal-factor-adjusted risk ratios
27546	Associations of risk factors with diabetes: sex-specific crude and adjusted risk ratios
27547	Interventions during the 20-week treatment period
27548	Primary and secondary outcome, safety, sensitivity, and post-hoc analyses
27549	Association between BMI and progression-free survival
27550	Association between BMI and overall survival
27551	Multivariable Firth's logistic regression prediction model for lobar intracerebral haemorrhage associated with moderate or severe cerebral amyloid angiopathy
27552	Prevalence of childhood  (age 0–11 years)  socioeconomic background factors by birth year and sex at the start of follow-up  (age 12 years)
27553	Cumulative incidence of specialised service use among girls from their 12th to their 18th birthday, stratified by birth cohort
27554	Cumulative incidence of specialised service use among boys from their 12th to their 18th birthday, stratified by birth cohort
27555	Summary of key safety results
27556	Most frequent treatment-emergent adverse events
27557	Survival and recurrence outcomes
27558	Multivariable analysis of prognostic factors for overall survival
27559	Multivariable analysis of prognostic factors for failure-free survival
27560	Adverse events reported during treatment
27561	Adverse events reported at 6 months after randomisation
27562	Chromatin heterogeneity in analysis of cancer-specific survival
27563	Questionnaire assessments
27564	Results of primary and secondary outcomes for the risk of repeat self-harm in the treatment groups and covariates
27565	Adverse events
27566	Results of cost-effectiveness analysis at 18 months
27567	Efficacy outcomes
27568	All grade 4 and 5 adverse events, and all adverse events of any grade in 20% or more patients, occurring during protocol treatment
27569	Overview of different treatment modalities by cancer type
27570	Obstetric outcomes, stratified by cancer type
27571	Multivariable analysis of the most common obstetric and neonatal complications
27572	Effect of independent variables on cost and inpatient bed days in the last year of life
27573	Effect of independent variables on early unplanned readmission in the last year of life and unplanned hospital death
27574	Efficacy outcomes for primary endpoint and major secondary endpoints
27575	Safety summary
27576	Highest allergen-specific IgE and age by primary efficacy outcome
27577	Definitions for clinical outcomes at follow-up
27578	Cumulative incidence and incidence of epilepsy, motor, and intellectual disability after childhood CSE
27579	Prevalence of epilepsy, motor, and intellectual functioning after CSE in childhood
27580	Health-care use and Parkinson's disease-related complications
27581	Regression results of the Cox's proportional hazard model to examine the effect of specialised physiotherapy on mortality
27582	Regression results of the random effects model to examine the effect of specialised physiotherapy on Parkinson's disease-related complications
27583	Outcomes at 12 months' follow-up
27584	Deaths by suicide  (2011–13) , hospital-presenting non-fatal self-harm  (2011–13) , and community-occurring non-fatal self-harm  (2015) , by sex and age group
27585	Logistic regression analysis of out-of-home placement and Cox proportional hazards model of time to first offence
27586	Police records of offending behaviour and recorded crimes
27587	Reports from parents and young people of antisocial behaviour, callous and unemotional traits, parenting skills, and family functioning
27588	Young people's self-reported delinquent behaviour, antisocial beliefs, attitudes, materialism, and wellbeing
27589	Parents' and teachers' reports of young people's wellbeing and behaviour and parents' own wellbeing
27590	Clinician-rated mental health outcomes
27591	Results of moderator analyses
27592	Differences in costs  (£ at 2012–13 prices)  and outcomes per participant over the 18 months' follow-up
27593	Adverse events that occurred in at least 20% of patients in either group
27594	Treatment exposure in the safety population
27595	Adverse events
27596	Risk factors for tuberculin skin test conversion and tuberculosis in multivariable model
27597	Adjusted mean difference in 12-month primary and secondary outcome measures in the DVDB, face-to-face, and usual care treatment groups in the intention-to-treat and per-protocol populations
27598	Number of patients having asthma attacks over 12 months in the DVDB, face-to-face, and usual care treatment groups in the intention-to-treat and per-protocol populations, by number of corticosteroid courses used
27599	Incidence of cardiometabolic outcomes and mortality
27600	Standardised cumulative incidence of cardiovascular events
27601	24 h urinary albumin excretion
27602	24 h urinary albumin-to-creatinine ratio
27603	Adverse events
27604	Outcomes in patients treated with standard care versus endovascular thrombectomy with or without GA
27605	Top signals of association at each locus that passed genome-wide threshold for significance and their replication and meta-analysis p values
27606	Top gene burden results
27607	Primary outcome
27608	Probability of primary outcome or relapse at 24 weeks
27609	Secondary outcomes
27610	All adverse events reported in at least 5% of patients in a treatment group  (in an overall category)
27611	Details of focused ultrasound subthalamotomy procedures
27612	Adverse events
27613	Trials of neoadjuvant versus adjuvant chemotherapy that began by 2005
27614	Local therapy, planned versus done, in women allocated to neoadjuvant chemotherapy, by clinical response
27615	Adverse events  (safety population)
27616	Maximum grade of targeted adverse events reported during the 5-year treatment period
27617	Univariate associations between childhood maltreatment and non-suicidal self-injury
27618	Univariate and multivariate moderator analyses
27619	Treatment-related adverse events by grade
27620	Best overall response to treatment according to local investigator assessment
27621	PIK3CA status assessed in plasma ctDNA at study entry by BEAMing assay and in archival tumour tissue by PCR
27622	Concordance in PIK3CA status between archival tumour tissue  (by PCR)  and plasma ctDNA assessed by BEAMing assay  *
27623	Most frequent  (≥10%)  adverse events regardless of study treatment
27624	Clinical outcomes at weeks 4 and 12 by initial therapy
27625	Multivariable logistic regression models of week 12 outcomes by treatment type
27626	Pooled relative risks of type 2 diabetes according to levels of linoleic acid and arachidonic acid biomarkers  *
27627	Adverse events
27628	Definitions of suicide in custody
27629	Number and rates of suicide in prisoners compared with the general population
27630	Results of meta-regression analyses comparing prison suicide rate with general population suicide rate, incarceration rate, and other prison-level variables
27631	Cause-specific mortality for people with and without mental disorders
27632	Life years lost and excess life years lost by cause of death in people with and without mental disorders
27633	Efficacy endpoint analyses at 5 years post randomisation in the intention-to-treat population
27634	Site of first invasive disease-free survival event in the intention-to-treat population
27635	Treatment-emergent adverse events
27636	Grade 2 adverse events occurring in at least 10% of patients in either group
27637	Grade 3–5 adverse events occurring in at least 1% patients in either group  (all attributions)
27638	Comparison of treatment responses  (RECIST 1.1)  among evaluable patients in the intention-to-treat population
27639	Treatment-related adverse events of interest, according to the MedDRA coding version 19.0 in the safety population
27640	Estimated new cancer cases and ASR per 100 000 people per year and by sex, for all cancers combined and 27 cancer types, among 20–39 year-olds worldwide in 2012
27641	Estimated cancer-related deaths and ASR per 100 000 people per year and by sex, for all cancers combined and 27 cancer types, among 20–39 year-olds worldwide in 2012
27642	Completion and compliance for the PRO instruments
27643	Association of disease progression with score for GHS/QOL
27644	Frequency and prevalence of background and adolescent covariates in 1671 participants by adolescent self-harm, and their association with adolescent self-harm, adjusted for gender and age
27645	Prevalence of outcomes at 35 years in 1671 participants by self-harm during adolescence, and unadjusted associations between adolescent self-harm and outcomes at 35 years  *
27646	A series of predictive models examining the associations between self-harm during adolescence and outcomes at 35 years with progressive adjustment for adolescent confounders or mediators in 1671 participants  *
27647	Clinical outcomes by AKI status
27648	Prediction models for clinical outcomes
27649	Country-level economic development, health, and gender equality indices
27650	Unadjusted mediating variables by country and gender
27651	Direct and indirect effects of gender on the EAP-ECDS composite score
27652	Retention in care at 18 months
27653	Primary and secondary outcomes
27654	Primary and secondary cardiovascular outcomes
27655	Selected adverse events
27656	Hypoglycaemic events
27657	Primary and secondary outcomes
27658	Adverse events
27659	Gene variants with genome-wide significance for idiopathic pulmonary fibrosis
27660	Changes in CGM values  (interstitial glucose)  at week 24
27661	Safety summary
27662	Summary of recurrent hypoglycaemic events
27663	Summary of events sent for diabetic ketoacidosis adjudication
27664	Association results for lead single-nucleotide polymorphisms reaching genome-wide significance in the discovery meta-analysis
27665	Candidate genes linked to functions in neurodevelopment
27666	Incidence ratios of ADHD per 1000 births by month of birth, in boys and girls
27667	Incidence ratios of ADHD per 1000 births by month of birth, in boys and girls
27668	Incidence ratios of ADHD by year of diagnosis, age at first diagnosis, and month of birth
27669	Included studies
27670	Parameters of model with best fit
27671	Expected proportion of patients with 10%, 20%, 30%, 40%, and 50% YMRS score reduction at 3 weeks and NNT.
27672	Efficacy endpoint events in patients who were disease-free at 3 years after randomisation
27673	Adverse events by treatment group
27674	Best overall response by masked independent review  (intention-to-treat population)
27675	Adverse events  (safety population)
27676	Adverse events  (safety analysis set)
27677	Overall response
27678	Summary of treatment-emergent adverse events occurring in 10% or more patients in the safety analysis set
27679	Site of infection and pathogens identified in neonates and children with blood culture-proven bacterial sepsis
27680	Severity of sepsis episodes in neonates and children with blood culture-proven bacterial sepsis
27681	Risk factors for death in neonates and children with blood culture-proven bacterial sepsis
27682	Summary of evidence of lung function measures used in the diagnosis of asthma
27683	Diagnostic values for individual tests in 477 children
27684	Diagnostic values for individual tests in 163 children reporting one or more respiratory symptoms
27685	Peanut ingestion and skin prick test
27686	Reported reactions from completion of study treatment to time of long-term follow-up study
27687	Peanut sIgE and sIgG4 concentrations, and sIgG4:sIgE ratio 4 years after completion of study treatment
27688	Long-term peanut challenge outcomes in participants who underwent sustained unresponsiveness food challenge after 8 weeks' peanut elimination
27689	Study outcomes
27690	Serious adverse events
27691	Studies included in analysis of prognostic effect of nodal status
27692	Effect of misclassified true LNP on observed prognostic discrimination
27693	Adjusted mean FACT-G total scores by treatment arm and time in study
27694	Summary of item “I am bothered by side-effects of treatment”
27695	Association of disease progression with HRQOL and utility
27696	Treatment exposure  (safety population)
27697	Summary of secondary efficacy endpoints
27698	Summary of adverse events in the safety population
27699	Subsequent antimyeloma therapies
27700	Adverse events
27701	Objective responses
27702	Adverse events
27703	Difference in quality-of-life outcomes at 12 weeks after randomisation
27704	Pathogen yields in relation to specimen type
27705	Overall yields in relation to specimen type, for any pathogen, for the entire cohort  (n=1519)
27706	Post-transplantation sensory, motor, and functional milestones
27707	Deaths due to asthma and COPD and number of prevalent cases of disease in 2015 and percentage change in all-age and age-standardised rates in locations grouped by SDI quintile
27708	YLLs, YLDs, and DALYs due to asthma and COPD in 2015 and percentage change in all-age counts and age-standardised DALY rates from 1990 to 2015 in locations grouped by SDI quintiles
27709	Proportional contribution of behavioural and environmental and occupational risks for COPD in DALYs per 100 000 people in locations grouped by SDI quintiles, 2015
27710	Weighted means of hazard ratios for cardiovascular, mortality, and other outcomes in Denmark, Norway, and Sweden for new users of SGLT2 inhibitors versus new users of other glucose-lowering drugs
27711	Features associated with acute complications of asparaginase-associated pancreatitis
27712	Factors associated with the risk of a second asparaginase-associated pancreatitis in patients re-exposed to asparaginase
27713	Associations between aspects of cannabis use and suicidal thoughts and behaviours in male and female twins from the Australian Twin Registry
27714	Unadjusted within-pair associations between aspects of cannabis use and suicidal thoughts and behaviours, in discordant monozygotic and dizygotic same-sex twin pairs, by dependent variable
27715	Within-pair associations between cannabis use and suicidal thoughts and behaviours in discordant monozygotic twin pairs
27716	Prevalence of major depressive disorder and suicidal ideation in monozygotic twins from pairs concordant for frequent cannabis use, pairs concordant for less frequent or never use, and discordant pairs where one twin reported frequent cannabis use and the other less frequent or never use
27717	Description of included studies
27718	Adverse events
27719	Dose modifications and discontinuations owing to adverse events
27720	Disease-free survival events
27721	Causes of death
27722	Non-breast cancers
27723	Adverse events reported in each treatment group
27724	Chemotherapy details
27725	Surgery details
27726	Chemotherapy toxicity
27727	Pathology details
27728	Antitumour responses assessed with RECIST in the intention-to-treat population
27729	Treatment-emergent adverse events
27730	Treatment-emergent adverse events of special interest
27731	Prevalence of single, dual, and triple infections with blood-borne viruses
27732	Odds of infection with blood-borne viruses in people with severe mental illness compared with the general population
27733	Overall compliance with questionnaires for health-related quality of life
27734	Modelled estimates of mean indices for health-related quality of life domains estimated over the 5 years of follow-up
27735	Modelled estimates of proportions of patients with ADT-related symptoms over the 5 years of follow-up
27736	Description of the 19 new trials
27737	Summary of main results for trials comparing altered fractionation and conventional fractionation radiotherapy
27738	Acute and late severe toxicities between conventional and altered fractionation radiotherapy
27739	Derivation of HALT-HCC model with preoperative factors in the CCF dataset
27740	Distribution of HALT-HCC scores, and 5-year overall survival estimates, by Milan criteria status
27741	Study drug and DEB-TACE administration and efficacy outcomes
27742	Disease response assessed locally using RECIST v1.1 and modified RECIST criteria
27743	CTC adverse event categories  (occurring in 10% or more of patients)
27744	SVR12 in the immediate treatment and deferred treatment groups
27745	Adverse events and laboratory safety
27746	Overview of study cohorts
27747	Global cognitive impairment with cognitive risk scores by quartile
27748	Risk of dementia with cognitive risk scores by quartile in the replication population
27749	Treatment-emergent adverse events in the safety analysis set
27750	Primary causes of death  (safety analysis set)
27751	Responses to gilteritinib, overall and by FLT3 mutation status  (full analysis set)
27752	Changes in tic severity, global health functioning, depression, anxiety, and quality of life during the double-blind period
27753	Adverse events
27754	Haematological and non-haematological adverse events
27755	Multivariable analysis on grade II–IV acute graft-versus-host disease, event-free survival, non-relapse mortality, and relapse risk
27756	Multivariable analysis for freedom from local recurrence
27757	Cognitive deterioration at 6 months
27758	Adverse events
27759	Spatial or service-setting identifiers present in the Mental Health Minimum Data Set 2010–11
27760	Results of four-level cross-classified null models
27761	Results of three-level  (patient-LSOA-provider trust)  cross-classified models
27762	Subsequent therapies
27763	Adverse events
27764	Treatment delivered
27765	Radiotherapy treatment delivered in patients receiving concurrent chemoradiotherapy  (as per protocol)
27766	Acute adverse events  (≤3 months after completion of study treatment)
27767	Late adverse events  (>3 months after study treatment)
27768	Outcomes of comparative studies
27769	Gastrointestinal adverse events of at least moderate severity, or vomiting, in participants in the three-dose study
27770	Gastrointestinal adverse events of at least moderate severity, or vomiting, in participants in the 16-dose study, by participant
27771	Whole blood interferon γ release assay with Nexvax2 peptides after gluten challenge after treatment  (post-hoc analysis)
27772	Incident rate ratios estimated by generalised additive mixed model and variables included in the model
27773	Parsimonious models assuming patients with missing smoking data are either smokers  (worst case scenario)  or non-smokers  (best case scenario)  and variables included in the model
27774	Efficacy outcomes
27775	Maximum grade adverse events, regardless of study drug relationship
27776	Events contributing to analyses of time to tumour recurrence and numbers of distant relapses, second cancers, and deaths
27777	Adverse events during cycles one to four of chemotherapy among patients in the quality-of-life and toxicity substudy
27778	Adverse events during cycles five to eight of chemotherapy among patients in the quality-of-life and toxicity substudy
27779	Late adverse events by epirubicin regimen
27780	Late adverse events by CMF or capecitabine group
27781	Risk of disease recurrence by nodal status in trials of dose-dense chemotherapy
27782	Adverse events
27783	Predictors of progression-free survival
27784	Predictors of overall survival
27785	Effect of previous thoracic radiotherapy on frequncy of all recorded pulmonary toxicities and treatment-related pulmonary toxicities
27786	Adverse events in all patients and by Child-Pugh score
27787	Serious adverse events
27788	Best tumour response
27789	Safety summary of events occurring in 10% or more of patients by grade
27790	Secondary and post-hoc outcomes
27791	Mean differences in cardiovascular risk factors between more intensive glucose control and less intensive glucose control to the end of follow–up
27792	Age at which the percentage of each ATN prevalence curve reaches its peak for women and men
27793	Incidence of colorectal cancer and unadjusted effect of surveillance on incidence of colorectal cancer by number of visits
27794	Cumulative colorectal cancer incidence and age-and-sex standardised incidence ratios
27795	Re-presentation for self-harm in the 6 months following the index presentation
27796	Logistical regression analyses investigating association between group assignment  (intervention vs control) , past admission to hospital for self-harm, and re-presentation with self-harm
27797	Negative binomial models to predict repeat self-harm as function of group and past admission to hospital for self-harm
27798	Associations between risk factors and violent crime in the derivation sample from the multiple regression model  (after multiple imputation)
27799	Haematological toxicity
27800	Non-haematological toxicity
27801	Dose intensity
27802	Treatment-related adverse events
27803	Adverse events by maximum grade and CTCAE  (version 3)  category
27804	Selected adverse events related to bevacizumab treatment
27805	Treatment-emergent adverse events
27806	Adverse events
27807	Summary of overall survival analyses in the EMILIA study
27808	All adverse events
27809	Mean number of standard drinks per day across countries, by sex and WHO drinking risk level
27810	Wave 1 drinkers, by WHO drinking risk levels
27811	Changes in WHO drinking risk level at Wave 2, by Wave 1 WHO drinking risk level for all drinkers and alcohol-dependent drinkers
27812	Alcohol dependence at Wave 2, by WHO drinking risk level at Wave 1 and change in WHO risk level between Waves 1 and 2
27813	Study outcomes by treatment group
27814	Adverse events overview in the safety analysis set
27815	HbA1c concentrations  (%)  by treatment groups, over the course of four visits
27816	Cumulative incidence of new initiation of insulin therapy in patients with diabetes not on insulin at screening during the course of follow-up in PARADIGM-HF, by treatment assignment
27817	Changes in triglycerides and HDL-cholesterol concentrations, and body-mass index by treatment groups, over the course of four visits
27818	Primary and selected secondary endpoints by treatment group
27819	Participants achieving study endpoints by treatment group
27820	Adverse events overview
27821	Secondary outcomes for groups 2 and 3 combined
27822	Treatment-emergent adverse events for groups 2 and 3 combined
27823	Post-hoc outcomes for early treatment  (<36 h)  for groups 2 and 3 combined
27824	Secondary clinical outcomes and other follow-up assessments up to 12 months post randomisation
27825	Accumulated causes of mortality at 90 days and 12 months post randomisation
27826	Group comparisons of 18F-FDOPA uptake and 11C-MP binding in the first study, by age
27827	11C-DTBZ and 11C-DASB binding in the second study, by group
27828	SMRs for selected causes in people with severe mental illness
27829	Adjusted HRs for all-cause mortality, by ethnic group and time since diagnosis
27830	Adjusted HRs for all-cause mortality, by covariates
27831	Sub-HRs for natural-cause and unnatural-cause mortality
27832	Primary outcome—Clincal Global Improvement raw score
27833	Adverse events
27834	Response to treatment
27835	Treatment-related adverse events  (safety population, initial treatment phase)
27836	Variables determining starting doses and stratification factors for random assignment
27837	Best tumour response
27838	Haematological and non-haematological adverse events
27839	Adverse events at 3 months after randomisation
27840	Post-study treatment
27841	Objective response rate and duration of response in the intention-to-treat population
27842	Overview of adverse events in the safety population
27843	Grade 3 or more adverse events with an incidence of 2% or more in either group in the safety population
27844	Tumour responses according to Response Evaluation Criteria in Solid Tumors version 1.1
27845	Adverse drug reactions occurring in at least 10% of patients in any group according to preferred term  (as-treated population set)
27846	Operative and pathological results
27847	Late grade 2–4 adverse events
27848	Effect of evolocumab uptitration on LDL cholesterol
27849	Safety and tolerability of evolocumab
27850	Main underlying diseases with the ASCOD phenotyping system
27851	Outcomes
27852	Association of variables with DNA-TGN concentration
27853	Adjusted HR for relapse-free survival in non-high-risk patients in clinical remission at start of maintenance therapy
27854	Logistic regression analyses of pathological complete response
27855	Pathological complete response at the time of surgery, by intrinsic molecular subtype assessed at day 14
27856	Adverse events
27857	Estimates of the generalised estimating equation analysis of frequent substance use and predictor variables
27858	Confirmed disease response per central review in the intention-to-treat population
27859	Adverse events irrespective of causality in at least 10%  (grade 1 or 2)  or at least 2%  (grade 3 or 4)  of patients in either treatment group
27860	Association results for the three markers that reached genome-wide significance
27861	Univariable analysis of prognostic variables
27862	Multivariable analysis by overall survival
27863	Adverse events by CTCAE category
27864	Frequency of carcinoid syndrome in patients with well differentiated  (grade I–II)  neuroendocrine tumours
27865	Cox regression model of overall survival
27866	Multivariable logistic regression analysis of treatment use in the 3 months after neuroendocrine tumour diagnosis
27867	Subsequent treatments  (intention-to-treat population)
27868	Selected adverse events  (safety analysis set)
27869	Results of the mega-analysis of subcortical brain volumes in the total sample
27870	Results of the mega-analysis of subcortical brain volumes in the stratified age groups
27871	Results of the exploration of the effect of medication on case-control differences
27872	Anti-HBs seroconversion
27873	Adverse events and laboratory abnormalities from week 0 to week 48
27874	Incidence rates of HCV reinfection in participants who cleared primary infections in British Columbia, Canada
27875	Hazard ratios from Cox proportional hazards models for time to HCV reinfection in British Columbia, Canada
27876	Adjusted hazard ratios from Cox proportional hazards models for time to HCV reinfection, stratified by clearance type, in British Columbia, Canada
27877	Hazard ratios from Cox proportional hazards model for time to HCV reinfection among current injection drug users in British Columbia, Canada
27878	Efficacy results  (intention-to-treat population)
27879	Adverse events
27880	Discontinuation clinical trials for patients with major depressive disorder
27881	Model selection
27882	Univariate associations between trajectory classes and categorical and quantitative predictors
27883	Effects of predictors on relapse trajectory membership and relapse
27884	Clinical outcomes  (MITT population)
27885	Incidence of adverse events occurring in 10% or more of patients in either treatment group
27886	Surgical and pathological findings
27887	Adverse events reported during pre-operative chemotherapy
27888	Adverse events reported during post-operative chemotherapy
27889	Confirmed objective responses
27890	Treatment-emergent adverse events leading to discontinuation of study drugs
27891	Treatment-emergent adverse events by predefined categories in the safety population
27892	Treatment-emergent serious adverse events  *   by preferred term in the safety population
27893	Oncological outcomes and postoperative complications by allocated treatment in the three-arm randomisation at the end of follow-up
27894	Oncological outcomes and postoperative complications by allocated treatment in the pooled short-course radiotherapy comparison at the end of follow-up
27895	Outcome measures at 12 months
27896	Best overall response to therapy
27897	Adverse events, irrespective of relation to study treatment
27898	Pre-migration potentially traumatic events and post-migration stressors of 2399 humanitarian migrants in the Building a New Life in Australia project, 2013–14
27899	Odds ratios and 95% CI for the association between pre-migration potentially traumatic events and post-migration stressors and mental health of humanitarian migrants, Building a New Life in Australia project, 2013–14
27900	Overall treatment response
27901	Responses in patients with or without del (17p)
27902	Responses in patients with unmutated or mutated IGHV
27903	Treatment-emergent adverse events and laboratory abnormalities  (occurring ≥10% of patients in both groups)
27904	Serious adverse events  (any grade; ≥2% of patients)
27905	Treatment-related adverse events leading to death  (per investigator assessment)
27906	Major gastrointestinal bleeding with different anticoagulant medications and prespecified sensitivity tests
27907	GRADE summary of findings reporting the comparative efficacy of drugs strategies
27908	Primary treatment of African patients with hepatocellular carcinoma
27909	Predictors of survival in African patients with hepatocellular carcinoma
27910	Adverse events  (in at least 10% of patients)
27911	Summary of the qualifying variant criteria in the four models, by cohort
27912	Genes that confer a risk of epilepsy
27913	Multivariable analysis of the Erasmus Breast Cancer Cohort for distant-metastasis-free survival
27914	Clinical cohort description and multivariate analysis for the effect of GARD on selected endpoints
27915	Longitudinal change in MFQ by current mental disorder and past-year contact with mental health services at T1
27916	MFQ clinical cutoff point at T3 predicted by propensity score weighted mental health service contact at T1
27917	Adverse events per breast
27918	Reoperations per breast
27919	Risk of medical complications, reoperation for medical reasons, and removal of implants
27920	Co-primary efficacy endpoints  *
27921	Treatment-emergent adverse effects
27922	Behavioural and emotional scores and problems for the CBCL seven-syndrome scales and the DSM-IV-oriented scales
27923	Factors associated with total behavioural and emotional problems in 2903 children who received the risk factor questionnaire
27924	Medical and neurocognitive comorbidities of behavioural and emotional problems by age group in children randomly selected for clinical assessment
27925	Stratified sensitivity analysis for patients who achieved the primary endpoint
27926	Post-hoc analysis of patients who achieved the primary endpoint, by individual endpoint components
27927	Treatment-emergent adverse events occurring in at least 10% of patients during the 8-week treatment period
27928	Sensitivity and specificity estimates for the individual biomarkers comparing non-dysplastic Barrett's oesophagus and Barrett's oesophagus with high-grade dysplasia
27929	Risk classification results for the discovery and validation cohorts
27930	Person-years of follow-up, number of deaths, and hazard ratios for all-cause mortality by levels of insulin dosage using conventional analyses
27931	Person-years of follow-up, number of deaths, and hazard ratios for all-cause mortality by insulin dose in sensitivity analyses
27932	Major adverse cardiovascular events according to insulin dosage using conventional analyses
27933	Rates of all-cause mortality and death with functioning graft up to 10 years after kidney transplantation stratified by diabetes status and age
27934	Infection in infancy and the risk of childhood obesity
27935	Exposure to antibiotics in infancy and the risk of childhood obesity
27936	Prevalence of prediabetes by definition
27937	Primary clinical outcome
27938	Lead time to treatment and response rate
27939	Electro-clinical secondary outcome
27940	Adverse reactions
27941	Model for prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease
27942	Comparison of Kaplan-Meier estimates of proportions of patients remaining free from seizures after 6 months of treatment at the last assessed dose
27943	Numbers of patients with treatment-emergent adverse events
27944	Objective response rates by homologous recombination deficiency subgroup
27945	Treatment-emergent adverse events
27946	Variant allele frequency changes of driver mutations by patient and gene from the time of primary cancer diagnosis to therapy-related myeloid neoplasm diagnosis
27947	Fine-Gray proportional hazard regression model for therapy-related myeloid neoplasm development in the external cohort
27948	Mean change in frequency-specific hearing thresholds
27949	Components of reported haematological toxicity  *
27950	Components of reported nephrotoxicity  *
27951	Outcome variables at 3 months
27952	Adverse events
27953	Differences between patients who were and were not admitted to acute mental health services within 12 months of index episode with crisis resolution and home treatment teams
27954	Risk factors for admission to acute mental health services within 12 months of index episodes with CRTs
27955	Risk factors for admission to inpatient wards within 12 months of index episodes with CRTs
27956	Univariate and multivariate analyses of progression-free survival and overall survival
27957	Adverse events occurring up to week 28, regardless of causality
27958	Prevalence of neuronal cell surface antibodies in patients and controls
